{"questions": [{"body": "Elaborate on the link between conserved noncoding elements (CNEs) and fractality.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26899868", "http://www.ncbi.nlm.nih.gov/pubmed/24787386"], "ideal_answer": ["Well-developed fractality is revealed for the chromosomal distribution of different classes of CNEs in the human genome by employing the scaling of block entropy and box-counting. This is characteristic of elements that are either extremely conserved between species or are of ancient origin, i.e. conserved between distant organisms across evolution. There are also power-law-like distributions, i.e. linearity in double logarithmic scale, in the inter-CNE distances, a feature which is connected with fractality and self-similarity."], "type": "summary", "id": "587f57f692a5b8ad44000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Fractality and entropic scaling in the chromosomal distribution of conserved noncoding elements in the human genome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26899868", "endSection": "title"}, {"offsetInBeginSection": 211, "offsetInEndSection": 696, "text": "We explored the chromosomal distribution of different classes of CNEs in the human genome. We employed two methodologies: the scaling of block entropy and box-counting, with the aim to assess fractal characteristics of different CNE datasets. Both approaches converged to the conclusion that well-developed fractality is characteristic of elements that are either extremely conserved between species or are of ancient origin, i.e. conserved between distant organisms across evolution. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26899868", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Conserved noncoding elements follow power-law-like distributions in several genomes as a result of genome dynamics.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24787386", "endSection": "title"}, {"offsetInBeginSection": 480, "offsetInEndSection": 666, "text": "We find widespread power-law-like distributions, i.e. linearity in double logarithmic scale, in the inter-CNE distances, a feature which is connected with fractality and self-similarity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24787386", "endSection": "abstract"}, {"offsetInBeginSection": 480, "offsetInEndSection": 667, "text": "We find widespread power-law-like distributions, i.e. linearity in double logarithmic scale, in the inter-CNE distances, a feature which is connected with fractality and self-similarity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24787386", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Conserved noncoding elements follow power-law-like distributions in several genomes as a result of genome dynamics.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24787386", "endSection": "title"}]}, {"body": "Which is the primary protein component of Lewy bodies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23180276", "http://www.ncbi.nlm.nih.gov/pubmed/11814405", "http://www.ncbi.nlm.nih.gov/pubmed/10722726", "http://www.ncbi.nlm.nih.gov/pubmed/20551689", "http://www.ncbi.nlm.nih.gov/pubmed/24252509", "http://www.ncbi.nlm.nih.gov/pubmed/12541013", "http://www.ncbi.nlm.nih.gov/pubmed/23965852", "http://www.ncbi.nlm.nih.gov/pubmed/10327208", "http://www.ncbi.nlm.nih.gov/pubmed/18510319", "http://www.ncbi.nlm.nih.gov/pubmed/22843682", "http://www.ncbi.nlm.nih.gov/pubmed/24058647", "http://www.ncbi.nlm.nih.gov/pubmed/26667592", "http://www.ncbi.nlm.nih.gov/pubmed/23344955", "http://www.ncbi.nlm.nih.gov/pubmed/18607609", "http://www.ncbi.nlm.nih.gov/pubmed/10764738", "http://www.ncbi.nlm.nih.gov/pubmed/11440819", "http://www.ncbi.nlm.nih.gov/pubmed/23557146", "http://www.ncbi.nlm.nih.gov/pubmed/22516611", "http://www.ncbi.nlm.nih.gov/pubmed/9726379", "http://www.ncbi.nlm.nih.gov/pubmed/16452621", "http://www.ncbi.nlm.nih.gov/pubmed/24392030", "http://www.ncbi.nlm.nih.gov/pubmed/26502720", "http://www.ncbi.nlm.nih.gov/pubmed/10825478", "http://www.ncbi.nlm.nih.gov/pubmed/17899395", "http://www.ncbi.nlm.nih.gov/pubmed/11900526", "http://www.ncbi.nlm.nih.gov/pubmed/19475665", "http://www.ncbi.nlm.nih.gov/pubmed/12722831", "http://www.ncbi.nlm.nih.gov/pubmed/18508479", "http://www.ncbi.nlm.nih.gov/pubmed/10762166", "http://www.ncbi.nlm.nih.gov/pubmed/20617407", "http://www.ncbi.nlm.nih.gov/pubmed/26401513", "http://www.ncbi.nlm.nih.gov/pubmed/11085897", "http://www.ncbi.nlm.nih.gov/pubmed/23796501", "http://www.ncbi.nlm.nih.gov/pubmed/12122208", "http://www.ncbi.nlm.nih.gov/pubmed/14502650", "http://www.ncbi.nlm.nih.gov/pubmed/16319716", "http://www.ncbi.nlm.nih.gov/pubmed/24586691", "http://www.ncbi.nlm.nih.gov/pubmed/9600990", "http://www.ncbi.nlm.nih.gov/pubmed/22483285", "http://www.ncbi.nlm.nih.gov/pubmed/26161848", "http://www.ncbi.nlm.nih.gov/pubmed/25846226", "http://www.ncbi.nlm.nih.gov/pubmed/11816795", "http://www.ncbi.nlm.nih.gov/pubmed/11207422", "http://www.ncbi.nlm.nih.gov/pubmed/16343531", "http://www.ncbi.nlm.nih.gov/pubmed/20890676"], "ideal_answer": ["The primary protein component of Lewy bodies are fibrils composed of alpha-synuclein."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016631", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051844"], "type": "factoid", "id": "58a2e5f760087bc10a000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "Aggregation of \u03b1-synuclein (\u03b1Syn), the primary protein component in Lewy body inclusions of patients with Parkinson's disease, arises when the normally soluble intrinsically disordered protein converts to amyloid fibrils. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058647", "endSection": "abstract"}, {"offsetInBeginSection": 245, "offsetInEndSection": 500, "text": "The primary structural component of Lewy bodies are fibrils composed primarily of alpha-synuclein, a highly conserved 140 amino acid protein that is predominantly expressed in neurons and which may play a role in synaptic plasticity and neurotransmission.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22483285", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Fibrillar \u03b1-synuclein (AS) is the major component of Lewy bodies, the pathological hallmark of Parkinson's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516611", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Alpha-synuclein (alphaS) is the primary component of Lewy bodies, the pathological hallmark of Parkinson's Disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19475665", "endSection": "abstract"}, {"offsetInBeginSection": 578, "offsetInEndSection": 827, "text": "For alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson's disease, we have used a combination of ssNMR and biochemical data to identify the key region for self-aggregation of the protein as residues 77-82 (VAQKTV). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18510319", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "The protein alpha-synuclein (AS) is the primary fibrillar component of Lewy bodies, the pathological hallmark of Parkinson's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17899395", "endSection": "abstract"}, {"offsetInBeginSection": 159, "offsetInEndSection": 276, "text": "Recently, the presynaptic protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10327208", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "Alpha-synuclein forms the major component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9726379", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "\u00e1-Synuclein is the major protein component of Lewy bodies--the pathological hallmark of Parkinson's disease (PD) and Dementia with Lewy bodies (DLB).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20617407", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the pathogenesis of Lewy bodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11085897", "endSection": "abstract"}, {"offsetInBeginSection": 926, "offsetInEndSection": 1089, "text": "The segregation of alpha-synuclein to Lewy body peripheral domain is consistent with the hypothesis that alpha-synuclein is continually deposited onto Lewy bodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11085897", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Identification of protein interfaces between \u03b1-synuclein, the principal component of Lewy bodies in Parkinson disease, and the molecular chaperones human Hsc70 and the yeast Ssa1p", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22843682", "endSection": "title"}, {"offsetInBeginSection": 374, "offsetInEndSection": 634, "text": "Whereas approximately 550 proteins were identified in the LB-enriched sample by mass spectrometry, quantitative comparison with the control sample revealed that approximately 40 proteins were co-enriched with alpha-synuclein, the major component in Lewy bodies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18508479", "endSection": "abstract"}, {"offsetInBeginSection": 509, "offsetInEndSection": 1085, "text": "This apparent conflict in protein levels might have arisen from examining Lewy body disease cases with coexisting Alzheimer-type pathologies.To assess whether ATP13A2 levels in Lewy body disease are modified by Alzheimer-type \u03b2-amyloid deposition, we evaluated cases of pure PD and pure dementia with Lewy bodies (DLB) for changes in ATP13A2, \u03b1-synuclein and \u03b2-amyloid protein levels in cortical regions with and without Lewy bodies.In all Lewy body disease cases, we identified decreased ATP13A2 protein levels that correlated with increases in both \u03b1-synuclein and \u03b2-amyloid", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24252509", "endSection": "abstract"}, {"offsetInBeginSection": 1087, "offsetInEndSection": 1444, "text": "Partial colocalization was observed between ATP13A2 and \u03b1-synuclein in Lewy bodies, whereas ATP13A2 did not colocalize with pathological \u03b2-amyloid deposition.Our data show that patients with Lewy body diseases have an overall deficit in ATP13A2 protein levels, with the remaining protein being more insoluble and partially redistributing towards Lewy bodies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24252509", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "Identification of protein interfaces between \u03b1-synuclein, the principal component of Lewy bodies in Parkinson disease, and the molecular chaperones human Hsc70 and the yeast Ssa1p.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22843682", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Human \u03b1-synuclein is a small-sized, natively unfolded protein that in fibrillar form is the primary component of Lewy bodies, the pathological hallmark of Parkinson's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23557146", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "Parkinson's disease is the most common neurodegenerative movement disorder. \u03b1-Synuclein is a small synaptic protein that has been linked to familial Parkinson's disease (PD) and is also the primary component of Lewy bodies, the hallmark neuropathology found in the brain of sporadic and familial PD patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20890676", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "The protein alpha-synuclein (AS) is the primary fibrillar component of Lewy bodies, the pathological hallmark of Parkinson's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17899395", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "\u03b1-Synuclein is an abundant presynaptic protein and a primary component of Lewy bodies in Parkinson disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344955", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "The natively disordered protein alpha-synuclein is the primary component of Lewy bodies, the cellular hallmark of Parkinson's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16343531", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 301, "text": "Common cellular and molecular mechanisms including protein aggregation and inclusion body formation are involved in many neurodegenerative diseases. \u03b1-Synuclein is a major component of Lewy bodies in Parkinson's disease (PD) as well as in glial cytoplasmic inclusions in multiple system atrophy (MSA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23965852", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Alpha-synuclein (\u03b1-Syn) is the principal protein component of Lewy bodies, a pathological hallmark of Parkinson's disease (PD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23796501", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 276, "text": "Lewy bodies and coarse Lewy neurites are the pathological hallmarks of degenerating neurons in the brains of patients suffering from Parkinson's disease (PD). Recently, the presynaptic protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10327208", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 433, "text": "Lewy bodies and coarse Lewy neurites are the pathological hallmarks of degenerating neurons in the brains of patients suffering from Parkinson's disease (PD). Recently, the presynaptic protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites. This study demonstrates for the first time that extensive and thin alpha-synuclein-immunoreactive inclusions are present in the axonal processes of neurons.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10327208", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "\u00e1-Synuclein is the major protein component of Lewy bodies--the pathological hallmark of Parkinson's disease (PD) and Dementia with Lewy bodies (DLB). Its accumulation into intracellular aggregates is implicated in the process of Lewy body formation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20617407", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9726379", "endSection": "title"}, {"offsetInBeginSection": 199, "offsetInEndSection": 330, "text": "Lewy bodies comprise of aggregated intracellular vesicles and proteins and \u03b1-synuclein is reported to be a major protein component.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26667592", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10764738", "endSection": "title"}, {"offsetInBeginSection": 1267, "offsetInEndSection": 1384, "text": "These findings indicate that alpha-synuclein forms the major filamentous component of Lewy bodies and Lewy neurites..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9600990", "endSection": "abstract"}, {"offsetInBeginSection": 1180, "offsetInEndSection": 1405, "text": "The protein alpha-synuclein appears to be an important structural component of Lewy bodies, an observation spurred by the discovery of point mutations in the alpha-synuclein gene linked to rare cases of autosomal dominant PD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11816795", "endSection": "abstract"}]}, {"body": "Are microtubules marked by glutamylation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26227334", "http://www.ncbi.nlm.nih.gov/pubmed/19700636", "http://www.ncbi.nlm.nih.gov/pubmed/23973077", "http://www.ncbi.nlm.nih.gov/pubmed/26000474", "http://www.ncbi.nlm.nih.gov/pubmed/25959773", "http://www.ncbi.nlm.nih.gov/pubmed/25030760"], "ideal_answer": ["Yes, glutamylation is the most prevalent tubulin posttranslational modification and marks stable microtubules."], "type": "yesno", "id": "58aa0a62396a458e50000007", "snippets": [{"offsetInBeginSection": 1220, "offsetInEndSection": 1385, "text": "Together with detyrosination, glutamylation and other modifications, tubulin acetylation may form a unique 'language' to regulate microtubule structure and function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26227334", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "Glutamylation, the most prevalent tubulin posttranslational modification, marks stable microtubules and regulates recruitment and activity of microtubule- interacting proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25959773", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "Enzymes of the tubulin tyrosine ligase-like (TTLL) family posttranslationally modify and thereby mark microtubules by glutamylation, generating specific recognition sites for microtubule-interacting proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26000474", "endSection": "abstract"}, {"offsetInBeginSection": 705, "offsetInEndSection": 942, "text": " PTMs of the cytoskeleton, including phosphorylation, glycosylation, ubiquitination, detyrosination/tyrosination, (poly)glutamylation and (poly)glycylation, acetylation, sumoylation, and palmitoylation, will be addressed in this chapter.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25030760", "endSection": "abstract"}, {"offsetInBeginSection": 250, "offsetInEndSection": 408, "text": "The tubulin posttranslational modifications: acetylation, detyrosination, polyglutamylation, and polyglycylation play important roles in microtubule functions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23973077", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "In most eukaryotic cells, tubulin is subjected to posttranslational glutamylation, a conserved modification of unclear function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700636", "endSection": "abstract"}]}, {"body": "What is known about the Kub5-Hera/RPRD1B interactome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26819409"], "ideal_answer": ["Ku70-binding protein 5 (Kub5)-Hera (K-H)/RPRD1B maintains genetic integrity by concomitantly minimizing persistent R-loops and promoting repair of DNA double strand breaks (DSBs). Thus, the Kub5-Hera/RPRD1B interactome plays a novel role in preserving genetic stability by regulating DNA mismatch repair."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053843"], "type": "summary", "id": "5881f0f1713cbdfd3d000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "The Kub5-Hera/RPRD1B interactome: a novel role in preserving genetic stability by regulating DNA mismatch repair", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26819409", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Ku70-binding protein 5 (Kub5)-Hera (K-H)/RPRD1B maintains genetic integrity by concomitantly minimizing persistent R-loops and promoting repair of DNA double strand breaks (DSBs)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26819409", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "The Kub5-Hera/RPRD1B interactome: a novel role in preserving genetic stability by regulating DNA mismatch repair.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26819409", "endSection": "title"}]}, {"body": "Willis-Ekbom disease is also known as?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24157095", "http://www.ncbi.nlm.nih.gov/pubmed/24605270", "http://www.ncbi.nlm.nih.gov/pubmed/25510187", "http://www.ncbi.nlm.nih.gov/pubmed/26329430", "http://www.ncbi.nlm.nih.gov/pubmed/25301914", "http://www.ncbi.nlm.nih.gov/pubmed/26725086", "http://www.ncbi.nlm.nih.gov/pubmed/22678064", "http://www.ncbi.nlm.nih.gov/pubmed/25113274", "http://www.ncbi.nlm.nih.gov/pubmed/26329447", "http://www.ncbi.nlm.nih.gov/pubmed/26545868", "http://www.ncbi.nlm.nih.gov/pubmed/24812538", "http://www.ncbi.nlm.nih.gov/pubmed/23963470", "http://www.ncbi.nlm.nih.gov/pubmed/24293752", "http://www.ncbi.nlm.nih.gov/pubmed/22937989", "http://www.ncbi.nlm.nih.gov/pubmed/27292821", "http://www.ncbi.nlm.nih.gov/pubmed/26298776", "http://www.ncbi.nlm.nih.gov/pubmed/23859128", "http://www.ncbi.nlm.nih.gov/pubmed/25093484", "http://www.ncbi.nlm.nih.gov/pubmed/26077324", "http://www.ncbi.nlm.nih.gov/pubmed/26329446", "http://www.ncbi.nlm.nih.gov/pubmed/24892899", "http://www.ncbi.nlm.nih.gov/pubmed/23397977", "http://www.ncbi.nlm.nih.gov/pubmed/26298794", "http://www.ncbi.nlm.nih.gov/pubmed/24992148", "http://www.ncbi.nlm.nih.gov/pubmed/27481386", "http://www.ncbi.nlm.nih.gov/pubmed/24001490", "http://www.ncbi.nlm.nih.gov/pubmed/26429756", "http://www.ncbi.nlm.nih.gov/pubmed/25201131", "http://www.ncbi.nlm.nih.gov/pubmed/15165536", "http://www.ncbi.nlm.nih.gov/pubmed/26874840", "http://www.ncbi.nlm.nih.gov/pubmed/24246378", "http://www.ncbi.nlm.nih.gov/pubmed/25230997", "http://www.ncbi.nlm.nih.gov/pubmed/27662970"], "ideal_answer": ["Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common movement disorder characterized by an uncontrollable urge to move because of uncomfortable, sometimes painful sensations in the legs with a diurnal variation and a release with movement."], "type": "factoid", "id": "5891f9e549702f2e01000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Defining the phenotype of restless legs syndrome/Willis-Ekbom disease (RLS/WED): a clinical and polysomnographic study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26725086", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 279, "text": "Clinical features variability between familial and sporadic restless legs syndrome/Willis-Ekbom disease (RLS/WED) has been previously reported. With this retrospective cohort study, we aimed to determine the clinical and polysomnographic characteristics of 400 RLS/WED patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26725086", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "\"Emplotted Narratives\" and Structured \"Behavioral Observations\" Supporting the Diagnosis of Willis-Ekbom Disease/Restless Legs Syndrome in Children with Neurodevelopmental Conditions.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292821", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 307, "text": "BACKGROUND: Willis-Ekbom disease/restless legs syndrome (WED/RLS) seems to be a frequent cause of intractable chronic insomnia (ICI) but is under-recognized in children/adolescents with neurodevelopmental conditions (NDCs), as many patients do not have the ability to express the underlying \"urge-to-move\". ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292821", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common movement disorder characterised by an uncontrollable urge to move because of uncomfortable, sometimes painful sensations in the legs with a diurnal variation and a release with movement. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27481386", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 306, "text": "OBJECTIVE: In the present study, we tested the hypothesis that having migraine in middle age is related to late-life parkinsonism and a related disorder, restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED).METHODS: The AGES-Reykjavik cohort (born 1907-1935) has been followed since 1967.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230997", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "BACKGROUND: Reported prevalence of restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), varies from country to country, and methodologic inconsistencies limit comparison of data.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25510187", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensory-motor neurological disorder with a circadian component.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22678064", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "There is no consensus about mechanisms underlying restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26429756", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common sensorimotor disorder that can generally be effectively managed in the primary care clinic", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26077324", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "Reported prevalence of restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), varies from country to country, and methodologic inconsistencies limit comparison of data", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25510187", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom Disease (WED), is a sensorimotor disorder for which the exact pathophysiology remains unclear", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25201131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensorimotor disorder that can result in considerable sleep disruption", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25093484", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 448, "text": "The SP790 study (ClinicalTrials.gov, NCT00136045) showed benefits of rotigotine over placebo in improving symptom severity of restless legs syndrome (RLS), also known as Willis-Ekbom disease, on the International Restless Legs Syndrome Study Group rating scale (IRLS), Clinical Global Impression item 1 (CGI-1), RLS 6-item questionnaire (RLS-6), and the RLS-quality of life questionnaire (RLS-QoL) in patients with moderate to severe idiopathic RLS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246378", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 285, "text": "In the present study, we tested the hypothesis that having migraine in middle age is related to late-life parkinsonism and a related disorder, restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED).The AGES-Reykjavik cohort (born 1907-1935) has been followed since 1967", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230997", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Restless leg syndrome (RLS), also known as Willis-Ekbom disease, is a condition that includes sensations such as crawling, tingling, or aching in the limbs and creates an urge to move", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992148", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "Recent genome-wide association studies (GWAS) for Caucasians identified several allelic variants associated with increased risk of developing restless legs syndrome (RLS), also known as Willis-Ekbom disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances in the field", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22937989", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "BACKGROUND: Reported prevalence of restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), varies from country to country, and methodologic inconsistencies limit comparison of data. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25510187", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "OBJECTIVES: Both restless legs syndrome ([RLS], also known as Willis-Ekbom Disease [WED]) and depression are common during pregnancy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24812538", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensory-motor neurological disorder with a circadian component. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22678064", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "OBJECTIVE: In the present study, we tested the hypothesis that having migraine in middle age is related to late-life parkinsonism and a related disorder, restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230997", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 263, "text": "BACKGROUND: Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances in the field. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22937989", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "STUDY OBJECTIVES: Recent genome-wide association studies (GWAS) for Caucasians identified several allelic variants associated with increased risk of developing restless legs syndrome (RLS), also known as Willis-Ekbom disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 462, "text": "BACKGROUND: The SP790 study (ClinicalTrials.gov, NCT00136045) showed benefits of rotigotine over placebo in improving symptom severity of restless legs syndrome (RLS), also known as Willis-Ekbom disease, on the International Restless Legs Syndrome Study Group rating scale (IRLS), Clinical Global Impression item 1 (CGI-1), RLS 6-item questionnaire (RLS-6), and the RLS-quality of life questionnaire (RLS-QoL) in patients with moderate to severe idiopathic RLS. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246378", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Psychological distress in patients with restless legs syndrome (Willis-Ekbom disease): a population-based door-to-door survey in rural Ecuador.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25510187", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances in the field.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22937989", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Restless leg syndrome/Willis-Ekbom disease has brain iron deficiency that produces excessive dopamine and known genetic risks, some of which contribute to the brain iron deficiency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26329430", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common sensorimotor disorder that can generally be effectively managed in the primary care clinic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26077324", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensorimotor disorder that can result in considerable sleep disruption.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25093484", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 449, "text": "The SP790 study (ClinicalTrials.gov, NCT00136045) showed benefits of rotigotine over placebo in improving symptom severity of restless legs syndrome (RLS), also known as Willis-Ekbom disease, on the International Restless Legs Syndrome Study Group rating scale (IRLS), Clinical Global Impression item 1 (CGI-1), RLS 6-item questionnaire (RLS-6), and the RLS-quality of life questionnaire (RLS-QoL) in patients with moderate to severe idiopathic RLS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246378", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Recent genome-wide association studies (GWAS) for Caucasians identified several allelic variants associated with increased risk of developing restless legs syndrome (RLS), also known as Willis-Ekbom disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 286, "text": "In the present study, we tested the hypothesis that having migraine in middle age is related to late-life parkinsonism and a related disorder, restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED).The AGES-Reykjavik cohort (born 1907-1935) has been followed since 1967.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230997", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Reported prevalence of restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), varies from country to country, and methodologic inconsistencies limit comparison of data.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25510187", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is characterised by abnormal sensations in the legs as well as dysaesthesia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27662970", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 398, "text": "STUDY OBJECTIVES: Recent genome-wide association studies (GWAS) for Caucasians identified several allelic variants associated with increased risk of developing restless legs syndrome (RLS), also known as Willis-Ekbom disease. Although the pathogenic mechanisms of RLS are not entirely understood, it is becoming increasingly evident that many diseases such as RLS can be attributed to an epistasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "OBJECTIVE: Restless legs syndrome, now called Willis-Ekbom Disease (RLS/WED), is a sensorimotor-related sleep disorder. Little is known of the effect of RLS/WED on motor function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25113274", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "OBJECTIVE: Restless legs syndrome, now called Willis-Ekbom Disease (RLS/WED), is a sensorimotor-related sleep disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25113274", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "STUDY OBJECTIVES: Recent genome-wide association studies (GWAS) for Caucasians identified several allelic variants associated with increased risk of developing restless legs syndrome (RLS), also known as Willis-Ekbom disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Upper limb function is normal in patients with restless legs syndrome (Willis-Ekbom Disease).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25113274", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 461, "text": "BACKGROUND: The SP790 study (ClinicalTrials.gov, NCT00136045) showed benefits of rotigotine over placebo in improving symptom severity of restless legs syndrome (RLS), also known as Willis-Ekbom disease, on the International Restless Legs Syndrome Study Group rating scale (IRLS), Clinical Global Impression item 1 (CGI-1), RLS 6-item questionnaire (RLS-6), and the RLS-quality of life questionnaire (RLS-QoL) in patients with moderate to severe idiopathic RLS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246378", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom Disease (WED), is a sensorimotor disorder for which the exact pathophysiology remains unclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25201131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common movement disorder characterised by an uncontrollable urge to move because of uncomfortable, sometimes painful sensations in the legs with a diurnal variation and a release with movement.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27481386", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "The relationship among restless legs syndrome (Willis-Ekbom Disease), hypertension, cardiovascular disease, and cerebrovascular disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23963470", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Willis-Ekbom Disease or Restless Legs Syndrome?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26298794", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Living with Restless Legs Syndrome/Willis-Ekbom Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26329446", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Restless Legs Syndrome/Willis-Ekbom Disease Morbidity: Burden, Quality of Life, Cardiovascular Aspects, and Sleep.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26329447", "endSection": "title"}]}, {"body": "List two most common symptoms of Aagenaes syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19498211", "http://www.ncbi.nlm.nih.gov/pubmed/23626552", "http://www.ncbi.nlm.nih.gov/pubmed/10968776", "http://www.ncbi.nlm.nih.gov/pubmed/25039919", "http://www.ncbi.nlm.nih.gov/pubmed/9350821", "http://www.ncbi.nlm.nih.gov/pubmed/24086631", "http://www.ncbi.nlm.nih.gov/pubmed/16635916", "http://www.ncbi.nlm.nih.gov/pubmed/27614462", "http://www.ncbi.nlm.nih.gov/pubmed/25317502", "http://www.ncbi.nlm.nih.gov/pubmed/8278949", "http://www.ncbi.nlm.nih.gov/pubmed/11446017", "http://www.ncbi.nlm.nih.gov/pubmed/20170991", "http://www.ncbi.nlm.nih.gov/pubmed/12712065"], "ideal_answer": ["Aagenaes syndrome, also called lymphoedema cholestasis syndrome 1, is characterized by neonatal intrahepatic cholestasis, often lessening and becoming intermittent with age and severe chronic lymphoedema, mainly affecting the lower extremities."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:6691", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012816"], "type": "list", "id": "5895f9cf78275d0c4a000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "Aagenaes syndrome, also called lymphoedema cholestasis syndrome 1 (LSC1), is characterized by neonatal intrahepatic cholestasis, often lessening and becoming intermittent with age and severe chronic lymphoedema, mainly affecting the lower extremities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27614462", "endSection": "abstract"}, {"offsetInBeginSection": 127, "offsetInEndSection": 319, "text": "In this study, 17 out of 20 Norweigian adult patients with lymphedema cholestasis syndrome 1 (LCS1)/Aagenaes syndrome were examined. The patients exhibited lymphedema and sporadic cholestasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25317502", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 268, "text": "BACKGROUND: Lymphedema-cholestasis syndrome (LCS; Aagenaes syndrome) is a rare autosomal recessive disorder, characterized by 1) neonatal intrahepatic cholestasis, often lessening and becoming intermittent with age, and 2) severe chronic lymphedema, mainly lower limb.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24086631", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 325, "text": "The disease was thought to be caused by a congenital cholestatic syndrome associated with intermittent oedema in childhood, resembling the rare Aagenaes syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23626552", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Do patients with lymphoedema cholestasis syndrome 1/Aagenaes syndrome need dietary counselling outside cholestatic episodes?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20170991", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "BACKGROUND & AIMS: Patients with lymphoedema cholestasis syndrome 1/Aagenaes Syndrome need a fat reduced diet when cholestatic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20170991", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Aagenaes syndrome, also called Lymphedema Cholestasis Syndrome (LSC 1), is a form of idiopathic familial intrahepatic cholestasis associated with lymphedema of the lower extremities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19498211", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "Aagenaes syndrome, also called Lymphedema Cholestasis Syndrome (LSC 1), is a form of idiopathic familial intrahepatic cholestasis associated with lymphedema of the lower extremities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19498211", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Parent-child transmission of infantile cholestasis with lymphoedema (Aagenaes syndrome).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9350821", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10968776", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Lymphedema-cholestasis syndrome (LCS, Aagenaes syndrome) is the only known form of hereditary lymphedema associated with cholestasis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12712065", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "OBJECTIVE: To investigate the prognosis of liver disease in Aagenaes syndrome (lymphoedema cholestasis syndrome 1 (LCS1)), which is an autosomal recessive inherited syndrome consisting of neonatal cholestasis with intermittent cholestatic episodes in childhood into adulthood and development of lymphoedema. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16635916", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "BACKGROUND: Lymphedema-cholestasis syndrome (LCS; Aagenaes syndrome) is a rare autosomal recessive disorder, characterized by 1) neonatal intrahepatic cholestasis, often lessening and becoming intermittent with age, and 2) severe chronic lymphedema, mainly lower limb. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24086631", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "[Aagenaes syndrome--lymphedema and intrahepatic cholestasis].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11446017", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Parent-child transmission of infantile cholestasis with lymphoedema (Aagenaes syndrome).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9350821", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Hereditary lymphedema, characteristics, and variations in 17 adult patients with lymphedema cholestasis syndrome 1/Aagenaes syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25317502", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Lymphedema-cholestasis syndrome (LCS, Aagenaes syndrome) is the only known form of hereditary lymphedema associated with cholestasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12712065", "endSection": "abstract"}]}, {"body": "Which are the side effects during tacrine administration in patients with Alzheimer's Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9808364", "http://www.ncbi.nlm.nih.gov/pubmed/22034058", "http://www.ncbi.nlm.nih.gov/pubmed/9226744", "http://www.ncbi.nlm.nih.gov/pubmed/9408186", "http://www.ncbi.nlm.nih.gov/pubmed/17883890", "http://www.ncbi.nlm.nih.gov/pubmed/8237620", "http://www.ncbi.nlm.nih.gov/pubmed/7737527", "http://www.ncbi.nlm.nih.gov/pubmed/19270633", "http://www.ncbi.nlm.nih.gov/pubmed/7579023", "http://www.ncbi.nlm.nih.gov/pubmed/25858345", "http://www.ncbi.nlm.nih.gov/pubmed/19370562", "http://www.ncbi.nlm.nih.gov/pubmed/8312036", "http://www.ncbi.nlm.nih.gov/pubmed/9209244", "http://www.ncbi.nlm.nih.gov/pubmed/2107926", "http://www.ncbi.nlm.nih.gov/pubmed/8119309", "http://www.ncbi.nlm.nih.gov/pubmed/22192081", "http://www.ncbi.nlm.nih.gov/pubmed/9050085", "http://www.ncbi.nlm.nih.gov/pubmed/7510447", "http://www.ncbi.nlm.nih.gov/pubmed/17636619", "http://www.ncbi.nlm.nih.gov/pubmed/10796507", "http://www.ncbi.nlm.nih.gov/pubmed/1406817", "http://www.ncbi.nlm.nih.gov/pubmed/7868848", "http://www.ncbi.nlm.nih.gov/pubmed/10325444", "http://www.ncbi.nlm.nih.gov/pubmed/7919566", "http://www.ncbi.nlm.nih.gov/pubmed/12939598", "http://www.ncbi.nlm.nih.gov/pubmed/8139084"], "ideal_answer": ["The side effects during tacrine administration in patients with Alzheimer's Disease are:\r\n1) Hepatotoxicity\r\n2) Gastrointestinal (diarrhea, anorexia, dyspepsia, abdominal pain, nausea, vomiting)\r\n3) Mitochondrial impairement"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4274748", "http://www.biosemantics.org/jochem#4274748", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013619"], "type": "list", "id": "58a2fac960087bc10a000009", "snippets": [{"offsetInBeginSection": 366, "offsetInEndSection": 537, "text": "Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25858345", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Tacrine and its analogues impair mitochondrial function and bioenergetics: a lipidomic analysis in rat brain.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22192081", "endSection": "title"}, {"offsetInBeginSection": 127, "offsetInEndSection": 235, "text": "However, its low therapeutic efficiency and a high incidence of side effects have limited its clinical use. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22192081", "endSection": "abstract"}, {"offsetInBeginSection": 1839, "offsetInEndSection": 2098, "text": "Tacrine induced significant perturbations in the mitochondrial PL profile, which were detected by means of changes in the relative abundance of phosphatidylcholine (PC), PE, phosphatidylinositol (PI) and CL and by the presence of oxidized phosphatidylserines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22192081", "endSection": "abstract"}, {"offsetInBeginSection": 2446, "offsetInEndSection": 2595, "text": "These results indicate that tacrine and its analogues impair mitochondrial function and bioenergetics, thus compromising the activity of brain cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22192081", "endSection": "abstract"}, {"offsetInBeginSection": 389, "offsetInEndSection": 561, "text": "Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370562", "endSection": "abstract"}, {"offsetInBeginSection": 262, "offsetInEndSection": 617, "text": "The antidementives are well tolerated and undesired effects are rare; except hepatotoxicity of tacrine and gastrointestinal side effects of donepezil, rivastigmine, galantamin and tacrine that result from acetylcholinesterase inhibition. Nausea, diarrhea, vomiting, and weight loss are the most common side effects of the acetylcholinesterase inhibitors. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270633", "endSection": "abstract"}, {"offsetInBeginSection": 2984, "offsetInEndSection": 3048, "text": "Raised serum liver enzymes was the major reason for withdrawal. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17636619", "endSection": "abstract"}, {"offsetInBeginSection": 3208, "offsetInEndSection": 3486, "text": "Gastrointestinal side effects (diarrhoea, anorexia, dyspepsia and abdominal pain) were the other major cause of adverse events and for withdrawal, and the odds ratio for withdrawal was also significantly different from one in favour of the control group (OR 3.8; 95%CI 2.8-5.1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17636619", "endSection": "abstract"}, {"offsetInBeginSection": 1145, "offsetInEndSection": 1231, "text": "To determine the clinical efficacy of tacrine for the symptoms of Alzheimer's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17636619", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 485, "text": "In Alzheimer's disease, cognition now responds to several drugs. Anticholinesterases target the acetylcholine deficit. In mild-to-moderate Alzheimer's disease, they all provide significant benefit versus placebo on the Alzheimer's Disease Assessment ScheduleCognitive Section (ADAS-Cog), Side effects, in 5% to 15% of cases, include nausea, vomiting, diarrhea, anorexia, and dizziness. Tacrine, the leading anticholinesterase, caused frequent hepatic enzyme elevation and was withdrawn", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22034058", "endSection": "abstract"}, {"offsetInBeginSection": 224, "offsetInEndSection": 637, "text": "This 12-week randomised, double-blind, placebo-controlled study was undertaken to evaluate the ability of silymarin to antagonise or prevent the hepatotoxic effects of tacrine and to analyse its action on tacrine efficacy and tolerability.METHODS: Outpatients suffering from mild-to-moderate dementia of the Alzheimer type were randomly assigned to two treatment groups: tacrine + silymarin and tacrine + placebo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10325444", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Hepatotoxic effects of tacrine administration in patients with Alzheimers disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8139084", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8139084", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Tremulous jaw movements produced by acute tacrine administration: possible relation to parkinsonian side effects.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9050085", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Administration of tacrine (THA) for the treatment of Alzheimer's disease results in a reversible hepatotoxicity in 30-50% of patients, as indicated by an increase in transaminase levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9808364", "endSection": "abstract"}, {"offsetInBeginSection": 62, "offsetInEndSection": 637, "text": "Tacrine, the first drug marketed for Alzheimer's disease (AD), induces an elevation of serum liver transaminase prohibiting an effective dosage in many patients. This 12-week randomised, double-blind, placebo-controlled study was undertaken to evaluate the ability of silymarin to antagonise or prevent the hepatotoxic effects of tacrine and to analyse its action on tacrine efficacy and tolerability.METHODS: Outpatients suffering from mild-to-moderate dementia of the Alzheimer type were randomly assigned to two treatment groups: tacrine + silymarin and tacrine + placebo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10325444", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 637, "text": "BACKGROUND: Silymarin is a well-known hepatoprotective agent. Tacrine, the first drug marketed for Alzheimer's disease (AD), induces an elevation of serum liver transaminase prohibiting an effective dosage in many patients. This 12-week randomised, double-blind, placebo-controlled study was undertaken to evaluate the ability of silymarin to antagonise or prevent the hepatotoxic effects of tacrine and to analyse its action on tacrine efficacy and tolerability.METHODS: Outpatients suffering from mild-to-moderate dementia of the Alzheimer type were randomly assigned to two treatment groups: tacrine + silymarin and tacrine + placebo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10325444", "endSection": "abstract"}, {"offsetInBeginSection": 62, "offsetInEndSection": 763, "text": "Tacrine, the first drug marketed for Alzheimer's disease (AD), induces an elevation of serum liver transaminase prohibiting an effective dosage in many patients. This 12-week randomised, double-blind, placebo-controlled study was undertaken to evaluate the ability of silymarin to antagonise or prevent the hepatotoxic effects of tacrine and to analyse its action on tacrine efficacy and tolerability.METHODS: Outpatients suffering from mild-to-moderate dementia of the Alzheimer type were randomly assigned to two treatment groups: tacrine + silymarin and tacrine + placebo. The study was double-blind for silymarin and open for tacrine and was conducted in 22 French neurology and geriatric centres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10325444", "endSection": "abstract"}, {"offsetInBeginSection": 62, "offsetInEndSection": 223, "text": "Tacrine, the first drug marketed for Alzheimer's disease (AD), induces an elevation of serum liver transaminase prohibiting an effective dosage in many patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10325444", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8139084", "endSection": "title"}]}, {"body": "Is synapsin a phosphoprotein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26425441", "http://www.ncbi.nlm.nih.gov/pubmed/26400944", "http://www.ncbi.nlm.nih.gov/pubmed/25843720", "http://www.ncbi.nlm.nih.gov/pubmed/25576091", "http://www.ncbi.nlm.nih.gov/pubmed/26538647", "http://www.ncbi.nlm.nih.gov/pubmed/25972175", "http://www.ncbi.nlm.nih.gov/pubmed/25967550", "http://www.ncbi.nlm.nih.gov/pubmed/26670182"], "ideal_answer": ["Yes, synapsin is an evolutionarily conserved presynaptic phosphoprotein."], "type": "yesno", "id": "58a8962338c171fb5b000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Synapsin is an evolutionarily conserved presynaptic phosphoprotein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26670182", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Synapsins as a family of presynaptic terminal phosphoprotein participates in neuronal development", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25576091", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "Synapsin III (SynIII) is a phosphoprotein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25843720", "endSection": "abstract"}, {"offsetInBeginSection": 285, "offsetInEndSection": 325, "text": "The neuronal phosphoprotein synapsin III", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25967550", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Synapsin II is a member of the neuronal phosphoprotein family.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26425441", "endSection": "abstract"}, {"offsetInBeginSection": 457, "offsetInEndSection": 480, "text": "phosphoprotein synapsin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26538647", "endSection": "abstract"}]}, {"body": "Is Thalidomide currently a marketed drug?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11604049", "http://www.ncbi.nlm.nih.gov/pubmed/26652728", "http://www.ncbi.nlm.nih.gov/pubmed/10512502", "http://www.ncbi.nlm.nih.gov/pubmed/9987477", "http://www.ncbi.nlm.nih.gov/pubmed/22650376", "http://www.ncbi.nlm.nih.gov/pubmed/11558112", "http://www.ncbi.nlm.nih.gov/pubmed/11899395", "http://www.ncbi.nlm.nih.gov/pubmed/11091366", "http://www.ncbi.nlm.nih.gov/pubmed/8592478", "http://www.ncbi.nlm.nih.gov/pubmed/25573527"], "ideal_answer": ["Several mechanisms for the teratogenic action of thalidomide are currently under review, but this mode of action of the drug still remains unclear and we review evidence-based hypotheses for the teratogenicity of thalidomide. Thalidomide is considered the drug of choice for the treatment of ENL, but for other conditions, it is recommended only when resistance to the currently available form of therapy is encountered. THE USE OF A DRUG WITH A TEMPORARY MARKETING AUTHORISATION: Thalidomide is currently available in France for nominative or cohort use with a temporary marketing authorisation (TMA). Examples of the basis for such regulation are drawn from historical situations (thalidomide, benoxaprofen) as well as currently marketed drugs (arylpropionic acids, disopyramide, indacrinone). In 1998 the US Food and Drug Administration approved thalidomide exclusively for the treatment of ENL, and strict conditions were stipulated for its use in order to prevent teratogenic adverse effects. The US Food and Drug Administration (FDA) has approved Thalomid (thalidomide) capsules for the acute treatment of the cutaneous manifestations of moderate to severe ENL. The revival of thalidomide began shortly after the drug was withdrawn from the market because of its teratogenic properties.", "Thalidomide is currently used to treat multiple Myeloma, possibly POEMS (Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes ) syndrome and IBS"], "type": "yesno", "id": "58a0d87a78275d0c4a000053", "snippets": [{"offsetInBeginSection": 210, "offsetInEndSection": 336, "text": "In this retrospective study, pharmacy claims were analyzed for those patients with a diagnosis of MM who received thalidomide,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26652728", "endSection": "abstract"}, {"offsetInBeginSection": 490, "offsetInEndSection": 730, "text": "The Japanese POEMS syndrome with Thalidomide (J-POST) Trial is a phase II/III multicentre, double-blinded, randomised, controlled trial that aims to evaluate the efficacy and safety of a 24-week treatment with thalidomide in POEMS syndrome,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25573527", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 188, "text": "Thalidomide could relieve clinical symptoms and intestinal mucosal lesions effectively in children with refractory inflammatory bowel disease (IBD) from the pre-clinical study.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24931258", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Thalidomide is now available as an investigational drug in the USA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8592478", "endSection": "abstract"}, {"offsetInBeginSection": 826, "offsetInEndSection": 1046, "text": "The STEPStrade mark (System for Thalidomide Education and Prescribing Safety) Program has been developed by Celgene, the commercial manufacturer of thalidomide, to ensure compliance with prescription and usage protocols.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11091366", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 24, "text": "New uses of thalidomide.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8592478", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Thalidomide is an anti-angiogenesis agent that currently is being evaluated in the treatment of various types of cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11899395", "endSection": "abstract"}, {"offsetInBeginSection": 993, "offsetInEndSection": 1160, "text": "The comeback of thalidomide to the legitimate status of a marketed drug came in 1998 when it received FDA approval for the treatment of erythema nodosum leprosum (ENL)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22650376", "endSection": "abstract"}, {"offsetInBeginSection": 643, "offsetInEndSection": 836, "text": "Thalidomide is considered the drug of choice for the treatment of ENL, but for other conditions, it is recommended only when resistance to the currently available form of therapy is encountered", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11558112", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "Thalidomide is an anti-inflammatory and anti-angiogenic drug currently used for the treatment of several diseases, including erythema nodosum leprosum, which occurs in patients with lepromatous leprosy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22695124", "endSection": "abstract"}, {"offsetInBeginSection": 279, "offsetInEndSection": 560, "text": "Thalidomide, once banned, has returned to the center of controversy with the Food and Drug Administration's (FDA's) announcement that thalidomide will be placed on the market for the treatment of erythema nodosum leprosum, a severe dermatological complication of Hansen's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9987477", "endSection": "abstract"}, {"offsetInBeginSection": 265, "offsetInEndSection": 337, "text": "In 1998, FDA approved the marketing of thalidomide (Thalomid, Celgene). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10512502", "endSection": "abstract"}, {"offsetInBeginSection": 1625, "offsetInEndSection": 1826, "text": "In 1998 the US Food and Drug Administration approved thalidomide exclusively for the treatment of ENL, and strict conditions were stipulated for its use in order to prevent teratogenic adverse effects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11604049", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 294, "text": "BACKGROUND: The use of thalidomide during the 1950s resulted in teratogenic effects in thousands of infants. Although thalidomide is currently approved for the treatment of a complication of leprosy, it is commercially available to treat other diseases through a controlled distribution system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11091366", "endSection": "abstract"}, {"offsetInBeginSection": 994, "offsetInEndSection": 1162, "text": "The comeback of thalidomide to the legitimate status of a marketed drug came in 1998 when it received FDA approval for the treatment of erythema nodosum leprosum (ENL).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22650376", "endSection": "abstract"}]}, {"body": "Which enzymes synthesize catecholamines in adrenal glands?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23508458", "http://www.ncbi.nlm.nih.gov/pubmed/12573802", "http://www.ncbi.nlm.nih.gov/pubmed/2427537", "http://www.ncbi.nlm.nih.gov/pubmed/20634527", "http://www.ncbi.nlm.nih.gov/pubmed/23903565", "http://www.ncbi.nlm.nih.gov/pubmed/8105763", "http://www.ncbi.nlm.nih.gov/pubmed/15135223", "http://www.ncbi.nlm.nih.gov/pubmed/3777139", "http://www.ncbi.nlm.nih.gov/pubmed/9061614", "http://www.ncbi.nlm.nih.gov/pubmed/9578504", "http://www.ncbi.nlm.nih.gov/pubmed/23469", "http://www.ncbi.nlm.nih.gov/pubmed/10423683", "http://www.ncbi.nlm.nih.gov/pubmed/24032", "http://www.ncbi.nlm.nih.gov/pubmed/7602797", "http://www.ncbi.nlm.nih.gov/pubmed/25903953", "http://www.ncbi.nlm.nih.gov/pubmed/26187454", "http://www.ncbi.nlm.nih.gov/pubmed/15094322", "http://www.ncbi.nlm.nih.gov/pubmed/6119179", "http://www.ncbi.nlm.nih.gov/pubmed/22473696", "http://www.ncbi.nlm.nih.gov/pubmed/6139026", "http://www.ncbi.nlm.nih.gov/pubmed/1969734", "http://www.ncbi.nlm.nih.gov/pubmed/15345906", "http://www.ncbi.nlm.nih.gov/pubmed/22934574"], "ideal_answer": ["The enzymes that synthesize catecholamines in adrenal glands are:\n1) Tyrosine Hydroxylase (TH)\n2) Aromatic L-amino acid decarboxylase (AAAD)\n3) Dopamine \u03b2-hydroxylase (DBH)\n4) Phenylethanolamine N-methyltransferase (PNMT)"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000311", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002395", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000302", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000313"], "type": "list", "id": "589c215778275d0c4a00003c", "snippets": [{"offsetInBeginSection": 318, "offsetInEndSection": 699, "text": "We analyzed the mRNA levels of catecholamine-synthesizing enzymes: tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AAAD), dopamine-\u03b2-hydroxylase (DBH) and phenylethanolamine N-methyltransferase (PNMT) in adrenal glands of 18 pigs with chronic systolic non-ischaemic HF (tachycardia-induced cardiomyopathy due to right ventricle pacing) and 6 sham-operated controls.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25903953", "endSection": "abstract"}, {"offsetInBeginSection": 212, "offsetInEndSection": 728, "text": "This study aimed to investigate physical exercise-related changes in gene expression of catecholamine biosynthetic enzymes (tyrosine hydroxylase, dopamine-\u00df-hydroxylase and phenylethanolamine N-methyltransferase) and cyclic adenosine monophosphate response element-binding (CREB) in the adrenal medulla, concentrations of catecholamines and corticosterone (CORT) in the plasma and the weight of adrenal glands of chronically psychosocially stressed adult rats exposed daily to 20 min treadmill running for 12 weeks. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903565", "endSection": "abstract"}, {"offsetInBeginSection": 1435, "offsetInEndSection": 1731, "text": "In the adrenal medulla, despite the absence of morphological changes, immunohistochemistry for tyrosine hydroxylase, dopamine \u03b2-hydroxylase and phenyl-ethanolamine-N-methyltransferase demonstrated an increased immunopositivity for these cathecolamine-synthesizing enzymes after intense exercise. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22473696", "endSection": "abstract"}, {"offsetInBeginSection": 623, "offsetInEndSection": 1152, "text": "Using isolated adrenal medulla we observed no difference in basal catecholamine secretion percentile between obese and lean animals. However, the percentile of catecholamine secretion stimulated by high K+ concentration was lower in the obese group. There was a decrease in the tyrosine hydroxylase enzyme expression (57.3%, P<0.004) in adrenal glands of obese mice. Interestingly, the expression of dopamine beta-hydroxylase was also reduced (47.0%, P<0.005). Phenylethanolamine N-methyltransferase expression was not affected. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15094322", "endSection": "abstract"}, {"offsetInBeginSection": 103, "offsetInEndSection": 534, "text": "Differential housing (single vs. group) and social defeat of rats is known to alter the activity of catecholamine-synthesizing enzymes in the medulla. The present studies examined the effect of 70 days of triad (3 rats per large cage) and individual housing of male rats on adrenal mRNA levels of tyrosine hydroxylase (TH), dopamine-beta-hydroxylase (DBH) and phenylethanolamine-N-methyltransferase (PNMT) and on TH protein levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15345906", "endSection": "abstract"}, {"offsetInBeginSection": 350, "offsetInEndSection": 651, "text": "As a first step toward understanding the molecular mechanisms by which catecholamine synthesis is controlled in the tumor, we measured the levels of mRNA coding for the catecholamine synthesizing enzyme, tyrosine hydroxylase (TH) and catecholamines in 6 pheochromocytomas and 2 normal adrenal glands. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7602797", "endSection": "abstract"}, {"offsetInBeginSection": 863, "offsetInEndSection": 1064, "text": "We also examined the gene expression of the messengers of other catecholamine synthesizing enzymes, dopamine beta-hydroxylase (DBH) and aromatic 1-amino acid decarboxylase (AADC) in pheochromocytomas. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7602797", "endSection": "abstract"}, {"offsetInBeginSection": 1146, "offsetInEndSection": 1334, "text": "These findings indicate that catecholamine overproduction in pheochromocytomas is mediated by the overexpression of genes coding for catecholamines synthesizing enzymes, TH, DBH, and AADC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7602797", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 208, "text": "he present study investigated the cellular localization of 3 catecholamine biosynthetic enzymes, tyrosine hydroxylase (TH), dopamine beta-hydroxylase (DBH), and phenylethanolamine N-methyltransferase (PNMT) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20634527", "endSection": "abstract"}, {"offsetInBeginSection": 713, "offsetInEndSection": 834, "text": "tyrosine hydroxylase (TH) the rate limiting catecholamine biosynthetic enzyme and also of dopamine beta-hydroxylase (DBH)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15135223", "endSection": "abstract"}, {"offsetInBeginSection": 339, "offsetInEndSection": 483, "text": "tyrosine hydroxylase (TH), dopamine-beta-hydroxylase (DBH) and phenylethanolamine-N-methyltransferase (PNMT) in sympathetic ganglia and adrenals", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6119179", "endSection": "abstract"}, {"offsetInBeginSection": 212, "offsetInEndSection": 726, "text": "This study aimed to investigate physical exercise-related changes in gene expression of catecholamine biosynthetic enzymes (tyrosine hydroxylase, dopamine-\u00df-hydroxylase and phenylethanolamine N-methyltransferase) and cyclic adenosine monophosphate response element-binding (CREB) in the adrenal medulla, concentrations of catecholamines and corticosterone (CORT) in the plasma and the weight of adrenal glands of chronically psychosocially stressed adult rats exposed daily to 20 min treadmill running for 12 weeks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903565", "endSection": "abstract"}, {"offsetInBeginSection": 350, "offsetInEndSection": 649, "text": "As a first step toward understanding the molecular mechanisms by which catecholamine synthesis is controlled in the tumor, we measured the levels of mRNA coding for the catecholamine synthesizing enzyme, tyrosine hydroxylase (TH) and catecholamines in 6 pheochromocytomas and 2 normal adrenal glands", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7602797", "endSection": "abstract"}, {"offsetInBeginSection": 318, "offsetInEndSection": 698, "text": "We analyzed the mRNA levels of catecholamine-synthesizing enzymes: tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AAAD), dopamine-\u03b2-hydroxylase (DBH) and phenylethanolamine N-methyltransferase (PNMT) in adrenal glands of 18 pigs with chronic systolic non-ischaemic HF (tachycardia-induced cardiomyopathy due to right ventricle pacing) and 6 sham-operated controls", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25903953", "endSection": "abstract"}, {"offsetInBeginSection": 212, "offsetInEndSection": 727, "text": "This study aimed to investigate physical exercise-related changes in gene expression of catecholamine biosynthetic enzymes (tyrosine hydroxylase, dopamine-\u00df-hydroxylase and phenylethanolamine N-methyltransferase) and cyclic adenosine monophosphate response element-binding (CREB) in the adrenal medulla, concentrations of catecholamines and corticosterone (CORT) in the plasma and the weight of adrenal glands of chronically psychosocially stressed adult rats exposed daily to 20 min treadmill running for 12 weeks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903565", "endSection": "abstract"}, {"offsetInBeginSection": 228, "offsetInEndSection": 482, "text": "We used immunocytochemistry to study the ontogeny of leu-enkephalin and the catecholamine-synthesizing enzymes dopamine beta-hydroxylase and phenylethanolamine N-methyltransferase in adjacent sections of 14 fetal rhesus and 31 fetal human adrenal glands.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2427537", "endSection": "abstract"}, {"offsetInBeginSection": 350, "offsetInEndSection": 650, "text": "As a first step toward understanding the molecular mechanisms by which catecholamine synthesis is controlled in the tumor, we measured the levels of mRNA coding for the catecholamine synthesizing enzyme, tyrosine hydroxylase (TH) and catecholamines in 6 pheochromocytomas and 2 normal adrenal glands.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7602797", "endSection": "abstract"}]}, {"body": "How many cysteines have alpha-defensins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24386139", "http://www.ncbi.nlm.nih.gov/pubmed/24557891", "http://www.ncbi.nlm.nih.gov/pubmed/25970658", "http://www.ncbi.nlm.nih.gov/pubmed/22168415"], "ideal_answer": ["Alpha defensins contain six cysteines, which form three well defined disulfide bridges under oxidizing conditions."], "type": "factoid", "id": "58a9c532396a458e50000002", "snippets": [{"offsetInBeginSection": 178, "offsetInEndSection": 293, "text": "Alpha defensins contain six cysteines, which form three well defined disulfide bridges under oxidizing conditions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25970658", "endSection": "abstract"}, {"offsetInBeginSection": 579, "offsetInEndSection": 636, "text": "All three kinds of defensins have six conserved cysteines", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24557891", "endSection": "abstract"}, {"offsetInBeginSection": 457, "offsetInEndSection": 522, "text": " There are six cysteines in the sequence of mature CFBD peptide, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24386139", "endSection": "abstract"}, {"offsetInBeginSection": 56, "offsetInEndSection": 179, "text": "They typically contain six conserved cysteines whose three intramolecular disulfides stabilize a largely \u03b2-sheet structure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22168415", "endSection": "abstract"}]}, {"body": "Could BRCA gene test used for breast and ovarian cancer risk?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24698998", "http://www.ncbi.nlm.nih.gov/pubmed/20221693", "http://www.ncbi.nlm.nih.gov/pubmed/18515440", "http://www.ncbi.nlm.nih.gov/pubmed/17394399", "http://www.ncbi.nlm.nih.gov/pubmed/21913181", "http://www.ncbi.nlm.nih.gov/pubmed/17901820", "http://www.ncbi.nlm.nih.gov/pubmed/26271414", "http://www.ncbi.nlm.nih.gov/pubmed/27004793", "http://www.ncbi.nlm.nih.gov/pubmed/19841329", "http://www.ncbi.nlm.nih.gov/pubmed/20711702", "http://www.ncbi.nlm.nih.gov/pubmed/24366376", "http://www.ncbi.nlm.nih.gov/pubmed/26848859", "http://www.ncbi.nlm.nih.gov/pubmed/26691940", "http://www.ncbi.nlm.nih.gov/pubmed/17109443", "http://www.ncbi.nlm.nih.gov/pubmed/25863477", "http://www.ncbi.nlm.nih.gov/pubmed/24731853", "http://www.ncbi.nlm.nih.gov/pubmed/23635950", "http://www.ncbi.nlm.nih.gov/pubmed/12632763", "http://www.ncbi.nlm.nih.gov/pubmed/18854964", "http://www.ncbi.nlm.nih.gov/pubmed/9150154", "http://www.ncbi.nlm.nih.gov/pubmed/23539753", "http://www.ncbi.nlm.nih.gov/pubmed/20233464", "http://www.ncbi.nlm.nih.gov/pubmed/18932252", "http://www.ncbi.nlm.nih.gov/pubmed/27928164", "http://www.ncbi.nlm.nih.gov/pubmed/20878485", "http://www.ncbi.nlm.nih.gov/pubmed/17079882", "http://www.ncbi.nlm.nih.gov/pubmed/26047126", "http://www.ncbi.nlm.nih.gov/pubmed/25849179", "http://www.ncbi.nlm.nih.gov/pubmed/16783967", "http://www.ncbi.nlm.nih.gov/pubmed/27276934", "http://www.ncbi.nlm.nih.gov/pubmed/25838294", "http://www.ncbi.nlm.nih.gov/pubmed/26852130", "http://www.ncbi.nlm.nih.gov/pubmed/19996028", "http://www.ncbi.nlm.nih.gov/pubmed/26402875", "http://www.ncbi.nlm.nih.gov/pubmed/16144895", "http://www.ncbi.nlm.nih.gov/pubmed/22381151", "http://www.ncbi.nlm.nih.gov/pubmed/27306910", "http://www.ncbi.nlm.nih.gov/pubmed/27403072", "http://www.ncbi.nlm.nih.gov/pubmed/23091540", "http://www.ncbi.nlm.nih.gov/pubmed/26922077", "http://www.ncbi.nlm.nih.gov/pubmed/24065545", "http://www.ncbi.nlm.nih.gov/pubmed/17579227", "http://www.ncbi.nlm.nih.gov/pubmed/10464631", "http://www.ncbi.nlm.nih.gov/pubmed/23165859", "http://www.ncbi.nlm.nih.gov/pubmed/22982855", "http://www.ncbi.nlm.nih.gov/pubmed/24950059", "http://www.ncbi.nlm.nih.gov/pubmed/22866093", "http://www.ncbi.nlm.nih.gov/pubmed/19479365", "http://www.ncbi.nlm.nih.gov/pubmed/19273395", "http://www.ncbi.nlm.nih.gov/pubmed/27376595", "http://www.ncbi.nlm.nih.gov/pubmed/27513691", "http://www.ncbi.nlm.nih.gov/pubmed/24366442", "http://www.ncbi.nlm.nih.gov/pubmed/25497409", "http://www.ncbi.nlm.nih.gov/pubmed/12708108", "http://www.ncbi.nlm.nih.gov/pubmed/11368874", "http://www.ncbi.nlm.nih.gov/pubmed/16174860", "http://www.ncbi.nlm.nih.gov/pubmed/23638402", "http://www.ncbi.nlm.nih.gov/pubmed/25236687", "http://www.ncbi.nlm.nih.gov/pubmed/21637635", "http://www.ncbi.nlm.nih.gov/pubmed/23528734", "http://www.ncbi.nlm.nih.gov/pubmed/23165893", "http://www.ncbi.nlm.nih.gov/pubmed/22438049", "http://www.ncbi.nlm.nih.gov/pubmed/16492929", "http://www.ncbi.nlm.nih.gov/pubmed/26411315", "http://www.ncbi.nlm.nih.gov/pubmed/22684231", "http://www.ncbi.nlm.nih.gov/pubmed/24161304", "http://www.ncbi.nlm.nih.gov/pubmed/25948675"], "ideal_answer": ["Yes, BRCA gene test could be used for breast and ovarian cancer risk, as female BRCA1 and BRCA2 mutations are significantly associated with risk of developing breast and ovarian cancers."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:2394", "http://www.disease-ontology.org/api/metadata/DOID:5683", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019313", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024682"], "type": "yesno", "id": "58a6bce660087bc10a000029", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Participation of Korean families at high risk for hereditary breast and ovarian cancer in BRCA1/2 genetic testing.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25838294", "endSection": "title"}, {"offsetInBeginSection": 1412, "offsetInEndSection": 1645, "text": "The prevalence of BRCA1/2 mutations in Korean ovarian cancer patients irrespective of the family history was significantly higher than previously reported. Possible founder mutations in Korean ovarian cancer patients were identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26402875", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26402875", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 260, "text": "The assessment of BRCA1 and BRCA2 coding sequences to identify pathogenic mutations associated with inherited breast/ovarian cancer syndrome has provided a method to identify high-risk individuals, allowing them to seek preventative treatments and strategies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950059", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Maximising survival: the main concern of women with hereditary breast and ovarian cancer who undergo genetic testing for BRCA1/2.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731853", "endSection": "title"}, {"offsetInBeginSection": 8, "offsetInEndSection": 342, "text": " Little is known about how women with hereditary breast and/or ovarian cancer who test positive for a BRCA gene manage the impact of a positive test result on their everyday lives and in the longer term. This study defined the experience and needs of women with hereditary breast and ovarian cancer and a positive BRCA test over time.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731853", "endSection": "abstract"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1310, "text": "The strongest evidence was for rs1466785 in the NEIL2 (endonuclease VIII-like 2) gene (HR: 1.09, 95% CI (1.03-1.16), p = 2.7 \u00d7 10(-3)) for association with breast cancer risk in BRCA2 mutation carriers, and rs2304277 in the OGG1 (8-guanine DNA glycosylase) gene, with ovarian cancer risk in BRCA1 mutation carriers (HR: 1.12 95%CI: 1.03-1.21, p = 4.8 \u00d7 10(-3)).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24698998", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 193, "text": "Female BRCA (breast cancer gene)-1 and BRCA-2 mutations are significantly associated with risk of developing breast and ovarian cancers, in turn, associated with female infertility. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23528734", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065545", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "BRCA1 and BRCA2 are two major genes associated with familial breast and ovarian cancer susceptibility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065545", "endSection": "abstract"}, {"offsetInBeginSection": 108, "offsetInEndSection": 276, "text": "Until 2006, she supervised a diagnostic unit for BRCA gene testing at the Interdisciplinary Center for Hereditary Breast Cancer (Max Delbr\u00fcck Center, Berlin, Germany). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24161304", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 218, "text": "Inherited BRCA gene mutations convey a high risk for breast and ovarian cancer, but current guidelines limit BRCA mutation testing to women with early-onset cancer and relatives of mutation-positive cases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23638402", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 162, "text": "Women who carry a BRCA1 or BRCA2 gene mutation face a risk of developing breast or ovarian cancer at an earlier age than women without such a mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982855", "endSection": "abstract"}, {"offsetInBeginSection": 342, "offsetInEndSection": 447, "text": "In 2006, participants were recruited from Web sites for women with breast cancer or BRCA gene mutations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982855", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 252, "text": "About 20 % of hereditary breast cancers are caused by mutations in BRCA1 and BRCA2 genes. Since BRCA1 and BRCA2 mutations may be spread throughout the gene, genetic testing is usually performed by direct sequencing of entire coding regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26852130", "endSection": "abstract"}, {"offsetInBeginSection": 1662, "offsetInEndSection": 1765, "text": "Suggestion of an association between BRCA2 c.7806-2A>G and risk of breast cancer in males has emerged. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26852130", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 221, "text": "The presence of deleterious mutations in breast cancer (BRCA)-1 or BRCA-2 gene has a decisive influence on the development of various types of neoplasms, such as breast, ovarian, tubal, and peritoneal cancers. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27403072", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "OBJECTIVE: Female BRCA (breast cancer gene)-1 and BRCA-2 mutations are significantly associated with risk of developing breast and ovarian cancers, in turn, associated with female infertility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23528734", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "BRCA1 and BRCA2 genes are responsible for 5-10% of breast and ovarian cancer cases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16783967", "endSection": "abstract"}, {"offsetInBeginSection": 1060, "offsetInEndSection": 1370, "text": "She was daughter of a woman, a carrier of BRCA 1 gene mutation, with early onset of breast cancer and positive family history.CONCLUSIONS: BRCA 1 and BRCA 2 gene mutations are of particular importance in the increasing risk of ovarian cancer and early onset of breast cancer as well as some other malignancies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12708108", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "BACKGROUND: Women who are diagnosed with a deleterious mutation in either breast cancer (BRCA) gene have a high risk of developing breast and ovarian cancers at young ages.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21913181", "endSection": "abstract"}, {"offsetInBeginSection": 384, "offsetInEndSection": 652, "text": "We identified AJ individuals with breast and/or ovarian cancer undergoing hereditary breast/ovarian cancer risk assessment since 2006 without evidence of a deleterious mutation on BRCA gene sequencing who were screened for major gene rearrangements in BRCA1 and BRCA2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20221693", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Germline BRCA gene mutations are reportedly associated with hereditary breast and ovarian cancers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26271414", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "[Detection and occurrence of BRCA 1 gene mutation in patients with carcinoma of the breast and ovary].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12708108", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 391, "text": "We investigated the relationship between BRCA mutations and the distribution of familial cancers other than breast or ovary in high-risk breast cancer patients.PATIENTS WITH BREAST CANCER WHO HAD AT LEAST ONE OF THE FOLLOWING RISK FACTORS WERE ENROLLED: reported family history of breast or ovarian cancer; 40 years of age or younger age at diagnosis; bilateral breast cancer; or male gender", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23091540", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 757, "text": "Mutations in breast cancer susceptibility genes (BRCA1 and BRCA2) are associated with increased risks for breast, ovarian, and other types of cancer.To review new evidence on the benefits and harms of risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women.MEDLINE and PsycINFO between 2004 and 30 July 2013, the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews from 2004 through the second quarter of 2013, Health Technology Assessment during the fourth quarter of 2012, Scopus, and reference lists.English-language studies about accuracy of risk assessment and benefits and harms of genetic counseling, genetic testing, and interventions to reduce cancer incidence and mortality.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24366442", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 441, "text": "The objective of this study was to assess the incidence of primary breast cancer (PBC) and contralateral breast cancer (CBC) in patients who had BRCA1/BRCA2-associated epithelial ovarian cancer (OC).From the database of the Rotterdam Family Cancer Clinic, patients who had BRCA-associated OC without a history of unilateral breast cancer (BC) (at risk of PBC; n = 79) or with a history of unilateral BC (at risk of CBC; n = 37) were selected", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23165859", "endSection": "abstract"}, {"offsetInBeginSection": 1105, "offsetInEndSection": 1471, "text": "Statistically significant earlier ages at diagnosis also were observed within subgroups of BRCA1 and BRCA2 mutations, maternal inheritance, paternal inheritance, breast cancer only, and breast cancer-identified and ovarian cancer-identified families.Breast and ovarian cancers in BRCA mutation carriers appeared to be diagnosed at an earlier age in later generations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21913181", "endSection": "abstract"}, {"offsetInBeginSection": 473, "offsetInEndSection": 1136, "text": "The USPSTF also reviewed interventions aimed at reducing the risk for BRCA-related cancer in women with potentially harmful BRCA mutations, including intensive cancer screening, medications, and risk-reducing surgery.This recommendation applies to asymptomatic women who have not been diagnosed with BRCA-related cancer.The USPSTF recommends that primary care providers screen women who have family members with breast, ovarian, tubal, or peritoneal cancer with 1 of several screening tools designed to identify a family history that may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibility genes (BRCA1 or BRCA2)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24366376", "endSection": "abstract"}, {"offsetInBeginSection": 1109, "offsetInEndSection": 1478, "text": "If a woman bearing a mutation develops cancer in one breast, her risk of developing cancer in the other breast depends on the particular gene that is mutated and on her age at the onset of disease.About half of all monogenically determined carcinomas of the breast and ovary are due to a mutation in one or the other of the highly penetrant BRCA genes (BRCA1 and BRCA2)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21637635", "endSection": "abstract"}, {"offsetInBeginSection": 689, "offsetInEndSection": 1070, "text": "A value of RHR greater than 1 indicated elevated breast cancer risk; a value of RHR less than 1 indicated elevated ovarian cancer risk.Mutations of BRCA1 or BRCA2.Breast and ovarian cancer risks.Among BRCA1 mutation carriers, 9052 women (46%) were diagnosed with breast cancer, 2317 (12%) with ovarian cancer, 1041 (5%) with breast and ovarian cancer, and 7171 (37%) without cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25849179", "endSection": "abstract"}, {"offsetInBeginSection": 212, "offsetInEndSection": 450, "text": "This study defined the experience and needs of women with hereditary breast and ovarian cancer and a positive BRCA test over time.METHODS: A grounded theory approach was taken using qualitative interviews (n = 49) and reflective diaries. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731853", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "Little is known about how women with hereditary breast and/or ovarian cancer who test positive for a BRCA gene manage the impact of a positive test result on their everyday lives and in the longer term.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731853", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 431, "text": "This study defined the experience and needs of women with hereditary breast and ovarian cancer and a positive BRCA test over time.A grounded theory approach was taken using qualitative interviews (n = 49) and reflective diaries.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731853", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "Women with a harmful mutation in the BReast CAncer (BRCA) gene are at significantly increased risk of developing hereditary breast and ovarian cancer (HBOC) during their lifetime, compared to those without.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27376595", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Genetic testing for BRCA genes, associated with hereditary breast-ovarian cancer risk, is an accepted cancer control strategy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26848859", "endSection": "abstract"}, {"offsetInBeginSection": 2081, "offsetInEndSection": 2225, "text": "Younger patients, those with a family history of breast or ovarian cancer, and those diagnosed more recently were more likely to be BRCA tested.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27004793", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Mutations in BRCA genes elevate risk for breast and ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23635950", "endSection": "abstract"}, {"offsetInBeginSection": 1483, "offsetInEndSection": 2030, "text": "Observational studies of prophylactic surgeries report reduced risks for breast and ovarian cancer in mutation carriers.No data describe the range of risk associated with BRCA mutations, genetic heterogeneity, and moderating factors; studies conducted in highly selected populations contain biases; and information on adverse effects is incomplete.A primary care approach to screening for inherited breast and ovarian cancer susceptibility has not been evaluated, and evidence is lacking to determine benefits and harms for the general population.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16144895", "endSection": "abstract"}, {"offsetInBeginSection": 384, "offsetInEndSection": 936, "text": "We identified AJ individuals with breast and/or ovarian cancer undergoing hereditary breast/ovarian cancer risk assessment since 2006 without evidence of a deleterious mutation on BRCA gene sequencing who were screened for major gene rearrangements in BRCA1 and BRCA2. For each proband, the pre-test probability of identifying a deleterious BRCA mutation was estimated using the Myriad II model. We identified 108 affected individuals who underwent large rearrangement testing (80 breast cancer, 19 ovarian cancer, nine both breast and ovarian cancer).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20221693", "endSection": "abstract"}, {"offsetInBeginSection": 782, "offsetInEndSection": 1370, "text": "Truncated proteins are easily discriminated from full size.RESULTS: Three BRCA 1 gene alterations were identified in the investigated group of women suffering from ovarian or breast cancer. One asymptomatic person--carrier of BRCA 1 gene mutation--was identified in this study. She was daughter of a woman, a carrier of BRCA 1 gene mutation, with early onset of breast cancer and positive family history.CONCLUSIONS: BRCA 1 and BRCA 2 gene mutations are of particular importance in the increasing risk of ovarian cancer and early onset of breast cancer as well as some other malignancies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12708108", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Germline BRCA gene mutations are reportedly associated with hereditary breast and ovarian cancers. Identification of BRCA mutations greatly improves the preventive strategies and management of breast cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26271414", "endSection": "abstract"}, {"offsetInBeginSection": 1125, "offsetInEndSection": 1505, "text": "Statistically significant earlier ages at diagnosis also were observed within subgroups of BRCA1 and BRCA2 mutations, maternal inheritance, paternal inheritance, breast cancer only, and breast cancer-identified and ovarian cancer-identified families.CONCLUSIONS: Breast and ovarian cancers in BRCA mutation carriers appeared to be diagnosed at an earlier age in later generations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21913181", "endSection": "abstract"}, {"offsetInBeginSection": 782, "offsetInEndSection": 971, "text": "Truncated proteins are easily discriminated from full size.RESULTS: Three BRCA 1 gene alterations were identified in the investigated group of women suffering from ovarian or breast cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12708108", "endSection": "abstract"}, {"offsetInBeginSection": 1419, "offsetInEndSection": 1621, "text": "However, some single risk factors without family histories (early-onset breast cancer, male breast cancer, or multiple organ cancers) may limit the utility of BRCA gene testing in the Korean population.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25863477", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26047126", "endSection": "title"}, {"offsetInBeginSection": 95, "offsetInEndSection": 279, "text": "Because infertility is associated with breast and ovarian cancer risks, we hypothesized that the mutations in the BRCA gene may be associated with low response to fertility treatments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19996028", "endSection": "abstract"}, {"offsetInBeginSection": 2358, "offsetInEndSection": 2491, "text": "Moreover, in families of breast cancer patients without BRCA mutations, breast cancer risk depends on the patient's age at diagnosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16492929", "endSection": "abstract"}, {"offsetInBeginSection": 817, "offsetInEndSection": 991, "text": "Among the 554 women who underwent genetic testing for BRCA mutation, 78 were found to have a deleterious mutation in the BRCA1 gene, and 54 had a mutation in the BRCA 2 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17109443", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 413, "text": "Frequent recurrent mutations in the breast and ovarian cancer susceptibility (BRCA) genes BRCA1 and BRCA2 among Hispanics, including a large rearrangement Mexican founder mutation (BRCA1 exon 9-12 deletion [ex9-12del]), suggest that an ancestry-informed BRCA-testing strategy could reduce disparities and promote cancer prevention by enabling economic screening for hereditary breast and ovarian cancer in Mexico.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25236687", "endSection": "abstract"}, {"offsetInBeginSection": 529, "offsetInEndSection": 678, "text": "Individuals who carry a BRCA gene mutation have increased lifetime risks of developing hereditary breast and ovarian cancer syndrome-related cancers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17901820", "endSection": "abstract"}, {"offsetInBeginSection": 1757, "offsetInEndSection": 1863, "text": "BRCA gene mutations have been well described to carry an increased risk of both breast and ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27306910", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23539753", "endSection": "title"}, {"offsetInBeginSection": 1978, "offsetInEndSection": 2185, "text": "Women who were BRCA carriers, women who had a history of breast cancer, DCIS, or breast biopsy, or had a family history of ovarian cancer were more likely to have undergone surgery for cancer risk reduction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17109443", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Genetic testing for breast cancer susceptibility became a reality after two cancer predisposition genes, BRCA1 and BRCA2, were identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10464631", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Germline mutations in BRCA genes are associated with breast and ovarian cancer susceptibility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19996028", "endSection": "abstract"}, {"offsetInBeginSection": 494, "offsetInEndSection": 690, "text": "We used person-years at risk to assess ovarian cancer rates in the study population, subdivided by genetic status (BRCA1, BRCA2, BRCA negative, BRCA untested) compared with the general population.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23539753", "endSection": "abstract"}]}, {"body": "What is Desomorphine?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27372715", "http://www.ncbi.nlm.nih.gov/pubmed/23388531", "http://www.ncbi.nlm.nih.gov/pubmed/23244560", "http://www.ncbi.nlm.nih.gov/pubmed/26282512", "http://www.ncbi.nlm.nih.gov/pubmed/25710781", "http://www.ncbi.nlm.nih.gov/pubmed/24650492", "http://www.ncbi.nlm.nih.gov/pubmed/27348169", "http://www.ncbi.nlm.nih.gov/pubmed/22468632", "http://www.ncbi.nlm.nih.gov/pubmed/25236385"], "ideal_answer": ["Desomorphine is an opioid misused as \"crocodile\", a cheaper alternative to heroin Desomorphine is the semi-synthetic opioid claimed to be the main component of krokodil", "Desomorphine is an opioid misused as \"crocodile\", a cheaper alternative to heroin", "Desomorphine is the semi-synthetic opioid claimed to be the main component of krokodil", "\"Krokodil\" is the street name for the homemade injectable mixture that has been used as a cheap substitute for heroin. Desomorphine is an opioid misused as \"crocodile\", a cheaper alternative to heroin.", "Desomorphine is the semi-synthetic opioid claimed to be the main component of krokodil Desomorphine is an opioid misused as \"crocodile\", a cheaper alternative to heroin", "Desomorphine is an opioid drug which is often synthsised using a combination of readily available ingredients and is often available on the \"street\" as a cheaper alternative to heroin."], "concepts": ["http://www.biosemantics.org/jochem#4011470", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4011470"], "type": "summary", "id": "58a5d7ef60087bc10a000026", "snippets": [{"offsetInBeginSection": 214, "offsetInEndSection": 300, "text": "Desomorphine is the semi-synthetic opioid claimed to be the main component of krokodil", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25710781", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Desomorphine is an opioid misused as \"crocodile\", a cheaper alternative to heroin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27372715", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "\"Krokodil\" is the street name for the semi-synthetic opioid derivative desomorphine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24650492", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Desomorphine is an opioid misused as \"crocodile\", a cheaper alternative to heroin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27372715", "endSection": "abstract"}, {"offsetInBeginSection": 231, "offsetInEndSection": 429, "text": "ince Soviet period the most popular injective narcotics have been opioids: home-made opium, heroine, buprenorphine and home-made desomorphine (\"Krokodile\") replacing each other on the black market. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27348169", "endSection": "abstract"}, {"offsetInBeginSection": 249, "offsetInEndSection": 472, "text": "ous increase in the number of addicted individuals since then. The psychoactive core agent of Krokodil is desomorphine, an opioid-analogon that can be manufactured by boiling tablets containing codeine and other ingredients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23244560", "endSection": "abstract"}, {"offsetInBeginSection": 341, "offsetInEndSection": 461, "text": "The core agent of \"Krokodil\" is desomorphine, an opioid-analogue that can be easily and cheaply manufactured by oneself.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22468632", "endSection": "abstract"}]}, {"body": "Which two drugs are included in the Harvoni pill?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27480956", "http://www.ncbi.nlm.nih.gov/pubmed/25837989", "http://www.ncbi.nlm.nih.gov/pubmed/25516691", "http://www.ncbi.nlm.nih.gov/pubmed/25859119", "http://www.ncbi.nlm.nih.gov/pubmed/26357632", "http://www.ncbi.nlm.nih.gov/pubmed/26327920", "http://www.ncbi.nlm.nih.gov/pubmed/26312999", "http://www.ncbi.nlm.nih.gov/pubmed/27606041", "http://www.ncbi.nlm.nih.gov/pubmed/25937625", "http://www.ncbi.nlm.nih.gov/pubmed/25850880", "http://www.ncbi.nlm.nih.gov/pubmed/25987834", "http://www.ncbi.nlm.nih.gov/pubmed/27193156", "http://www.ncbi.nlm.nih.gov/pubmed/26788571", "http://www.ncbi.nlm.nih.gov/pubmed/27276081"], "ideal_answer": ["Harvoni contains 400 mg sofosbuvir and 90 mg ledipasvir. It used for treatment of hepatitis C virus infection."], "type": "list", "id": "5896deff78275d0c4a000013", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27276081", "endSection": "title"}, {"offsetInBeginSection": 1216, "offsetInEndSection": 1435, "text": "The developed method was applied to the analysis of the two drugs after a single oral administration of Harvoni 400/90 mg film-coated tablets containing 400 mg sofosbuvir and 90 mg ledipasvir to four healthy volunteers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480956", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "After the introductions of sofosbuvir (Sovaldi) and ledipasvir plus sofosbuvir (Harvoni) for the treatment of hepatitis C, employers have become very sensitive to new, and especially unforeseen, factors that significantly raise healthcare costs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27606041", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "The single-tablet regimen of the hepatitis C virus (HCV) NS5A inhibitor ledipasvir and the HCV NS5B polymerase inhibitor sofosbuvir (ledipasvir/sofosbuvir; Harvoni(\u00ae)) was recently approved in the US and the EU. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25837989", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25859119", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Ledipasvir/sofosbuvir (Harvoni): improving options for hepatitis C virus infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25859119", "endSection": "abstract"}, {"offsetInBeginSection": 677, "offsetInEndSection": 936, "text": "Also reviewed were recent practice guidelines on the management of HCV infections, prescribing information on all HCV drugs approved by the US Food and Drug Administration, and health technology assessments of Sovaldi\u00ae and Harvoni(TM) (sofosbuvir/ledipasvir).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25850880", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25859119", "endSection": "title"}, {"offsetInBeginSection": 851, "offsetInEndSection": 1104, "text": "This review will summarize the data regarding these interferon-free regimens, including Gilead's Harvoni (sofosbuvir/ledipasvir), AbbVie's Viekira Pak (paritaprevir/ritonavir/ombitasvir with dasabuvir), and Janssen's Olysio (simeprevir) with sofosbuvir.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26327920", "endSection": "abstract"}]}, {"body": "What is the result of Mff overexpression in mitochondria?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26446846", "http://www.ncbi.nlm.nih.gov/pubmed/21149567", "http://www.ncbi.nlm.nih.gov/pubmed/24167709"], "ideal_answer": ["The Drp1 receptor Mff is a major regulator of mitochondrial fission, and its overexpression results in increased fission."], "type": "summary", "id": "58a874c338c171fb5b000003", "snippets": [{"offsetInBeginSection": 337, "offsetInEndSection": 459, "text": "The Drp1 receptor Mff is a major regulator of mitochondrial fission, and its overexpression results in increased fission. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26446846", "endSection": "abstract"}, {"offsetInBeginSection": 961, "offsetInEndSection": 1088, "text": "Overexpression of MFF also increases the interaction between DLP1 and Pex11p\u03b2, which knockdown of MFF, but not Fis1, abolishes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24167709", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 621, "text": "whereas Mff overexpression stimulated mitochondrial recruitment of Drp1 accompanied by mitochondrial fission", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21149567", "endSection": "abstract"}]}, {"body": "Has Glucose-6-phosphate dehydrogenase (G6PD) deficiency an X-linked inheritance?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24865682", "http://www.ncbi.nlm.nih.gov/pubmed/15297240", "http://www.ncbi.nlm.nih.gov/pubmed/25189226", "http://www.ncbi.nlm.nih.gov/pubmed/12169625", "http://www.ncbi.nlm.nih.gov/pubmed/1953691", "http://www.ncbi.nlm.nih.gov/pubmed/3377761", "http://www.ncbi.nlm.nih.gov/pubmed/2912069", "http://www.ncbi.nlm.nih.gov/pubmed/25771467", "http://www.ncbi.nlm.nih.gov/pubmed/7801429", "http://www.ncbi.nlm.nih.gov/pubmed/25116429", "http://www.ncbi.nlm.nih.gov/pubmed/26827633", "http://www.ncbi.nlm.nih.gov/pubmed/15226563", "http://www.ncbi.nlm.nih.gov/pubmed/24460025", "http://www.ncbi.nlm.nih.gov/pubmed/23429543", "http://www.ncbi.nlm.nih.gov/pubmed/1147889", "http://www.ncbi.nlm.nih.gov/pubmed/26139767", "http://www.ncbi.nlm.nih.gov/pubmed/1634454", "http://www.ncbi.nlm.nih.gov/pubmed/9290617", "http://www.ncbi.nlm.nih.gov/pubmed/21164249", "http://www.ncbi.nlm.nih.gov/pubmed/26275698", "http://www.ncbi.nlm.nih.gov/pubmed/26226515", "http://www.ncbi.nlm.nih.gov/pubmed/6350992", "http://www.ncbi.nlm.nih.gov/pubmed/24943486", "http://www.ncbi.nlm.nih.gov/pubmed/10698963", "http://www.ncbi.nlm.nih.gov/pubmed/1188317", "http://www.ncbi.nlm.nih.gov/pubmed/11271380", "http://www.ncbi.nlm.nih.gov/pubmed/24551713", "http://www.ncbi.nlm.nih.gov/pubmed/17355169", "http://www.ncbi.nlm.nih.gov/pubmed/23152723", "http://www.ncbi.nlm.nih.gov/pubmed/1554817", "http://www.ncbi.nlm.nih.gov/pubmed/3810219", "http://www.ncbi.nlm.nih.gov/pubmed/1225290", "http://www.ncbi.nlm.nih.gov/pubmed/631693", "http://www.ncbi.nlm.nih.gov/pubmed/24958328", "http://www.ncbi.nlm.nih.gov/pubmed/23834949", "http://www.ncbi.nlm.nih.gov/pubmed/1296572", "http://www.ncbi.nlm.nih.gov/pubmed/10645652"], "ideal_answer": ["Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the commonest red cell enzymopathy in humans and has an X-linked inheritance."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005952", "http://www.uniprot.org/uniprot/G6PD_HELPY", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005955", "http://www.disease-ontology.org/api/metadata/DOID:2862", "http://www.uniprot.org/uniprot/G6PD_HAEIN", "http://www.uniprot.org/uniprot/G6PD_MACRO", "http://www.uniprot.org/uniprot/G6PD_HUMAN", "http://www.uniprot.org/uniprot/G6PD_CRIGR", "http://www.uniprot.org/uniprot/G6PD_GLUOX", "http://www.uniprot.org/uniprot/G6PD_EMENI", "http://www.uniprot.org/uniprot/G6PD_HELPJ", "http://amigo.geneontology.org/amigo/term/GO:0004345", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005954", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019298", "http://www.uniprot.org/uniprot/G6PD_ENCCU", "http://www.uniprot.org/uniprot/G6PD_TAKRU", "http://www.uniprot.org/uniprot/G6PD_DIDVI"], "type": "yesno", "id": "58a2da4260087bc10a000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the commonest red cell enzymopathy in humans and has an X-linked inheritance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226563", "endSection": "abstract"}, {"offsetInBeginSection": 226, "offsetInEndSection": 302, "text": "This genetic defect shows sex linked inheritance and a marked heterogeneity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10645652", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "G6PD deficiency is the most common enzymopathy in the world. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10645652", "endSection": "abstract"}, {"offsetInBeginSection": 461, "offsetInEndSection": 605, "text": "Study of the deficiency pattern amongst family members of the enzyme deficient subjects confirmed the X-linked inheritance of G-6-PD deficiency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1634454", "endSection": "abstract"}, {"offsetInBeginSection": 394, "offsetInEndSection": 706, "text": "This was caused by Glucose-6-Phosphate-Dehydrogenase-Deficiency, which could be demonstrated by a red-cell-enzyme analysis. The investigation of the patient's whole family showed the typical recessive X-linked inheritance of this enzyme-defect. Frequency and clinical manifestations of this defect are discussed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6350992", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 296, "text": "After having described in detail the pathophysiology, symptomatology, X-chromosomal inheritance and some laboratory methods in detecting G-6-PD-deficiency by demonstrating a case of favism (Schulz et al. 1977), the authors now discuss the particularities of the enzyme deficiency in the newborn. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/631693", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 326, "text": "Severe red cell glucose-6-phosphate dehydrogenase (G-6-PD) deficiency has been found in an 'aboriginal' Finnish family. 2 male and 9 female carriers of the variant G-6-PD were studied. The genetic pattern is consistent with x-linked recessive inheritance and the defect is associated with drug (primaquine) induced haemolysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1188317", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the commonest red cell enzymopathy in humans and has an X-linked inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226563", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "X-linked glucose-6-phosphate dehydrogenase deficiency in Mus musculus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3377761", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common X-linked enzyme defect.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9290617", "endSection": "abstract"}, {"offsetInBeginSection": 173, "offsetInEndSection": 309, "text": "Glucose-6-phosphate dehydrogenase deficiency is an X-linked recessive hereditary disease characterised by abnormally low levels of G6PD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24943486", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "UNLABELLED: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive disorder in which haemolytic anaemia is the major symptom.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11271380", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most frequent enzyme deficiency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15297240", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is transmitted as an X-linked recessive disorder, and thus female infants are expected to be only rarely affected.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3810219", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Erythrocytic glucose-6-phosphate dehydrogenase (G6PD) of a mutant mouse strain with X-linked G6PD-deficiency was purified and compared with the wildtype G6PD by biochemical and physiological characteristics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1953691", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "A mouse with X-linked glucose-6-phosphate dehydrogenase (G6PD) deficiency has been recovered in offspring of 1-ethyl-1-nitrosourea-treated male mice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3377761", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the commonest red cell enzymopathy in humans and has an X-linked inheritance", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226563", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive hemolytic anemia caused by a mutation in the G6PD gene on Xq28", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275698", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive genetic defect that can cause hemolytic crisis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25116429", "endSection": "abstract"}, {"offsetInBeginSection": 154, "offsetInEndSection": 359, "text": "Glucose-6-phosphate-dehydrogenase (G6PD) deficiency is an X-linked genetic defect, affecting around 400 million people worldwide and is characterized by considerable biochemical and molecular heterogeneity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26139767", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Glucose-6-phosphate dehydrogenase deficiency (G6PD) is an X-linked genetic disorder with a relatively high frequency in malaria-endemic regions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25771467", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Glucose-6-phosphate dehydrogenase deficiency (G6PD) is the most common enzyme pathology in humans; it is X-linked inherited and causes neonatal hyperbilirubinaemia, chronic nonspherocytic haemolytic anaemia and drug-induced acute haemolytic anaemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25189226", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked hereditary disease that predisposes red blood cells to oxidative damage", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26226515", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common human genetic abnormalities, and it has a significant prevalence in the male population (X chromosome linked)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24865682", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common X-linked enzymopathy can lead to severe hyperbilirubinemia, acute bilirubin encephalopathy and kernicterus in the United States", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23429543", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "Glucose-6-phosphate dehydrogenase deficiency (G6PD), an x-linked inherited enzymopathy, is a barrier to malaria control because primaquine cannot be readily applied for radical cure in individuals with the condition", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23834949", "endSection": "abstract"}, {"offsetInBeginSection": 298, "offsetInEndSection": 480, "text": "G6PD deficiency has an x-linked pattern of inheritance in which hemizygous males are deficient, while females may or may not be deficient depending on the number of affected alleles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26827633", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 298, "text": "Phenotype frequencies and family data verified the X-linked inheritance of the G6PD polymorphism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1296572", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 309, "text": "BACKGROUND: Glucose-6-phosphate dehydrogenase (G6PD) is a metabolic enzyme involved in the pentose phosphate pathway, its especially important in red blood cell metabolism. Glucose-6-phosphate dehydrogenase deficiency is an X-linked recessive hereditary disease characterised by abnormally low levels of G6PD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24943486", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 378, "text": "BACKGROUND: Glucose-6-phosphate dehydrogenase (G6PD) is a metabolic enzyme involved in the pentose phosphate pathway, its especially important in red blood cell metabolism. Glucose-6-phosphate dehydrogenase deficiency is an X-linked recessive hereditary disease characterised by abnormally low levels of G6PD. About 400 million people worldwide have a deficiency of this enzyme.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24943486", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common X-linked enzyme defect. We report a new variant, G6PD Durham713G, that is associated with chronic nonspherocytic hemolytic anemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9290617", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common human genetic abnormalities, and it has a significant prevalence in the male population (X chromosome linked).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24865682", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "The human X-linked gene encoding glucose 6-phosphate dehydrogenase (G6PD) is highly polymorphic; more than 300 G6PD variants have been identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2912069", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked incompletely dominant enzyme deficiency that results from G6PD gene mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24958328", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive genetic defect that can cause hemolytic crisis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25116429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive hemolytic anemia caused by a mutation in the G6PD gene on Xq28.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275698", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 297, "text": "Glucose-6-phosphate dehydrogenase deficiency is an X-linked recessive hereditary disease characterised by abnormally low levels of G6PD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24943486", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "X-linked glucose-6-phosphate dehydrogenase (G6PD) and autosomal 6-phosphogluconate dehydrogenase (6PGD) polymorphisms in baboons.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1296572", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "X-linked glucose-6-phosphate dehydrogenase deficiency in Mus musculus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3377761", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive disorder in which haemolytic anaemia is the major symptom.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11271380", "endSection": "abstract"}]}, {"body": "What is FFI, fatal familial insomnia", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8105681", "http://www.ncbi.nlm.nih.gov/pubmed/25473397", "http://www.ncbi.nlm.nih.gov/pubmed/27943639", "http://www.ncbi.nlm.nih.gov/pubmed/22040318", "http://www.ncbi.nlm.nih.gov/pubmed/12111447", "http://www.ncbi.nlm.nih.gov/pubmed/26074146", "http://www.ncbi.nlm.nih.gov/pubmed/8909448", "http://www.ncbi.nlm.nih.gov/pubmed/11079543", "http://www.ncbi.nlm.nih.gov/pubmed/27056979", "http://www.ncbi.nlm.nih.gov/pubmed/14732629", "http://www.ncbi.nlm.nih.gov/pubmed/16109494", "http://www.ncbi.nlm.nih.gov/pubmed/9270595", "http://www.ncbi.nlm.nih.gov/pubmed/24851016", "http://www.ncbi.nlm.nih.gov/pubmed/1347910", "http://www.ncbi.nlm.nih.gov/pubmed/17013786", "http://www.ncbi.nlm.nih.gov/pubmed/9818894"], "ideal_answer": ["Familial fatal insomnia (FFI) is a prion disease caused by a mutation (D178N-129M haplotype) in the Prion Protein gene (PRNP). FFI is manifested by sleep disturbances with insomnia, autonomic disorders and spontaneous and evoked myoclonus, among other symptoms. FFI is considered to be a rare disease."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D034062", "http://www.disease-ontology.org/api/metadata/DOID:0050433"], "type": "summary", "id": "58a3160d60087bc10a00000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Fatal familial insomnia is a rare disease caused by a D178N mutation in combination with methionine (Met) at codon 129 in the mutated allele of PRNP (D178N-129M haplotype).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27056979", "endSection": "abstract"}, {"offsetInBeginSection": 173, "offsetInEndSection": 306, "text": "FFI is manifested by sleep disturbances with insomnia, autonomic disorders and spontaneous and evoked myoclonus, among other symptoms", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27056979", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Familial fatal insomnia (FFI) is fatal disorder characterized by damage to select thalamic nuclei, together with progressive insomnia and dysautonomia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26074146", "endSection": "abstract"}, {"offsetInBeginSection": 322, "offsetInEndSection": 568, "text": "Point mutations or the insertions of one or more copies of a 24 bp repeat are associated with familial human prion diseases including familial Creutzfeldt-Jakob disease (CJD), Gerstmann-Str\u00e4ussler-Scheinker syndrome, and fatal familial insomnia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24851016", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Fatal familial insomnia (FFI) is a unique hereditary prion disease with characteristic disturbances of sleep.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11079543", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Fatal familial insomnia (FFI) is a rare hereditary human prion disease with unique clinical features including progressive sleep impairment and autonomic dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12111447", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Fatal familial insomnia (FFI), a condition characterized by inability to sleep, dysautonomia, motor disturbances, and selective thalamic atrophy is a prion disease linked to a GAC----AAC mutation at codon 178 of the prion gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1347910", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 256, "text": "Fatal familial insomnia (FFI), or familial selective thalamic degeneration with a mutation at codon 178 of the prion protein (PrP) gene, is a rapidly progressive autosomal dominant disease characterized by progressive insomnia, dysautonomia, and myoclonus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8909448", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 508, "text": "BACKGROUND: Fatal familial insomnia (FFI) is an autosomal dominant disease linked to a mutation in the prion protein gene. Fatal familial insomnia is characterized by sleep disturbance and loss of neurons, with gliosis in the thalamic nuclei.OBJECTIVE: To describe the clinical, neurophysiological, radiological, and neuropathological data in a Chinese family with FFI.SETTING: Tertiary referral university hospital setting.PATIENTS: Patient 1 was a 36-year-old man who presented with insomnia and myoclonus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14732629", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Fatal familial insomnia (FFI) is a rare genetic disease characterized by intractable insomnia, dysautonomia, and dementia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25473397", "endSection": "abstract"}, {"offsetInBeginSection": 130, "offsetInEndSection": 303, "text": "FFI is characterized clinically by untreatable progressive insomnia, dysautonomia, and motor dysfunctions and is characterized pathologically by selective thalamic atrophy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8105681", "endSection": "abstract"}, {"offsetInBeginSection": 266, "offsetInEndSection": 463, "text": "FFI is associated with an aspartic acid to asparagine mutation at codon 178 of the PrP gene (D178N) in conjunction with methionine at the codon 129 polymorphic site on the mutant allele (cis-129M).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9270595", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 211, "text": "The propositus had behavioral, sleep, cognitive, and motor impairment associated with thalamic and olivary atrophy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9818894", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 106, "text": " Sporadic fatal insomnia (sFI) and fatal familial insomnia (FFI) are rare human prion diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22040318", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 164, "text": "Fatal familial insomnia (FFI) is an autosomal dominant prion disease characterized clinically by inattention, sleep loss, dysautonomia, and motor signs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026528", "endSection": "abstract"}]}, {"body": "Which mutated genes are associated with the Tourette's syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23825391", "http://www.ncbi.nlm.nih.gov/pubmed/16224024", "http://www.ncbi.nlm.nih.gov/pubmed/18021920", "http://www.ncbi.nlm.nih.gov/pubmed/23990902", "http://www.ncbi.nlm.nih.gov/pubmed/20445167", "http://www.ncbi.nlm.nih.gov/pubmed/25464894", "http://www.ncbi.nlm.nih.gov/pubmed/24411733", "http://www.ncbi.nlm.nih.gov/pubmed/24978639", "http://www.ncbi.nlm.nih.gov/pubmed/19018236"], "ideal_answer": ["A mutation in histidine decarboxylase (Hdc) gene as well as mutations in the SLITRK1 (Slit and Trk-like 1) gene have been implicated as rare genetic causes of Tourette's syndrome."], "type": "list", "id": "58a7fb2860087bc10a000034", "snippets": [{"offsetInBeginSection": 276, "offsetInEndSection": 473, "text": " A rare genetic form of Tourette syndrome due to L-histidine-decarboxylase mutation, with similar features in human and rodent, has inspired new research on functional anatomy of Tourette syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24978639", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 280, "text": "A mutation in histidine decarboxylase (Hdc), the key enzyme for the biosynthesis of histamine (HA), has been implicated as a rare genetic cause.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24411733", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24411733", "endSection": "title"}, {"offsetInBeginSection": 225, "offsetInEndSection": 372, "text": "Tourette syndrome (TS), the most severe end of the continuum of tic disorders, is substantially genetic, but causative mutations have been elusive.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25464894", "endSection": "abstract"}, {"offsetInBeginSection": 307, "offsetInEndSection": 524, "text": "The SLITRK1 gene encodes a developmentally regulated stimulator of neurite outgrowth and previous studies have implicated rare variants in this gene in disorders in the OC spectrum, specifically Tourette syndrome (TS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23990902", "endSection": "abstract"}, {"offsetInBeginSection": 286, "offsetInEndSection": 493, "text": "The recent implication of the histamine decarboxylase (HDC) gene, the key enzyme in histamine production, raises the intriguing hypothesis of a possible role of histaminergic dysfunction leading to TS onset.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23825391", "endSection": "abstract"}, {"offsetInBeginSection": 240, "offsetInEndSection": 467, "text": "we describe an analysis of linkage in a two-generation pedigree leading to the identification of a rare functional mutation in the HDC gene encoding L-histidine decarboxylase, the rate-limiting enzyme in histamine biosynthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20445167", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Mutations in the gene SLITRK1 (Slit and Trk-like 1) have been reported in patients with Tourette's disorder (TD)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19018236", "endSection": "abstract"}, {"offsetInBeginSection": 87, "offsetInEndSection": 339, "text": "Recently, two variants, including a single-base deletion resulting in a truncated protein and a 3'-untranslated-region variant altering a binding site for micro-RNA in the Slit and Trk-like 1 gene, were found to be a genetic cause of Tourette syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18021920", "endSection": "abstract"}, {"offsetInBeginSection": 752, "offsetInEndSection": 847, "text": "Collectively, these findings support the association of rare SLITRK1 sequence variants with TS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16224024", "endSection": "abstract"}]}, {"body": "Which enzyme is inhibited by niraparib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27898364", "http://www.ncbi.nlm.nih.gov/pubmed/26217019", "http://www.ncbi.nlm.nih.gov/pubmed/23810788", "http://www.ncbi.nlm.nih.gov/pubmed/23934192", "http://www.ncbi.nlm.nih.gov/pubmed/27141070", "http://www.ncbi.nlm.nih.gov/pubmed/27614696", "http://www.ncbi.nlm.nih.gov/pubmed/27717299", "http://www.ncbi.nlm.nih.gov/pubmed/25761096", "http://www.ncbi.nlm.nih.gov/pubmed/26281686", "http://www.ncbi.nlm.nih.gov/pubmed/25685067", "http://www.ncbi.nlm.nih.gov/pubmed/26513298", "http://www.ncbi.nlm.nih.gov/pubmed/25758918", "http://www.ncbi.nlm.nih.gov/pubmed/26518726", "http://www.ncbi.nlm.nih.gov/pubmed/27141062", "http://www.ncbi.nlm.nih.gov/pubmed/26351319", "http://www.ncbi.nlm.nih.gov/pubmed/24356813", "http://www.ncbi.nlm.nih.gov/pubmed/27716873", "http://www.ncbi.nlm.nih.gov/pubmed/23118055", "http://www.ncbi.nlm.nih.gov/pubmed/24970803", "http://www.ncbi.nlm.nih.gov/pubmed/27810860"], "ideal_answer": ["Niraparib is a Poly(ADP-ribose) Polymerase (PARP) Inhibitor. It is used for ovarian cancer treatment."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004791", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004789"], "type": "factoid", "id": "5880be1dc872c95565000007", "snippets": [{"offsetInBeginSection": 1323, "offsetInEndSection": 1607, "text": "While olaparib is the first PARP inhibitor to receive approval for ovarian cancer treatment, others including rucaparib and niraparib are clearly effective in this disease and, within the next year or two, the results of ongoing randomised trials will clarify their respective roles. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141062", "endSection": "abstract"}, {"offsetInBeginSection": 1219, "offsetInEndSection": 1358, "text": "Similar trials with other PARP inhibitors (rucaparib, niraparib and veliparib) are in progress and include non-BRCA-mutated ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141070", "endSection": "abstract"}, {"offsetInBeginSection": 384, "offsetInEndSection": 689, "text": "We report here that while the activities of the four human sirtuin isoforms SIRT1, SIRT2, SIRT3 and SIRT6 are blocked by sirtuin inhibitor Ex527 in vitro, they are unaffected by the seven clinical and commonly used PARP inhibitors niraparib, olaparib, rucaparib, talazoparib, veliparib, PJ34, and XAV939. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26518726", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27810860", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27614696", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 492, "text": "OBJECTIVE: Poly(ADP-ribose) polymerase (PARP) inhibitors have yielded encouraging responses in high-grade serous ovarian carcinomas (HGSOCs), but the optimal treatment setting remains unknown. We assessed the effect of niraparib on HGSOC patient-derived xenograft (PDX) models as well as the relationship between certain markers of homologous recombination (HR) status, including BRCA1/2 mutations and formation of RAD51 foci after DNA damage, and response of these PDXs to niraparib in vivo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27614696", "endSection": "abstract"}, {"offsetInBeginSection": 1256, "offsetInEndSection": 1413, "text": "There are a number of other PARP inhibitors in late phase clinical development in ovarian cancer including rucaparib, niraparib, veliparib, and talazoparib. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716873", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Background Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27717299", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685067", "endSection": "title"}, {"offsetInBeginSection": 452, "offsetInEndSection": 653, "text": "METHODS: Here we examine the response to niraparib, a potent PARP-1/PARP-2 inhibitor currently under clinical evaluation, in MSI versus microsatellite stable (MSS) CRC cell lines in vitro and in vivo. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685067", "endSection": "abstract"}, {"offsetInBeginSection": 319, "offsetInEndSection": 483, "text": "Several clinical-stage PARP inhibitors, including veliparib, rucaparib, olaparib, niraparib, and talazoparib, have been evaluated for their PARP-trapping activity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25758918", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25761096", "endSection": "title"}, {"offsetInBeginSection": 292, "offsetInEndSection": 506, "text": "We describe the rationale for this approach and the design and discovery of niraparib, a potent PARP-1/2 inhibitor with good cell based activity, selectivity for cancer over normal cells, and oral bioavailability. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25761096", "endSection": "abstract"}, {"offsetInBeginSection": 1362, "offsetInEndSection": 1571, "text": "Niraparib (50 mg/kg) inhibited PARP1 activity in vivo and extended survival of mice with orthotopic pHGA xenografts, when administered before IR (20 Gy, fractionated), relative to control mice (40 vs. 25 days)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26351319", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24970803", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23810788", "endSection": "title"}, {"offsetInBeginSection": 506, "offsetInEndSection": 800, "text": "Niraparib was characterized in a number of preclinical models before moving to phase I clinical trials, where it showed excellent human pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PARP inhibition, and had promising activity in cancer patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25761096", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "The aim of this study was to assess niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase (PARP) inhibitor, for its ability to radiosensitize human tumor cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24970803", "endSection": "abstract"}, {"offsetInBeginSection": 105, "offsetInEndSection": 280, "text": "Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in preclinical tumour models with loss of BRCA and PTEN function. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23810788", "endSection": "abstract"}, {"offsetInBeginSection": 552, "offsetInEndSection": 778, "text": "Moreover, the potency in trapping PARP differed markedly among inhibitors with niraparib (MK-4827) > olaparib (AZD-2281) >> veliparib (ABT-888), a pattern not correlated with the catalytic inhibitory properties for each drug. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118055", "endSection": "abstract"}, {"offsetInBeginSection": 319, "offsetInEndSection": 482, "text": "Several clinical-stage PARP inhibitors, including veliparib, rucaparib, olaparib, niraparib, and talazoparib, have been evaluated for their PARP-trapping activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25758918", "endSection": "abstract"}, {"offsetInBeginSection": 910, "offsetInEndSection": 1071, "text": "These results indicate that human tumor cells are significantly radiosensitized by the potent and selective PARP-1 inhibitor, niraparib, in the in vitro setting.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24970803", "endSection": "abstract"}, {"offsetInBeginSection": 105, "offsetInEndSection": 279, "text": "Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in preclinical tumour models with loss of BRCA and PTEN function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23810788", "endSection": "abstract"}, {"offsetInBeginSection": 552, "offsetInEndSection": 773, "text": "Moreover, the potency in trapping PARP differed markedly among inhibitors with niraparib (MK-4827)>olaparib (AZD-2281)>>veliparib (ABT-888), a pattern not correlated with the catalytic inhibitory properties for each drug.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118055", "endSection": "abstract"}, {"offsetInBeginSection": 1362, "offsetInEndSection": 1562, "text": "Niraparib (50 mg/kg) inhibited PARP1 activity in vivo and extended survival of mice with orthotopic pHGA xenografts, when administered before IR (20 Gy, fractionated), relative to control mice (40 vs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26351319", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25761096", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685067", "endSection": "title"}, {"offsetInBeginSection": 558, "offsetInEndSection": 675, "text": "Other PARP inhibitors under clinical trials include rucaparib, niraparib, veliparib, and the \"PARP-trapping\" BMN-673.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26281686", "endSection": "abstract"}, {"offsetInBeginSection": 626, "offsetInEndSection": 844, "text": "The high-throughput screens identified multiple clinical poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors, such as olaparib (AZD-2281), niraparib (MK-4827) and BMN 673, as being selective for ERCC1 deficiency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23934192", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) have demonstrated clinical proof of concept for cancer treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26513298", "endSection": "abstract"}, {"offsetInBeginSection": 552, "offsetInEndSection": 777, "text": "Moreover, the potency in trapping PARP differed markedly among inhibitors with niraparib (MK-4827) > olaparib (AZD-2281) >> veliparib (ABT-888), a pattern not correlated with the catalytic inhibitory properties for each drug.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118055", "endSection": "abstract"}]}, {"body": "Which peak calling algorithm employs mixture model clustering under the hood?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25223640"], "ideal_answer": ["JAMM (Joint Analysis of NGS replicates via Mixture Model clustering) is a peak finder that can integrate information from biological replicates, determine enrichment site widths accurately and resolve neighboring narrow peaks. JAMM is a universal peak finder that is applicable to different types of datasets."], "type": "factoid", "id": "587f760792a5b8ad44000005", "snippets": [{"offsetInBeginSection": 352, "offsetInEndSection": 946, "text": "We developed JAMM (Joint Analysis of NGS replicates via Mixture Model clustering): a peak finder that can integrate information from biological replicates, determine enrichment site widths accurately and resolve neighboring narrow peaks. JAMM is a universal peak finder that is applicable to different types of datasets. We show that JAMM is among the best performing peak finders in terms of site detection accuracy and in terms of accurate determination of enrichment sites widths. In addition, JAMM's replicate integration improves peak spatial resolution, sorting and peak finding accuracy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25223640", "endSection": "abstract"}]}, {"body": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27084938"], "ideal_answer": ["The DeepBlue Epigenomic Data Server contains data from four major epigenome projects, namely ENCODE, ROADMAP, BLUEPRINT and DEEP."], "type": "list", "id": "588fd8f3621ea6ff7e000001", "snippets": [{"offsetInBeginSection": 597, "offsetInEndSection": 956, "text": "Here we present the DeepBlue Epigenomic Data Server, which streamlines epigenomic data analysis as well as software development. DeepBlue provides a comprehensive programmatic interface for finding, selecting, filtering, summarizing and downloading region sets. It contains data from four major epigenome projects, namely ENCODE, ROADMAP, BLUEPRINT and DEEP. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27084938", "endSection": "abstract"}]}, {"body": "Which diseases that can be treated using the focused ultrasound thalamotomy.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26382842", "http://www.ncbi.nlm.nih.gov/pubmed/25438838", "http://www.ncbi.nlm.nih.gov/pubmed/27822200", "http://www.ncbi.nlm.nih.gov/pubmed/24291848", "http://www.ncbi.nlm.nih.gov/pubmed/25343176", "http://www.ncbi.nlm.nih.gov/pubmed/25512869", "http://www.ncbi.nlm.nih.gov/pubmed/24876191", "http://www.ncbi.nlm.nih.gov/pubmed/27399411", "http://www.ncbi.nlm.nih.gov/pubmed/26499271", "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "http://www.ncbi.nlm.nih.gov/pubmed/24620914", "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "http://www.ncbi.nlm.nih.gov/pubmed/20033983", "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "http://www.ncbi.nlm.nih.gov/pubmed/26769606", "http://www.ncbi.nlm.nih.gov/pubmed/24761224", "http://www.ncbi.nlm.nih.gov/pubmed/27557301", "http://www.ncbi.nlm.nih.gov/pubmed/26877873"], "ideal_answer": ["Focused ultrasound thalamotomy is used for treatment of Parkinson disease, essential tremor, obsessive-compulsive disorder and chronic neuropathic pain."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057086"], "type": "list", "id": "58846be0e56acf5176000005", "snippets": [{"offsetInBeginSection": 718, "offsetInEndSection": 927, "text": "Besides DBS and standard thalamotomy, novel surgical approaches for ET are on the horizon. The development of MRI-guided focused ultrasound technique has been the new frontier of deep brain lesional therapies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26382842", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "132\u2003A Randomized, Sham-Controlled Trial of Transcranial Magnetic Resonance-Guided Focused Ultrasound Thalamotomy Trial for the Treatment of Tremor-Dominant, Idiopathic Parkinson Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399411", "endSection": "title"}, {"offsetInBeginSection": 158, "offsetInEndSection": 442, "text": "Recently, transcranial magnetic resonance-guided focused ultrasound (MRgFUS) has been used to successfully perform thalamotomy for essential tremor. We designed a double-blinded, randomized controlled trial to investigate the effectiveness of MRgFUS thalamotomy in tremor-dominant PD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399411", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 398, "text": "Thalamotomy at the ventralis intermedius nucleus has been an effective treatment method for essential tremor, but how the brain network changes immediately responding to this deliberate lesion and then reorganizes afterwards are not clear. Taking advantage of a non-cranium-opening MRI-guided focused ultrasound ablation technique, we investigated functional network changes due to a focal lesion. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27822200", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Unilateral magnetic resonance guided focused ultrasound thalamotomy for essential tremor: practices and clinicoradiological outcomes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24876191", "endSection": "title"}, {"offsetInBeginSection": 1482, "offsetInEndSection": 1637, "text": "CONCLUSIONS: Our results demonstrate that MRgFUS thalamotomy is a safe, effective and less-invasive surgical method for treating medication-refractory ET. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24876191", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 472, "text": "OBJECT: The authors report different MRI patterns in patients with essential tremor (ET) or obsessive-compulsive disorder (OCD) after transcranial MR-guided focused ultrasound (MRgFUS) and discuss possible causes of occasional MRgFUS failure.METHODS: Between March 2012 and August 2013, MRgFUS was used to perform unilateral thalamotomy in 11 ET patients and bilateral anterior limb capsulotomy in 6 OCD patients; in all patients symptoms were refractory to drug therapy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25343176", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 421, "text": "To discern the neurophysiologic correlates of its therapeutic effects, we applied MRgHIFU to an intractable neurologic disorder, essential tremor, while measuring magnetoencephalogram mu rhythms from the motor cortex. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25438838", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "MRI Guided Focused Ultrasound Thalamotomy for Moderate-to-Severe Tremor in Parkinson's Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "title"}, {"offsetInBeginSection": 88, "offsetInEndSection": 416, "text": "Methods. Seven PD patients, mean age 59.4 \u00b1 9.8 years (range, 46-74) with a mean disease duration of 5.4 \u00b1 2.8 years (range, 2-10) suffering from severe refractory tremor, underwent ventral intermediate nucleus thalamotomy using MRI guided focused ultrasound (MRgFUS), an innovative technology that enables noninvasive surgery. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "abstract"}, {"offsetInBeginSection": 1016, "offsetInEndSection": 1078, "text": "Thalamotomy using MRgFUS is safe and effective in PD patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Evolution of Movement Disorders Surgery Leading to Contemporary Focused Ultrasound Therapy for Tremor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26499271", "endSection": "title"}, {"offsetInBeginSection": 338, "offsetInEndSection": 463, "text": "A noninvasive approach using transcranial high-energy focused ultrasound has emerged for the treatment of intractable tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26499271", "endSection": "abstract"}, {"offsetInBeginSection": 649, "offsetInEndSection": 775, "text": "This article describes the evolution of magnetic resonance-guided focused ultrasound for ventrolateral thalamotomy for tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26499271", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Thalamic connectivity in patients with essential tremor treated with MR imaging-guided focused ultrasound: in vivo fiber tracking by using diffusion-tensor MR imaging.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24620914", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 763, "text": "PURPOSE: To use diffusion-tensor (DT) magnetic resonance (MR) imaging in patients with essential tremor who were treated with transcranial MR imaging-guided focused ultrasound lesion inducement to identify the structural connectivity of the ventralis intermedius nucleus of the thalamus and determine how DT imaging changes correlated with tremor changes after lesion inducement.MATERIALS AND METHODS: With institutional review board approval, and with prospective informed consent, 15 patients with medication-refractory essential tremor were enrolled in a HIPAA-compliant pilot study and were treated with transcranial MR imaging-guided focused ultrasound surgery targeting the ventralis intermedius nucleus of the thalamus contralateral to their dominant hand.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24620914", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "A pilot study of focused ultrasound thalamotomy for essential tremor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "title"}, {"offsetInBeginSection": 168, "offsetInEndSection": 585, "text": "This preliminary study investigates the use of transcranial MRI-guided focused ultrasound thalamotomy for the treatment of essential tremor.METHODS: From February 2011 through December 2011, in an open-label, uncontrolled study, we used transcranial MRI-guided focused ultrasound to target the unilateral ventral intermediate nucleus of the thalamus in 15 patients with severe, medication-refractory essential tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 1599, "offsetInEndSection": 1729, "text": "CONCLUSIONS: In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "title"}, {"offsetInBeginSection": 383, "offsetInEndSection": 566, "text": "MR-guided focused ultrasound has been developed as a non-invasive means of generating precisely placed focal lesions. We examined its application to the management of essential tremor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "abstract"}, {"offsetInBeginSection": 653, "offsetInEndSection": 818, "text": "Four patients with chronic and medication-resistant essential tremor were treated with MR-guided focused ultrasound to ablate tremor-mediating areas of the thalamus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "abstract"}, {"offsetInBeginSection": 1540, "offsetInEndSection": 1739, "text": "INTERPRETATION: MR-guided focused ultrasound might be a safe and effective approach to generation of focal intracranial lesions for the management of disabling, medication-resistant essential tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Transcranial magnetic resonance imaging-guided focused ultrasound: noninvasive central lateral thalamotomy for chronic neuropathic pain.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "endSection": "title"}, {"offsetInBeginSection": 147, "offsetInEndSection": 493, "text": "The goal of this study was to apply the new transcranial magnetic resonance imaging-guided focused ultrasound (tcMRgFUS) technology to perform noninvasive central lateral thalamotomies (CLTs) as a treatment for chronic neuropathic pain.METHODS: In 12 patients suffering from chronic therapy-resistant neuropathic pain, tcMRgFUS CLT was proposed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "endSection": "abstract"}, {"offsetInBeginSection": 2063, "offsetInEndSection": 2225, "text": "CONCLUSIONS: The authors assert that tcMRgFUS represents a noninvasive, precise, and radiation-free neurosurgical technique for the treatment of neuropathic pain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "endSection": "abstract"}, {"offsetInBeginSection": 481, "offsetInEndSection": 585, "text": "A new less invasive treatment of tremor using MR guided focused ultrasound has started and is promising.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24291848", "endSection": "abstract"}, {"offsetInBeginSection": 1541, "offsetInEndSection": 1729, "text": "Quality-of-life scores improved from 37% to 11% (P=0.001).CONCLUSIONS: In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 96, "offsetInEndSection": 413, "text": "Seven PD patients, mean age 59.4 \u00b1 9.8 years (range, 46-74) with a mean disease duration of 5.4 \u00b1 2.8 years (range, 2-10) suffering from severe refractory tremor, underwent ventral intermediate nucleus thalamotomy using MRI guided focused ultrasound (MRgFUS), an innovative technology that enables noninvasive surgery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "abstract"}, {"offsetInBeginSection": 490, "offsetInEndSection": 975, "text": "We hypothesized that all three would effectively treat the dominant hand and positively impact functional outcomes and quality of life as measured with the Clinical Rating Scale for Tremor and the Quality of Life in Essential Tremor Questionnaire.This is a retrospective study of medication-refractory essential tremor patients treated at the University of Virginia with bilateral Vim DBS (n\u2009=\u200957), unilateral Vim DBS (n\u2009=\u200913), or unilateral focused ultrasound Vim thalamotomy (n\u2009=\u200915)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26769606", "endSection": "abstract"}, {"offsetInBeginSection": 1510, "offsetInEndSection": 1684, "text": "Quality-of-life scores improved from 37% to 11% (P=0.001).In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "MRI Guided Focused Ultrasound Thalamotomy for Moderate-to-Severe Tremor in Parkinsons Disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "title"}, {"offsetInBeginSection": 97, "offsetInEndSection": 415, "text": "Seven PD patients, mean age 59.4 \u00b1 9.8 years (range, 46-74) with a mean disease duration of 5.4 \u00b1 2.8 years (range, 2-10) suffering from severe refractory tremor, underwent ventral intermediate nucleus thalamotomy using MRI guided focused ultrasound (MRgFUS), an innovative technology that enables noninvasive surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 553, "text": "Transcranial magnetic resonance imaging-guided high-intensity focused ultrasound (MRgHIFU) is gaining attention as a potent substitute for surgical intervention in the treatment of neurologic disorders. To discern the neurophysiologic correlates of its therapeutic effects, we applied MRgHIFU to an intractable neurologic disorder, essential tremor, while measuring magnetoencephalogram mu rhythms from the motor cortex. Focused ultrasound sonication destroyed tissues by focusing a high-energy beam on the ventralis intermedius nucleus of the thalamus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25438838", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 585, "text": "BACKGROUND: Recent advances have enabled delivery of high-intensity focused ultrasound through the intact human cranium with magnetic resonance imaging (MRI) guidance. This preliminary study investigates the use of transcranial MRI-guided focused ultrasound thalamotomy for the treatment of essential tremor.METHODS: From February 2011 through December 2011, in an open-label, uncontrolled study, we used transcranial MRI-guided focused ultrasound to target the unilateral ventral intermediate nucleus of the thalamus in 15 patients with severe, medication-refractory essential tremor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "MRI Guided Focused Ultrasound Thalamotomy for Moderate-to-Severe Tremor in Parkinson's Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "132\u2003A Randomized, Sham-Controlled Trial of Transcranial Magnetic Resonance-Guided Focused Ultrasound Thalamotomy Trial for the Treatment of Tremor-Dominant, Idiopathic Parkinson Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399411", "endSection": "title"}, {"offsetInBeginSection": 1572, "offsetInEndSection": 1689, "text": "In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23944301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27557301", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523144", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Unilateral magnetic resonance guided focused ultrasound thalamotomy for essential tremor: practices and clinicoradiological outcomes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24876191", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Functional assessment and quality of life in essential tremor with bilateral or unilateral DBS and focused ultrasound thalamotomy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26769606", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Transcranial magnetic resonance imaging-guided focused ultrasound: noninvasive central lateral thalamotomy for chronic neuropathic pain.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22208894", "endSection": "title"}, {"offsetInBeginSection": 738, "offsetInEndSection": 977, "text": "This is a retrospective study of medication-refractory essential tremor patients treated at the University of Virginia with bilateral Vim DBS (n\u2009=\u200957), unilateral Vim DBS (n\u2009=\u200913), or unilateral focused ultrasound Vim thalamotomy (n\u2009=\u200915).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26769606", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 776, "text": "Twenty-one consecutive patients suffering from chronic (mean disease duration 29.9\u00a0years), therapy-resistant ET were treated with MRgFUS CTT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26877873", "endSection": "abstract"}]}, {"body": "Is the toxin produced by Clostridium botulinum always deadly?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12926199", "http://www.ncbi.nlm.nih.gov/pubmed/20173718", "http://www.ncbi.nlm.nih.gov/pubmed/23871478", "http://www.ncbi.nlm.nih.gov/pubmed/26866491", "http://www.ncbi.nlm.nih.gov/pubmed/24997242", "http://www.ncbi.nlm.nih.gov/pubmed/15244362", "http://www.ncbi.nlm.nih.gov/pubmed/19488551", "http://www.ncbi.nlm.nih.gov/pubmed/23097586", "http://www.ncbi.nlm.nih.gov/pubmed/22513950", "http://www.ncbi.nlm.nih.gov/pubmed/24867833", "http://www.ncbi.nlm.nih.gov/pubmed/17674683", "http://www.ncbi.nlm.nih.gov/pubmed/19160335", "http://www.ncbi.nlm.nih.gov/pubmed/20693440", "http://www.ncbi.nlm.nih.gov/pubmed/26697417"], "ideal_answer": ["There are numerous examples where children and animals survived infection with clostridium botulinum."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001905", "http://www.disease-ontology.org/api/metadata/DOID:11976"], "type": "yesno", "id": "58a341a660087bc10a000017", "snippets": [{"offsetInBeginSection": 1759, "offsetInEndSection": 1941, "text": "Animals treated with trace elements recovered. It appears that intestinal microbiota dysbiosis and trace element deficiency could explain the extensive emergence of chronic Botulism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24997242", "endSection": "abstract"}, {"offsetInBeginSection": 1082, "offsetInEndSection": 1316, "text": "The patient was treated with human botulism immune globulin and had rapid recovery in weakness. A stool sample from the patient was positive for Type A Clostridium botulinum toxin eventually confirming the diagnosis of infant botulism", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26697417", "endSection": "abstract"}, {"offsetInBeginSection": 1199, "offsetInEndSection": 1363, "text": "The botulism immunoglobulin was administered, and a diagnosis was confirmed with positive botulinum toxin in the stool samples. Full recovery was made by the infant", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23871478", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Botulinum neurotoxin (BoNT) serotype B (BoNT/B) is one of the serotypes of BoNT that causes deadly human botulism, though it is used clinically for treatment of many neuromuscular diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20693440", "endSection": "abstract"}, {"offsetInBeginSection": 197, "offsetInEndSection": 311, "text": "Foodborne botulism is a rare and sometimes fatal illness caused by consuming foods containing botulinum neurotoxin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23097586", "endSection": "abstract"}, {"offsetInBeginSection": 578, "offsetInEndSection": 692, "text": "To assess the effectiveness and safety of botulinum toxin in treating MPS, excluding MPS in neck and head muscles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22513950", "endSection": "abstract"}, {"offsetInBeginSection": 27, "offsetInEndSection": 174, "text": "Botulinum toxin (BTX) is one of the most potent bacterial toxins known and its effectiveness in the treatment of some pain syndromes is well known.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488551", "endSection": "abstract"}, {"offsetInBeginSection": 525, "offsetInEndSection": 751, "text": " An emerging treatment option to address these issues is the use of a paralyzing material such as botulinum toxin A (Botox) to decrease the appearance of the wrinkles, which yields a more esthetic and youthful facial appearanc", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17674683", "endSection": "abstract"}, {"offsetInBeginSection": 249, "offsetInEndSection": 413, "text": "lthough BoNT is an extremely toxic molecule, it is now increasingly used for the treatment of disorders related to muscle hyperactivity and glandular hyperactivity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26866491", "endSection": "abstract"}]}, {"body": "Is ocrelizumab effective for treatment of multiple sclerosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27270678", "http://www.ncbi.nlm.nih.gov/pubmed/21341224", "http://www.ncbi.nlm.nih.gov/pubmed/24494635", "http://www.ncbi.nlm.nih.gov/pubmed/27116720", "http://www.ncbi.nlm.nih.gov/pubmed/22047971", "http://www.ncbi.nlm.nih.gov/pubmed/25887773", "http://www.ncbi.nlm.nih.gov/pubmed/26600872", "http://www.ncbi.nlm.nih.gov/pubmed/27718747", "http://www.ncbi.nlm.nih.gov/pubmed/24494619", "http://www.ncbi.nlm.nih.gov/pubmed/27552111", "http://www.ncbi.nlm.nih.gov/pubmed/27813441", "http://www.ncbi.nlm.nih.gov/pubmed/18951300", "http://www.ncbi.nlm.nih.gov/pubmed/24732658", "http://www.ncbi.nlm.nih.gov/pubmed/27389598", "http://www.ncbi.nlm.nih.gov/pubmed/25888198", "http://www.ncbi.nlm.nih.gov/pubmed/23609782", "http://www.ncbi.nlm.nih.gov/pubmed/22229582", "http://www.ncbi.nlm.nih.gov/pubmed/25887766", "http://www.ncbi.nlm.nih.gov/pubmed/26729332", "http://www.ncbi.nlm.nih.gov/pubmed/24928997", "http://www.ncbi.nlm.nih.gov/pubmed/20500147", "http://www.ncbi.nlm.nih.gov/pubmed/27756172", "http://www.ncbi.nlm.nih.gov/pubmed/26702336", "http://www.ncbi.nlm.nih.gov/pubmed/22673950", "http://www.ncbi.nlm.nih.gov/pubmed/26788130", "http://www.ncbi.nlm.nih.gov/pubmed/25732947", "http://www.ncbi.nlm.nih.gov/pubmed/24507535"], "ideal_answer": ["Yes, ocrelizumab is effective for primary progressive form of multiple sclerosis."], "concepts": ["http://www.biosemantics.org/jochem#4002285", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009103", "http://www.disease-ontology.org/api/metadata/DOID:2377"], "type": "yesno", "id": "588fa4b9ed9bbee70d000006", "snippets": [{"offsetInBeginSection": 672, "offsetInEndSection": 995, "text": " Advances made in immunomodulation are driving the progress being made in the treatment of MS. Ocrelizumab is the first treatment with positive results in the primarily progressive forms and tocilizumab, a drug product for rheumatoid arthritis, stands out as a potential candidate for the treatment of neuromyelitis optica.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27270678", "endSection": "abstract"}, {"offsetInBeginSection": 682, "offsetInEndSection": 903, "text": " Expert commentary: The recent encouraging results of the ocrelizumab trial in PP MS, the first to reach the primary disability endpoint, indicate B cells as a promising therapeutic target to prevent disease progression. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813441", "endSection": "abstract"}, {"offsetInBeginSection": 1038, "offsetInEndSection": 1124, "text": "Ocrelizumab also shows efficacy in the primary progressive form of multiple sclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27389598", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552111", "endSection": "title"}, {"offsetInBeginSection": 737, "offsetInEndSection": 959, "text": "Expert commentary: The topline results of two phase-III randomized clinical trials demonstrate superiority of ocrelizumab over interferon beta in RRMS patients with regards to clinical and paraclinical outcome parameters. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552111", "endSection": "abstract"}, {"offsetInBeginSection": 852, "offsetInEndSection": 1109, "text": "The efficacy of three of them, rituximab, ocrelizumab and ofatumumab in MS has been confirmed by placebo-controlled clinical trials demonstrating a significant reduction of the annualized relapsing rate (ARR), new gadolinium-enhancing (GdE) and T2 lesions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27718747", "endSection": "abstract"}, {"offsetInBeginSection": 1133, "offsetInEndSection": 1291, "text": "Ongoing PMS trials are currently being conducted with the phosphodiesterase inhibitor ibudilast, S1P modulator siponimod and anti-B-cell therapy ocrelizumab. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25887766", "endSection": "abstract"}, {"offsetInBeginSection": 213, "offsetInEndSection": 407, "text": "RECENT FINDINGS: Novel and imminently emerging DMTs for the treatment of RRMS include alemtuzumab, daclizumab, ocrelizumab, pegylated interferon-\u03b2-1a, and three times weekly glatiramer acetate. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25887773", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 369, "text": "To summarize mechanisms of action, efficacy, and safety of novel and imminently emerging disease-modifying treatments (DMTs) intended to be used in relapsing-remitting multiple sclerosis (RRMS).Novel and imminently emerging DMTs for the treatment of RRMS include alemtuzumab, daclizumab, ocrelizumab, pegylated interferon-\u03b2-1a, and three times weekly glatiramer acetate", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25887773", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971", "endSection": "title"}, {"offsetInBeginSection": 84, "offsetInEndSection": 260, "text": "We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "In multiple sclerosis (MS), B cell-depleting therapy using monoclonal anti-CD20 Abs, including rituximab (RTX) and ocrelizumab, effectively reduces disease activity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928997", "endSection": "abstract"}, {"offsetInBeginSection": 998, "offsetInEndSection": 1234, "text": "Ocrelizumab also shows efficacy in the primary progressive form of multiple sclerosis.Most of the presented cell-depleting and myeloablative therapies are highly effective treatment options but are also accompanied by significant risks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27389598", "endSection": "abstract"}, {"offsetInBeginSection": 879, "offsetInEndSection": 1288, "text": "The armamentarium of approved disease-modifying therapies in MS and those in development include: (1) the first approved, moderately effective, injectable interferon-\u03b2 and glatiramer acetate; (2) oral drugs (fingolimod, laquinimod, teriflunomide, dimethyl fumarate); (3) monoclonal antibodies (rituximab, ocrelizumab, ofatumumab, daclizumab, alemtuzumab); and (4) immunosuppressive agents (e.g. mitoxantrone).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24732658", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 700, "text": "BACKGROUND: B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis.METHODS: We did a multicentre, randomised, parallel, double-blind, placebo-controlled study involving 79 centres in 20 countries. Patients aged 18-55 years with relapsing-remitting multiple sclerosis were randomly assigned (1:1:1:1) via an interactive voice response system to receive either placebo, low-dose (600 mg) or high-dose (2000 mg) ocrelizumab in two doses on days 1 and 15, or intramuscular interferon beta-1a (30 \u00ecg) once a week.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552111", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26788130", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971", "endSection": "title"}, {"offsetInBeginSection": 1001, "offsetInEndSection": 1087, "text": "Ocrelizumab also shows efficacy in the primary progressive form of multiple sclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27389598", "endSection": "abstract"}]}, {"body": "Elaborate on the role of CARMEN in cardiac specification.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26423156"], "ideal_answer": ["CARMEN, (CAR)diac (M)esoderm (E)nhancer-associated (N)oncoding RNA, is a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. CARMEN exhibits RNA-dependent enhancing activity and is upstream of the cardiac mesoderm-specifying gene regulatory network. CARMEN interacts with SUZ12 and EZH2, two components of the polycomb repressive complex 2 (PRC2). CARMEN expression is activated during pathological remodeling in the mouse and human hearts, and is necessary for maintaining cardiac identity in differentiated cardiomyocytes."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:2000043", "http://amigo.geneontology.org/amigo/term/GO:0060912"], "type": "summary", "id": "58837dd72305cd7e21000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26423156", "endSection": "title"}, {"offsetInBeginSection": 575, "offsetInEndSection": 1487, "text": "One of the most upregulated lncRNAs was a SE-associated lncRNA that was named CARMEN, (CAR)diac (M)esoderm (E)nhancer-associated (N)oncoding RNA. CARMEN exhibits RNA-dependent enhancing activity and is upstream of the cardiac mesoderm-specifying gene regulatory network. Interestingly, CARMEN interacts with SUZ12 and EZH2, two components of the polycomb repressive complex 2 (PRC2). We demonstrate that CARMEN knockdown inhibits cardiac specification and differentiation in cardiac precursor cells independently of MIR-143 and -145 expression, two microRNAs located proximal to the enhancer sequences. Importantly, CARMEN expression was activated during pathological remodeling in the mouse and human hearts, and was necessary for maintaining cardiac identity in differentiated cardiomyocytes. This study demonstrates therefore that CARMEN is a crucial regulator of cardiac cell differentiation and homeostasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26423156", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26423156", "endSection": "title"}, {"offsetInBeginSection": 959, "offsetInEndSection": 1176, "text": "We demonstrate that CARMEN knockdown inhibits cardiac specification and differentiation in cardiac precursor cells independently of MIR-143 and -145 expression, two microRNAs located proximal to the enhancer sequences", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26423156", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26423156", "endSection": "title"}]}, {"body": "Is there a role of regorafenib for sarcoma treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24266804", "http://www.ncbi.nlm.nih.gov/pubmed/26266019", "http://www.ncbi.nlm.nih.gov/pubmed/25301268", "http://www.ncbi.nlm.nih.gov/pubmed/27751846", "http://www.ncbi.nlm.nih.gov/pubmed/26907871", "http://www.ncbi.nlm.nih.gov/pubmed/24756792", "http://www.ncbi.nlm.nih.gov/pubmed/25884155"], "ideal_answer": ["Yes, there is evidence to suggest that regorafenib can be effective for sarcoma treatment. Clinical trials are under-way."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:1115", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012509", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012380"], "type": "yesno", "id": "58848a13e56acf517600000d", "snippets": [{"offsetInBeginSection": 809, "offsetInEndSection": 862, "text": "Regorafenib has been approved for third-line therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26907871", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25884155", "endSection": "title"}, {"offsetInBeginSection": 1795, "offsetInEndSection": 1972, "text": "DISCUSSION: The design of this trial allows an assessment of regorafenib activity over placebo in four sarcoma strata and might provide evidence for launching a phase III trial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25884155", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 533, "text": "This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26266019", "endSection": "abstract"}, {"offsetInBeginSection": 525, "offsetInEndSection": 718, "text": "Thus, the Phase III studies with pazopanib, regorafenib, muramyl tripeptide (MTP) and ridaforolimus are extensively discussed as well as the biological rationale for the use of these compounds.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24266804", "endSection": "abstract"}, {"offsetInBeginSection": 726, "offsetInEndSection": 935, "text": "Currently, regorafenib is examined in several clinical trials (mostly phase II) in different tumor entities, including renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and soft tissue sarcoma (STS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24756792", "endSection": "abstract"}, {"offsetInBeginSection": 1674, "offsetInEndSection": 1852, "text": "Analysis of primary human sarcoma samples revealed direct cytotoxicity following exposure to sorafenib and regorafenib with a corresponding increase in ALDHbright cells (P<0.05).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301268", "endSection": "abstract"}, {"offsetInBeginSection": 954, "offsetInEndSection": 1299, "text": "Parametric and non-parametric statistical analyses were performed as appropriate.RESULTS: After functionally validating the CSC phenotype of ALDHbright sarcoma cells, we observed that sorafenib and regorafenib were cytotoxic to sarcoma cell lines (P<0.05), with a corresponding 1.4 - 2.8 fold increase in ALDHbright cells from baseline (P<0.05).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301268", "endSection": "abstract"}, {"offsetInBeginSection": 595, "offsetInEndSection": 1299, "text": "We evaluated survival and CSC phenotype in mice harboring sarcoma metastases after TKI therapy. We exposed dissociated primary sarcoma tumors to sorafenib, regorafenib, and pazopanib, and we used tissue microarray (TMA) and primary sarcoma samples to evaluate the frequency and intensity of CSC markers after neoadjuvant therapy with sorafenib and pazopanib. Parametric and non-parametric statistical analyses were performed as appropriate.RESULTS: After functionally validating the CSC phenotype of ALDHbright sarcoma cells, we observed that sorafenib and regorafenib were cytotoxic to sarcoma cell lines (P<0.05), with a corresponding 1.4 - 2.8 fold increase in ALDHbright cells from baseline (P<0.05).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301268", "endSection": "abstract"}, {"offsetInBeginSection": 691, "offsetInEndSection": 1299, "text": "We exposed dissociated primary sarcoma tumors to sorafenib, regorafenib, and pazopanib, and we used tissue microarray (TMA) and primary sarcoma samples to evaluate the frequency and intensity of CSC markers after neoadjuvant therapy with sorafenib and pazopanib. Parametric and non-parametric statistical analyses were performed as appropriate.RESULTS: After functionally validating the CSC phenotype of ALDHbright sarcoma cells, we observed that sorafenib and regorafenib were cytotoxic to sarcoma cell lines (P<0.05), with a corresponding 1.4 - 2.8 fold increase in ALDHbright cells from baseline (P<0.05).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301268", "endSection": "abstract"}, {"offsetInBeginSection": 691, "offsetInEndSection": 1396, "text": "We exposed dissociated primary sarcoma tumors to sorafenib, regorafenib, and pazopanib, and we used tissue microarray (TMA) and primary sarcoma samples to evaluate the frequency and intensity of CSC markers after neoadjuvant therapy with sorafenib and pazopanib. Parametric and non-parametric statistical analyses were performed as appropriate.RESULTS: After functionally validating the CSC phenotype of ALDHbright sarcoma cells, we observed that sorafenib and regorafenib were cytotoxic to sarcoma cell lines (P<0.05), with a corresponding 1.4 - 2.8 fold increase in ALDHbright cells from baseline (P<0.05). In contrast, we observed negligible effects on viability and CSC sub-populations with pazopanib.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301268", "endSection": "abstract"}, {"offsetInBeginSection": 1016, "offsetInEndSection": 1275, "text": "After functionally validating the CSC phenotype of ALDHbright sarcoma cells, we observed that sorafenib and regorafenib were cytotoxic to sarcoma cell lines (P < 0.05), with a corresponding 1.4 - 2.8 fold increase in ALDHbright cells from baseline (P < 0.05).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301268", "endSection": "abstract"}]}, {"body": "Which drug was tested in the TEMSO Trial for multiple sclerosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21991951", "http://www.ncbi.nlm.nih.gov/pubmed/24321165", "http://www.ncbi.nlm.nih.gov/pubmed/23852658", "http://www.ncbi.nlm.nih.gov/pubmed/27937746", "http://www.ncbi.nlm.nih.gov/pubmed/26944956", "http://www.ncbi.nlm.nih.gov/pubmed/22723573", "http://www.ncbi.nlm.nih.gov/pubmed/26758290", "http://www.ncbi.nlm.nih.gov/pubmed/21157651", "http://www.ncbi.nlm.nih.gov/pubmed/26434194", "http://www.ncbi.nlm.nih.gov/pubmed/26865517", "http://www.ncbi.nlm.nih.gov/pubmed/26365096", "http://www.ncbi.nlm.nih.gov/pubmed/23695001", "http://www.ncbi.nlm.nih.gov/pubmed/27919491"], "ideal_answer": ["Teriflunomide was evaluated in the Teriflunomide Multiple Sclerosis Oral (TEMSO) trial."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017428", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009103", "http://www.disease-ontology.org/api/metadata/DOID:2377"], "type": "factoid", "id": "589a246078275d0c4a00002a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865517", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 220, "text": "OBJECTIVE: To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865517", "endSection": "abstract"}, {"offsetInBeginSection": 1378, "offsetInEndSection": 1556, "text": "CONCLUSIONS: In the TEMSO extension, safety observations were consistent with the core trial, with no new or unexpected AEs in patients receiving teriflunomide for up to 9 years.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865517", "endSection": "abstract"}, {"offsetInBeginSection": 649, "offsetInEndSection": 830, "text": "Teriflunomide, approved on the basis of the two placebo-controlled trials TEMSO and TOWER, demonstrated a reduction in the ARR from 0.54 to 0.37 and from 0.50 to 0.32 respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26944956", "endSection": "abstract"}, {"offsetInBeginSection": 584, "offsetInEndSection": 964, "text": "Using data from pivotal studies of DMF (DEFINE, NCT00420212; CONFIRM, NCT00451451), fingolimod (FREEDOMS, NCT00289978; FREEDOMS II, NCT00355134), and teriflunomide (TEMSO, NCT00134563; TOWER, NCT00751881), we calculated NNTs to prevent any relapse, more severe relapses (such as those leading to hospitalization or requiring intravenous corticosteroids), and disability worsening.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27919491", "endSection": "abstract"}, {"offsetInBeginSection": 218, "offsetInEndSection": 488, "text": "METHODS: In September 2012, the US Food and Drug Administration granted approval for the use of teriflunomide, 14 mg and 7 mg once daily, to treat RMS on the basis of the results of a Phase II study and the Phase III TEMSO (Teriflunomide Multiple Sclerosis Oral) trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26365096", "endSection": "abstract"}, {"offsetInBeginSection": 1039, "offsetInEndSection": 1362, "text": "In the TEMSO and TOWER studies, the 14-mg dose of teriflunomide significantly reduced annualized relapse rate (31% and 36% relative risk reduction compared with placebo, respectively; both P<0.001) and risk of disability progression sustained for 12 weeks (hazard ratio vs placebo 0.70 and 0.69, respectively; both P<0.05).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26365096", "endSection": "abstract"}, {"offsetInBeginSection": 1543, "offsetInEndSection": 1758, "text": "Teriflunomide treatment was also associated with significant efficacy on MRI measures of disease activity in TEMSO; both doses significantly reduced total lesion volume and number of gadolinium-enhancing T1 lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26365096", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 468, "text": "The purpose was to summarize US prescribing information for teriflunomide in the treatment of patients with relapsing forms of multiple sclerosis (RMS), with reference to clinical efficacy and safety outcomes.In September 2012, the US Food and Drug Administration granted approval for the use of teriflunomide, 14 mg and 7 mg once daily, to treat RMS on the basis of the results of a Phase II study and the Phase III TEMSO (Teriflunomide Multiple Sclerosis Oral) trial", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26365096", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 589, "text": "The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), disease progression and magnetic resonance imaging (MRI) activity, with a favorable safety profile in relapsing multiple sclerosis (RMS) patients.The purpose of this study was to report the effects of teriflunomide on ARR and disability progression in pre-specified subgroups.RMS patients (n=1088) were randomized to placebo or teriflunomide, 7 mg or 14 mg, once daily, for 108 weeks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22723573", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 623, "text": "BACKGROUND: The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), disease progression and magnetic resonance imaging (MRI) activity, with a favorable safety profile in relapsing multiple sclerosis (RMS) patients.OBJECTIVE: The purpose of this study was to report the effects of teriflunomide on ARR and disability progression in pre-specified subgroups.METHODS: RMS patients (n=1088) were randomized to placebo or teriflunomide, 7 mg or 14 mg, once daily, for 108 weeks. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22723573", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 469, "text": "The purpose was to summarize US prescribing information for teriflunomide in the treatment of patients with relapsing forms of multiple sclerosis (RMS), with reference to clinical efficacy and safety outcomes.In September 2012, the US Food and Drug Administration granted approval for the use of teriflunomide, 14 mg and 7 mg once daily, to treat RMS on the basis of the results of a Phase II study and the Phase III TEMSO (Teriflunomide Multiple Sclerosis Oral) trial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26365096", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 590, "text": "The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), disease progression and magnetic resonance imaging (MRI) activity, with a favorable safety profile in relapsing multiple sclerosis (RMS) patients.The purpose of this study was to report the effects of teriflunomide on ARR and disability progression in pre-specified subgroups.RMS patients (n=1088) were randomized to placebo or teriflunomide, 7 mg or 14 mg, once daily, for 108 weeks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22723573", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 255, "text": "To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563).A total of 742 patients entered the extension.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865517", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 622, "text": "BACKGROUND: The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), disease progression and magnetic resonance imaging (MRI) activity, with a favorable safety profile in relapsing multiple sclerosis (RMS) patients.OBJECTIVE: The purpose of this study was to report the effects of teriflunomide on ARR and disability progression in pre-specified subgroups.METHODS: RMS patients (n=1088) were randomized to placebo or teriflunomide, 7 mg or 14 mg, once daily, for 108 weeks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22723573", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 352, "text": "The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), disease progression and magnetic resonance imaging (MRI) activity, with a favorable safety profile in relapsing multiple sclerosis (RMS) patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22723573", "endSection": "abstract"}, {"offsetInBeginSection": 424, "offsetInEndSection": 627, "text": "Two phase III clinical trials (TEMSO, TOWER) tested teriflunomide in patients with relapsing forms of MS: efficacy was shown, with positive effects on relapse rates and disease progression for 14 mg/day.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321165", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865517", "endSection": "abstract"}, {"offsetInBeginSection": 210, "offsetInEndSection": 470, "text": "In September 2012, the US Food and Drug Administration granted approval for the use of teriflunomide, 14 mg and 7 mg once daily, to treat RMS on the basis of the results of a Phase II study and the Phase III TEMSO (Teriflunomide Multiple Sclerosis Oral) trial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26365096", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of peginesatide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22406924", "http://www.ncbi.nlm.nih.gov/pubmed/24748667", "http://www.ncbi.nlm.nih.gov/pubmed/24905967", "http://www.ncbi.nlm.nih.gov/pubmed/23840463", "http://www.ncbi.nlm.nih.gov/pubmed/27551882", "http://www.ncbi.nlm.nih.gov/pubmed/22935486", "http://www.ncbi.nlm.nih.gov/pubmed/23675762", "http://www.ncbi.nlm.nih.gov/pubmed/23318685", "http://www.ncbi.nlm.nih.gov/pubmed/20730698", "http://www.ncbi.nlm.nih.gov/pubmed/21290916", "http://www.ncbi.nlm.nih.gov/pubmed/23111861", "http://www.ncbi.nlm.nih.gov/pubmed/23343062", "http://www.ncbi.nlm.nih.gov/pubmed/24348017", "http://www.ncbi.nlm.nih.gov/pubmed/26079829", "http://www.ncbi.nlm.nih.gov/pubmed/23343061", "http://www.ncbi.nlm.nih.gov/pubmed/22188389", "http://www.ncbi.nlm.nih.gov/pubmed/23847411", "http://www.ncbi.nlm.nih.gov/pubmed/22719216", "http://www.ncbi.nlm.nih.gov/pubmed/22192713", "http://www.ncbi.nlm.nih.gov/pubmed/21710591", "http://www.ncbi.nlm.nih.gov/pubmed/21816551", "http://www.ncbi.nlm.nih.gov/pubmed/23989045", "http://www.ncbi.nlm.nih.gov/pubmed/24023516", "http://www.ncbi.nlm.nih.gov/pubmed/22884786", "http://www.ncbi.nlm.nih.gov/pubmed/24584613", "http://www.ncbi.nlm.nih.gov/pubmed/27279382", "http://www.ncbi.nlm.nih.gov/pubmed/22592927", "http://www.ncbi.nlm.nih.gov/pubmed/26122516", "http://www.ncbi.nlm.nih.gov/pubmed/23506424", "http://www.ncbi.nlm.nih.gov/pubmed/23338536", "http://www.ncbi.nlm.nih.gov/pubmed/21649477", "http://www.ncbi.nlm.nih.gov/pubmed/23243269", "http://www.ncbi.nlm.nih.gov/pubmed/22642238", "http://www.ncbi.nlm.nih.gov/pubmed/22971699", "http://www.ncbi.nlm.nih.gov/pubmed/27174804", "http://www.ncbi.nlm.nih.gov/pubmed/21940838", "http://www.ncbi.nlm.nih.gov/pubmed/22745925"], "ideal_answer": ["Peginesatide (Omontys) is synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent that is designed to specifically stimulate the erythropoietin receptor. It was recalled because of serious side-effects including cases of death."], "type": "summary", "id": "58962dac78275d0c4a000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "The erythropoietin-mimetic peptide (EMP) peginesatide belongs to the group of erythropoiesis-stimulating agents (ESAs) that are prohibited when misused in sports. Peginesatide is a synthetic pegylated homodimer of two cyclic 21-amino acid chains. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27279382", "endSection": "abstract"}, {"offsetInBeginSection": 916, "offsetInEndSection": 1120, "text": "Epo mimetic peptides have also raised expectations. Yet the prototype peginesatide was recalled after just 1 year of its widespread use in the USA because of serious side-effects including cases of death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24748667", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The erythropoietin analog peginesatide was withdrawn from marketing due to unexpected severe anaphylactic reactions associated with administration of the multi-use formulation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26079829", "endSection": "abstract"}, {"offsetInBeginSection": 1275, "offsetInEndSection": 1486, "text": "Method characterization was conducted for the EMP-based drug peginesatide concerning specificity, linearity, precision, recovery, stability, ion suppression/enhancement, and limit of detection (LOD, 0.25 ng/mL).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26122516", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "PURPOSE: Peginesatide, a long-acting erythropoiesis-stimulating agent, was recalled in February 2013 following reports of serious and sometimes fatal hypersensitivity reactions in dialysis patients who received a first dose. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24905967", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "BACKGROUND AND OBJECTIVES: Peginesatide (Omontys) is a novel, synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23243269", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318685", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318685", "endSection": "abstract"}, {"offsetInBeginSection": 749, "offsetInEndSection": 973, "text": "Peginesatide is a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816551", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "BACKGROUND: Peginesatide is a peptide-based erythropoiesis-stimulating agent that was designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22935486", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Peginesatide is a synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22406924", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "BACKGROUND: Peginesatide is a peptide-based erythropoiesis-stimulating agent (ESA) that may have therapeutic potential for anemia in patients with advanced chronic kidney disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23343062", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "The pharmacokinetics (PK) (absorption, distribution, metabolism, excretion) of peginesatide, a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent (ESA), was evaluated in rats.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22188389", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22188389", "endSection": "title"}, {"offsetInBeginSection": 119, "offsetInEndSection": 244, "text": "Peginesatide is an investigational pegylated, peptide-based, once-monthly ESA for increasing and maintaining hemoglobin (Hb).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21290916", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21290916", "endSection": "title"}, {"offsetInBeginSection": 749, "offsetInEndSection": 1069, "text": "Peginesatide is a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. It is undetectable using current anti-doping tests due to its lack of sequence homology to EPO.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816551", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 364, "text": "Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis. Studies were designed to determine the erythropoietic response, pharmacokinetics (PK), tissue distribution, metabolism, and excretion of peginesatide in nonhuman primates following a single i.v.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318685", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 370, "text": "Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis. Studies were designed to determine the erythropoietic response, pharmacokinetics (PK), tissue distribution, metabolism, and excretion of peginesatide in nonhuman primates following a single i.v. dose.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318685", "endSection": "abstract"}, {"offsetInBeginSection": 749, "offsetInEndSection": 1313, "text": "Peginesatide is a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. It is undetectable using current anti-doping tests due to its lack of sequence homology to EPO. To detect and deter potential abuse of peginesatide, we initiated an industry/antidoping laboratory collaboration to develop and validate screening and confirmation assays so that they would be available before peginesatide reaches the market.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816551", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 490, "text": "Peginesatide is a synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. Peginesatide has a unique structure that consists of a synthetic peptide dimer (with no sequence similarity to erythropoietin) conjugated to a 40-kDa PEG moiety. Peginesatide is being developed for the treatment of anemia associated with chronic kidney disease in dialysis patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22406924", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 369, "text": "Peginesatide is a synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. Peginesatide has a unique structure that consists of a synthetic peptide dimer (with no sequence similarity to erythropoietin) conjugated to a 40-kDa PEG moiety.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22406924", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21290916", "endSection": "title"}]}, {"body": "Describe mechanism of action of Eteplirsen?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27807823", "http://www.ncbi.nlm.nih.gov/pubmed/27854228", "http://www.ncbi.nlm.nih.gov/pubmed/22086232", "http://www.ncbi.nlm.nih.gov/pubmed/27936976", "http://www.ncbi.nlm.nih.gov/pubmed/23907995", "http://www.ncbi.nlm.nih.gov/pubmed/26573217", "http://www.ncbi.nlm.nih.gov/pubmed/23995279", "http://www.ncbi.nlm.nih.gov/pubmed/23075107", "http://www.ncbi.nlm.nih.gov/pubmed/24282529"], "ideal_answer": ["Eteplirsen (Exondys 51) is an antisense oligonucleotide designed to induce exon 51 skipping. Eteplirsen is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping."], "type": "summary", "id": "5891869b621ea6ff7e00000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 346, "text": "Eteplirsen (Exondys\u00a051) is an antisense oligonucleotide designed to induce exon 51 skipping that is developed by Sarepta Therapeutics. Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823", "endSection": "abstract"}, {"offsetInBeginSection": 447, "offsetInEndSection": 563, "text": "The first AON (eteplirsen) has recently received accelerated approval by the Food and Drug Administration in the US.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27936976", "endSection": "abstract"}, {"offsetInBeginSection": 543, "offsetInEndSection": 645, "text": "Currently, the most promising potential drugs are the exon-skipping agents eteplirsen and drisapersen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23995279", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "OBJECTIVE: In prior open-label studies, eteplirsen, a phosphorodiamidate morpholino oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907995", "endSection": "abstract"}, {"offsetInBeginSection": 995, "offsetInEndSection": 1241, "text": "We also assessed the effect of dystrophin restoration on the expression of the five dystromirs in serum of DMD patients treated systemically for 12 weeks with antisense oligomer eteplirsen that induces skipping of exon 51 in the dystrophin gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24282529", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23075107", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 383, "text": "We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.) injection. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086232", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "To continue evaluation of the long-term efficacy and safety of eteplirsen, a phosphorodiamidate morpholino oligomer designed to skip DMD exon 51 in patients with Duchenne muscular dystrophy (DMD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26573217", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "In prior open-label studies, eteplirsen, a phosphorodiamidate morpholino oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907995", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 638, "text": "The present study used a double-blind placebo-controlled protocol to test eteplirsen's ability to induce dystrophin production and improve distance walked on the 6-minute walk test (6MWT).DMD boys aged 7 to 13 years, with confirmed deletions correctable by skipping exon 51 and ability to walk 200 to 400 m on 6 MWT, were randomized to weekly intravenous infusions of 30 or 50 mg/kg/wk eteplirsen or placebo for 24 weeks (n\u2009=\u20094/group).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907995", "endSection": "abstract"}, {"offsetInBeginSection": 739, "offsetInEndSection": 1002, "text": "Here we describe the development of a Taqman quantitative (q)RT-PCR assay to quantify exon skipping and highlight its use to determine the levels of exon skipping in DMD patients treated intramuscularly with a morpholino AO to skip exon 51, eteplirsen (AVI-4658).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23075107", "endSection": "abstract"}, {"offsetInBeginSection": 1462, "offsetInEndSection": 1783, "text": "The subset of patients amenable to exon 51 skipping showed a more severe disease course than those amenable to any exon skipping.Over 3 years of follow-up, eteplirsen-treated patients showed a slower rate of decline in ambulation assessed by 6MWT compared to untreated matched HC.<CopyrightInformation>\u00a9 2016 The Authors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26573217", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 382, "text": "We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.) injection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086232", "endSection": "abstract"}]}, {"body": "Which genes of the marmoset genome exhibit rapid sequence evolution?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25038751"], "ideal_answer": ["Both protein-coding and microRNA genes related to reproduction exhibit evidence of rapid sequence evolution in the marmoset genome."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019143", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005075", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019020"], "type": "list", "id": "58839d892305cd7e21000006", "snippets": [{"offsetInBeginSection": 494, "offsetInEndSection": 864, "text": "We observed positive selection in growth hormone/insulin-like growth factor genes (growth pathways), respiratory complex I genes (metabolic pathways), and genes encoding immunobiological factors and proteases (reproductive and immunity pathways). In addition, both protein-coding and microRNA genes related to reproduction exhibited evidence of rapid sequence evolution.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25038751", "endSection": "abstract"}, {"offsetInBeginSection": 741, "offsetInEndSection": 864, "text": "In addition, both protein-coding and microRNA genes related to reproduction exhibited evidence of rapid sequence evolution.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25038751", "endSection": "abstract"}, {"offsetInBeginSection": 741, "offsetInEndSection": 865, "text": "In addition, both protein-coding and microRNA genes related to reproduction exhibited evidence of rapid sequence evolution. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25038751", "endSection": "abstract"}]}, {"body": "What is the importance of Janus Kinases in dermatology?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12794134", "http://www.ncbi.nlm.nih.gov/pubmed/27692733", "http://www.ncbi.nlm.nih.gov/pubmed/24825142", "http://www.ncbi.nlm.nih.gov/pubmed/24131352", "http://www.ncbi.nlm.nih.gov/pubmed/8022486", "http://www.ncbi.nlm.nih.gov/pubmed/26800231", "http://www.ncbi.nlm.nih.gov/pubmed/23294276", "http://www.ncbi.nlm.nih.gov/pubmed/26051365", "http://www.ncbi.nlm.nih.gov/pubmed/21347402", "http://www.ncbi.nlm.nih.gov/pubmed/25129481", "http://www.ncbi.nlm.nih.gov/pubmed/26345342", "http://www.ncbi.nlm.nih.gov/pubmed/23829933", "http://www.ncbi.nlm.nih.gov/pubmed/26899199", "http://www.ncbi.nlm.nih.gov/pubmed/19234192"], "ideal_answer": ["Janus Kinase (JAK) is active in many skin diseases and recent evidence show that inhibitors of JAK kinase could be used to treat vitiligo, psoriasis, lupus, alopecia areata and other inflammatory skin diseases.", "Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis"], "type": "summary", "id": "58a3261e60087bc10a00000c", "snippets": [{"offsetInBeginSection": 76, "offsetInEndSection": 205, "text": "Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26051365", "endSection": "abstract"}, {"offsetInBeginSection": 1232, "offsetInEndSection": 1409, "text": "Taken together, our results provided new evidence for the effectiveness of EGCG in vitiligo treatment and supported JAK2 as a molecular target for vitiligo medicine development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26345342", "endSection": "abstract"}, {"offsetInBeginSection": 1431, "offsetInEndSection": 1656, "text": "Notably, three patients treated with oral ruxolitinib, an inhibitor of JAK1 and JAK2, achieved near-complete hair regrowth within 5 months of treatment, suggesting the potential clinical utility of JAK inhibition in human AA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25129481", "endSection": "abstract"}, {"offsetInBeginSection": 539, "offsetInEndSection": 708, "text": "Jaks have recently gained significant attention as therapeutic targets in inflammation and autoimmunity, and several Jak inhibitory small molecules have been developed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24131352", "endSection": "abstract"}, {"offsetInBeginSection": 851, "offsetInEndSection": 1099, "text": "Efficacy and safety data suggest that some of these oral Jak inhibitors as well as their topical formulations may soon enter the daily clinical practice for treating patients with psoriasis, lupus erythematosus or other inflammatory skin diseases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24131352", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase essential for signaling via cytokine receptors that comprise the common gamma-chain (gammac), i.e., the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12794134", "endSection": "abstract"}, {"offsetInBeginSection": 1110, "offsetInEndSection": 1429, "text": "Systemically administered pharmacological inhibitors of Janus kinase (JAK) family protein tyrosine kinases, downstream effectors of the IFN-\u03b3 and \u03b3c cytokine receptors, eliminated the IFN signature and prevented the development of AA, while topical administration promoted hair regrowth and reversed established disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25129481", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 371, "text": "Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.We sought to report longer-term tofacitinib efficacy and safety in patients with moderate to severe psoriasis.Data from 2 identical phase-III studies, Oral-treatment Psoriasis Trial Pivotal 1 and 2, were pooled with data from these patients in an ongoing open-label long-term extension study.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26899199", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 498, "text": "Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process.To evaluate the safety and efficacy of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis in a randomized, double-blind, placebo-controlled, dose-ranging phase 2b study.Patients were randomized (n = 271) to receive placebo or oral baricitinib at 2, 4, 8 or 10 mg once daily for 12 weeks (Part A).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26800231", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Oclacitinib (Apoquel(\u00ae) ) inhibits the function of a variety of pro-inflammatory, pro-allergic and pruritogenic cytokines that are dependent on Janus kinase enzyme activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23829933", "endSection": "abstract"}, {"offsetInBeginSection": 38, "offsetInEndSection": 642, "text": "the Janus kinase/signal transducer and activator of transcription (JAK-STAT) cytokine signalling mechanism in disease pathogenesis. This signalling pathway is involved in haematopoiesis and immune development. Mutations in genes regulating JAK-STAT signalling can cause common inflammatory disorders and myeloproliferative disorders. JAK and STAT inhibitors are new management tools for disorders such as myelofibrosis and rheumatoid arthritis. Evidence suggests that the cytokine components of the JAK-STAT pathways play a crucial role in common skin disorders, including psoriasis and atopic dermatitis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24825142", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 102, "text": "Tofacitinib is an oral Janus kinase inhibitor that improves clinical measures of psoriasis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27692733", "endSection": "abstract"}]}, {"body": "What is the incidence of beta-thalassemia in Greek population?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7590514", "http://www.ncbi.nlm.nih.gov/pubmed/12091129", "http://www.ncbi.nlm.nih.gov/pubmed/1620378"], "ideal_answer": ["The incidence of beta-thalassemia trait is 8% in Greek population."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:10241", "http://www.disease-ontology.org/api/metadata/DOID:12241", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013789", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011153", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015994", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017086"], "type": "factoid", "id": "58a2df9c60087bc10a000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Hemoglobinopathies are very common in Greece, the incidence of beta-thalassemia trait being 8% and that of sickle cell trait ranging from 1 to 32% in various districts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12091129", "endSection": "abstract"}, {"offsetInBeginSection": 821, "offsetInEndSection": 982, "text": "No statistically significant differences were found in the frequency of beta-thalassaemia trait between control subjects (8.49%) and the whole Greek population. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7590514", "endSection": "abstract"}, {"offsetInBeginSection": 685, "offsetInEndSection": 798, "text": "beta-Thalassemia was found with an average incidence of 5.476% and alpha-Thalassemia with an incidence of 0.201%.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1620378", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 797, "text": "Following this program, 64,814 recruits, representing 0.651% of the total Greek population and 9.917% of the 20-year-old Greek male population, were tested. beta-Thalassemia was found with an average incidence of 5.476% and alpha-Thalassemia with an incidence of 0.201%", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1620378", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 798, "text": "Following this program, 64,814 recruits, representing 0.651% of the total Greek population and 9.917% of the 20-year-old Greek male population, were tested. beta-Thalassemia was found with an average incidence of 5.476% and alpha-Thalassemia with an incidence of 0.201%.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1620378", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 906, "text": "Following this program, 64,814 recruits, representing 0.651% of the total Greek population and 9.917% of the 20-year-old Greek male population, were tested. beta-Thalassemia was found with an average incidence of 5.476% and alpha-Thalassemia with an incidence of 0.201%. Hemoglobinopathy Lepore was detected in 51 samples (0.079%) and hemoglobinopathy-S in 352 samples (0.543%).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1620378", "endSection": "abstract"}]}, {"body": "Is exon skipping correlated with exon circularization?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25728652"], "ideal_answer": ["Yes. Circularization of exons is widespread and correlates with exon skipping, a feature that adds considerably to the regulatory complexity of the human transcriptome."], "type": "yesno", "id": "587f5d6492a5b8ad44000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Exon Skipping Is Correlated with Exon Circularization", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25728652", "endSection": "title"}, {"offsetInBeginSection": 457, "offsetInEndSection": 632, "text": "We find that circularization of exons is widespread and correlates with exon skipping, a feature that adds considerably to the regulatory complexity of the human transcriptome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25728652", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "Exon Skipping Is Correlated with Exon Circularization.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25728652", "endSection": "title"}, {"offsetInBeginSection": 458, "offsetInEndSection": 710, "text": "We find that circularization of exons is widespread and correlates with exon skipping, a feature that adds considerably to the regulatory complexity of the human transcriptome. <CopyrightInformation>Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.</", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25728652", "endSection": "abstract"}, {"offsetInBeginSection": 458, "offsetInEndSection": 711, "text": "We find that circularization of exons is widespread and correlates with exon skipping, a feature that adds considerably to the regulatory complexity of the human transcriptome. <CopyrightInformation>Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25728652", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Exon Skipping Is Correlated with Exon Circularization.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25728652", "endSection": "title"}]}, {"body": "What is the target of daratumumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24471924", "http://www.ncbi.nlm.nih.gov/pubmed/21109694", "http://www.ncbi.nlm.nih.gov/pubmed/25626316", "http://www.ncbi.nlm.nih.gov/pubmed/24971019", "http://www.ncbi.nlm.nih.gov/pubmed/27195659", "http://www.ncbi.nlm.nih.gov/pubmed/26812873", "http://www.ncbi.nlm.nih.gov/pubmed/24053207", "http://www.ncbi.nlm.nih.gov/pubmed/24849305", "http://www.ncbi.nlm.nih.gov/pubmed/27859027", "http://www.ncbi.nlm.nih.gov/pubmed/24555809", "http://www.ncbi.nlm.nih.gov/pubmed/25878332", "http://www.ncbi.nlm.nih.gov/pubmed/25531698", "http://www.ncbi.nlm.nih.gov/pubmed/26778538", "http://www.ncbi.nlm.nih.gov/pubmed/27557302", "http://www.ncbi.nlm.nih.gov/pubmed/27780867", "http://www.ncbi.nlm.nih.gov/pubmed/26658418", "http://www.ncbi.nlm.nih.gov/pubmed/27363983", "http://www.ncbi.nlm.nih.gov/pubmed/26362528", "http://www.ncbi.nlm.nih.gov/pubmed/27222480", "http://www.ncbi.nlm.nih.gov/pubmed/25760767", "http://www.ncbi.nlm.nih.gov/pubmed/24253022", "http://www.ncbi.nlm.nih.gov/pubmed/25964097", "http://www.ncbi.nlm.nih.gov/pubmed/27896689", "http://www.ncbi.nlm.nih.gov/pubmed/26308596", "http://www.ncbi.nlm.nih.gov/pubmed/26631114", "http://www.ncbi.nlm.nih.gov/pubmed/25975191", "http://www.ncbi.nlm.nih.gov/pubmed/24350987", "http://www.ncbi.nlm.nih.gov/pubmed/25988285", "http://www.ncbi.nlm.nih.gov/pubmed/21187443", "http://www.ncbi.nlm.nih.gov/pubmed/25398450", "http://www.ncbi.nlm.nih.gov/pubmed/25764134", "http://www.ncbi.nlm.nih.gov/pubmed/25865943", "http://www.ncbi.nlm.nih.gov/pubmed/27913523", "http://www.ncbi.nlm.nih.gov/pubmed/26137203"], "ideal_answer": ["Daratumumab is a fully human anti-CD38 IgG1-\u03ba monoclonal antibody. It is approved for treatment of multiple myeloma."], "type": "factoid", "id": "5880aef4c872c95565000001", "snippets": [{"offsetInBeginSection": 290, "offsetInEndSection": 407, "text": "Dominantly daratumumab (anti-CD38) and elotuzumab (anti-CS1) showed extraordinary effectiveness in phase I/II trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26362528", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "In the last few weeks, the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26658418", "endSection": "abstract"}, {"offsetInBeginSection": 183, "offsetInEndSection": 464, "text": "Of these agents, CD38-targeting antibodies have marked single agent activity in extensively pretreated MM, and preliminary results from studies with relapsed/refractory patients have shown enhanced therapeutic efficacy when daratumumab and isatuximab are combined with other agents", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26631114", "endSection": "abstract"}, {"offsetInBeginSection": 1445, "offsetInEndSection": 1800, "text": "Furthermore, daratumumab, and probably also other CD38-targeting antibodies, interfere with blood compatibility testing and thereby complicate the safe release of blood products. Neutralization of the therapeutic CD38 antibody or CD38 denaturation on reagent red blood cells mitigates daratumumab interference with transfusion laboratory serologic tests. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26631114", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "Daratumumab is a fully human anti-CD38 IgG1-\u03ba monoclonal antibody (mAb) currently being evaluated in several Phase 2 and 3 clinical studies for the treatment of multiple myeloma (MM). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26812873", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 336, "text": "In this study, we describe the cytotoxic mechanisms of action of daratumumab, a novel, high-affinity, therapeutic human mAb against a unique CD38 epitope.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", "endSection": "abstract"}, {"offsetInBeginSection": 262, "offsetInEndSection": 443, "text": "This article focuses on the basic and clinical aspects of several emerging and promising novel MoAbs for MM, such as elotuzumab which targets CS1 and daratumumab which targets CD38.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25626316", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", "endSection": "title"}, {"offsetInBeginSection": 188, "offsetInEndSection": 702, "text": "Daratumumab is a novel human CD38 monoclonal antibody which kills CD38+ multiple myeloma cells via antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and apoptosis.To explore the effect of lenalidomide combined with daratumumab, we first carried out standard antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity assays in which the CD38+ multiple myeloma cell line UM-9 and primary multiple myeloma cells isolated from patients were used as target cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21109694", "endSection": "abstract"}, {"offsetInBeginSection": 542, "offsetInEndSection": 798, "text": "However, we discovered, next to an expected effect of effector (natural killer cells/monocytes) to target (MM cells) ratio on ADCC, a significant association between CD38 expression and daratumumab-mediated ADCC (127 patients), as well as CDC (56 patients)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25975191", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26308596", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21109694", "endSection": "title"}, {"offsetInBeginSection": 63, "offsetInEndSection": 409, "text": "We studied daratumumab, a CD38-targeting, human IgG1\ufffd monoclonal antibody, in a phase 1-2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy.METHODS: In part 1, the dose-escalation phase, we administered daratumumab at doses of 0.005 to 24 mg per kilogram of body weight. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26308596", "endSection": "abstract"}, {"offsetInBeginSection": 1888, "offsetInEndSection": 2027, "text": "Antibodies targeting CS-1 (elotuzumab) and CD38 (daratumumab) in particular are currently undergoing advanced clinical phase II/III trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24849305", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 337, "text": "In this study, we describe the cytotoxic mechanisms of action of daratumumab, a novel, high-affinity, therapeutic human mAb against a unique CD38 epitope. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", "endSection": "abstract"}, {"offsetInBeginSection": 188, "offsetInEndSection": 703, "text": "Daratumumab is a novel human CD38 monoclonal antibody which kills CD38+ multiple myeloma cells via antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and apoptosis.To explore the effect of lenalidomide combined with daratumumab, we first carried out standard antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity assays in which the CD38+ multiple myeloma cell line UM-9 and primary multiple myeloma cells isolated from patients were used as target cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21109694", "endSection": "abstract"}, {"offsetInBeginSection": 542, "offsetInEndSection": 799, "text": "However, we discovered, next to an expected effect of effector (natural killer cells/monocytes) to target (MM cells) ratio on ADCC, a significant association between CD38 expression and daratumumab-mediated ADCC (127 patients), as well as CDC (56 patients).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25975191", "endSection": "abstract"}, {"offsetInBeginSection": 267, "offsetInEndSection": 425, "text": "These mechanisms may also target nonplasma cells that express CD38, which prompted evaluation of daratumumab's effects on CD38-positive immune subpopulations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27222480", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 302, "text": "In the last few weeks, the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively. <CopyrightInformation>\u00a92016 American Association for Cancer Research.</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26658418", "endSection": "abstract"}, {"offsetInBeginSection": 509, "offsetInEndSection": 677, "text": "This review focuses on the basic and clinical aspects of two emerging and promising novel MoAbs for MM, elotuzumab which targets CS1 and daratumumab which targets CD38.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24053207", "endSection": "abstract"}, {"offsetInBeginSection": 566, "offsetInEndSection": 748, "text": "In this regard, some of these novel agents seem promising, such as monoclonal antibodies (anti-CD38 - daratumumab or anti-CS1 - elotuzumab) or the kinesin protein inhibitor Arry-520.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24350987", "endSection": "abstract"}, {"offsetInBeginSection": 288, "offsetInEndSection": 569, "text": "This is likely to change within the next few years with a number of mAb therapies being assessed in late stage clinical trials, most notably, the anti-CS-1 mAb, elotuzumab, and the anti-CD38 mAb, daratumumab, which are currently being evaluated in Phase III clinical trials for MM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25964097", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 336, "text": "CD38, a type II transmembrane glycoprotein highly expressed in hematological malignancies including multiple myeloma (MM), represents a promising target for mAb-based immunotherapy. In this study, we describe the cytotoxic mechanisms of action of daratumumab, a novel, high-affinity, therapeutic human mAb against a unique CD38 epitope.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 537, "text": "CD38, a type II transmembrane glycoprotein highly expressed in hematological malignancies including multiple myeloma (MM), represents a promising target for mAb-based immunotherapy. In this study, we describe the cytotoxic mechanisms of action of daratumumab, a novel, high-affinity, therapeutic human mAb against a unique CD38 epitope. Daratumumab induced potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines as well as in patient MM cells, both with autologous and allogeneic effector cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", "endSection": "abstract"}, {"offsetInBeginSection": 102, "offsetInEndSection": 443, "text": "One of novel fields for anti-MM therapeutic strategy is the development of immunotherapy using monoclonal antibodies (MoAbs) against myeloma-specific antigens. This article focuses on the basic and clinical aspects of several emerging and promising novel MoAbs for MM, such as elotuzumab which targets CS1 and daratumumab which targets CD38.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25626316", "endSection": "abstract"}, {"offsetInBeginSection": 102, "offsetInEndSection": 641, "text": "One of novel fields for anti-MM therapeutic strategy is the development of immunotherapy using monoclonal antibodies (MoAbs) against myeloma-specific antigens. This article focuses on the basic and clinical aspects of several emerging and promising novel MoAbs for MM, such as elotuzumab which targets CS1 and daratumumab which targets CD38. Both antigens are highly expressed in more than 90% of MM patients, and the clinical trials have shown promising anti-MM effects, especially in combination with immunomodulatory agent lenalidomide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25626316", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 443, "text": "Multiple myeloma (MM) remains mostly incurable despite the recent progress in the treatment strategy. One of novel fields for anti-MM therapeutic strategy is the development of immunotherapy using monoclonal antibodies (MoAbs) against myeloma-specific antigens. This article focuses on the basic and clinical aspects of several emerging and promising novel MoAbs for MM, such as elotuzumab which targets CS1 and daratumumab which targets CD38.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25626316", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 537, "text": "In this study, we describe the cytotoxic mechanisms of action of daratumumab, a novel, high-affinity, therapeutic human mAb against a unique CD38 epitope. Daratumumab induced potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines as well as in patient MM cells, both with autologous and allogeneic effector cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 667, "text": "In this study, we describe the cytotoxic mechanisms of action of daratumumab, a novel, high-affinity, therapeutic human mAb against a unique CD38 epitope. Daratumumab induced potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines as well as in patient MM cells, both with autologous and allogeneic effector cells. Daratumumab stood out from other CD38 mAbs in its strong ability to induce complement-dependent cytotoxicity in patient MM cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", "endSection": "abstract"}, {"offsetInBeginSection": 262, "offsetInEndSection": 641, "text": "This article focuses on the basic and clinical aspects of several emerging and promising novel MoAbs for MM, such as elotuzumab which targets CS1 and daratumumab which targets CD38. Both antigens are highly expressed in more than 90% of MM patients, and the clinical trials have shown promising anti-MM effects, especially in combination with immunomodulatory agent lenalidomide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25626316", "endSection": "abstract"}, {"offsetInBeginSection": 200, "offsetInEndSection": 735, "text": "Daratumumab is a novel human CD38 monoclonal antibody which kills CD38+ multiple myeloma cells via antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and apoptosis.DESIGN AND METHODS: To explore the effect of lenalidomide combined with daratumumab, we first carried out standard antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity assays in which the CD38+ multiple myeloma cell line UM-9 and primary multiple myeloma cells isolated from patients were used as target cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21109694", "endSection": "abstract"}, {"offsetInBeginSection": 538, "offsetInEndSection": 667, "text": "Daratumumab stood out from other CD38 mAbs in its strong ability to induce complement-dependent cytotoxicity in patient MM cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", "endSection": "abstract"}, {"offsetInBeginSection": 63, "offsetInEndSection": 408, "text": "We studied daratumumab, a CD38-targeting, human IgG1\u00ea monoclonal antibody, in a phase 1-2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy.METHODS: In part 1, the dose-escalation phase, we administered daratumumab at doses of 0.005 to 24 mg per kilogram of body weight.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26308596", "endSection": "abstract"}, {"offsetInBeginSection": 1047, "offsetInEndSection": 1219, "text": "Collectively, our results show the versatility of daratumumab to effectively kill CD38-expressing tumor cells, including patient MM cells, via diverse cytotoxic mechanisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187443", "endSection": "abstract"}, {"offsetInBeginSection": 590, "offsetInEndSection": 761, "text": "Amongst these antibodies, elotuzumab which targets SLAMF-7 and daratumumab which targets CD38, have been recently approved by FDA for patients with relapsed/refractory MM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27195659", "endSection": "abstract"}, {"offsetInBeginSection": 775, "offsetInEndSection": 937, "text": "This review focuses on the CD38 antigen and its targeting with daratumumab and provides an update on the results of recent clinical studies involving daratumumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137203", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26308596", "endSection": "title"}, {"offsetInBeginSection": 140, "offsetInEndSection": 253, "text": "We assessed daratumumab, a novel CD38-targeted monoclonal antibody, in patients with refractory multiple myeloma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26778538", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27363983", "endSection": "abstract"}, {"offsetInBeginSection": 1445, "offsetInEndSection": 1623, "text": "Furthermore, daratumumab, and probably also other CD38-targeting antibodies, interfere with blood compatibility testing and thereby complicate the safe release of blood products.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26631114", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 310, "text": "Daratumumab, a human IgG\u03ba monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27557302", "endSection": "abstract"}, {"offsetInBeginSection": 582, "offsetInEndSection": 681, "text": "Importantly, IFN\u03b3 was able to up-regulate CD38, the target of the therapeutic antibody daratumumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27780867", "endSection": "abstract"}]}, {"body": "Which gene-defect causes the Vel-blood type?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26732700", "http://www.ncbi.nlm.nih.gov/pubmed/23505126"], "ideal_answer": ["A cohort of 70 Vel- individuals was found to be uniformly homozygous for a 17 nucleotide deletion in the coding sequence of SMIM"], "type": "factoid", "id": "58a872bd38c171fb5b000002", "snippets": [{"offsetInBeginSection": 649, "offsetInEndSection": 779, "text": "A cohort of 70 Vel- individuals was found to be uniformly homozygous for a 17 nucleotide deletion in the coding sequence of SMIM1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23505126", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 209, "text": "The SMIM1 protein carries the Vel blood group antigen, and homozygosity for a 17 bp deletion in the coding region of the SMIM1 gene represents the molecular basis of the Vel- blood group phenotype.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732700", "endSection": "abstract"}]}, {"body": "Is NADPH oxidase 5 expressed in rodents?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22511941", "http://www.ncbi.nlm.nih.gov/pubmed/17612411", "http://www.ncbi.nlm.nih.gov/pubmed/24262797", "http://www.ncbi.nlm.nih.gov/pubmed/17400358", "http://www.ncbi.nlm.nih.gov/pubmed/25415612", "http://www.ncbi.nlm.nih.gov/pubmed/24688893"], "ideal_answer": ["No, NADPH oxidase 5 is not expressed in rodents, because the gene is absent."], "concepts": ["http://www.biosemantics.org/jochem#4270191", "http://www.uniprot.org/uniprot/NOX5_HUMAN", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019255"], "type": "yesno", "id": "58a5b01760087bc10a000023", "snippets": [{"offsetInBeginSection": 865, "offsetInEndSection": 1004, "text": "Because the Nox5 gene is absent in rodents, we generated transgenic mice expressing human Nox5 in a podocyte-specific manner (Nox5(pod+)). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24262797", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 179, "text": "The NADPH oxidase 5 (NOX5) gene is present in humans but not rodents. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24688893", "endSection": "abstract"}, {"offsetInBeginSection": 1490, "offsetInEndSection": 1643, "text": "The data document that the NOX5 gene was expressed in cells of lagomorphs unlike rodents, making the rabbit an interesting model to study NOX5 functions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22511941", "endSection": "abstract"}, {"offsetInBeginSection": 1124, "offsetInEndSection": 1305, "text": "Nox5 was lost in rodents, and Nox3, which functions in the inner ear in gravity perception, emerged the most recently, corresponding to full-time adaptation of vertebrates to land. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17612411", "endSection": "abstract"}, {"offsetInBeginSection": 1137, "offsetInEndSection": 1361, "text": "NOX expression patterns in animals are complex and ancestral NOXes, NOX5-like isoforms and DUOXes are generally found. But there are exceptions; for example rodents lack NOX5 and Caenorhabditis elegans expresses only DUOXes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17400358", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 178, "text": "The NADPH oxidase 5 (NOX5) gene is present in humans but not rodents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24688893", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 177, "text": "The NADPH oxidase 5 (NOX5) gene is present in humans but not rodents", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24688893", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "NADPH oxidases are the major sources of reactive oxygen species in cardiovascular, neural, and kidney cells. The NADPH oxidase 5 (NOX5) gene is present in humans but not rodents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24688893", "endSection": "abstract"}, {"offsetInBeginSection": 1256, "offsetInEndSection": 1361, "text": "But there are exceptions; for example rodents lack NOX5 and Caenorhabditis elegans expresses only DUOXes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17400358", "endSection": "abstract"}, {"offsetInBeginSection": 865, "offsetInEndSection": 1003, "text": "Because the Nox5 gene is absent in rodents, we generated transgenic mice expressing human Nox5 in a podocyte-specific manner (Nox5(pod+)).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24262797", "endSection": "abstract"}, {"offsetInBeginSection": 1453, "offsetInEndSection": 1606, "text": "The data document that the NOX5 gene was expressed in cells of lagomorphs unlike rodents, making the rabbit an interesting model to study NOX5 functions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22511941", "endSection": "abstract"}, {"offsetInBeginSection": 689, "offsetInEndSection": 857, "text": "The most recently identified member of the Nox family, Nox5, has for the most part been overlooked in renal disease, partly owing to its absence from the rodent genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25415612", "endSection": "abstract"}]}, {"body": "List selective estrogen receptor degraders.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21501600", "http://www.ncbi.nlm.nih.gov/pubmed/25609068", "http://www.ncbi.nlm.nih.gov/pubmed/27005559", "http://www.ncbi.nlm.nih.gov/pubmed/25879485", "http://www.ncbi.nlm.nih.gov/pubmed/27178332", "http://www.ncbi.nlm.nih.gov/pubmed/26289836", "http://www.ncbi.nlm.nih.gov/pubmed/27151773", "http://www.ncbi.nlm.nih.gov/pubmed/26162914", "http://www.ncbi.nlm.nih.gov/pubmed/24601804", "http://www.ncbi.nlm.nih.gov/pubmed/26164151"], "ideal_answer": ["Selective estrogen receptor degraders (SERD) are fulvestrant, RAD1901 and ARN-810. Fulvestrant is the only SERD approved for the treatment of breast cancer."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011960"], "type": "list", "id": "58919aad621ea6ff7e00000d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 311, "text": "For women with hormone receptor-positive advanced breast cancer, endocrine therapies, including the selective estrogen receptor modulator tamoxifen, the aromatase inhibitors anastrozole, letrozole, and exemestane, and the selective estrogen receptor degrader fulvestrant, are recommended in clinical guidelines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27151773", "endSection": "abstract"}, {"offsetInBeginSection": 629, "offsetInEndSection": 828, "text": "Here we describe and characterize a novel, orally bioavailable small-molecule selective estrogen receptor degrader, RAD1901, and evaluate its therapeutic potential for the treatment of breast cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26164151", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25879485", "endSection": "title"}, {"offsetInBeginSection": 447, "offsetInEndSection": 633, "text": "Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-\u03b1 and is active in patients who have progressed on antihormonal agents. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25879485", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26162914", "endSection": "title"}, {"offsetInBeginSection": 1528, "offsetInEndSection": 1694, "text": "However, being the only SERD currently known to access the brain, RAD1901 merits evaluation as a targeted therapy for the treatment of breast cancer brain metastases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26162914", "endSection": "abstract"}, {"offsetInBeginSection": 800, "offsetInEndSection": 991, "text": "Tamoxifen, toremifene, and the selective estrogen receptor degrader fulvestrant are used to treat breast cancer, and tamoxifen and raloxifene protect against breast cancer in high-risk women.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26289836", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "The turnover of estrogen receptor \u03b1 by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501600", "endSection": "title"}, {"offsetInBeginSection": 305, "offsetInEndSection": 409, "text": "Currently, ICI 182,780 (ICI, fulvestrant) is the only SERD approved for the treatment of breast cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501600", "endSection": "abstract"}, {"offsetInBeginSection": 447, "offsetInEndSection": 632, "text": "Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-\u00e1 and is active in patients who have progressed on antihormonal agents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25879485", "endSection": "abstract"}, {"offsetInBeginSection": 447, "offsetInEndSection": 631, "text": "Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-\u03b1 and is active in patients who have progressed on antihormonal agents", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25879485", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26164151", "endSection": "title"}, {"offsetInBeginSection": 829, "offsetInEndSection": 954, "text": "RAD1901 selectively binds to and degrades the ER and is a potent antagonist of ER-positive breast cancer cell proliferation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26164151", "endSection": "abstract"}, {"offsetInBeginSection": 1113, "offsetInEndSection": 1430, "text": "The selective estrogen receptor degrader, fulvestrant, significantly reduced the anchorage-independent growth of ESR1 mutant-expressing cells, while combination treatments with the mTOR inhibitor everolimus, or an inhibitor blocking IGF1R, and the insulin receptor significantly enhanced anti-proliferative responses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27178332", "endSection": "abstract"}, {"offsetInBeginSection": 445, "offsetInEndSection": 677, "text": "SUM-44\u00a0cells do not require exogenous estrogen for growth in\u00a0vitro; however, they are dependent on ER\u03b1 expression, as ESR1 knock-down or exposure to the selective estrogen receptor degrader fulvestrant resulted in growth inhibition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27005559", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26162914", "endSection": "title"}, {"offsetInBeginSection": 447, "offsetInEndSection": 632, "text": "Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-\u03b1 and is active in patients who have progressed on antihormonal agents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25879485", "endSection": "abstract"}]}, {"body": "What is the role of ZNF335 in microcephaly?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23178126", "http://www.ncbi.nlm.nih.gov/pubmed/27540107"], "ideal_answer": ["Znf335 null mice are embryonically lethal, and conditional knockout leads to severely reduced cortical size. RNA-interference and postmortem human studies show that ZNF335 is essential for neural progenitor self-renewal, neurogenesis, and neuronal differentiation.", "Microcephaly gene links trithorax and REST/NRSF to control neural stem cell proliferation and differentiation. RNA-interference and postmortem human studies show that ZNF335 is essential for neural progenitor self-renewal, neurogenesis, and neuronal differentiation. Znf335 null mice are embryonically lethal, and conditional knockout leads to severely reduced cortical size.", "Microcephaly gene links trithorax and REST/NRSF to control neural stem cell proliferation and differentiation. Znf335 null mice are embryonically lethal, and conditional knockout leads to severely reduced cortical size. RNA-interference and postmortem human studies show that ZNF335 is essential for neural progenitor self-renewal, neurogenesis, and neuronal differentiation."], "concepts": ["http://www.uniprot.org/uniprot/ZN335_RAT", "http://www.uniprot.org/uniprot/ZN335_HUMAN", "http://www.disease-ontology.org/api/metadata/DOID:10907", "http://www.uniprot.org/uniprot/ZN335_MOUSE", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008831"], "type": "summary", "id": "5889f0ed3b87a8a73800000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Microcephaly gene links trithorax and REST/NRSF to control neural stem cell proliferation and differentiation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23178126", "endSection": "title"}, {"offsetInBeginSection": 366, "offsetInEndSection": 630, "text": "Znf335 null mice are embryonically lethal, and conditional knockout leads to severely reduced cortical size. RNA-interference and postmortem human studies show that ZNF335 is essential for neural progenitor self-renewal, neurogenesis, and neuronal differentiation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23178126", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 366, "text": "Here, we identify and characterize a nuclear zinc finger protein, ZNF335/NIF-1, as a causative gene for severe microcephaly, small somatic size, and neonatal death. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23178126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 365, "text": "Microcephaly is a neurodevelopmental disorder causing significantly reduced cerebral cortex size. Many known microcephaly gene products localize to centrosomes, regulating cell fate and proliferation. Here, we identify and characterize a nuclear zinc finger protein, ZNF335/NIF-1, as a causative gene for severe microcephaly, small somatic size, and neonatal death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23178126", "endSection": "abstract"}, {"offsetInBeginSection": 1295, "offsetInEndSection": 1436, "text": "For infants presenting with both microcephaly and invisible basal ganglia, ZNF335 mutations should be considered as a differential diagnosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27540107", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 365, "text": "Here, we identify and characterize a nuclear zinc finger protein, ZNF335/NIF-1, as a causative gene for severe microcephaly, small somatic size, and neonatal death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23178126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "ZNF335 was first reported in 2012 as a causative gene for microcephaly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27540107", "endSection": "abstract"}]}, {"body": "What molecule is targeted by Avelumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27172898", "http://www.ncbi.nlm.nih.gov/pubmed/27350882", "http://www.ncbi.nlm.nih.gov/pubmed/26921031", "http://www.ncbi.nlm.nih.gov/pubmed/26014098", "http://www.ncbi.nlm.nih.gov/pubmed/27815822", "http://www.ncbi.nlm.nih.gov/pubmed/27544053", "http://www.ncbi.nlm.nih.gov/pubmed/27490642", "http://www.ncbi.nlm.nih.gov/pubmed/27592805", "http://www.ncbi.nlm.nih.gov/pubmed/26880697", "http://www.ncbi.nlm.nih.gov/pubmed/26477470", "http://www.ncbi.nlm.nih.gov/pubmed/27716622", "http://www.ncbi.nlm.nih.gov/pubmed/27196116"], "ideal_answer": ["Avelumab is a monoclonal antibody that binds programmed death-ligand 1 (PD-L1)."], "type": "factoid", "id": "5884c72fe56acf517600000f", "snippets": [{"offsetInBeginSection": 240, "offsetInEndSection": 409, "text": "Several drugs targeting PD-1 (pembrolizumab and nivolumab) or PD-L1 (atezolizumab, durvalumab, and avelumab) have been approved or are in the late stages of development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27196116", "endSection": "abstract"}, {"offsetInBeginSection": 644, "offsetInEndSection": 923, "text": "We then focus on the recent breakthrough work concerning the structural basis of the PD-1/PD-Ls interaction and how therapeutic antibodies, pembrolizumab targeting PD-1 and avelumab targeting PD-L1, compete with the binding of PD-1/PD-L1 to interrupt the PD-1/PD-L1 interaction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815822", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490642", "endSection": "title"}, {"offsetInBeginSection": 683, "offsetInEndSection": 829, "text": "In addition, we assessed the safety and biological activity of a human anti-PD-L1 antibody (Avelumab) in chronically SIV-infected rhesus macaques.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490642", "endSection": "abstract"}, {"offsetInBeginSection": 439, "offsetInEndSection": 608, "text": "We assessed treatment with avelumab, an anti-PD-L1 monoclonal antibody, in patients with stage IV Merkel cell carcinoma that had progressed after cytotoxic chemotherapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27592805", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716622", "endSection": "title"}, {"offsetInBeginSection": 220, "offsetInEndSection": 448, "text": "Here, we describe the efficacy of NIR-PIT, using fully human IgG1 anti-PD-L1 monoclonal antibody (mAb), avelumab, conjugated to the photo-absorber, IR700DX, in a PD-L1 expressing H441 cell line, papillary adenocarcinoma of lung.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716622", "endSection": "abstract"}, {"offsetInBeginSection": 1075, "offsetInEndSection": 1313, "text": "In conclusion, the anti-PD-L1 antibody, avelumab, is suitable as an APC for NIR-PIT. Furthermore, NIR-PIT with avelumab-IR700 is a promising candidate of the treatment of PD-L1-expressing tumors that could be readily translated to humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716622", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26014098", "endSection": "title"}, {"offsetInBeginSection": 612, "offsetInEndSection": 683, "text": "MSB0010718C (designated avelumab) is a fully human IgG1 anti-PD-L1 mAb.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26014098", "endSection": "abstract"}, {"offsetInBeginSection": 1409, "offsetInEndSection": 1576, "text": "These studies thus provide an additional mode of action for an anti-PD-L1 mAb and support the rationale for further studies to enhance avelumab-mediated ADCC activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26014098", "endSection": "abstract"}, {"offsetInBeginSection": 644, "offsetInEndSection": 922, "text": "We then focus on the recent breakthrough work concerning the structural basis of the PD-1/PD-Ls interaction and how therapeutic antibodies, pembrolizumab targeting PD-1 and avelumab targeting PD-L1, compete with the binding of PD-1/PD-L1 to interrupt the PD-1/PD-L1 interaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815822", "endSection": "abstract"}, {"offsetInBeginSection": 2142, "offsetInEndSection": 2241, "text": "In addition, mesothelioma tumor cells are susceptible to ADCC by the anti-PD-L1 antibody avelumab..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27544053", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921031", "endSection": "title"}, {"offsetInBeginSection": 664, "offsetInEndSection": 810, "text": "In addition, we assessed the safety and biological activity of a human anti-PD-L1 antibody (Avelumab) in chronically SIV-infected rhesus macaques.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490642", "endSection": "abstract"}, {"offsetInBeginSection": 781, "offsetInEndSection": 1006, "text": "Different mechanisms to prevent immunologic escape have been characterized during the last years; in particular the PD-1/PD-L1 inhibitors pembrolizumab, avelumab, durvalumab and atezolizumab have shown early sign of efficacy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26880697", "endSection": "abstract"}]}, {"body": "What are the exonic splice enhancers?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24359918"], "ideal_answer": ["In mammals there is a bias in amino acid usage near splice sites that is explained, in large part, by the high density of exonic splicing enhancers (ESEs) in these regions. Exonic splicing enhancers (ESEs) activate pre-mRNA splicing by promoting the use of the flanking splice sites. Some of these variants may have an effect on pre-mRNA splicing, either by altering degenerate positions of splice site sequences or by affecting intronic or exonic splicing regulatory sequences such as exonic splicing enhancers (ESEs). For inherited disease, the main mechanism responsible for the splicing defect is splice site loss, whereas for cancer the predominant mechanism of splicing disruption is predicted to be exon skipping via loss of exonic splicing enhancers or gain of exonic splicing silencer elements. FELINES was shown to be useful for characterizing branchsites, polypyrimidine tracts and 5' and 3' splice sites in the intron databases and exonic splicing enhancers (ESEs) in S.pombe exons. Unexpectedly, a fully experimental dataset identifies motifs that commonly behave opposite to the consensus, for example, being enriched in exon cores where splice-associated mutations are rare.Prior analyses that used the RESCUE-ESE set of hexamers captured the properties of consensus exonic splice enhancers.", "Exonic splice enhancers are one of the principle non-splice site motifs. Four high-throughput studies have provided a compendium of motifs that function as exonic splice enhancers, but only one, RESCUE-ESE, has been generally employed to examine the properties of enhancers. In humans, much of the information specifying splice sites is not at the splice site.", "In humans, much of the information specifying splice sites is not at the splice site. Exonic splice enhancers are one of the principle non-splice site motifs. Four high-throughput studies have provided a compendium of motifs that function as exonic splice enhancers, but only one, RESCUE-ESE, has been generally employed to examine the properties of enhancers."], "type": "summary", "id": "5880acbb0a76a87357000003", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 372, "text": "In humans, much of the information specifying splice sites is not at the splice site. Exonic splice enhancers are one of the principle non-splice site motifs. Four high-throughput studies have provided a compendium of motifs that function as exonic splice enhancers, but only one, RESCUE-ESE, has been generally employed to examine the properties of enhancers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24359918", "endSection": "abstract"}, {"offsetInBeginSection": 98, "offsetInEndSection": 170, "text": "Exonic splice enhancers are one of the principle non-splice site motifs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24359918", "endSection": "abstract"}, {"offsetInBeginSection": 86, "offsetInEndSection": 158, "text": "Exonic splice enhancers are one of the principle non-splice site motifs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24359918", "endSection": "abstract"}]}, {"body": "What are the birth defects associated with Zika-virus infection?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27032458", "http://www.ncbi.nlm.nih.gov/pubmed/27293547", "http://www.ncbi.nlm.nih.gov/pubmed/27052792", "http://www.ncbi.nlm.nih.gov/pubmed/27366760", "http://www.ncbi.nlm.nih.gov/pubmed/27279226", "http://www.ncbi.nlm.nih.gov/pubmed/27032431", "http://www.ncbi.nlm.nih.gov/pubmed/27143174", "http://www.ncbi.nlm.nih.gov/pubmed/27617189", "http://www.ncbi.nlm.nih.gov/pubmed/27366586", "http://www.ncbi.nlm.nih.gov/pubmed/27812690", "http://www.ncbi.nlm.nih.gov/pubmed/27345865", "http://www.ncbi.nlm.nih.gov/pubmed/27490087", "http://www.ncbi.nlm.nih.gov/pubmed/27009036"], "ideal_answer": ["Although the full spectrum of adverse reproductive outcomes caused by Zika virus infection is not yet determined, a distinctive phenotype-the congenital Zika syndrome-has emerged. Zika virus infection during pregnancy is a cause of microcephaly and other severe birth defects."], "type": "summary", "id": "58a989571978bbde22000002", "snippets": [{"offsetInBeginSection": 768, "offsetInEndSection": 1090, "text": "the first time after the discovery of ZIKV, the Brazilian scientists are studying the possibility for the virus to cause severe congenital infection related to microcephaly and serious birth defects due to the time-spatial coincidence of the alarming increase of newborns with microcephaly and the Brazilian ZIKV epidemic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27143174", "endSection": "abstract"}, {"offsetInBeginSection": 116, "offsetInEndSection": 286, "text": " Although a causal relationship between Zika infection during pregnancy and microcephaly is strongly suspected, such a connection has not yet been scientifically proven. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27052792", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 302, "text": "a convincing association between Zika virus infection during pregnancy and birth defects, like microcephaly, among some of the newborns.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27032431", "endSection": "abstract"}, {"offsetInBeginSection": 955, "offsetInEndSection": 1039, "text": "counseling pregnant women on the risks of fetal microcephaly and other birth defects", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27032458", "endSection": "abstract"}, {"offsetInBeginSection": 576, "offsetInEndSection": 711, "text": "evidence suggests that congenital Zika virus infection is associated with microcephaly and other adverse pregnancy and infant outcomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009036", "endSection": "abstract"}, {"offsetInBeginSection": 734, "offsetInEndSection": 885, "text": "the virus has been linked to congenital malformations, including microcephaly and other severe neurological diseases, such as Guillain-Barr\u00e9 syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27279226", "endSection": "abstract"}, {"offsetInBeginSection": 282, "offsetInEndSection": 380, "text": " severe birth defects, such as microcephaly, have been linked to infection during early pregnancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27293547", "endSection": "abstract"}, {"offsetInBeginSection": 31, "offsetInEndSection": 290, "text": "n can be prenatally passed from a pregnant woman to her fetus. There is sufficient evidence to conclude that intrauterine Zika virus infection is a cause of microcephaly and serious brain anomalies, but the full spectrum of anomalies has not been delineated. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27812690", "endSection": "abstract"}, {"offsetInBeginSection": 1699, "offsetInEndSection": 1878, "text": "Although the full spectrum of adverse reproductive outcomes caused by Zika virus infection is not yet determined, a distinctive phenotype-the congenital Zika syndrome-has emerged.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27812690", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "The current Zika virus (ZIKV) outbreak is associated with high numbers of human congenital birth defects", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345865", "endSection": "abstract"}, {"offsetInBeginSection": 282, "offsetInEndSection": 427, "text": "However, ZIKV infection in early pregnancy has been associated with severe birth defects, including microcephaly and other developmental issues. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Zika virus (ZIKV) infection is a new emerging threat around the globe which might be responsible for microcephaly and Guillain-Barre syndrome in the infants. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27366760", "endSection": "abstract"}, {"offsetInBeginSection": 186, "offsetInEndSection": 282, "text": "Zika virus infection during pregnancy is a cause of microcephaly and other severe birth defects ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490087", "endSection": "abstract"}]}, {"body": "What is Neisseria adhesin A?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27452726", "http://www.ncbi.nlm.nih.gov/pubmed/19401383", "http://www.ncbi.nlm.nih.gov/pubmed/19356620", "http://www.ncbi.nlm.nih.gov/pubmed/19290916", "http://www.ncbi.nlm.nih.gov/pubmed/23717687", "http://www.ncbi.nlm.nih.gov/pubmed/26232542", "http://www.ncbi.nlm.nih.gov/pubmed/26950303", "http://www.ncbi.nlm.nih.gov/pubmed/23803905", "http://www.ncbi.nlm.nih.gov/pubmed/26304221", "http://www.ncbi.nlm.nih.gov/pubmed/24779381", "http://www.ncbi.nlm.nih.gov/pubmed/19428890", "http://www.ncbi.nlm.nih.gov/pubmed/25630407", "http://www.ncbi.nlm.nih.gov/pubmed/26204985", "http://www.ncbi.nlm.nih.gov/pubmed/22426368", "http://www.ncbi.nlm.nih.gov/pubmed/21949862", "http://www.ncbi.nlm.nih.gov/pubmed/20041170", "http://www.ncbi.nlm.nih.gov/pubmed/21471204", "http://www.ncbi.nlm.nih.gov/pubmed/18299457", "http://www.ncbi.nlm.nih.gov/pubmed/24807056", "http://www.ncbi.nlm.nih.gov/pubmed/23409129", "http://www.ncbi.nlm.nih.gov/pubmed/25347845", "http://www.ncbi.nlm.nih.gov/pubmed/27105075", "http://www.ncbi.nlm.nih.gov/pubmed/25404323"], "ideal_answer": ["Neisseria adhesin A (NadA) is one of the antigens of Bexsero, the recently licensed multicomponent vaccine against serogroup B Neisseria meningitidis (MenB). NadA belongs to the class of oligomeric coiled-coil adhesins and is able to mediate adhesion and invasion of human epithelial cells. As a vaccine antigen, NadA has been shown to induce high levels of bactericidal antibodies. More than 89 distinct NadA allele sequences and 43 distinct peptides have been described."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009343", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009345"], "type": "summary", "id": "589afa6978275d0c4a000039", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Exploiting chimeric human antibodies to characterize a protective epitope of Neisseria adhesin A, one of the Bexsero vaccine components.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26304221", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 381, "text": "Neisseria adhesin A (NadA) is one of the antigens of Bexsero, the recently licensed multicomponent vaccine against serogroup B Neisseria meningitidis (MenB). NadA belongs to the class of oligomeric coiled-coil adhesins and is able to mediate adhesion and invasion of human epithelial cells. As a vaccine antigen, NadA has been shown to induce high levels of bactericidal antibodies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26304221", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 330, "text": "A new vaccine (the 4CMenB 4-component protein vaccine [Bexsero], which includes PorA, factor H-binding protein [fHbp], neisserial heparin-binding antigen [NHBA], and Neisseria adhesin A [NadA]) against serogroup B meningococci has recently been approved for use in people older than age 2 months in Europe, Australia, and Canada. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25630407", "endSection": "abstract"}, {"offsetInBeginSection": 662, "offsetInEndSection": 976, "text": "Serum bactericidal activity using human complement (hSBA) was measured against three reference strains 44/76-SL, 5/99 and NZ98/254, selected to express one of the vaccine antigens; Neisseria adhesin A (NadA), factor H binding protein (fHbp) and porin A (PorA) containing outer membrane vesicle (OMV), respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26232542", "endSection": "abstract"}, {"offsetInBeginSection": 661, "offsetInEndSection": 851, "text": "Isolates were genotyped by analysis of their 4CMenB vaccine antigen genes of PorA, factor H binding protein (fHbp), Neisserial Heparin Binding Antigen (NHBA), and Neisseria Adhesin A (NadA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26204985", "endSection": "abstract"}, {"offsetInBeginSection": 534, "offsetInEndSection": 689, "text": "Vaccine components were typed by sequencing for factor H-binding protein (fHbp), Neisserial Heparin Binding Antigen (NHBA) and Neisseria adhesin A (NadA). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24779381", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 921, "text": "Neisseria adhesin A (NadA), involved in the adhesion and invasion of Neisseria meningitidis into host tissues, is one of the major components of Bexsero, a novel multicomponent vaccine licensed for protection against meningococcal serogroup B in Europe, Australia, and Canada. NadA has been identified in approximately 30% of clinical isolates and in a much lower proportion of carrier isolates. Three protein variants were originally identified in invasive meningococci and named NadA-1, NadA-2, and NadA-3, whereas most carrier isolates either lacked the gene or harbored a different variant, NadA-4. Further analysis of isolates belonging to the sequence type 213 (ST-213) clonal complex identified NadA-5, which was structurally similar to NadA-4, but more distantly related to NadA-1, -2, and -3. At the time of this writing, more than 89 distinct nadA allele sequences and 43 distinct peptides have been described. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24807056", "endSection": "abstract"}, {"offsetInBeginSection": 1088, "offsetInEndSection": 1484, "text": "The main features of this new scheme include (i) the grouping of the previously named NadA-2 and NadA-3 variants into a single NadA-2/3 variant, (ii) the grouping of the previously assigned NadA-4 and NadA-5 variants into a single NadA-4/5 variant, (iii) the introduction of an additional variant (NadA-6), and (iv) the classification of the variants into two main groups, named groups I and II. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24807056", "endSection": "abstract"}, {"offsetInBeginSection": 385, "offsetInEndSection": 702, "text": "To broaden the scope of its protection, the multicomponent vaccine (4CMenB) incorporates a PorA-containing outer membrane vesicle (OMV) alongside relatively conserved recombinant protein components, including factor H-binding protein (fHbp), Neisseria adhesin A (NadA), and neisserial heparin-binding antigen (NHBA). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23803905", "endSection": "abstract"}, {"offsetInBeginSection": 1129, "offsetInEndSection": 1579, "text": "Nine N. meningitidis isolates (eight MenB and one MenY) were found to possess at least one gene that encoded for an antigen that matched exactly with protein variants in the 4CMenB vaccine. Two MenB expressed PorA antigen P1.4 and possessed the nhba gene for peptide 2; four other MenB were predicted to have NHBA peptide 2; another two MenB were predicted to encode fHbp peptide 1.1; and a single MenY was found to have nadA gene for NadA peptide 8.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26204985", "endSection": "abstract"}, {"offsetInBeginSection": 649, "offsetInEndSection": 953, "text": "Isolates were genotyped by analysis of their 4CMenB vaccine antigen genes of PorA, factor H binding protein (fHbp), Neisserial Heparin Binding Antigen (NHBA), and Neisseria Adhesin A (NadA).Of the 263 IMD isolates analysed, 229, 16, 10, 7, and 1 belonged to MenB, MenY, MenW, MenC, and MenX, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26204985", "endSection": "abstract"}, {"offsetInBeginSection": 207, "offsetInEndSection": 437, "text": "We analyzed the sequence variability of factor H-binding protein (fHbp), Neisserial Heparin-Binding Antigen (NHBA) and Neisseria adhesin A (NadA), three major antigens in the multicomponent meningococcal serogroup B vaccine 4CMenB", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23717687", "endSection": "abstract"}, {"offsetInBeginSection": 385, "offsetInEndSection": 700, "text": "To broaden the scope of its protection, the multicomponent vaccine (4CMenB) incorporates a PorA-containing outer membrane vesicle (OMV) alongside relatively conserved recombinant protein components, including factor H-binding protein (fHbp), Neisseria adhesin A (NadA), and neisserial heparin-binding antigen (NHBA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23803905", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 495, "text": "Novartis Vaccines has developed a vaccine for the prevention of MenB disease that contains four antigenic components: factor H binding protein (fHbp), neisserial adhesin A (NadA), Neisseria heparin binding antigen (NHBA) and outer membrane vesicles from a New Zealand epidemic strain (which provides PorA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426368", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "The Oca (Oligomeric coiled-coil adhesin) family is a subgroup of the bacterial trimeric autotransporter adhesins, which includes structurally related proteins, such as YadA of Yersinia enterocolitica and NadA of Neisseria meningitidis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19290916", "endSection": "abstract"}, {"offsetInBeginSection": 240, "offsetInEndSection": 349, "text": "Here we elucidate a novel phase variable mechanism for NadA, an adhesin and invasin of Neisseria meningitidis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20041170", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Neisseria meningitidis adhesin NadA targets beta1 integrins: functional similarity to Yersinia invasin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21471204", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Human monocytes/macrophages are a target of Neisseria meningitidis Adhesin A (NadA).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18299457", "endSection": "title"}, {"offsetInBeginSection": 141, "offsetInEndSection": 253, "text": "We have previously shown that NadA also promotes bacterial internalization in a heterologous expression system. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25347845", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 286, "text": "Its recombinant form NadA(\u0394351-405,) devoid of the outer membrane domain, is an immunogenic candidate for an anti-MenB vaccine able to stimulate monocytes, macrophages and dendritic cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21949862", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Role of ARF6, Rab11 and external Hsp90 in the trafficking and recycling of recombinant-soluble Neisseria meningitidis adhesin A (rNadA) in human epithelial cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25347845", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 329, "text": "A new vaccine (the 4CMenB 4-component protein vaccine [Bexsero], which includes PorA, factor H-binding protein [fHbp], neisserial heparin-binding antigen [NHBA], and Neisseria adhesin A [NadA]) against serogroup B meningococci has recently been approved for use in people older than age 2 months in Europe, Australia, and Canada.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25630407", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 276, "text": "Neisseria adhesin A (NadA), involved in the adhesion and invasion of Neisseria meningitidis into host tissues, is one of the major components of Bexsero, a novel multicomponent vaccine licensed for protection against meningococcal serogroup B in Europe, Australia, and Canada.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24807056", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 444, "text": "With the aim of studying the molecular diversity of the antigens of a new recombinant vaccine against meningococcus serogroup B, the three genes coding for the main vaccine components GNA (Genome-derived Neisseria Antigen) 1870 (fHbp, factor H Binding Protein), GNA1994 (NadA, Neisseria adhesin A) and GNA2132 were sequenced in a panel of 85 strains collected worldwide and selected as representative of the serogroup B meningococcal diversity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19428890", "endSection": "abstract"}, {"offsetInBeginSection": 385, "offsetInEndSection": 701, "text": "To broaden the scope of its protection, the multicomponent vaccine (4CMenB) incorporates a PorA-containing outer membrane vesicle (OMV) alongside relatively conserved recombinant protein components, including factor H-binding protein (fHbp), Neisseria adhesin A (NadA), and neisserial heparin-binding antigen (NHBA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23803905", "endSection": "abstract"}, {"offsetInBeginSection": 820, "offsetInEndSection": 994, "text": "4CMenB vaccine antigens, PorA, factor H binding protein (fHbp), Neisseria Heparin Binding Antigen (NHBA) and Neisserial adhesin A (NadA) were molecularly typed by sequencing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26950303", "endSection": "abstract"}, {"offsetInBeginSection": 522, "offsetInEndSection": 676, "text": "Vaccine components were typed by sequencing for factor H-binding protein (fHbp), Neisserial Heparin Binding Antigen (NHBA) and Neisseria adhesin A (NadA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24779381", "endSection": "abstract"}, {"offsetInBeginSection": 649, "offsetInEndSection": 954, "text": "Isolates were genotyped by analysis of their 4CMenB vaccine antigen genes of PorA, factor H binding protein (fHbp), Neisserial Heparin Binding Antigen (NHBA), and Neisseria Adhesin A (NadA).Of the 263 IMD isolates analysed, 229, 16, 10, 7, and 1 belonged to MenB, MenY, MenW, MenC, and MenX, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26204985", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Neisseria adhesin A (NadA) is one of the antigens of Bexsero, the recently licensed multicomponent vaccine against serogroup B Neisseria meningitidis (MenB).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26304221", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Neisseria adhesin A (NadA) is present on the meningococcal surface and contributes to adhesion to and invasion of human cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27105075", "endSection": "abstract"}, {"offsetInBeginSection": 649, "offsetInEndSection": 839, "text": "Isolates were genotyped by analysis of their 4CMenB vaccine antigen genes of PorA, factor H binding protein (fHbp), Neisserial Heparin Binding Antigen (NHBA), and Neisseria Adhesin A (NadA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26204985", "endSection": "abstract"}, {"offsetInBeginSection": 207, "offsetInEndSection": 438, "text": "We analyzed the sequence variability of factor H-binding protein (fHbp), Neisserial Heparin-Binding Antigen (NHBA) and Neisseria adhesin A (NadA), three major antigens in the multicomponent meningococcal serogroup B vaccine 4CMenB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23717687", "endSection": "abstract"}]}, {"body": "Which R package is used for the detection of chromosomal abnormalities from microarray data?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24451624"], "ideal_answer": ["CAFE is an R package for the detection of gross chromosomal abnormalities from gene expression microarray data."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D025063", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D043171", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002869", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012729", "http://www.disease-ontology.org/api/metadata/DOID:0060388", "http://www.disease-ontology.org/api/metadata/DOID:0080014"], "type": "factoid", "id": "5880a8ec0a76a87357000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "CAFE: an R package for the detection of gross chromosomal abnormalities from gene expression microarray data", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24451624", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "CAFE: an R package for the detection of gross chromosomal abnormalities from gene expression microarray data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24451624", "endSection": "title"}, {"offsetInBeginSection": 184, "offsetInEndSection": 470, "text": "It is implemented as an R package that analyzes Affymetrix *.CEL files and comes with flexible plotting functions, easing visualization of chromosomal abnormalities.CAFE is available from https://bitbucket.org/cob87icW6z/cafe/ as both source and compiled packages for Linux and Windows.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24451624", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 512, "text": "SUMMARY: The current methods available to detect chromosomal abnormalities from DNA microarray expression data are cumbersome and inflexible. CAFE has been developed to alleviate these issues. It is implemented as an R package that analyzes Affymetrix *.CEL files and comes with flexible plotting functions, easing visualization of chromosomal abnormalities.AVAILABILITY AND IMPLEMENTATION: CAFE is available from https://bitbucket.org/cob87icW6z/cafe/ as both source and compiled packages for Linux and Windows.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24451624", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "SUMMARY: The current methods available to detect chromosomal abnormalities from DNA microarray expression data are cumbersome and inflexible. CAFE has been developed to alleviate these issues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24451624", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "CAFE: an R package for the detection of gross chromosomal abnormalities from gene expression microarray data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24451624", "endSection": "title"}]}, {"body": "List all the available databases of super enhancers", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26438538", "http://www.ncbi.nlm.nih.gov/pubmed/26578594"], "ideal_answer": ["dbSUPER and SEA are the available databases of super enhancers.", "dbSUPER and SEA are the most well-known and widely used Super-Enhancer Databases."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D030561", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019991", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009696"], "type": "list", "id": "587d2700fe8a08052f000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "dbSUPER: a database of super-enhancers in mouse and human genome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438538", "endSection": "title"}, {"offsetInBeginSection": 565, "offsetInEndSection": 1550, "text": "We developed dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/), the first integrated and interactive database of super-enhancers, with the primary goal of providing a resource for assistance in further studies related to transcriptional control of cell identity and disease. dbSUPER provides a responsive and user-friendly web interface to facilitate efficient and comprehensive search and browsing. The data can be easily sent to Galaxy instances, GREAT and Cistrome web-servers for downstream analysis, and can also be visualized in the UCSC genome browser where custom tracks can be added automatically. The data can be downloaded and exported in variety of formats. Furthermore, dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt and Entrez. dbSUPER also provides an overlap analysis tool to annotate user-defined regions. We believe dbSUPER is a valuable resource for the biology and genetic research communities", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438538", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 29, "text": "SEA: a super-enhancer archive", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26578594", "endSection": "title"}, {"offsetInBeginSection": 377, "offsetInEndSection": 1587, "text": "Here, we present a specifically designed web-accessible database, Super-Enhancer Archive (SEA, http://sea.edbc.org). SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in the regulation of cell identity gene expression. The current release of SEA incorporates 83 996 super-enhancers computationally or experimentally identified in 134 cell types/tissues/diseases, including human (75 439, three of which were experimentally identified), mouse (5879, five of which were experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans (904). To facilitate data extraction, SEA supports multiple search options, including species, genome location, gene name, cell type/tissue and super-enhancer name. The response provides detailed (epi)genetic information, incorporating cell type specificity, nearby genes, transcriptional factor binding sites, CRISPR/Cas9 target sites, evolutionary conservation, SNPs, H3K27ac, DNA methylation, gene expression and TF ChIP-seq data. Moreover, analytical tools and a genome browser were developed for users to explore super-enhancers and their roles in defining cell identity and disease processes in depth", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26578594", "endSection": "abstract"}, {"offsetInBeginSection": 494, "offsetInEndSection": 646, "text": "SEA focuses on integrating super-enhancers in multiple species and annotating their potential roles in the regulation of cell identity gene expression. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26578594", "endSection": "abstract"}, {"offsetInBeginSection": 669, "offsetInEndSection": 987, "text": "SEA incorporates 83 996 super-enhancers computationally or experimentally identified in 134 cell types/tissues/diseases, including human (75 439, three of which were experimentally identified), mouse (5879, five of which were experimentally identified), Drosophila melanogaster (1774) and Caenorhabditis elegans (904).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26578594", "endSection": "abstract"}, {"offsetInBeginSection": 565, "offsetInEndSection": 841, "text": "We developed dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/), the first integrated and interactive database of super-enhancers, with the primary goal of providing a resource for assistance in further studies related to transcriptional control of cell identity and disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438538", "endSection": "abstract"}, {"offsetInBeginSection": 1238, "offsetInEndSection": 1458, "text": "Furthermore, dbSUPER lists genes associated with super-enhancers and also links to external databases such as GeneCards, UniProt and Entrez. dbSUPER also provides an overlap analysis tool to annotate user-defined regions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438538", "endSection": "abstract"}, {"offsetInBeginSection": 565, "offsetInEndSection": 966, "text": "We developed dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/), the first integrated and interactive database of super-enhancers, with the primary goal of providing a resource for assistance in further studies related to transcriptional control of cell identity and disease. dbSUPER provides a responsive and user-friendly web interface to facilitate efficient and comprehensive search and browsing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438538", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "dbSUPER: a database of super-enhancers in mouse and human genome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26438538", "endSection": "title"}]}, {"body": "Which are the consequences of the hyperphosphorylated tau in Alzheimers' Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23640887", "http://www.ncbi.nlm.nih.gov/pubmed/20942790", "http://www.ncbi.nlm.nih.gov/pubmed/10214944", "http://www.ncbi.nlm.nih.gov/pubmed/24448785", "http://www.ncbi.nlm.nih.gov/pubmed/22315694", "http://www.ncbi.nlm.nih.gov/pubmed/7666054", "http://www.ncbi.nlm.nih.gov/pubmed/19459590", "http://www.ncbi.nlm.nih.gov/pubmed/22536363", "http://www.ncbi.nlm.nih.gov/pubmed/24965601", "http://www.ncbi.nlm.nih.gov/pubmed/17662457", "http://www.ncbi.nlm.nih.gov/pubmed/11052669", "http://www.ncbi.nlm.nih.gov/pubmed/21715616", "http://www.ncbi.nlm.nih.gov/pubmed/26258756", "http://www.ncbi.nlm.nih.gov/pubmed/9427351", "http://www.ncbi.nlm.nih.gov/pubmed/23340677", "http://www.ncbi.nlm.nih.gov/pubmed/15450610", "http://www.ncbi.nlm.nih.gov/pubmed/22203915", "http://www.ncbi.nlm.nih.gov/pubmed/9832145", "http://www.ncbi.nlm.nih.gov/pubmed/7616230", "http://www.ncbi.nlm.nih.gov/pubmed/17372746", "http://www.ncbi.nlm.nih.gov/pubmed/16793187", "http://www.ncbi.nlm.nih.gov/pubmed/17906291", "http://www.ncbi.nlm.nih.gov/pubmed/23946388", "http://www.ncbi.nlm.nih.gov/pubmed/23805125", "http://www.ncbi.nlm.nih.gov/pubmed/25220759", "http://www.ncbi.nlm.nih.gov/pubmed/24788298", "http://www.ncbi.nlm.nih.gov/pubmed/12214106", "http://www.ncbi.nlm.nih.gov/pubmed/19451179", "http://www.ncbi.nlm.nih.gov/pubmed/22110363", "http://www.ncbi.nlm.nih.gov/pubmed/19525898", "http://www.ncbi.nlm.nih.gov/pubmed/8960316", "http://www.ncbi.nlm.nih.gov/pubmed/25031639", "http://www.ncbi.nlm.nih.gov/pubmed/9084440", "http://www.ncbi.nlm.nih.gov/pubmed/20678074"], "ideal_answer": ["The consequences of the hyperphosphorylated tau in Alzheimers' Disease is:\n1) The formation of neurofibrillary tangles (NFTs)\n2) Impaired glutamate metabolism\n3) Decreased tau affinity for microtubules binding\n4) Dendritic and axonal instability\n5) Synaptic degeneration\n6) Neuronal loss."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016875", "http://www.uniprot.org/uniprot/TAU_HUMAN", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544", "http://www.disease-ontology.org/api/metadata/DOID:10652", "http://www.uniprot.org/uniprot/TAU_MACMU", "http://www.uniprot.org/uniprot/TAU_CAPHI", "http://www.disease-ontology.org/api/metadata/DOID:1289"], "type": "list", "id": "58a2efec60087bc10a000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "The formation of neurofibrillary tangles from the assembly of hyperphosphorylated tau leads to dendritic and axonal instability, synaptic degeneration, and neuronal loss. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24448785", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340677", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "In neurodegenerative diseases including Alzheimer's disease and frontotemporal dementia, the protein tau is hyperphosphorylated and eventually aggregates to develop neurofibrillary tangles. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23340677", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Neurofibrillary tangles (NFTs), a marker of neuronal alterations in Alzheimer's disease (AD) and other tauopathies, are comprised of aggregates of hyperphosphorylated tau protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23946388", "endSection": "abstract"}, {"offsetInBeginSection": 772, "offsetInEndSection": 878, "text": "At 24 months, NFTs progress, tau inclusions propagate to the dentate gyrus, and neuronal loss is evident. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23946388", "endSection": "abstract"}, {"offsetInBeginSection": 372, "offsetInEndSection": 554, "text": "At autopsy, brains of AD and a subset of TBI victims display some similarities including accumulation of A\u03b2 peptides and neurofibrillary tangles of hyperphosphorylated tau proteins. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23805125", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 374, "text": "The pathological hallmarks of Alzheimer's disease (AD)--widespread synaptic and neuronal loss and the pathological accumulation of amyloid-beta peptide (A\u03b2) in senile plaques, as well as hyperphosphorylated tau in neurofibrillary tangles--have been known for many decades, but the links between AD pathology and dementia and effective therapeutic strategies remain elusive. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22203915", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "The microtubule-associated protein tau, in a hyperphosphorylated form, aggregates into insoluble paired-helical filaments (PHFs) in Alzheimer's disease (AD) and other tauopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19459590", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19459590", "endSection": "title"}, {"offsetInBeginSection": 368, "offsetInEndSection": 647, "text": "In AD, kinases such as glycogen synthase kinase-3beta (GSK-3beta) are believed to be involved in the generation of hyperphosphorylated tau. However, the functional consequences of hyperphosphorylation on the microtubule binding and polymerization of tau are not well understood. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19459590", "endSection": "abstract"}, {"offsetInBeginSection": 942, "offsetInEndSection": 1161, "text": "Pseudophosphorylation of tau decreases its affinity for microtubules, and pseudohyperphosphorylated forms of tau do not have significantly decreased levels of microtubule binding as compared to single and double sites. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19459590", "endSection": "abstract"}, {"offsetInBeginSection": 1396, "offsetInEndSection": 1795, "text": "On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimer's disease and also explain the potentially beneficial role of tau polymerization and NFT formation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19459590", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Microtubule-associated protein tau is abnormally hyperphosphorylated and aggregated in affected neurons of Alzheimer disease brain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7616230", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "In several neurodegenerative diseases, including Alzheimer disease, the neuronal microtubule-associated protein tau becomes hyperphosphorylated, accumulates in the somatodendritic compartment, and aggregates into insoluble filaments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19525898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Tau is the major component of the neurofibrillar tangles that are a pathological hallmark of Alzheimers' disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10214944", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Aggregates of hyperphosphorylated tau protein are found in a group of diseases called tauopathies, which includes Alzheimers disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24788298", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "In several neurodegenerative diseases, including Alzheimer disease, the neuronal microtubule-associated protein tau becomes hyperphosphorylated, accumulates in the somatodendritic compartment, and aggregates into insoluble filaments", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19525898", "endSection": "abstract"}, {"offsetInBeginSection": 1395, "offsetInEndSection": 1792, "text": "On the basis of the observations that pseudohyperphosphorylated tau has decreased affinity for microtubules and reduced inducer-initiated rates of nucleation and polymerization, we propose that this combination could be the cause of the increased cytotoxicity of hyperphosphorylated tau in Alzheimers disease and also explain the potentially beneficial role of tau polymerization and NFT formation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19459590", "endSection": "abstract"}, {"offsetInBeginSection": 76, "offsetInEndSection": 237, "text": "In the brains of individuals with Alzheimers disease, tau is hyperphosphorylated and aggregated into intraneuronal deposits called neurofibrillary tangles (NFTs)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15450610", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Neurofibrillary tangles and neuropil threads, both made of hyperphosphorylated tau proteins, point to an alteration of microtubules in Alzheimers disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9427351", "endSection": "abstract"}, {"offsetInBeginSection": 177, "offsetInEndSection": 405, "text": "Hyperphosphorylation, which diminishes the microtubule-binding capacity of tau, destabilizes microtubules and may enhance the formation of paired helical filaments that constitute neurofibrillary tangles in Alzheimer's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7666054", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 439, "text": "In several neurodegenerative diseases, including Alzheimer disease, the neuronal microtubule-associated protein tau becomes hyperphosphorylated, accumulates in the somatodendritic compartment, and aggregates into insoluble filaments. The consequences of the accumulation of hyperphosphorylated tau in the somatodendritic compartment remain poorly characterized at the early stage of disease before the formation of tau insoluble filaments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19525898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 285, "text": "Microtubule-associated protein tau is abnormally hyperphosphorylated and aggregated in affected neurons of Alzheimer disease brain. This hyperphosphorylated tau can be dephosphorylated at some of the abnormal phosphorylated sites by purified protein phosphatase-1, 2A, and 2B in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7616230", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 404, "text": "Adult human nerve cells contain tau protein, a phosphorylated microtubule-associated protein, that is hyperphosphorylated in the fetus and in patients with Alzheimer's disease. Hyperphosphorylation, which diminishes the microtubule-binding capacity of tau, destabilizes microtubules and may enhance the formation of paired helical filaments that constitute neurofibrillary tangles in Alzheimer's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7666054", "endSection": "abstract"}, {"offsetInBeginSection": 776, "offsetInEndSection": 1047, "text": "Importantly, hyperphosphorylated tau comprises the paired helical filament, whose pathological deposition as neurofibrillary tangles is implicated in Alzheimer's disease; hyperphosphorylated tau is also implicated in the pathogenesis of other neurodegenerative disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16793187", "endSection": "abstract"}, {"offsetInBeginSection": 548, "offsetInEndSection": 826, "text": "In Alzheimer disease (AD) brain tau is ~three to four-fold more hyperphosphorylated than the normal adult brain tau and in this hyperphosphorylated state it is polymerized into paired helical filaments ([PHF) admixed with straight filaments (SF) forming neurofibrillary tangles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20678074", "endSection": "abstract"}]}, {"body": "Which is the \"bonding hormone\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24430853", "http://www.ncbi.nlm.nih.gov/pubmed/26025428", "http://www.ncbi.nlm.nih.gov/pubmed/27825953", "http://www.ncbi.nlm.nih.gov/pubmed/25619431", "http://www.ncbi.nlm.nih.gov/pubmed/26442453"], "ideal_answer": ["Oxytocin is known as the 'bonding hormone' due its role in promoting mother-child and pair bonding."], "type": "factoid", "id": "58aa0c6f396a458e50000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 223, "text": "The neurohypophysial hormone oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social behaviors, including social recognition, pair bonding, parental behavior, and stress-related responses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26442453", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Neuropeptide hormone oxytocin has roles in social bonding, energy metabolism, and wound healing contributing to good physical, mental and social health. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825953", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Oxytocin is known as the 'love hormone' due its role in promoting mother-child and pair bonding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25619431", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "The oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR) has been implicated in pair bonding behavior in mammalian lineages.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26025428", "endSection": "abstract"}, {"offsetInBeginSection": 303, "offsetInEndSection": 359, "text": "oxytocin, a hormone involved in parent-offspring bonding", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24430853", "endSection": "abstract"}]}, {"body": "What causes Scurvy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11581484", "http://www.ncbi.nlm.nih.gov/pubmed/26144910", "http://www.ncbi.nlm.nih.gov/pubmed/15949874", "http://www.ncbi.nlm.nih.gov/pubmed/8942253", "http://www.ncbi.nlm.nih.gov/pubmed/27502755", "http://www.ncbi.nlm.nih.gov/pubmed/23734160", "http://www.ncbi.nlm.nih.gov/pubmed/23747864", "http://www.ncbi.nlm.nih.gov/pubmed/26358868", "http://www.ncbi.nlm.nih.gov/pubmed/23214273", "http://www.ncbi.nlm.nih.gov/pubmed/25983516", "http://www.ncbi.nlm.nih.gov/pubmed/16521952", "http://www.ncbi.nlm.nih.gov/pubmed/17644699", "http://www.ncbi.nlm.nih.gov/pubmed/26783325", "http://www.ncbi.nlm.nih.gov/pubmed/26063195", "http://www.ncbi.nlm.nih.gov/pubmed/16251606", "http://www.ncbi.nlm.nih.gov/pubmed/26590972", "http://www.ncbi.nlm.nih.gov/pubmed/23734365"], "ideal_answer": [" Scurvy, or \"Barlow's disease\", is a widely described disease involving cutaneous and mucosal lesions resulting from vitamin C deficiency.", "Scurvy, or \"Barlow's disease\", is a widely described disease resulting from vitamin C deficiency"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012614", "http://www.disease-ontology.org/api/metadata/DOID:13724"], "type": "summary", "id": "58a5d54860087bc10a000025", "snippets": [{"offsetInBeginSection": 312, "offsetInEndSection": 502, "text": "They presented with limp, and an elaborate panel of tests and procedures were undertaken before the diagnosis of scurvy was made. Treatment with vitamin C led to rapid recovery of symptoms. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26590972", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 151, "text": " Scurvy, or \"Barlow's disease\", is a widely described disease involving cutaneous and mucosal lesions resulting from vitamin C deficiency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27502755", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Scurvy, a disease of dietary deficiency of vitamin C, is uncommon today.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11581484", "endSection": "abstract"}, {"offsetInBeginSection": 681, "offsetInEndSection": 902, "text": "Because many of the early symptoms of vitamin C deficiency (fatigue, malaise, depression and irritability) are non-specific, the diagnostic possibility of scurvy is usually delayed until haemorrhagic manifestations occur.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23214273", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Scurvy is caused by prolonged dietary deficiency of vitamin C, the plasma concentration of which appears inversely related to mortality from all causes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23214273", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Scurvy is a rarely seen disease resulting from a deficiency of vitamin C. We present a case of scurvy in a 65-year-old man", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17644699", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Ascorbic acid is a vitamin soluble in water and its deficiency in human body causes scurvy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16521952", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 312, "text": "Deficiencies in vitamin C can lead to conditions such as scurvy, which, among other ailments, causes gingivia, bone pain, and impaired wound healing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358868", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 344, "text": "Severe deficiency leads to scurvy, whereas a limited vitamin C intake causes general symptoms, such as increased susceptibility to infections, fatigue, insomnia, and weight loss.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23734160", "endSection": "abstract"}, {"offsetInBeginSection": 462, "offsetInEndSection": 694, "text": "Vitamin C deficiency causes scurvy a serious and painful disease in which defective collagen prevents the formation of strong connective tissue, gums deteriorate and bleed, with loss of teeth; skin discolors, and wounds do not heal.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26144910", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 382, "text": "The human body is unable to synthesise Vitamin C and a diet deficient in Vitamin C leads to scurvy. Scurvy may mimic other medical conditions, like bleeding diasthesis or deep vein thrombosis, leading to delay in diagnosis and treatment, thus prolonging sufferings of patients. Often, scurvy could have been diagnosed if it is thought of and features of scurvy carefully looked for.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8942253", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Scurvy, a disease of dietary deficiency of vitamin C, is uncommon today. Among diseases, scurvy has a rich history and an ancient past.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11581484", "endSection": "abstract"}, {"offsetInBeginSection": 100, "offsetInEndSection": 441, "text": "Scurvy may mimic other medical conditions, like bleeding diasthesis or deep vein thrombosis, leading to delay in diagnosis and treatment, thus prolonging sufferings of patients. Often, scurvy could have been diagnosed if it is thought of and features of scurvy carefully looked for. Scurvy is easily treated with high dose of oral vitamin C.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8942253", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Scurvy is caused by prolonged severe dietary deficiency of vitamin C.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25983516", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Scurvy, caused by lack of vitamin C, was a major problem for polar explorers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23734365", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 73, "text": "curvy is the clinical manifestation of vitamin C deficiency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15949874", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Scurvy is a nondiscriminatory disease process resulting from a nutritional deficiency of ascorbic acid (vitamin C).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16301149", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "In modern times scurvy is a rarely encountered disease caused by ascorbic acid (vitamin C) deficiency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25109378", "endSection": "abstract"}]}, {"body": "Describe clinical presentation of Ambras syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18328202", "http://www.ncbi.nlm.nih.gov/pubmed/12053598", "http://www.ncbi.nlm.nih.gov/pubmed/18713754", "http://www.ncbi.nlm.nih.gov/pubmed/8275569", "http://www.ncbi.nlm.nih.gov/pubmed/15305058", "http://www.ncbi.nlm.nih.gov/pubmed/27080973", "http://www.ncbi.nlm.nih.gov/pubmed/27601862", "http://www.ncbi.nlm.nih.gov/pubmed/15365467", "http://www.ncbi.nlm.nih.gov/pubmed/26620032", "http://www.ncbi.nlm.nih.gov/pubmed/11471181", "http://www.ncbi.nlm.nih.gov/pubmed/25961852", "http://www.ncbi.nlm.nih.gov/pubmed/9712536"], "ideal_answer": ["Ambras syndrome is a distinct form of congenital hypertrichosis characterized by excessive hair growth over the body and face associated with facial and occasional dental anomalies. In patients with this syndrome, the whole body is covered with fine long hair, except for areas where normally no hair grows. There is accompanying facial dysmorphism and teeth abnormalities, including retarded first and second dentition and absence of teeth."], "type": "summary", "id": "5895fc7e78275d0c4a000003", "snippets": [{"offsetInBeginSection": 200, "offsetInEndSection": 456, "text": "In 1993, Baumister et al. described congenital hypertrichosis lanuginose or Ambras syndrome: a distinct form of congenital hypertrichosis characterized by excessive hair growth over the body and face associated with facial and occasional dental anomalies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26620032", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Ambras syndrome (AS) is a rare form of congenital hypertrichosis with excessive hair on the shoulders, face and ears. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18713754", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 339, "text": "Ambras syndrome (AMS) is a unique form of universal congenital hypertrichosis. In patients with this syndrome, the whole body is covered with fine long hair, except for areas where normally no hair grows. There is accompanying facial dysmorphism and teeth abnormalities, including retarded first and second dentition and absence of teeth. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15305058", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "We report two siblings with congenital generalized hypertrichosis and distinctive facial appearance consistent with the dysmorphic facial features described in Ambras syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15365467", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Ambras syndrome is a rare and special form of congenital hypertrichosis, characterized by dysmorphic facial features and familial pattern of inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27601862", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Ambras syndrome (AS) is a special form of congenital universal hypertrichosis described for the first time by Baumeister et al. (1). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9712536", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Ambras syndrome (AMS) is a unique form of universal congenital hypertrichosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15305058", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Ambras syndrome (AMS) is a unique form of congenital universal hypertrichosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11471181", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Ambras syndrome (AMS) is a unique form of universal congenital hypertrichosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15305058", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Ambras syndrome (AMS) is a unique form of congenital universal hypertrichosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11471181", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "[Ambras syndrome--a form of generalised congenital hypertrichosis].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12053598", "endSection": "title"}, {"offsetInBeginSection": 226, "offsetInEndSection": 455, "text": "described congenital hypertrichosis lanuginose or Ambras syndrome: a distinct form of congenital hypertrichosis characterized by excessive hair growth over the body and face associated with facial and occasional dental anomalies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26620032", "endSection": "abstract"}]}, {"body": "Which diseases are involved in the severe cutaneous reactions (SCAR) spectrum?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27779083", "http://www.ncbi.nlm.nih.gov/pubmed/27106261", "http://www.ncbi.nlm.nih.gov/pubmed/23136927", "http://www.ncbi.nlm.nih.gov/pubmed/23551241", "http://www.ncbi.nlm.nih.gov/pubmed/20541690", "http://www.ncbi.nlm.nih.gov/pubmed/7636511", "http://www.ncbi.nlm.nih.gov/pubmed/21162721", "http://www.ncbi.nlm.nih.gov/pubmed/26894082", "http://www.ncbi.nlm.nih.gov/pubmed/25946710", "http://www.ncbi.nlm.nih.gov/pubmed/18657400", "http://www.ncbi.nlm.nih.gov/pubmed/15767024", "http://www.ncbi.nlm.nih.gov/pubmed/21917426", "http://www.ncbi.nlm.nih.gov/pubmed/23904296", "http://www.ncbi.nlm.nih.gov/pubmed/23484337", "http://www.ncbi.nlm.nih.gov/pubmed/25115449", "http://www.ncbi.nlm.nih.gov/pubmed/14528522", "http://www.ncbi.nlm.nih.gov/pubmed/8957644", "http://www.ncbi.nlm.nih.gov/pubmed/23232549", "http://www.ncbi.nlm.nih.gov/pubmed/15743917", "http://www.ncbi.nlm.nih.gov/pubmed/27154258", "http://www.ncbi.nlm.nih.gov/pubmed/24193402", "http://www.ncbi.nlm.nih.gov/pubmed/24322785", "http://www.ncbi.nlm.nih.gov/pubmed/26170788", "http://www.ncbi.nlm.nih.gov/pubmed/25938070", "http://www.ncbi.nlm.nih.gov/pubmed/17921614", "http://www.ncbi.nlm.nih.gov/pubmed/24819643", "http://www.ncbi.nlm.nih.gov/pubmed/25657416", "http://www.ncbi.nlm.nih.gov/pubmed/22116946", "http://www.ncbi.nlm.nih.gov/pubmed/21545408", "http://www.ncbi.nlm.nih.gov/pubmed/25070588", "http://www.ncbi.nlm.nih.gov/pubmed/20064188"], "ideal_answer": ["The diseases that are involved in the severe cutaneous reactions (SCAR) spectrum are:\n1) Stevens-Johnson syndrome (SJS)\n2) Toxic epidermal necrolysis (TEN)\n3) Acute generalized exanthematous pustulosis (AGEP)."], "type": "list", "id": "58a45d6060087bc10a00001d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are diseases within the spectrum of severe cutaneous adverse reactions affecting skin and mucous membranes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26170788", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Toxic epidermal necrolysis (TEN) and Stevens Johnson Syndrome (SJS) are severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21162721", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 689, "text": "Currently, TEN and SJS are considered to be two ends of a spectrum of severe epidermolytic adverse cutaneous drug reactions, differing only by their extent of skin detachment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21162721", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are considered part of a spectrum of adverse cutaneous drug reactions showing severe and extensive skin detachment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18657400", "endSection": "abstract"}, {"offsetInBeginSection": 83, "offsetInEndSection": 308, "text": "Our aim was to study patch testing in severe cutaneous adverse drug reactions (ADRs) (Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), and other cutaneous ADRs)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8957644", "endSection": "abstract"}, {"offsetInBeginSection": 88, "offsetInEndSection": 297, "text": "However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens\u2013Johnson syndrome, and toxic epidermal necrolysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23232549", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 479, "text": "Drug eruptions range from transient erythema to the life threatening severe cutaneous adverse reactions (SCAR) that encompass Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms complex (DRESS).To study the clinical and epidemiological aspects of cutaneous adverse drug reactions (CADR).Ethical clearance was obtained from the institutional ethics committee", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25657416", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) are severe cutaneous adverse reactions (SCAR) which are majorly caused by drugs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25938070", "endSection": "abstract"}, {"offsetInBeginSection": 236, "offsetInEndSection": 726, "text": "This study investigated the association between the HLA class I genotype and carbamazepine-induced severe cutaneous adverse reaction (SCAR) in Koreans.Twenty-four patients who had developed carbamazepine-induced SCAR (7 Stevens-Johnson syndrome (SJS), 17 drug hypersensitivity syndrome (HSS)), 50 carbamazepine-tolerant controls from the Korean Pharmacogenetic Adverse Drug Reaction Research Network and data of 485 Korean general population from a previously published study were recruited", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21917426", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "Severe cutaneous adverse reactions (SCARs) include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193402", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Severe Cutaneous Adverse Reaction (SCAR) represents the spectrum of adverse drug reactions from erythema multiforme, Stevens - Johnson syndrome (SJS) to Toxic Epidermal Necrolysis (TEN). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23484337", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 375, "text": "Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are uncommon but extremely serious and often life-threatening mucocutaneous reactions characterized by extensive epithelial sloughing and systemic symptoms. There is no effective evidence-based treatment for severe cutaneous adverse reactions (SCAR) to drugs and no consensus on how to treat these patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20541690", "endSection": "abstract"}, {"offsetInBeginSection": 88, "offsetInEndSection": 417, "text": "However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens\u2013Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B*58:01, associates strongly with allopurinolinduced SCAR.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23232549", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 682, "text": "The skin is often involved in ADRs and although most cutaneous ADRs have a favorable course, they may present as severe adverse cutaneous drug reactions (SCARs), such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (also referred to as drug-induced hypersensitivity syndrome), and acute generalized exanthematous pustulosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24819643", "endSection": "abstract"}, {"offsetInBeginSection": 120, "offsetInEndSection": 253, "text": "By comparison, Stevens-Johnson syndrome (SJS) is a life-threatening severe cutaneous adverse reaction (SCAR), mainly caused by drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23904296", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "The study sought to identify the magnitude and characteristic of severe cutaneous adverse reactions (SCAR's) like Steven-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26894082", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 268, "text": "Allopurinol, an antihyperuricaemic agent, is one of the common causes of life-threatening severe cutaneous adverse reactions (SCAR), including drug rash with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25115449", "endSection": "abstract"}]}, {"body": "Which tool employs self organizing maps for analyzing synonymous codon usage?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15059815"], "ideal_answer": ["INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage. Finally, INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.", "INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage."], "type": "factoid", "id": "5891c90949702f2e01000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059815", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 606, "text": "INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage. Finally, INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059815", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "UNLABELLED: INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059815", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059815", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059815", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059815", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 700, "text": "UNLABELLED: INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage. Finally, INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INCA is available for the Win32 platform and is free of charge for academic use.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059815", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 433, "text": "UNLABELLED: INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059815", "endSection": "abstract"}, {"offsetInBeginSection": 145, "offsetInEndSection": 700, "text": "In addition to computing codon frequencies and several usage indices, such as 'codon bias', effective Nc and CAI, the primary strength of INCA has numerous options for the interactive graphical display of calculated values, thus allowing visual detection of various trends in codon usage. Finally, INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INCA is available for the Win32 platform and is free of charge for academic use.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059815", "endSection": "abstract"}, {"offsetInBeginSection": 434, "offsetInEndSection": 700, "text": "Finally, INCA includes a specific unsupervised neural network algorithm, the self-organizing map, used for gene clustering according to the preferred utilization of codons.AVAILABILITY: INCA is available for the Win32 platform and is free of charge for academic use.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059815", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059815", "endSection": "title"}]}, {"body": "What is MINDY-1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27292798"], "ideal_answer": ["MINDY-1 (motif interacting with Ub-containing novel DUB family) is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes. Found in all eukaryotes, MINDY-family DUBs are highly selective at cleaving K48-linked polyUb, a signal that targets proteins for degradation. MINDY-1 prefers cleaving long polyUb chains and works by trimming chains from the distal end.", "MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes"], "concepts": ["http://www.uniprot.org/uniprot/FA63A_MOUSE", "http://www.uniprot.org/uniprot/FA63A_PONAB", "http://www.uniprot.org/uniprot/FA63A_BOVIN", "http://www.uniprot.org/uniprot/FA63A_RAT", "http://www.uniprot.org/uniprot/FA63A_DANRE", "http://www.uniprot.org/uniprot/FA63A_HUMAN"], "type": "summary", "id": "587e42032420191125000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798", "endSection": "title"}, {"offsetInBeginSection": 138, "offsetInEndSection": 983, "text": "Here we report the discovery of a new family of DUBs, which we have named MINDY (motif interacting with Ub-containing novel DUB family). Found in all eukaryotes, MINDY-family DUBs are highly selective at cleaving K48-linked polyUb, a signal that targets proteins for degradation. We identify the catalytic activity to be encoded within a previously unannotated domain, the crystal structure of which reveals a distinct protein fold with no homology to any of the known DUBs. The crystal structure of MINDY-1 (also known as FAM63A) in complex with propargylated Ub reveals conformational changes that realign the active site for catalysis. MINDY-1 prefers cleaving long polyUb chains and\u00a0works by trimming chains from the distal end. Collectively, our results reveal a new family of DUBs that may have specialized roles in regulating proteostasis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798", "endSection": "abstract"}]}, {"body": "What is the benserazide's mechanism of function when co-administered with L-DOPA in patients with Parkinson's Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20303948", "http://www.ncbi.nlm.nih.gov/pubmed/3768865", "http://www.ncbi.nlm.nih.gov/pubmed/12703659", "http://www.ncbi.nlm.nih.gov/pubmed/11166288", "http://www.ncbi.nlm.nih.gov/pubmed/8584079", "http://www.ncbi.nlm.nih.gov/pubmed/11587490", "http://www.ncbi.nlm.nih.gov/pubmed/25511986", "http://www.ncbi.nlm.nih.gov/pubmed/6437857", "http://www.ncbi.nlm.nih.gov/pubmed/9372552", "http://www.ncbi.nlm.nih.gov/pubmed/452602"], "ideal_answer": ["Benserazide is a peripheral decarboxylase inhibitor. Benserazide in combination with L-DOPA constitutes a slow-release formulation of L-DOPA in patients with Parkinson's disease (PD), it reduces peaks and rapid fluctuations of L-DOPA plasma levels (possibly responsible for peak-dose dyskinesias and end-of-dose deterioration) and considered as the best available therapy."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:14330", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275540", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010300", "http://www.biosemantics.org/jochem#4275540"], "type": "summary", "id": "58a5723c60087bc10a00001e", "snippets": [{"offsetInBeginSection": 160, "offsetInEndSection": 776, "text": "Recent human and animal biochemical investigations clearly confirm and extend previous findings indicating that benserazide is much more potent than carbidopa as peripheral decarboxylase inhibitor. L-DOPA in combination with benserazide or carbidopa constitutes the best available therapy for Parkinson's disease (PD). To reduce peaks and rapid fluctuations of L-DOPA plasma levels (possibly responsible for peak-dose dyskinesias and end-of-dose deterioration) a slow-release formulation of L-DOPA in combination with benserazide or with benserazide plus catechol-O-methyltransferase inhibitors should be developed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6437857", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 322, "text": "In an open label study 63 patients with idiopathic Parkinson's disease suffering from end-of-dose akinesia were switched from a treatment with a L-DOPA standard formulation to a combined therapy of L-DOPA standard in the morning and L-DOPA slow release (levodopa, benserazide, Madopar Depot) at the remaining single doses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8584079", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 438, "text": "In the present study, L-dopa and benserazide were loaded by poly (lactic-co-glycolic acid) microspheres (LBM), which can release levodopa and benserazide in a sustained manner in order to continuous stimulate dopaminergic receptors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25511986", "endSection": "abstract"}]}, {"body": "What is regioneR?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26424858"], "ideal_answer": ["Statistically assessing the relation between a set of genomic regions and other genomic features is a common challenging task in genomic and epigenomic analyses. regioneR is an R package that implements a permutation test framework specifically designed to work with genomic regions. In addition to the predefined randomization and evaluation strategies, regioneR is fully customizable allowing the use of custom strategies to adapt it to specific questions. Finally, it also implements a novel function to evaluate the local specificity of the detected association. regioneR is an R package released under Artistic-2.0 License. The source code and documents are freely available through Bioconductor (http://www.bioconductor.org/packages/regioneR).", "RegioneR is an R/Bioconductor package for the association analysis of genomic regions based on permutation tests. It implements a permutation test framework specifically designed to work with genomic regions. In addition to the predefined randomization and evaluation strategies, regioneR is fully customizable allowing the use of custom strategies to adapt it to specific questions. Finally, it also implements a novel function to evaluate the local specificity of the detected association.", "Statistically assessing the relation between a set of genomic regions and other genomic features is a common challenging task in genomic and epigenomic analyses. Randomization based approaches implicitly take into account the complexity of the genome without the need of assuming an underlying statistical model. regioneR is an R package that implements a permutation test framework specifically designed to work with genomic regions. In addition to the predefined randomization and evaluation strategies, regioneR is fully customizable allowing the use of custom strategies to adapt it to specific questions. Finally, it also implements a novel function to evaluate the local specificity of the detected association. The source code and documents are freely available through Bioconductor (http://www.bioconductor.org/packages/regioneR)."], "type": "summary", "id": "587e3f4e2420191125000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26424858", "endSection": "title"}, {"offsetInBeginSection": 333, "offsetInEndSection": 737, "text": "regioneR is an R package that implements a permutation test framework specifically designed to work with genomic regions. In addition to the predefined randomization and evaluation strategies, regioneR is fully customizable allowing the use of custom strategies to adapt it to specific questions. Finally, it also implements a novel function to evaluate the local specificity of the detected association.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26424858", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 432, "text": "Randomization based approaches implicitly take into account the complexity of the genome without the need of assuming an underlying statistical model.regioneR is an R package that implements a permutation test framework specifically designed to work with genomic regions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26424858", "endSection": "abstract"}, {"offsetInBeginSection": 434, "offsetInEndSection": 607, "text": "In addition to the predefined randomization and evaluation strategies, regioneR is fully customizable allowing the use of custom strategies to adapt it to specific questions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26424858", "endSection": "abstract"}, {"offsetInBeginSection": 609, "offsetInEndSection": 776, "text": "Finally, it also implements a novel function to evaluate the local specificity of the detected association.regioneR is an R package released under Artistic-2.0 License", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26424858", "endSection": "abstract"}, {"offsetInBeginSection": 778, "offsetInEndSection": 970, "text": "The source code and documents are freely available through Bioconductor (http://www.bioconductor.org/packages/regioneR).rmalinverni@carrerasresearch.org.<CopyrightInformation>\u00a9 The Author 2015", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26424858", "endSection": "abstract"}]}, {"body": "For what indications is thalidomide currently marketed?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12423428", "http://www.ncbi.nlm.nih.gov/pubmed/18034532", "http://www.ncbi.nlm.nih.gov/pubmed/26462773", "http://www.ncbi.nlm.nih.gov/pubmed/26652728", "http://www.ncbi.nlm.nih.gov/pubmed/18050580", "http://www.ncbi.nlm.nih.gov/pubmed/24931258", "http://www.ncbi.nlm.nih.gov/pubmed/11809002", "http://www.ncbi.nlm.nih.gov/pubmed/9098920", "http://www.ncbi.nlm.nih.gov/pubmed/24196904", "http://www.ncbi.nlm.nih.gov/pubmed/22650376", "http://www.ncbi.nlm.nih.gov/pubmed/25828060", "http://www.ncbi.nlm.nih.gov/pubmed/23142220", "http://www.ncbi.nlm.nih.gov/pubmed/11717819", "http://www.ncbi.nlm.nih.gov/pubmed/11235821", "http://www.ncbi.nlm.nih.gov/pubmed/25573527", "http://www.ncbi.nlm.nih.gov/pubmed/17274497", "http://www.ncbi.nlm.nih.gov/pubmed/8592478", "http://www.ncbi.nlm.nih.gov/pubmed/12190008", "http://www.ncbi.nlm.nih.gov/pubmed/6841082"], "ideal_answer": ["Drug repositioning, exemplified by sildenafil and thalidomide, is a promising way to explore alternative indications for existing drugs. THE USE OF A DRUG WITH A TEMPORARY MARKETING AUTHORISATION: Thalidomide is currently available in France for nominative or cohort use with a temporary marketing authorisation (TMA). Currently, it is used for a few indications; in Brazil, where leprosy is endemic, thalidomide is used for the treatment of erythema nodosum leprosum, and recent cases of thalidomide embryopathy have been reported.We analyzed the frequency of births with phenotypes consistent with thalidomide embryopathy (TEP) and correlated this with the distribution of thalidomide and the prevalence of leprosy between 2005 and 2010 in Brazil.A total of 5,889,210 thalidomide tablets were distributed; the prevalence of limb reduction defects was 1.60 (CI95%: 1.54-1.66) and TEP was 0.11 (CI95%: 0.10-0.13) Currently it includes a group of new drugs (immunosuppressives tacrolimus mycophenolate, thalidomide, biologic therapy, probiotics, neuroinflammation blockers), new treatment techniques (cytaphereses, sequential immunosuppression, immunosuppression with high doses), and finally new indications (chemoprophylaxis). A review of the therapeutic indications for thalidomide in dermatology as well as the mechanisms of action and side-effects of this drug are presented.", "Thalidomide can be used to treat multiple myeloma, polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS) syndrome and possibly Irritable Bowel Syndrome."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056687", "http://www.biosemantics.org/jochem#4018109", "http://www.biosemantics.org/jochem#4017077", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4250023", "http://www.biosemantics.org/jochem#4250023", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013792"], "type": "list", "id": "58a0da5278275d0c4a000054", "snippets": [{"offsetInBeginSection": 210, "offsetInEndSection": 456, "text": "In this retrospective study, pharmacy claims were analyzed for those patients with a diagnosis of MM who received thalidomide, lenalidomide, or pomalidomide from a large specialty pharmacy in the US between January 1, 2011, and December 31, 2013.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26652728", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 729, "text": "Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS) syndrome is a fatal systemic disorder associated with plasma cell dyscrasia and the overproduction of the vascular endothelial growth factor (VEGF). Recently, the prognosis of POEMS was substantially improved by introduction of therapeutic intervention for myeloma. However, no randomised clinical trial has been performed because of the rarity and severity of the disease.METHODS AND ANALYSIS: The Japanese POEMS syndrome with Thalidomide (J-POST) Trial is a phase II/III multicentre, double-blinded, randomised, controlled trial that aims to evaluate the efficacy and safety of a 24-week treatment with thalidomide in POEMS syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25573527", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 188, "text": "Thalidomide could relieve clinical symptoms and intestinal mucosal lesions effectively in children with refractory inflammatory bowel disease (IBD) from the pre-clinical study.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24931258", "endSection": "abstract"}, {"offsetInBeginSection": 170, "offsetInEndSection": 240, "text": "In reactional states of leprosy the use of thalidomide is established.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6841082", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "The use of thalidomide was never discontinued in Brazil where it is prescribed for leprosy type 2 reaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24196904", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 24, "text": "New uses of thalidomide.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8592478", "endSection": "title"}, {"offsetInBeginSection": 83, "offsetInEndSection": 695, "text": "Currently, it is used for a few indications; in Brazil, where leprosy is endemic, thalidomide is used for the treatment of erythema nodosum leprosum, and recent cases of thalidomide embryopathy have been reported.We analyzed the frequency of births with phenotypes consistent with thalidomide embryopathy (TEP) and correlated this with the distribution of thalidomide and the prevalence of leprosy between 2005 and 2010 in Brazil.A total of 5,889,210 thalidomide tablets were distributed; the prevalence of limb reduction defects was 1.60 (CI95%: 1.54-1.66) and TEP was 0.11 (CI95%: 0.10-0.13) per 10,000 births.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25828060", "endSection": "abstract"}, {"offsetInBeginSection": 993, "offsetInEndSection": 1160, "text": "The comeback of thalidomide to the legitimate status of a marketed drug came in 1998 when it received FDA approval for the treatment of erythema nodosum leprosum (ENL)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22650376", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 580, "text": "To explore the inhibitory effect of thalidomide combined with interferon (IFN) on the human acute myeloid leukemia cell line Kasumi- 1 and its mechanism.The inhibitiory effect of Kasumi- 1 cells by thalidomide, interferon or combination was detected by CCK- 8 method, the apoptosis by flow cytometry, the expression of apoptosis related proteins by Western blot, vascular endothelial growth factor (VEGF) concentration in culture supernatant by ELISA.Thalidomide inhibited the proliferation of Kasumi- 1 in a dose- dependent manner from 50 \u03bcg/ml to 500 \u03bcg/ml with an IC\u2085\u2080 of (451.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26462773", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Interferon (INF)-\u03b1 was the maintenance treatment of choice after autologous stem cell transplantation in multiple myeloma in the past, but currently Thalidomide is commonly used", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23142220", "endSection": "abstract"}, {"offsetInBeginSection": 347, "offsetInEndSection": 745, "text": "However, no randomised clinical trial has been performed because of the rarity and severity of the disease.The Japanese POEMS syndrome with Thalidomide (J-POST) Trial is a phase II/III multicentre, double-blinded, randomised, controlled trial that aims to evaluate the efficacy and safety of a 24-week treatment with thalidomide in POEMS syndrome, with an additional 48-week open-label safety study", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25573527", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Thalidomide, mainly used for the treatment of leprosy, is a current teratogen in South America, and it is reasonable to assume that at present this situation is affecting many births in underdeveloped countries. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9098920", "endSection": "abstract"}, {"offsetInBeginSection": 83, "offsetInEndSection": 676, "text": "Currently, it is used for a few indications; in Brazil, where leprosy is endemic, thalidomide is used for the treatment of erythema nodosum leprosum, and recent cases of thalidomide embryopathy have been reported.We analyzed the frequency of births with phenotypes consistent with thalidomide embryopathy (TEP) and correlated this with the distribution of thalidomide and the prevalence of leprosy between 2005 and 2010 in Brazil.A total of 5,889,210 thalidomide tablets were distributed; the prevalence of limb reduction defects was 1.60 (CI95%: 1.54-1.66) and TEP was 0.11 (CI95%: 0.10-0.13)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25828060", "endSection": "abstract"}, {"offsetInBeginSection": 617, "offsetInEndSection": 768, "text": "A review of the therapeutic indications for thalidomide in dermatology as well as the mechanisms of action and side-effects of this drug are presented.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12423428", "endSection": "abstract"}, {"offsetInBeginSection": 385, "offsetInEndSection": 675, "text": "Thalidomide first was marketed as a sedative in the 1950s and withdrawn from the market in 1961 following reports of teratogenicity. Later, it was used as an investigational agent for the treatment of Hansen's disease, Kaposi's sarcoma, myelofibrosis, RAUs, and wasting associated with HIV.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18050580", "endSection": "abstract"}, {"offsetInBeginSection": 317, "offsetInEndSection": 391, "text": "The drug has since been found effective for several different indications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8592478", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Based on present publications we review indications of the therapy of dermatoses with thalidomide as well as possible mechanisms of action and side effects of this drug.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6841082", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Use of thalidomide in dermatological indications.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18034532", "endSection": "title"}, {"offsetInBeginSection": 373, "offsetInEndSection": 507, "text": "Current data demonstrates that thalidomide is clinically promising in multiple myeloma, glioblastoma multiforme and renal cell cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11717819", "endSection": "abstract"}, {"offsetInBeginSection": 685, "offsetInEndSection": 804, "text": "Erythema nodosum leprosum is the only registered indication for the use of thalidomide in the United States of America.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12190008", "endSection": "abstract"}, {"offsetInBeginSection": 406, "offsetInEndSection": 623, "text": "Thalidomide is currently under investigation for the treatment of a wide variety of diseases, including conditions thought to have an inflammatory or immune basis, malignancies and complications of infection with HIV.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11235821", "endSection": "abstract"}, {"offsetInBeginSection": 157, "offsetInEndSection": 455, "text": "Gradually, thalidomide was reintroduced for the treatment of a few skin diseases including leprous erythema nodosum, severe mucosal ulcers (e.g., associated with HIV infection or Beh\u00e7et's disease), lymphocytic skin infiltrations, cutaneous lupus erythematosus, and chronic graft-versus-host disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11809002", "endSection": "abstract"}, {"offsetInBeginSection": 138, "offsetInEndSection": 391, "text": "Thalidomide has been used in several cutaneous inflammatory disorders (such as erythema nodosum leprosum in lepromatous leprosy, cutaneous lupus erythematosus, severe aphtosis), cancers (relapsed/refractory multiple myeloma) and inflammatory conditions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17274497", "endSection": "abstract"}, {"offsetInBeginSection": 134, "offsetInEndSection": 312, "text": "This drug was more recently rediscovered as a powerful immunomodulatory and antiinflammatory agent and was approved by the FDA in 1998 for treatment of erythema nodosum leprosum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15148528", "endSection": "abstract"}, {"offsetInBeginSection": 139, "offsetInEndSection": 226, "text": " Since, however, it has been found to be an effective drug in erythema nodosum leprosum", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10028338", "endSection": "abstract"}]}, {"body": "What are reactive metabolites?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/159767", "http://www.ncbi.nlm.nih.gov/pubmed/8987247", "http://www.ncbi.nlm.nih.gov/pubmed/25363902", "http://www.ncbi.nlm.nih.gov/pubmed/26627130", "http://www.ncbi.nlm.nih.gov/pubmed/21469730", "http://www.ncbi.nlm.nih.gov/pubmed/25851819", "http://www.ncbi.nlm.nih.gov/pubmed/23090860", "http://www.ncbi.nlm.nih.gov/pubmed/26735163", "http://www.ncbi.nlm.nih.gov/pubmed/12093356", "http://www.ncbi.nlm.nih.gov/pubmed/9614200", "http://www.ncbi.nlm.nih.gov/pubmed/16235238", "http://www.ncbi.nlm.nih.gov/pubmed/25174933", "http://www.ncbi.nlm.nih.gov/pubmed/22681489", "http://www.ncbi.nlm.nih.gov/pubmed/21148252", "http://www.ncbi.nlm.nih.gov/pubmed/16967439", "http://www.ncbi.nlm.nih.gov/pubmed/18788755", "http://www.ncbi.nlm.nih.gov/pubmed/1628536", "http://www.ncbi.nlm.nih.gov/pubmed/9144833", "http://www.ncbi.nlm.nih.gov/pubmed/21083235", "http://www.ncbi.nlm.nih.gov/pubmed/17145699"], "ideal_answer": ["Reactive metabolites are generated when a small molecule, commonly a drug or hydrocarbon, is broken down in the body. Reactive metabolites can cause cancer and other diseases as well as hepatoxicty. "], "type": "summary", "id": "58a3264e60087bc10a00000d", "snippets": [{"offsetInBeginSection": 1184, "offsetInEndSection": 1683, "text": "The results implicate the cis-enedial reactive metabolite of DIOB was responsible for the observed toxicities. The observed modest depletion of hepatic GSH in DIOB-treated animals suggests the actions of one or more reactive metabolites, and the hepatic injury observed could be due at least in part to reactions of these metabolites with crucial biomolecules. Cytochrome P450 3A enzymes are implicated in DIOB-induced hepatotoxicities by catalyzing the formation of the reactive metabolite of DIOB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25851819", "endSection": "abstract"}, {"offsetInBeginSection": 1351, "offsetInEndSection": 1470, "text": ". The neurotoxicity of endosulfan and its metabolites is closely related to oxidative damage and antioxidative deficit.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25363902", "endSection": "abstract"}, {"offsetInBeginSection": 1302, "offsetInEndSection": 1462, "text": "Our data from this study strongly indicate that Dic as well as its metabolites could be involved in the hepato-toxic action through inhibition of ATP synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26627130", "endSection": "abstract"}, {"offsetInBeginSection": 330, "offsetInEndSection": 461, "text": "Reactive metabolites can form adducts with trapping reagents, such as glutathione, which makes the reactive metabolites detectable.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21469730", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "[Reactive metabolites of xenobiotics : their role in the hepatotoxicity of drugs].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/159767", "endSection": "title"}, {"offsetInBeginSection": 127, "offsetInEndSection": 218, "text": "The formation of reactive metabolites has been associated with the observed hepatotoxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18788755", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Electrochemical oxidation of troglitazone: identification and characterization of the major reactive metabolite in liver microsomes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18788755", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "DNA bases attack by reactive metabolites produced during carbon tetrachloride biotransformation and promotion of liver microsomal lipid peroxidation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9144833", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 336, "text": "Certain drugs are transformed into reactive metabolites by cytochrome P-450, a hepatic microsomal enzyme. The reactive metabolites covalently bind to hepatocyte macromolecules, thus determining liver lesions. Induction of microsomial enzymes increases the formation of reactive metabolites and exaggerates hepatotoxicity of these drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/159767", "endSection": "abstract"}, {"offsetInBeginSection": 270, "offsetInEndSection": 397, "text": "It is generally accepted that a predominant pathway of drug-induced toxicity is through the generation of reactive metabolites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21148252", "endSection": "abstract"}, {"offsetInBeginSection": 596, "offsetInEndSection": 836, "text": "In addition, the incidence and nature of adverse reactions associated with a given drug is probably determined in large measure by the location of reactive metabolite formation, as well as the chemical reactivity of the reactive metabolite.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1628536", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Reactive metabolite-mediated toxicity is frequently limited to the organ where the electrophilic metabolites are generated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22681489", "endSection": "abstract"}, {"offsetInBeginSection": 1199, "offsetInEndSection": 1438, "text": "While there is a disproportionate number of compounds metabolized to reactive metabolites that are associated with drug-induced hepatotoxicity and serious skin toxicities such as toxic endothelial necrolysis and Steven's Johnson syndrome, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25174933", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Central to most hypotheses of the mechanism of idiosyncratic drug-induced blood dyscrasias is the involvement of reactive metabolite", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8987247", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Although idiosyncratic adverse drug reactions are rare, they are still a major concern to patient safety. Reactive metabolites are widely accepted as playing a pivotal role in the pathogenesis of idiosyncratic adverse drug reactions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26735163", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 433, "text": "detection and identification of minor reactive metabolites are equally important since the minor metabolites, even though at low levels, may be highly reactive and also play an important role in drug-induced adverse reactions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16235238", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Metabolic activation of a drug leading to reactive metabolite(s) that can covalently modify proteins is considered an initial step that may lead to drug-induced organ toxicities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16967439", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Reactive metabolites are believed to be responsible for most idiosyncratic drug reactions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145699", "endSection": "abstract"}, {"offsetInBeginSection": 1009, "offsetInEndSection": 1172, "text": " This review will focus on our current understanding and speculative views on how a reactive metabolite of a drug might ultimately lead to immune-mediated toxicity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12093356", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 259, "text": "he decline in approval of new drugs during the past decade has led to a close analysis of the drug discovery process. One of the main reasons for attrition is preclinical toxicity, frequently attributed to the generation of protein-reactive drug metabolites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090860", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Reactive metabolites are estimated to be one of the main reasons behind unexpected drug-induced toxicity, by binding covalently to cell proteins or DNA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504003", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 210, "text": "rug metabolism can result in the formation of highly reactive metabolites that are known to play a role in toxicity resulting in a significant proportion of attrition during drug development and clinical use. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312212", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "The formation of reactive metabolites through biotransformation is the suspected cause of many adverse drug reactions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27031942", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Drug bioactivation leading to the formation of reactive species capable of covalent binding to proteins represents an important cause of drug-induced toxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20391594", "endSection": "abstract"}, {"offsetInBeginSection": 172, "offsetInEndSection": 338, "text": "The traditional view of these reactive oxygen metabolites is one of oxidative stress and damage that leads to decline of tissue and organ systems in aging and disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21769097", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 238, "text": " A number of withdrawn drugs are known to undergo bioactivation by a range of drug metabolizing enzymes to chemically reactive metabolites that bind covalently to protein and DNA resulting in organ toxicity and carcinogenesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26005795", "endSection": "abstract"}]}, {"body": "What is the \"wearing-off\" phenomenon in levodopa-treated patients with Parkinson's Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25616444", "http://www.ncbi.nlm.nih.gov/pubmed/16805724", "http://www.ncbi.nlm.nih.gov/pubmed/14960500", "http://www.ncbi.nlm.nih.gov/pubmed/15098347", "http://www.ncbi.nlm.nih.gov/pubmed/10654309", "http://www.ncbi.nlm.nih.gov/pubmed/11889758", "http://www.ncbi.nlm.nih.gov/pubmed/3435068", "http://www.ncbi.nlm.nih.gov/pubmed/16381182", "http://www.ncbi.nlm.nih.gov/pubmed/12722172", "http://www.ncbi.nlm.nih.gov/pubmed/3042912", "http://www.ncbi.nlm.nih.gov/pubmed/3579222", "http://www.ncbi.nlm.nih.gov/pubmed/15824341", "http://www.ncbi.nlm.nih.gov/pubmed/26347184", "http://www.ncbi.nlm.nih.gov/pubmed/26101038", "http://www.ncbi.nlm.nih.gov/pubmed/19793544", "http://www.ncbi.nlm.nih.gov/pubmed/21942133", "http://www.ncbi.nlm.nih.gov/pubmed/8024257", "http://www.ncbi.nlm.nih.gov/pubmed/17878397", "http://www.ncbi.nlm.nih.gov/pubmed/2682215", "http://www.ncbi.nlm.nih.gov/pubmed/9339691", "http://www.ncbi.nlm.nih.gov/pubmed/9343116", "http://www.ncbi.nlm.nih.gov/pubmed/25985062", "http://www.ncbi.nlm.nih.gov/pubmed/27942720", "http://www.ncbi.nlm.nih.gov/pubmed/24830331", "http://www.ncbi.nlm.nih.gov/pubmed/12658373", "http://www.ncbi.nlm.nih.gov/pubmed/18922214", "http://www.ncbi.nlm.nih.gov/pubmed/10439935", "http://www.ncbi.nlm.nih.gov/pubmed/8771074", "http://www.ncbi.nlm.nih.gov/pubmed/9591523", "http://www.ncbi.nlm.nih.gov/pubmed/9591522", "http://www.ncbi.nlm.nih.gov/pubmed/19715385", "http://www.ncbi.nlm.nih.gov/pubmed/25649051", "http://www.ncbi.nlm.nih.gov/pubmed/9399217", "http://www.ncbi.nlm.nih.gov/pubmed/9203084", "http://www.ncbi.nlm.nih.gov/pubmed/8255478"], "ideal_answer": ["Chronic administration of traditional levodopa/dopa decarboxylase inhibitor formulations to Paskinson's Disease patients is associated with the development of complications, such as wearing-off phenomenon. Wearing-off phenomenon is characterized by the predictable emergence of motor symptoms (e.g. rigidity and freezing) and nonmotor PD symptoms (e.g. anxiety and shortness of breath), before the next scheduled dose of medication."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010300", "http://www.biosemantics.org/jochem#4222145", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007980", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275540", "http://www.disease-ontology.org/api/metadata/DOID:14330", "http://www.biosemantics.org/jochem#4001922", "http://www.biosemantics.org/jochem#4257430", "http://www.biosemantics.org/jochem#4275540"], "type": "summary", "id": "589c389278275d0c4a00003e", "snippets": [{"offsetInBeginSection": 1624, "offsetInEndSection": 1759, "text": "It is unlike the \"wearing-off\" phenomenon that occurs when dopaminergic drug levels decline and responds to dopaminergic rescue drugs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15824341", "endSection": "abstract"}, {"offsetInBeginSection": 85, "offsetInEndSection": 266, "text": "Unfortunately, chronic use of traditional levodopa/dopa decarboxylase inhibitor formulations is associated with the development of complications, such as wearing-off and dyskinesia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16805724", "endSection": "abstract"}, {"offsetInBeginSection": 835, "offsetInEndSection": 1227, "text": "One of the first complications observed with levodopa therapy is wearing-off, which can emerge within 1-3 years of initiation of levodopa treatment. Wearing-off is characterized by the predictable emergence of motor and nonmotor PD symptoms before the next scheduled dose of medication. Despite effective treatment options to tackle wearing-off, it remains underrecognized and under treated. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17878397", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715385", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 624, "text": "Although levodopa is considered the gold standard for Parkinson's disease therapy, prolonged use of this drug can result in motor complications such as a 'wearing-off' phenomenon. This outcome is seen in a significant number of patients with Parkinson's disease taking levodopa and, in some cases, is observed only a few hours after intake of the last dose of levodopa. Patients experiencing the wearing-off period may present with sensory, autonomic, psychiatric and motor fluctuations. Although infrequent, shortness of breath is an important non-motor wearing-off symptom experienced by patients with Parkinson's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715385", "endSection": "abstract"}, {"offsetInBeginSection": 903, "offsetInEndSection": 1067, "text": "We report here on a patient with Parkinson's disease who was taking levodopa and developed both shortness of breath and hyperventilation during wearing-off periods.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715385", "endSection": "abstract"}, {"offsetInBeginSection": 1152, "offsetInEndSection": 1324, "text": "His shortness of breath was determined to be a wearing-off phenomenon and his condition improved with the addition of a catechol-O-methyltransferase inhibitor (entacapone).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715385", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 325, "text": "The wearing-off phenomenon in patients with Parkinson's disease (PD) is a complication of prolonged levodopa usage. During this phenomenon, motor symptoms such as rigidity and freezing re-emerge. This is often accompanied by non-motor symptoms, including anxiety, the so-called wearing-off related anxiety (WRA). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26101038", "endSection": "abstract"}, {"offsetInBeginSection": 1140, "offsetInEndSection": 1253, "text": "Patients with wearing-off tended to receive higher L-dopa dosage and endure longer duration of L-dopa treatment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25616444", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "The wearing-off phenomenon frequently complicates levodopa therapy of Parkinson's disease (PD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8255478", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "The effects of tolcapone, a catechol-O-methyltransferase inhibitor, on the bioavailability and efficacy of levodopa were evaluated in 12 patients with Parkinson's disease (PD), 8 of whom showed signs of daily motor fluctuations (wearing-off phenomenon).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9203084", "endSection": "abstract"}, {"offsetInBeginSection": 488, "offsetInEndSection": 624, "text": "Although infrequent, shortness of breath is an important non-motor wearing-off symptom experienced by patients with Parkinson's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715385", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Although levodopa is considered the gold standard for Parkinson's disease therapy, prolonged use of this drug can result in motor complications such as a 'wearing-off' phenomenon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715385", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "More than 50% of patients with Parkinsons disease develop motor response fluctuations (the wearing off\" phenomenon) after more than five years of levodopa therapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9591522", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "More than 50% of patients with Parkinsons disease develop motor response fluctuations (the \"wearing off\" phenomenon) after more than five years of levodopa therapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9343116", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "The wearing-off phenomenon in patients with Parkinsons disease (PD) is a complication of prolonged levodopa usage", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26101038", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Short-term effect of a single levodopa dose on micturition disturbance in Parkinsons disease patients with the wearing-off phenomenon", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12722172", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 399, "text": "To evaluate the effectiveness of entacapone in the management of levodopa wearing-off in Parkinsons disease (PD) in a naturalistic, real-life setting.This prospective, open-label, observational study included patients with idiopathic PD. Patients were eligible for inclusion if they had been taking 3-5 doses of levodopa per day for \u22652 months and had shown signs of levodopa wearing-off for \u22651 month", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18922214", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 350, "text": "The duration of clinical control of motor symptoms of Parkinson disease (PD) treated with levodopa/carbidopa preparations eventually starts to shorten, a phenomenon known as end-of-dose \"wearing off.\" The involvement of core nonmotor symptoms of \"wearing off\" (depressed mood, pain/aching, anxiety, and cloudy/slowed thinking) is not well understood.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19793544", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Efficacy and tolerability of entacapone in patients with Parkinsons disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12658373", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 263, "text": "The efficacy and tolerability of entacapone was investigated in a randomized, double-blind, placebo-controlled, 3-month study of 162 patients with Parkinsons disease (PD) treated with levodopa and a dopamine agonist and experiencing wearing-off motor fluctuations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12658373", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinsons disease patients with wearing-off", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26347184", "endSection": "title"}, {"offsetInBeginSection": 1446, "offsetInEndSection": 1592, "text": "We conclude that tolcapone as an adjunct offers promise for the relief of the \"wearing-off \" phenomenon in levodopa-treated parkinsonian patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9591523", "endSection": "abstract"}, {"offsetInBeginSection": 1446, "offsetInEndSection": 1591, "text": "We conclude that tolcapone as an adjunct offers promise for the relief of the \"wearing-off\" phenomenon in levodopa-treated parkinsonian patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9339691", "endSection": "abstract"}, {"offsetInBeginSection": 490, "offsetInEndSection": 650, "text": "Our data also support the involvement of postsynaptic dopamine receptor mechanisms in the wearing-off phenomenon seen in levodopa-treated parkinsonian patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8771074", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12722172", "endSection": "title"}, {"offsetInBeginSection": 1629, "offsetInEndSection": 1764, "text": "It is unlike the \"wearing-off\" phenomenon that occurs when dopaminergic drug levels decline and responds to dopaminergic rescue drugs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15824341", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "More than 50% of patients with Parkinson's disease develop motor response fluctuations (the 'wearing off\" phenomenon) after more than five years of levodopa therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9591522", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "The primary objective of this study was to assess the effect of tolcapone on levodopa dosage in parkinsonian patients whose \"wearing-off\" phenomenon has been controlled with more frequent levodopa dosage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9399217", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "More than 50% of patients with Parkinson's disease develop motor response fluctuations (the \"wearing off\" phenomenon) after more than five years of levodopa therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9343116", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 360, "text": "To evaluate the role of the practicing pharmacist in the identification and current treatment of the levodopa wearing-off phenomenon experienced by patients with Parkinson's disease (PD) who are receiving chronic levodopa therapy.Literature retrieval was accessed through MEDLINE (1967-June 2007) using the terms levodopa, wearing-off, and Parkinson's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17878397", "endSection": "abstract"}, {"offsetInBeginSection": 127, "offsetInEndSection": 611, "text": "This study investigated the effects of OPC in comparison with placebo on levodopa pharmacokinetics, tolerability and safety, COMT activity and motor response to levodopa in Parkinson's disease (PD) patients with motor fluctuations.This was a randomized, multicentre, double-blind and placebo-controlled study in four parallel groups of PD patients treated with standard-release 100/25 mg levodopa/carbidopa or levodopa/benserazide and with motor fluctuations (wearing-OFF phenomenon).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25649051", "endSection": "abstract"}, {"offsetInBeginSection": 370, "offsetInEndSection": 624, "text": "Patients experiencing the wearing-off period may present with sensory, autonomic, psychiatric and motor fluctuations. Although infrequent, shortness of breath is an important non-motor wearing-off symptom experienced by patients with Parkinson's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715385", "endSection": "abstract"}, {"offsetInBeginSection": 180, "offsetInEndSection": 624, "text": "This outcome is seen in a significant number of patients with Parkinson's disease taking levodopa and, in some cases, is observed only a few hours after intake of the last dose of levodopa. Patients experiencing the wearing-off period may present with sensory, autonomic, psychiatric and motor fluctuations. Although infrequent, shortness of breath is an important non-motor wearing-off symptom experienced by patients with Parkinson's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715385", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 487, "text": "Although levodopa is considered the gold standard for Parkinson's disease therapy, prolonged use of this drug can result in motor complications such as a 'wearing-off' phenomenon. This outcome is seen in a significant number of patients with Parkinson's disease taking levodopa and, in some cases, is observed only a few hours after intake of the last dose of levodopa. Patients experiencing the wearing-off period may present with sensory, autonomic, psychiatric and motor fluctuations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715385", "endSection": "abstract"}, {"offsetInBeginSection": 1230, "offsetInEndSection": 1356, "text": "It is suggested that tolcapone may be useful drug adjunct to levodopa in treating patients with PD with wearing-off phenomena.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9203084", "endSection": "abstract"}, {"offsetInBeginSection": 1230, "offsetInEndSection": 1357, "text": "It is suggested that tolcapone may be useful drug adjunct to levodopa in treating patients with PD with wearing-off phenomena..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9203084", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Levodopa-treated Parkinson's disease is often complicated by the occurrence of motor fluctuations, which can be predictable ('wearing-off') or unpredictable ('on-off').", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14960500", "endSection": "abstract"}, {"offsetInBeginSection": 478, "offsetInEndSection": 659, "text": "She was treated with 400 mg/day of levodopa-carbidopa, which improved her symptoms, however, she developed wearing off phenomenon 3 years after the initiation of levodopa treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10654309", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "[Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11889758", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "To evaluate the role of the practicing pharmacist in the identification and current treatment of the levodopa wearing-off phenomenon experienced by patients with Parkinson's disease (PD) who are receiving chronic levodopa therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17878397", "endSection": "abstract"}, {"offsetInBeginSection": 1779, "offsetInEndSection": 1995, "text": "However, once the decision to initiate levodopa therapy has been made, studies generally support the use of entacapone as an adjunct to levodopa in patients with Parkinson's disease and the 'wearing off' phenomenon..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10439935", "endSection": "abstract"}, {"offsetInBeginSection": 1218, "offsetInEndSection": 1623, "text": "These results suggest that wearing-off phenomenon may arise as a consequence of the degeneration of dopamine terminals due to natural disease progression with a resultant inability to buffer variations in levodopa availability; on-off phenomenon, may reflect additional postsynaptic dopamine receptor dysregulation, possibly in response to the resultant, nonphysiologic fluctuations in synaptic dopamine..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3042912", "endSection": "abstract"}, {"offsetInBeginSection": 762, "offsetInEndSection": 988, "text": "Conversion from oral to intravenous levodopa treatment immediately stabilized plasma levodopa levels in both the wearing-off and on-off groups; motor variability also decreased, especially in those with wearing-off phenomenon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3042912", "endSection": "abstract"}]}, {"body": "What are prions?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26297259", "http://www.ncbi.nlm.nih.gov/pubmed/27833227", "http://www.ncbi.nlm.nih.gov/pubmed/22363733", "http://www.ncbi.nlm.nih.gov/pubmed/25645281", "http://www.ncbi.nlm.nih.gov/pubmed/27293325", "http://www.ncbi.nlm.nih.gov/pubmed/24390581"], "ideal_answer": ["Prion diseases are protein conformation disorders and neither caused by viroid or virus but is a transmissible particle labeled a prion by Pruisner. Normal prion protein becomes infectious by a different folding, but the triggers are not known. ", "A prion is an infectious agent composed entirely of protein and is responsible for a number of neurodegenerative diseases. Prions are self-propagating infectious protein isoforms. "], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011328", "http://www.disease-ontology.org/api/metadata/DOID:649", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017096", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000072002"], "type": "summary", "id": "58a0f95c78275d0c4a000055", "snippets": [{"offsetInBeginSection": 14, "offsetInEndSection": 259, "text": "Prion diseases are protein conformation disorders and neither caused by viroid or virus but is a transmissible particle labeled a prion by Pruisner. Normal prion protein becomes infectious by a different folding, but the triggers are not known. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27833227", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 485, "text": "Prions are proteins most commonly associated with fatal neurodegenerative diseases in mammals but are also responsible for a number of harmless heritable phenotypes in yeast. These states arise when a misfolded form of a protein appears and, rather than be removed by cellular quality control mechanisms, persists. The misfolded prion protein forms aggregates and is capable of converting normally folded protein to the misfolded state through direct interaction between the two forms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26297259", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Prion diseases or transmissible spongiform encephalopathies are fatal neurodegenerative diseases characterized by the aggregation and deposition of the misfolded prion protein in the brain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27293325", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "Several neurodegenerative diseases such as transmissible spongiform encephalopathies, Alzheimer's and Parkinson's diseases are caused by the conversion of cellular proteins to a pathogenic conformer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25645281", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Prions are self-propagating infectious protein isoforms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24390581", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Prions are units of propagation of an altered state of a protein or proteins; prions can propagate from organism to organism, through cooption of other protein copies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22363733", "endSection": "abstract"}]}, {"body": "Does Vitamin D induce  autophagy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27915989", "http://www.ncbi.nlm.nih.gov/pubmed/27430408", "http://www.ncbi.nlm.nih.gov/pubmed/26562100", "http://www.ncbi.nlm.nih.gov/pubmed/27174720"], "ideal_answer": ["Yes, vitamin D induces autophagy."], "type": "yesno", "id": "58a957a8cc344ae31e000001", "snippets": [{"offsetInBeginSection": 1441, "offsetInEndSection": 1503, "text": " 1,25(OH)2D treatment was accompanied by autophagy activation ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26562100", "endSection": "abstract"}, {"offsetInBeginSection": 79, "offsetInEndSection": 134, "text": "Autophagy signaling pathway was regulated by vitamin D3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174720", "endSection": "abstract"}, {"offsetInBeginSection": 1447, "offsetInEndSection": 1474, "text": "vitamin D induces autophagy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27430408", "endSection": "abstract"}, {"offsetInBeginSection": 740, "offsetInEndSection": 923, "text": "Vitamin D shows promise for the prevention and amelioration of pathologic responses in IBD, an effect that is mediated, at least in part, by the induction and modulation of autophagy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27915989", "endSection": "abstract"}]}, {"body": "What is sQTLseekeR?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25140736"], "ideal_answer": ["sQTLseekeR is an R package for the identification of genetic variants associated with alternative splicing. It is based on a statistical framework that uses a distance-based approach to compute the variability of splicing ratios across observations, and a non-parametric analogue to multivariate analysis of variance."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017398", "http://amigo.geneontology.org/amigo/term/GO:0000380"], "type": "summary", "id": "5883868b2305cd7e21000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Identification of genetic variants associated with alternative splicing using sQTLseekeR.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25140736", "endSection": "title"}, {"offsetInBeginSection": 397, "offsetInEndSection": 1107, "text": "We develop a statistical framework that uses a distance-based approach to compute the variability of splicing ratios across observations, and a non-parametric analogue to multivariate analysis of variance. We implement this approach in the R package sQTLseekeR and use it to analyze RNA-Seq data from the Geuvadis project in 465 individuals. We identify hundreds of single nucleotide polymorphisms (SNPs) as splicing QTLs (sQTLs), including some falling in genome-wide association study SNPs. By developing the appropriate metrics, we show that sQTLseekeR compares favorably with existing methods that rely on univariate approaches, predicting variants that behave as expected from mutations affecting splicing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25140736", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Identification of genetic variants associated with alternative splicing using sQTLseekeR", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25140736", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Identification of genetic variants associated with alternative splicing using sQTLseekeR.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25140736", "endSection": "title"}]}, {"body": "What is Creutzfeldt-Jakob Disease (CJD)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21303352", "http://www.ncbi.nlm.nih.gov/pubmed/11115241", "http://www.ncbi.nlm.nih.gov/pubmed/1777133", "http://www.ncbi.nlm.nih.gov/pubmed/26840797", "http://www.ncbi.nlm.nih.gov/pubmed/16023527", "http://www.ncbi.nlm.nih.gov/pubmed/9660576", "http://www.ncbi.nlm.nih.gov/pubmed/26840342", "http://www.ncbi.nlm.nih.gov/pubmed/22930754", "http://www.ncbi.nlm.nih.gov/pubmed/19702572", "http://www.ncbi.nlm.nih.gov/pubmed/26646926", "http://www.ncbi.nlm.nih.gov/pubmed/12811992", "http://www.ncbi.nlm.nih.gov/pubmed/25552850", "http://www.ncbi.nlm.nih.gov/pubmed/27665282", "http://www.ncbi.nlm.nih.gov/pubmed/26454226"], "ideal_answer": ["Creutzfeldt-Jakob disease (CJD) is the most prevalent of the human prion diseases, which are fatal and transmissible neurodegenerative diseases caused by the infectious prion protein (PrP(Sc)). The origin of CJD is unknown, although the initiating event is thought to be the stochastic misfolding of endogenous prion protein (PrP(C)) into infectious PrP(Sc).", "Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive, and fatal neurodegenerative disease affecting the central nervous system Creutzfeldt-Jakob disease (sCJD) is the most prevalent of the human prion diseases, which are fatal and transmissible neurodegenerative diseases caused by the infectious prion protein (PrP(Sc)", "Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive, and fatal neurodegenerative disease affecting the central nervous system"], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:11949", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007562"], "type": "summary", "id": "58a3423e60087bc10a000019", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 148, "text": "Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive, and fatal neurodegenerative disease affecting the central nervous system", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26454226", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 201, "text": "Creutzfeldt-Jakob disease (sCJD) is the most prevalent of the human prion diseases, which are fatal and transmissible neurodegenerative diseases caused by the infectious prion protein (PrP(Sc)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26840342", "endSection": "abstract"}, {"offsetInBeginSection": 204, "offsetInEndSection": 369, "text": "The origin of sCJD is unknown, although the initiating event is thought to be the stochastic misfolding of endogenous prion protein (PrP(C)) into infectious PrP(Sc).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26840342", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Creutzfeldt-Jakob disease (CJD) is a progressive, fatal, neurodegenerative disease classified under transmissible spongiform encephalopathies (TSE) or prion diseases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25552850", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Sporadic Creutzfeldt-Jakob disease (CJD) is the most prevalent manifestation of the transmissible spongiform encephalopathies or prion diseases affecting humans", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22930754", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Creutzfeldt-Jakob disease (CJD) is a rare, degenerative and fatal brain disease that appears to be caused by an abnormal form of a protein called a prion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19702572", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 255, "text": "Creutzfeldt-Jakob disease (CJD) is presumably caused by a slow infectious pathogen or prion. The principal clinical features of Creutzfeldt-Jakob disease are dementia, pyramidal and extrapyramidal symptoms and signs, cerebellar dysfunction, and myoclonus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1777133", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Creutzfeldt-Jakob disease (CJD) is a rapidly progressive, neurodegenerative disorder causing dramatic neuromuscular symptoms, profound dementia, and death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12811992", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Creutzfeldt-Jakob disease (CJD) is a rare neurodegenerative disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16023527", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Creutzfeldt-Jakob disease (CJD) is a rare neurodegenerative condition with a rapid disease course and a mortality rate of 100%.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26646926", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Creutzfeldt-Jakob disease is a rare, but rapidly progressive, up to now untreatable and fatal neurodegenerative disorder", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27665282", "endSection": "abstract"}, {"offsetInBeginSection": 158, "offsetInEndSection": 318, "text": "Creutzfeldt-Jakob disease is a rare neurodegenerative disease that belongs to the group of human spongiform encephalopathies and usually affects elderly people.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11115241", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 88, "text": "Creutzfeldt-Jakob disease (CJD) is a transmissible spongiform encephalopathy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9660576", "endSection": "abstract"}]}, {"body": "Describe what is athelia syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24872738", "http://www.ncbi.nlm.nih.gov/pubmed/24781087", "http://www.ncbi.nlm.nih.gov/pubmed/15950955"], "ideal_answer": ["Athelia is a very rare entity that is defined by the absence of the nipple-areola complex."], "type": "summary", "id": "5895b9ae7d9090f35300000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Athelia is a very rare entity that is defined by the absence of the nipple-areola complex. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24781087", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 737, "text": "Absence of the nipple, areola (athelia), or the breast tissue (amastia) is less frequent.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24872738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "The absence of nipple-areola complex is a rare entity and is always associated with other anomalies. This paper described a case of bilateral athelia without other alterations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15950955", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 599, "text": "Athelia is a very rare entity that is defined by the absence of the nipple-areola complex. It can affect either sex and is mostly part of syndromes including other congenital or ectodermal anomalies, such as limb-mammary syndrome, scalp-ear-nipple syndrome, or ectodermal dysplasias. Here, we report on three children from two branches of an extended consanguineous Israeli Arab family, a girl and two boys, who presented with a spectrum of nipple anomalies ranging from unilateral hypothelia to bilateral athelia but no other consistently associated anomalies except a characteristic eyebrow shape.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24781087", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Athelia is a very rare entity that is defined by the absence of the nipple-areola complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24781087", "endSection": "abstract"}]}, {"body": "Is RASA2 involved in melanoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26502337"], "ideal_answer": ["Yes. Analysis of 501 melanoma exomes identified RASA2, encoding a RasGAP, as a tumor-suppressor gene mutated in 5% of melanomas. Recurrent loss-of-function mutations in RASA2 were found to increase RAS activation, melanoma cell growth and migration. RASA2 expression was lost in \u226530% of human melanomas and was associated with reduced patient survival. These findings identify RASA2 inactivation as a melanoma driver and highlight the importance of RasGAPs in cancer."], "concepts": ["http://www.uniprot.org/uniprot/RASA2_RAT", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008545", "http://www.disease-ontology.org/api/metadata/DOID:1909", "http://www.uniprot.org/uniprot/RASA2_HUMAN", "http://www.uniprot.org/uniprot/RASA2_MOUSE"], "type": "yesno", "id": "5896399978275d0c4a00000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 462, "text": "Analysis of 501 melanoma exomes identified RASA2, encoding a RasGAP, as a tumor-suppressor gene mutated in 5% of melanomas. Recurrent loss-of-function mutations in RASA2 were found to increase RAS activation, melanoma cell growth and migration. RASA2 expression was lost in \u226530% of human melanomas and was associated with reduced patient survival. These findings identify RASA2 inactivation as a melanoma driver and highlight the importance of RasGAPs in cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26502337", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Analysis of 501 melanoma exomes identified RASA2, encoding a RasGAP, as a tumor-suppressor gene mutated in 5% of melanomas", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26502337", "endSection": "abstract"}, {"offsetInBeginSection": 348, "offsetInEndSection": 462, "text": "These findings identify RASA2 inactivation as a melanoma driver and highlight the importance of RasGAPs in cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26502337", "endSection": "abstract"}, {"offsetInBeginSection": 124, "offsetInEndSection": 244, "text": "Recurrent loss-of-function mutations in RASA2 were found to increase RAS activation, melanoma cell growth and migration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26502337", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Analysis of 501 melanoma exomes identified RASA2, encoding a RasGAP, as a tumor-suppressor gene mutated in 5% of melanomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26502337", "endSection": "abstract"}]}, {"body": "What is BioCreative?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18629295", "http://www.ncbi.nlm.nih.gov/pubmed/18834491", "http://www.ncbi.nlm.nih.gov/pubmed/22151647", "http://www.ncbi.nlm.nih.gov/pubmed/23327936", "http://www.ncbi.nlm.nih.gov/pubmed/18834496", "http://www.ncbi.nlm.nih.gov/pubmed/16504116", "http://www.ncbi.nlm.nih.gov/pubmed/23160416", "http://www.ncbi.nlm.nih.gov/pubmed/27589962", "http://www.ncbi.nlm.nih.gov/pubmed/22151968", "http://www.ncbi.nlm.nih.gov/pubmed/20498514", "http://www.ncbi.nlm.nih.gov/pubmed/22438567", "http://www.ncbi.nlm.nih.gov/pubmed/18834487", "http://www.ncbi.nlm.nih.gov/pubmed/22151178", "http://www.ncbi.nlm.nih.gov/pubmed/15960842", "http://www.ncbi.nlm.nih.gov/pubmed/15960843", "http://www.ncbi.nlm.nih.gov/pubmed/15960821"], "ideal_answer": ["A community wide effort to evaluate biomedical information extraction and text mining."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063369"], "type": "summary", "id": "589c8ef878275d0c4a000042", "snippets": [{"offsetInBeginSection": 142, "offsetInEndSection": 272, "text": " two biomedical named entity recognition (NER) comparative evaluations that have been held to date, namely BioCreative and Coling ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18629295", "endSection": "abstract"}, {"offsetInBeginSection": 483, "offsetInEndSection": 807, "text": "The BioCreative II.5 community challenge addressed these tasks in a competition-style assessment to evaluate and compare different methodologies, to make aware of the increasing accuracy of automated methods, and to guide future implementations. In this paper, we present our approaches for protein-named entity recognition,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20498514", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "In task 1A of the BioCreAtIvE evaluation, systems had to be devised that recognize words and phrases forming gene or protein names in natural language sentences", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15960843", "endSection": "abstract"}, {"offsetInBeginSection": 346, "offsetInEndSection": 417, "text": "BioCreAtIvE, a competition for automated gene/protein name recognition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15960842", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "An overview of the BioCreative 2012 Workshop Track III: interactive text mining task.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23327936", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Biocuration workflows and text mining: overview of the BioCreative 2012 Workshop Track II.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23160416", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Evaluation of text-mining systems for biology: overview of the Second BioCreative community challenge.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18834487", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "How to link ontologies and protein-protein interactions to literature: text-mining approaches and the BioCreative experience.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22438567", "endSection": "title"}, {"offsetInBeginSection": 563, "offsetInEndSection": 713, "text": "The 2006 BioCreative competition was aimed at evaluating text-mining procedures in comparison with manual annotation of protein-protein interactions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18834496", "endSection": "abstract"}, {"offsetInBeginSection": 780, "offsetInEndSection": 927, "text": "RESULTS: The Biocreative 2010 competition addressed three tasks: gene normalization, article classification and interaction method identification. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22151178", "endSection": "abstract"}, {"offsetInBeginSection": 979, "offsetInEndSection": 1222, "text": "BioCreAtIvE task 2 was an experiment to test if automatically derived classification using information retrieval and extraction could assist expert biologists in the annotation of the GO vocabulary to the proteins in the UniProt Knowledgebase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15960829", "endSection": "abstract"}, {"offsetInBeginSection": 230, "offsetInEndSection": 465, "text": "To this end BioCreative I was held in 2004, BioCreative II in 2007, and BioCreative II.5 in 2009. Each of these workshops involved humanly annotated test data for several basic tasks in text mining applied to the biomedical literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22151647", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 327, "text": "BACKGROUND: The overall goal of the BioCreative Workshops is to promote the development of text mining and text processing tools which are useful to the communities of researchers and database curators in the biological sciences. To this end BioCreative I was held in 2004, BioCreative II in 2007, and BioCreative II.5 in 2009.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22151647", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 465, "text": "BACKGROUND: The overall goal of the BioCreative Workshops is to promote the development of text mining and text processing tools which are useful to the communities of researchers and database curators in the biological sciences. To this end BioCreative I was held in 2004, BioCreative II in 2007, and BioCreative II.5 in 2009. Each of these workshops involved humanly annotated test data for several basic tasks in text mining applied to the biomedical literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22151647", "endSection": "abstract"}, {"offsetInBeginSection": 230, "offsetInEndSection": 650, "text": "To this end BioCreative I was held in 2004, BioCreative II in 2007, and BioCreative II.5 in 2009. Each of these workshops involved humanly annotated test data for several basic tasks in text mining applied to the biomedical literature. Participants in the workshops were invited to compete in the tasks by constructing software systems to perform the tasks automatically and were given scores based on their performance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22151647", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Overview of BioCreAtIvE: critical assessment of information extraction for biology.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15960821", "endSection": "title"}]}, {"body": "What is Contrave prescribed for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20673995", "http://www.ncbi.nlm.nih.gov/pubmed/22313529", "http://www.ncbi.nlm.nih.gov/pubmed/26679384", "http://www.ncbi.nlm.nih.gov/pubmed/26105116", "http://www.ncbi.nlm.nih.gov/pubmed/25258511", "http://www.ncbi.nlm.nih.gov/pubmed/26222044", "http://www.ncbi.nlm.nih.gov/pubmed/26957883", "http://www.ncbi.nlm.nih.gov/pubmed/20509712", "http://www.ncbi.nlm.nih.gov/pubmed/26313898", "http://www.ncbi.nlm.nih.gov/pubmed/21951371", "http://www.ncbi.nlm.nih.gov/pubmed/26648466", "http://www.ncbi.nlm.nih.gov/pubmed/19777400", "http://www.ncbi.nlm.nih.gov/pubmed/23408728"], "ideal_answer": ["Contrave(?) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity", "Contrave(\u00ae) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity", "Contrave(\u00ae) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009271", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055553", "http://www.biosemantics.org/jochem#4276121", "http://www.biosemantics.org/jochem#4249647", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016642"], "type": "factoid", "id": "58a32edd60087bc10a000012", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Contrave(\u00ae) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679384", "endSection": "abstract"}, {"offsetInBeginSection": 751, "offsetInEndSection": 984, "text": "Assuming that the results of the Contrave phase III clinical program reaffirm the efficacy and safety of the drug combination, this agent could be approved and launched to become a market leader in the anti-obesity therapeutic arena.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777400", "endSection": "abstract"}, {"offsetInBeginSection": 494, "offsetInEndSection": 924, "text": "Current antiobesity medications and pharmacological strategies will be reviewed.Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications available for the treatment of obesity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898", "endSection": "abstract"}, {"offsetInBeginSection": 271, "offsetInEndSection": 698, "text": "The Contrave Obesity Research I (COR-I) study assessed the effect of such treatment on bodyweight in overweight and obese participants.Men and women aged 18-65 years who had a body-mass index (BMI) of 30-45 kg/m(2) and uncomplicated obesity or BMI 27-45 kg/m(2) with dyslipidaemia or hypertension were eligible for enrolment in this randomised, double-blind, placebo-controlled, phase 3 trial undertaken at 34 sites in the USA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20673995", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777400", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Contrave(\u00ae) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679384", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20509712", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777400", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26957883", "endSection": "abstract"}, {"offsetInBeginSection": 939, "offsetInEndSection": 1110, "text": " The use of synergies of anti-obesity drugs with different mechanisms of action is an effective approach for developing new combined pharmaceutical compositions (Contrave\u00ae", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26648466", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 448, "text": "Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave(\u00ae), Mysimba(\u2122)) is available as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of \u2265 30 kg/m(2) (i.e. obese) or a BMI of \u2265 27 kg/m(2) (i.e. overweight) in the presence of at least one bodyweight-related comorbidity, such as type 2 diabetes mellitus, hypertension or dyslipidaemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26105116", "endSection": "abstract"}, {"offsetInBeginSection": 330, "offsetInEndSection": 370, "text": "naltrexone/bupropion (NB32 or Contrave\u00ae)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26222044", "endSection": "abstract"}]}, {"body": "Which is the chromosome area that the human gene coding for the dopamine transporter (DAT1) is located to?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16222334", "http://www.ncbi.nlm.nih.gov/pubmed/1478653", "http://www.ncbi.nlm.nih.gov/pubmed/19779799", "http://www.ncbi.nlm.nih.gov/pubmed/16861140", "http://www.ncbi.nlm.nih.gov/pubmed/17579611"], "ideal_answer": ["The gene encoding DAT1 consists of 15 exons spanning 60 kb and is located on chromosome 5p15.3."], "concepts": ["http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275128", "http://www.biosemantics.org/jochem#4275128", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004298", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050483"], "type": "factoid", "id": "58a2ced760087bc10a000004", "snippets": [{"offsetInBeginSection": 171, "offsetInEndSection": 252, "text": "The gene encoding DAT1 consists of 15 exons spanning 60 kb on chromosome 5p15.32.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19779799", "endSection": "abstract"}, {"offsetInBeginSection": 932, "offsetInEndSection": 1094, "text": "The locus of the solute carrier 6A3 (SLC6A3; dopamine transporter 1; DAT1) localizes to 5p15.33; the gene has repeatedly been implicated in the etiology of ADHD. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16222334", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "In 29 adults with attention deficit hyperactivity disorder (ADHD) striatal dopamine transporter (DAT) availability was assessed by [(99m)Tc]TRODAT-1 SPECT and correlated with 3' VNTR polymorphism of the DAT gene on chromosome 5p15.3. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16861140", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1478653", "endSection": "title"}, {"offsetInBeginSection": 171, "offsetInEndSection": 253, "text": "The gene encoding DAT1 consists of 15 exons spanning 60 kb on chromosome 5p15.32. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19779799", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 369, "text": "The dopamine transporter (DAT1) is a membrane spanning protein that binds the neurotransmitter dopamine and performs re-uptake of dopamine from the synapse into a neuron. The gene encoding DAT1 consists of 15 exons spanning 60 kb on chromosome 5p15.32. Several studies have investigated the possible associations between variants in DAT1 gene and psychiatric disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19779799", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "The dopamine transporter (DAT1) is a membrane spanning protein that binds the neurotransmitter dopamine and performs re-uptake of dopamine from the synapse into a neuron. The gene encoding DAT1 consists of 15 exons spanning 60 kb on chromosome 5p15.32.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19779799", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1478653", "endSection": "title"}]}, {"body": "What type of mutation is causing the industrial melanism phenotype in peppered moths?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27251284", "http://www.ncbi.nlm.nih.gov/pubmed/12298233", "http://www.ncbi.nlm.nih.gov/pubmed/12140267"], "ideal_answer": ["The mutation event giving rise to industrial melanism in Britain was the insertion of a large, tandemly repeated, transposable element into the first intron of the gene cortex."], "type": "factoid", "id": "58a877cf38c171fb5b000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "The industrial melanism mutation in British peppered moths is a transposable element.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27251284", "endSection": "title"}, {"offsetInBeginSection": 685, "offsetInEndSection": 879, "text": "Here we show that the mutation event giving rise to industrial melanism in Britain was the insertion of a large, tandemly repeated, transposable element into the first intron of the gene cortex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27251284", "endSection": "abstract"}]}, {"body": "What gene is mutated in Huntington's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25993131", "http://www.ncbi.nlm.nih.gov/pubmed/1839672", "http://www.ncbi.nlm.nih.gov/pubmed/25254119", "http://www.ncbi.nlm.nih.gov/pubmed/26863614", "http://www.ncbi.nlm.nih.gov/pubmed/18651325", "http://www.ncbi.nlm.nih.gov/pubmed/19059613", "http://www.ncbi.nlm.nih.gov/pubmed/26160070", "http://www.ncbi.nlm.nih.gov/pubmed/16109169", "http://www.ncbi.nlm.nih.gov/pubmed/15651335", "http://www.ncbi.nlm.nih.gov/pubmed/11723754", "http://www.ncbi.nlm.nih.gov/pubmed/19816846", "http://www.ncbi.nlm.nih.gov/pubmed/26079385", "http://www.ncbi.nlm.nih.gov/pubmed/12805114", "http://www.ncbi.nlm.nih.gov/pubmed/9392570", "http://www.ncbi.nlm.nih.gov/pubmed/25931812", "http://www.ncbi.nlm.nih.gov/pubmed/12523115", "http://www.ncbi.nlm.nih.gov/pubmed/16847693", "http://www.ncbi.nlm.nih.gov/pubmed/27400454", "http://www.ncbi.nlm.nih.gov/pubmed/26466780", "http://www.ncbi.nlm.nih.gov/pubmed/8985734", "http://www.ncbi.nlm.nih.gov/pubmed/24196395", "http://www.ncbi.nlm.nih.gov/pubmed/11494364"], "ideal_answer": ["Huntington disease (HD; OMIM 143100), a progressive neurodegenerative disorder, is caused by an expanded trinucleotide CAG (polyQ) motif in the HTT gene. Mutations of the huntingtin protein (HTT) gene underlie both adult-onset and juvenile forms of Huntington's disease (HD).", "Huntington disease  is a progressive neurodegenerative disorder and is caused by an expanded trinucleotide CAG (polyQ) motif in the HTT gene."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:1289", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006816", "http://www.disease-ontology.org/api/metadata/DOID:12858"], "type": "factoid", "id": "58a3428d60087bc10a00001b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Huntington disease (HD; OMIM 143100), a progressive neurodegenerative disorder, is caused by an expanded trinucleotide CAG (polyQ) motif in the HTT gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25993131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Huntington's disease (HD) is caused by a genetic mutation that results in polyglutamine expansion in the N-terminal regions of huntingtin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25931812", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Mutations of the huntingtin protein (HTT) gene underlie both adult-onset and juvenile forms of Huntington's disease (HD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26863614", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "Huntington's disease is an inherited disorder caused by expansion of a CAG trinucleotide repeat in the IT15 gene, which leads to expansion of a polyglutamine tract within the protein called huntingtin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9392570", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 267, "text": "Huntington disease is a monogenic, autosomal dominant, progressive neurodegenerative disorder caused by a trinucleotide CAG repeat expansion in exon 1 of the huntingtin (HTT) gene; age of onset of clinical symptoms inversely correlates with expanded CAG repeat length", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24196395", "endSection": "abstract"}, {"offsetInBeginSection": 170, "offsetInEndSection": 446, "text": "The causative gene (mutated HTT) is widely expressed outside the CNS and several peripheral signs of disease, including weight loss and increased proinflammatory signalling, are often seen; however, their importance in the pathophysiology of Huntington's disease is not clear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26466780", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Huntington's disease (HD) is an inherited, neurodegenerative disorder caused by a single-gene mutation: a CAG expansion in the huntingtin (HTT) gene that results in production of a mutated protein, mutant HTT, with a polyglutamine tail (polyQ-HTT).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26160070", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 666, "text": "Huntington's disease is an inherited disorder caused by expansion of a CAG trinucleotide repeat in the IT15 gene, which leads to expansion of a polyglutamine tract within the protein called huntingtin. Despite the characterization of the IT15 gene and the mutation involved in the disease, the normal function of huntingtin and the effects of the mutation on its function and on its neuronal location remain unknown. To study whether mutated huntingtin has the same neuronal distribution and intracellular location as normal huntingtin, we analyzed immunohistochemically both forms of this protein in the brain of 5 controls and 5 patients with Huntington's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9392570", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 416, "text": "Huntington's disease is an inherited disorder caused by expansion of a CAG trinucleotide repeat in the IT15 gene, which leads to expansion of a polyglutamine tract within the protein called huntingtin. Despite the characterization of the IT15 gene and the mutation involved in the disease, the normal function of huntingtin and the effects of the mutation on its function and on its neuronal location remain unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9392570", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Huntingtons disease (HD) is a hereditary disorder involving the central nervous system. Its effects are devastating, to the affected person as well as his family.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1839672", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Huntington disease (HD) is a neurodegenerative disorder due to an excessive number of CAG repeats in the IT15 gene on chromosome 4.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17941857", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Huntington disease in subjects from an Israeli Karaite community carrying alleles of intermediate and expanded CAG repeats in the HTT gene", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19059613", "endSection": "title"}, {"offsetInBeginSection": 79, "offsetInEndSection": 176, "text": "The causative mutation is an expansion of more than 36 CAG repeats in the first exon of IT15 gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25254119", "endSection": "abstract"}, {"offsetInBeginSection": 35, "offsetInEndSection": 124, "text": "Huntington's disease in relation to the number of trinucleotide CAG repeats in IT-15 gene", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12523115", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Huntington's disease (HD) is a neurological condition of progressive course that results from abnormally increased number of CAG repeats within IT-15 gene, coding for huntington.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12523115", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Huntington's disease (HD) is a neurodegenerative disorder characterized by the expansion of CAG repeats in exon 1 of the HD gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11494364", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 268, "text": "However, not all patients with an HD phenotype carry the pathological expansion in HTT, and the positive diagnosis rate is poor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27400454", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "The expansion of a polymorphic CAG repeat in the HD gene encoding huntingtin has been identified as the major cause of Huntington's disease (HD) and determines 42-73% of the variance in the age-at-onset of the disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847693", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Huntington disease (HD) is a progressive autosomal dominant neurodegenerative disorder, characterized by abnormal movements, cognitive decline, and psychiatric symptoms, caused by a CAG repeat expansion in the huntingtin (HTT) gene on chromosome 4p", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26079385", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 245, "text": "The disorder is caused by mutation in the gene encoding the huntingtin protein (Htt), producing intracellular aggregates", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19816846", "endSection": "abstract"}, {"offsetInBeginSection": 480, "offsetInEndSection": 700, "text": "HD is less common in other ethnic groups. Huntington's disease is caused by an expanded trinucleotide CAG repeat in the HD gene on chromosome 4. The gene encodes for the protein huntingtin, with an as yet unknown functio", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11723754", "endSection": "abstract"}]}, {"body": "Which software package is available for the analysis of conserved genomic loci?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26530724"], "ideal_answer": ["PHYLUCE is a software package for the analysis of conserved genomic loci. It identifies targeted, enriched loci from the off-target background data; aligns enriched contigs representing conserved loci to one another; and prepare and manipulate these alignments for subsequent phylogenomic inference. PHYLUCE is an efficient and easy-to-install software package that accomplishes these tasks across hundreds of taxa and thousands of enriched loci", "PHYLUCE is a software package for the analysis of conserved genomic loci"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012984", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017124"], "type": "factoid", "id": "587e07023ec846c24f000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "PHYLUCE is a software package for the analysis of conserved genomic loci", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530724", "endSection": "title"}, {"offsetInBeginSection": 199, "offsetInEndSection": 716, "text": "Prior to downstream inference, data from these types of targeted enrichment studies must undergo preprocessing to assemble contigs from sequence data; identify targeted, enriched loci from the off-target background data; align enriched contigs representing conserved loci to one another; and prepare and manipulate these alignments for subsequent phylogenomic inference. PHYLUCE is an efficient and easy-to-install software package that accomplishes these tasks across hundreds of taxa and thousands of enriched loci.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530724", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "PHYLUCE is a software package for the analysis of conserved genomic loci.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530724", "endSection": "title"}]}, {"body": "Mutation of which gene is implicated in the Christianson syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24630051", "http://www.ncbi.nlm.nih.gov/pubmed/18342287", "http://www.ncbi.nlm.nih.gov/pubmed/26421989", "http://www.ncbi.nlm.nih.gov/pubmed/25044251", "http://www.ncbi.nlm.nih.gov/pubmed/25273398", "http://www.ncbi.nlm.nih.gov/pubmed/27142213", "http://www.ncbi.nlm.nih.gov/pubmed/26515654", "http://www.ncbi.nlm.nih.gov/pubmed/27256868", "http://www.ncbi.nlm.nih.gov/pubmed/20949524", "http://www.ncbi.nlm.nih.gov/pubmed/25002837", "http://www.ncbi.nlm.nih.gov/pubmed/27590723", "http://www.ncbi.nlm.nih.gov/pubmed/24839169", "http://www.ncbi.nlm.nih.gov/pubmed/24285247", "http://www.ncbi.nlm.nih.gov/pubmed/24779060", "http://www.ncbi.nlm.nih.gov/pubmed/21964919", "http://www.ncbi.nlm.nih.gov/pubmed/21932316", "http://www.ncbi.nlm.nih.gov/pubmed/22541666"], "ideal_answer": ["Christianson syndrome is caused by mutations in SLC9A6 and is characterized by severe intellectual disability, absent speech, microcephaly, ataxia, seizures, and behavioral abnormalities."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154"], "type": "factoid", "id": "5895bc397d9090f35300000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "X-linked Christianson syndrome: heterozygous female Slc9a6 knockout mice develop mosaic neuropathological changes and related behavioral abnormalities.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26515654", "endSection": "title"}, {"offsetInBeginSection": 251, "offsetInEndSection": 434, "text": "CS is caused by mutations in the SLC9A6 gene, which encodes a multipass transmembrane sodium (potassium)-hydrogen exchanger 6 (NHE6) protein, functional in early recycling endosomes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26515654", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "A Christianson syndrome-linked deletion mutation (\u2206(287)ES(288)) in SLC9A6 disrupts recycling endosomal function and elicits neurodegeneration and cell death.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27590723", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "BACKGROUND: Christianson Syndrome, a recently identified X-linked neurodevelopmental disorder, is caused by mutations in the human gene SLC9A6 encoding the recycling endosomal alkali cation/proton exchanger NHE6. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27590723", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 286, "text": "BACKGROUND: Mutations of SLC9A6 may cause an X-linked clinical syndrome first described by Christianson in 1999 in which affected males exhibited profound intellectual disability, autism, drug-resistant epilepsy, ophthalmoplegia, mild craniofacial dysmorphism, microcephaly, and ataxia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26421989", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "OBJECTIVE: Recently, Christianson syndrome (CS) has been determined to be caused by mutations in the X-linked Na(+) /H(+) exchanger 6 (NHE6). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25044251", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Genetic and phenotypic diversity of NHE6 mutations in Christianson syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25044251", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 583, "text": "Mutations in the solute carrier family 9, subfamily A member 6 (SLC9A6) gene, encoding the endosomal Na+/H+ exchanger 6 (NHE6) are associated with Christianson syndrome, a syndromic form of X-linked intellectual disability characterized by microcephaly, severe global developmental delay, autistic behavior, early onset seizures and ataxia. In a 7-year-old boy with characteristic clinical and neuroimaging features of Christianson syndrome and epileptic encephalopathy with continuous spikes and waves during sleep, we identified a novel splice site mutation (IVS10-1G>A) in SLC9A6.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24630051", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Christianson syndrome (CS) is caused by mutations in SLC9A6 and is characterized by severe intellectual disability, absent speech, microcephaly, ataxia, seizures, and behavioral abnormalities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285247", "endSection": "abstract"}, {"offsetInBeginSection": 342, "offsetInEndSection": 481, "text": "We report on two children with CS and confirmed mutations in SLC9A6 focusing on neuroimaging findings and review the available literature. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285247", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Mutations in the SLC9A6 gene cause Christianson syndrome in boys.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22541666", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Novel mutation in SLC9A6 gene in a patient with Christianson syndrome and retinitis pigmentosum.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22541666", "endSection": "title"}, {"offsetInBeginSection": 1308, "offsetInEndSection": 1432, "text": "This patient broadens the spectrum of SLC9A6 mutations and contributes to the clinical delineation of Christianson syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21932316", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Novel mutation in SLC9A6 gene in a patient with Christianson syndrome and retinitis pigmentosum", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22541666", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Mutations in the SLC9A6 gene cause Christianson syndrome in boys. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22541666", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "A novel mutation in the endosomal Na+/H+ exchanger NHE6 (SLC9A6) causes Christianson syndrome with electrical status epilepticus during slow-wave sleep (ESES).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24630051", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 341, "text": "Mutations in the solute carrier family 9, subfamily A member 6 (SLC9A6) gene, encoding the endosomal Na+/H+ exchanger 6 (NHE6) are associated with Christianson syndrome, a syndromic form of X-linked intellectual disability characterized by microcephaly, severe global developmental delay, autistic behavior, early onset seizures and ataxia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24630051", "endSection": "abstract"}, {"offsetInBeginSection": 224, "offsetInEndSection": 443, "text": "Mutations in SLC9A6 are associated with Christianson syndrome (OMIM 300243), a syndromic form of X-linked mental retardation (XLMR) characterized by microcephaly, severe global developmental delay, ataxia and seizures. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21932316", "endSection": "abstract"}, {"offsetInBeginSection": 1308, "offsetInEndSection": 1433, "text": "This patient broadens the spectrum of SLC9A6 mutations and contributes to the clinical delineation of Christianson syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21932316", "endSection": "abstract"}, {"offsetInBeginSection": 792, "offsetInEndSection": 972, "text": "The single-gene disorders include Pitt\u2013Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat\u2013Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24779060", "endSection": "abstract"}, {"offsetInBeginSection": 341, "offsetInEndSection": 583, "text": "In a 7-year-old boy with characteristic clinical and neuroimaging features of Christianson syndrome and epileptic encephalopathy with continuous spikes and waves during sleep, we identified a novel splice site mutation (IVS10-1G>A) in SLC9A6.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24630051", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 340, "text": "Mutations in the solute carrier family 9, subfamily A member 6 (SLC9A6) gene, encoding the endosomal Na+/H+ exchanger 6 (NHE6) are associated with Christianson syndrome, a syndromic form of X-linked intellectual disability characterized by microcephaly, severe global developmental delay, autistic behavior, early onset seizures and ataxia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24630051", "endSection": "abstract"}, {"offsetInBeginSection": 224, "offsetInEndSection": 442, "text": "Mutations in SLC9A6 are associated with Christianson syndrome (OMIM 300243), a syndromic form of X-linked mental retardation (XLMR) characterized by microcephaly, severe global developmental delay, ataxia and seizures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21932316", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "Christianson Syndrome, a recently identified X-linked neurodevelopmental disorder, is caused by mutations in the human gene SLC9A6 encoding the recycling endosomal alkali cation/proton exchanger NHE6.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27590723", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "A new family with an SLC9A6 mutation expanding the phenotypic spectrum of Christianson syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27256868", "endSection": "title"}, {"offsetInBeginSection": 251, "offsetInEndSection": 433, "text": "CS is caused by mutations in the SLC9A6 gene, which encodes a multipass transmembrane sodium (potassium)-hydrogen exchanger 6 (NHE6) protein, functional in early recycling endosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26515654", "endSection": "abstract"}, {"offsetInBeginSection": 1674, "offsetInEndSection": 2010, "text": "Our studies in heterozygous Slc9a6 KO female mice provide important clues for understanding the likely phenotypic range of Christianson syndrome among females heterozygous for SLC9A6 mutations and might improve diagnostic practice and genetic counseling by helping to characterize this presumably underappreciated patient/carrier group.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26515654", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "A novel mutation in the endosomal Na+/H+ exchanger NHE6 (SLC9A6) causes Christianson syndrome with electrical status epilepticus during slow-wave sleep (ESES).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24630051", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "X-linked Christianson syndrome: heterozygous female Slc9a6 knockout mice develop mosaic neuropathological changes and related behavioral abnormalities.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26515654", "endSection": "title"}]}, {"body": "What is Eteplirsen (Exondys 51)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27807823", "http://www.ncbi.nlm.nih.gov/pubmed/21540335", "http://www.ncbi.nlm.nih.gov/pubmed/25980936", "http://www.ncbi.nlm.nih.gov/pubmed/22086232", "http://www.ncbi.nlm.nih.gov/pubmed/27936976", "http://www.ncbi.nlm.nih.gov/pubmed/23907995", "http://www.ncbi.nlm.nih.gov/pubmed/23995279", "http://www.ncbi.nlm.nih.gov/pubmed/23075107"], "ideal_answer": ["Eteplirsen (Exondys 51) is an antisense oligonucleotide designed to induce exon 51 skipping that is developed by Sarepta Therapeutics. Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping.\nBy the method of exon skipping in dystrophin pre-mRNA the reading frame is restored and the internally deleted but functional dystrophin is produced."], "type": "summary", "id": "58a9d3cd396a458e50000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 346, "text": "Eteplirsen (Exondys\u00a051) is an antisense oligonucleotide designed to induce exon 51 skipping that is developed by Sarepta Therapeutics. Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 299, "text": "Exon skipping is a therapeutic approach for Duchenne muscular dystrophy (DMD) that has been in development for close to two decades. This approach uses antisense oligonucleotides (AONs) to modulate pre-mRNA splicing of dystrophin transcripts to restore the disrupted DMD reading frame. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27936976", "endSection": "abstract"}, {"offsetInBeginSection": 421, "offsetInEndSection": 571, "text": "By the method of exon skipping in dystrophin pre-mRNA the reading frame is restored and the internally deleted but functional dystrophin is produced. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25980936", "endSection": "abstract"}, {"offsetInBeginSection": 37, "offsetInEndSection": 214, "text": "s, eteplirsen, a phosphorodiamidate morpholino oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907995", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "Restoration of the open reading frame of the DMD gene and dystrophin protein production in Duchenne muscular dystrophy (DMD) can be achieved by exon skipping using antisense oligomers (AOs) targeted to splicing elements. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23075107", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 382, "text": "We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.) injection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086232", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "AVI-4658 is a phosphorodiamidate morpholino oligomer (PMO) designed to induce skipping of dystrophin exon 51 and restore its expression in patients with Duchenne muscular dystrophy (DMD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21540335", "endSection": "abstract"}]}, {"body": "What are the SINEUPs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26259533", "http://www.ncbi.nlm.nih.gov/pubmed/27646849", "http://www.ncbi.nlm.nih.gov/pubmed/26029048", "http://www.ncbi.nlm.nih.gov/pubmed/26045368", "http://www.ncbi.nlm.nih.gov/pubmed/25883552", "http://www.ncbi.nlm.nih.gov/pubmed/27265476"], "ideal_answer": ["SINEUPs represent a new class of natural and synthetic antisense long non-coding RNAs that activate translation. These molecules have been named SINEUPs since their function requires the activity of an embedded inverted SINEB2 sequence to UP-regulate translation. Natural SINEUPs suggest that embedded Transposable Elements may represent functional domains in long non-coding RNAs. Synthetic SINEUPs may be designed by targeting the antisense sequence to the mRNA of choice representing the first scalable tool to increase protein synthesis of potentially any gene of interest."], "type": "summary", "id": "587d3873ae41fa4569000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "SINEUPs: A new class of natural and synthetic antisense long non-coding RNAs that activate translation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259533", "endSection": "title"}, {"offsetInBeginSection": 208, "offsetInEndSection": 828, "text": "In this review, we will detail the discovery of a new functional class of natural and synthetic antisense lncRNAs that stimulate translation of sense mRNAs. These molecules have been named SINEUPs since their function requires the activity of an embedded inverted SINEB2 sequence to UP-regulate translation. Natural SINEUPs suggest that embedded Transposable Elements may represent functional domains in long non-coding RNAs. Synthetic SINEUPs may be designed by targeting the antisense sequence to the mRNA of choice representing the first scalable tool to increase protein synthesis of potentially any gene of interest", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259533", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "SINEUPs are modular antisense long non-coding RNAs that increase synthesis of target proteins in cells", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26029048", "endSection": "title"}, {"offsetInBeginSection": 1736, "offsetInEndSection": 1973, "text": "In summary, SINEUPs represent the first scalable tool to increase synthesis of proteins of interest. We propose SINEUPs as reagents for molecular biology experiments, in protein manufacturing as well as in therapy of haploinsufficiencies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26029048", "endSection": "abstract"}, {"offsetInBeginSection": 1734, "offsetInEndSection": 1833, "text": "In summary, SINEUPs represent the first scalable tool to increase synthesis of proteins of interest", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26029048", "endSection": "abstract"}, {"offsetInBeginSection": 1835, "offsetInEndSection": 1971, "text": "We propose SINEUPs as reagents for molecular biology experiments, in protein manufacturing as well as in therapy of haploinsufficiencies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26029048", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 514, "text": "These molecules have been named SINEUPs since their function requires the activity of an embedded inverted SINEB2 sequence to UP-regulate translation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259533", "endSection": "abstract"}, {"offsetInBeginSection": 516, "offsetInEndSection": 632, "text": "Natural SINEUPs suggest that embedded Transposable Elements may represent functional domains in long non-coding RNAs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259533", "endSection": "abstract"}, {"offsetInBeginSection": 634, "offsetInEndSection": 828, "text": "Synthetic SINEUPs may be designed by targeting the antisense sequence to the mRNA of choice representing the first scalable tool to increase protein synthesis of potentially any gene of interest", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259533", "endSection": "abstract"}, {"offsetInBeginSection": 508, "offsetInEndSection": 749, "text": "We have previously identified SINEUPs as a new functional class of natural and synthetic long non-coding RNAs that through the activity of an inverted SINEB2 element are able to promote translation of partially overlapping sense coding mRNAs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26045368", "endSection": "abstract"}, {"offsetInBeginSection": 751, "offsetInEndSection": 894, "text": "Here we show that by taking advantage of their modular structure, synthetic SINEUPs can be designed to increase production of secreted proteins", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26045368", "endSection": "abstract"}, {"offsetInBeginSection": 1065, "offsetInEndSection": 1355, "text": "These results lead us to propose synthetic SINEUPs as new versatile tools to optimize production of secreted proteins in manufacturing pipelines and natural SINEUPs as new regulatory RNAs in the secretory pathways. <CopyrightInformation>Copyright \u00a9 2015 Elsevier B.V. All rights reserved.</", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26045368", "endSection": "abstract"}, {"offsetInBeginSection": 932, "offsetInEndSection": 1119, "text": "It is the representative member of SINEUPs (SINEB2 sequence to UP-regulate translation), a new functional class of natural antisense lncRNAs that activate translation of their sense genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883552", "endSection": "abstract"}, {"offsetInBeginSection": 113, "offsetInEndSection": 376, "text": "Recently, an antisense lncRNA to mouse Ubiquitin carboxyl-terminal hydrolase L1 (Uchl1) was reported to increase UCHL1 protein synthesis, representing a new functional class of lncRNAs, designated as SINEUPs, for SINE element-containing translation UP-regulators.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27646849", "endSection": "abstract"}, {"offsetInBeginSection": 508, "offsetInEndSection": 750, "text": "We have previously identified SINEUPs as a new functional class of natural and synthetic long non-coding RNAs that through the activity of an inverted SINEB2 element are able to promote translation of partially overlapping sense coding mRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26045368", "endSection": "abstract"}, {"offsetInBeginSection": 975, "offsetInEndSection": 1118, "text": "We named this class of RNAs SINEUPs for their requirement of the inverted SINEB2 sequence to UP-regulate translation in a gene-specific manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26029048", "endSection": "abstract"}, {"offsetInBeginSection": 933, "offsetInEndSection": 1121, "text": "It is the representative member of SINEUPs (SINEB2 sequence to UP-regulate translation), a new functional class of natural antisense lncRNAs that activate translation of their sense genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883552", "endSection": "abstract"}, {"offsetInBeginSection": 342, "offsetInEndSection": 552, "text": "SINEUPs are long antisense non-coding RNAs that up-regulate translation in mammalian cells in a gene-specific manner, although, so far evidence of SINEUP efficacy has only been demonstrated in in vitro systems.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27265476", "endSection": "abstract"}]}, {"body": "What is trichotillomania?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27137957", "http://www.ncbi.nlm.nih.gov/pubmed/26001984", "http://www.ncbi.nlm.nih.gov/pubmed/26580849"], "ideal_answer": ["Trichotillomania is a hair pulling disorder."], "type": "factoid", "id": "58a8045860087bc10a000035", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Trichotillomania (hair pulling disorder, HPD) is characterized by significant psychological distress, childhood-onset, and, in adults, certain cognitive deficits such as inhibitory control. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26001984", "endSection": "abstract"}, {"offsetInBeginSection": 44, "offsetInEndSection": 84, "text": "TRICHOTILLOMANIA (HAIR PULLING DISORDER)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26580849", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Hair pulling disorder (HPD; trichotillomania) is thought to be associated with significant psychiatric comorbidity and functional impairment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27137957", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of raxibacumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24812521", "http://www.ncbi.nlm.nih.gov/pubmed/20068396", "http://www.ncbi.nlm.nih.gov/pubmed/26648915", "http://www.ncbi.nlm.nih.gov/pubmed/23344456", "http://www.ncbi.nlm.nih.gov/pubmed/26094508", "http://www.ncbi.nlm.nih.gov/pubmed/25487792", "http://www.ncbi.nlm.nih.gov/pubmed/26097803", "http://www.ncbi.nlm.nih.gov/pubmed/24447197", "http://www.ncbi.nlm.nih.gov/pubmed/20450444", "http://www.ncbi.nlm.nih.gov/pubmed/19587338", "http://www.ncbi.nlm.nih.gov/pubmed/20811384"], "ideal_answer": ["Raxibacumab is a recombinant human IgG1 monoclonal antibody that binds the protective antigen of Bacillus anthracis, thus blocking toxin effects.\nIt is approved to treat inhalational anthrax."], "concepts": ["http://www.biosemantics.org/jochem#4002353", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504"], "type": "summary", "id": "587f857b8ce3255b64000001", "snippets": [{"offsetInBeginSection": 116, "offsetInEndSection": 334, "text": " Raxibacumab, an IgG1 monoclonal antibody, binds the protective antigen (PA) of Bacillus anthracis, thus blocking toxin effects and leading to improved survival in the rabbit and monkey models of inhalational anthrax. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25487792", "endSection": "abstract"}, {"offsetInBeginSection": 945, "offsetInEndSection": 1063, "text": "RESULTS: Interesting results were obtained using monoclonal antibodies: raxibacumab, cAb29 or cocktails of antibodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26094508", "endSection": "abstract"}, {"offsetInBeginSection": 94, "offsetInEndSection": 299, "text": "We showed previously in a 96-h sedated canine model that raxibacumab, a monoclonal antibody against protective antigen, augmented hemodynamic support (HS) and improved survival with lethal toxin challenge.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26097803", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "On December 14, 2012, the FDA approved Raxibacumab, the first monoclonal antibody product developed under Project BioShield to achieve this milestone, and the first biologic product to be approved through the FDA animal efficacy rule (or \"Animal Rule\").", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26648915", "endSection": "abstract"}, {"offsetInBeginSection": 1077, "offsetInEndSection": 1281, "text": "With the only anthrax toxin inhibiting therapy (protective antigen-targeting with a monoclonal antibody, raxibacumab) approved to treat inhalational anthrax, the situation, in our view, is still insecure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24447197", "endSection": "abstract"}, {"offsetInBeginSection": 430, "offsetInEndSection": 524, "text": "Raxibacumab is a recombinant human monoclonal antibody developed against inhalational anthrax.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24812521", "endSection": "abstract"}, {"offsetInBeginSection": 973, "offsetInEndSection": 1122, "text": "Raxibacumab is the first monoclonal antitoxin antibody made available that can be used with the antibiotics recommended for treatment of the disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24812521", "endSection": "abstract"}, {"offsetInBeginSection": 299, "offsetInEndSection": 410, "text": "Antibiotics can control B. anthracis bacteremia, whereas raxibacumab binds PA and blocks lethal toxin effects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344456", "endSection": "abstract"}, {"offsetInBeginSection": 209, "offsetInEndSection": 379, "text": "Blocking the activity of the toxins with raxibacumab, a fully-human mAb directed against the protective antigen of Bacillus anthracis, may serve as an adjunct treatment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20450444", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 260, "text": "Raxibacumab is a human IgG1lambda monoclonal antibody directed against protective antigen, a component of the anthrax toxin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587338", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20068396", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "Raxibacumab for the treatment of inhalational anthrax.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587338", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25487792", "endSection": "title"}, {"offsetInBeginSection": 334, "offsetInEndSection": 731, "text": "To assess raxibacumab's added benefit over levofloxacin (LVX) alone, rabbits surviving to 84 h after a challenge with 200 times the median (50%) lethal dose of B. anthracis spores were randomized to receive 3 daily intragastric LVX doses of 50 mg/kg of body weight, with the first LVX dose administered just prior to administration of a single intravenous dose of placebo or 40 mg/kg raxibacumab. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25487792", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 261, "text": "Raxibacumab is a human IgG1lambda monoclonal antibody directed against protective antigen, a component of the anthrax toxin. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587338", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344456", "endSection": "title"}, {"offsetInBeginSection": 254, "offsetInEndSection": 537, "text": "Raxibacumab is approved for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibiotic drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or not appropriate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26648915", "endSection": "abstract"}, {"offsetInBeginSection": 332, "offsetInEndSection": 518, "text": "The availability of bioterrorism countermeasures has become more important since the September 2001 anthrax attacks, and development of raxibacumab is a significant advance in this area.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20068396", "endSection": "abstract"}, {"offsetInBeginSection": 1032, "offsetInEndSection": 1236, "text": "With the only anthrax toxin inhibiting therapy (protective antigen-targeting with a monoclonal antibody, raxibacumab) approved to treat inhalational anthrax, the situation, in our view, is still insecure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24447197", "endSection": "abstract"}, {"offsetInBeginSection": 326, "offsetInEndSection": 409, "text": "anthracis bacteremia, whereas raxibacumab binds PA and blocks lethal toxin effects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344456", "endSection": "abstract"}, {"offsetInBeginSection": 1911, "offsetInEndSection": 2138, "text": "Concentrations of raxibacumab provide a surrogate end point that should be predictive of clinical benefit.CONCLUSIONS: A single dose of raxibacumab improved survival in rabbits and monkeys with symptomatic inhalational anthrax.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587338", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 449, "text": "Raxibacumab is a human IgG1lambda monoclonal antibody directed against protective antigen, a component of the anthrax toxin.METHODS: We evaluated the efficacy of raxibacumab as a prophylactic agent and after disease onset in a total of four randomized, placebo-controlled studies conducted in rabbits and monkeys.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587338", "endSection": "abstract"}, {"offsetInBeginSection": 117, "offsetInEndSection": 333, "text": "Raxibacumab, an IgG1 monoclonal antibody, binds the protective antigen (PA) of Bacillus anthracis, thus blocking toxin effects and leading to improved survival in the rabbit and monkey models of inhalational anthrax.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25487792", "endSection": "abstract"}, {"offsetInBeginSection": 1225, "offsetInEndSection": 1378, "text": "Raxibacumab provides additional protection against inhalational anthrax via a mechanism different from that of either antibiotics or active immunization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24812521", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Raxibacumab for the treatment of inhalational anthrax.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587338", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Raxibacumab for inhalational anthrax: an effective specific therapeutic approach?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20450444", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25487792", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration \"Animal Rule\".", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26648915", "endSection": "title"}]}, {"body": "What is the effect of CPEB3 binding to the CPE domain?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17481902", "http://www.ncbi.nlm.nih.gov/pubmed/26398195", "http://www.ncbi.nlm.nih.gov/pubmed/25066254", "http://www.ncbi.nlm.nih.gov/pubmed/17923234", "http://www.ncbi.nlm.nih.gov/pubmed/23776146"], "ideal_answer": ["The cytoplasmic polyadenylation element (CPE) is the binding platform for CPE-binding protein (CPEB), which promotes polyadenylation-induced translation."], "type": "summary", "id": "58a8a51b7f77222767000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "CPEB (Cytoplasmic Polyadenylation Element Binding) proteins are a family of four RNA-binding proteins that regulate the translation of maternal mRNAs controlling meiotic cell cycle progression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26398195", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "The family of cytoplasmic polyadenylation element binding proteins CPEB1, CPEB2, CPEB3, and CPEB4 binds to the 3'-untranslated region (3'-UTR) of mRNA, and plays significant roles in mRNA metabolism and translation regulation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25066254", "endSection": "abstract"}, {"offsetInBeginSection": 218, "offsetInEndSection": 372, "text": "This cytoplasmic polyadenylation element (CPE) is the binding platform for CPE-binding protein (CPEB), which promotes polyadenylation-induced translation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17481902", "endSection": "abstract"}]}, {"body": "Is SUMOylation a post-translational modification in eukaryotes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18468939", "http://www.ncbi.nlm.nih.gov/pubmed/20414307", "http://www.ncbi.nlm.nih.gov/pubmed/25561743", "http://www.ncbi.nlm.nih.gov/pubmed/15744326", "http://www.ncbi.nlm.nih.gov/pubmed/21178495", "http://www.ncbi.nlm.nih.gov/pubmed/22192309", "http://www.ncbi.nlm.nih.gov/pubmed/27012284", "http://www.ncbi.nlm.nih.gov/pubmed/21255632", "http://www.ncbi.nlm.nih.gov/pubmed/26259101", "http://www.ncbi.nlm.nih.gov/pubmed/25218447", "http://www.ncbi.nlm.nih.gov/pubmed/24797264", "http://www.ncbi.nlm.nih.gov/pubmed/18547337", "http://www.ncbi.nlm.nih.gov/pubmed/20074036", "http://www.ncbi.nlm.nih.gov/pubmed/20562097", "http://www.ncbi.nlm.nih.gov/pubmed/25997832", "http://www.ncbi.nlm.nih.gov/pubmed/24616021", "http://www.ncbi.nlm.nih.gov/pubmed/24880118", "http://www.ncbi.nlm.nih.gov/pubmed/25867063", "http://www.ncbi.nlm.nih.gov/pubmed/25959766", "http://www.ncbi.nlm.nih.gov/pubmed/25833950", "http://www.ncbi.nlm.nih.gov/pubmed/23273862", "http://www.ncbi.nlm.nih.gov/pubmed/26142185", "http://www.ncbi.nlm.nih.gov/pubmed/20299342", "http://www.ncbi.nlm.nih.gov/pubmed/24140722", "http://www.ncbi.nlm.nih.gov/pubmed/22525038", "http://www.ncbi.nlm.nih.gov/pubmed/27195426", "http://www.ncbi.nlm.nih.gov/pubmed/23387271", "http://www.ncbi.nlm.nih.gov/pubmed/21832256", "http://www.ncbi.nlm.nih.gov/pubmed/18218095", "http://www.ncbi.nlm.nih.gov/pubmed/24970140", "http://www.ncbi.nlm.nih.gov/pubmed/25308709", "http://www.ncbi.nlm.nih.gov/pubmed/22438991", "http://www.ncbi.nlm.nih.gov/pubmed/18621739", "http://www.ncbi.nlm.nih.gov/pubmed/27152458", "http://www.ncbi.nlm.nih.gov/pubmed/25533125", "http://www.ncbi.nlm.nih.gov/pubmed/22584054"], "ideal_answer": ["Yes, SUMOylation that is the conjugation of target proteins with SUMO (small ubiquitin-related modifier), is a type of post-translational modification in eukaryotes."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0043687", "http://amigo.geneontology.org/amigo/term/GO:0016925", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058207"], "type": "yesno", "id": "58a6b98860087bc10a000028", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "SUMOylation, the conjugation of target proteins with SUMO (small ubiquitin-related modifier), is a type of post-translational modification in eukaryotes and involves the sequential action of activation (E1), conjugation (E2) and ligation (E3) enzymes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27152458", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Plants have evolved to cope with changing environmental conditions. One way plants achieve this is through post-translational modification of target proteins by ubiquitination and SUMOylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27012284", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Sumoylation is a post-translational modification essential in most eukaryotes that regulates stability, localization, activity, or interaction of a multitude of proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25833950", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "SUMOylation, the covalent attachment of a member of the small ubiquitin-like modifier (SUMO) family of proteins to lysines in target substrates, is an essential post-translational modification in eukaryotes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25308709", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Post-translational modification by SUMO is a highly conserved pathway in eukaryotes that plays very important regulatory roles in many cellular processes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24797264", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 340, "text": "SUMOylation is an essential post-translational modification that regulates a variety of cellular processes including cell cycle progression. Although the SUMOylation pathway has been identified and investigated in many eukaryotes, the mechanisms of SUMOylation in regulating the functions of various substrates are still poorly understood. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24880118", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "SUMOylation is a relevant protein post-translational modification in eukaryotes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21832256", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "SUMOylation is a reversible post-translational modification essential for genome stability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25218447", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 696, "text": "Many SUMOylated lysines have previously been reported to be ubiquitinated, acetylated or methylated, thus indicating cross-talk between SUMO and other post-translational modifications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25218447", "endSection": "abstract"}, {"offsetInBeginSection": 179, "offsetInEndSection": 281, "text": "Sumoylation is a post-translational modification shown to play a role in diverse biological processes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20299342", "endSection": "abstract"}, {"offsetInBeginSection": 363, "offsetInEndSection": 574, "text": "Besides phosphorylation or ubiquitylation, for which many examples of modulation by pathogens exist, a post-translational modification called SUMOylation was recently shown to be targeted by pathogenic bacteria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21178495", "endSection": "abstract"}, {"offsetInBeginSection": 1669, "offsetInEndSection": 1808, "text": "cruzi SUMOylated proteins are similarly modified, indicating conserved functions for protein SUMOylation in this early divergent eukaryote.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21832256", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "PML is a potent tumor suppressor and proapoptotic factor and is functionally regulated by post-translational modifications such as phosphorylation, sumoylation, and ubiquitination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18621739", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "SUMOylation is an essential post-translational modification that regulates a variety of cellular processes including cell cycle progression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24880118", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "SUMOylation in Giardia lamblia: A Conserved Post-Translational Modification in One of the Earliest Divergent Eukaryotes", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24970140", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "SUMOylation, the covalent attachment of a member of the small ubiquitin-like modifier (SUMO) family of proteins to lysines in target substrates, is an essential post-translational modification in eukaryotes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25308709", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "SUMOylation is a relevant protein post-translational modification in eukaryotes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21832256", "endSection": "abstract"}, {"offsetInBeginSection": 817, "offsetInEndSection": 1167, "text": "Post-translational modifications (PTMs) are one facet of this proteasomal regulation, with over 400 known phosphorylation sites, over 500 ubiquitination sites and 83 internal lysine acetylation sites, as well as multiple sites for caspase cleavage, glycosylation (such as O-GlcNAc modification), methylation, nitrosylation, oxidation, and SUMOylation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140722", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 218, "text": "SUMOylation is an important post-translational modification, and Akt SUMOylation was found to regulate cell proliferation, tumorigenesis and cell cycle, but the molecular mechanism of Akt SUMOylation is less well known", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25867063", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "SUMOylation is a form of post-translational modification where small ubiquitin-like modifiers (SUMO) are covalently attached to target proteins to regulate their properties", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25533125", "endSection": "abstract"}, {"offsetInBeginSection": 61, "offsetInEndSection": 256, "text": "One distinctive feature in acute proteotoxic stresses, such as heat shock (HS), is rapid post-translational modification of proteins by SUMOs (small ubiquitin-like modifier proteins; SUMOylation)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259101", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Post-translational modification by the Small Ubiquitin-like Modifier (SUMO) proteins, a process termed SUMOylation, is involved in many fundamental cellular processes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142185", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 260, "text": "SUMOylation is an important post-translational modification that is involved in many key biological processes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22192309", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "Group III metabotropic glutamate receptors (mGluRs) undergo post-translational modification by SUMO in in vitro assays but the SUMOylation of full-length mGluRs in mammalian cells has not been reported", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21255632", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "SUMOylation is a relevant protein post-translational modification in eukaryotes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21832256", "endSection": "abstract"}, {"offsetInBeginSection": 424, "offsetInEndSection": 574, "text": "However, the effects of pathogenic bacteria on SUMOylation, an essential post-translational modification in eukaryotic cells, remain largely unknown. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20414307", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "A novel post-translational modification of nucleolin, SUMOylation at Lys-294, mediates arsenite-induced cell death by regulating gadd45\ufffd mRNA stability.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25561743", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Drosophila Bicoid is a substrate of sumoylation and its activator function is subject to inhibition by this post-translational modification.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22584054", "endSection": "title"}, {"offsetInBeginSection": 665, "offsetInEndSection": 829, "text": "Here, we demonstrate that SUMOylation of RelB might be one of these post-translational modifications rendering the function of the NF-\ufffdB transcription factor RelB. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24616021", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "In the last decade, SUMOylation has emerged as an essential post-translational modification in eukaryotes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20074036", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 251, "text": "SUMOylation, the conjugation of target proteins with SUMO (small ubiquitin-related modifier), is a type of post-translational modification in eukaryotes and involves the sequential action of activation (E1), conjugation (E2) and ligation (E3) enzymes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27152458", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "SUMOylation, the covalent attachment of a member of the small ubiquitin-like modifier (SUMO) family of proteins to lysines in target substrates, is an essential post-translational modification in eukaryotes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25308709", "endSection": "abstract"}, {"offsetInBeginSection": 68, "offsetInEndSection": 192, "text": "One way plants achieve this is through post-translational modification of target proteins by ubiquitination and SUMOylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27012284", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "The small ubiquitin-like modifier (SUMO) pathway in eukaryotes is an essential post-translational modification required for a variety of cellular processes, development and organelle biogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22525038", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Post-translational modification by SUMO is a highly conserved pathway in eukaryotes that plays very important regulatory roles in many cellular processes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24797264", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 1058, "text": "Many SUMOylated lysines have previously been reported to be ubiquitinated, acetylated or methylated, thus indicating cross-talk between SUMO and other post-translational modifications. We identified 70 phosphorylation and four acetylation events in proximity to SUMOylation sites, and we provide evidence for acetylation-dependent SUMOylation of endogenous histone H3. SUMOylation regulates target proteins involved in all nuclear processes including transcription, DNA repair, chromatin remodeling, precursor-mRNA splicing and ribosome assembly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25218447", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 260, "text": "SUMOylation is a reversible post-translational modification essential for genome stability. Using high-resolution MS, we have studied global SUMOylation in human cells in a site-specific manner, identifying a total of>4,300 SUMOylation sites in>1,600 proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25218447", "endSection": "abstract"}, {"offsetInBeginSection": 386, "offsetInEndSection": 880, "text": "We quantitatively studied SUMOylation dynamics in response to SUMO protease inhibition, proteasome inhibition and heat shock. Many SUMOylated lysines have previously been reported to be ubiquitinated, acetylated or methylated, thus indicating cross-talk between SUMO and other post-translational modifications. We identified 70 phosphorylation and four acetylation events in proximity to SUMOylation sites, and we provide evidence for acetylation-dependent SUMOylation of endogenous histone H3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25218447", "endSection": "abstract"}, {"offsetInBeginSection": 179, "offsetInEndSection": 589, "text": "Sumoylation is a post-translational modification shown to play a role in diverse biological processes. Here, we demonstrate that sumoylation is essential for proper heterochromatin function in Drosophila through modification of SU(VAR)3-7. Indeed, SU(VAR)3-7 is sumoylated at lysine K839; this modification is required for localization of SU(VAR)3-7 at pericentric heterochromatin, chromosome 4, and telomeres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20299342", "endSection": "abstract"}, {"offsetInBeginSection": 179, "offsetInEndSection": 418, "text": "Sumoylation is a post-translational modification shown to play a role in diverse biological processes. Here, we demonstrate that sumoylation is essential for proper heterochromatin function in Drosophila through modification of SU(VAR)3-7.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20299342", "endSection": "abstract"}, {"offsetInBeginSection": 800, "offsetInEndSection": 952, "text": "Our results suggest a new level of regulation of Sall activity in vivo during animal development through post-translational modification by sumoylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20562097", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 485, "text": "BACKGROUND: Small Ubiquitin-like MOdifier protein (SUMO) is a key regulator of nuclear functions but little is known regarding the role of the post-translational modification sumoylation outside of the nucleus, particularly in the Central Nervous System (CNS).METHODOLOGY/PRINCIPAL FINDINGS: Here, we report that the expression levels of SUMO-modified substrates as well as the components of the sumoylation machinery are temporally and spatially regulated in the developing rat brain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22438991", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "SUMOylation in Giardia lamblia: A Conserved Post-Translational Modification in One of the Earliest Divergent Eukaryotes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24970140", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Identification of a novel post-translational modification in Plasmodium falciparum: protein sumoylation in different cellular compartments.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18547337", "endSection": "title"}, {"offsetInBeginSection": 659, "offsetInEndSection": 899, "text": "More recently, Akt has been identified as a substrate for many different post-translational modifications, including not only phosphorylation of other residues, but also acetylation, glycosylation, oxidation, ubiquitination and SUMOylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25997832", "endSection": "abstract"}]}, {"body": "What is the Shelterin complex?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27814571", "http://www.ncbi.nlm.nih.gov/pubmed/26598048", "http://www.ncbi.nlm.nih.gov/pubmed/26748096", "http://www.ncbi.nlm.nih.gov/pubmed/26921407", "http://www.ncbi.nlm.nih.gov/pubmed/27135879", "http://www.ncbi.nlm.nih.gov/pubmed/26871633", "http://www.ncbi.nlm.nih.gov/pubmed/26119943"], "ideal_answer": ["Human telomeres are associated with the shelterin complex which consists of six telomere-associated proteins that specifically bind to telomeric DNA. Alterations or removal of individual shelterin components would lead to telomere uncapping and telomere dysfunction, resulting in cellular senescence and transformation to a malignant state."], "type": "summary", "id": "58a9cd03396a458e50000003", "snippets": [{"offsetInBeginSection": 424, "offsetInEndSection": 764, "text": "Human telomeres are associated with the shelterin complex which consists of six telomere-associated proteins that specifically bind to telomeric DNA. Alterations or removal of individual shelterin components would lead to telomere uncapping and telomere dysfunction, resulting in cellular senescence and transformation to a malignant state.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814571", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "Telomeres interact with numerous proteins, including components of the shelterin complex, whose alteration, similarly to proliferation-induced telomere shortening, initiates cellular senescence.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26119943", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Telomere repeat binding factor TRF2 is a member of shelterin complex with an important role in protecting and stabilizing chromosomal ends.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598048", "endSection": "abstract"}, {"offsetInBeginSection": 139, "offsetInEndSection": 236, "text": "In human, the shelterin complex binds TTAGGG DNA repeats and provides capping to chromosome ends.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26748096", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Shelterin Protects Chromosome Ends by Compacting Telomeric Chromatin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26871633", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Telomeres, repetitive DNA sequences at chromosome ends, are shielded against the DNA damage response (DDR) by the shelterin complex. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26871633", "endSection": "abstract"}, {"offsetInBeginSection": 106, "offsetInEndSection": 357, "text": "Telomeres need to be protected by the shelterin complex to avoid junctions occurring between chromosomes while failing topoisomerases or clustered DNA damage processing may produce double-strand breaks, thus requiring swift repair to avoid cell death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921407", "endSection": "abstract"}, {"offsetInBeginSection": 164, "offsetInEndSection": 274, "text": "A multiprotein complex known as shelterin prevents recognition of telomeric sequences as sites of DNA damage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27135879", "endSection": "abstract"}]}, {"body": "What disease is the drug aducanumab targeting?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27025652", "http://www.ncbi.nlm.nih.gov/pubmed/27810931", "http://www.ncbi.nlm.nih.gov/pubmed/27582220", "http://www.ncbi.nlm.nih.gov/pubmed/27251914"], "ideal_answer": ["Aducanumab is an anti-A\u03b2 antibody being developed for the treatment of Alzheimer's disease (AD)."], "type": "factoid", "id": "58a95c711978bbde22000001", "snippets": [{"offsetInBeginSection": 1462, "offsetInEndSection": 1658, "text": " Most importantly, recent trials of three different A\u03b2 antibodies (solanezumab, crenezumab, and aducanumab) have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27025652", "endSection": "abstract"}, {"offsetInBeginSection": 773, "offsetInEndSection": 999, "text": "ecent results from trials of agents such as aducanumab are encouraging but must also be interpreted with caution. Such medicines could potentially delay the onset of dementia and would therefore markedly reduce its prevalence.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27251914", "endSection": "abstract"}, {"offsetInBeginSection": 1266, "offsetInEndSection": 1520, "text": "Aducanumab is an anti-A\u03b2 antibody being developed for the treatment of AD, and interim analyses of a phase 1b clinical trial have suggested potential beneficial effects on the amyloid pathology and the cognitive status in patients treated with aducanumab", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27810931", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582220", "endSection": "title"}]}, {"body": "Which human syndromes have been detected with Fluorescence in situ hybridization (FISH)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26355708", "http://www.ncbi.nlm.nih.gov/pubmed/1394103", "http://www.ncbi.nlm.nih.gov/pubmed/16351727", "http://www.ncbi.nlm.nih.gov/pubmed/12505257", "http://www.ncbi.nlm.nih.gov/pubmed/26066831", "http://www.ncbi.nlm.nih.gov/pubmed/11424143", "http://www.ncbi.nlm.nih.gov/pubmed/22749034", "http://www.ncbi.nlm.nih.gov/pubmed/9806578", "http://www.ncbi.nlm.nih.gov/pubmed/14669212", "http://www.ncbi.nlm.nih.gov/pubmed/10699172", "http://www.ncbi.nlm.nih.gov/pubmed/16222476", "http://www.ncbi.nlm.nih.gov/pubmed/26829723", "http://www.ncbi.nlm.nih.gov/pubmed/24056568", "http://www.ncbi.nlm.nih.gov/pubmed/17867985", "http://www.ncbi.nlm.nih.gov/pubmed/9763574", "http://www.ncbi.nlm.nih.gov/pubmed/25754580", "http://www.ncbi.nlm.nih.gov/pubmed/10485139", "http://www.ncbi.nlm.nih.gov/pubmed/10493892", "http://www.ncbi.nlm.nih.gov/pubmed/16857771", "http://www.ncbi.nlm.nih.gov/pubmed/1897521", "http://www.ncbi.nlm.nih.gov/pubmed/11769675", "http://www.ncbi.nlm.nih.gov/pubmed/27134897", "http://www.ncbi.nlm.nih.gov/pubmed/17394204", "http://www.ncbi.nlm.nih.gov/pubmed/12513811", "http://www.ncbi.nlm.nih.gov/pubmed/8634784", "http://www.ncbi.nlm.nih.gov/pubmed/15287942", "http://www.ncbi.nlm.nih.gov/pubmed/15949578", "http://www.ncbi.nlm.nih.gov/pubmed/18991056", "http://www.ncbi.nlm.nih.gov/pubmed/8260718", "http://www.ncbi.nlm.nih.gov/pubmed/20064152", "http://www.ncbi.nlm.nih.gov/pubmed/12744739", "http://www.ncbi.nlm.nih.gov/pubmed/11484160", "http://www.ncbi.nlm.nih.gov/pubmed/7627929", "http://www.ncbi.nlm.nih.gov/pubmed/17631477", "http://www.ncbi.nlm.nih.gov/pubmed/8152255", "http://www.ncbi.nlm.nih.gov/pubmed/26509426", "http://www.ncbi.nlm.nih.gov/pubmed/8795688", "http://www.ncbi.nlm.nih.gov/pubmed/9951451", "http://www.ncbi.nlm.nih.gov/pubmed/10464634", "http://www.ncbi.nlm.nih.gov/pubmed/18356781", "http://www.ncbi.nlm.nih.gov/pubmed/12673589", "http://www.ncbi.nlm.nih.gov/pubmed/9359505", "http://www.ncbi.nlm.nih.gov/pubmed/25011965", "http://www.ncbi.nlm.nih.gov/pubmed/10408793", "http://www.ncbi.nlm.nih.gov/pubmed/8882776", "http://www.ncbi.nlm.nih.gov/pubmed/9040786", "http://www.ncbi.nlm.nih.gov/pubmed/12437640", "http://www.ncbi.nlm.nih.gov/pubmed/19758696", "http://www.ncbi.nlm.nih.gov/pubmed/8362906", "http://www.ncbi.nlm.nih.gov/pubmed/10330122", "http://www.ncbi.nlm.nih.gov/pubmed/26815134", "http://www.ncbi.nlm.nih.gov/pubmed/14749005", "http://www.ncbi.nlm.nih.gov/pubmed/24405535", "http://www.ncbi.nlm.nih.gov/pubmed/20226525", "http://www.ncbi.nlm.nih.gov/pubmed/8207974", "http://www.ncbi.nlm.nih.gov/pubmed/10598142", "http://www.ncbi.nlm.nih.gov/pubmed/8149646", "http://www.ncbi.nlm.nih.gov/pubmed/19806569", "http://www.ncbi.nlm.nih.gov/pubmed/12040758", "http://www.ncbi.nlm.nih.gov/pubmed/17701956", "http://www.ncbi.nlm.nih.gov/pubmed/24604040", "http://www.ncbi.nlm.nih.gov/pubmed/12616613", "http://www.ncbi.nlm.nih.gov/pubmed/18428311", "http://www.ncbi.nlm.nih.gov/pubmed/16468325", "http://www.ncbi.nlm.nih.gov/pubmed/27576943", "http://www.ncbi.nlm.nih.gov/pubmed/20677157", "http://www.ncbi.nlm.nih.gov/pubmed/7977469", "http://www.ncbi.nlm.nih.gov/pubmed/25947045", "http://www.ncbi.nlm.nih.gov/pubmed/23450488", "http://www.ncbi.nlm.nih.gov/pubmed/11783350", "http://www.ncbi.nlm.nih.gov/pubmed/9831340", "http://www.ncbi.nlm.nih.gov/pubmed/24398791", "http://www.ncbi.nlm.nih.gov/pubmed/24370037", "http://www.ncbi.nlm.nih.gov/pubmed/8723064", "http://www.ncbi.nlm.nih.gov/pubmed/17649717", "http://www.ncbi.nlm.nih.gov/pubmed/7649555", "http://www.ncbi.nlm.nih.gov/pubmed/18000985", "http://www.ncbi.nlm.nih.gov/pubmed/14666267", "http://www.ncbi.nlm.nih.gov/pubmed/12116251", "http://www.ncbi.nlm.nih.gov/pubmed/11876976", "http://www.ncbi.nlm.nih.gov/pubmed/26392809", "http://www.ncbi.nlm.nih.gov/pubmed/18591625", "http://www.ncbi.nlm.nih.gov/pubmed/17653548", "http://www.ncbi.nlm.nih.gov/pubmed/7666455", "http://www.ncbi.nlm.nih.gov/pubmed/21223721", "http://www.ncbi.nlm.nih.gov/pubmed/7934162"], "ideal_answer": ["To explore the clonal evolution of monosomy 7 in patients with aplastic anemia (AA).Monosomy 7 (-7) in 81 AA patients with normal karyotype at diagnosis and 46 AA treated with immunosuppressive therapy (IST) and more than 6 months of recombinant human granulocyte colony-stimulating factor (rhuG-CSF) were detected by interphase- fluorescence in situ hybridization (FISH) retrospectively.There were 5.4% - 7.6% of -7 cells in 11 (13.6%) of 81 patients at diagnosis, the survival and response rate to IST in -7 positive patients did not differ s Former molecular cytogenetic studies showed that such aberrations as an equivalent of intrinsic radiosensitivity can be detected by fluorescence in-situ hybridization (FISH) techniques using whole chromosome painting (wcp) probes. Five-color FISH was performed using human DNA segments specific for peri-CEN or subTEL, which were labeled with five different fluorescent dyes [7-diethylaminocoumarin (DEAC): blue, fluorescein isothiocyanate (FITC): green, rhodamine 6G (R6G): yellow, TexRed: red, and cyanine5 (Cy5): purple]. Using this technique, followed by cell-by-cell multicolor fluorescence in situ hybridization (FISH) analysis of purified FNRBCs, we were able to detect some of the most common human aneuploidies (including Down syndrome, Klinefelter syndrome, and trisomy 13) in 33 pregnant women referred for amniocentesis.", "The human syndromes which can be detected with FISH are:\n1) Myelodysplastic Syndrome (MDS)\n2) Genetic syndromes caused by somatic chromosomal mosaicism\n3) Prader Willi syndrome (PWS)\n4) Angelman syndrome (AS)\n5) Williams syndrome\n6) Smith Magenis syndrome \n7) Velocardiofacial syndrome\n8) Jacobsen syndrome\n9) Shwachman-Diamond syndrome\n10) Saethre-Chotzen syndrome \n11) DiGeorge syndrome (DGS) \n12) Velo-cardio-facial syndrome (VCFS)\n13) Miller-Dieker syndrome\n14) Deletion 22q11.2 syndrome (D22S)"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017404", "http://www.disease-ontology.org/api/metadata/DOID:11983", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011218", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013050", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017403"], "type": "list", "id": "58932cd87d9090f353000001", "snippets": [{"offsetInBeginSection": 806, "offsetInEndSection": 1077, "text": "We demonstrate that, using a sensitive FISH technique, 12p deletion occurs significantly more frequently in MDS than previously described (7.6% by CD34+ PB-FISH vs. 1.6% by CBA, P<0.001) and is often associated with other aberrations (93% by CD34+ PB-FISH vs. 60% by CBA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26355708", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Somatic chromosomal mosaicism arising from post-zygotic errors is known to cause several well-defined genetic syndromes as well as contribute to phenotypic variation in diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24398791", "endSection": "abstract"}, {"offsetInBeginSection": 428, "offsetInEndSection": 931, "text": "The mosaicism was characterized and confirmed by fluorescence in situ hybridization (FISH) and/or chromosome analysis. Different categories of abnormal cell lines were detected: (1) aneuploidy, including sex chromosome abnormalities and isochromosomes (22 cases), (2) ring or marker chromosomes (12 cases), (3) single deletion/duplication copy number variations (CNVs) (11 cases), (4) multiple deletion/duplication CNVs (5 cases), (5) exonic CNVs (4 cases), and (6) unbalanced translocations (3 cases). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24398791", "endSection": "abstract"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1147, "text": "Positive cases with MLPA technique were confirmed using either fluorescence in situ hybridization (FISH) or follow up confirmatory MLPA probe sets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24604040", "endSection": "abstract"}, {"offsetInBeginSection": 1555, "offsetInEndSection": 1739, "text": "The deletions/duplications detected in non telomeric regions include regions for Prader Willi/Angelman regions, Williams syndrome, Smith Magenis syndrome and Velocardiofacial syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24604040", "endSection": "abstract"}, {"offsetInBeginSection": 199, "offsetInEndSection": 547, "text": "The bone marrow specimen from a patient with MDS was comprehensively analyzed by a combination of genomic approaches, including chromosomal karyotyping, fluorescence in situ hybridization (FISH), genome scanning using Affymetrix high density SNP microarray platform, and next-generation sequencing (NGS) analysis using IonTorrent Cancer Gene Panel.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24370037", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22749034", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25754580", "endSection": "title"}, {"offsetInBeginSection": 222, "offsetInEndSection": 356, "text": "Fluorescence in situ hybridization (FISH) can effectively demonstrate TET2 deletions and is often used to validate molecular results. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22749034", "endSection": "abstract"}, {"offsetInBeginSection": 1130, "offsetInEndSection": 1285, "text": "These findings demonstrate that 1) FISH is an effective and economical method to reveal cryptic abnormalities of band 4q22-q24 resulting in TET2 deletions;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22749034", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19758696", "endSection": "title"}, {"offsetInBeginSection": 603, "offsetInEndSection": 875, "text": " Using a standardized approach, we focused our investigation on detection of -5/del(5q), -7/del(7q), trisomy 8 and del(20q) in patients with MDS (N=52), MDS/myeloproliferative overlap syndromes (N=7) and acute myeloid leukemia (N=15) using MC, FISH and SNP-A karyotyping. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19758696", "endSection": "abstract"}, {"offsetInBeginSection": 1272, "offsetInEndSection": 1518, "text": "We conclude that MC, FISH and SNP-A are complementary techniques that, when applied and interpreted together, can improve the diagnostic yield for identifying genetic lesions in MDS and contribute to the better description of abnormal karyotypes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19758696", "endSection": "abstract"}, {"offsetInBeginSection": 247, "offsetInEndSection": 456, "text": "Here, we report the detection of a reciprocal translocation t(7;21)(p22;q22) in the marrow of two adults with MDS and AML, using conventional cytogenetic analysis and fluorescence-in situ-hybridization (FISH).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20064152", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 170, "text": "Detection of cytogenetic abnormalities involving chromosomes 5,7 and 8 in myelodysplastic syndromes with fluorescence in situ hybridization and its clinical significance", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17649717", "endSection": "title"}, {"offsetInBeginSection": 11, "offsetInEndSection": 177, "text": "To identify the abnormal karyotypes by fluorescence in situ hybridization (FISH) and explore prognostic implications in patients with myelodysplastic syndromes (MDS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17649717", "endSection": "abstract"}, {"offsetInBeginSection": 186, "offsetInEndSection": 297, "text": "FISH was used to detect the frequently occurring chromosome abnormalities (-5/5q, +8, -7/7q-) in 37 MDS cases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17649717", "endSection": "abstract"}, {"offsetInBeginSection": 1430, "offsetInEndSection": 1544, "text": "FISH detected monosomy 7 in 6 samples at the time MDS was diagnosed and in 2 samples at the time AA was diagnosed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17701956", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 327, "text": "As chromosomal instability may contribute to leukemogenesis in patients with congenital bone marrow failure (CBMF) disorders, it was the aim of this study to characterize chromosomally aberrant clones that arise during the clinical course of disease by means of R-banding and fluorescence in situ hybridization (FISH) analyses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653548", "endSection": "abstract"}, {"offsetInBeginSection": 739, "offsetInEndSection": 1232, "text": "In one child with congenital thrombocytopenia, Jacobsen syndrome [del(11)(q24)c] was diagnosed, and thus a CBMF could be excluded. In a girl with Shwachman-Diamond syndrome, two independent clones, one with an isochromosome i(7)(q10), another with a complex aberrant karyotype, were identified. Simultaneously, transition into a myelodysplastic syndrome (MDS) occurred. The brother, who was also afflicted with Shwachman-Diamond syndrome, showed an isochromosome i(7q) as a single aberration. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653548", "endSection": "abstract"}, {"offsetInBeginSection": 1452, "offsetInEndSection": 1698, "text": "In summary, we suggest that follow-up of patients with CBMF using chromosome and FISH analyses will be helpful for the early detection of transition into MDS or AML and thus should be an integral part of the clinical management of these patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653548", "endSection": "abstract"}, {"offsetInBeginSection": 442, "offsetInEndSection": 751, "text": "Here we assess this capability by applying array CGH to the analysis of copy number alterations in 44 patients with a phenotype of the 22q11.2 deletion syndrome. Twenty-five patients had the deletion on chromosome 22 characteristic of this syndrome as determined by fluorescence in situ hybridization (FISH). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394204", "endSection": "abstract"}, {"offsetInBeginSection": 495, "offsetInEndSection": 1056, "text": "Subtelomeric aberrations previously detected by fluorescence in situ hybridization (FISH) analysis were confirmed in two patients, and accurate diagnosis was provided in two previously undiagnosed complex cases. Microdeletions at 15q11.2-q13 in a newborn with hypotonia, cryptorchidism, and hypopigmentation were detected with few discrepancies between the array results and FISH analysis. Contiguous microdeletion of GSCL, HIRA and TBX1 genes at 22q11.2 was identified in a previously undiagnosed boy with an unusual presentation of the VCF/DiGeorge spectrum. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16857771", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 120, "text": "Detection of 20q(-) chromosome abnormality in myelodysplastic syndrome by interphase fluorescence in situ hybridization", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12744739", "endSection": "title"}, {"offsetInBeginSection": 698, "offsetInEndSection": 1028, "text": "The results showed that among 52 cases of MDS, 7 (13.5%) cases were positive by FISH, however, of which, 4 cases were positive and the other 3 cases were negative by CC assay. It is concluded that YAC912C3 and interphase FISH providing a powerful technique in the detection of 20q(-) in MDS is an important complement to CC assay.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12744739", "endSection": "abstract"}, {"offsetInBeginSection": 302, "offsetInEndSection": 418, "text": "A FISH assay was performed to analyze 70 AML/MDS patients who had received conventional cytogenetic analysis (CCA). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14669212", "endSection": "abstract"}, {"offsetInBeginSection": 1536, "offsetInEndSection": 1887, "text": "FISH is a powerful tool to identify or refine chromosomal structural aberrations involving 7q, and it provides accurate evaluation of -7/7q- in all the patients. -7 and 7q- clone frequently coexist in the same specimen, and the significantly increasing percentage of 7q- cells implies that -7 clone secondary to 7q- clone is a result from loss of 7q-.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14669212", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Saethre-Chotzen syndrome is a common craniosynostosis syndrome characterized by craniofacial and limb anomalies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12116251", "endSection": "abstract"}, {"offsetInBeginSection": 1468, "offsetInEndSection": 1736, "text": "We propose that initial screening for the FGFR3 P250R mutation, followed by sequencing of TWIST and then fluorescence in situ hybridization (FISH) for deletion detection of TWIST, is sufficient to detect mutations in>80% of patients with the Saethre-Chotzen phenotype.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12116251", "endSection": "abstract"}, {"offsetInBeginSection": 769, "offsetInEndSection": 983, "text": "We clearly present that the use of SKY combined with conventional G-banding analysis and FISH has assisted in the identification of important chromosomal events that may play a key role in the development of t-MDS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12505257", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 272, "text": "n this study, we used spectral karyotyping (SKY) and fluorescence in situ hybridization (FISH) as complementary techniques for the analysis of two therapy-related secondary myelodysplastic syndrome (t-MDS) cases with complex karyotypes, previously analyzed by G-banding. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12505257", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 141, "text": "Comparison of detection of trisomy 8 with fluorescence in situ hybridization and conventional karyotype analysis in myelodysplastic syndrome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12513811", "endSection": "title"}, {"offsetInBeginSection": 298, "offsetInEndSection": 418, "text": "The trisomy 8 clones were simultaneously detected in 48 MDS cases with FISH and conventional cytogenetic analysis (CCA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12513811", "endSection": "abstract"}, {"offsetInBeginSection": 801, "offsetInEndSection": 905, "text": "Trisomy 8 was detected in 1 of 15 specimens with normal or abnormal karyotype without trisomy 8 by FISH.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12513811", "endSection": "abstract"}, {"offsetInBeginSection": 1149, "offsetInEndSection": 1381, "text": "In conclusion, our results showed that FISH is a sensitive and accurate technique to detect trisomy 8 in MDS patients. It can provide contribute to diagnosis, assessment of curative effect and predicting progress of disease in MDS. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12513811", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 121, "text": "Detection of common chromosome abnormalities in myelodysplastic syndrome with a panel fluorescence in situ hybridization", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12673589", "endSection": "title"}, {"offsetInBeginSection": 1094, "offsetInEndSection": 1207, "text": "Panel FISH is a useful tool of molecular cytogenetics in the detection of common chromosome abnormalities in MDS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12673589", "endSection": "abstract"}, {"offsetInBeginSection": 556, "offsetInEndSection": 772, "text": "Among 20 cases, 13 cases were found to carry common chromosome abnormalities by panel FISH (trisomy 8, five cases; -5/5q-, one case; 20q-, five cases; 5q- accompanying 20q-, one case; complex abnormalities, one case)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12673589", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 121, "text": "Detection of -5/5q- chromosome abnormality in myelodysplastic syndromes by interphase fluorescence in situ hybridization", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11769675", "endSection": "title"}, {"offsetInBeginSection": 498, "offsetInEndSection": 636, "text": "In 48 MDS patients, 13 were positive for interphase FISH, of whom, 7 were positive and 6 were negative for conventional cytogenetics (CC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11769675", "endSection": "abstract"}, {"offsetInBeginSection": 767, "offsetInEndSection": 844, "text": "Interphase FISH is more sensitive than CC for the detection of -5/5q- in MDS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11769675", "endSection": "abstract"}, {"offsetInBeginSection": 571, "offsetInEndSection": 874, "text": "Three cases displayed -7/7q- by conventional cytogenetics(CC) and were confirmed by interphase FISH. Six cases in 43 cases who did not show -7/7q- by CC displayed -7/7q- by interphase FISH.CONCLUSION: Interphase FISH is very useful for the detection of -7 or 7q- in MDS and it is more sensitive than CC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11484160", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Diagnosis of microdeletion syndromes by fluorescence in situ hybridization (FISH).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18428311", "endSection": "title"}, {"offsetInBeginSection": 1, "offsetInEndSection": 103, "text": "Detection of trisomy 8 with interphase fluorescence in situ hybridization in myelodysplastic syndromes", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11876976", "endSection": "title"}, {"offsetInBeginSection": 834, "offsetInEndSection": 976, "text": "Interphase FISH was a useful method for the detection of trisomy 8 in MDS, especially in patients with normal karyotype or marker chromosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11876976", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 315, "text": "Congenital cardiovascular (c-v) malformations are the leading signs of two syndromes of highly variable phenotypes, the DiGeorge syndrome (DGS) and the velo-cardio-facial syndrome (VCFS), both of which in the majority of cases are caused by microdeletion in the chromosome region 22q11.2. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951451", "endSection": "abstract"}, {"offsetInBeginSection": 1977, "offsetInEndSection": 2158, "text": "In patients with congenital c-v and associated malformations of dysmorphism microdeletion diagnosis of 22q11.2 by FISH is indicated in addition to conventional cytogenetic testing. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9951451", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Discordant detection of monosomy 7 by GTG-banding and FISH in a patient with Shwachman-Diamond syndrome without evidence of myelodysplastic syndrome or acute myelogenous leukemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10598142", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 218, "text": "Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9763574", "endSection": "title"}, {"offsetInBeginSection": 1236, "offsetInEndSection": 1540, "text": "We conclude that the combination of FACS/FISH/BUdR, which determines the number, phenotype and proliferation rate of very rare leukaemic cells in patients with AML or MDS in clinical remission, provides information that is useful in the identification of patients with high and low likelihood of relapse.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9359505", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "FISH detection of chromosome 15 deletions in Prader-Willi and Angelman syndromes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882776", "endSection": "title"}, {"offsetInBeginSection": 855, "offsetInEndSection": 1059, "text": "We conclude that FISH analysis is a rapid and reliable method for detection of deletions within 15q11-q13 and whenever a deletion is found, FISH analysis of parental chromosomes should also be considered.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "We have evaluated fluorescence in situ hybridization (FISH) analysis for the clinical laboratory detection of the 15q11-q13 deletion seen in Prader-Willi syndrome (PWS) and Angelman syndrome (AS) using probes for loci D15S11, SNRPN, D15S10, and GABRB3. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Study of clonality in myelodysplastic syndromes: detection of trisomy 8 in bone marrow cell smears by fluorescence in situ hybridization.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8795688", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Investigations with fluorescence in situ hybridization (FISH) demonstrate loss of the telomeres on the reciprocal chromosome in three unbalanced translocations involving chromosome 15 in the Prader-Willi and Angelman syndromes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7649555", "endSection": "title"}, {"offsetInBeginSection": 245, "offsetInEndSection": 513, "text": "Fluorescence in situ hybridization (FISH) was used for the detection of chromosome 15(q11-13) deletions (with probes from the PWS/AS region) and to define the involvement of the telomere in the derivative chromosomes (with library probes and telomere-specific probes).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7649555", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Fluorescence in situ hybridization improves the detection of monosomy 7 in myelodysplastic syndromes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8207974", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Detection of monosomy 7 by fluorescence in situ hybridization in acute nonlymphocytic leukemia and myelodysplastic syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8260718", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 261, "text": "Fluorescence in situ hybridization (FISH) with a chromosome 7 specific alpha satellite DNA probe was used to detect monosomy 7 in interphase and metaphase cells obtained from patients with myelodysplastic syndrome (MDS) and acute nonlymphocytic leukemia (ANLL).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8260718", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 261, "text": "A 15-year-old male with myelodysplastic syndrome (MDS) characterized by monosomy 7 was cytogenetically evaluated by metaphase karyotyping and fluorescence in situ hybridization (FISH) of interphase cells at six different points during the course of his disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1394103", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "Fluorescence in situ hybridization (FISH) using two cosmid probes (41A and P13) from the Miller-Dieker syndrome (MDS) critical region in 17p13.3 was performed in a blinded comparison of three MDS patients with submicroscopic deletions and in four normal relatives used as controls.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1897521", "endSection": "abstract"}, {"offsetInBeginSection": 1046, "offsetInEndSection": 1172, "text": "These studies demonstrate that in situ hybridization is an efficient method for deletion detection in Miller-Dieker syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1897521", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "This study identified cytogenetic abnormalities in a population screened for deletion 22q11.2 syndrome (D22S) by fluorescence in situ hybridization (FISH) and G-banding and correlated these abnormalities to referring specialty and submitted indications. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16222476", "endSection": "abstract"}, {"offsetInBeginSection": 360, "offsetInEndSection": 516, "text": "Positive test results for D22S FISH and other abnormalities found by other FISH assays and G-banding were correlated to submitting specialist and indication", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16222476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Use of fluorescence in situ hybridization (FISH) in the diagnosis of DiGeorge sequence and related diseases.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8634784", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 246, "text": "Deletions of 22q11.2 have been detected in the majority of patients with DiGeorge, velocardiofacial, and conotruncal anomaly face syndromes by either cytogenetic analysis, fluorescence in situ hybridization (FISH), or Southern blot hybridization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10464634", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18591625", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 674, "text": "To explore the value of multiplex fluorescence in situ hybridization (M-FISH) technique in the detection of the complex chromosomal aberrations (CCAs) in myelodysplastic syndromes (MDS).M-FISH was used in ten MDS patients with R-banding CCAs to refine the complex chromosomal rearrangements, the constitute of marker chromosomes, and to identify the cryptic translocations.Thirty-seven kinds of structural rearrangements were detected by M-FISH including insertion, deletion, translocation and derivative chromosomes, among which 34 kinds were unbalanced rearrangements, and 3 were balanced rearrangements including t(6;22) (q21; q12), t(9; 19) (q13; p13) and t(3;5) (?; ?).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16468325", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 598, "text": "To explore the clonal evolution of monosomy 7 in patients with aplastic anemia (AA).Monosomy 7 (-7) in 81 AA patients with normal karyotype at diagnosis and 46 AA treated with immunosuppressive therapy (IST) and more than 6 months of recombinant human granulocyte colony-stimulating factor (rhuG-CSF) were detected by interphase- fluorescence in situ hybridization (FISH) retrospectively.There were 5.4% - 7.6% of -7 cells in 11 (13.6%) of 81 patients at diagnosis, the survival and response rate to IST in -7 positive patients did not differ significantly from that in -7 negative patients (P = 0.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21223721", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 487, "text": "To compare the results of fluorescence in situ hybridization (FISH) versus conventional cytogenetics (CC) in the detection of common chromosomal abnormalities and evaluate the significance of FISH in myelodysplastic syndrome (MDS) .A total of 344 patients with de novo MDS from June 2008 to October 2012 were detected by 6 pairs of probes, including CSF1R/D5S23-D5S721 (5q33) , EGR1/ D5S23-D5S721 (5q31) , D7S486 (7q31) /CSP7, D7S522 (7q31) /CSP7, D20S108/CSP8 (20q12/CSP8) and CSPX/CSPY", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24405535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Unbalanced translocation, t(18;21), detected by fluorescence in situ hybridization (FISH) in a child with 18q- syndrome and a ring chromosome 21", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8362906", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 648, "text": "To evaluate the conventional cytogenetic methods in genetic diagnosis and prenatal diagnosis in the family with a proband of Angelman syndrome (AS).High-resolution G-banding karyotyping and fluorescence in situ hybridization (FISH) on metaphase chromosomes were performed.Two AS patients and 1 normal fetus in the family were successfully detected by FISH.Our result demonstrated that patient with type I AS could be detected by combining the techniques of high-resolution G-banding and FISH with clinical observation, which would offer accurate genetic counseling information to the geneticists and provide the prenatal diagnosis for the AS family", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19806569", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 349, "text": "To investigate the prenatal diagnosis of trisomy 21 syndrome using chromosome 13/21 alpha satellite probe fluorescence in situ hybridization (FISH) on uncultured interphase cells from amniotic fluid.The interphase amniocytes of 10 fetuses who were detected normal and 3 fetus who were detected trisomy by prenatal cytogenetic diagnosis were selected", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11783350", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 594, "text": "To optimize the prenatal diagnosis platform by using domestically made fluorescence in situ hybridization(FISH) kit and to explore the clinical application of FISH to rapid prenatal diagnosis of a wide range of chromosomal abnormalities.Amniotic fluid samples from 110 pregnant women were studied with the rapid prenatal diagnosis method of FISH and the conventional cell culture method of karyotyping, the results from both methods were compared.Four cases of trisomy 21, 1 case of trisomy 18, 58 cases of 46, XX, and 47 cases of 46, XY were detected by FISH in the 110 amniotic fluid samples.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20677157", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Implementation of Fluorescent in situ hybridization (FISH) as a method for detecting microdeletion syndromes - our first experiences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18356781", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Prenatal detection of cri du chat syndrome on uncultured amniocytes using fluorescence in situ hybridization (FISH).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8149646", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Fluorescence in situ hybridization (FISH) using non-commercial probes in the diagnosis of clinically suspected microdeletion syndromes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24056568", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Unbalanced translocation, t(18;21), detected by fluorescence in situ hybridization (FISH) in a child with 18q- syndrome and a ring chromosome 21.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8362906", "endSection": "title"}, {"offsetInBeginSection": 725, "offsetInEndSection": 1032, "text": "Using this technique, followed by cell-by-cell multicolor fluorescence in situ hybridization (FISH) analysis of purified FNRBCs, we were able to detect some of the most common human aneuploidies (including Down syndrome, Klinefelter syndrome, and trisomy 13) in 33 pregnant women referred for amniocentesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11424143", "endSection": "abstract"}, {"offsetInBeginSection": 923, "offsetInEndSection": 1293, "text": "FISH with 5p subtelomeric probes and 18p subtelomeric probe further confirmed that the derivative chromosome 5 has derived from a translocation between 5p and 18p, which has given rise to a 46,XY,der(5)t(5;18)(p15.1;p11.31)dn karyotype.A de novo 5p partial deletion in conjunction with a cryptic 18p duplication has been detected in a boy featuring Cri-du-Chat syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450488", "endSection": "abstract"}, {"offsetInBeginSection": 1425, "offsetInEndSection": 1556, "text": "We conclude that FISH is a useful, easily applied technique for the diagnosis of 22q11.2 microdeletion syndromes, particularly DGS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8634784", "endSection": "abstract"}, {"offsetInBeginSection": 1195, "offsetInEndSection": 1765, "text": "In group B (n=79), the 5q deletion had been observed by cytogenetics and was confirmed to be present in all cases by fluorescence in situ hybridization of 5q31.CONCLUSIONS: Fluorescence in situ hybridization of 5q31 detected the 5q deletion in 6% of cases without clear evidence of del(5q) by conventional banding cytogenetics. We suggest that fluorescence in situ hybridization of 5q31 should be performed in cases of a suspected '5q- syndrome' and/or if the cytogenetic study shows no metaphases or an aberrant karyotype with chromosome 5 involved (no 5q- chromosome).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18591625", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "Although conventional cytogenetics is considered the gold standard to detect chromosomal abnormalities in myelodysplastic syndromes (MDS), fluorescence in situ hybridization (FISH) is being increasingly used additionally.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20226525", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Cytogenetic aberrations in myelodysplastic syndrome detected by comparative genomic hybridization and fluorescence in situ hybridization.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10408793", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "To detect chromosomal abnormalities in myelodysplastic syndrome (MDS) patients by fluorescence in situ hybridization (FISH) and conventional cytogenetic analysis (CCA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25011965", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Comparison of high resolution chromosome banding and fluorescence in situ hybridization (FISH) for the laboratory evaluation of Prader-Willi syndrome and Angelman syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7977469", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "Deletion of small nuclear ribonucleoprotein polypeptide N (SNRPN) in Prader-Willi syndrome detected by fluorescence in situ hybridization: two sibs with the typical phenotype without a cytogenetic deletion in chromosome 15q.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8723064", "endSection": "title"}, {"offsetInBeginSection": 133, "offsetInEndSection": 254, "text": "We describe two sibs with typical PWS presenting deletion of SNRPN detected by fluorescence in situ hybridization (FISH).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8723064", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Use of fluorescence in situ hybridization (FISH) in the diagnosis of DiGeorge sequence and related diseases.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8634784", "endSection": "title"}]}, {"body": "List symptoms of EAST syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27500072", "http://www.ncbi.nlm.nih.gov/pubmed/21300747", "http://www.ncbi.nlm.nih.gov/pubmed/21633011", "http://www.ncbi.nlm.nih.gov/pubmed/23471908", "http://www.ncbi.nlm.nih.gov/pubmed/23924083", "http://www.ncbi.nlm.nih.gov/pubmed/20651251", "http://www.ncbi.nlm.nih.gov/pubmed/21849804", "http://www.ncbi.nlm.nih.gov/pubmed/21221631"], "ideal_answer": ["Epilepsy, ataxia, sensorineural deafness, and tubulopathy comprise EAST syndrome that is associated with recessive mutations in the KCNJ10 gene."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012816"], "type": "list", "id": "589a246378275d0c4a00002c", "snippets": [{"offsetInBeginSection": 191, "offsetInEndSection": 362, "text": "This condition is characterized by 4 cardinal features; Epilepsy, Ataxia, Sensorineural deafness, and (a renal salt-wasting) Tubulopathy, hence the acronym EAST syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27500072", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Generation and validation of a zebrafish model of EAST (epilepsy, ataxia, sensorineural deafness and tubulopathy) syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23471908", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 316, "text": "Recessive mutations in KCNJ10, which encodes an inwardly rectifying potassium channel, were recently identified as the cause of EAST syndrome, a severe and disabling multi-organ disorder consisting of epilepsy, ataxia, sensorineural deafness and tubulopathy that becomes clinically apparent with seizures in infancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23471908", "endSection": "abstract"}, {"offsetInBeginSection": 666, "offsetInEndSection": 861, "text": "We next injected splice- and translation-blocking kcnj10 antisense morpholino oligonucleotides and reproduced the cardinal symptoms of EAST syndrome - ataxia, epilepsy and renal tubular defects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23471908", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "AIM: Recently, we reported a previously unrecognized symptom constellation comprising epilepsy, ataxia, sensorineural deafness, and tubulopathy (EAST syndrome) associated with recessive mutations in the KCNJ10 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23924083", "endSection": "abstract"}, {"offsetInBeginSection": 1253, "offsetInEndSection": 1498, "text": "EAST syndrome should be considered in any patient with a renal Gitelman-like phenotype with additional neurological signs and symptoms like ataxia, epilepsy or sensorineural deafness.<CopyrightInformation>Copyright \u00a9 2011 S. Karger AG, Basel.</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21849804", "endSection": "abstract"}, {"offsetInBeginSection": 135, "offsetInEndSection": 343, "text": "Recently, mutations in KCNJ10 were recognised as pathogenic in man, causing a constellation of symptoms, including epilepsy, ataxia, sensorineural deafness and a renal tubulopathy designated as EAST syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300747", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "Recently, we reported a previously unrecognized symptom constellation comprising epilepsy, ataxia, sensorineural deafness, and tubulopathy (EAST syndrome) associated with recessive mutations in the KCNJ10 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23924083", "endSection": "abstract"}, {"offsetInBeginSection": 1250, "offsetInEndSection": 1434, "text": "EAST syndrome should be considered in any patient with a renal Gitelman-like phenotype with additional neurological signs and symptoms like ataxia, epilepsy or sensorineural deafness..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21849804", "endSection": "abstract"}]}, {"body": "When did the polio vaccine becomes available?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12931339", "http://www.ncbi.nlm.nih.gov/pubmed/14997988", "http://www.ncbi.nlm.nih.gov/pubmed/11326104"], "ideal_answer": ["Inactivated poliovirus vaccine (IPV), developed in the USA by Jonas Salk in the early 1950s, was field tested in 1954,", "The Salk polio Vaccine was field tested in 1954."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000071497", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011051", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011052", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011054", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011055", "http://www.disease-ontology.org/api/metadata/DOID:9786", "http://www.disease-ontology.org/api/metadata/DOID:0050513", "http://www.disease-ontology.org/api/metadata/DOID:0050514"], "type": "factoid", "id": "58a1c0f178275d0c4a000056", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Inactivated poliovirus vaccine (IPV), developed in the USA by Jonas Salk in the early 1950s, was field tested in 1954,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14997988", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 340, "text": "the use of an oral polio vaccine (OPV) during a vaccination campaign launched by the Wistar Institute, Philadelphia, PA, USA, in the Belgian Congo in 1958 and 1959. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11326104", "endSection": "abstract"}]}, {"body": "Is Annexin V an apoptotic marker?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24412631", "http://www.ncbi.nlm.nih.gov/pubmed/16046522", "http://www.ncbi.nlm.nih.gov/pubmed/23000925", "http://www.ncbi.nlm.nih.gov/pubmed/20122665", "http://www.ncbi.nlm.nih.gov/pubmed/26582221", "http://www.ncbi.nlm.nih.gov/pubmed/27619241", "http://www.ncbi.nlm.nih.gov/pubmed/9776585", "http://www.ncbi.nlm.nih.gov/pubmed/26734508", "http://www.ncbi.nlm.nih.gov/pubmed/24021657", "http://www.ncbi.nlm.nih.gov/pubmed/7812008", "http://www.ncbi.nlm.nih.gov/pubmed/16740972", "http://www.ncbi.nlm.nih.gov/pubmed/20444920", "http://www.ncbi.nlm.nih.gov/pubmed/16331047", "http://www.ncbi.nlm.nih.gov/pubmed/22913657", "http://www.ncbi.nlm.nih.gov/pubmed/9461328", "http://www.ncbi.nlm.nih.gov/pubmed/11585299", "http://www.ncbi.nlm.nih.gov/pubmed/14676140", "http://www.ncbi.nlm.nih.gov/pubmed/25339644", "http://www.ncbi.nlm.nih.gov/pubmed/12573319", "http://www.ncbi.nlm.nih.gov/pubmed/25591763", "http://www.ncbi.nlm.nih.gov/pubmed/26935620", "http://www.ncbi.nlm.nih.gov/pubmed/9359032", "http://www.ncbi.nlm.nih.gov/pubmed/21340828", "http://www.ncbi.nlm.nih.gov/pubmed/25116573", "http://www.ncbi.nlm.nih.gov/pubmed/16737615", "http://www.ncbi.nlm.nih.gov/pubmed/21203987", "http://www.ncbi.nlm.nih.gov/pubmed/22960471", "http://www.ncbi.nlm.nih.gov/pubmed/16253964", "http://www.ncbi.nlm.nih.gov/pubmed/12552341", "http://www.ncbi.nlm.nih.gov/pubmed/14666384", "http://www.ncbi.nlm.nih.gov/pubmed/18441250", "http://www.ncbi.nlm.nih.gov/pubmed/16813956", "http://www.ncbi.nlm.nih.gov/pubmed/20520578", "http://www.ncbi.nlm.nih.gov/pubmed/7622868", "http://www.ncbi.nlm.nih.gov/pubmed/9462458", "http://www.ncbi.nlm.nih.gov/pubmed/14734682", "http://www.ncbi.nlm.nih.gov/pubmed/18554742", "http://www.ncbi.nlm.nih.gov/pubmed/16239600", "http://www.ncbi.nlm.nih.gov/pubmed/11708469", "http://www.ncbi.nlm.nih.gov/pubmed/20430734", "http://www.ncbi.nlm.nih.gov/pubmed/10541822", "http://www.ncbi.nlm.nih.gov/pubmed/16306419", "http://www.ncbi.nlm.nih.gov/pubmed/26112094"], "ideal_answer": ["Yes, annexin V is an early apoptotic marker.", "Yes, Annexin V is an apoptotic marker."], "concepts": ["http://www.uniprot.org/uniprot/ANXA5_CYNPY", "http://www.uniprot.org/uniprot/ANXA5_MOUSE", "http://www.uniprot.org/uniprot/ANXA5_HUMAN", "http://www.uniprot.org/uniprot/ANXA5_MACFA", "http://www.uniprot.org/uniprot/ANXA5_BOVIN", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017304", "http://www.uniprot.org/uniprot/ANXA5_CHICK", "http://www.uniprot.org/uniprot/ANXA5_PANTR", "http://www.uniprot.org/uniprot/ANXA5_RAT"], "type": "yesno", "id": "5894597e7d9090f353000004", "snippets": [{"offsetInBeginSection": 430, "offsetInEndSection": 579, "text": "The apoptosis of the MSCs was induced by subjecting the cells to OGD conditions for 4 h and was detected by Annexin V/PI and Hoechst 33258 staining. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935620", "endSection": "abstract"}, {"offsetInBeginSection": 969, "offsetInEndSection": 1304, "text": "In addition to the antimicrobial activity, we found that treatment of the cancer cell lines, Jurkat T-cells, Granta cells, and melanoma cells, with the Pseudomonas sp. In5 crude extract increased staining with the apoptotic marker Annexin V while no staining of healthy normal cells, i.e., na\u00efve or activated CD4 T-cells, was observed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26734508", "endSection": "abstract"}, {"offsetInBeginSection": 1175, "offsetInEndSection": 1402, "text": "At the same time, the expressions of CD105, CD31, and the apoptotic marker of Annexin V were detected through flow cytometry for analyzing the relationship between the expression of cell surface markers and biological behavior.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26582221", "endSection": "abstract"}, {"offsetInBeginSection": 354, "offsetInEndSection": 505, "text": "However, we found decreased sperm concentration, increase of morphologically abnormal spermatozoa and increased binding of apoptotic marker annexin V. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24412631", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 895, "text": "hCG enhanced viability of granulosa-lutein cells through antiapoptosis but not proliferation, because the apoptotic marker of annexin V was decreased, but the proliferative markers of Ki67 and proliferating cell nuclear antigen were not increased.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20444920", "endSection": "abstract"}, {"offsetInBeginSection": 650, "offsetInEndSection": 863, "text": "However, as the DOTAP concentration increased from 50 to 800 microM, the apoptotic marker Annexin V and ROS double positive cells increased, suggesting that high dose of DOTAP-generated ROS causes cell apoptosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18554742", "endSection": "abstract"}, {"offsetInBeginSection": 1093, "offsetInEndSection": 1326, "text": "Expression of the apoptotic marker annexin V was unaffected by antibiotic exposure, whereas the uptake of the necrotic marker PI was increased by ofloxacin (5 mg/mL) but not by netilmicin (ofloxacin versus netilmicin, ANOVA, P<0.05).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16331047", "endSection": "abstract"}, {"offsetInBeginSection": 751, "offsetInEndSection": 797, "text": "he apoptotic marker of annexin V was decreased", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20444920", "endSection": "abstract"}, {"offsetInBeginSection": 719, "offsetInEndSection": 749, "text": "the apoptotic marker Annexin V", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18554742", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Annexin V labels apoptotic neurons following hypoxia-ischemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9462458", "endSection": "title"}, {"offsetInBeginSection": 430, "offsetInEndSection": 584, "text": "In the present study, the apoptotic cell population was identified immunocytochemically using Annexin V, a marker of cells in an early stage of apoptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11708469", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Use of annexin V antibody to identify apoptotic cells during pregnancy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11708469", "endSection": "title"}, {"offsetInBeginSection": 629, "offsetInEndSection": 726, "text": "Only few SF Treg cells were apoptotic, as indicated by limited annexin V staining of these cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25339644", "endSection": "abstract"}, {"offsetInBeginSection": 470, "offsetInEndSection": 697, "text": "Eosinophils 'aged' in vitro for 48 h exhibited endonuclease DNA degradation, apoptotic morphology, increased red autofluorescence and externalisation of phosphatidylserine (PS) as assessed by binding of FITC-labelled annexin V.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9776585", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 672, "text": "In vivo detection of apoptotic cells with fluorescently labeled annexin V is an emerging technique that we evaluated for detecting apoptotic germ cells in a mouse model of testicular torsion.Annexin V labeled with an indocyanine fluorophore (bisfunctional succinimidyl ester of cyanine 5.5) (Amersham, Little Chalfont, United Kingdom) was injected intravenously in mice 18 hours after the repair of unilateral 720-degree testicular torsion for 2 hours", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16813956", "endSection": "abstract"}, {"offsetInBeginSection": 238, "offsetInEndSection": 1091, "text": "Here, we tested the hypothesis that enhanced endothelial apoptotic microparticles and decreased endothelial progenitor cell (EPC) levels might contribute to the pathophysiology of microalbuminuria or macroalbuminuria in cardiovascular disease.Flow cytometry was used to assess endothelial cell apoptosis and circulating EPC levels by quantification of circulating CD31/annexin V apoptotic microparticles and EPC markers (defined as KDRCD133, CD34CD133, CD34KDR) in peripheral blood.In total, 125 patients with hypertension were enrolled in the study, of whom 80 patients (64%) were with normoalbuminuria (albumin excretion rate of &lt;20 microg/min, overnight urine samples), 35 patients (28%) with microalbuminuria (an albumin excretion rate of 20-200 microg/min), and 10 patients (8%) with macroalbuminuria (an albumin excretion rate >200 microg/min).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20520578", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Surfactant protein A (SP-A) binds to phosphatidylserine and competes with annexin V binding on late apoptotic cells", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21203987", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14676140", "endSection": "title"}, {"offsetInBeginSection": 86, "offsetInEndSection": 469, "text": "Because annexin V has a high affinity for exposed phosphatidylserine on apoptotic cells, radiolabeled annexin V may be used for noninvasive detection of apoptosis in atherosclerotic lesions.Atherosclerotic plaques were produced in 5 rabbits by deendothelialization of the infradiaphragmatic aorta followed by 12 weeks of cholesterol diet; 5 controls were studied without manipulation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14676140", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Apoptotic abscess imaging with 99mTc-HYNIC-rh-Annexin-V.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20122665", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12573319", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Sensitive and visible detection of apoptotic cells on Annexin-V modified substrate using aminophenylboronic acid modified gold nanoparticles (APBA-GNPs) labeling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24021657", "endSection": "title"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1148, "text": "Fluorescence-activated cell sorting (FACS) for expression of the early apoptosis marker Annexin V and for nuclear staining by 7-aminoactinomycin (7-AAD) revealed different extents of apoptosis versus non-apoptotic cell death for the three agents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22960471", "endSection": "abstract"}, {"offsetInBeginSection": 680, "offsetInEndSection": 876, "text": "At immunofluorescence these cells contained lipid vesicles positive for the apoptotic cell marker Annexin V suggesting the phagocytosis of apoptotic bodies derived from dead fat-laden hepatocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26112094", "endSection": "abstract"}, {"offsetInBeginSection": 1612, "offsetInEndSection": 1708, "text": "In this respect, we identified binding of Annexin V as an convenient marker for apoptotic cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7812008", "endSection": "abstract"}, {"offsetInBeginSection": 540, "offsetInEndSection": 697, "text": "DR5 expression was elevated and associated with the apoptotic marker annexin V. Apoptosis was reduced in CD4(+) T cells when cultured with anti-DR5 antibody.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16046522", "endSection": "abstract"}, {"offsetInBeginSection": 924, "offsetInEndSection": 1080, "text": "Flow cytometric analysis using the apoptotic marker, Annexin V, shows that this endogenous re-expression is sufficient to drive the SCLC cells to apoptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25116573", "endSection": "abstract"}, {"offsetInBeginSection": 664, "offsetInEndSection": 853, "text": "Apoptotic cell death was evaluated by staining nuclei with propidium iodide and phosphatidylserine (a marker of early apoptotic events) with Annexin V as well as by DNA fragmentation assay.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16253964", "endSection": "abstract"}, {"offsetInBeginSection": 429, "offsetInEndSection": 638, "text": "Decreased cell growth was not caused by cell death as BEL exposure did not alter nuclear morphology or increase annexin V (apoptotic cell marker) or propidium iodide (necrotic cell marker) staining after 48 h.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18441250", "endSection": "abstract"}, {"offsetInBeginSection": 2979, "offsetInEndSection": 3261, "text": "Four populations of cells can be identified: region R1: vital cells (annexin V negative/PI negative), region R2: apoptotic cells (annexin V positive/PI negative), region R3: dead cells (annexin V positive/ PI positive); and region R4: damaged cells (annexin V negative/PI positive).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21340828", "endSection": "abstract"}, {"offsetInBeginSection": 2109, "offsetInEndSection": 2222, "text": "Furthermore, uptake of (111)In-DTPA-PEG-annexin V by tumors correlated with apoptotic index (r = 0.87, P = 0.02).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14734682", "endSection": "abstract"}, {"offsetInBeginSection": 1177, "offsetInEndSection": 1309, "text": "Annexin V(+)/PI(-) cells were characterized as early apoptotic, Annexin V(+)/PI(+) as late apoptotic and Annexin V(-)/PI(+) as dead.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20430734", "endSection": "abstract"}, {"offsetInBeginSection": 501, "offsetInEndSection": 580, "text": "Targeting ability of Annexin V for apoptotic macrophages was kept and enhanced.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27619241", "endSection": "abstract"}, {"offsetInBeginSection": 817, "offsetInEndSection": 923, "text": "[18F]annexin V accumulated in the infarct area of the left ventricle, where apoptotic cells were observed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14666384", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 714, "text": "The viability of SiHa cells was evaluated using the MTT assay, apoptosis by acridine orange/ethidium bromide, propidium iodide, TUNEL assay, and Annexin V-Cy3, cell cycle distribution and mitochondrial transmembrane potential using flow cytometry, and apoptotic marker genes using quantitative real-time PCR. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22913657", "endSection": "abstract"}, {"offsetInBeginSection": 1242, "offsetInEndSection": 1325, "text": "Furthermore, hesperetin-induced apoptosis was confirmed by TUNEL and Annexin V-Cy3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22913657", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 274, "text": "The procedure delivers two sperm fractions: annexin V-negative (nonapoptotic) and annexin V-positive (apoptotic).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16306419", "endSection": "abstract"}, {"offsetInBeginSection": 603, "offsetInEndSection": 811, "text": "The percentage of cells stained with annexin V, an early apoptotic marker, increased dramatically after cytoskeletal disruption with cytochalasin D compared with non-cytochalasin-D-treated controls (P<0.05). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16740972", "endSection": "abstract"}, {"offsetInBeginSection": 373, "offsetInEndSection": 498, "text": "Apoptotic marker Annexin V analysis showed that the apoptotic rate of NB4 cells was increased after treatment with quercetin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16737615", "endSection": "abstract"}, {"offsetInBeginSection": 149, "offsetInEndSection": 291, "text": "The cytomorphology of NB4 cells was assessed by Wright-stain, apoptosis rate by apoptotic marker Annexin V, and VEGF secretion level by ELISA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16737615", "endSection": "abstract"}, {"offsetInBeginSection": 707, "offsetInEndSection": 923, "text": " We have coupled annexin V with the bifunctional hydrazinonicotinamide reagent (HYNIC) to prepare technetium-99m HYNIC-annexin V and demonstrated localization of radioactivity in tissues undergoing apoptosis in vivo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10541822", "endSection": "abstract"}, {"offsetInBeginSection": 2914, "offsetInEndSection": 3070, "text": "In conlusion, these studies confirm the value of (99m)Tc-HYNIC-annexin V uptake as a marker for the detection and quantification of apoptotic cells in vivo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10541822", "endSection": "abstract"}, {"offsetInBeginSection": 1111, "offsetInEndSection": 1265, "text": "The application of Annexin V labeling at electron microscopy will allow a more refined description of the morphological events occurring during apoptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9359032", "endSection": "abstract"}, {"offsetInBeginSection": 690, "offsetInEndSection": 753, "text": "Apoptotic cells were identified by Annexin V-FITC/PI staining. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25591763", "endSection": "abstract"}]}, {"body": "Which are the lipid lowering drugs administered in patients with Coronary Artery Disease (CAD)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23074505", "http://www.ncbi.nlm.nih.gov/pubmed/23409830", "http://www.ncbi.nlm.nih.gov/pubmed/15174957", "http://www.ncbi.nlm.nih.gov/pubmed/19801853", "http://www.ncbi.nlm.nih.gov/pubmed/19090788", "http://www.ncbi.nlm.nih.gov/pubmed/23538020", "http://www.ncbi.nlm.nih.gov/pubmed/10987597", "http://www.ncbi.nlm.nih.gov/pubmed/20574136", "http://www.ncbi.nlm.nih.gov/pubmed/10637948", "http://www.ncbi.nlm.nih.gov/pubmed/19563393", "http://www.ncbi.nlm.nih.gov/pubmed/25934512", "http://www.ncbi.nlm.nih.gov/pubmed/15809368", "http://www.ncbi.nlm.nih.gov/pubmed/18674471", "http://www.ncbi.nlm.nih.gov/pubmed/11113401", "http://www.ncbi.nlm.nih.gov/pubmed/11597936", "http://www.ncbi.nlm.nih.gov/pubmed/24527682", "http://www.ncbi.nlm.nih.gov/pubmed/27923158", "http://www.ncbi.nlm.nih.gov/pubmed/18973424", "http://www.ncbi.nlm.nih.gov/pubmed/20671371", "http://www.ncbi.nlm.nih.gov/pubmed/16098846", "http://www.ncbi.nlm.nih.gov/pubmed/25999102", "http://www.ncbi.nlm.nih.gov/pubmed/20124992"], "ideal_answer": ["The lipid lowering drugs administered in patients with Coronary Artery Disease (CAD) are:\n1) Statins\n2) Fibrates\n3) Resins\n4) Niacin\n5) Cholesterol absorption-inhibiting drugs."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:3393", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003324", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003327"], "type": "list", "id": "589c42b178275d0c4a00003f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23538020", "endSection": "title"}, {"offsetInBeginSection": 544, "offsetInEndSection": 658, "text": "After maximizing statin dose, ezetimibe was added to reach the LDL cholesterol goal in 34% of patients (n\u00a0= 734). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23538020", "endSection": "abstract"}, {"offsetInBeginSection": 1212, "offsetInEndSection": 1607, "text": "Using Cox regression analysis, the most significant factors associated with achieving LDL cholesterol goals were lower baseline LDL cholesterol, average statin dose, and ezetimibe use. In conclusion, after maximizing statin dose, the addition of ezetimibe results in a substantial increase in the percentage of patients who reach LDL cholesterol goal, a key component of optimal medical therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23538020", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574136", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 297, "text": "Remnant lipoproteinemia is a strong risk factor for cardiovascular (CV) diseases. This study examined which of 2 common lipid-lowering drugs (fibrates and statins) is more effective in patients with remnant lipoproteinemia and if lowering remnant lipoprotein levels can reduce CV risk.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574136", "endSection": "abstract"}, {"offsetInBeginSection": 767, "offsetInEndSection": 896, "text": "RLP-C levels at 1 year of treatment were reduced more by bezafibrate than pravastatin (37% and 25% from baseline, respectively). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574136", "endSection": "abstract"}, {"offsetInBeginSection": 1245, "offsetInEndSection": 1438, "text": "Bezafibrate therapy decreased RLP-C levels to a greater extent than pravastatin and a decrease in RLP-C level may be associated with a reduction in CV events in patients with high RLP-C levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574136", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Statins are powerful lipid-lowering drugs, widely used in patients with hyperlipidemia and coronary artery disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18973424", "endSection": "abstract"}, {"offsetInBeginSection": 3479, "offsetInEndSection": 3636, "text": "Patients are frequently treated with lipid-lowering drugs such as resins, fibrates, niacin, statins and cholesterol absorption-inhibiting drugs (ezetimibe). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074505", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 590, "text": "This study sought to investigate the effect of daily glucose fluctuation on coronary plaque properties in patients with coronary artery disease (CAD) pre-treated with lipid-lowering therapy.There is growing evidence that glucose fluctuation, as a residual risk apart from dyslipidemia, is an important factor contributing to the development of CAD.This prospective study enrolled 70 consecutive CAD patients who were referred for percutaneous coronary intervention and whose low-density lipoprotein cholesterol level was &lt;120 mg/dl under statin treatment or &lt;100 mg/dl without statins", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25999102", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 319, "text": "To investigate the impact of lipid lowering therapy by different means on skin microvascular function in patients with dysglycaemia and coronary artery disease (CAD).Thirty-six patients were randomized to simvastatin 80 mg daily (S80, n = 19) or ezetimibe 10 mg and simvastatin 10 mg daily (E10/S10, n = 17) for 6 weeks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19563393", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Large clinical trials have elucidated that lipid-lowering therapy using statins reduces cardiovascular events in patients with coronary artery disease (CAD)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20671371", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 342, "text": "The aim of the present study was to investigate whether LLT (lipid-lowering therapy) with statins could attenuate EPC telomere erosion in patients with CAD (coronary artery disease)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19090788", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11113401", "endSection": "title"}]}, {"body": "What are PD-1 inhibitors?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27534574", "http://www.ncbi.nlm.nih.gov/pubmed/25682878", "http://www.ncbi.nlm.nih.gov/pubmed/22740686", "http://www.ncbi.nlm.nih.gov/pubmed/26775720", "http://www.ncbi.nlm.nih.gov/pubmed/27936870", "http://www.ncbi.nlm.nih.gov/pubmed/26588948", "http://www.ncbi.nlm.nih.gov/pubmed/26177645", "http://www.ncbi.nlm.nih.gov/pubmed/26581237", "http://www.ncbi.nlm.nih.gov/pubmed/18203952", "http://www.ncbi.nlm.nih.gov/pubmed/26567614", "http://www.ncbi.nlm.nih.gov/pubmed/27310809", "http://www.ncbi.nlm.nih.gov/pubmed/24402925", "http://www.ncbi.nlm.nih.gov/pubmed/27059553", "http://www.ncbi.nlm.nih.gov/pubmed/27063329", "http://www.ncbi.nlm.nih.gov/pubmed/27729774", "http://www.ncbi.nlm.nih.gov/pubmed/23032366", "http://www.ncbi.nlm.nih.gov/pubmed/26598057", "http://www.ncbi.nlm.nih.gov/pubmed/27622603", "http://www.ncbi.nlm.nih.gov/pubmed/25823918", "http://www.ncbi.nlm.nih.gov/pubmed/26477470", "http://www.ncbi.nlm.nih.gov/pubmed/27573048", "http://www.ncbi.nlm.nih.gov/pubmed/26850630", "http://www.ncbi.nlm.nih.gov/pubmed/26041735"], "ideal_answer": ["The programmed death-1 (PD-1) pathway negatively regulates T-cell activation and has an important role in regulating antitumor host immunity. Monoclonal antibodies directed against PD-1 or the PD-1 ligand (PD-L1) are used to treat cancer. "], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061026", "http://www.uniprot.org/uniprot/PDCD1_MOUSE"], "type": "summary", "id": "58a3196360087bc10a00000b", "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 354, "text": " The programmed death-1 (PD-1) pathway negatively regulates T-cell activation and has an important role in regulating antitumor host immunity. Monoclonal antibodies directed against PD-1 or the PD-1 ligand (PD-L1) have shown activity in several tumor types with preliminary data suggesting a relationship between PD-L1 expression and response.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775720", "endSection": "abstract"}, {"offsetInBeginSection": 121, "offsetInEndSection": 329, "text": "Pembrolizumab is a selective humanized IgG4 kappa monoclonal antibody that inhibits the programmed death-1 (PD-1) receptor, an integral component of immune checkpoint regulation in the tumor microenvironment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26588948", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Checkpoint inhibitors with monoclonal antibodies targeting the CTLA-4 or PD-1 axis have revolutionized treatment in some solid tumors, especially melanoma and lung", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26581237", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "In recent years, the introduction and Federal Drug Administration approval of immune checkpoint inhibitor antibodies has dramatically improved the clinical outcomes for patients with advanced melanoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850630", "endSection": "abstract"}, {"offsetInBeginSection": 481, "offsetInEndSection": 618, "text": "Nivolumab and pembrolizumab target programmed cell death protein 1 (PD-1) receptors and have proven to be superior to ipilimumab alone. T", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850630", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25823918", "endSection": "title"}, {"offsetInBeginSection": 570, "offsetInEndSection": 738, "text": "PD-1 inhibitors are also poised to become standard of care treatment for other cancers, including non-small cell lung cancer, renal cell carcinoma and Hodgkins lymphoma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25682878", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 39, "text": "PD-1 inhibitors raise survival in NSCLC", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24402925", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 40, "text": "PD-1 inhibitors raise survival in NSCLC.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24402925", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18203952", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 268, "text": "The development of programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) checkpoint inhibitors has changed the landscape of non-small-cell lung cancer (NSCLC) therapy, with 2 approvals from the US Food and Drug Administration of PD-1 inhibitors for second-line therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27310809", "endSection": "abstract"}, {"offsetInBeginSection": 205, "offsetInEndSection": 506, "text": "In this article, we will review the unique biologic features that predispose cHL to PD-1 inhibition, current data regarding the safety and efficacy of PD-1 inhibitors in the treatment of cHL, biomarkers of immune response, ongoing clinical trials with PD-1 inhibitors, as well as areas of uncertainty.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27622603", "endSection": "abstract"}, {"offsetInBeginSection": 192, "offsetInEndSection": 368, "text": "To determine how PD-1 signaling inhibits T cell proliferation, we used human CD4(+) T cells to examine the effects of PD-1 signaling on the molecular control of the cell cycle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22740686", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23032366", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "The field of immuno-oncology has witnessed unprecedented success in recent years, with several programmed cell death 1 and PD-L1 inhibitors obtaining US FDA registration and breakthrough drug therapy designation in multiple tumor types.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27936870", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "The use of antibodies against programmed cell death 1 (PD-1), such as nivolumab and pembrolizumab, has dramatically improved the prognosis of patients with advanced melanoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27291635", "endSection": "abstract"}, {"offsetInBeginSection": 126, "offsetInEndSection": 420, "text": " Since 2010, treatment options for metastatic melanoma have been developed including chemotherapies, checkpoint inhibition immunotherapies, e.g., anti\u2011cytotoxic T\u2011lymphocyte antigen\u20114\u00a0(CTLA\u20114) and anti\u2011programmed death\u20111\u00a0(PD\u20111), and molecular-targeted therapies, e.g., BRAF and MEK inhibitors. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573048", "endSection": "abstract"}, {"offsetInBeginSection": 1455, "offsetInEndSection": 1686, "text": "his strategy may be particularly advantageous for vaccines targeting prostate cancer, a disease for which antitumor vaccines have demonstrated clinical benefit and yet PD-1 pathway inhibitors alone have shown little efficacy to dat", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26041735", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Manipulation of co-stimulatory or co-inhibitory checkpoint proteins allows for the reversal of tumor-induced T-cell anergy observed in cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26567614", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Colorectal cancers (CRCs) have been identified as potential targets for immunotherapy with programmed cell death (PD)-1 inhibitors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27553906", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 300, "text": "Blockading the interaction of programmed death-1 (PD-1) protein with its ligands (PD-Ls, such as PD-L1) was proved to be a pathway for suppressing the development of tumors and other degradations of biological species. Thus, finding PD-1 inhibitors situated at the convergence point of drug discovery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27063329", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 124, "text": "Anti-programmed cell death receptor-1 (PD-1) antibodies have demonstrated antitumor activity in many cancer entitie", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729774", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 135, "text": " Emerging agents blocking the programmed cell death 1 (PD-1) pathway show activity in metastatic clear cell renal cell carci", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27059553", "endSection": "abstract"}, {"offsetInBeginSection": 267, "offsetInEndSection": 424, "text": "The effectiveness of a CTLA-targeted antibody in treating melanoma was an impetus for the use of programmed cell death-1 (PD-1) inhibitors in cancer treatmen", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598057", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 189, "text": " Monoclonal antibodies that target the programmed death-1 (PD-1)/programmed death-ligand 1(PD-L1) pathway have shown antitumour activity in metastatic renal cell carcinoma (mRCC)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346135", "endSection": "abstract"}]}, {"body": "Is the protein lefty an inhibitor of nodal?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26506307", "http://www.ncbi.nlm.nih.gov/pubmed/25669884", "http://www.ncbi.nlm.nih.gov/pubmed/25672326", "http://www.ncbi.nlm.nih.gov/pubmed/26377939", "http://www.ncbi.nlm.nih.gov/pubmed/25684355"], "ideal_answer": ["Yes, lefty is an inhibitor of nodal."], "type": "yesno", "id": "58a93877ee23e0236b000001", "snippets": [{"offsetInBeginSection": 99, "offsetInEndSection": 178, "text": "The expression of lefty, an inhibitor of nodal is often reduced in tumor cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25672326", "endSection": "abstract"}, {"offsetInBeginSection": 384, "offsetInEndSection": 416, "text": " Nodal, and an inhibitor, Lefty.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25684355", "endSection": "abstract"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1097, "text": "as well as the expression of Lefty, an inhibitor of nodal signaling,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26377939", "endSection": "abstract"}, {"offsetInBeginSection": 624, "offsetInEndSection": 648, "text": "he Nodal inhibitor lefty", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25669884", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 367, "text": "The morphogen Nodal was proposed to form a long-range signaling gradient via a reaction-diffusion system, on the basis of differential diffusion rates of Nodal and its antagonist Lefty.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26506307", "endSection": "abstract"}]}, {"body": "List drugs withdrawn from the market for cardiovascular adverse events.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21265828", "http://www.ncbi.nlm.nih.gov/pubmed/21412876", "http://www.ncbi.nlm.nih.gov/pubmed/26934640", "http://www.ncbi.nlm.nih.gov/pubmed/19034038", "http://www.ncbi.nlm.nih.gov/pubmed/21249650", "http://www.ncbi.nlm.nih.gov/pubmed/25084209", "http://www.ncbi.nlm.nih.gov/pubmed/16255660", "http://www.ncbi.nlm.nih.gov/pubmed/19933959", "http://www.ncbi.nlm.nih.gov/pubmed/25806762", "http://www.ncbi.nlm.nih.gov/pubmed/23424288", "http://www.ncbi.nlm.nih.gov/pubmed/16119973", "http://www.ncbi.nlm.nih.gov/pubmed/21751825", "http://www.ncbi.nlm.nih.gov/pubmed/25114779", "http://www.ncbi.nlm.nih.gov/pubmed/25340915", "http://www.ncbi.nlm.nih.gov/pubmed/18782007"], "ideal_answer": ["Over the years, a number of different drugs have been withdrawn for Cardiotoxicity. Drugs like Clobutinol, that  induce cardiac arrhythmias by a blockade of the potassium channel coded by the hERG channel, sibutramine for weight loss and Cox2 inhibitors, Rofecoxib and Valdecoxib have been withdrawn from the market."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064420", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000069451"], "type": "list", "id": "58a326da60087bc10a00000e", "snippets": [{"offsetInBeginSection": 351, "offsetInEndSection": 538, "text": " rofecoxib was voluntarily removed from the market for increased cardiovascular risk and in April 2005, valdecoxib was also withdrawn, at least in part, due to excess cardiovascular risk.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16255660", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 255, "text": "A common over-the-counter (OTC) non-opioid antitussive drug, clobutinol, was recently withdrawn from the market due to its potential to induce cardiac arrhythmias by a blockade of the potassium channel coded by the human ether-\u00e0-go-go-related gene (hERG).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19034038", "endSection": "abstract"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1186, "text": "n. However, despite this, at the time of writing orlistat (Europe; USA) remains the only drug currently marketed for the treatment of obesity, with sibutramine having recently been withdrawn from sale globally due to the increased incidence of serious, non-fatal cardiovascular events", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21265828", "endSection": "abstract"}, {"offsetInBeginSection": 1775, "offsetInEndSection": 1900, "text": "Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424288", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 832, "text": "Sibutramine was associated with an increase in major adverse cardiovascular events in the Sibutramine Cardiovascular Outcomes (SCOUT) trial and it was withdrawn from the market in 2010", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25114779", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 1238, "text": "The safety of the most popular agent, aprotinin, has been challenged, and it was withdrawn from world markets in May 2008 because of concerns that it increased the risk of cardiovascular complications and death.To assess the comparative effects of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA) on blood loss during surgery, the need for red blood cell (RBC) transfusion, and adverse events, particularly vascular occlusion, renal dysfunction, and death.We searched: the Cochrane Injuries Groups Specialised Register (July 2010), Cochrane Central Register of Controlled Trials (The Cochrane Library 2010, Issue 3), MEDLINE (Ovid SP) 1950 to July 2010, EMBASE (Ovid SP) 1980 to July 2010.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21412876", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 1238, "text": "The safety of the most popular agent, aprotinin, has been challenged, and it was withdrawn from world markets in May 2008 because of concerns that it increased the risk of cardiovascular complications and death.To assess the comparative effects of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA) on blood loss during surgery, the need for red blood cell (RBC) transfusion, and adverse events, particularly vascular occlusion, renal dysfunction, and death.We searched: the Cochrane Injuries Groups Specialised Register (July 2010), Cochrane Central Register of Controlled Trials (The Cochrane Library 2010, Issue 3), MEDLINE (Ovid SP) 1950 to July 2010, EMBASE (Ovid SP) 1980 to July 2010.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249650", "endSection": "abstract"}, {"offsetInBeginSection": 580, "offsetInEndSection": 801, "text": "Rofecoxib and valdecoxib have been withdrawn from the market worldwide due to safety concerns (most importantly for cardiovascular adverse events) and lumiracoxib has been withdrawn in many countries due to liver toxicity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340915", "endSection": "abstract"}, {"offsetInBeginSection": 556, "offsetInEndSection": 777, "text": "In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21751825", "endSection": "abstract"}, {"offsetInBeginSection": 1777, "offsetInEndSection": 1903, "text": "Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424288", "endSection": "abstract"}, {"offsetInBeginSection": 580, "offsetInEndSection": 802, "text": "Rofecoxib and valdecoxib have been withdrawn from the market worldwide due to safety concerns (most importantly for cardiovascular adverse events) and lumiracoxib has been withdrawn in many countries due to liver toxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340915", "endSection": "abstract"}, {"offsetInBeginSection": 235, "offsetInEndSection": 357, "text": "Sertindole , first withdrawn from the market for cardiovascular safety concerns, is currently available in many countries.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25084209", "endSection": "abstract"}, {"offsetInBeginSection": 556, "offsetInEndSection": 1193, "text": "In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market. The lesson learnt from this is the importance of patient selection, limiting the duration of treatment and stopping treatment in non-responders. Currently, phentermine and amfepramone (diethylpropion) are approved for short-term treatment of obesity (up to 3 months) and orlistat is approved for longer-term treatment; however, the gastrointestinal adverse effects of orlistat may be intolerable for some patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21751825", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "BACKGROUND: Certain non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., rofecoxib [Vioxx]) increase the risk of heart attack and stroke and should be avoided in patients at high risk of cardiovascular events.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424288", "endSection": "abstract"}, {"offsetInBeginSection": 556, "offsetInEndSection": 778, "text": "In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21751825", "endSection": "abstract"}, {"offsetInBeginSection": 1730, "offsetInEndSection": 1855, "text": "Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424288", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 303, "text": " Rofecoxib, a selective cyclo-oxygenase (COX)-2 inhibitor, was a widely marketed drug that was used for relief of pain and inflammation in arthritic conditions. It was withdrawn from the market worldwide in September 2004 because of an increased risk of cardiovascular events. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16119973", "endSection": "abstract"}]}, {"body": "Is Migalastat used for treatment of Fabry Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27834756", "http://www.ncbi.nlm.nih.gov/pubmed/27351440", "http://www.ncbi.nlm.nih.gov/pubmed/27657681", "http://www.ncbi.nlm.nih.gov/pubmed/23474038", "http://www.ncbi.nlm.nih.gov/pubmed/19387866", "http://www.ncbi.nlm.nih.gov/pubmed/24189976", "http://www.ncbi.nlm.nih.gov/pubmed/23176611", "http://www.ncbi.nlm.nih.gov/pubmed/21211680", "http://www.ncbi.nlm.nih.gov/pubmed/21598360", "http://www.ncbi.nlm.nih.gov/pubmed/27509102", "http://www.ncbi.nlm.nih.gov/pubmed/23472096", "http://www.ncbi.nlm.nih.gov/pubmed/27121667", "http://www.ncbi.nlm.nih.gov/pubmed/26252393", "http://www.ncbi.nlm.nih.gov/pubmed/21517827"], "ideal_answer": ["Yes, Migalastat is approved for treatment of Fabry disease. Migalastat is an oral pharmacological chaperone developed as an alternative to intravenous enzyme replacement therapy (ERT), stabilises specific mutant (amenable) forms of \u03b1-Gal to facilitate normal lysosomal trafficking."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:14499", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000795"], "type": "yesno", "id": "5884793ce56acf5176000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27834756", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 408, "text": "BACKGROUND: Fabry disease is an X-linked lysosomal storage disorder caused by GLA mutations, resulting in \u03b1-galactosidase (\u03b1-Gal) deficiency and accumulation of lysosomal substrates. Migalastat, an oral pharmacological chaperone being developed as an alternative to intravenous enzyme replacement therapy (ERT), stabilises specific mutant (amenable) forms of \u03b1-Gal to facilitate normal lysosomal trafficking.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27834756", "endSection": "abstract"}, {"offsetInBeginSection": 1672, "offsetInEndSection": 1844, "text": "CONCLUSIONS: Migalastat offers promise as a first-in-class oral monotherapy alternative treatment to intravenous ERT for patients with Fabry disease and amenable mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27834756", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Migalastat (Galafold\u2122)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of \u03b1-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351440", "endSection": "abstract"}, {"offsetInBeginSection": 426, "offsetInEndSection": 652, "text": "This article summarizes the milestones in the development of migalastat leading to this first approval in the EU for the long-term treatment of adults and adolescents aged \u226516 years with a confirmed diagnosis of Fabry disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351440", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27509102", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 284, "text": "BACKGROUND: Fabry's disease, an X-linked disorder of lysosomal \u03b1-galactosidase deficiency, leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of \u03b1-galactosidase, increasing enzyme trafficking to lysosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27509102", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active \u03b1-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252393", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 243, "text": "UNLABELLED: Migalastat HCl (AT1001, 1-Deoxygalactonojirimycin) is an investigational pharmacological chaperone for the treatment of \u03b1-galactosidase A (\u03b1-Gal A) deficiency, which leads to Fabry disease, an X-linked, lysosomal storage disorder. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252393", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23472096", "endSection": "title"}, {"offsetInBeginSection": 1567, "offsetInEndSection": 1647, "text": "migalastat for Fabry disease) and inhibitors of glucosylceramide synthesis (e.g.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211680", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23474038", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "Migalastat HCl (AT1001, 1-Deoxygalactonojirimycin) is an investigational pharmacological chaperone for the treatment of \u03b1-galactosidase A (\u03b1-Gal A) deficiency, which leads to Fabry disease, an X-linked, lysosomal storage disorder", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252393", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Migalastat HCl is an investigational, oral treatment for Fabry disease, an X-linked lysosomal storage disorder", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121667", "endSection": "abstract"}, {"offsetInBeginSection": 381, "offsetInEndSection": 511, "text": "Oral administration of migalastat HCl reduces tissue GL-3 in Fabry transgenic mice, and in urine and kidneys of some FD patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23472096", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Migalastat HCl is an investigational, oral treatment for Fabry disease, an X-linked lysosomal storage disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121667", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Migalastat HCl (AT1001, 1-Deoxygalactonojirimycin) is an investigational pharmacological chaperone for the treatment of \u03b1-galactosidase A (\u03b1-Gal A) deficiency, which leads to Fabry disease, an X-linked, lysosomal storage disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252393", "endSection": "abstract"}, {"offsetInBeginSection": 1540, "offsetInEndSection": 1810, "text": "Molecular chaperones (e.g. migalastat for Fabry disease) and inhibitors of glucosylceramide synthesis (e.g. eliglustat tartrate for Gaucher disease) are currently under investigation in various clinical trials.<CopyrightInformation>Copyright \u00c2\u00a9 2010 Elsevier Masson SAS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211680", "endSection": "abstract"}, {"offsetInBeginSection": 1305, "offsetInEndSection": 1452, "text": "Migalastat HCl was well tolerated.Migalastat HCl is a candidate pharmacological chaperone that provides a novel genotype-specific treatment for FD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23176611", "endSection": "abstract"}, {"offsetInBeginSection": 1268, "offsetInEndSection": 1512, "text": "Additionally, these three patients all demonstrated decreases in GL-3 inclusions in kidney peri-tubular capillaries.Migalastat HCl is a candidate oral pharmacological chaperone that provides a potential novel genotype-specific treatment for FD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23474038", "endSection": "abstract"}, {"offsetInBeginSection": 1567, "offsetInEndSection": 1750, "text": "migalastat for Fabry disease) and inhibitors of glucosylceramide synthesis (e.g. eliglustat tartrate for Gaucher disease) are currently under investigation in various clinical trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211680", "endSection": "abstract"}, {"offsetInBeginSection": 1540, "offsetInEndSection": 1750, "text": "Molecular chaperones (e.g. migalastat for Fabry disease) and inhibitors of glucosylceramide synthesis (e.g. eliglustat tartrate for Gaucher disease) are currently under investigation in various clinical trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211680", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27509102", "endSection": "title"}, {"offsetInBeginSection": 1211, "offsetInEndSection": 1447, "text": "The GLP HEK assay is a clinically validated method of identifying male and female Fabry patients for treatment with migalastat.Genet Med advance online publication 22 September 2016Genetics in Medicine (2016); doi:10.1038/gim.2016.122..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27657681", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23474038", "endSection": "title"}, {"offsetInBeginSection": 1646, "offsetInEndSection": 1805, "text": "Migalastat offers promise as a first-in-class oral monotherapy alternative treatment to intravenous ERT for patients with Fabry disease and amenable mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27834756", "endSection": "abstract"}]}, {"body": "Where are Paneth cells located?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21122555", "http://www.ncbi.nlm.nih.gov/pubmed/19397593", "http://www.ncbi.nlm.nih.gov/pubmed/23006982", "http://www.ncbi.nlm.nih.gov/pubmed/24439803", "http://www.ncbi.nlm.nih.gov/pubmed/23232853", "http://www.ncbi.nlm.nih.gov/pubmed/19788585"], "ideal_answer": ["Paneth cells are located in the intestinal crypt base columnar cells (CBCCs)."], "type": "factoid", "id": "58a9bbe81978bbde22000007", "snippets": [{"offsetInBeginSection": 615, "offsetInEndSection": 710, "text": "The intestinal stem cell niche comprises both epithelial cells, in particular the Paneth cell, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24439803", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Paneth cells have been reported in colorectal adenomas and adenocarcinomas;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23232853", "endSection": "abstract"}, {"offsetInBeginSection": 230, "offsetInEndSection": 284, "text": " injury to Paneth cells (PCs) in the intestinal crypts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23006982", "endSection": "abstract"}, {"offsetInBeginSection": 265, "offsetInEndSection": 331, "text": "resence of Paneth cells at the bottom of the crypts of Lieberk\u00fchn.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21122555", "endSection": "abstract"}, {"offsetInBeginSection": 946, "offsetInEndSection": 977, "text": "Paneth cells at the crypt base ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19397593", "endSection": "abstract"}, {"offsetInBeginSection": 727, "offsetInEndSection": 776, "text": " Paneth cells (crypt base columnar cells (CBCCs))", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19788585", "endSection": "abstract"}]}, {"body": "Which are the types of viral meningitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16909784", "http://www.ncbi.nlm.nih.gov/pubmed/22246843", "http://www.ncbi.nlm.nih.gov/pubmed/25042344", "http://www.ncbi.nlm.nih.gov/pubmed/26568804", "http://www.ncbi.nlm.nih.gov/pubmed/22798048", "http://www.ncbi.nlm.nih.gov/pubmed/8972676", "http://www.ncbi.nlm.nih.gov/pubmed/14226105", "http://www.ncbi.nlm.nih.gov/pubmed/21501303", "http://www.ncbi.nlm.nih.gov/pubmed/18680414", "http://www.ncbi.nlm.nih.gov/pubmed/18354820", "http://www.ncbi.nlm.nih.gov/pubmed/6612271", "http://www.ncbi.nlm.nih.gov/pubmed/9810831", "http://www.ncbi.nlm.nih.gov/pubmed/18669052", "http://www.ncbi.nlm.nih.gov/pubmed/21412795", "http://www.ncbi.nlm.nih.gov/pubmed/16849723", "http://www.ncbi.nlm.nih.gov/pubmed/1418647", "http://www.ncbi.nlm.nih.gov/pubmed/14503358", "http://www.ncbi.nlm.nih.gov/pubmed/9265274", "http://www.ncbi.nlm.nih.gov/pubmed/25975649", "http://www.ncbi.nlm.nih.gov/pubmed/25983131", "http://www.ncbi.nlm.nih.gov/pubmed/15927848", "http://www.ncbi.nlm.nih.gov/pubmed/25562123", "http://www.ncbi.nlm.nih.gov/pubmed/24313836", "http://www.ncbi.nlm.nih.gov/pubmed/26334674", "http://www.ncbi.nlm.nih.gov/pubmed/18565120"], "ideal_answer": ["Aseptic meningitis is the most common type of meningitis and is characterized by meningeal inflammation that is not linked to identifiable bacterial pathogens in cerebrospinal fluid (CSF). It can be originated from infection from:\n1) Varicella-zoster virus (VZV)\n2) Herpes simplex types I and II (HSV-1, HSV-2)\n3) Epstein-Barr virus (EBV) \n4) Cytomegalovirus (CMV) \n5) Enteroviruses (EV) \n6) Parechoviruses (HPeV) \n7) Human rhinoviruses (HRVs) \n8) Echovirus types 6, 9, 11\n9) West Nile Virus (WNV)"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008581", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008582", "http://www.disease-ontology.org/api/metadata/DOID:10310", "http://www.disease-ontology.org/api/metadata/DOID:12157", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008587"], "type": "list", "id": "589aec4778275d0c4a000037", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 200, "text": "Aseptic meningitis is the most common type of meningitis and is characterized by meningeal inflammation that is not linked to identifiable bacterial pathogens in cerebrospinal fluid (CSF).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26568804", "endSection": "abstract"}, {"offsetInBeginSection": 1220, "offsetInEndSection": 1405, "text": "The results indicate a considerable rate of herpesvirus infection in patients with aseptic meningitis, and that VZV is the most common herpesvirus to cause infection followed by HSV-1. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26568804", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Detection of herpes viruses in the cerebrospinal fluid of adults with suspected viral meningitis in Malawi.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22798048", "endSection": "title"}, {"offsetInBeginSection": 692, "offsetInEndSection": 994, "text": "Of these, 59 (32 %) had proven meningitis (bacterial, tuberculous or cryptococcal), 39 (21 %) had normal CSF and 14 (8 %) had aseptic meningitis. For the latter group, a herpes virus was detected in 9 (64 %): 7 (50 %) had EBV and 2 (14 %) had CMV, all were human immunodeficiency virus (HIV)-positive. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22798048", "endSection": "abstract"}, {"offsetInBeginSection": 1294, "offsetInEndSection": 1513, "text": "Results confirm that EV-specific RT-PCR can detect HRVs, and at a practical level, identify potential problems of interpretation if fecal samples are used for surrogate screening in cases of suspected viral meningitis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22246843", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Human rhinoviruses (HRVs) can be divided into three species; HRV-A to HRV-C.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22246843", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 157, "text": "Enteroviruses (EV) and parechoviruses (HPeV) are the most common causes of aseptic meningitis, encephalitis and sepsis-like syndrome in neonates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18354820", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 67, "text": "Serous meningitis associated with primary genital herpes infection", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9265274", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 497, "text": "Aseptic meningitis is not an uncommon complication to primary genital herpes infection caused by herpes simplex virus type 2 (HSV-2). Compared with other types of viral meningitis, HSV-2-meningitis is associated with a significant rate of neurological complications in the acute stage. In addition, some patients will suffer from recurrent aseptic meningitis (Mollaret's meningitis) later. We describe six patients, five women and one man, age 26-35 years, with aseptic meningitis caused by HSV-2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9265274", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Viral meningitis due to echovirus types 6 and 9: epidemiological data from Western Australia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8972676", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "During the autumn of 1992, Western Australia experienced a large viral meningitis outbreak of dual aetiology. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8972676", "endSection": "abstract"}, {"offsetInBeginSection": 248, "offsetInEndSection": 416, "text": "Echovirus 9 caused 41% of cases and occurred mainly in the metropolitan areas of Western Australia whereas echovirus 6, which caused 37% of cases, was more widespread. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8972676", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 154, "text": "Sensitive virologic evaluation in suspected meningitis: study of a radioimmunotest for the detection of IgM antibodies against ECHO 9 and ECHO 11 viruses", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6612271", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "The majority of viral meningitis cases is known to be due to ECHO virus infections on one hand, and mumps on the other. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6612271", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 250, "text": "The West Nile Virus (WNV) is a Flavivirus which is transmitted to man by means of different species of mosquitoes and causes outbreaks and sporadic cases of illness in different regions of the Old World, including the Mediterranean Basin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9810831", "endSection": "abstract"}, {"offsetInBeginSection": 1888, "offsetInEndSection": 2254, "text": "Bearing in mind the high percentage of neurological complications found to exist in the most recent outbreaks of WNV infections recorded in the Mediterranean Basin (Bucharest, Algeria), it can be thought that the WNV plays some role in the factors contributing to viral meningitis and encephalitis which occur within the population of the areas at risk within Spain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9810831", "endSection": "abstract"}, {"offsetInBeginSection": 212, "offsetInEndSection": 436, "text": "This study aimed to evaluate the frequency of aseptic meningitis caused by herpesviruses, namely herpes simplex types I and II (HSV-1, HSV-2), Epstein-Barr virus (EBV), cytomegalovirus (CMV) and varicella-zoster virus (VZV).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26568804", "endSection": "abstract"}, {"offsetInBeginSection": 126, "offsetInEndSection": 578, "text": "We compared data obtained from patients with mumps meningitis and patients with aseptic meningitis caused by other viruses in order to identify mumps meningitis-specific cytokine/chemokine alterations in cerebrospinal fluid (CSF).METHODS: \u2002 We elucidated the cytokine/chemokine network based on the cytokine/chemokine profiles in CSF from children with mumps meningitis and meningitis due to other viral infections using multiplex cytokine measurement.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501303", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "SPORADIC OCCURRENCE OF ECHO VIRUS TYPES 27 AND 31 ASSOCIATED WITH ASEPTIC MENINGITIS IN ONTARIO.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14226105", "endSection": "title"}, {"offsetInBeginSection": 579, "offsetInEndSection": 1536, "text": "Seventeen cytokines/chemokines, namely interleukin (IL)-1\u00e2, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17, interferon (IFN)-\u00e3, tumor necrosis factor (TNF)-\u00e1, granulocyte colony-stimulating factor (G-CSF), granulocyte monocyte colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1\u00e2 (MIP-1\u00e2), were measured simultaneously in CSF supernatants from eight children with mumps meningitis, 11 children with other types of viral meningitis and eight children with fever without neurological complications such as convulsion.RESULTS: \u2002 We found that IL-8, IL-10, IL-12, IL-13 and IFN-\u00e3 showed a statistically significant increase in CSF from mumps meningitis when compared to other types of viral meningitis and fever without neurological complications.CONCLUSION: \u2002 Mumps meningitis may induce a distinct immunological response when compared with other types of viral meningitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501303", "endSection": "abstract"}, {"offsetInBeginSection": 1162, "offsetInEndSection": 1378, "text": "We found that IL-8, IL-10, IL-12, IL-13 and IFN-\u03b3 showed a statistically significant increase in CSF from mumps meningitis when compared to other types of viral meningitis and fever without neurological complications", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501303", "endSection": "abstract"}, {"offsetInBeginSection": 1381, "offsetInEndSection": 1593, "text": "Mumps meningitis may induce a distinct immunological response when compared with other types of viral meningitis.<CopyrightInformation>\u00a9 2011 The Authors.Pediatrics International \u00a9 2011 Japan Pediatric Society.</", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501303", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "[Adult cases of viral meningitis caused by echovirus type 13].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14503358", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "[Epidemic outbreak of viral meningitis caused by type 30 ECHO virus].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1418647", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "[Outbreak of viral meningitis caused by echovirus type 4 in Misiones province].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18669052", "endSection": "title"}, {"offsetInBeginSection": 134, "offsetInEndSection": 285, "text": "Compared with other types of viral meningitis, HSV-2-meningitis is associated with a significant rate of neurological complications in the acute stage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9265274", "endSection": "abstract"}, {"offsetInBeginSection": 558, "offsetInEndSection": 1077, "text": "Seventeen cytokines/chemokines, namely interleukin (IL)-1\u03b2, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17, interferon (IFN)-\u03b3, tumor necrosis factor (TNF)-\u03b1, granulocyte colony-stimulating factor (G-CSF), granulocyte monocyte colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1\u03b2 (MIP-1\u03b2), were measured simultaneously in CSF supernatants from eight children with mumps meningitis, 11 children with other types of viral meningitis a", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501303", "endSection": "abstract"}, {"offsetInBeginSection": 1162, "offsetInEndSection": 1379, "text": "We found that IL-8, IL-10, IL-12, IL-13 and IFN-\u03b3 showed a statistically significant increase in CSF from mumps meningitis when compared to other types of viral meningitis and fever without neurological complications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501303", "endSection": "abstract"}, {"offsetInBeginSection": 1381, "offsetInEndSection": 1594, "text": "Mumps meningitis may induce a distinct immunological response when compared with other types of viral meningitis.<CopyrightInformation>\u00a9 2011 The Authors.Pediatrics International \u00a9 2011 Japan Pediatric Society.</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501303", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 578, "text": "BACKGROUND: \u2002 The mumps virus is frequently the causative agent in aseptic meningitis and mumps has still prevailed in Japan. We compared data obtained from patients with mumps meningitis and patients with aseptic meningitis caused by other viruses in order to identify mumps meningitis-specific cytokine/chemokine alterations in cerebrospinal fluid (CSF).METHODS: \u2002 We elucidated the cytokine/chemokine network based on the cytokine/chemokine profiles in CSF from children with mumps meningitis and meningitis due to other viral infections using multiplex cytokine measurement.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501303", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1536, "text": "BACKGROUND: \u2002 The mumps virus is frequently the causative agent in aseptic meningitis and mumps has still prevailed in Japan. We compared data obtained from patients with mumps meningitis and patients with aseptic meningitis caused by other viruses in order to identify mumps meningitis-specific cytokine/chemokine alterations in cerebrospinal fluid (CSF).METHODS: \u2002 We elucidated the cytokine/chemokine network based on the cytokine/chemokine profiles in CSF from children with mumps meningitis and meningitis due to other viral infections using multiplex cytokine measurement. Seventeen cytokines/chemokines, namely interleukin (IL)-1\u00e2, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17, interferon (IFN)-\u00e3, tumor necrosis factor (TNF)-\u00e1, granulocyte colony-stimulating factor (G-CSF), granulocyte monocyte colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1\u00e2 (MIP-1\u00e2), were measured simultaneously in CSF supernatants from eight children with mumps meningitis, 11 children with other types of viral meningitis and eight children with fever without neurological complications such as convulsion.RESULTS: \u2002 We found that IL-8, IL-10, IL-12, IL-13 and IFN-\u00e3 showed a statistically significant increase in CSF from mumps meningitis when compared to other types of viral meningitis and fever without neurological complications.CONCLUSION: \u2002 Mumps meningitis may induce a distinct immunological response when compared with other types of viral meningitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501303", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "[Adult cases of viral meningitis caused by echovirus type 13].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14503358", "endSection": "title"}, {"offsetInBeginSection": 1382, "offsetInEndSection": 1498, "text": "\u2002 Mumps meningitis may induce a distinct immunological response when compared with other types of viral meningitis..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501303", "endSection": "abstract"}, {"offsetInBeginSection": 245, "offsetInEndSection": 481, "text": "A hospitalization with viral meningitis was defined as any discharge with diagnoses of mumps meningitis (B26.1), enteroviral meningitis (A85.0), tick-born encephalitis (A84.1) and viral undifferentiated meningitis (A87.9) due to ICD-10.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16909784", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Molecular typing of enteroviruses associated with viral meningitis in Cyprus, 2000-2002.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16849723", "endSection": "title"}]}, {"body": "What are the different classes of orally administered drugs used to treat diabetes", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12766122", "http://www.ncbi.nlm.nih.gov/pubmed/26932742", "http://www.ncbi.nlm.nih.gov/pubmed/26158794", "http://www.ncbi.nlm.nih.gov/pubmed/9540451", "http://www.ncbi.nlm.nih.gov/pubmed/11075314", "http://www.ncbi.nlm.nih.gov/pubmed/26787264", "http://www.ncbi.nlm.nih.gov/pubmed/18840004", "http://www.ncbi.nlm.nih.gov/pubmed/26928029", "http://www.ncbi.nlm.nih.gov/pubmed/15296954", "http://www.ncbi.nlm.nih.gov/pubmed/11105786", "http://www.ncbi.nlm.nih.gov/pubmed/23671395", "http://www.ncbi.nlm.nih.gov/pubmed/23522121", "http://www.ncbi.nlm.nih.gov/pubmed/16236069", "http://www.ncbi.nlm.nih.gov/pubmed/18220763", "http://www.ncbi.nlm.nih.gov/pubmed/24160357", "http://www.ncbi.nlm.nih.gov/pubmed/27038028", "http://www.ncbi.nlm.nih.gov/pubmed/26597596", "http://www.ncbi.nlm.nih.gov/pubmed/18559413", "http://www.ncbi.nlm.nih.gov/pubmed/11592575", "http://www.ncbi.nlm.nih.gov/pubmed/23919507", "http://www.ncbi.nlm.nih.gov/pubmed/3298298", "http://www.ncbi.nlm.nih.gov/pubmed/26890317", "http://www.ncbi.nlm.nih.gov/pubmed/26551045", "http://www.ncbi.nlm.nih.gov/pubmed/25805649", "http://www.ncbi.nlm.nih.gov/pubmed/17206165", "http://www.ncbi.nlm.nih.gov/pubmed/18316956", "http://www.ncbi.nlm.nih.gov/pubmed/7110736", "http://www.ncbi.nlm.nih.gov/pubmed/10321452", "http://www.ncbi.nlm.nih.gov/pubmed/17355730", "http://www.ncbi.nlm.nih.gov/pubmed/22767115", "http://www.ncbi.nlm.nih.gov/pubmed/18827867", "http://www.ncbi.nlm.nih.gov/pubmed/26587691", "http://www.ncbi.nlm.nih.gov/pubmed/18078018", "http://www.ncbi.nlm.nih.gov/pubmed/25648671", "http://www.ncbi.nlm.nih.gov/pubmed/15251678", "http://www.ncbi.nlm.nih.gov/pubmed/16254468"], "ideal_answer": ["There are a number of classes of medications tha are used to treat Type 2 diabetes. These include biguanides like metformin, which decreased hepatic glucose release; sulfonyureas like Glimepride, metglitinides like repaglin and d-phenylalanine derivatives, all of which stimulate pancreatic insulin release; Glitizones or thiazolidinediones which make the body more sensitive to insulin; DPP-4 inhibitors which lower the amount of glucose made in the body; alpha-glucosidase inhibitors which slow the absorbtion of carbohydrate in the blood; and bile acid sequestrants that lower blood glucose"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016640", "http://www.disease-ontology.org/api/metadata/DOID:11714", "http://www.disease-ontology.org/api/metadata/DOID:0050524", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048909", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003922", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003921", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020790"], "type": "list", "id": "58a0c09778275d0c4a000052", "snippets": [{"offsetInBeginSection": 162, "offsetInEndSection": 238, "text": " achieved by selectively inhibiting sodium-glucose co-transporter 2 (SGLT2).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26158794", "endSection": "abstract"}, {"offsetInBeginSection": 632, "offsetInEndSection": 764, "text": "After a decade-long effort to improve the pharmacokinetics of GLP1, a number of GLP1 analogues are currently available on the market", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26551045", "endSection": "abstract"}, {"offsetInBeginSection": 458, "offsetInEndSection": 542, "text": " short-acting glucagon-like peptide-1 receptor agonists exenatide and lixisenatide. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26787264", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 391, "text": " Sulphonylurea (SU) drugs have a history stretching back over 60 years, and have traditionally been the mainstay choice as second-line agents to be added to metformin once glycaemic control with metformin monotherapy deteriorates;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26597596", "endSection": "abstract"}, {"offsetInBeginSection": 695, "offsetInEndSection": 778, "text": "In 2013, sulfonylureas were the most common second-line treatment after metformin i", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26890317", "endSection": "abstract"}, {"offsetInBeginSection": 820, "offsetInEndSection": 863, "text": "this position was taken by DPP-4 inhibitors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26890317", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "[Studies on resorption of orally administered antibiotics and chemotherapeutic agents in children and its modification.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7110736", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "The drugs used to treat diabetes mellitus are diverse and include several classes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592575", "endSection": "abstract"}, {"offsetInBeginSection": 313, "offsetInEndSection": 525, "text": "Many of the therapeutic agents used to treat diabetes mellitus have the ability to lower blood glucose to dangerous concentrations; these include the sulfonylurea, meglitinide, and thiazolidinedione drug classes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22767115", "endSection": "abstract"}, {"offsetInBeginSection": 750, "offsetInEndSection": 956, "text": "The most common therapeutic classes of drugs used in all participating regions, in the previous week, were cardiovascular, gastrointestinal, metabolic (including drugs to treat diabetes) and nervous system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17206165", "endSection": "abstract"}, {"offsetInBeginSection": 1229, "offsetInEndSection": 1397, "text": "Use of oral antidiabetic agents, by drug class, did not differ significantly by race/ethnicity (p = 0.33 for TZDs, p = 0.43 for metformin, p = 0.38 for sulfonylureas). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17355730", "endSection": "abstract"}, {"offsetInBeginSection": 1210, "offsetInEndSection": 1340, "text": "The use of these drugs was also common among insulin treated diabetics but did not differ significantly from among non-diabetics. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3298298", "endSection": "abstract"}, {"offsetInBeginSection": 761, "offsetInEndSection": 972, "text": "Drug use among those treated with insulin and those treated orally was substantially higher than among non-diabetics while the difference between diabetics on dietary regimen and non-diabetics was much smaller. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3298298", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 292, "text": "UNLABELLED: The aims of the study were to evaluate differences in dietary, oral hygiene habits and social class in children with Type I diabetes mellitus (DM), compared to non-diabetics, and to investigate relationship between selected caries-risk factors and caries experience in diabetics. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16254468", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 237, "text": "Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-4), orally active, that improves glycemic control in patients with type 2 diabetes (T2DM) primarily by enhancing pancreatic (alpha and beta) islet function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18827867", "endSection": "abstract"}, {"offsetInBeginSection": 557, "offsetInEndSection": 974, "text": "The literature covered includes original studies and meta-analyses identified in PubMed, recent abstracts presented at major diabetes scientific conferences, and clinical trials registered at ClinicalTrials.gov.Although there are some differences in the pharmacokinetic and pharmacodynamic profiles of the different DPP-4 inhibitors, all are small orally active compounds with broadly similar HbA1c-lowering efficacy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23919507", "endSection": "abstract"}, {"offsetInBeginSection": 1431, "offsetInEndSection": 1653, "text": "The authors conclude that rosiglitazone can be safely administered with metformin and, due to the different mechanisms of action of these agents, may offer a therapeutic advantage in patients with type 2 diabetes mellitus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11075314", "endSection": "abstract"}, {"offsetInBeginSection": 923, "offsetInEndSection": 1001, "text": "There are different classes of anti-diabetic drugs reported to treat diabetes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160357", "endSection": "abstract"}, {"offsetInBeginSection": 441, "offsetInEndSection": 616, "text": "There are now four different classes of oral medications which are available to treat diabetes-sulfonylureas, biguanides, thiazolidinediones, and alpha-glucosidase inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9540451", "endSection": "abstract"}, {"offsetInBeginSection": 586, "offsetInEndSection": 734, "text": "During followup, incident treated diabetes was defined as a self-report of a new physician diagnosis of diabetes treated with insulin or oral drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18559413", "endSection": "abstract"}, {"offsetInBeginSection": 487, "offsetInEndSection": 639, "text": "This systematic review will compare adherence and persistence rates across the different classes of medication available to people with type 2 diabetes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26928029", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "Five classes of oral hypoglycaemic drugs and two trace minerals used to treat diabetes mellitus in humans are reviewed and current knowledge on the use of these drugs in diabetic dogs and cats is presented.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11105786", "endSection": "abstract"}, {"offsetInBeginSection": 400, "offsetInEndSection": 650, "text": "Sulfonylureas, biguanides, alpha-glucosidase, meglitinides, DPP-4 inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18220763", "endSection": "abstract"}, {"offsetInBeginSection": 1442, "offsetInEndSection": 1649, "text": "Currently, four classes of orally administered antidiabetic agents are available for use in patients with type 2 diabetes: insulin secretagogues, biguanides, a-glucosidase inhibitors, and thiazolidinediones.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15251678", "endSection": "abstract"}]}, {"body": "Which pipelines are used for analyzing data from ChIP-nexus experiments?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27814676", "http://www.ncbi.nlm.nih.gov/pubmed/27587683"], "ideal_answer": ["PeakXus and Q-nexus enable comprehensive transcription factor binding site discovery from ChIP-nexus experiments."], "type": "list", "id": "5883bce3e56acf5176000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27587683", "endSection": "title"}, {"offsetInBeginSection": 611, "offsetInEndSection": 987, "text": "We describe a peak caller PeakXus that is specifically designed to leverage the increased resolution of ChIP-exo/Nexus and developed with the aim of making as few assumptions of the data as possible to allow discoveries of novel binding patterns. We apply PeakXus to ChIP-Nexus and ChIP-exo experiments performed both in Homo sapiens and in Drosophila melanogaster cell lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27587683", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-nexus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676", "endSection": "title"}, {"offsetInBeginSection": 572, "offsetInEndSection": 1042, "text": "Here, we present a comprehensive software package for ChIP-nexus data that exploits the random barcodes for selective removal of PCR duplicates and for quality control. Furthermore, we developed bespoke methods to estimate the width of the protected region resulting from protein-DNA binding and to infer binding positions from ChIP-nexus data. Finally, we applied our peak calling method as well as the two other methods MACE and MACS2 to the available ChIP-nexus data.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-nexus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "PeakXus: comprehensive transcription factor binding site discovery from ChIP-Nexus and ChIP-Exo experiments.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27587683", "endSection": "title"}]}, {"body": "What do statins do?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21784376", "http://www.ncbi.nlm.nih.gov/pubmed/17245169", "http://www.ncbi.nlm.nih.gov/pubmed/26405105", "http://www.ncbi.nlm.nih.gov/pubmed/17001070", "http://www.ncbi.nlm.nih.gov/pubmed/23629822", "http://www.ncbi.nlm.nih.gov/pubmed/19225884", "http://www.ncbi.nlm.nih.gov/pubmed/27829091", "http://www.ncbi.nlm.nih.gov/pubmed/12921488", "http://www.ncbi.nlm.nih.gov/pubmed/26758951", "http://www.ncbi.nlm.nih.gov/pubmed/23500327", "http://www.ncbi.nlm.nih.gov/pubmed/16723812", "http://www.ncbi.nlm.nih.gov/pubmed/26474612", "http://www.ncbi.nlm.nih.gov/pubmed/15541327", "http://www.ncbi.nlm.nih.gov/pubmed/25208056", "http://www.ncbi.nlm.nih.gov/pubmed/23464862", "http://www.ncbi.nlm.nih.gov/pubmed/17463321", "http://www.ncbi.nlm.nih.gov/pubmed/22129898", "http://www.ncbi.nlm.nih.gov/pubmed/23618535", "http://www.ncbi.nlm.nih.gov/pubmed/22286441", "http://www.ncbi.nlm.nih.gov/pubmed/23880257", "http://www.ncbi.nlm.nih.gov/pubmed/22457675", "http://www.ncbi.nlm.nih.gov/pubmed/24470059", "http://www.ncbi.nlm.nih.gov/pubmed/20078616", "http://www.ncbi.nlm.nih.gov/pubmed/14499877", "http://www.ncbi.nlm.nih.gov/pubmed/20545813", "http://www.ncbi.nlm.nih.gov/pubmed/24777857", "http://www.ncbi.nlm.nih.gov/pubmed/19370615", "http://www.ncbi.nlm.nih.gov/pubmed/17241784", "http://www.ncbi.nlm.nih.gov/pubmed/15625077", "http://www.ncbi.nlm.nih.gov/pubmed/21802861", "http://www.ncbi.nlm.nih.gov/pubmed/21342078", "http://www.ncbi.nlm.nih.gov/pubmed/20506142", "http://www.ncbi.nlm.nih.gov/pubmed/23919640", "http://www.ncbi.nlm.nih.gov/pubmed/19154957", "http://www.ncbi.nlm.nih.gov/pubmed/19370693"], "ideal_answer": ["Statins lower high cholesterol", "Statins, which specifically inhibit HMG Co-A reductase, the rate-limiting step of cholesterol biosynthesis, are widely prescribed to reduce serum cholesterol and cardiac risk,"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019161", "http://amigo.geneontology.org/amigo/term/GO:0036273"], "type": "summary", "id": "589c8e5e78275d0c4a000041", "snippets": [{"offsetInBeginSection": 509, "offsetInEndSection": 631, "text": "Statins are inhibitors of HMG-CoA reductase, the enzyme that catalyzes the reduction of HMG-CoA to mevalonic acid by NADPH", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26758951", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Statins, which specifically inhibit HMG Co-A reductase, the rate-limiting step of cholesterol biosynthesis, are widely prescribed to reduce serum cholesterol and cardiac risk,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26405105", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "OBJECTIVES: Statins are a lipid-lowering treatment, prescribed frequently to prevent cardiovascular events.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20545813", "endSection": "abstract"}, {"offsetInBeginSection": 1318, "offsetInEndSection": 1571, "text": "The doctors' beliefs about statins' ability to prolong life were associated significantly with their willingness to initiate treatment.CONCLUSION: The overall results imply that doctors have varying and suboptimal understanding of the effect of statins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20545813", "endSection": "abstract"}, {"offsetInBeginSection": 1140, "offsetInEndSection": 1376, "text": "However, the meta-regression analysis indicated that age of study participants modified the association between statin use and cancer risk (P = .003).CONCLUSION: Our findings do not support a protective effect of statins against cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17001070", "endSection": "abstract"}, {"offsetInBeginSection": 104, "offsetInEndSection": 238, "text": "What is less well known is a phenomenon whereby statins may induce a myopathy, which persists or may progress after stopping the drug.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241784", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241784", "endSection": "abstract"}, {"offsetInBeginSection": 828, "offsetInEndSection": 1197, "text": "* Our data do not show any beneficial effect of statins in reducing disease inflammation in RA patients.AIM: To investigate the possible anti-inflammatory effect of statins in a cohort of rheumatoid arthritis (RA) patients.METHODS: We conducted a cohort study consisting of all patients with at least one claim for RA using LifeLink, a health insurance claims database.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20078616", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 819, "text": "Statins are widely used in kidney transplant patients given their established benefits in the general population, however evidence favouring their use is lacking.To assess the benefits and harms of statin therapy on mortality and renal outcomes in kidney transplant recipients.We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), and hand searched reference lists of articles and scientific proceedings.Randomised controlled trials (RCTs) and quasi-RCTs comparing statins with placebo, no treatment or other statins in kidney transplant recipients.Two authors independently assessed study quality and extracted data", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370615", "endSection": "abstract"}, {"offsetInBeginSection": 354, "offsetInEndSection": 784, "text": "Thus, it is important to understand whether other signaling pathways that are involved in atherosclerosis could be targets of statins, and if so, whether individuals with \"overactivity\" of these pathways could benefit from statin therapy, regardless of serum cholesterol level.Statins inhibit the synthesis of isoprenoids, which are important for the function of the Rho/Rho-associated coiled-coil containing kinase (ROCK) pathway", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23919640", "endSection": "abstract"}, {"offsetInBeginSection": 3877, "offsetInEndSection": 4180, "text": "Evidence for statins in people who have had a kidney transplant were sparse and lower quality due to imprecise effect estimates and provided limited systematic evaluation of treatment harm.Statins may reduce cardiovascular events in kidney transplant recipients, although treatment effects are imprecise", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24470059", "endSection": "abstract"}, {"offsetInBeginSection": 1643, "offsetInEndSection": 2298, "text": "Statins decreased 24-hour urinary protein excretion (6 studies, 311 patients: MD -0.73 g/24 h, 95% CI -0.95 to -0.52), but there was no significant improvement in creatinine clearance - a surrogate marker of renal function (11 studies, 548 patients: MD 1.48 mL/min, 95% CI -2.32 to 5.28).The incidence of rhabdomyolysis, elevated liver enzymes and withdrawal rates due to adverse events (well known complications of statins use), were not significantly different between patients receiving statins and placebo.Statins significantly reduced the risk of all-cause and cardiovascular mortality in CKD patients who are not receiving renal replacement therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370693", "endSection": "abstract"}, {"offsetInBeginSection": 1335, "offsetInEndSection": 1630, "text": "Statins are less cost-effective when obtained at average retail prices, particularly in patients at lower CVD risk.Although statins reduce absolute CVD risk in patients with CKD, the increased risk of rhabdomyolysis, and competing risks associated with progressive CKD, partly offset these gains", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23500327", "endSection": "abstract"}, {"offsetInBeginSection": 350, "offsetInEndSection": 1133, "text": "In this review, we debate the relative effect of statins in driving insulin resistance and the impairment of insulin secretion.Narrative overview of the literature synthesizing the findings of literature was retrieved from searches of computerized databases, hand searches, and authoritative texts employing the key words \"Statins\", \"Randomized Clinical Trial\", \"Insulin sensitivity\", \"Insulin resistance\", \"Insulin Secretion\", \"Diabetes Mellitus\" alone and/or in combination.The weight of clinical evidence suggests a worsening effect of statins on insulin resistance and secretion, anyway basic science studies did not find a clear molecular explanation, providing conflicting evidence regarding both the beneficial and the adverse effects of statin therapy on insulin sensitivity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25208056", "endSection": "abstract"}, {"offsetInBeginSection": 545, "offsetInEndSection": 994, "text": "This study was undertaken to investigate the immunomodulatory mechanisms of statins that target the IFN response in PDCs.We isolated human blood PDCs by flow cytometry and examined the effects of simvastatin and pitavastatin on PDC activation, IFNalpha production, and intracellular signaling.Statins inhibited IFNalpha production profoundly and tumor necrosis factor alpha production modestly in human PDCs in response to Toll-like receptor ligands", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20506142", "endSection": "abstract"}, {"offsetInBeginSection": 1042, "offsetInEndSection": 1217, "text": "The earlier JUPITER (Justification for the Use of Statins in Primary Prevention) trial provided appealing evidence that the risk of venous thrombosis may be lowered by statins", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629822", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17245169", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14499877", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "HMG-CoA reductase inhibitors (statins) activate expression of PPARalpha/PPARgamma and ABCA1 in cultured gallbladder epithelial cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19225884", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16723812", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "HMG-CoA reductase inhibitors (statins) reduce hypertrophic scar formation in a rabbit ear wounding model.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22286441", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15625077", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24777857", "endSection": "title"}, {"offsetInBeginSection": 535, "offsetInEndSection": 794, "text": "Two meta-analyses have shown statins do not improve survival, whereas two others showed improved cardiac function and reduced inflammation in HF. It appears lipophilic statins produce better survival and other outcome benefits compared to hydrophilic statins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23618535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 414, "text": "Statins are the current basis of lipid-lowering therapy, despite which may have limitations on efficacy and safety. In high risk patients who do not achieve current lipid goals, in those intolerant to statins or those with atherogenic dyslipidemia, it is possible combine two or more lipid lowering drugs, including statins, ezetimibe, bile acid sequestrants, fibrates, niacin and prescription omega-3 fatty acids.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880257", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 516, "text": "Statins are the current basis of lipid-lowering therapy, despite which may have limitations on efficacy and safety. In high risk patients who do not achieve current lipid goals, in those intolerant to statins or those with atherogenic dyslipidemia, it is possible combine two or more lipid lowering drugs, including statins, ezetimibe, bile acid sequestrants, fibrates, niacin and prescription omega-3 fatty acids. However, for most of these combination therapies pivotal data on clinical outcomes are still lacking.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880257", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Statins are the current basis of lipid-lowering therapy, despite which may have limitations on efficacy and safety.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880257", "endSection": "abstract"}, {"offsetInBeginSection": 387, "offsetInEndSection": 534, "text": "However, the findings of two large RCTs do not support the evidence provided by previous studies and suggest statins lack beneficial effects in HF.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23618535", "endSection": "abstract"}, {"offsetInBeginSection": 124, "offsetInEndSection": 253, "text": "Subsequently, a number of nonrandomised studies have shown statins improve clinical outcomes in patients with heart failure (HF).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23618535", "endSection": "abstract"}, {"offsetInBeginSection": 41, "offsetInEndSection": 150, "text": "AND WHAT DOES THE STUDY ADD?: Statins have shown broad spectrum anti-cancer properties in laboratory studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23464862", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Statin-induced myopathy is an important cause of statin intolerance and the most common cause of statin discontinuation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21342078", "endSection": "abstract"}, {"offsetInBeginSection": 1994, "offsetInEndSection": 2168, "text": "These findings underscore the need to better define the pathophysiology of statin-induced myalgia and develop methodologies to guide treatment of statin-intolerant patients..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21784376", "endSection": "abstract"}]}, {"body": "Which cells secretes alpha defensin 5?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26206286", "http://www.ncbi.nlm.nih.gov/pubmed/25664683", "http://www.ncbi.nlm.nih.gov/pubmed/25643281", "http://www.ncbi.nlm.nih.gov/pubmed/25433720", "http://www.ncbi.nlm.nih.gov/pubmed/25970658", "http://www.ncbi.nlm.nih.gov/pubmed/25540379", "http://www.ncbi.nlm.nih.gov/pubmed/25547793"], "ideal_answer": ["Human enteric \u03b1-defensins (HD5 and HD6), major antimicrobial peptides produced by Paneth cells in the intestine, play important roles in intestinal innate immunity."], "type": "factoid", "id": "58a9c152396a458e50000001", "snippets": [{"offsetInBeginSection": 391, "offsetInEndSection": 573, "text": "The major tissue in which HD5 is expressed is the crypt of the small intestine, an anaerobic niche that should allow for substantial pools of both oxidized and (partly) reduced HD5. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25970658", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Human \u03b1-defensin 5 (HD5) exhibits broad spectrum antimicrobial activity and plays an important role in mucosal immunity of the small intestine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26206286", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Human enteric \u03b1-defensins (HD5 and HD6), major antimicrobial peptides produced by Paneth cells in the intestine, play important roles in intestinal innate immunity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25433720", "endSection": "abstract"}, {"offsetInBeginSection": 288, "offsetInEndSection": 362, "text": "Human \u03b1-defensin 5 (HD5), the most abundant enteric antimicrobial peptide,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25547793", "endSection": "abstract"}, {"offsetInBeginSection": 1380, "offsetInEndSection": 1469, "text": "HD5, naturally present at very high concentrations in the mucosa of the small intestine, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25547793", "endSection": "abstract"}, {"offsetInBeginSection": 133, "offsetInEndSection": 250, "text": "Human \u03b1-defensin 5 (HD5) is an innate immune effector peptide secreted by epithelial cells in the genitourinary tract", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25540379", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "Human \u03b1-defensin 5 (HD5) is a 32-residue cysteine-rich host-defense peptide that exhibits broad-spectrum antimicrobial activity and contributes to innate immunity in the human gut and other organ systems. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25664683", "endSection": "abstract"}, {"offsetInBeginSection": 1512, "offsetInEndSection": 1645, "text": "The concentrations of lactoferrin and defensins in preterm breast milk have antimicrobial activity against common neonatal pathogens.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25643281", "endSection": "abstract"}]}, {"body": "Do statins cause diabetes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26806344", "http://www.ncbi.nlm.nih.gov/pubmed/25245638", "http://www.ncbi.nlm.nih.gov/pubmed/24404512", "http://www.ncbi.nlm.nih.gov/pubmed/26597211", "http://www.ncbi.nlm.nih.gov/pubmed/25208056", "http://www.ncbi.nlm.nih.gov/pubmed/22845189", "http://www.ncbi.nlm.nih.gov/pubmed/24373206", "http://www.ncbi.nlm.nih.gov/pubmed/25939296", "http://www.ncbi.nlm.nih.gov/pubmed/24874977", "http://www.ncbi.nlm.nih.gov/pubmed/23704171", "http://www.ncbi.nlm.nih.gov/pubmed/23496027", "http://www.ncbi.nlm.nih.gov/pubmed/25312577", "http://www.ncbi.nlm.nih.gov/pubmed/26437128", "http://www.ncbi.nlm.nih.gov/pubmed/22658337", "http://www.ncbi.nlm.nih.gov/pubmed/26466221", "http://www.ncbi.nlm.nih.gov/pubmed/17496714"], "ideal_answer": ["The relationship between T2DM and statins is further complicated since these drugs can cause new onset diabetes (NOD) although there is an overall benefit in terms of preventing vascular events.", "Statin use has been associated with increased risk of developing type 2 diabetes (T2DM), and with impaired glycemic control in T2DM patients"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003924"], "type": "yesno", "id": "58a341eb60087bc10a000018", "snippets": [{"offsetInBeginSection": 6, "offsetInEndSection": 146, "text": "Statin use has been associated with increased risk of developing type 2 diabetes (T2DM), and with impaired glycemic control in T2DM patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26597211", "endSection": "abstract"}, {"offsetInBeginSection": 336, "offsetInEndSection": 530, "text": "The relationship between T2DM and statins is further complicated since these drugs can cause new onset diabetes (NOD) although there is an overall benefit in terms of preventing vascular events ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26806344", "endSection": "abstract"}, {"offsetInBeginSection": 160, "offsetInEndSection": 248, "text": "It has been repeatedly reported that statins may cause new-onset diabetes mellitus (DM).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312577", "endSection": "abstract"}, {"offsetInBeginSection": 118, "offsetInEndSection": 230, "text": "However, a small, but significant risk of new-onset diabetes has been reported in patients treated with statins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496027", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 348, "text": "The National Lipid Association (NLA) Statin Diabetes Safety Task Force concluded that the cardiovascular benefit of statin therapy outweighs the risk for developing diabetes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25939296", "endSection": "abstract"}, {"offsetInBeginSection": 149, "offsetInEndSection": 236, "text": "It has been repeatedly reported that statins may cause new-onset diabetes mellitus (DM)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312577", "endSection": "abstract"}, {"offsetInBeginSection": 160, "offsetInEndSection": 378, "text": "It has been repeatedly reported that statins may cause new-onset diabetes mellitus (DM). However, limited evidence exists from direct head to head comparisons of statins on whether the risk of DM differs among statins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312577", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Short-term statin exposure is associated with reduced all-cause mortality in persons with diabetes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17496714", "endSection": "title"}, {"offsetInBeginSection": 702, "offsetInEndSection": 937, "text": "Despite the fact that higher statin doses are more likely to lead to new-onset diabetes, for every case of diabetes caused, there are approximately three cardiovascular events reduced with high dose versus moderate dose statin therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24373206", "endSection": "abstract"}, {"offsetInBeginSection": 149, "offsetInEndSection": 237, "text": "It has been repeatedly reported that statins may cause new-onset diabetes mellitus (DM).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312577", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 186, "text": " Statins are evidence-based drugs to prevent cardiovascular (CV) disease. However, their benefits have been disputed by a statin-related increased risk of new onset diabetes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26437128", "endSection": "abstract"}, {"offsetInBeginSection": 1929, "offsetInEndSection": 2101, "text": " Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704171", "endSection": "abstract"}, {"offsetInBeginSection": 1339, "offsetInEndSection": 1456, "text": " statins are associated with a small increase in incidence of diabetes in patients predisposed to glycemic alteration", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26466221", "endSection": "abstract"}, {"offsetInBeginSection": 1542, "offsetInEndSection": 1748, "text": " Higher potency statin use is associated with a moderate increase in the risk of new onset diabetes compared with lower potency statins in patients treated for secondary prevention of cardiovascular disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24874977", "endSection": "abstract"}, {"offsetInBeginSection": 1600, "offsetInEndSection": 1732, "text": "An increased risk of new onset treated diabetes was found in those treated with statins showing significant duration and dose effect", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22845189", "endSection": "abstract"}, {"offsetInBeginSection": 1170, "offsetInEndSection": 1564, "text": "Although most of the clinical studies suggest a worsening of insulin resistance and secretion, the cardiovascular benefits of statin therapy outweigh the risk of developing insulin resistance, thus the data suggest the need to treat dyslipidemia and to make patients aware of the possible risk of developing type 2 diabetes or, if they already are diabetic, of worsening their metabolic control", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25208056", "endSection": "abstract"}, {"offsetInBeginSection": 1217, "offsetInEndSection": 1318, "text": "Statin therapy can slightly increase risk of incident diabetes in subjects with hypercholesterolemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27652354", "endSection": "abstract"}]}, {"body": "What is the effect of nocodazole cell treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27177335", "http://www.ncbi.nlm.nih.gov/pubmed/27609478", "http://www.ncbi.nlm.nih.gov/pubmed/27262873", "http://www.ncbi.nlm.nih.gov/pubmed/27815904", "http://www.ncbi.nlm.nih.gov/pubmed/27815897", "http://www.ncbi.nlm.nih.gov/pubmed/27833610"], "ideal_answer": ["Nocodazole trigger mitotic arrest."], "type": "factoid", "id": "58a8903b38c171fb5b000006", "snippets": [{"offsetInBeginSection": 664, "offsetInEndSection": 713, "text": "antimitotic SAC-inducing agents (i.e., nocodazole", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815897", "endSection": "abstract"}, {"offsetInBeginSection": 196, "offsetInEndSection": 229, "text": "spindle assembly checkpoint (SAC)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815897", "endSection": "abstract"}, {"offsetInBeginSection": 503, "offsetInEndSection": 557, "text": "Cells can also be enriched in mitosis using nocodazole", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815904", "endSection": "abstract"}, {"offsetInBeginSection": 598, "offsetInEndSection": 660, "text": " escape of metaphase I arrest induced by nocodazole treatment ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27177335", "endSection": "abstract"}, {"offsetInBeginSection": 1877, "offsetInEndSection": 1964, "text": " the treatment of CD4+T-cells with nocodazole, which disrupts the microtubular network,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27833610", "endSection": "abstract"}, {"offsetInBeginSection": 449, "offsetInEndSection": 485, "text": "nocodazole-triggered mitotic arrest.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27609478", "endSection": "abstract"}]}, {"body": "What is Path2PPI?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26733452"], "ideal_answer": ["Path2PPI is an R package to identify protein-protein interaction (PPI) networks for fully sequenced organisms for which nearly none PPI are known. Path2PPI predicts PPI networks based on sets of proteins from well-established model organisms, providing an intuitive visualization and usability. It can be used to combine and transfer information of a certain pathway or biological process from several reference organisms to one target organism."], "type": "summary", "id": "587e2a0cc32c812009000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Path2PPI: an R package to predict protein-protein interaction networks for a set of proteins", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733452", "endSection": "title"}, {"offsetInBeginSection": 14, "offsetInEndSection": 473, "text": "We introduce Path2PPI, a new R package to identify protein-protein interaction (PPI) networks for fully sequenced organisms for which nearly none PPI are known. Path2PPI predicts PPI networks based on sets of proteins from well-established model organisms, providing an intuitive visualization and usability. It can be used to combine and transfer information of a certain pathway or biological process from several reference organisms to one target organism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733452", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": ": We introduce Path2PPI, a new R package to identify protein-protein interaction (PPI) networks for fully sequenced organisms for which nearly none PPI are known.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733452", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 310, "text": "Path2PPI predicts PPI networks based on sets of proteins from well-established model organisms, providing an intuitive visualization and usability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733452", "endSection": "abstract"}]}, {"body": "SPAG5 was implicated in which cancers?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24853425", "http://www.ncbi.nlm.nih.gov/pubmed/21412013", "http://www.ncbi.nlm.nih.gov/pubmed/27312051", "http://www.ncbi.nlm.nih.gov/pubmed/27037000", "http://www.ncbi.nlm.nih.gov/pubmed/24194916"], "ideal_answer": ["SPAG5 was implicated in prostate cancer, lung cancer and cervical cancer."], "concepts": ["http://www.uniprot.org/uniprot/SPAG5_HUMAN", "http://www.uniprot.org/uniprot/SPAG5_MOUSE"], "type": "list", "id": "5884fe4ce56acf5176000010", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 349, "text": "BACKGROUND: We conducted multiple microarray datasets analyses from clinical and xenograft tumor tissues to search for disease progression-driving oncogenes in prostate cancer (PCa). Sperm-associated antigen 5 (SPAG5) attracted our attention. SPAG5 was recently identified as an oncogene participating in lung cancer and cervical cancer progression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27037000", "endSection": "abstract"}, {"offsetInBeginSection": 1533, "offsetInEndSection": 1737, "text": "CONCLUSION: Our results collectively showed a progression-driving role of SPAG5 in PCa which can be regulated by miR-539, suggesting that miR-539/SPAG5 can serve as a potential therapeutic target for PCa.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27037000", "endSection": "abstract"}, {"offsetInBeginSection": 886, "offsetInEndSection": 1277, "text": "RESULTS: We identified that SPAG5 expression was gradually increased in PCa progression and its level was significantly associated with lymph node metastasis, clinical stage, Gleason score, and biochemical recurrence. Our results indicated that SPAG5 knockdown can drastically inhibit PCa cell proliferation, migration, and invasion in vitro and supress tumor growth and metastasis in vivo. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27037000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "miR-539 inhibits prostate cancer progression by directly targeting SPAG5.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27037000", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051", "endSection": "title"}, {"offsetInBeginSection": 2450, "offsetInEndSection": 3859, "text": "Copy number aberration leading to SPAG5 gain or amplification and high SPAG5 transcript and SPAG5 protein concentrations were associated with shorter overall breast cancer-specific survival (METABRIC cohort [copy number aberration]: hazard ratio [HR]1\u00b750, 95% CI 1\u00b718-1\u00b792, p=0\u00b700010; METABRIC cohort [transcript]: 1\u00b768, 1\u00b740-2\u00b701, p<0\u00b70001; and Nottingham-HES-breast cancer cohort [protein]: 1\u00b768, 1\u00b732-2\u00b712, p<0\u00b70001). In multivariable analysis, high SPAG5 transcript and SPAG5 protein expression were associated with reduced breast cancer-specific survival at 10 years compared with lower concentrations (Uppsala: HR 1\u00b762, 95% CI 1\u00b703-2\u00b753, p=0\u00b7036; METABRIC: 1\u00b727, 1\u00b702-1\u00b758, p=0\u00b7034; untreated lymph node-negative cohort: 2\u00b734, 1\u00b724-4\u00b742, p=0\u00b70090; and Nottingham-HES: 1\u00b773, 1\u00b723-2\u00b746, p=0\u00b70020). In patients with oestrogen receptor-negative breast cancer with high SPAG5 protein expression, anthracycline-based adjuvant chemotherapy increased breast cancer-specific survival overall compared with that for patients who did not receive chemotherapy (Nottingham-oestrogen receptor-negative-ACT cohort: HR 0\u00b737, 95% CI 0\u00b720-0\u00b760, p=0\u00b70010). Multivariable analysis showed high SPAG5 transcript concentrations to be independently associated with longer distant relapse-free survival after receiving taxane plus anthracycline neoadjuvant chemotherapy (MD Anderson-NeoACT: HR 0\u00b768, 95% CI 0\u00b748-0\u00b797, p=0\u00b7031). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051", "endSection": "abstract"}, {"offsetInBeginSection": 4201, "offsetInEndSection": 4533, "text": "INTERPRETATION: SPAG5 is a novel amplified gene on Ch17q11.2 in breast cancer. The transcript and protein products of SPAG5 are independent prognostic and predictive biomarkers that might have clinical utility as biomarkers for combination cytotoxic chemotherapy sensitivity, especially in oestrogen receptor-negative breast cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853425", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Previously, we found that sperm-associated antigen 5 (SPAG5) was upregulated in pelvic lymph node metastasis-positive cervical cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853425", "endSection": "abstract"}, {"offsetInBeginSection": 1261, "offsetInEndSection": 1431, "text": "In general, SPAG5 upregulation relates to poor prognosis in cervical cancer patients, and SPAG5 is a regulator of mTOR activity during taxol treatment in cervical cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853425", "endSection": "abstract"}, {"offsetInBeginSection": 496, "offsetInEndSection": 742, "text": "RESULTS: We identified novel genes whose expression was upregulated in NSCLC, including SPAG5, POLH, KIF23, and RAD54L, which are associated with mitotic spindle formation, DNA repair, chromosome segregation, and dsDNA break repair, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21412013", "endSection": "abstract"}, {"offsetInBeginSection": 1431, "offsetInEndSection": 1546, "text": "Another module identified among male breast cancers, regulated by SPAG5, was closely associated with proliferation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194916", "endSection": "abstract"}, {"offsetInBeginSection": 300, "offsetInEndSection": 633, "text": "In our study, SPAG5 expression in cervical cancer patients was detected using quantitative real-time polymerase chain reaction, western blotting, and immunohistochemistry; cervical cancer cell function with downregulated SPAG5 in vitro was explored using tetrazolium assay, flow cytometry, and colony formation and Transwell assays. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853425", "endSection": "abstract"}, {"offsetInBeginSection": 3228, "offsetInEndSection": 3569, "text": "In patients with oestrogen receptor-negative breast cancer with high SPAG5 protein expression, anthracycline-based adjuvant chemotherapy increased breast cancer-specific survival overall compared with that for patients who did not receive chemotherapy (Nottingham-oestrogen receptor-negative-ACT cohort: HR 0\u00b737, 95% CI 0\u00b720-0\u00b760, p=0\u00b70010).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051", "endSection": "abstract"}, {"offsetInBeginSection": 1084, "offsetInEndSection": 1735, "text": "We investigated the clinicopathological relevance of SPAG5 gene copy number aberrations, mRNA transcript expression, and protein expression and analysed the associations of SPAG5 copy number aberrations, transcript expression, and protein expression with breast cancer-specific survival, disease-free survival, distant relapse-free survival, pathological complete response, and residual cancer burden in the Nottingham discovery cohort, Uppsala cohort, METABRIC cohort, a pooled untreated lymph node-negative cohort (n=684), a multicentre combined cohort (n=5439), the Nottingham historical early stage breast cancer cohort (Nottingham-HES; n=1650), N", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051", "endSection": "abstract"}, {"offsetInBeginSection": 2847, "offsetInEndSection": 3227, "text": "In multivariable analysis, high SPAG5 transcript and SPAG5 protein expression were associated with reduced breast cancer-specific survival at 10 years compared with lower concentrations (Uppsala: HR 1\u00b762, 95% CI 1\u00b703-2\u00b753, p=0\u00b7036; METABRIC: 1\u00b727, 1\u00b702-1\u00b758, p=0\u00b7034; untreated lymph node-negative cohort: 2\u00b734, 1\u00b724-4\u00b742, p=0\u00b70090; and Nottingham-HES: 1\u00b773, 1\u00b723-2\u00b746, p=0\u00b70020).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051", "endSection": "abstract"}, {"offsetInBeginSection": 1354, "offsetInEndSection": 1546, "text": "THY1 may thus be a promising novel prognostic marker for male breast cancer. Another module identified among male breast cancers, regulated by SPAG5, was closely associated with proliferation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194916", "endSection": "abstract"}, {"offsetInBeginSection": 1266, "offsetInEndSection": 1546, "text": "Furthermore, men with THY1 positive breast cancers had significantly inferior survival. THY1 may thus be a promising novel prognostic marker for male breast cancer. Another module identified among male breast cancers, regulated by SPAG5, was closely associated with proliferation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194916", "endSection": "abstract"}, {"offsetInBeginSection": 231, "offsetInEndSection": 337, "text": "SPAG5 was recently identified as an oncogene participating in lung cancer and cervical cancer progression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27037000", "endSection": "abstract"}, {"offsetInBeginSection": 4174, "offsetInEndSection": 4236, "text": "SPAG5 is a novel amplified gene on Ch17q11.2 in breast cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051", "endSection": "abstract"}, {"offsetInBeginSection": 2421, "offsetInEndSection": 2842, "text": "Copy number aberration leading to SPAG5 gain or amplification and high SPAG5 transcript and SPAG5 protein concentrations were associated with shorter overall breast cancer-specific survival (METABRIC cohort [copy number aberration]: hazard ratio [HR] 1\u00b750, 95% CI 1\u00b718-1\u00b792, p=0\u00b700010; METABRIC cohort [transcript]: 1\u00b768, 1\u00b740-2\u00b701, p<0\u00b70001; and Nottingham-HES-breast cancer cohort [protein]: 1\u00b768, 1\u00b732-2\u00b712, p<0\u00b70001).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312051", "endSection": "abstract"}]}, {"body": "What are some of the effects of Zika Virus in infected individuals?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26897108", "http://www.ncbi.nlm.nih.gov/pubmed/22389730", "http://www.ncbi.nlm.nih.gov/pubmed/27557413", "http://www.ncbi.nlm.nih.gov/pubmed/25294619", "http://www.ncbi.nlm.nih.gov/pubmed/27149205", "http://www.ncbi.nlm.nih.gov/pubmed/27088494", "http://www.ncbi.nlm.nih.gov/pubmed/24626205", "http://www.ncbi.nlm.nih.gov/pubmed/27862959", "http://www.ncbi.nlm.nih.gov/pubmed/27631604", "http://www.ncbi.nlm.nih.gov/pubmed/27010422", "http://www.ncbi.nlm.nih.gov/pubmed/489960", "http://www.ncbi.nlm.nih.gov/pubmed/27654889", "http://www.ncbi.nlm.nih.gov/pubmed/27337505", "http://www.ncbi.nlm.nih.gov/pubmed/27695855", "http://www.ncbi.nlm.nih.gov/pubmed/26969497", "http://www.ncbi.nlm.nih.gov/pubmed/27009036", "http://www.ncbi.nlm.nih.gov/pubmed/27490087", "http://www.ncbi.nlm.nih.gov/pubmed/27464346"], "ideal_answer": ["While most of the symptoms of zika virus are relatively mild, zika virus in pregnant mothers can cause microcephaly and other congenital defects in the fetus."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000071243", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000071244", "http://www.disease-ontology.org/api/metadata/DOID:0060478"], "type": "summary", "id": "58a3275960087bc10a00000f", "snippets": [{"offsetInBeginSection": 513, "offsetInEndSection": 710, "text": "Maternal-fetal transmission of Zika virus has been documented; evidence suggests that congenital Zika virus infection is associated with microcephaly and other adverse pregnancy and infant outcomes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009036", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 181, "text": "Recent studies have reported an increase in the number of fetuses and neonates with microcephaly whose mothers were infected with the Zika virus (ZIKV) during pregnancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695855", "endSection": "abstract"}, {"offsetInBeginSection": 1577, "offsetInEndSection": 2008, "text": "While the symptoms associated with Zika virus infection are generally mild, consisting of fever, maculopapular rash, arthralgia and conjunctivitis, there have been reports of more severe reactions that are associated with neurological complications. In pregnant women, fetal neurological complications include brain damage and microcephaly, while in adults there have been several cases of virus-associated Guillain-Barre syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26925496", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 330, "text": "ika virus is a flavivirus transmitted primarily by Aedes species mosquitoes, and symptoms of infection can include rash, fever, arthralgia, and conjunctivitis (1).* Zika virus infection during pregnancy is a cause of microcephaly and other severe brain defects (2). Infection has also been associated with Guillain-Barr\u00e9 syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27149205", "endSection": "abstract"}, {"offsetInBeginSection": 385, "offsetInEndSection": 502, "text": "To better understand the etiologic role and mechanism(s) of Zika virus in causing birth defects such as microcephaly,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27557413", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 623, "text": "Most persons infected with Zika virus have a mild illness or are asymptomatic. However, increasing evidence supports a link between Zika virus infection during pregnancy and adverse pregnancy and birth outcomes (1), and a possible association between recent Zika virus infection and Guillain-Barr\u00e9 syndrome has been reported (2).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27010422", "endSection": "abstract"}, {"offsetInBeginSection": 642, "offsetInEndSection": 775, "text": "There is now strong biologic evidence of causality between Zika virus and microcephaly and other neurologic abnormalities identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612155", "endSection": "abstract"}, {"offsetInBeginSection": 670, "offsetInEndSection": 812, "text": "Several pieces of evidence suggest that maternal Zika virus infection is associated with adverse neonatal outcomes, most notably microcephaly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26889662", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 259, "text": " Zika virus has gained international attention due to concerns for infection in pregnant women potentially causing fetal microcephaly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27330653", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 394, "text": "Zika virus is a flavivirus transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes, and infection can be asymptomatic or result in an acute febrile illness with rash (1). Zika virus infection during pregnancy is a cause of microcephaly and other severe birth defects (2). Infection has also been associated with Guillain-Barr\u00e9 syndrome (GBS) (3) and severe thrombocytopenia (4,5)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490087", "endSection": "abstract"}, {"offsetInBeginSection": 358, "offsetInEndSection": 712, "text": "Most Zika virus infections are asymptomatic (1,6). Clinical illness, when it occurs, is generally mild and characterized by acute onset of fever, maculopapular rash, arthralgia, or nonpurulent conjunctivitis. However, Zika virus infection during pregnancy can cause adverse outcomes such as fetal loss, and microcephaly and other serious brain anomalies ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27631604", "endSection": "abstract"}, {"offsetInBeginSection": 1742, "offsetInEndSection": 2004, "text": "In 2015, Zika virus infection was diagnosed in Brazil where it was associated with microcephaly in the infants of some women who were pregnant when they contracted the disease. Cases of the Guillain-Barr\u00e9 syndrome were also found to be associated with Zika virus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26969497", "endSection": "abstract"}, {"offsetInBeginSection": 2405, "offsetInEndSection": 2522, "text": "These findings strengthen the putative association between Zika virus and cases of microcephaly in neonates in Brazil", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26897108", "endSection": "abstract"}, {"offsetInBeginSection": 54, "offsetInEndSection": 310, "text": " In response to the current cluster of congenital malformations (microcephaly) and other neurological complications (Guillain-Barr\u00e9 Syndrome) that could be linked to Zika virus infection, WHO declares that Zika virus is of global public health importance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27087204", "endSection": "abstract"}, {"offsetInBeginSection": 218, "offsetInEndSection": 328, "text": "Zika virus infection during pregnancy can cause spontaneous abortion and birth defects, including microcephaly", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27337505", "endSection": "abstract"}, {"offsetInBeginSection": 252, "offsetInEndSection": 497, "text": "n the case of Zika virus, an accumulating body of recent evidence implicates the virus in the etiology of serious pathologies of the human nervous system, that is, the occurrence of microcephaly in neonates and Guillain-Barr\u00e9 syndrome in adults.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27464346", "endSection": "abstract"}, {"offsetInBeginSection": 272, "offsetInEndSection": 471, "text": "We describe the first case of Guillain-Barr\u00e9 syndrome (GBS) occurring immediately after a Zika virus infection, during the current Zika and type 1 and 3 dengue fever co-epidemics in French Polynesia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24626205", "endSection": "abstract"}, {"offsetInBeginSection": 112, "offsetInEndSection": 226, "text": "We report a case of Zika virus infection in an Australian traveler who returned from Indonesia with fever and rash", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23878182", "endSection": "abstract"}, {"offsetInBeginSection": 2, "offsetInEndSection": 701, "text": "woman who recently traveled to Thailand came to a local emergency department with a fever and papular rash. She was tested for measles, malaria, and dengue. Positive finding for IgM antibody against dengue and a failure to seroconvert for IgG against dengue for multiple blood samples suggested an alternate flavivirus etiology. Amplification of a conserved region of the non-structural protein 5 gene of the genus Flavivirus yielded a polymerase chain reaction product with a matching sequence of 99% identity with Zika virus. A urine sample and a nasopharygeal swab specimen obtained for the measles investigation were also positive for this virus by reverse transcription polymerase chain reactio", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25294619", "endSection": "abstract"}, {"offsetInBeginSection": 906, "offsetInEndSection": 1548, "text": " It is estimated that approximately 18% of individuals infected with ZIKV will go on to develop symptoms. When symptoms develop, it is usually within 3-12 days, although this may vary. Most often, symptoms are mild and self-limited. The most common symptoms are fever, arthralgia, maculopapular rash, and conjunctivitis lasting up to seven days. Less frequent symptoms include headache, vertigo, myalgia, vomiting, and diarrhea. At present, there is no vaccine available to prevent ZIKV and no specific antiviral treatment. Supportive care consisting of rest, hydration, analgesics, antihistamines, and antipyretics is recommended as needed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27862959", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 211, "text": "marked increase in infants born with microcephaly in Brazil after a 2015 outbreak of Zika virus (Zika virus) disease suggests an association between maternal Zika virus infection and congenital microcephaly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27088494", "endSection": "abstract"}, {"offsetInBeginSection": 153, "offsetInEndSection": 357, "text": "Zika virus causes a self-limiting, systemic illness; however, the current outbreak of Zika virus in the Americas has been associated with increased rates of fetal malformations and Guillain-Barr\u00e9 syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27654889", "endSection": "abstract"}]}, {"body": "What is the function of Oseltamivir when administered during flu?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23810646", "http://www.ncbi.nlm.nih.gov/pubmed/23794010", "http://www.ncbi.nlm.nih.gov/pubmed/12058885", "http://www.ncbi.nlm.nih.gov/pubmed/22754968", "http://www.ncbi.nlm.nih.gov/pubmed/19273546", "http://www.ncbi.nlm.nih.gov/pubmed/10708809", "http://www.ncbi.nlm.nih.gov/pubmed/22666678", "http://www.ncbi.nlm.nih.gov/pubmed/27341844", "http://www.ncbi.nlm.nih.gov/pubmed/20843284", "http://www.ncbi.nlm.nih.gov/pubmed/20537158", "http://www.ncbi.nlm.nih.gov/pubmed/19453477", "http://www.ncbi.nlm.nih.gov/pubmed/18457919", "http://www.ncbi.nlm.nih.gov/pubmed/12825569", "http://www.ncbi.nlm.nih.gov/pubmed/23208833", "http://www.ncbi.nlm.nih.gov/pubmed/24825206", "http://www.ncbi.nlm.nih.gov/pubmed/19523442", "http://www.ncbi.nlm.nih.gov/pubmed/21677258", "http://www.ncbi.nlm.nih.gov/pubmed/27490658", "http://www.ncbi.nlm.nih.gov/pubmed/20056566", "http://www.ncbi.nlm.nih.gov/pubmed/16838232", "http://www.ncbi.nlm.nih.gov/pubmed/26049014", "http://www.ncbi.nlm.nih.gov/pubmed/10866439", "http://www.ncbi.nlm.nih.gov/pubmed/19457254", "http://www.ncbi.nlm.nih.gov/pubmed/20218988", "http://www.ncbi.nlm.nih.gov/pubmed/23214216", "http://www.ncbi.nlm.nih.gov/pubmed/15750458", "http://www.ncbi.nlm.nih.gov/pubmed/20635821", "http://www.ncbi.nlm.nih.gov/pubmed/23997307", "http://www.ncbi.nlm.nih.gov/pubmed/19557131", "http://www.ncbi.nlm.nih.gov/pubmed/10536125", "http://www.ncbi.nlm.nih.gov/pubmed/23100798", "http://www.ncbi.nlm.nih.gov/pubmed/16494733", "http://www.ncbi.nlm.nih.gov/pubmed/24366750", "http://www.ncbi.nlm.nih.gov/pubmed/20499654", "http://www.ncbi.nlm.nih.gov/pubmed/24524404", "http://www.ncbi.nlm.nih.gov/pubmed/20885781"], "ideal_answer": ["Oseltamivir (has known by its brand name 'Tamiflu') is a prodrug, requiring ester hydrolysis for conversion to the active form, Oseltamivir carboxylate. Oseltamivir is the first orally active neuraminidase inhibitor and it is an antiviral drug for the treatment of Swine Flu."], "concepts": ["http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4242246", "http://www.biosemantics.org/jochem#4242246", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053139", "http://www.disease-ontology.org/api/metadata/DOID:8469", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4242585", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007251", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007252"], "type": "summary", "id": "589ae59c78275d0c4a000036", "snippets": [{"offsetInBeginSection": 796, "offsetInEndSection": 861, "text": "All patients were given specific antiviral therapy (oseltamivir).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23214216", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 614, "text": "Oseltamivir (has known by its brand name 'Tamiflu') is a prodrug, requiring ester hydrolysis for conversion to the active form, Oseltamivir carboxylate. Oseltamivir was the first orally active neuraminidase inhibitor commercially developed by US based Gilead Sciences and is currently marketed by F. Hoffmann-La Roche (Roche). Oseltamivir is an antiviral drug which works by blocking the function of the viral neuraminidase protein. US FDA approved Oseltamivir for prophylaxis of uncomplicated influenza A and B. Currently, Oseltamivir is the only first line defense drug available for the treatment of Swine Flu. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20843284", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 705, "text": "The latter is the binding cavity for 3 currently used neuraminidase inhibitors: oseltamivir (Tamiflu), zanamivir (Relenza) and peramivir; thus, the drugs should remain effective for treatment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19457254", "endSection": "abstract"}, {"offsetInBeginSection": 2829, "offsetInEndSection": 3050, "text": "Though therapeutic dose of oseltamivir was given as antiviral treatment for the early therapy, and other therapeutic measures such as energetic respiratory and circulatory support, and immunosuppressant therapy were given", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524404", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Oseltamivir (Tamiflu), a neuraminidase inhibitor, is widely used for treatment of influenza.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19273546", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Oseltamivir (Tamiflu), a neuraminidase inhibitor, is effective for treating both seasonal flu and H5N1 influenza A virus infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18457919", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "BACKGROUND: Oseltamivir phosphate (OP; Tamiflu) is a prodrug of the anti-influenza neuraminidase inhibitor oseltamivir carboxylate (OC) and has been developed for the treatment and prevention of both A and B strains of influenza.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20056566", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 220, "text": "Oseltamivir (Tamiflu) is currently the frontline antiviral drug employed to fight the flu virus in infected individuals by inhibiting neuraminidase, a flu protein responsible for the release of newly synthesized virions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20885781", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Oseltamivir (Tamiflu) is the most important antiviral drug available and a cornerstone in the defence against a future influenza pandemic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19557131", "endSection": "abstract"}, {"offsetInBeginSection": 454, "offsetInEndSection": 546, "text": "The country where oseltamivir is used most is Japan, where it is used to treat seasonal flu.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19557131", "endSection": "abstract"}, {"offsetInBeginSection": 1353, "offsetInEndSection": 1449, "text": "Oseltamivir safety and tolerability were verified in patients with new variant infection A/H1N1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20499654", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 620, "text": "To investigate oseltamivir and oseltamivir carboxylate pharmacokinetics in critically ill patients who were receiving continuous venovenous hemodialysis (CVVHD) and/or extracorporeal membrane oxygenation (ECMO).Prospective, open-label, pharmacokinetic study.Intensive care units of an academic medical center.Thirteen critically ill patients aged 13\u00a0years or older with suspected or confirmed H1N1 influenza who had a prescription for oseltamivir and were concurrently receiving CVVHD and/or ECMO between October 2009 and January 2010.Oseltamivir 150\u00a0mg was administered nasogastrically or nasoenterically every 12\u00a0hours", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23208833", "endSection": "abstract"}, {"offsetInBeginSection": 186, "offsetInEndSection": 748, "text": "The study included 3351 patients in whom influenza had been diagnosed by use of an antigen detection test kit.Oseltamivir was administered to 1818 patients with influenza A and 1485 patients with influenza B. No anti-influenza drugs were administered to 21 patients with influenza A or to 27 patients with influenza B. Patients receiving oseltamivir therapy were divided into 4 groups according to the time between the onset of fever (temperature, > or = 37.5 degrees C) and administration of the first dose of oseltamivir (0-12 h, 13-24 h, 25-36 h, and 37-48 h)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16838232", "endSection": "abstract"}, {"offsetInBeginSection": 331, "offsetInEndSection": 856, "text": "To clarify the usefulness of oseltamivir in the elderly we administered oseltamivir to all residents when an influenza A outbreak occurred in a nursing home.Sixty-eight residents in the nursing home were investigated in which the influenza A outbreak occurred; 32 residents had fever and 28 residents were positive for influenza A with direct enzyme immunoassay.Oseltamivir was administered at 75 mg twice daily for 5 days to all residents.Oseltamivir almost inhibited symptom onset in the influenza A-positive afebrile group", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12058885", "endSection": "abstract"}, {"offsetInBeginSection": 101, "offsetInEndSection": 261, "text": "Oseltamivir was administered to patients with influenza like illness and confirmed influenza, while their close contacts were given oseltamivir prophylactically", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16494733", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19523442", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Evaluation of treatment with Oseltamivir during the 2009 H1N1 (swine flu) pandemic: the problem of incomplete clinical information.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22754968", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10708809", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15750458", "endSection": "title"}, {"offsetInBeginSection": 107, "offsetInEndSection": 336, "text": "Oseltamivir (Tamiflu) is a potent and selective antiviral drug employed to fight the flu virus in infected individuals by inhibiting neuraminidase (NA), a flu protein responsible for the release and spread of the progeny virions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23794010", "endSection": "abstract"}, {"offsetInBeginSection": 327, "offsetInEndSection": 432, "text": "Oseltamivir is an antiviral drug which works by blocking the function of the viral neuraminidase protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20843284", "endSection": "abstract"}, {"offsetInBeginSection": 334, "offsetInEndSection": 432, "text": "Neuraminidase (NA) inhibitors (Oseltamivir and Zanamivir) are presently used as an anti-flu drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23100798", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 613, "text": "US FDA approved Oseltamivir for prophylaxis of uncomplicated influenza A and B. Currently, Oseltamivir is the only first line defense drug available for the treatment of Swine Flu.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20843284", "endSection": "abstract"}, {"offsetInBeginSection": 739, "offsetInEndSection": 872, "text": "Oseltamivir and Zanamivir have good number of interactions with H1N1 2009 virus and the scoring function also support to this result.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23100798", "endSection": "abstract"}, {"offsetInBeginSection": 1323, "offsetInEndSection": 1480, "text": "The number of interaction and scoring function shows that Oseltamivir and Zanamivir will be able to effectively control the present pandemic H1N1 virus 2009.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23100798", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "Oseltamivir (Tamiflu), a neuraminidase inhibitor, is effective for treating both seasonal flu and H5N1 influenza A virus infection. Oseltamivir is generally well tolerated, and its most common adverse effects are nausea and vomiting.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18457919", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 322, "text": "Oseltamivir (Tamiflu) is currently the frontline antiviral drug employed to fight the flu virus in infected individuals by inhibiting neuraminidase, a flu protein responsible for the release of newly synthesized virions. However, oseltamivir resistance has become a critical problem due to rapid mutation of the flu virus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20885781", "endSection": "abstract"}, {"offsetInBeginSection": 340, "offsetInEndSection": 592, "text": "Approximately 1.4% of tested isolates are oseltamivir resistant. We report a patient with an underlying hematological malignancy who was hospitalized with influenza A (H1N1) swine-origin and whose strain developed oseltamivir resistance during therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20218988", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 357, "text": "Oseltamivir (Tamiflu), a neuraminidase inhibitor, is widely used for treatment of influenza. Because abnormal behaviors have been observed in some Japanese teenagers following oseltamivir use, its safety has been questioned. Oseltamivir is known to alter neuronal function and behavior in animals, particularly when administered in combination with ethanol.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19273546", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 462, "text": "Oseltamivir (Tamiflu), a neuraminidase inhibitor, is effective for treating both seasonal flu and H5N1 influenza A virus infection. Oseltamivir is generally well tolerated, and its most common adverse effects are nausea and vomiting. However, neuropsychiatric behaviors including jumping and falling from balconies by young patients being treated by oseltamivir have been reported from Japan; this has led to warnings against its prescribing by many authorities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18457919", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 322, "text": "However, oseltamivir resistance has become a critical problem due to rapid mutation of the flu virus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20885781", "endSection": "abstract"}, {"offsetInBeginSection": 900, "offsetInEndSection": 1186, "text": "We observed also 10 infections A/H1N1 influenza during pregnancy, with good oseltamivir tolerance and without recent perinathal complications.CONCLUSIONS: Among 109 individuals with swine flu influenza, 67% have not complicated clinical manifestation and they recovered during 3-4 days.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20499654", "endSection": "abstract"}, {"offsetInBeginSection": 1323, "offsetInEndSection": 1481, "text": "The number of interaction and scoring function shows that Oseltamivir and Zanamivir will be able to effectively control the present pandemic H1N1 virus 2009..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23100798", "endSection": "abstract"}, {"offsetInBeginSection": 1446, "offsetInEndSection": 1516, "text": "Most reported that oseltamivir was an effective treatment for the flu.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490658", "endSection": "abstract"}, {"offsetInBeginSection": 582, "offsetInEndSection": 658, "text": "It is needed to perform surveillance on oseltamivir resistance in swine flu.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666678", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "The neuraminidase (NA) of influenza virus is the target of anti-flu drugs oseltamivir and zanamivir.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19523442", "endSection": "abstract"}, {"offsetInBeginSection": 330, "offsetInEndSection": 468, "text": "According to one trial, oseltamivir was moderately effective as a prophylactic for close contacts of 'flu cases (6.6% in absolute values).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12825569", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Oseltamivir: a first line defense against swine flu.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20843284", "endSection": "title"}, {"offsetInBeginSection": 2312, "offsetInEndSection": 2430, "text": "Oseltamivir administered daily for six weeks by the oral route is safe and effective for the prevention of influenza..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10536125", "endSection": "abstract"}]}, {"body": "What is the composition of the gamma-secretase complex?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15591316", "http://www.ncbi.nlm.nih.gov/pubmed/24723404", "http://www.ncbi.nlm.nih.gov/pubmed/24338474", "http://www.ncbi.nlm.nih.gov/pubmed/20299451", "http://www.ncbi.nlm.nih.gov/pubmed/12644463", "http://www.ncbi.nlm.nih.gov/pubmed/27059953", "http://www.ncbi.nlm.nih.gov/pubmed/15766275", "http://www.ncbi.nlm.nih.gov/pubmed/20534834", "http://www.ncbi.nlm.nih.gov/pubmed/18650432", "http://www.ncbi.nlm.nih.gov/pubmed/12821663", "http://www.ncbi.nlm.nih.gov/pubmed/11867728", "http://www.ncbi.nlm.nih.gov/pubmed/12834808", "http://www.ncbi.nlm.nih.gov/pubmed/12684521", "http://www.ncbi.nlm.nih.gov/pubmed/15322084", "http://www.ncbi.nlm.nih.gov/pubmed/20130175", "http://www.ncbi.nlm.nih.gov/pubmed/17560791", "http://www.ncbi.nlm.nih.gov/pubmed/16135086", "http://www.ncbi.nlm.nih.gov/pubmed/16249316", "http://www.ncbi.nlm.nih.gov/pubmed/17276981", "http://www.ncbi.nlm.nih.gov/pubmed/12805296", "http://www.ncbi.nlm.nih.gov/pubmed/16539675", "http://www.ncbi.nlm.nih.gov/pubmed/20178366", "http://www.ncbi.nlm.nih.gov/pubmed/14724271", "http://www.ncbi.nlm.nih.gov/pubmed/14602727", "http://www.ncbi.nlm.nih.gov/pubmed/24413617", "http://www.ncbi.nlm.nih.gov/pubmed/18359496"], "ideal_answer": ["Gamma-secretase is a multisubunit enzyme complex which is consists of four proteins: presenilin 1 (PS1) or presenilin 2 (PS2), nicastrin, Aph-1 and Pen-2."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0070765", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053829"], "type": "summary", "id": "58a2ccec60087bc10a000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "Gamma-secretase is a widely expressed multisubunit enzyme complex which is involved in the pathogenesis of Alzheimer disease and hematopoietic malignancies through its aberrant processing of the amyloid precursor protein (APP) and Notch1, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20178366", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "Presenilin (PS1 or PS2) is the catalytic component of the gamma-secretase complex, which mediates the final proteolytic processing step leading to the Alzheimer's disease (AD)-characterizing amyloid beta-peptide. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20534834", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "gamma-Secretase is a membrane-embedded multi-protein complex that catalyzes the final cut of the Alzheimer's disease-related amyloid precursor protein (APP) to amyloid-beta peptides of variable length (37-43 amino acids) via an unusual intramembrane cleavage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18359496", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "The gamma-secretase complex processes substrate proteins within membranes and consists of four proteins: presenilin (PS), nicastrin, Aph-1 and Pen-2. PS harbours the enzymatic activity of the complex, and there are two mammalian PS homologues: PS1 and PS2. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16135086", "endSection": "abstract"}, {"offsetInBeginSection": 170, "offsetInEndSection": 330, "text": "gamma-Secretase is known to contain four major protein constituents: presenilin (PS), nicastrin, Aph-1, and Pen-2, all of which are integral membrane proteins. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14724271", "endSection": "abstract"}, {"offsetInBeginSection": 583, "offsetInEndSection": 893, "text": "Here we describe the association of all four components of the gamma-secretase complex, namely presenilin 1 (PS1)-derived fragments, mature nicastrin, APH-1, and PEN-2, with cholesterol-rich detergent insoluble membrane (DIM) domains of non-neuronal cells and neurons that fulfill the criteria of lipid rafts. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15322084", "endSection": "abstract"}, {"offsetInBeginSection": 927, "offsetInEndSection": 1103, "text": "In contrast, the authentic TMD of NCT is critically required for the interaction with gamma-secretase complex components and for formation of an active gamma-secretase complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14602727", "endSection": "abstract"}, {"offsetInBeginSection": 223, "offsetInEndSection": 352, "text": "Active gamma-secretase is a tetrameric protein complex consisting of presenilin-1 (or -2), nicastrin, PEN-2, and Aph-1a (or -1b).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16249316", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "The gamma-secretase complex processes substrate proteins within membranes and consists of four proteins: presenilin (PS), nicastrin, Aph-1 and Pen-2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16135086", "endSection": "abstract"}, {"offsetInBeginSection": 703, "offsetInEndSection": 813, "text": "Maturation of exogenous NCT, gamma-secretase complex formation and proteolytic function was then investigated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14602727", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "gamma-Secretase complexes containing N- and C-terminal fragments of different presenilin origin retain normal gamma-secretase activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16135086", "endSection": "title"}, {"offsetInBeginSection": 1250, "offsetInEndSection": 1419, "text": "Co-overexpression of presenilin-1 or APH-1 abrogated gamma-secretase inhibition probably through prevention of the incorporation of CRB2 into the gamma-secretase complex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20299451", "endSection": "abstract"}, {"offsetInBeginSection": 1417, "offsetInEndSection": 1640, "text": "We conclude that a PS1/Pen2/Aph1a trimeric complex is an active enzyme, displaying biochemical properties similar to those of gamma-secretase and roughly 50% of its activity when normalized to PS1 N-terminal fragment levels", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20130175", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 285, "text": "\u03b3-Secretase is involved in the regulated intramembrane proteolysis of amyloid-\u03b2 protein precursor (A\u03b2PP) and of many other important physiological substrates. \u03b3-secretase is a multiproteic complex made of four main core components, namely presenilin 1 or 2, APH-1, PEN-2, and Nicastrin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24413617", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "Amyloid precursor protein associates with a nicastrin-dependent docking site on the presenilin 1-gamma-secretase complex in cells demonstrated by fluorescence lifetime imaging.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12805296", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11867728", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Characterization of the reconstituted gamma-secretase complex from Sf9 cells co-expressing presenilin 1, nicastrin [correction of nacastrin], aph-1a, and pen-2.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15766275", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "p53-Dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the integrity of the gamma-secretase complex but is independent of its activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17276981", "endSection": "title"}, {"offsetInBeginSection": 618, "offsetInEndSection": 820, "text": "Here we show that all known gamma-secretase complexes are active in APP processing and that all combinations of APH-1 variants with either FAD mutant PS1 or PS2 support pathogenic Abeta(42) production. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17560791", "endSection": "abstract"}, {"offsetInBeginSection": 386, "offsetInEndSection": 629, "text": "To characterize the functional similarity between complexes of various PS composition, we analysed PS1, PS2, and chimeric PS composed of the NTF from PS1 and CTF from PS2, or vice versa, in assembly and function of the gamma-secretase complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16135086", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 475, "text": "While beta-secretase is a classical aspartyl protease, gamma-secretase activity is associated with a high molecular weight complex. One of the complex components, which is critically required for gamma-secretase activity is nicastrin (NCT). Here we investigate the assembly of NCT into the gamma-secretase complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14602727", "endSection": "abstract"}, {"offsetInBeginSection": 703, "offsetInEndSection": 1103, "text": "Maturation of exogenous NCT, gamma-secretase complex formation and proteolytic function was then investigated. This revealed that the cytoplasmic tail of NCT is dispensable for gamma-secretase complex assembly and function. In contrast, the authentic TMD of NCT is critically required for the interaction with gamma-secretase complex components and for formation of an active gamma-secretase complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14602727", "endSection": "abstract"}, {"offsetInBeginSection": 814, "offsetInEndSection": 1103, "text": "This revealed that the cytoplasmic tail of NCT is dispensable for gamma-secretase complex assembly and function. In contrast, the authentic TMD of NCT is critically required for the interaction with gamma-secretase complex components and for formation of an active gamma-secretase complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14602727", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 401, "text": "While beta-secretase is a classical aspartyl protease, gamma-secretase activity is associated with a high molecular weight complex. One of the complex components, which is critically required for gamma-secretase activity is nicastrin (NCT).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14602727", "endSection": "abstract"}, {"offsetInBeginSection": 814, "offsetInEndSection": 1237, "text": "This revealed that the cytoplasmic tail of NCT is dispensable for gamma-secretase complex assembly and function. In contrast, the authentic TMD of NCT is critically required for the interaction with gamma-secretase complex components and for formation of an active gamma-secretase complex. Neither soluble NCT lacking any membrane anchor nor NCT containing a heterologous TMD were inserted into the gamma-secretase complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14602727", "endSection": "abstract"}, {"offsetInBeginSection": 927, "offsetInEndSection": 1237, "text": "In contrast, the authentic TMD of NCT is critically required for the interaction with gamma-secretase complex components and for formation of an active gamma-secretase complex. Neither soluble NCT lacking any membrane anchor nor NCT containing a heterologous TMD were inserted into the gamma-secretase complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14602727", "endSection": "abstract"}, {"offsetInBeginSection": 703, "offsetInEndSection": 926, "text": "Maturation of exogenous NCT, gamma-secretase complex formation and proteolytic function was then investigated. This revealed that the cytoplasmic tail of NCT is dispensable for gamma-secretase complex assembly and function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14602727", "endSection": "abstract"}, {"offsetInBeginSection": 402, "offsetInEndSection": 475, "text": "Here we investigate the assembly of NCT into the gamma-secretase complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14602727", "endSection": "abstract"}, {"offsetInBeginSection": 1250, "offsetInEndSection": 1420, "text": "Co-overexpression of presenilin-1 or APH-1 abrogated gamma-secretase inhibition probably through prevention of the incorporation of CRB2 into the gamma-secretase complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20299451", "endSection": "abstract"}, {"offsetInBeginSection": 1231, "offsetInEndSection": 1401, "text": "This could be demonstrated also in cell-free assays, where in addition presenilin-1, the catalytic subunit of the gamma-secretase complex, was shifted out of lipid rafts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18359496", "endSection": "abstract"}, {"offsetInBeginSection": 893, "offsetInEndSection": 1096, "text": "In PS1(-/-)/PS2(-/-) and NCT(-/-) fibroblasts, gamma-secretase components that still remain fail to become detergent-resistant, suggesting that raft association requires gamma-secretase complex assembly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15322084", "endSection": "abstract"}]}, {"body": "List kinases that phosphorylates the protein Bora.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27831827", "http://www.ncbi.nlm.nih.gov/pubmed/25803405", "http://www.ncbi.nlm.nih.gov/pubmed/26038951", "http://www.ncbi.nlm.nih.gov/pubmed/24675888", "http://www.ncbi.nlm.nih.gov/pubmed/23442801"], "ideal_answer": ["During cell division Bora becomes multiply phosphorylated by a variety of cell cycle kinases, including Aurora A and Plk1, and GSK3\u03b2 and Cdk1 albeit at distinctive sites."], "type": "list", "id": "58a80bc838c171fb5b000001", "snippets": [{"offsetInBeginSection": 1009, "offsetInEndSection": 1160, "text": "During cell division Bora becomes multiply phosphorylated by a variety of cell cycle kinases, including Aurora A and Plk1, albeit at distinctive sites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25803405", "endSection": "abstract"}, {"offsetInBeginSection": 849, "offsetInEndSection": 1010, "text": "Likewise, we find that phosphorylation of Bora by Cdk1 promotes phosphorylation of human Plk1 by Aurora A suggesting that this mechanism is conserved in humans. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26038951", "endSection": "abstract"}, {"offsetInBeginSection": 390, "offsetInEndSection": 500, "text": "we show that the master mitotic kinase Cdk1 contributes to Plk1 activation through SPAT-1/Bora phosphorylation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27831827", "endSection": "abstract"}, {"offsetInBeginSection": 1121, "offsetInEndSection": 1187, "text": "the potential role of Bora phosphorylation by Cdk1 in this process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27831827", "endSection": "abstract"}, {"offsetInBeginSection": 676, "offsetInEndSection": 754, "text": "phosphorylation of Bora on the Cdk consensus site T52 blocks Bora degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24675888", "endSection": "abstract"}, {"offsetInBeginSection": 299, "offsetInEndSection": 504, "text": "Here, we used the LC-MS/MS phosphopeptide mapping assay to identify 13 in vivo hBora phosphorylation sites and characterized that GSK3\u03b2 can interact with hBora and phosphorylate hBora at Ser274 and Ser278.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23442801", "endSection": "abstract"}]}, {"body": "Are deletions of chromosomal regulatory boundaries associated with congenital disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25315429"], "ideal_answer": ["Yes. Enhancer adoption caused by deletions of regulatory boundaries may contribute to a substantial minority of copy-number variation phenotypes and should thus be taken into account in their medical interpretation."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002872", "http://www.disease-ontology.org/api/metadata/DOID:1086", "http://www.disease-ontology.org/api/metadata/DOID:0080014"], "type": "yesno", "id": "587f56c392a5b8ad44000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Deletions of chromosomal regulatory boundaries are associated with congenital disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25315429", "endSection": "title"}, {"offsetInBeginSection": 1404, "offsetInEndSection": 1638, "text": "Our results suggest that enhancer adoption caused by deletions of regulatory boundaries may contribute to a substantial minority of copy-number variation phenotypes and should thus be taken into account in their medical interpretation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25315429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Deletions of chromosomal regulatory boundaries are associated with congenital disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25315429", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Deletions of chromosomal regulatory boundaries are associated with congenital disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25315429", "endSection": "title"}]}, {"body": "What is the role of the UBC9 enzyme in the protein sumoylation pathway?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24991007", "http://www.ncbi.nlm.nih.gov/pubmed/20561671", "http://www.ncbi.nlm.nih.gov/pubmed/25311713", "http://www.ncbi.nlm.nih.gov/pubmed/23628505", "http://www.ncbi.nlm.nih.gov/pubmed/21510985", "http://www.ncbi.nlm.nih.gov/pubmed/20800867", "http://www.ncbi.nlm.nih.gov/pubmed/16862185", "http://www.ncbi.nlm.nih.gov/pubmed/18617892", "http://www.ncbi.nlm.nih.gov/pubmed/19323834", "http://www.ncbi.nlm.nih.gov/pubmed/21518767", "http://www.ncbi.nlm.nih.gov/pubmed/21390240", "http://www.ncbi.nlm.nih.gov/pubmed/25097219", "http://www.ncbi.nlm.nih.gov/pubmed/20865051", "http://www.ncbi.nlm.nih.gov/pubmed/23708104", "http://www.ncbi.nlm.nih.gov/pubmed/21444718", "http://www.ncbi.nlm.nih.gov/pubmed/25637535", "http://www.ncbi.nlm.nih.gov/pubmed/26582473", "http://www.ncbi.nlm.nih.gov/pubmed/26889037", "http://www.ncbi.nlm.nih.gov/pubmed/23097446", "http://www.ncbi.nlm.nih.gov/pubmed/17698038", "http://www.ncbi.nlm.nih.gov/pubmed/26826302", "http://www.ncbi.nlm.nih.gov/pubmed/23381475", "http://www.ncbi.nlm.nih.gov/pubmed/27425617", "http://www.ncbi.nlm.nih.gov/pubmed/23187003", "http://www.ncbi.nlm.nih.gov/pubmed/22525038", "http://www.ncbi.nlm.nih.gov/pubmed/15546615", "http://www.ncbi.nlm.nih.gov/pubmed/11867732", "http://www.ncbi.nlm.nih.gov/pubmed/27142163", "http://www.ncbi.nlm.nih.gov/pubmed/23078246", "http://www.ncbi.nlm.nih.gov/pubmed/25191977", "http://www.ncbi.nlm.nih.gov/pubmed/15087395", "http://www.ncbi.nlm.nih.gov/pubmed/21278366", "http://www.ncbi.nlm.nih.gov/pubmed/22904261", "http://www.ncbi.nlm.nih.gov/pubmed/19826484"], "ideal_answer": ["The small ubiquitin-like modifier (SUMO) pathway in eukaryotes is an essential post-translational modification required for a variety of cellular processes, development and organelle biogenesis. SUMO-conjugating enzyme (Ubc9) is the sole conjunction enzyme in the SUMO pathway."], "concepts": ["http://www.uniprot.org/uniprot/UBC9_CHICK", "http://www.uniprot.org/uniprot/UBC9_MESAU", "http://www.uniprot.org/uniprot/UBC9_XENLA", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058207", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798", "http://www.uniprot.org/uniprot/UBC9_ARATH", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D025841", "http://www.uniprot.org/uniprot/UBC9_YEAST", "http://www.uniprot.org/uniprot/UBC9_SCHPO", "http://www.uniprot.org/uniprot/UBC9_HUMAN", "http://www.uniprot.org/uniprot/UBC9_DICDI", "http://amigo.geneontology.org/amigo/term/GO:0016925", "http://www.uniprot.org/uniprot/UBC9_ICTTR", "http://www.uniprot.org/uniprot/UBC9_MOUSE"], "type": "factoid", "id": "58a5b1fe60087bc10a000024", "snippets": [{"offsetInBeginSection": 117, "offsetInEndSection": 335, "text": "Among the proteins involved in the sumoylation pathway, Ubc9 is the sole E2-conjugating enzyme required for sumoylation and plays a central role by interacting with almost all of the partners required for sumoylation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191977", "endSection": "abstract"}, {"offsetInBeginSection": 933, "offsetInEndSection": 1032, "text": "We also found a marked rise in levels of Ubc9, the only SUMO conjugation enzyme identified so far. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23078246", "endSection": "abstract"}, {"offsetInBeginSection": 98, "offsetInEndSection": 279, "text": "Ubiquitin-conjugating enzyme 9 (Ubc9), the sole conjugating enzyme for sumoylation, regulates protein function and plays an important role in sumoylation-mediated cellular pathways.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23708104", "endSection": "abstract"}, {"offsetInBeginSection": 1026, "offsetInEndSection": 1166, "text": "We observed steady-state expression of SUMO1-3, SUMO-conjugated enzyme-UBC9 and deSUMOylating enzymes - SENPs, throughout normal gestation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628505", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 282, "text": "The small ubiquitin-like modifier (SUMO) pathway in eukaryotes is an essential post-translational modification required for a variety of cellular processes, development and organelle biogenesis. SUMO-conjugating enzyme (Ubc9) is an important conjunction enzyme in the SUMO pathway. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22525038", "endSection": "abstract"}, {"offsetInBeginSection": 1174, "offsetInEndSection": 1669, "text": "Western blot analysis, EMSA, ELISA, confocal microscopy and immunoprecipitation demonstrated that drastic tissue hypoxia, elevated levels of proteins conjugated by small ubiquitin-related modifier-1 (SUMO-1), Ubc9 (the only known conjugating enzyme for the sumoylation pathway) or HIF-1\u03b1, augmented sumoylation of HIF-1\u03b1, nucleus-bound translocation and enhanced transcriptional activity of HIF-1\u03b1 in RVLM neurons took place preferentially during the pro-life phase of experimental brain death. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390240", "endSection": "abstract"}, {"offsetInBeginSection": 116, "offsetInEndSection": 333, "text": "Among the proteins involved in the sumoylation pathway, Ubc9 is the sole E2-conjugating enzyme required for sumoylation and plays a central role by interacting with almost all of the partners required for sumoylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191977", "endSection": "abstract"}, {"offsetInBeginSection": 309, "offsetInEndSection": 436, "text": "UBC9 is the only E2 conjugating enzyme involved in this process, and loss of UBC9 completely abolishes the SUMOylation pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27425617", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 235, "text": "Here we have identified host cell proteins involved with the cellular SUMOylation pathway, SUMO-1 (small ubiquitin-like modifier) and UBC9, a SUMO-1 conjugating enzyme that interact with classical swine fever virus (CSFV) Core protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20800867", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 278, "text": "Ubiquitin-conjugating enzyme 9 (Ubc9), the sole conjugating enzyme for sumoylation, regulates protein function and plays an important role in sumoylation-mediated cellular pathways.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23708104", "endSection": "abstract"}, {"offsetInBeginSection": 341, "offsetInEndSection": 573, "text": "In this study, we found that the SUMOylation pathway was involved in the DENV life cycle, since DENV replication was reduced by silencing the cellular gene Ubc9, which encodes the sole E2-conjugating enzyme required for SUMOylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26889037", "endSection": "abstract"}, {"offsetInBeginSection": 202, "offsetInEndSection": 349, "text": "Here we demonstrate that the synaptic diffusion of Ubc9, the sole conjugating enzyme of the sumoylation pathway, is regulated by synaptic activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25311713", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "The SUMO pathway parallels the classical ubiquitinylation pathway with three discrete steps: activation involving the enzyme E1, conjugation involving the E2 enzyme UBC9, and substrate modification through the cooperative association of UBC9 and E3 ligases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15546615", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "RAP80 interacts with the SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17698038", "endSection": "title"}, {"offsetInBeginSection": 117, "offsetInEndSection": 334, "text": "Among the proteins involved in the sumoylation pathway, Ubc9 is the sole E2-conjugating enzyme required for sumoylation and plays a central role by interacting with almost all of the partners required for sumoylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191977", "endSection": "abstract"}, {"offsetInBeginSection": 134, "offsetInEndSection": 273, "text": "Although there are multiple E2 enzymes required for ubiquitination, there is only one E2-conjugating enzyme for sumoylation, which is Ubc9.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20561671", "endSection": "abstract"}, {"offsetInBeginSection": 492, "offsetInEndSection": 709, "text": "Consistent with a role of sumoylation in inhibiting Tec1 activity, specifically increasing sumoylation of Tec1 by fusing it to the sumoylating enzyme Ubc9 leads to a dramatic decrease of Tec1 transcriptional activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19826484", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Ubc9 is an E2-conjugating enzyme required for sumoylation and has been implicated in regulating several critical cellular pathways.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15087395", "endSection": "abstract"}, {"offsetInBeginSection": 901, "offsetInEndSection": 1132, "text": "We also exposed placental explants to hypoxia to study the effect on the SUMOylation pathway.We observed steady-state expression of SUMO1-3, SUMO-conjugated enzyme-UBC9 and deSUMOylating enzymes - SENPs, throughout normal gestation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628505", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "It has been reported that ubiquitin-conjugating enzyme 9 (Ubc9), the unique enzyme2 in the sumoylation pathway, is up-regulated in many cancers", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23187003", "endSection": "abstract"}, {"offsetInBeginSection": 117, "offsetInEndSection": 333, "text": "Among the proteins involved in the sumoylation pathway, Ubc9 is the sole E2-conjugating enzyme required for sumoylation and plays a central role by interacting with almost all of the partners required for sumoylation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191977", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 349, "text": "Here we demonstrate that the synaptic diffusion of Ubc9, the sole conjugating enzyme of the sumoylation pathway, is regulated by synaptic activity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25311713", "endSection": "abstract"}, {"offsetInBeginSection": 174, "offsetInEndSection": 416, "text": "Here, we investigated inhibition of sumoylation as a novel antifibrotic approach.Sumoylation was inhibited by siRNA-mediated knockdown of the Small Ubiquitin-like MOdifiers (SUMO) E2-conjugating enzyme Ubc9, which is essential for sumoylation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22904261", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Here we have identified host cell proteins involved with the cellular SUMOylation pathway, SUMO-1 (small ubiquitin-like modifier) and UBC9, a SUMO-1 conjugating enzyme that interact with classical swine fever virus (CSFV) Core protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20800867", "endSection": "abstract"}, {"offsetInBeginSection": 347, "offsetInEndSection": 566, "text": "A new pathway that contributes to mutant CFTR degradation is mediated by the small heat shock protein, Hsp27, which cooperates with Ubc9, the E2 enzyme for SUMOylation, to selectively conjugate mutant CFTR with SUMO-2/3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26582473", "endSection": "abstract"}, {"offsetInBeginSection": 420, "offsetInEndSection": 749, "text": "Using transfection of Ets-1 wildtype (WT) or its sumoylation deficient version (Ets-1 K15R/K227R), as well as WT or mutant proteins of the SUMO pathway, we further demonstrated that the E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation, while a SUMO protease, SENP1, can desumoylate Ets-1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16862185", "endSection": "abstract"}, {"offsetInBeginSection": 485, "offsetInEndSection": 863, "text": "The results show that basal SUMO modification is required for stimuli-induced p100 phosphorylation and that blocking SUMOylation of p100, either by site-directed mutation or by short interfering RNA-targeted diminution of E2 SUMO-conjugating enzyme Ubc9, inhibits various physiological stimuli-induced p100 processing and ultimate activation of the alternative NF-kappaB pathway", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18617892", "endSection": "abstract"}, {"offsetInBeginSection": 290, "offsetInEndSection": 482, "text": "Sumoylation proceeds via an enzymatic pathway that is mechanistically analogous to ubiquitination, but requires a different E1-activating enzyme and Ubc9, a SUMO-specific E2-conjugating enzyme", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11867732", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23097446", "endSection": "title"}, {"offsetInBeginSection": 526, "offsetInEndSection": 695, "text": "OBJECTIVE: To determine the role of ubiquitin-conjugating enzyme 9 (UBC9), a small ubiquitin-like modifier-conjugating enzyme, in cardiomyocyte protein quality control. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25097219", "endSection": "abstract"}, {"offsetInBeginSection": 521, "offsetInEndSection": 695, "text": "Ubiquitin-conjugating enzyme             9 (Ubc9), the sole conjugating enzyme for sumoylation, regulates protein function             and plays a key role in tumorigenesis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23381475", "endSection": "abstract"}, {"offsetInBeginSection": 311, "offsetInEndSection": 438, "text": "UBC9 is the only E2 conjugating enzyme involved in this process, and loss of UBC9 completely abolishes the SUMOylation pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27425617", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 350, "text": "Here we demonstrate that the synaptic diffusion of Ubc9, the sole conjugating enzyme of the sumoylation pathway, is regulated by synaptic activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25311713", "endSection": "abstract"}, {"offsetInBeginSection": 290, "offsetInEndSection": 483, "text": "Sumoylation proceeds via an enzymatic pathway that is mechanistically analogous to ubiquitination, but requires a different E1-activating enzyme and Ubc9, a SUMO-specific E2-conjugating enzyme.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11867732", "endSection": "abstract"}, {"offsetInBeginSection": 1130, "offsetInEndSection": 1624, "text": "Western blot analysis, EMSA, ELISA, confocal microscopy and immunoprecipitation demonstrated that drastic tissue hypoxia, elevated levels of proteins conjugated by small ubiquitin-related modifier-1 (SUMO-1), Ubc9 (the only known conjugating enzyme for the sumoylation pathway) or HIF-1\u03b1, augmented sumoylation of HIF-1\u03b1, nucleus-bound translocation and enhanced transcriptional activity of HIF-1\u03b1 in RVLM neurons took place preferentially during the pro-life phase of experimental brain death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390240", "endSection": "abstract"}, {"offsetInBeginSection": 343, "offsetInEndSection": 575, "text": "In this study, we found that the SUMOylation pathway was involved in the DENV life cycle, since DENV replication was reduced by silencing the cellular gene Ubc9, which encodes the sole E2-conjugating enzyme required for SUMOylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26889037", "endSection": "abstract"}, {"offsetInBeginSection": 168, "offsetInEndSection": 311, "text": "In this study, we revisited the role of Tax SUMOylation using a strategy based on the targeting of Ubc9, the unique E2 SUMO-conjugating enzyme.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991007", "endSection": "abstract"}, {"offsetInBeginSection": 933, "offsetInEndSection": 1155, "text": "Taken together, these findings provide evidence for regulated sumoylation as a mechanism to modulate the activity of Tec1 and validate Ubc9 fusion-directed sumoylation as a useful approach for studying protein sumoylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19826484", "endSection": "abstract"}, {"offsetInBeginSection": 353, "offsetInEndSection": 518, "text": "We report that the high risk HPVE6 proteins reduce the intracellular quantity of the sole SUMO conjugation enzyme, Ubc9, concomitant with decreased host sumoylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21510985", "endSection": "abstract"}, {"offsetInBeginSection": 996, "offsetInEndSection": 1135, "text": "We observed steady-state expression of SUMO1-3, SUMO-conjugated enzyme-UBC9 and deSUMOylating enzymes - SENPs, throughout normal gestation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628505", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "As the sole E2 enzyme for SUMOylation, Ubc9 is predominantly nuclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25637535", "endSection": "abstract"}, {"offsetInBeginSection": 135, "offsetInEndSection": 397, "text": "Expression of small ubiquitin-like modifier (SUMO) molecules, SUMO E1 activating enzymes SAE1 and SAE2, SUMO E2 conjugating enzyme UBC9, and de-sumoylation enzyme sentrin/SUMO-specific proteases (SENP)1 was immunolocalized in rat intervertebral disc (IVD) cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26826302", "endSection": "abstract"}]}, {"body": "Can the Micro-C XL method achieve mononucleosome resolution?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27723753"], "ideal_answer": ["Yes. Micro-C XL is an improved method for analysis of chromosome folding at mononucleosome resolution."], "type": "yesno", "id": "587dfde9ae05ffb474000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "We present Micro-C XL, an improved method for analysis of chromosome folding at mononucleosome resolution", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "We present Micro-C XL, an improved method for analysis of chromosome folding at mononucleosome resolution.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Micro-C XL: assaying chromosome conformation from the nucleosome to the entire genome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753", "endSection": "title"}, {"offsetInBeginSection": 413, "offsetInEndSection": 538, "text": "Micro-C XL provides a single assay to interrogate chromosome folding at length scales from the nucleosome to the full genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723753", "endSection": "abstract"}]}, {"body": "Can Diabetes be caused by a defect in a potassium chanel?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25931474", "http://www.ncbi.nlm.nih.gov/pubmed/27118464", "http://www.ncbi.nlm.nih.gov/pubmed/15746700", "http://www.ncbi.nlm.nih.gov/pubmed/24827651"], "ideal_answer": ["Mutations in the KATP channel can lead to neonatal diabetes.", "Mutations in KATP channel genes can result in hypo- or hypersecretion of insulin, as in neonatal diabetes mellitus and congenital hyperinsulinism, respectively."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016640", "http://www.disease-ontology.org/api/metadata/DOID:11717", "http://www.disease-ontology.org/api/metadata/DOID:9351", "http://www.biosemantics.org/jochem#4277521", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011188", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011189", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003921", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003923", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003922", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4277521", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003920", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024681", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003924", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015221"], "type": "yesno", "id": "58a0a28a78275d0c4a000051", "snippets": [{"offsetInBeginSection": 146, "offsetInEndSection": 306, "text": "Mutations in KATP channel genes can result in hypo- or hypersecretion of insulin, as in neonatal diabetes mellitus and congenital hyperinsulinism, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27118464", "endSection": "abstract"}, {"offsetInBeginSection": 307, "offsetInEndSection": 472, "text": "To date, all patients affected by neonatal diabetes due to a mutation in the pore-forming subunit of the channel (Kir6.2, KCNJ11) are heterozygous for the mutation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27118464", "endSection": "abstract"}, {"offsetInBeginSection": 479, "offsetInEndSection": 571, "text": "e report the first clinical case of neonatal diabetes caused by a homozygous KCNJ11 mutation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27118464", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Diffuse congenital hyperinsulinism in infancy (CHI-D) arises from mutations inactivating the KATP channel;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25931474", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "We report a case of a 6-week-old infant with diabetes mellitus based on a genetic defect in the sulfonylurea receptor 1 (SUR1), an ATP-sensitive potassium (KATP) channel protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24827651", "endSection": "abstract"}, {"offsetInBeginSection": 1094, "offsetInEndSection": 1150, "text": "In diabetes, vascular KATP channel function is impaired.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15746700", "endSection": "abstract"}]}, {"body": "Which fimA genotypes are associated with disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22549664", "http://www.ncbi.nlm.nih.gov/pubmed/20219603", "http://www.ncbi.nlm.nih.gov/pubmed/22466890", "http://www.ncbi.nlm.nih.gov/pubmed/23264452", "http://www.ncbi.nlm.nih.gov/pubmed/26387644", "http://www.ncbi.nlm.nih.gov/pubmed/22053966", "http://www.ncbi.nlm.nih.gov/pubmed/23646850", "http://www.ncbi.nlm.nih.gov/pubmed/24466164", "http://www.ncbi.nlm.nih.gov/pubmed/26937292", "http://www.ncbi.nlm.nih.gov/pubmed/26600627"], "ideal_answer": ["FimA has been characterized as an important virulence factor for P. gingivalis, and many studies, both animal experiments and clinical investigations, have characterized fimA genotypes II, Ib, and IV to be associated with disease (periodontitis and cardiovascular disease)"], "type": "list", "id": "58a94483ee23e0236b000003", "snippets": [{"offsetInBeginSection": 476, "offsetInEndSection": 750, "text": " FimA has been characterized as an important virulence factor for P. gingivalis, and many studies, both animal experiments and clinical investigations, have characterized fimA genotypes II, Ib, and IV to be associated with disease (periodontitis and cardiovascular disease) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26387644", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 179, "text": "Long fimbriae (FimA) are important virulence factors of Porphyromonas gingivalis. Based on the diversity of the fimA gene, this species is classified into 6 genotypes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20219603", "endSection": "abstract"}, {"offsetInBeginSection": 782, "offsetInEndSection": 1066, "text": " In cases of chronic apical periodontitis, P. gingivalis variant type IV was the most prevalent (24%), followed by types I (20%), II (16%), and III (8%). In acute abscess samples, variant type II was the most prevalent (12%), followed by types III and IV (8% of each) and type I (4%).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20219603", "endSection": "abstract"}, {"offsetInBeginSection": 959, "offsetInEndSection": 1082, "text": "We show that P. gingivalis strains with genotype I and II of FimA are efficient in interaction with saliva or S. gordonii. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22053966", "endSection": "abstract"}, {"offsetInBeginSection": 1238, "offsetInEndSection": 1435, "text": "A strong association between Porphyromonas gingivalis fimA genotypes II and Ib and chronic periodontitis exists in the Spanish population. The most prevalent genotype in periodontal patients is II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22549664", "endSection": "abstract"}, {"offsetInBeginSection": 1022, "offsetInEndSection": 1206, "text": "Our results suggest that the presence of P. gingivalis is associated with periodontal diseases, and that the type II, IV and Ib/II combination are the most common among fimA genotypes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22466890", "endSection": "abstract"}, {"offsetInBeginSection": 1218, "offsetInEndSection": 1361, "text": "Statistical analysis, however, revealed that a more significant correlation was found between periodontitis and the occurrence of type Ib fimA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23264452", "endSection": "abstract"}, {"offsetInBeginSection": 1667, "offsetInEndSection": 1755, "text": " Type II of fimA was the most prevalent genotype of P. gingivalis in patients with AgP. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23646850", "endSection": "abstract"}, {"offsetInBeginSection": 1211, "offsetInEndSection": 1409, "text": "The population of Tregs further decreased in patients with type II FimA compared with the other types. P.gingivlias FimA genotype II was the dominant type associated with decreased Treg population. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24466164", "endSection": "abstract"}, {"offsetInBeginSection": 1099, "offsetInEndSection": 1220, "text": "A trend toward a greater frequency of FimA II genotype in patients with moderate and severe periodontitis was determined.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26600627", "endSection": "abstract"}, {"offsetInBeginSection": 1251, "offsetInEndSection": 1441, "text": "The fimA type Ib genotype of P. gingivalis was found to play a critical role in the destruction of peri-implant tissue, suggesting that it may be a distinct risk factor for peri-implantitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26937292", "endSection": "abstract"}]}, {"body": "Is rucaparib used for ovarian cancer treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24962512", "http://www.ncbi.nlm.nih.gov/pubmed/27141070", "http://www.ncbi.nlm.nih.gov/pubmed/27087632", "http://www.ncbi.nlm.nih.gov/pubmed/27940438", "http://www.ncbi.nlm.nih.gov/pubmed/26281686", "http://www.ncbi.nlm.nih.gov/pubmed/27141062", "http://www.ncbi.nlm.nih.gov/pubmed/27702817", "http://www.ncbi.nlm.nih.gov/pubmed/27908594", "http://www.ncbi.nlm.nih.gov/pubmed/27002934", "http://www.ncbi.nlm.nih.gov/pubmed/27716873", "http://www.ncbi.nlm.nih.gov/pubmed/27022037", "http://www.ncbi.nlm.nih.gov/pubmed/23729402"], "ideal_answer": ["Yes, rucaparib is a PARP inhibitor that is used for ovarian cancer treatment."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", "http://www.disease-ontology.org/api/metadata/DOID:2394", "http://www.disease-ontology.org/api/metadata/DOID:4001", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024221"], "type": "yesno", "id": "588485bbe56acf517600000b", "snippets": [{"offsetInBeginSection": 1323, "offsetInEndSection": 1607, "text": "While olaparib is the first PARP inhibitor to receive approval for ovarian cancer treatment, others including rucaparib and niraparib are clearly effective in this disease and, within the next year or two, the results of ongoing randomised trials will clarify their respective roles. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141062", "endSection": "abstract"}, {"offsetInBeginSection": 1219, "offsetInEndSection": 1359, "text": "Similar trials with other PARP inhibitors (rucaparib, niraparib and veliparib) are in progress and include non-BRCA-mutated ovarian cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141070", "endSection": "abstract"}, {"offsetInBeginSection": 1570, "offsetInEndSection": 1840, "text": "IMPLICATIONS FOR PRACTICE: The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib has recently received approval from the Food and Drug Administration (FDA) and European Medicines Agency (EMA), with a second agent (rucaparib) likely to be approved in the near future.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27022037", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27702817", "endSection": "title"}, {"offsetInBeginSection": 1256, "offsetInEndSection": 1413, "text": "There are a number of other PARP inhibitors in late phase clinical development in ovarian cancer including rucaparib, niraparib, veliparib, and talazoparib. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716873", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27908594", "endSection": "title"}, {"offsetInBeginSection": 3353, "offsetInEndSection": 3757, "text": "INTERPRETATION: In patients with BRCA mutant or BRCA wild-type and LOH high platinum-sensitive ovarian carcinomas treated with rucaparib, progression-free survival was longer than in patients with BRCA wild-type LOH low carcinomas. Our results suggest that assessment of tumour LOH can be used to identify patients with BRCA wild-type platinum-sensitive ovarian cancers who might benefit from rucaparib. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27908594", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Genomic LOH May Predict Rucaparib Response in Ovarian Cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940438", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "High LOH is associated with response to the PARP inhibitor rucaparib in BRCA wild-type ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940438", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "title"}, {"offsetInBeginSection": 1317, "offsetInEndSection": 1600, "text": "While olaparib is the first PARP inhibitor to receive approval for ovarian cancer treatment, others including rucaparib and niraparib are clearly effective in this disease and, within the next year or two, the results of ongoing randomised trials will clarify their respective roles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141062", "endSection": "abstract"}, {"offsetInBeginSection": 1596, "offsetInEndSection": 1762, "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 501, "offsetInEndSection": 704, "text": "Rucaparib received US FDA Breakthrough Therapy designation for treatment of platinum-sensitive BRCA-mutated advanced ovarian cancer patients who received greater than two lines of platinum-based therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27087632", "endSection": "abstract"}, {"offsetInBeginSection": 1605, "offsetInEndSection": 1771, "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 124, "offsetInEndSection": 650, "text": "Ongoing clinical trials are assessing the efficacy of rucaparib alone or in combination with other cytotoxic drugs, mainly in breast and ovarian cancer patients with mutations in the breast cancer associated (BRCA) genes.PURPOSE: We aimed to establish whether the multidrug efflux transporters ABCG2 (BCRP) and ABCB1 (P-gp, MDR1) affect the oral availability and brain penetration of rucaparib in mice.RESULTS: In vitro, rucaparib was efficiently transported by both human ABCB1 and ABCG2, and very efficiently by mouse Abcg2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24962512", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 1605, "offsetInEndSection": 1805, "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.<CopyrightInformation>\u00a92013 AACR</", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 112, "offsetInEndSection": 619, "text": "Ongoing clinical trials are assessing the efficacy of rucaparib alone or in combination with other cytotoxic drugs, mainly in breast and ovarian cancer patients with mutations in the breast cancer associated (BRCA) genes.We aimed to establish whether the multidrug efflux transporters ABCG2 (BCRP) and ABCB1 (P-gp, MDR1) affect the oral availability and brain penetration of rucaparib in mice.In vitro, rucaparib was efficiently transported by both human ABCB1 and ABCG2, and very efficiently by mouse Abcg2", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24962512", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 1323, "offsetInEndSection": 1606, "text": "While olaparib is the first PARP inhibitor to receive approval for ovarian cancer treatment, others including rucaparib and niraparib are clearly effective in this disease and, within the next year or two, the results of ongoing randomised trials will clarify their respective roles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141062", "endSection": "abstract"}, {"offsetInBeginSection": 253, "offsetInEndSection": 570, "text": "We investigated the efficacy and safety of single-agent rucaparib in germline (g) BRCA mutation carriers with advanced breast and ovarian cancers.Phase II, open-label, multicentre trial of rucaparib in proven BRCA-1/2 mutation carriers with advanced breast and or ovarian cancer, WHO PS 0-1 and normal organ function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27002934", "endSection": "abstract"}, {"offsetInBeginSection": 1605, "offsetInEndSection": 1806, "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.<CopyrightInformation>\u00a92013 AACR</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}, {"offsetInBeginSection": 1190, "offsetInEndSection": 1329, "text": "Similar trials with other PARP inhibitors (rucaparib, niraparib and veliparib) are in progress and include non-BRCA-mutated ovarian cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27141070", "endSection": "abstract"}, {"offsetInBeginSection": 504, "offsetInEndSection": 707, "text": "Rucaparib received US FDA Breakthrough Therapy designation for treatment of platinum-sensitive BRCA-mutated advanced ovarian cancer patients who received greater than two lines of platinum-based therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27087632", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "title"}, {"offsetInBeginSection": 1605, "offsetInEndSection": 1772, "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402", "endSection": "abstract"}]}, {"body": "What is the role of cohesins at the IFNG locus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19458616"], "ideal_answer": ["Cohesins form cell-type-specific long-range chromosomal cis-interactions at the developmentally regulated IFNG locus. Hence, the ability of cohesin to constrain chromosome topology is used not only for the purpose of sister chromatid cohesion, but also to dynamically define the spatial conformation of specific loci. This new aspect of cohesin function is probably important for normal development and disease."], "concepts": ["http://www.uniprot.org/uniprot/IFNG_NUMME", "http://www.uniprot.org/uniprot/IFNG_PHOSU", "http://www.uniprot.org/uniprot/IFNG_PHACO", "http://www.uniprot.org/uniprot/IFNG_PAPAN", "http://www.uniprot.org/uniprot/IFNG_LAMGL", "http://www.uniprot.org/uniprot/IFNG_RABIT", "http://www.uniprot.org/uniprot/IFNG_MACMU", "http://www.uniprot.org/uniprot/IFNG_PANTR", "http://www.uniprot.org/uniprot/IFNG_PERMA", "http://www.uniprot.org/uniprot/IFNG_MACFA"], "type": "summary", "id": "588533cee56acf5176000014", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Cohesins form chromosomal cis-interactions at the developmentally regulated IFNG locus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", "endSection": "title"}, {"offsetInBeginSection": 828, "offsetInEndSection": 1310, "text": "Here we show that cohesin forms the topological and mechanistic basis for cell-type-specific long-range chromosomal interactions in cis at the developmentally regulated cytokine locus IFNG. Hence, the ability of cohesin to constrain chromosome topology is used not only for the purpose of sister chromatid cohesion, but also to dynamically define the spatial conformation of specific loci. This new aspect of cohesin function is probably important for normal development and disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", "endSection": "abstract"}, {"offsetInBeginSection": 823, "offsetInEndSection": 1012, "text": "Here we show that cohesin forms the topological and mechanistic basis for cell-type-specific long-range chromosomal interactions in cis at the developmentally regulated cytokine locus IFNG.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Cohesins form chromosomal cis-interactions at the developmentally regulated IFNG locus", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", "endSection": "title"}, {"offsetInBeginSection": 828, "offsetInEndSection": 1016, "text": "Here we show that cohesin forms the topological and mechanistic basis for cell-type-specific long-range chromosomal interactions in cis at the developmentally regulated cytokine locus IFNG", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Cohesins form chromosomal cis-interactions at the developmentally regulated IFNG locus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", "endSection": "title"}, {"offsetInBeginSection": 828, "offsetInEndSection": 1017, "text": "Here we show that cohesin forms the topological and mechanistic basis for cell-type-specific long-range chromosomal interactions in cis at the developmentally regulated cytokine locus IFNG.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458616", "endSection": "abstract"}]}, {"body": "Describe Wellens' Syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27609724", "http://www.ncbi.nlm.nih.gov/pubmed/23420731", "http://www.ncbi.nlm.nih.gov/pubmed/21106319", "http://www.ncbi.nlm.nih.gov/pubmed/12442245", "http://www.ncbi.nlm.nih.gov/pubmed/16380872", "http://www.ncbi.nlm.nih.gov/pubmed/27951539", "http://www.ncbi.nlm.nih.gov/pubmed/26432739", "http://www.ncbi.nlm.nih.gov/pubmed/25161778", "http://www.ncbi.nlm.nih.gov/pubmed/18649894", "http://www.ncbi.nlm.nih.gov/pubmed/14708424", "http://www.ncbi.nlm.nih.gov/pubmed/27041816", "http://www.ncbi.nlm.nih.gov/pubmed/25954534", "http://www.ncbi.nlm.nih.gov/pubmed/21267975", "http://www.ncbi.nlm.nih.gov/pubmed/17720261", "http://www.ncbi.nlm.nih.gov/pubmed/27473406", "http://www.ncbi.nlm.nih.gov/pubmed/18394847", "http://www.ncbi.nlm.nih.gov/pubmed/21699846", "http://www.ncbi.nlm.nih.gov/pubmed/2357882"], "ideal_answer": ["Wellens Syndrome (WS) is a condition characterized by typical changes in ECG, which are biphasic T-wave inversions (less common) or symmetric and deeply inverted T waves (including 75%) in lead V2-V3 chest derivations."], "type": "summary", "id": "589a246578275d0c4a00002e", "snippets": [{"offsetInBeginSection": 1, "offsetInEndSection": 233, "text": "NTRODUCTION: Wellens Syndrome (WS) is a condition characterized by typical changes in ECG, which are biphasic T-wave inversions (less common) or symmetric and deeply inverted T waves (including 75%) in lead V2-V3 chest derivations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27041816", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "BACKGROUND: Reperfusion after coronary occlusion (myocardial infarction, MI), as in Wellens' syndrome, is often represented on ECG as T-wave inversion in the leads overlying the affected myocardial wall(s). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27473406", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 394, "text": "Her presentation was concerning for acute coronary syndrome, Wellens syndrome in particular, given the elevated troponin levels, lack of ST segment changes, and characteristic T-wave findings. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27951539", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Omnious T-wave inversions: Wellens' syndrome revisited.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27609724", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Wellens' syndrome is characterized by T-wave changes in electrocardiogram (EKG) during pain-free period in a patient with intermittent angina chest pain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27609724", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 314, "text": "We describe a case of a 42-year-old man, with a previous episode of angina and a normal ECG and serum cardiac markers, and a two months later finding of biphasic T wave in leads V2-V3 and deeply inverted T wave in V4-V5 at a asymptomatic occupational evaluation. This is a typical ECG pattern of Wellens' syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25954534", "endSection": "abstract"}, {"offsetInBeginSection": 518, "offsetInEndSection": 859, "text": "Whereas the Wellens' syndrome is characterized by symmetrically inverted T-waves with preserved R waves in the precordial leads suggestive of impending myocardial infarction due to a critical proximal left anterior descending stenosis, the pseudo-Wellens' syndrome caused by coronary artery spasm has also rarely been reported in literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26432739", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 243, "text": "The Wellens electrocardiogram (ECG) pattern of dynamic T-wave inversion in the anterior leads is observed in clinical conditions characterized by reversible left ventricular (LV) dysfunction (stunned myocardium), either ischemic or nonischemic", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21699846", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 218, "text": "Wellens Syndrome (WS) is a condition characterized by typical changes in ECG, which are biphasic T-wave inversions (less common) or symmetric and deeply inverted T waves (including 75%) in lead V2-V3 chest derivations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27041816", "endSection": "abstract"}, {"offsetInBeginSection": 113, "offsetInEndSection": 260, "text": "The initial electrocardiogram (ECG) showed biphasic T-waves in V2-V4, which was recognized as Wellens' syndrome, or acute coronary T-wave syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18394847", "endSection": "abstract"}]}, {"body": "Which human disease is associated with mutated UBQLN2", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27400686", "http://www.ncbi.nlm.nih.gov/pubmed/27480424", "http://www.ncbi.nlm.nih.gov/pubmed/25398946", "http://www.ncbi.nlm.nih.gov/pubmed/26075709", "http://www.ncbi.nlm.nih.gov/pubmed/27834214", "http://www.ncbi.nlm.nih.gov/pubmed/27477512"], "ideal_answer": ["Ggene mutations in UBQLN2 cause dominant inheritance of amyotrophic lateral sclerosis (ALS)."], "type": "factoid", "id": "58bc5e2202b8c60953000002", "snippets": [{"offsetInBeginSection": 851, "offsetInEndSection": 1039, "text": "Finally, we found that mutations in UBQLN2, which lead to neurodegeneration in humans, are defective in chaperone binding, impair aggregate clearance, and cause cognitive deficits in mice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27477512", "endSection": "abstract"}, {"offsetInBeginSection": 1008, "offsetInEndSection": 1051, "text": "UBQLN2 mutations are detected in ALS cases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480424", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "C9ORF72 and UBQLN2 mutations are causes of amyotrophic lateral sclerosis in New Zealand", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480424", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Missense mutations in ubiquilin 2 (UBQLN2) cause ALS with frontotemporal dementia (ALS-FTD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27834214", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 519, "text": "Amyotrophic Lateral Sclerosis (ALS) is the most frequent motor neuron disease in adults. Classical ALS is characterized by the death of upper and lower motor neurons leading to progressive paralysis. Approximately 10\u00a0% of ALS patients have familial form of the disease. Numerous different gene mutations have been found in familial cases of ALS, such as mutations in superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TDP-43), fused in sarcoma (FUS), C9ORF72, ubiquilin-2 (UBQLN2), optineurin (OPTN) and others.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27400686", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "A mutation in the ubiquilin 2 gene (UBQLN2) was recently identified as a cause of X-linked amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25398946", "endSection": "abstract"}, {"offsetInBeginSection": 100, "offsetInEndSection": 258, "text": "Interest in the proteins has been heightened by the discovery that gene mutations in UBQLN2 cause dominant inheritance of amyotrophic lateral sclerosis (ALS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26075709", "endSection": "abstract"}]}, {"body": "Which ApoE isoform is associated with hyperlipoproteinemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18823563", "http://www.ncbi.nlm.nih.gov/pubmed/8175773", "http://www.ncbi.nlm.nih.gov/pubmed/11163021", "http://www.ncbi.nlm.nih.gov/pubmed/2609136", "http://www.ncbi.nlm.nih.gov/pubmed/11701639", "http://www.ncbi.nlm.nih.gov/pubmed/15630629", "http://www.ncbi.nlm.nih.gov/pubmed/2341812", "http://www.ncbi.nlm.nih.gov/pubmed/6578216", "http://www.ncbi.nlm.nih.gov/pubmed/9649566", "http://www.ncbi.nlm.nih.gov/pubmed/25328986", "http://www.ncbi.nlm.nih.gov/pubmed/2804053", "http://www.ncbi.nlm.nih.gov/pubmed/3585172", "http://www.ncbi.nlm.nih.gov/pubmed/10419818", "http://www.ncbi.nlm.nih.gov/pubmed/21716749", "http://www.ncbi.nlm.nih.gov/pubmed/21467726", "http://www.ncbi.nlm.nih.gov/pubmed/22981543", "http://www.ncbi.nlm.nih.gov/pubmed/8198763", "http://www.ncbi.nlm.nih.gov/pubmed/7635945", "http://www.ncbi.nlm.nih.gov/pubmed/2048769", "http://www.ncbi.nlm.nih.gov/pubmed/11076954", "http://www.ncbi.nlm.nih.gov/pubmed/1730728"], "ideal_answer": ["Type III hyperlipoproteinemia (HLP) is characterized by the accumulation of remnant lipoproteins in the plasma and it is associated with ApoE2 isoform. ApoE2 binds poorly to low density lipoprotein receptors, resulting in defective remnant lipoprotein clearance."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006951", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053329", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006952", "http://www.disease-ontology.org/api/metadata/DOID:3145", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011973"], "type": "factoid", "id": "58b6bd2622d300530900000c", "snippets": [{"offsetInBeginSection": 557, "offsetInEndSection": 860, "text": "ApoE2 which differs from apoE3 by the single amino acid substitution Arg158Cys located near the LDLR recognition site exhibits impaired binding to the receptor and an inability to promote clearance of TG-rich lipoprotein remnant particles; this isoform is associated with Type-III hyperlipoproteinemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25328986", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 557, "text": "Type III hyperlipoproteinemia (HLP), a disorder associated with a high incidence of premature cardiovascular diseases, is characterized by the accumulation of remnant lipoproteins in the plasma. The primary genetic defect in patients with type III HLP is the presence of apolipoprotein E2 (apoE2), an isoform of apoE, and accumulation of remnant lipoproteins in the plasma has been thought to be attributable to the presence of apoE2, which bind poorly to low density lipoprotein receptors, resulting in defective remnant lipoprotein clearance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22981543", "endSection": "abstract"}, {"offsetInBeginSection": 321, "offsetInEndSection": 470, "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform is encoded by the R158C allele. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467726", "endSection": "abstract"}, {"offsetInBeginSection": 171, "offsetInEndSection": 359, "text": "Reduced expression of the LDLR is believed to be a precipitating factor in the pathogenesis of type III hyperlipoproteinemia (HLP) in some humans homozygous for the apoE2 allele (APOE*2). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11076954", "endSection": "abstract"}, {"offsetInBeginSection": 935, "offsetInEndSection": 1140, "text": "Overall, the 2.3-fold normal level of LDLR message in heterozygotes completely ameliorates type III HLP caused by the homozygosity for the human APOE*2 allele, normalizing their plasma lipoprotein profile.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11076954", "endSection": "abstract"}, {"offsetInBeginSection": 757, "offsetInEndSection": 1175, "text": "Isoform (allele)-specific effects include the association of apoE2 with the genetic disorder type III hyperlipoproteinemia and with both increased and decreased risk for atherosclerosis and the association of apoE4 with increased risk for both atherosclerosis and Alzheimer's disease, impaired cognitive function, and reduced neurite outgrowth; isoform-specific differences in cellular signaling events may also exist.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11701639", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9649566", "endSection": "title"}, {"offsetInBeginSection": 202, "offsetInEndSection": 309, "text": "Mice expressing human apoE2 (2/2) have virtually all the characteristics of type III hyperlipoproteinemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9649566", "endSection": "abstract"}, {"offsetInBeginSection": 137, "offsetInEndSection": 377, "text": "ApoE has three major genetically determined isoproteins in plasma, designated apoE-2, apoE-3 and apoE-4, with homozygosity for the allele coding for apoE-2 being associated with dysbetalipoproteinemia or type III hyperlipoproteinemia (HLP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2804053", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Type III hyperlipoproteinemia typically is associated with homozygosity for apolipoprotein (apo) E2(Arg158----Cys).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1730728", "endSection": "abstract"}, {"offsetInBeginSection": 156, "offsetInEndSection": 271, "text": "ApoE is a polymorphic protein, and homozygosity for the E2 allele is associated with type III hyperlipoproteinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6578216", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Homozygosity for the apolipoprotein (apo) E variant apoE2(158 Arg----Cys) invariably gives rise to dysbetalipoproteinemia, and when associated with obesity or a gene for hyperlipidemia, results in type III hyperlipoproteinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2341812", "endSection": "abstract"}, {"offsetInBeginSection": 138, "offsetInEndSection": 378, "text": "ApoE has three major genetically determined isoproteins in plasma, designated apoE-2, apoE-3 and apoE-4, with homozygosity for the allele coding for apoE-2 being associated with dysbetalipoproteinemia or type III hyperlipoproteinemia (HLP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2804053", "endSection": "abstract"}, {"offsetInBeginSection": 1389, "offsetInEndSection": 1565, "text": "From the data of a high association of apo E4 allele and cardiovascular disease with hypercholesterolemia, apo E isoform may be one of the determinants of hyperlipoproteinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8198763", "endSection": "abstract"}, {"offsetInBeginSection": 756, "offsetInEndSection": 1172, "text": "Isoform (allele)-specific effects include the association of apoE2 with the genetic disorder type III hyperlipoproteinemia and with both increased and decreased risk for atherosclerosis and the association of apoE4 with increased risk for both atherosclerosis and Alzheimers disease, impaired cognitive function, and reduced neurite outgrowth; isoform-specific differences in cellular signaling events may also exist", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11701639", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 478, "text": "Whereas the association of the apo E2 isoform with primary dysbetalipoproteinemia and hyperlipoproteinemia type III is well established, the plasma- and LDL-cholesterol lowering effects of apo E2 and the phenomenon of apo E4 raising these parameters on the development of coronary heart disease is still a matter of controversial discussion. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2048769", "endSection": "abstract"}, {"offsetInBeginSection": 207, "offsetInEndSection": 557, "text": "The primary genetic defect in patients with type III HLP is the presence of apolipoprotein E2 (apoE2), an isoform of apoE, and accumulation of remnant lipoproteins in the plasma has been thought to be attributable to the presence of apoE2, which bind poorly to low density lipoprotein receptors, resulting in defective remnant lipoprotein clearance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22981543", "endSection": "abstract"}, {"offsetInBeginSection": 249, "offsetInEndSection": 379, "text": "In the normal population, ApoE3 isoform is the most prevalent, and ApoE2 or E4 is frequently associated with hyperlipoproteinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21716749", "endSection": "abstract"}, {"offsetInBeginSection": 557, "offsetInEndSection": 859, "text": "ApoE2 which differs from apoE3 by the single amino acid substitution Arg158Cys located near the LDLR recognition site exhibits impaired binding to the receptor and an inability to promote clearance of TG-rich lipoprotein remnant particles; this isoform is associated with Type-III hyperlipoproteinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25328986", "endSection": "abstract"}, {"offsetInBeginSection": 246, "offsetInEndSection": 372, "text": "In the normal population apo E3 isoform is most prevalent and apo E2 or E4 is frequently associated with hyperlipoproteinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8198763", "endSection": "abstract"}, {"offsetInBeginSection": 1394, "offsetInEndSection": 1570, "text": "From the data of a high association of apo E4 allele and cardiovascular disease with hypercholesterolemia, apo E isoform may be one of the determinants of hyperlipoproteinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8198763", "endSection": "abstract"}, {"offsetInBeginSection": 379, "offsetInEndSection": 505, "text": "We describe a new variant of apoE, apoE-1Harrisburg, which is, in contrast to apoE-2, dominantly associated with type III HLP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2804053", "endSection": "abstract"}, {"offsetInBeginSection": 321, "offsetInEndSection": 469, "text": "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform is encoded by the R158C allele.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467726", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Type III hyperlipoproteinemia is characterized by delayed chylomicron and VLDL remnant catabolism and is associated with homozygosity for the apoE-2 allele.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7635945", "endSection": "abstract"}, {"offsetInBeginSection": 228, "offsetInEndSection": 429, "text": "The association of the E2/2 phenotype with type IV/V hyperlipoproteinemia rather than type III hyperlipoproteinemia in identical twin brothers led us to investigate the primary structure of their apoE.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2341812", "endSection": "abstract"}, {"offsetInBeginSection": 290, "offsetInEndSection": 402, "text": "ApoE2 is defective in binding and homozygosity for apoE2 is associated with type III hyperlipoproteinemia (HLP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11163021", "endSection": "abstract"}, {"offsetInBeginSection": 304, "offsetInEndSection": 486, "text": "Homozygous carriers of apoE2 have an increased risk to develop type III hyperlipoproteinemia, whereas apoE4 is associated with elevated levels of low-density lipoprotein cholesterol.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15630629", "endSection": "abstract"}, {"offsetInBeginSection": 276, "offsetInEndSection": 407, "text": "Patients homozygous for apolipoprotein E2 are predisposed to type III hyperlipoproteinemia, and apoE2 may be protective against AD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10419818", "endSection": "abstract"}]}, {"body": "Could hypophosphatemic rickets cause craniosynostosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26824597", "http://www.ncbi.nlm.nih.gov/pubmed/22220162", "http://www.ncbi.nlm.nih.gov/pubmed/26510652", "http://www.ncbi.nlm.nih.gov/pubmed/23466123", "http://www.ncbi.nlm.nih.gov/pubmed/23348263", "http://www.ncbi.nlm.nih.gov/pubmed/19242361", "http://www.ncbi.nlm.nih.gov/pubmed/27303470", "http://www.ncbi.nlm.nih.gov/pubmed/6265607", "http://www.ncbi.nlm.nih.gov/pubmed/25014884", "http://www.ncbi.nlm.nih.gov/pubmed/17551721", "http://www.ncbi.nlm.nih.gov/pubmed/9069051"], "ideal_answer": ["Yes, hypophosphatemic rickets could cause craniosynostosis."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005624", "http://www.disease-ontology.org/api/metadata/DOID:2340", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012279", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053098", "http://www.disease-ontology.org/api/metadata/DOID:0050445", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010294", "http://www.disease-ontology.org/api/metadata/DOID:0050948", "http://www.disease-ontology.org/api/metadata/DOID:0050949", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003398", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063730", "http://www.disease-ontology.org/api/metadata/DOID:10609"], "type": "yesno", "id": "58b9585c22d3005309000010", "snippets": [{"offsetInBeginSection": 10, "offsetInEndSection": 177, "text": "This study examines a series of patients with hypophosphatemic rickets and craniosynostosis to characterize the clinical course and associated craniofacial anomalies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824597", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Hypophosphatemic rickets and craniosynostosis: a multicenter case series.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824597", "endSection": "title"}, {"offsetInBeginSection": 185, "offsetInEndSection": 330, "text": "A 20-year retrospective review identified patients with hypophosphatemic rickets and secondary craniosynostosis at 3 major craniofacial centers. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824597", "endSection": "abstract"}, {"offsetInBeginSection": 1244, "offsetInEndSection": 1549, "text": "Secondary craniosynostosis develops postnatally due to metabolic or mechanical factors. The most common metabolic cause is hypophosphatemic rickets, which has a variety of etiologies. Head shape changes occur later and with a more heterogeneous presentation compared with that of primary craniosynostosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824597", "endSection": "abstract"}, {"offsetInBeginSection": 1513, "offsetInEndSection": 1651, "text": "Patients with multisutural involvement or X-linked hypophosphatemic rickets had a significant delay in presentation for craniosynostosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23348263", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 466, "text": "Craniosynostosis can be gene-linked, or caused by metabolic diseases, such as rickets, which results from a deficiency or impaired metabolism of vitamin D, magnesium, phosphorus or calcium leading to hypomineralization of the bone. X-linked dominant hypophosphatemic rickets (XLHR) is the most prevalent genetic type of hypophosphatemic rickets and is caused by germ line mutations in the PHEX-gene. In XLHR, only few case reports of craniosynostosis were described.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466123", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Papilledema in the setting of x-linked hypophosphatemic rickets with craniosynostosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22220162", "endSection": "title"}, {"offsetInBeginSection": 165, "offsetInEndSection": 277, "text": "Case report of a 3-year-old female presenting with papilledema resulting from craniosynostosis secondary to XLH.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22220162", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "X-linked hypophosphatemic rickets and craniosynostosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", "endSection": "title"}, {"offsetInBeginSection": 333, "offsetInEndSection": 599, "text": "X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets, and there have been reports linking XLH rickets to craniosynostosis. A clinical report of a patient with XLH rickets and craniosynostosis is presented with a review of literature. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", "endSection": "abstract"}, {"offsetInBeginSection": 758, "offsetInEndSection": 845, "text": "This may be the reason for the common association of craniosynostosis and XLH rickets. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 287, "text": "Craniosynostosis and associated craniofacial deformities, such as frontal bossing, often occur as symptoms of vitamin D-resistant rickets in children. Similar skull deformities develop in mice with X-linked dominant hypophosphatemia, the most common form of vitamin D-resistant rickets. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6265607", "endSection": "abstract"}, {"offsetInBeginSection": 914, "offsetInEndSection": 1191, "text": "The x-linked hypophosphatemic mouse is an animal model that can be used to study the role of vitamin D-resistant rickets in the development of craniosynostosis, to relate craniosynostosis to the development of associated skull deformities, and to test new treatment procedures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6265607", "endSection": "abstract"}, {"offsetInBeginSection": 449, "offsetInEndSection": 627, "text": "Craniosynostosis secondary to rickets is rarely reported, but since neither rickets nor craniosynostosis is a reportable disease, the exact incidence of both diseases is unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27303470", "endSection": "abstract"}, {"offsetInBeginSection": 331, "offsetInEndSection": 485, "text": "X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets, and there have been reports linking XLH rickets to craniosynostosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", "endSection": "abstract"}, {"offsetInBeginSection": 485, "offsetInEndSection": 595, "text": "A clinical report of a patient with XLH rickets and craniosynostosis is presented with a review of literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", "endSection": "abstract"}, {"offsetInBeginSection": 176, "offsetInEndSection": 328, "text": "METHODS A 20-year retrospective review identified patients with hypophosphatemic rickets and secondary craniosynostosis at 3 major craniofacial centers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824597", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Bilateral coronal and sagittal synostosis in X-linked hypophosphatemic rickets: a case report.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466123", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "X-linked hypophosphatemic rickets and sagittal craniosynostosis: three patients requiring operative cranial expansion: case series and literature review", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26510652", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "X-linked hypophosphatemic rickets and craniosynostosis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", "endSection": "title"}, {"offsetInBeginSection": 333, "offsetInEndSection": 486, "text": "X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets, and there have been reports linking XLH rickets to craniosynostosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 582, "text": "The recent observations of two new cases of X-linked hypophosphatemic rickets associated with premature closure of the sagittal suture prompted a review of similar cases seen in this institution.To review the clinical records and skull radiographs of 28 children with hypophosphatemic rickets in order to investigate the frequency and type of craniosynostosis and other cranial vault changes seen in these conditions and to review the literature for relevant findings.Clinical and imaging records were reviewed on 28 patients with hypophosphatemic rickets, all younger than 18 years", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17551721", "endSection": "abstract"}, {"offsetInBeginSection": 1344, "offsetInEndSection": 1606, "text": "Those with multisutural synostosis presented at a significantly older age than patients with sagittal or bicoronal synostosis.Patients with multisutural involvement or X-linked hypophosphatemic rickets had a significant delay in presentation for craniosynostosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23348263", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Papilledema in the setting of x-linked hypophosphatemic rickets with craniosynostosis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22220162", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 510, "text": "INTRODUCTION TO THE OPHTHALMIC LITERATURE OF AN UNUSUAL CAUSE OF PAPILLEDEMA AND SUBSEQUENT OPTIC ATROPHY: X-linked hypophosphatemic rickets (XLH).Case report of a 3-year-old female presenting with papilledema resulting from craniosynostosis secondary to XLH.Early intervention with craniofacial surgery prevented the development of optic atrophy.Children with XLH should be screened for ophthalmic evidence of elevated intracranial pressure to aid early intervention and prevention of permanent loss of vision", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22220162", "endSection": "abstract"}, {"offsetInBeginSection": 1503, "offsetInEndSection": 1654, "text": "CONCLUSIONS: Patients with multisutural involvement or X-linked hypophosphatemic rickets had a significant delay in presentation for craniosynostosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23348263", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "Craniosynostosis can be gene-linked, or caused by metabolic diseases, such as rickets, which results from a deficiency or impaired metabolism of vitamin D, magnesium, phosphorus or calcium leading to hypomineralization of the bone. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466123", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 286, "text": "Similar skull deformities develop in mice with X-linked dominant hypophosphatemia, the most common form of vitamin D-resistant rickets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6265607", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Craniosynostosis in vitamin D-resistant rickets.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6265607", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 231, "text": "Craniosynostosis can be gene-linked, or caused by metabolic diseases, such as rickets, which results from a deficiency or impaired metabolism of vitamin D, magnesium, phosphorus or calcium leading to hypomineralization of the bone.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466123", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "X-linked hypophosphatemic rickets and craniosynostosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", "endSection": "title"}, {"offsetInBeginSection": 333, "offsetInEndSection": 487, "text": "X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets, and there have been reports linking XLH rickets to craniosynostosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242361", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Hypophosphatemic rickets and craniosynostosis: a multicenter case series.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824597", "endSection": "title"}]}, {"body": "Is vortioxetine effective for treatment of depression?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26346592", "http://www.ncbi.nlm.nih.gov/pubmed/25249164", "http://www.ncbi.nlm.nih.gov/pubmed/25851751", "http://www.ncbi.nlm.nih.gov/pubmed/26525043", "http://www.ncbi.nlm.nih.gov/pubmed/26546771", "http://www.ncbi.nlm.nih.gov/pubmed/24787143", "http://www.ncbi.nlm.nih.gov/pubmed/25087600", "http://www.ncbi.nlm.nih.gov/pubmed/26464458", "http://www.ncbi.nlm.nih.gov/pubmed/24570588", "http://www.ncbi.nlm.nih.gov/pubmed/27067232", "http://www.ncbi.nlm.nih.gov/pubmed/25418918", "http://www.ncbi.nlm.nih.gov/pubmed/25650503", "http://www.ncbi.nlm.nih.gov/pubmed/23252878", "http://www.ncbi.nlm.nih.gov/pubmed/26035185", "http://www.ncbi.nlm.nih.gov/pubmed/26035186", "http://www.ncbi.nlm.nih.gov/pubmed/25893002", "http://www.ncbi.nlm.nih.gov/pubmed/22963932", "http://www.ncbi.nlm.nih.gov/pubmed/25562777", "http://www.ncbi.nlm.nih.gov/pubmed/26641142", "http://www.ncbi.nlm.nih.gov/pubmed/26358483", "http://www.ncbi.nlm.nih.gov/pubmed/26679430", "http://www.ncbi.nlm.nih.gov/pubmed/24424707", "http://www.ncbi.nlm.nih.gov/pubmed/24524096", "http://www.ncbi.nlm.nih.gov/pubmed/27139079", "http://www.ncbi.nlm.nih.gov/pubmed/26316764", "http://www.ncbi.nlm.nih.gov/pubmed/24871704", "http://www.ncbi.nlm.nih.gov/pubmed/26020712", "http://www.ncbi.nlm.nih.gov/pubmed/24676550", "http://www.ncbi.nlm.nih.gov/pubmed/25907797", "http://www.ncbi.nlm.nih.gov/pubmed/25260373", "http://www.ncbi.nlm.nih.gov/pubmed/25350320", "http://www.ncbi.nlm.nih.gov/pubmed/24684240", "http://www.ncbi.nlm.nih.gov/pubmed/25874839"], "ideal_answer": ["Yes. Vortioxetine is the most recently approved medication for the treatment of major depressive disorder."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003863", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003866"], "type": "yesno", "id": "589a246878275d0c4a000030", "snippets": [{"offsetInBeginSection": 316, "offsetInEndSection": 424, "text": "Vortioxetine is the most recently approved medication for the treatment of major depressive disorder (MDD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546771", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "[Vortioxetine: a new antidepressant to treat depressive episodes].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358483", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7\u00a0receptors and the serotonin transporter (5-HTT). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358483", "endSection": "abstract"}, {"offsetInBeginSection": 334, "offsetInEndSection": 990, "text": "In short-term studies (8\u00a0weeks), vortioxetine is more efficacious than placebo in decreasing depressive symptoms as measured by the MADRS total score, response rate (vortioxetine: 53.2% vs placebo: 35.2%) and remission rate (vortioxetine: 29.2% vs placebo: 19.3%). In a long-term study (52\u00a0weeks), vortioxetine is also superior to placebo in preventing relapses and recurrences. Moreover, in second line treatment, after failure of a first line selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrin reuptake inhibitor (SNRI), vortioxetine is superior to agomelatine in improving depressive symptoms and achieving response and remission. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358483", "endSection": "abstract"}, {"offsetInBeginSection": 1027, "offsetInEndSection": 1386, "text": "Against this background, we feature the novel antidepressants vortioxetine, vilazodone and milnacipran/levomilnacipran with regard to their serotonin receptor targets such as the 5-HT1A, 5-HT3 and 5-HT7 which may account for their specific effects on certain symptoms of depression (e.g. cognition and anxiety) as well as a characteristic side-effect profile.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26464458", "endSection": "abstract"}, {"offsetInBeginSection": 990, "offsetInEndSection": 1139, "text": "CONCLUSION: Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDD patients initiating or switching therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26641142", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "Vortioxetine: a New Treatment for Major Depressive Disorder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679430", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "INTRODUCTION: Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679430", "endSection": "abstract"}, {"offsetInBeginSection": 1433, "offsetInEndSection": 1584, "text": "EXPERT OPINION: Results of placebo-controlled trials suggest efficacy and an overall safety profile comparable to existing first-line antidepressants. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679430", "endSection": "abstract"}, {"offsetInBeginSection": 1941, "offsetInEndSection": 2132, "text": "The authors suggest that vortioxetine is currently a good second-line antidepressant option and shows promise, pending additional long-term data, to become a first-line antidepressant option.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679430", "endSection": "abstract"}, {"offsetInBeginSection": 264, "offsetInEndSection": 428, "text": "Clinical studies indicate that vortioxetine is effective in the treatment of major depression, though there is no suggestion of superiority over active comparators.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24570588", "endSection": "abstract"}, {"offsetInBeginSection": 486, "offsetInEndSection": 694, "text": "Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096", "endSection": "abstract"}, {"offsetInBeginSection": 913, "offsetInEndSection": 1068, "text": "Vortioxetine was significantly more effective than was placebo, with a standardized mean difference (SMD) of\u00a0-0.118 (95% CIs,\u00a0-0.203 to\u00a0-0.033, P\u00a0=\u00a00.007).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25851751", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 45, "text": "Vortioxetine for the treatment of depression.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24676550", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "Vortioxetine for the treatment of major depression.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Vortioxetine (Lu-AA-21004; 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine hydrobromide) is a novel orally active molecule that is being investigated by Lundbeck and Takeda for the treatment of major depression and generalized anxiety disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Vortioxetine (Lu AA21004) is a multi-modal antidepressant in clinical development for the treatment of major depressive disorder (MDD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22963932", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10\u2009mg in acute treatment of adults with generalized anxiety disorder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424707", "endSection": "title"}, {"offsetInBeginSection": 489, "offsetInEndSection": 697, "text": "Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096", "endSection": "abstract"}, {"offsetInBeginSection": 678, "offsetInEndSection": 1177, "text": "Secondary endpoints included response and remission rates, anxiety symptoms(Hamilton Anxiety Rating Scale), Clinical Global Impression, overall functioning (Sheehan Disability Scale), health-related quality of life(EuroQol 5 Dimensions), productivity (work limitation questionnaire) and family functioning (Depression and Family Functioning Scale).RESULTS: Primary endpoint noninferiority was established and vortioxetine (n = 252) was superior to agomelatine (n = 241) by 2.2 MADRS points (p<0.01).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25087600", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 711, "text": "Vortioxetine (Lu AA21004) is an antidepressant with a mechanism of action thought to be related to a combination of 2 pharmacologic actions: direct modulation of several receptors and inhibition of the serotonin transporter.To evaluate the efficacy of vortioxetine 10 and 20 mg once daily in outpatients with major depressive disorder.This 8-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study was conducted from July 2010 to January 2012 among adults with a primary diagnosis of recurrent major depressive disorder (DSM-IV-TR).Eligible subjects were randomized in 1:1:1 ratio to 1 of 3 treatment arms: vortioxetine 10 mg, vortioxetine 20 mg, or placebo once daily for 8 weeks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26035185", "endSection": "abstract"}, {"offsetInBeginSection": 188, "offsetInEndSection": 478, "text": "Vortioxetine (Lu AA21004) is a new antidepressant that combines a number of neurotransmitter reuptake and receptor effects that have been thought to predict efficacy as a treatment for depressive and anxiety disorders.This review summarizes the pharmacology and neurobiology of vortioxetine", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24684240", "endSection": "abstract"}, {"offsetInBeginSection": 1723, "offsetInEndSection": 2190, "text": "In the study of elderly patients, vortioxetine 5 mg (n = 136) improved 12-item Health Status Questionnaire scores significantly more than placebo (n = 148) for the domains of health perception (10.4, P &lt; 0.0001, SES of 0.54), mental health (7.9, P &lt; 0.001, SES of 0.44), and energy (6.4, P &lt; 0.05, SES of 0.28) (FAS, mixed model for repeated measures).Vortioxetine yielded significant, meaningful HRQoL improvements in 6 MDD studies of 6 to 8 weeks duration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346592", "endSection": "abstract"}, {"offsetInBeginSection": 324, "offsetInEndSection": 749, "text": "All references included were published between 1999 and 2014.All studies that included humans and were published in English, with data describing vortioxetine for the treatment of MDD, were reviewed.Vortioxetine is a novel multimodal antidepressant agent, which inhibits the 5-HT transporter protein, acts as a 5-HT3 antagonist, 5-HT1A receptor agonist, 5-HT7 receptor antagonist, and a partial agonist of the 5-HT1B receptor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24676550", "endSection": "abstract"}, {"offsetInBeginSection": 489, "offsetInEndSection": 696, "text": "Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 355, "text": "Vortioxetine is an antidepressant with multimodal activity which has shown efficacy in major depressive disorder (MDD) patients in six of ten short-term, randomized, placebo-controlled trials (completed end 2012).We performed meta-regression analyses to indirectly compare vortioxetine to seven marketed antidepressants with different mechanisms of action", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25249164", "endSection": "abstract"}, {"offsetInBeginSection": 661, "offsetInEndSection": 1043, "text": "Data were available from 51 human trials involving vortioxetine, and included a total of 7,666 healthy volunteers and patients with a diagnosis of major depressive disorder (MDD) or generalized anxiety disorder who were exposed to at least 1 dose of vortioxetine for a total of 2,743 patient-years.Vortioxetine was effective in treating MDD in the United States at a dose of 20 mg/d", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25562777", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 386, "text": "Vortioxetine is a recently approved multimodal antidepressant with anxiolytic properties in preclinical studies.This double-blind, placebo-controlled study assessed the efficacy and tolerability of vortioxetine in subjects with a primary diagnosis of generalized anxiety disorder.Subjects (n\u2009=\u2009457) were randomized 1:1:1 to treatment with placebo or vortioxetine 2.5 or 10\u2009mg once daily", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424707", "endSection": "abstract"}, {"offsetInBeginSection": 1359, "offsetInEndSection": 1744, "text": "There was a significant difference for nausea between the two groups (OR=3.01, 95 % CI=2.22-4.09, Z=7.08, P=0.00001), but no significant differences were observed for the other four adverse effects.CONCLUSIONS: For the treatment of major depressive disorder, our results show that a dose of 5 mg/day vortioxetine was more effective, but more easily induced nausea, compared to placebo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24871704", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24871704", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25350320", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25260373", "endSection": "title"}, {"offsetInBeginSection": 489, "offsetInEndSection": 698, "text": "Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524096", "endSection": "abstract"}, {"offsetInBeginSection": 266, "offsetInEndSection": 430, "text": "Clinical studies indicate that vortioxetine is effective in the treatment of major depression, though there is no suggestion of superiority over active comparators.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24570588", "endSection": "abstract"}, {"offsetInBeginSection": 1432, "offsetInEndSection": 1642, "text": "The incidence of treatment-emergent adverse events was significantly higher in the duloxetine group than in the vortioxetine group.Duloxetine was more effective but less well-tolerated than vortioxetine in MDD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067232", "endSection": "abstract"}, {"offsetInBeginSection": 2085, "offsetInEndSection": 2676, "text": "There was no significant difference in discontinuation rates between vortioxetine and comparators owing to inefficacy (OR 0.983, 95% CI 0.585 to 1.650), whereas discontinuation owing to AEs was significantly less common in the vortioxetine than in the comparator group (OR 0.728, 95% CI 0.554 to 0.957).Studies examining the role of vortioxetine in the treatment of MDD are limited.Although our results suggest that vortioxetine may be an effective treatment option for MDD, they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a l", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25350320", "endSection": "abstract"}, {"offsetInBeginSection": 285, "offsetInEndSection": 533, "text": "We performed a meta-analysis to increase the statistical power of these studies and enhance our current understanding of the role of vortioxetine in the treatment of MDD.We performed an extensive search of databases and the clinical trial registry.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25350320", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 419, "text": "BACKGROUND: Vortioxetine is a recently approved multimodal antidepressant with anxiolytic properties in preclinical studies.OBJECTIVE: This double-blind, placebo-controlled study assessed the efficacy and tolerability of vortioxetine in subjects with a primary diagnosis of generalized anxiety disorder.METHODS: Subjects (n\u2009=\u2009457) were randomized 1:1:1 to treatment with placebo or vortioxetine 2.5 or 10\u2009mg once daily.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424707", "endSection": "abstract"}, {"offsetInBeginSection": 1524, "offsetInEndSection": 1735, "text": "Vortioxetine significantly improved objective and subjective measures of cognitive function in adults with recurrent MDD and these effects were largely independent of its effect on improving depressive symptoms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24787143", "endSection": "abstract"}, {"offsetInBeginSection": 1545, "offsetInEndSection": 1731, "text": "Furthermore, a statistically significant number of patients with MDD who were on vortioxetine have achieved a greater than or equal to 50% reduction in depression symptoms from baseline.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25260373", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "BACKGROUND: Vortioxetine is a novel multimodal compound that has recently been approved by the FDA for the treatment of major depressive disorder (MDD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25260373", "endSection": "abstract"}, {"offsetInBeginSection": 2471, "offsetInEndSection": 2717, "text": "Although our results suggest that vortioxetine may be an effective treatment option for MDD, they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a limited number of heterogeneous RCTs..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25350320", "endSection": "abstract"}, {"offsetInBeginSection": 1284, "offsetInEndSection": 1427, "text": "Vortioxetine is an effective agent for the treatment of MDD, but it does not have any clear advantages over other available treatment options..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24676550", "endSection": "abstract"}, {"offsetInBeginSection": 1827, "offsetInEndSection": 1941, "text": "Vortioxetine was significantly more effective than placebo for acute treatment of major depressive disorder (MDD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874839", "endSection": "abstract"}, {"offsetInBeginSection": 1566, "offsetInEndSection": 1645, "text": "Duloxetine was more effective but less well-tolerated than vortioxetine in MDD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067232", "endSection": "abstract"}]}, {"body": "Which server is used for simulation of macromolecular diffusional association?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25883142"], "ideal_answer": ["Macromolecular interactions play a crucial role in biological systems. Simulation of diffusional association (SDA) is a software for carrying out Brownian dynamics simulations that can be used to study the interactions between two or more biological macromolecules. webSDA allows users to run Brownian dynamics simulations with SDA to study bimolecular association and encounter complex formation, to compute association rate constants, and to investigate macromolecular crowding using atomically detailed macromolecular structures. webSDA facilitates and automates the use of the SDA software, and offers user-friendly visualization of results.", "Simulation of diffusional association (SDA) is a software for carrying out Brownian dynamics simulations that can be used to study the interactions between two or more biological macromolecules. webSDA allows users to run Brownian dynamics simulations with SDA to study bimolecular association and encounter complex formation, to compute association rate constants, and to investigate macromolecular crowding using atomically detailed macromolecular structures.", "webSDA allows users to run Brownian dynamics simulations with SDA to study bimolecular association and encounter complex formation, to compute association rate constants, and to investigate macromolecular crowding using atomically detailed macromolecular structures. webSDA currently has three modules: 'SDA docking' to generate structures of the diffusional encounter complexes of two macromolecules, 'SDA association' to calculate bimolecular diffusional association rate constants, and 'SDA multiple molecules' to simulate the diffusive motion of hundreds of macromolecules."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056004", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003198", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D039301"], "type": "factoid", "id": "589480b47d9090f353000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "webSDA: a web server to simulate macromolecular diffusional association.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 645, "text": "Macromolecular interactions play a crucial role in biological systems. Simulation of diffusional association (SDA) is a software for carrying out Brownian dynamics simulations that can be used to study the interactions between two or more biological macromolecules. webSDA allows users to run Brownian dynamics simulations with SDA to study bimolecular association and encounter complex formation, to compute association rate constants, and to investigate macromolecular crowding using atomically detailed macromolecular structures. webSDA facilitates and automates the use of the SDA software, and offers user-friendly visualization of results.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", "endSection": "abstract"}, {"offsetInBeginSection": 642, "offsetInEndSection": 952, "text": "webSDA currently has three modules: 'SDA docking' to generate structures of the diffusional encounter complexes of two macromolecules, 'SDA association' to calculate bimolecular diffusional association rate constants, and 'SDA multiple molecules' to simulate the diffusive motion of hundreds of macromolecules.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", "endSection": "abstract"}, {"offsetInBeginSection": 71, "offsetInEndSection": 950, "text": "Simulation of diffusional association (SDA) is a software for carrying out Brownian dynamics simulations that can be used to study the interactions between two or more biological macromolecules. webSDA allows users to run Brownian dynamics simulations with SDA to study bimolecular association and encounter complex formation, to compute association rate constants, and to investigate macromolecular crowding using atomically detailed macromolecular structures. webSDA facilitates and automates the use of the SDA software, and offers user-friendly visualization of results. webSDA currently has three modules: SDA docking to generate structures of the diffusional encounter complexes of two macromolecules, SDA association to calculate bimolecular diffusional association rate constants, and SDA multiple molecules to simulate the diffusive motion of hundreds of macromolecules.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "webSDA: a web server to simulate macromolecular diffusional association", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "webSDA: a web server to simulate macromolecular diffusional association.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", "endSection": "title"}, {"offsetInBeginSection": 266, "offsetInEndSection": 532, "text": "webSDA allows users to run Brownian dynamics simulations with SDA to study bimolecular association and encounter complex formation, to compute association rate constants, and to investigate macromolecular crowding using atomically detailed macromolecular structures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", "endSection": "abstract"}, {"offsetInBeginSection": 646, "offsetInEndSection": 956, "text": "webSDA currently has three modules: 'SDA docking' to generate structures of the diffusional encounter complexes of two macromolecules, 'SDA association' to calculate bimolecular diffusional association rate constants, and 'SDA multiple molecules' to simulate the diffusive motion of hundreds of macromolecules.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883142", "endSection": "abstract"}]}, {"body": "Can beans induce apoptosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24952025", "http://www.ncbi.nlm.nih.gov/pubmed/15302513", "http://www.ncbi.nlm.nih.gov/pubmed/23194196", "http://www.ncbi.nlm.nih.gov/pubmed/25997867", "http://www.ncbi.nlm.nih.gov/pubmed/23027830", "http://www.ncbi.nlm.nih.gov/pubmed/19723093", "http://www.ncbi.nlm.nih.gov/pubmed/15527074", "http://www.ncbi.nlm.nih.gov/pubmed/26769089", "http://www.ncbi.nlm.nih.gov/pubmed/22916808", "http://www.ncbi.nlm.nih.gov/pubmed/23394551", "http://www.ncbi.nlm.nih.gov/pubmed/26290674", "http://www.ncbi.nlm.nih.gov/pubmed/22524832"], "ideal_answer": ["White kidney bean lectin  has been shown to exert anti-proliferative and apoptotic effects on cancer cells"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017209"], "type": "yesno", "id": "58bca1c202b8c6095300000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 413, "text": "A 60-kDa glucosamine binding lectin, white kidney bean lectin (WKBL), was purified from Phaseolus vulgaris cv. white kidney beans, by application of anion exchange chromatography on Q-Sepharose, affinity chromatography on Affi-gel blue gel, and FPLC-size exclusion on Superdex 75. The anti-proliferative activity of WKBL on HONE1 cells and HepG2 cells was stronger than the activity on MCF7 cells and WRL68 cells ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26769089", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Treatment of human stomach cancer KATO III cells with hot-water extracts from adzuki beans led to their growth inhibition as well as apoptosis induction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15527074", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Stimulation of dendritic cell maturation and induction of apoptosis in leukemia cells by a heat-stable extract from azuki bean (Vigna angularis), a promising immunopotentiating food and dietary supplement for cancer prevention.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22524832", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "Human gut flora-fermented nondigestible fraction from cooked bean ( Phaseolus vulgaris L.) modifies protein expression associated with apoptosis, cell cycle arrest, and proliferation in human adenocarcinoma colon cancer cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23194196", "endSection": "title"}, {"offsetInBeginSection": 218, "offsetInEndSection": 461, "text": "This paper reports the effect of fermentation products (FP) by hgf (FP-hgf) from NDF of cooked beans on survival and protein expression associated with apoptosis, cell cycle arrest, and proliferation in human adenocarcinoma colon cancer cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23194196", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "PHA-E is a natural product extracted from red kidney beans, and it has been reported to induce cell apoptosis by blocking EGFR in lung cancer cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394551", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "A Glucosamine-Specific Lectin from Green Dragon No. 8 Beans (Phaseolus vulgaris) Induced Apoptosis on Nasopharyngeal Carcinoma Cells", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26290674", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "PHA-E is a natural product extracted from red kidney beans, and it has been reported to induce cell apoptosis by blocking EGFR in lung cancer cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394551", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 344, "text": "The anticancer activity of \u03b4-tocotrienol, a bioactive vitamin E present in whole grain cereals, annatto beans and palm fruit, is strongly dependent on its effect on the induction of apoptosis. \u03b4-Tocotrienol-induced apoptosis is associated with consistent induction in the expression of the proapoptotic protein Bcl-2-associated X protein (Bax).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25997867", "endSection": "abstract"}, {"offsetInBeginSection": 1077, "offsetInEndSection": 1316, "text": "NDF of cooked common beans inhibited colon carcinogenesis at an early stage by inducing cell cycle arrest of colon cells and morphological changes linked to apoptosis, thus confirming previous results obtained with gene expression studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24952025", "endSection": "abstract"}, {"offsetInBeginSection": 921, "offsetInEndSection": 1025, "text": "Azuki extract also inhibited the growth of human leukemia U937 cells, leading to induction of apoptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22524832", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Fermentation product of soybean, black bean, and green bean mixture induces apoptosis in a wide variety of cancer cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23027830", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "A non-digestible fraction of the common bean (Phaseolus vulgaris L.) induces cell cycle arrest and apoptosis during early carcinogenesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24952025", "endSection": "title"}]}, {"body": "What is the function of transthyretin in cerebrospinal fluid?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25737004", "http://www.ncbi.nlm.nih.gov/pubmed/16325339", "http://www.ncbi.nlm.nih.gov/pubmed/25311081", "http://www.ncbi.nlm.nih.gov/pubmed/7965021", "http://www.ncbi.nlm.nih.gov/pubmed/24160776", "http://www.ncbi.nlm.nih.gov/pubmed/25009532", "http://www.ncbi.nlm.nih.gov/pubmed/12553433", "http://www.ncbi.nlm.nih.gov/pubmed/3601096", "http://www.ncbi.nlm.nih.gov/pubmed/23579071", "http://www.ncbi.nlm.nih.gov/pubmed/19682646", "http://www.ncbi.nlm.nih.gov/pubmed/10718550", "http://www.ncbi.nlm.nih.gov/pubmed/19075702", "http://www.ncbi.nlm.nih.gov/pubmed/1519448", "http://www.ncbi.nlm.nih.gov/pubmed/2309926", "http://www.ncbi.nlm.nih.gov/pubmed/9630636", "http://www.ncbi.nlm.nih.gov/pubmed/11294981", "http://www.ncbi.nlm.nih.gov/pubmed/7553078", "http://www.ncbi.nlm.nih.gov/pubmed/12182890", "http://www.ncbi.nlm.nih.gov/pubmed/25784853"], "ideal_answer": ["Transthyretin (TTR) is a protein synthesized in the choroid plexus, which forms the blood-cerebrospinal fluid barrier.  TTR is the physiological carrier of thyroxine (T4) and retinol from the blood into the cerebrospinal fluid and their distribution in the brain. The transport of T4 is important for normal development of the brain."], "concepts": ["http://www.uniprot.org/uniprot/TTHY_MACEU", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002555", "http://www.uniprot.org/uniprot/TTHY_MACGI", "http://www.uniprot.org/uniprot/TTHY_TILRU", "http://www.uniprot.org/uniprot/TTHY_PIG", "http://www.uniprot.org/uniprot/TTHY_HUMAN", "http://www.uniprot.org/uniprot/TTHY_MONDO", "http://www.uniprot.org/uniprot/TTHY_SMIMA", "http://www.uniprot.org/uniprot/TTHY_CROPO", "http://www.uniprot.org/uniprot/TTHY_BOVIN", "http://www.uniprot.org/uniprot/TTHY_SHEEP"], "type": "summary", "id": "58b6a42522d300530900000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 452, "text": "Transthyretin (TTR) is a protein that binds and distributes thyroid hormones (THs). TTR synthesised in the liver is secreted into the bloodstream and distributes THs around the body, whereas TTR synthesised in the choroid plexus is involved in movement of thyroxine from the blood into the cerebrospinal fluid and the distribution of THs in the brain. This is important because an adequate amount of TH is required for normal development of the brain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25737004", "endSection": "abstract"}, {"offsetInBeginSection": 204, "offsetInEndSection": 847, "text": "The choroid plexus forms the blood-cerebrospinal fluid barrier. In reptiles, birds and mammals, the main protein synthesized and secreted by the choroid plexus is a thyroid hormone distributor protein: transthyretin. This transthyretin is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood into the cerebrospinal fluid. Maximal transthyretin synthesis in the choroid plexus occurs just prior to the period of rapid brain growth, suggesting that choroid plexus-derived transthyretin moves thyroid hormones from blood into cerebrospinal fluid just prior to when thyroid hormones are required for rapid brain growth. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Transthyretin (TTR) is a visceral protein, which facilitates the transport of thyroid hormones in blood and cerebrospinal fluid. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25311081", "endSection": "abstract"}, {"offsetInBeginSection": 291, "offsetInEndSection": 702, "text": "Serum TH binding proteins play a major role for the availability of TH since only free hormone concentrations may dictate cellular uptake. One of these proteins, transthyretin is also present in the cerebrospinal fluid (CSF) after being secreted by the choroid plexus. Entry routes into the brain like the blood-brain-barrier (BBB) and the blood-CSF-barrier will be explicated regarding fetal and adult status. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25009532", "endSection": "abstract"}, {"offsetInBeginSection": 148, "offsetInEndSection": 426, "text": "Some POPs, i.e., hydroxylated metabolites of polychlorinated biphenyls (OH-PCBs), pentachlorophenol (PCP), and perfluorooctane sulfonate (PFOS), compete with thyroxin (T4) for binding sites on transthyretin (TTR), a T4 transport protein found in plasma and cerebrospinal fluid. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "Transthyretin (TTR), a plasma and cerebrospinal fluid protein secreted by the liver and choroid plexus, is mainly known as the physiological carrier of thyroxine (T(4)) and retinol. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19682646", "endSection": "abstract"}, {"offsetInBeginSection": 134, "offsetInEndSection": 305, "text": "The secretion of transthyretin by the choroid plexus into the cerebrospinal fluid may have an important function in the transport of thyroxine from the blood to the brain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1519448", "endSection": "abstract"}, {"offsetInBeginSection": 417, "offsetInEndSection": 548, "text": "This transthyretin is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood into the cerebrospinal fluid.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", "endSection": "abstract"}, {"offsetInBeginSection": 1488, "offsetInEndSection": 1775, "text": "Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave the choroid plexus to enter the cerebrospinal fluid via either thyroid hormone transmembrane transporters or via choroid plexus-derived transthyretin secreted into the cerebrospinal fluid.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", "endSection": "abstract"}, {"offsetInBeginSection": 421, "offsetInEndSection": 551, "text": "This transthyretin is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood into the cerebrospinal fluid", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", "endSection": "abstract"}, {"offsetInBeginSection": 553, "offsetInEndSection": 845, "text": "Maximal transthyretin synthesis in the choroid plexus occurs just prior to the period of rapid brain growth, suggesting that choroid plexus-derived transthyretin moves thyroid hormones from blood into cerebrospinal fluid just prior to when thyroid hormones are required for rapid brain growth", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", "endSection": "abstract"}, {"offsetInBeginSection": 1499, "offsetInEndSection": 1785, "text": "Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave the choroid plexus to enter the cerebrospinal fluid via either thyroid hormone transmembrane transporters or via choroid plexus-derived transthyretin secreted into the cerebrospinal fluid", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Transthyretin (TTR) is a visceral protein, which facilitates the transport of thyroid hormones in blood and cerebrospinal fluid", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25311081", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Transthyretin (TTR) is a plasma and cerebrospinal fluid (CSF)-circulating homotetrameric protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23579071", "endSection": "abstract"}, {"offsetInBeginSection": 148, "offsetInEndSection": 424, "text": "Some POPs, i.e., hydroxylated metabolites of polychlorinated biphenyls (OH-PCBs), pentachlorophenol (PCP), and perfluorooctane sulfonate (PFOS), compete with thyroxin (T4) for binding sites on transthyretin (TTR), a T4 transport protein found in plasma and cerebrospinal fluid", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Transthyretin (TTR) is a homotetrameric serum and cerebrospinal fluid protein that transports both thyroxine (T(4)) and the retinol-retinol binding protein complex (holoRBP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19075702", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Dose-dependent transthyretin inhibition of T4 uptake from cerebrospinal fluid in sheep.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16325339", "endSection": "title"}, {"offsetInBeginSection": 135, "offsetInEndSection": 306, "text": "The secretion of transthyretin by the choroid plexus into the cerebrospinal fluid may have an important function in the transport of thyroxine from the blood to the brain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1519448", "endSection": "abstract"}, {"offsetInBeginSection": 888, "offsetInEndSection": 1086, "text": "High-affinity cellular binding sites for TTR have been described; however, their function and that of choroid plexus synthesis of TTR and transport of T4 into the cerebrospinal fluid remain unclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10718550", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Transthyretin is the major thyroxine-binding protein in the plasma of rodents, and the main thyroxine-binding protein in the cerebrospinal fluid of both rodents and humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12182890", "endSection": "abstract"}, {"offsetInBeginSection": 421, "offsetInEndSection": 552, "text": "This transthyretin is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood into the cerebrospinal fluid.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", "endSection": "abstract"}, {"offsetInBeginSection": 1499, "offsetInEndSection": 1786, "text": "Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave the choroid plexus to enter the cerebrospinal fluid via either thyroid hormone transmembrane transporters or via choroid plexus-derived transthyretin secreted into the cerebrospinal fluid.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784853", "endSection": "abstract"}]}, {"body": "Can you define iatrogenic disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21610562", "http://www.ncbi.nlm.nih.gov/pubmed/26767158", "http://www.ncbi.nlm.nih.gov/pubmed/10979347", "http://www.ncbi.nlm.nih.gov/pubmed/25660151", "http://www.ncbi.nlm.nih.gov/pubmed/19063792", "http://www.ncbi.nlm.nih.gov/pubmed/2173098", "http://www.ncbi.nlm.nih.gov/pubmed/8133999", "http://www.ncbi.nlm.nih.gov/pubmed/17091219", "http://www.ncbi.nlm.nih.gov/pubmed/8642152", "http://www.ncbi.nlm.nih.gov/pubmed/8608668", "http://www.ncbi.nlm.nih.gov/pubmed/18176826", "http://www.ncbi.nlm.nih.gov/pubmed/18242414", "http://www.ncbi.nlm.nih.gov/pubmed/3961454", "http://www.ncbi.nlm.nih.gov/pubmed/2534534", "http://www.ncbi.nlm.nih.gov/pubmed/25600788", "http://www.ncbi.nlm.nih.gov/pubmed/24719163", "http://www.ncbi.nlm.nih.gov/pubmed/22197283", "http://www.ncbi.nlm.nih.gov/pubmed/12561154", "http://www.ncbi.nlm.nih.gov/pubmed/17497458", "http://www.ncbi.nlm.nih.gov/pubmed/21481093", "http://www.ncbi.nlm.nih.gov/pubmed/2240392", "http://www.ncbi.nlm.nih.gov/pubmed/355046", "http://www.ncbi.nlm.nih.gov/pubmed/17470323", "http://www.ncbi.nlm.nih.gov/pubmed/8420729", "http://www.ncbi.nlm.nih.gov/pubmed/26386902", "http://www.ncbi.nlm.nih.gov/pubmed/20650043", "http://www.ncbi.nlm.nih.gov/pubmed/133304"], "ideal_answer": ["An iatrogenic disease is one that arises from treatment of another illness, such as an arrythmia that results from surgery or and hospital aquired infection in an immunocompromised patient."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007049"], "type": "factoid", "id": "58a342e760087bc10a00001c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Iatrogenic neurologic deficits after lumbar spine surgery are rare complications, but important to recognize and manage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26386902", "endSection": "abstract"}, {"offsetInBeginSection": 174, "offsetInEndSection": 399, "text": "However, we analyze its etiology in order to determine if it is from iatrogenic causes. This syndrome can be categorized as follows: mistaken diagnoses, transoperative error, technique error, poor application, poor indication", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17470323", "endSection": "abstract"}, {"offsetInBeginSection": 548, "offsetInEndSection": 863, "text": "However, the clinical events that occur during iatrogenic immunosuppression (transplantation and cancer therapy) and as a result of immunocompromise due to human immunodeficiency virus infection are currently promoting our understanding of the epidemiology of CMV disease and the definition of its clinical spectrum", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2173098", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "The authors observed one case of an iatrogenic subarachnoid-pleural fistula secondary to the resection of an upper lobe carcinoma of the lung.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8133999", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Radiological procedures require the intravascular administration of iodinated contrast media, which are becoming a great source of an iatrogenic disease known as contrast-induced nephropathy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17497458", "endSection": "abstract"}, {"offsetInBeginSection": 135, "offsetInEndSection": 273, "text": "Many studies have reported that AED therapy is associated with metabolic bone disease and is a major iatrogenic risk factor for fractures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17091219", "endSection": "abstract"}, {"offsetInBeginSection": 673, "offsetInEndSection": 750, "text": " The aetiology of arrhythmias can be either iatrogenic, such as postsurgical,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19063792", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Iatrogenic diseases are defined as illnesses due to diagnostic or therapeutic procedures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3961454", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "BACKGROUND: Iatrogenic illness, defined as a disease that results from a diagnostic procedure or from any form of therapy, is a well-recognized phenomenon in clinical practice. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Iatrogenic diseases are defined as illnesses due to diagnostic or therapeutic procedures. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3961454", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 477, "text": "Iatrogenic illness, defined as a disease that results from a diagnostic procedure or from any form of therapy, is a well-recognized phenomenon in clinical practice.To study and evaluate major cardiac iatrogenic disease as the cause of admission to the intensive cardiac care unit in the modern era.We assessed 64 critically ill patients suffering from major cardiac iatrogenic problems among a total of 2,559 patients admitted to the intensive cardiac care unit during 3 years.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347", "endSection": "abstract"}, {"offsetInBeginSection": 265, "offsetInEndSection": 436, "text": "Iatrogenic disease was defined as adverse drug reactions according to the World Health Organization Definition and complications induced by non-drug medical interventions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20650043", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Iatrogenic illness, defined as a disease that results from a diagnostic procedure or from any form of therapy, is a well-recognized phenomenon in clinical practice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347", "endSection": "abstract"}, {"offsetInBeginSection": 480, "offsetInEndSection": 553, "text": "Iatrogenic illness was defined as any problem that resulted from therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10979347", "endSection": "abstract"}, {"offsetInBeginSection": 895, "offsetInEndSection": 980, "text": "An iatrogenic event was defined as \"an adverse event related to a medical procedure\".", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600788", "endSection": "abstract"}, {"offsetInBeginSection": 1402, "offsetInEndSection": 1608, "text": "Patients with colorectal cancer who had splenectomy as a result of iatrogenic damage of the spleen while undergoing resection of the sigmoid or rectum for adenocarcinoma had a significantly worse prognosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18176826", "endSection": "abstract"}, {"offsetInBeginSection": 1243, "offsetInEndSection": 1635, "text": "Intraoperative aortic dissection remains a rare and unpredictable complication of cardiac surgery, with worse outcomes than spontaneous aortic dissection. Increased age and atheromatous disease at the site of cannulation are significant risk factors for iatrogenic dissection. In this series, off-pump coronary artery bypass did not appear to be a risk factor for iatrogenic aortic dissection", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24719163", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 392, "text": " Iatrogenic injury to the spleen is not an uncommon complication. Left nephrectomy has been reported as the second commonest cause of iatrogenic splenectomy with a reported incidence between 1.3 and 24%. Iatrogenic splenectomy is associated with significant morbidity and mortality.AIMS: We reviewed the occurrence of iatrogenic splenectomy during left nephrectomy at our centre.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21701137", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 380, "text": "Hallux valgus is a common forefoot pathology often requiring surgical intervention for symptomatic relief. One complication of hallux valgus correction is flexible hallux varus. Iatrogenic flexible hallux varus often requires surgical repair; however, the most advantageous surgical procedure for repair of iatrogenic flexible hallux varus and their sustainability remains unclear", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22197283", "endSection": "abstract"}, {"offsetInBeginSection": 703, "offsetInEndSection": 833, "text": "The possible interrelationship between such deposition and cranial irradiation and/or i.t. MTX suggests a new iatrogenic disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/417541", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 207, "text": " report of a patient with granulomatous peritonitis following general surgery is presented. Laparoscopy was performed as the final diagnostic procedure. Prevention is the remedy for this iatrogenic problem.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/133304", "endSection": "abstract"}, {"offsetInBeginSection": 521, "offsetInEndSection": 914, "text": "This report reviews both the medical and surgical literature during the past 15 years of patients treated for pseudomembranous colitis. Analysis of this clinical data has provided us with the opportunity to both define the role of surgery in this disorder and illustrate the necessity for a combined medical and surgical cooperative approach in the early management of this iatrogenic disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2240392", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "Iatrogenic problems following gastric surgery.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/355046", "endSection": "title"}, {"offsetInBeginSection": 6, "offsetInEndSection": 238, "text": "difficult to truly define iatrogenic complications in the postsurgical state in that the surgery is a condition originated by physician intervention and thus any problems that occur may be technically considered as physician created", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/355046", "endSection": "abstract"}, {"offsetInBeginSection": 1260, "offsetInEndSection": 1839, "text": "he most severe iatrogenic events were nosocomial infections (49/62 [79%]) and respiratory events (nine of 26 [35%]). Cutaneous injuries were frequent (n=94) but generally minor (89 [95%]), as were medication errors (15/19 [76%]). Most medication errors occurred during administration stage (12/19 [63%]) and were ten-fold errors (nine of 19 [47%]). The major risk factors were low birthweight and gestational age (both p<0.0001), length of stay (p<0.0001), a central venous line (p<0.0001), mechanical ventilation (p=0.0021), and support with continuous positive airwary pressure", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18242414", "endSection": "abstract"}]}, {"body": "Where do the Schwann cells and melanocytes originate from?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24760871", "http://www.ncbi.nlm.nih.gov/pubmed/17652534", "http://www.ncbi.nlm.nih.gov/pubmed/21501576", "http://www.ncbi.nlm.nih.gov/pubmed/8834474", "http://www.ncbi.nlm.nih.gov/pubmed/23858437", "http://www.ncbi.nlm.nih.gov/pubmed/9142492", "http://www.ncbi.nlm.nih.gov/pubmed/12702775", "http://www.ncbi.nlm.nih.gov/pubmed/23347447", "http://www.ncbi.nlm.nih.gov/pubmed/7684712", "http://www.ncbi.nlm.nih.gov/pubmed/8320168", "http://www.ncbi.nlm.nih.gov/pubmed/17631447", "http://www.ncbi.nlm.nih.gov/pubmed/10885676", "http://www.ncbi.nlm.nih.gov/pubmed/25805416", "http://www.ncbi.nlm.nih.gov/pubmed/20454996", "http://www.ncbi.nlm.nih.gov/pubmed/8269857", "http://www.ncbi.nlm.nih.gov/pubmed/10906452", "http://www.ncbi.nlm.nih.gov/pubmed/19931641", "http://www.ncbi.nlm.nih.gov/pubmed/20683859", "http://www.ncbi.nlm.nih.gov/pubmed/18636017", "http://www.ncbi.nlm.nih.gov/pubmed/1504451", "http://www.ncbi.nlm.nih.gov/pubmed/3085152", "http://www.ncbi.nlm.nih.gov/pubmed/22170630", "http://www.ncbi.nlm.nih.gov/pubmed/1967835", "http://www.ncbi.nlm.nih.gov/pubmed/9247201", "http://www.ncbi.nlm.nih.gov/pubmed/3425403", "http://www.ncbi.nlm.nih.gov/pubmed/14576682", "http://www.ncbi.nlm.nih.gov/pubmed/25752517", "http://www.ncbi.nlm.nih.gov/pubmed/2685414", "http://www.ncbi.nlm.nih.gov/pubmed/6517351", "http://www.ncbi.nlm.nih.gov/pubmed/23815504"], "ideal_answer": ["Schwann cells and melanocytes originate from the multipotent population of neural crest cells."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008544", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012583", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D039904", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D039902"], "type": "factoid", "id": "58b56fe422d3005309000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 419, "text": "The development of the nervous system involves cells remaining within the neural tube (CNS) and a group of cells that delaminate from the dorsal neural tube and migrate extensively throughout the developing embryo called neural crest cells (NCC). These cells are a mesenchymal highly migratory group of cells that give rise to a wide variety of cell derivatives: melanocytes, sensory neurons, bone, Schwann cells, etc. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25805416", "endSection": "abstract"}, {"offsetInBeginSection": 235, "offsetInEndSection": 460, "text": "Cell types with neural crest ancestry consequently comprise a number of specialized varieties, such as ectodermal neurons, melanocytes and Schwann cells, as well as mesodermal osteoblasts, adipocytes and smooth muscle cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170630", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 294, "text": "Melanocytes, the pigmented cells of the skin, and the glial Schwann cells lining peripheral nerves are developmentally derived from an early and transient ectodermal structure of the vertebrate embryo, the neural crest, which is also at the origin of multiple neural and non-neural cell types. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501576", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 608, "text": "Later, SoxE proteins drive the formation of multiple neural crest derivatives including chondrocytes, melanocytes, and cells of the peripheral nervous system, particularly Schwann cells/peripheral glia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19931641", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Melanocytes and Schwann cells are derived from the multipotent population of neural crest cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20454996", "endSection": "abstract"}, {"offsetInBeginSection": 909, "offsetInEndSection": 1086, "text": "The present results suggest that the induced hamster melanomas originate from neural crest-derived cells which are able to differentiate into both melanocytes and Schwann cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8320168", "endSection": "abstract"}, {"offsetInBeginSection": 244, "offsetInEndSection": 423, "text": "Melanocytes and Schwann cells both arise from the neural crest during development, and some melanocytes arise directly from Schwann cell precursors lining developing spinal nerves", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23815504", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Schwann cells, the myelinating glia of the peripheral nervous system (PNS), originate from multipotent neural crest cells that also give rise to other cells, including neurons, melanocytes, chondrocytes, and smooth muscle cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760871", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": "In the vertebrate embryo, Schwann cells lining the peripheral nerves originate from the neural crest (NC), a structure that also gives rise to ganglion satellite cells, most of the neurons of the peripheral nervous system, melanocytes, and part of the cranial mesenchyme", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1967835", "endSection": "abstract"}, {"offsetInBeginSection": 909, "offsetInEndSection": 1085, "text": "The present results suggest that the induced hamster melanomas originate from neural crest-derived cells which are able to differentiate into both melanocytes and Schwann cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8320168", "endSection": "abstract"}, {"offsetInBeginSection": 901, "offsetInEndSection": 1215, "text": "Thus, the nevus cells shared a common nature with epidermal melanocytes and Schwann cells which originate from the neural crest; however, the former cells were somewhat different from the latter two kinds and from benign and malignant tumors derived from these cells in the expression of these antigenic substances", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2685414", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 292, "text": "Melanocytes, the pigmented cells of the skin, and the glial Schwann cells lining peripheral nerves are developmentally derived from an early and transient ectodermal structure of the vertebrate embryo, the neural crest, which is also at the origin of multiple neural and non-neural cell types", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501576", "endSection": "abstract"}, {"offsetInBeginSection": 508, "offsetInEndSection": 823, "text": "Furthermore, although both populations are initially part of the Foxd3 lineage, hypaxial melanocytes lose Foxd3 at late stages upon separation from the nerve, whereas we recently found that epaxial melanocytes segregate earlier from Foxd3-positive neural progenitors while still residing in the dorsal neural tube. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23858437", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Reversal of developmental restrictions in neural crest lineages: transition from Schwann cells to glial-melanocytic precursors in vitro.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12702775", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "Schwann cells, the myelinating glia of the peripheral nervous system (PNS), originate from multipotent neural crest cells that also give rise to other cells, including neurons, melanocytes, chondrocytes, and smooth muscle cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760871", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "In the vertebrate embryo, Schwann cells lining the peripheral nerves originate from the neural crest (NC), a structure that also gives rise to ganglion satellite cells, most of the neurons of the peripheral nervous system, melanocytes, and part of the cranial mesenchyme.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1967835", "endSection": "abstract"}, {"offsetInBeginSection": 901, "offsetInEndSection": 1216, "text": "Thus, the nevus cells shared a common nature with epidermal melanocytes and Schwann cells which originate from the neural crest; however, the former cells were somewhat different from the latter two kinds and from benign and malignant tumors derived from these cells in the expression of these antigenic substances.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2685414", "endSection": "abstract"}, {"offsetInBeginSection": 1501, "offsetInEndSection": 1737, "text": "Other already committed cells are the angioblasts forming the endothelial lining of the blood vessels, the neural crest cells differentiating into melanocytes and Schwann cells, and the blood-derived cells like chrondro- or osteoclasts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3425403", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 243, "text": "The dorsal neural tube first generates neural crest cells that exit the neural primordium following an epithelial-to-mesenchymal conversion to become sympathetic ganglia, Schwann cells, dorsal root sensory ganglia, and melanocytes of the skin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20683859", "endSection": "abstract"}, {"offsetInBeginSection": 1024, "offsetInEndSection": 1228, "text": "We show here that neural crest cells arising from the neural tube located at the level of somites 47-53 can differentiate both in vitro and in vivo into melanocytes and Schwann cells but not into neurons.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906452", "endSection": "abstract"}, {"offsetInBeginSection": 270, "offsetInEndSection": 369, "text": "This capacity may be due to the common origin of Schwann cells and melanocytes in the neural crest.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1504451", "endSection": "abstract"}, {"offsetInBeginSection": 244, "offsetInEndSection": 424, "text": "Melanocytes and Schwann cells both arise from the neural crest during development, and some melanocytes arise directly from Schwann cell precursors lining developing spinal nerves.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23815504", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "In the vertebrate embryo, multiple cell types originate from a common structure, the neural crest (NC), which forms at the dorsal tips of the neural epithelium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17631447", "endSection": "abstract"}]}, {"body": "Please list 3 diseases associated with the PIEZO2 gene.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24726473", "http://www.ncbi.nlm.nih.gov/pubmed/27843126", "http://www.ncbi.nlm.nih.gov/pubmed/27714920", "http://www.ncbi.nlm.nih.gov/pubmed/23487782"], "ideal_answer": ["Recently, Gordon syndrome has been associated to heterozygous mutations in the piezo-type mechanosensitive ion channel component 2 gene (PIEZO2). Different mutations of this gene also cause distal arthrogryposis type 5 and Marden-Walker syndrome."], "concepts": ["http://www.uniprot.org/uniprot/PIEZ2_HUMAN"], "type": "list", "id": "58bd645702b8c60953000010", "snippets": [{"offsetInBeginSection": 241, "offsetInEndSection": 487, "text": "Recently, Gordon syndrome has been associated to heterozygous mutations in the piezo-type mechanosensitive ion channel component 2 gene (PIEZO2). Different mutations of this gene also cause distal arthrogryposis type 5 and Marden-Walker syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27714920", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Mutations in PIEZO2 cause Gordon syndrome, Marden-Walker syndrome, and distal arthrogryposis type 5.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726473", "endSection": "title"}, {"offsetInBeginSection": 903, "offsetInEndSection": 1117, "text": "Both types of changes in kinetics result in increased channel activity in response to a given mechanical stimulus, suggesting that Distal Arthrogryposis Type 5 can be caused by gain-of-function mutations in PIEZO2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23487782", "endSection": "abstract"}, {"offsetInBeginSection": 318, "offsetInEndSection": 588, "text": "Here, we describe two distinct PIEZO2 mutations in patients with a subtype of Distal Arthrogryposis Type 5 characterized by generalized autosomal dominant contractures with limited eye movements, restrictive lung disease, and variable absence of cruciate knee ligaments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23487782", "endSection": "abstract"}, {"offsetInBeginSection": 241, "offsetInEndSection": 386, "text": "Recently, Gordon syndrome has been associated to heterozygous mutations in the piezo-type mechanosensitive ion channel component 2 gene (PIEZO2).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27714920", "endSection": "abstract"}, {"offsetInBeginSection": 794, "offsetInEndSection": 1091, "text": "In contrast, heterozygous gain-of-function missense mutations, mainly localized at the C terminus, cause dominant distal arthrogryposis 3 (DA3), distal arthrogryposis 5 (DA5), or Marden-Walker syndrome (MWKS), which encompass contractures of hands and feet, scoliosis, ophthalmoplegia, and ptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Dominant mutations in PIEZO2, which codes for the principal mechanotransduction channel for proprioception and touch sensation, have been found to cause different forms of distal arthrogryposi", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27607563", "endSection": "abstract"}]}, {"body": "Is treatment resistant depression related to vitamin B9?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25229175", "http://www.ncbi.nlm.nih.gov/pubmed/22762295", "http://www.ncbi.nlm.nih.gov/pubmed/27655070", "http://www.ncbi.nlm.nih.gov/pubmed/24324965", "http://www.ncbi.nlm.nih.gov/pubmed/23538072", "http://www.ncbi.nlm.nih.gov/pubmed/24519190", "http://www.ncbi.nlm.nih.gov/pubmed/18370582"], "ideal_answer": ["Treatment with SAMe, as well as with various formulations of folates and analogues, appears to be efficacious and well tolerated in reducing depressive symptoms in treatment resistant depression."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003863", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061218", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003865"], "type": "yesno", "id": "58a337af60087bc10a000016", "snippets": [{"offsetInBeginSection": 253, "offsetInEndSection": 616, "text": "Suboptimal serum and red blood cell folate levels have been associated with a poorer response to antidepressant therapy, a greater severity of symptoms, later onset of clinical improvement, and overall treatment resistance. This article reviews the evidence for L-methylfolate and folic acid as antidepressive agents in depression and discusses their clinical use", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24519190", "endSection": "abstract"}, {"offsetInBeginSection": 1220, "offsetInEndSection": 1377, "text": "Although further randomized controlled trials in this area appear warranted, SAMe and L-methylfolate may represent a useful addition to the AD armamentarium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22762295", "endSection": "abstract"}, {"offsetInBeginSection": 478, "offsetInEndSection": 972, "text": "Patients with depression have consistently been found to have lower levels of serum and red blood cell folate than normal or nondepressed psychiatric patients. Decreased folate levels have been associated with lowered response rates to standard antidepressant pharmacotherapy. Recent studies have shown that augmentation with a folate supplement increases medication response in both treatment-na\u00efve and treatment-resistant depressed patients irrespective of whether there is folate deficiency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18370582", "endSection": "abstract"}, {"offsetInBeginSection": 985, "offsetInEndSection": 1223, "text": "Depressed patients with both low and normal folate levels may benefit from augmenting a primary antidepressant medication either initially, at the onset of treatment, or later after some degree of treatment resistance has been recognized.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18370582", "endSection": "abstract"}, {"offsetInBeginSection": 526, "offsetInEndSection": 768, "text": "The results of this study suggest that intake of vitamin B9 may modulate the total score of Center for Epidemiological Studies Depression Scale (CES-D) and two subscales of the CES-D including depressive affect and interpersonal difficulties.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24324965", "endSection": "abstract"}, {"offsetInBeginSection": 526, "offsetInEndSection": 769, "text": "The results of this study suggest that intake of vitamin B9 may modulate the total score of Center for Epidemiological Studies Depression Scale (CES-D) and two subscales of the CES-D including depressive affect and interpersonal difficulties. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24324965", "endSection": "abstract"}, {"offsetInBeginSection": 301, "offsetInEndSection": 459, "text": "This article reviews the metabolic and clinical importance of folate, vitamin B12, and SAMe, as well as clinical trials in relation to depression and dementia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23538072", "endSection": "abstract"}, {"offsetInBeginSection": 423, "offsetInEndSection": 554, "text": "In particular, vitamins B1, B3, B6, B9 and B12 are essential for neuronal function and deficiencies have been linked to depression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27655070", "endSection": "abstract"}]}, {"body": "Where is the protein slitrk1 localized?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25379384", "http://www.ncbi.nlm.nih.gov/pubmed/21315458", "http://www.ncbi.nlm.nih.gov/pubmed/22703893", "http://www.ncbi.nlm.nih.gov/pubmed/27273464"], "ideal_answer": ["Slitrk1 is enriched in postsynaptic fractions and is localized to excitatory synapses. "], "type": "summary", "id": "58a87bd338c171fb5b000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 43, "text": "Slitrk1 is localized to excitatory synapses", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27273464", "endSection": "title"}, {"offsetInBeginSection": 500, "offsetInEndSection": 587, "text": " Slitrk1 is enriched in postsynaptic fractions and is localized to excitatory synapses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27273464", "endSection": "abstract"}, {"offsetInBeginSection": 587, "offsetInEndSection": 655, "text": " The porcine SLITRK1 gene is expressed exclusively in brain tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25379384", "endSection": "abstract"}, {"offsetInBeginSection": 124, "offsetInEndSection": 226, "text": "Six family members exist (Slitrk1-6) and all are highly expressed in the central nervous system (CNS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21315458", "endSection": "abstract"}]}, {"body": "Describe clinical manifestation of the Harlequin syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9555141", "http://www.ncbi.nlm.nih.gov/pubmed/18769278", "http://www.ncbi.nlm.nih.gov/pubmed/16918633", "http://www.ncbi.nlm.nih.gov/pubmed/21796071", "http://www.ncbi.nlm.nih.gov/pubmed/23726525", "http://www.ncbi.nlm.nih.gov/pubmed/8292878", "http://www.ncbi.nlm.nih.gov/pubmed/26513674", "http://www.ncbi.nlm.nih.gov/pubmed/25923501", "http://www.ncbi.nlm.nih.gov/pubmed/9219751", "http://www.ncbi.nlm.nih.gov/pubmed/22638078", "http://www.ncbi.nlm.nih.gov/pubmed/26964837", "http://www.ncbi.nlm.nih.gov/pubmed/26943985", "http://www.ncbi.nlm.nih.gov/pubmed/2331828", "http://www.ncbi.nlm.nih.gov/pubmed/17569597", "http://www.ncbi.nlm.nih.gov/pubmed/27024906", "http://www.ncbi.nlm.nih.gov/pubmed/25933078", "http://www.ncbi.nlm.nih.gov/pubmed/8250530", "http://www.ncbi.nlm.nih.gov/pubmed/24882829"], "ideal_answer": ["Harlequin syndrome is characterized by the sudden onset of unilateral facial flushing and sweating, often preceded by exercise, excessive heat, or, rarely, regional anesthesia. It is a rare autonomic disorder due to a hemifacial cutaneous sympathetic denervation."], "type": "summary", "id": "5895db407d9090f35300000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Harlequin syndrome is characterized by the sudden onset of unilateral facial flushing and sweating, often preceded by exercise, excessive heat, or, rarely, regional anesthesia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26513674", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "UNLABELLED: Harlequin syndrome (HS) is a rare autonomic disorder due to a hemifacial cutaneous sympathetic denervation. It is characterized by unilateral diminished sweating and flushing of the face even though after heat or prolonged exercise. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26943985", "endSection": "abstract"}, {"offsetInBeginSection": 236, "offsetInEndSection": 390, "text": "OBSERVATION: A 38-year-old melanoderm man, without any history of surgery or neck trauma, consulted for a strictly right unilateral facial hyperhidrosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26964837", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 220, "text": "Harlequin syndrome (HS) is a rare disorder of the sympathetic nervous system which presents with unilateral decreased sweating and flushing of the face, neck, and chest in response to heat, exercise, or emotional factors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25933078", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "A 42-year-old woman had symptoms of unilateral flushing and sweating of her face during exercise. The clinical diagnosis was 'harlequin syndrome'. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25923501", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Harlequin sign and harlequin syndrome, which are used interchangeably in the literature, are characterized by sudden onset of hemifacial sweating and flushing, induced by exercise and heat.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17569597", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Harlequin syndrome is a rare, clinically striking syndrome characterized by distinctly demarcated asymmetric facial flushing and sweating.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27024906", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "Harlequin sign and harlequin syndrome, which are used interchangeably in the literature, are characterized by sudden onset of hemifacial sweating and flushing, induced by exercise and heat", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17569597", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Harlequin sign (hemifacial flushing and contralateral hypohidrosis) in a 4-year-old girl with Horner syndrome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16918633", "endSection": "title"}, {"offsetInBeginSection": 250, "offsetInEndSection": 357, "text": "She also exhibited left hemifacial flushing and loss of sweating on the contralateral side (harlequin sign)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16918633", "endSection": "abstract"}]}, {"body": "What is the role of the constitutive photomorphogenesis 9 signalosome (CSN)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27412572", "http://www.ncbi.nlm.nih.gov/pubmed/18854373", "http://www.ncbi.nlm.nih.gov/pubmed/11731421", "http://www.ncbi.nlm.nih.gov/pubmed/27581057", "http://www.ncbi.nlm.nih.gov/pubmed/23818606", "http://www.ncbi.nlm.nih.gov/pubmed/16844902", "http://www.ncbi.nlm.nih.gov/pubmed/16275352", "http://www.ncbi.nlm.nih.gov/pubmed/21051661", "http://www.ncbi.nlm.nih.gov/pubmed/15342494", "http://www.ncbi.nlm.nih.gov/pubmed/10585392", "http://www.ncbi.nlm.nih.gov/pubmed/12368504", "http://www.ncbi.nlm.nih.gov/pubmed/12324474", "http://www.ncbi.nlm.nih.gov/pubmed/17914096", "http://www.ncbi.nlm.nih.gov/pubmed/26976604", "http://www.ncbi.nlm.nih.gov/pubmed/22956996", "http://www.ncbi.nlm.nih.gov/pubmed/23288897", "http://www.ncbi.nlm.nih.gov/pubmed/11337588", "http://www.ncbi.nlm.nih.gov/pubmed/21403132", "http://www.ncbi.nlm.nih.gov/pubmed/14502989", "http://www.ncbi.nlm.nih.gov/pubmed/27546621", "http://www.ncbi.nlm.nih.gov/pubmed/21317535", "http://www.ncbi.nlm.nih.gov/pubmed/24973710", "http://www.ncbi.nlm.nih.gov/pubmed/27833851", "http://www.ncbi.nlm.nih.gov/pubmed/16310364", "http://www.ncbi.nlm.nih.gov/pubmed/15867213", "http://www.ncbi.nlm.nih.gov/pubmed/24286178", "http://www.ncbi.nlm.nih.gov/pubmed/21876386"], "ideal_answer": ["The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) is a protein complex involved in the ubiquitin proteasome system and plays a role in regulating the degradation of polyubiquitinated proteins. The mammalian CSN is also involved in embryonic development, in cancer and the DNA damage response, whereas in plants CSN plays a role in innate immunity."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012380", "http://amigo.geneontology.org/amigo/term/GO:0008180"], "type": "summary", "id": "58b576b622d3005309000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "The family of cullin-RING E3 Ligases (CRLs) and the constitutive photomorphogenesis 9 (COP9) signalosome (CSN) form dynamic complexes that mediate ubiquitylation of 20% of the proteome, yet regulation of their assembly/disassembly remains poorly understood. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976604", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "The COP9 (constitutive photomorphogenesis 9) signalosome (CSN) is a protein complex involved in the ubiquitin proteasome system and a common host target of diverse pathogens in Arabidopsis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27581057", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "The COP9 (Constitutive photomorphogenesis 9) signalosome (CSN), a large multiprotein complex that resembles the 19S lid of the 26S proteasome, plays a central role in the regulation of the E3-cullin RING ubiquitin ligases (CRLs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288897", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 251, "text": "The mammalian constitutive photomorphogenesis 9 (COP9) signalosome (CSN), a protein complex involved in embryonic development, is implicated in cell cycle regulation and the DNA damage response. Its role in tumor development, however, remains unclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 44, "text": "COP9 plays a role in plant innate immunity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403132", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 342, "text": "The constitutive photomorphogenesis\u00a09 signalosome (COP9 or CSN) is an evolutionarily conserved multiprotein complex found in plants and animals. Because of the homology between the COP9 signalosome and the 19S lid complex of the proteosome, COP9 has been postulated to play a role in regulating the degradation of polyubiquitinated proteins. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876386", "endSection": "abstract"}, {"offsetInBeginSection": 464, "offsetInEndSection": 673, "text": "Therefore, it is conceivable that COP9 plays a significant role in cancer, regulating processes relevant to carcinogenesis and cancer progression (e.g., cell cycle control, signal transduction and apoptosis). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876386", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 251, "text": "The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) plays key roles in many biological processes, such as repression of photomorphogenesis in plants and protein subcellular localization, DNA-damage response, and NF-\u03baB activation in mammals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818606", "endSection": "abstract"}, {"offsetInBeginSection": 267, "offsetInEndSection": 419, "text": "The COP9 (constitutive photomorphogenesis mutant 9) signalosome (CSN) may regulate the UPS, but this has not been tested in a critical vertebrate organ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051661", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "The mammalian constitutive photomorphogenesis 9 (COP9) signalosome (CSN), a protein complex involved in embryonic development, is implicated in cell cycle regulation and the DNA damage response.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317535", "endSection": "abstract"}, {"offsetInBeginSection": 205, "offsetInEndSection": 378, "text": "Here we show that the production of vascular endothelial growth factor (VEGF) in HeLa and HL-60 cells is directed by the constitutive photomorphogenesis 9 signalosome (CSN).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731421", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "The family of cullin-RING E3 Ligases (CRLs) and the constitutive photomorphogenesis 9 (COP9) signalosome (CSN) form dynamic complexes that mediate ubiquitylation of 20% of the proteome, yet regulation of their assembly/disassembly remains poorly understood.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976604", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "CSN6 is one subunit of the constitutive photomorphogenesis 9 (COP9) signalosome (CSN), which is an evolutionarily conserved multiprotein complex found in plants and animals and originally described as a repressor of light-dependent growth and transcription in Arabidopsis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24286178", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 291, "text": "CSN6, a critical subunit of the constitutive photomorphogenesis 9 (COP9) signalosome (CSN), has received attention as a regulator of the degradation of cancer-related proteins such as p53, c-myc and c-Jun, through the ubiquitin-proteasome system, suggesting its importance in cancerogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27546621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "The COP9 signalosome (CSN) is a complex of eight proteins first identified as a repressor of plant photomorphogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12324474", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "COP10 is a ubiquitin-conjugating enzyme variant (UEV), which is thought to act together with COP1, DET1, and the COP9 signalosome (CSN) in Arabidopsis to repress photomorphogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15342494", "endSection": "abstract"}, {"offsetInBeginSection": 280, "offsetInEndSection": 432, "text": "The COP9 (constitutive photomorphogenesis mutant 9) signalosome (CSN) may regulate the UPS, but this has not been tested in a critical vertebrate organ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051661", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "The COP9 signalosome (CSN) is an evolutionarily conserved multiprotein complex that mediates the repression of photomorphogenesis in the dark in Arabidopsis through the degradation of transcription factors such as HY5 and HYH.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12368504", "endSection": "abstract"}, {"offsetInBeginSection": 231, "offsetInEndSection": 449, "text": "The COP9 signalosome (CSN), a suppressor of plant photomorphogenesis, associated with multiple cullins and promoted cleavage of the ubiquitin-like protein NEDD8 from Schizosaccharomyces pombe CUL1 in vivo and in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11337588", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 251, "text": "The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) plays key roles in many biological processes, such as repression of photomorphogenesis in plants and protein subcellular localization, DNA-damage response, and NF-\u00eaB activation in mammals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818606", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Repression of photomorphogenesis in Arabidopsis thaliana requires activity of the COP9 signalosome (CSN), CDD, and COP1 complexes, but how these three complexes work in concert to accomplish this important developmental switch has remained unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16844902", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) plays key roles in many biological processes, such as repression of photomorphogenesis in plants and protein subcellular localization, DNA-damage response, and NF-\u03baB activation in mammals", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818606", "endSection": "abstract"}, {"offsetInBeginSection": 207, "offsetInEndSection": 379, "text": "Here we show that the production of vascular endothelial growth factor (VEGF) in HeLa and HL-60 cells is directed by the constitutive photomorphogenesis 9 signalosome (CSN)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731421", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "The COP9 (Constitutive photomorphogenesis 9) signalosome (CSN), a large multiprotein complex that resembles the 19S lid of the 26S proteasome, plays a central role in the regulation of the E3-cullin RING ubiquitin ligases (CRLs)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288897", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "CSN6 is one subunit of the constitutive photomorphogenesis 9 (COP9) signalosome (CSN), which is an evolutionarily conserved multiprotein complex found in plants and animals and originally described as a repressor of light-dependent growth and transcription in Arabidopsis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24286178", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "The mammalian constitutive photomorphogenesis 9 (COP9) signalosome (CSN), a protein complex involved in embryonic development, is implicated in cell cycle regulation and the DNA damage response", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317535", "endSection": "abstract"}, {"offsetInBeginSection": 269, "offsetInEndSection": 420, "text": "The COP9 (constitutive photomorphogenesis mutant 9) signalosome (CSN) may regulate the UPS, but this has not been tested in a critical vertebrate organ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051661", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "The COP9 Signalosome (CSN) is a multiprotein complex that was originally identified in Arabidopsis thaliana as a negative regulator of photomorphogenesis and subsequently shown to be a general eukaryotic regulator of developmental signaling", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18854373", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "Repression of photomorphogenesis in Arabidopsis thaliana requires activity of the COP9 signalosome (CSN), CDD, and COP1 complexes, but how these three complexes work in concert to accomplish this important developmental switch has remained unknown", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16844902", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "COP10 is a ubiquitin-conjugating enzyme variant (UEV), which is thought to act together with COP1, DET1, and the COP9 signalosome (CSN) in Arabidopsis to repress photomorphogenesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15342494", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731421", "endSection": "title"}, {"offsetInBeginSection": 207, "offsetInEndSection": 381, "text": "Here we show that the production of vascular endothelial growth factor (VEGF) in HeLa and HL-60 cells is directed by the constitutive photomorphogenesis 9 signalosome (CSN). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731421", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) plays key roles in many biological processes, such as repression of photomorphogenesis in plants and protein subcellular localization, DNA-damage response, and NF-\u03baB activation in mammals. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818606", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "The COP9 (Constitutive photomorphogenesis 9) signalosome (CSN), a large multiprotein complex that resembles the 19S lid of the 26S proteasome, plays a central role in the regulation of the E3-cullin RING ubiquitin ligases (CRLs). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288897", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Plant homologue constitutive photomorphogenesis 9 (COP9) signalosome subunit CSN5 regulates innate immune responses in macrophages.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403132", "endSection": "title"}, {"offsetInBeginSection": 280, "offsetInEndSection": 433, "text": "The COP9 (constitutive photomorphogenesis mutant 9) signalosome (CSN) may regulate the UPS, but this has not been tested in a critical vertebrate organ. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051661", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "The mammalian constitutive photomorphogenesis 9 (COP9) signalosome (CSN), a protein complex involved in embryonic development, is implicated in cell cycle regulation and the DNA damage response. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317535", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 449, "text": "Recent studies indicate that Int6 is a multifaceted protein involved in the regulation of protein translation and degradation through binding with three complexes: the eukaryotic translation initiation factor 3, the proteasome regulatory lid, and the constitutive photomorphogenesis 9 signalosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15867213", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "The COP9 Signalosome (CSN) is a multiprotein complex that was originally identified in Arabidopsis thaliana as a negative regulator of photomorphogenesis and subsequently shown to be a general eukaryotic regulator of developmental signaling. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18854373", "endSection": "abstract"}, {"offsetInBeginSection": 518, "offsetInEndSection": 662, "text": "In this report we demonstrate a JNK-independent activation of c-Jun in vivo directed by the constitutive photomorphogenesis (COP9) signalosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10585392", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "The COP9 signalosome (CSN) is a multiprotein complex that was initially identified in plants as a repressor of photomorphogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14502989", "endSection": "abstract"}, {"offsetInBeginSection": 960, "offsetInEndSection": 1129, "text": "This study suggests that AtItpk-1 may function as a protein kinase that is involved in photomorphogenesis possibly via interaction with COP9 signalosome under red light.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16310364", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "The Arabidopsis inositol 1,3,4-trisphosphate 5/6 kinase, AtItpk-1, is involved in plant photomorphogenesis under red light conditions, possibly via interaction with COP9 signalosome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16310364", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "The COP9 (constitutive photomorphogenesis 9) signalosome (CSN) is a protein complex involved in the ubiquitin proteasome system and a common host target of diverse pathogens in Arabidopsis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27581057", "endSection": "abstract"}, {"offsetInBeginSection": 207, "offsetInEndSection": 380, "text": "Here we show that the production of vascular endothelial growth factor (VEGF) in HeLa and HL-60 cells is directed by the constitutive photomorphogenesis 9 signalosome (CSN).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731421", "endSection": "abstract"}, {"offsetInBeginSection": 269, "offsetInEndSection": 421, "text": "The COP9 (constitutive photomorphogenesis mutant 9) signalosome (CSN) may regulate the UPS, but this has not been tested in a critical vertebrate organ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051661", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731421", "endSection": "title"}]}, {"body": "Is adalimumab effective for hidradenitis suppurativa?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25580790", "http://www.ncbi.nlm.nih.gov/pubmed/26470624", "http://www.ncbi.nlm.nih.gov/pubmed/26201313", "http://www.ncbi.nlm.nih.gov/pubmed/26831295", "http://www.ncbi.nlm.nih.gov/pubmed/18754844", "http://www.ncbi.nlm.nih.gov/pubmed/27665300", "http://www.ncbi.nlm.nih.gov/pubmed/23670060", "http://www.ncbi.nlm.nih.gov/pubmed/25040429", "http://www.ncbi.nlm.nih.gov/pubmed/21091684", "http://www.ncbi.nlm.nih.gov/pubmed/21756155", "http://www.ncbi.nlm.nih.gov/pubmed/24144253", "http://www.ncbi.nlm.nih.gov/pubmed/19997689", "http://www.ncbi.nlm.nih.gov/pubmed/26801356", "http://www.ncbi.nlm.nih.gov/pubmed/19371236", "http://www.ncbi.nlm.nih.gov/pubmed/20652119", "http://www.ncbi.nlm.nih.gov/pubmed/27799806", "http://www.ncbi.nlm.nih.gov/pubmed/23247938", "http://www.ncbi.nlm.nih.gov/pubmed/23106519", "http://www.ncbi.nlm.nih.gov/pubmed/20628295", "http://www.ncbi.nlm.nih.gov/pubmed/19213236", "http://www.ncbi.nlm.nih.gov/pubmed/22644772", "http://www.ncbi.nlm.nih.gov/pubmed/27136622", "http://www.ncbi.nlm.nih.gov/pubmed/22013960", "http://www.ncbi.nlm.nih.gov/pubmed/19451504", "http://www.ncbi.nlm.nih.gov/pubmed/21457202", "http://www.ncbi.nlm.nih.gov/pubmed/21128923", "http://www.ncbi.nlm.nih.gov/pubmed/27518661", "http://www.ncbi.nlm.nih.gov/pubmed/27388530"], "ideal_answer": ["Yes, Adalimumab, a recombinant, fully humanized, anti-tumor necrosis factor alpha (anti-TNF-\u03b1) monoclonal antibody, is the only officially approved treatment for the management of moderate-to-severe hidradenitis suppurativa."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:2280", "http://www.biosemantics.org/jochem#4002010", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000068879", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017497"], "type": "yesno", "id": "58847e36e56acf5176000009", "snippets": [{"offsetInBeginSection": 1819, "offsetInEndSection": 2061, "text": "If patient is not improved, then Adalimumab 160\u00a0mg at week 0, 80\u00a0mg at week 2; then 40\u00a0mg subcutaneously weekly should be administered (LOE Ib, SOR A). If improvement occurs then therapy should be maintained as long as HS lesions are present.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26831295", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136622", "endSection": "title"}, {"offsetInBeginSection": 144, "offsetInEndSection": 241, "text": "Adalimumab treatment for 16 weeks improved HS lesions significantly versus placebo\u00a0(NCT00918255).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136622", "endSection": "abstract"}, {"offsetInBeginSection": 1406, "offsetInEndSection": 1615, "text": "CONCLUSION: Patients with moderate to severe HS had a high degree of pain and depressive symptoms\u00a0at baseline. Adalimumabtherapy was associated with decreased pain and depressive symptoms compared to baseline.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136622", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799806", "endSection": "title"}, {"offsetInBeginSection": 465, "offsetInEndSection": 1280, "text": "Adalimumab, a recombinant, fully humanized, anti-tumor necrosis factor alpha (anti-TNF-\u03b1) monoclonal antibody, is the only officially approved treatment for the management of moderate-to-severe HS. Case reports, concerning 42 patients who received adalimumab for severe HS (with the standard dose regimen for psoriasis), reported a cumulative response rate of 58% (\u226550% in 23 patients) with a relapse rate of 71% (10 out of 14 patients). The most recent and most well-powered phase III, randomized placebo-controlled trials for the evaluation of the efficacy and safety of adalimumab in treatment of moderate-to-severe HS (PIONEER studies I and II) showed that the Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 12 was significantly higher for patients randomized to adalimumab compared to placebo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799806", "endSection": "abstract"}, {"offsetInBeginSection": 1324, "offsetInEndSection": 1423, "text": "In conclusion, adalimumab, to date, holds the most robust data regarding treatment efficacy in HS. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799806", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27388530", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Adalimumab (Humira\u00ae) is a novel therapy approved by the US Food and Drug Administration, Health Canada, and the European Commission for the treatment of hidradenitis suppurativa (HS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27388530", "endSection": "abstract"}, {"offsetInBeginSection": 1338, "offsetInEndSection": 1560, "text": "Taken together, these data conclude that treatment of HS with adalimumab is a safe and effective therapy resulting in a significant decrease in abscess and inflammatory nodule counts within the first 12 weeks of treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27388530", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091684", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "Hidradenitis suppurativa managed with adalimumab.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19213236", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Long-term successful adalimumab therapy in severe hidradenitis suppurativa.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451504", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756155", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 218, "text": "HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201313", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24144253", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Adalimumab (antitumour necrosis factor-\u03b1) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22013960", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236", "endSection": "title"}, {"offsetInBeginSection": 115, "offsetInEndSection": 404, "text": "In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor \u03b1, showed efficacy against hidradenitis suppurativa.PIONEER I and II were similarly designed, phase 3 multicenter trials of adalimumab for hidradenitis suppurativa, with two double-blind, placebo-controlled periods.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27518661", "endSection": "abstract"}, {"offsetInBeginSection": 731, "offsetInEndSection": 853, "text": "Here we report a case of a patient with severe recalcitrant hidradenitis suppurativa successfully treated with adalimumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236", "endSection": "abstract"}, {"offsetInBeginSection": 312, "offsetInEndSection": 495, "text": "Recent reports have demonstrated that adalimumab, a tumor necrosis factor (TNF) antagonist, may be effective in the treatment of patients with HS who have failed conventional therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19213236", "endSection": "abstract"}, {"offsetInBeginSection": 1351, "offsetInEndSection": 1437, "text": "Conclusion Adalimumab appears to be an effective and safe treatment for refractory HS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451504", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091684", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Hidradenitis suppurativa managed with adalimumab.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19213236", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27518661", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25580790", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Long-term successful adalimumab therapy in severe hidradenitis suppurativa.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451504", "endSection": "title"}, {"offsetInBeginSection": 1352, "offsetInEndSection": 1439, "text": "Conclusion Adalimumab appears to be an effective and safe treatment for refractory HS..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451504", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756155", "endSection": "title"}, {"offsetInBeginSection": 731, "offsetInEndSection": 854, "text": "Here we report a case of a patient with severe recalcitrant hidradenitis suppurativa successfully treated with adalimumab..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236", "endSection": "abstract"}, {"offsetInBeginSection": 1272, "offsetInEndSection": 1407, "text": "Adalimumab is suitable for the long-term treatment of hidradenitis suppurativa and presents a further conservative treatment approach..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091684", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 220, "text": "HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201313", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799806", "endSection": "title"}]}, {"body": "What is Legg-Calv\u00e9-Perthes Disease", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27064472", "http://www.ncbi.nlm.nih.gov/pubmed/26780125", "http://www.ncbi.nlm.nih.gov/pubmed/12208918", "http://www.ncbi.nlm.nih.gov/pubmed/21606991", "http://www.ncbi.nlm.nih.gov/pubmed/20048104"], "ideal_answer": ["Legg-Calve-Perthes disease is  idiopathic avascular necrosis of the hip, usually occurring in pediatric populations.", "Legg-Calv\u00e9-Perthes' (Perthes') disease is a developmental disease of the hip joint that may result in numerous short and long term problems. Legg-Calve-Perthes disease (LCPD) is the insidious onset of idiopathic avascular necrosis of the hip in the pediatric population."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:14415", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007873"], "type": "summary", "id": "58bc8e5002b8c60953000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Legg-Calv\u00e9-Perthes' (Perthes') disease is a developmental disease of the hip joint that may result in numerous short and long term problems. The etiology of the disease remains largely unknown, but the me", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26780125", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 283, "text": "Legg-Calve-Perthes disease (LCPD) is the insidious onset of idiopathic avascular necrosis of the hip in the pediatric population. The disease encompasses a wide spectrum of pathology, from mild with no long-term sequelae to severe with permanent degenerative change of the hip joint.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27064472", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "BACKGROUND: Legg-Perthes disease is associated with ischemia of the capital femoral epiphysis in children.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12208918", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 127, "text": "Legg-Calv\u00e9-Perthes disease is a pediatric disorder characterized by osteonecrosis of the proximal femoral epiphysis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20048104", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 103, "text": "Legg-Calv\u00e9-Perthes disease is characterized by avascular necrosis of the head of the femur.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21606991", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 124, "text": "Legg-Calv\u00e9-Perthes disease is a childhood hip disorder that may result in a deformed and poorly functioning hip.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19034171", "endSection": "abstract"}]}, {"body": "What is promoted by ERAP1-ERAP2 dimerization?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24928998"], "ideal_answer": ["ERAP1-ERAP2 dimerization increases peptide-trimming efficiency.", "ERAP1-ERAP2 dimerization increases peptide-trimming efficiency. ERAP1-ERAP2 heterodimers produce several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize. Physical interaction with ERAP2 changes basic enzymatic parameters of ERAP1 and improves its substrate-binding affinity. Thus, by bringing the two enzymes in proximity and by producing allosteric effects on ERAP1, dimerization of ERAP1/2 creates complexes with superior peptide-trimming efficacy. Such complexes are likely to enhance Ag presentation by cells displaying coordinated expression of the two enzymes.", "The endoplasmic reticulum aminopeptidases (ERAP)1 and ERAP2 play a critical role in the production of final epitopes presented by MHC class I molecules."], "concepts": ["http://www.uniprot.org/uniprot/ERAP1_RAT", "http://www.uniprot.org/uniprot/ERAP1_HUMAN", "http://www.uniprot.org/uniprot/ERAP2_PONAB", "http://www.uniprot.org/uniprot/ERAP2_HUMAN", "http://www.uniprot.org/uniprot/ERAP2_BOVIN", "http://www.uniprot.org/uniprot/ERAP1_MOUSE"], "type": "summary", "id": "588800f43b87a8a738000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "ERAP1-ERAP2 dimerization increases peptide-trimming efficiency.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", "endSection": "title"}, {"offsetInBeginSection": 335, "offsetInEndSection": 930, "text": "In this study, we produced stabilized ERAP1-ERAP2 heterodimers and found that they produced several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize. Physical interaction with ERAP2 changes basic enzymatic parameters of ERAP1 and improves its substrate-binding affinity. Thus, by bringing the two enzymes in proximity and by producing allosteric effects on ERAP1, dimerization of ERAP1/2 creates complexes with superior peptide-trimming efficacy. Such complexes are likely to enhance Ag presentation by cells displaying coordinated expression of the two enzymes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", "endSection": "abstract"}, {"offsetInBeginSection": 333, "offsetInEndSection": 515, "text": "In this study, we produced stabilized ERAP1-ERAP2 heterodimers and found that they produced several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", "endSection": "abstract"}, {"offsetInBeginSection": 153, "offsetInEndSection": 334, "text": "Formation of heterodimers by ERAP1 and ERAP2 has been proposed to facilitate trimming of epitope precursor peptides, but the effects of dimerization on ERAP function remain unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "ERAP1-ERAP2 dimerization increases peptide-trimming efficiency", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", "endSection": "title"}, {"offsetInBeginSection": 335, "offsetInEndSection": 518, "text": "In this study, we produced stabilized ERAP1-ERAP2 heterodimers and found that they produced several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", "endSection": "abstract"}, {"offsetInBeginSection": 335, "offsetInEndSection": 517, "text": "In this study, we produced stabilized ERAP1-ERAP2 heterodimers and found that they produced several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "ERAP1-ERAP2 dimerization increases peptide-trimming efficiency.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928998", "endSection": "title"}]}, {"body": "What is plantar fasciitis", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26655866", "http://www.ncbi.nlm.nih.gov/pubmed/26184993", "http://www.ncbi.nlm.nih.gov/pubmed/26665894", "http://www.ncbi.nlm.nih.gov/pubmed/25429080", "http://www.ncbi.nlm.nih.gov/pubmed/23037146", "http://www.ncbi.nlm.nih.gov/pubmed/21272731", "http://www.ncbi.nlm.nih.gov/pubmed/15134611", "http://www.ncbi.nlm.nih.gov/pubmed/21916393", "http://www.ncbi.nlm.nih.gov/pubmed/22166747", "http://www.ncbi.nlm.nih.gov/pubmed/27904584", "http://www.ncbi.nlm.nih.gov/pubmed/12756315", "http://www.ncbi.nlm.nih.gov/pubmed/27957702"], "ideal_answer": ["Plantar fascia (PF) disorders like plantar fasciitis commonly cause heel pain and disability and are thought to be degenerative rather than inflammatory in nature"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005208", "http://www.disease-ontology.org/api/metadata/DOID:9598", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D036981", "http://www.disease-ontology.org/api/metadata/DOID:9600"], "type": "factoid", "id": "58bc8e7a02b8c60953000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Plantar fascia (PF) disorders commonly cause heel pain and disability", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27957702", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 216, "text": "Plantar fasciitis (PF) is a common foot complaint, affects both active sportsmen and physically inactive middle age group. It is believed that PF results from degenerative changes rather than inflammation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27904584", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Plantar fasciitis (PF) is present in 10% of the population and is the most common cause of plantar heel pain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26665894", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Plantar fasciitis, a chronic degenerative process that causes medial plantar heel pain, is responsible for approximately 1 million physician visits each year", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25429080", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Plantar fasciitis (PF)is the most common cause of plantar heel pain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26184993", "endSection": "abstract"}, {"offsetInBeginSection": 411, "offsetInEndSection": 641, "text": "Plantar fasciitis is the most common cause of heel pain and is estimated to affect 2 million people in the United States alone.For adults suffering from plantar fasciitis, are foot orthoses a viable treatment option to reduce pain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23037146", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Plantar fasciitis: a degenerative process (fasciosis) without inflammation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12756315", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "BACKGROUND: Plantar fasciitis is a common foot disorder that impacts many functional activities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15134611", "endSection": "abstract"}, {"offsetInBeginSection": 529, "offsetInEndSection": 792, "text": "The second purpose was to determine whether chronic plantar fasciitis is accompanied by atrophy of plantar intrinsic foot muscles and tibialis posterior.METHODS: Magnetic resonance images were taken bilaterally in eight subjects with unilateral plantar fasciitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22166747", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 139, "text": "Plantar fasciitis, a common injury in runners, has been speculated to be associated with weakness of the intrinsic foot muscles", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26655866", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 77, "text": "Although plantar fasciitis is the most common cause of heel pain,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19952249", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "Plantar fasciitis, a self-limiting condition, is a common cause of heel pain in adults. It affects more than 1 million persons per year, and two-thirds of patients with plantar fasciitis will seek care from their family physician", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21916393", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Plantar fasciitis is a common cause of heel pain and is the result of a degenerative process of the plantar fascia at its calcaneal attachment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21272731", "endSection": "abstract"}]}, {"body": "Which is the enzymatic activity of OTULIN?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26503766", "http://www.ncbi.nlm.nih.gov/pubmed/23746843", "http://www.ncbi.nlm.nih.gov/pubmed/24461064", "http://www.ncbi.nlm.nih.gov/pubmed/24726327", "http://www.ncbi.nlm.nih.gov/pubmed/26235645", "http://www.ncbi.nlm.nih.gov/pubmed/26085216", "http://www.ncbi.nlm.nih.gov/pubmed/23806334", "http://www.ncbi.nlm.nih.gov/pubmed/24726323", "http://www.ncbi.nlm.nih.gov/pubmed/27559085"], "ideal_answer": ["OTULIN is a deubiquitinase, that specifically cleaves Met1-linked polyUb."], "type": "factoid", "id": "58a9a8631978bbde22000003", "snippets": [{"offsetInBeginSection": 58, "offsetInEndSection": 79, "text": "deubiquitinase OTULIN", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503766", "endSection": "title"}, {"offsetInBeginSection": 186, "offsetInEndSection": 230, "text": "OTULIN (FAM105B), encoding a deubiquitinase ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27559085", "endSection": "abstract"}, {"offsetInBeginSection": 912, "offsetInEndSection": 993, "text": " Otulin/Gumby/FAM105b are by far the most active DUBs acting on these precursors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26235645", "endSection": "abstract"}, {"offsetInBeginSection": 991, "offsetInEndSection": 1088, "text": "Removal of ubiquitin chains is mediated by deubiquitinases (DUBs). Two of them, OTULIN and CYLD, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085216", "endSection": "abstract"}, {"offsetInBeginSection": 219, "offsetInEndSection": 291, "text": " are disassembled by the linear ubiquitin-specific deubiquitinase OTULIN", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726327", "endSection": "abstract"}, {"offsetInBeginSection": 100, "offsetInEndSection": 131, "text": "deubiquitinases CYLD and OTULIN", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461064", "endSection": "title"}, {"offsetInBeginSection": 201, "offsetInEndSection": 295, "text": "We recently discovered OTULIN as a deubiquitinase that specifically cleaves Met1-linked polyUb", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726323", "endSection": "abstract"}, {"offsetInBeginSection": 343, "offsetInEndSection": 399, "text": "deubiquitinase OTULIN specifically disassembles Met1-Ub.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23806334", "endSection": "abstract"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1091, "text": " Our data suggest that OTULIN regulates Met1-polyUb signaling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23746843", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23746843", "endSection": "title"}]}, {"body": "List diseases that could be targeted by disaggregases?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27255695", "http://www.ncbi.nlm.nih.gov/pubmed/26312418", "http://www.ncbi.nlm.nih.gov/pubmed/25620563", "http://www.ncbi.nlm.nih.gov/pubmed/26300264"], "ideal_answer": ["UBQLN2 acts with the HSP70-HSP110 disaggregase machinery to clear protein aggregates via the 26S proteasome. UBQLN2 recognizes client-bound HSP70 and links it to the proteasome to allow for the degradation of aggregated and misfolded proteins. We further show that this process is active in the cell nucleus, where another system for aggregate clearance, autophagy, does not act."], "type": "list", "id": "58bc666702b8c60953000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "Therapeutic agents are urgently required to cure several common and fatal neurodegenerative disorders caused by protein misfolding and aggregation, including amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27255695", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Human Hsp70 Disaggregase Reverses Parkinson's-Linked \u03b1-Synuclein Amyloid Fibrils.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26300264", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Disaggregases, molecular chaperones that resolubilize protein aggregates.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26312418", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "The structural basis by which Hsp104 dissolves disordered aggregates and prions is unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25620563", "endSection": "abstract"}]}, {"body": "Can NEECHAM Confusion Scale be used for evaluation of postoperative delirium?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24175169", "http://www.ncbi.nlm.nih.gov/pubmed/16732742", "http://www.ncbi.nlm.nih.gov/pubmed/18282269", "http://www.ncbi.nlm.nih.gov/pubmed/25337310", "http://www.ncbi.nlm.nih.gov/pubmed/23121489", "http://www.ncbi.nlm.nih.gov/pubmed/10701282", "http://www.ncbi.nlm.nih.gov/pubmed/19711147", "http://www.ncbi.nlm.nih.gov/pubmed/22441728", "http://www.ncbi.nlm.nih.gov/pubmed/27576903", "http://www.ncbi.nlm.nih.gov/pubmed/21511473", "http://www.ncbi.nlm.nih.gov/pubmed/15077440", "http://www.ncbi.nlm.nih.gov/pubmed/10095647", "http://www.ncbi.nlm.nih.gov/pubmed/21539718", "http://www.ncbi.nlm.nih.gov/pubmed/15038935", "http://www.ncbi.nlm.nih.gov/pubmed/1811781", "http://www.ncbi.nlm.nih.gov/pubmed/11915156", "http://www.ncbi.nlm.nih.gov/pubmed/17394635", "http://www.ncbi.nlm.nih.gov/pubmed/15792498", "http://www.ncbi.nlm.nih.gov/pubmed/24928237", "http://www.ncbi.nlm.nih.gov/pubmed/16351715", "http://www.ncbi.nlm.nih.gov/pubmed/19319925"], "ideal_answer": ["Yes, NEECHAM Confusion Scale can be used for evaluation of postoperative delirium."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023362", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003693", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000067290", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063189", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011569"], "type": "yesno", "id": "5886222a3b87a8a738000005", "snippets": [{"offsetInBeginSection": 361, "offsetInEndSection": 473, "text": "Sampling was achieved in a nonrandomized targeted manner and delirium was assessed using NeeCham questionnaire. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25337310", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Delirium in older patients: a diagnostic study of NEECHAM Confusion Scale in surgical intensive care unit.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121489", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "AIMS AND OBJECTIVES: To estimate the diagnostic value and determine the feasibility of the NEECHAM Confusion Scale on critically ill older patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121489", "endSection": "abstract"}, {"offsetInBeginSection": 1447, "offsetInEndSection": 1845, "text": "CONCLUSIONS: Findings from this study confirm the good diagnostic value and ease of application of the NEECHAM scale with nonventilated intensive care patients.RELEVANCE TO CLINICAL PRACTICE: The NEECHAM scale can be used to detect delirium during the routine nursing assessment of nonintubated older patients as it requires minimal demand and stress on the patient as well as on the bedside nurse.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121489", "endSection": "abstract"}, {"offsetInBeginSection": 540, "offsetInEndSection": 647, "text": "The NEECHAM Confusion Scale and the validated chart review instrument were used for diagnosis of delirium. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22441728", "endSection": "abstract"}, {"offsetInBeginSection": 344, "offsetInEndSection": 594, "text": "Among the various screening instruments, NEECHAM confusion scale and delirium observation scale appear to be most suitable screening instrument for patients' in general medical and surgical wards, depending on the type of rater (physician or nurse). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24175169", "endSection": "abstract"}, {"offsetInBeginSection": 662, "offsetInEndSection": 894, "text": "Use of NEECHAM scaling enabled medical staff to identify cases of possible confusion early, indicating that the NEECHAM confusion scale should be useful for the detection of postoperative delirium and confusion in the surgical ward.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Early detection of postoperative delirium and confusion in a surgical ward using the NEECHAM confusion scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", "endSection": "title"}, {"offsetInBeginSection": 406, "offsetInEndSection": 696, "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Assessment of the risk of postoperative delirium in elderly patients using E-PASS and the NEECHAM Confusion Scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", "endSection": "title"}, {"offsetInBeginSection": 372, "offsetInEndSection": 659, "text": "The aim of this study was to determine which of the two delirium observation screening scales, the NEECHAM Confusion Scale or the Delirium Observation Screening (DOS) scale, has the best discriminative capacity for diagnosing delirium and which is more practical for daily use by nurses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394635", "endSection": "abstract"}, {"offsetInBeginSection": 1121, "offsetInEndSection": 1205, "text": "For delirium diagnosis and severity assessment, we used the NEECHAM Confusion Scale.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", "endSection": "abstract"}, {"offsetInBeginSection": 666, "offsetInEndSection": 898, "text": "Use of NEECHAM scaling enabled medical staff to identify cases of possible confusion early, indicating that the NEECHAM confusion scale should be useful for the detection of postoperative delirium and confusion in the surgical ward.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", "endSection": "abstract"}, {"offsetInBeginSection": 546, "offsetInEndSection": 684, "text": "The NEECHAM Confusion Scale was performed upon admission and prior to discharge.RESULTS: The incidence of DSM-IV related delirium was 24%.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539718", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "A comparison of the CAM-ICU and the NEECHAM Confusion Scale in intensive care delirium assessment: an observational study in non-intubated patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18282269", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Predictive value and validation of the NEECHAM Confusion Scale using DSM-IV criteria for delirium as gold standard.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539718", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Early detection of postoperative delirium and confusion in a surgical ward using the NEECHAM confusion scale", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", "endSection": "title"}, {"offsetInBeginSection": 375, "offsetInEndSection": 753, "text": "The aim of this study was to determine which of the two delirium observation screening scales, the NEECHAM Confusion Scale or the Delirium Observation Screening (DOS) scale, has the best discriminative capacity for diagnosing delirium and which is more practical for daily use by nurses.The project was conducted on four wards of a university hospital; 87 patients were included", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394635", "endSection": "abstract"}, {"offsetInBeginSection": 597, "offsetInEndSection": 909, "text": "In addition, we scored the participants on the NEECHAM Scale and evaluated their postoperative delirium and postoperative arrhythmia.On the nights of Days 4 and 5, the amount of activity of the exposure group was significantly lower and The sympathetic nervous index was significantly lower on the night of Day 5", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21511473", "endSection": "abstract"}, {"offsetInBeginSection": 422, "offsetInEndSection": 713, "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", "endSection": "abstract"}, {"offsetInBeginSection": 1207, "offsetInEndSection": 1381, "text": "The cut-off value of the NEECHAM score was established as 20 points, and patients showing values less than this after surgery were regarded as having postoperative delirium. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", "endSection": "abstract"}, {"offsetInBeginSection": 504, "offsetInEndSection": 663, "text": "Identification of delirium was based on evaluation of the level of consciousness with the NEECHAM Confusion Scale and/or a chart-based instrument for delirium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19711147", "endSection": "abstract"}, {"offsetInBeginSection": 1100, "offsetInEndSection": 1184, "text": "For delirium diagnosis and severity assessment, we used the NEECHAM Confusion Scale.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", "endSection": "abstract"}, {"offsetInBeginSection": 410, "offsetInEndSection": 777, "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS.The subjects were 160 patients aged more than 75 years who underwent surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", "endSection": "abstract"}, {"offsetInBeginSection": 280, "offsetInEndSection": 414, "text": "In this study a nursing screening instrument, the NEECHAM confusion scale, was studied for early recognition of delirium ICU patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351715", "endSection": "abstract"}, {"offsetInBeginSection": 1644, "offsetInEndSection": 1775, "text": "The psychometric characteristics and the ease of use of the NEECHAM confusion scale enables ICU nurses to early recognize delirium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351715", "endSection": "abstract"}, {"offsetInBeginSection": 487, "offsetInEndSection": 665, "text": "The trends of the NEECHAM scores in the 3 groups were compared, and the relationship between the NEECHAM scores and suspected clinical risk factors for delirium was investigated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", "endSection": "abstract"}, {"offsetInBeginSection": 1836, "offsetInEndSection": 2171, "text": "In groups showing an MMSE score of less than 25 or a preoperative NEECHAM score of less than 27, the incidence of postoperative delirium was 76%.CONCLUSION: The results suggest that E-PASS and the NEECHAM score facilitate assessment of the risk of postoperative delirium in elderly patients, contributing to early prevention/treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", "endSection": "abstract"}, {"offsetInBeginSection": 410, "offsetInEndSection": 700, "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", "endSection": "abstract"}, {"offsetInBeginSection": 666, "offsetInEndSection": 899, "text": "Use of NEECHAM scaling enabled medical staff to identify cases of possible confusion early, indicating that the NEECHAM confusion scale should be useful for the detection of postoperative delirium and confusion in the surgical ward..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Early detection of postoperative delirium and confusion in a surgical ward using the NEECHAM confusion scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Assessment of the risk of postoperative delirium in elderly patients using E-PASS and the NEECHAM Confusion Scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", "endSection": "title"}, {"offsetInBeginSection": 1101, "offsetInEndSection": 1185, "text": "For delirium diagnosis and severity assessment, we used the NEECHAM Confusion Scale.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "The Neecham Confusion Scale and the Delirium Observation Screening Scale: capacity to discriminate and ease of use in clinical practice.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394635", "endSection": "title"}, {"offsetInBeginSection": 375, "offsetInEndSection": 662, "text": "The aim of this study was to determine which of the two delirium observation screening scales, the NEECHAM Confusion Scale or the Delirium Observation Screening (DOS) scale, has the best discriminative capacity for diagnosing delirium and which is more practical for daily use by nurses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394635", "endSection": "abstract"}]}, {"body": "What is adhesive capsulitis", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2702506", "http://www.ncbi.nlm.nih.gov/pubmed/27942856", "http://www.ncbi.nlm.nih.gov/pubmed/25919473", "http://www.ncbi.nlm.nih.gov/pubmed/19011582", "http://www.ncbi.nlm.nih.gov/pubmed/21885699", "http://www.ncbi.nlm.nih.gov/pubmed/19589853", "http://www.ncbi.nlm.nih.gov/pubmed/7754892", "http://www.ncbi.nlm.nih.gov/pubmed/24652474", "http://www.ncbi.nlm.nih.gov/pubmed/24283550", "http://www.ncbi.nlm.nih.gov/pubmed/10890460", "http://www.ncbi.nlm.nih.gov/pubmed/24374758", "http://www.ncbi.nlm.nih.gov/pubmed/24211154", "http://www.ncbi.nlm.nih.gov/pubmed/10738419", "http://www.ncbi.nlm.nih.gov/pubmed/3871127"], "ideal_answer": ["Adhesive capsulitis also known as \"frozen shoulder\" is characterized by painful, gradual loss of active and passive shoulder motion resulting from fibrosis and contracture of the joint capsule."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:14188"], "type": "summary", "id": "58bca3eb02b8c6095300000d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Adhesive capsulitis (frozen shoulder) is a common cause of shoulder pain and disability", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25919473", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Adhesive capsulitis is characterized by painful, gradual loss of active and passive shoulder motion resulting from fibrosis and contracture of the joint capsule.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21885699", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Painful stiffening of the shoulder, 'frozen shoulder' is a common cause of shoulder pain and disability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19011582", "endSection": "abstract"}, {"offsetInBeginSection": 281, "offsetInEndSection": 439, "text": "Current adhesive capsulitis was defined as restriction of external rotation and one or more additional directional restrictions with history of shoulder pain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27942856", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 189, "text": "Adhesive capsulitis is a clinical syndrome of pain and severely decreased joint motion (\"frozen shoulder\") caused by thickening and contraction of the joint capsule and synovium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7754892", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Adhesive capsulitis is, in most cases, a self-limiting condition of poorly understood etiology that results in shoulder pain and large mobility deficits. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24374758", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Adhesive capsulitis of the shoulder is a condition of unknown etiology that results in the development of restriction of active and passive glenohumeral motion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10738419", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Adhesive capsulitis of the shoulder is an idiopathic condition characterized clinically by pain and limitation of movement", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2702506", "endSection": "abstract"}]}, {"body": "Describe the applicability of Semantic MediaWiki in the case of FANTOM5", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27402679"], "ideal_answer": ["To make the heterogeneous data set accessible and useful for investigators, a web-based database called Semantic catalog of Samples, Transcription initiation And Regulators (SSTAR) has been developed. SSTAR utilizes the open source wiki software MediaWiki along with the Semantic MediaWiki (SMW) extension, which provides flexibility to model, store, and display a series of data sets produced during the course of the FANTOM5 project. The use of SMW demonstrates the utility of the framework for dissemination of large-scale analysis results. SSTAR is a case study in handling biological data generated from a large-scale research project in terms of maintenance and growth alongside research activities"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012660", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059467"], "type": "summary", "id": "587d36ab859bf79568000001", "snippets": [{"offsetInBeginSection": 691, "offsetInEndSection": 1389, "text": "To make the heterogeneous data set accessible and useful for investigators, we developed a web-based database called Semantic catalog of Samples, Transcription initiation And Regulators (SSTAR). SSTAR utilizes the open source wiki software MediaWiki along with the Semantic MediaWiki (SMW) extension, which provides flexibility to model, store, and display a series of data sets produced during the course of the FANTOM5 project. Our use of SMW demonstrates the utility of the framework for dissemination of large-scale analysis results. SSTAR is a case study in handling biological data generated from a large-scale research project in terms of maintenance and growth alongside research activities", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27402679", "endSection": "abstract"}, {"offsetInBeginSection": 882, "offsetInEndSection": 1116, "text": "SSTAR utilizes the open source wiki software MediaWiki along with the Semantic MediaWiki (SMW) extension, which provides flexibility to model, store, and display a series of data sets produced during the course of the FANTOM5 project.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27402679", "endSection": "abstract"}, {"offsetInBeginSection": 886, "offsetInEndSection": 1120, "text": "SSTAR utilizes the open source wiki software MediaWiki along with the Semantic MediaWiki (SMW) extension, which provides flexibility to model, store, and display a series of data sets produced during the course of the FANTOM5 project.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27402679", "endSection": "abstract"}]}, {"body": "Is there an association between Muenke Syndrome and FGFR3 gene mutation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17103449", "http://www.ncbi.nlm.nih.gov/pubmed/11571861", "http://www.ncbi.nlm.nih.gov/pubmed/21403557", "http://www.ncbi.nlm.nih.gov/pubmed/22872265", "http://www.ncbi.nlm.nih.gov/pubmed/21233754", "http://www.ncbi.nlm.nih.gov/pubmed/10696568", "http://www.ncbi.nlm.nih.gov/pubmed/14613973", "http://www.ncbi.nlm.nih.gov/pubmed/18818193", "http://www.ncbi.nlm.nih.gov/pubmed/19086028", "http://www.ncbi.nlm.nih.gov/pubmed/24686979", "http://www.ncbi.nlm.nih.gov/pubmed/26740388", "http://www.ncbi.nlm.nih.gov/pubmed/15241680", "http://www.ncbi.nlm.nih.gov/pubmed/26028288", "http://www.ncbi.nlm.nih.gov/pubmed/19215249", "http://www.ncbi.nlm.nih.gov/pubmed/19755431", "http://www.ncbi.nlm.nih.gov/pubmed/24168007", "http://www.ncbi.nlm.nih.gov/pubmed/20592905", "http://www.ncbi.nlm.nih.gov/pubmed/18000976", "http://www.ncbi.nlm.nih.gov/pubmed/23044018", "http://www.ncbi.nlm.nih.gov/pubmed/24448525", "http://www.ncbi.nlm.nih.gov/pubmed/16251895", "http://www.ncbi.nlm.nih.gov/pubmed/24705944", "http://www.ncbi.nlm.nih.gov/pubmed/19449410", "http://www.ncbi.nlm.nih.gov/pubmed/14963686", "http://www.ncbi.nlm.nih.gov/pubmed/17070479", "http://www.ncbi.nlm.nih.gov/pubmed/22446440", "http://www.ncbi.nlm.nih.gov/pubmed/23378035", "http://www.ncbi.nlm.nih.gov/pubmed/22016144", "http://www.ncbi.nlm.nih.gov/pubmed/22544111"], "ideal_answer": ["Yes, Muenke syndrome is caused by point mutation (C749G) in the Fibroblast Growth Factor Receptor3 (FGFR3) gene. It affects 1 in 30,000 newborns and accounts for 25% to 30% of genetic causes of craniosynostosis."], "concepts": ["http://www.uniprot.org/uniprot/FGFR3_CHICK", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001244", "http://www.disease-ontology.org/api/metadata/DOID:0060703", "http://www.uniprot.org/uniprot/FGFR3_PLEWA", "http://www.uniprot.org/uniprot/FGFR3_HUMAN", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051498"], "type": "yesno", "id": "5895ec5e7d9090f353000015", "snippets": [{"offsetInBeginSection": 579, "offsetInEndSection": 810, "text": "RESULTS: Forty-four with a positive FGFR3 mutation, median age 9 years, range 7 months to 52 years were enrolled. In addition, 10 unaffected siblings served as controls (5 males, 5 females; median age, 13 years; range, 3-18 years).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26028288", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Muenke is a fibroblast growth factor receptor 3 (FGFR-3)-associated syndrome, which was first described in late 1990 s. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24168007", "endSection": "abstract"}, {"offsetInBeginSection": 275, "offsetInEndSection": 455, "text": "The syndrome is defined molecularly by a unique point mutation c.749C>G in exon 7 of the FGFR3 gene which results to an amino acid substitution p.Pro250Arg of the protein product. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24168007", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Muenke syndrome caused by point mutation (C749G) in the FGFR3 gene affects 1 in 30,000 newborns and accounts for 25% to 30% of genetic causes of craniosynostosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24448525", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Phenotypic variability in two families of Muenke syndrome with FGFR3 mutation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24705944", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 282, "text": "PURPOSE: There are a number of craniosynostosis syndromes with hearing loss-including Muenke, Apert, Pfeiffer, Crouzon, Beare-Stevenson, Crouzon with acanthosis nigricans, and Jackson-Weiss syndromes-that result from mutations in the fibroblast growth factor receptor (FGFR) genes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24686979", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Muenke syndrome is an autosomal dominant craniosynostosis syndrome resulting from a defining point mutation in the Fibroblast Growth Factor Receptor3 (FGFR3) gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23378035", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Talocalcaneal coalition in Muenke syndrome: report of a patient, review of the literature in FGFR-related craniosynostoses, and consideration of mechanism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23378035", "endSection": "title"}, {"offsetInBeginSection": 331, "offsetInEndSection": 591, "text": "To better understand the pathophysiology of the Muenke syndrome, we present collective findings from several recent studies that have characterized a genetically equivalent mouse model for Muenke syndrome (FgfR3 (P244R)) and compare them with human phenotypes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872265", "endSection": "abstract"}, {"offsetInBeginSection": 407, "offsetInEndSection": 733, "text": "We show in this study that knock-in mice harboring the mutation responsible for the Muenke syndrome (FgfR3(P244R)) display postnatal shortening of the cranial base along with synchondrosis growth plate dysfunction characterized by loss of resting, proliferating and hypertrophic chondrocyte zones and decreased Ihh expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22016144", "endSection": "abstract"}, {"offsetInBeginSection": 408, "offsetInEndSection": 526, "text": "Muenke syndrome is caused by a single defining point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23044018", "endSection": "abstract"}, {"offsetInBeginSection": 265, "offsetInEndSection": 434, "text": "The Pro250Arg mutation in the FGFR3 gene is found in patients with Muenke syndrome and is one of the most frequently encountered mutations in craniosynostosis syndromes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403557", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "Epilepsy in Muenke syndrome: FGFR3-related craniosynostosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23044018", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Muenke syndrome (FGFR3-related craniosynostosis): expansion of the phenotype and review of the literature.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18000976", "endSection": "title"}, {"offsetInBeginSection": 267, "offsetInEndSection": 436, "text": "The Pro250Arg mutation in the FGFR3 gene is found in patients with Muenke syndrome and is one of the most frequently encountered mutations in craniosynostosis syndromes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403557", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "PURPOSE: The Muenke syndrome mutation (FGFR3 (P250R)), which was discovered 15 years ago, represents the single most common craniosynostosis mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872265", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "The heterozygous Pro250Arg substitution mutation in fibroblast growth factor receptor 3 (FGFR3), which increases ligand-dependent signalling, is the most common genetic cause of craniosynostosis in humans and defines Muenke syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18818193", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "P250R mutation in the FGFR3 gene also known as Muenke syndrome is associated with coronal craniosynostosis, sensorineural deafness, craniofacial, and digital abnormalities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103449", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Muenke syndrome caused by the FGFR3 Pro250Arg mutation is associated with craniosynostosis, hearing loss, and various bony anomalies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446440", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 223, "text": "Muenke syndrome is an autosomal dominant disorder characterized by coronal suture craniosynostosis, hearing loss, developmental delay, carpal and tarsal fusions, and the presence of the Pro250Arg mutation in the FGFR3 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18000976", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Muenke syndrome, defined by heterozygosity for a Pro250Arg substitution in fibroblast growth factor receptor 3 (FGFR3), is the most common genetic cause of craniosynostosis in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19086028", "endSection": "abstract"}, {"offsetInBeginSection": 1041, "offsetInEndSection": 1173, "text": "In addition, sensorineural hearing loss is detected in all FgfR3 (P244R) mutant mice as in the majority of Muenke syndrome patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872265", "endSection": "abstract"}, {"offsetInBeginSection": 133, "offsetInEndSection": 772, "text": "Genetic testing identifies a pathogenic mutation or chromosomal abnormality in \u223c 21% of cases, but it is likely that further causative mutations remain to be discovered.To identify a shared signature of genetically determined craniosynostosis by comparing the expression patterns in three monogenic syndromes with a control group of patients with non-syndromic sagittal synostosis.Fibroblasts from 10 individuals each with Apert syndrome (FGFR2 substitution S252W), Muenke syndrome (FGFR3 substitution P250R), Saethre-Chotzen syndrome (various mutations in TWIST1) and non-syndromic sagittal synostosis (no mutation detected) were cultured", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19755431", "endSection": "abstract"}, {"offsetInBeginSection": 581, "offsetInEndSection": 819, "text": "The craniosynostosis syndromes: Apert syndrome, Beare-Stevenson syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Muenke syndrome, Pfeiffer syndrome and Saethre-Chotzen syndrome can be caused by mutation in either FGFR1, FGFR2, or FGFR3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11571861", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "Identical proline-->arginine gain-of-function mutations in fibroblast growth factor receptor (FGFR) 1 (Pro252Arg), FGFR2 (Pro253Arg) and FGFR3 (Pro250Arg), result in type I Pfeiffer, Apert and Muenke craniosynostosis syndromes, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14613973", "endSection": "abstract"}, {"offsetInBeginSection": 267, "offsetInEndSection": 435, "text": "The Pro250Arg mutation in the FGFR3 gene is found in patients with Muenke syndrome and is one of the most frequently encountered mutations in craniosynostosis syndromes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403557", "endSection": "abstract"}, {"offsetInBeginSection": 818, "offsetInEndSection": 1043, "text": "Mutation analysis of FGFR-3 revealed a missense mutation in exon 6, c.749 C>G, with a resultant amino acid change from proline to arginine at codon 250 (P250R), in keeping with Muenke syndrome (Am J Hum Genet 1997;60:555-564)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21233754", "endSection": "abstract"}, {"offsetInBeginSection": 219, "offsetInEndSection": 441, "text": "In an attempt to delineate functional features separating SCS from Muenkes syndrome, we screened patients presenting with coronal suture synostosis for mutations in the TWIST 1 gene, and for the Pro250Arg mutation in FGFR3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16251895", "endSection": "abstract"}, {"offsetInBeginSection": 942, "offsetInEndSection": 1237, "text": "Since the Gly380Arg achondroplasia mutation was recognized, similar observations regarding the conserved nature of FGFR mutations and resulting phenotype have been made regarding other skeletal phenotypes, including hypochondroplasia, thanatophoric dysplasia, and Muenke coronal craniosynostosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10696568", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 418, "text": "Mutations in the gene that encodes Fibroblast Growth Factor Receptor 3 (FGFR3) are associated with Achondroplasia (MIM 100800), Hypochondroplasia (MIM 146000), Muenke Syndrome (MIM 602849), Thanatophoric Dysplasia (MIM 187600, MIM 187601) and Lacrimo-Auriculo-Dento-Digital Syndrome (MIM 149730).Here we report a clinical and molecular study in a large cohort of 125 Portuguese patients with these skeletal disorders. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19215249", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "The Muenke syndrome (MS) is characterized by unicoronal or bicoronal craniosynostosis, midfacial hypoplasia, ocular hypertelorism, and a variety of minor abnormalities associated with a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20592905", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "P250R mutation in the FGFR3 gene also known as Muenke syndrome is associated with coronal craniosynostosis, sensorineural deafness, craniofacial, and digital abnormalities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103449", "endSection": "abstract"}, {"offsetInBeginSection": 539, "offsetInEndSection": 808, "text": "METHODS: Fibroblasts from 10 individuals each with Apert syndrome (FGFR2 substitution S252W), Muenke syndrome (FGFR3 substitution P250R), Saethre-Chotzen syndrome (various mutations in TWIST1) and non-syndromic sagittal synostosis (no mutation detected) were cultured. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19755431", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "Muenke syndrome is an autosomal dominant disorder characterized by coronal suture craniosynostosis, hearing loss, developmental delay, carpal and tarsal fusions, and the presence of the Pro250Arg mutation in the FGFR3 gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18000976", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": "Muenke syndrome, also known as FGFR3-associated coronal synostosis, is defined molecularly by the presence of a heterozygous nucleotide transversion, c.749C>G, encoding the amino acid substitution Pro250Arg, in the fibroblast growth factor receptor type 3 gene (FGFR3). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15241680", "endSection": "abstract"}, {"offsetInBeginSection": 323, "offsetInEndSection": 487, "text": "In spite of a variable phenotype, Muenke syndrome has been related to a unique mutation on the FGFR3 gene, Pro 250 to Arg, which is characteristic of this disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14963686", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Skeletal analysis of the Fgfr3(P244R) mouse, a genetic model for the Muenke craniosynostosis syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19086028", "endSection": "title"}, {"offsetInBeginSection": 410, "offsetInEndSection": 528, "text": "Muenke syndrome is caused by a single defining point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23044018", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Epilepsy in Muenke syndrome: FGFR3-related craniosynostosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23044018", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "Muenke syndrome, also known as FGFR3-associated coronal synostosis, is defined molecularly by the presence of a heterozygous nucleotide transversion, c.749C>G, encoding the amino acid substitution Pro250Arg, in the fibroblast growth factor receptor type 3 gene (FGFR3).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15241680", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "The Muenke syndrome mutation (FGFR3 (P250R)), which was discovered 15 years ago, represents the single most common craniosynostosis mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872265", "endSection": "abstract"}]}, {"body": "Which R package is used for visualization of linear and circular karyotypes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26791998"], "ideal_answer": ["The chromDraw graphical tool was developed as a user-friendly graphical tool for visualizing both linear and circular karyotypes based on the same input data matrix. The output graphics, saved in two different formats (EPS and SVG), can be easily imported to and modified in presentation and image-editing computer programs. The tool is freely distributed under GNU General Public License (GPL) and can be installed from Bioconductor or from the chromDraw home page.", "The chromDraw graphical tool was developed as a user-friendly graphical tool for visualizing both linear and circular karyotypes based on the same input data matrix. The tool is freely distributed under GNU General Public License (GPL) and can be installed from Bioconductor or from the chromDraw home page."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059785"], "type": "factoid", "id": "588f2de394c1512c50000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "chromDraw: an R package for visualization of linear and circular karyotypes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26791998", "endSection": "title"}, {"offsetInBeginSection": 470, "offsetInEndSection": 936, "text": "The chromDraw graphical tool was developed as a user-friendly graphical tool for visualizing both linear and circular karyotypes based on the same input data matrix. The output graphics, saved in two different formats (EPS and SVG), can be easily imported to and modified in presentation and image-editing computer programs. The tool is freely distributed under GNU General Public License (GPL) and can be installed from Bioconductor or from the chromDraw home page.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26791998", "endSection": "abstract"}, {"offsetInBeginSection": 467, "offsetInEndSection": 632, "text": "The chromDraw graphical tool was developed as a user-friendly graphical tool for visualizing both linear and circular karyotypes based on the same input data matrix.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26791998", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "chromDraw: an R package for visualization of linear and circular karyotypes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26791998", "endSection": "title"}, {"offsetInBeginSection": 470, "offsetInEndSection": 635, "text": "The chromDraw graphical tool was developed as a user-friendly graphical tool for visualizing both linear and circular karyotypes based on the same input data matrix.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26791998", "endSection": "abstract"}]}, {"body": "Has small pox been eradicated from the world?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22566811", "http://www.ncbi.nlm.nih.gov/pubmed/11808015", "http://www.ncbi.nlm.nih.gov/pubmed/10742580", "http://www.ncbi.nlm.nih.gov/pubmed/14969309", "http://www.ncbi.nlm.nih.gov/pubmed/23436190", "http://www.ncbi.nlm.nih.gov/pubmed/7013291", "http://www.ncbi.nlm.nih.gov/pubmed/11503361", "http://www.ncbi.nlm.nih.gov/pubmed/22185830"], "ideal_answer": ["smallpox is now eradicated.", "Yes, small pox has been eradicated.", "smallpox is now eradicated", "small pox has been eradicated."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:8736", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012899", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012900"], "type": "yesno", "id": "58a1da4e78275d0c4a000059", "snippets": [{"offsetInBeginSection": 153, "offsetInEndSection": 183, "text": "small pox has been eradicated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10742580", "endSection": "abstract"}, {"offsetInBeginSection": 837, "offsetInEndSection": 863, "text": "smallpox is now eradicated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11808015", "endSection": "abstract"}, {"offsetInBeginSection": 819, "offsetInEndSection": 1144, "text": "In May 1980 the World Health Assembly in Geneva announced in solemn form the world-wide eradication of the small-pox and gave recommendations to the member countries for concluding measures concerning the small-pox vaccination, the foundation of vaccine reserves and the control of the epidemiological situation in the world.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7013291", "endSection": "abstract"}, {"offsetInBeginSection": 65, "offsetInEndSection": 182, "text": "As a result of vaccination, diseases such as polio and measles have been controlled and small pox has been eradicated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10742580", "endSection": "abstract"}, {"offsetInBeginSection": 144, "offsetInEndSection": 277, "text": "Small pox eradication from the world is the perfect example of the role of mass vaccination of the entire community of the universe. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23436190", "endSection": "abstract"}, {"offsetInBeginSection": 914, "offsetInEndSection": 1057, "text": "The French owe a lot to this Central Committee of Vaccine, which greatly contributed to fighting small pox and eradicating the disease finally.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11503361", "endSection": "abstract"}, {"offsetInBeginSection": 144, "offsetInEndSection": 276, "text": "Small pox eradication from the world is the perfect example of the role of mass vaccination of the entire community of the universe.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23436190", "endSection": "abstract"}, {"offsetInBeginSection": 669, "offsetInEndSection": 868, "text": "Also, the vaccine that Jenner used, which decreased the prevalence of Small Pox worldwide in his own time, and later was used to eradicate Small Pox altogether, is discussed in light of recent data..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22566811", "endSection": "abstract"}, {"offsetInBeginSection": 516, "offsetInEndSection": 760, "text": "the only known cases of smallpox happened from an outbreak in Birmingham, England caused by a laboratory accident in the year of 1979. On May the 8 th 1980 the disease was declared as eliminated from the world by the WHO (WHO-Resolution 33.33).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12822115", "endSection": "abstract"}]}, {"body": "Where is Akkermansia muciniphila found?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25795669", "http://www.ncbi.nlm.nih.gov/pubmed/26100928"], "ideal_answer": ["Akkermansia muciniphila is a Gram-negative mucin-degrading bacterium that resides in the gastrointestinal tracts of humans and animals.", "RYGB led to altered relative abundances of 31 species (P\u2009<\u20090.05, q\u2009<\u20090.15) within the first 3\u00a0months, including those of Escherichia coli, Klebsiella pneumoniae, Veillonella spp., Streptococcus spp., Alistipes spp., and Akkermansia muciniphila. Main findings are as follows: (1) gut microbiota compositions of cecal and fecal samples were altered in BTBR compared to control mice, indicating that this model may be of utility in understanding gut-brain interactions in ASD; (2) KD consumption caused an anti-microbial-like effect by significantly decreasing total host bacterial abundance in cecal and fecal matter; (3) specific to BTBR animals, the KD counteracted the common ASD phenotype of a low Firmicutes to Bacteroidetes ratio in both sample types; and (4) the KD reversed elevated Akkermansia m However, faeces from the UC cohort had lower proportions of Akkermansia muciniphila and increased diversity within Clostridium cluster XIVa compared to controls.Gut fermentation of NSP and starch is diminished in patients with UC. Specific members of the microbiota such as Akkermansia muciniphila might be decreased in diabetes and when administered to murines exerted antidiabetic effects. In parallel, the antibiotic susceptibility of Akkermansia muciniphila Muc(T) strain was studied and this strain was observed by electron microscopy."], "type": "factoid", "id": "58bc363622d300530900001f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Akkermansia muciniphila is a Gram-negative mucin-degrading bacterium that resides in the gastrointestinal tracts of humans and animals. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25795669", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 365, "text": "Individuals with obesity and type 2 diabetes differ from lean and healthy individuals in their abundance of certain gut microbial species and microbial gene richness. Abundance of Akkermansia muciniphila, a mucin-degrading bacterium, has been inversely associated with body fat mass and glucose intolerance in mice, but more evidence is needed in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26100928", "endSection": "abstract"}]}, {"body": "Is there alternative polyadenylation during zebrafish development?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22722342"], "ideal_answer": ["Yes. There is extensive alternative polyadenylation during zebrafish development."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D026723", "http://amigo.geneontology.org/amigo/term/GO:1900365", "http://amigo.geneontology.org/amigo/term/GO:1900364", "http://amigo.geneontology.org/amigo/term/GO:1900363", "http://amigo.geneontology.org/amigo/term/GO:0006378", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015027"], "type": "yesno", "id": "58963b0278275d0c4a00000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Extensive alternative polyadenylation during zebrafish development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722342", "endSection": "title"}, {"offsetInBeginSection": 1145, "offsetInEndSection": 1525, "text": "At 2 h post-fertilization, thousands of unique poly(A) sites appear at locations lacking a typical polyadenylation signal, which suggests a wave of widespread cytoplasmic polyadenylation of mRNA degradation intermediates. Our insights into the identities, formation, and evolution of zebrafish 3' UTRs provide a resource for studying gene regulation during vertebrate development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722342", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Extensive alternative polyadenylation during zebrafish development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22722342", "endSection": "title"}]}, {"body": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18929641", "http://www.ncbi.nlm.nih.gov/pubmed/15507761", "http://www.ncbi.nlm.nih.gov/pubmed/15507762", "http://www.ncbi.nlm.nih.gov/pubmed/15824103", "http://www.ncbi.nlm.nih.gov/pubmed/27540115", "http://www.ncbi.nlm.nih.gov/pubmed/17900370", "http://www.ncbi.nlm.nih.gov/pubmed/23322165", "http://www.ncbi.nlm.nih.gov/pubmed/23957209", "http://www.ncbi.nlm.nih.gov/pubmed/16329988", "http://www.ncbi.nlm.nih.gov/pubmed/17583407", "http://www.ncbi.nlm.nih.gov/pubmed/16507994", "http://www.ncbi.nlm.nih.gov/pubmed/20454568", "http://www.ncbi.nlm.nih.gov/pubmed/20609497", "http://www.ncbi.nlm.nih.gov/pubmed/22549734", "http://www.ncbi.nlm.nih.gov/pubmed/17913709", "http://www.ncbi.nlm.nih.gov/pubmed/16762923", "http://www.ncbi.nlm.nih.gov/pubmed/16911517", "http://www.ncbi.nlm.nih.gov/pubmed/26781991", "http://www.ncbi.nlm.nih.gov/pubmed/18463161"], "ideal_answer": ["NADPH oxidase 1 (NOX1) requires interaction with NOXO1 for function."], "concepts": ["http://www.uniprot.org/uniprot/NOXO1_HUMAN", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019255", "http://www.uniprot.org/uniprot/NOXO1_MOUSE", "http://amigo.geneontology.org/amigo/term/GO:0043020", "http://www.biosemantics.org/jochem#4270191", "http://www.uniprot.org/uniprot/NOXA1_MOUSE", "http://www.uniprot.org/uniprot/NOXA1_RAT"], "type": "factoid", "id": "58a5a51060087bc10a000021", "snippets": [{"offsetInBeginSection": 203, "offsetInEndSection": 439, "text": "A unique member of this family, Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox), respectively, the latter of which is functional in vascular smooth muscle cells (VSMC). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27540115", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Phosphorylation of Noxo1 at threonine 341 regulates its interaction with Noxa1 and the superoxide-producing activity of Nox1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23957209", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 329, "text": "Superoxide production by Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and is markedly enhanced upon cell stimulation with phorbol 12-myristate 13-acetate (PMA), a potent activator of protein kinase C (PKC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23957209", "endSection": "abstract"}, {"offsetInBeginSection": 814, "offsetInEndSection": 1430, "text": "Phosphorylation of Thr341 allows Noxo1 to sufficiently interact with Noxa1, an interaction that participates in Nox1 activation. Thus phosphorylation of Noxo1 at Thr341 appears to play a crucial role in PMA-elicited activation of Nox1, providing a molecular link between PKC-mediated signal transduction and Nox1-catalyzed superoxide production. Furthermore, Ser154 in Noxo1 is phosphorylated in both resting and PMA-stimulated cells, and the phosphorylation probably participates in a PMA-independent constitutive activity of Nox1. Ser154 may also be involved in protein kinase A (PKA) mediated regulation of Nox1; ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23957209", "endSection": "abstract"}, {"offsetInBeginSection": 1503, "offsetInEndSection": 1612, "text": "Thus phosphorylation of Noxo1 at Thr341 and at Ser154 appears to regulate Nox1 activity in different manners.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23957209", "endSection": "abstract"}, {"offsetInBeginSection": 184, "offsetInEndSection": 529, "text": "The activity of other Nox enzymes such as gp91(phox)/Nox2 and Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67(phox) or Noxa1); for the p47(phox)-dependent activation of these oxidases, treatment of cells with stimulants such as phorbol 12-myristate 13-acetate is also indispensable. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15824103", "endSection": "abstract"}, {"offsetInBeginSection": 529, "offsetInEndSection": 782, "text": "Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15507761", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 755, "text": "Additionally, NADPH oxidase Organizer 1 (NoxO1) is shown to interact with the NADPH-binding region of Nox1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16329988", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762923", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "NOXO1 phosphorylation on serine 154 is critical for optimal NADPH oxidase 1 assembly and activation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23322165", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Activation of the superoxide-producing NADPH oxidase Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16911517", "endSection": "abstract"}, {"offsetInBeginSection": 373, "offsetInEndSection": 643, "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component p22(phox) for maximal activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20454568", "endSection": "abstract"}, {"offsetInBeginSection": 732, "offsetInEndSection": 917, "text": "Activation of Nox1, an oxidase that is likely involved in host defence at the colon, requires novel proteins homologous to p47phox and p67phox, designated Noxo1 and Noxa1, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15507762", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Molecular interaction of NADPH oxidase 1 with betaPix and Nox Organizer 1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16329988", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1), and Rac1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23322165", "endSection": "abstract"}, {"offsetInBeginSection": 373, "offsetInEndSection": 642, "text": "NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component p22(phox) for maximal activity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20454568", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Activation of the superoxide-producing NADPH oxidase Nox1 requires both the organizer protein Noxo1 and the activator protein Noxa1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16911517", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16762923", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18929641", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 330, "text": "UNLABELLED: Superoxide production by Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and is markedly enhanced upon cell stimulation with phorbol 12-myristate 13-acetate (PMA), a potent activator of protein kinase C (PKC). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23957209", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "The p47phox- and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a streptozotocin-induced murine model of diabetes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22549734", "endSection": "title"}, {"offsetInBeginSection": 532, "offsetInEndSection": 785, "text": "Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15507761", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Nox activator 1 (NoxA1) is a homologue of p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17913709", "endSection": "abstract"}, {"offsetInBeginSection": 373, "offsetInEndSection": 568, "text": "Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well as the binding of Rac1 GTPase, for its activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20609497", "endSection": "abstract"}, {"offsetInBeginSection": 354, "offsetInEndSection": 508, "text": "Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for its activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18463161", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 255, "text": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1), and Rac1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23322165", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 317, "text": "Superoxide production by Nox1, a member of the Nox family NAPDH oxidases, requires expression of its regulatory soluble proteins Noxo1 (Nox organizer 1) and Noxa1 (Nox activator 1) and is markedly enhanced upon cell stimulation with phorbol 12-myristate 13-acetate (PMA), a potent activator of protein kinase C (PKC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23957209", "endSection": "abstract"}]}, {"body": "Are alterations in ultraconserved elements implicated in breast cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18174240", "http://www.ncbi.nlm.nih.gov/pubmed/21331621"], "ideal_answer": ["Yes. SNPs in ultraconserved elements (UCEs) might be associated with cancer risk."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001943", "http://www.disease-ontology.org/api/metadata/DOID:0060548", "http://www.disease-ontology.org/api/metadata/DOID:1612", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000069584", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000072656", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050436", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058922", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001940", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018567", "http://www.disease-ontology.org/api/metadata/DOID:14521", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061325", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064726"], "type": "yesno", "id": "587e276be96a600607000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "SNPs in ultraconserved elements and familial breast cancer risk", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240", "endSection": "title"}, {"offsetInBeginSection": 639, "offsetInEndSection": 822, "text": " In the present study, we investigated the influence of six SNPs within UCEs on familial breast cancer risk. Two out of six SNPs showed an association with familial breast cancer risk", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240", "endSection": "abstract"}, {"offsetInBeginSection": 1456, "offsetInEndSection": 1545, "text": "This is the first study indicating that SNPs in UCEs might be associated with cancer risk", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "SNPs in ultraconserved elements and familial breast cancer risk.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240", "endSection": "title"}, {"offsetInBeginSection": 103, "offsetInEndSection": 244, "text": "Recent studies have indicated that UCEs are not mutation cold regions and likely to be concerned with cancers, including breast cancer (BC). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "SNPs in ultraconserved elements and familial breast cancer risk.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18174240", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Genetic variants in ultraconserved elements and risk of breast cancer in Chinese population.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331621", "endSection": "title"}]}, {"body": "What is the mechanism of action of Osimertinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27861144", "http://www.ncbi.nlm.nih.gov/pubmed/27393507", "http://www.ncbi.nlm.nih.gov/pubmed/27923714", "http://www.ncbi.nlm.nih.gov/pubmed/26902828", "http://www.ncbi.nlm.nih.gov/pubmed/27169328", "http://www.ncbi.nlm.nih.gov/pubmed/27835594", "http://www.ncbi.nlm.nih.gov/pubmed/27912836", "http://www.ncbi.nlm.nih.gov/pubmed/26620497", "http://www.ncbi.nlm.nih.gov/pubmed/27885838", "http://www.ncbi.nlm.nih.gov/pubmed/27196753", "http://www.ncbi.nlm.nih.gov/pubmed/26515464", "http://www.ncbi.nlm.nih.gov/pubmed/27660466", "http://www.ncbi.nlm.nih.gov/pubmed/27071706", "http://www.ncbi.nlm.nih.gov/pubmed/27649127", "http://www.ncbi.nlm.nih.gov/pubmed/26720671", "http://www.ncbi.nlm.nih.gov/pubmed/26898616", "http://www.ncbi.nlm.nih.gov/pubmed/26943236"], "ideal_answer": ["Osimertinib is a third-generation irreversible tyrosine kinase inhibitor of both activating EGFR mutations and resistance-associated T790M point mutation."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504"], "type": "summary", "id": "58848822e56acf517600000c", "snippets": [{"offsetInBeginSection": 761, "offsetInEndSection": 1004, "text": "In addition, mutations leading to resistance to first-line EGFR and ALK TKIs can now be successfully inhibited by soon to be approved third-generation EGFR TKIs (osimertinib, rociletinib) and second-generation ALK TKIs (ceritinib, alectinib). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26620497", "endSection": "abstract"}, {"offsetInBeginSection": 308, "offsetInEndSection": 598, "text": "Gefitinib, erlotinib, and afatinib are the EGFR tyrosine kinase inhibitors that are presently in clinical use. Understanding resistance mechanisms has led to the identification of a secondary mutational target, T790M, in more than half of patients, for which osimertinib has been approved. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27912836", "endSection": "abstract"}, {"offsetInBeginSection": 243, "offsetInEndSection": 429, "text": "Third-generation EGFR TKIs against the T790M mutation have been in active clinical development. These agents include osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27071706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 381, "text": "PURPOSE: Osimertinib (AZD9291) 80\u00a0mg once daily is approved by the US FDA for the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has previously progressed on EGFR-TKI therapy. Osimertinib PK was evaluated to define the dose and dosing interval, whether a fixed-dosing approach can be used globally, and the impact of formulation and food on exposure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902828", "endSection": "abstract"}, {"offsetInBeginSection": 540, "offsetInEndSection": 649, "text": "RECENT FINDINGS: Third-generation TKIs in clinical development include osimertinib, rociletinib, and HM61713.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26720671", "endSection": "abstract"}, {"offsetInBeginSection": 580, "offsetInEndSection": 790, "text": "In this study, we investigated the interaction between ABCB1 and osimertinib, a novel selective, irreversible third-generation EGFR TKI that has recently been approved by the U.S. Food and Drug Administration. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27169328", "endSection": "abstract"}, {"offsetInBeginSection": 1532, "offsetInEndSection": 1758, "text": "Considering that osimertinib is a clinically approved third-generation EGFR TKI, our findings suggest that a combination therapy with osimertinib and conventional anticancer drugs may be beneficial to patients with MDR tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27169328", "endSection": "abstract"}, {"offsetInBeginSection": 159, "offsetInEndSection": 682, "text": "In our study, we investigated whether osimertinib (AZD9291), a third-generation irreversible tyrosine kinase inhibitor of both activating EGFR mutations and resistance-associated T790M point mutation, could reverse MDR induced by ABCB1 and ABCG2 in vitro, in vivo, and ex vivo Our results showed that osimertinib significantly increased the sensitivity of ABCB1- and ABCG2-overexpressing cells to their substrate chemotherapeutic agents in vitro and in the model of ABCB1-overexpressing KBv200 cell xenograft in nude mice. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27196753", "endSection": "abstract"}, {"offsetInBeginSection": 542, "offsetInEndSection": 771, "text": "The potency of 1st (erlotinib), 2nd (afatinib) and 3rd (osimertinib and rociletinib) generation EGFR-TKIs was compared in vitro for human lung cancer cell lines and Ba/F3 cells, which exogenously express mutated or wild type EGFR", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26515464", "endSection": "abstract"}, {"offsetInBeginSection": 409, "offsetInEndSection": 561, "text": "Osimertinib (AZD9291, Tagrisso\u2122), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27660466", "endSection": "abstract"}, {"offsetInBeginSection": 850, "offsetInEndSection": 1003, "text": "Early phase clinical data suggest the third generation EGFR TKIs such as osimertinib, rociletinib, and HM61713 are highly efficacious and well tolerated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26898616", "endSection": "abstract"}, {"offsetInBeginSection": 900, "offsetInEndSection": 1039, "text": "We review the rapid clinical development and approval of the third-generation EGFR TKI osimertinib for treatment of NSCLCs with EGFR-T790M.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26943236", "endSection": "abstract"}]}, {"body": "What is Bartter syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25810436", "http://www.ncbi.nlm.nih.gov/pubmed/23164417", "http://www.ncbi.nlm.nih.gov/pubmed/18800266", "http://www.ncbi.nlm.nih.gov/pubmed/9203176", "http://www.ncbi.nlm.nih.gov/pubmed/9502562", "http://www.ncbi.nlm.nih.gov/pubmed/1328936", "http://www.ncbi.nlm.nih.gov/pubmed/19915517", "http://www.ncbi.nlm.nih.gov/pubmed/15056980", "http://www.ncbi.nlm.nih.gov/pubmed/12920401", "http://www.ncbi.nlm.nih.gov/pubmed/22142744", "http://www.ncbi.nlm.nih.gov/pubmed/20127218", "http://www.ncbi.nlm.nih.gov/pubmed/23342992", "http://www.ncbi.nlm.nih.gov/pubmed/7869998", "http://www.ncbi.nlm.nih.gov/pubmed/15875219", "http://www.ncbi.nlm.nih.gov/pubmed/24696311", "http://www.ncbi.nlm.nih.gov/pubmed/27277374", "http://www.ncbi.nlm.nih.gov/pubmed/21705784", "http://www.ncbi.nlm.nih.gov/pubmed/21431899", "http://www.ncbi.nlm.nih.gov/pubmed/10906158", "http://www.ncbi.nlm.nih.gov/pubmed/16953151", "http://www.ncbi.nlm.nih.gov/pubmed/6395627"], "ideal_answer": ["All forms of Bartter syndrome are characterized by hypokalemia, metabolic alkalosis, and secondary hyperaldosteronism", "All forms of hereditary Bartter syndrome are characterized by hypokalemia, metabolic alkalosis, and secondary hyperaldosteronism."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:0110147", "http://www.disease-ontology.org/api/metadata/DOID:0110146", "http://www.disease-ontology.org/api/metadata/DOID:0110145", "http://www.disease-ontology.org/api/metadata/DOID:0110144", "http://www.disease-ontology.org/api/metadata/DOID:0110143", "http://www.disease-ontology.org/api/metadata/DOID:0110142", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001477", "http://www.disease-ontology.org/api/metadata/DOID:445"], "type": "summary", "id": "58bcb83d02b8c6095300000f", "snippets": [{"offsetInBeginSection": 199, "offsetInEndSection": 316, "text": "All forms of Bartter syndrome are characterized by hypokalemia, metabolic alkalosis, and secondary hyperaldosteronism", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25810436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "The mutations in the CLCNKB gene encoding the ClC-Kb chloride channel are responsible for Bartter syndrome type 3, one of the four variants of Bartter syndrome in the genetically based nomenclature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25810436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Bartter syndrome (BS) is a hereditary disease, with an autosomal recessive or autosomal dominant mode of transmission. It is characterized by salt wasting hypochloraemic, hypokalaemic", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27277374", "endSection": "abstract"}, {"offsetInBeginSection": 156, "offsetInEndSection": 345, "text": "Bartter syndrome Type III is caused by genetic alterations in the chloride channel kidney B (CLCNKB) gene and often presents in the first 2 years of life, known as classic Bartter syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23164417", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Bartter syndrome encompasses a variety of inheritable renal tubular transport disorders characterized by hypokalemia and hypochloremic metabolic alkalosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23164417", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 774, "text": "Classic Bartter syndrome and neonatal Bartter syndrome have defects in genes that affect transport channels in the ascending loop of Henle, where as in Gitleman syndrome the defect occurs in the transport channels of the distal convoluted tubule.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18800266", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Bartter syndrome type III and congenital anomalies of the kidney and urinary tract: an antenatal presentation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23164417", "endSection": "title"}, {"offsetInBeginSection": 33, "offsetInEndSection": 129, "text": "Bartter's syndrome associated with hydramnios, prematurity, hypercalciuria and nephrocalcinosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6395627", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Bartter syndrome (BS) is a rare renal tubular disorder presenting with hypokalemic metabolic alkalosis, which is classified into five types", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21431899", "endSection": "abstract"}, {"offsetInBeginSection": 275, "offsetInEndSection": 977, "text": "It has been described in patients with chronic diarrhoea, eating disorders, laxative abuse and primary hyperaldosteronism; also occasionally in Bartter syndrome (BS), in which severe hypokalaemia accompanies significant renal sodium and water losses, though rarely in Gitelman syndrome (GS), in which there is equally severe hypokalaemia, but only modest sodium losses.We hypothesized that hypokalaemic nephropathy may not be due to potassium depletion per se, but persistently elevated circulating levels of aldosterone, possibly with superimposed episodes of renal hypoperfusion.We searched UK and European data sets to retrospectively compare serum and urinary parameters in patients with GS and BS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21705784", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "Acquired Bartter-like syndrome (BLS), characterized by hypokalemic metabolic alkalosis, hypomagnesemia, hypocalcemia, and normal kidney function, can be induced by diuretics or antibiotics", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23342992", "endSection": "abstract"}, {"offsetInBeginSection": 15, "offsetInEndSection": 129, "text": "lassic Bartter syndrome is a salt-wasting tubulopathy caused by mutations in the CLCNKB (chloride channel Kb) gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24377430", "endSection": "abstract"}, {"offsetInBeginSection": 33, "offsetInEndSection": 167, "text": "clinical features of two renal tubular disorders characterized by sodium and potassium wasting: Bartter syndrome and Gitelman syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22282380", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Bartter syndrome is an autosomic recessive disease characterized by severe polyuria and sodium renal loss", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19915517", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "The term \"Bartter syndrome\" encompasses a group of closely related inherited tubulopathies characterized by markedly reduced NaCl transport by the distal nephron. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15875219", "endSection": "abstract"}, {"offsetInBeginSection": 115, "offsetInEndSection": 353, "text": " true Bartter's syndrome, diagnosed as a normotensive, hyperreninaemic, hypokalaemic metabolic alkalosis with normal urine chloride excretion, low CH2O/(CH2O+CCl) ratio during maximal water diuresis and negative urine screen for diuretics", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1328936", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Bartter's syndrome belongs to a group of hypokalemic renal channel diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16953151", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 197, "text": "Hypokalemia due to renal potassium wasting in the absence of hypertension, moderate metabolic alkalosis, hyperreninism and hyperaldosteronism suggest the presence of Bartter's syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7869998", "endSection": "abstract"}, {"offsetInBeginSection": 10, "offsetInEndSection": 294, "text": " Inherited hypokalemic renal tubulopathies are differentiated into at least three clinical subtypes: (1) the Gitelman variant of Bartter syndrome (GS); (2) hyperprostaglandin E syndrome, the antenatal variant of Bartter syndrome (HPS/aBS); and (3) the classic Bartter syndrome (cBS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10906158", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 306, "text": "Bartter syndrome, a group of autosomal recessive disorders that are characterized by markedly reduced or absent salt transport by the thick ascending limb of Henle. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12920401", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Bartter's and Gitelman's syndromes are characterized by hypokalemia, normal to low blood pressure and hypochloremic metabolic alkalosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15056980", "endSection": "abstract"}, {"offsetInBeginSection": 21, "offsetInEndSection": 217, "text": "Bartter's syndrome has been used to describe a spectrum of inherited renal tubular disorders with hypokalemic metabolic alkalosis and overlapping and additional clinical and biochemical features. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8897553", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 168, "text": "antenatal variant of Bartter syndrome is characterized by a history of polyhydramnios, premature birth, metabolic alkalosis, hypokalemia, polyuria and renal", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20127218", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 354, "text": "Most patients with Bartter syndrome have defects in transporters in the thick ascending limb of the loop of Henle, such as the Na-K-2Cl cotransporter, NKCC2, or the ATP-sensitive potassium channel, ROMK. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9502562", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 158, "text": "Gitelman's syndrome or familial hypokalemia-hypomagnesemia and Bartter syndrome share some common features but their prognosis is quite different.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7842074", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Bartter syndrome is a group of inherited, salt-losing tubulopathies presenting as hypokalemic metabolic alkalosis with normotensive hyperreninemia and hyperaldosteronism", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24696311", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 447, "text": "Bartter's and Gitelman's syndromes are two different genetic renal diseases, but are both characterised by hypokalaemia and metabolic alkalosis. Bartter's syndrome is characterised by multiple gene mutations (Na-K-2Cl cotransporter; K(+) channels renal outer medullary potassium channel (ROMK); Cl channels, chloride channel Kb (ClCNKb); regulatory protein Barttin; and Ca(2+) -sensing receptor, CaSR) at the thick ascending limb of Henle's loop, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22142744", "endSection": "abstract"}]}, {"body": "Is there any tool that facilitates the functional analysis of cis-regulatory regions in zebrafish?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19653328"], "ideal_answer": ["Yes. The zebrafish enhancer detection (ZED) vector is a tool that facilitates transgenesis and the functional analysis of cis-regulatory regions in zebrafish."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004742", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015027", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011401", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012045"], "type": "yesno", "id": "588f5e9994c1512c50000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Zebrafish enhancer detection (ZED) vector: a new tool to facilitate transgenesis and the functional analysis of cis-regulatory regions in zebrafish.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19653328", "endSection": "title"}, {"offsetInBeginSection": 197, "offsetInEndSection": 1144, "text": "he cis-regulatory sequences control when, where, and how much genes are transcribed and can activate (enhancers) or repress (silencers) gene expression. Here, we describe a novel Tol2 transposon-based vector for assessing enhancer activity in the zebrafish (Danio rerio). This Zebrafish Enhancer Detector (ZED) vector harbors several key improvements, among them a sensitive and specific minimal promoter chosen for optimal enhancer activity detection, insulator sequences to shield the minimal promoter from position effects, and a positive control for transgenesis. Additionally, we demonstrate that highly conserved noncoding sequences homologous between humans and zebrafish largely with enhancer activity largely retain their tissue-specific enhancer activity during vertebrate evolution. More strikingly, insulator sequences from mouse and chicken, but not conserved in zebrafish, maintain their insulator capacity when tested in this model.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19653328", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Zebrafish enhancer detection (ZED) vector: a new tool to facilitate transgenesis and the functional analysis of cis-regulatory regions in zebrafish", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19653328", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Zebrafish enhancer detection (ZED) vector: a new tool to facilitate transgenesis and the functional analysis of cis-regulatory regions in zebrafish.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19653328", "endSection": "title"}]}, {"body": "List RNA modifications databases", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26464443", "http://www.ncbi.nlm.nih.gov/pubmed/27016142", "http://www.ncbi.nlm.nih.gov/pubmed/23118484"], "ideal_answer": ["RMBase and MODOMICS"], "type": "list", "id": "58bbb71f22d3005309000016", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "RMBase: a resource for decoding the landscape of RNA modifications from high-throughput sequencing data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26464443", "endSection": "title"}, {"offsetInBeginSection": 366, "offsetInEndSection": 608, "text": "we developed a novel resource, RMBase (RNA Modification Base, http://mirlab.sysu.edu.cn/rmbase/), to decode the genome-wide landscape of RNA modifications identified from high-throughput modification data generated by 18 independent studies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26464443", "endSection": "abstract"}, {"offsetInBeginSection": 859, "offsetInEndSection": 921, "text": " known pathways of RNA modification from the MODOMICS database", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27016142", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 251, "text": "MODOMICS is a database of RNA modifications that provides comprehensive information concerning the chemical structures of modified ribonucleosides, their biosynthetic pathways, RNA-modifying enzymes and location of modified residues in RNA sequences. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118484", "endSection": "abstract"}]}, {"body": "Please list the 3 findings in HELLP syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26953551", "http://www.ncbi.nlm.nih.gov/pubmed/11854637", "http://www.ncbi.nlm.nih.gov/pubmed/23871223", "http://www.ncbi.nlm.nih.gov/pubmed/11720149", "http://www.ncbi.nlm.nih.gov/pubmed/23040928", "http://www.ncbi.nlm.nih.gov/pubmed/8765269", "http://www.ncbi.nlm.nih.gov/pubmed/26446688", "http://www.ncbi.nlm.nih.gov/pubmed/8678146", "http://www.ncbi.nlm.nih.gov/pubmed/1471661", "http://www.ncbi.nlm.nih.gov/pubmed/9914607", "http://www.ncbi.nlm.nih.gov/pubmed/10847654", "http://www.ncbi.nlm.nih.gov/pubmed/19703145", "http://www.ncbi.nlm.nih.gov/pubmed/26016316", "http://www.ncbi.nlm.nih.gov/pubmed/8059835", "http://www.ncbi.nlm.nih.gov/pubmed/23697398"], "ideal_answer": ["hemolysis, elevated liver enzymes and low platelets constitute the hellp syndrome.", "HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) is an obstetric complication and is characterized by microangiopathic hemolytic anemia, elevated liver enzymes by intravascular breakdown of fibrin in hepatic sinusoids and reduction of platelet circulation by its increased consumption"], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:13133", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017359"], "type": "list", "id": "58bc9a5002b8c60953000008", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 374, "text": "HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) is an obstetric complication with heterogonous presentation and multisystemic involvement. It is characterized by microangiopathic hemolytic anemia, elevated liver enzymes by intravascular breakdown of fibrin in hepatic sinusoids and reduction of platelet circulation by its increased consumption", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26446688", "endSection": "abstract"}, {"offsetInBeginSection": 349, "offsetInEndSection": 431, "text": "Hemolysis, elevated liver enzymes and low platelets constitute the HELLP syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26953551", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 262, "text": "Our objective was to describe the hepatic imaging findings in selected patients with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) and to correlate these findings with the severity of concurrent clinical and laboratory abnormalities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8678146", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Our objective was to categorize the histologic findings in the liver in patients with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) and to correlate these findings with the severity of clinical laboratory abnormalities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1471661", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 451, "text": "OBJECTIVE: Our purpose was to test the hypothesis that the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome is the result of excessive vasoconstriction of the hepatic arterial circulation.STUDY DESIGN: Doppler ultrasonography was used to measure the pulsatility index of the common hepatic artery in 14 women with preeclampsia, 15 with preeclampsia complicated by HELLP syndrome, and 8 with HELLP syndrome but without proteinuria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8059835", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "Extensive hepatic infarction in severe preeclampsia as part of the HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): evolution of CT findings and successful treatment with plasma exchange therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23040928", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 260, "text": "OBJECTIVE: Our objective was to categorize the histologic findings in the liver in patients with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) and to correlate these findings with the severity of clinical laboratory abnormalities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1471661", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "The syndrome of haemolysis, elevated liver enzymes and low platelets (HELLP syndrome) is a life threatening, severe complication of pre-eclampsia with typical laboratory findings.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10847654", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome ", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11720149", "endSection": "title"}, {"offsetInBeginSection": 19, "offsetInEndSection": 93, "text": "hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11720149", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "HELLP syndrome, a syndrome of hemolysis, elevated liver enzymes and low platelets", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10843242", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "HELLP syndrome is a collection of symptoms described as hemolysis, elevated liver enzymes and low platelets", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25806101", "endSection": "abstract"}, {"offsetInBeginSection": 168, "offsetInEndSection": 333, "text": "The HELLP syndrome is characterized by the presence of hypertension disorder more a triad: microangiopathic hemolysis, elevated liver enzymes and low platelet count.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26016316", "endSection": "abstract"}, {"offsetInBeginSection": 55, "offsetInEndSection": 115, "text": "HELLP (hemolysis, elevated liver enzymes, and low platelets)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8765269", "endSection": "title"}, {"offsetInBeginSection": 88, "offsetInEndSection": 160, "text": " HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8765269", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 136, "text": "Hepatic hemorrhage occurs in less than 5% of patients with hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23871223", "endSection": "abstract"}, {"offsetInBeginSection": 39, "offsetInEndSection": 100, "text": " HELLP (haemolysis, elevated liver enzymes and low platelets)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15027924", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 93, "text": "Hemolysis, elevated liver enzymes, and low platelet count syndrome (HELLP syndrome) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19703145", "endSection": "abstract"}, {"offsetInBeginSection": 108, "offsetInEndSection": 174, "text": " hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501125", "endSection": "abstract"}, {"offsetInBeginSection": 19, "offsetInEndSection": 90, "text": " hemolysis, elevated liver enzymes and low platelet (HELLP) syndrome, i", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19663680", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 81, "text": "Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23697398", "endSection": "abstract"}, {"offsetInBeginSection": 79, "offsetInEndSection": 144, "text": "HELLP (hemolysis, elevated liver enzymes, and low platelet count)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9914607", "endSection": "title"}, {"offsetInBeginSection": 373, "offsetInEndSection": 438, "text": "HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11854637", "endSection": "abstract"}, {"offsetInBeginSection": 30, "offsetInEndSection": 95, "text": "hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17666652", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 227, "text": "hemolysis, elevated liver enzymes, and low platelets (HELLP),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15572962", "endSection": "abstract"}]}, {"body": "Which mutated gene is associated with Waardenburg and Tietz syndromes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10952390", "http://www.ncbi.nlm.nih.gov/pubmed/22371403", "http://www.ncbi.nlm.nih.gov/pubmed/24379252", "http://www.ncbi.nlm.nih.gov/pubmed/23098757", "http://www.ncbi.nlm.nih.gov/pubmed/22258527", "http://www.ncbi.nlm.nih.gov/pubmed/23020089", "http://www.ncbi.nlm.nih.gov/pubmed/19938076", "http://www.ncbi.nlm.nih.gov/pubmed/23787126", "http://www.ncbi.nlm.nih.gov/pubmed/20485200", "http://www.ncbi.nlm.nih.gov/pubmed/9546825", "http://www.ncbi.nlm.nih.gov/pubmed/10790403", "http://www.ncbi.nlm.nih.gov/pubmed/10536986", "http://www.ncbi.nlm.nih.gov/pubmed/23512835", "http://www.ncbi.nlm.nih.gov/pubmed/10851256", "http://www.ncbi.nlm.nih.gov/pubmed/27604145", "http://www.ncbi.nlm.nih.gov/pubmed/22196401", "http://www.ncbi.nlm.nih.gov/pubmed/26252099"], "ideal_answer": ["Mutations in microphthalmia-associated transcription factor (MITF) gene cause Waardenburg and Tietz syndromes."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051739", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014849", "http://www.uniprot.org/uniprot/MITF_HUMAN"], "type": "factoid", "id": "58a57f9460087bc10a00001f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Tietz/Waardenburg type 2A syndrome associated with posterior microphthalmos in two unrelated patients with novel MITF gene mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27604145", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Tietz syndrome and Waardenburg syndrome type 2A are allelic conditions caused by MITF mutations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27604145", "endSection": "abstract"}, {"offsetInBeginSection": 953, "offsetInEndSection": 1054, "text": "For example, mutations of the MITF gene cause Waardenburg syndrome type 2A as well as Tietz syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379252", "endSection": "abstract"}, {"offsetInBeginSection": 1152, "offsetInEndSection": 1346, "text": "For example, mutations of MITF, SNAI2 and SOX10 genes are observed in Waardenburg syndrome type II and mutations of EDNRB, EDN3 and SOX10 genes are responsible for Waardenburg syndrome type IV. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379252", "endSection": "abstract"}, {"offsetInBeginSection": 480, "offsetInEndSection": 636, "text": "These disorders are represented by Waardenburg syndrome, piebaldism and Tietz syndrome, and are caused by different mutations of various or the same genes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379252", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 344, "text": "Mutations in the MITF have been found in patients with the dominantly inherited hypopigmentation and deafness syndromes Waardenburg syndrome type 2A (WS2A) and Tietz syndrome (TS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23787126", "endSection": "abstract"}, {"offsetInBeginSection": 1164, "offsetInEndSection": 1342, "text": "All patients with PAX3 mutations had typical phenotype of WS with dystopia canthorum (WS1), whereas patients with MITF gene mutations presented without dystopia canthorum (WS2). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23512835", "endSection": "abstract"}, {"offsetInBeginSection": 1491, "offsetInEndSection": 1676, "text": "MITF 3-bp deletions at amino acid position 217 have previously been described in patients with Tietz syndrome (TS), a clinical entity with hearing loss and generalised hypopigmentation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23512835", "endSection": "abstract"}, {"offsetInBeginSection": 1689, "offsetInEndSection": 2048, "text": "On the basis of these findings, we conclude that sequencing and copy number analysis of both PAX3 and MITF have to be recommended in the routine molecular diagnostic setting for patients, WS1 and WS2. Furthermore, our genotype-phenotype analyses indicate that WS2 and TS correspond to a clinical spectrum that is influenced by MITF mutation type and position.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23512835", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Novel and recurrent non-truncating mutations of the MITF basic domain: genotypic and phenotypic variations in Waardenburg and Tietz syndromes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258527", "endSection": "title"}, {"offsetInBeginSection": 200, "offsetInEndSection": 487, "text": "A notable relationship has been described between non-truncating mutations of its basic domain and Tietz syndrome, which is characterized by albinoid-like hypopigmentation of the skin and hair, rather than the patchy depigmentation seen in Waardenburg syndrome, and severe hearing loss. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258527", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 348, "text": "Mutations in microphthalmia-associated transcription factor (MITF) lead to Waardenburg syndrome type 2 (WS2), a dominantly inherited disorder involving hearing loss and pigment disturbances caused by a lack of melanocytes. On rare occasions, mutations in MITF lead to Tietz syndrome (TS), which is characterized by a severe WS2 phenotype. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20485200", "endSection": "abstract"}, {"offsetInBeginSection": 257, "offsetInEndSection": 389, "text": "In humans, haploinsufficiency of MITF causes Waardenburg syndrome type 2, while a dominant-negative mutation causes Tietz syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10952390", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Tietz syndrome (hypopigmentation/deafness) caused by mutation of MITF.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10851256", "endSection": "title"}, {"offsetInBeginSection": 474, "offsetInEndSection": 869, "text": "This family was reascertained and a missense mutation was found in the basic region of the MITF gene in family members with Tietz syndrome. Mutations in other regions of this gene have been found to produce Waardenburg syndrome type 2 (WS2), which also includes pigmentary changes and hearing loss, but in contrast to Tietz syndrome, depigmentation is patchy and hearing loss is variable in WS2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10851256", "endSection": "abstract"}, {"offsetInBeginSection": 266, "offsetInEndSection": 427, "text": "In humans, MITF mutations cause Waardenburg syndrome type 2A (WS2A) and Tietz syndrome, autosomal dominant disorders resulting in deafness and hypopigmentation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10790403", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Mutation of the MITF gene in albinism-deafness syndrome (Tietz syndrome).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9546825", "endSection": "title"}, {"offsetInBeginSection": 260, "offsetInEndSection": 334, "text": "MITF gene mutations account for 20% of Waardenburg syndrome (WS) type II. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9546825", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 343, "text": "Mutations in the MITF have been found in patients with the dominantly inherited hypopigmentation and deafness syndromes Waardenburg syndrome type 2A (WS2A) and Tietz syndrome (TS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23787126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 485, "text": "The microphthalmia-associated transcription factor (MITF) is a basic helix-loop-helix leucine zipper transcription factor, which regulates melanocyte development and the biosynthetic melanin pathway. A notable relationship has been described between non-truncating mutations of its basic domain and Tietz syndrome, which is characterized by albinoid-like hypopigmentation of the skin and hair, rather than the patchy depigmentation seen in Waardenburg syndrome, and severe hearing loss", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258527", "endSection": "abstract"}, {"offsetInBeginSection": 1650, "offsetInEndSection": 1750, "text": "Mutations of the MITF gene may lead to hereditary diseases: Waardenburg type II and Tietz syndromes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22371403", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "The human deafness-pigmentation syndromes, Waardenburg syndrome (WS) type 2a, and Tietz syndrome are characterized by profound deafness but only partial cutaneous pigmentary abnormalities. Both syndromes are caused by mutations in MITF.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23020089", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "On some occasions, mutations of a gene cause different syndromes that may have similar phenotypes. For example, mutations of the MITF gene cause Waardenburg syndrome type 2 (Tassabehji et al, 1994; Nobukuni et al, 1996) as well as Tietz syndrome (Smith et al, 1997)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10536986", "endSection": "abstract"}, {"offsetInBeginSection": 1638, "offsetInEndSection": 1738, "text": "Mutations of the MITF gene may lead to hereditary diseases: Waardenburg type II and Tietz syndromes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22371403", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 342, "text": "Mutations in the MITF have been found in patients with the dominantly inherited hypopigmentation and deafness syndromes Waardenburg syndrome type 2A (WS2A) and Tietz syndrome (TS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23787126", "endSection": "abstract"}, {"offsetInBeginSection": 947, "offsetInEndSection": 1048, "text": "For example, mutations of the MITF gene cause Waardenburg syndrome type 2A as well as Tietz syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379252", "endSection": "abstract"}, {"offsetInBeginSection": 98, "offsetInEndSection": 265, "text": "For example, mutations of the MITF gene cause Waardenburg syndrome type 2 (Tassabehji et al, 1994; Nobukuni et al, 1996) as well as Tietz syndrome (Smith et al, 1997).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10536986", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Hearing dysfunction in heterozygous Mitf(Mi-wh) /+ mice, a model for Waardenburg syndrome type 2 and Tietz syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23020089", "endSection": "title"}, {"offsetInBeginSection": 527, "offsetInEndSection": 720, "text": "By analyzing the genes for Waardenburg syndrome, we showed that PAX3, the gene responsible for Waardenburg syndrome type 1, regulates MITF, the gene responsible for Waardenburg syndrome type 2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10536986", "endSection": "abstract"}, {"offsetInBeginSection": 260, "offsetInEndSection": 333, "text": "MITF gene mutations account for 20% of Waardenburg syndrome (WS) type II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9546825", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 342, "text": "Mutations in the MITF have been found in patients with the dominantly inherited hypopigmentation and deafness syndromes Waardenburg syndrome type 2A (WS2A) and Tietz syndrome (TS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23787126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Novel and recurrent non-truncating mutations of the MITF basic domain: genotypic and phenotypic variations in Waardenburg and Tietz syndromes", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258527", "endSection": "title"}, {"offsetInBeginSection": 953, "offsetInEndSection": 1053, "text": "For example, mutations of the MITF gene cause Waardenburg syndrome type 2A as well as Tietz syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379252", "endSection": "abstract"}, {"offsetInBeginSection": 474, "offsetInEndSection": 614, "text": "This family was reascertained and a missense mutation was found in the basic region of the MITF gene in family members with Tietz syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10851256", "endSection": "abstract"}, {"offsetInBeginSection": 232, "offsetInEndSection": 348, "text": "On rare occasions, mutations in MITF lead to Tietz syndrome (TS), which is characterized by a severe WS2 phenotype. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20485200", "endSection": "abstract"}, {"offsetInBeginSection": 99, "offsetInEndSection": 267, "text": "For example, mutations of the MITF gene cause Waardenburg syndrome type 2 (Tassabehji et al, 1994; Nobukuni et al, 1996) as well as Tietz syndrome (Smith et al, 1997). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10536986", "endSection": "abstract"}, {"offsetInBeginSection": 99, "offsetInEndSection": 266, "text": "For example, mutations of the MITF gene cause Waardenburg syndrome type 2 (Tassabehji et al, 1994; Nobukuni et al, 1996) as well as Tietz syndrome (Smith et al, 1997).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10536986", "endSection": "abstract"}, {"offsetInBeginSection": 266, "offsetInEndSection": 426, "text": "In humans, MITF mutations cause Waardenburg syndrome type 2A (WS2A) and Tietz syndrome, autosomal dominant disorders resulting in deafness and hypopigmentation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10790403", "endSection": "abstract"}, {"offsetInBeginSection": 257, "offsetInEndSection": 388, "text": "In humans, haploinsufficiency of MITF causes Waardenburg syndrome type 2, while a dominant-negative mutation causes Tietz syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10952390", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Tietz/Waardenburg type 2A syndrome associated with posterior microphthalmos in two unrelated patients with novel MITF gene mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27604145", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Tietz syndrome and Waardenburg syndrome type 2A are allelic conditions caused by MITF mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27604145", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Hearing dysfunction in heterozygous Mitf(Mi-wh) /+ mice, a model for Waardenburg syndrome type 2 and Tietz syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23020089", "endSection": "title"}, {"offsetInBeginSection": 1152, "offsetInEndSection": 1345, "text": "For example, mutations of MITF, SNAI2 and SOX10 genes are observed in Waardenburg syndrome type II and mutations of EDNRB, EDN3 and SOX10 genes are responsible for Waardenburg syndrome type IV.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379252", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Mutation of the MITF gene in albinism-deafness syndrome (Tietz syndrome).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9546825", "endSection": "title"}]}, {"body": "List the three most abundant bacterial phyla present in mouse feces.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25537565", "http://www.ncbi.nlm.nih.gov/pubmed/20926643", "http://www.ncbi.nlm.nih.gov/pubmed/23457582", "http://www.ncbi.nlm.nih.gov/pubmed/19159975"], "ideal_answer": ["Firmicutes\nProteobacteria \nBacteroidetes"], "type": "list", "id": "58bbbe6822d300530900001a", "snippets": [{"offsetInBeginSection": 862, "offsetInEndSection": 1047, "text": "Amplicons representing the major phyla encountered in the rumen (Firmicutes, 43.7%; Proteobacteria, 28.7%; Bacteroidetes, 25.3%; Spirochea, 1.1%, and Synergistes, 1.1%) were recovered, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19159975", "endSection": "abstract"}, {"offsetInBeginSection": 68, "offsetInEndSection": 152, "text": "alterations in the gut microbiota (increased Firmicutes and decreased Bacteroidetes)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20926643", "endSection": "abstract"}, {"offsetInBeginSection": 385, "offsetInEndSection": 536, "text": "The taxonomic analysis of the metagenomic reads indicated that pygmy loris fecal microbiomes were dominated by Bacteroidetes and Proteobacteria phyla. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23457582", "endSection": "abstract"}, {"offsetInBeginSection": 1025, "offsetInEndSection": 1193, "text": "Specifically, intermittent hypoxia-exposed mice showed a higher abundance of Firmicutes and a smaller abundance of Bacteroidetes and Proteobacteria phyla than controls.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25537565", "endSection": "abstract"}]}, {"body": "What gene is mutated in Sickle Cell Anemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27802215", "http://www.ncbi.nlm.nih.gov/pubmed/27814292", "http://www.ncbi.nlm.nih.gov/pubmed/17662889", "http://www.ncbi.nlm.nih.gov/pubmed/1301951", "http://www.ncbi.nlm.nih.gov/pubmed/11172667", "http://www.ncbi.nlm.nih.gov/pubmed/20886046", "http://www.ncbi.nlm.nih.gov/pubmed/8745433", "http://www.ncbi.nlm.nih.gov/pubmed/6310991", "http://www.ncbi.nlm.nih.gov/pubmed/7624311"], "ideal_answer": ["Sickle cell anemia (SCA) is an autosomal recessive disease caused by by the HBB:c.20A>T mutation that leads to hemoglobin S synthesis.", " sca patients present clinical and hematologic variability that cannot be only explained by the single mutation in the beta-globin gene."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000755", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006451", "http://www.disease-ontology.org/api/metadata/DOID:10923", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012805"], "type": "factoid", "id": "58bcabc702b8c6095300000e", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 204, "text": "Sickle cell anemia (SCA) is an inherited blood disorder. SCA patients present clinical and hematologic variability that cannot be only explained by the single mutation in the beta-globin gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27802215", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Sickle cell anemia (SCA) is an autosomal recessive disease caused by the HBB:c.20A>T mutation that leads to hemoglobin S synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814292", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Sickle cell anemia is caused by a single type of mutation, a homozygous A\u2192T substitution in the \u00df globin gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20886046", "endSection": "abstract"}, {"offsetInBeginSection": 159, "offsetInEndSection": 486, "text": "Implementation of this approach for disorders resulting from mutations affecting the beta-globin gene (e.g., beta-thalassemia and sickle cell anemia), however, has been hampered by the inability to generate recombinant viruses able to efficiently and faithfully transmit the necessary sequences for appropriate gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7624311", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 398, "text": "The allele-specific PCR approach has been modified by introducing a second mismatch at the 3'-penultimate link of the primer and used to identify the sickle cell anemia mutation (A-->T transversion in the sixth codon of the human beta-globin gene causing Glu-->Val substitution in the protein), thus obviating the problem of an interpretationally ambiguous 3'-terminal mismatch including T residue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1301951", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Sickle-cell anemia results from an A leads to T transversion in the second nucleotide of codon 6 of the beta-globin gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6310991", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "Sickle cell anemia is a genetic blood disorder arising from a point mutation in the beta-globin gene that leads to the replacement of glutamic acid residue by valine at the sixth position of the beta--chain of hemoglobin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11172667", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 153, "text": "Sickle cell anemia is a genetic blood disease resulting from production of mutant beta-globin (beta(S)) and has severe clinical consequences. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662889", "endSection": "abstract"}]}, {"body": "What is the function of the Indian hedgehog protein in chondrocytes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24821091", "http://www.ncbi.nlm.nih.gov/pubmed/17328886", "http://www.ncbi.nlm.nih.gov/pubmed/11517192", "http://www.ncbi.nlm.nih.gov/pubmed/18059015", "http://www.ncbi.nlm.nih.gov/pubmed/10328918", "http://www.ncbi.nlm.nih.gov/pubmed/12213208", "http://www.ncbi.nlm.nih.gov/pubmed/23928032", "http://www.ncbi.nlm.nih.gov/pubmed/10631175", "http://www.ncbi.nlm.nih.gov/pubmed/21795282", "http://www.ncbi.nlm.nih.gov/pubmed/25028519", "http://www.ncbi.nlm.nih.gov/pubmed/19906842", "http://www.ncbi.nlm.nih.gov/pubmed/18434416", "http://www.ncbi.nlm.nih.gov/pubmed/10615989", "http://www.ncbi.nlm.nih.gov/pubmed/11850620", "http://www.ncbi.nlm.nih.gov/pubmed/25808752", "http://www.ncbi.nlm.nih.gov/pubmed/17907424", "http://www.ncbi.nlm.nih.gov/pubmed/8662546", "http://www.ncbi.nlm.nih.gov/pubmed/9486541", "http://www.ncbi.nlm.nih.gov/pubmed/22507129", "http://www.ncbi.nlm.nih.gov/pubmed/11714677", "http://www.ncbi.nlm.nih.gov/pubmed/12745383", "http://www.ncbi.nlm.nih.gov/pubmed/10742444", "http://www.ncbi.nlm.nih.gov/pubmed/21411723", "http://www.ncbi.nlm.nih.gov/pubmed/10208865", "http://www.ncbi.nlm.nih.gov/pubmed/15355563", "http://www.ncbi.nlm.nih.gov/pubmed/11748145", "http://www.ncbi.nlm.nih.gov/pubmed/10465785", "http://www.ncbi.nlm.nih.gov/pubmed/11466306", "http://www.ncbi.nlm.nih.gov/pubmed/22190639", "http://www.ncbi.nlm.nih.gov/pubmed/14991716", "http://www.ncbi.nlm.nih.gov/pubmed/21566205", "http://www.ncbi.nlm.nih.gov/pubmed/10491221", "http://www.ncbi.nlm.nih.gov/pubmed/25479004", "http://www.ncbi.nlm.nih.gov/pubmed/19035497", "http://www.ncbi.nlm.nih.gov/pubmed/11332615", "http://www.ncbi.nlm.nih.gov/pubmed/24844414", "http://www.ncbi.nlm.nih.gov/pubmed/12968668"], "ideal_answer": ["Indian hedgehog is a protein that regulates endochondral differentiation and ossification in both a parathyroid hormone-related protein (PTHrP)-dependent and -independent manner by activating transcriptional mediator Gli2 and is an essential factor for proper skeletal development."], "concepts": ["http://www.uniprot.org/uniprot/IHH_DANAT", "http://www.uniprot.org/uniprot/IHH_RASEL", "http://www.uniprot.org/uniprot/IHH_CARAU", "http://www.uniprot.org/uniprot/IHH_TRIHE", "http://www.uniprot.org/uniprot/IHH_DANAP", "http://www.uniprot.org/uniprot/IHH_DEVDE", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019902", "http://www.uniprot.org/uniprot/IHH_DEVPA", "http://www.uniprot.org/uniprot/IHH_RASPA", "http://www.uniprot.org/uniprot/IHH_DANKE", "http://www.uniprot.org/uniprot/IHH_XENLA", "http://www.uniprot.org/uniprot/IHH_MOUSE", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019485", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053823", "http://www.uniprot.org/uniprot/IHH_PUNTE", "http://www.uniprot.org/uniprot/IHH_HUMAN", "http://www.uniprot.org/uniprot/IHH_CHICK", "http://www.uniprot.org/uniprot/IHH_DEVMA"], "type": "summary", "id": "58b95ea222d3005309000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Indian hedgehog (Ihh) regulates endochondral ossification in both a parathyroid hormone-related protein (PTHrP)-dependent and -independent manner by activating transcriptional mediator Gli2. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25808752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Wnt/\u03b2-catenin, Indian hedgehog (Ihh)/Parathyroid-related peptide (PTHrP) and retinoid signaling pathways regulate cartilage differentiation, growth, and function during development and play a key role in endochondral ossification.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25479004", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 434, "text": "Indian hedgehog (Ihh) is essential for chondrocyte differentiation and endochondral ossification and acts with parathyroid hormone-related peptide in a negative feedback loop to regulate early chondrocyte differentiation and entry to hypertrophic differentiation. Independent of this function, we and others recently reported independent Ihh functions to promote chondrocyte hypertrophy and matrix mineralization in vivo and in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25028519", "endSection": "abstract"}, {"offsetInBeginSection": 540, "offsetInEndSection": 708, "text": "We recently discovered that Ihh overexpression in chondrocytes stimulated the expression of late chondrocyte differentiation markers and induced matrix mineralization. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25028519", "endSection": "abstract"}, {"offsetInBeginSection": 985, "offsetInEndSection": 1155, "text": "In addition, we found that Ihh induced Runx2 expression in chondrocytes without up-regulating other modulators of chondrocyte maturation such as Mef2c, Foxa2, and Foxa3. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25028519", "endSection": "abstract"}, {"offsetInBeginSection": 1611, "offsetInEndSection": 1756, "text": "Thus, Ihh signaling could be an important player for not only early chondrocyte differentiation but maturation and calcification of chondrocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25028519", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "The Ihh signal is essential for regulating proliferation and hypertrophy of cultured chicken chondrocytes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928032", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "The Indian hedgehog (Ihh) signal plays a vital role in regulating proliferation and hypertrophy of chondrocytes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928032", "endSection": "abstract"}, {"offsetInBeginSection": 912, "offsetInEndSection": 1246, "text": "Based on these results, the Ihh signal is essential for balancing chicken chondrocyte proliferation and hypertrophy, and the regulatory function of PTHrP acts in an Ihh-dependent manner. Furthermore, BMP-6 and Bcl-2 played roles in maintaining the development of chondrocytes and may be downstream regulatory factors of Ihh signaling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928032", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Atf4 is a leucine zipper-containing transcription factor that activates osteocalcin (Ocn) in osteoblasts and indian hedgehog (Ihh) in chondrocytes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22190639", "endSection": "abstract"}, {"offsetInBeginSection": 118, "offsetInEndSection": 327, "text": "Indian hedgehog (Ihh) is produced by prehypertrophic chondrocytes in developing long bones and regulates chondrocyte proliferation and other events, but it is not known whether it requires HS-PGs for function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14991716", "endSection": "abstract"}, {"offsetInBeginSection": 330, "offsetInEndSection": 459, "text": "We have shown that Indian hedgehog gene (Ihh) is expressed in cartilage anlage and later in mature and hypertrophic chondrocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10615989", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8662546", "endSection": "title"}, {"offsetInBeginSection": 798, "offsetInEndSection": 1049, "text": "In normal growth plates, differentiation of proliferative chondrocytes to post-mitotic hypertrophic chondrocytes is regulated in part by a tightly coupled signaling relay involving parathyroid hormone related protein (PTHrP) and Indian hedgehog (IHH).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850620", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "The Indian hedgehog (Ihh) signal plays a vital role in regulating proliferation and hypertrophy of chondrocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928032", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Indian hedgehog and syndecans-3 coregulate chondrocyte proliferation and function during chick limb skeletogenesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14991716", "endSection": "title"}, {"offsetInBeginSection": 714, "offsetInEndSection": 902, "text": "We further demonstrate that misexpression of Indian hedgehog appears to directly upregulate BMP2 and BMP4 expression, independent of the differentiation state of the flanking chondrocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10328918", "endSection": "abstract"}, {"offsetInBeginSection": 119, "offsetInEndSection": 328, "text": "Indian hedgehog (Ihh) is produced by prehypertrophic chondrocytes in developing long bones and regulates chondrocyte proliferation and other events, but it is not known whether it requires HS-PGs for function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14991716", "endSection": "abstract"}, {"offsetInBeginSection": 1155, "offsetInEndSection": 1409, "text": "The cellular expression of two markers of chondrocyte differentiation, Indian hedgehog, expressed in pre-hypertrophic cells and collagen type X, expressed in hypertrophic chondrocytes, were both significantly inhibited after incubation with isoproterenol", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18059015", "endSection": "abstract"}, {"offsetInBeginSection": 119, "offsetInEndSection": 327, "text": "Indian hedgehog (Ihh) is produced by prehypertrophic chondrocytes in developing long bones and regulates chondrocyte proliferation and other events, but it is not known whether it requires HS-PGs for function", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14991716", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Four distinct chondrocyte populations in the fetal bovine growth plate: highest expression levels of PTH/PTHrP receptor, Indian hedgehog, and MMP-13 in hypertrophic chondrocytes and their suppression by PTH (1-34) and PTHrP (1-40)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12213208", "endSection": "title"}, {"offsetInBeginSection": 129, "offsetInEndSection": 365, "text": "Although it is known that parathyroid hormone related protein (PTHrP) and Indian hedgehog regulate the differentiation of growth plate chondrocytes, how these pathways interact to regulate chondrocyte development is not fully elucidated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17328886", "endSection": "abstract"}, {"offsetInBeginSection": 160, "offsetInEndSection": 411, "text": "Indian hedgehog (Ihh) signaling from prehypertrophic chondrocytes has been implicated in the control of chondrocyte maturation by way of feedback control of a second secreted factor parathyroid hormone-related peptide (PTHrP) at the articular surfaces", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10465785", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "Mutant BMP receptors were transfected into cultured embryonic upper sternal chrondrocytes using retroviral vectors to determine if BMP signaling is required for chondrocyte maturation and the expression of a key regulatory molecule, Indian hedgehog (Ihh)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11332615", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Chondrocytes of the epiphyseal growth zone are regulated by the Indian hedgehog (IHH)-parathyroid hormone-related protein (PTHrP) axis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19035497", "endSection": "abstract"}, {"offsetInBeginSection": 738, "offsetInEndSection": 1008, "text": "The polymorphic layer in P15 mutants contained fewer Sox9-expressing chondroprogenitor cells because of reduced mitotic activity, and newly differentiated chondrocytes underwent precocious hypertrophic enlargement accompanied by early activation of Indian hedgehog (Ihh)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21566205", "endSection": "abstract"}, {"offsetInBeginSection": 849, "offsetInEndSection": 1116, "text": "In an effort to lessen the severity of bone defects caused by HhAntag, we treated young mice simultaneously with HhAntag and parathyroid hormone-related protein (PTHrP), which functions downstream of Indian Hedgehog to maintain chondrocytes in a proliferative state. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21411723", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Chondrocyte differentiation during embryonic bone growth is controlled by interactions between PTHrP and Indian hedgehog.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517192", "endSection": "abstract"}, {"offsetInBeginSection": 225, "offsetInEndSection": 329, "text": "Hedgehog genes encode secreted proteins which mediate patterning and growth during skeletal development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10615989", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Indian hedgehog (Ihh) has recently been shown to be expressed in prehypertrophic and hypertrophic chondrocytes during embryonic development, and it has been implicated in the regulation of terminal differentiation of chondrocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10742444", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Indian hedgehog and syndecans-3 coregulate chondrocyte proliferation and function during chick limb skeletogenesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14991716", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Indian Hedgehog signalling triggers Nkx3.2 protein degradation during chondrocyte maturation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22507129", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Regulation of articular chondrocyte proliferation and differentiation by indian hedgehog and parathyroid hormone-related protein in mice.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19035497", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Chondrocytes of the epiphyseal growth zone are regulated by the Indian hedgehog (IHH)-parathyroid hormone-related protein (PTHrP) axis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19035497", "endSection": "abstract"}, {"offsetInBeginSection": 655, "offsetInEndSection": 746, "text": "Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9486541", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Expression of indian hedgehog, bone morphogenetic protein 6 and gli during skeletal morphogenesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9486541", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Indian hedgehog signals independently of PTHrP to promote chondrocyte hypertrophy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18434416", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Age-dependent effects of hedgehog protein on chondrocytes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10615989", "endSection": "title"}, {"offsetInBeginSection": 367, "offsetInEndSection": 568, "text": "Indian hedgehog (Ihh), a secreted protein expressed in early hypertrophic chondrocytes, is thought to be involved in regulation of hypertrophic conversion via a feedback loop through the perichondrium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10208865", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8662546", "endSection": "title"}, {"offsetInBeginSection": 1949, "offsetInEndSection": 2127, "text": "These observations are in keeping with the proposed function of gli as a negative regulator of Ihh signaling and the induction of Bmps by Hedgehog proteins (Roberts et al., 1995.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9486541", "endSection": "abstract"}]}, {"body": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26993089"], "ideal_answer": ["R-spondin 1 and noggin facilitate expansion of resident stem cells from non-damaged gallbladders."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005704", "http://www.biosemantics.org/jochem#4264633", "http://www.uniprot.org/uniprot/NOGG_HUMAN", "http://www.uniprot.org/uniprot/RSPO1_MOUSE", "http://www.uniprot.org/uniprot/RSPO1_DANRE", "http://www.uniprot.org/uniprot/SPON1_MOUSE", "http://www.uniprot.org/uniprot/RSPO1_HUMAN", "http://www.uniprot.org/uniprot/SPON1_RAT", "http://www.uniprot.org/uniprot/SPON1_CHICK", "http://www.uniprot.org/uniprot/NOGG_XENLA", "http://www.uniprot.org/uniprot/SPON1_XENLA"], "type": "factoid", "id": "5883a727e56acf5176000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "R-spondin 1 and noggin facilitate expansion of resident stem cells from non-damaged gallbladders.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26993089", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "R-spondin 1 and noggin facilitate expansion of resident stem cells from non-damaged gallbladders.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26993089", "endSection": "title"}]}, {"body": "List the classical triad of symptoms of the Melkersson\u2013Rosenthal syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16856704", "http://www.ncbi.nlm.nih.gov/pubmed/1597367", "http://www.ncbi.nlm.nih.gov/pubmed/15865255", "http://www.ncbi.nlm.nih.gov/pubmed/16989500", "http://www.ncbi.nlm.nih.gov/pubmed/10481507", "http://www.ncbi.nlm.nih.gov/pubmed/11995671", "http://www.ncbi.nlm.nih.gov/pubmed/24874612", "http://www.ncbi.nlm.nih.gov/pubmed/10938204", "http://www.ncbi.nlm.nih.gov/pubmed/10534638", "http://www.ncbi.nlm.nih.gov/pubmed/14980194", "http://www.ncbi.nlm.nih.gov/pubmed/10332378", "http://www.ncbi.nlm.nih.gov/pubmed/12783021", "http://www.ncbi.nlm.nih.gov/pubmed/1923442", "http://www.ncbi.nlm.nih.gov/pubmed/24827666", "http://www.ncbi.nlm.nih.gov/pubmed/15068454", "http://www.ncbi.nlm.nih.gov/pubmed/24656464", "http://www.ncbi.nlm.nih.gov/pubmed/7856459", "http://www.ncbi.nlm.nih.gov/pubmed/8725591", "http://www.ncbi.nlm.nih.gov/pubmed/2584463", "http://www.ncbi.nlm.nih.gov/pubmed/24225172", "http://www.ncbi.nlm.nih.gov/pubmed/22836908", "http://www.ncbi.nlm.nih.gov/pubmed/7640193", "http://www.ncbi.nlm.nih.gov/pubmed/17103360", "http://www.ncbi.nlm.nih.gov/pubmed/26635986", "http://www.ncbi.nlm.nih.gov/pubmed/8302226", "http://www.ncbi.nlm.nih.gov/pubmed/12081001", "http://www.ncbi.nlm.nih.gov/pubmed/16096940", "http://www.ncbi.nlm.nih.gov/pubmed/9224474", "http://www.ncbi.nlm.nih.gov/pubmed/3228056", "http://www.ncbi.nlm.nih.gov/pubmed/26698837"], "ideal_answer": ["The Melkersson-Rosenthal syndrome consists of the classical triad of symptoms:\n1) orofacial oedema \n2) fissured tongue (lingua plicata) and\n3) facial paralysis."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008556", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "http://www.disease-ontology.org/api/metadata/DOID:1761", "http://www.disease-ontology.org/api/metadata/DOID:225"], "type": "list", "id": "58b53bf722d3005309000004", "snippets": [{"offsetInBeginSection": 310, "offsetInEndSection": 451, "text": "The Melkersson-Rosenthal syndrome consists of a triad of recurrent lip and/or face swelling, fissured tongue, and intermittent facial palsy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26698837", "endSection": "abstract"}, {"offsetInBeginSection": 1007, "offsetInEndSection": 1150, "text": "The patient has a typical for Melkersson-Rosenthal syndrome triad of symptoms: bilateral facial nerve palsy, lingua plicata and facial oedema. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26698837", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 182, "text": "Melkersson-Rosenthal syndrome (MRS) is a rare disorder of unknown cause. The classical triad of MRS is orofacial edema, recurrent facial paralysis, and a fissured tongue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24656464", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Melkersson-Rosenthal syndrome (MRS) is a rare granulomatous inflammatory disease characterised by the triad of orofacial oedema, facial nerve palsy and furrowed tongue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24827666", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 221, "text": "Melkersson-Rosenthal syndrome (MRS) is a rare neuro-mucocutaneous granulomatous disorder of unknown etiology, characterized by the triad of facial palsy, lingua plicata (fissured tongue), and orofacial edema. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24874612", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 352, "text": "Melkerrson-Rosenthal syndrome is a rare disorder of unknown etiology. The classical triad of recurrent facial paralysis, swelling of the face, lips and deep furrowed tongue (Lingua Plicata) is seen in very few cases, majority of the patients often present with one or two symptoms only, which often leads to misdiagnosis and mismanagement. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24225172", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Melkersson-Rosenthal syndrome (MRS) is a rare neuromucocutaneous syndrome marked by the triad of recurrent nonpitting orofacial edema, fissured dorsal tongue (lingua plicata), and lower motoneuron facial paralysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22836908", "endSection": "abstract"}, {"offsetInBeginSection": 236, "offsetInEndSection": 510, "text": "Recurrent facial nerve palsy, facial swelling, and fissured tongue are the symptoms and signs of this condition. However, this triad is not typical in all patients as patients may present with one or more of the symptoms, which makes management of this condition difficult. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26635986", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 220, "text": "Melkersson-Rosenthal syndrome may manifest as the classical triad (orofacial edema, facial nerve palsy and stable lingua plicata) but monosymptomatic manifestations or combinations of typical symptoms are not infrequent.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14980194", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "Melkersson-Rosenthal Syndrome (MRS) is a systemic neuro-mucocutaneous granulomatous disease, characterized in its classical form by a triad of recurrent facial nerve paralysis, swelling of the lips and lingua plicata.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16856704", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Melkersson-Rosenthal syndrome is classically described as a triad of orofacial swelling, facial palsy, and fissured tongue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10332378", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Melkersson-Rosenthal syndrome is a rare disorder consisting of the triad of persistent or recurrent orofacial edema, relapsing facial paralysis and fissured tongue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938204", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "The Melkersson-Rosenthal syndrome consists of a triad of recurrent lip and/or face swelling, fissured tongue, and intermittent facial palsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10534638", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "The Melkersson-Rosenthal syndrome consists of a triad of symptoms: peripheral facial nerve paralysis, congenital \"lingua plicata\" and noninflammatory facial oedema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10481507", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "The Melkersson-Rosenthal syndrome consists of triad of symptoms: recurrent oedema of lips, recurrent facial nerve paralysis and lingua plicata.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15865255", "endSection": "abstract"}, {"offsetInBeginSection": 115, "offsetInEndSection": 254, "text": "Melkersson-Rosenthal syndrome is characterised by a triad of recurrent orofacial swelling, relapsing facial paralysis, and fissured tongue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103360", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "The Melkersson-Rosenthal syndrome consists of triad of symptoms: recurrent oedema of lips, recurrent facial nerve paralysis and lingua plicata", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15865255", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "Melkersson-Rosenthal syndrome may manifest as the classical triad (orofacial edema, facial nerve palsy and stable lingua plicata) but monosymptomatic manifestations or combinations of typical symptoms are not infrequent", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14980194", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "Melkersson-Rosenthal syndrome (MRS) is a rare disorder of unknown etiology characterized by a triad of symptoms: recurrent orofacial swelling, relapsing facial palsy. and a fissured tongue", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11995671", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "The Melkersson-Rosenthal syndrome consists of a triad of symptoms: peripheral facial nerve paralysis, congenital \"lingua plicata\" and noninflammatory facial oedema", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10481507", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Melkersson-Rosenthal syndrome (MRS) is characterized by the triad of facial paralysis, facial oedema, and lingua plicata in association with other symptoms, such as headache and mental changes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1597367", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Peripheral facial nerve palsy, recurrent or persistent oral or facial swelling, and fissured tongue constitute a triad of symptoms known as Melkersson-Rosenthal syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1923442", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Melkersson-Rosenthal (MRS) syndrome is characterized by a classical triad of recurrent or persistent orofacial swelling, peripheral facial nerve paralysis and lingua plicata. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15068454", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "BACKGROUND: Melkersson-Rosenthal syndrome may manifest as the classical triad (orofacial edema, facial nerve palsy and stable lingua plicata) but monosymptomatic manifestations or combinations of typical symptoms are not infrequent. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14980194", "endSection": "abstract"}, {"offsetInBeginSection": 79, "offsetInEndSection": 312, "text": "The syndrome is classically characterized by a triad of signs consisting of facial edema, recurrent peripheral facial nerve paralysis, and congenital fissured tongue, although it may also present in a mono- or oligosymptomatic form. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16096940", "endSection": "abstract"}, {"offsetInBeginSection": 96, "offsetInEndSection": 209, "text": "The classic triad of signs includes recurrent orofacial edema, recurrent facial nerve palsy, and lingua plicata. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2584463", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Melkersson-Rosenthal syndrome (MRS) is characterized by the triad of facial paralysis, facial oedema, and lingua plicata in association with other symptoms, such as headache and mental changes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1597367", "endSection": "abstract"}, {"offsetInBeginSection": 971, "offsetInEndSection": 1113, "text": "The patient has a typical for Melkersson-Rosenthal syndrome triad of symptoms: bilateral facial nerve palsy, lingua plicata and facial oedema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26698837", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Peripheral facial nerve palsy, recurrent or persistent oral or facial swelling, and fissured tongue constitute a triad of symptoms known as Melkersson-Rosenthal syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1923442", "endSection": "abstract"}, {"offsetInBeginSection": 77, "offsetInEndSection": 160, "text": "Classical signs include recurrent facial palsy, lingua plicata and orofacial edema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8302226", "endSection": "abstract"}, {"offsetInBeginSection": 73, "offsetInEndSection": 236, "text": "The classical triad includes recurrent orofacial oedema involving predominantly the lips (macrocheilitis), intermittent peripheral facial palsy and scrotal tongue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7856459", "endSection": "abstract"}, {"offsetInBeginSection": 972, "offsetInEndSection": 1114, "text": "The patient has a typical for Melkersson-Rosenthal syndrome triad of symptoms: bilateral facial nerve palsy, lingua plicata and facial oedema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26698837", "endSection": "abstract"}]}, {"body": "Which disease is treated with taliglucerase alfa?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27102949", "http://www.ncbi.nlm.nih.gov/pubmed/23980545", "http://www.ncbi.nlm.nih.gov/pubmed/27174694", "http://www.ncbi.nlm.nih.gov/pubmed/21235447", "http://www.ncbi.nlm.nih.gov/pubmed/24630271", "http://www.ncbi.nlm.nih.gov/pubmed/21900191", "http://www.ncbi.nlm.nih.gov/pubmed/27499018", "http://www.ncbi.nlm.nih.gov/pubmed/26053270", "http://www.ncbi.nlm.nih.gov/pubmed/22654679", "http://www.ncbi.nlm.nih.gov/pubmed/23199589", "http://www.ncbi.nlm.nih.gov/pubmed/24950666", "http://www.ncbi.nlm.nih.gov/pubmed/27839981", "http://www.ncbi.nlm.nih.gov/pubmed/25453586", "http://www.ncbi.nlm.nih.gov/pubmed/23046562", "http://www.ncbi.nlm.nih.gov/pubmed/27559188", "http://www.ncbi.nlm.nih.gov/pubmed/25812601", "http://www.ncbi.nlm.nih.gov/pubmed/22916340"], "ideal_answer": ["Taliglucerase alfa, the first available plant cell-expressed recombinant therapeutic protein, is an enzyme replacement therapy approved for Gaucher disease."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:4", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"], "type": "factoid", "id": "5891b125621ea6ff7e00000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102949", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 231, "text": "Taliglucerase alfa is the first available plant cell-expressed human recombinant therapeutic protein. It is indicated for treatment of patients with type 1 Gaucher disease (GD) in adult and pediatric patients in several countries. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102949", "endSection": "abstract"}, {"offsetInBeginSection": 1425, "offsetInEndSection": 1656, "text": "The 36-month results of switching from imiglucerase to taliglucerase alfa treatment in adults with GD provide further data on the clinical safety and efficacy of taliglucerase alfa beyond the initial 9 months of the original study.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102949", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-na\u00efve patients with Gaucher disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174694", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 320, "text": "Taliglucerase alfa is an intravenous enzyme replacement therapy approved for treatment of type 1 Gaucher disease (GD), and is the first available plant cell-expressed recombinant therapeutic protein. Herein, we report long-term safety and efficacy results of taliglucerase alfa in treatment-na\u00efve adult patients with GD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174694", "endSection": "abstract"}, {"offsetInBeginSection": 996, "offsetInEndSection": 1168, "text": " These 36-month results of taliglucerase alfa in treatment-na\u00efve adult patients with GD demonstrate continued improvement in disease parameters with no new safety concerns.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174694", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-na\u00efve patients with Gaucher disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27499018", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Taliglucerase alfa, the first available plant cell-expressed recombinant therapeutic protein, is an enzyme replacement therapy approved for Gaucher disease (GD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27499018", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-na\u00efve or previously treated with imiglucerase.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27839981", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 261, "text": "A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", "endSection": "title"}, {"offsetInBeginSection": 1412, "offsetInEndSection": 1496, "text": "These results support safety and efficacy of taliglucerase alfa for Gaucher disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21900191", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23199589", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Taliglucerase alfa for the treatment of Gaucher's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22916340", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25453586", "endSection": "title"}, {"offsetInBeginSection": 1422, "offsetInEndSection": 1506, "text": "These results support safety and efficacy of taliglucerase alfa for Gaucher disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21900191", "endSection": "abstract"}, {"offsetInBeginSection": 1217, "offsetInEndSection": 1372, "text": "These findings provide evidence of the efficacy and safety profile of taliglucerase alfa as an ERT for GD in patients previously treated with imiglucerase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", "endSection": "abstract"}, {"offsetInBeginSection": 388, "offsetInEndSection": 543, "text": "This multicenter, randomized, double-blind, parallel-dose, 12-month study assessed efficacy and safety of taliglucerase alfa in pediatric patients with GD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25453586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 260, "text": "A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", "endSection": "title"}, {"offsetInBeginSection": 308, "offsetInEndSection": 520, "text": "A Phase 3, multicenter, open-label, 9-month study assessed safety and efficacy of switching to taliglucerase alfa in adult and pediatric patients with GD treated with imiglucerase for at least the previous 2years", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", "endSection": "abstract"}, {"offsetInBeginSection": 1217, "offsetInEndSection": 1371, "text": "These findings provide evidence of the efficacy and safety profile of taliglucerase alfa as an ERT for GD in patients previously treated with imiglucerase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", "endSection": "abstract"}, {"offsetInBeginSection": 1174, "offsetInEndSection": 1396, "text": "Clinical trials have demonstrated that taliglucerase alfa is efficacious, with a well-established safety profile in adult, ERT-na\u00efve patients with symptomatic GD1, and for such patients previously treated with imiglucerase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24630271", "endSection": "abstract"}, {"offsetInBeginSection": 2407, "offsetInEndSection": 3070, "text": "One study examined substrate reduction therapy in people with chronic neuronopathic (type 3) Gaucher disease who continued to receive enzyme replacement therapy.Treatment-na\u00efve participants had similar increases in haemoglobin when comparing those receiving imiglucerase or alglucerase at 60 units/kg, imiglucerase or velaglucerase alfa at 60 U/kg, taliglucerase alfa at 30 units/kg or 60 units/kg, and velaglucerase alfa at 45 units/g or 60 units/kg. For platelet count response in participants with intact spleens, a benefit for imiglucerase over velaglucerase alfa at 60 units/kg was observed, mean difference -79.87 (95% confidence interval -137.57 to -22.17)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25812601", "endSection": "abstract"}, {"offsetInBeginSection": 1217, "offsetInEndSection": 1373, "text": "These findings provide evidence of the efficacy and safety profile of taliglucerase alfa as an ERT for GD in patients previously treated with imiglucerase. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Taliglucerase alfa (Protalix Biotherapeutics, Israel) is a carrot-cell-expressed recombinant human beta-glucocerebrosidase recently approved in the United States for the treatment of type 1 Gaucher disease (GD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23199589", "endSection": "abstract"}, {"offsetInBeginSection": 997, "offsetInEndSection": 1168, "text": "These 36-month results of taliglucerase alfa in treatment-na\u00efve adult patients with GD demonstrate continued improvement in disease parameters with no new safety concerns.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174694", "endSection": "abstract"}, {"offsetInBeginSection": 308, "offsetInEndSection": 521, "text": "A Phase 3, multicenter, open-label, 9-month study assessed safety and efficacy of switching to taliglucerase alfa in adult and pediatric patients with GD treated with imiglucerase for at least the previous 2years.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", "endSection": "abstract"}, {"offsetInBeginSection": 1174, "offsetInEndSection": 1397, "text": "Clinical trials have demonstrated that taliglucerase alfa is efficacious, with a well-established safety profile in adult, ERT-na\u00efve patients with symptomatic GD1, and for such patients previously treated with imiglucerase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24630271", "endSection": "abstract"}, {"offsetInBeginSection": 1509, "offsetInEndSection": 1628, "text": "These data suggest that taliglucerase alfa has the potential to be a therapeutic treatment option for children with GD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25453586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102949", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-na\u00efve or previously treated with imiglucerase.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27839981", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 262, "text": "A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950666", "endSection": "title"}]}, {"body": "What is formin associated with in the snail?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26923788"], "ideal_answer": ["Formin is associated with Left-Right asymmetry in the pond snail and the frog.", "Formin Is Associated with Left-Right Asymmetry in the Pond Snail and the Frog"], "concepts": ["http://www.uniprot.org/uniprot/FMNL1_HUMAN", "http://www.biosemantics.org/jochem#4263720", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052078", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012908"], "type": "factoid", "id": "587f795d92a5b8ad44000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Formin Is Associated with Left-Right Asymmetry in the Pond Snail and the Frog", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26923788", "endSection": "title"}, {"offsetInBeginSection": 467, "offsetInEndSection": 1355, "text": " Here, we report that a disabling mutation in one copy of a tandemly duplicated, diaphanous-related formin is perfectly associated with symmetry breaking in the pond snail. This is supported by the observation that an anti-formin drug treatment converts dextral snail embryos to a sinistral phenocopy, and in frogs, drug inhibition or overexpression by microinjection of formin has a chirality-randomizing effect in early (pre-cilia) embryos. Contrary to expectations based on existing models [3, 4 and 5], we discovered asymmetric gene expression in 2- and 4-cell snail embryos, preceding morphological asymmetry. As the formin-actin filament has been shown to be part of an asymmetry-breaking switch in vitro [6 and 7], together these results are consistent with the view that animals with diverse body plans may derive their asymmetries from the same intracellular chiral elements [8].", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26923788", "endSection": "abstract"}, {"offsetInBeginSection": 465, "offsetInEndSection": 636, "text": "Here, we report that a disabling mutation in one copy of a tandemly duplicated, diaphanous-related formin is perfectly associated with symmetry breaking in the pond snail.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26923788", "endSection": "abstract"}, {"offsetInBeginSection": 637, "offsetInEndSection": 906, "text": "This is supported by the observation that an anti-formin drug treatment converts dextral snail embryos to a sinistral phenocopy, and in frogs, drug inhibition or overexpression by microinjection of formin has a chirality-randomizing effect in early (pre-cilia) embryos.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26923788", "endSection": "abstract"}, {"offsetInBeginSection": 468, "offsetInEndSection": 639, "text": "Here, we report that a disabling mutation in one copy of a tandemly duplicated, diaphanous-related formin is perfectly associated with symmetry breaking in the pond snail.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26923788", "endSection": "abstract"}, {"offsetInBeginSection": 640, "offsetInEndSection": 909, "text": "This is supported by the observation that an anti-formin drug treatment converts dextral snail embryos to a sinistral phenocopy, and in frogs, drug inhibition or overexpression by microinjection of formin has a chirality-randomizing effect in early (pre-cilia) embryos.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26923788", "endSection": "abstract"}]}, {"body": "What is the major difference between eucaryotes and procaryotes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16775624", "http://www.ncbi.nlm.nih.gov/pubmed/3271526", "http://www.ncbi.nlm.nih.gov/pubmed/7533711", "http://www.ncbi.nlm.nih.gov/pubmed/7786016", "http://www.ncbi.nlm.nih.gov/pubmed/98518", "http://www.ncbi.nlm.nih.gov/pubmed/2345155", "http://www.ncbi.nlm.nih.gov/pubmed/3023854"], "ideal_answer": ["Eucaryotes have a nucleolus, Procaryotes do not. Eucrayotes have a nuclear membrane, organelles and differ in transcription and translation. Procaryotes have polycistronic RNA and the initiation of protein synthesis proceeds with an initiator tRNA which is found to be modified (formylated) in procaryotes and not in eucaryotes. ", "The nucleolus is the most prominent compartment in the nucleus and known as the site for ribosome biogenesis in eucaryotes. In contrast, there is no such equivalent structure for ribosome synthesis in procaryotes Eucaryotic and procaryotic organisms differ in two aspects of their translation machinery: polycistronic messengers are expressed as a sequence of individual proteins only in procaryotes, and the initiation of protein synthesis proceeds with an initiator tRNA which is found to be modified (formylated) in procaryotes and not in eucaryotes.", "The nucleolus is the most prominent compartment in the nucleus and known as the site for ribosome biogenesis in eucaryotes. In contrast, there is no such equivalent structure for ribosome synthesis in procaryotes Eucaryotic and procaryotic organisms differ in two aspects of their translation machinery: polycistronic messengers are expressed as a sequence of individual proteins only in procaryotes, and the initiation of protein synthesis proceeds with an initiator tRNA which is found to be modified (formylated) in procaryotes and not in eucaryotes. extra guanylate at the 5' end of mature E. coli tRNAHis is encoded in the gene and is found in tRNA as the result of an unusual cleavage by RNase P  There are considerable differences of run distributions in DNA sequences of procaryotes, invertebrates and vertebrates. However, some interesting exceptions from this rule exist for the run distribution of adenine in procaryotes and for the arrangement of purine-pyrimidine runs in eucaryotes"], "type": "summary", "id": "58a1c6b678275d0c4a000057", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "The nucleolus is the most prominent compartment in the nucleus and known as the site for ribosome biogenesis in eucaryotes. In contrast, there is no such equivalent structure for ribosome synthesis in procaryotes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16775624", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 340, "text": "Eucaryotic and procaryotic organisms differ in two aspects of their translation machinery: polycistronic messengers are expressed as a sequence of individual proteins only in procaryotes, and the initiation of protein synthesis proceeds with an initiator tRNA which is found to be modified (formylated) in procaryotes and not in eucaryotes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/98518", "endSection": "abstract"}, {"offsetInBeginSection": 356, "offsetInEndSection": 503, "text": "extra guanylate at the 5' end of mature E. coli tRNAHis is encoded in the gene and is found in tRNA as the result of an unusual cleavage by RNase P", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3023854", "endSection": "abstract"}, {"offsetInBeginSection": 130, "offsetInEndSection": 250, "text": " There are considerable differences of run distributions in DNA sequences of procaryotes, invertebrates and vertebrates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3271526", "endSection": "abstract"}, {"offsetInBeginSection": 399, "offsetInEndSection": 571, "text": "However, some interesting exceptions from this rule exist for the run distribution of adenine in procaryotes and for the arrangement of purine-pyrimidine runs in eucaryotes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3271526", "endSection": "abstract"}, {"offsetInBeginSection": 1320, "offsetInEndSection": 1447, "text": "This was thought to be explained by the lack of mitochondria in procaryotes, the target site of uncoupling agents in eucaryotes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7533711", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 341, "text": "Eucaryotic and procaryotic organisms differ in two aspects of their translation machinery: polycistronic messengers are expressed as a sequence of individual proteins only in procaryotes, and the initiation of protein synthesis proceeds with an initiator tRNA which is found to be modified (formylated) in procaryotes and not in eucaryotes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/98518", "endSection": "abstract"}]}, {"body": "What is the HSP70-HSP110 disaggregase machinery?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27477512"], "ideal_answer": ["Clearance of misfolded and aggregated proteins is central to cell survival. UBQLN2 acts with the HSP70-HSP110 disaggregase machinery to clear protein aggregates via the 26S proteasome. UBQLN2 recognizes client-bound HSP70 and links it to the proteasome to allow for the degradation of aggregated and misfolded proteins. We further show that this process is active in the cell nucleus, where another system for aggregate clearance, autophagy, does not act."], "type": "summary", "id": "58bc640002b8c60953000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Clearance of misfolded and aggregated proteins is central to cell survival.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27477512", "endSection": "abstract"}, {"offsetInBeginSection": 471, "offsetInEndSection": 851, "text": "UBQLN2 acts with the HSP70-HSP110 disaggregase machinery to clear protein aggregates via the 26S proteasome. UBQLN2 recognizes client-bound HSP70 and links it to the proteasome to allow for the degradation of aggregated and misfolded proteins. We further show that this process is active in the cell nucleus, where another system for aggregate clearance, autophagy, does not act. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27477512", "endSection": "abstract"}]}, {"body": "Has whole exome sequencing been performed in Alzheimer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22153900", "http://www.ncbi.nlm.nih.gov/pubmed/23237904", "http://www.ncbi.nlm.nih.gov/pubmed/24958194", "http://www.ncbi.nlm.nih.gov/pubmed/27822510", "http://www.ncbi.nlm.nih.gov/pubmed/22472873", "http://www.ncbi.nlm.nih.gov/pubmed/26522186"], "ideal_answer": ["Yes, numerous whole exome sequencing studies of ALzheimer patients have been conducted."], "type": "yesno", "id": "58bbb8ae22d3005309000018", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26522186", "endSection": "title"}, {"offsetInBeginSection": 129, "offsetInEndSection": 304, "text": "We performed whole-exome sequencing in early-onset Alzheimer disease (EOAD) and late-onset Alzheimer disease (LOAD) families followed by functional studies of select variants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27822510", "endSection": "abstract"}, {"offsetInBeginSection": 202, "offsetInEndSection": 480, "text": "Whole-exome sequencing revealed a nonsense mutation in PRNP (NM_000311, c.C478T; p.Q160*; rs80356711) associated with homozygosity for the V allele at position 129 of the protein, further highlighting how very similar genotypes in PRNP result in strikingly different phenotypes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24958194", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 293, "text": "In the search for new genes in Alzheimer's disease, classic linkage-based and candidate-gene-based association studies have been supplanted by exome sequencing, genome-wide sequencing (for mendelian forms of Alzheimer's disease), and genome-wide association studies (for non-mendelian forms). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237904", "endSection": "abstract"}, {"offsetInBeginSection": 361, "offsetInEndSection": 493, "text": "We performed whole exome sequencing in a Turkish patient clinically diagnosed with Alzheimer's disease from a consanguineous family ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22153900", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 322, "text": "Performing exome sequencing in 14 autosomal dominant early-onset Alzheimer disease (ADEOAD) index cases without mutation on known genes (amyloid precursor protein (APP), presenilin1 (PSEN1) and presenilin2 (PSEN2)), we found that in five patients, the SORL1 gene harbored unknown nonsense (n=1) or missense (n=4) mutations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22472873", "endSection": "abstract"}]}, {"body": "Which is the genome browser database for DNA shape annotations?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25326329"], "ideal_answer": ["GBshape provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms. Additional genomes can easily be added using the GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019991", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678"], "type": "factoid", "id": "587e1bfdfc7e8dd84f000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "GBshape: a genome browser database for DNA shape annotations", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", "endSection": "title"}, {"offsetInBeginSection": 531, "offsetInEndSection": 1352, "text": "Our Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms. Additional genomes can easily be added using the GBshape framework. GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution. As biological applications, we illustrate the periodicity of DNA shape features that are present in nucleosome-occupied sequences from human, fly and worm, and we demonstrate structural similarities between transcription start sites in the genomes of four Drosophila species", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "GBshape: a genome browser database for DNA shape annotations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", "endSection": "title"}, {"offsetInBeginSection": 852, "offsetInEndSection": 1072, "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 785, "text": "Our Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", "endSection": "abstract"}, {"offsetInBeginSection": 857, "offsetInEndSection": 1078, "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", "endSection": "abstract"}, {"offsetInBeginSection": 857, "offsetInEndSection": 1077, "text": "GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "GBshape: a genome browser database for DNA shape annotations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", "endSection": "title"}, {"offsetInBeginSection": 531, "offsetInEndSection": 788, "text": "Our Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25326329", "endSection": "abstract"}]}, {"body": "Is Stat4 a transcription factor?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25178516", "http://www.ncbi.nlm.nih.gov/pubmed/25829541", "http://www.ncbi.nlm.nih.gov/pubmed/25798064", "http://www.ncbi.nlm.nih.gov/pubmed/25852285"], "ideal_answer": ["Yes, Stat4 is a transcription factor.\nStat4 is a member of the signal transducer and activator of transcription (STAT) family of molecules that localizes to the cytoplasm. STAT4 regulates various genes expression as a transcription factor after it is phosphorylated, dimerizes and translocates to the nucleus."], "type": "yesno", "id": "58bc58c302b8c60953000001", "snippets": [{"offsetInBeginSection": 713, "offsetInEndSection": 750, "text": "transcription factors T-bet and STAT4", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25829541", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "STAT4 is a member of the signal transducer and activator of transcription (STAT) family of molecules that localizes to the cytoplasm. STAT4 regulates various genes expression as a transcription factor after it is phosphorylated, dimerizes and translocates to the nucleus. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25798064", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "STAT4 is a latent cytosolic factor that encodes a transcription factor transmitting signals stimulated by cytokines. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25178516", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 168, "text": " To investigate the role of signal transduction and activation of transcription 4 (STAT4) in the development and progression of human hepatocellular carcinoma (HCC)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852285", "endSection": "abstract"}]}, {"body": "Have the promoter regions of the genes implicated in Rett Syndrome been characterized with CAGE?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25539566"], "ideal_answer": ["Yes. Promoter regions of the genes implicated in Rett Syndrome have been characterized using CAGE."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015518", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011401", "http://www.disease-ontology.org/api/metadata/DOID:1206"], "type": "yesno", "id": "589644c478275d0c4a00000d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "CAGE-defined promoter regions of the genes implicated in Rett Syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539566", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 1212, "text": "Mutations in three functionally diverse genes cause Rett Syndrome. Although the functions of Forkhead box G1 (FOXG1), Methyl CpG binding protein 2 (MECP2) and Cyclin-dependent kinase-like 5 (CDKL5) have been studied individually, not much is known about their relation to each other with respect to expression levels and regulatory regions. Here we analyzed data from hundreds of mouse and human samples included in the FANTOM5 project, to identify transcript initiation sites, expression levels, expression correlations and regulatory regions of the three genes.RESULTS: Our investigations reveal the predominantly used transcription start sites (TSSs) for each gene including novel transcription start sites for FOXG1. We show that FOXG1 expression is poorly correlated with the expression of MECP2 and CDKL5. We identify promoter shapes for each TSS, the predicted location of enhancers for each gene and the common transcription factors likely to regulate the three genes. Our data imply Polycomb Repressive Complex 2 (PRC2) mediated silencing of Foxg1 in cerebellum.CONCLUSIONS: Our analyses provide a comprehensive picture of the regulatory regions of the three genes involved in Rett Syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539566", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "CAGE-defined promoter regions of the genes implicated in Rett Syndrome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539566", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "CAGE-defined promoter regions of the genes implicated in Rett Syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539566", "endSection": "title"}]}, {"body": "Has \"RNA interference\" been awarded Nobel prize?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20717561", "http://www.ncbi.nlm.nih.gov/pubmed/24235106", "http://www.ncbi.nlm.nih.gov/pubmed/26648823", "http://www.ncbi.nlm.nih.gov/pubmed/25048083"], "ideal_answer": ["Since the first unequivocal description of RNA interference (RNAi) in 1998, it has remained one of the hottest topics under investigation, culminating in the award of a Nobel Prize to its discoverers in 2006."], "type": "yesno", "id": "58bbb68b22d3005309000015", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "Since the first unequivocal description of RNA interference (RNAi) in 1998, it has remained one of the hottest topics under investigation, culminating in the award of a Nobel Prize to its discoverers in 2006.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20717561", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 341, "text": "RNA interference (RNAi) is considered one of the most powerful genomic tools which allows the study of drug discovery and understanding of the complex cellular processes by high-content screens. This field of study, which was the subject of 2006 Nobel Prize of medicine, has drastically changed the conventional methods of analysis of genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24235106", "endSection": "abstract"}, {"offsetInBeginSection": 187, "offsetInEndSection": 373, "text": " Almost 10 years after Fire and Mello received the Nobel Prize for the discovery of this mechanism in flat worms, RNA interference is on the edge of becoming a new class of therapeutics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26648823", "endSection": "abstract"}]}, {"body": "Is there any role for Pds5b in cohesion establishment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24141881"], "ideal_answer": ["Yes. Pds5 proteins are essential for cohesion establishment by allowing Smc3 acetylation by the cohesin acetyl transferases (CoATs) Esco1/2 and binding of Sororin."], "concepts": ["http://www.uniprot.org/uniprot/PD5AA_XENLA", "http://www.uniprot.org/uniprot/PD5BA_XENLA", "http://www.uniprot.org/uniprot/PDS5A_RAT", "http://amigo.geneontology.org/amigo/term/GO:0034085", "http://www.uniprot.org/uniprot/PDS5B_RAT", "http://amigo.geneontology.org/amigo/term/GO:0034087", "http://www.uniprot.org/uniprot/PDS5B_MOUSE", "http://amigo.geneontology.org/amigo/term/GO:0034089"], "type": "yesno", "id": "5889e2c83b87a8a73800000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Pds5B is required for cohesion establishment and Aurora B accumulation at centromeres.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141881", "endSection": "title"}, {"offsetInBeginSection": 444, "offsetInEndSection": 1070, "text": "Here, we demonstrate that Pds5 proteins are essential for cohesion establishment by allowing Smc3 acetylation by the cohesin acetyl transferases (CoATs) Esco1/2 and binding of Sororin. While both proteins contribute to telomere and arm cohesion, Pds5B is specifically required for centromeric cohesion. Furthermore, reduced accumulation of Aurora B at the inner centromere region in cells lacking Pds5B impairs its error correction function, promoting chromosome mis-segregation and aneuploidy. Our work supports a model in which the composition and function of cohesin complexes differs between different chromosomal regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141881", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Pds5B is required for cohesion establishment and Aurora B accumulation at centromeres.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141881", "endSection": "title"}, {"offsetInBeginSection": 444, "offsetInEndSection": 628, "text": "Here, we demonstrate that Pds5 proteins are essential for cohesion establishment by allowing Smc3 acetylation by the cohesin acetyl transferases (CoATs) Esco1/2 and binding of Sororin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141881", "endSection": "abstract"}]}, {"body": "Which factors are considered in the FUNC score for intracerebral hemorrhage?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18556582"], "ideal_answer": ["FUNC score includes Age, Glasgow Coma Scale, ICH location, volume and pre-ICH cognitive impairment."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020299"], "type": "list", "id": "58850e50e56acf5176000013", "snippets": [{"offsetInBeginSection": 782, "offsetInEndSection": 1065, "text": "Age, Glasgow Coma Scale, ICH location, volume (all P<0.0001), and pre-ICH cognitive impairment (P=0.005) were independently associated with Glasgow Outcome Score>or = 4. The FUNC score was developed as a sum of individual points (0-11) based on strength of association with outcome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18556582", "endSection": "abstract"}, {"offsetInBeginSection": 782, "offsetInEndSection": 951, "text": "Age, Glasgow Coma Scale, ICH location, volume (all P<0.0001), and pre-ICH cognitive impairment (P=0.005) were independently associated with Glasgow Outcome Score>or = 4.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18556582", "endSection": "abstract"}]}, {"body": "Where is the respirasome located?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27830641", "http://www.ncbi.nlm.nih.gov/pubmed/27912054"], "ideal_answer": ["Respirasomes are macromolecular assemblies of the respiratory chain complexes I, III and IV in the inner mitochondrial membrane. The 4.0 \u00c5 cryo-EM structure of one of the most intricate enzyme systems, the respirasome, in the mitochondrial inner membrane is now available."], "type": "factoid", "id": "58a9d8a1396a458e50000005", "snippets": [{"offsetInBeginSection": 181, "offsetInEndSection": 305, "text": "he 4.0\u00a0\u00c5 cryo-EM structure of one of the most intricate enzyme systems, the respirasome, in the mitochondrial inner membrane", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27912054", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Respirasomes are macromolecular assemblies of the respiratory chain complexes I, III and IV in the inner mitochondrial membrane.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27830641", "endSection": "abstract"}]}, {"body": "Describe the usefulness of MiRduplexSVM.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25961860"], "ideal_answer": ["MiRduplexSVM is a high-performing miRNA-duplex prediction and evaluation methodology. It's a method that combines a unique problem representation and an unbiased optimization protocol to learn from mirBase19.0 an accurate predictive model. It is the first model that provides precise information about all four ends of the miRNA duplex."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683"], "type": "summary", "id": "5895ee638707e6ea39000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "MiRduplexSVM: A High-Performing MiRNA-Duplex Prediction and Evaluation Methodology.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", "endSection": "title"}, {"offsetInBeginSection": 160, "offsetInEndSection": 426, "text": "Our method combines a unique problem representation and an unbiased optimization protocol to learn from mirBase19.0 an accurate predictive model, termed MiRduplexSVM. This is the first model that provides precise information about all four ends of the miRNA duplex. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", "endSection": "abstract"}, {"offsetInBeginSection": 1418, "offsetInEndSection": 1565, "text": "In relation with recent confidence evaluation methods used in miRBase, MiRduplexSVM was successful in identifying high confidence potential miRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", "endSection": "abstract"}, {"offsetInBeginSection": 159, "offsetInEndSection": 325, "text": "Our method combines a unique problem representation and an unbiased optimization protocol to learn from mirBase19.0 an accurate predictive model, termed MiRduplexSVM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", "endSection": "abstract"}, {"offsetInBeginSection": 685, "offsetInEndSection": 908, "text": "(b) In all comparisons, MiRduplexSVM shows superior performance, achieving up to a 60% increase in prediction accuracy for mammalian hairpins and can generalize very well on plant hairpins, without any special optimization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "MiRduplexSVM: A High-Performing MiRNA-Duplex Prediction and Evaluation Methodology.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", "endSection": "title"}, {"offsetInBeginSection": 1426, "offsetInEndSection": 1573, "text": "In relation with recent confidence evaluation methods used in miRBase, MiRduplexSVM was successful in identifying high confidence potential miRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", "endSection": "abstract"}, {"offsetInBeginSection": 160, "offsetInEndSection": 326, "text": "Our method combines a unique problem representation and an unbiased optimization protocol to learn from mirBase19.0 an accurate predictive model, termed MiRduplexSVM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", "endSection": "abstract"}, {"offsetInBeginSection": 689, "offsetInEndSection": 912, "text": "(b) In all comparisons, MiRduplexSVM shows superior performance, achieving up to a 60% increase in prediction accuracy for mammalian hairpins and can generalize very well on plant hairpins, without any special optimization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961860", "endSection": "abstract"}]}, {"body": "What genes are drug targets for Fibrodysplasia Ossificans Progressiva (FOP)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15940369", "http://www.ncbi.nlm.nih.gov/pubmed/22011642", "http://www.ncbi.nlm.nih.gov/pubmed/25136070", "http://www.ncbi.nlm.nih.gov/pubmed/17967130", "http://www.ncbi.nlm.nih.gov/pubmed/23646137", "http://www.ncbi.nlm.nih.gov/pubmed/26695699", "http://www.ncbi.nlm.nih.gov/pubmed/24047559", "http://www.ncbi.nlm.nih.gov/pubmed/11076054", "http://www.ncbi.nlm.nih.gov/pubmed/23599718", "http://www.ncbi.nlm.nih.gov/pubmed/15288357", "http://www.ncbi.nlm.nih.gov/pubmed/23229308", "http://www.ncbi.nlm.nih.gov/pubmed/19795179", "http://www.ncbi.nlm.nih.gov/pubmed/26621707", "http://www.ncbi.nlm.nih.gov/pubmed/19400542", "http://www.ncbi.nlm.nih.gov/pubmed/16080294", "http://www.ncbi.nlm.nih.gov/pubmed/25413979", "http://www.ncbi.nlm.nih.gov/pubmed/16753021", "http://www.ncbi.nlm.nih.gov/pubmed/18830232", "http://www.ncbi.nlm.nih.gov/pubmed/17477807", "http://www.ncbi.nlm.nih.gov/pubmed/18328989", "http://www.ncbi.nlm.nih.gov/pubmed/19929436", "http://www.ncbi.nlm.nih.gov/pubmed/22408438", "http://www.ncbi.nlm.nih.gov/pubmed/26058333", "http://www.ncbi.nlm.nih.gov/pubmed/22977237", "http://www.ncbi.nlm.nih.gov/pubmed/26896819", "http://www.ncbi.nlm.nih.gov/pubmed/9042799", "http://www.ncbi.nlm.nih.gov/pubmed/26626181", "http://www.ncbi.nlm.nih.gov/pubmed/16831905", "http://www.ncbi.nlm.nih.gov/pubmed/26333933", "http://www.ncbi.nlm.nih.gov/pubmed/11140409", "http://www.ncbi.nlm.nih.gov/pubmed/22408652"], "ideal_answer": [" Recently, FOP has been associated with a specific mutation of ACVR1, the gene coding for a bone morphogenetic protein type I receptor. ", "here, it is noted that if b cells are found to be the lymphocytes responsible for excess bmp-4 production in fop, use of rituximab, a monoclonal anti-cd20 antibody which effectively targets b cells, could be a less permanent and less risky treatment alternative for fop.", "Inhibitors of ALK2(ACVR1) are used for the treatment of FOP. Current therapies for FOP are Dorsomorphin analogues which function as BMP inhibitor.  if B cells control excess BMP-4 production in FOP, use of Rituximab, a monoclonal which targets B cells, could be a treatment alternative for FOP."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:13374", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055415", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052005"], "type": "list", "id": "589dee3778275d0c4a000050", "snippets": [{"offsetInBeginSection": 294, "offsetInEndSection": 430, "text": " Recently, FOP has been associated with a specific mutation of ACVR1, the gene coding for a bone morphogenetic protein type I receptor. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18830232", "endSection": "abstract"}, {"offsetInBeginSection": 148, "offsetInEndSection": 371, "text": "Small molecule inhibitors of the bone morphogenetic protein (BMP) receptor kinase ALK2 (ACVR1) are needed urgently to treat the progressively debilitating musculoskeletal disease fibrodysplasia ossificans progressiva (FOP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23646137", "endSection": "abstract"}, {"offsetInBeginSection": 372, "offsetInEndSection": 484, "text": "Dorsomorphin analogues, first identified in zebrafish, remain the only BMP inhibitor chemotype reported to date.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23646137", "endSection": "abstract"}, {"offsetInBeginSection": 485, "offsetInEndSection": 733, "text": "By screening an assay panel of 250 recombinant human kinases we identified a highly selective 2-aminopyridine-based inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concentrations similar to the current lead compound LDN-193189", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23646137", "endSection": "abstract"}, {"offsetInBeginSection": 780, "offsetInEndSection": 1050, "text": "Here, it is noted that if B cells are found to be the lymphocytes responsible for excess BMP-4 production in FOP, use of Rituximab, a monoclonal anti-CD20 antibody which effectively targets B cells, could be a less permanent and less risky treatment alternative for FOP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15288357", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 280, "text": "A new mutation of the Noggin gene in a French Fybrodysplasia ossificans progressiva (FOP) family: Fibrodysplasia ossificans progressiva (FOP) is a very rare disease characterized by congenital malformation of the great toes and progressive heterotopic ossification of the muscles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16080294", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Localization of the gene for fibrodysplasia ossificans progressiva (FOP) to chromosome 17q21-22.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11140409", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "A new mutation of the noggin gene in a French Fibrodysplasia ossificans progressiva (FOP) family.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16080294", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19795179", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 279, "text": "A new mutation of the Noggin gene in a French Fybrodysplasia ossificans progressiva (FOP) family: Fibrodysplasia ossificans progressiva (FOP) is a very rare disease characterized by congenital malformation of the great toes and progressive heterotopic ossification of the muscles", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16080294", "endSection": "abstract"}, {"offsetInBeginSection": 81, "offsetInEndSection": 368, "text": "Mutations in the ACVR1 gene are associated with Fibrodysplasia Ossificans Progressiva (FOP), a rare and extremely disabling disorder characterized by congenital malformation of the great toes and progressive heterotopic endochondral ossification in muscles and other non-skeletal tissues", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24047559", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Mutations of the noggin (NOG) and of the activin A type I receptor (ACVR1) genes in a series of twenty-seven French fibrodysplasia ossificans progressiva (FOP) patients", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19400542", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "ACVR1, a therapeutic target of fibrodysplasia ossificans progressiva, is negatively regulated by miR-148a.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22408438", "endSection": "title"}, {"offsetInBeginSection": 1037, "offsetInEndSection": 1140, "text": "These mutations represent new targets for therapeutic intervention in this otherwise incurable disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24705252", "endSection": "abstract"}, {"offsetInBeginSection": 894, "offsetInEndSection": 1041, "text": "In this study, we examined downstream signaling targets to study the BMP-Smad and BMP-p38 mitogen-activated protein kinase (MAPK) pathways in FOP. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16753021", "endSection": "abstract"}, {"offsetInBeginSection": 93, "offsetInEndSection": 382, "text": "Mutations in the ACVR1 gene are associated with Fibrodysplasia Ossificans Progressiva (FOP), a rare and extremely disabling disorder characterized by congenital malformation of the great toes and progressive heterotopic endochondral ossification in muscles and other non-skeletal tissues. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24047559", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Linkage exclusion and mutational analysis of the noggin gene in patients with fibrodysplasia ossificans progressiva (FOP).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11076054", "endSection": "title"}, {"offsetInBeginSection": 170, "offsetInEndSection": 375, "text": "Fibrodysplasia ossificans progressiva (FOP), a rare disorder characterized by progressive ossification of connective tissue, is caused by an activating mutation in Acvr1 (the gene that encodes ACVR1/ALK2).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25413979", "endSection": "abstract"}, {"offsetInBeginSection": 185, "offsetInEndSection": 488, "text": "This gene encodes the type I bone morphogenic protein receptor ALK2, with the residues affected identical to those that, when mutated in the germline, give rise to the congenital malformation syndrome fibrodysplasia ossificans progressiva (FOP), resulting in the transformation of soft tissue into bone.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25136070", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "ACVR1, a therapeutic target of fibrodysplasia ossificans progressiva, is negatively regulated by miR-148a.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22408438", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "A new mutation of the noggin gene in a French Fibrodysplasia ossificans progressiva (FOP) family.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16080294", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26621707", "endSection": "title"}, {"offsetInBeginSection": 276, "offsetInEndSection": 554, "text": "The discovery of the FOP gene establishes a crucial milestone in understanding FOP, reveals a highly conserved target in the BMP signaling pathway for drug development and specifically stimulates therapeutic approaches for the development of inhibitors for ACVR1/ALK2 signaling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23599718", "endSection": "abstract"}, {"offsetInBeginSection": 749, "offsetInEndSection": 1069, "text": "The discovery of the FOP gene establishes a critical milestone in understanding FOP, reveals a highly conserved druggable target in the TGF-beta/bone morphogenetic protein signaling pathway and compels therapeutic approaches for the development of small molecule signal transduction inhibitors for activin-like kinase-2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17477807", "endSection": "abstract"}]}, {"body": "What kind of analyses are performed with the software tool \"unipept\"", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26819472", "http://www.ncbi.nlm.nih.gov/pubmed/26058579", "http://www.ncbi.nlm.nih.gov/pubmed/27380722", "http://www.ncbi.nlm.nih.gov/pubmed/23153116", "http://www.ncbi.nlm.nih.gov/pubmed/25477242"], "ideal_answer": ["The Unipept web application (http://unipept.ugent.be) supports biodiversity analysis of large and complex metaproteome samples using tryptic peptide information obtained from shotgun MS/MS experiments. The application designed for metaproteomics analysis with a focus on interactive datavisualization."], "type": "summary", "id": "58bbbf3722d300530900001b", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 146, "text": "Unipept is an open source web application that is designed for metaproteomics analysis with a focus on interactive datavisualization. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26819472", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "The Unique Peptide Finder (http://unipept.ugent.be/peptidefinder) is an interactive web application to quickly hunt for tryptic peptides that are unique to a particular species, genus, or any other taxon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27380722", "endSection": "abstract"}, {"offsetInBeginSection": 928, "offsetInEndSection": 1164, "text": "Computations are extremely fast since they are underpinned by the Unipept database, the lowest common ancestor algorithm implemented in Unipept and modern web technologies that facilitate in-browser data storage and parallel processing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27380722", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Unipept (http://unipept.ugent.be) is a web application that offers a user-friendly way to explore the biodiversity of complex metaproteome samples by providing interactive visualizations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25477242", "endSection": "abstract"}, {"offsetInBeginSection": 1169, "offsetInEndSection": 1281, "text": "Outputted results are compatible with tools for taxonomic and functional characterization (e.g. Unipept, MEGAN5)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26058579", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "The Unipept web application (http://unipept.ugent.be) supports biodiversity analysis of large and complex metaproteome samples using tryptic peptide information obtained from shotgun MS/MS experiments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23153116", "endSection": "abstract"}]}, {"body": "What is the role of gamma-secreatase complex in Alzheimer's Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18320103", "http://www.ncbi.nlm.nih.gov/pubmed/26559975", "http://www.ncbi.nlm.nih.gov/pubmed/24900409", "http://www.ncbi.nlm.nih.gov/pubmed/17298085", "http://www.ncbi.nlm.nih.gov/pubmed/15766275", "http://www.ncbi.nlm.nih.gov/pubmed/19299585", "http://www.ncbi.nlm.nih.gov/pubmed/19958468", "http://www.ncbi.nlm.nih.gov/pubmed/20600609", "http://www.ncbi.nlm.nih.gov/pubmed/18063223", "http://www.ncbi.nlm.nih.gov/pubmed/23316412", "http://www.ncbi.nlm.nih.gov/pubmed/20035833", "http://www.ncbi.nlm.nih.gov/pubmed/18038124", "http://www.ncbi.nlm.nih.gov/pubmed/17560791", "http://www.ncbi.nlm.nih.gov/pubmed/16675392", "http://www.ncbi.nlm.nih.gov/pubmed/15992373", "http://www.ncbi.nlm.nih.gov/pubmed/19625750", "http://www.ncbi.nlm.nih.gov/pubmed/16804564", "http://www.ncbi.nlm.nih.gov/pubmed/23379308", "http://www.ncbi.nlm.nih.gov/pubmed/18393798", "http://www.ncbi.nlm.nih.gov/pubmed/20445084", "http://www.ncbi.nlm.nih.gov/pubmed/19376115", "http://www.ncbi.nlm.nih.gov/pubmed/19181896", "http://www.ncbi.nlm.nih.gov/pubmed/21487536", "http://www.ncbi.nlm.nih.gov/pubmed/20129170", "http://www.ncbi.nlm.nih.gov/pubmed/16944319"], "ideal_answer": ["The gamma-secretase complex has a decisive role in the development of Alzheimer's disease, as it cleaves a precursor protein to create the amyloid beta peptide whose aggregates form the senile plaques encountered in the brains of patients. Gamma-secretase is a member of the intramembrane-cleaving proteases which process their transmembrane substrates within the bilayer."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544", "http://www.disease-ontology.org/api/metadata/DOID:10652", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012380", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053829"], "type": "factoid", "id": "58a2c77a60087bc10a000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "gamma-Secretase is critically involved in the Notch pathway and in Alzheimer's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19958468", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 374, "text": "Presenilins are the catalytic subunit of the large gamma-secretase complex, that promotes intramembranous proteolysis of the beta-amyloid precursor protein (APP), resulting in the production of beta-amyloid (A beta). Mutant presenilin causes early-onset familial Alzheimer's disease (FAD), is related to abnormal Ca(2+) signaling, and render cells vulnerable to cell death. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20035833", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 406, "text": "Presenilins form the catalytic part of the gamma-secretases, protein complexes that are responsible for the intramembranous cleavage of transmembrane proteins. The presenilins are involved in several biological functions, but are best known for their role in the generation of the beta-amyloid (Abeta) peptide in Alzheimer's disease and are therefore thought to be important drug targets for this disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20129170", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "Amyloid-beta peptides (Abeta) generated by proteolysis of the beta-amyloid precursor protein (APP) by beta- and gamma-secretases play an important role in the pathogenesis of Alzheimer's disease (AD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20600609", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 369, "text": "The gamma-secretase complex has a decisive role in the development of Alzheimer's disease, in that it cleaves a precursor to create the amyloid beta peptide whose aggregates form the senile plaques encountered in the brains of patients. Gamma-secretase is a member of the intramembrane-cleaving proteases which process their transmembrane substrates within the bilayer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20445084", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The GxxxG motif in the transmembrane domain of AbetaPP plays an essential role in the interaction of CTF beta with the gamma-secretase complex and the formation of amyloid-beta.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19625750", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "Gamma-secretase-mediated processing of the amyloid-beta protein precursor (AbetaPP) is a crucial step in the formation of the amyloid-beta peptide (Abeta), but little is known about how the substrate AbetaPP interacts with the gamma-secretase complex. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19625750", "endSection": "abstract"}, {"offsetInBeginSection": 816, "offsetInEndSection": 977, "text": "Thus, the present study revealed an essential role for the GxxxG motif in the interaction of AbetaPP with the gamma-secretase complex and the formation of Abeta.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19625750", "endSection": "abstract"}, {"offsetInBeginSection": 1111, "offsetInEndSection": 1318, "text": "Taken together, our results suggest an important role of hypoxia in modulating the APP processing by facilitating both beta- and gamma-cleavage which may result in a significant increase of Abeta generation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18063223", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "The gamma-secretase, composed of presenilin-1 (PS1) or presenilin-2 (PS2), nicastrin (NCT), anterior pharynx-defective phenotype 1 (APH-1), and PEN-2, is critical for the development of Alzheimer's disease (AD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19376115", "endSection": "abstract"}, {"offsetInBeginSection": 177, "offsetInEndSection": 741, "text": "APP is a ubiquitous membrane protein that is physiologically processed by site-specific proteolysis firstly by alpha- or beta-secretases, releasing a large fragment called APP(S) that contains most of the extracellular sequences of APP, a small extracellular stub, the transmembrane region and the cytoplasmic tail of APP (;AICD'-APP intracellular domain). These are subsequently cleaved by gamma-secretase at multiple sites in the transmembrane region, releasing small peptides, Abeta(1-40) and Abeta(1-42), the major components of AD-associated amyloid fibrils. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19181896", "endSection": "abstract"}, {"offsetInBeginSection": 850, "offsetInEndSection": 1108, "text": "As PS1 has been shown to play a critical role in facilitating gamma-secretase activity, and mutations in this protein are associated with familial AD (FAD), we have cloned it from SAMP8 mouse hippocampus and compared its sequence with those of other species.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19181896", "endSection": "abstract"}, {"offsetInBeginSection": 1475, "offsetInEndSection": 1709, "text": "An increased amount or mutation(s) in PS1, which alters the stoichiometric balance of the gamma-secretase complex, may be the cause of aberrant or increased processing of APP, resulting in Abeta accumulation leading to loss of memory.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19181896", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "The gamma-secretase complex plays a role in Alzheimer's disease and cancer progression. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299585", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "The gamma-secretase complex plays a role in Alzheimer's disease and cancer progression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299585", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Suppressor Mutations for Presenilin 1 Familial Alzheimer Disease Mutants Modulate \u03b3-Secretase Activities", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559975", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Synthesis and SAR Studies of Fused Oxadiazines as \u03b3-Secretase Modulators for Treatment of Alzheimers Disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24900409", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Pathological activity of familial Alzheimer's disease-associated mutant presenilin can be executed by six different gamma-secretase complexes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17560791", "endSection": "title"}, {"offsetInBeginSection": 500, "offsetInEndSection": 851, "text": "The reconstituted enzyme processes C99 and the Notch-like substrate N160 and displays the characteristic features of gamma-secretase in terms of sensitivity to a gamma-secretase inhibitor, upregulation of Abeta42 production by a familial Alzheimer's disease (FAD) mutation in the APP gene, and downregulation of Notch processing by PS1 FAD mutations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15766275", "endSection": "abstract"}, {"offsetInBeginSection": 702, "offsetInEndSection": 923, "text": "The Aph1B complex contributes to total gamma-secretase activity in the human brain, and thus specific targeting of Aph1B-containing gamma-secretase complexes may help generate less toxic therapies for Alzheimer's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299585", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 295, "text": "Genetic analysis of familial Alzheimer's disease has revealed that mutations in the gamma-secretase enzyme presenilin promote toxic Abeta secretion; however, presenilin mutations might also influence tau hyperphosphorylation and neurodegeneration through gamma-secretase-independent mechanisms. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16675392", "endSection": "abstract"}, {"offsetInBeginSection": 517, "offsetInEndSection": 728, "text": "Here, we show that familial Alzheimer's disease mutations clustered near the sites of gamma-secretase cleavage actually decrease gamma-secretase-mediated release of the intracellular fragment of APP (CTFgamma). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15992373", "endSection": "abstract"}, {"offsetInBeginSection": 120, "offsetInEndSection": 350, "text": "Beside the well investigated role of presenilins as the catalytic unit in \u03b3-secretase complex, their involvement in regulation of intracellular calcium homeostasis has recently come into more focus of Alzheimer's disease research.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23379308", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "The \u03b3-secretase complex is a promising target in Alzheimer's disease because of its role in the amyloidogenic processing of \u03b2-amyloid precursor protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23316412", "endSection": "abstract"}, {"offsetInBeginSection": 344, "offsetInEndSection": 644, "text": "Genetic studies of early-onset familial Alzheimer's disease cases revealed causative mutations in the genes encoding \u03b2-amyloid precursor protein and the \u03b3-secretase-complex components presenilin-1 and presenilin-2, supporting an important role of \u03b2-amyloid in the pathogenesis of Alzheimer's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21487536", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18393798", "endSection": "title"}, {"offsetInBeginSection": 216, "offsetInEndSection": 352, "text": "Gamma-secretase was first recognized because of its role in the production of Abeta peptides that are pathogenic in Alzheimer's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16804564", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Regulation of gamma-secretase activity in Alzheimer's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17298085", "endSection": "title"}, {"offsetInBeginSection": 560, "offsetInEndSection": 835, "text": "Drugs that regulate the production of Abeta by inhibiting or modulating gamma-secretase activity could provide a disease-modifying effect on Alzheimer's disease, although recent studies suggest that gamma-secretase plays important roles in cellular signaling including Notch.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18038124", "endSection": "abstract"}, {"offsetInBeginSection": 702, "offsetInEndSection": 924, "text": "The Aph1B complex contributes to total gamma-secretase activity in the human brain, and thus specific targeting of Aph1B-containing gamma-secretase complexes may help generate less toxic therapies for Alzheimer's disease..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299585", "endSection": "abstract"}, {"offsetInBeginSection": 350, "offsetInEndSection": 458, "text": "The gamma-secretase complex is therefore believed to be critical in the pathogenesis of Alzheimer's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17298085", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299585", "endSection": "title"}]}, {"body": "Which syndromes are associated with heterochromia iridum?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25971175", "http://www.ncbi.nlm.nih.gov/pubmed/22174915", "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "http://www.ncbi.nlm.nih.gov/pubmed/6823113", "http://www.ncbi.nlm.nih.gov/pubmed/23840513", "http://www.ncbi.nlm.nih.gov/pubmed/21339912", "http://www.ncbi.nlm.nih.gov/pubmed/7702105", "http://www.ncbi.nlm.nih.gov/pubmed/20199465", "http://www.ncbi.nlm.nih.gov/pubmed/17878817", "http://www.ncbi.nlm.nih.gov/pubmed/1480396", "http://www.ncbi.nlm.nih.gov/pubmed/8092450", "http://www.ncbi.nlm.nih.gov/pubmed/8981698", "http://www.ncbi.nlm.nih.gov/pubmed/12825064", "http://www.ncbi.nlm.nih.gov/pubmed/14166458", "http://www.ncbi.nlm.nih.gov/pubmed/16814183", "http://www.ncbi.nlm.nih.gov/pubmed/16826074", "http://www.ncbi.nlm.nih.gov/pubmed/3792843"], "ideal_answer": ["The syndromes that are associated with heterochromia iridum are:\n1) Ascher's syndrome\n2) Waardenburg Syndrome type II (WS2)\n3) Horner's syndrome."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577"], "type": "list", "id": "58b52c8822d3005309000001", "snippets": [{"offsetInBeginSection": 532, "offsetInEndSection": 797, "text": "To our knowledge, this is the first reported case of Ascher's syndrome associated with iris coloboma, heterochromia iridum, and narrowing of horizontal palpebral fissure and decreased outer intercanthal distance secondary to lengthening of lateral canthal ligament.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971175", "endSection": "abstract"}, {"offsetInBeginSection": 604, "offsetInEndSection": 763, "text": " Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 280, "text": "Waardenburg Syndrome (WS) is an autosomal-dominant disorder characterized by sensorineural hearing loss and pigmentary abnormalities of the eyes, hair, and skin. Microphthalmia-associated transcription factor (MITF) gene mutations account for about 15% of WS type II (WS2) cases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "endSection": "abstract"}, {"offsetInBeginSection": 659, "offsetInEndSection": 815, "text": "The association of congenital Horner's syndrome and hypochromia iridum without anhidrosis is highly suggestive of sympathetic pathway injury early in life. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339912", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 246, "text": "The Waardenburg syndrome (WS) consists of at least two distinct autosomal dominant hereditary disorders. WS Type I has been mapped to the distal part of chromosome 2q and the gene identified as PAX3. Other gene(s) are responsible for WS Type II. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7702105", "endSection": "abstract"}, {"offsetInBeginSection": 574, "offsetInEndSection": 704, "text": "Sensorineural hearing loss (77%) and heterochromia iridum (47%) were the two most important diagnostic indicators for WS Type II. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7702105", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "WAARDENBURG'S SYNDROME AND HETEROCHROMIA IRIDUM IN A DEAF SCHOOL POPULATION.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "Waardenburg's syndrome consists of lateral displacement of the inner canthi of the eyes (dystopia canthorum), a broad nasal root and confluent eyebrows, heterochromia iridum, a white forelock and congenital deafness.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 793, "text": "To our knowledge, this is the first reported case of Ascher's syndrome associated with iris coloboma, heterochromia iridum, and narrowing of horizontal palpebral fissure and decreased outer intercanthal distance secondary to lengthening of lateral canthal ligament.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971175", "endSection": "abstract"}, {"offsetInBeginSection": 569, "offsetInEndSection": 698, "text": "Sensorineural hearing loss (77%) and heterochromia iridum (47%) were the two most important diagnostic indicators for WS Type II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7702105", "endSection": "abstract"}, {"offsetInBeginSection": 600, "offsetInEndSection": 757, "text": "Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 278, "text": "We present the genetic analyses conducted on a three-generation family (14 individuals) with three members affected with isolated-Hirschsprung disease (HSCR) and one with HSCR and heterochromia iridum (syndromic-HSCR), a phenotype reminiscent of Waardenburg-Shah syndrome (WS4).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23840513", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Heterochromia iridis and Horner's syndrome due to paravertebral neurilemmoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6823113", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "[Iris heterochromia in acquired Horner's syndrome].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17878817", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "BACKGROUND: Heterochromia iridis, asymmetry of iris pigmentation, has been well described with congenital Horner syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1480396", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "A case of heterochromia iridis and Horner's syndrome is reported in a 7-year old girl with paravertebral neurilemmoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6823113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 277, "text": "We present the genetic analyses conducted on a three-generation family (14 individuals) with three members affected with isolated-Hirschsprung disease (HSCR) and one with HSCR and heterochromia iridum (syndromic-HSCR), a phenotype reminiscent of Waardenburg-Shah syndrome (WS4)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23840513", "endSection": "abstract"}, {"offsetInBeginSection": 531, "offsetInEndSection": 794, "text": "To our knowledge, this is the first reported case of Aschers syndrome associated with iris coloboma, heterochromia iridum, and narrowing of horizontal palpebral fissure and decreased outer intercanthal distance secondary to lengthening of lateral canthal ligament", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971175", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "WAARDENBURGS SYNDROME AND HETEROCHROMIA IRIDUM IN A DEAF SCHOOL POPULATION", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Waardenburgs syndrome consists of lateral displacement of the inner canthi of the eyes (dystopia canthorum), a broad nasal root and confluent eyebrows, heterochromia iridum, a white forelock and congenital deafness", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", "endSection": "abstract"}, {"offsetInBeginSection": 605, "offsetInEndSection": 761, "text": "Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "endSection": "abstract"}, {"offsetInBeginSection": 605, "offsetInEndSection": 763, "text": "Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "A dominantly inherited syndrome associated with hypopigmentation, heterochromia irides, colobomatous eyes and bilateral hearing loss has been ascertained in Fleckvieh cattle (German White Fleckvieh syndrome). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22174915", "endSection": "abstract"}, {"offsetInBeginSection": 574, "offsetInEndSection": 703, "text": "Sensorineural hearing loss (77%) and heterochromia iridum (47%) were the two most important diagnostic indicators for WS Type II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7702105", "endSection": "abstract"}, {"offsetInBeginSection": 605, "offsetInEndSection": 762, "text": "Sensorineural hearing loss (17/20, 85.0%) and heterochromia iridum (20/20, 100.0%) were the most commonly observed clinical features in Chinese WS2 patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194866", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "WAARDENBURG'S SYNDROME AND HETEROCHROMIA IRIDUM IN A DEAF SCHOOL POPULATION.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14166458", "endSection": "title"}]}, {"body": "What is the target of tanezumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22004765", "http://www.ncbi.nlm.nih.gov/pubmed/18505735", "http://www.ncbi.nlm.nih.gov/pubmed/24452657", "http://www.ncbi.nlm.nih.gov/pubmed/27936977", "http://www.ncbi.nlm.nih.gov/pubmed/25326242", "http://www.ncbi.nlm.nih.gov/pubmed/21130822", "http://www.ncbi.nlm.nih.gov/pubmed/23628600", "http://www.ncbi.nlm.nih.gov/pubmed/21696889", "http://www.ncbi.nlm.nih.gov/pubmed/21420111", "http://www.ncbi.nlm.nih.gov/pubmed/24830649", "http://www.ncbi.nlm.nih.gov/pubmed/24809946", "http://www.ncbi.nlm.nih.gov/pubmed/27381034", "http://www.ncbi.nlm.nih.gov/pubmed/23707270", "http://www.ncbi.nlm.nih.gov/pubmed/24691709", "http://www.ncbi.nlm.nih.gov/pubmed/21802499", "http://www.ncbi.nlm.nih.gov/pubmed/25527221", "http://www.ncbi.nlm.nih.gov/pubmed/25073573", "http://www.ncbi.nlm.nih.gov/pubmed/20942668", "http://www.ncbi.nlm.nih.gov/pubmed/23852695", "http://www.ncbi.nlm.nih.gov/pubmed/23010344", "http://www.ncbi.nlm.nih.gov/pubmed/26962464", "http://www.ncbi.nlm.nih.gov/pubmed/26940379", "http://www.ncbi.nlm.nih.gov/pubmed/25594611", "http://www.ncbi.nlm.nih.gov/pubmed/23028238", "http://www.ncbi.nlm.nih.gov/pubmed/20140821"], "ideal_answer": ["Tanezumab is a humanized monoclonal antibody against nerve growth factor."], "type": "factoid", "id": "5890e163621ea6ff7e000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27381034", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "OBJECTIVE: To investigate whether the effects of nerve growth factor (NGF) inhibition with tanezumab on rats with medial meniscal tear (MMT) effectively model rapidly progressive osteoarthritis (RPOA) observed in clinical trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27381034", "endSection": "abstract"}, {"offsetInBeginSection": 559, "offsetInEndSection": 847, "text": " Current research focuses on the development of new OA drugs (such as sprifermin/recombinant human fibroblast growth factor-18, tanezumab/monoclonal antibody against \u03b2-nerve growth factor), which aims for more effectiveness and less incidence of adverse effects than the traditional ones.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962464", "endSection": "abstract"}, {"offsetInBeginSection": 549, "offsetInEndSection": 775, "text": "Areas covered: This manuscript is a review that examines both the pharmacological properties and clinical studies of tanezumab, the most widely studied antibody to NGF, for management of osteoarthritis (OA) and low back pain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27936977", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "OBJECTIVE: Evaluate efficacy and safety of tanezumab, a humanized monoclonal antibody against nerve growth factor, in neuropathic pain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25594611", "endSection": "abstract"}, {"offsetInBeginSection": 696, "offsetInEndSection": 852, "text": "In preclinical studies, tanezumab, and its murine precursor muMab-911, effectively targeted the NGF pathway in various chronic and inflammatory pain models.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", "endSection": "abstract"}, {"offsetInBeginSection": 514, "offsetInEndSection": 696, "text": "Tanezumab (RN-624), a first-in-class recombinant humanized mAb targeting NGF, is being developed by Pfizer Inc for the potential treatment of pain associated with several conditions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", "endSection": "abstract"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1343, "text": "Given that tanezumab is an antibody, the drug demonstrates the general advantages of this class of products (including good specificity and favorable pharmacokinetics), and also appears to be particularly well suited for targeting the chronic and inflammatory-mediating pain actions of NGF and its receptor system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 323, "text": "In this randomized, double-blind, placebo controlled phase 2 study we investigated tanezumab, a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for interstitial cystitis pain.Patients with interstitial cystitis received a single intravenous dose of 200 \u03bcg/kg tanezumab or placebo", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21420111", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25073573", "endSection": "title"}, {"offsetInBeginSection": 700, "offsetInEndSection": 856, "text": "In preclinical studies, tanezumab, and its murine precursor muMab-911, effectively targeted the NGF pathway in various chronic and inflammatory pain models.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", "endSection": "abstract"}, {"offsetInBeginSection": 517, "offsetInEndSection": 699, "text": "Tanezumab (RN-624), a first-in-class recombinant humanized mAb targeting NGF, is being developed by Pfizer Inc for the potential treatment of pain associated with several conditions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", "endSection": "abstract"}, {"offsetInBeginSection": 1035, "offsetInEndSection": 1350, "text": "Given that tanezumab is an antibody, the drug demonstrates the general advantages of this class of products (including good specificity and favorable pharmacokinetics), and also appears to be particularly well suited for targeting the chronic and inflammatory-mediating pain actions of NGF and its receptor system..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", "endSection": "abstract"}]}, {"body": "Could plasmepsins be used as targets for developing anti-malaria drugs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12767832", "http://www.ncbi.nlm.nih.gov/pubmed/25827401", "http://www.ncbi.nlm.nih.gov/pubmed/21334328", "http://www.ncbi.nlm.nih.gov/pubmed/26214367", "http://www.ncbi.nlm.nih.gov/pubmed/18442137", "http://www.ncbi.nlm.nih.gov/pubmed/17727268", "http://www.ncbi.nlm.nih.gov/pubmed/16838300", "http://www.ncbi.nlm.nih.gov/pubmed/15181345", "http://www.ncbi.nlm.nih.gov/pubmed/19472268", "http://www.ncbi.nlm.nih.gov/pubmed/21136953", "http://www.ncbi.nlm.nih.gov/pubmed/14636976", "http://www.ncbi.nlm.nih.gov/pubmed/8816746", "http://www.ncbi.nlm.nih.gov/pubmed/11841219", "http://www.ncbi.nlm.nih.gov/pubmed/24975562", "http://www.ncbi.nlm.nih.gov/pubmed/23466235", "http://www.ncbi.nlm.nih.gov/pubmed/16054370", "http://www.ncbi.nlm.nih.gov/pubmed/12435452", "http://www.ncbi.nlm.nih.gov/pubmed/16138859", "http://www.ncbi.nlm.nih.gov/pubmed/25719272", "http://www.ncbi.nlm.nih.gov/pubmed/22242846", "http://www.ncbi.nlm.nih.gov/pubmed/21382523", "http://www.ncbi.nlm.nih.gov/pubmed/27718413", "http://www.ncbi.nlm.nih.gov/pubmed/24468190", "http://www.ncbi.nlm.nih.gov/pubmed/26566224", "http://www.ncbi.nlm.nih.gov/pubmed/19437467", "http://www.ncbi.nlm.nih.gov/pubmed/9561244", "http://www.ncbi.nlm.nih.gov/pubmed/21760810", "http://www.ncbi.nlm.nih.gov/pubmed/17585371", "http://www.ncbi.nlm.nih.gov/pubmed/24983235", "http://www.ncbi.nlm.nih.gov/pubmed/20056606", "http://www.ncbi.nlm.nih.gov/pubmed/21428877", "http://www.ncbi.nlm.nih.gov/pubmed/15011947"], "ideal_answer": ["Yes, plasmepsins, which are essential Plasmodium proteases, could be highly promising anti-malarial drug targets."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000962", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015195", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016780", "http://www.disease-ontology.org/api/metadata/DOID:12365", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008288"], "type": "yesno", "id": "58a6d89660087bc10a00002b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Fighting malaria: structure-guided discovery of nonpeptidomimetic plasmepsin inhibitors.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25719272", "endSection": "title"}, {"offsetInBeginSection": 116, "offsetInEndSection": 274, "text": "Given that the parasite needs the resulting amino acid building blocks for its growth and development, plasmepsins are an important antimalarial drug target. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25719272", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 1056, "text": "Due to early crystallographic evidence, plasmepsin II (Plm II) emerged as well explored target to develop novel antimalarials as well as a starting point to develop inhibitors targeting some other subtypes of plasmepsins i.e. Plm I, II, IV and V. With the advancements in drug discovery, several computational and synthetic approaches were employed in order to develop novel inhibitors targeting Plm II. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214367", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 295, "text": "Plasmepsin V, an essential aspartyl protease of malaria parasites, has a key role in the export of effector proteins to parasite-infected erythrocytes. Consequently, it is an important drug target for the two most virulent malaria parasites of humans, Plasmodium falciparum and Plasmodium vivax.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214367", "endSection": "abstract"}, {"offsetInBeginSection": 219, "offsetInEndSection": 388, "text": "Plasmepsin V (PmV) is an essential Plasmodium protease and a highly promising antimalarial target, which still lacks molecular characterization and drug-like inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566224", "endSection": "abstract"}, {"offsetInBeginSection": 1375, "offsetInEndSection": 1503, "text": "Our inhibitors act 'on-target', confirmed by cellular interference of PmV function and biochemical interaction with inhibitors. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566224", "endSection": "abstract"}, {"offsetInBeginSection": 1826, "offsetInEndSection": 2191, "text": "Our work disclosed novel pursuable drug design strategies for highly efficient PmV inhibition highlighting novel molecular elements necessary for picomolar activity against PmV. All the presented data are discussed in respect to human aspartic proteases and previously reported inhibitors, highlighting differences and proposing new strategies for drug development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566224", "endSection": "abstract"}, {"offsetInBeginSection": 362, "offsetInEndSection": 458, "text": "High binding likeness on antimalarial target plasmepsin was detected through molecular docking. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24975562", "endSection": "abstract"}, {"offsetInBeginSection": 1097, "offsetInEndSection": 1303, "text": "This provides the first direct evidence that PMV activity is essential for protein export in Plasmodium spp. and for parasite survival in human erythrocytes and validates PMV as an antimalarial drug target.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983235", "endSection": "abstract"}, {"offsetInBeginSection": 169, "offsetInEndSection": 310, "text": "The export mechanism involves the Plasmodium export element (PEXEL), which is a cleavage site for the parasite protease, Plasmepsin V (PMV). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983235", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Plasmepsin II (PM II) is an attractive target for anti-malaria drug discovery, which involves in host hemoglobin degradation in the acidic food vacuole.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466235", "endSection": "abstract"}, {"offsetInBeginSection": 202, "offsetInEndSection": 480, "text": "These methods are utilized to search for inhibitors of the aspartyl proteases, plasmepsin II and cathepsin D. Plasmepsin II, a protease found in the malaria parasite, hydrolyzes human hemoglobin, the nutrient source for the parasite and is a new target for anti-malaria therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9561244", "endSection": "abstract"}, {"offsetInBeginSection": 836, "offsetInEndSection": 1040, "text": "Given recent advances in understanding the fundamental roles of the various plasmepsins, it is likely that the most effective antimalarial plasmepsin targets will be the non-digestive vacuole plasmepsins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242846", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Plasmepsins (PMs) are essential proteases of the plasmodia parasites and are therefore promising targets for developing drugs against malaria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19472268", "endSection": "abstract"}, {"offsetInBeginSection": 165, "offsetInEndSection": 274, "text": "Therefore, the plasmepsins of malaria parasites have been recognized as attractive antimalarial drug targets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21334328", "endSection": "abstract"}, {"offsetInBeginSection": 85, "offsetInEndSection": 201, "text": "As inhibition of plasmepsins leads to the parasite's death, these enzymes can be utilized as potential drug targets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16138859", "endSection": "abstract"}, {"offsetInBeginSection": 377, "offsetInEndSection": 515, "text": "falciparum plasmepsins II and IV make structure-based drug design of antimalarial compounds that focus on inhibiting plasmepsins possible.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18442137", "endSection": "abstract"}, {"offsetInBeginSection": 250, "offsetInEndSection": 462, "text": "The malarial parasite encodes two homologous aspartic proteases, plasmepsins I and II, which are essential components of its hemoglobin-degradation pathway and are novel targets for antimalarial drug development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8816746", "endSection": "abstract"}, {"offsetInBeginSection": 1906, "offsetInEndSection": 2052, "text": "vivax plasmepsins (PvPMs) from different geographical regions are of utmost importance for drugs and vaccine designs for anti-malarial strategies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382523", "endSection": "abstract"}, {"offsetInBeginSection": 155, "offsetInEndSection": 345, "text": "In P.falciparum, plasmepsins I, II, IV and HAP have been directly implicated in hemoglobin degradation during malaria infection, and are now considered targets for anti-malarial drug design.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12767832", "endSection": "abstract"}, {"offsetInBeginSection": 1531, "offsetInEndSection": 1743, "text": "These results shed light on the role of V105 and T108 residues in plasmepsin specificities, and they should be useful in structure-based design of novel, selective inhibitors that may serve as antimalarial drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18442137", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 245, "text": "The aspartic proteases plasmepsins, whose inhibition leads to parasite death, are classified as targets for the design of potent drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21760810", "endSection": "abstract"}, {"offsetInBeginSection": 818, "offsetInEndSection": 994, "text": "A large compound library of about 1 million chemical compounds was docked on 5 different targets of plasmepsins using two different docking software, namely FlexX and AutoDock.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17727268", "endSection": "abstract"}, {"offsetInBeginSection": 114, "offsetInEndSection": 281, "text": "Plasmodium aspartic proteases known as plasmepsins play an important role on haemoglobin degradation and are being studied as drug targets for chemotherapy of malaria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636976", "endSection": "abstract"}, {"offsetInBeginSection": 615, "offsetInEndSection": 815, "text": "Our study revealed about 100 parasite-coded gene products that included many known drug targets such as Pf hypoxanthine guanine phosphoribosyl transferase, Pf L-lactate dehydrogenase, and Plasmepsins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21136953", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 295, "text": "The two aspartic proteases, plasmepsins I and II, from Plasmodium falciparum have recently emerged as potential targets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16054370", "endSection": "abstract"}, {"offsetInBeginSection": 146, "offsetInEndSection": 303, "text": "Plasmepsins are highly promising as drug targets, especially when combined with the inhibition of falcipains that are also involved in hemoglobin catabolism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17585371", "endSection": "abstract"}, {"offsetInBeginSection": 984, "offsetInEndSection": 1133, "text": "Among such enzymes, Plasmepsins (aspartic proteases) and, especially, Falcipains (cysteine proteases) are highly promising antimalarial drug targets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21428877", "endSection": "abstract"}, {"offsetInBeginSection": 703, "offsetInEndSection": 878, "text": "The high sequence conservations between the plasmepsins from the isolates support the notion that the enzymes could be reliable targets for new antimalarial chemotherapeutics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15181345", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 877, "text": "Due to early crystallographic evidence, plasmepsin II (Plm II) emerged as well explored target to develop novel antimalarials as well as a starting point to develop inhibitors targeting some other subtypes of plasmepsins i.e.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401", "endSection": "abstract"}, {"offsetInBeginSection": 469, "offsetInEndSection": 651, "text": "Plasmepsin, an aspartic protease, which is involved in the hemoglobin breakdown into smaller peptides emerged as a crucial target to develop new chemical entities to counter malaria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401", "endSection": "abstract"}, {"offsetInBeginSection": 1160, "offsetInEndSection": 1233, "text": "were employed in order to develop new chemical entities targeting Plm II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401", "endSection": "abstract"}, {"offsetInBeginSection": 899, "offsetInEndSection": 1055, "text": "With the advancements in drug discovery, several computational and synthetic approaches were employed in order to develop novel inhibitors targeting Plm II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401", "endSection": "abstract"}, {"offsetInBeginSection": 1906, "offsetInEndSection": 2053, "text": "vivax plasmepsins (PvPMs) from different geographical regions are of utmost importance for drugs and vaccine designs for anti-malarial strategies..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382523", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 422, "text": "We developed a potent inhibitor of plasmepsin V, called WEHI-842, which directly mimics the Plasmodium export element (PEXEL).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214367", "endSection": "abstract"}, {"offsetInBeginSection": 1768, "offsetInEndSection": 1905, "text": "In order to validate appropriate use of PM4 as potential anti-malarial drug target, studies on genetic and structural variations among P.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382523", "endSection": "abstract"}, {"offsetInBeginSection": 482, "offsetInEndSection": 642, "text": "Over the past decade, much effort has been placed towards developing plasmepsin inhibitors as antimalarial agents, particularly targeting the digestive vacuole.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242846", "endSection": "abstract"}]}, {"body": "What is MRSA?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18347206", "http://www.ncbi.nlm.nih.gov/pubmed/8851953", "http://www.ncbi.nlm.nih.gov/pubmed/26684366", "http://www.ncbi.nlm.nih.gov/pubmed/22291965", "http://www.ncbi.nlm.nih.gov/pubmed/15472807", "http://www.ncbi.nlm.nih.gov/pubmed/24267132", "http://www.ncbi.nlm.nih.gov/pubmed/27025639", "http://www.ncbi.nlm.nih.gov/pubmed/17581935", "http://www.ncbi.nlm.nih.gov/pubmed/15884297", "http://www.ncbi.nlm.nih.gov/pubmed/27721155", "http://www.ncbi.nlm.nih.gov/pubmed/27112442", "http://www.ncbi.nlm.nih.gov/pubmed/19130105", "http://www.ncbi.nlm.nih.gov/pubmed/19777772", "http://www.ncbi.nlm.nih.gov/pubmed/21075466", "http://www.ncbi.nlm.nih.gov/pubmed/19732087", "http://www.ncbi.nlm.nih.gov/pubmed/19162372", "http://www.ncbi.nlm.nih.gov/pubmed/27736763", "http://www.ncbi.nlm.nih.gov/pubmed/12723397", "http://www.ncbi.nlm.nih.gov/pubmed/21571749", "http://www.ncbi.nlm.nih.gov/pubmed/19252301", "http://www.ncbi.nlm.nih.gov/pubmed/23756924", "http://www.ncbi.nlm.nih.gov/pubmed/23824338", "http://www.ncbi.nlm.nih.gov/pubmed/24322533", "http://www.ncbi.nlm.nih.gov/pubmed/22814471", "http://www.ncbi.nlm.nih.gov/pubmed/19129414", "http://www.ncbi.nlm.nih.gov/pubmed/20071545", "http://www.ncbi.nlm.nih.gov/pubmed/26047024", "http://www.ncbi.nlm.nih.gov/pubmed/25108628", "http://www.ncbi.nlm.nih.gov/pubmed/26812054", "http://www.ncbi.nlm.nih.gov/pubmed/22176801", "http://www.ncbi.nlm.nih.gov/pubmed/27450316", "http://www.ncbi.nlm.nih.gov/pubmed/23405883", "http://www.ncbi.nlm.nih.gov/pubmed/19828738", "http://www.ncbi.nlm.nih.gov/pubmed/25865979", "http://www.ncbi.nlm.nih.gov/pubmed/20861339", "http://www.ncbi.nlm.nih.gov/pubmed/19710260", "http://www.ncbi.nlm.nih.gov/pubmed/25113379", "http://www.ncbi.nlm.nih.gov/pubmed/24850346", "http://www.ncbi.nlm.nih.gov/pubmed/17385151", "http://www.ncbi.nlm.nih.gov/pubmed/24045390", "http://www.ncbi.nlm.nih.gov/pubmed/19506056", "http://www.ncbi.nlm.nih.gov/pubmed/15060266", "http://www.ncbi.nlm.nih.gov/pubmed/20524852", "http://www.ncbi.nlm.nih.gov/pubmed/20071548", "http://www.ncbi.nlm.nih.gov/pubmed/17537949"], "ideal_answer": ["community-associated methicillin resistant staphylococcus aureus (ca-mrsa) has become a severe health concern because of its treatment difficulties.", "Methicillin resistant Staphylococcus aureus (MRSA) has become a severe health concern because of its treatment difficulties.", "(MRSA, methicillin-resistant S. aureus)"], "type": "factoid", "id": "58a32efe60087bc10a000013", "snippets": [{"offsetInBeginSection": 137, "offsetInEndSection": 176, "text": "(MRSA, methicillin-resistant S. aureus)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27736763", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) has become a severe health concern because of its treatment difficulties.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27721155", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "We investigated the distribution of MRSA (methicillin-resistant Staphylococcus aureus) on and around six patients with MRSA infection in our neurosurgical ward.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8851953", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "The aim of this study was to assess to what extent patients with meticillin-resistant Staphylococcus aureus (MRSA) at respiratory sites shed viable MRSA into the air of hospital rooms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19162372", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is increasing in prevalence among asymptomatic carriers and in cases of paediatric soft-tissue infections alike.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24322533", "endSection": "abstract"}, {"offsetInBeginSection": 665, "offsetInEndSection": 875, "text": "Most of MRSA strains and a part of methicillin-susceptible S. aureus (MSSA) strains harbored unique combinations of non-\u00df-lactamase genes aac(6)/aph(2\u2033), aph(3)-III, ant (4,4\u2033), ermA, ermC, mrsA, tetM, and tetK", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23405883", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Healthcare- and Community-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) and Fatal Pneumonia with Pediatric Deaths in Krasnoyarsk, Siberian Russia: Unique MRSAs Multiple Virulence Factors, Genome, and Stepwise Evolution", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26047024", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 309, "text": "It was found in the present study that combined use of fusidic acid (FA) and berberine chloride (BBR) offered an in vitro synergistic action against 7 of the 30 clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, with a fractional inhibitory concentration (FIC) index ranging from 0.5 to 0.19", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108628", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25865979", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "To assess whether vancomycin minimum inhibitory concentration (MIC) creeps among clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in a regional hospital in China", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25865979", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 261, "text": "Detection of methicillin-resistant Staphylococcus aureus (MRSA) in specimens from various body sites: performance characteristics of the BD GeneOhm MRSA assay, the Xpert MRSA assay, and broth-enriched culture in an area with a low prevalence of MRSA infections.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20861339", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Rapid detection of Methicillin-Resistant Staphylococcus aureus MRSA in nose, groin, and axilla swabs by the BD GeneOhm MRSA achromopeptidase assay and comparison with culture.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23756924", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "Methicillin-resistant Staphylococcus aureus (MRSA) detection: comparison of two molecular methods (IDI-MRSA PCR assay and GenoType MRSA Direct PCR assay) with three selective MRSA agars (MRSA ID, MRSASelect, and CHROMagar MRSA) for use with infection-control swabs.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17537949", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Comparison of the Xpert methicillin-resistant Staphylococcus aureus (MRSA) assay, BD GeneOhm MRSA assay, and culture for detection of nasal and cutaneous groin colonization by MRSA.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19710260", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "Comparison of the BD Max methicillin-resistant Staphylococcus aureus (MRSA) assay and the BD GeneOhm MRSA achromopeptidase assay with direct- and enriched-culture techniques using clinical specimens for detection of MRSA.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22814471", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "Comparison of MRSASelect Agar, CHROMagar Methicillin-Resistant Staphylococcus aureus (MRSA) Medium, and Xpert MRSA PCR for detection of MRSA in Nares: diagnostic accuracy for surveillance samples with various bacterial densities.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19828738", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) in diverse clinical specimens by the BD GeneOhm MRSA assay and comparison with culture.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20071545", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Multicenter evaluation of the Cepheid Xpert methicillin-resistant Staphylococcus aureus (MRSA) test as a rapid screening method for detection of MRSA in nares.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19129414", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19506056", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "Long-term control of endemic hospital-wide methicillin-resistant Staphylococcus aureus (MRSA): the impact of targeted active surveillance for MRSA in patients and healthcare workers.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20524852", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a major challenge in health care, yet the limited heterogeneity within this group hinders molecular investigations of related outbreaks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24850346", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 380, "text": "In a previous study, we reported that two kaempferol glycosides isolated from Laurus nobilis L., kaempferol-3-O-alpha-L-(2'',4''-di-E-p-coumaroyl)-rhamnoside (C2) and kaempferol-3-O-alpha-L-(2''-E-p-coumaroyl-4''-Z-p-coumaroyl)-rhamnoside (C3), showed strong antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19252301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "This article explains what methicillin-resistant Staphylococcus aureus (MRSA) is, how it is spread and what the real challenges are in healthcare settings in the UK.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15884297", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging threat to public health, especially in correctional settings.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21571749", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 328, "text": "There are few more compelling questions in clinical microbiology today than the issue of whether or not to screen for the presence of methicillin-resistant Staphylococcus aureus (MRSA), with the results being used to institute infection control interventions aimed at preventing transmission of MRSA in health care environments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20071548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 266, "text": "Methicillin-resistant Staphylococcus aureus (MRSA) detection: comparison of two molecular methods (IDI-MRSA PCR assay and GenoType MRSA Direct PCR assay) with three selective MRSA agars (MRSA ID, MRSASelect, and CHROMagar MRSA) for use with infection-control swabs.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17537949", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Do methicillin resistant staphylococcus (MRSA) carrier patients influence MRSA infection more than MRSA-carrier medical officers and MRSA-carrier family?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045390", "endSection": "title"}, {"offsetInBeginSection": 126, "offsetInEndSection": 176, "text": "methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19732087", "endSection": "abstract"}, {"offsetInBeginSection": 88, "offsetInEndSection": 142, "text": " methicillin-resistant Staphylococcus aureus (CA-MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15060266", "endSection": "abstract"}, {"offsetInBeginSection": 45, "offsetInEndSection": 96, "text": "methicillin-resistant Staphylococcus aureus (MRSA) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19130105", "endSection": "abstract"}, {"offsetInBeginSection": 23, "offsetInEndSection": 84, "text": "methicillin-resistant Staphylococcus aureus (MRSA) infections", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23824338", "endSection": "abstract"}, {"offsetInBeginSection": 29, "offsetInEndSection": 86, "text": "methicillin resistant Staphylococcus aureus (MRSA CC398) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21075466", "endSection": "abstract"}, {"offsetInBeginSection": 138, "offsetInEndSection": 190, "text": " (methicillin-resistant Staphylococcus aureus) MRSA ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25113379", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 62, "text": "Methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27450316", "endSection": "abstract"}, {"offsetInBeginSection": 349, "offsetInEndSection": 399, "text": "methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26812054", "endSection": "abstract"}, {"offsetInBeginSection": 72, "offsetInEndSection": 122, "text": "methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17385151", "endSection": "abstract"}, {"offsetInBeginSection": 66, "offsetInEndSection": 116, "text": "methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24267132", "endSection": "abstract"}, {"offsetInBeginSection": 54, "offsetInEndSection": 105, "text": "methicillin-resistant Staphylococcus aureus (MRSA) ", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17581935", "endSection": "title"}, {"offsetInBeginSection": 60, "offsetInEndSection": 110, "text": "methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18347206", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 43, "text": "Methicillin-resistant Staphylococcus aureus", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22176801", "endSection": "title"}, {"offsetInBeginSection": 65, "offsetInEndSection": 116, "text": " methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648247", "endSection": "abstract"}, {"offsetInBeginSection": 33, "offsetInEndSection": 86, "text": "methicillin-resistant Staphylococcus aureus-(CA-MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22291965", "endSection": "abstract"}, {"offsetInBeginSection": 396, "offsetInEndSection": 446, "text": "methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777772", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25240872", "endSection": "abstract"}, {"offsetInBeginSection": 84, "offsetInEndSection": 134, "text": "methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12723397", "endSection": "title"}, {"offsetInBeginSection": 45, "offsetInEndSection": 95, "text": "methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26684366", "endSection": "title"}, {"offsetInBeginSection": 73, "offsetInEndSection": 123, "text": "methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26684366", "endSection": "abstract"}, {"offsetInBeginSection": 58, "offsetInEndSection": 111, "text": "methicillin-resistant Staphylococcus aureus (HA-MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27025639", "endSection": "abstract"}, {"offsetInBeginSection": 43, "offsetInEndSection": 94, "text": "methicillin-resistant Staphylococcus aureus (MRSA) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15472807", "endSection": "abstract"}, {"offsetInBeginSection": 229, "offsetInEndSection": 280, "text": "methicillin-resistant Staphylococcus aureus (MRSA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17121622", "endSection": "abstract"}, {"offsetInBeginSection": 52, "offsetInEndSection": 102, "text": "methicillin-resistant Staphylococcus aureus (MRSA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27112442", "endSection": "abstract"}]}, {"body": "List peptide fragmentations methods in mass spectrometry", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26780731", "http://www.ncbi.nlm.nih.gov/pubmed/27613306", "http://www.ncbi.nlm.nih.gov/pubmed/27914015", "http://www.ncbi.nlm.nih.gov/pubmed/27139140", "http://www.ncbi.nlm.nih.gov/pubmed/27098412", "http://www.ncbi.nlm.nih.gov/pubmed/27520322"], "ideal_answer": ["CID, HCD, ECD, ETD and PSD are different peptide fragmentation technologies used in mass spectrometry."], "type": "list", "id": "58a8071760087bc10a000037", "snippets": [{"offsetInBeginSection": 585, "offsetInEndSection": 632, "text": " using the CID and HCD fragmentation techniques", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26780731", "endSection": "abstract"}, {"offsetInBeginSection": 947, "offsetInEndSection": 982, "text": "By integrating HCD-MS/MS, CID-MS/MS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27139140", "endSection": "abstract"}, {"offsetInBeginSection": 787, "offsetInEndSection": 840, "text": "ECD and ETD induced different fragmentation processes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27098412", "endSection": "abstract"}, {"offsetInBeginSection": 118, "offsetInEndSection": 496, "text": "MALDI post-source decay (PSD), MALDI 157 nm photodissociation, tris(2,4,6-trimethoxyphenyl)phosphonium bromide (TMPP) charge tagging in PSD and photodissociation, ESI collision-induced dissociation (CID), electron transfer dissociation (ETD), and free-radical initiated peptide sequencing (FRIPS) with CID were applied to peptides containing either aspartic or isoaspartic acid.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27613306", "endSection": "abstract"}, {"offsetInBeginSection": 650, "offsetInEndSection": 705, "text": "automated analysis of HCD and ETD fragmentation spectra", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27520322", "endSection": "abstract"}, {"offsetInBeginSection": 1064, "offsetInEndSection": 1147, "text": "The combination of DIA analysis and ETD fragmentation with supplemental CID energy ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914015", "endSection": "abstract"}]}, {"body": "Is avanafil indicated for treatment of erectile dysfunction?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23321580", "http://www.ncbi.nlm.nih.gov/pubmed/27121186", "http://www.ncbi.nlm.nih.gov/pubmed/25591992", "http://www.ncbi.nlm.nih.gov/pubmed/25684196", "http://www.ncbi.nlm.nih.gov/pubmed/22704456", "http://www.ncbi.nlm.nih.gov/pubmed/22248153", "http://www.ncbi.nlm.nih.gov/pubmed/23955441", "http://www.ncbi.nlm.nih.gov/pubmed/22448738", "http://www.ncbi.nlm.nih.gov/pubmed/22857780", "http://www.ncbi.nlm.nih.gov/pubmed/23521325", "http://www.ncbi.nlm.nih.gov/pubmed/23219537", "http://www.ncbi.nlm.nih.gov/pubmed/22788525", "http://www.ncbi.nlm.nih.gov/pubmed/25455484", "http://www.ncbi.nlm.nih.gov/pubmed/24589460", "http://www.ncbi.nlm.nih.gov/pubmed/26784833", "http://www.ncbi.nlm.nih.gov/pubmed/22759639", "http://www.ncbi.nlm.nih.gov/pubmed/27377089", "http://www.ncbi.nlm.nih.gov/pubmed/25801159", "http://www.ncbi.nlm.nih.gov/pubmed/25582903", "http://www.ncbi.nlm.nih.gov/pubmed/24259695", "http://www.ncbi.nlm.nih.gov/pubmed/24331245", "http://www.ncbi.nlm.nih.gov/pubmed/26316720", "http://www.ncbi.nlm.nih.gov/pubmed/24701971", "http://www.ncbi.nlm.nih.gov/pubmed/23590161"], "ideal_answer": ["Yes, avanafil is indicated for treatment of erectile dysfunction."], "concepts": ["http://www.biosemantics.org/jochem#4243720", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007172"], "type": "yesno", "id": "5895d0457d9090f35300000d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "CONTEXT: Avanafil (AVA) is used in the treatment of erectile dysfunction, but is reported for its poor aqueous solubility. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26784833", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "BACKGROUND: Phosphodiesterase 5 inhibitors (PDE5-Is) sildenafil, vardenafil, tadalafil and the recently approved avanafil represent the first-line choice for both on-demand and chronic treatment of erectile dysfunction (ED). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121186", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377089", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25591992", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "PURPOSE: We examined the therapeutic effects of avanafil 15 minutes after dosing in men with mild to severe erectile dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25591992", "endSection": "abstract"}, {"offsetInBeginSection": 307, "offsetInEndSection": 440, "text": "Sildenafil, vardenafil, tadalafil and avanafil are FDA approved drugs in market as PDE5 inhibitors for treating erectile dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25801159", "endSection": "abstract"}, {"offsetInBeginSection": 1428, "offsetInEndSection": 1711, "text": "CONCLUSION: Avanafil along with the other PDE5Is has shown to be a safe and effective oral treatment for ED, with avanafil's possible place in therapy for patients who want an on-demand option or as an alternative in patients who experience visual disturbances with the other agents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26316720", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Avanafil (STENDRA\u2122, SPEDRA\u2122, Zepeeed\u2122) is an oral phosphodiesterase type 5 inhibitor indicated for the treatment of erectile dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441", "endSection": "abstract"}, {"offsetInBeginSection": 260, "offsetInEndSection": 669, "text": "In a 12-week, randomized, double-blind, placebo-controlled, multicentre trial in patients with erectile dysfunction, avanafil 50, 100 and 200 mg recipients had significantly greater improvements from baseline than placebo recipients in mean international index of erectile dysfunction-erectile function domain scores and in successful vaginal penetration and sexual intercourse attempts (coprimary endpoints).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Avanafil for the treatment of erectile dysfunction. An updated review.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25582903", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22759639", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22248153", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704456", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23321580", "endSection": "title"}, {"offsetInBeginSection": 1809, "offsetInEndSection": 1912, "text": "Cumulative data suggest that avanafil has a promising pharmacological profile for erectile dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704456", "endSection": "abstract"}, {"offsetInBeginSection": 1475, "offsetInEndSection": 1630, "text": "These findings suggest that intracavernosal administration of avanafil might be beneficial for the treatment of erectile dysfunction in patients with T2DM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24331245", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23521325", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24331245", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219537", "endSection": "title"}, {"offsetInBeginSection": 118, "offsetInEndSection": 246, "text": "Avanafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor newly developed for treating erectile dysfunction (ED).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22448738", "endSection": "abstract"}, {"offsetInBeginSection": 1259, "offsetInEndSection": 1546, "text": "Adverse events most commonly reported with avanafil treatment were headache, nasopharyngitis, flushing, and sinus congestion.Avanafil was safe and effective for treating erectile dysfunction in men with diabetes and was effective as early as 15 minutes and more than 6 hours after dosing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Avanafil (STENDRA\u2122, SPEDRA\u2122, Zepeeed\u2122) is an oral phosphodiesterase type 5 inhibitor indicated for the treatment of erectile dysfunction", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441", "endSection": "abstract"}, {"offsetInBeginSection": 138, "offsetInEndSection": 670, "text": "Avanafil is rapidly absorbed after oral administration, with a median time to maximum plasma concentration of 30 to 45 min. In a 12-week, randomized, double-blind, placebo-controlled, multicentre trial in patients with erectile dysfunction, avanafil 50, 100 and 200 mg recipients had significantly greater improvements from baseline than placebo recipients in mean international index of erectile dysfunction-erectile function domain scores and in successful vaginal penetration and sexual intercourse attempts (coprimary endpoints)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22788525", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 375, "text": "To evaluate the safety, efficacy and time course of three doses of avanafil (50 mg, 100 mg and 200 mg) compared with sildenafil 50 mg or placebo, given in conjunction with visual sexual stimulation (VSS) videos in men with mild to moderate erectile dysfunction (ED).Male patients, 35-70 years of age, with mild to moderate ED of \u22656 months duration, were included in the study", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22788525", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 33, "text": "Avanafil for erectile dysfunction", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259695", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 472, "text": "To review the pharmacology, pharmacokinetics, safety, and efficacy of avanafil and evaluate relevant clinical trial data.A MEDLINE, International Pharmaceutical Abstracts, ClinicalTrials.gov, and Google Scholar searches (1966 to July 2013) were conducted using the key words: avanafil, erectile dysfunction, and phosphodiesterase type 5 (PDE5) inhibitor.Articles evaluating avanafil for erectile dysfunction (ED) published in English and using human subjects were selected", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259695", "endSection": "abstract"}, {"offsetInBeginSection": 1060, "offsetInEndSection": 1305, "text": "In trials in patients with erectile dysfunction in association with diabetes mellitus, and after nerve-sparing radical prostatectomy, avanafil 100 or 200 mg was significantly more efficacious than placebo for primary and most secondary endpoints", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23955441", "endSection": "abstract"}, {"offsetInBeginSection": 1321, "offsetInEndSection": 1864, "text": "However, the potentiating effect of avanafil at 1 mg/kg was significantly weaker than that of sildenafil (p &lt;0.05).Data suggest that avanafil has a favorable safety profile for erectile dysfunction, which is attributable to its high inhibitory selectivity for phosphodiesterase type 5 against type 6 (retina) and 1 (vessels, etc), respectively, and its short acting pharmacodynamic property.<CopyrightInformation>Copyright \u00a9 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.</", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23321580", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25455484", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22448738", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Phosphodiesterase 5 inhibitors (PDE5-Is) sildenafil, vardenafil, tadalafil and the recently approved avanafil represent the first-line choice for both on-demand and chronic treatment of erectile dysfunction (ED).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121186", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "The phosphodiesterese-5 (PDE5) inhibitors, including sildenafil (Viagra\u2122), vardenafil (Levitra\u2122), tadalafil (Cialis\u2122) and avanafil (Stendra\u2122) have been developed for the treatment of erectile dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23590161", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 299, "text": "To compare the efficacy and safety between different dosages of avanafil for the treatment of erectile dysfunction (ED).PubMed, Cochrane Library, and Embase were searched to identify randomized controlled trials which compared avanafil with placebo, or compared different dosages of avanafil for ED.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24701971", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 389, "text": "We evaluated the safety and efficacy of 100 and 200 mg avanafil for the treatment of adult males with erectile dysfunction after bilateral nerve sparing radical prostatectomy.This was a double-blind, placebo controlled, parallel group, phase 3 study in males age 18 to 70 years with a history of erectile dysfunction of 6 months or more after bilateral nerve sparing radical prostatectomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219537", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 279, "text": "To determine the effect of avanafil, a novel phosphodiesterase-5 inhibitor, on the treatment of erectile dysfunction associated with type 2 diabetes mellitus (T2DM).In 2-day-old rats, T2DM was induced by single intraperitoneal injection of 90 mg/kg of streptozotocin (STZ; i.p.).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24331245", "endSection": "abstract"}, {"offsetInBeginSection": 1434, "offsetInEndSection": 1665, "text": "These findings suggest that intracavernosal administration of avanafil might be beneficial for the treatment of erectile dysfunction in patients with T2DM.<CopyrightInformation>Copyright \u00a9 2014 Elsevier Inc. All rights reserved.</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24331245", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Avanafil, a potent new selective phosphodiesterase type 5 (PDE5) inhibitor, has been developed for the treatment of erectile dysfunction (ED).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24589460", "endSection": "abstract"}, {"offsetInBeginSection": 1260, "offsetInEndSection": 1548, "text": "Adverse events most commonly reported with avanafil treatment were headache, nasopharyngitis, flushing, and sinus congestion.Avanafil was safe and effective for treating erectile dysfunction in men with diabetes and was effective as early as 15 minutes and more than 6 hours after dosing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780", "endSection": "abstract"}, {"offsetInBeginSection": 481, "offsetInEndSection": 1150, "text": "Coprimary end points assessed changes in the percentage of sexual attempts in which men were able to maintain an erection of sufficient duration to have successful intercourse (Sexual Encounter Profile [SEP] 3), percentage of sexual attempts in which men were able to insert the penis into the partner's vagina (SEP 2), and International Index of Erectile Function erectile function domain score.RESULTS: Compared with placebo, least-squares mean change from baseline to study end in SEP 3, SEP 2, and International Index of Erectile Function erectile function domain score were significantly improved with both avanafil, 100 mg (P?.002), and avanafil, 200 mg (P<.001).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780", "endSection": "abstract"}, {"offsetInBeginSection": 1299, "offsetInEndSection": 1599, "text": "Adverse events most commonly reported with avanafil treatment were headache, nasopharyngitis, flushing, and sinus congestion.CONCLUSION: Avanafil was safe and effective for treating erectile dysfunction in men with diabetes and was effective as early as 15 minutes and more than 6 hours after dosing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Avanafil for the treatment of erectile dysfunction. An updated review.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25582903", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 35, "text": "Avanafil for erectile dysfunction.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259695", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857780", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "To compare the efficacy and safety between different dosages of avanafil for the treatment of erectile dysfunction (ED).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24701971", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22759639", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219537", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "We evaluated the safety and efficacy of 100 and 200 mg avanafil for the treatment of adult males with erectile dysfunction after bilateral nerve sparing radical prostatectomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219537", "endSection": "abstract"}]}, {"body": "What is \"Epitranscriptome analysis\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27808276", "http://www.ncbi.nlm.nih.gov/pubmed/26501195", "http://www.ncbi.nlm.nih.gov/pubmed/26176336", "http://www.ncbi.nlm.nih.gov/pubmed/27911721", "http://www.ncbi.nlm.nih.gov/pubmed/27172004", "http://www.ncbi.nlm.nih.gov/pubmed/26733207", "http://www.ncbi.nlm.nih.gov/pubmed/25370990"], "ideal_answer": ["Modified nucleotides in messenger RNA (mRNA) have been discovered over 40 years ago, but until recently little was known about which transcripts contain them and what their function is. High-throughput sequencing approaches revealed a dynamic landscape of the 'Epitranscriptome' for many mRNA modifications in various organisms from yeast to humans.\t\t\nThe detection methods of RNA modifications has enabled investigation of a new layer of gene regulation - the epitranscriptome."], "type": "summary", "id": "58bbb64422d3005309000014", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "The simultaneous detection of all the post-transcriptional modifications (PTMs) that decorate cellular RNA can provide comprehensive information on the effects of changing environmental conditions on the entire epitranscriptome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733207", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "The advent of high-throughput sequencing technologies coupled with new detection methods of RNA modifications has enabled investigation of a new layer of gene regulation - the epitranscriptome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27172004", "endSection": "abstract"}, {"offsetInBeginSection": 557, "offsetInEndSection": 787, "text": " Other mRNA modifications, including N1-methyladenosine (m1A), 5-methylcytosine (m5C) and pseudouridine, together with m6A form the epitranscriptome and collectively code a new layer of information that controls protein synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27808276", "endSection": "abstract"}, {"offsetInBeginSection": 1589, "offsetInEndSection": 1742, "text": " the utility of mass spectrometry approaches for discovery-based analyses of RNA modifications, such as are required for studies of the epitranscriptome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176336", "endSection": "abstract"}, {"offsetInBeginSection": 176, "offsetInEndSection": 429, "text": "Despite the intriguing advancements, little is known so far about the dynamic landscape of RNA methylome across different cell types and how the epitranscriptome is regulated at the system level by enzymes, i.e., RNA methyltransferases and demethylases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25370990", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 350, "text": "Modified nucleotides in messenger RNA (mRNA) have been discovered over 40 years ago, but until recently little was known about which transcripts contain them and what their function is. High-throughput sequencing approaches revealed a dynamic landscape of the 'Epitranscriptome' for many mRNA modifications in various organisms from yeast to humans. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27911721", "endSection": "abstract"}]}, {"body": "Which infection can be prevented with Dapivirine?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25845860", "http://www.ncbi.nlm.nih.gov/pubmed/26061040", "http://www.ncbi.nlm.nih.gov/pubmed/26900902", "http://www.ncbi.nlm.nih.gov/pubmed/24693866", "http://www.ncbi.nlm.nih.gov/pubmed/27398859", "http://www.ncbi.nlm.nih.gov/pubmed/20854207", "http://www.ncbi.nlm.nih.gov/pubmed/25880636", "http://www.ncbi.nlm.nih.gov/pubmed/24449442", "http://www.ncbi.nlm.nih.gov/pubmed/14693562", "http://www.ncbi.nlm.nih.gov/pubmed/24901365", "http://www.ncbi.nlm.nih.gov/pubmed/19029331", "http://www.ncbi.nlm.nih.gov/pubmed/26732684", "http://www.ncbi.nlm.nih.gov/pubmed/24862093", "http://www.ncbi.nlm.nih.gov/pubmed/20574411", "http://www.ncbi.nlm.nih.gov/pubmed/26837628", "http://www.ncbi.nlm.nih.gov/pubmed/22708075", "http://www.ncbi.nlm.nih.gov/pubmed/26514157", "http://www.ncbi.nlm.nih.gov/pubmed/19623693", "http://www.ncbi.nlm.nih.gov/pubmed/25079391", "http://www.ncbi.nlm.nih.gov/pubmed/26963505", "http://www.ncbi.nlm.nih.gov/pubmed/18086845", "http://www.ncbi.nlm.nih.gov/pubmed/19388819", "http://www.ncbi.nlm.nih.gov/pubmed/23360246", "http://www.ncbi.nlm.nih.gov/pubmed/23965226", "http://www.ncbi.nlm.nih.gov/pubmed/23177261", "http://www.ncbi.nlm.nih.gov/pubmed/21109069", "http://www.ncbi.nlm.nih.gov/pubmed/19958831", "http://www.ncbi.nlm.nih.gov/pubmed/25089538"], "ideal_answer": ["Vaginal ring containing Dapivirine is used for HIV prevention in women."], "concepts": ["http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4243195", "http://www.biosemantics.org/jochem#4243195", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007239", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017053"], "type": "factoid", "id": "5880b812c872c95565000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 519, "text": "OBJECTIVES: The objectives of this study were to comprehensively assess mRNA expression of 84 drug transporters in human colorectal biopsies and six representative cell lines, and to investigate the alteration of drug transporter gene expression after exposure to three candidate microbicidal antiretroviral (ARV) drugs (tenofovir, darunavir and dapivirine) in the colorectal epithelium. The outcome of the objectives informs development of optimal ARV-based microbicidal formulations for prevention of HIV-1 infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26514157", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "We evaluated the adherence and acceptability of a vaginal ring containing dapivirine, maraviroc, or both drugs for 28\u00a0days during a Phase I placebo-controlled trial in 48 HIV-negative sexually abstinent U.S. women aged 18-40.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26837628", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26900902", "endSection": "title"}, {"offsetInBeginSection": 423, "offsetInEndSection": 1292, "text": "Methods We conducted a phase 3, randomized, double-blind, placebo-controlled trial of a monthly vaginal ring containing dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, involving women between the ages of 18 and 45 years in Malawi, South Africa, Uganda, and Zimbabwe. Results Among the 2629 women who were enrolled, 168 HIV-1 infections occurred: 71 in the dapivirine group and 97 in the placebo group (incidence, 3.3 and 4.5 per 100 person-years, respectively). The incidence of HIV-1 infection in the dapivirine group was lower by 27% (95% confidence interval [CI], 1 to 46; P=0.05) than that in the placebo group. In an analysis that excluded data from two sites that had reduced rates of retention and adherence, the incidence of HIV-1 infection in the dapivirine group was lower by 37% (95% CI, 12 to 56; P=0.007) than that in the placebo group.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26900902", "endSection": "abstract"}, {"offsetInBeginSection": 1713, "offsetInEndSection": 1902, "text": "Conclusions A monthly vaginal ring containing dapivirine reduced the risk of HIV-1 infection among African women, with increased efficacy in subgroups with evidence of increased adherence. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26900902", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 442, "text": "BACKGROUND: This was the first microbicide trial conducted in Africa to evaluate an antiretroviral-containing vaginal ring as an HIV prevention technology for women.OBJECTIVES: The trial assessed and compared the safety, acceptability and adherence to product use of a 4-weekly administered vaginal ring containing the antiretroviral microbicide, dapivirine, with a matching placebo ring among women from four countries in sub-Saharan Africa.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26963505", "endSection": "abstract"}, {"offsetInBeginSection": 1817, "offsetInEndSection": 2046, "text": "CONCLUSIONS: The dapivirine vaginal ring has a favourable safety and acceptability profile. If proven safe and effective in large-scale trials, it will be an important component of combination HIV prevention approaches for women.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26963505", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "PURPOSE: To develop polymeric films containing dual combinations of anti-HIV drug candidate tenofovir, maraviroc and dapivirine for vaginal application as topical microbicides.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25079391", "endSection": "abstract"}, {"offsetInBeginSection": 332, "offsetInEndSection": 532, "text": "Efficacy trials with a dapivirine-containing vaginal ring for HIV prevention are ongoing and plans to develop multi-purpose vaginal rings for prevention of both HIV and pregnancy have been elaborated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25880636", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19029331", "endSection": "title"}, {"offsetInBeginSection": 900, "offsetInEndSection": 1054, "text": "The incidence of HIV-1 infection in the dapivirine group was lower by 27% (95% confidence interval [CI], 1 to 46; P=0.046) than that in the placebo group.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26900902", "endSection": "abstract"}, {"offsetInBeginSection": 1054, "offsetInEndSection": 1287, "text": "In an analysis that excluded data from two sites that had reduced rates of retention and adherence, the incidence of HIV-1 infection in the dapivirine group was lower by 37% (95% CI, 12 to 56; P=0.007) than that in the placebo group.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26900902", "endSection": "abstract"}, {"offsetInBeginSection": 608, "offsetInEndSection": 830, "text": "Within this study the in vitro bioactivity of dapivirine as compared to the NNRTI UC781 was further established and a quick dissolve film was developed for vaginal application of dapivirine for prevention of HIV infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22708075", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Dapivirine, a nonnucleoside reverse transcriptase inhibitor, is in development as a microbicide for the protection of women against HIV infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20574411", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Dapivirine is a nonnucleoside reverse transcriptase inhibitor being developed as a topical microbicide for the prevention of human immunodeficiency virus infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18086845", "endSection": "abstract"}, {"offsetInBeginSection": 705, "offsetInEndSection": 960, "text": "Dapivirine from both IVRs was successfully distributed throughout the lower genital tract at concentrations>1000x the EC(50) against wild-type HIV-1 (LAI) in MT4 cells suggesting that IVR delivery of microbicides is a viable option meriting further study.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19388819", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "The nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 (Dapivirine) effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14693562", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 345, "text": "To assess the potential of polymeric nanoparticles (NPs) to affect the genital distribution and local and systemic pharmacokinetics (PK) of the anti-HIV microbicide drug candidate dapivirine after vaginal delivery.Dapivirine-loaded, poly(ethylene oxide)-coated poly(epsilon-caprolactone) (PEO-PCL) NPs were prepared by a nanoprecipitation method", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24449442", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "The nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 (Dapivirine) effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14693562", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Dapivirine is a nonnucleoside reverse transcriptase inhibitor being developed as a topical microbicide for the prevention of human immunodeficiency virus infection. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18086845", "endSection": "abstract"}, {"offsetInBeginSection": 972, "offsetInEndSection": 1144, "text": "CONCLUSIONS: The study demonstrates proof of concept for a dapivirine-releasing diaphragm with daily release quantities potentially capable of preventing HIV transmission. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23177261", "endSection": "abstract"}, {"offsetInBeginSection": 304, "offsetInEndSection": 740, "text": "Antiretroviral-containing vaginal microbicide rings, which release medication over a month or longer, may reduce these adherence challenges.ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention of HIV-1 infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26061040", "endSection": "abstract"}, {"offsetInBeginSection": 642, "offsetInEndSection": 774, "text": "Dapivirine demonstrated potent dose-dependent inhibitory effects against a broad panel of HIV type 1 isolates from different clades.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19029331", "endSection": "abstract"}, {"offsetInBeginSection": 657, "offsetInEndSection": 829, "text": "Two large efficacy trials of a vaginal ring containing the investigational drug dapivirine demonstrated efficacy and safety in preventing HIV infections in women in Africa.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27398859", "endSection": "abstract"}, {"offsetInBeginSection": 575, "offsetInEndSection": 831, "text": "In doing so, we discovered that dapivirine and maraviroc, a non-nucleoside reverse transcriptase inhibitor and an entry inhibitor currently in development as microbicides for HIV PrEP, are differentially metabolized in colorectal tissue and vaginal tissue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23965226", "endSection": "abstract"}, {"offsetInBeginSection": 1267, "offsetInEndSection": 1611, "text": "Plasma dapivirine concentrations were low (<1 ng/ml) and remained well below those observed at the maximum tolerated dose for oral treatment (mean Cmax of 2286 \u200ang/ml).CONCLUSION: The dapivirine vaginal ring has a safety and pharmacokinetic profile that supports its use as a sustained-release topical microbicide for HIV-1 prevention in women.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24901365", "endSection": "abstract"}, {"offsetInBeginSection": 445, "offsetInEndSection": 741, "text": "ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention of HIV-1 infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26061040", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "Dual segment polyurethane intravaginal rings (IVRs) were fabricated to enable sustained release of antiretroviral agents dapivirine and tenofovir to prevent the male to female sexual transmission of the human immunodeficiency virus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19958831", "endSection": "abstract"}, {"offsetInBeginSection": 937, "offsetInEndSection": 1095, "text": "The study demonstrates proof of concept for a dapivirine-releasing diaphragm with daily release quantities potentially capable of preventing HIV transmission.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23177261", "endSection": "abstract"}]}, {"body": "What is Bexsero?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26853725", "http://www.ncbi.nlm.nih.gov/pubmed/25043395", "http://www.ncbi.nlm.nih.gov/pubmed/26603630", "http://www.ncbi.nlm.nih.gov/pubmed/27109566", "http://www.ncbi.nlm.nih.gov/pubmed/27808594", "http://www.ncbi.nlm.nih.gov/pubmed/27923519", "http://www.ncbi.nlm.nih.gov/pubmed/23472347", "http://www.ncbi.nlm.nih.gov/pubmed/25161192", "http://www.ncbi.nlm.nih.gov/pubmed/26686570", "http://www.ncbi.nlm.nih.gov/pubmed/25713028", "http://www.ncbi.nlm.nih.gov/pubmed/22426368", "http://www.ncbi.nlm.nih.gov/pubmed/26788734", "http://www.ncbi.nlm.nih.gov/pubmed/26788735", "http://www.ncbi.nlm.nih.gov/pubmed/21615224", "http://www.ncbi.nlm.nih.gov/pubmed/27163398", "http://www.ncbi.nlm.nih.gov/pubmed/26304221", "http://www.ncbi.nlm.nih.gov/pubmed/25301037", "http://www.ncbi.nlm.nih.gov/pubmed/27002504", "http://www.ncbi.nlm.nih.gov/pubmed/25368410", "http://www.ncbi.nlm.nih.gov/pubmed/26379162", "http://www.ncbi.nlm.nih.gov/pubmed/27573083", "http://www.ncbi.nlm.nih.gov/pubmed/27521232", "http://www.ncbi.nlm.nih.gov/pubmed/25986879", "http://www.ncbi.nlm.nih.gov/pubmed/23811804", "http://www.ncbi.nlm.nih.gov/pubmed/24631075", "http://www.ncbi.nlm.nih.gov/pubmed/26068564", "http://www.ncbi.nlm.nih.gov/pubmed/26433141", "http://www.ncbi.nlm.nih.gov/pubmed/24141209", "http://www.ncbi.nlm.nih.gov/pubmed/23575646", "http://www.ncbi.nlm.nih.gov/pubmed/24815780", "http://www.ncbi.nlm.nih.gov/pubmed/24462403", "http://www.ncbi.nlm.nih.gov/pubmed/26487381", "http://www.ncbi.nlm.nih.gov/pubmed/27302338", "http://www.ncbi.nlm.nih.gov/pubmed/25325113", "http://www.ncbi.nlm.nih.gov/pubmed/23954380", "http://www.ncbi.nlm.nih.gov/pubmed/24807056", "http://www.ncbi.nlm.nih.gov/pubmed/24284038", "http://www.ncbi.nlm.nih.gov/pubmed/26126001", "http://www.ncbi.nlm.nih.gov/pubmed/25882169"], "ideal_answer": ["Bexsero is a 4-component vaccine against capsular Meningococcus serogroup B (4CMenB), which has recently been licensed in Europe, Canada and Australia.", "Bexsero is amulticomponent vaccine against serogroup B Neisseria meningitidis (MenB)."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008585", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008589", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065288", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D022401", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D038541", "http://www.disease-ontology.org/api/metadata/DOID:13668"], "type": "summary", "id": "589af57a78275d0c4a000038", "snippets": [{"offsetInBeginSection": 529, "offsetInEndSection": 662, "text": "A capsular group B meningococcal vaccine - 4CMenB (Bexsero) - has recently been licensed in the European Union, Canada and Australia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26126001", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "The 4-component meningococcal serogroup B vaccine 4CMenB (Bexsero) is the first vaccine against this serogroup and has been approved by licensing authorities in Europe, Canada and Australia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26379162", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 149, "text": "Implementation of meningococcal B vaccination (Bexsero\u00ae) in France: Physicians' perceptions and experiences of a few months after marketing approval", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26603630", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 215, "text": "In December 2013, the French public health authorities recommended the use of Bexsero\u00ae (meningococcus B vaccine) in areas with endemic risk and for patients at risk for invasive meningococcal B disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26603630", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 47, "text": "Bexsero, a novel vaccine against meningococcus", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26853725", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Meningococcus B is the most prevalent Neisseria meningitidis serogroup isolated in Hungary. Bexsero is one of the vaccines developed against it, which has been available in Hungary since the summer of 2014. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26853725", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Vaccinating Italian infants with a new multicomponent vaccine (Bexsero\u00ae) against meningococcal B disease: A cost-effectiveness analysis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27163398", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "The European Medicines Agency has approved a multicomponent serogroup B meningococcal vaccine (Bexsero\u00ae) for use in individuals of 2 months of age and older.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27163398", "endSection": "abstract"}, {"offsetInBeginSection": 1620, "offsetInEndSection": 1856, "text": "Our results suggest that vaccinating infants in Italy with Bexsero\u00ae has the ability to significantly reduce meningococcal disease and, if the probable underestimation of disease incidence is considered, routine vaccination is advisable.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27163398", "endSection": "abstract"}, {"offsetInBeginSection": 593, "offsetInEndSection": 802, "text": "Since the antigens selected for Bexsero\u00ae are also harbored by meningococci belonging to other serogroups there may be the potential for Bexsero\u00ae to offer a certain level of protection against non-B serogroups.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26788735", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "[Bexsero, a novel vaccine against meningococcus].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26853725", "endSection": "title"}, {"offsetInBeginSection": 452, "offsetInEndSection": 506, "text": "The new available vaccines are Bexsero\u00ae and Trumenba\u00ae.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26788734", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 359, "text": "Surface-expressed protein antigens such as factor H-binding protein (fHbp), Neisserial adhesin A (NadA), Neisserial heparin-binding antigen (NHBA) and Porin protein A (PorA); all express sequence variability that can affect their function as protective immunogens when used in meningococcal serogroup B vaccines like the recently-approved 4CMenB (Bexsero(\u00ae)).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24631075", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Proteinaceous meningococcal B vaccines are under development, and the most advanced, Bexsero, is currently being evaluated by the European Medicines Agency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23472347", "endSection": "abstract"}, {"offsetInBeginSection": 228, "offsetInEndSection": 468, "text": "Among them, the Reverse Vaccinology approach was successfully applied to the development of an innovative vaccine against Neisseria meningitidis serogroup B, now available on the market with the commercial name BEXSERO\u00ae (Novartis Vaccines).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25368410", "endSection": "abstract"}, {"offsetInBeginSection": 256, "offsetInEndSection": 516, "text": "Recently, a vaccine, 4CMenB (Bexsero(\u00ae)), containing three recombinant proteins, and outer membrane vesicles (OMV) derived from a serogroup B meningococcal strain (MenB) has been licensed in Europe and Australia and is indicated for persons aged 2 mo or older.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141209", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(\u00ae)) is a unique vaccine containing four main immunogenic components: three recombinant proteins combined with outer membrane vesicles derived from meningococcal NZ98/254 strain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23575646", "endSection": "abstract"}, {"offsetInBeginSection": 253, "offsetInEndSection": 453, "text": "Recently, a universal serogroup B meningococcal vaccine, Bexsero(\u00ae), was licensed in Europe, Australia and United States, following several clinical studies demonstrating its immunogenicity and safety", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25986879", "endSection": "abstract"}, {"offsetInBeginSection": 807, "offsetInEndSection": 992, "text": "Like any drug, Bexsero(\u00ae) and Trumemba(\u00ae) will require close observation to assess their impact on meningococcal epidemiology. <CopyrightInformation>Copyright \u00a9 2015 Elsevier Masson SAS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25986879", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Bexsero, a new vaccine against Neisseria meningitidis serogroup B (MenB), is composed of 3 main recombinant proteins and an outer membrane vesicle component", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25713028", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "The meningococcal 4CMenB vaccine (Bexsero; Novartis) contains four antigens that can elicit serum bactericidal activity, one of which is factor H (FH)-binding protein (FHbp)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25161192", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "In December 2013 Bexsero\u00ae became available in Germany for vaccination against serogroup B meningococci (MenB)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26487381", "endSection": "abstract"}, {"offsetInBeginSection": 376, "offsetInEndSection": 495, "text": "Bexsero\u00ae is based on surface protein antigens expressed by about 80% of circulating serogroup B meningococci in Germany", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26487381", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301037", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Bexsero: a multicomponent vaccine for prevention of meningococcal disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426368", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 502, "text": "OBJECTIVE: To use mathematical and economic models to predict the epidemiological and economic impact of vaccination with Bexsero, designed to protect against group B meningococcal disease, to help inform vaccine policy in the United Kingdom.DESIGN: Modelling study.SETTING: England.POPULATION: People aged 0-99.INTERVENTIONS: Incremental impact of introductory vaccine strategies simulated with a transmission dynamic model of meningococcal infection and vaccination including potential herd effects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301037", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero(\ufffd)).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25043395", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Modelled evaluation of multi-component meningococcal vaccine (Bexsero\u00ae) for the prevention of invasive meningococcal disease in infants and adolescents in the UK.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24284038", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "BACKGROUND: 4CMenB (Bexsero), a vaccine developed against invasive meningococcal disease caused by capsular group B strains (MenB), was recently licensed for use by the European Medicines Agency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23954380", "endSection": "abstract"}, {"offsetInBeginSection": 133, "offsetInEndSection": 216, "text": "Bexsero is the first meningococcal B vaccine to be approved in the European Union. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25325113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero\u00ae vaccine.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24462403", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "We previously demonstrated the immunogenicity and tolerability of the serogroup B meningococcal vaccine, 4CMenB (Bexsero), in 11-17 y-olds randomized to receive 1, 2, or 3 doses at 1, 2, or 6 mo intervals. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23811804", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 316, "text": "This policy statement provides recommendations for the prevention of serogroup B meningococcal disease through the use of 2 newly licensed serogroup B meningococcal vaccines: MenB-FHbp (Trumenba; Wyeth Pharmaceuticals, a subsidiary of Pfizer, Philadelphia, PA) and MenB-4C (Bexsero; Novartis Vaccines, Siena, Italy).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573083", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 283, "text": "An outbreak of Neisseria meningitidis serotype B infection occurred at a small residential university; public health announced an organizational vaccination program with the 4-component Meningococcal B (4CMenB) vaccine (Bexsero(TM), Novartis/GlaxoSmithKline Inc.) several days later.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27302338", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Bexsero, a new vaccine against serogroup B meningococcal disease (MenB), was licensed in Europe in January 2013.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27109566", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 291, "text": "Recently approved in the EU, US, Australia, and Canada, 4CMenB (Bexsero(\u00ae), GSK Vaccines) is a multi-component meningococcal B (MenB) vaccine containing 3 surface exposed recombinant proteins (fHbp, NadA, and NHBA) and New Zealand strain outer membrane vesicles (NZ OMV) containing PorA 1.4.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25882169", "endSection": "abstract"}, {"offsetInBeginSection": 113, "offsetInEndSection": 257, "text": "In Germany, Bexsero is recommended for persons at increased risk of invasive meningococcal disease, but not for universal childhood vaccination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27109566", "endSection": "abstract"}, {"offsetInBeginSection": 258, "offsetInEndSection": 488, "text": "To support decision making we adapted the independently developed model for England to the German setting to predict the potential health impact and cost-effectiveness of universal vaccination with Bexsero(\u00ae) against MenB disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27109566", "endSection": "abstract"}, {"offsetInBeginSection": 463, "offsetInEndSection": 955, "text": "This has resulted in a multicomponent, recombinant, meningococcal serogroup B vaccine: 4CMenB (Bexsero(\u00ae), Novartis Vaccines & Diagnostics, NC, USA), containing four main immunogenic components: two recombinant fusion proteins (Neisseria heparin-binding antigen-GNA1030 and factor H-binding protein-GNA2091); recombinant Neisserial adhesion A; and detergent-treated outer membrane vesicles derived from the meningococcal NZ98/254 strain, where porin A 1.4 is the major immunodominant antigen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24815780", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "BACKGROUND: 4CMenB (Bexsero), a vaccine developed against invasive meningococcal disease caused by capsular group B strains (MenB), was recently licensed for use by the European Medicines Agency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23954380", "endSection": "abstract"}, {"offsetInBeginSection": 188, "offsetInEndSection": 298, "text": "In January 2015, FDA licensed a second MenB vaccine (MenB-4C [Bexsero, Novartis Vaccines]) as a 2-dose series.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26068564", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Bexsero, a new vaccine against Neisseria meningitidis serogroup B (MenB), is composed of 3 main recombinant proteins and an outer membrane vesicle component.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25713028", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero(\u00ae)).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25043395", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "[Bexsero, a novel vaccine against meningococcus].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26853725", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27923519", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25301037", "endSection": "title"}, {"offsetInBeginSection": 476, "offsetInEndSection": 592, "text": "The novel vaccine Bexsero (previously 4CMenB) has been developed and proven safe and immunogenic in clinical trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615224", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(\u00ae)): a review of its use in primary and booster vaccination.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23575646", "endSection": "title"}, {"offsetInBeginSection": 53, "offsetInEndSection": 157, "text": "Bexsero, the recently licensed multicomponent vaccine against serogroup B Neisseria meningitidis (MenB).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26304221", "endSection": "abstract"}, {"offsetInBeginSection": 197, "offsetInEndSection": 342, "text": "Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero\u00ae vaccine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27808594", "endSection": "abstract"}, {"offsetInBeginSection": 804, "offsetInEndSection": 894, "text": "Clinical recommendations for the use of Bexsero have been published in several countries. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26686570", "endSection": "abstract"}]}, {"body": "Is there a role for gamma knife in treatment of Obsessive-Compulsive Disorder?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7841817", "http://www.ncbi.nlm.nih.gov/pubmed/8517190", "http://www.ncbi.nlm.nih.gov/pubmed/18188146", "http://www.ncbi.nlm.nih.gov/pubmed/25165567", "http://www.ncbi.nlm.nih.gov/pubmed/21150752", "http://www.ncbi.nlm.nih.gov/pubmed/24093580", "http://www.ncbi.nlm.nih.gov/pubmed/12856488", "http://www.ncbi.nlm.nih.gov/pubmed/24099662", "http://www.ncbi.nlm.nih.gov/pubmed/18081480", "http://www.ncbi.nlm.nih.gov/pubmed/25050687", "http://www.ncbi.nlm.nih.gov/pubmed/10099102", "http://www.ncbi.nlm.nih.gov/pubmed/23872618", "http://www.ncbi.nlm.nih.gov/pubmed/23829816", "http://www.ncbi.nlm.nih.gov/pubmed/19996247", "http://www.ncbi.nlm.nih.gov/pubmed/15554782", "http://www.ncbi.nlm.nih.gov/pubmed/18835422", "http://www.ncbi.nlm.nih.gov/pubmed/10069581", "http://www.ncbi.nlm.nih.gov/pubmed/25054836", "http://www.ncbi.nlm.nih.gov/pubmed/27903196"], "ideal_answer": ["Yes. Gamma knife radiosurgery is being increasingly to treat refractory obsessive- compulsive disorder (OCD). It is reserved for severe, treatment-refractory disease that has not responded to multiple treatments."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:10933", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009771"], "type": "yesno", "id": "5898500478275d0c4a000017", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "OBJECTIVE Functional Gamma Knife radiosurgery (GKRS) procedures have been increasingly used for treating patients with tremor, trigeminal neuralgia (TN), and refractory obsessive-compulsive disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27903196", "endSection": "abstract"}, {"offsetInBeginSection": 825, "offsetInEndSection": 1165, "text": "METHODS The authors constructed a linear-quadratic model of BED in functional GKRS with a dose-protraction factor to correct for intrafraction DNA-damage repair and used standard single-fraction doses for trigeminal nerve ablation for TN (85 Gy), thalamotomy for tremor (130 Gy), and capsulotomy for obsessive-compulsive disorder (180 Gy). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27903196", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Gamma knife for obsessive compulsive disorder: can it be detrimental?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25050687", "endSection": "title"}, {"offsetInBeginSection": 205, "offsetInEndSection": 318, "text": "Gamma knife radiosurgery (GKRS) is also being practised to treat refractory obsessive- compulsive disorder (OCD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25050687", "endSection": "abstract"}, {"offsetInBeginSection": 1078, "offsetInEndSection": 1344, "text": "Radio and neurosurgical procedures, including gamma knife radiation and deep brain stimulation, are reserved for severe, treatment-refractory disease that has not responded to multiple treatments, and some patients may benefit from transcranial magnetic stimulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25165567", "endSection": "abstract"}, {"offsetInBeginSection": 906, "offsetInEndSection": 1000, "text": " We close with a discussion of gamma knife capsulotomy, a modality with deep historical roots.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24099662", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Results following gamma knife radiosurgical anterior capsulotomies for obsessive compulsive disorder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150752", "endSection": "title"}, {"offsetInBeginSection": 203, "offsetInEndSection": 316, "text": "Gamma knife radiosurgery (GKRS) is also being practised to treat refractory obsessive- compulsive disorder (OCD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25050687", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Lesion topography and outcome after thermocapsulotomy or gamma knife capsulotomy for obsessive-compulsive disorder: relevance of the right hemisphere.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10069581", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Neuropsychological outcome of ventral capsular/ventral striatal gamma capsulotomy for refractory obsessive-compulsive disorder: a pilot study", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19996247", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Gamma ventral capsulotomy for treatment of resistant obsessive-compulsive disorder: a structural MRI pilot prospective study", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18835422", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Results following gamma knife radiosurgical anterior capsulotomies for obsessive compulsive disorder", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150752", "endSection": "title"}, {"offsetInBeginSection": 1334, "offsetInEndSection": 1553, "text": "At 28 months, the third patient is living and working independently, and her YBOCS score is 18.CONCLUSION: Within a strict protocol, gamma knife radiosurgery provided improvement of OCD behavior with no adverse effects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Gamma knife for obsessive compulsive disorder: can it be detrimental?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25050687", "endSection": "title"}]}, {"body": "What is the mechanism of action of the biguanide class of diabetes drugs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23292513", "http://www.ncbi.nlm.nih.gov/pubmed/27939359", "http://www.ncbi.nlm.nih.gov/pubmed/8914439", "http://www.ncbi.nlm.nih.gov/pubmed/25793062", "http://www.ncbi.nlm.nih.gov/pubmed/21147283", "http://www.ncbi.nlm.nih.gov/pubmed/26166607"], "ideal_answer": ["this biguanide is an oral insulin-sensitizing agent capable of increasing insulin sensitivity and decreasing plasma fasting insulin levels.", "Bioguaides like Metformin, decrease amount of glucose released from liver and increases insulin sensitivity. "], "concepts": ["http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275167", "http://www.disease-ontology.org/api/metadata/DOID:9351", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001645", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003920", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003924", "http://www.biosemantics.org/jochem#4275167", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008687"], "type": "summary", "id": "58a22eb460087bc10a000001", "snippets": [{"offsetInBeginSection": 753, "offsetInEndSection": 792, "text": "Metformin sensitizes the insulin action", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939359", "endSection": "abstract"}, {"offsetInBeginSection": 471, "offsetInEndSection": 611, "text": "This biguanide is an oral insulin-sensitizing agent capable of increasing insulin sensitivity and decreasing plasma fasting insulin levels. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26166607", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Metformin is an oral anti-diabetic drug of the biguanide class that is commonly used to treat type 2 diabetes mellitus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21147283", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Metformin, an oral anti-diabetic agent in the biguanide class is a widely prescribed drug to treat high blood glucose in patients with type 2 diabetes mellitus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25793062", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 401, "text": "etformin has three different roles, including blood glucose regulatory effect, protection of kidney tubular cell by acting as an effective antioxidant and finally ameliorative effect on diabetic kidney disease through saving the podocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25793062", "endSection": "abstract"}]}, {"body": "Where is the proteasome located?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9799224", "http://www.ncbi.nlm.nih.gov/pubmed/26743630", "http://www.ncbi.nlm.nih.gov/pubmed/17428875", "http://www.ncbi.nlm.nih.gov/pubmed/9321388", "http://www.ncbi.nlm.nih.gov/pubmed/16371511", "http://www.ncbi.nlm.nih.gov/pubmed/15791592", "http://www.ncbi.nlm.nih.gov/pubmed/11734567", "http://www.ncbi.nlm.nih.gov/pubmed/11295498", "http://www.ncbi.nlm.nih.gov/pubmed/7957966", "http://www.ncbi.nlm.nih.gov/pubmed/22411744", "http://www.ncbi.nlm.nih.gov/pubmed/10995887", "http://www.ncbi.nlm.nih.gov/pubmed/20026058", "http://www.ncbi.nlm.nih.gov/pubmed/18948196", "http://www.ncbi.nlm.nih.gov/pubmed/10502681", "http://www.ncbi.nlm.nih.gov/pubmed/20491623", "http://www.ncbi.nlm.nih.gov/pubmed/9050876", "http://www.ncbi.nlm.nih.gov/pubmed/21976669", "http://www.ncbi.nlm.nih.gov/pubmed/17977463", "http://www.ncbi.nlm.nih.gov/pubmed/25413350", "http://www.ncbi.nlm.nih.gov/pubmed/22458048", "http://www.ncbi.nlm.nih.gov/pubmed/11175258", "http://www.ncbi.nlm.nih.gov/pubmed/9804081", "http://www.ncbi.nlm.nih.gov/pubmed/10657252"], "ideal_answer": ["The proteasome can be found in perinuclear and nuclear location, as well as in cytosolic compartments, such as mitochondria and endoplasmic reticulum. Proteasome-mediated degradation of cell cycle regulatory proteins, production and loading of antigenic peptides onto HLA molecules, and transient homing of diverse virion proteins required for entry and/or egress have been also shown to be coordinated at the centrosome."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0000502", "http://amigo.geneontology.org/amigo/term/GO:0031144"], "type": "summary", "id": "58b558d522d3005309000006", "snippets": [{"offsetInBeginSection": 409, "offsetInEndSection": 611, "text": "Cellular regulation by UPS- mediated protein degradation is a highly specific and selective process that depends on time (e.g. cell cycle) and location (nucleus, mitochondria or endoplasmic reticulum). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26743630", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "In eukaryotic cells, regulated protein degradation of intracellular proteins is mediated largely by the ubiquitin proteasome system (UPS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26743630", "endSection": "abstract"}, {"offsetInBeginSection": 468, "offsetInEndSection": 689, "text": "We followed two key parameters of this process: the distribution of proteasomes in nuclear and cytosolic compartments, and the formation of cytoplasmic aggregate-like structures called proteasome storage granules (PSGs). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25413350", "endSection": "abstract"}, {"offsetInBeginSection": 736, "offsetInEndSection": 1042, "text": "Subsequently, cellular distribution of the PAI-2\u00b7proteasome complexes was established by immunogold staining and electron microscopy analyses. As judged by confocal microscopy, both proteins appeared in a diffuse cytosolic pattern, but they also could be found in a dense perinuclear and nuclear location. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21976669", "endSection": "abstract"}, {"offsetInBeginSection": 204, "offsetInEndSection": 302, "text": " Frequently ubiquitinated proteins are targeted to the proteasome for degradation in the cytosol. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18948196", "endSection": "abstract"}, {"offsetInBeginSection": 1354, "offsetInEndSection": 1636, "text": " More recently, proteasome-mediated degradation of cell cycle regulatory proteins, production and loading of antigenic peptides onto HLA molecules, and transient homing of diverse virion proteins required for entry and/or egress have been shown to be coordinated at the centrosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17428875", "endSection": "abstract"}, {"offsetInBeginSection": 1127, "offsetInEndSection": 1363, "text": "We conclude that N-terminal sequences of Wld(S) protein influence the intranuclear location of both ubiquitin proteasome and NAD(+) synthesis machinery and that an evolutionary recent sequence mediates binding of mammalian Ube4b to VCP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16371511", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "Two new forms of proteasomes, designated as the endoplasmic reticulum (ER) membrane-associated proteasome (ERa proteasome) and ER membrane-bound proteasome (ERb proteasome), were purified to homogeneity from 0.0125 and 2.5% sodium cholate extracts, respectively, of a rat liver microsomal fraction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502681", "endSection": "abstract"}, {"offsetInBeginSection": 276, "offsetInEndSection": 396, "text": "The proteasome is a large multicatalytic, proteinase complex located in the cytosol and the nucleus of eukaryotic cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22458048", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Subcellular distribution of proteasomes implicates a major location of protein degradation in the nuclear envelope-ER network in yeast.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9799224", "endSection": "title"}, {"offsetInBeginSection": 1177, "offsetInEndSection": 1500, "text": "JAB1, which is thought to bind p27KIP1 and transport it from the nucleus to the cytoplasm for proteasome/ubiquitin-mediated degradation, was found to be localized both in the cytoplasm and the nucleus in undifferentiated and differentiating tumors whereas located predominantly in the nucleus of differentiated tumor cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10995887", "endSection": "abstract"}, {"offsetInBeginSection": 764, "offsetInEndSection": 896, "text": "20S proteasomes are present in all areas where ATPase subunits are detected, consistent with the presence of intact 26S proteasomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11175258", "endSection": "abstract"}, {"offsetInBeginSection": 979, "offsetInEndSection": 1091, "text": "Inhibition of proteasomes located in axons resulted in an accumulation of ubiquitinated proteins in these axons.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22411744", "endSection": "abstract"}, {"offsetInBeginSection": 1432, "offsetInEndSection": 1639, "text": "All these observations indicate that the mouse sperm proteasome participates in the binding to the zona pellucida and the acrosome reaction and that there is a pool of proteasomes located on the sperm head..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15791592", "endSection": "abstract"}, {"offsetInBeginSection": 1204, "offsetInEndSection": 1387, "text": "Thus, newly synthesized apoB is localized throughout the entire ER and degraded homogeneously, most likely by neighboring proteasomes located on the cytosolic side of the ER membrane.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11734567", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "While misfolded and short-lived proteins are degraded in proteasomes located in the nucleus and cytoplasm, the degradation of organelles and long-lived proteins in the lysosome occurs by the process of autophagy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17977463", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 610, "text": "The GFP-tagged proteasomes were located within both the cytoplasm and the nucleus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9321388", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Proteasomes are large multicatalytic proteinase complexes located in the cytosol and the nucleus of eukaryotic cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20491623", "endSection": "abstract"}, {"offsetInBeginSection": 418, "offsetInEndSection": 549, "text": "Immunohistochemically, proteasomes (26S) were located in the cytoplasm in normal human muscle, but the staining intensity was weak.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9804081", "endSection": "abstract"}, {"offsetInBeginSection": 746, "offsetInEndSection": 867, "text": "In DMRV, proteasomes often were located within or on the rim of rimmed vacuoles, and in the cytoplasm of atrophic fibers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9804081", "endSection": "abstract"}]}, {"body": "What is clinical presentation of the Gardner-Diamond syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26078671", "http://www.ncbi.nlm.nih.gov/pubmed/15956886", "http://www.ncbi.nlm.nih.gov/pubmed/18417404", "http://www.ncbi.nlm.nih.gov/pubmed/2345102", "http://www.ncbi.nlm.nih.gov/pubmed/12838436", "http://www.ncbi.nlm.nih.gov/pubmed/27011410", "http://www.ncbi.nlm.nih.gov/pubmed/23825859", "http://www.ncbi.nlm.nih.gov/pubmed/21548659", "http://www.ncbi.nlm.nih.gov/pubmed/4059144", "http://www.ncbi.nlm.nih.gov/pubmed/23580908", "http://www.ncbi.nlm.nih.gov/pubmed/26137346", "http://www.ncbi.nlm.nih.gov/pubmed/23723552", "http://www.ncbi.nlm.nih.gov/pubmed/26101006", "http://www.ncbi.nlm.nih.gov/pubmed/19192020", "http://www.ncbi.nlm.nih.gov/pubmed/19030312", "http://www.ncbi.nlm.nih.gov/pubmed/16023271", "http://www.ncbi.nlm.nih.gov/pubmed/10966177", "http://www.ncbi.nlm.nih.gov/pubmed/3627621", "http://www.ncbi.nlm.nih.gov/pubmed/20204908", "http://www.ncbi.nlm.nih.gov/pubmed/921453", "http://www.ncbi.nlm.nih.gov/pubmed/11475645"], "ideal_answer": ["Psychogenic purpura, also known as Gardner-Diamond syndrome, is a rare, distinctive, localized cutaneous reaction pattern mostly affecting psychologically disturbed adult women. Repeated crops of tender, ill-defined ecchymotic lesions on the extremities and external bleeding from other sites characterize the condition."], "type": "summary", "id": "5895e2567d9090f353000011", "snippets": [{"offsetInBeginSection": 542, "offsetInEndSection": 771, "text": "Antidepressants were prescribed by the psychiatrist that not only cured the depression with time but also the bleeding episodes which were actually related to child's depression (Gardner-Diamond syndrome or psychogenic purpura). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26101006", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "Psychogenic Purpura (Gardner-Diamond Syndrome).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137346", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 316, "text": "Psychogenic purpura, also known as Gardner-Diamond syndrome or autoerythrocyte sensitization syndrome, is a rare condition characterized by spontaneous development of painful edematous skin lesions progressing to ecchymosis over the next 24 hours. Severe stress and emotional trauma always precede the skin lesions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137346", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 237, "text": "Gardner Diamond syndrome is a rare condition characterized with painful ecchymoses in different parts of the body and cutaneous and mucosal hemorrhages. The etiology is not known fully and psychogenic factors are thought to be involved. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26078671", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 321, "text": "Psychogenic purpura, also known as Gardner-Diamond syndrome, is a rare, distinctive, localized cutaneous reaction pattern mostly affecting psychologically disturbed adult women. Repeated crops of tender, ill-defined ecchymotic lesions on the extremities and external bleeding from other sites characterize the condition. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23825859", "endSection": "abstract"}, {"offsetInBeginSection": 520, "offsetInEndSection": 766, "text": "PPDDM includes impulse control disorders, obsessive-compulsive disorders, factitious disorder, factitious disorder by proxy, self-mutilation, delusions of parasitosis, psychogenic purpura/Gardner-Diamond syndrome, and cutaneous sensory disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548659", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Psychogenic purpura (Gardner-Diamond syndrome) is the occurrence and spontaneous recurrence of painful ecchymosis following emotional stress and minor trauma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20204908", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "We describe the clinical presentation and course of a patient with autoerythrocyte sensitization (Gardner-Diamond) syndrome, and review the literature for similar cases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10966177", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Gardner-Diamond syndrome (GDS) is also known as psychogenic purpura, autoerythrocyte sensitization syndrome and painful bruising syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23580908", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Autoerythrocyte sensitization (Gardner-Diamond) syndrome mimicking compartment syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12838436", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Autoerythrocyte sensitization syndrome (Gardner-Diamond syndrome): review of the literature.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19192020", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "We report a case with an unusual manifestation of autoerythrocyte sensitization syndrome (Gardner-Diamond syndrome).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12838436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "The Gardner-Diamond syndrome is a disorder characterized by recurrent spontaneous painful bruising in patients with underlying psychosis and neurosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15956886", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "A 54-year old anorectic patient with painful bruising syndrome (Gardner-Diamond syndrome) suffered from various gastrointestinal and psychologic complaints.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11475645", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 285, "text": "This paper presents a 26-year-old woman with the characteristic features of Gardner-Diamond syndrome: recurrent painful bruises reproducible by intradermal injection of autologous red blood cells, and a \"hysterical\" personality pattern together with nonspecific multisystem complaints.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2345102", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Gardner-Diamond's syndrome, or autoerythrocyte sensitization, is a disorder of spontaneous, painful ecchymoses whose pathogenesis is unresolved.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/921453", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Autoerythrocyte sensitization (Gardner-Diamond) syndrome mimicking compartment syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12838436", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Autoerythrocyte sensitization (Gardner-Diamond) syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10966177", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Autoerythrocyte sensitization syndrome (Gardner-Diamond syndrome) associated with cutaneous vasculitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18417404", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "Gardner-Diamond syndrome (GDS) is an uncommon disease clinically characterized by a wide spectrum of psycho-emotive symptoms associated with painful ecchymoses/purpuric lesions and positivity of auto-erythrocyte sensitization skin test.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27011410", "endSection": "abstract"}]}, {"body": "Where can you find the annulus of Zinn?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24697862", "http://www.ncbi.nlm.nih.gov/pubmed/25650797", "http://www.ncbi.nlm.nih.gov/pubmed/9783284", "http://www.ncbi.nlm.nih.gov/pubmed/22336122", "http://www.ncbi.nlm.nih.gov/pubmed/21772799", "http://www.ncbi.nlm.nih.gov/pubmed/16917665", "http://www.ncbi.nlm.nih.gov/pubmed/16955671", "http://www.ncbi.nlm.nih.gov/pubmed/22581081", "http://www.ncbi.nlm.nih.gov/pubmed/11601571", "http://www.ncbi.nlm.nih.gov/pubmed/17080461", "http://www.ncbi.nlm.nih.gov/pubmed/25744329", "http://www.ncbi.nlm.nih.gov/pubmed/8604741", "http://www.ncbi.nlm.nih.gov/pubmed/17667093", "http://www.ncbi.nlm.nih.gov/pubmed/8827557"], "ideal_answer": ["Annulus of Zinn is in the orbit."], "type": "factoid", "id": "58917c88621ea6ff7e00000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Should the annular tendon of the eye be named 'annulus of Zinn' or 'of Valsalva'?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24697862", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "The annular tendon is commonly named 'annulus of Zinn', from the German anatomist and botanist Johann Gottfried Zinn (1727-1759) who described this structure in his Descriptio anatomica oculi humani (Anatomical Description of the Human Eye, 1755).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24697862", "endSection": "abstract"}, {"offsetInBeginSection": 536, "offsetInEndSection": 683, "text": "It arose at the annulus of Zinn, passing forwards between the inferior rectus muscle and lateral rectus muscle, and insert directly on the sclera. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22336122", "endSection": "abstract"}, {"offsetInBeginSection": 1007, "offsetInEndSection": 1133, "text": "Drilling was continued toward the annulus of Zinn (AZ) and optic nerve superiorly and over the intracavernous ICA posteriorly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21772799", "endSection": "abstract"}, {"offsetInBeginSection": 498, "offsetInEndSection": 811, "text": "Measurements before and after resection of the ACP included the length of C6 segment of the ICA on its lateral aspect; C6 segment length on its medial aspect; and medial length of the optic nerve from the optic chiasm to falciform ligament (before ACP resection) then to the annulus of Zinn (after ACP resection).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16917665", "endSection": "abstract"}, {"offsetInBeginSection": 200, "offsetInEndSection": 499, "text": "The muscles, situated between the optic nerve and the lateral rectus muscle, originated from the annulus of Zinn and branched off two heads; one inserted into the medial inferior side of the superior rectus muscle and the other inserted into the central superior side of the inferior rectus muscle. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16955671", "endSection": "abstract"}, {"offsetInBeginSection": 404, "offsetInEndSection": 603, "text": " In 30 cadavers, the superior division of the oculomotor nerve was severed en bloc 1.5 cm anterior to the annulus of Zinn with the levator palpebrae superioris (LPS) and the superior rectus muscles. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11601571", "endSection": "abstract"}, {"offsetInBeginSection": 357, "offsetInEndSection": 474, "text": "The optic canal was subsequently removed en bloc, beginning at the annulus of Zinn and extending to the optic chiasm.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17667093", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 609, "text": "PURPOSE: To describe a combined transcranial-orbital approach for en bloc resection of optic nerve gliomas with preservation of the annulus of Zinn that minimizes recurrence and prevents postoperative paralytic ptosis.DESIGN: A retrospective, noncomparative, interventional case series.STUDY POPULATION: All patients who underwent optic nerve glioma resections using this technique with the authors between 1994 and 2010.PROCEDURE: A transcranial-orbital approach is used to resect the intracranial segment of the optic nerve glioma from 2 mm anterior to the chiasm to the posterior extent of annulus of Zinn.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", "endSection": "abstract"}, {"offsetInBeginSection": 1274, "offsetInEndSection": 1565, "text": "No patients had tumor recurrence or developed postoperative paralytic ptosis.CONCLUSIONS: The combined transcranial-orbital approach with preservation of the annulus of Zinn is a safe and effective way to remove optic nerve gliomas and ensure tumor clearance while avoiding paralytic ptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 562, "text": "To describe a combined transcranial-orbital approach for en bloc resection of optic nerve gliomas with preservation of the annulus of Zinn that minimizes recurrence and prevents postoperative paralytic ptosis.A retrospective, noncomparative, interventional case series.All patients who underwent optic nerve glioma resections using this technique with the authors between 1994 and 2010.A transcranial-orbital approach is used to resect the intracranial segment of the optic nerve glioma from 2 mm anterior to the chiasm to the posterior extent of annulus of Zinn", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", "endSection": "abstract"}, {"offsetInBeginSection": 663, "offsetInEndSection": 798, "text": "Through a superior orbitotomy exposure, the entire retrobulbar segment of the tumor is transected from the globe to the annulus of Zinn", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", "endSection": "abstract"}, {"offsetInBeginSection": 800, "offsetInEndSection": 1194, "text": "A simulation of the procedure in a cadaver and en bloc resection of the orbital apex are performed to demonstrate the subdural plane of dissection within the annulus of Zinn.Postoperative outcome measures include: health of the ipsilateral globe, paralytic ptosis, postoperative complications, and tumor recurrence.Eleven patients underwent resection of optic nerve gliomas using this technique", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", "endSection": "abstract"}, {"offsetInBeginSection": 1196, "offsetInEndSection": 1473, "text": "No patients had tumor recurrence or developed postoperative paralytic ptosis.The combined transcranial-orbital approach with preservation of the annulus of Zinn is a safe and effective way to remove optic nerve gliomas and ensure tumor clearance while avoiding paralytic ptosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", "endSection": "abstract"}, {"offsetInBeginSection": 412, "offsetInEndSection": 575, "text": "The orbital surface of the medial rectus and inferior rectus are exposed from the annulus of Zinn to a position close to where the muscles penetrate Tenons capsule", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8827557", "endSection": "abstract"}, {"offsetInBeginSection": 413, "offsetInEndSection": 579, "text": "The orbital surface of the medial rectus and inferior rectus are exposed from the annulus of Zinn to a position close to where the muscles penetrate Tenon's capsule. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8827557", "endSection": "abstract"}, {"offsetInBeginSection": 200, "offsetInEndSection": 498, "text": "The muscles, situated between the optic nerve and the lateral rectus muscle, originated from the annulus of Zinn and branched off two heads; one inserted into the medial inferior side of the superior rectus muscle and the other inserted into the central superior side of the inferior rectus muscle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16955671", "endSection": "abstract"}, {"offsetInBeginSection": 339, "offsetInEndSection": 456, "text": "The optic canal was subsequently removed en bloc, beginning at the annulus of Zinn and extending to the optic chiasm.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17667093", "endSection": "abstract"}, {"offsetInBeginSection": 862, "offsetInEndSection": 1114, "text": "The distance from the annulus of Zinn to the trochlea was the same in both eyes.The findings for our patients, particularly in those who underwent additional high resolution MRI, did not provide evidence of a lack of CN IV as a cause of Brown syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25744329", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Should the annular tendon of the eye be named 'annulus of Zinn' or 'of Valsalva'?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24697862", "endSection": "title"}, {"offsetInBeginSection": 864, "offsetInEndSection": 944, "text": "The distance from the annulus of Zinn to the trochlea was the same in both eyes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25744329", "endSection": "abstract"}, {"offsetInBeginSection": 340, "offsetInEndSection": 457, "text": "The optic canal was subsequently removed en bloc, beginning at the annulus of Zinn and extending to the optic chiasm.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17667093", "endSection": "abstract"}, {"offsetInBeginSection": 666, "offsetInEndSection": 802, "text": "Through a superior orbitotomy exposure, the entire retrobulbar segment of the tumor is transected from the globe to the annulus of Zinn.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581081", "endSection": "abstract"}]}, {"body": "What is the indication for SLCO1B1 genotyping?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26131212", "http://www.ncbi.nlm.nih.gov/pubmed/27595674", "http://www.ncbi.nlm.nih.gov/pubmed/25181036", "http://www.ncbi.nlm.nih.gov/pubmed/25150868", "http://www.ncbi.nlm.nih.gov/pubmed/25563221"], "ideal_answer": ["HMG Co-A reductase inhibitors, commonly known as statins, also display wide interindividual variability in plasma concentration, response and toxicity due in part to polymorphisms in transporter genes, including SLCO1B1 and ABCG2.  The SLCO1B1*5 variant is a risk factor for statin side effects and exhibits statin-specific effects: highest with simvastatin/atorvastatin and lowest with pravastatin/rosuvastatin."], "type": "factoid", "id": "58bbc0fc22d300530900001c", "snippets": [{"offsetInBeginSection": 264, "offsetInEndSection": 509, "text": "including the well-known genetic variant associated with statin-associated muscle symptoms-solute carrier organic anion transporter family, member 1B1 (SLCO1B1) rs4149056-also increase the risk of statin-associated muscle symptoms in FH patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27595674", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27595674", "endSection": "title"}, {"offsetInBeginSection": 1834, "offsetInEndSection": 2075, "text": "Similarly, HMG Co-A reductase inhibitors, commonly known as statins, also display wide interindividual variability in plasma concentration, response and toxicity due in part to polymorphisms in transporter genes, including SLCO1B1 and ABCG2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25181036", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26131212", "endSection": "title"}, {"offsetInBeginSection": 610, "offsetInEndSection": 775, "text": " development of SLCO1B1 genotyping to avoid statin induced adverse drug reactions is discussed as a model case for transporter pharmacogenetics clinical development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25150868", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 306, "text": "Statin adherence is often limited by side effects. The SLCO1B1*5 variant is a risk factor for statin side effects and exhibits statin-specific effects: highest with simvastatin/atorvastatin and lowest with pravastatin/rosuvastatin. The effects of SLCO1B1*5 genotype guided statin therapy (GGST) are unknown", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25563221", "endSection": "abstract"}]}, {"body": "List available circular RNA prediction tools.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26657634"], "ideal_answer": ["circRNA_finder, find_circ, CIRCexplorer, CIRI, and MapSplice."], "type": "list", "id": "588f220e3b87a8a73800000d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 1119, "text": "CircRNAs are novel members of the non-coding RNA family. For several decades circRNAs have been known to exist, however only recently the widespread abundance has become appreciated. Annotation of circRNAs depends on sequencing reads spanning the backsplice junction and therefore map as non-linear reads in the genome. Several pipelines have been developed to specifically identify these non-linear reads and consequently predict the landscape of circRNAs based on deep sequencing datasets. Here, we use common RNAseq datasets to scrutinize and compare the output from five different algorithms; circRNA_finder, find_circ, CIRCexplorer, CIRI, and MapSplice and evaluate the levels of bona fide and false positive circRNAs based on RNase R resistance. By this approach, we observe surprisingly dramatic differences between the algorithms specifically regarding the highly expressed circRNAs and the circRNAs derived from proximal splice sites. Collectively, this study emphasizes that circRNA annotation should be handled with care and that several algorithms should ideally be combined to achieve reliable predictions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657634", "endSection": "abstract"}]}, {"body": "Which disease is treated with Nusinersen?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26823478", "http://www.ncbi.nlm.nih.gov/pubmed/27939059", "http://www.ncbi.nlm.nih.gov/pubmed/26865511"], "ideal_answer": ["Nusinersen us used for treatment of Spinal Muscular Atrophy."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:4", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"], "type": "factoid", "id": "589185cc621ea6ff7e00000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26823478", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 284, "text": "Nusinersen (ISIS-SMNRx or ISIS 396443) is an antisense oligonucleotide drug administered intrathecally to treat spinal muscular atrophy. We summarize lumbar puncture experience in children with spinal muscular atrophy during a phase 1 open-label study of nusinersen and its extension.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26823478", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 465, "text": "OBJECTIVE: To examine safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of intrathecal nusinersen (previously ISIS-SMNRx), an antisense oligonucleotide designed to alter splicing of SMN2 mRNA, in patients with childhood spinal muscular atrophy (SMA).METHODS: Nusinersen was delivered by intrathecal injection to medically stable patients with type 2 and type 3 SMA aged 2-14 years in an open-label phase 1 study and its long-term extension. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", "endSection": "abstract"}, {"offsetInBeginSection": 1422, "offsetInEndSection": 1695, "text": "CONCLUSIONS: Results from this study support continued development of nusinersen for treatment of SMA.CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in children with SMA, intrathecal nusinersen is not associated with safety or tolerability concerns.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 626, "text": "BACKGROUND: Nusinersen is a 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular atrophy. Nusinersen is specifically designed to alter splicing of SMN2 pre-mRNA and thus increase the amount of functional survival motor neuron (SMN) protein that is deficient in patients with spinal muscular atrophy.METHODS: This open-label, phase 2, escalating dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusinersen (6 mg and 12 mg dose equivalents) in patients with infantile-onset spinal muscular atrophy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", "endSection": "abstract"}, {"offsetInBeginSection": 3149, "offsetInEndSection": 3289, "text": "Results informed the design of an ongoing, sham-controlled, phase 3 clinical study of nusinersen in infantile-onset spinal muscular atrophy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Nusinersen is a 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular atrophy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Nusinersen (ISIS-SMNRx or ISIS 396443) is an antisense oligonucleotide drug administered intrathecally to treat spinal muscular atrophy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26823478", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 283, "text": "We summarize lumbar puncture experience in children with spinal muscular atrophy during a phase 1 open-label study of nusinersen and its extension.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26823478", "endSection": "abstract"}, {"offsetInBeginSection": 124, "offsetInEndSection": 333, "text": "Nusinersen is specifically designed to alter splicing of SMN2 pre-mRNA and thus increase the amount of functional survival motor neuron (SMN) protein that is deficient in patients with spinal muscular atrophy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 263, "text": "To examine safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of intrathecal nusinersen (previously ISIS-SMNRx), an antisense oligonucleotide designed to alter splicing of SMN2 mRNA, in patients with childhood spinal muscular atrophy (SMA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26823478", "endSection": "title"}, {"offsetInBeginSection": 1396, "offsetInEndSection": 1485, "text": "Results from this study support continued development of nusinersen for treatment of SMA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", "endSection": "title"}, {"offsetInBeginSection": 3105, "offsetInEndSection": 3245, "text": "Results informed the design of an ongoing, sham-controlled, phase 3 clinical study of nusinersen in infantile-onset spinal muscular atrophy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27939059", "endSection": "abstract"}, {"offsetInBeginSection": 1486, "offsetInEndSection": 1630, "text": "This study provides Class IV evidence that in children with SMA, intrathecal nusinersen is not associated with safety or tolerability concerns..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26865511", "endSection": "abstract"}, {"offsetInBeginSection": 137, "offsetInEndSection": 284, "text": "We summarize lumbar puncture experience in children with spinal muscular atrophy during a phase 1 open-label study of nusinersen and its extension.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26823478", "endSection": "abstract"}]}, {"body": "Which disease the London mutation involved in?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17431643", "http://www.ncbi.nlm.nih.gov/pubmed/10525535", "http://www.ncbi.nlm.nih.gov/pubmed/16426772", "http://www.ncbi.nlm.nih.gov/pubmed/20523046", "http://www.ncbi.nlm.nih.gov/pubmed/15380017", "http://www.ncbi.nlm.nih.gov/pubmed/24145776", "http://www.ncbi.nlm.nih.gov/pubmed/27421117", "http://www.ncbi.nlm.nih.gov/pubmed/21389247", "http://www.ncbi.nlm.nih.gov/pubmed/22171952", "http://www.ncbi.nlm.nih.gov/pubmed/16467370", "http://www.ncbi.nlm.nih.gov/pubmed/24524897", "http://www.ncbi.nlm.nih.gov/pubmed/17215062", "http://www.ncbi.nlm.nih.gov/pubmed/15197738", "http://www.ncbi.nlm.nih.gov/pubmed/23747045", "http://www.ncbi.nlm.nih.gov/pubmed/20409323", "http://www.ncbi.nlm.nih.gov/pubmed/15314265", "http://www.ncbi.nlm.nih.gov/pubmed/19771217", "http://www.ncbi.nlm.nih.gov/pubmed/25108425", "http://www.ncbi.nlm.nih.gov/pubmed/20025930", "http://www.ncbi.nlm.nih.gov/pubmed/10500121"], "ideal_answer": ["London mutation that is the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile) is involved in Alzheimer's Disease."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017354", "http://www.disease-ontology.org/api/metadata/DOID:4", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020125", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016564", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194"], "type": "factoid", "id": "58b6978822d300530900000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "In the present study, we used a new training paradigm in the intelliCage automatic behavioral assessment system to investigate cognitive functions of the transgenic mice harboring London mutation of the human amyloid precursor protein (APP.V717I). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171952", "endSection": "abstract"}, {"offsetInBeginSection": 914, "offsetInEndSection": 1092, "text": "The novel approach to study the transgenic mice cognitive abilities presented in this paper offers new insight into cognitive dysfunctions of the Alzheimer's disease mouse model.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171952", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 856, "text": "One major hallmark of Alzheimer's disease (AD) is the massive loss of synapses that occurs at an early clinical stage of the disease. In this study, we characterize alterations in spine density and the expression of synapse-associated immediate early gene Arc (activity-regulated cytoskeleton-associated protein) in the hippocampal CA1 regions of two different amyloid precursor protein (APP) transgenic mouse lines before plaque development and their connection to performance in hippocampus-dependent memory tests. The density of mushroom-type spines was reduced by 34% in the basal dendrites proximal to the soma of CA1 pyramidal neurons in 5.5-month-old Tg2576 mice, carrying the Swedish mutation, compared with wild-type littermates. A similar reduction of 42% was confirmed in the same region of 8-month-old APP/Lo mice, carrying the London mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21389247", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", "endSection": "title"}, {"offsetInBeginSection": 145, "offsetInEndSection": 310, "text": "We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", "endSection": "abstract"}, {"offsetInBeginSection": 319, "offsetInEndSection": 579, "text": "In 1 family, this mutation was responsible for AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far. Two subjects of the other family with AD diagnosis were carriers of the same mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", "endSection": "abstract"}, {"offsetInBeginSection": 73, "offsetInEndSection": 628, "text": "A pathological hallmark in the brain of an AD patient is extracellular amyloid plaques formed by accumulated beta-amyloid protein (Abeta), a metabolic product of amyloid precursor protein (APP). Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD. For example, some mutant APPs are transmitted dominantly and are segregated with inheritance of early onset AD. These mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON)) are examples of these mutants. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426772", "endSection": "abstract"}, {"offsetInBeginSection": 1258, "offsetInEndSection": 1487, "text": "The sequences that are effective to silence APP(SW) and APP(LON) as identified in this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426772", "endSection": "abstract"}, {"offsetInBeginSection": 333, "offsetInEndSection": 638, "text": "Here, we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and carrying mutant and wild-type allelic sequences in their 3'-untranslated regions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19771217", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 341, "text": "Transgenic mice over-expressing a mutated form of the human amyloid precursor protein (APP, 695 isoform) bearing a mutation associated with Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age periods (3 and 10 months) prior to the overt development of neuritic amyloid plaques.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15380017", "endSection": "abstract"}, {"offsetInBeginSection": 521, "offsetInEndSection": 622, "text": "The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON)) are examples of these mutants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426772", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Allele-specific silencing of Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426772", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 455, "text": "Mutations in the amyloid precursor protein gene were the first to be recognized as a cause of Alzheimers disease (AD).We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation.In 1 family, this mutation was responsible for AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimers disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", "endSection": "title"}, {"offsetInBeginSection": 415, "offsetInEndSection": 584, "text": "We analyzed the cytotoxic mechanisms of the London-type AbetaPP mutant, V642I-AbetaPP, in primary cortical neurons utilizing an adenovirus-mediated gene transfer system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15197738", "endSection": "abstract"}, {"offsetInBeginSection": 1806, "offsetInEndSection": 2003, "text": "We demonstrate that the APP-London and PS1 mutations have additive effects on the increased secretion of betaA4(1-42) relative to betaA4(1-40), indicating that both mutations operate independently.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10525535", "endSection": "abstract"}, {"offsetInBeginSection": 1193, "offsetInEndSection": 1323, "text": "Pathogenic mutations in APP at codon 717 (APP \"London\") lead to an increased proportion of Abeta 1-42 being produced and secreted.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10500121", "endSection": "abstract"}, {"offsetInBeginSection": 526, "offsetInEndSection": 627, "text": "The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON)) are examples of these mutants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426772", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Allele-specific silencing of Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426772", "endSection": "title"}, {"offsetInBeginSection": 120, "offsetInEndSection": 285, "text": "We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "The London APP mutation (Val717Ile) associated with early shifting abilities and behavioral changes in two Italian families with early-onset Alzheimer's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20523046", "endSection": "title"}, {"offsetInBeginSection": 246, "offsetInEndSection": 341, "text": "Such cleavage is promoted by the Swedish and London mutations (APPSwe/Lon) inside the APP gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20025930", "endSection": "abstract"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1121, "text": "We also show that the Swedish and London mutations reduce the amount of APP in the lysosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20409323", "endSection": "abstract"}, {"offsetInBeginSection": 1375, "offsetInEndSection": 1479, "text": "This rapid transit to the lysosome is blocked by the presence of either the London or Swedish mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20409323", "endSection": "abstract"}]}, {"body": "Define lncRNA.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26207516", "http://www.ncbi.nlm.nih.gov/pubmed/26166759", "http://www.ncbi.nlm.nih.gov/pubmed/25994219", "http://www.ncbi.nlm.nih.gov/pubmed/26004516", "http://www.ncbi.nlm.nih.gov/pubmed/26142536", "http://www.ncbi.nlm.nih.gov/pubmed/27729273"], "ideal_answer": ["Long noncoding RNAs (lncRNAs) represent a newly discovered class of regulatory molecules that impact a variety of biological processes in cells and organ systems. In humans, it is estimated that there may be more than twice as many lncRNA genes than protein-coding genes. However, only a handful of lncRNAs have been analyzed in detail.\nLong non-coding RNAs (lncRNAs) are emerging as key molecules in cancers, yet their potential molecular mechanisms are not well understood.\nlong noncoding RNAs (lncRNAs), the largest family of noncoding transcripts, have emerged as common regulators of many cellular stressors; including heat shock, metabolic deprivation and DNA damage."], "type": "summary", "id": "58bc696b02b8c60953000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "Protein-coding genes account for only 2% of the human genome, whereas the vast majority of transcripts are noncoding RNAs including long noncoding RNAs. LncRNAs are involved in the regulation of a diverse array of biological processes, including cancer progression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26207516", "endSection": "abstract"}, {"offsetInBeginSection": 208, "offsetInEndSection": 336, "text": "Recently, aberrant expression of long noncoding RNAs (lncRNAs) has been considered as a primary feature of many types of cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729273", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 336, "text": "Long noncoding RNAs (lncRNAs) represent a newly discovered class of regulatory molecules that impact a variety of biological processes in cells and organ systems. In humans, it is estimated that there may be more than twice as many lncRNA genes than protein-coding genes. However, only a handful of lncRNAs have been analyzed in detail.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26166759", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Genomic imprinting has been a great resource for studying transcriptional and post-transcriptional-based gene regulation by long noncoding RNAs (lncRNAs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26004516", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 150, "text": "Long non-coding RNAs (lncRNAs) are emerging as key molecules in cancers, yet their potential molecular mechanisms are not well understood. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25994219", "endSection": "abstract"}, {"offsetInBeginSection": 706, "offsetInEndSection": 904, "text": "long noncoding RNAs (lncRNAs), the largest family of noncoding transcripts, have emerged as common regulators of many cellular stressors; including heat shock, metabolic deprivation and DNA damage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142536", "endSection": "abstract"}]}, {"body": "How many microorganisms are present in human normal gut?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26613639", "http://www.ncbi.nlm.nih.gov/pubmed/26627987", "http://www.ncbi.nlm.nih.gov/pubmed/26908163", "http://www.ncbi.nlm.nih.gov/pubmed/26945826"], "ideal_answer": ["Human gut microbiota is home to 10 to 100 trillions microorganisms."], "type": "factoid", "id": "58bc347422d300530900001e", "snippets": [{"offsetInBeginSection": 267, "offsetInEndSection": 494, "text": ". A major breakthrough in understanding the etiology of neurological disorders is the recent insight on the role of the gut microbiota (GM). Human GM also referred to as the \"forgotten organ\" is home to 10(13-14) microorganisms", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26613639", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "The gut microbiome comprises the collective genome of the trillions of microorganisms residing in our gastrointestinal ecosystem.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26627987", "endSection": "abstract"}, {"offsetInBeginSection": 655, "offsetInEndSection": 847, "text": "The gut microbiome (i.e. the 100 trillion symbiotic microorganisms which inhabit the mammalian gastrointestinal tract) influences numerous aspects of host metabolism, development and immunity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908163", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "The microorganisms inhabiting the human gut are abundant (10(14) cells) and diverse (approximately 500 species per individual).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26945826", "endSection": "abstract"}]}, {"body": "What is the role of 3,4-diaminobenzoic acid derivatives in the immune system?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25635706"], "ideal_answer": ["3,4-diaminobenzoic acid derivatives are inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties. Cell-based analysis indicated that the lead compounds can be effective in downregulating macrophage activation induced by lipopolysaccharide and interferon-\u03b3 as well as cross-presentation by bone marrow-derived dendritic cells."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007154", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4258378", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007107", "http://www.biosemantics.org/jochem#4258378"], "type": "factoid", "id": "5887fe7d3b87a8a738000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "3,4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635706", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1029, "text": "Members of the oxytocinase subfamily of M1 aminopeptidases (ERAP1, ERAP2, and IRAP) play important roles in both the adaptive and innate human immune responses. Their enzymatic activity can contribute to the pathogenesis of several major human diseases ranging from viral and parasitic infections to autoimmunity and cancer. We have previously demonstrated that diaminobenzoic acid derivatives show promise as selective inhibitors for this group of aminopeptidases. In this study, we have thoroughly explored a series of 3,4-diaminobenzoic acid derivatives as inhibitors of this class of enzymes, achieving submicromolar inhibitors for ERAP2 (IC50 = 237 nM) and IRAP (IC50 = 105 nM). Cell-based analysis indicated that the lead compounds can be effective in downregulating macrophage activation induced by lipopolysaccharide and interferon-\u03b3 as well as cross-presentation by bone marrow-derived dendritic cells. Our results indicate that this class of inhibitors may be useful for the targeted downregulation of immune responses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "3,4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635706", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Members of the oxytocinase subfamily of M1 aminopeptidases (ERAP1, ERAP2, and IRAP) play important roles in both the adaptive and innate human immune responses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "3,4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635706", "endSection": "title"}]}, {"body": "Can NADPH oxidase be inhibited by apocynin and diphenylene iodonium?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22503982", "http://www.ncbi.nlm.nih.gov/pubmed/21693104", "http://www.ncbi.nlm.nih.gov/pubmed/17962358", "http://www.ncbi.nlm.nih.gov/pubmed/17046555", "http://www.ncbi.nlm.nih.gov/pubmed/19819434", "http://www.ncbi.nlm.nih.gov/pubmed/1324836", "http://www.ncbi.nlm.nih.gov/pubmed/15271858", "http://www.ncbi.nlm.nih.gov/pubmed/12424096", "http://www.ncbi.nlm.nih.gov/pubmed/16393992", "http://www.ncbi.nlm.nih.gov/pubmed/15308331", "http://www.ncbi.nlm.nih.gov/pubmed/25920934", "http://www.ncbi.nlm.nih.gov/pubmed/18195159", "http://www.ncbi.nlm.nih.gov/pubmed/24794531", "http://www.ncbi.nlm.nih.gov/pubmed/26728380", "http://www.ncbi.nlm.nih.gov/pubmed/24037962", "http://www.ncbi.nlm.nih.gov/pubmed/22134950", "http://www.ncbi.nlm.nih.gov/pubmed/11755128", "http://www.ncbi.nlm.nih.gov/pubmed/20698853", "http://www.ncbi.nlm.nih.gov/pubmed/16741139", "http://www.ncbi.nlm.nih.gov/pubmed/17341601", "http://www.ncbi.nlm.nih.gov/pubmed/19892012", "http://www.ncbi.nlm.nih.gov/pubmed/15845907", "http://www.ncbi.nlm.nih.gov/pubmed/3800872", "http://www.ncbi.nlm.nih.gov/pubmed/17662968", "http://www.ncbi.nlm.nih.gov/pubmed/17904225", "http://www.ncbi.nlm.nih.gov/pubmed/23229789", "http://www.ncbi.nlm.nih.gov/pubmed/21159852", "http://www.ncbi.nlm.nih.gov/pubmed/12867501", "http://www.ncbi.nlm.nih.gov/pubmed/19281832", "http://www.ncbi.nlm.nih.gov/pubmed/2121828", "http://www.ncbi.nlm.nih.gov/pubmed/15346654", "http://www.ncbi.nlm.nih.gov/pubmed/25666589", "http://www.ncbi.nlm.nih.gov/pubmed/20860666"], "ideal_answer": ["Yes, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase can be inhibited by apocynin or diphenylene iodonium (DPI)."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0016174", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4251947", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019255", "http://www.biosemantics.org/jochem#4270191", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4276074", "http://amigo.geneontology.org/amigo/term/GO:0043020"], "type": "yesno", "id": "58a5924060087bc10a000020", "snippets": [{"offsetInBeginSection": 637, "offsetInEndSection": 968, "text": "Ang II treatment also led to a significant increment in intracellular reactive oxygen species generation, which could be fully abolished by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitors apocynin or diphenylene iodonium, indicating that Ang II enhanced oxidative stress via a NADPH oxidase-dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25666589", "endSection": "abstract"}, {"offsetInBeginSection": 1220, "offsetInEndSection": 1390, "text": "NOX inhibitors (diphenylene iodonium (DPI) or apocynin) were able to achieve similar results to that of ML-7 except no effect on MLCK activity and MLC20 phosphorylation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25920934", "endSection": "abstract"}, {"offsetInBeginSection": 1211, "offsetInEndSection": 1375, "text": "Significant reductions of AII effects on podocyte TRPC6 were also observed after pretreatment with NADPH oxidase inhibitors apocynin or diphenylene iodonium (DPI). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24037962", "endSection": "abstract"}, {"offsetInBeginSection": 930, "offsetInEndSection": 1216, "text": "Furthermore, inhibition of NOX-mediated ROS production with apocynin, diphenylene iodonium (DPI) or NOX2 docking sequence (Nox2ds)-tat peptide during these first 4h of PE stimulation significantly inhibited PE-induced hypertrophy of H9c2 cells, both after 24 and 48h of PE stimulation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24794531", "endSection": "abstract"}, {"offsetInBeginSection": 603, "offsetInEndSection": 820, "text": "Remarkably, Ang-II induced reactive oxygen species (ROS) via a NAD(P)H oxidase-dependent mechanism, as shown by inhibition of ROS production via the NAD(P)H oxidase inhibitors diphenylene iodonium (DPI) and apocynin. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21693104", "endSection": "abstract"}, {"offsetInBeginSection": 998, "offsetInEndSection": 1194, "text": "Moreover, NADPH oxidase activation by beta CD (145.5+/-9.0%; control: 98.6+/-1.6%) was also abrogated by the NADPH oxidase inhibitors apocynin (100.4+/-3.2%) and diphenylene iodonium (9.5+/-3.3%).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18195159", "endSection": "abstract"}, {"offsetInBeginSection": 627, "offsetInEndSection": 870, "text": "We used structurally diverse NADPH oxidase inhibitors, aminoethyl-benzenesulfonylfluoride (AEBSF, 100-1000microM), apocynin (100-1000microM), and diphenylene iodonium (DPI, 3-30microM), to inhibit intrinsic NADPH oxidase activity in N27 cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17904225", "endSection": "abstract"}, {"offsetInBeginSection": 972, "offsetInEndSection": 1149, "text": "Paraquat-induced ROS production was inhibited by NADPH oxidase inhibitors, apocynin and diphenylene iodonium (DPI), but not the xanthine/xanthine oxidase inhibitor, allopurinol.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662968", "endSection": "abstract"}, {"offsetInBeginSection": 174, "offsetInEndSection": 453, "text": "With the use of dihydroethidium as a superoxide indicator, C(2)-ceramide was found to increase superoxide production in the endothelial cells of small coronary arteries, which was inhibited by the NADPH oxidase inhibitors N-vanillylnonanamide, apocynin, and diphenylene iodonium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12424096", "endSection": "abstract"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1057, "text": "The contractile responses to U46619 in isolated PA were inhibited by PEG-catalase and the NADPH oxidase inhibitors diphenylene iodonium (DPI) and apocynin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17341601", "endSection": "abstract"}, {"offsetInBeginSection": 587, "offsetInEndSection": 732, "text": "The effects of diphenylene iodonium (DPI) and apocynin, inhibitors of NADPH oxidase, on key parameters of PSC activation were evaluated in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17962358", "endSection": "abstract"}, {"offsetInBeginSection": 1084, "offsetInEndSection": 1250, "text": "These effects could be inhibited by diphenylene iodonium and apocynin, indicating a self-cycle regulated by NADPH oxidase in microglial activation in response to oA\u00e2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229789", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Diphenylene iodonium is an inhibitor of the respiratory burst-generating NADPH oxidase of phagocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2121828", "endSection": "abstract"}, {"offsetInBeginSection": 628, "offsetInEndSection": 861, "text": "NADPH oxidase inhibitors [diphenylene iodonium (DPI) and apocynin (4-hydroxy-3-methoxy-acetophenone)] prevented the microglial activation induced by oA\u00e2, suggesting that NADPH oxidase activation was involved in microglial activation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229789", "endSection": "abstract"}, {"offsetInBeginSection": 517, "offsetInEndSection": 693, "text": "In addition, inhibitors of NADPH oxidase (diphenylene iodonium or apocynin) also prevented microglia proliferation, suggesting that this may be the source of hydrogen peroxide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16393992", "endSection": "abstract"}, {"offsetInBeginSection": 632, "offsetInEndSection": 861, "text": "Inhibitors of NADPH oxidase (diphenylene iodonium, apocynin, D-(+)-neopterine) also significantly blunted the generation of reactive oxygen species, activation of K(+), Cl(-)-cotransport and apoptosis induced by N-ethylmaleimide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11755128", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 454, "text": "With the use of dihydroethidium as a superoxide indicator, C(2)-ceramide was found to increase superoxide production in the endothelial cells of small coronary arteries, which was inhibited by the NADPH oxidase inhibitors N-vanillylnonanamide, apocynin, and diphenylene iodonium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12424096", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "NADPH-dependent superoxide production by the solubilized oxidase of neutrophils was inhibited 36% by diphenylene iodonium at a 1:1 stoichiometry with the enzyme flavoprotein content.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3800872", "endSection": "abstract"}, {"offsetInBeginSection": 1084, "offsetInEndSection": 1249, "text": "These effects could be inhibited by diphenylene iodonium and apocynin, indicating a self-cycle regulated by NADPH oxidase in microglial activation in response to oA\u03b2", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229789", "endSection": "abstract"}, {"offsetInBeginSection": 540, "offsetInEndSection": 941, "text": "Moreover, CSE-regulated COX-2, PGE(2), and IL-6 generation was inhibited by pretreatment with TLR4 Ab; inhibitors of c-Src (PP1), NADPH oxidase (diphenylene iodonium chloride and apocynin), p38 MAPK (SB202190), MEK1/2 (U0126), JNK1/2 (SP600125), and NF-kappaB (helenalin); a ROS scavenger (N-acetyl-l-cysteine); and transfection with siRNA of TLR4, MyD88, TRAF6, Src, p47(phox), p38, p42, JNK2, or p65", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19892012", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 747, "text": "Treatment of the cells with the NADPH oxidase inhibitors, apocynin and diphenylene iodonium, inhibited these effects", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17046555", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 453, "text": "With the use of dihydroethidium as a superoxide indicator, C(2)-ceramide was found to increase superoxide production in the endothelial cells of small coronary arteries, which was inhibited by the NADPH oxidase inhibitors N-vanillylnonanamide, apocynin, and diphenylene iodonium", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12424096", "endSection": "abstract"}, {"offsetInBeginSection": 394, "offsetInEndSection": 745, "text": "UVB irradiation generated ROS in a dose-dependent manner, and this was significantly inhibited by diphenylene iodonium (DPI), apocynin (Apo) and neopterine (Neo), inhibitors of the NADPH oxidase, and indomethacin (Indo), a cyclooxygenase (COX) inhibitor, but not by the mitochondrial electron transport inhibitors and other cytosolic enzyme inhibitors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15308331", "endSection": "abstract"}, {"offsetInBeginSection": 802, "offsetInEndSection": 1121, "text": "In RBA-1 cells, JEV induced MMP-9 expression and promoter activity, which was inhibited by pretreatment with inhibitors of NADPH oxidase (diphenylene iodonium chloride or apocynin), MAPKs (U0126, SB203580 or SP600125) and a ROS scavenger (N-acetylcysteine), or transfection with siRNAs of p47(phox) , ERK1, JNK2 and p38", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20698853", "endSection": "abstract"}, {"offsetInBeginSection": 750, "offsetInEndSection": 955, "text": "Such discharge of Dectin-1-reactive \u03b2-glucan from macrophage cells was inhibited by either NADPH oxidase inhibitors (apocynin and diphenylene iodonium) or radical scavengers (N-acetyl cysteine and MCI-186)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22503982", "endSection": "abstract"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1056, "text": "The contractile responses to U46619 in isolated PA were inhibited by PEG-catalase and the NADPH oxidase inhibitors diphenylene iodonium (DPI) and apocynin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17341601", "endSection": "abstract"}, {"offsetInBeginSection": 1213, "offsetInEndSection": 1385, "text": "ANG II further increased superoxide production in LP only, and this was inhibited by coincubation with diphenylene iodonium or apocynin (inhibitor of NADPH oxidase complex)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16741139", "endSection": "abstract"}, {"offsetInBeginSection": 411, "offsetInEndSection": 973, "text": "Our results showed that IL-1beta enhanced HTSMCs-monocyte adhesion through up-regulation of VCAM-1, which was inhibited by pretreatment with selective inhibitors of PKCalpha (G\u00f66976), c-Src (PP1), NADPH oxidase [diphenylene iodonium (DPI) and apocynin (APO)], intracellular calcium chelator (BAPTA/AM), PI-PLC (U73122), CaM (calmidazolium chloride), CaM kinase II (KN62), p300 (garcinol), NF-kappaB (Bay11-7082), HDAC (trichostatin A), and ROS scavenger [N-acetyl-L-cysteine (NAC)] or transfection with siRNAs of MyD88, PKCalpha, Src, p47(phox), p300, and HDAC4.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19281832", "endSection": "abstract"}, {"offsetInBeginSection": 388, "offsetInEndSection": 640, "text": "Here we show that cAMP-dependent decidualization can be attenuated or enhanced upon treatment of primary cultures with a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor (diphenylen iodonium) or activator (apocynin), respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21159852", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 455, "text": "With the use of dihydroethidium as a superoxide indicator, C(2)-ceramide was found to increase superoxide production in the endothelial cells of small coronary arteries, which was inhibited by the NADPH oxidase inhibitors N-vanillylnonanamide, apocynin, and diphenylene iodonium. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12424096", "endSection": "abstract"}, {"offsetInBeginSection": 622, "offsetInEndSection": 1011, "text": "The inhibition of NAD(P)H oxidase by apocynin and diphenylene iodonium, and of the mitochondrial electron transport system at complex II by thenoyltrifluoroacetone (TTFA), significantly inhibited both AGE-induced ROS production and VCAM-1 expression, whereas these effects were potentiated by rotenone and antimycin A, specific inhibitors of mitochondrial complex I and III, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15845907", "endSection": "abstract"}, {"offsetInBeginSection": 977, "offsetInEndSection": 1155, "text": "Paraquat-induced ROS production was inhibited by NADPH oxidase inhibitors, apocynin and diphenylene iodonium (DPI), but not the xanthine/xanthine oxidase inhibitor, allopurinol. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662968", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 749, "text": "Treatment of the cells with the NADPH oxidase inhibitors, apocynin and diphenylene iodonium, inhibited these effects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17046555", "endSection": "abstract"}, {"offsetInBeginSection": 218, "offsetInEndSection": 626, "text": "The G6PD inhibitor DHEA and the inhibitors of NADPH oxidase apocynin and diphenylene iodonium (DPI) prevented both superoxide generation and capacitation in human spermatozoa, but whereas DPI and DHEA inhibited PPP, apocynin did not influence it, suggesting that PPP activation during capacitation is not a response to increased oxidative stress but exerts a role by supplying reducing equivalents to oxygen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19819434", "endSection": "abstract"}, {"offsetInBeginSection": 586, "offsetInEndSection": 809, "text": "Ang II induced a time-dependent increase in Rac1 activation and O(2)(*-) production in Neuro-2A cells, and this was abolished by pretreatment with AdN17Rac1 or the NADPH oxidase inhibitors apocynin or diphenylene iodonium. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15271858", "endSection": "abstract"}, {"offsetInBeginSection": 977, "offsetInEndSection": 1154, "text": "Paraquat-induced ROS production was inhibited by NADPH oxidase inhibitors, apocynin and diphenylene iodonium (DPI), but not the xanthine/xanthine oxidase inhibitor, allopurinol.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662968", "endSection": "abstract"}, {"offsetInBeginSection": 802, "offsetInEndSection": 1122, "text": "In RBA-1 cells, JEV induced MMP-9 expression and promoter activity, which was inhibited by pretreatment with inhibitors of NADPH oxidase (diphenylene iodonium chloride or apocynin), MAPKs (U0126, SB203580 or SP600125) and a ROS scavenger (N-acetylcysteine), or transfection with siRNAs of p47(phox) , ERK1, JNK2 and p38.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20698853", "endSection": "abstract"}, {"offsetInBeginSection": 1084, "offsetInEndSection": 1250, "text": "These effects could be inhibited by diphenylene iodonium and apocynin, indicating a self-cycle regulated by NADPH oxidase in microglial activation in response to oA\u03b2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229789", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 748, "text": "Treatment of the cells with the NADPH oxidase inhibitors, apocynin and diphenylene iodonium, inhibited these effects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17046555", "endSection": "abstract"}, {"offsetInBeginSection": 394, "offsetInEndSection": 746, "text": "UVB irradiation generated ROS in a dose-dependent manner, and this was significantly inhibited by diphenylene iodonium (DPI), apocynin (Apo) and neopterine (Neo), inhibitors of the NADPH oxidase, and indomethacin (Indo), a cyclooxygenase (COX) inhibitor, but not by the mitochondrial electron transport inhibitors and other cytosolic enzyme inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15308331", "endSection": "abstract"}, {"offsetInBeginSection": 750, "offsetInEndSection": 956, "text": "Such discharge of Dectin-1-reactive \u03b2-glucan from macrophage cells was inhibited by either NADPH oxidase inhibitors (apocynin and diphenylene iodonium) or radical scavengers (N-acetyl cysteine and MCI-186).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22503982", "endSection": "abstract"}, {"offsetInBeginSection": 411, "offsetInEndSection": 910, "text": "Our results showed that IL-1beta enhanced HTSMCs-monocyte adhesion through up-regulation of VCAM-1, which was inhibited by pretreatment with selective inhibitors of PKCalpha (G\u00f66976), c-Src (PP1), NADPH oxidase [diphenylene iodonium (DPI) and apocynin (APO)], intracellular calcium chelator (BAPTA/AM), PI-PLC (U73122), CaM (calmidazolium chloride), CaM kinase II (KN62), p300 (garcinol), NF-kappaB (Bay11-7082), HDAC (trichostatin A), and ROS scavenger [N-acetyl-L-cysteine (NAC)] or transfection w", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19281832", "endSection": "abstract"}, {"offsetInBeginSection": 540, "offsetInEndSection": 942, "text": "Moreover, CSE-regulated COX-2, PGE(2), and IL-6 generation was inhibited by pretreatment with TLR4 Ab; inhibitors of c-Src (PP1), NADPH oxidase (diphenylene iodonium chloride and apocynin), p38 MAPK (SB202190), MEK1/2 (U0126), JNK1/2 (SP600125), and NF-kappaB (helenalin); a ROS scavenger (N-acetyl-l-cysteine); and transfection with siRNA of TLR4, MyD88, TRAF6, Src, p47(phox), p38, p42, JNK2, or p65.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19892012", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "The use of diphenylene iodonium, an inhibitor of NADPH oxidase, to investigate the antimicrobial action of human monocyte derived macrophages.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2121828", "endSection": "title"}, {"offsetInBeginSection": 628, "offsetInEndSection": 861, "text": "NADPH oxidase inhibitors [diphenylene iodonium (DPI) and apocynin (4-hydroxy-3-methoxy-acetophenone)] prevented the microglial activation induced by oA\u03b2, suggesting that NADPH oxidase activation was involved in microglial activation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229789", "endSection": "abstract"}, {"offsetInBeginSection": 930, "offsetInEndSection": 1215, "text": "Furthermore, inhibition of NOX-mediated ROS production with apocynin, diphenylene iodonium (DPI) or NOX2 docking sequence (Nox2ds)-tat peptide during these first 4h of PE stimulation significantly inhibited PE-induced hypertrophy of H9c2 cells, both after 24 and 48h of PE stimulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24794531", "endSection": "abstract"}, {"offsetInBeginSection": 434, "offsetInEndSection": 664, "text": "We compared the pharmacological profiles of the commonly used NADPH oxidase inhibitors, diphenylene iodonium (DPI), apocynin and 4-(2-amino-ethyl)-benzolsulphonyl-fluoride (AEBSF), as well as the novel triazolo pyrimidine VAS3947.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20860666", "endSection": "abstract"}, {"offsetInBeginSection": 694, "offsetInEndSection": 939, "text": "IL-1beta and TNF-alpha rapidly stimulated the rate of hydrogen peroxide produced by isolated microglia, and this was inhibited by diphenylene iodonium, implying that the cytokines were acting directly on microglia to stimulate the NADPH oxidase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16393992", "endSection": "abstract"}, {"offsetInBeginSection": 1062, "offsetInEndSection": 1224, "text": "The fractions achieved the same effects that known NADPH oxidase inhibitors, such as diphenylene iodonium and apocynin, but they presented better hydrosolubility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134950", "endSection": "abstract"}, {"offsetInBeginSection": 586, "offsetInEndSection": 808, "text": "Ang II induced a time-dependent increase in Rac1 activation and O(2)(*-) production in Neuro-2A cells, and this was abolished by pretreatment with AdN17Rac1 or the NADPH oxidase inhibitors apocynin or diphenylene iodonium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15271858", "endSection": "abstract"}]}, {"body": "Viliuisk encephalomyelitis is diagnosed in which geographical area?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7848104", "http://www.ncbi.nlm.nih.gov/pubmed/20010208", "http://www.ncbi.nlm.nih.gov/pubmed/19618339", "http://www.ncbi.nlm.nih.gov/pubmed/1393513", "http://www.ncbi.nlm.nih.gov/pubmed/15182325", "http://www.ncbi.nlm.nih.gov/pubmed/18379734", "http://www.ncbi.nlm.nih.gov/pubmed/9223130", "http://www.ncbi.nlm.nih.gov/pubmed/24586232", "http://www.ncbi.nlm.nih.gov/pubmed/18252102", "http://www.ncbi.nlm.nih.gov/pubmed/2894813"], "ideal_answer": ["Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:640", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004679"], "type": "factoid", "id": "588f9f83ed9bbee70d000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "BACKGROUND: Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586232", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Communicating hydrocephalus following eosinophilic meningitis is pathogenic for chronic Viliuisk encephalomyelitis in Northeastern Siberia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586232", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Epidemiology of Viliuisk encephalomyelitis in Eastern Siberia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010208", "endSection": "title"}, {"offsetInBeginSection": 245, "offsetInEndSection": 350, "text": ". An epidemic of this disease has been spreading throughout the Yakut Republic of the Russian Federation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010208", "endSection": "abstract"}, {"offsetInBeginSection": 502, "offsetInEndSection": 729, "text": "METHODS: Detailed clinical, pathologic, laboratory, and epidemiologic studies have identified 414 patients with definite Viliuisk encephalomyelitis in 15 of 33 administrative regions of the Yakut Republic between 1940 and 1999.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010208", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Viliuisk encephalomyelitis in Eastern Siberia - analysis of 390 cases.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19618339", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Viliuisk encephalomyelitis (VE) is a unique disease occurring in the Yakut (Sakha) population of Eastern Siberia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19618339", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Viliuisk encephalomyelitis in Northeastern Siberia is not caused by Borrelia burgdorferi infection.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18379734", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeastern Siberia and generally believed to be a chronic encephalomyelitis of unknown origin. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18379734", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeastern Siberia and generally believed to be a chronic encephalomyelitis of unknown origin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18379734", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586232", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Viliuisk encephalomyelitis in the Iakut people of Siberia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1393513", "endSection": "title"}, {"offsetInBeginSection": 727, "offsetInEndSection": 983, "text": "Initially identified in a small Yakut-Evenk population on the Viliui River of eastern Siberia, the disease subsequently spread through human contacts to new geographic areas, thus characterizing Viliuisk encephalomyelitis as an emerging infectious disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18252102", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Viliuisk encephalomyelitis (VE) is an unique neurological disease occurring in the Iakut (Sakha) people of Siberia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9223130", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Viliuisk encephalomyelitis (VEM) appears to be endemic disease, affecting native population in Yakutia (Yakut, Even, Evenk).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7848104", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 534, "text": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic.In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586232", "endSection": "abstract"}, {"offsetInBeginSection": 732, "offsetInEndSection": 987, "text": "Initially identified in a small Yakut-Evenk population on the Viliui River of eastern Siberia, the disease subsequently spread through human contacts to new geographic areas, thus characterizing Viliuisk encephalomyelitis as an emerging infectious disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18252102", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Viliuisk encephalomyelitis (VE) is a unique disease occurring in the Yakut (Sakha) population of Eastern Siberia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19618339", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Viliuisk encephalomyelitis in Northeastern Siberia is not caused by Borrelia burgdorferi infection", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18379734", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeastern Siberia and generally believed to be a chronic encephalomyelitis of unknown origin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18379734", "endSection": "abstract"}, {"offsetInBeginSection": 732, "offsetInEndSection": 988, "text": "Initially identified in a small Yakut-Evenk population on the Viliui River of eastern Siberia, the disease subsequently spread through human contacts to new geographic areas, thus characterizing Viliuisk encephalomyelitis as an emerging infectious disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18252102", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 535, "text": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic.In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586232", "endSection": "abstract"}, {"offsetInBeginSection": 447, "offsetInEndSection": 926, "text": "IgG antibodies to HTLV-I were measured in the sera and/or cerebrospinal fluid from 82 Guamanian patients with amyotrophic lateral sclerosis and parkinsonism-dementia, 164 Guamanian normal controls, 10 patients with kuru from the Eastern Highlands of Papua New Guinea, 4 patients with Viliuisk encephalomyelitis from the Iakut region of eastern Siberia, 45 Italian patients with multiple sclerosis, and 56 patients with polymyositis (49 from the United States and 7 from Jamaica).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2894813", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Viliuisk encephalomyelitis (VE), a progressive neurological disorder with a fatal outcome usually in several months to 6 yrs after disease onset, is seen only among the Iakut people of Siberia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1393513", "endSection": "abstract"}, {"offsetInBeginSection": 559, "offsetInEndSection": 731, "text": "Transmission to unrelated persons was documented in a densely populated region around the city of Yakutsk in which Viliuisk encephalomyelitis had not been previously known.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18252102", "endSection": "abstract"}, {"offsetInBeginSection": 732, "offsetInEndSection": 989, "text": "Initially identified in a small Yakut-Evenk population on the Viliui River of eastern Siberia, the disease subsequently spread through human contacts to new geographic areas, thus characterizing Viliuisk encephalomyelitis as an emerging infectious disease..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18252102", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Epidemiology of Viliuisk encephalomyelitis in Eastern Siberia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20010208", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Viliuisk encephalomyelitis in the Iakut people of Siberia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1393513", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Viliuisk encephalomyelitis in Eastern Siberia - analysis of 390 cases.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19618339", "endSection": "title"}]}, {"body": "What are Septins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8636235", "http://www.ncbi.nlm.nih.gov/pubmed/18586950", "http://www.ncbi.nlm.nih.gov/pubmed/11238387", "http://www.ncbi.nlm.nih.gov/pubmed/22815479", "http://www.ncbi.nlm.nih.gov/pubmed/18541672", "http://www.ncbi.nlm.nih.gov/pubmed/23204191", "http://www.ncbi.nlm.nih.gov/pubmed/8791410", "http://www.ncbi.nlm.nih.gov/pubmed/27473901", "http://www.ncbi.nlm.nih.gov/pubmed/17922164", "http://www.ncbi.nlm.nih.gov/pubmed/24367716", "http://www.ncbi.nlm.nih.gov/pubmed/27048593", "http://www.ncbi.nlm.nih.gov/pubmed/27044893", "http://www.ncbi.nlm.nih.gov/pubmed/24664283", "http://www.ncbi.nlm.nih.gov/pubmed/22767579", "http://www.ncbi.nlm.nih.gov/pubmed/20517926", "http://www.ncbi.nlm.nih.gov/pubmed/26700173", "http://www.ncbi.nlm.nih.gov/pubmed/21824004", "http://www.ncbi.nlm.nih.gov/pubmed/26780475", "http://www.ncbi.nlm.nih.gov/pubmed/15214843", "http://www.ncbi.nlm.nih.gov/pubmed/14517318", "http://www.ncbi.nlm.nih.gov/pubmed/20885997", "http://www.ncbi.nlm.nih.gov/pubmed/10607590", "http://www.ncbi.nlm.nih.gov/pubmed/21082023", "http://www.ncbi.nlm.nih.gov/pubmed/21883761", "http://www.ncbi.nlm.nih.gov/pubmed/25217462", "http://www.ncbi.nlm.nih.gov/pubmed/18826657", "http://www.ncbi.nlm.nih.gov/pubmed/25575596", "http://www.ncbi.nlm.nih.gov/pubmed/25957401"], "ideal_answer": ["Septins are an evolutionarily conserved family of GTP-binding proteins. They are involved in diverse processes including cytokinesis, apoptosis, infection, neurodegeneration and neoplasia. In yeast, septins assemble into a highly ordered array of filaments at the mother bud neck in Saccharomyces cerevisiae cells. Septins have been implicated in a diverse range of cancers, including gastric cancer, but the underlying mechanisms remain unclear.", "Septins are an evolutionarily conserved family of GTP-binding proteins. discover that septins, a component of the cytoskeleton, recognize membrane curvature at the micron scale, a common morphological hallmark of eukaryotic cellular processes. eptins are a family of cytoskeletal GTP-binding proteins that assemble into membrane-associated hetero-oligomers and organize scaffolds for recruitment of cytosolic proteins or stabilization of membrane proteins. "], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058112"], "type": "summary", "id": "58a327bf60087bc10a000011", "snippets": [{"offsetInBeginSection": 154, "offsetInEndSection": 325, "text": "discover that septins, a component of the cytoskeleton, recognize membrane curvature at the micron scale, a common morphological hallmark of eukaryotic cellular processes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27044893", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Septins are an evolutionarily conserved family of GTP-binding proteins. They are involved in diverse processes including cytokinesis, apoptosis, infection, neurodegeneration and neoplasia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26700173", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 346, "text": "eptins are a family of cytoskeletal GTP-binding proteins that assemble into membrane-associated hetero-oligomers and organize scaffolds for recruitment of cytosolic proteins or stabilization of membrane proteins. Septins have been implicated in a diverse range of cancers, including gastric cancer, but the underlying mechanisms remain unclear. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048593", "endSection": "abstract"}, {"offsetInBeginSection": 282, "offsetInEndSection": 386, "text": "nidulans septins contain the highly conserved GTP binding and coiled-coil domains seen in other septins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11238387", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "The septins: roles in cytokinesis and other processes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8791410", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "The septins are a novel family of proteins that were first recognized in yeast as proteins associated with the neck filaments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8791410", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Septin9 is involved in septin filament formation and cellular stability.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21824004", "endSection": "title"}, {"offsetInBeginSection": 703, "offsetInEndSection": 881, "text": "Here, we review these findings and discuss emerging mechanisms by which septins promote cell asymmetry in fungi and animals.<CopyrightInformation>\u00a9 2011 John Wiley & Sons A/S.</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21883761", "endSection": "abstract"}, {"offsetInBeginSection": 632, "offsetInEndSection": 749, "text": "These observations together with conserved sequence motifs identify the septins as members of the GTPase superfamily.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8636235", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "BACKGROUND: Septins belong to the GTPase superclass of proteins and have been functionally implicated in cytokinesis and the maintenance of cellular morphology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21082023", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Septins are important components of the cytoskeleton that are highly conserved in eukaryotes and play major roles in cytokinesis, patterning, and many developmental processes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24664283", "endSection": "abstract"}, {"offsetInBeginSection": 376, "offsetInEndSection": 480, "text": "The septins also appear to be involved in various other aspects of the organization of the cell surface.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8791410", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Septins are a family of eukaryotic GTP binding proteins conserved from yeasts to humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24367716", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 157, "text": "Septins are a highly conserved family of GTP-binding proteins involved in multiple cellular functions, including cell division and morphogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20885997", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Septin proteins are conserved structural proteins that often demarcate regions of cell division.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25217462", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Septins are GTP-binding proteins that form filaments and higher-order structures on the cell cortex of eukaryotic cells and associate with actin and microtubule cytoskeletal networks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25957401", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Septins are guanosine-5'-triphosphate-binding proteins involved in wide-ranging cellular processes including cytokinesis, vesicle trafficking, membrane remodelling and scaffolds, and with diverse binding partners", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24768753", "endSection": "abstract"}, {"offsetInBeginSection": 2058, "offsetInEndSection": 2178, "text": "Septins are a group of GTP-binding proteins that can organize into heteromeric complexes and then into large filaments. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25293760", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Septins are a conserved family of GTPases that regulate important cellular processes such as cell wall integrity, and septation in fungi.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26051489", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 318, "text": "Septins are a cytosolic GTP-binding protein family first characterized in yeast, but gaining increasing recognition as critical protagonists in higher eukaryotic cellular events. Mammalian septins have been associated with cytokinesis and exocytosis, along with contributing to the development of neurological disorder", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15214843", "endSection": "abstract"}, {"offsetInBeginSection": 176, "offsetInEndSection": 326, "text": "Septins are a family of proteins that assemble a ring structure at the mother-daughter neck during vegetative growth, where they control cytokinesis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18826657", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "Septins are a class of GTP-binding proteins conserved throughout many eukaryotes. Individual septin subunits associate with one another and assemble into heteromeric complexes that form filaments and higher-order structures in vivo. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204191", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "The septins are a conserved family of GTP-binding, filament-forming proteins. I", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14517318", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 280, "text": "The septins are filament-forming, GTP-binding proteins that are conserved from yeast to humans. Septins assemble into higher-order structures such as rings, bars, and gauzes with diverse functions including serving as membrane diffusion barriers and scaffolds for cell signaling. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20517926", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Septins are a family of 14 cytoskeletal proteins that dynamically form hetero-oligomers and organize membrane microdomains for protein complexes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25575596", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 319, "text": "Septins are highly conserved and essential eukaryotic cytoskeletal proteins that interact with the inner plasma membrane. They are involved in essential functions requiring cell membrane remodeling and compartmentalization, such as cell division and dendrite morphogenesis, and have been implicated in numerous diseases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27473901", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Septins are conserved GTP-binding proteins that assemble into heteromeric complexes that form filaments and higher-order structures in cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22767579", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 122, "text": " Septins are members of a conserved family of GTPases found in organisms as diverse as budding yeast and mammal", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10607590", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Septins are a family of conserved proteins that are essential for cytokinesis in a wide range of organisms including fungi, Drosophila and mammals. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16857012", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "The human genome codes for 13 members of a family of filament-forming GTP-binding proteins known as septins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23163726", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Septins are evolutionary conserved cytoskeletal GTPases forming heteropolymer complexes involved in cytokinesis and other cellular processes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12023038", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Septins comprise a conserved family of GTPases important in cytokinesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815479", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "Septins are a highly conserved family of GTP-binding cytoskeletal proteins implicated in multiple cellular functions, including membrane transport, apoptosis, cell polarity, cell cycle regulation, cytokinesis, and oncogenesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17922164", "endSection": "abstract"}]}, {"body": "What is the drug target for Simtuzumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23821193", "http://www.ncbi.nlm.nih.gov/pubmed/27939076", "http://www.ncbi.nlm.nih.gov/pubmed/26085906", "http://www.ncbi.nlm.nih.gov/pubmed/27232579"], "ideal_answer": [" These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", " these results suggest that loxl2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from gs-607601.", "Simtuzumab is a humanized monoclonal antibody drug that targets LOXL2"], "type": "factoid", "id": "58a644e560087bc10a000027", "snippets": [{"offsetInBeginSection": 1530, "offsetInEndSection": 1767, "text": " These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193", "endSection": "abstract"}, {"offsetInBeginSection": 1490, "offsetInEndSection": 1725, "text": "These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193", "endSection": "abstract"}, {"offsetInBeginSection": 1534, "offsetInEndSection": 1770, "text": "These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193", "endSection": "abstract"}, {"offsetInBeginSection": 1296, "offsetInEndSection": 1458, "text": "Other potential agents will be silent information regulator protein Sirtuin and antifibrotic monoclonal antibody Simtuzumab against lysyl oxidase like molecule 2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906", "endSection": "abstract"}, {"offsetInBeginSection": 1491, "offsetInEndSection": 1727, "text": "These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 446, "text": " aim of this study was to study the safety and tolerability of simtuzumab, a monoclonal antibody directed against lysyl oxidase-like 2 (LOXL2) enzyme, i", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27232579", "endSection": "abstract"}]}, {"body": "What is Dravet syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19203856", "http://www.ncbi.nlm.nih.gov/pubmed/26995069", "http://www.ncbi.nlm.nih.gov/pubmed/19589774", "http://www.ncbi.nlm.nih.gov/pubmed/20184819", "http://www.ncbi.nlm.nih.gov/pubmed/21504428", "http://www.ncbi.nlm.nih.gov/pubmed/25778844", "http://www.ncbi.nlm.nih.gov/pubmed/12503502", "http://www.ncbi.nlm.nih.gov/pubmed/21719429", "http://www.ncbi.nlm.nih.gov/pubmed/25666511", "http://www.ncbi.nlm.nih.gov/pubmed/22104018", "http://www.ncbi.nlm.nih.gov/pubmed/24254932", "http://www.ncbi.nlm.nih.gov/pubmed/26017580", "http://www.ncbi.nlm.nih.gov/pubmed/25243660", "http://www.ncbi.nlm.nih.gov/pubmed/23762420", "http://www.ncbi.nlm.nih.gov/pubmed/23517304", "http://www.ncbi.nlm.nih.gov/pubmed/24665294", "http://www.ncbi.nlm.nih.gov/pubmed/20184820", "http://www.ncbi.nlm.nih.gov/pubmed/22848613", "http://www.ncbi.nlm.nih.gov/pubmed/27264139"], "ideal_answer": ["Dravet syndrome is one of the most severe epilepsy syndromes of early childhood, and it comes with very high morbidity and mortality. It is likely that Dravet syndrome is underdiagnosed in adults with treatment-resistant epilepsy.", "dravet syndrome is one of the most severe epilepsy syndromes of early childhood, and it comes with very high morbidity and mortality.", "Dravet syndrome is one of the most severe epilepsy syndromes of early childhood, and it comes with very high morbidity and mortality. The typical presentation is characterized by hemiclonic or generalized clonic seizures triggered by fever during the first year of life, followed by myoclonic, absence, focal and generalized tonic-clonic seizures.", "Dravet syndrome is one of the most severe epilepsy syndromes of early childhood, and it comes with very high morbidity and mortality.", "Dravet syndrome is one of the most severe epilepsy syndromes of early childhood, and is associated with high morbidity and mortality. The typical presentation is characterized by hemiclonic or generalized clonic seizures triggered by fever during the first year of life, followed by myoclonic, absence, focal and generalized tonic-clonic seizures."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004831", "http://www.disease-ontology.org/api/metadata/DOID:0060171"], "type": "factoid", "id": "58bca08702b8c6095300000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 347, "text": "Dravet syndrome is one of the most severe epilepsy syndromes of early childhood, and it comes with very high morbidity and mortality. The typical presentation is characterized by hemiclonic or generalized clonic seizures triggered by fever during the first year of life, followed by myoclonic, absence, focal and generalized tonic-clonic seizures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264139", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "BACKGROUND: Dravet syndrome is a severe form of epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848613", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Dravet syndrome, a severe infantile epilepsy syndrome, is typically resistant to anti-epileptic drugs (AED).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25243660", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Dravet syndrome is an epilepsy syndrome of infantile onset, frequently caused by SCN1A mutations or deletions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Dravet syndrome is an epileptic encephalopathy characterized by multiple types of seizures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517304", "endSection": "abstract"}, {"offsetInBeginSection": 154, "offsetInEndSection": 364, "text": "Haploinsufficiency of the voltage-gated sodium channel Nav1.1 causes Dravet syndrome, an intractable childhood-onset epilepsy with hyperactivity, cognitive deficit, autistic-like behaviours, and premature death", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26017580", "endSection": "abstract"}, {"offsetInBeginSection": 1555, "offsetInEndSection": 1814, "text": "Thus, the multi-faceted phenotypes of Dravet syndrome can be genetically dissected, revealing synergy in causing epilepsy, premature death and deficits in long-term spatial memory, but interneuron-specific effects on hyperactivity and autistic-like behaviours", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26017580", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Dravet syndrome, or as it was called in the past severe myoclonic epilepsy in infancy, is a drug-resistant epilepsy first described by Charlotte Dravet in 1978", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504428", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 45, "text": "Dravet syndrome is a severe form of epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22848613", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 543, "text": "Severe myoclonic epilepsy in infants (SMEI), also known as Dravet syndrome, is a rare, refractory form of epilepsy, for whose treatment stiripentol (STP) has been recently licensed for add-on use.To evaluate the efficacy and tolerability of STP and other antiepileptic drug treatments (including ketogenic diet) as therapy for patients with SMEI.We searched the Cochrane Epilepsy Group Specialised Register (15 May 2013), the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 4 of 12, The Cochrane Library, April 2013), MEDLINE (1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24254932", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Dravet syndrome is a severe infantile-onset epileptic encephalopathy associated with mutations in the sodium channel alpha-1 subunit gene SCN1A.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25778844", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Dravet syndrome is a rare form of epilepsy largely refractory to current antiepileptic medications. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25666511", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 122, "text": "Dravet syndrome is a rare epileptic encephalopathy characterized by treatment-resistant polymorphic seizures. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26995069", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Dravet syndrome is a severe form of epileptic encephalopathy characterized by early onset epileptic seizures followed by ataxia and cognitive decline.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23148524", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 147, "text": "Dravet syndrome is a severe form of intractable pediatric epilepsy with a high incidence of SUDEP: Sudden Unexpected Death in epilepsy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155976", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 151, "text": "Dravet syndrome or severe myoclonic epilepsy of infancy (SMEI) is a baleful epileptic encephalopathy that begins in the first year of life. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665294", "endSection": "abstract"}, {"offsetInBeginSection": 445, "offsetInEndSection": 574, "text": "Dravet syndrome is a severe infantile onset epilepsy syndrome with multiple seizure types, developmental slowing and poor outcome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19203856", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Dravet syndrome is an intractable epileptic syndrome beginning in the first year of life.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103419", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Dravet syndrome is an epileptic syndrome of infancy and early childhood.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184819", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Dravet syndrome is an epileptic syndrome of infancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20184820", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 211, "text": "patients with severe myoclonic epilepsy of infancy (Dravet's syndrome)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12503502", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 179, "text": "Dravet syndrome is a severe infantile epileptic encephalopathy caused in approximately 80% of cases by mutations in the voltage gated sodium channel subunit gene SCN1A", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19589774", "endSection": "abstract"}]}, {"body": "What makes telomerase a good drug target?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12678727", "http://www.ncbi.nlm.nih.gov/pubmed/23558965", "http://www.ncbi.nlm.nih.gov/pubmed/25550449", "http://www.ncbi.nlm.nih.gov/pubmed/24053596", "http://www.ncbi.nlm.nih.gov/pubmed/21208462", "http://www.ncbi.nlm.nih.gov/pubmed/18763067", "http://www.ncbi.nlm.nih.gov/pubmed/16112419", "http://www.ncbi.nlm.nih.gov/pubmed/14594517", "http://www.ncbi.nlm.nih.gov/pubmed/12689331", "http://www.ncbi.nlm.nih.gov/pubmed/27118336", "http://www.ncbi.nlm.nih.gov/pubmed/22044621", "http://www.ncbi.nlm.nih.gov/pubmed/24109558", "http://www.ncbi.nlm.nih.gov/pubmed/16549043", "http://www.ncbi.nlm.nih.gov/pubmed/26771897", "http://www.ncbi.nlm.nih.gov/pubmed/21802433", "http://www.ncbi.nlm.nih.gov/pubmed/25744732", "http://www.ncbi.nlm.nih.gov/pubmed/25256442", "http://www.ncbi.nlm.nih.gov/pubmed/11342355", "http://www.ncbi.nlm.nih.gov/pubmed/10857992", "http://www.ncbi.nlm.nih.gov/pubmed/26742579", "http://www.ncbi.nlm.nih.gov/pubmed/12750550", "http://www.ncbi.nlm.nih.gov/pubmed/27657809", "http://www.ncbi.nlm.nih.gov/pubmed/14649329"], "ideal_answer": ["Human telomerase is absent in most normal tissues, but is abnormally activated in all major cancer cells. Telomerase enables tumor cells to maintain telomere length, allowing indefinite replicative capacity.", "Telomerase, a ribonucleoprotein enzyme is considered as a universal therapeutic target of cancer because of its preferential expression in cancer cells and its presence in 90 % of tumors. Human telomerase is absent in most normal tissues, but is abnormally activated in all major cancer cells.", " telomerase, a ribonucleoprotein enzyme is considered as a universal therapeutic target of cancer because of its preferential expression in cancer cells and its presence in 90 % of tumors.", "Human telomerase is absent in most normal tissues, but is abnormally activated in all major cancer cells. Telomerase enables tumor cells to maintain telomere length, allowing indefinite replicative capacity. telomerase is believed to be necessary for cancer cells to grow without limit", " Telomerase, a ribonucleoprotein enzyme is considered as a universal therapeutic target of cancer because of its preferential expression in cancer cells and its presence in 90 % of tumors. "], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019098", "http://www.biosemantics.org/jochem#4221288"], "type": "summary", "id": "58bc9dbb02b8c60953000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Human telomerase is absent in most normal tissues, but is abnormally activated in all major cancer cells. Telomerase enables tumor cells to maintain telomere length, allowing indefinite replicative capacity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26742579", "endSection": "abstract"}, {"offsetInBeginSection": 261, "offsetInEndSection": 338, "text": "telomerase is believed to be necessary for cancer cells to grow without limit", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26742579", "endSection": "abstract"}, {"offsetInBeginSection": 317, "offsetInEndSection": 506, "text": " Telomerase, a ribonucleoprotein enzyme is considered as a universal therapeutic target of cancer because of its preferential expression in cancer cells and its presence in 90 % of tumors. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25744732", "endSection": "abstract"}, {"offsetInBeginSection": 1072, "offsetInEndSection": 1231, "text": "Interestingly, almost 100 % of adenocarcinoma, including breast cancer cells, expresses telomerase which makes it a good target for telomerase-related therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23558965", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 319, "text": "The observation that the enzyme telomerase is up-regulated in 80-90% of cancer cells isolated from primary human tumors but is absent in neighboring cells of healthy tissue has resulted in significant efforts to validate telomerase as an anticancer drug target and to develop effective approaches toward its inhibition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24053596", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Telomerase plays an important role in cell proliferation and carcinogenesis and is believed to be a good target for anti-cancer drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18763067", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "In contrast to cancer cells, most normal human cells have no or low telomerase levels which makes it an attractive target for anti-cancer drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25256442", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Telomerase activity is repressed in normal human somatic cells, but is activated in most cancers, suggesting that telomerase may be an important target for cancer therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16112419", "endSection": "abstract"}, {"offsetInBeginSection": 303, "offsetInEndSection": 471, "text": "Telomerase is expressed in more than 85% of cancer cells, making it a nearly universal cancer marker, while the majority of normal somatic cells are telomerase negative", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21802433", "endSection": "abstract"}, {"offsetInBeginSection": 156, "offsetInEndSection": 304, "text": "The activity of telomerase is highly associated with carcinogenesis which makes the enzyme an attractive biomarker in cancer diagnosis and treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24109558", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 321, "text": "The human telomerase reverse transcriptase (hTERT) is expressed in more than 85% of tumor cells but is usually not found in normal cells, which makes hTERT as an ideal tumor-associate antigen (TAA) to develop potential vaccine specifically destroying cancers without impairing normal tissues in human cancer immunotherapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16549043", "endSection": "abstract"}, {"offsetInBeginSection": 120, "offsetInEndSection": 219, "text": "The differential expression of telomerase in cancer cells makes it an attractive therapeutic target", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14594517", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 385, "text": "The evidence that telomerase is also present in normal B cells at different levels according to their differentiation and activation state makes the study of telomerase activity in B cell tumors particularly interesting", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11342355", "endSection": "abstract"}, {"offsetInBeginSection": 334, "offsetInEndSection": 477, "text": "Telomerase is up-regulated in the majority of cancer cells and is essential for their survival, making it a potential anti-cancer drug target. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "In contrast to cancer cells, most normal human cells have no or low telomerase levels which makes it an attractive target for anti-cancer drugs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25256442", "endSection": "abstract"}, {"offsetInBeginSection": 554, "offsetInEndSection": 718, "text": "As normal cells have a considerable telomere reserve, even in elderly humans, this makes telomerase an attractive and potentially selective anti-cancer drug target.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14649329", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "The expression of telomerase in approximately 85% of cancers and its absence in the majority of normal cells makes it an attractive target for cancer therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27657809", "endSection": "abstract"}, {"offsetInBeginSection": 765, "offsetInEndSection": 919, "text": "Moreover, since telomerase is not or slightly expressed in normal cells, it has been postulated that drugs targeting telomerase would induce low toxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10857992", "endSection": "abstract"}, {"offsetInBeginSection": 290, "offsetInEndSection": 443, "text": "Telomerase is expressed in most cancer cells, but not in normal somatic cells, suggesting that telomerase is an attractive target for cancer chemotherapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12689331", "endSection": "abstract"}, {"offsetInBeginSection": 119, "offsetInEndSection": 299, "text": "elomerase, a special reverse transcriptase, has been recognized as a common factor in most tumor cells, and in turn a distinctive characteristic with respect to non-malignant cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27118336", "endSection": "abstract"}, {"offsetInBeginSection": 706, "offsetInEndSection": 823, "text": "Telomerase is detected in the majority of prostate cancers, but not in normal or benign prostatic hyperplasia tissue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369445", "endSection": "abstract"}, {"offsetInBeginSection": 148, "offsetInEndSection": 403, "text": "The catalytic component of telomerase in humans, hTERT, is upregulated in nearly 90% of all cancers, making it the most widely expressed marker of malignancy. With the exception of germ cells and stem cells, hTERT is undetectable in somatic human tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12750550", "endSection": "abstract"}, {"offsetInBeginSection": 146, "offsetInEndSection": 320, "text": "he notion that telomerase is reactivated in 80-90% of human cancers has led to the proposal of telomerase as a promising therapeutic target for novel anticancer interventions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12678727", "endSection": "abstract"}]}, {"body": "What is DENdb?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26342387"], "ideal_answer": ["DENdb is a centralized on-line repository of predicted enhancers derived from multiple human cell-lines. DENdb integrates enhancers predicted by five different methods generating an enriched catalogue of putative enhancers for each of the analysed cell-lines. DENdb provides information about the overlap of enhancers with DNase I hypersensitive regions, ChIP-seq regions of a number of transcription factors and transcription factor binding motifs, means to explore enhancer interactions with DNA using several chromatin interaction assays and enhancer neighbouring genes. DENdb is designed as a relational database that facilitates fast and efficient searching, browsing and visualization of information."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D030561"], "type": "summary", "id": "587f90fa8ce3255b64000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 45, "text": "DENdb: database of integrated human enhancers", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "title"}, {"offsetInBeginSection": 332, "offsetInEndSection": 1050, "text": "We developed DENdb, a centralized on-line repository of predicted enhancers derived from multiple human cell-lines. DENdb integrates enhancers predicted by five different methods generating an enriched catalogue of putative enhancers for each of the analysed cell-lines. DENdb provides information about the overlap of enhancers with DNase I hypersensitive regions, ChIP-seq regions of a number of transcription factors and transcription factor binding motifs, means to explore enhancer interactions with DNA using several chromatin interaction assays and enhancer neighbouring genes. DENdb is designed as a relational database that facilitates fast and efficient searching, browsing and visualization of information. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "DENdb: database of integrated human enhancers.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "title"}, {"offsetInBeginSection": 330, "offsetInEndSection": 445, "text": "We developed DENdb, a centralized on-line repository of predicted enhancers derived from multiple human cell-lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 912, "offsetInEndSection": 1044, "text": "DENdb is designed as a relational database that facilitates fast and efficient searching, browsing and visualization of information.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 445, "offsetInEndSection": 599, "text": "DENdb integrates enhancers predicted by five different methods generating an enriched catalogue of putative enhancers for each of the analysed cell-lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 599, "offsetInEndSection": 912, "text": "DENdb provides information about the overlap of enhancers with DNase I hypersensitive regions, ChIP-seq regions of a number of transcription factors and transcription factor binding motifs, means to explore enhancer interactions with DNA using several chromatin interaction assays and enhancer neighbouring genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 332, "offsetInEndSection": 446, "text": "We developed DENdb, a centralized on-line repository of predicted enhancers derived from multiple human cell-lines", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 448, "offsetInEndSection": 601, "text": "DENdb integrates enhancers predicted by five different methods generating an enriched catalogue of putative enhancers for each of the analysed cell-lines", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 603, "offsetInEndSection": 915, "text": "DENdb provides information about the overlap of enhancers with DNase I hypersensitive regions, ChIP-seq regions of a number of transcription factors and transcription factor binding motifs, means to explore enhancer interactions with DNA using several chromatin interaction assays and enhancer neighbouring genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 917, "offsetInEndSection": 1048, "text": "DENdb is designed as a relational database that facilitates fast and efficient searching, browsing and visualization of information", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 1050, "offsetInEndSection": 1142, "text": "Database URL: http://www.cbrc.kaust.edu.sa/dendb/.<CopyrightInformation>\u00a9 The Author(s) 2015", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "DENdb: database of integrated human enhancers.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "title"}, {"offsetInBeginSection": 1050, "offsetInEndSection": 1101, "text": "Database URL: http://www.cbrc.kaust.edu.sa/dendb/..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 332, "offsetInEndSection": 447, "text": "We developed DENdb, a centralized on-line repository of predicted enhancers derived from multiple human cell-lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 917, "offsetInEndSection": 1049, "text": "DENdb is designed as a relational database that facilitates fast and efficient searching, browsing and visualization of information.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 448, "offsetInEndSection": 602, "text": "DENdb integrates enhancers predicted by five different methods generating an enriched catalogue of putative enhancers for each of the analysed cell-lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}, {"offsetInBeginSection": 603, "offsetInEndSection": 916, "text": "DENdb provides information about the overlap of enhancers with DNase I hypersensitive regions, ChIP-seq regions of a number of transcription factors and transcription factor binding motifs, means to explore enhancer interactions with DNA using several chromatin interaction assays and enhancer neighbouring genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26342387", "endSection": "abstract"}]}, {"body": "List scales that are used for scoring of patients with spinal metastasis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24212518", "http://www.ncbi.nlm.nih.gov/pubmed/23179121", "http://www.ncbi.nlm.nih.gov/pubmed/24120144", "http://www.ncbi.nlm.nih.gov/pubmed/26713145", "http://www.ncbi.nlm.nih.gov/pubmed/26160329", "http://www.ncbi.nlm.nih.gov/pubmed/24912121", "http://www.ncbi.nlm.nih.gov/pubmed/21223698", "http://www.ncbi.nlm.nih.gov/pubmed/27584676", "http://www.ncbi.nlm.nih.gov/pubmed/27080411", "http://www.ncbi.nlm.nih.gov/pubmed/24869611", "http://www.ncbi.nlm.nih.gov/pubmed/18787846", "http://www.ncbi.nlm.nih.gov/pubmed/26602195", "http://www.ncbi.nlm.nih.gov/pubmed/27018903", "http://www.ncbi.nlm.nih.gov/pubmed/25869337", "http://www.ncbi.nlm.nih.gov/pubmed/25085251"], "ideal_answer": ["Tokuhashi, Tomita, Bauer, and Oswestry scores are used for survival prediction of patients with spinal metastases."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009362"], "type": "list", "id": "589a245878275d0c4a000025", "snippets": [{"offsetInBeginSection": 556, "offsetInEndSection": 682, "text": "METHODS: Outcomes of surgery, prognostic factors for survival, and relevance of Tomita and Tokuhashi scores were investigated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24120144", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "PURPOSE: To assess variability in the use of Tomita and modified Bauer scores in spine metastases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25869337", "endSection": "abstract"}, {"offsetInBeginSection": 1111, "offsetInEndSection": 1213, "text": "Only the Tomita scoring system was shown to be an independent prognostic factor for overall survival. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26713145", "endSection": "abstract"}, {"offsetInBeginSection": 1359, "offsetInEndSection": 1462, "text": ".CONCLUSION: The Tomita scoring system represents a practicable and highly predictive prognostic tool. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26713145", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Analysis of the predictive role and new proposal for surgical strategies based on the modified Tomita and Tokuhashi scoring systems for spinal metastasis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25085251", "endSection": "title"}, {"offsetInBeginSection": 95, "offsetInEndSection": 276, "text": "We also aimed to evaluate the validity of the prognostic scores in the Tomita and Tokuhashi systems and discuss several aspects to improve the predictive accuracy of these systems. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25085251", "endSection": "abstract"}, {"offsetInBeginSection": 1527, "offsetInEndSection": 1612, "text": "CONCLUSIONS: Tomita scores more accurately predicted survival than Tokuhashi scores. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25085251", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "A comparison of the modified Tokuhashi and Tomita scores in determining prognosis for patients afflicted with spinal metastasis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869611", "endSection": "title"}, {"offsetInBeginSection": 103, "offsetInEndSection": 215, "text": " It is for this reason that scoring systems, such as the modified Tokuhashi and Tomita scores, have been created", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869611", "endSection": "abstract"}, {"offsetInBeginSection": 1417, "offsetInEndSection": 1497, "text": "The modified Tokuhashi score had better accuracy in determining actual survival.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869611", "endSection": "abstract"}, {"offsetInBeginSection": 142, "offsetInEndSection": 316, "text": "Tokuhashi, Tomita, Bauer, and Oswestry scores have been devised for survival prediction; however, none of these systems have been evaluated in nasopharyngeal carcinoma (NPC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24912121", "endSection": "abstract"}, {"offsetInBeginSection": 2366, "offsetInEndSection": 2491, "text": "All four scoring systems could be used to prognosticate these patients. The modified Tokuhashi score is the best in doing so.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24912121", "endSection": "abstract"}, {"offsetInBeginSection": 1292, "offsetInEndSection": 1399, "text": "Primary tumor type and Tokuhashi score independently predicted survival in patients with spinal metastases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23179121", "endSection": "abstract"}, {"offsetInBeginSection": 1586, "offsetInEndSection": 1710, "text": " Primary tumor type and Tokuhashi scoring independently predicted survival in patients with spinal metastases after surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23179121", "endSection": "abstract"}, {"offsetInBeginSection": 977, "offsetInEndSection": 1133, "text": "A predictive score was then developed and compared against that of the modified Bauer score alone in terms of prognosticating 1-year survival after surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26160329", "endSection": "abstract"}, {"offsetInBeginSection": 2301, "offsetInEndSection": 2456, "text": "Our predictive score performed better than the modified Bauer alone and may be used to predict survival after surgical intervention for metastatic disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26160329", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Tokuhashi Scoring System has limited applicability in the majority of patients with spinal cord compression secondary to vertebral metastasis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24212518", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Tokuhashi Scoring System has limited applicability in the majority of patients with spinal cord compression secondary to vertebral metastasis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24212518", "endSection": "title"}, {"offsetInBeginSection": 121, "offsetInEndSection": 704, "text": "Tokuhashi, Tomita, Bauer, and Oswestry scores have been devised for survival prediction; however, none of these systems have been evaluated in nasopharyngeal carcinoma (NPC).To investigate the accuracy of these scoring systems in predicting survival and to identify prognostic factors for survival of the patients with spinal metastases from NPC.Retrospective analysis of the patients with spinal metastases from NPC who were treated in our institution.The study included 87 patients with spinal metastases from NPC.The primary outcome measure was the survival time of these patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24912121", "endSection": "abstract"}, {"offsetInBeginSection": 2083, "offsetInEndSection": 2267, "text": "Predictive value of survival by modified Tokuhashi score was the highest among all four scoring systems.Patients with spinal metastases from NPC have relatively good survival prognosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24912121", "endSection": "abstract"}, {"offsetInBeginSection": 1748, "offsetInEndSection": 1994, "text": "The data of the present study emphasize that the original Bauer score and a modified Bauer score without scoring for pathologic fracture seem to be practicable and highly predictive preoperative scoring systems for patients with spinal metastases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18787846", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 423, "text": "A retrospective study of 180 patients with lung cancer spinal metastases, wherein prognostic score-predicted survival was compared with actual survival.To evaluate and compare the accuracy of prognostic scoring systems in lung cancer spinal metastases.The modified Tokuhashi, Tomita, modified Bauer, and Oswestry scores are currently used to guide decisions regarding operative treatment of patients with spinal metastases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27018903", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "To evaluate the predictive values of Tokuhashi score, revised Tokuhashi score and Tomita score systems for life expectancy and treatment options in patients with spinal metastasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21223698", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "A comparison of the modified Tokuhashi and Tomita scores in determining prognosis for patients afflicted with spinal metastasis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24869611", "endSection": "title"}, {"offsetInBeginSection": 1789, "offsetInEndSection": 1975, "text": "The combination of Tokuhashi score and Tomita score may be applied to better predict postoperative survival prognosis and guide the surgical options for patients with spinal metastasis..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21223698", "endSection": "abstract"}, {"offsetInBeginSection": 291, "offsetInEndSection": 441, "text": "reported a composite model taking into account a modified Bauer score, preoperative albumin, and ambulatory status of patients with spinal metastasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27080411", "endSection": "abstract"}]}, {"body": "Does NADPH oxidase 5 require any subunit for function?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21319793", "http://www.ncbi.nlm.nih.gov/pubmed/15994299"], "ideal_answer": ["No, NADPH oxidase 5 (NOX5) does not require any subunits for function."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0016175", "http://www.uniprot.org/uniprot/NOXO1_HUMAN", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019255", "http://amigo.geneontology.org/amigo/term/GO:0016174", "http://www.biosemantics.org/jochem#4270191", "http://www.uniprot.org/uniprot/NOX5_HUMAN"], "type": "yesno", "id": "58a5add260087bc10a000022", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Nox5 forms a functional oligomer mediated by self-association of its dehydrogenase domain.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319793", "endSection": "title"}, {"offsetInBeginSection": 290, "offsetInEndSection": 399, "text": " While Nox1-4 require regulatory subunits, including p22phox, Nox5 activity does not depend on any subunits. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319793", "endSection": "abstract"}, {"offsetInBeginSection": 1566, "offsetInEndSection": 1678, "text": " Thus, Nox5 forms a catalytically active oligomer in the membrane that is mediated by its dehydrogenase domain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319793", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 934, "text": "Coexpression of specific Nox catalytic subunits (Nox1, Nox2, Nox3, Nox4, or Nox5) along with their corresponding regulatory subunits (NOXO1/NOXA1 for Nox1; p47phox/p67phox/Rac for Nox2; NOXO1 for Nox3; no subunits for Nox4 or Nox5) resulted in marked production of reactive oxygen. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15994299", "endSection": "abstract"}]}, {"body": "What are the side effects during statins administration in patients with atherosclerosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25678839", "http://www.ncbi.nlm.nih.gov/pubmed/24840269", "http://www.ncbi.nlm.nih.gov/pubmed/21796961", "http://www.ncbi.nlm.nih.gov/pubmed/21267417", "http://www.ncbi.nlm.nih.gov/pubmed/12891851", "http://www.ncbi.nlm.nih.gov/pubmed/27878791", "http://www.ncbi.nlm.nih.gov/pubmed/17042673", "http://www.ncbi.nlm.nih.gov/pubmed/24788803", "http://www.ncbi.nlm.nih.gov/pubmed/25644328", "http://www.ncbi.nlm.nih.gov/pubmed/19039148", "http://www.ncbi.nlm.nih.gov/pubmed/26490078", "http://www.ncbi.nlm.nih.gov/pubmed/26575138", "http://www.ncbi.nlm.nih.gov/pubmed/24601937", "http://www.ncbi.nlm.nih.gov/pubmed/25936326", "http://www.ncbi.nlm.nih.gov/pubmed/18585718", "http://www.ncbi.nlm.nih.gov/pubmed/22913216", "http://www.ncbi.nlm.nih.gov/pubmed/23299641", "http://www.ncbi.nlm.nih.gov/pubmed/21972203"], "ideal_answer": ["The side effects during statins administration in patients with atherosclerosis are:\n1) Myopathy\n2) Transaminase elevations\n3) Diabetes mellitus \n4) Renal and neurologic adverse effects."], "type": "list", "id": "589c4c9078275d0c4a000040", "snippets": [{"offsetInBeginSection": 1081, "offsetInEndSection": 1224, "text": "A history of side effects was reported by 40 (19.5%) of the patients, and mainly consisted of muscle complaints and gastrointestinal symptoms. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25644328", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Treatment Options for Statin-Associated Muscle Symptoms.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138", "endSection": "title"}, {"offsetInBeginSection": 383, "offsetInEndSection": 457, "text": "Muscle symptoms are a clinically relevant side effect of statin treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138", "endSection": "abstract"}, {"offsetInBeginSection": 641, "offsetInEndSection": 727, "text": "At least 5% of patients taking statins have statin-associated muscle symptoms (SAMS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 237, "text": "Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26490078", "endSection": "abstract"}, {"offsetInBeginSection": 632, "offsetInEndSection": 838, "text": "It was estimated that rosuvastatin-associated absolute hazards of muscle-, liver- and renal-related adverse effects are lower than the corresponding vascular benefits in moderate vascular risk individuals. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24788803", "endSection": "abstract"}, {"offsetInBeginSection": 1654, "offsetInEndSection": 1856, "text": "Rosuvastatin-induced proteinuria appears to be of tubular origin, not relating to kidney injury. Rosuvastatin increases the risk of new-onset diabetes by dose-dependently impairing insulin sensitivity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24788803", "endSection": "abstract"}, {"offsetInBeginSection": 469, "offsetInEndSection": 736, "text": "Statins are associated with myopathy, transaminase elevations, and an increased risk of incident diabetes mellitus among some patients; connections between statins and other processes, such as renal and neurologic function, have also been studied with mixed results. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24840269", "endSection": "abstract"}, {"offsetInBeginSection": 371, "offsetInEndSection": 696, "text": "Muscle symptoms are a clinically relevant side effect of statin treatment.This review is based on pertinent publications retrieved by a selective literature search, and on the current recommendations of the European Atherosclerosis Society.At least 5% of patients taking statins have statin-associated muscle symptoms (SAMS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138", "endSection": "abstract"}, {"offsetInBeginSection": 1018, "offsetInEndSection": 1239, "text": "Nevertheless, patients may develop side effects such as muscle pain and weakness years after starting statin therapy; however, the absolute number of patients affected by statin myopathy increases with treatment duration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23299641", "endSection": "abstract"}, {"offsetInBeginSection": 1122, "offsetInEndSection": 1311, "text": "Better understanding of the molecular mechanisms involved in statin-induced myopathy may help identify patient groups susceptible to statins' side effects, thereby increasing their safety..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18585718", "endSection": "abstract"}]}, {"body": "Entresto is composed of which two drugs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27697814", "http://www.ncbi.nlm.nih.gov/pubmed/26642078", "http://www.ncbi.nlm.nih.gov/pubmed/26976916", "http://www.ncbi.nlm.nih.gov/pubmed/27284124", "http://www.ncbi.nlm.nih.gov/pubmed/26417173", "http://www.ncbi.nlm.nih.gov/pubmed/26992459", "http://www.ncbi.nlm.nih.gov/pubmed/26975167", "http://www.ncbi.nlm.nih.gov/pubmed/26466333", "http://www.ncbi.nlm.nih.gov/pubmed/27378659", "http://www.ncbi.nlm.nih.gov/pubmed/27804100", "http://www.ncbi.nlm.nih.gov/pubmed/26873495"], "ideal_answer": ["Entresto is composed of sacubitril and valsartan. It is newly FDA-approved medication that dually inhibits angiotensin and neprilysin, in the treatment of heart failure."], "type": "list", "id": "58962ed178275d0c4a000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 342, "text": "The PARADIGM-HF study, a large outcome trial in heart failure and reduced ejection fraction (HFrEF), has recently shown improved cardiovascular outcomes with sacubitril/valsartan (Entresto\u00ae, Novartis), still commonly referred to as LCZ696, compared to ACE-inhibitor therapy, possibly leading us to a new era for heart failure (HF) treatment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642078", "endSection": "abstract"}, {"offsetInBeginSection": 387, "offsetInEndSection": 627, "text": "This article reviews the background, current knowledge and data supporting the use of sacubitril/valsartan (Entresto(\u00ae) ), the newly FDA-approved medication that dually inhibits angiotensin and neprilysin, in the treatment of heart failure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26992459", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "\u25bc Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27284124", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto\u2122) in a 63-Year-Old Woman.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27804100", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 367, "text": "A 63-year-old woman previously stable on a regimen of atorvastatin 40\u00a0mg daily, carvedilol 25\u00a0mg twice daily, digoxin 0.125\u00a0mg daily, furosemide 40\u00a0mg daily, spironolactone 25\u00a0mg daily, rivaroxaban 15\u00a0mg daily, and enalapril 20\u00a0mg twice daily for heart failure developed rhabdomyolysis 26\u00a0days after enalapril was stopped and sacubitril/valsartan (Entresto\u2122) started.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27804100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 319, "text": "Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is the first in a new class of drugs that combines neprilysin inhibition with angiotensin II receptor antagonism, the combination of which acts to increase endogenous natriuretic peptides while inhibiting the renin-angiotensin-aldosterone system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26466333", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 669, "text": "In July 2015, the US Food and Drug Administration approved the first of a new class of drugs for the treatment of heart failure: Valsartan/sacubitril (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysin inhibitor prodrug sacubitril in a 1:1 ratio in a sodium supramolecular complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976916", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "Sacubitril/valsartan (Entresto) for chronic heart failure; brexpiprazole (Rexulti) for major depressive disorder and schizophrenia; and lumacaftor/ivacaftor (Orkambi) for cystic fibrosis involving specific CFTR mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26417173", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Sacubritil\u2217valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27378659", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 251, "text": "The molecular combination of sacubitril and valsartan (Entresto) is a new drug for reducing the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26975167", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 457, "text": "\u25bc Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.(1) It is described as an angiotensin receptor neprilysin inhibitor and contains the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan.(1-3) Here, we review the evidence for sacubitril valsartan and consider its place in the management of heart failure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27284124", "endSection": "abstract"}]}, {"body": "What is the doRiNA database?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25416797", "http://www.ncbi.nlm.nih.gov/pubmed/22086949"], "ideal_answer": ["doRina is a database of RNA interactions in post-transcriptional regulation."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D030561", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012323"], "type": "summary", "id": "588f365194c1512c50000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "doRiNA: a database of RNA interactions in post-transcriptional regulation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", "endSection": "title"}, {"offsetInBeginSection": 394, "offsetInEndSection": 1242, "text": " We provide a database that supports the quest for deciphering this regulatory code. Within doRiNA, we are systematically curating, storing and integrating binding site data for RBPs and miRNAs. Users are free to take a target (mRNA) or regulator (RBP and/or miRNA) centric view on the data. We have implemented a database framework with short query response times for complex searches (e.g. asking for all targets of a particular combination of regulators). All search results can be browsed, inspected and analyzed in conjunction with a huge selection of other genome-wide data, because our database is directly linked to a local copy of the UCSC genome browser. At the time of writing, doRiNA encompasses RBP data for the human, mouse and worm genomes. For computational miRNA target site predictions, we provide an update of PicTar predictions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "DoRiNA 2.0--upgrading the doRiNA database of RNA interactions in post-transcriptional regulation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25416797", "endSection": "title"}, {"offsetInBeginSection": 1050, "offsetInEndSection": 1140, "text": "At the time of writing, doRiNA encompasses RBP data for the human, mouse and worm genomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", "endSection": "abstract"}, {"offsetInBeginSection": 475, "offsetInEndSection": 584, "text": "Within doRiNA, we are systematically curating, storing and integrating binding site data for RBPs and miRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "doRiNA: a database of RNA interactions in post-transcriptional regulation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", "endSection": "title"}, {"offsetInBeginSection": 479, "offsetInEndSection": 587, "text": "Within doRiNA, we are systematically curating, storing and integrating binding site data for RBPs and miRNAs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", "endSection": "abstract"}, {"offsetInBeginSection": 1059, "offsetInEndSection": 1148, "text": "At the time of writing, doRiNA encompasses RBP data for the human, mouse and worm genomes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", "endSection": "abstract"}, {"offsetInBeginSection": 479, "offsetInEndSection": 589, "text": "Within doRiNA, we are systematically curating, storing and integrating binding site data for RBPs and miRNAs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", "endSection": "abstract"}, {"offsetInBeginSection": 1059, "offsetInEndSection": 1150, "text": "At the time of writing, doRiNA encompasses RBP data for the human, mouse and worm genomes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", "endSection": "abstract"}, {"offsetInBeginSection": 479, "offsetInEndSection": 588, "text": "Within doRiNA, we are systematically curating, storing and integrating binding site data for RBPs and miRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", "endSection": "abstract"}, {"offsetInBeginSection": 1059, "offsetInEndSection": 1149, "text": "At the time of writing, doRiNA encompasses RBP data for the human, mouse and worm genomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "DoRiNA 2.0--upgrading the doRiNA database of RNA interactions in post-transcriptional regulation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25416797", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "doRiNA: a database of RNA interactions in post-transcriptional regulation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086949", "endSection": "title"}]}, {"body": "Is NSD-1015 an inhibitor of Aromatic L-Amino Acid Decarboxylase?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7664818", "http://www.ncbi.nlm.nih.gov/pubmed/20501080", "http://www.ncbi.nlm.nih.gov/pubmed/2320657", "http://www.ncbi.nlm.nih.gov/pubmed/323424", "http://www.ncbi.nlm.nih.gov/pubmed/6164221", "http://www.ncbi.nlm.nih.gov/pubmed/8371833", "http://www.ncbi.nlm.nih.gov/pubmed/6811255", "http://www.ncbi.nlm.nih.gov/pubmed/8836582", "http://www.ncbi.nlm.nih.gov/pubmed/1348847", "http://www.ncbi.nlm.nih.gov/pubmed/15927700", "http://www.ncbi.nlm.nih.gov/pubmed/10619466", "http://www.ncbi.nlm.nih.gov/pubmed/11343835", "http://www.ncbi.nlm.nih.gov/pubmed/6432557", "http://www.ncbi.nlm.nih.gov/pubmed/7616241", "http://www.ncbi.nlm.nih.gov/pubmed/1997008", "http://www.ncbi.nlm.nih.gov/pubmed/24084697", "http://www.ncbi.nlm.nih.gov/pubmed/1904482", "http://www.ncbi.nlm.nih.gov/pubmed/3917287", "http://www.ncbi.nlm.nih.gov/pubmed/11135014", "http://www.ncbi.nlm.nih.gov/pubmed/2414683", "http://www.ncbi.nlm.nih.gov/pubmed/2426412", "http://www.ncbi.nlm.nih.gov/pubmed/20408420", "http://www.ncbi.nlm.nih.gov/pubmed/1436125", "http://www.ncbi.nlm.nih.gov/pubmed/7692885", "http://www.ncbi.nlm.nih.gov/pubmed/1470299", "http://www.ncbi.nlm.nih.gov/pubmed/6780662", "http://www.ncbi.nlm.nih.gov/pubmed/6746835", "http://www.ncbi.nlm.nih.gov/pubmed/12658372", "http://www.ncbi.nlm.nih.gov/pubmed/16292508", "http://www.ncbi.nlm.nih.gov/pubmed/8287902", "http://www.ncbi.nlm.nih.gov/pubmed/26830512", "http://www.ncbi.nlm.nih.gov/pubmed/7690229", "http://www.ncbi.nlm.nih.gov/pubmed/17066255", "http://www.ncbi.nlm.nih.gov/pubmed/23940784", "http://www.ncbi.nlm.nih.gov/pubmed/19168057", "http://www.ncbi.nlm.nih.gov/pubmed/1663587", "http://www.ncbi.nlm.nih.gov/pubmed/904693", "http://www.ncbi.nlm.nih.gov/pubmed/8361951", "http://www.ncbi.nlm.nih.gov/pubmed/3103858", "http://www.ncbi.nlm.nih.gov/pubmed/7889269", "http://www.ncbi.nlm.nih.gov/pubmed/22841861", "http://www.ncbi.nlm.nih.gov/pubmed/8096696", "http://www.ncbi.nlm.nih.gov/pubmed/8511717"], "ideal_answer": ["Yes, NSD-1015 is an ihnibitor of Aromatic L-Amino Decarboxylase."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0004058", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4251263", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065105", "http://www.biosemantics.org/jochem#4251263", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024322", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001142"], "type": "yesno", "id": "589c334e78275d0c4a00003d", "snippets": [{"offsetInBeginSection": 1341, "offsetInEndSection": 1550, "text": "When pretreated with a central AADC inhibitor (NSD-1015), further application of l-dopa failed to increase the motoneuron activity although the expression of DA in the AADC cells was not completely inhibited. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26830512", "endSection": "abstract"}, {"offsetInBeginSection": 609, "offsetInEndSection": 739, "text": "Inhibition of Ddc by AADC inhibitor NSD-1015 or anti-sense morpholino oligonucleotides (MO) reduced brain volume and body length. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23940784", "endSection": "abstract"}, {"offsetInBeginSection": 399, "offsetInEndSection": 577, "text": "We evaluated this in vivo by reverse dialysis of the aromatic-l-amino-acid decarboxylase (EC 4.1.1.28) inhibitor NSD-1015 (20\u03bcM) and selected concentrations of l- or d-tyrosine. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22841861", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 296, "text": "Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20408420", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 401, "text": "To establish the neurotransmitter role(s) of L-3,4-dihydroxyphenylalanine (DOPA) in its own right, we attempted to clarify whether i.p. injection of a DOPA antagonist, DOPA cyclohexyl ester (CHE), would antagonize the behavioral responses of conscious rats to DOPA in the presence of 3-hydroxybenzylhydrazine (NSD-1015) (100 mg/kg i.p.), a central aromatic L-amino acid decarboxylase (AADC) inhibitor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19168057", "endSection": "abstract"}, {"offsetInBeginSection": 245, "offsetInEndSection": 459, "text": "TH and TPH activities were determined in tissue extracts by measuring the accumulation of L-Dopa and 5-HTP respectively, following the administration of the aromatic L-amino acid decarboxylase inhibitor, NSD-1015. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17066255", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 342, "text": "Results of a neurochemical study of the effects of the new anxiolytic drugs afobazole and ladasten on the synthesis and metabolism of monoamines and their metabolites determined by HPLC on the model of monoamine synthesis blockade induced by NSD-1015 (aromatic L-amino acid decarboxylase) in the brain structures of Wistar rats are reported. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20408420", "endSection": "abstract"}, {"offsetInBeginSection": 1339, "offsetInEndSection": 1397, "text": ". When pretreated with a central AADC inhibitor (NSD-1015)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26830512", "endSection": "abstract"}, {"offsetInBeginSection": 815, "offsetInEndSection": 848, "text": "NSD 1015 (general AADC inhibitor)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24084697", "endSection": "abstract"}, {"offsetInBeginSection": 202, "offsetInEndSection": 289, "text": "monoamine synthesis blockade induced by NSD-1015 (aromatic L-amino acid decarboxylase) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20408420", "endSection": "abstract"}, {"offsetInBeginSection": 448, "offsetInEndSection": 520, "text": "the aromatic-l-amino-acid decarboxylase (EC 4.1.1.28) inhibitor NSD-1015", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22841861", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 386, "text": "An accumulation of L-dihydroxyphenylalanine (DOPA) in the median eminence of female rats treated with 3-hydroxybenzylhydrazine (NSD 1015), and inhibitor of aromatic L-amino acid decarboxylase (DOPA decarboxylase) activity, was associated with a decreased concentration of dopamine in the median eminence and pronounced reduction in the release of dopamine into hypophysial portal blood.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6811255", "endSection": "abstract"}, {"offsetInBeginSection": 787, "offsetInEndSection": 1019, "text": "6S-BH4 increased extracellular DOPA levels in the presence of NSD 1015, an inhibitor of aromatic L-amino acid decarboxylase (an index of in vivo tyrosine hydroxylase activity), to an extent similar to the increase induced by 6R-BH4.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7616241", "endSection": "abstract"}, {"offsetInBeginSection": 515, "offsetInEndSection": 774, "text": "5-HT synthesis was estimated by measuring the accumulation of the 5-HT precursor, 5-hydroxytryptophan (5-HTP), in the neurointermediate lobe of male Long-Evans rats following the administration of NSD 1015, an inhibitor of aromatic L-amino acid decarboxylase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3103858", "endSection": "abstract"}, {"offsetInBeginSection": 804, "offsetInEndSection": 1062, "text": "Monoamine synthesis was studied in different parts of the brain by measuring the accumulated dopa and 5-hydroxytryptophan (5-HTP), 30 min after NSD 1015 (3-hydroxybenzylhydrazine HCl, 100 mg/kg) an inhibitor of aromatic L-amino-acid decarboxylase, given i.p.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/904693", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 377, "text": "HPLC coupled with electrochemical detection was used to make concurrent measurements of the rate of accumulation of 5-hydroxytryptophan and 3,4-dihydroxyphenylalanine in selected brain regions (striatum, nucleus accumbens, septum, medial periventricular hypothalamus) and thoracic spinal cords of rats treated with NSD 1015, an inhibitor of aromatic-L-amino-acid decarboxylase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3917287", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 551, "text": "The activity of 5-hydroxytryptaminergic neurons has been estimated from measurements of: concentrations of 5-hydroxyindoleacetic acid; the ratio of the concentrations of 5-hydroxyindoleacetic acid to 5-hydroxytryptamine; the rate of accumulation of 5-hydroxytryptophan following the administration of an aromatic L-amino acid decarboxylase inhibitor (e.g., NSD 1015); the rate of accumulation of 5-hydroxytryptamine, and the rate of decline of 5-hydroxyindoleacetic acid following the administration of a monoamine oxidase inhibitor (e.g., pargyline).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2426412", "endSection": "abstract"}, {"offsetInBeginSection": 1006, "offsetInEndSection": 1183, "text": "The accumulation of dopa (3,4-dihydroxyphenylalanine) after administration of NSD 1015 to inhibit aromatic l-amino acid decarboxylase was determined as an index of NE synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20501080", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11135014", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "The centrally acting aromatic amino acid dopa decarboxylase (AADC) inhibitor, 3-hydroxybenzyl hydrazine (NSD-1015), is widely used to study the neurotransmitter-like actions of L-DOPA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11135014", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "The aromatic amino acid decarboxylase inhibitor, NSD-1015, increases release of dopamine: response characteristics.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1470299", "endSection": "title"}, {"offsetInBeginSection": 450, "offsetInEndSection": 549, "text": "The aromatic amino acid decarboxylase inhibitor NSD 1015 markedly increased the dopa concentration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6164221", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 343, "text": "Using a microdialysis technique, the rat striatum was perfused with NSD-1015, an inhibitor of aromatic L-amino acid decarboxylase, and the amount of L-3,4-dihydroxyphenylalanine (L-DOPA) and 5-hydroxytryptophan (5-HTP) accumulating in dialysate was measured as an index of in vivo activities of tyrosine hydroxylase and tryptophan hydroxylase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7692885", "endSection": "abstract"}, {"offsetInBeginSection": 308, "offsetInEndSection": 489, "text": "Also, we studied the effect of MnCl2 on extracellular levels of l-Dopa in the presence of aromatic amino acid decarboxylase (AADC) inhibitor 3-hydroxybencilhydracine-HCl (NSD 1015).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16292508", "endSection": "abstract"}, {"offsetInBeginSection": 102, "offsetInEndSection": 283, "text": "The role of L-DOPA itself was investigated by administering several doses of an aromatic L-amino acid decarboxylase inhibitor, NSD 1015, prior to 100 mg/kg L-DOPA to 5-day-old rats.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8836582", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 387, "text": "An accumulation of L-dihydroxyphenylalanine (DOPA) in the median eminence of female rats treated with 3-hydroxybenzylhydrazine (NSD 1015), and inhibitor of aromatic L-amino acid decarboxylase (DOPA decarboxylase) activity, was associated with a decreased concentration of dopamine in the median eminence and pronounced reduction in the release of dopamine into hypophysial portal blood. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6811255", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "[Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20408420", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "DOPA was measured in the anterior pituitary and hypothalamic-hypophysial portal blood after treatment with NSD-1015, a DOPA decarboxylase inhibitor. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1348847", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Central action of an inhibitor of brain dopa-decarboxylase, NSD-1015, on cyanamide-induced alcohol drinking in rats.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2320657", "endSection": "title"}, {"offsetInBeginSection": 102, "offsetInEndSection": 284, "text": "The role of L-DOPA itself was investigated by administering several doses of an aromatic L-amino acid decarboxylase inhibitor, NSD 1015, prior to 100 mg/kg L-DOPA to 5-day-old rats. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8836582", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "The centrally acting aromatic amino acid dopa decarboxylase (AADC) inhibitor, 3-hydroxybenzyl hydrazine (NSD-1015), is widely used to study the neurotransmitter-like actions of L-DOPA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11135014", "endSection": "abstract"}, {"offsetInBeginSection": 643, "offsetInEndSection": 944, "text": "Furthermore, the ethanol-induced enhancement of 3,4-dihydroxyphenylalanine accumulation in the mesolimbic dopamine terminal area after NSD 1015 (an inhibitor of l-aromatic amino acid decarboxylase) was completely antagonized by mecamylamine in doses (3.0 and 6.0 mg/kg) that exerted no effects per se.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8287902", "endSection": "abstract"}, {"offsetInBeginSection": 271, "offsetInEndSection": 630, "text": "The acetylcholinesterase inhibitor physostigmine (0.5 mg/kg s.c.) enhanced L-dihydroxyphenylalanine (DOPA) and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in both the corpus striatum and limbic areas (nucleus accumbens) after inhibition of aromatic amino acid decarboxylase with NSD-1015, indicating an enhanced synthesis of dopamine in these brain regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1436125", "endSection": "abstract"}, {"offsetInBeginSection": 1021, "offsetInEndSection": 1376, "text": "Estradiol benzoate-treated rats had significantly lower anterior pituitary DOPA accumulation after intraperitoneal administration of 3,4-hydroxybenzyl-hydrazine dihydrochloride (NSD-1015), an irreversible inhibitor of L-aromatic amino acid decarboxylase whereas methylene blue did not affect anterior pituitary DOPA accumulation when compared to controls.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11343835", "endSection": "abstract"}, {"offsetInBeginSection": 260, "offsetInEndSection": 433, "text": "The accumulation of dihydroxyphenylalanine (DOPA) following administration of the L-aromatic amino acid decarboxylase inhibitor, NSD 1015, was used to estimate DA synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6432557", "endSection": "abstract"}, {"offsetInBeginSection": 1016, "offsetInEndSection": 1189, "text": "Inhibition of PE synthesis by i.p. injection of the aromatic L-amino acid decarboxylase inhibitor, NSD 1015, produced a reversal of the effects of MDL 72,145 and Ro 19-6327.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7889269", "endSection": "abstract"}, {"offsetInBeginSection": 275, "offsetInEndSection": 482, "text": "After 42 hr of abstinence, rats were challenged with either cocaine (15 mg/kg, ip) or saline, followed by the aromatic L-amino acid decarboxylase inhibitor 3-hydroxybenzylhydrazine (NSD-1015; 100 mg/kg, ip).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8511717", "endSection": "abstract"}, {"offsetInBeginSection": 304, "offsetInEndSection": 633, "text": "Following motor activity observations, the cerebral aromatic L-amino acid decarboxylase inhibitor NSD-1015 (100 mg kg-1 intraperitoneally) was administered and 30 min. later the animals were decapitated for subsequent analysis of the accumulated forebrain DOPA and 5-HTP levels, as an estimate of the rate of monoamine synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8361951", "endSection": "abstract"}, {"offsetInBeginSection": 566, "offsetInEndSection": 834, "text": "The utility of this technique was demonstrated by comparing the effects on the scans of halothane and pentobarbital anesthesia and by the administration of NSD 1015, a peripheral and central inhibitor of L-aromatic amino-acid decarboxylase, between back-to-back scans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1904482", "endSection": "abstract"}, {"offsetInBeginSection": 351, "offsetInEndSection": 571, "text": "Addition of the aromatic amino acid decarboxylase inhibitor, 3-hydroxybenzylhydrazine (NSD 1015), prevented the formation of N-acetylcompounds from L-[3H]tyrosine, without resulting in an accumulation of label in L-DOPA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6780662", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "The effects of the peripheral aromatic amino acid decarboxylase (AADC) inhibitors, carbidopa and benserazide, and the central AADC inhibitor, 3-hydroxybenzylhydrazine (NSD-1015) on peripheral and brain monoamine oxidase (MAO) A and B activity were investigated in the rat.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12658372", "endSection": "abstract"}, {"offsetInBeginSection": 847, "offsetInEndSection": 1105, "text": "Although the putative role of NSD-1015 is as an aromatic amino acid decarboxylase inhibitor, the present results demonstrate that, either as a result of this function and/or in addition to this role, NSD-1015 is a potent activator of the release of dopamine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1470299", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "The aromatic amino acid decarboxylase inhibitor, NSD-1015, increases release of dopamine: response characteristics.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1470299", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11135014", "endSection": "title"}, {"offsetInBeginSection": 472, "offsetInEndSection": 697, "text": "The L-aromatic amino acid decarboxylase inhibitor, NSD-1015 (3-hydroxybenzylhydrazine dihydrochloride) was then given ICV twice daily in a volume of 5.0 microliters in the following doses: 0.005, 0.01, 0.1 and 1.0 micrograms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2320657", "endSection": "abstract"}, {"offsetInBeginSection": 847, "offsetInEndSection": 1106, "text": "Although the putative role of NSD-1015 is as an aromatic amino acid decarboxylase inhibitor, the present results demonstrate that, either as a result of this function and/or in addition to this role, NSD-1015 is a potent activator of the release of dopamine..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1470299", "endSection": "abstract"}]}, {"body": "Is pseudouridine a RNA modification?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25616362", "http://www.ncbi.nlm.nih.gov/pubmed/20106954", "http://www.ncbi.nlm.nih.gov/pubmed/15659360"], "ideal_answer": ["Yes, pseudouridine (\u03a8) is the most abundant of>150 nucleoside modifications in RNA."], "type": "yesno", "id": "58bbb77e22d3005309000017", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Pseudouridine (\u03a8) is the most abundant of>150 nucleoside modifications in RNA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25616362", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 292, "text": "The number and position of the pseudouridines of Haloarcula marismortui and Deinococcus radiodurans large subunit RNA have been determined by a combination of total nucleoside analysis by HPLC-mass spectrometry and pseudouridine sequencing by the reverse transcriptase method and by LC/MS/MS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15659360", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Pseudouridine is the most abundant of more than 100 chemically distinct natural ribonucleotide modifications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20106954", "endSection": "abstract"}]}, {"body": "What does the human ABCC gene  product do?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16006996", "http://www.ncbi.nlm.nih.gov/pubmed/21799180", "http://www.ncbi.nlm.nih.gov/pubmed/16815813", "http://www.ncbi.nlm.nih.gov/pubmed/15631998", "http://www.ncbi.nlm.nih.gov/pubmed/19118502", "http://www.ncbi.nlm.nih.gov/pubmed/16357150", "http://www.ncbi.nlm.nih.gov/pubmed/18535159", "http://www.ncbi.nlm.nih.gov/pubmed/18691054", "http://www.ncbi.nlm.nih.gov/pubmed/18668432", "http://www.ncbi.nlm.nih.gov/pubmed/26191068", "http://www.ncbi.nlm.nih.gov/pubmed/12499391", "http://www.ncbi.nlm.nih.gov/pubmed/18484914", "http://www.ncbi.nlm.nih.gov/pubmed/20360301", "http://www.ncbi.nlm.nih.gov/pubmed/21740521", "http://www.ncbi.nlm.nih.gov/pubmed/11483364"], "ideal_answer": ["The important drug resistance-conferring members belong to three subfamilies of the human ABC family; these are ABCB1 (MDR1/P-glycoprotein of subfamily ABCB), subfamily ABCC (MRPs), and ABCG2 (BCRP of subfamily ABCG), which are expressed in various organs. The ATP-binding cassette (ABC) transporters constitute a large family of membrane proteins, which transport a variety of compounds through the membrane against a concentration gradient at the cost of ATP hydrolysis"], "type": "factoid", "id": "58c99fcc02b8c60953000029", "snippets": [{"offsetInBeginSection": 616, "offsetInEndSection": 915, "text": "structure, function, and expression of the important drug resistance-conferring members belonging to three subfamilies of the human ABC family; these are ABCB1 (MDR1/P-glycoprotein of subfamily ABCB), subfamily ABCC (MRPs), and ABCG2 (BCRP of subfamily ABCG), which are expressed in various organs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16815813", "endSection": "abstract"}, {"offsetInBeginSection": 79, "offsetInEndSection": 455, "text": "Transport proteins, including members of the multidrug resistance protein (MRP)/ABCC subfamily, have been recognized to contribute to the latter function. MRP5 (ABCC5) was identified as transmembrane transport protein for cyclic nucleotides, especially 3',5'-cyclic GMP (cGMP), indicating an additional role in signal transduction and a potential role in placenta development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15631998", "endSection": "abstract"}, {"offsetInBeginSection": 519, "offsetInEndSection": 791, "text": "According to the new nomenclature of human ABC transporter genes, the 'ABCC' gene sub-family comprises three classes involving multidrug resistance-associated proteins (MRPs), sulfonylurea receptors (SURs), and a cystic fibrosis transmembrane conductance regulator (CFTR).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18668432", "endSection": "abstract"}, {"offsetInBeginSection": 376, "offsetInEndSection": 599, "text": "With the addition of these two genes, the complete human ABCC subfamily has 12 identified members (ABCC1-12), nine from the multidrug resistance-like subgroup, two from the sulfonylurea receptor subgroup, and the CFTR gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11483364", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Identification and bioinformatic characterization of a multidrug resistance associated protein (ABCC) gene in Plasmodium berghei.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19118502", "endSection": "title"}, {"offsetInBeginSection": 89, "offsetInEndSection": 198, "text": "One major group of transporters is known as multidrug resistance associated proteins (MRP; ABCC gene family).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12499391", "endSection": "abstract"}, {"offsetInBeginSection": 466, "offsetInEndSection": 741, "text": "On the other hand, several human multidrug resistance proteins [human ATP-binding cassette transporter, subfamily C (ABCC)] cause resistance against nucleoside analogs and mediate transport of phosphorylated nucleoside derivatives out of the cells in an ATP-dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20360301", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 796, "text": "According to the new nomenclature of human ABC transporter genes, the 'ABCC' gene sub-family comprises three classes involving multidrug resistance-associated proteins (MRPs), sulfonylurea receptors (SURs), and a cystic fibrosis transmembrane conductance regulator (CFTR).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18668432", "endSection": "abstract"}, {"offsetInBeginSection": 1955, "offsetInEndSection": 2178, "text": "Several MRP/ABCC members (MRPs 1-3) are associated with tumor resistance which is often caused by an increased efflux and decreased intracellular accumulation of natural product anticancer drugs and other anticancer agents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18691054", "endSection": "abstract"}, {"offsetInBeginSection": 1548, "offsetInEndSection": 1954, "text": "In vitro, the MRP/ABCC transporters can collectively confer resistance to natural product anticancer drugs and their conjugated metabolites, platinum compounds, folate antimetabolites, nucleoside and nucleotide analogs, arsenical and antimonial oxyanions, peptide-based agents, and in concert with alterations in phase II conjugating or biosynthetic enzymes, classical alkylating agents, alkylating agents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18691054", "endSection": "abstract"}, {"offsetInBeginSection": 1061, "offsetInEndSection": 1219, "text": "The human MRP/ABCC transporters except MRP9/ABCC12 are all able to transport organic anions, such as drugs conjugated to glutathione, sulphate or glucuronate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18691054", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 239, "text": "The ABCC multidrug resistance associated proteins (ABCC-MRP), a subclass of ABC transporters are involved in multiple physiological processes that include cellular homeostasis, metal detoxification, and transport of glutathione-conjugates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26191068", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 212, "text": "he ABCC subfamily of the ATP binding cassette (ABC) transporters, which were formerly known as multidrug resistance-related proteins (MRPs), consists of closely related members found in all eukaryotic organisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20712617", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 375, "text": "The ATP-binding cassette (ABC) transporters are a superfamily of membrane proteins that are best known for their ability to transport a wide variety of exogenous and endogenous substances across membranes against a concentration gradient via ATP hydrolysis. There are seven subfamilies of human ABC transporters, one of the largest being the 'C' subfamily (gene symbol ABCC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21740521", "endSection": "abstract"}, {"offsetInBeginSection": 376, "offsetInEndSection": 642, "text": "Nine ABCC subfamily members, the so-called multidrug resistance proteins (MRPs) 1-9, have been implicated in mediating multidrug resistance in tumor cells to varying degrees as the efflux extrude chemotherapeutic compounds (or their metabolites) from malignant cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21740521", "endSection": "abstract"}]}, {"body": "What is the connection between furin and hepcidin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19070914", "http://www.ncbi.nlm.nih.gov/pubmed/23390091", "http://www.ncbi.nlm.nih.gov/pubmed/20634490", "http://www.ncbi.nlm.nih.gov/pubmed/24808863", "http://www.ncbi.nlm.nih.gov/pubmed/18664504", "http://www.ncbi.nlm.nih.gov/pubmed/17905609", "http://www.ncbi.nlm.nih.gov/pubmed/18775801", "http://www.ncbi.nlm.nih.gov/pubmed/19610021"], "ideal_answer": ["The iron-regulatory peptide hepcidin is synthesized in the liver as an 84-aa pre-pro-hormone maturated by proteolysis through a consensus furin cleavage site to generate the bioactive 25-aa peptide secreted in the circulation. The hepatic prohormone convertase furin mediates the posttranslational processing of hepcidin."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045683", "http://www.uniprot.org/uniprot/HEPC_RAT", "http://www.uniprot.org/uniprot/HEPC_PONAB", "http://www.uniprot.org/uniprot/HEPC_MOUSE", "http://www.uniprot.org/uniprot/FURIN_BOVIN", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064451"], "type": "summary", "id": "58bebc4c02b8c60953000015", "snippets": [{"offsetInBeginSection": 101, "offsetInEndSection": 213, "text": "Hepcidin is mainly produced by the liver as a propeptide and processed by furin into the mature active peptide. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24808863", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Implication of the proprotein convertases in iron homeostasis: proprotein convertase 7 sheds human transferrin receptor 1 and furin activates hepcidin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23390091", "endSection": "title"}, {"offsetInBeginSection": 1074, "offsetInEndSection": 1276, "text": "Analysis of primary hepatocytes from mice lacking furin, PC5, PACE4, or PC7 revealed that hepcidin, which limits iron availability in the circulation, is specifically generated by furin and not by PC7. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23390091", "endSection": "abstract"}, {"offsetInBeginSection": 1433, "offsetInEndSection": 1604, "text": "Among the PC family members, only furin activates hepcidin in hepatocytes, and uniquely the full-length membrane-bound PC7 can directly shed hTfR1 by cleavage at Arg100 \u2193.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23390091", "endSection": "abstract"}, {"offsetInBeginSection": 595, "offsetInEndSection": 815, "text": "The human hepcidin gene contains three exons that encode a 72-aa precursor (pro-hepcidin) with a characteristic furin cleavage site immediately N-terminal to the 25-aa major hepcidin species found in plasma and urine [3]", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19610021", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "title"}, {"offsetInBeginSection": 17, "offsetInEndSection": 392, "text": "The iron-regulatory peptide hepcidin is synthesized in the liver as an 84-aa pre-pro-hormone maturated by proteolysis through a consensus furin cleavage site to generate the bioactive 25-aa peptide secreted in the circulation. This peptide regulates iron export from enterocytes and macrophages by binding the membrane iron exporter, ferroportin, leading to its degradation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 1293, "offsetInEndSection": 1451, "text": "Our results demonstrate that pro-hepcidin lacks biological activity, unless fully maturated by a furin-dependent process to yield the bioactive 25-aa peptide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17905609", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 327, "text": "Hepcidin is encoded as an 84 amino acid prepropeptide containing a typical N-terminal 24 amino acid endoplasmic reticulum targeting signal sequence, and a 35 amino acid proregion (pro) with a consensus furin cleavage site immediately followed by the C-terminal 25 amino acid bioactive iron-regulatory hormone (mature peptide). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17905609", "endSection": "abstract"}, {"offsetInBeginSection": 1129, "offsetInEndSection": 1238, "text": "In conclusion, the hepatic prohormone convertase furin mediates the posttranslational processing of hepcidin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17905609", "endSection": "abstract"}, {"offsetInBeginSection": 1123, "offsetInEndSection": 1232, "text": "In conclusion, the hepatic prohormone convertase furin mediates the posttranslational processing of hepcidin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17905609", "endSection": "abstract"}, {"offsetInBeginSection": 1401, "offsetInEndSection": 1447, "text": "Furin in turn may control hepcidin expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20634490", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Regulation of prohepcidin processing and activity by the subtilisin-like proprotein convertases Furin, PC5, PACE4 and PC7.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18664504", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 243, "text": "BACKGROUND/AIMS: The iron-regulatory peptide hepcidin is synthesized in the liver as an 84-aa pre-pro-hormone maturated by proteolysis through a consensus furin cleavage site to generate the bioactive 25-aa peptide secreted in the circulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 783, "offsetInEndSection": 1031, "text": "Furin activity was also modulated using furin inhibitor or siRNA-mediated furin mRNA knockdown.RESULTS: We found that pro-hepcidin could fully induce ferroportin degradation, but only when processed by furin to generate the mature hepcidin-25 form.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 757, "offsetInEndSection": 995, "text": "Furin activity was also modulated using furin inhibitor or siRNA-mediated furin mRNA knockdown.We found that pro-hepcidin could fully induce ferroportin degradation, but only when processed by furin to generate the mature hepcidin-25 form", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 1460, "offsetInEndSection": 1808, "text": "CONCLUSIONS: These results demonstrate the key role of the convertases Furin, PACE4, PC5 and/or PC7 in the generation and secretion of active hepcidin and suggest that the control of hepcidin processing as a potential therapeutic/diagnostic strategy in hepcidin-related disorders such as haemochromatosis, inflammatory diseases, anaemia and cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18664504", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 244, "text": "BACKGROUND/AIMS: The iron-regulatory peptide hepcidin is synthesized in the liver as an 84-aa pre-pro-hormone maturated by proteolysis through a consensus furin cleavage site to generate the bioactive 25-aa peptide secreted in the circulation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 1283, "offsetInEndSection": 1454, "text": "CONCLUSIONS: Our results demonstrate that pro-hepcidin lacks biological activity, unless fully maturated by a furin-dependent process to yield the bioactive 25-aa peptide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "The iron-regulatory peptide hepcidin is synthesized in the liver as an 84-aa pre-pro-hormone maturated by proteolysis through a consensus furin cleavage site to generate the bioactive 25-aa peptide secreted in the circulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 757, "offsetInEndSection": 996, "text": "Furin activity was also modulated using furin inhibitor or siRNA-mediated furin mRNA knockdown.We found that pro-hepcidin could fully induce ferroportin degradation, but only when processed by furin to generate the mature hepcidin-25 form.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 1347, "offsetInEndSection": 1393, "text": "Furin in turn may control hepcidin expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20634490", "endSection": "abstract"}, {"offsetInBeginSection": 1062, "offsetInEndSection": 1263, "text": "Analysis of primary hepatocytes from mice lacking furin, PC5, PACE4, or PC7 revealed that hepcidin, which limits iron availability in the circulation, is specifically generated by furin and not by PC7.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23390091", "endSection": "abstract"}, {"offsetInBeginSection": 1164, "offsetInEndSection": 1451, "text": "Furthermore, the mutated version of pro-hepcidin was completely inefficient at degrading ferroportin in macrophages.CONCLUSIONS: Our results demonstrate that pro-hepcidin lacks biological activity, unless fully maturated by a furin-dependent process to yield the bioactive 25-aa peptide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 485, "offsetInEndSection": 782, "text": "However, the activity of the pro-peptide on ferroportin degradation has never been addressed.METHODS: To answer this question, we produced recombinant pro-hepcidin, both the wild-type form and a furin cleavage site mutant, and tested their activity on ferroportin levels in macrophagic J774 cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 1350, "offsetInEndSection": 1397, "text": "Furin in turn may control hepcidin expression..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20634490", "endSection": "abstract"}, {"offsetInBeginSection": 854, "offsetInEndSection": 998, "text": "We found that pro-hepcidin could fully induce ferroportin degradation, but only when processed by furin to generate the mature hepcidin-25 form.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17905609", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Implication of the proprotein convertases in iron homeostasis: proprotein convertase 7 sheds human transferrin receptor 1 and furin activates hepcidin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23390091", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19070914", "endSection": "title"}, {"offsetInBeginSection": 1418, "offsetInEndSection": 1754, "text": "These results demonstrate the key role of the convertases Furin, PACE4, PC5 and/or PC7 in the generation and secretion of active hepcidin and suggest that the control of hepcidin processing as a potential therapeutic/diagnostic strategy in hepcidin-related disorders such as haemochromatosis, inflammatory diseases, anaemia and cancer..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18664504", "endSection": "abstract"}]}, {"body": "Which cells express CIDEC protein in humans?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20945533", "http://www.ncbi.nlm.nih.gov/pubmed/21636835", "http://www.ncbi.nlm.nih.gov/pubmed/25255829", "http://www.ncbi.nlm.nih.gov/pubmed/18845124", "http://www.ncbi.nlm.nih.gov/pubmed/26927378", "http://www.ncbi.nlm.nih.gov/pubmed/24065549", "http://www.ncbi.nlm.nih.gov/pubmed/23399566", "http://www.ncbi.nlm.nih.gov/pubmed/26770990", "http://www.ncbi.nlm.nih.gov/pubmed/18311595", "http://www.ncbi.nlm.nih.gov/pubmed/18509062", "http://www.ncbi.nlm.nih.gov/pubmed/24126816", "http://www.ncbi.nlm.nih.gov/pubmed/26367078", "http://www.ncbi.nlm.nih.gov/pubmed/18702959", "http://www.ncbi.nlm.nih.gov/pubmed/18198355", "http://www.ncbi.nlm.nih.gov/pubmed/25210844", "http://www.ncbi.nlm.nih.gov/pubmed/20154362", "http://www.ncbi.nlm.nih.gov/pubmed/19661960", "http://www.ncbi.nlm.nih.gov/pubmed/26176546", "http://www.ncbi.nlm.nih.gov/pubmed/25418138", "http://www.ncbi.nlm.nih.gov/pubmed/26099526", "http://www.ncbi.nlm.nih.gov/pubmed/25477509", "http://www.ncbi.nlm.nih.gov/pubmed/24742676", "http://www.ncbi.nlm.nih.gov/pubmed/26733203", "http://www.ncbi.nlm.nih.gov/pubmed/20596603", "http://www.ncbi.nlm.nih.gov/pubmed/24627478", "http://www.ncbi.nlm.nih.gov/pubmed/27062372", "http://www.ncbi.nlm.nih.gov/pubmed/20190390", "http://www.ncbi.nlm.nih.gov/pubmed/17884815", "http://www.ncbi.nlm.nih.gov/pubmed/23220584"], "ideal_answer": ["The cell death-inducing DNA fragmentation factor alpha-like effector c (CIDEC) is a lipid droplet-associated protein that promotes intracellular triglyceride (TAG) storage. CIDEC is highly expressed in adipocytes, but undetectable in normal liver. However, its hepatic expression rises during fasting or under genetic or diet-induced hepatosteatosis in patients."], "type": "summary", "id": "58ca746d02b8c6095300002d", "snippets": [{"offsetInBeginSection": 976, "offsetInEndSection": 1170, "text": "The expression levels of related adipocyte markers (PPAR\u03b3, C/EBP\u03b1), mature white adipose tissue specific markers (Cidec, RIP140) increased at the presence of NPY (10(-7), 10(-9), 10(-11) mol/L).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26927378", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 458, "text": "The cell death-inducing DNA fragmentation factor alpha-like effector c (CIDEC; also known in rodents as FSP27 or fat-specific protein 27) is a lipid droplet-associated protein that promotes intracellular triglyceride (TAG) storage. CIDEC/Fsp27 is highly expressed in adipose tissue, but undetectable in normal liver. However, its hepatic expression rises during fasting or under genetic or diet-induced hepatosteatosis in both mice and patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418138", "endSection": "abstract"}, {"offsetInBeginSection": 1187, "offsetInEndSection": 1363, "text": " Our results also suggest that patients taking fibrates likely have elevated levels of hepatic CIDEC, which may limit the efficient mobilization and catabolism of hepatic TAGs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418138", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 365, "text": "Fat-specific protein 27 (FSP27, CIDEC in humans) is a lipid-coating protein highly expressed in mature white adipocytes that contributes to unilocular lipid droplet formation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25477509", "endSection": "abstract"}, {"offsetInBeginSection": 158, "offsetInEndSection": 460, "text": "We studied mouse models and human tissues to identify molecules associated with ASH progression and focused on the mouse fat-specific protein 27 (FSP-27)/human cell death-inducing DFF45-like effector C (CIDEC) protein, which is expressed in white adipose tissues and promotes formation of fat droplets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26099526", "endSection": "abstract"}, {"offsetInBeginSection": 2073, "offsetInEndSection": 2230, "text": "Hepatic CIDEC mRNA expression was increased in patients with AH and correlated with the degree of hepatic steatosis and disease severity including mortality.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26099526", "endSection": "abstract"}, {"offsetInBeginSection": 2382, "offsetInEndSection": 2580, "text": "Hepatic expression of FSP27/CIDEC is highly up-regulated in mice following chronic-plus-binge ethanol feeding and in patients with AH; this up-regulation contributes to alcohol-induced liver damage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26099526", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "FSP27 [cell death-inducing DFFA-like effector c (CIDEC) in humans] is a protein associated with lipid droplets that downregulates the fatty acid oxidation (FAO) rate when it is overexpressed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23220584", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Fsp27/CIDEC is a CREB target gene induced during early fasting in liver and regulated by FA oxidation rate.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23220584", "endSection": "title"}, {"offsetInBeginSection": 951, "offsetInEndSection": 1393, "text": "Similarly, CIDEC expression was upregulated in HepG2 cells by either etomoxir or HMGCS2 interference. Our data indicate that there is a kinetic mechanism of autoregulation between short- and long-term fasting, by which free FAs delivered to the liver during early fasting are accumulated/exported by FSP27/CIDEC, whereas over longer periods of fasting, they are degraded in the mitochondria through the carnitine palmitoyl transferase system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23220584", "endSection": "abstract"}, {"offsetInBeginSection": 801, "offsetInEndSection": 956, "text": "However, in adipose tissue the changes in Cidec mRNA did not correspond to the changes in Cidec protein levels, as a HFD decreased Cidec protein abundance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176546", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Cell death-inducing DFFA-like effector c (CIDEC) protein, also known as fat specific protein 27 (Fsp27), is localized to lipid droplets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065549", "endSection": "abstract"}, {"offsetInBeginSection": 138, "offsetInEndSection": 440, "text": "We studied mouse models and human tissues to identify molecules associated with ASH progression and focused on the mouse fat-specific protein 27 (FSP-27)/human cell death-inducing DFF45-like effector C (CIDEC) protein, which is expressed in white adipose tissues and promotes formation of fat droplets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26099526", "endSection": "abstract"}, {"offsetInBeginSection": 956, "offsetInEndSection": 1280, "text": "Interestingly, in adipose tissue Cidea protein expression was significantly related to body weight (R=.725), epididymal adipose tissue (EWAT) mass (R=.475) and insulin resistance (R=.706), whereas Cidec protein expression was inversely related to body weight (R=-.787), EWAT mass (R=-.706), and insulin resistance (R=-.679).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176546", "endSection": "abstract"}, {"offsetInBeginSection": 1280, "offsetInEndSection": 1626, "text": "Similar to adipose tissue, Cidea protein expression in liver was significantly related to body weight (R=.660), EWAT mass (R=.468), and insulin resistance (R=.599); however, unlike adipose tissue, Cidec protein levels in liver were not related to body weight or EWAT mass and only moderately associated with insulin resistance (R=-.422, P=0.051).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176546", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "The CIDEC protein is located in lipid droplets (LDs) and the endoplasmic reticulum (ER) and is induced in fat deposition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25255829", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 302, "text": "CIDEC protein is required for unilocular lipid droplet formation and optimal energy storage in addition to controlling lipid metabolism in adipocytes and hepatocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065549", "endSection": "abstract"}, {"offsetInBeginSection": 951, "offsetInEndSection": 1052, "text": "Similarly, CIDEC expression was upregulated in HepG2 cells by either etomoxir or HMGCS2 interference.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23220584", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "The hepatic expression of the cell death-inducing DNA fragmentation factor A-like effector family (CIDEA, CIDEB, and CIDEC) genes is markedly upregulated in mouse models of obesity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19661960", "endSection": "abstract"}, {"offsetInBeginSection": 307, "offsetInEndSection": 413, "text": "After the differentiation of adipocyte, the expression pattern of Cidec was similar to that of PPARgamma2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18845124", "endSection": "abstract"}, {"offsetInBeginSection": 697, "offsetInEndSection": 861, "text": "This paper examined the tissue expression profile of CIDEC gene in cattle using real-time RT-PCR to suggest that bovine CIDEC is highly expressed in adipose tissue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065549", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "Human adipocytes express high levels of two distinct lipid droplet proteins, fat specific protein 27 (FSP27; also called CIDEC), a member of the CIDE family, and perilipin1 (PLIN1), a member of the PAT family", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23399566", "endSection": "abstract"}, {"offsetInBeginSection": 1280, "offsetInEndSection": 1481, "text": "These results suggest that insulin regulates CIDEA and CIDEC expression via PI3K, and it regulates expression of each protein via Akt1/2- and JNK2-dependent pathways, respectively, in human adipocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21636835", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Differential regulation of CIDEA and CIDEC expression by insulin via Akt1/2- and JNK2-dependent pathways in human adipocytes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21636835", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Differential roles of CIDEA and CIDEC in insulin-induced anti-apoptosis and lipid droplet formation in human adipocytes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20154362", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "Human adipocytes express high levels of two distinct lipid droplet proteins, fat specific protein 27 (FSP27; also called CIDEC), a member of the CIDE family, and perilipin1 (PLIN1), a member of the PAT family. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23399566", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 366, "text": "Fat-specific protein 27 (FSP27, CIDEC in humans) is a lipid-coating protein highly expressed in mature white adipocytes that contributes to unilocular lipid droplet formation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25477509", "endSection": "abstract"}, {"offsetInBeginSection": 1147, "offsetInEndSection": 1376, "text": "Using human primary pre-adipocytes, we confirmed that the expression of CIDEC was elevated during the differentiation of pre-adipocytes, and knockdown of CIDEC in human primary pre-adipocytes resulted in differentiation defects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20945533", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Cell death-inducing DFF45-like effector C (CIDEC) is a lipid droplet-coating protein that promotes triglyceride accumulation and inhibits lipolysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27062372", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 231, "text": "The cell death-inducing DNA fragmentation factor alpha-like effector c (CIDEC; also known in rodents as FSP27 or fat-specific protein 27) is a lipid droplet-associated protein that promotes intracellular triglyceride (TAG) storage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418138", "endSection": "abstract"}, {"offsetInBeginSection": 457, "offsetInEndSection": 678, "text": "Here we demonstrate that knockdown of the lipid droplet protein FSP27 (a.k.a. CIDEC) in human adipocytes increases expression of ATGL at the level of transcription, whereas overexpression of FSP27 has the opposite effect.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24742676", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 209, "text": "However, the transcriptional regulation of Cidec in adipocyte remains unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18845124", "endSection": "abstract"}, {"offsetInBeginSection": 889, "offsetInEndSection": 970, "text": "Moreover, the hepatic expression of CIDEC is downregulated by marked weight loss.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19661960", "endSection": "abstract"}, {"offsetInBeginSection": 721, "offsetInEndSection": 888, "text": "These data demonstrate that, consistent with previous studies conducted in rodents, hepatic expression of CIDEA and CIDEC, but not CIDEB, is increased in obese humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19661960", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Transcriptional activation of Cidec by PPARgamma2 in adipocyte.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18845124", "endSection": "title"}, {"offsetInBeginSection": 952, "offsetInEndSection": 1112, "text": "Our data indicated additional fatty acids stimulated hepatic CIDEC expression and an increasing level of CIDEC induced hepatic LD fusion and lipid accumulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25255829", "endSection": "abstract"}, {"offsetInBeginSection": 139, "offsetInEndSection": 441, "text": "We studied mouse models and human tissues to identify molecules associated with ASH progression and focused on the mouse fat-specific protein 27 (FSP-27)/human cell death-inducing DFF45-like effector C (CIDEC) protein, which is expressed in white adipose tissues and promotes formation of fat droplets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26099526", "endSection": "abstract"}, {"offsetInBeginSection": 486, "offsetInEndSection": 622, "text": "By analysis of CIDEC expression in 65 human tissues, we conclude that human CIDEC is predominantly expressed in subcutaneous adipocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18702959", "endSection": "abstract"}, {"offsetInBeginSection": 232, "offsetInEndSection": 316, "text": "CIDEC/Fsp27 is highly expressed in adipose tissue, but undetectable in normal liver.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418138", "endSection": "abstract"}, {"offsetInBeginSection": 729, "offsetInEndSection": 839, "text": "Interestingly, FSP27/CIEDC was expressed in mouse and human livers and was upregulated in obese C57BL/6J mice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26770990", "endSection": "abstract"}, {"offsetInBeginSection": 807, "offsetInEndSection": 962, "text": "However, in adipose tissue the changes in Cidec mRNA did not correspond to the changes in Cidec protein levels, as a HFD decreased Cidec protein abundance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176546", "endSection": "abstract"}]}, {"body": "Which is the relation between coffee consumption and stroke risk?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24326448"], "ideal_answer": ["The coffee paradox in stroke: Increased consumption linked with fewer strokes."], "type": "factoid", "id": "58ce363b02b8c60953000046", "snippets": [{"offsetInBeginSection": 450, "offsetInEndSection": 854, "text": "The majority of prospective studies have reported a weak inverse association between moderate consumption of coffee and risk of stroke. However, there are yet no clear biological mechanisms whereby coffee might provide cardiovascular health benefits. Awaiting the results from further long-term RCTs and prospective studies, moderate consumption of filtered coffee, tea, and dark chocolate seems prudent.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24326448", "endSection": "abstract"}]}, {"body": "What is the purpose of the Orpington Prognostic Scale?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17903924", "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "http://www.ncbi.nlm.nih.gov/pubmed/11300243", "http://www.ncbi.nlm.nih.gov/pubmed/15595254", "http://www.ncbi.nlm.nih.gov/pubmed/16418057", "http://www.ncbi.nlm.nih.gov/pubmed/16634344", "http://www.ncbi.nlm.nih.gov/pubmed/16690572", "http://www.ncbi.nlm.nih.gov/pubmed/15083439", "http://www.ncbi.nlm.nih.gov/pubmed/16097508", "http://www.ncbi.nlm.nih.gov/pubmed/8463526", "http://www.ncbi.nlm.nih.gov/pubmed/9731605", "http://www.ncbi.nlm.nih.gov/pubmed/12173758", "http://www.ncbi.nlm.nih.gov/pubmed/16337699", "http://www.ncbi.nlm.nih.gov/pubmed/19785245", "http://www.ncbi.nlm.nih.gov/pubmed/12961913"], "ideal_answer": ["The Orpington Prognostic Scale (OPS) is used to predict futue functional status of stroke patients, to asses stroke severity, outcome and response to subacute rehabilitation. In patients with stroke, OPS and NIHSS had significant contribution to the estimation of the functional status and OPS was more effective than NIHSS. However, other reported that the OPS has limited predictive accuracy for discharge destination and is a poor predictor of follow-up services."], "type": "summary", "id": "58861f8b3b87a8a738000003", "snippets": [{"offsetInBeginSection": 339, "offsetInEndSection": 407, "text": "Stroke severity was determined using the Orpington Prognostic Scale.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16634344", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Predicting response to rehabilitation in elderly patients with stroke using the Orpington Prognostic Scale and selected clinical variables.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "title"}, {"offsetInBeginSection": 130, "offsetInEndSection": 315, "text": " The purpose of this study was to determine the ability of the Orpington Prognostic Scale (OPS) to predict outcome and response to subacute rehabilitation in older patients with stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "abstract"}, {"offsetInBeginSection": 794, "offsetInEndSection": 1005, "text": "The OPS scores were strong predictors of response to subacute rehabilitation and discharge FIM motor subscale scores. The OPS may warrant a broader application as a prognostic indicator for patients with stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 239, "text": "PURPOSE: The aim of our study is to compare the Orpington Prognostic Scale (OPS) and the National Institutes of Health Stroke Scale (NIHSS) and to evaluate whether they help us estimate the future functional status of patients with stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690572", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Comparison of the Orpington Prognostic Scale (OPS) and the National Institutes of Health Stroke Scale (NIHSS) for the prediction of the functional status of patients with stroke.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690572", "endSection": "title"}, {"offsetInBeginSection": 1089, "offsetInEndSection": 1250, "text": "CONCLUSION: In patients with stroke, OPS and NIHSS had significant contribution to the estimation of the functional status and OPS was more effective than NIHSS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690572", "endSection": "abstract"}, {"offsetInBeginSection": 180, "offsetInEndSection": 332, "text": "The Orpington Prognostic Score (OPS) is a clinically derived stroke severity scale that can be used to stratify patients into different severity groups.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16097508", "endSection": "abstract"}, {"offsetInBeginSection": 1539, "offsetInEndSection": 1613, "text": "The OPS is a valid measure of stroke severity in Irish stroke in-patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16097508", "endSection": "abstract"}, {"offsetInBeginSection": 1158, "offsetInEndSection": 1337, "text": "CONCLUSIONS: Despite high inter-rater and test-retest reliability, the OPS has limited predictive accuracy for discharge destination and is a poor predictor of follow-up services.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16418057", "endSection": "abstract"}, {"offsetInBeginSection": 345, "offsetInEndSection": 536, "text": "PARTICIPANTS: Sixty-four patients with recent stroke admitted for inpatient rehabilitation were randomized within severity strata (Orpington Prognostic Scale) into 1 of 3 intervention groups.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15083439", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Predicting final disposition after stroke using the Orpington Prognostic Score.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15595254", "endSection": "title"}, {"offsetInBeginSection": 256, "offsetInEndSection": 374, "text": "In Calgary, the Orpington Prognostic Score (OPS) has been used to predict outcome as an aid to rehabilitation triage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15595254", "endSection": "abstract"}, {"offsetInBeginSection": 1301, "offsetInEndSection": 1370, "text": "CONCLUSIONS: The first week OPS can be used to predict final outcome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15595254", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Predicting stroke recovery: three- and six-month rates of patient-centered functional outcomes based on the orpington prognostic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11300243", "endSection": "title"}, {"offsetInBeginSection": 1536, "offsetInEndSection": 1657, "text": "CONCLUSION: OPS scores can predict widely differing rates of functional recovery in five important functional abilities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11300243", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Prediction of functional outcome after stroke: comparison of the Orpington Prognostic Scale and the NIH Stroke Scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9731605", "endSection": "title"}, {"offsetInBeginSection": 1550, "offsetInEndSection": 1806, "text": "CONCLUSIONS: Our results demonstrate that in a sample of mostly mild and moderate strokes, the Orpington Prognostic Scale compared with the NIH Stroke Scale is simpler to use and is a slightly better predictor of ADL and higher levels of physical function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9731605", "endSection": "abstract"}, {"offsetInBeginSection": 1400, "offsetInEndSection": 1631, "text": "CONCLUSIONS: The Orpington score when assessed at 2-weeks post-stroke is a useful prognostic indicator with special suitability for the elderly and may help to select patients most likely to benefit from stroke unit rehabilitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8463526", "endSection": "abstract"}, {"offsetInBeginSection": 1211, "offsetInEndSection": 1456, "text": "The OPS at 48 hours is a good predictor of outcome at 6 months and 2 years after ischemic stroke and allows early identification of 3 prognostic groups, which may help in identifying patients most likely to benefit from intensive rehabilitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17903924", "endSection": "abstract"}, {"offsetInBeginSection": 121, "offsetInEndSection": 305, "text": "The purpose of this study was to determine the ability of the Orpington Prognostic Scale (OPS) to predict outcome and response to subacute rehabilitation in older patients with stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "This study investigates the prognostic ability of the Orpington Prognostic Scale within 48 hours (OPS-1) after admission in predicting outcome at 6 months and 2 years in acute ischemic stroke and compares it with the 2 week OPS (OPS-2).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17903924", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "The aim of our study is to compare the Orpington Prognostic Scale (OPS) and the National Institutes of Health Stroke Scale (NIHSS) and to evaluate whether they help us estimate the future functional status of patients with stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690572", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 380, "text": "This study compared the ability of 2 stroke impairment scales, Orpington Prognostic Scale and National Institutes of Health (NIH) Stroke Scale, to predict disability as measured by the Barthel activities of daily living (ADL) Index and higher level of self-reported physical functioning as measured by the SF-36 physical functioning index (PFI) at 1, 3, and 6 months after stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9731605", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "To provide recovery rates after stroke for specific functions using the Orpington Prognostic Scale (OPS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11300243", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "To study the validity of the Orpington scale as a predictive instrument of functional prognosis in patients with stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12961913", "endSection": "abstract"}, {"offsetInBeginSection": 256, "offsetInEndSection": 373, "text": "In Calgary, the Orpington Prognostic Score (OPS) has been used to predict outcome as an aid to rehabilitation triage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15595254", "endSection": "abstract"}, {"offsetInBeginSection": 122, "offsetInEndSection": 409, "text": "The purpose of this study was to determine the ability of the Orpington Prognostic Scale (OPS) to predict outcome and response to subacute rehabilitation in older patients with stroke.Twenty-two subjects in the subacute care setting diagnosed with acute stroke were prospectively studied", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 235, "text": "This study investigates the prognostic ability of the Orpington Prognostic Scale within 48 hours (OPS-1) after admission in predicting outcome at 6 months and 2 years in acute ischemic stroke and compares it with the 2 week OPS (OPS-2)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17903924", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Predicting response to rehabilitation in elderly patients with stroke using the Orpington Prognostic Scale and selected clinical variables", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Comparison of the Orpington Prognostic Scale (OPS) and the National Institutes of Health Stroke Scale (NIHSS) for the prediction of the functional status of patients with stroke", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690572", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Prediction of functional outcome after stroke: comparison of the Orpington Prognostic Scale and the NIH Stroke Scale", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9731605", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 405, "text": "BACKGROUND AND PURPOSE: This study compared the ability of 2 stroke impairment scales, Orpington Prognostic Scale and National Institutes of Health (NIH) Stroke Scale, to predict disability as measured by the Barthel activities of daily living (ADL) Index and higher level of self-reported physical functioning as measured by the SF-36 physical functioning index (PFI) at 1, 3, and 6 months after stroke. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9731605", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 316, "text": "The purpose of this study was to determine the ability of the Orpington Prognostic Scale (OPS) to predict outcome and response to subacute rehabilitation in older patients with stroke. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "PURPOSE: The aim of our study is to compare the Orpington Prognostic Scale (OPS) and the National Institutes of Health Stroke Scale (NIHSS) and to evaluate whether they help us estimate the future functional status of patients with stroke. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690572", "endSection": "abstract"}, {"offsetInBeginSection": 122, "offsetInEndSection": 410, "text": "The purpose of this study was to determine the ability of the Orpington Prognostic Scale (OPS) to predict outcome and response to subacute rehabilitation in older patients with stroke.Twenty-two subjects in the subacute care setting diagnosed with acute stroke were prospectively studied.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "abstract"}, {"offsetInBeginSection": 122, "offsetInEndSection": 306, "text": "The purpose of this study was to determine the ability of the Orpington Prognostic Scale (OPS) to predict outcome and response to subacute rehabilitation in older patients with stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Prediction of functional outcome after stroke: comparison of the Orpington Prognostic Scale and the NIH Stroke Scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9731605", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Comparison of the Orpington Prognostic Scale (OPS) and the National Institutes of Health Stroke Scale (NIHSS) for the prediction of the functional status of patients with stroke.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16690572", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Predicting response to rehabilitation in elderly patients with stroke using the Orpington Prognostic Scale and selected clinical variables.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16914069", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "The Orpington Prognostic Scale within the first 48 hours of admission as a predictor of outcome in ischemic stroke.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17903924", "endSection": "title"}]}, {"body": "Do IEG create a ripple effect of transcription?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19160492"], "ideal_answer": ["Rapid induction of immediate-early genes (IEGs) in response to growth factor stimulations is accompanied by co-upregulation of their neighbouring genes. Profiling the primary transcripts in the nucleus with whole-genome tiling arrays delineated simultaneous activation of transcription centred on IEGs.", "rapid induction of immediate-early genes (iegs) in response to growth factor stimulations is accompanied by co-upregulation of their neighbouring genes.", "Rapid induction of immediate-early genes (IEGs) in response to growth factor stimulations is accompanied by co-upregulation of their neighbouring genes. Even in surrounding intergenic regions, transcriptional activation took place at the same time.", "Rapid induction of immediate-early genes (IEGs) in response to growth factor stimulations is accompanied by co-upregulation of their neighbouring genes.", "Here we show that intensive transcription at one locus frequently spills over into its physical neighbouring loci. Rapid induction of immediate-early genes (IEGs) in response to growth factor stimulations is accompanied by co-upregulation of their neighbouring genes."], "type": "yesno", "id": "58c276bc02b8c60953000020", "snippets": [{"offsetInBeginSection": 524, "offsetInEndSection": 676, "text": "Rapid induction of immediate-early genes (IEGs) in response to growth factor stimulations is accompanied by co-upregulation of their neighbouring genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19160492", "endSection": "abstract"}, {"offsetInBeginSection": 827, "offsetInEndSection": 923, "text": "Even in surrounding intergenic regions, transcriptional activation took place at the same time. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19160492", "endSection": "abstract"}, {"offsetInBeginSection": 409, "offsetInEndSection": 523, "text": "Here we show that intensive transcription at one locus frequently spills over into its physical neighbouring loci.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19160492", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 40, "text": "Ripples from neighbouring transcription.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19160492", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "Ripples from neighbouring transcription.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19160492", "endSection": "title"}]}, {"body": "Which R package is used for the analysis of genome-wide DNA methylation profiles?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23034086"], "ideal_answer": ["MethylKit is a comprehensive R package for the analysis of genome-wide DNA methylation profiles. MethylKit includes functions for clustering, sample quality visualization, differential methylation analysis and annotation features, thus automating and simplifying many of the steps for discerning statistically significant bases or regions of DNA methylation."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:1905643", "http://amigo.geneontology.org/amigo/term/GO:1905642", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019175", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008745", "http://amigo.geneontology.org/amigo/term/GO:0044728"], "type": "factoid", "id": "588f8e9794c1512c50000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034086", "endSection": "title"}, {"offsetInBeginSection": 144, "offsetInEndSection": 592, "text": " Here, we describe an R package, methylKit, that rapidly analyzes genome-wide cytosine epigenetic profiles from high-throughput methylation and hydroxymethylation sequencing experiments. methylKit includes functions for clustering, sample quality visualization, differential methylation analysis and annotation features, thus automating and simplifying many of the steps for discerning statistically significant bases or regions of DNA methylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034086", "endSection": "abstract"}, {"offsetInBeginSection": 145, "offsetInEndSection": 330, "text": "Here, we describe an R package, methylKit, that rapidly analyzes genome-wide cytosine epigenetic profiles from high-throughput methylation and hydroxymethylation sequencing experiments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034086", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034086", "endSection": "title"}, {"offsetInBeginSection": 145, "offsetInEndSection": 591, "text": "Here, we describe an R package, methylKit, that rapidly analyzes genome-wide cytosine epigenetic profiles from high-throughput methylation and hydroxymethylation sequencing experiments. methylKit includes functions for clustering, sample quality visualization, differential methylation analysis and annotation features, thus automating and simplifying many of the steps for discerning statistically significant bases or regions of DNA methylation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034086", "endSection": "abstract"}, {"offsetInBeginSection": 145, "offsetInEndSection": 592, "text": "Here, we describe an R package, methylKit, that rapidly analyzes genome-wide cytosine epigenetic profiles from high-throughput methylation and hydroxymethylation sequencing experiments. methylKit includes functions for clustering, sample quality visualization, differential methylation analysis and annotation features, thus automating and simplifying many of the steps for discerning statistically significant bases or regions of DNA methylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034086", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034086", "endSection": "title"}]}, {"body": "Do T-Cells regulate neuropathic pain?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27646435", "http://www.ncbi.nlm.nih.gov/pubmed/22789131", "http://www.ncbi.nlm.nih.gov/pubmed/25787078", "http://www.ncbi.nlm.nih.gov/pubmed/24553941", "http://www.ncbi.nlm.nih.gov/pubmed/25608762", "http://www.ncbi.nlm.nih.gov/pubmed/23747724", "http://www.ncbi.nlm.nih.gov/pubmed/15541898", "http://www.ncbi.nlm.nih.gov/pubmed/22189457"], "ideal_answer": ["Macrophage-T cell interactions can mediate neuropathic pain through the glucocorticoid-induced TNF"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013601", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050378", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010146"], "type": "yesno", "id": "58c0825502b8c6095300001b", "snippets": [{"offsetInBeginSection": 346, "offsetInEndSection": 501, "text": "here is evidence for a considerable impact of the immune system also in neuropathic pain. However, the role of the adaptive immune system is still unclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25608762", "endSection": "abstract"}, {"offsetInBeginSection": 1806, "offsetInEndSection": 1927, "text": " Our investigation revealed a clear shift of T-cell subsets towards anti-inflammation in patients with neuropathic pain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25608762", "endSection": "abstract"}, {"offsetInBeginSection": 1209, "offsetInEndSection": 1346, "text": " GITRL expressed on macrophages drives cytokine release and T cell activation, resulting in neuropathic pain via GITR-dependent actions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25787078", "endSection": "abstract"}, {"offsetInBeginSection": 1664, "offsetInEndSection": 1842, "text": "Thus, this T-cell subset may be specifically targeted to alleviate chronic neuropathic pain.<CopyrightInformation>Copyright \u00a9 2012 International Association for the Study of Pain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22789131", "endSection": "abstract"}, {"offsetInBeginSection": 105, "offsetInEndSection": 211, "text": "Recent studies show that T cells play an important role in neuropathic pain following nerve injury in rats", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22189457", "endSection": "abstract"}, {"offsetInBeginSection": 1409, "offsetInEndSection": 1558, "text": "These results show a peripheral pivotal role of CatS in the development of neuropathic pain through the antigen-specific activation of CD4(+) T-cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553941", "endSection": "abstract"}, {"offsetInBeginSection": 338, "offsetInEndSection": 619, "text": "Chemokine (C-C motif) ligand 1 (CCL-1), a well-characterized chemokine secreted by activated T cells, has been shown to play an important role in neuropathic pain induced by nerve injury and is also produced in various cell types in the CNS, especially in dorsal root ganglia (DRG)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23747724", "endSection": "abstract"}, {"offsetInBeginSection": 490, "offsetInEndSection": 640, "text": "In the present study, we investigated systemic T-cell subset responses and T-cell related cytokine profiles in patients with chronic neuropathic pain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25608762", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Anti-inflammatory T-cell shift in neuropathic pain.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25608762", "endSection": "title"}, {"offsetInBeginSection": 1664, "offsetInEndSection": 1757, "text": "Thus, this T-cell subset may be specifically targeted to alleviate chronic neuropathic pain..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22789131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Regulatory T cells attenuate neuropathic pain following peripheral nerve injury and experimental autoimmune neuritis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22789131", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Macrophage-T cell interactions mediate neuropathic pain through the glucocorticoid-induced tumor necrosis factor ligand system.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25787078", "endSection": "title"}]}, {"body": "What is the incidence of new cases of X-linked adrenoleukodystrophy (ALD) in Australian and New Zealand in the late 1990's?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9556302"], "ideal_answer": ["cases of ALD diagnosed in Australia and New Zealand between 1981 and 1996 and their families. We estimate that the combined incidence of ALD and its variants in Australasia is at least 1.6 per 100,000. ", "cases of ALD diagnosed in Australia and New Zealand between 1981 and 1996 and their families. We estimate that the combined incidence of ALD and its variants in Australasia is at least 1.6 per 100,000.", "When looking cases of  ALD diagnosed in Australia and New Zealand between 1981 and 1996, it was estimated that the combined incidence of ALD and its variants in Australasia is at least 1.6 per 100,000."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000326", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009520", "http://www.disease-ontology.org/api/metadata/DOID:10588"], "type": "factoid", "id": "58cc5bae02b8c60953000037", "snippets": [{"offsetInBeginSection": 453, "offsetInEndSection": 655, "text": "cases of ALD diagnosed in Australia and New Zealand between 1981 and 1996 and their families. We estimate that the combined incidence of ALD and its variants in Australasia is at least 1.6 per 100,000. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9556302", "endSection": "abstract"}]}, {"body": "Can telomere length shortening be reversed by telomerase?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27401551", "http://www.ncbi.nlm.nih.gov/pubmed/27154402", "http://www.ncbi.nlm.nih.gov/pubmed/26903545", "http://www.ncbi.nlm.nih.gov/pubmed/27483324", "http://www.ncbi.nlm.nih.gov/pubmed/27029895"], "ideal_answer": ["Yes, telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia."], "type": "yesno", "id": "58cd675c02b8c6095300003b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 284, "text": "Telomere length is regulated around an equilibrium set point. Telomeres shorten during replication and are lengthened by telomerase. Disruption of the length equilibrium leads to disease; thus, it is important to understand the mechanisms that regulate length at the molecular level. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401551", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 455, "text": "High telomerase activity is detected in nearly all human cancers but most human cells are devoid of telomerase activity. There is well-documented evidence that reactivation of telomerase occurs during cellular transformation. In humans, tumors can rely in reactivation of telomerase or originate in a telomerase positive stem/progenitor cell, or rely in alternative lengthening of telomeres, a telomerase-independent telomere-length maintenance mechanism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27483324", "endSection": "abstract"}, {"offsetInBeginSection": 1019, "offsetInEndSection": 1247, "text": " Together, these observations may provoke a re-evaluation of telomere and telomerase based therapies, both in telomerase inhibition for cancer therapy and telomerase activation for tissue regeneration and anti-ageing strategies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27483324", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 253, "text": "Telomeres progressively shorten throughout life. A hallmark of advanced malignancies is the ability for continuous cell divisions that almost universally correlates with the stabilization of telomere length by the reactivation of telomerase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27029895", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "Telomerase-mediated telomere elongation provides cell populations with the ability to proliferate indefinitely. Telomerase is capable of recognizing and extending the shortest telomeres in cells;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27154402", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26903545", "endSection": "title"}]}, {"body": "Is ABCE1 involved in ribosomal recycling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27824037", "http://www.ncbi.nlm.nih.gov/pubmed/26276635", "http://www.ncbi.nlm.nih.gov/pubmed/25001285", "http://www.ncbi.nlm.nih.gov/pubmed/25659154", "http://www.ncbi.nlm.nih.gov/pubmed/25128630"], "ideal_answer": ["Yes, recent studies have identified ABCE1 as a ribosome-recycling factor important for translation termination in mammalian cells, yeast and also archaea"], "type": "yesno", "id": "58ce5a1602b8c60953000049", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "Ribosome recycling orchestrated by the ATP binding cassette (ABC) protein ABCE1 can be considered as the final-or the first-step within the cyclic process of protein synthesis, connecting translation termination and mRNA surveillance with re-initiation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27824037", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 260, "text": " Recent studies have identified ABCE1 as a ribosome-recycling factor important for translation termination in mammalian cells, yeast and also archaea.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25659154", "endSection": "abstract"}, {"offsetInBeginSection": 502, "offsetInEndSection": 560, "text": "d a termination/prerecycling complex containing eRF1-ABCE1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25001285", "endSection": "abstract"}, {"offsetInBeginSection": 653, "offsetInEndSection": 698, "text": "ABCE1, a eukaryotic ribosome recycling factor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25128630", "endSection": "abstract"}]}, {"body": "What are clinical features of the de Morsier syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23233151", "http://www.ncbi.nlm.nih.gov/pubmed/10951302", "http://www.ncbi.nlm.nih.gov/pubmed/26842535", "http://www.ncbi.nlm.nih.gov/pubmed/27136085", "http://www.ncbi.nlm.nih.gov/pubmed/3625236", "http://www.ncbi.nlm.nih.gov/pubmed/12373677", "http://www.ncbi.nlm.nih.gov/pubmed/6475068", "http://www.ncbi.nlm.nih.gov/pubmed/18018427", "http://www.ncbi.nlm.nih.gov/pubmed/10037251", "http://www.ncbi.nlm.nih.gov/pubmed/23422579", "http://www.ncbi.nlm.nih.gov/pubmed/24379556", "http://www.ncbi.nlm.nih.gov/pubmed/308321", "http://www.ncbi.nlm.nih.gov/pubmed/9606688", "http://www.ncbi.nlm.nih.gov/pubmed/19270460", "http://www.ncbi.nlm.nih.gov/pubmed/24678945", "http://www.ncbi.nlm.nih.gov/pubmed/22330852", "http://www.ncbi.nlm.nih.gov/pubmed/17876417", "http://www.ncbi.nlm.nih.gov/pubmed/20602044", "http://www.ncbi.nlm.nih.gov/pubmed/20049400", "http://www.ncbi.nlm.nih.gov/pubmed/12733175"], "ideal_answer": ["Classic triad of the De Morsier syndrome (septooptic dysplasia) includes optic nerve hypoplasia, the absence of septum pellucidum, and pituitary hypoplasia."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "http://www.disease-ontology.org/api/metadata/DOID:225"], "type": "list", "id": "588f952994c1512c50000007", "snippets": [{"offsetInBeginSection": 76, "offsetInEndSection": 228, "text": " SOD was formerly known as de Morsier syndrome, which associated a midline brain defect such as an absent septum pellucidum with optic nerve hypoplasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26842535", "endSection": "abstract"}, {"offsetInBeginSection": 323, "offsetInEndSection": 506, "text": "The triad consists of optic nerve hypoplasia, pituitary hormone abnormalities, and midline brain defects, although it can vary in the severity of clinical presentation and phenotype. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26842535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "INTRODUCTION: Previous studies have described septooptic dysplasia (SOD) to describe patients who have optic nerve hypoplasia, the absence of septum pellucidum, and pituitary hypoplasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136085", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "BACKGROUND: Septo-optic dysplasia, also referred to as de Morsier syndrome, is a congenital condition characterized by classic triad features: midline brain abnormalities, optic nerve hypoplasia and pituitary endocrine dysfunction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24678945", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 235, "text": "Septo-optic dysplasia (SOD), otherwise called De Morsier syndrome, is a developmental anomaly of mid-line brain structures and includes optic nerve hypoplasia, absence of the septum pellucidum and hypothalamo-pituitary abnormalities). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23422579", "endSection": "abstract"}, {"offsetInBeginSection": 88, "offsetInEndSection": 261, "text": "The frequently associated features of hypopituitarism and absent septum pellucidum were felt to have embryonic linkage as \"septo-optic dysplasia\" or \"de Morsier's syndrome.\"", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23233151", "endSection": "abstract"}, {"offsetInBeginSection": 122, "offsetInEndSection": 269, "text": "An MRI of the brain demonstrated the absence of the septum pellucidum, which confirmed a diagnosis of septo-optic dysplasia or de Morsier syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18018427", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "Septo-optic dysplasia (De Morsier syndrome) is a developmental anomaly of mid-line brain structures and includes optic nerve hypoplasia, absence of the septum pellucidum and hypothalamo-pituitary abnormalities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10037251", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "Septo-optic dysplasia, also known as de Morsier syndrome, is a rare congenital entity almost always characterized by hypoplasia/dysplasia of the optical nerve, chiasma or optic radiations and the complete or partial absence of the septum pellucidum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270460", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "The de Morsier syndrome, or septo-optic dysplasia, is a developmental anomaly characterized by involvement of the optic system, hypothalamic-pituitary axis and septum pellucidum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3625236", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "The term septooptic dysplasia was coined in 1956 by de Morsier, who pointed out the association of optic nerve hypoplasia and absence of the septum pellucidum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12733175", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 218, "text": "Septo-optic dysplasia, also referred to as de Morsier syndrome, is a congenital condition characterized by classic triad features: midline brain abnormalities, optic nerve hypoplasia and pituitary endocrine dysfunction", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24678945", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "Septo-optic dysplasia (SOD), also referred to as de Morsier syndrome, is a rare congenital condition, characterized by two of the classic triad features: midline brain abnormalities, optic nerve hypoplasia (ONH) and pituitary endocrine dysfunction", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20602044", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "Septo-optic dysplasia (SOD), also referred to as de Morsier syndrome, is a rare congenital condition, characterized by two of the classic triad features: midline brain abnormalities, optic nerve hypoplasia (ONH) and pituitary endocrine dysfunction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20602044", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "Septo-optic dysplasia, also referred to as de Morsier syndrome, is a congenital condition characterized by classic triad features: midline brain abnormalities, optic nerve hypoplasia and pituitary endocrine dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24678945", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Septo-optic dysplasia (SOD), also referred to as de Morsier syndrome, is a rare congenital condition, characterized by two of the classic triad features: midline brain abnormalities, optic nerve hypoplasia (ONH) and pituitary endocrine dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20602044", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "[Optic nerve hypoplasia and growth hormone deficiency: de Morsier's syndrome].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6475068", "endSection": "title"}]}, {"body": "Does oculocutaneous albinism show an autosomal recessive inheritance?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22088535", "http://www.ncbi.nlm.nih.gov/pubmed/14599068", "http://www.ncbi.nlm.nih.gov/pubmed/8190479", "http://www.ncbi.nlm.nih.gov/pubmed/20019752", "http://www.ncbi.nlm.nih.gov/pubmed/17768386", "http://www.ncbi.nlm.nih.gov/pubmed/12829739", "http://www.ncbi.nlm.nih.gov/pubmed/8618053", "http://www.ncbi.nlm.nih.gov/pubmed/25703744", "http://www.ncbi.nlm.nih.gov/pubmed/24054038", "http://www.ncbi.nlm.nih.gov/pubmed/16752321", "http://www.ncbi.nlm.nih.gov/pubmed/23112997", "http://www.ncbi.nlm.nih.gov/pubmed/22817390", "http://www.ncbi.nlm.nih.gov/pubmed/8302318", "http://www.ncbi.nlm.nih.gov/pubmed/10960773", "http://www.ncbi.nlm.nih.gov/pubmed/26165494", "http://www.ncbi.nlm.nih.gov/pubmed/8042664", "http://www.ncbi.nlm.nih.gov/pubmed/19208379", "http://www.ncbi.nlm.nih.gov/pubmed/12727022", "http://www.ncbi.nlm.nih.gov/pubmed/11045591", "http://www.ncbi.nlm.nih.gov/pubmed/17355913", "http://www.ncbi.nlm.nih.gov/pubmed/7064008", "http://www.ncbi.nlm.nih.gov/pubmed/25919014", "http://www.ncbi.nlm.nih.gov/pubmed/16868655", "http://www.ncbi.nlm.nih.gov/pubmed/3742854"], "ideal_answer": ["Yes, oculocutaneous albinism shows an autosomal recessive inheritance."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:0050632", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016115", "http://www.disease-ontology.org/api/metadata/DOID:0050737", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000417"], "type": "yesno", "id": "58cbb55402b8c60953000033", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Oculocutaneous albinism (OCA) is an autosomal recessive disorder characterized by hypopigmentation in eyes, hair and skin, accompanied with vision loss. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26165494", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 152, "text": "Oculocutaneous albinism (OCA) is an autosomal recessive hereditary pigmentation disorder affecting humans and several other animal species. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22817390", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Oculocutaneous albinism type 2 (OCA2) is a human autosomal-recessive hypopigmentation disorder associated with pathological mutations of the OCA2 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20019752", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 186, "text": "Oculocutaneous albinism type1 (OCA1) is characterized by the absence of melanin pigmentation. The mutation on TYR gene makes OCA1 as an autosomal recessive genetic disorder. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23112997", "endSection": "abstract"}, {"offsetInBeginSection": 804, "offsetInEndSection": 953, "text": "Our patients were diagnosed as affected with Oculocutaneous albinism type1a. Analysis of pedigree pattern showed an autosomal recessive inheritance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23112997", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 174, "text": "Oculocutaneous albinism (OCA) is an autosomal recessive disorder of melanin biosynthesis that results in congenital hypopigmentation of ocular and cutaneous tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17768386", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Oculocutaneous albinism is an autosomal recessive genetic disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10960773", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Melanin biosynthesis is reduced in oculocutaneous albinism, an autosomal recessive disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24054038", "endSection": "abstract"}, {"offsetInBeginSection": 1384, "offsetInEndSection": 1554, "text": "The pedigrees were consistent with an autosomal recessive inheritance pattern.CONCLUSION: This unique type of oculocutaneous albinism has heterogeneous clinical features.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8190479", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "BACKGROUND: Oculocutaneous albinism (OCA) is an autosomal recessive hereditary pigmentation disorder affecting humans and several other animal species.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22817390", "endSection": "abstract"}, {"offsetInBeginSection": 346, "offsetInEndSection": 522, "text": "The Q402 allele has been associated with autosomal recessive ocular albinism when it is in trans with a tyrosinase gene mutation associated with oculocutaneous albinism type 1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19208379", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 301, "text": "Analysis using the POINTER program showed that this type of oculocutaneous albinism was inherited in an autosomal recessive pattern, with an estimated gene frequency of 0.025 +/- 0.007 in this population.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3742854", "endSection": "abstract"}, {"offsetInBeginSection": 523, "offsetInEndSection": 815, "text": "We have identified 12 families with oculocutaneous albinism type 1 that exhibit segregation of the c.1205G>A variant with a known pathologic mutation on the homologous chromosome, and demonstrate no genetic association between autosomal recessive oculocutaneous albinism and the Q402 variant.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19208379", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "BACKGROUND: Type II (tyrosinase-positive) oculocutaneous albinism is an autosomal recessive disorder that has recently been mapped to chromosome segment 15q11-q13.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8302318", "endSection": "abstract"}, {"offsetInBeginSection": 1389, "offsetInEndSection": 1735, "text": "The child with ocular albinism was heterozygous for two different mutations in the P gene.CONCLUSIONS: Abnormalities of the P gene are associated with a wide range of clinical phenotypes, including type II oculocutaneous albinism, albinism associated with the Prader-Willi syndrome, and at least some cases of autosomal recessive ocular albinism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8302318", "endSection": "abstract"}, {"offsetInBeginSection": 583, "offsetInEndSection": 768, "text": "Mutations in the TYR gene (TYR, 11q14-21, MIM 606933) cause oculocutaneous albinism type 1 (OCA1, MIM 203100), a developmental disorder having an autosomal recessive mode of inheritance", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17355913", "endSection": "abstract"}, {"offsetInBeginSection": 1357, "offsetInEndSection": 1514, "text": "The pedigrees were consistent with an autosomal recessive inheritance pattern.This unique type of oculocutaneous albinism has heterogeneous clinical features", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8190479", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "Oculocutaneous albinism (OCA) is an autosomal recessive disorder", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25919014", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Oculocutaneous albinism (OCA) is an autosomal recessive disorder of abnormal melanin formation, which results in hypopigmentation of skin, hair and eyes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25703744", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "The mutation of the tyrosinase (TYR) gene results in oculocutaneous albinism type 1 (OCA1), an autosomal recessive genetic disorder", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22088535", "endSection": "abstract"}, {"offsetInBeginSection": 419, "offsetInEndSection": 690, "text": "We found oculo-cutaneous albinism in two brothers and granular dystrophy in three brothers, the mother and a son.Corneal dystrophy is an autosomal dominant disorder inherited independently of oculocutaneous albinism, which is inherited as an autosomal recessive condition", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16752321", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Oculocutaneous albinism (OCA) type 4 is a newly identified human autosomal recessive hypopigmentary disorder that disrupts pigmentation in the skin, hair and eyes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12829739", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 302, "text": "Analysis using the POINTER program showed that this type of oculocutaneous albinism was inherited in an autosomal recessive pattern, with an estimated gene frequency of 0.025 +/- 0.007 in this population. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3742854", "endSection": "abstract"}, {"offsetInBeginSection": 548, "offsetInEndSection": 720, "text": "DISCUSSION: Corneal dystrophy is an autosomal dominant disorder inherited independently of oculocutaneous albinism, which is inherited as an autosomal recessive condition. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16752321", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "BACKGROUND: Oculocutaneous albinism type II (OCA2) is an autosomal recessively inherited disorder, characterized by white hair and skin, and loss of pigment in the eyes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12727022", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Is autosomal recessive deafness associated with oculocutaneous albinism a \"coincidence syndrome\"?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16868655", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Oculocutaneous albinism, immunodeficiency, hematological disorders, and minor anomalies: a new autosomal recessive syndrome?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8042664", "endSection": "title"}, {"offsetInBeginSection": 583, "offsetInEndSection": 769, "text": "Mutations in the TYR gene (TYR, 11q14-21, MIM 606933) cause oculocutaneous albinism type 1 (OCA1, MIM 203100), a developmental disorder having an autosomal recessive mode of inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17355913", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Oculocutaneous albinism (OCA) is an autosomal recessive disorder characterized by hypopigmentation in eyes, hair and skin, accompanied with vision loss.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26165494", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Oculocutaneous albinism (OCA) is an autosomal recessive hereditary pigmentation disorder affecting humans and several other animal species.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22817390", "endSection": "abstract"}]}, {"body": "Which is the largest metabolic gene cluster in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15951822", "http://www.ncbi.nlm.nih.gov/pubmed/22916115"], "ideal_answer": ["The DAL cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source.", "the dal cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable saccharomyces cerevisiae to use allantoin as a nitrogen source.", "The DAL cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source. The DAL cluster is located in a domain of modified chromatin involving both H2A.Z histone exchange and Hst1-Sum1-mediated histone deacetylation, and it may be a coadapted gene complex formed by epistatic selection.", "The DAL cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source. Six of the eight genes involved in allantoin degradation, which were previously scattered around the genome, became relocated to a single subtelomeric site in an ancestor of S. cerevisiae and Saccharomyces castellii."], "type": "factoid", "id": "58d0dc878acda34529000004", "snippets": [{"offsetInBeginSection": 217, "offsetInEndSection": 408, "text": "The DAL cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15951822", "endSection": "abstract"}, {"offsetInBeginSection": 215, "offsetInEndSection": 406, "text": "The DAL cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15951822", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Birth of a metabolic gene cluster in yeast by adaptive gene relocation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15951822", "endSection": "title"}, {"offsetInBeginSection": 217, "offsetInEndSection": 407, "text": "The DAL cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15951822", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Birth of a metabolic gene cluster in yeast by adaptive gene relocation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15951822", "endSection": "title"}, {"offsetInBeginSection": 217, "offsetInEndSection": 409, "text": "The DAL cluster is the largest metabolic gene cluster in yeast and consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15951822", "endSection": "abstract"}, {"offsetInBeginSection": 255, "offsetInEndSection": 488, "text": "For example the DAL metabolic cluster in yeast was assembled in recent evolutionary times in the Hemiascomycetes lineage, through a set of rearrangements that brought together the genes involved in the allantoin degradation pathway. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22916115", "endSection": "abstract"}, {"offsetInBeginSection": 255, "offsetInEndSection": 487, "text": "For example the DAL metabolic cluster in yeast was assembled in recent evolutionary times in the Hemiascomycetes lineage, through a set of rearrangements that brought together the genes involved in the allantoin degradation pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22916115", "endSection": "abstract"}]}, {"body": "What is the applicability of the MCAST algorithm?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16253142", "http://www.ncbi.nlm.nih.gov/pubmed/14534166", "http://www.ncbi.nlm.nih.gov/pubmed/26704599"], "ideal_answer": ["The MCAST algorithm uses a hidden Markov model with a P-value-based scoring scheme to identify candidate CRMs."], "type": "summary", "id": "5895f75aad49cff847000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "MCAST: scanning for cis-regulatory motif clusters.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704599", "endSection": "title"}, {"offsetInBeginSection": 577, "offsetInEndSection": 1340, "text": " The MCAST algorithm uses a hidden Markov model with a P-value-based scoring scheme to identify candidate CRMs. Here, we introduce a new version of MCAST that offers improved graphical output, a dynamic background model, statistical confidence estimates based on false discovery rate estimation and, most significantly, the ability to predict CRMs while taking into account epigenomic data such as DNase I sensitivity or histone modification data. We demonstrate the validity of MCAST's statistical confidence estimates and the utility of epigenomic priors in identifying CRMs.AVAILABILITY AND IMPLEMENTATION: MCAST is part of the MEME Suite software toolkit. A web server and source code are available at http://meme-suite.org and http://alternate.meme-suite.org", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704599", "endSection": "abstract"}, {"offsetInBeginSection": 620, "offsetInEndSection": 857, "text": "On a data set of 16 gap and pair-rule genes containing 52 known CRMs, predictions made by HexDiff had a higher correlation with the known CRMs than several existing CRM prediction algorithms: Ahab, Cluster Buster, MSCAN, MCAST, and LWF. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16253142", "endSection": "abstract"}, {"offsetInBeginSection": 1023, "offsetInEndSection": 1385, "text": "The p-value scoring also allows mcast to only accept motif occurrences with significance below a user-specified threshold, while still assigning better scores to motif occurrences with lower p-values. mcast can search long DNA sequences, modeling length distributions between motifs within a regulatory module, but ignoring length distributions between modules. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14534166", "endSection": "abstract"}, {"offsetInBeginSection": 326, "offsetInEndSection": 667, "text": "Given a collection of known transcription factor binding motifs, many bioinformatics methods have been proposed over the past 15 years for identifying within a genomic sequence candidate CRMs consisting of clusters of those motifs.The MCAST algorithm uses a hidden Markov model with a P-value-based scoring scheme to identify candidate CRMs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704599", "endSection": "abstract"}, {"offsetInBeginSection": 643, "offsetInEndSection": 853, "text": "The algorithm, called mcast, takes as input a DNA database and a collection of binding site motifs that are known to operate in concert. mcast uses a motif-based hidden Markov model with several novel features.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14534166", "endSection": "abstract"}, {"offsetInBeginSection": 644, "offsetInEndSection": 780, "text": "The algorithm, called mcast, takes as input a DNA database and a collection of binding site motifs that are known to operate in concert.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14534166", "endSection": "abstract"}, {"offsetInBeginSection": 599, "offsetInEndSection": 835, "text": "On a data set of 16 gap and pair-rule genes containing 52 known CRMs, predictions made by HexDiff had a higher correlation with the known CRMs than several existing CRM prediction algorithms: Ahab, Cluster Buster, MSCAN, MCAST, and LWF.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16253142", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "MCAST: scanning for cis-regulatory motif clusters.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704599", "endSection": "title"}]}, {"body": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15014128", "http://www.ncbi.nlm.nih.gov/pubmed/16903824", "http://www.ncbi.nlm.nih.gov/pubmed/24633805", "http://www.ncbi.nlm.nih.gov/pubmed/18823563", "http://www.ncbi.nlm.nih.gov/pubmed/15570172", "http://www.ncbi.nlm.nih.gov/pubmed/14614898", "http://www.ncbi.nlm.nih.gov/pubmed/27683909", "http://www.ncbi.nlm.nih.gov/pubmed/15475580", "http://www.ncbi.nlm.nih.gov/pubmed/22918225", "http://www.ncbi.nlm.nih.gov/pubmed/25871773", "http://www.ncbi.nlm.nih.gov/pubmed/10816430", "http://www.ncbi.nlm.nih.gov/pubmed/7846048", "http://www.ncbi.nlm.nih.gov/pubmed/21705182", "http://www.ncbi.nlm.nih.gov/pubmed/22401921", "http://www.ncbi.nlm.nih.gov/pubmed/16540478", "http://www.ncbi.nlm.nih.gov/pubmed/21907569", "http://www.ncbi.nlm.nih.gov/pubmed/8726460", "http://www.ncbi.nlm.nih.gov/pubmed/10949525", "http://www.ncbi.nlm.nih.gov/pubmed/22393530", "http://www.ncbi.nlm.nih.gov/pubmed/26427386", "http://www.ncbi.nlm.nih.gov/pubmed/15649697", "http://www.ncbi.nlm.nih.gov/pubmed/11701639", "http://www.ncbi.nlm.nih.gov/pubmed/18359298", "http://www.ncbi.nlm.nih.gov/pubmed/24754513", "http://www.ncbi.nlm.nih.gov/pubmed/23293020", "http://www.ncbi.nlm.nih.gov/pubmed/8782820", "http://www.ncbi.nlm.nih.gov/pubmed/20531185", "http://www.ncbi.nlm.nih.gov/pubmed/8367470", "http://www.ncbi.nlm.nih.gov/pubmed/7891887", "http://www.ncbi.nlm.nih.gov/pubmed/23781009", "http://www.ncbi.nlm.nih.gov/pubmed/19033669", "http://www.ncbi.nlm.nih.gov/pubmed/19549280"], "ideal_answer": ["The ApoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD)."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:4", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544", "http://www.disease-ontology.org/api/metadata/DOID:10652", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050197", "http://www.disease-ontology.org/api/metadata/DOID:1936", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053327"], "type": "factoid", "id": "58b6cd3222d300530900000d", "snippets": [{"offsetInBeginSection": 206, "offsetInEndSection": 334, "text": "Among three isoforms, the apoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16903824", "endSection": "abstract"}, {"offsetInBeginSection": 442, "offsetInEndSection": 589, "text": "Homozygosity for ApoE epsilon4 is associated with atherosclerosis and Alzheimer's disease whereas ApoE epsilon2 and epsilon3 tend to be protective.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823563", "endSection": "abstract"}, {"offsetInBeginSection": 515, "offsetInEndSection": 715, "text": "Importantly, lipoproteins containing the apoE3 isoform had higher TGF-beta levels and bioactivity than those containing apoE4, a major genetic risk factor for atherosclerosis and Alzheimer's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19549280", "endSection": "abstract"}, {"offsetInBeginSection": 226, "offsetInEndSection": 332, "text": "ApoE4 is positively associated with atherosclerosis and late-onset and sporadic Alzheimer's disease (AD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15475580", "endSection": "abstract"}, {"offsetInBeginSection": 757, "offsetInEndSection": 1176, "text": "Isoform (allele)-specific effects include the association of apoE2 with the genetic disorder type III hyperlipoproteinemia and with both increased and decreased risk for atherosclerosis and the association of apoE4 with increased risk for both atherosclerosis and Alzheimer's disease, impaired cognitive function, and reduced neurite outgrowth; isoform-specific differences in cellular signaling events may also exist. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11701639", "endSection": "abstract"}, {"offsetInBeginSection": 55, "offsetInEndSection": 187, "text": "Although APOE-epsilon3 is considered a longevity gene, APOE-epsilon4 is a dual risk factor to atherosclerosis and Alzheimer disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16540478", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "The apolipoprotein E (apoE) type epsilon 4 isoform specifies increased cerebral and cerebrovascular accumulation of amyloid-beta protein (A beta) and contributes to the genetic susceptibility underlying a large proportion (approximately 60%) of typical, sporadic Alzheimer disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8726460", "endSection": "abstract"}, {"offsetInBeginSection": 1299, "offsetInEndSection": 1504, "text": "The structural preference of apoE4 to remain functional in solution may explain the enhanced opportunity of apoE4 isoform to display its pathophysiologic functions in atherosclerosis and Alzheimer disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16540478", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "The apolipoprotein E (APOE) E4 allele is associated with Alzheimer's disease, cardiovascular disease, and decreased longevity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8782820", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "The apolipoprotein E type 4 allele is a susceptibility gene for late-onset Alzheimer's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7891887", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 276, "text": "The apolipoprotein E (ApoE) \u03b54 allele is the strongest risk factor of sporadic Alzheimers disease (AD), however, the fluid concentrations of ApoE and its different isoforms (ApoE2, ApoE3 and ApoE4) in AD patients and among APOE genotypes (APOE \u03b52, \u03b53, \u03b54) remain controversial", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24633805", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 331, "text": "Among three isoforms, the apoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimers disease (AD)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16903824", "endSection": "abstract"}, {"offsetInBeginSection": 429, "offsetInEndSection": 574, "text": "Homozygosity for ApoE epsilon4 is associated with atherosclerosis and Alzheimers disease whereas ApoE epsilon2 and epsilon3 tend to be protective", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823563", "endSection": "abstract"}, {"offsetInBeginSection": 442, "offsetInEndSection": 590, "text": "Homozygosity for ApoE epsilon4 is associated with atherosclerosis and Alzheimer's disease whereas ApoE epsilon2 and epsilon3 tend to be protective. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823563", "endSection": "abstract"}, {"offsetInBeginSection": 56, "offsetInEndSection": 189, "text": "Although APOE-epsilon3 is considered a longevity gene, APOE-epsilon4 is a dual risk factor to atherosclerosis and Alzheimer disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16540478", "endSection": "abstract"}, {"offsetInBeginSection": 301, "offsetInEndSection": 461, "text": "The apoE4 allele is a major risk factor for late-onset familial and sporadic Alzheimer's disease (AD) and is associated with a poor outcome after brain injury. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14614898", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 333, "text": "Among three isoforms, the apoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16903824", "endSection": "abstract"}, {"offsetInBeginSection": 430, "offsetInEndSection": 577, "text": "Homozygosity for ApoE epsilon4 is associated with atherosclerosis and Alzheimer's disease whereas ApoE epsilon2 and epsilon3 tend to be protective.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823563", "endSection": "abstract"}, {"offsetInBeginSection": 515, "offsetInEndSection": 714, "text": "Importantly, lipoproteins containing the apoE3 isoform had higher TGF-beta levels and bioactivity than those containing apoE4, a major genetic risk factor for atherosclerosis and Alzheimer's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19549280", "endSection": "abstract"}, {"offsetInBeginSection": 757, "offsetInEndSection": 1175, "text": "Isoform (allele)-specific effects include the association of apoE2 with the genetic disorder type III hyperlipoproteinemia and with both increased and decreased risk for atherosclerosis and the association of apoE4 with increased risk for both atherosclerosis and Alzheimer's disease, impaired cognitive function, and reduced neurite outgrowth; isoform-specific differences in cellular signaling events may also exist.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11701639", "endSection": "abstract"}, {"offsetInBeginSection": 578, "offsetInEndSection": 728, "text": "The decreased antioxidant activity of E4 could contribute to its association with Alzheimer's disease, cardiovascular disease and decreased longevity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8782820", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 647, "text": "The isoform apoE4 is associated with an increased risk of Alzheimer's disease and it has been postulated that high intracellular cholesterol levels promote the amyloidogenic processing of amyloid precursor protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18359298", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 337, "text": "Among three \u025b2, \u025b3, \u025b4 alleles, \u025b4 allele is associated with the increase in cholesterol level, risk of atherosclerosis and Alzheimer disease, while \u025b2 allele is associated with the decrease in cholesterol level and risk of atherosclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21705182", "endSection": "abstract"}, {"offsetInBeginSection": 56, "offsetInEndSection": 188, "text": "Although APOE-epsilon3 is considered a longevity gene, APOE-epsilon4 is a dual risk factor to atherosclerosis and Alzheimer disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16540478", "endSection": "abstract"}, {"offsetInBeginSection": 1307, "offsetInEndSection": 1513, "text": "The structural preference of apoE4 to remain functional in solution may explain the enhanced opportunity of apoE4 isoform to display its pathophysiologic functions in atherosclerosis and Alzheimer disease..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16540478", "endSection": "abstract"}]}, {"body": "Are Ultra-conserved elements (UCEs) enriched in segmental duplications?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25340765", "http://www.ncbi.nlm.nih.gov/pubmed/16998490", "http://www.ncbi.nlm.nih.gov/pubmed/22987666", "http://www.ncbi.nlm.nih.gov/pubmed/18957701", "http://www.ncbi.nlm.nih.gov/pubmed/24349264", "http://www.ncbi.nlm.nih.gov/pubmed/21092253"], "ideal_answer": ["ULEs are located in intergenic or intronic regions and are depleted from segmental duplications. In addition, here we show that these elements are preferentially found in pathogenic deletions (enrichment ratio 3.6 vs. 0.5 in duplications), and that this association is not related with a higher content of genes.", "we begin by showing that depletion for uces characterizes the most recent large-scale human cnv datasets and then find that even newly formed de novo cnvs, which have passed through meiosis at most once, are significantly depleted for uces.", "Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell. These elements are most often located either overlapping exons in genes involved in RNA processing or in introns or nearby genes involved in the regulation of transcription and development.", "Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants. Notably, of the UCEs that are found in segmental duplications or copy number variants, the majority overlap exons, indicating, along with other findings presented, that UCEs overlapping exons represent a distinct subset.", "Here we address the process by which CNVs become depleted of UCEs. We begin by showing that depletion for UCEs characterizes the most recent large-scale human CNV datasets and then find that even newly formed de novo CNVs, which have passed through meiosis at most once, are significantly depleted for UCEs.", "Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants."], "type": "yesno", "id": "58a71bb960087bc10a00002d", "snippets": [{"offsetInBeginSection": 227, "offsetInEndSection": 293, "text": "Here we address the process by which CNVs become depleted of UCEs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 534, "text": "We begin by showing that depletion for UCEs characterizes the most recent large-scale human CNV datasets and then find that even newly formed de novo CNVs, which have passed through meiosis at most once, are significantly depleted for UCEs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "abstract"}, {"offsetInBeginSection": 535, "offsetInEndSection": 680, "text": "In striking contrast, CNVs arising specifically in cancer cells are, as a rule, not depleted for UCEs and can even become significantly enriched.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "abstract"}, {"offsetInBeginSection": 863, "offsetInEndSection": 954, "text": "Alternatively, lack of depletion for UCEs from cancer CNVs may reflect the diseased state. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "abstract"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1045, "text": "ULEs are located in intergenic or intronic regions and are depleted from segmental duplications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22987666", "endSection": "abstract"}, {"offsetInBeginSection": 442, "offsetInEndSection": 579, "text": "Interestingly, human UCEs have been reported to be strongly depleted among segmental duplications and benign copy number variants (CNVs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092253", "endSection": "abstract"}, {"offsetInBeginSection": 1126, "offsetInEndSection": 1341, "text": "In addition, here we show that these elements are preferentially found in pathogenic deletions (enrichment ratio 3.6 vs. 0.5 in duplications), and that this association is not related with a higher content of genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092253", "endSection": "abstract"}, {"offsetInBeginSection": 1342, "offsetInEndSection": 1433, "text": "In contrast, pathogenic CNVs lacking UCEs showed almost a threefold higher content in genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092253", "endSection": "abstract"}, {"offsetInBeginSection": 362, "offsetInEndSection": 581, "text": "We have demonstrated that nonexonic UCEs are depleted among segmental duplications (SDs) and copy number variants (CNVs) and proposed that their ultraconservation may reflect a mechanism of copy counting via comparison.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18957701", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998490", "endSection": "title"}, {"offsetInBeginSection": 610, "offsetInEndSection": 936, "text": "Here, we show that UCEs are significantly depleted among segmental duplications and copy number variants. Notably, of the UCEs that are found in segmental duplications or copy number variants, the majority overlap exons, indicating, along with other findings presented, that UCEs overlapping exons represent a distinct subset.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998490", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "abstract"}, {"offsetInBeginSection": 609, "offsetInEndSection": 714, "text": "Here, we show that UCEs are significantly depleted among segmental duplications and copy number variants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998490", "endSection": "abstract"}, {"offsetInBeginSection": 359, "offsetInEndSection": 578, "text": "We have demonstrated that nonexonic UCEs are depleted among segmental duplications (SDs) and copy number variants (CNVs) and proposed that their ultraconservation may reflect a mechanism of copy counting via comparison.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18957701", "endSection": "abstract"}, {"offsetInBeginSection": 610, "offsetInEndSection": 715, "text": "Here, we show that UCEs are significantly depleted among segmental duplications and copy number variants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998490", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340765", "endSection": "abstract"}, {"offsetInBeginSection": 817, "offsetInEndSection": 931, "text": "melanogaster genome revealed depletion of the P-element and piggyBac insertions in and around the Sophophora UCEs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349264", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998490", "endSection": "title"}, {"offsetInBeginSection": 612, "offsetInEndSection": 717, "text": "Here, we show that UCEs are significantly depleted among segmental duplications and copy number variants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998490", "endSection": "abstract"}, {"offsetInBeginSection": 430, "offsetInEndSection": 567, "text": "Interestingly, human UCEs have been reported to be strongly depleted among segmental duplications and benign copy number variants (CNVs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092253", "endSection": "abstract"}]}, {"body": "What organism causes woolsorter's disease", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18959192", "http://www.ncbi.nlm.nih.gov/pubmed/15486181"], "ideal_answer": ["Woolsorter's disease is caused by the same organism as Anthrax, bacillus Anthrax. "], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:7427", "http://www.disease-ontology.org/api/metadata/DOID:0050160", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009784"], "type": "factoid", "id": "58caf0be02b8c6095300002f", "snippets": [{"offsetInBeginSection": 661, "offsetInEndSection": 756, "text": "Today, woolsorters' disease and other industrial manifestations of anthrax are extremely rare, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15486181", "endSection": "abstract"}, {"offsetInBeginSection": 575, "offsetInEndSection": 943, "text": "Working independently of their more famous counterparts (Robert Koch and Louis Pasteur), Anglo-American anthrax investigators used visual representations of anthrax bacilli to persuade their peers that a specific, identifiable cause produced all forms of anthrax-malignant pustule (cutaneous anthrax), intestinal anthrax, and woolsorter's disease (pneumonic anthrax). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18959192", "endSection": "abstract"}, {"offsetInBeginSection": 661, "offsetInEndSection": 913, "text": "Today, woolsorters' disease and other industrial manifestations of anthrax are extremely rare, but the increasing threat of bioterrorism means that the international dread and historical lessons of this significant condition should never be forgotten. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15486181", "endSection": "abstract"}, {"offsetInBeginSection": 661, "offsetInEndSection": 912, "text": "Today, woolsorters' disease and other industrial manifestations of anthrax are extremely rare, but the increasing threat of bioterrorism means that the international dread and historical lessons of this significant condition should never be forgotten.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15486181", "endSection": "abstract"}]}, {"body": "Which annotated database of A-to-I RNA editing is available?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24163250"], "ideal_answer": ["RADAR is a rigorously annotated database of A-to-I RNA editing. RADAR includes a comprehensive collection of A-to-I RNA editing sites identified in humans (Homo sapiens), mice (Mus musculus) and flies (Drosophila melanogaster), together with extensive manually curated annotations for each editing site. RADAR also includes an expandable listing of tissue-specific editing levels for each editing site, which will facilitate the assignment of biological functions to specific editing sites.", "The identification of A-to-I RNA editing sites has been dramatically accelerated in the past few years by high-throughput RNA sequencing studies. RADAR includes a comprehensive collection of A-to-I RNA editing sites identified in humans (Homo sapiens), mice (Mus musculus) and flies (Drosophila melanogaster), together with extensive manually curated annotations for each editing site."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017393"], "type": "factoid", "id": "587e1a01fc7e8dd84f000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "RADAR: a rigorously annotated database of A-to-I RNA editing", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163250", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "We present RADAR--a rigorously annotated database of A-to-I RNA editing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163250", "endSection": "abstract"}, {"offsetInBeginSection": 107, "offsetInEndSection": 678, "text": "The identification of A-to-I RNA editing sites has been dramatically accelerated in the past few years by high-throughput RNA sequencing studies. RADAR includes a comprehensive collection of A-to-I RNA editing sites identified in humans (Homo sapiens), mice (Mus musculus) and flies (Drosophila melanogaster), together with extensive manually curated annotations for each editing site. RADAR also includes an expandable listing of tissue-specific editing levels for each editing site, which will facilitate the assignment of biological functions to specific editing sites", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163250", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "We present RADAR--a rigorously annotated database of A-to-I RNA editing (available at http://RNAedit.com).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163250", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "RADAR: a rigorously annotated database of A-to-I RNA editing.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163250", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "We present RADAR--a rigorously annotated database of A-to-I RNA editing (available at http://RNAedit.com). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163250", "endSection": "abstract"}, {"offsetInBeginSection": 253, "offsetInEndSection": 493, "text": "RADAR includes a comprehensive collection of A-to-I RNA editing sites identified in humans (Homo sapiens), mice (Mus musculus) and flies (Drosophila melanogaster), together with extensive manually curated annotations for each editing site. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163250", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "RADAR: a rigorously annotated database of A-to-I RNA editing.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163250", "endSection": "title"}]}, {"body": "Do normal cells express the protein TERT?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21790308", "http://www.ncbi.nlm.nih.gov/pubmed/18956258", "http://www.ncbi.nlm.nih.gov/pubmed/17346111", "http://www.ncbi.nlm.nih.gov/pubmed/17531113"], "ideal_answer": ["\u039d\u03bf, telomerase activity is found in 85%-90% of all human cancers but not in their adjacent normal cells. Human telomerase reverse transcriptase (hTERT) is an essential component in the telomerase complex that plays an important role in telomerase activity."], "type": "yesno", "id": "58cd6d9702b8c6095300003c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Since telomerase has been recognized as a relevant factor distinguishing cancer cells from normal cells, it has become a very promising target for anti-cancer therapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21790308", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 326, "text": "Telomerase plays a pivotal role in cellular immortality and tumorigenesis. Its activity is normally not detectable in most somatic cells while it is reactivated in the vast majority of cancer cells. Therefore, inhibition of telomerase has been viewed as a promising anticancer approach due to its specificity for cancer cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18956258", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 264, "text": "Telomerase activity is found in 85%-90% of all human cancers but not in their adjacent normal cells. Human telomerase reverse transcriptase (hTERT) is an essential component in the telomerase complex that plays an important role in telomerase activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17531113", "endSection": "abstract"}, {"offsetInBeginSection": 497, "offsetInEndSection": 890, "text": "elomerase activation is considered to be a critical step in carcinogenesis and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. Since only tumor cells that express telomerase activity would activate this promoter, the hTERT proximal promoter allows for preferential expression of viral genes in tumor cells, leading to selective viral replication", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17346111", "endSection": "abstract"}]}, {"body": "Which protein complexes recognize centromeric (CEN) DNA in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22693454", "http://www.ncbi.nlm.nih.gov/pubmed/3464952", "http://www.ncbi.nlm.nih.gov/pubmed/23620291"], "ideal_answer": ["The Schizosaccharomyces pombe centromere-linked genes, LYS1 and CYH1 on chromosome I and TPS13 and RAN1 on chromosome II, have been isolated. In budding yeast, as well as in other eukaryotes, the Cse4 histone variant (known in vertebrates as CENP-A) is believed to substitute for histone H3 at the centromeric nucleosome.", "The Schizosaccharomyces pombe centromere-linked genes, LYS1 and CYH1 on chromosome I and TPS13 and RAN1 on chromosome II, have been isolated Histone H3 localizes to the centromeric DNA in budding yeast  In budding yeast, as well as in other eukaryotes, the Cse4 histone variant (known in vertebrates as CENP-A) is believed to substitute for histone H3 at the centromeric nucleosome", "The Schizosaccharomyces pombe centromere-linked genes, LYS1 and CYH1 on chromosome I and TPS13 and RAN1 on chromosome II, have been isolated"], "type": "list", "id": "58a71f7460087bc10a00002e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "The Schizosaccharomyces pombe centromere-linked genes, LYS1 and CYH1 on chromosome I and TPS13 and RAN1 on chromosome II, have been isolated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3464952", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "Histone H3 localizes to the centromeric DNA in budding yeast", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693454", "endSection": "title"}, {"offsetInBeginSection": 503, "offsetInEndSection": 682, "text": " In budding yeast, as well as in other eukaryotes, the Cse4 histone variant (known in vertebrates as CENP-A) is believed to substitute for histone H3 at the centromeric nucleosome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693454", "endSection": "abstract"}, {"offsetInBeginSection": 915, "offsetInEndSection": 1142, "text": "Surprisingly, we observed a strong interaction of H3, as well as Cse4, H4, H2A, and H2B, but not histone chaperone Scm3 (HJURP in human) with the centromeric DNA. H3 localizes to centromeric DNA at all stages of the cell cycle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693454", "endSection": "abstract"}, {"offsetInBeginSection": 1246, "offsetInEndSection": 1325, "text": "Our results favor a H3-Cse4 heterotypic octamer at the budding yeast centromere", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693454", "endSection": "abstract"}, {"offsetInBeginSection": 92, "offsetInEndSection": 257, "text": "In budding yeast, a single right-handed cenH3/H4/H2A/H2B tetramer wraps the \u223c80-bp Centromere DNA Element II (CDE II) sequence of each centromere into a 'hemisome'. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23620291", "endSection": "abstract"}, {"offsetInBeginSection": 446, "offsetInEndSection": 559, "text": "Here, we show that Cse4 octamers remain intact under conditions of low salt and urea that dissociate H3 octamers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23620291", "endSection": "abstract"}]}, {"body": "Is there any involvement of the long non-coding RNA Gomafu in schizophrenia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23628989", "http://www.ncbi.nlm.nih.gov/pubmed/25145264"], "ideal_answer": ["Yes. The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062085", "http://www.disease-ontology.org/api/metadata/DOID:5419", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019967", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012561", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012559"], "type": "yesno", "id": "588fbedced9bbee70d000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989", "endSection": "title"}, {"offsetInBeginSection": 308, "offsetInEndSection": 1154, "text": "Here, we profile these transcriptomic responses and show that long non-coding RNAs (lncRNAs) are dynamically regulated by neuronal activation, including acute downregulation of the lncRNA Gomafu, previously implicated in brain and retinal development. Moreover, we demonstrate that Gomafu binds directly to the splicing factors QKI and SRSF1 (serine/arginine-rich splicing factor 1) and dysregulation of Gomafu leads to alternative splicing patterns that resemble those observed in SZ for the archetypal SZ-associated genes DISC1 and ERBB4. Finally, we show that Gomafu is downregulated in post-mortem cortical gray matter from the superior temporal gyrus in SZ. These results functionally link activity-regulated lncRNAs and alternative splicing in neuronal function and suggest that their dysregulation may contribute to neurological disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Gomafu/MIAT/Rncr2 is a long noncoding RNA that has been proposed to control retinal cell specification, stem cell differentiation and alternative splicing of schizophrenia-related genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25145264", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989", "endSection": "title"}, {"offsetInBeginSection": 560, "offsetInEndSection": 849, "text": "Moreover, we demonstrate that Gomafu binds directly to the splicing factors QKI and SRSF1 (serine/arginine-rich splicing factor 1) and dysregulation of Gomafu leads to alternative splicing patterns that resemble those observed in SZ for the archetypal SZ-associated genes DISC1 and ERBB4. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989", "endSection": "abstract"}, {"offsetInBeginSection": 849, "offsetInEndSection": 971, "text": "Finally, we show that Gomafu is downregulated in post-mortem cortical gray matter from the superior temporal gyrus in SZ. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23628989", "endSection": "title"}]}, {"body": "Is butterfly rash a symptom of Systemic lupus erythematosus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8000104", "http://www.ncbi.nlm.nih.gov/pubmed/27878308", "http://www.ncbi.nlm.nih.gov/pubmed/24948869", "http://www.ncbi.nlm.nih.gov/pubmed/19082832", "http://www.ncbi.nlm.nih.gov/pubmed/7065728", "http://www.ncbi.nlm.nih.gov/pubmed/1440087", "http://www.ncbi.nlm.nih.gov/pubmed/7979581", "http://www.ncbi.nlm.nih.gov/pubmed/17728372", "http://www.ncbi.nlm.nih.gov/pubmed/1765991", "http://www.ncbi.nlm.nih.gov/pubmed/1437923", "http://www.ncbi.nlm.nih.gov/pubmed/23934402", "http://www.ncbi.nlm.nih.gov/pubmed/9598885", "http://www.ncbi.nlm.nih.gov/pubmed/3769804", "http://www.ncbi.nlm.nih.gov/pubmed/2674762", "http://www.ncbi.nlm.nih.gov/pubmed/23019977", "http://www.ncbi.nlm.nih.gov/pubmed/17113236", "http://www.ncbi.nlm.nih.gov/pubmed/17569152", "http://www.ncbi.nlm.nih.gov/pubmed/20120828", "http://www.ncbi.nlm.nih.gov/pubmed/2585838", "http://www.ncbi.nlm.nih.gov/pubmed/7607795", "http://www.ncbi.nlm.nih.gov/pubmed/7924059", "http://www.ncbi.nlm.nih.gov/pubmed/25516474", "http://www.ncbi.nlm.nih.gov/pubmed/12672213"], "ideal_answer": ["Yes, butterfly rash is symptom of Systemic lupus erythematosus."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:8857", "http://www.disease-ontology.org/api/metadata/DOID:9074", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008180"], "type": "yesno", "id": "58bfeb2b02b8c6095300001a", "snippets": [{"offsetInBeginSection": 374, "offsetInEndSection": 605, "text": "Diagnosing SLE can be challenging because of the myriad of clinical features and substantial variability between patients. Cutaneous involvement is present in about 60% of cases and typically manifests as a malar or butterfly rash.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120828", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "The prevalence of systemic lupus erythematosus (SLE) is 28 per 100,000. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120828", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "We report a 12 years old female patient with an overlap syndrome involving autoimmune hepatitis (AIH) and systemic lupus erythematosus (SLE). The patient presented with jaundice, hepatosplenomegaly, malaise, polyarthralgia, arthritis and butterfly rash on the face.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17569152", "endSection": "abstract"}, {"offsetInBeginSection": 486, "offsetInEndSection": 764, "text": "Some of the clinical characteristics of SLE patients observed were nephritis (53.7%), fever (53.26%), neuropsychological disorder (36.18%), malar/butterfly rash (27.6%), pulmonary disorder (22.6%), photosensitivity (21.6%), cardiac involvement (21.1%) and oral ulcers (19.09%). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17728372", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Systemic lupus erythematosus and infections: a retrospective study in Saudis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17728372", "endSection": "title"}, {"offsetInBeginSection": 801, "offsetInEndSection": 1123, "text": "The prevalence of the following manifestations was significantly higher for pediatric than for adult-onset disease including: lupus nephritis (43% pediatric vs 26.4% for adult-onset), hematological disorders (57% vs 36.4%), photosensitivity (20% vs 9%), butterfly rash (61% vs 35.5%) and mucosal ulceration (11.4% vs 4%). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516474", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease with highest prevalence among women of childbearing age. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516474", "endSection": "abstract"}, {"offsetInBeginSection": 462, "offsetInEndSection": 1069, "text": "We described a unique case of a 25-year-old Arab young woman who was diagnosed with SLE, depending on clinical, laboratory investigations and after she had fulfilled the diagnostic criteria for SLE and had presented the following findings: constitutional findings (fatigue, fever, and arthralgia); dermatologic finding (photosensitivity and butterfly rash); chronic renal failure (proteinuria up to 400 mg in 24 hours); hematologic and antinuclear antibodies (positivity for antinuclear factor (ANF), anti-double-stranded DNA antibodies, direct Coombs, ANA and anti-DNA, low C4 and C3, aCL by IgG and IgM). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24948869", "endSection": "abstract"}, {"offsetInBeginSection": 492, "offsetInEndSection": 771, "text": "Grade 1 and 2-3 inflammatory process occurred in 53 (63%) and 31 (37%) patients respectively. Symptom complexes \"systemic inflammation\", \"butterfly rash\", \"wrist petechiae\", \"enanthema of the oral mucous membrane\", and other lesions were regarded as the markers of SLE activity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019977", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Systemic lupus erythematosus (SLE) remains a challenging medical problem. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019977", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Rembrandt's Maria Bockenolle has a butterfly rash and digital deformities: overlapping syndrome of rheumatoid arthritis and systemic lupus erythematosus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17113236", "endSection": "title"}, {"offsetInBeginSection": 125, "offsetInEndSection": 224, "text": "A butterfly rash on the patient's face suggested a diagnosis of systemic lupus erythematosus (SLE).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19082832", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 222, "text": "A butterfly rash on the patients face suggested a diagnosis of systemic lupus erythematosus (SLE)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19082832", "endSection": "abstract"}, {"offsetInBeginSection": 286, "offsetInEndSection": 437, "text": "The diagnosis of SLE could be excluded and the butterfly rash attributed to a laminar hemorrhage, an ecchymosis due to the autoimmune thrombocytopenia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19082832", "endSection": "abstract"}, {"offsetInBeginSection": 362, "offsetInEndSection": 447, "text": "We describe a case of KD who developed a typical butterfly rash, reminiscent of SLE. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12672213", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 262, "text": "The diagnosis of SLE was made 22 years ago based on Raynaud's phenomenon, butterfly rash, hair loss, photosensitivity and positive antinuclear antibody. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1440087", "endSection": "abstract"}, {"offsetInBeginSection": 586, "offsetInEndSection": 770, "text": "Symptom complexes \"systemic inflammation\", \"butterfly rash\", \"wrist petechiae\", \"enanthema of the oral mucous membrane\", and other lesions were regarded as the markers of SLE activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23019977", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Rembrandt's Maria Bockenolle has a butterfly rash and digital deformities: overlapping syndrome of rheumatoid arthritis and systemic lupus erythematosus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17113236", "endSection": "title"}, {"offsetInBeginSection": 111, "offsetInEndSection": 391, "text": "To investigate, various unspecific, but otherwise typical clinical symptoms of skin and mucous membranes that arise in SLE patients other than those defined as SLE criteria such as butterfly rash, chronic cutaneous lupus erythematosus, oral ulcers, and increased photosensitivity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27878308", "endSection": "abstract"}]}, {"body": "What is the function of yeast Clr4 on chromatin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9620780", "http://www.ncbi.nlm.nih.gov/pubmed/11273706", "http://www.ncbi.nlm.nih.gov/pubmed/16127433", "http://www.ncbi.nlm.nih.gov/pubmed/17504808", "http://www.ncbi.nlm.nih.gov/pubmed/23771057", "http://www.ncbi.nlm.nih.gov/pubmed/21060862", "http://www.ncbi.nlm.nih.gov/pubmed/8937982", "http://www.ncbi.nlm.nih.gov/pubmed/19117951"], "ideal_answer": ["Clr4 is known to regulate silencing and switching at the mating-type loci and to affect chromatin structure at centromeres. The Clr4 methyltransferase determines the subnuclear localization of the mating-type region in fission yeast. Heterochromatin assembly in fission yeast depends on the Clr4 histone methyltransferase, which targets H3K9."], "type": "summary", "id": "58ab1e19396a458e5000000f", "snippets": [{"offsetInBeginSection": 308, "offsetInEndSection": 455, "text": "Mutations in the clr4+, rik1+ and swi6+ genes dramatically reduce silencing at certain centromeric regions and cause elevated chromosome loss rates", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8937982", "endSection": "abstract"}, {"offsetInBeginSection": 918, "offsetInEndSection": 1076, "text": "The Swi6 protein was found to be delocalised from all three silent chromosomal regions, and dispersed within the nucleus, in both clr4 and rik1 mutant cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8937982", "endSection": "abstract"}, {"offsetInBeginSection": 1274, "offsetInEndSection": 1469, "text": "Mutations in clr4, rik1 and swi6 also result in elevated sensitivity to reagents which destabilise microtubules and show a synergistic interaction with a mutation in the beta-tubulin gene (nda3).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8937982", "endSection": "abstract"}, {"offsetInBeginSection": 1470, "offsetInEndSection": 1770, "text": "These observations suggest that clr4+ and rik1+ must play a role in the assembly of Swi6p into a transcriptionally silent, inaccessible chromatin structure at fission yeast centromeres which is required to facilitate interactions with spindle microtubules and to ensure normal chromosome segregation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8937982", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "The chromo and SET domains of the Clr4 protein are essential for silencing in fission yeast.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9620780", "endSection": "title"}, {"offsetInBeginSection": 752, "offsetInEndSection": 868, "text": "Like Su(var)3-9p, Clr4p contains SET and chromo domains, motifs found in proteins that modulate chromatin structure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9620780", "endSection": "abstract"}, {"offsetInBeginSection": 1052, "offsetInEndSection": 1188, "text": "Surprisingly, RNA differential display experiments demonstrated that clr4+ can mediate transcriptional activation of certain other loci.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9620780", "endSection": "abstract"}, {"offsetInBeginSection": 1189, "offsetInEndSection": 1400, "text": "These results show that clr4 plays a critical role in silencing at mating-type loci and centromeres through the organization of repressive chromatin structure and demonstrate a new, activator function for Clr4p.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9620780", "endSection": "abstract"}, {"offsetInBeginSection": 452, "offsetInEndSection": 576, "text": "Clr4 is known to regulate silencing and switching at the mating-type loci and to affect chromatin structure at centromeres. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11273706", "endSection": "abstract"}, {"offsetInBeginSection": 638, "offsetInEndSection": 743, "text": "Mutations in Cul4 result in defective localization of Clr4 and loss of silencing at heterochromatic loci.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16127433", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "The Clr4 methyltransferase determines the subnuclear localization of the mating-type region in fission yeast.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17504808", "endSection": "title"}, {"offsetInBeginSection": 623, "offsetInEndSection": 789, "text": "In a strain lacking the histone methyltransferase Clr4, crucial for the formation of heterochromatin, the mating-type region had a random localization in the nucleus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17504808", "endSection": "abstract"}, {"offsetInBeginSection": 1009, "offsetInEndSection": 1238, "text": "Cut4 and Cut9 interact directly with Swi6/HP1 and Clr4, whereas the mutant Cut4 does not, suggesting that a direct physical interaction of APC subunits Cut4 and Cut9 with Swi6 and Clr4 is instrumental in heterochromatin assembly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19117951", "endSection": "abstract"}, {"offsetInBeginSection": 1647, "offsetInEndSection": 1858, "text": "Thus, APC and heterochromatin proteins Swi6 and Clr4 play a mutually cooperative role in heterochromatin assembly, thereby ensuring chromosomal integrity, inheritance, and segregation during mitosis and meiosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19117951", "endSection": "abstract"}, {"offsetInBeginSection": 171, "offsetInEndSection": 426, "text": "Positive feedback mechanisms that link the RNAi pathway and the Clr4/Suv39h1 histone H3K9 methyltransferase complex (Clr-C) result in requirements for H3K9 methylation for full siRNA production and for siRNA production to achieve full histone methylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21060862", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Heterochromatin assembly in fission yeast depends on the Clr4 histone methyltransferase, which targets H3K9.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771057", "endSection": "abstract"}, {"offsetInBeginSection": 1166, "offsetInEndSection": 1277, "text": "These analyses place Sir2 and H3K14 deacetylation upstream of Clr4 recruitment during heterochromatin assembly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771057", "endSection": "abstract"}, {"offsetInBeginSection": 1189, "offsetInEndSection": 1399, "text": "These results show that clr4 plays a critical role in silencing at mating-type loci and centromeres through the organization of repressive chromatin structure and demonstrate a new, activator function for Clr4p", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9620780", "endSection": "abstract"}, {"offsetInBeginSection": 1189, "offsetInEndSection": 1401, "text": "These results show that clr4 plays a critical role in silencing at mating-type loci and centromeres through the organization of repressive chromatin structure and demonstrate a new, activator function for Clr4p..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9620780", "endSection": "abstract"}]}, {"body": "What is the role of LIMT lncRNA?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27485121", "http://www.ncbi.nlm.nih.gov/pubmed/27123924"], "ideal_answer": ["LINC01089 (LncRNA Inhibiting Metastasis; LIMT) is a highly conserved lncRNA, which is depleted in basal-like and in HER2-positive tumors, and the low expression of which predicts poor patient prognosis. Interestingly, EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter. LIMT inhibits extracellular matrix invasion of mammary cells in vitro and tumor metastasis in vivo.", "LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001943", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018567", "http://www.uniprot.org/uniprot/BCAS1_MOUSE", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000069584", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000072656", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058922", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062085", "http://www.uniprot.org/uniprot/BRMS1_HUMAN", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064726", "http://www.uniprot.org/uniprot/BCAS1_HUMAN"], "type": "summary", "id": "5896381a78275d0c4a00000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27485121", "endSection": "title"}, {"offsetInBeginSection": 602, "offsetInEndSection": 1301, "text": "This led to the identification of 11 prognostic lncRNAs. Functional analyses of this group uncovered LINC01089 (here renamed LncRNA Inhibiting Metastasis; LIMT), a highly conserved lncRNA, which is depleted in basal-like and in HER2-positive tumors, and the low expression of which predicts poor patient prognosis. Interestingly, EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter. We also find that LIMT inhibits extracellular matrix invasion of mammary cells in\u00a0vitro and tumor metastasis in\u00a0vivo In conclusion, lncRNAs dynamically regulated by growth factors might act as novel drivers of cancer progression and serve as prognostic biomarkers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27485121", "endSection": "abstract"}, {"offsetInBeginSection": 655, "offsetInEndSection": 912, "text": "Functional analyses of this group uncovered LINC01089 (here renamed LncRNA Inhibiting Metastasis; LIMT), a highly conserved lncRNA, which is depleted in basal-like and in HER2-positive tumors, and the low expression of which predicts poor patient prognosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27485121", "endSection": "abstract"}, {"offsetInBeginSection": 912, "offsetInEndSection": 1031, "text": "Interestingly, EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27485121", "endSection": "abstract"}, {"offsetInBeginSection": 1031, "offsetInEndSection": 1295, "text": "We also find that LIMT inhibits extracellular matrix invasion of mammary cells in\u00a0vitro and tumor metastasis in\u00a0vivo In conclusion, lncRNAs dynamically regulated by growth factors might act as novel drivers of cancer progression and serve as prognostic biomarkers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27485121", "endSection": "abstract"}, {"offsetInBeginSection": 659, "offsetInEndSection": 916, "text": "Functional analyses of this group uncovered LINC01089 (here renamed LncRNA Inhibiting Metastasis; LIMT), a highly conserved lncRNA, which is depleted in basal-like and in HER2-positive tumors, and the low expression of which predicts poor patient prognosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27485121", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27485121", "endSection": "title"}, {"offsetInBeginSection": 1037, "offsetInEndSection": 1301, "text": "We also find that LIMT inhibits extracellular matrix invasion of mammary cells in\u00a0vitro and tumor metastasis in\u00a0vivo In conclusion, lncRNAs dynamically regulated by growth factors might act as novel drivers of cancer progression and serve as prognostic biomarkers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27485121", "endSection": "abstract"}]}, {"body": "Is infertility characteristic of individuals with Fanconi anemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24438373", "http://www.ncbi.nlm.nih.gov/pubmed/16946016", "http://www.ncbi.nlm.nih.gov/pubmed/12913077", "http://www.ncbi.nlm.nih.gov/pubmed/19101574", "http://www.ncbi.nlm.nih.gov/pubmed/21915857", "http://www.ncbi.nlm.nih.gov/pubmed/25016020", "http://www.ncbi.nlm.nih.gov/pubmed/20494929", "http://www.ncbi.nlm.nih.gov/pubmed/16078221", "http://www.ncbi.nlm.nih.gov/pubmed/20598602", "http://www.ncbi.nlm.nih.gov/pubmed/10915769", "http://www.ncbi.nlm.nih.gov/pubmed/25575015", "http://www.ncbi.nlm.nih.gov/pubmed/15128600", "http://www.ncbi.nlm.nih.gov/pubmed/21951543"], "ideal_answer": ["Yes, infertility is characteristic of individuals with Fanconi anemia."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005199", "http://www.disease-ontology.org/api/metadata/DOID:2355", "http://www.disease-ontology.org/api/metadata/DOID:13636", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007248", "http://www.disease-ontology.org/api/metadata/DOID:5223", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007246", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007247"], "type": "yesno", "id": "58b6d26122d300530900000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 244, "text": "PALB2 links BRCA1 and BRCA2 in homologous recombinational repair of DNA double strand breaks (DSBs). Mono-allelic mutations in PALB2 increase the risk of breast, pancreatic, and other cancers, and biallelic mutations cause Fanconi anemia (FA). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25016020", "endSection": "abstract"}, {"offsetInBeginSection": 621, "offsetInEndSection": 888, "text": "Moreover, mutant males showed reduced fertility due to impaired meiosis and increased apoptosis in germ cells. Interestingly, mutant meiocytes showed a significant defect in sex chromosome synapsis, which likely contributed to the germ cell loss and fertility defect.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25016020", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 217, "text": "In females with Fanconi anemia (FA), infertility is often accompanied by diminished ovarian reserve and hypergonadotropic amenorrhea before the age of 30 years, suggesting primary ovarian insufficiency (POI).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24438373", "endSection": "abstract"}, {"offsetInBeginSection": 1368, "offsetInEndSection": 1740, "text": "Substantially reduced AMH levels in females with FA suggest a primary ovarian defect associated with reduced fertility. Measurement of AMH at the time of FA diagnosis and subsequent monitoring of AMH levels at regular intervals may be useful for the timely management of complications related to POI such as subfertility/infertility, osteoporosis, and menopausal symptoms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24438373", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Fanconi anemia (FA) is a human disease of bone marrow failure, leukemia, squamous cell carcinoma, and developmental anomalies, including hypogonadism and infertility. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21951543", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Reduced fertility is one clinical manifestation among other well known Fanconi anemia features. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20494929", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Fanconi anemia (FA) is a human disease of bone marrow failure, leukemia, squamous cell carcinoma, and developmental anomalies, including hypogonadism and infertility", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21951543", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12913077", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Fanconi anemia (FA) is a human disease of bone marrow failure, leukemia, squamous cell carcinoma, and developmental anomalies, including hypogonadism and infertility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21951543", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 452, "text": "To potentially reduce late effects of malignancy, chronic graft-versus-host disease (GVHD), endocrinopathy, and infertility in patients with Fanconi anemia (FA) undergoing HLA-matched related donor hematopoietic cell transplantation (HCT), we developed a regimen using fludarabine (FLU), cyclophosphamide (CY), and anti-thymocyte globulin (ATG) followed by infusion of T-cell depleted (TCD) bone marrow (BM) or unmanipulated umbilical cord blood (UCB).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16078221", "endSection": "abstract"}, {"offsetInBeginSection": 795, "offsetInEndSection": 998, "text": "Mutations in Fanca account for the majority of cases of Fanconi anemia (FA), a recessively inherited disease identified by congenital defects, bone marrow failure, infertility, and cancer susceptibility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15128600", "endSection": "abstract"}, {"offsetInBeginSection": 474, "offsetInEndSection": 697, "text": "FANCA is mutated in more than 60% of cases of Fanconi anemia (FA), a rare genetically heterogeneous autosomal recessive disorder characterized by bone marrow failure, endocrine tissue cancer susceptibility, and infertility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16946016", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "In females with Fanconi anemia (FA), infertility is often accompanied by diminished ovarian reserve and hypergonadotropic amenorrhea before the age of 30 years, suggesting primary ovarian insufficiency (POI).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24438373", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "Fanconi anemia (FA) is a complex cancer susceptibility disorder associated with DNA repair defects and infertility, yet the precise function of the FA proteins in genome maintenance remains unclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20598602", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "Fanconi anemia (FA) is a genetic disease resulting in bone marrow failure, high cancer risks, and infertility, and developmental anomalies including microphthalmia, microcephaly, hypoplastic radius and thumb.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19101574", "endSection": "abstract"}]}, {"body": "What are Kupffer cells and what is their role?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15693545", "http://www.ncbi.nlm.nih.gov/pubmed/26908374", "http://www.ncbi.nlm.nih.gov/pubmed/8621159", "http://www.ncbi.nlm.nih.gov/pubmed/27717685", "http://www.ncbi.nlm.nih.gov/pubmed/26553134", "http://www.ncbi.nlm.nih.gov/pubmed/12964033", "http://www.ncbi.nlm.nih.gov/pubmed/26613891", "http://www.ncbi.nlm.nih.gov/pubmed/1748476"], "ideal_answer": ["Kupffer cells (KCs)are hepatic macrophages which can secrete matrix metalloproteinases (MMPs), and can contribute to decreased hepatic insulin sensitivity. KCs may play a role in the development of drug induced liver injury (DILI)", "Kupffer cells (KCs) play a role in the development of drug induced liver injury (DILI). Hepatic macrophages consist of Kupffer cells, which are originated from the fetal yolk-sack, and infiltrated bone marrow-derived monocytes/macrophages. "], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007728"], "type": "summary", "id": "58cdb38f02b8c60953000041", "snippets": [{"offsetInBeginSection": 45, "offsetInEndSection": 132, "text": "Kupffer cells (KCs) play a role in the development of drug induced liver injury (DILI).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27717685", "endSection": "abstract"}, {"offsetInBeginSection": 159, "offsetInEndSection": 311, "text": "Hepatic macrophages consist of Kupffer cells, which are originated from the fetal yolk-sack, and infiltrated bone marrow-derived monocytes/macrophages. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908374", "endSection": "abstract"}, {"offsetInBeginSection": 920, "offsetInEndSection": 967, "text": "Kupffer cells (KCs) are the main source of MMP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26613891", "endSection": "abstract"}, {"offsetInBeginSection": 833, "offsetInEndSection": 949, "text": "liver, both Kupffer cells and recruited hepatic macrophages can contribute to decreased hepatic insulin sensitivity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26553134", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Macrophages such as Kupffer cells in the liver are multifunctional cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8621159", "endSection": "abstract"}, {"offsetInBeginSection": 253, "offsetInEndSection": 478, "text": "Kupffer cells--the resident macrophages of the liver--are able to release a tremendous array of mediators upon inflammatory conditions, such as infection, and their role in innate immunity is well described in the literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15693545", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Kupffer cells are the tissue macrophages in the liver and play an important role in the defense mechanisms of the body", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12964033", "endSection": "abstract"}]}, {"body": "What is known about saponins in crops and human consumption?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8121473", "http://www.ncbi.nlm.nih.gov/pubmed/23533206", "http://www.ncbi.nlm.nih.gov/pubmed/9839832", "http://www.ncbi.nlm.nih.gov/pubmed/11336236", "http://www.ncbi.nlm.nih.gov/pubmed/20725585"], "ideal_answer": ["Saponins are considered antinutrients for humans and have a bitter taste. They should be removed from the crops before consumption."], "type": "summary", "id": "58cd729502b8c6095300003d", "snippets": [{"offsetInBeginSection": 335, "offsetInEndSection": 706, "text": "Saponins are readily soluble in water and are approved by the US FDA for inclusion in beverages intended for human consumption. The addition of saponins to existing water supplies offers a new form of intervention into the cycle of rotavirus infection. We believe that saponins will 'coat' the epithelium of the host's small intestine and prevent attachment of rotavirus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20725585", "endSection": "abstract"}, {"offsetInBeginSection": 451, "offsetInEndSection": 762, "text": "The levels of antinutrients in meal from the raw seeds were: trypsin inhibitor activity (14.6-28.7 mg trypsin inhibited/g), lectin (25.6-52.2 unit; one unit is the reverse of minimum amount of mg meal/ml assay which produced haemagglutination), saponins (1.9-2.3% as diosgenin equivalent) and phytate (8.4-10%).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9839832", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Quinoa cultivars currently grown in North America and Europe require removal of bitter-tasting saponins from the grain prior to human consumption.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11336236", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 685, "text": " Antinutrients, including phytate, glycoside, saponin and tannin, were screened and quantified. Phytate (112.82 \u00b1 0.1 mg/100 g), glycoside (2.33 \u00b1 0.00 mg/100 g), saponin (1.31 \u00b1 0.00 mg/100g) and tannin (0.21 \u00b1 0.00 mg/100 g) were present in the fruit but phlobatanin and glycosides with steroidal rings were not found.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533206", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 279, "text": "antinutritional factors (phytic acid, trypsin inhibitor activity (TIA) and saponins)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8121473", "endSection": "abstract"}]}, {"body": "Is golimumab effective for ulcerative colitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24955447", "http://www.ncbi.nlm.nih.gov/pubmed/27494322", "http://www.ncbi.nlm.nih.gov/pubmed/24502344", "http://www.ncbi.nlm.nih.gov/pubmed/26907481", "http://www.ncbi.nlm.nih.gov/pubmed/25609972", "http://www.ncbi.nlm.nih.gov/pubmed/24285003", "http://www.ncbi.nlm.nih.gov/pubmed/26738756", "http://www.ncbi.nlm.nih.gov/pubmed/24160948", "http://www.ncbi.nlm.nih.gov/pubmed/24774504", "http://www.ncbi.nlm.nih.gov/pubmed/18683105", "http://www.ncbi.nlm.nih.gov/pubmed/27498886", "http://www.ncbi.nlm.nih.gov/pubmed/25876561", "http://www.ncbi.nlm.nih.gov/pubmed/23344099", "http://www.ncbi.nlm.nih.gov/pubmed/23735746", "http://www.ncbi.nlm.nih.gov/pubmed/26600980", "http://www.ncbi.nlm.nih.gov/pubmed/24842416", "http://www.ncbi.nlm.nih.gov/pubmed/24506179", "http://www.ncbi.nlm.nih.gov/pubmed/26786341", "http://www.ncbi.nlm.nih.gov/pubmed/27440869", "http://www.ncbi.nlm.nih.gov/pubmed/25729432", "http://www.ncbi.nlm.nih.gov/pubmed/23897288", "http://www.ncbi.nlm.nih.gov/pubmed/25817087", "http://www.ncbi.nlm.nih.gov/pubmed/27699641", "http://www.ncbi.nlm.nih.gov/pubmed/25294262", "http://www.ncbi.nlm.nih.gov/pubmed/23770005", "http://www.ncbi.nlm.nih.gov/pubmed/26893582", "http://www.ncbi.nlm.nih.gov/pubmed/27695502", "http://www.ncbi.nlm.nih.gov/pubmed/27723166"], "ideal_answer": ["Yes. Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003093", "http://www.disease-ontology.org/api/metadata/DOID:8577", "http://www.biosemantics.org/jochem#4002191"], "type": "yesno", "id": "5896e4d478275d0c4a000015", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Initial experience with golimumab in clinical practice for ulcerative colitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786341", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "BACKGROUND: Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786341", "endSection": "abstract"}, {"offsetInBeginSection": 1200, "offsetInEndSection": 1341, "text": "CONCLUSIONS: In this short study, golimumab seems to be an alternative treatment in naive and non-naive anti-TNF ulcerative colitis patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786341", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27494322", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "OBJECTIVE: The objective of this study was to assess the cost-effectiveness of induction and maintenance treatment up to 1 year of ulcerative colitis with golimumab/standard care and standard care alone in Poland.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27494322", "endSection": "abstract"}, {"offsetInBeginSection": 1406, "offsetInEndSection": 1575, "text": "CONCLUSIONS: The biologic treatment of ulcerative colitis patients with golimumab/standard care is more effective but also more costly compared with standard care alone.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27494322", "endSection": "abstract"}, {"offsetInBeginSection": 246, "offsetInEndSection": 448, "text": "Currently, infliximab, adalimumab, and golimumab are available in the East Asian medical market, and these agents have been shown to be effective for inducing and maintaining long-term remission of IBD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723166", "endSection": "abstract"}, {"offsetInBeginSection": 356, "offsetInEndSection": 457, "text": "Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27699641", "endSection": "abstract"}, {"offsetInBeginSection": 1488, "offsetInEndSection": 1750, "text": "CONCLUSIONS: No significant differences in efficacy in the maintenance phase between infliximab and golimumab or adalimumab were revealed. Infliximab proved to be more effective than adalimumab but of similar efficacy to that of golimumab in the induction phase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695502", "endSection": "abstract"}, {"offsetInBeginSection": 603, "offsetInEndSection": 811, "text": "In this review, we will provide a detailed discussion of the three tumor necrosis factor-alpha (TNF-\u03b1) inhibitors currently approved for treatment of ulcerative colitis: infliximab, adalimumab, and golimumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25609972", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Golimumab, a human anti-TNF antibody, is effective in patients with ulcerative colitis, according to new findings from an international phase III double-blind trial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23897288", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Golimumab for moderately to severely active ulcerative colitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498886", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23770005", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735746", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 484, "text": "Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-\u03b1 (TNF\u03b1), was evaluated as maintenance therapy in TNF\u03b1 antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy.We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment, eg, PURSUIT)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23770005", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Golimumab, a human anti-TNF antibody, is effective in patients with ulcerative colitis, according to new findings from an international phase III double-blind trial", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23897288", "endSection": "abstract"}, {"offsetInBeginSection": 300, "offsetInEndSection": 646, "text": "The purpose of this review was to describe the management of ulcerative colitis with emphasis on the use of anti-tumor necrosis factor (TNF) agents.Recent research has shown that new anti-TNF agents, adalimumab (ADA) and golimumab, are effective in induction of remission and maintenance of remission in patients with extensive ulcerative colitis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285003", "endSection": "abstract"}, {"offsetInBeginSection": 1593, "offsetInEndSection": 1794, "text": "Vedolizumab and golimumab occurred more effective, and comparably as safe as placebo in patients with active moderate to severe ulcerative colitis increasing the number of available therapeutic options", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955447", "endSection": "abstract"}, {"offsetInBeginSection": 1138, "offsetInEndSection": 1471, "text": "The required sample sizes for direct head-to-head trials between infliximab and adalimumab for induction and maintenance are 174 and 204 subjects respectively.This study demonstrates that, compared to placebo, infliximab, adalimumab and golimumab are all effective for the induction and maintenance of remission in ulcerative colitis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24506179", "endSection": "abstract"}, {"offsetInBeginSection": 559, "offsetInEndSection": 769, "text": "The biosimilar of infliximab is as effective and as safe as its originator in rheumatologic conditions, while a new anti-TNF agent, namely golimumab, has been recently approved for refractory ulcerative colitis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25729432", "endSection": "abstract"}, {"offsetInBeginSection": 179, "offsetInEndSection": 327, "text": "We evaluated subcutaneous golimumab induction therapy in TNF-\u03b1 antagonist-na\u00efve patients with moderate-to-severe UC despite conventional treatment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735746", "endSection": "abstract"}, {"offsetInBeginSection": 1641, "offsetInEndSection": 1843, "text": "Vedolizumab and golimumab occurred more effective, and comparably as safe as placebo in patients with active moderate to severe ulcerative colitis increasing the number of available therapeutic options.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955447", "endSection": "abstract"}, {"offsetInBeginSection": 300, "offsetInEndSection": 647, "text": "The purpose of this review was to describe the management of ulcerative colitis with emphasis on the use of anti-tumor necrosis factor (TNF) agents.Recent research has shown that new anti-TNF agents, adalimumab (ADA) and golimumab, are effective in induction of remission and maintenance of remission in patients with extensive ulcerative colitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285003", "endSection": "abstract"}, {"offsetInBeginSection": 1593, "offsetInEndSection": 1795, "text": "Vedolizumab and golimumab occurred more effective, and comparably as safe as placebo in patients with active moderate to severe ulcerative colitis increasing the number of available therapeutic options.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955447", "endSection": "abstract"}, {"offsetInBeginSection": 560, "offsetInEndSection": 771, "text": "The biosimilar of infliximab is as effective and as safe as its originator in rheumatologic conditions, while a new anti-TNF agent, namely golimumab, has been recently approved for refractory ulcerative colitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25729432", "endSection": "abstract"}, {"offsetInBeginSection": 1120, "offsetInEndSection": 1533, "text": "The incremental cost-utility ratio of golimumab/standard care compared to the standard care alone is estimated to be 391,252 PLN/QALY gained (93,155 \u20ac/QALYG) from public payer perspective and 374,377 PLN/QALY gained (89,137 \u20ac/QALYG) from social perspective.The biologic treatment of ulcerative colitis patients with golimumab/standard care is more effective but also more costly compared with standard care alone.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27494322", "endSection": "abstract"}, {"offsetInBeginSection": 1138, "offsetInEndSection": 1472, "text": "The required sample sizes for direct head-to-head trials between infliximab and adalimumab for induction and maintenance are 174 and 204 subjects respectively.This study demonstrates that, compared to placebo, infliximab, adalimumab and golimumab are all effective for the induction and maintenance of remission in ulcerative colitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24506179", "endSection": "abstract"}, {"offsetInBeginSection": 592, "offsetInEndSection": 819, "text": "Recently, 2 new antibodies have been approved: golimumab is a new option for ulcerative colitis and with another more selective mechanism of action; vedolizumab could be useful for ulcerative colitis as well as Crohn's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25294262", "endSection": "abstract"}, {"offsetInBeginSection": 345, "offsetInEndSection": 588, "text": "The present review summarizes the literature on the role of golimumab, a new anti TNF agent, in ulcerative colitis.Literature search was done on PubMed using the search terms 'golimumab' AND 'ulcerative colitis' from inception till March 2016.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498886", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 325, "text": "The aim of this systematic review was to evaluate the efficacy and safety of biological agents (vedolizumab, abatacept, visilizumab, golimumab) in patients with active moderate to severe ulcerative colitis.This paper was prepared according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955447", "endSection": "abstract"}, {"offsetInBeginSection": 1632, "offsetInEndSection": 1834, "text": "Vedolizumab and golimumab occurred more effective, and comparably as safe as placebo in patients with active moderate to severe ulcerative colitis increasing the number of available therapeutic options.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955447", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 513, "text": "BACKGROUND & AIMS: Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-\u00e1 (TNF\u00e1), was evaluated as maintenance therapy in TNF\u00e1 antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy.METHODS: We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment, eg, PURSUIT).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23770005", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "BACKGROUND & AIMS: Little is known about the efficacy of golimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF) -\u00e1, for treatment of ulcerative colitis (UC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735746", "endSection": "abstract"}, {"offsetInBeginSection": 1301, "offsetInEndSection": 1476, "text": "This study demonstrates that, compared to placebo, infliximab, adalimumab and golimumab are all effective for the induction and maintenance of remission in ulcerative colitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24506179", "endSection": "abstract"}, {"offsetInBeginSection": 1590, "offsetInEndSection": 1793, "text": "Vedolizumab and golimumab occurred more effective, and comparably as safe as placebo in patients with active moderate to severe ulcerative colitis increasing the number of available therapeutic options..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955447", "endSection": "abstract"}, {"offsetInBeginSection": 449, "offsetInEndSection": 648, "text": "Recent research has shown that new anti-TNF agents, adalimumab (ADA) and golimumab, are effective in induction of remission and maintenance of remission in patients with extensive ulcerative colitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285003", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "Golimumab for moderately to severely active ulcerative colitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498886", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Initial experience with golimumab in clinical practice for ulcerative colitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786341", "endSection": "title"}, {"offsetInBeginSection": 863, "offsetInEndSection": 1045, "text": "Golimumab was found to be effective and safe in inducing and maintaining clinical remission, clinical response and mucosal healing in patients with UC in the two registration trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498886", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 43, "text": "[Golimumab Therapy in Ulcerative Colitis].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26907481", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Golimumab: clinical update on its use for ulcerative colitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25876561", "endSection": "title"}, {"offsetInBeginSection": 558, "offsetInEndSection": 624, "text": "This review will focus on golimumab therapy in ulcerative colitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26907481", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "To assess golimumab pharmacokinetics [PK] and exposure-response [ER] in adults with moderate-to-severe ulcerative colitis [UC] from the Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment [PURSUIT] studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27440869", "endSection": "abstract"}]}, {"body": "What is the role of histone variant H2A.W?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24995981", "http://www.ncbi.nlm.nih.gov/pubmed/25983206", "http://www.ncbi.nlm.nih.gov/pubmed/25781491"], "ideal_answer": ["The histone variant H2A.W defines heterochromatin and promotes chromatin condensation in Arabidopsis. The histone variant H2A.W marks heterochromatin specifically and acts in synergy with heterochromatic marks H3K9me2 and DNA methylation to maintain transposon silencing. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization. In vitro, H2A.W enhances chromatin condensation by promoting fiber-to-fiber interactions via its conserved C-terminal motif. In non-flowering land plants, we identify a new class of H2A variants and propose their possible role in the emergence of the H2A.W variant class in flowering plants. ", "The histone variant H2A.W defines heterochromatin and promotes chromatin condensation in Arabidopsis The histone variant H2A.W marks heterochromatin specifically and acts in synergy with heterochromatic marks H3K9me2 and DNA methylation to maintain transposon silencing In vitro, H2A.W enhances chromatin condensation by promoting fiber-to-fiber interactions via its conserved C-terminal motif. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization.  In non-flowering land plants, we identify a new class of H2A variants and propose their possible role in the emergence of the H2A.W variant class in flowering plants Covalent histone modifications (e.g.", "The histone variant H2A.W marks heterochromatin specifically and acts in synergy with heterochromatic marks H3K9me2 and DNA methylation to maintain transposon silencing. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization. Histone chaperones escort histones, and play key functions during nucleosome assembly/disassembly and in nucleosome structure configuration. Here we focus on plant histone H2A/H2B chaperones, particularly members of the NUCLEOSOME ASSEMBLY PROTEIN-1 (NAP1) and FACILITATES CHROMATIN TRANSCRIPTION (FACT) families, discussing their molecular features, properties, regulation and function. We further discuss roles of NAP1 and FACT in chromatin-based processes, such as transcription, DNA replication and repair. Future major challenges remain in order to define in more detail the overlapping and specific roles of various members of the NAP1 family as well as differences and similarities between NAP1 and FACT family members, and to identify and characterize their partners as well as new families of chaperones to understand histone variant incorporation and chromatin target specificity.", " In non-flowering land plants, we identify a new class of H2A variants and propose their possible role in the emergence of the H2A.W variant class in flowering plants In vitro, H2A.W enhances chromatin condensation by promoting fiber-to-fiber interactions via its conserved C-terminal motif. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization.", "The histone variant H2A.W defines heterochromatin and promotes chromatin condensation in Arabidopsis", "Histone variants play crucial roles in gene expression, genome integrity, and chromosome segregation. The histone variant H2A.W marks heterochromatin specifically and acts in synergy with heterochromatic marks H3K9me2 and DNA methylation to maintain transposon silencing. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization. Histone chaperones escort histones, and play key functions during nucleosome assembly/disassembly and in nucleosome structure configuration. Covalent histone modifications (e.g. ubiquitination, phosphorylation, methylation, acetylation) and H2A variants (H2A.Z, H2A.X and H2A.W) are also discussed in view of their crucial importance in modulating nucleosome organization and function.", "The histone variant H2A.W marks heterochromatin specifically and acts in synergy with heterochromatic marks H3K9me2 and DNA methylation to maintain transposon silencing. In vitro, H2A.W enhances chromatin condensation by promoting fiber-to-fiber interactions via its conserved C-terminal motif. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization."], "type": "summary", "id": "58ab1f209ef3c34033000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "The histone variant H2A.W defines heterochromatin and promotes chromatin condensation in Arabidopsis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24995981", "endSection": "title"}, {"offsetInBeginSection": 235, "offsetInEndSection": 403, "text": "The histone variant H2A.W marks heterochromatin specifically and acts in synergy with heterochromatic marks H3K9me2 and DNA methylation to maintain transposon silencing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24995981", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 669, "text": "In vitro, H2A.W enhances chromatin condensation by promoting fiber-to-fiber interactions via its conserved C-terminal motif. In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24995981", "endSection": "abstract"}, {"offsetInBeginSection": 629, "offsetInEndSection": 795, "text": " In non-flowering land plants, we identify a new class of H2A variants and propose their possible role in the emergence of the H2A.W variant class in flowering plants", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25983206", "endSection": "abstract"}, {"offsetInBeginSection": 669, "offsetInEndSection": 913, "text": "Covalent histone modifications (e.g. ubiquitination, phosphorylation, methylation, acetylation) and H2A variants (H2A.Z, H2A.X and H2A.W) are also discussed in view of their crucial importance in modulating nucleosome organization and function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25781491", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "The histone variant H2A.W defines heterochromatin and promotes chromatin condensation in Arabidopsis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24995981", "endSection": "title"}, {"offsetInBeginSection": 530, "offsetInEndSection": 670, "text": "In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24995981", "endSection": "abstract"}, {"offsetInBeginSection": 530, "offsetInEndSection": 669, "text": "In vivo, H2A.W is required for heterochromatin condensation, demonstrating that H2A.W plays critical roles in heterochromatin organization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24995981", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "The histone variant H2A.W defines heterochromatin and promotes chromatin condensation in Arabidopsis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24995981", "endSection": "title"}, {"offsetInBeginSection": 670, "offsetInEndSection": 844, "text": "Similarities in conserved motifs between H2A.W and another H2A variant in metazoans suggest that plants and animals share common mechanisms for heterochromatin condensation..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24995981", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 529, "text": "In vitro, H2A.W enhances chromatin condensation by promoting fiber-to-fiber interactions via its conserved C-terminal motif.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24995981", "endSection": "abstract"}]}, {"body": "Which are the main brain dysfunctions caused by hyperbilirubinemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3174510", "http://www.ncbi.nlm.nih.gov/pubmed/16361175", "http://www.ncbi.nlm.nih.gov/pubmed/27746217", "http://www.ncbi.nlm.nih.gov/pubmed/25524299", "http://www.ncbi.nlm.nih.gov/pubmed/21575408", "http://www.ncbi.nlm.nih.gov/pubmed/22966025", "http://www.ncbi.nlm.nih.gov/pubmed/23283699", "http://www.ncbi.nlm.nih.gov/pubmed/19754366", "http://www.ncbi.nlm.nih.gov/pubmed/11726727", "http://www.ncbi.nlm.nih.gov/pubmed/23086523", "http://www.ncbi.nlm.nih.gov/pubmed/25793115", "http://www.ncbi.nlm.nih.gov/pubmed/14684236", "http://www.ncbi.nlm.nih.gov/pubmed/25534357", "http://www.ncbi.nlm.nih.gov/pubmed/24309481", "http://www.ncbi.nlm.nih.gov/pubmed/27393040", "http://www.ncbi.nlm.nih.gov/pubmed/21163242", "http://www.ncbi.nlm.nih.gov/pubmed/17342778", "http://www.ncbi.nlm.nih.gov/pubmed/8631524", "http://www.ncbi.nlm.nih.gov/pubmed/23375301", "http://www.ncbi.nlm.nih.gov/pubmed/8340096", "http://www.ncbi.nlm.nih.gov/pubmed/20971088", "http://www.ncbi.nlm.nih.gov/pubmed/26480925", "http://www.ncbi.nlm.nih.gov/pubmed/18821100"], "ideal_answer": ["Bilirubin-induced neurologic dysfunction (BIND) and classical kernicterus are the main dysfunctions of hyperbilirubinemia, whenever bilirubin levels exceed the capacity of the brain defensive mechanisms in preventing its entrance and cytotoxicity. Bilirubin accumulation may lead to deficits in auditory, cognitive, and motor processing, due to neuronal cell death, reduced myelination and glial activation."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006933", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006932", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051556", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001921", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001663"], "type": "summary", "id": "58c66a4b02b8c60953000025", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 616, "text": "Bilirubin-induced neurologic dysfunction (BIND) and classical kernicterus are clinical manifestations of moderate to severe hyperbilirubinemia whenever bilirubin levels exceed the capacity of the brain defensive mechanisms in preventing its entrance and cytotoxicity. In such circumstances and depending on the associated co-morbidities, bilirubin accumulation may lead to short- or long-term neurodevelopmental disabilities, which may include deficits in auditory, cognitive, and motor processing. Neuronal cell death, astrocytic reactivity, and microglia activation are part of the bilirubin-induced pathogenesis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534357", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Reduced Myelination and Increased Glia Reactivity Resulting from Severe Neonatal Hyperbilirubinemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26480925", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 239, "text": "Bilirubin-induced neurologic dysfunction (BIND) and kernicterus has been used to describe moderate to severe neurologic dysfunction observed in children exposed to excessive levels of total serum bilirubin (TSB) during the neonatal period.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26480925", "endSection": "abstract"}, {"offsetInBeginSection": 584, "offsetInEndSection": 769, "text": "Histologic studies of brain tissue demonstrate that the onset of severe neonatal hyperbilirubinemia, characterized by seizures, leads to alterations in myelination and glia reactivity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26480925", "endSection": "abstract"}, {"offsetInBeginSection": 1467, "offsetInEndSection": 1702, "text": "Thus, kernicterus in this model displays not only axonal damage but also myelination deficits and glial activation in different brain regions that are usually related to the neurologic sequelae observed after severe hyperbilirubinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26480925", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 388, "text": "Advances in the care of neonatal hyperbilirubinemia have led to a decreased incidence of kernicterus. However, neonatal exposure to high levels of bilirubin continues to cause severe motor symptoms and cerebral palsy (CP). Exposure to moderate levels of unconjugated bilirubin may also cause damage to the developing central nervous system, specifically the basal ganglia and cerebellum. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25524299", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "High levels of serum unconjugated bilirubin (UCB) in newborns are associated with axonal damage and glial reactivity that may contribute to subsequent neurologic injury and encephalopathy (kernicterus). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23086523", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 295, "text": "Hyperbilirubinemia remains one of the most frequent clinical diagnoses in the neonatal period. This condition may lead to the deposition of unconjugated bilirubin (UCB) in the central nervous system, causing nerve cell damage by molecular and cellular mechanisms that are still being clarified. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23283699", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 254, "text": "\"Kernicterus\" is a term currently used to describe bilirrubin induced brain injury in the neuro-pathological studies. This is a confusing term and nowadays we prefer bilirrubin encephalopathy or bilirrubin induced neurological dysfunction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21163242", "endSection": "abstract"}, {"offsetInBeginSection": 1203, "offsetInEndSection": 1390, "text": "We then review the possible alteration of the neuroprotective and trophic barrier functions in the course of bilirubin-induced neurological dysfunctions resulting from hyperbilirubinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19754366", "endSection": "abstract"}, {"offsetInBeginSection": 224, "offsetInEndSection": 349, "text": "It has been suggested recently that there is an association between hyperbilirubinemia and long-term neurologic dysfunctions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17342778", "endSection": "abstract"}, {"offsetInBeginSection": 618, "offsetInEndSection": 875, "text": "In this article, we review computational insights into the brain dysfunctions underlying Parkinson's disease, Huntington's disease, and dystonia, with particular foci on dysfunctions of the dopamine system, basal ganglia pathways, and neuronal oscillations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27393040", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Hyperbilirubinemia may accompany harmful effects such as jaundice, brain dysfunction, and pharmacokinetic alterations of drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18821100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 370, "text": "Neonatal jaundice is a common cause of sensorneural hearing loss in children.We aimed to detect the neurotoxic effects of pathologic hyperbilirubinemia on brain stem and auditory tract by auditory brain stem evoked response (ABR) which could predict early effects of hyperbilirubinemia.This case-control study was performed on newborns with pathologic hyperbilirubinemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25793115", "endSection": "abstract"}, {"offsetInBeginSection": 1763, "offsetInEndSection": 2138, "text": "For example, the mean latencies time of wave I was significantly higher in right ear of the case group than in controls (2.16 \u00b1 0.26 vs. 1.77 \u00b1 0.15 milliseconds, respectively) (P &lt; 0.001).Pathologic hyperbilirubinemia causes acute disorder on brain stem function; therefore, early diagnosis of neonatal jaundice for prevention of bilirubin neurotoxic effects is essential", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25793115", "endSection": "abstract"}, {"offsetInBeginSection": 1241, "offsetInEndSection": 1553, "text": "Wave amplitudes are valuable BAER variables to detect functional impairment of the brainstem and auditory pathway in neonatal hyperbilirubinemia, and are recommended to be used in assessing bilirubin neurotoxicity to the neonatal brain.<CopyrightInformation>Copyright \u00a9 2013 European Paediatric Neurology Society", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24309481", "endSection": "abstract"}, {"offsetInBeginSection": 584, "offsetInEndSection": 767, "text": "Histologic studies of brain tissue demonstrate that the onset of severe neonatal hyperbilirubinemia, characterized by seizures, leads to alterations in myelination and glia reactivity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26480925", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "[Characteristics of auditory brain stem response in neonatal hyperbilirubinemia induced by different causes].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21575408", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Excessive hyperbilirubinemia in human neonates can cause permanent dysfunction of the auditory system, as assessed with brainstem auditory evoked potentials (BAEPs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20971088", "endSection": "abstract"}, {"offsetInBeginSection": 129, "offsetInEndSection": 571, "text": "A recent surge in reported cases of classical kernicterus, due in part to earlier hospital discharge and relaxation of treatment criteria for hyperbilirubinemia, and new reports of hyperbilirubinemia-induced auditory dysfunction using evoked potential based infant testing and hearing screening, underscore the need to better understand how hyperbilirubinemia causes brain damage in some infants, especially because the damage is preventable.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14684236", "endSection": "abstract"}, {"offsetInBeginSection": 1944, "offsetInEndSection": 2128, "text": "Pathologic hyperbilirubinemia causes acute disorder on brain stem function; therefore, early diagnosis of neonatal jaundice for prevention of bilirubin neurotoxic effects is essential.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25793115", "endSection": "abstract"}]}, {"body": "Does mTOR regulate the translation of MAPKAPK2?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26269117", "http://www.ncbi.nlm.nih.gov/pubmed/26280535"], "ideal_answer": ["Yes. mTOR regulates the translation of the MK2 (also known as MAPKAPK2) kinase through 4EBP1.  In turn, MAPKAPK2 phosphorylates the RNA-binding protein ZFP36L1 during senescence, inhibiting its ability to degrade the transcripts of numerous senescence-associated secretory phenotype (SASP) components. Consequently, mTOR inhibition or constitutive activation of ZFP36L1 impairs the non-cell-autonomous effects of senescent cells in both tumour-suppressive and tumour-promoting contexts."], "concepts": ["http://www.uniprot.org/uniprot/MAPK2_RABIT", "http://amigo.geneontology.org/amigo/term/GO:0070438", "http://www.uniprot.org/uniprot/MAPK2_DROME", "http://amigo.geneontology.org/amigo/term/GO:0038201", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058570", "http://www.uniprot.org/uniprot/MAPK2_HUMAN", "http://www.uniprot.org/uniprot/MAPK2_CRILO"], "type": "yesno", "id": "58967c9978275d0c4a000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280535", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1073, "text": "Senescent cells secrete a combination of factors collectively known as the senescence-associated secretory phenotype (SASP). The SASP reinforces senescence and activates an immune surveillance response, but it can also show pro-tumorigenic properties and contribute to age-related pathologies. In a drug screen to find new SASP regulators, we uncovered the mTOR inhibitor rapamycin as a potent SASP suppressor. Here we report a mechanism by which mTOR controls the SASP by differentially regulating the translation of the MK2 (also known as MAPKAPK2) kinase through 4EBP1. In turn, MAPKAPK2 phosphorylates the RNA-binding protein ZFP36L1 during senescence, inhibiting its ability to degrade the transcripts of numerous SASP components. Consequently, mTOR inhibition or constitutive activation of ZFP36L1 impairs the non-cell-autonomous effects of senescent cells in both tumour-suppressive and tumour-promoting contexts. Altogether, our results place regulation of the SASP as a key mechanism by which mTOR could influence cancer, age-related diseases and immune responses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280535", "endSection": "abstract"}, {"offsetInBeginSection": 408, "offsetInEndSection": 569, "text": "Here we report a mechanism by which mTOR controls the SASP by differentially regulating the translation of the MK2 (also known as MAPKAPK2) kinase through 4EBP1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280535", "endSection": "title"}, {"offsetInBeginSection": 411, "offsetInEndSection": 571, "text": "Here we report a mechanism by which mTOR controls the SASP by differentially regulating the translation of the MK2 (also known as MAPKAPK2) kinase through 4EBP1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280535", "endSection": "abstract"}, {"offsetInBeginSection": 411, "offsetInEndSection": 572, "text": "Here we report a mechanism by which mTOR controls the SASP by differentially regulating the translation of the MK2 (also known as MAPKAPK2) kinase through 4EBP1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280535", "endSection": "abstract"}, {"offsetInBeginSection": 1257, "offsetInEndSection": 1475, "text": "Both Beclin1-PI3KIII and Beclin1-MAPKAPK2 interactions as were remarkably affected by silencing either ATM or MAPK14.ATM promoted IR-induced autophagy via the MAPK14 pathway, mTOR pathway and Beclin1/PI3KIII complexes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26269117", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280535", "endSection": "title"}]}, {"body": "What chromosome is affected in Turner's syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19909521", "http://www.ncbi.nlm.nih.gov/pubmed/20197675", "http://www.ncbi.nlm.nih.gov/pubmed/10689047", "http://www.ncbi.nlm.nih.gov/pubmed/15797949", "http://www.ncbi.nlm.nih.gov/pubmed/25800473", "http://www.ncbi.nlm.nih.gov/pubmed/20017317", "http://www.ncbi.nlm.nih.gov/pubmed/8517687", "http://www.ncbi.nlm.nih.gov/pubmed/26757887", "http://www.ncbi.nlm.nih.gov/pubmed/20122165", "http://www.ncbi.nlm.nih.gov/pubmed/17663292", "http://www.ncbi.nlm.nih.gov/pubmed/8151646", "http://www.ncbi.nlm.nih.gov/pubmed/23602925", "http://www.ncbi.nlm.nih.gov/pubmed/3625764", "http://www.ncbi.nlm.nih.gov/pubmed/22711287", "http://www.ncbi.nlm.nih.gov/pubmed/12667526", "http://www.ncbi.nlm.nih.gov/pubmed/26322078", "http://www.ncbi.nlm.nih.gov/pubmed/1240972"], "ideal_answer": ["Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome", "Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome.", "Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome. ", "turner's syndrome (ts) is a chromosomal defect with partial or total absence of the x chromosome."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D025063", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014960", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D025064", "http://www.disease-ontology.org/api/metadata/DOID:3491", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014424", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D041321"], "type": "factoid", "id": "58bca2f302b8c6095300000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26757887", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Turner syndrome is a genetic disorder caused by the complete or partial absence of an X chromosome in affected women", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22711287", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Turner syndrome (TS) is a chromosomal disorder caused by complete or partial X chromosome monosomy that manifests various clinical features depending on the karyotype and on the genetic background of affected girls", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25800473", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "CONTEXT: Turner syndrome (TS) is the most common genetic problem affecting women and occurs when an X chromosome is completely deleted, portions of an X chromosome are deleted, or chromosomal mosaicism occurs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15797949", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Turner's syndrome (TS) is a chromosomal disorder that results from the loss of the entire or a part of the X-chromosome and occurs in 1/2,500 female births.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17663292", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Women with Turner's syndrome (TS), who lack a complete X-chromosome, show an impairment in remembering faces and in classifying \"fear\" in face images.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12667526", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "The proposition that finger print variability between individuals might be reduced by the absence of an X-chromosome in Turner's syndrome was rejected.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3625764", "endSection": "abstract"}, {"offsetInBeginSection": 241, "offsetInEndSection": 435, "text": "While the classic karyotype related to Turner's syndrome is 45,X, the majority of those affected actually have a mosaic chromosomal complement, most often with a second normal cell line (46,XX).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20197675", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "45,X Turner's syndrome in monozygotic twin sisters.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1240972", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Monosomy for the X chromosome is the most frequent cause of Turner's syndrome, a common clinical syndrome associated with particular physical and neurobehavioral features.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8517687", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Turner syndrome is a chromosomal abnormality in which there is complete or partial absence of the X chromosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26322078", "endSection": "abstract"}, {"offsetInBeginSection": 10, "offsetInEndSection": 160, "text": " To identify the origin and study the morphology of small supernumerary marker chromosome (sSMC) in Turner syndrome with 45, X/46, X, + mar karyotype.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20017317", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Turner syndrome is a chromosomal disorder in which all or part of one X chromosome is missing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11807897", "endSection": "abstract"}, {"offsetInBeginSection": 85, "offsetInEndSection": 186, "text": "urner phenotype in this family is the result of deletion of the entire short arm of one X chromosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/697225", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 122, "text": "X monosomic mice (39,XO) have a remarkably mild phenotype when compared to women with Turner syndrome (45,XO).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20122165", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "X-monosomy is a form of Turner syndrome (TS) in which an entire X chromosome is missing. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10689047", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "Turner's syndrome is defined as a congenital disease determining by quantitative and/or structural aberrations of one from two X chromosomes with frequent presence of mosaicism", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16821224", "endSection": "abstract"}]}, {"body": "What is the aim of the TRAP assay?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26965413", "http://www.ncbi.nlm.nih.gov/pubmed/24528514", "http://www.ncbi.nlm.nih.gov/pubmed/23288413", "http://www.ncbi.nlm.nih.gov/pubmed/26683936", "http://www.ncbi.nlm.nih.gov/pubmed/25225832", "http://www.ncbi.nlm.nih.gov/pubmed/23296661", "http://www.ncbi.nlm.nih.gov/pubmed/23913300"], "ideal_answer": ["Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP)."], "type": "factoid", "id": "58cd7af402b8c6095300003e", "snippets": [{"offsetInBeginSection": 285, "offsetInEndSection": 452, "text": "Positive activity by the telomerase repeat amplification protocol (TRAP) was identified in cell extracts of Escherichia coli expressing a sequence-optimized hTERT gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26965413", "endSection": "abstract"}, {"offsetInBeginSection": 793, "offsetInEndSection": 1031, "text": "The regulatory role of PCDH10 in telomerase activity was confirmed by a telomeric repeat amplification protocol (TRAP) assay, and the biological functions of it were characterized by in vitro proliferation, migration, and invasion assays.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26683936", "endSection": "abstract"}, {"offsetInBeginSection": 847, "offsetInEndSection": 947, "text": "TRAP assay is a standard method for detecting telomerase activity in various tissues or cell lines. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25225832", "endSection": "abstract"}, {"offsetInBeginSection": 630, "offsetInEndSection": 679, "text": "Telomerase activity was determined by TRAP assay.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24528514", "endSection": "abstract"}, {"offsetInBeginSection": 805, "offsetInEndSection": 858, "text": "The telomerase activity was evaluated by TRAP assay. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288413", "endSection": "abstract"}, {"offsetInBeginSection": 470, "offsetInEndSection": 1178, "text": "The telomeric repeat amplification protocol (TRAP) represents an easy and rapid method for detection of telomerase activity in cells. A non-telomeric TS primer is extended by telomerase in the first step followed by the PCR amplification of the products. The PCR step renders this protocol very sensitive to detect telomerase activity at the single cell level making it compatible with the analysis of tumor samples. When run on a polyacrylamide gel, the PCR product is a characteristic ladder of bands due to the repetitive nature of telomeric DNA sequence. The densitometric analysis of the ladder allows the TRAP assay to be used for comparative quantification of telomerase activity in different samples.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23913300", "endSection": "abstract"}, {"offsetInBeginSection": 189, "offsetInEndSection": 371, "text": "Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23296661", "endSection": "abstract"}]}, {"body": "Describe clinical applications of the PIM2 scoring system.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21132231", "http://www.ncbi.nlm.nih.gov/pubmed/25996320", "http://www.ncbi.nlm.nih.gov/pubmed/25396011", "http://www.ncbi.nlm.nih.gov/pubmed/24051223", "http://www.ncbi.nlm.nih.gov/pubmed/25025075", "http://www.ncbi.nlm.nih.gov/pubmed/23940977", "http://www.ncbi.nlm.nih.gov/pubmed/17549454", "http://www.ncbi.nlm.nih.gov/pubmed/24339640", "http://www.ncbi.nlm.nih.gov/pubmed/26337557", "http://www.ncbi.nlm.nih.gov/pubmed/20019069", "http://www.ncbi.nlm.nih.gov/pubmed/24862750", "http://www.ncbi.nlm.nih.gov/pubmed/26744626", "http://www.ncbi.nlm.nih.gov/pubmed/23429969", "http://www.ncbi.nlm.nih.gov/pubmed/24868211", "http://www.ncbi.nlm.nih.gov/pubmed/17251883", "http://www.ncbi.nlm.nih.gov/pubmed/23100008"], "ideal_answer": ["The Pediatric Index of Mortality 2 (PIM2) is one of the most commonly used scoring systems to predict mortality in patients admitted to pediatric intensive care units. The PIM2 score adequately discriminates survivors from non-survivor"], "type": "summary", "id": "589a245678275d0c4a000023", "snippets": [{"offsetInBeginSection": 433, "offsetInEndSection": 731, "text": "In this study, we examine if transfusion is an independent predictor of mortality, or if outcomes are merely a result of the initial severity as predicted by Pediatric Risk of Mortality (PRISM) III, Pediatric Index of Mortality (PIM2), and day 1 Pediatric Logistic Organ Dysfunction (PELOD) scores.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26744626", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "INTRODUCTION: The Pediatric Index of Mortality 2 (PIM2) is one of the most commonly used scoring systems to predict mortality in patients admitted to pediatric intensive care units (PICU) in Argentina.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996320", "endSection": "abstract"}, {"offsetInBeginSection": 1451, "offsetInEndSection": 1533, "text": "CONCLUSIONS: The PIM2 score adequately discriminates survivors from non-survivors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996320", "endSection": "abstract"}, {"offsetInBeginSection": 1286, "offsetInEndSection": 1373, "text": "PIM2 scoring did not explain the outcome adequately, suggesting need for recalibration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24868211", "endSection": "abstract"}, {"offsetInBeginSection": 1214, "offsetInEndSection": 1436, "text": "CONCLUSION: PIM2 scoring system show adequate discriminatory function and well calibrated for the case mix of patients in PICU of Fayoum, Egypt. It can be used as beneficial tool for evaluation of risk adjusted mortality. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25396011", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "The aim of the study was to explore the association between Glasgow Coma Scale (GCS), Paediatric Index of Mortality (PIM2) and Injury Severity Score (ISS), and the long-term outcome of children with injuries.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23940977", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Pediatric index of mortality 2 score as an outcome predictor in pediatric Intensive Care Unit in India.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24339640", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "BACKGROUND AND AIMS: Pediatric index of mortality (PIM) 2 score is one of the severity scoring systems being used for predicting outcome of patients admitted to intensive care units (ICUs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24339640", "endSection": "abstract"}, {"offsetInBeginSection": 1356, "offsetInEndSection": 1434, "text": "CONCLUSION: PIM2 score discriminated well between survivors and death at PICU.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24339640", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "OBJECTIVE: A study to validate and calibrate Pediatric Index of Mortality-2 (PIM2) in children admitted to our pediatric intensive care unit (PICU).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23429969", "endSection": "abstract"}, {"offsetInBeginSection": 1205, "offsetInEndSection": 1304, "text": "CONCLUSION: PIM2 is a good index for prediction of mortality in our pediatric intensive care unit. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23429969", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "The Pediatric Index of Mortality 2 (PIM2) is one of the most commonly used scoring systems to predict mortality in patients admitted to pediatric intensive care units (PICU) in Argentina.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996320", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "Pediatric Index of Mortality 2 (PIM2) and Pediatric Risk of Mortality (PRISM) are scoring systems to predict mortality likehood; thus, it is necessary to validate such predictors in Pediatric Intensive Care Units' population.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21132231", "endSection": "abstract"}, {"offsetInBeginSection": 1188, "offsetInEndSection": 1397, "text": "Although PRISM, PIM and PIM2 have displayed good discrimination and calibration in the present setting, PIM is considered as the most accurate and appropriate tool for predicting mortality in the studied NICU.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20019069", "endSection": "abstract"}, {"offsetInBeginSection": 1411, "offsetInEndSection": 1480, "text": "The PIM2 score adequately discriminates survivors from non-survivors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996320", "endSection": "abstract"}]}, {"body": "Do histone variant mH2A (macro-H2A) levels decrease upon differentiation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21738686", "http://www.ncbi.nlm.nih.gov/pubmed/22449192", "http://www.ncbi.nlm.nih.gov/pubmed/23595991", "http://www.ncbi.nlm.nih.gov/pubmed/23077180", "http://www.ncbi.nlm.nih.gov/pubmed/23463008", "http://www.ncbi.nlm.nih.gov/pubmed/21552206"], "ideal_answer": ["MacroH2A.1 was found to be present at low levels upon the establishment of pluripotency in the inner cell mass and epiblast, but it was highly enriched in the trophectoderm and differentiated somatic cells later in mouse development. Chromatin immunoprecipitation revealed that macroH2A.1 is incorporated in the chromatin of regulatory regions of pluripotency genes in somatic cells such as mouse embryonic fibroblasts and adult neural stem cells, but not in embryonic stem cells. In addition, overexpression of macroH2A isoforms prevented efficient reprogramming of epiblast stem cells to na\u00efve pluripotency.", "1 was found to be present at low levels upon the establishment of pluripotency in the inner cell mass and epiblast, but it was highly enriched in the trophectoderm and differentiated somatic cells later in mouse development.", "Histone variant macroH2A confers resistance to nuclear reprogramming Histone variant macroH2A marks embryonic differentiation in vivo and acts as an epigenetic barrier to induced pluripotency.", "Resistance to reprogramming is associated with incorporation of the histone variant macroH2A, which is retained on the Xi of differentiated cells, but absent from the Xi of EpiSCs. The histone variant macroH2A acts as a component of an epigenetic multilayer that heritably maintains the silent X chromosome and has been shown to restrict tumor development.", "Through manipulation of macroH2A isoforms, we further demonstrate that macroH2A2 is the predominant barrier to reprogramming. In particular, we find macroH2A isoforms to be highly enriched at target genes of the K27me3 demethylase, Utx, which are reactivated early in iPS reprogramming", "MacroH2A.1 was found to be present at low levels upon the establishment of pluripotency in the inner cell mass and epiblast, but it was highly enriched in the trophectoderm and differentiated somatic cells later in mouse development. Histone variant macroH2A marks embryonic differentiation in vivo and acts as an epigenetic barrier to induced pluripotency."], "type": "yesno", "id": "58ab1f6c9ef3c34033000002", "snippets": [{"offsetInBeginSection": 268, "offsetInEndSection": 393, "text": "Through manipulation of macroH2A isoforms, we further demonstrate that macroH2A2 is the predominant barrier to reprogramming.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23463008", "endSection": "abstract"}, {"offsetInBeginSection": 532, "offsetInEndSection": 691, "text": "In particular, we find macroH2A isoforms to be highly enriched at target genes of the K27me3 demethylase, Utx, which are reactivated early in iPS reprogramming", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23463008", "endSection": "abstract"}, {"offsetInBeginSection": 880, "offsetInEndSection": 1121, "text": " Therefore, we propose that macroH2A isoforms provide a redundant silencing layer or terminal differentiation 'lock' at critical pluripotency genes that presents as an epigenetic barrier when differentiated cells are challenged to reprogram.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23463008", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Histone variant macroH2A confers resistance to nuclear reprogramming", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21552206", "endSection": "title"}, {"offsetInBeginSection": 871, "offsetInEndSection": 1051, "text": "Resistance to reprogramming is associated with incorporation of the histone variant macroH2A, which is retained on the Xi of differentiated cells, but absent from the Xi of EpiSCs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21552206", "endSection": "abstract"}, {"offsetInBeginSection": 580, "offsetInEndSection": 758, "text": "We highlight the role of macroH2A in the establishment and maintenance of differentiated states and we discuss its still poorly recognized function in transcriptional activation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22449192", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Histone variant macroH2A marks embryonic differentiation in vivo and acts as an epigenetic barrier to induced pluripotency.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23077180", "endSection": "title"}, {"offsetInBeginSection": 603, "offsetInEndSection": 836, "text": "MacroH2A.1 was found to be present at low levels upon the establishment of pluripotency in the inner cell mass and epiblast, but it was highly enriched in the trophectoderm and differentiated somatic cells later in mouse development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23077180", "endSection": "abstract"}, {"offsetInBeginSection": 837, "offsetInEndSection": 1083, "text": "Chromatin immunoprecipitation revealed that macroH2A.1 is incorporated in the chromatin of regulatory regions of pluripotency genes in somatic cells such as mouse embryonic fibroblasts and adult neural stem cells, but not in embryonic stem cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23077180", "endSection": "abstract"}, {"offsetInBeginSection": 1326, "offsetInEndSection": 1455, "text": "In addition, overexpression of macroH2A isoforms prevented efficient reprogramming of epiblast stem cells to na\u00efve pluripotency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23077180", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Macro histone variants are critical for the differentiation of human pluripotent cells", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23595991", "endSection": "title"}, {"offsetInBeginSection": 151, "offsetInEndSection": 356, "text": "Here we show that the knockdown of macro histone variants impaired the in vitro and in vivo differentiation of human pluripotent cells, likely through defects in the silencing of pluripotency-related genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23595991", "endSection": "abstract"}, {"offsetInBeginSection": 802, "offsetInEndSection": 982, "text": "Furthermore, male and female mH2A-deficient ESCs proliferate normally under pluripotency culture conditions, and respond to several standard differentiation procedures efficiently.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21738686", "endSection": "abstract"}]}, {"body": "Which disease is associated with mutations in SLC40A1 gene?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21175851", "http://www.ncbi.nlm.nih.gov/pubmed/27896572", "http://www.ncbi.nlm.nih.gov/pubmed/17540536", "http://www.ncbi.nlm.nih.gov/pubmed/21199650", "http://www.ncbi.nlm.nih.gov/pubmed/25744502", "http://www.ncbi.nlm.nih.gov/pubmed/22408404", "http://www.ncbi.nlm.nih.gov/pubmed/16351644", "http://www.ncbi.nlm.nih.gov/pubmed/20648054", "http://www.ncbi.nlm.nih.gov/pubmed/20691492", "http://www.ncbi.nlm.nih.gov/pubmed/16258219", "http://www.ncbi.nlm.nih.gov/pubmed/14636642", "http://www.ncbi.nlm.nih.gov/pubmed/19907151", "http://www.ncbi.nlm.nih.gov/pubmed/17997113", "http://www.ncbi.nlm.nih.gov/pubmed/21411349", "http://www.ncbi.nlm.nih.gov/pubmed/19937651", "http://www.ncbi.nlm.nih.gov/pubmed/27170390", "http://www.ncbi.nlm.nih.gov/pubmed/23943237", "http://www.ncbi.nlm.nih.gov/pubmed/24714983", "http://www.ncbi.nlm.nih.gov/pubmed/26059880", "http://www.ncbi.nlm.nih.gov/pubmed/24644245", "http://www.ncbi.nlm.nih.gov/pubmed/19342478", "http://www.ncbi.nlm.nih.gov/pubmed/22890139", "http://www.ncbi.nlm.nih.gov/pubmed/22297252", "http://www.ncbi.nlm.nih.gov/pubmed/17373275", "http://www.ncbi.nlm.nih.gov/pubmed/15692071", "http://www.ncbi.nlm.nih.gov/pubmed/22584997"], "ideal_answer": ["Mutations in the SLC40A1 gene, which encodes the cellular iron exporter ferroportin, are associated with the autosomal dominant hemochromatosis type 4 or Ferroportin disease. The patients characteristically have hyperferritinemia and iron overload."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:4", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", "http://www.uniprot.org/uniprot/S40A1_DANRE", "http://www.uniprot.org/uniprot/S40A1_RAT", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", "http://www.uniprot.org/uniprot/S40A1_HUMAN"], "type": "summary", "id": "58bd6c5802b8c60953000012", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "Ferroportin disease is a rare type of autosomal dominantly inherited hemochromatosis caused with mutations in the ferroportin gene (SLC40A1). The patients characteristically have hyperferritinemia but normal transferin saturations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25744502", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Novel gain of function mutation in the SLC40A1 gene associated with hereditary haemochromatosis type 4.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26059880", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 294, "text": "Here we report the case of a 69-year-old Chinese Han woman who presented with liver cirrhosis, diabetes mellitus, skin hyperpigmentation, hyperferritinaemia and high transferrin saturation. Subsequent genetic analyses identified a novel heterozygous mutation (p.Cys326Phe) in the SLC40A1 gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26059880", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "A novel mutation in the SLC40A1 gene associated with reduced iron export in vitro.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24644245", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 302, "text": "Ferroportin disease is an inherited disorder of iron metabolism and is caused by mutations in the ferroportin gene (SLC40A1). We present a patient with hyperferritinemia, iron overload in the liver with reticuloendothelial distribution and also in the spleen, and under treatment with erythropheresis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24644245", "endSection": "abstract"}, {"offsetInBeginSection": 825, "offsetInEndSection": 1037, "text": "These findings and the iron overload phenotype of the patient suggest that the novel mutation c.386T>C (p.L129P) in the SLC40A1 gene has incomplete penetrance and causes the classical form of ferroportin disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24644245", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 353, "text": "Ferroportin (FPN) mediates iron export from cells and this function is modulated by serum hepcidin. Mutations in the FPN gene (SLC40A1) lead to autosomal dominant iron overload diseases related either to loss or to gain of function, and usually characterized by normal or low transferrin saturation versus elevated transferrin saturation, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23943237", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 501, "text": "Hemochromatosis type 4 is a rare form of primary iron overload transmitted as an autosomal dominant trait caused by mutations in the gene encoding the iron transport protein ferroportin 1 (SLC40A1). SLC40A1 mutations fall into two functional categories (loss- versus gain-of-function) underlying two distinct clinical entities (hemochromatosis type 4A versus type 4B). However, the vast majority of SLC40A1 mutations are rare missense variations, with only a few showing strong evidence of causality. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24714983", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 274, "text": "p.C282Y mutation and rare variants in the HFE gene have been associated with hereditary hemochromatosis (HH). HH is also caused by mutations in other genes, such as the hemojuvelin (HJV), hepcidin (HAMP), transferrin receptor 2 (TFR2) and ferroportin (SLC40A1). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21411349", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Two novel mutations in the SLC40A1 and HFE genes implicated in iron overload in a Spanish man.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21175851", "endSection": "title"}, {"offsetInBeginSection": 19, "offsetInEndSection": 239, "text": "Ferroportin disease is characterized by iron overload. It has an autosomal-dominant pattern of inheritance and has been associated with mutations in the SLC40A1 gene, which encodes the cellular iron exporter ferroportin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21199650", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 335, "text": "Mutations in the SLC40A1 gene, which encodes ferroportin, are associated with autosomal dominant hemochromatosis. Ferroportin is inhibited directly by hepcidin, a key iron-regulatory peptide, and functional consequences of SLC40A1 mutations account for observed phenotypic differences in patients with ferroportin disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19937651", "endSection": "abstract"}, {"offsetInBeginSection": 489, "offsetInEndSection": 618, "text": "The entire coding sequence of the SLC40A1 gene was sequenced in a pedigree, presenting with autosomal dominant hyperferritinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19937651", "endSection": "abstract"}, {"offsetInBeginSection": 940, "offsetInEndSection": 1097, "text": "A novel SLC40A1 mutation p.R489K segregated with iron overload in a family with clinical and histopathological signs of macrophage-type ferroportin disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19937651", "endSection": "abstract"}, {"offsetInBeginSection": 1405, "offsetInEndSection": 1881, "text": "We report a novel pathological SLC40A1 variant associated with abnormal cell surface expression of ferroportin due to intracellular retention of the mutant protein. These findings predict macrophage-type ferroportin disease, the phenotype observed in this kindred. Study of the molecular cell biology of ferroportin and its mutants is key to understanding the pathogenesis of this increasingly recognized form of hemochromatosis, which responds poorly to conventional therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19937651", "endSection": "abstract"}, {"offsetInBeginSection": 19, "offsetInEndSection": 386, "text": "Classical ferroportin disease is characterized by hyperferritinemia, normal transferrin saturation, and iron overload in macrophages. A non-classical form is characterized by additional hepatocellular iron deposits and a high transferrin saturation. Both forms demonstrate autosomal dominant transmission and are associated with ferroportin gene (SLC40A1) mutations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20691492", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 400, "text": "Mutations in the SLC40A1 gene result in a dominant genetic disorder [ferroportin disease; hereditary hemochromatosis type (HH) IV], characterized by iron overload with two different clinical manifestations, normal transferrin saturation with macrophage iron accumulation (the most prevalent type) or high transferrin saturation with hepatocyte iron accumulation (classical hemochromatosis phenotype).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17997113", "endSection": "abstract"}, {"offsetInBeginSection": 108, "offsetInEndSection": 316, "text": "SLC40A1 gene mutations are associated with an autosomal type of genetic iron overload described as haemochromatosis type 4, or HFE4 (Online Mendelian Inheritance in Man number 606069), or ferroportin disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351644", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Ferroportin disease is an inherited disorder of iron metabolism and is caused by mutations in the ferroportin gene (SLC40A1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24644245", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Mutations in the SLC40A1 gene, which encodes ferroportin, are associated with autosomal dominant hemochromatosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19937651", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16258219", "endSection": "title"}, {"offsetInBeginSection": 819, "offsetInEndSection": 1031, "text": "These findings and the iron overload phenotype of the patient suggest that the novel mutation c.386T>C (p.L129P) in the SLC40A1 gene has incomplete penetrance and causes the classical form of ferroportin disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24644245", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "UNLABELLED: Mutations in the SLC40A1 gene, which encodes ferroportin, are associated with autosomal dominant hemochromatosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19937651", "endSection": "abstract"}, {"offsetInBeginSection": 952, "offsetInEndSection": 1374, "text": "This deletion affects not only COL3A1 but also 21 other known genes (GULP1, DIRC1, COL5A2, WDR75, SLC40A1, ASNSD1, ANKAR, OSGEPL1, ORMDL1, LOC100129592, PMS1, MSTN, C2orf88, HIBCH, INPP1, MFSD6, TMEM194B, NAB1, GLS, STAT1, and STAT4), mutations in three of which (COL5A2, SLC40A1, and MSTN) have also been associated with an autosomal dominant disorder (EDS classical type, hemochromatosis type 4, and muscle hypertrophy).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20648054", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17997113", "endSection": "title"}, {"offsetInBeginSection": 384, "offsetInEndSection": 618, "text": "The iron overload was similar to that observed in HFE hemochromatosis, and the patient was double heterozygous for two novel mutations, c.-20G>A and c.718A>G (p.K240E), in the HFE and ferroportin (FPN1 or SLC40A1) genes, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21175851", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 316, "text": "SLC40A1 gene mutations are associated with an autosomal type of genetic iron overload described as haemochromatosis type 4, or HFE4 (Online Mendelian Inheritance in Man number 606069), or ferroportin disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351644", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16258219", "endSection": "title"}, {"offsetInBeginSection": 109, "offsetInEndSection": 318, "text": "SLC40A1 gene mutations are associated with an autosomal type of genetic iron overload described as haemochromatosis type 4, or HFE4 (Online Mendelian Inheritance in Man number 606069), or ferroportin disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351644", "endSection": "abstract"}, {"offsetInBeginSection": 1236, "offsetInEndSection": 1412, "text": "The proposed procedure would facilitate the wide-range molecular analysis of the SLC40A1 gene, contributing to better understanding the pathogenesis of the ferroportin disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17997113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 401, "text": "Mutations in the SLC40A1 gene result in a dominant genetic disorder [ferroportin disease; hereditary hemochromatosis type (HH) IV], characterized by iron overload with two different clinical manifestations, normal transferrin saturation with macrophage iron accumulation (the most prevalent type) or high transferrin saturation with hepatocyte iron accumulation (classical hemochromatosis phenotype). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17997113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Type IV hemochromatosis is associated with dominant mutations in the SLC40A1 gene encoding ferroportin (FPN).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15692071", "endSection": "abstract"}, {"offsetInBeginSection": 55, "offsetInEndSection": 220, "text": "It has an autosomal-dominant pattern of inheritance and has been associated with mutations in the SLC40A1 gene, which encodes the cellular iron exporter ferroportin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21199650", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 317, "text": "SLC40A1 gene mutations are associated with an autosomal type of genetic iron overload described as haemochromatosis type 4, or HFE4 (Online Mendelian Inheritance in Man number 606069), or ferroportin disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351644", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 373, "text": "It includes hereditary hemochromatosis related to mutations of other genes, ferroportin disease (also known as hemochromatosis type 4), and entities associated with specific clinical manifestations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17540536", "endSection": "abstract"}, {"offsetInBeginSection": 1107, "offsetInEndSection": 1229, "text": "Ferroportin disease is a special dominantly inherited clinical form of iron overload due to mutations of the SLC40A1 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17540536", "endSection": "abstract"}, {"offsetInBeginSection": 1094, "offsetInEndSection": 1246, "text": "Ferroportin disease represents a protean genetic condition in which the different SLC40A1 mutations appear to be responsible for phenotypic variability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351644", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Novel gain of function mutation in the SLC40A1 gene associated with hereditary haemochromatosis type 4.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26059880", "endSection": "title"}, {"offsetInBeginSection": 825, "offsetInEndSection": 1038, "text": "These findings and the iron overload phenotype of the patient suggest that the novel mutation c.386T>C (p.L129P) in the SLC40A1 gene has incomplete penetrance and causes the classical form of ferroportin disease..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24644245", "endSection": "abstract"}]}, {"body": "Could divalent metal transporter 1 deficiency lead to anemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11090085", "http://www.ncbi.nlm.nih.gov/pubmed/25562168", "http://www.ncbi.nlm.nih.gov/pubmed/10751401", "http://www.ncbi.nlm.nih.gov/pubmed/15024413", "http://www.ncbi.nlm.nih.gov/pubmed/20336479", "http://www.ncbi.nlm.nih.gov/pubmed/15736955", "http://www.ncbi.nlm.nih.gov/pubmed/22580996", "http://www.ncbi.nlm.nih.gov/pubmed/27331785", "http://www.ncbi.nlm.nih.gov/pubmed/26294671", "http://www.ncbi.nlm.nih.gov/pubmed/16085548", "http://www.ncbi.nlm.nih.gov/pubmed/26047847"], "ideal_answer": ["Yes, divalent metal transporter 1 (DMT1) deficiency could result in anemia, as DMT1 is a major iron transporter required for iron absorption and erythropoiesis. DMT1 deficiency impairs erythroid differentiation and induces apoptosis of erythroid cells."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:11758", "http://amigo.geneontology.org/amigo/term/GO:0070838", "http://www.disease-ontology.org/api/metadata/DOID:2355", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018798", "http://www.disease-ontology.org/api/metadata/DOID:13121", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000740"], "type": "yesno", "id": "58bd672d02b8c60953000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "The divalent metal transporter 1 (DMT1) is a major iron transporter required for iron absorption and erythropoiesis. Loss of DMT1 function results in microcytic anemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27331785", "endSection": "abstract"}, {"offsetInBeginSection": 621, "offsetInEndSection": 891, "text": "Dysfunction of human DMT1 is associated with several pathologies such as iron deficiency anemia hemochromatosis, Parkinson's disease and Alzheimer's disease, as well as colorectal cancer and esophageal adenocarcinoma, making DMT1 an attractive target for drug discovery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26047847", "endSection": "abstract"}, {"offsetInBeginSection": 17, "offsetInEndSection": 233, "text": "Deficiency of the divalent metal transporter 1 (DMT1) leads to hypochromic microcytic anemia. We have previously shown that DMT1 deficiency impairs erythroid differentiation and induces apoptosis of erythroid cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25562168", "endSection": "abstract"}, {"offsetInBeginSection": 1315, "offsetInEndSection": 1516, "text": "We propose that DMT1 deficiency negatively affects metabolism and life span of mature erythrocytes; two other aspects of defective erythropoiesis which contribute to the pathophysiology of the disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25562168", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 217, "text": "Hypochromic microcytic anemia associated with ineffective erythropoiesis caused by recessive mutations in divalent metal transporter 1 (DMT1) can be improved with high-dose erythropoietin supplementation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22580996", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 363, "text": "Belgrade rats exhibit microcytic, hypochromic anemia and systemic iron deficiency due to a glycine-to-arginine mutation at residue 185 in a metal ion transporter of a divalent metal transporter/divalent cation transporter/solute carrier 11 group A member 2 or 3 (DMT1/DCT1/SLC11A2), a member of the natural-resistance-associated macrophage protein (Nramp) family.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15736955", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Deficiency of the divalent metal transporter 1 (DMT1) leads to hypochromic microcytic anemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25562168", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 362, "text": "Belgrade rats exhibit microcytic, hypochromic anemia and systemic iron deficiency due to a glycine-to-arginine mutation at residue 185 in a metal ion transporter of a divalent metal transporter/divalent cation transporter/solute carrier 11 group A member 2 or 3 (DMT1/DCT1/SLC11A2), a member of the natural-resistance-associated macrophage protein (Nramp) family", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15736955", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "BACKGROUND/AIMS: Deficiency of the divalent metal transporter 1 (DMT1) leads to hypochromic microcytic anemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25562168", "endSection": "abstract"}, {"offsetInBeginSection": 466, "offsetInEndSection": 652, "text": "Microcytic anemia (mk/mk) mice defective in DMT1 and wild-type mice were exposed to either bleomycin or saline via intratracheal instillation and the resultant lung injury was compared. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20336479", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Deficiency of the divalent metal transporter 1 (DMT1) leads to hypochromic microcytic anemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25562168", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "The divalent metal transporter 1 (DMT1) is a major iron transporter required for iron absorption and erythropoiesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27331785", "endSection": "abstract"}, {"offsetInBeginSection": 702, "offsetInEndSection": 819, "text": "This mutation severely impairs the iron transport capability of DMT1, leading to systemic iron deficiency and anemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15024413", "endSection": "abstract"}]}, {"body": "Does the hERG gene code for a protein which is part of a sodium channel?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26363003", "http://www.ncbi.nlm.nih.gov/pubmed/24475291", "http://www.ncbi.nlm.nih.gov/pubmed/9272507", "http://www.ncbi.nlm.nih.gov/pubmed/14975928", "http://www.ncbi.nlm.nih.gov/pubmed/25498859", "http://www.ncbi.nlm.nih.gov/pubmed/8521555", "http://www.ncbi.nlm.nih.gov/pubmed/25247487", "http://www.ncbi.nlm.nih.gov/pubmed/17882949", "http://www.ncbi.nlm.nih.gov/pubmed/16244363", "http://www.ncbi.nlm.nih.gov/pubmed/9556090", "http://www.ncbi.nlm.nih.gov/pubmed/19139152", "http://www.ncbi.nlm.nih.gov/pubmed/25218469", "http://www.ncbi.nlm.nih.gov/pubmed/24154981", "http://www.ncbi.nlm.nih.gov/pubmed/8873679", "http://www.ncbi.nlm.nih.gov/pubmed/10613047", "http://www.ncbi.nlm.nih.gov/pubmed/23103450", "http://www.ncbi.nlm.nih.gov/pubmed/12142119", "http://www.ncbi.nlm.nih.gov/pubmed/8995352", "http://www.ncbi.nlm.nih.gov/pubmed/24642409", "http://www.ncbi.nlm.nih.gov/pubmed/16472284", "http://www.ncbi.nlm.nih.gov/pubmed/16967046", "http://www.ncbi.nlm.nih.gov/pubmed/12063277", "http://www.ncbi.nlm.nih.gov/pubmed/17311278", "http://www.ncbi.nlm.nih.gov/pubmed/10816797", "http://www.ncbi.nlm.nih.gov/pubmed/26775140", "http://www.ncbi.nlm.nih.gov/pubmed/9272155", "http://www.ncbi.nlm.nih.gov/pubmed/26659724", "http://www.ncbi.nlm.nih.gov/pubmed/26519040", "http://www.ncbi.nlm.nih.gov/pubmed/8587608", "http://www.ncbi.nlm.nih.gov/pubmed/23792956", "http://www.ncbi.nlm.nih.gov/pubmed/18250496", "http://www.ncbi.nlm.nih.gov/pubmed/10531299", "http://www.ncbi.nlm.nih.gov/pubmed/9570196", "http://www.ncbi.nlm.nih.gov/pubmed/18617000", "http://www.ncbi.nlm.nih.gov/pubmed/24045971", "http://www.ncbi.nlm.nih.gov/pubmed/10483966"], "ideal_answer": ["The hERG AKA Human ether-a-go-go-related gene coded for a protein subunit of a potassium channel that conducts delayed rectifier K(+) current"], "type": "yesno", "id": "58bdc76102b8c60953000013", "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 115, "text": " The human ether-\u00e0-go-go-related gene (hERG 1a) potassium channel is critical for cardiac repolarization", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775140", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Human ether-a-go-go-related gene (hERG) channels conduct delayed rectifier K(+) current. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26659724", "endSection": "abstract"}, {"offsetInBeginSection": 939, "offsetInEndSection": 1187, "text": "The KvLQT1 and minK genes code the slowly activating, delayed rectifier (Iks) potassium channel, the HERG gene code the rapidly activating, delayed rectifier (Ikr) potassium channel of the heart, while the SCN5A gene codes a cardiac sodium channel.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10613047", "endSection": "abstract"}, {"offsetInBeginSection": 432, "offsetInEndSection": 705, "text": "The molecular basis of inherited disorders caused by a mutation in either the gene coding for a particular potassium channel called HERG-or another gene, SCN5A, which codes for the sodium channel and disruption of which results in a loss of inactivation of the Na+ current.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250496", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "The aim of this study was to test whether a recently reported polymorphism in the HERG gene coding for the rapidly activating delayed rectifier K+ channel has influence on myocardial repolarization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12142119", "endSection": "abstract"}, {"offsetInBeginSection": 1187, "offsetInEndSection": 1426, "text": "Mutations in KvLQT1, minK and HERG genes affects repolarising, rectifier potassium currents, while SCN5A mutations cause delayed inactivation and reopening of the cardiac sodium channel, which initiates the depolarisation of cardiac cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10613047", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "A human genetic defect associated with 'long Q-T syndrome', an abnormality of cardiac rhythm involving the repolarization of the action potential, was recently found to lie in the HERG gene, which codes for a potassium channel.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8587608", "endSection": "abstract"}, {"offsetInBeginSection": 1433, "offsetInEndSection": 1612, "text": "Therefore, matrine and oxymatrine may have the potential to cure LQT2 as a potassium channel activator by promoting hERG channel activation and increasing hERG channel expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103450", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "The human delta1261 mutation of the HERG potassium channel results in a truncated protein that contains a subunit interaction domain and decreases the channel expression.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8995352", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "HERG (human eag-related gene) encodes an inward-rectifier potassium channel formed by the assembly of four subunits.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8995352", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "The human ether-?-go-go-related gene (HERG) encodes the pore-forming subunit of the rapidly activating delayed rectifier potassium channel in the heart.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12063277", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "The human ether-a-go-go-related gene (hERG) encodes the rapidly activating, delayed rectifier potassium channel (IKr) important for cardiac repolarization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103450", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Role of glycosylation in cell surface expression and stability of HERG potassium channels.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12063277", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "The human ERG protein (HERG or Kv 11.1) encoded by the human ether-a-go-go-related gene (herg) is the pore-forming subunit of the cardiac delayed rectifier potassium current (IKr) responsible for action potential (AP) repolarization", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24154981", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Human ether-a-go-go related gene (herg) encoding HERG K(+) channel has been demonstrated in many previous studies with its association to cell cycle progression and growth in tumor cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25247487", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "A human genetic defect associated with 'long Q-T syndrome', an abnormality of cardiac rhythm involving the repolarization of the action potential, was recently found to lie in the HERG gene, which codes for a potassium channel. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8587608", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16967046", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "OBJECTIVES: The aim of this study was to test whether a recently reported polymorphism in the HERG gene coding for the rapidly activating delayed rectifier K+ channel has influence on myocardial repolarization. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12142119", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 477, "text": "The aim of this study was to test whether the K897T polymorphism of the KCNH2 (HERG) gene coding for the rapidly activating delayed rectifier K+ channel influences cardiac repolarization assessed by principal component analysis (PCA) of T-wave morphology. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16472284", "endSection": "abstract"}, {"offsetInBeginSection": 944, "offsetInEndSection": 1192, "text": "The KvLQT1 and minK genes code the slowly activating, delayed rectifier (Iks) potassium channel, the HERG gene code the rapidly activating, delayed rectifier (Ikr) potassium channel of the heart, while the SCN5A gene codes a cardiac sodium channel.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10613047", "endSection": "abstract"}, {"offsetInBeginSection": 953, "offsetInEndSection": 1264, "text": "All code for subunits of sodium or potassium channels: two a subunits of the potassium channels (QVLQT1 for LQT1, HERG for LQT2), the a subunit of the sodium channel INa (SCN5A for LQT3), and two regulatory subunits of potassium channels (KCNE1 for LQT5 regulating the KvLQT1 channel and MiRP1 regulating HERG).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10816797", "endSection": "abstract"}, {"offsetInBeginSection": 445, "offsetInEndSection": 563, "text": "The corresponding genes code for potassium channels KVLQT1 (LQT1) and HERG (LQT2) and the sodium channel SCN5A (LQT3).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9272155", "endSection": "abstract"}, {"offsetInBeginSection": 436, "offsetInEndSection": 709, "text": "The molecular basis of inherited disorders caused by a mutation in either the gene coding for a particular potassium channel called HERG-or another gene, SCN5A, which codes for the sodium channel and disruption of which results in a loss of inactivation of the Na+ current.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250496", "endSection": "abstract"}, {"offsetInBeginSection": 1276, "offsetInEndSection": 1449, "text": "There may also be correlation between the strength of binding of the medicinal substance to the potassium channel coded by the HERG gene and prolongation of the QT interval.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250496", "endSection": "abstract"}, {"offsetInBeginSection": 416, "offsetInEndSection": 723, "text": "We demonstrate that the mRNA 3'UTR of ppk29 affects neuronal firing rates and associated heat-induced seizures by acting as a natural antisense transcript (NAT) that regulates the neuronal mRNA levels of seizure (sei), the Drosophila homolog of the human Ether-\u00e0-go-go Related Gene (hERG) potassium channel.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24642409", "endSection": "abstract"}, {"offsetInBeginSection": 1193, "offsetInEndSection": 1432, "text": "Mutations in KvLQT1, minK and HERG genes affects repolarising, rectifier potassium currents, while SCN5A mutations cause delayed inactivation and reopening of the cardiac sodium channel, which initiates the depolarisation of cardiac cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10613047", "endSection": "abstract"}, {"offsetInBeginSection": 710, "offsetInEndSection": 903, "text": "Among the congenital forms, particularly interest is focused on the potassium channel coded by the HERG gene located on chromosome 7 and with a key role in the normal electric cardiac activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250496", "endSection": "abstract"}, {"offsetInBeginSection": 147, "offsetInEndSection": 531, "text": "By employing heterologous expression and making comparisons to cells expressing wild-type human-ether-a-go-go-related protein (HERG), a potassium channel that contributes to I(Kr) current in ventricular cardiomyocytes, we demonstrate activation of an elevated endoplasmic reticulum (ER) stress response by the mutant I593R HERG potassium channel implicated in long QT syndrome type 2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16244363", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10531299", "endSection": "title"}, {"offsetInBeginSection": 493, "offsetInEndSection": 603, "text": "Mutations in the human ether-\u00e0-go-go-related gene (HERG), which encodes a delayed-rectifier potassium channel,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8873679", "endSection": "abstract"}, {"offsetInBeginSection": 372, "offsetInEndSection": 413, "text": "s HERG and KvLQT1 potassium channel genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9272507", "endSection": "abstract"}, {"offsetInBeginSection": 722, "offsetInEndSection": 771, "text": "HERG encodes the cardiac I(Kr) potassium channel.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9556090", "endSection": "abstract"}, {"offsetInBeginSection": 160, "offsetInEndSection": 239, "text": "block of the cardiac potassium channel human ether-\u00e0-go-go-related gene (hERG) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19139152", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "The human ether-a-go-go-related gene (hERG) encodes the pore-forming \u03b1-subunit of the rapidly activating delayed rectifier K(+) channel in the heart, which plays a critical role in cardiac action potential repolarization. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23792956", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Effects of donepezil on hERG potassium channels.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25498859", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "Human ether-a-go-go related-gene K\u207a channels (hERG) participate in the regulation of tumor cell proliferation and apoptosis. HERG channel activity is up-regulated by growth factors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24475291", "endSection": "abstract"}, {"offsetInBeginSection": 21, "offsetInEndSection": 45, "text": " hERG potassium channels", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24045971", "endSection": "title"}, {"offsetInBeginSection": 161, "offsetInEndSection": 185, "text": "HERG, a K+ channel gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8521555", "endSection": "abstract"}]}, {"body": "Is lenvatinib effective for renal cell carcinoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27467136", "http://www.ncbi.nlm.nih.gov/pubmed/27267515", "http://www.ncbi.nlm.nih.gov/pubmed/24190702", "http://www.ncbi.nlm.nih.gov/pubmed/27690664", "http://www.ncbi.nlm.nih.gov/pubmed/27047959", "http://www.ncbi.nlm.nih.gov/pubmed/24387233", "http://www.ncbi.nlm.nih.gov/pubmed/26482279", "http://www.ncbi.nlm.nih.gov/pubmed/27339111", "http://www.ncbi.nlm.nih.gov/pubmed/27621699"], "ideal_answer": ["Yes, combination of lenvatinib and everolimus is approved to treat advanced or metastatic renal cell carcinoma."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002292", "http://www.disease-ontology.org/api/metadata/DOID:4450", "http://www.disease-ontology.org/api/metadata/DOID:4451"], "type": "yesno", "id": "589a245778275d0c4a000024", "snippets": [{"offsetInBeginSection": 221, "offsetInEndSection": 406, "text": "However, the combination of lenvatinib, a multitargeted agent that inhibits VEGF as well as FGF receptors, and everolimus demonstrated promising results in a randomized phase II trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27047959", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "The FDA has approved the combination of lenvatinib and everolimus to treat advanced or metastatic renal cell carcinoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267515", "endSection": "abstract"}, {"offsetInBeginSection": 1386, "offsetInEndSection": 1642, "text": "Moreover, a recent Phase II study demonstrated a significant benefit for the second-line combination treatment with everolimus plus lenvatinib (a novel TKI) in terms of progression-free survival and overall survival compared to the single-agent everolimus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27621699", "endSection": "abstract"}, {"offsetInBeginSection": 769, "offsetInEndSection": 1030, "text": "We then discuss two recently approved growth factor receptor antagonists i.e. cabozantinib and lenvatinib, and a recently approved checkpoint inhibitor, nivolumab, and issues pertaining to drug development, and future directions in treatment of metastatic RCC. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690664", "endSection": "abstract"}, {"offsetInBeginSection": 2654, "offsetInEndSection": 2878, "text": "INTERPRETATION: Lenvatinib plus everolimus and lenvatinib alone resulted in a progression-free survival benefit for patients with metastatic renal cell carcinoma who have progressed after one previous VEGF-targeted therapy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26482279", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27339111", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27339111", "endSection": "title"}]}, {"body": "Which proteins form part of the NRD complex in S. cerevisiae?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9804427", "http://www.ncbi.nlm.nih.gov/pubmed/25877920", "http://www.ncbi.nlm.nih.gov/pubmed/21211720", "http://www.ncbi.nlm.nih.gov/pubmed/10545197"], "ideal_answer": ["The purification of an ATR complex allowed identification of chromodomain-helicase-DNA-binding protein 4 (CHD4) as an ATR-associated protein by tandem mass spectrometric sequencing. CHD4 (also called Mi-2beta) is a component of a histone-deacetylase-2 (HDAC2)-containing complex, the nucleosome remodeling and deacetylating (NRD) complex. Endogenous ATR, CHD4, and HDAC2 are shown to coimmunoprecipitate, and ATR and HDAC2 coelute through two biochemical purification steps. Other members of the NRD complex, HDAC1, MTA1, and MTA2, are also detectable in ATR immunoprecipitates. Sen1 of S. cerevisiae is a known component of the NRD complex implicated in transcription termination of nonpolyadenylated as well as some polyadenylated RNA polymerase II transcripts.  We now show that Pcf11, a component of the cleavage and polyadenylation complex (CPAC), is also generally required for NRD-dependent transcription termination through the action of its C-terminal domain (CTD)-interacting domain (CID)."], "type": "list", "id": "58adb9919ef3c34033000004", "snippets": [{"offsetInBeginSection": 1007, "offsetInEndSection": 1314, "text": "This activity is derived from the CHD3 and CHD4 proteins which contain helicase/ATPase domains found in SWI2-related chromatin remodelling factors, and facilitates the deacetylation of oligonucleosomal histones in vitro. We refer to this complex as the nucleosome remodelling and deacetylating (NRD) complex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9804427", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Molecular association between ATR and two components of the nucleosome remodeling and deacetylating complex, HDAC2 and CHD4", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10545197", "endSection": "title"}, {"offsetInBeginSection": 265, "offsetInEndSection": 602, "text": "The purification of an ATR complex allowed identification of chromodomain-helicase-DNA-binding protein 4 (CHD4) as an ATR-associated protein by tandem mass spectrometric sequencing. CHD4 (also called Mi-2beta) is a component of a histone-deacetylase-2 (HDAC2)-containing complex, the nucleosome remodeling and deacetylating (NRD) complex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10545197", "endSection": "abstract"}, {"offsetInBeginSection": 604, "offsetInEndSection": 843, "text": "Endogenous ATR, CHD4, and HDAC2 are shown to coimmunoprecipitate, and ATR and HDAC2 coelute through two biochemical purification steps. Other members of the NRD complex, HDAC1, MTA1, and MTA2, are also detectable in ATR immunoprecipitates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10545197", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Sen1 of S. cerevisiae is a known component of the NRD complex implicated in transcription termination of nonpolyadenylated as well as some polyadenylated RNA polymerase II transcripts. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211720", "endSection": "abstract"}, {"offsetInBeginSection": 167, "offsetInEndSection": 401, "text": "We now show that Pcf11, a component of the cleavage and polyadenylation complex (CPAC), is also generally required for NRD-dependent transcription termination through the action of its C-terminal domain (CTD)-interacting domain (CID).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25877920", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "In Saccharomyces cerevisiae, short noncoding RNA (ncRNA) generated by RNA polymerase II (Pol II) are terminated by the NRD complex consisting of Nrd1, Nab3, and Sen1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25877920", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "Sen1 of S. cerevisiae is a known component of the NRD complex implicated in transcription termination of nonpolyadenylated as well as some polyadenylated RNA polymerase II transcripts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211720", "endSection": "abstract"}, {"offsetInBeginSection": 445, "offsetInEndSection": 601, "text": "CHD4 (also called Mi-2beta) is a component of a histone-deacetylase-2 (HDAC2)-containing complex, the nucleosome remodeling and deacetylating (NRD) complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10545197", "endSection": "abstract"}, {"offsetInBeginSection": 736, "offsetInEndSection": 839, "text": "Other members of the NRD complex, HDAC1, MTA1, and MTA2, are also detectable in ATR immunoprecipitates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10545197", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "In Saccharomyces cerevisiae, short noncoding RNA (ncRNA) generated by RNA polymerase II (Pol II) are terminated by the NRD complex consisting of Nrd1, Nab3, and Sen1. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25877920", "endSection": "abstract"}]}, {"body": "Which R / bioconductor package is used for performing SNP enrichment analysis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26685307"], "ideal_answer": ["traseR is an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs in LD."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000704"], "type": "factoid", "id": "587e3129c32c812009000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26685307", "endSection": "title"}, {"offsetInBeginSection": 668, "offsetInEndSection": 916, "text": "Here, we present traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs in LD", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26685307", "endSection": "abstract"}, {"offsetInBeginSection": 674, "offsetInEndSection": 916, "text": "we present traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs in LD", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26685307", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 901, "text": "Here, we present traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs in LD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26685307", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26685307", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "traseR: an R package for performing trait-associated SNP enrichment analysis in genomic intervals.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26685307", "endSection": "title"}, {"offsetInBeginSection": 656, "offsetInEndSection": 905, "text": "Here, we present traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs in LD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26685307", "endSection": "abstract"}, {"offsetInBeginSection": 906, "offsetInEndSection": 1107, "text": "The traseR R package preloaded with up-to-date collection of trait-associated SNPs are freely available in Bioconductor zhaohui.qin@emory.edu Supplementary data are available at Bioinformatics online..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26685307", "endSection": "abstract"}]}, {"body": "Does HuR bind to the untranslated regions (UTRs) of mRNAs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27941336", "http://www.ncbi.nlm.nih.gov/pubmed/23389914", "http://www.ncbi.nlm.nih.gov/pubmed/25841336", "http://www.ncbi.nlm.nih.gov/pubmed/25265983", "http://www.ncbi.nlm.nih.gov/pubmed/23312841", "http://www.ncbi.nlm.nih.gov/pubmed/24687854"], "ideal_answer": ["Yes, the RNA-binding protein HuR binds at 3' untranslated regions (UTRs) of target transcripts, thereby protecting them against degradation."], "type": "yesno", "id": "58ce69cd1f5fb2b734000003", "snippets": [{"offsetInBeginSection": 115, "offsetInEndSection": 347, "text": "HuR is also overexpressed during tumourigenesis and is abnormally present within the cytoplasm, where it binds to AU-rich elements in the 3'UTRs of target mRNA and post-transcriptionally regulates the expression of its target genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27941336", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 220, "text": "Human antigen R (HuR) is a ubiquitous 32 kDa protein comprising three RNA Recognition Motifs (RRMs), whose main function is to bind Adenylate and uridylate Rich Elements (AREs) in 3' UnTranslated Regions (UTRs) of mRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25841336", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 147, "text": "Human antigen R (HuR) is a ubiquitously expressed RNA-binding protein that modulates gene expression at the post-transcriptional level.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25265983", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "The RNA-binding protein HuR binds at 3' untranslated regions (UTRs) of target transcripts, thereby protecting them against degradation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24687854", "endSection": "abstract"}, {"offsetInBeginSection": 619, "offsetInEndSection": 812, "text": "ELAV/Hu proteins bind to AU-rich elements (ARE) in mRNAs and regulate their stability from splicing to translation, and the ubiquitous HuR protein has been implicated in cancerous cell growth. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23312841", "endSection": "abstract"}, {"offsetInBeginSection": 240, "offsetInEndSection": 381, "text": "This is achieved by altered expression of the proteins TTP and HuR, which bind 3' untranslated region (UTR) elements in cancer-related genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23389914", "endSection": "abstract"}]}, {"body": "Describe Exploding head syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24703829", "http://www.ncbi.nlm.nih.gov/pubmed/24907167", "http://www.ncbi.nlm.nih.gov/pubmed/20112796", "http://www.ncbi.nlm.nih.gov/pubmed/1896728", "http://www.ncbi.nlm.nih.gov/pubmed/20726288", "http://www.ncbi.nlm.nih.gov/pubmed/25773787", "http://www.ncbi.nlm.nih.gov/pubmed/11309216", "http://www.ncbi.nlm.nih.gov/pubmed/2030791", "http://www.ncbi.nlm.nih.gov/pubmed/2769286", "http://www.ncbi.nlm.nih.gov/pubmed/23467433"], "ideal_answer": ["Exploding head syndrome is characterized by the perception of abrupt, loud noises when going to sleep or waking up."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "http://www.disease-ontology.org/api/metadata/DOID:225"], "type": "summary", "id": "588f9756ed9bbee70d000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Exploding head syndrome is characterized by the perception of loud noises during sleep-wake or wake-sleep transitions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Exploding head syndrome is characterized by the perception of abrupt, loud noises when going to sleep or waking up.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24703829", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "BACKGROUND: Exploding head syndrome (EHS) is characterized by attacks of a sudden noise or explosive feeling experienced in the head occurring during the transition from wake to sleep or from sleep to wake.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24907167", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "INTRODUCTION: Exploding head syndrome (EHS) is a rare parasomnia in which affected individuals awaken from sleep with the sensation of a loud bang.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23467433", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "Exploding head syndrome (EHS) is characterized by attacks of a sudden noise or explosive feeling experienced in the head occurring during the transition from wake to sleep or from sleep to wake.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24907167", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Exploding head syndrome (EHS) attacks are characterized by the sensation of sudden loud banging noises, and are occasionally accompanied by the sensation of a flash light.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20112796", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": "Exploding head syndrome (EHS) is characterized by attacks of a sudden noise or explosive feeling experienced in the head occurring during the transition from wake to sleep or from sleep to wake.We present six new cases extending the clinical experience with the syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24907167", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Exploding head syndrome (EHS) is a rare parasomnia in which affected individuals awaken from sleep with the sensation of a loud bang", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23467433", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Exploding head syndrome (EHS) attacks are characterized by the sensation of sudden loud banging noises, and are occasionally accompanied by the sensation of a flash light. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20112796", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "Exploding head syndrome (EHS) is characterized by attacks of a sudden noise or explosive feeling experienced in the head occurring during the transition from wake to sleep or from sleep to wake.We present six new cases extending the clinical experience with the syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24907167", "endSection": "abstract"}]}, {"body": "Is H4K20 methylation associated with DNA replication?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24049080", "http://www.ncbi.nlm.nih.gov/pubmed/24013172", "http://www.ncbi.nlm.nih.gov/pubmed/23152447", "http://www.ncbi.nlm.nih.gov/pubmed/20735237", "http://www.ncbi.nlm.nih.gov/pubmed/23924899", "http://www.ncbi.nlm.nih.gov/pubmed/23345616", "http://www.ncbi.nlm.nih.gov/pubmed/26598646", "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "http://www.ncbi.nlm.nih.gov/pubmed/27268234", "http://www.ncbi.nlm.nih.gov/pubmed/23754963"], "ideal_answer": ["We employed genetic, cytological, and genomic approaches to better understand the role of PR-Set7 and H4K20 methylation in regulating DNA replication and genome stability in Drosophila cells. Thus, coordinating the status of H4K20 methylation is pivotal for the proper selection of DNA replication origins in higher eukaryotes. The methylation state of lysine 20 on histone H4 (H4K20) has been linked to chromatin compaction, transcription, DNA repair and DNA replication. Histone turnover is often associated with various histone modifications such as H3K56 acetylation (H3K56Ac), H3K36 methylation (H3K36me), and H4K20 methylation (H4K20me). We review the signaling pathways and functions associated with a single residue, H4K20, as a model chromatin and clinically important mark that regulates biological processes ranging from the DNA damage response and DNA replication to gene expression and silencing. <CopyrightInformation>\u00a9 2016 by The American Society for Biochemistry and Molecular Biology, Inc.</C In particular, the methylation states of H3K4, H3K36 and H4K20 have been associated with establishing active, repressed or poised origins depending on the timing and extent of methylation. 5BrC and 5ClC may cause aberrant methylation of cytosine during DNA replication and mimic the endogenous methylation signal associated with gene silencing.", "H4K20 methylation regulates quiescence and chromatin compaction. H4K20 methylation status plays a direct role in recruiting ORC through the binding properties of ORC1 and ORCA/LRWD1. Thus, coordinating the status of H4K20 methylation is pivotal for the proper selection of DNA replication origins in higher eukaryotes.  Intense research during the past few years has revealed histone H4 lysine 20 methylation (H4K20me) as critically important for the biological processes that ensure genome integrity, such as DNA damage repair, DNA replication and chromatin compaction.", "The methylation state of lysine 20 on histone H4 (H4K20) has been linked to chromatin compaction, transcription, DNA repair and DNA replication. Disruption of these H4K20-specific histone methyltransferases leads to genomic instability, demonstrating the important functions of H4K20 methylation in genome maintenance.", "Thus, coordinating the status of H4K20 methylation is pivotal for the proper selection of DNA replication origins in higher eukaryotes. The methylation state of lysine 20 on histone H4 (H4K20) has been linked to chromatin compaction, transcription, DNA repair and DNA replication."], "type": "yesno", "id": "58adbe999ef3c34033000005", "snippets": [{"offsetInBeginSection": 923, "offsetInEndSection": 1178, "text": "It seems likely that continued study of the methylation of H4K20 will yield extremely valuable insights concerning the regulation of histone modifications before and during cell division and the impact of these modifications on subsequent gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735237", "endSection": "abstract"}, {"offsetInBeginSection": 505, "offsetInEndSection": 629, "text": "Aberrant rereplication correlates with decreased levels of H4K20me1 and increased levels of H4K20 trimethylation (H4K20me3).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152447", "endSection": "abstract"}, {"offsetInBeginSection": 980, "offsetInEndSection": 1255, "text": "Consistent with this, H4K20 methylation status plays a direct role in recruiting ORC through the binding properties of ORC1 and ORCA/LRWD1. Thus, coordinating the status of H4K20 methylation is pivotal for the proper selection of DNA replication origins in higher eukaryotes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152447", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "H4K20 methylation regulates quiescence and chromatin compaction.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23924899", "endSection": "title"}, {"offsetInBeginSection": 371, "offsetInEndSection": 580, "text": "Mass spectrometry analysis of histone modifications reveals that H4K20me2 and H4K20me3 increase in quiescence and other histone modifications are present at similar levels in proliferating and quiescent cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23924899", "endSection": "abstract"}, {"offsetInBeginSection": 581, "offsetInEndSection": 726, "text": "Analysis of cells in S, G2/M, and G1 phases shows that H4K20me1 increases after S phase and is converted to H4K20me2 and H4K20me3 in quiescence. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23924899", "endSection": "abstract"}, {"offsetInBeginSection": 898, "offsetInEndSection": 1249, "text": "Overexpression of Suv4-20h1, the enzyme that creates H4K20me2 from H4K20me1, results in G2 arrest, consistent with a role for H4K20me1 in mitosis. The results suggest that the same lysine on H4K20 may, in its different methylation states, facilitate mitotic functions in M phase and promote chromatin compaction and cell cycle exit in quiescent cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23924899", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23345616", "endSection": "title"}, {"offsetInBeginSection": 360, "offsetInEndSection": 611, "text": " Intense research during the past few years has revealed histone H4 lysine 20 methylation (H4K20me) as critically important for the biological processes that ensure genome integrity, such as DNA damage repair, DNA replication and chromatin compaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23345616", "endSection": "abstract"}, {"offsetInBeginSection": 820, "offsetInEndSection": 994, "text": "Disruption of these H4K20-specific histone methyltransferases leads to genomic instability, demonstrating the important functions of H4K20 methylation in genome maintenance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23345616", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Both H4K20 mono-methylation and H3K56 acetylation mark transcription-dependent histone turnover in fission yeast.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27268234", "endSection": "title"}, {"offsetInBeginSection": 121, "offsetInEndSection": 291, "text": "Histone turnover is often associated with various histone modifications such as H3K56 acetylation (H3K56Ac), H3K36 methylation (H3K36me), and H4K20 methylation (H4K20me).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27268234", "endSection": "abstract"}, {"offsetInBeginSection": 974, "offsetInEndSection": 1121, "text": "These results together indicate that H4K20me1 as well as H3K56Ac are bona fide marks for transcription-dependent histone turnover in fission yeast.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27268234", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Methylation of histone H4 lysine 20 by PR-Set7 ensures the integrity of late replicating sequence domains in Drosophila.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "endSection": "title"}, {"offsetInBeginSection": 453, "offsetInEndSection": 636, "text": "However, these studies were limited to only a handful of mammalian origins, and it remains unclear how PR-Set7 and H4K20 methylation impact the replication program on a genomic scale.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "The methylation state of lysine 20 on histone H4 (H4K20) has been linked to chromatin compaction, transcription, DNA repair and DNA replication. Monomethylation of H4K20 (H4K20me1) is mediated by the cell cycle-regulated histone methyltransferase PR-Set7", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "endSection": "abstract"}, {"offsetInBeginSection": 828, "offsetInEndSection": 1066, "text": " We find that deregulation of H4K20 methylation had no impact on origin activation throughout the genome. Instead, depletion of PR-Set7 and loss of H4K20me1 results in the accumulation of DNA damage and an ATR-dependent cell cycle arrest.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "endSection": "abstract"}, {"offsetInBeginSection": 610, "offsetInEndSection": 875, "text": "We review the signaling pathways and functions associated with a single residue, H4K20, as a model chromatin and clinically important mark that regulates biological processes ranging from the DNA damage response and DNA replication to gene expression and silencing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598646", "endSection": "abstract"}, {"offsetInBeginSection": 1113, "offsetInEndSection": 1248, "text": "Thus, coordinating the status of H4K20 methylation is pivotal for the proper selection of DNA replication origins in higher eukaryotes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152447", "endSection": "abstract"}, {"offsetInBeginSection": 633, "offsetInEndSection": 824, "text": "We employed genetic, cytological, and genomic approaches to better understand the role of PR-Set7 and H4K20 methylation in regulating DNA replication and genome stability in Drosophila cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "The methylation state of lysine 20 on histone H4 (H4K20) has been linked to chromatin compaction, transcription, DNA repair and DNA replication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "endSection": "abstract"}, {"offsetInBeginSection": 450, "offsetInEndSection": 633, "text": "However, these studies were limited to only a handful of mammalian origins, and it remains unclear how PR-Set7 and H4K20 methylation impact the replication program on a genomic scale.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "endSection": "abstract"}, {"offsetInBeginSection": 205, "offsetInEndSection": 351, "text": "Methylation of histone H4 lysine-20 has been implicated in DNA repair, transcriptional silencing, genomic stability and regulation of replication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24049080", "endSection": "abstract"}, {"offsetInBeginSection": 1120, "offsetInEndSection": 1254, "text": "Thus, coordinating the status of H4K20 methylation is pivotal for the proper selection of DNA replication origins in higher eukaryotes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152447", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Methylation of histone H3 on lysine 79 associates with a group of replication origins and helps limit DNA replication once per cell cycle", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754963", "endSection": "title"}, {"offsetInBeginSection": 637, "offsetInEndSection": 828, "text": "We employed genetic, cytological, and genomic approaches to better understand the role of PR-Set7 and H4K20 methylation in regulating DNA replication and genome stability in Drosophila cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131378", "endSection": "abstract"}, {"offsetInBeginSection": 610, "offsetInEndSection": 976, "text": "We review the signaling pathways and functions associated with a single residue, H4K20, as a model chromatin and clinically important mark that regulates biological processes ranging from the DNA damage response and DNA replication to gene expression and silencing. <CopyrightInformation>\u00a9 2016 by The American Society for Biochemistry and Molecular Biology, Inc.</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598646", "endSection": "abstract"}, {"offsetInBeginSection": 1120, "offsetInEndSection": 1256, "text": "Thus, coordinating the status of H4K20 methylation is pivotal for the proper selection of DNA replication origins in higher eukaryotes..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23152447", "endSection": "abstract"}, {"offsetInBeginSection": 361, "offsetInEndSection": 611, "text": "Intense research during the past few years has revealed histone H4 lysine 20 methylation (H4K20me) as critically important for the biological processes that ensure genome integrity, such as DNA damage repair, DNA replication and chromatin compaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23345616", "endSection": "abstract"}]}, {"body": "Describe crowned dens syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27818601", "http://www.ncbi.nlm.nih.gov/pubmed/22303531", "http://www.ncbi.nlm.nih.gov/pubmed/23392827", "http://www.ncbi.nlm.nih.gov/pubmed/27902956", "http://www.ncbi.nlm.nih.gov/pubmed/19210868", "http://www.ncbi.nlm.nih.gov/pubmed/20646716", "http://www.ncbi.nlm.nih.gov/pubmed/15497527", "http://www.ncbi.nlm.nih.gov/pubmed/24715874", "http://www.ncbi.nlm.nih.gov/pubmed/22470810", "http://www.ncbi.nlm.nih.gov/pubmed/25196626", "http://www.ncbi.nlm.nih.gov/pubmed/27733419", "http://www.ncbi.nlm.nih.gov/pubmed/19727898", "http://www.ncbi.nlm.nih.gov/pubmed/25910825", "http://www.ncbi.nlm.nih.gov/pubmed/19834710", "http://www.ncbi.nlm.nih.gov/pubmed/24926265", "http://www.ncbi.nlm.nih.gov/pubmed/20960401", "http://www.ncbi.nlm.nih.gov/pubmed/12614858", "http://www.ncbi.nlm.nih.gov/pubmed/21799227", "http://www.ncbi.nlm.nih.gov/pubmed/25243939", "http://www.ncbi.nlm.nih.gov/pubmed/17361376", "http://www.ncbi.nlm.nih.gov/pubmed/19783114", "http://www.ncbi.nlm.nih.gov/pubmed/24703344", "http://www.ncbi.nlm.nih.gov/pubmed/23806762", "http://www.ncbi.nlm.nih.gov/pubmed/10879718", "http://www.ncbi.nlm.nih.gov/pubmed/20051747", "http://www.ncbi.nlm.nih.gov/pubmed/26370870", "http://www.ncbi.nlm.nih.gov/pubmed/8748801", "http://www.ncbi.nlm.nih.gov/pubmed/19668044", "http://www.ncbi.nlm.nih.gov/pubmed/15316123", "http://www.ncbi.nlm.nih.gov/pubmed/24842523", "http://www.ncbi.nlm.nih.gov/pubmed/26008686", "http://www.ncbi.nlm.nih.gov/pubmed/23932725", "http://www.ncbi.nlm.nih.gov/pubmed/23569451", "http://www.ncbi.nlm.nih.gov/pubmed/24891867", "http://www.ncbi.nlm.nih.gov/pubmed/18056506"], "ideal_answer": ["Crowned dens syndrome is a rare form of \"crown-like\" calcifications around the dens and often presents with recurrent neck pain, stiffness of neck, increased erythrocyte sedimentation rate, and episodes of fever."], "type": "summary", "id": "589a245e78275d0c4a000029", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "BACKGROUND: Patients with crowned dens syndrome (CDS), which is pseudogout of the atlantoaxial junction induced by \"crown-like\" calcifications around the dens, present with symptoms of severe neck pain, rigidity, and high fever. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25910825", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "BACKGROUND CONTEXT: Crowned dens syndrome (CDS) is a rare form of calcium phosphate crystal depositions and often presents with recurrent neck pain, stiffness of neck, increased erythrocyte sedimentation rate, and episodes of fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26008686", "endSection": "abstract"}, {"offsetInBeginSection": 73, "offsetInEndSection": 295, "text": "A CT scan revealed calcification of the transverse ligament and crown-like calcification around the odontoid process. According to the clinical and radiological findings, she was diagnosed with crowned dens syndrome (CDS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26370870", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 285, "text": "Crystal deposition in the cervical spine around the odontoid process may lead to acute neck pain. This rare condition is called crowned dens syndrome and should be considered in the differential diagnosis of a possible etiology for fever, headache and cervical pain of unknown origin. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25196626", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 352, "text": "Crowned dens syndrome (CDS), related to microcrystalline deposition in the periodontoid process, is the main cause of acute or chronic cervical pain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24926265", "endSection": "abstract"}, {"offsetInBeginSection": 71, "offsetInEndSection": 292, "text": "Axial calcium pyrophosphate dihydrate deposition disease (CPDD) is well known for cervical spine involvement with the crowned dens syndrome but other localisations are probably underdiagnosed in sterile spondylodiscitis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23932725", "endSection": "abstract"}, {"offsetInBeginSection": 682, "offsetInEndSection": 855, "text": "We describe a patient with crowned dens syndrome which manifested with clinical (acute occipital headache) and radiographic (calcium deposits in the alar ligament) features.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25196626", "endSection": "abstract"}, {"offsetInBeginSection": 157, "offsetInEndSection": 371, "text": "FDG uptake in the immediate vicinity of the odontoid process, with a crownlike calcification, was identified on the CT scan on the posterior side of the dens, thus confirming the diagnosis of crowned dens syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25243939", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 859, "text": "We describe a patient with crowned dens syndrome which manifested with clinical (acute occipital headache) and radiographic (calcium deposits in the alar ligament) features", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25196626", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 470, "text": "Crowned dens syndrome (CDS), related to microcrystalline deposition in the periodontoid process, is the main cause of acute or chronic cervical pain.This report describes the case of an 87-year-old woman who had severe bradykinesia, muscle rigidity, gait disturbance and neck pain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24926265", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 335, "text": "The crowned dens syndrome, related to microcrystalline deposition in the peri-odontoid articular and abarticular structures, is mainly responsible for acute or chronic cervical pain.We report eight cases of crowned dens syndrome with atypical presentations mimicking giant cell arteritis, polymyalgia rheumatica, meningitis or discitis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15316123", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "The crowned dens syndrome as a cause of neck pain: clinical and computed tomography study in patients with calcium pyrophosphate dihydrate deposition disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19210868", "endSection": "title"}, {"offsetInBeginSection": 891, "offsetInEndSection": 1047, "text": "Computed tomography of the cervical spine demonstrated linear calcific deposits in the transverse ligament of atlas (crowned dens syndrome) in all patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20646716", "endSection": "abstract"}, {"offsetInBeginSection": 1882, "offsetInEndSection": 2098, "text": "Crystals located in the transverse ligament of the atlas give rise to the crowned dens syndrome, usually in patients affected by severe degenerative lesions of the atlantoaxial joint and peripheral chondrocalcinosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17361376", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "BACKGROUND: Patients with crowned dens syndrome typically present with severe neck pain and have calcium deposits around the odontoid process of the axis on radiographs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056506", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 860, "text": "We describe a patient with crowned dens syndrome which manifested with clinical (acute occipital headache) and radiographic (calcium deposits in the alar ligament) features.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25196626", "endSection": "abstract"}]}, {"body": "Does CRISPR inversion of CTCF sites alter genome topology?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26276636"], "ideal_answer": ["Yes. CRISPR inversion of CTCF sites alters genome topology."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064113", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064112"], "type": "yesno", "id": "587e440f2420191125000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "CRISPR Inversion of CTCF Sites Alters Genome Topology and Enhancer/Promoter Function", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26276636", "endSection": "title"}, {"offsetInBeginSection": 258, "offsetInEndSection": 1185, "text": "To test the functional significance of this observation, we combined CRISPR/Cas9-based genomic-DNA-fragment editing with chromosome-conformation-capture experiments to show that the location and relative orientations of CBSs determine the specificity of long-range chromatin looping in mammalian genomes, using protocadherin (Pcdh) and \u03b2-globin as model genes. Inversion of CBS elements within the Pcdh enhancer reconfigures the topology of chromatin loops between the distal enhancer and target promoters and alters gene-expression patterns. Thus, although enhancers can function in an orientation-independent manner in reporter assays, in the native chromosome context, the orientation of at least some enhancers carrying CBSs can determine both the architecture of topological chromatin domains and enhancer/promoter specificity. These findings reveal how 3D chromosome architecture can be encoded by linear genome sequences", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26276636", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "CRISPR Inversion of CTCF Sites Alters Genome Topology and Enhancer/Promoter Function.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26276636", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "CRISPR Inversion of CTCF Sites Alters Genome Topology and Enhancer/Promoter Function.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26276636", "endSection": "title"}]}, {"body": "How are looped genes identified in yest?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19602510", "http://www.ncbi.nlm.nih.gov/pubmed/24124207"], "ideal_answer": ["Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB.", "gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as tfiib.", "Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB", "Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB. . . . . "], "type": "summary", "id": "58d4d7578acda34529000007", "snippets": [{"offsetInBeginSection": 249, "offsetInEndSection": 361, "text": "Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24124207", "endSection": "abstract"}, {"offsetInBeginSection": 837, "offsetInEndSection": 983, "text": "Instead, activators physically interacted with the general transcription factor TFIIB when the genes were activated and in a looped configuration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19602510", "endSection": "abstract"}]}, {"body": "Which are the causes of the Koebner phenomenon?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24011283", "http://www.ncbi.nlm.nih.gov/pubmed/12195563", "http://www.ncbi.nlm.nih.gov/pubmed/10348006", "http://www.ncbi.nlm.nih.gov/pubmed/10884082", "http://www.ncbi.nlm.nih.gov/pubmed/10884083", "http://www.ncbi.nlm.nih.gov/pubmed/18499373", "http://www.ncbi.nlm.nih.gov/pubmed/16476320", "http://www.ncbi.nlm.nih.gov/pubmed/15893715", "http://www.ncbi.nlm.nih.gov/pubmed/19894099", "http://www.ncbi.nlm.nih.gov/pubmed/8507375", "http://www.ncbi.nlm.nih.gov/pubmed/23302147", "http://www.ncbi.nlm.nih.gov/pubmed/26131802", "http://www.ncbi.nlm.nih.gov/pubmed/15683664", "http://www.ncbi.nlm.nih.gov/pubmed/8056902", "http://www.ncbi.nlm.nih.gov/pubmed/12634998", "http://www.ncbi.nlm.nih.gov/pubmed/12444521", "http://www.ncbi.nlm.nih.gov/pubmed/21396563", "http://www.ncbi.nlm.nih.gov/pubmed/1702353", "http://www.ncbi.nlm.nih.gov/pubmed/9169322", "http://www.ncbi.nlm.nih.gov/pubmed/10748764", "http://www.ncbi.nlm.nih.gov/pubmed/11089373", "http://www.ncbi.nlm.nih.gov/pubmed/19489859", "http://www.ncbi.nlm.nih.gov/pubmed/27106503", "http://www.ncbi.nlm.nih.gov/pubmed/15854039", "http://www.ncbi.nlm.nih.gov/pubmed/20042161", "http://www.ncbi.nlm.nih.gov/pubmed/2102235", "http://www.ncbi.nlm.nih.gov/pubmed/21715249", "http://www.ncbi.nlm.nih.gov/pubmed/23588149", "http://www.ncbi.nlm.nih.gov/pubmed/25046469", "http://www.ncbi.nlm.nih.gov/pubmed/26557075", "http://www.ncbi.nlm.nih.gov/pubmed/8175343", "http://www.ncbi.nlm.nih.gov/pubmed/17656943", "http://www.ncbi.nlm.nih.gov/pubmed/11056428", "http://www.ncbi.nlm.nih.gov/pubmed/9173061"], "ideal_answer": ["The causes of the Koebner phenomenon are:\n1) Lichen sclerosus\n2) Vitiligo\n3) Psoriasis and \n4) Physical stress."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:12306", "http://www.disease-ontology.org/api/metadata/DOID:9201", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014820", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011565", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008010"], "type": "list", "id": "58bfcb8702b8c60953000016", "snippets": [{"offsetInBeginSection": 205, "offsetInEndSection": 284, "text": "Lichen sclerosus has been reported at sites of injury as a Koebner phenomenon. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25046469", "endSection": "abstract"}, {"offsetInBeginSection": 1260, "offsetInEndSection": 1504, "text": "Therefore, lower expression of keratinocyte-derived factors, including SCF, in vitiliginous keratinocytes, which could result from keratinocyte apoptosis, might be responsible for passive melanocyte death and may explain the Koebner phenomenon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15854039", "endSection": "abstract"}, {"offsetInBeginSection": 88, "offsetInEndSection": 300, "text": "Deprivation of survival factors causes the apoptosis of melanocytes. Vitiligo often develops following physical trauma, even if this is minor. The exact mechanism of the Koebner phenomenon in vitiligo is unclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15854039", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "First described in 1877 as the appearance of psoriatic lesions in the uninvolved skin of psoriatic patients as a consequence of trauma, the Koebner phenomenon has since been described in numerous diseases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12195563", "endSection": "abstract"}, {"offsetInBeginSection": 983, "offsetInEndSection": 1210, "text": "The Koebner phenomenon is known to occur (lichen sclerosus occurs in skin already scarred or damaged), so trauma, injury, and sexual abuse have been suggested as possible triggers of symptoms in genetically predisposed people. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10348006", "endSection": "abstract"}, {"offsetInBeginSection": 764, "offsetInEndSection": 948, "text": "The triggering role of physical stress is seen in the \"deep Koebner\" phenomenon, which causes inflammation in the synovial membrane and in enthesis, resulting in peripheral arthritis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715249", "endSection": "abstract"}, {"offsetInBeginSection": 758, "offsetInEndSection": 941, "text": "The triggering role of physical stress is seen in the \"deep Koebner\" phenomenon, which causes inflammation in the synovial membrane and in enthesis, resulting in peripheral arthritis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715249", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Two patients with unusual skin stimuli causing koebner phenomenon in psoriasis are reported.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17656943", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "To document the role of striae distensae and striae gravidarum in causing Koebner phenomenon in cases of vitiligo, psoriasis and lichen planus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19489859", "endSection": "abstract"}, {"offsetInBeginSection": 146, "offsetInEndSection": 239, "text": "In addition, psoriasis can be caused by a\u00a0local cutaneus trauma, known as Koebner phenomenon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27106503", "endSection": "abstract"}, {"offsetInBeginSection": 143, "offsetInEndSection": 373, "text": "Striae are documented to cause Koebner phenomenon in patients with preexisting vitiligo, psoriasis and lichen planus, the three conditions where 'true kobenerisation' has been suggested according to Boyd and Nelder classification.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19489859", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "[Unusual Koebner phenomenon in psoriasis caused by varicella and UVB].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9173061", "endSection": "title"}, {"offsetInBeginSection": 259, "offsetInEndSection": 412, "text": "A 48 year-old woman developed an exacerbation of a latent psoriasis as a Koebner phenomenon in a migrating erythema caused by Borrelia afzelii infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12444521", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "[Psoriasis as Koebner phenomenon in erythma migrans].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12444521", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "[Characteristics of the Koebner phenomenon in patients with psoriasis vulgaris].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11089373", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Vitiligo appearing in striae distensae as a Koebner phenomenon.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20042161", "endSection": "title"}, {"offsetInBeginSection": 511, "offsetInEndSection": 615, "text": "The appearance of vitiligo in striae distensae as a form of Koebner phenomenon has been reported rarely.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20042161", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "The Koebner phenomenon originally described the appearance of psoriatic lesions in the uninvolved skin of patients with psoriasis as a consequence of trauma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18499373", "endSection": "abstract"}, {"offsetInBeginSection": 764, "offsetInEndSection": 946, "text": "The triggering role of physical stress is seen in the \"deep Koebner\" phenomenon, which causes inflammation in the synovial membrane and in enthesis, resulting in peripheral arthritis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715249", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 438, "text": "To document the role of striae distensae and striae gravidarum in causing Koebner phenomenon in cases of vitiligo, psoriasis and lichen planus.Striae are documented to cause Koebner phenomenon in patients with preexisting vitiligo, psoriasis and lichen planus, the three conditions where true kobenerisation has been suggested according to Boyd and Nelder classification.Striae distensae and striae gravidarum are examples of blunt trauma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19489859", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "[Unusual Koebner phenomenon in psoriasis caused by varicella and UVB]", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9173061", "endSection": "title"}, {"offsetInBeginSection": 261, "offsetInEndSection": 413, "text": "A 48 year-old woman developed an exacerbation of a latent psoriasis as a Koebner phenomenon in a migrating erythema caused by Borrelia afzelii infection", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12444521", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Intradermal antigen tests and the Koebner phenomenon in psoriasis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9169322", "endSection": "title"}, {"offsetInBeginSection": 950, "offsetInEndSection": 1283, "text": "In addition, intensity of delayed hypersensitivity reaction and resolution times demonstrate no significant difference between psoriatic and nonpsoriatic subjects statistically (P > 0.05).These findings may indicate that intradermal antigens used in this study were more effective in inducing the Koebner phenomenon than injury alone", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9169322", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 390, "text": "RESULTS: Striae are documented to cause Koebner phenomenon in patients with preexisting vitiligo, psoriasis and lichen planus, the three conditions where 'true kobenerisation' has been suggested according to Boyd and Nelder classification. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19489859", "endSection": "abstract"}, {"offsetInBeginSection": 702, "offsetInEndSection": 1021, "text": "According to the presence of Koebner phenomenon they were divided in two groups, one with positive and the other with negative Koebner phenomenon which presented the control group at the same time.RESULTS AND DISCUSSION: The Koebner reaction is often thought to be more frequent in actively spreading, severe psoriasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11089373", "endSection": "abstract"}, {"offsetInBeginSection": 158, "offsetInEndSection": 312, "text": "We describe a case of concurrent lichen planus and sarcoidosis in the auditory canal, which represents an unusual manifestation of the Koebner phenomenon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18499373", "endSection": "abstract"}, {"offsetInBeginSection": 639, "offsetInEndSection": 999, "text": "According to the presence of Koebner phenomenon they were divided into two groups, 20 patients with positive and 40 patients with negative Koebner reaction, who were the control group at the same time.RESULTS AND DISCUSSION: 95% of patients treated with PUVA, were cleared of psoriatic changes in the Koebner positive, as well as in the Koebner negative group.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10748764", "endSection": "abstract"}, {"offsetInBeginSection": 144, "offsetInEndSection": 374, "text": "Striae are documented to cause Koebner phenomenon in patients with preexisting vitiligo, psoriasis and lichen planus, the three conditions where 'true kobenerisation' has been suggested according to Boyd and Nelder classification.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19489859", "endSection": "abstract"}]}, {"body": "Is there a role of proton beam therapy in medulloblastoma treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16165914", "http://www.ncbi.nlm.nih.gov/pubmed/9231669", "http://www.ncbi.nlm.nih.gov/pubmed/25415685", "http://www.ncbi.nlm.nih.gov/pubmed/24105630", "http://www.ncbi.nlm.nih.gov/pubmed/16332594", "http://www.ncbi.nlm.nih.gov/pubmed/15637691", "http://www.ncbi.nlm.nih.gov/pubmed/26548600", "http://www.ncbi.nlm.nih.gov/pubmed/25927402", "http://www.ncbi.nlm.nih.gov/pubmed/9240650", "http://www.ncbi.nlm.nih.gov/pubmed/9112448", "http://www.ncbi.nlm.nih.gov/pubmed/12377335", "http://www.ncbi.nlm.nih.gov/pubmed/23322160", "http://www.ncbi.nlm.nih.gov/pubmed/22553304", "http://www.ncbi.nlm.nih.gov/pubmed/1310964", "http://www.ncbi.nlm.nih.gov/pubmed/16168831", "http://www.ncbi.nlm.nih.gov/pubmed/24187330", "http://www.ncbi.nlm.nih.gov/pubmed/23433794", "http://www.ncbi.nlm.nih.gov/pubmed/25403752", "http://www.ncbi.nlm.nih.gov/pubmed/15701271"], "ideal_answer": ["Yes, proton beam therapy is used for treatment of medulloblastoma."], "concepts": ["http://www.biosemantics.org/jochem#4058240", "http://www.disease-ontology.org/api/metadata/DOID:0050902", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061766", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011878", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008527"], "type": "yesno", "id": "58850ac7e56acf5176000012", "snippets": [{"offsetInBeginSection": 746, "offsetInEndSection": 952, "text": "All papers directly compared outcomes from protons with photons, five papers included medulloblastoma, four papers each included craniopharyngioma and low grade gliomas and three papers included ependymoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25927402", "endSection": "abstract"}, {"offsetInBeginSection": 1872, "offsetInEndSection": 2212, "text": "There are many indications of protontherapy for paediatric brain tumours in curative intent, either for localized treatment of ependymomas, germ-cell tumours, craniopharyngiomas, low-grade gliomas; or panventricular irradiation of pure non-secreting germinoma; or craniospinal irradiation of medulloblastomas and metastatic pure germinomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26548600", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Cost-effectiveness analysis of cochlear dose reduction by proton beam therapy for medulloblastoma in childhood.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187330", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 360, "text": "BACKGROUND: The aim of this study is to evaluate the cost-effectiveness of proton beam therapy with cochlear dose reduction compared with conventional X-ray radiotherapy for medulloblastoma in childhood.METHODS: We developed a Markov model to describe health states of 6-year-old children with medulloblastoma after treatment with proton or X-ray radiotherapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187330", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Evaluation of permanent alopecia in pediatric medulloblastoma patients treated with proton radiation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25403752", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "BACKGROUND: To precisely calculate skin dose and thus to evaluate the relationship between the skin dose and permanent alopecia for pediatric medulloblastoma patients treated with proton beams.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25403752", "endSection": "abstract"}, {"offsetInBeginSection": 1139, "offsetInEndSection": 1314, "text": "CONCLUSIONS: Our results based on 12 patients provide a relationship between the skin dose and permanent alopecia for pediatric medulloblastoma patients treated with protons. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25403752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23433794", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "PURPOSE: Efficacy and acute toxicity of proton craniospinal irradiation (p-CSI) were compared with conventional photon CSI (x-CSI) for adults with medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23433794", "endSection": "abstract"}, {"offsetInBeginSection": 1235, "offsetInEndSection": 1358, "text": "CONCLUSIONS: This report is the first analysis of clinical outcomes for adult medulloblastoma patients treated with p-CSI. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23433794", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Dilemmas concerning dose distribution and the influence of relative biological effect in proton beam therapy of medulloblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553304", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "OBJECTIVE: To improve medulloblastoma proton therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553304", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "The aim of this study is to evaluate the cost-effectiveness of proton beam therapy with cochlear dose reduction compared with conventional X-ray radiotherapy for medulloblastoma in childhood.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187330", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 338, "text": "The aim of this study is to evaluate the cost-effectiveness of proton beam therapy with cochlear dose reduction compared with conventional X-ray radiotherapy for medulloblastoma in childhood.We developed a Markov model to describe health states of 6-year-old children with medulloblastoma after treatment with proton or X-ray radiotherapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187330", "endSection": "abstract"}, {"offsetInBeginSection": 1311, "offsetInEndSection": 1528, "text": "All patients completed therapy without interruption.Our proton-beam technique for craniospinal irradiation of pediatric medulloblastoma has successfully reduced normal-tissue doses and acute treatment-related sequelae", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15701271", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuro-ectodermal tumors: spinal theca irradiation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9240650", "endSection": "title"}, {"offsetInBeginSection": 1146, "offsetInEndSection": 1569, "text": "For 6 MV x-rays > 60% of the dose prescribed to the target was delivered to 44% of the heart volume, while the proton beam was able to completely avoid the heart, the liver, and in all likelihood the thyroid and gonads as well.The present study demonstrates a potential role of proton therapy in decreasing the dose (and toxicity) to the critical structures in the irradiation of the spinal neuraxis in medulloblastoma/PNET", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9240650", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuroectodermal tumors: reduction of the supratentorial target volume", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9231669", "endSection": "title"}, {"offsetInBeginSection": 1228, "offsetInEndSection": 1515, "text": "This review describes the role of radiation in general and proton therapy in particular for the treatment of medulloblastoma, central nervous system primitive neuroectodermal tumors, atypical teratoid/rhabdoid tumors, and the recently described embryonal tumor with multilayered rosettes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25415685", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15701271", "endSection": "title"}, {"offsetInBeginSection": 2674, "offsetInEndSection": 3031, "text": "Intensity-modulated radiotherapy did show more bladder dose reduction than the other techniques in pelvic sarcoma irradiation.CONCLUSIONS: In the diseases studied, using various techniques of 3D-CRT, electrons, IMRT, and protons, protons are most optimal in treating retinoblastomas, medulloblastomas (posterior fossa and craniospinal), and pelvic sarcomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16168831", "endSection": "abstract"}, {"offsetInBeginSection": 1185, "offsetInEndSection": 1619, "text": "For 6 MV x-rays>60% of the dose prescribed to the target was delivered to 44% of the heart volume, while the proton beam was able to completely avoid the heart, the liver, and in all likelihood the thyroid and gonads as well.CONCLUSION: The present study demonstrates a potential role of proton therapy in decreasing the dose (and toxicity) to the critical structures in the irradiation of the spinal neuraxis in medulloblastoma/PNET.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9240650", "endSection": "abstract"}, {"offsetInBeginSection": 766, "offsetInEndSection": 872, "text": "In medulloblastoma, three posterior fossa irradiation techniques were analyzed: 3D-CRT, IMRT, and protons.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16168831", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuro-ectodermal tumors: spinal theca irradiation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9240650", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuroectodermal tumors: reduction of the supratentorial target volume.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9231669", "endSection": "title"}, {"offsetInBeginSection": 1376, "offsetInEndSection": 1573, "text": "The present study demonstrates a potential role of proton therapy in decreasing the dose (and toxicity) to the critical structures in the irradiation of the spinal neuraxis in medulloblastoma/PNET.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9240650", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Cost-effectiveness analysis of cochlear dose reduction by proton beam therapy for medulloblastoma in childhood.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24187330", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Dilemmas concerning dose distribution and the influence of relative biological effect in proton beam therapy of medulloblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553304", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 42, "text": "To improve medulloblastoma proton therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22553304", "endSection": "abstract"}, {"offsetInBeginSection": 1366, "offsetInEndSection": 1532, "text": "Our proton-beam technique for craniospinal irradiation of pediatric medulloblastoma has successfully reduced normal-tissue doses and acute treatment-related sequelae.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15701271", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16168831", "endSection": "title"}]}, {"body": "What is the function of the DGAT1 gene product?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17592768", "http://www.ncbi.nlm.nih.gov/pubmed/21264296", "http://www.ncbi.nlm.nih.gov/pubmed/15834126", "http://www.ncbi.nlm.nih.gov/pubmed/15797871", "http://www.ncbi.nlm.nih.gov/pubmed/23539897", "http://www.ncbi.nlm.nih.gov/pubmed/25687632", "http://www.ncbi.nlm.nih.gov/pubmed/16534144", "http://www.ncbi.nlm.nih.gov/pubmed/12825687", "http://www.ncbi.nlm.nih.gov/pubmed/12407108", "http://www.ncbi.nlm.nih.gov/pubmed/11481333", "http://www.ncbi.nlm.nih.gov/pubmed/23055800", "http://www.ncbi.nlm.nih.gov/pubmed/16130466", "http://www.ncbi.nlm.nih.gov/pubmed/20876538"], "ideal_answer": ["Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in the acyl-CoA-dependent triacylglycerol biosynthesis", "Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in the acyl-CoA-dependent triacylglycerol biosynthesis. . . . . ", "Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in the acyl-CoA-dependent triacylglycerol biosynthesis.", "Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in the acyl-CoA-dependent triacylglycerol biosynthesis, the enzyme catalyzes a key step in lipid biosynthesis.", "diacylglycerol acyltransferase 1 (dgat1) catalyzes the final step in the acyl-coa-dependent triacylglycerol biosynthesis."], "concepts": ["http://www.uniprot.org/uniprot/DGAT1_DICDI", "http://www.uniprot.org/uniprot/DGAT1_ARATH", "http://www.uniprot.org/uniprot/DGAT1_CHLAE", "http://www.uniprot.org/uniprot/DGAT1_HUMAN", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051048", "http://www.uniprot.org/uniprot/DGAT1_MOUSE", "http://www.uniprot.org/uniprot/DGAT1_BOVIN"], "type": "summary", "id": "58cbf1f402b8c60953000036", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in the acyl-CoA-dependent triacylglycerol biosynthesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25687632", "endSection": "abstract"}, {"offsetInBeginSection": 139, "offsetInEndSection": 283, "text": "This genomic area includes the DGAT1 gene, which encodes acyl-CoA:diacylglycerol acyltransferase 1, the key enzyme of triglyceride biosynthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16534144", "endSection": "abstract"}, {"offsetInBeginSection": 100, "offsetInEndSection": 222, "text": "Diacylglycerol acyltransferase (DGAT1) is considered the key enzyme in controlling the rate of synthesis of triglycerides.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17592768", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Acyl-CoA:diacylglycerol acyltransferase-1 (DGAT1) catalyzes the final step of triglyceride synthesis in mammalian cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12407108", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Diacylglycerol O-acyltransferase 1 (DGAT1) is a microsomal enzyme that catalyzes the final step of triglyceride synthesis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23055800", "endSection": "abstract"}, {"offsetInBeginSection": 236, "offsetInEndSection": 342, "text": "The enzyme 1,2-acylCoA:diacylglyceroltransferase-1 (DGAT1) esterifies a fatty acyl-CoA on DAG to form TAG.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21264296", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "DGAT1 is a microsomal enzyme that catalyses the final step in triglycerides synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16130466", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Diacylglycerol-O-acyltransferase (DGAT1) gene encodes the rate-limiting enzyme of triglyceride synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24676595", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Acyl CoA:diacylglycerol acyltransferase (DGAT) is an integral membrane protein of the endoplasmic reticulum that catalyzes the synthesis of triacylglycerols", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20876538", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "The final step of triacylglycerol biosynthesis is catalyzed by acyl CoA:diacylglycerol acyltransferase (DGAT) enzymes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15834126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Triacylglycerol (TAG) is the major carbon storage reserve in oilseeds such as Arabidopsis. Acyl-CoA:diacylglycerol acyltransferase (DGAT) catalyses the final step of the TAG synthesis pathway", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12825687", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Acyl-CoA:diacylglycerol acyltransferases (DGATs) catalyze the last step in triglyceride (TG) synthesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15797871", "endSection": "abstract"}, {"offsetInBeginSection": 892, "offsetInEndSection": 997, "text": " This study further confirmed the importance of DGAT1 in triglyceride synthesis in bovine mammary tissue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23539897", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Acyl CoA:diacylgycerol acyltransferase (EC; DGAT) catalyzes the final step in the production of triacylglycerol. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11481333", "endSection": "abstract"}]}, {"body": "Which histone mutation is associated with gliomas?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26957305", "http://www.ncbi.nlm.nih.gov/pubmed/24242757", "http://www.ncbi.nlm.nih.gov/pubmed/27034984", "http://www.ncbi.nlm.nih.gov/pubmed/27701736", "http://www.ncbi.nlm.nih.gov/pubmed/26297251", "http://www.ncbi.nlm.nih.gov/pubmed/27392443", "http://www.ncbi.nlm.nih.gov/pubmed/26517431", "http://www.ncbi.nlm.nih.gov/pubmed/23603901", "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "http://www.ncbi.nlm.nih.gov/pubmed/24285547", "http://www.ncbi.nlm.nih.gov/pubmed/23539183", "http://www.ncbi.nlm.nih.gov/pubmed/25170156", "http://www.ncbi.nlm.nih.gov/pubmed/25773741", "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "http://www.ncbi.nlm.nih.gov/pubmed/25401693"], "ideal_answer": ["Pediatric central nervous system tumors are the most common solid tumor of childhood. Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3.", "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3. Genome-wide analyses indicate a resetting of the transformed precursors to a developmentally more primitive stem cell state, with evidence of major modifications of histone marks at several master regulator genes.", "some of these molecular changes with clinicopathological utility have been used for the first time in the most recent edition of the world health organization (who) classification of cns tumours to define entities like ependymoma, rela fusion-positive or diffuse midline glioma, h3 k27m-mutant.", "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3"], "type": "factoid", "id": "58bac71222d3005309000013", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "abstract"}, {"offsetInBeginSection": 359, "offsetInEndSection": 546, "text": "We show that H3.3K27M expression synergizes with p53 loss and PDGFRA activation in neural progenitor cells derived from human embryonic stem cells, resulting in neoplastic transformation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "abstract"}, {"offsetInBeginSection": 436, "offsetInEndSection": 730, "text": "Some of these molecular changes with clinicopathological utility have been used for the first time in the most recent edition of the World Health Organization (WHO) classification of CNS tumours to define entities like ependymoma, RELA fusion-positive or diffuse midline glioma, H3 K27M-mutant.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27701736", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 828, "text": "The recent discovery of somatic oncogenic mutations affecting chromatin regulation in pediatric high-grade glioma has markedly improved our understanding of disease pathogenesis, and these findings have stimulated the development of novel therapeutic approaches targeting epigenetic regulators for disease treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27034984", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "title"}, {"offsetInBeginSection": 1184, "offsetInEndSection": 1444, "text": "In this series, histone H3-K27M mutation was mutually exclusive with IDH1 mutation and EGFR amplification, rarely co-occurred with BRAF-V600E mutation, and was commonly associated with p53 overexpression, ATRX loss (except in pontine gliomas), and monosomy 10.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26517431", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "Histone H3.3 (H3F3A) mutation in the codon for lysine 27 (K27M) has been found as driver mutations in pediatric glioblastoma and has been suggested to play critical roles in the pathogenesis of thalamic gliomas and diffuse intrinsic pontine gliomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27392443", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26517431", "endSection": "title"}, {"offsetInBeginSection": 392, "offsetInEndSection": 479, "text": "Here, we describe a series of 47 diffuse midline gliomas with histone H3-K27M mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26517431", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Histone H3 lysine(27)-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25170156", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Sequencing of pediatric gliomas has identified missense mutations Lys27Met (K27M) and Gly34Arg/Val (G34R/V) in genes encoding histone H3.3 (H3F3A) and H3.1 (HIST3H1B).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23539183", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Pediatric brainstem gliomas often harbor oncogenic K27M mutation of histone H3.3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25401693", "endSection": "abstract"}, {"offsetInBeginSection": 168, "offsetInEndSection": 454, "text": "We report that human diffuse intrinsic pontine gliomas (DIPGs) containing the K27M mutation display significantly lower overall amounts of H3 with trimethylated lysine 27 (H3K27me3) and that histone H3K27M transgenes are sufficient to reduce the amounts of H3K27me3 in vitro and in vivo", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23539183", "endSection": "abstract"}, {"offsetInBeginSection": 1599, "offsetInEndSection": 1739, "text": "In particular, histone genes (H3F3A (K27M) , HIST1H3B (K27M) ) mutations are frequent in adult DIBG whereas IDH1 (R132H) mutations are rare.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24242757", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "endSection": "title"}, {"offsetInBeginSection": 214, "offsetInEndSection": 290, "text": "The role of the H3.3K27M mutation in tumorigenesis is not fully understood. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", "endSection": "title"}, {"offsetInBeginSection": 1191, "offsetInEndSection": 1524, "text": "In this series, histone H3-K27M mutation was mutually exclusive with IDH1 mutation and EGFR amplification, rarely co-occurred with BRAF-V600E mutation, and was commonly associated with p53 overexpression, ATRX loss (except in pontine gliomas), and monosomy 10. <CopyrightInformation>\u00a9 2015 International Society of Neuropathology.</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26517431", "endSection": "abstract"}, {"offsetInBeginSection": 118, "offsetInEndSection": 385, "text": "We established a Drosophila animal model for the pathogenic histone H3K27M mutation and show that its overexpression resembles polycomb repressive complex 2 (PRC2) loss-of-function phenotypes, causing derepression of PRC2 target genes and developmental perturbations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25170156", "endSection": "abstract"}, {"offsetInBeginSection": 394, "offsetInEndSection": 481, "text": "Here, we describe a series of 47 diffuse midline gliomas with histone H3-K27M mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26517431", "endSection": "abstract"}, {"offsetInBeginSection": 168, "offsetInEndSection": 455, "text": "We report that human diffuse intrinsic pontine gliomas (DIPGs) containing the K27M mutation display significantly lower overall amounts of H3 with trimethylated lysine 27 (H3K27me3) and that histone H3K27M transgenes are sufficient to reduce the amounts of H3K27me3 in vitro and in vivo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23539183", "endSection": "abstract"}, {"offsetInBeginSection": 1285, "offsetInEndSection": 1552, "text": "In contrast, thalamic gliomas with wild-type H3F3A had DNA methylation profiles similar to those of hemispheric glioblastomas.CONCLUSION: We found that high-grade thalamic gliomas from young adults, like those from children and adolescents, frequently had H3F3A K27M.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285547", "endSection": "abstract"}, {"offsetInBeginSection": 1168, "offsetInEndSection": 1284, "text": "Gliomas with H3F3A K27M from pediatric or young adult patients had similar, characteristic DNA methylation profiles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285547", "endSection": "abstract"}, {"offsetInBeginSection": 1489, "offsetInEndSection": 1692, "text": "Although the K27M mutation was frequently observed in adult brainstem and thalamic gliomas, this mutation tended to be associated with a poorer prognosis in brainstem gliomas but not in thalamic gliomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26297251", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26517431", "endSection": "title"}, {"offsetInBeginSection": 1191, "offsetInEndSection": 1451, "text": "In this series, histone H3-K27M mutation was mutually exclusive with IDH1 mutation and EGFR amplification, rarely co-occurred with BRAF-V600E mutation, and was commonly associated with p53 overexpression, ATRX loss (except in pontine gliomas), and monosomy 10.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26517431", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26297251", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "endSection": "title"}, {"offsetInBeginSection": 400, "offsetInEndSection": 651, "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", "endSection": "abstract"}, {"offsetInBeginSection": 1011, "offsetInEndSection": 1153, "text": "Interestingly, the G34 mutations, the K36M mutations, and the majority of K27M mutations occur in genes encoding the replacement histone H3.3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", "endSection": "abstract"}]}, {"body": "Are there canonical marks of active chromatin in developmentally regulated genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26280901"], "ideal_answer": ["No. The transcription of genes temporally regulated during fly and worm development occurs in the absence of canonically active histone modifications. Conversely, strong chromatin marking is related to transcriptional and post-transcriptional stability, an association also observed in mammals. Consequently, chromatin marking is associated with the stable production of RNA, whereas unmarked chromatin would permit rapid gene activation and deactivation during development. In the latter case, regulation by transcription factors would have a comparatively more important regulatory role than chromatin marks."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0035327", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018507"], "type": "yesno", "id": "588383172305cd7e21000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Absence of canonical marks of active chromatin in developmentally regulated genes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280901", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 823, "text": "The interplay of active and repressive histone modifications is assumed to have a key role in the regulation of gene expression. In contrast to this generally accepted view, we show that the transcription of genes temporally regulated during fly and worm development occurs in the absence of canonically active histone modifications. Conversely, strong chromatin marking is related to transcriptional and post-transcriptional stability, an association that we also observe in mammals. Our results support a model in which chromatin marking is associated with the stable production of RNA, whereas unmarked chromatin would permit rapid gene activation and deactivation during development. In the latter case, regulation by transcription factors would have a comparatively more important regulatory role than chromatin marks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280901", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Absence of canonical marks of active chromatin in developmentally regulated genes", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280901", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Absence of canonical marks of active chromatin in developmentally regulated genes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280901", "endSection": "title"}, {"offsetInBeginSection": 129, "offsetInEndSection": 333, "text": "In contrast to this generally accepted view, we show that the transcription of genes temporally regulated during fly and worm development occurs in the absence of canonically active histone modifications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26280901", "endSection": "abstract"}]}, {"body": "What is the purpose of HaploReg v4?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26657631", "http://www.ncbi.nlm.nih.gov/pubmed/27539526"], "ideal_answer": ["HaploReg v4 enables the systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056726"], "type": "summary", "id": "587f60f892a5b8ad44000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657631", "endSection": "title"}, {"offsetInBeginSection": 725, "offsetInEndSection": 1351, "text": "Since first launching the website in 2011, we have greatly expanded HaploReg, increasing the number of chromatin state maps to 127 reference epigenomes from ENCODE 2012 and Roadmap Epigenomics, incorporating regulator binding data, expanding regulatory motif disruption annotations, and integrating expression quantitative trait locus (eQTL) variants and their tissue-specific target genes from GTEx, Geuvadis, and other recent studies. We present these updates as HaploReg v4, and illustrate a use case of HaploReg for attention deficit hyperactivity disorder (ADHD)-associated SNPs with putative brain regulatory mechanisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657631", "endSection": "abstract"}, {"offsetInBeginSection": 1158, "offsetInEndSection": 1347, "text": "We present these updates as HaploReg v4, and illustrate a use case of HaploReg for attention deficit hyperactivity disorder (ADHD)-associated SNPs with putative brain regulatory mechanisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657631", "endSection": "abstract"}, {"offsetInBeginSection": 1162, "offsetInEndSection": 1351, "text": "We present these updates as HaploReg v4, and illustrate a use case of HaploReg for attention deficit hyperactivity disorder (ADHD)-associated SNPs with putative brain regulatory mechanisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657631", "endSection": "abstract"}, {"offsetInBeginSection": 828, "offsetInEndSection": 921, "text": "HaploReg V4.1 and Regulome DB were used to understand functional annotation on important SNV.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27539526", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657631", "endSection": "title"}]}, {"body": "Which are the typical symptoms of M\u00e9ni\u00e8re's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12806289", "http://www.ncbi.nlm.nih.gov/pubmed/3631415", "http://www.ncbi.nlm.nih.gov/pubmed/18046258", "http://www.ncbi.nlm.nih.gov/pubmed/15198043", "http://www.ncbi.nlm.nih.gov/pubmed/22705835", "http://www.ncbi.nlm.nih.gov/pubmed/1896679", "http://www.ncbi.nlm.nih.gov/pubmed/1896669", "http://www.ncbi.nlm.nih.gov/pubmed/16640061", "http://www.ncbi.nlm.nih.gov/pubmed/23418296", "http://www.ncbi.nlm.nih.gov/pubmed/11936909", "http://www.ncbi.nlm.nih.gov/pubmed/18229792", "http://www.ncbi.nlm.nih.gov/pubmed/21851581", "http://www.ncbi.nlm.nih.gov/pubmed/22801040", "http://www.ncbi.nlm.nih.gov/pubmed/3968944", "http://www.ncbi.nlm.nih.gov/pubmed/12160282", "http://www.ncbi.nlm.nih.gov/pubmed/2610793", "http://www.ncbi.nlm.nih.gov/pubmed/11074796", "http://www.ncbi.nlm.nih.gov/pubmed/11583396"], "ideal_answer": ["The typical symptoms of M\u00e9ni\u00e8re's disease are:\n1) sensorineural hearing loss, \n2) vertigo and \n3) tinnitus."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008575", "http://www.disease-ontology.org/api/metadata/DOID:9849"], "type": "list", "id": "58c6a6c502b8c60953000027", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 156, "text": "To evaluate the onset of vertigo, hearing loss and tinnitus in M\u00e9ni\u00e8re's disease and the associated endolymphatic hydrops (EH) of the inner ear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418296", "endSection": "abstract"}, {"offsetInBeginSection": 1554, "offsetInEndSection": 1783, "text": "We suggest that a 3T MRI measurement should be carried out in patients with sensory-neural hearing loss, vertigo and tinnitus, 4 h after the intravenous injection of a gadolinium-contrast agent to verify the inner ear pathology. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418296", "endSection": "abstract"}, {"offsetInBeginSection": 519, "offsetInEndSection": 819, "text": "Eleven of the 17425 veterans appeared to have typical M\u00e9ni\u00e8re's Disease. Their symptoms included attacks of vertigo, lasting between half an hour and a few hours and no more than 24 hours; the sensation of aural fullness; and tinnitus accompanied by a fluctuating or permanent low-tone hearing loss. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12806289", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "Diagnosis of Meni\u00e8re's Disease is based upon the wellknown labyrinthic syndrome (hypoacusia, tinnitus and dizziness) which manifests with the typical abscessual, recurrent and unforeseeable course. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15198043", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 814, "text": "Typical clinical manifestations of M\u00e9ni\u00e8re's disease (vertigo, sensorineural hearing loss and tinnitus) were found in 6/11 patients (54.5%) in the Lyme disease group.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11936909", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 428, "text": "Among 93 patients presenting the typical symptoms of a M\u00e9ni\u00e8re's disease associating an unilateral fluctuating hearing loss of sensorineural type, tinnitus and vertiginous attacks lasting minutes to hours, 40 patients (43%) presented in their personal history a particular otologic insult in the ear which later on developed into the full M\u00e9ni\u00e8re's symptomatology, or a particular systemic disease with otologic manifestations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1896669", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "Fourteen children (aged 14 years or younger) with typical M\u00e9ni\u00e8re's triad with cochlear sensorineural hearing loss, tinnitus, and intermittent vertigo attacks lasting from minutes to hours were investigated in four different neuro-otologic centers. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3631415", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 427, "text": "Among 93 patients presenting the typical symptoms of a M\u00e9ni\u00e8re's disease associating an unilateral fluctuating hearing loss of sensorineural type, tinnitus and vertiginous attacks lasting minutes to hours, 40 patients (43%) presented in their personal history a particular otologic insult in the ear which later on developed into the full M\u00e9ni\u00e8re's symptomatology, or a particular systemic disease with otologic manifestations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1896669", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 355, "text": "To evaluate the onset of vertigo, hearing loss and tinnitus in M\u00e9ni\u00e8res disease and the associated endolymphatic hydrops (EH) of the inner ear.Multicentre evaluation of three patient groups.Disease-specific symptoms were reviewed among referred patients in a tertiary referral hospital in Finland and in members of a Finnish M\u00e9ni\u00e8re Association in Finland", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418296", "endSection": "abstract"}, {"offsetInBeginSection": 1116, "offsetInEndSection": 1441, "text": "In monosymptomatic patients with vertigo, tinnitus or hearing loss; EH was demonstrated in 55-90% of the patients either in the cochlea and/or the vestibulum of the symptomatic ear.M\u00e9ni\u00e8res disease often shows bilateral EH and comprises a continuum from a monosymptomatic disease to the typical symptom complex of the disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418296", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 815, "text": "Typical clinical manifestations of M\u00e9ni\u00e8re's disease (vertigo, sensorineural hearing loss and tinnitus) were found in 6/11 patients (54.5%) in the Lyme disease group. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11936909", "endSection": "abstract"}, {"offsetInBeginSection": 249, "offsetInEndSection": 401, "text": "Nine children, labeled as having \"idiopathic M\u00e9ni\u00e8re's disease,\" developed the auditory and vestibular symptoms without any detectable causative factor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3631415", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 357, "text": "To evaluate the onset of vertigo, hearing loss and tinnitus in M\u00e9ni\u00e8re's disease and the associated endolymphatic hydrops (EH) of the inner ear.Multicentre evaluation of three patient groups.Disease-specific symptoms were reviewed among referred patients in a tertiary referral hospital in Finland and in members of a Finnish M\u00e9ni\u00e8re Association in Finland.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23418296", "endSection": "abstract"}, {"offsetInBeginSection": 1202, "offsetInEndSection": 1658, "text": "In each twin pair, one twin had migraine and M\u00e9ni\u00e8re's disease, whereas the other experienced migraine and episodic vertigo without auditory symptoms.The frequent association of episodic vertigo, migraine, and M\u00e9ni\u00e8re's disease in closely related individuals, including identical twins supports the heritability of a migraine-M\u00e9ni\u00e8re's syndrome, with variable expression of the individual features of hearing loss, episodic vertigo, and migraine headaches.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18046258", "endSection": "abstract"}, {"offsetInBeginSection": 255, "offsetInEndSection": 400, "text": "There has been literature, beginning with M\u00e9ni\u00e8re himself, suggesting a relationship between M\u00e9ni\u00e8re's disease and migraine-associated dizziness.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16640061", "endSection": "abstract"}, {"offsetInBeginSection": 111, "offsetInEndSection": 254, "text": "In the characterizations of the migraine-associated dizziness, the signs and symptoms show overlap with those characterizing Meniere's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16640061", "endSection": "abstract"}]}, {"body": "What tissue is most affected in Ehlers-Danlos syndromes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26958560", "http://www.ncbi.nlm.nih.gov/pubmed/15589118", "http://www.ncbi.nlm.nih.gov/pubmed/26452443", "http://www.ncbi.nlm.nih.gov/pubmed/22981642", "http://www.ncbi.nlm.nih.gov/pubmed/25103963", "http://www.ncbi.nlm.nih.gov/pubmed/15817074", "http://www.ncbi.nlm.nih.gov/pubmed/8526413", "http://www.ncbi.nlm.nih.gov/pubmed/26433894", "http://www.ncbi.nlm.nih.gov/pubmed/16513057", "http://www.ncbi.nlm.nih.gov/pubmed/27084695", "http://www.ncbi.nlm.nih.gov/pubmed/11642233", "http://www.ncbi.nlm.nih.gov/pubmed/16338669", "http://www.ncbi.nlm.nih.gov/pubmed/9762220", "http://www.ncbi.nlm.nih.gov/pubmed/24278273", "http://www.ncbi.nlm.nih.gov/pubmed/18328988", "http://www.ncbi.nlm.nih.gov/pubmed/27931023", "http://www.ncbi.nlm.nih.gov/pubmed/22871544", "http://www.ncbi.nlm.nih.gov/pubmed/17621503", "http://www.ncbi.nlm.nih.gov/pubmed/20847697", "http://www.ncbi.nlm.nih.gov/pubmed/25518796", "http://www.ncbi.nlm.nih.gov/pubmed/21667916", "http://www.ncbi.nlm.nih.gov/pubmed/23405630", "http://www.ncbi.nlm.nih.gov/pubmed/16638060", "http://www.ncbi.nlm.nih.gov/pubmed/2721265"], "ideal_answer": ["the ehlers-danlos syndromes (eds) are a group of connective tissue disorders characterized by triad of joint hypermobility, skin extensibility, and tissue fragility.", "The Ehlers-Danlos syndromes (EDS) are a group of connective tissue disorders characterized by triad of joint hypermobility, skin extensibility, and tissue fragility.", "The Ehlers-Danlos syndromes (EDS) are a group of connective tissue disorders characterized by triad of joint hypermobility, skin extensibility, and tissue fragility. "], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004535", "http://www.disease-ontology.org/api/metadata/DOID:13359", "http://www.disease-ontology.org/api/metadata/DOID:14759", "http://www.disease-ontology.org/api/metadata/DOID:14757", "http://www.disease-ontology.org/api/metadata/DOID:14756", "http://www.disease-ontology.org/api/metadata/DOID:14720"], "type": "factoid", "id": "58cdb41302b8c60953000042", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "The Ehlers-Danlos syndromes (EDS) are a group of connective tissue disorders characterized by triad of joint hypermobility, skin extensibility, and tissue fragility. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26958560", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Ehlers-Danlos syndromes (EDSs) constitute a rare group of inherited connective tissue diseases, characterized by multisystemic manifestations and general tissue fragility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27931023", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Ehlers-Danlos syndromes (EDS) are a heterogeneous group of hereditary connective tissue disorders characterized by joint hypermobility, widespread musculoskeletal pain and tissue fragility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433894", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "The Ehlers-Danlos syndromes (EDS) comprise a heterogenous group of heritable disorders of connective tissue, characterized by joint hypermobility, skin hyperextensibility and tissue fragility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15817074", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Ehlers-Danlos syndrome denotes a group of inherited connective tissue diseases comprising nine types.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9762220", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "The Ehlers-Danlos syndromes comprise a clinically and genetically heterogeneous group of heritable connective tissue disorders characterized by articular hypermobility, skin extensibility, and tissue fragility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21667916", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Ehlers-Danlos syndrome is a heterogeneous group of heritable connective tissue disorders characterized by increased fragility of various non-ossified tissues", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26452443", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "The Ehlers-Danlos Syndrome (EDS) is a rare connective tissue disorder characterised by fragility of the soft connective tissues and widespread manifestations in skin, ligaments, joints, blood vessels and internal organs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22981642", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "The Ehlers-Danlos syndromes (EDS) comprise a heterogenous group of heritable disorders of connective tissue, characterized by joint hypermobility, skin hyperextensibility and tissue fragility", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15817074", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24278273", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "The Ehlers-Danlos syndromes (EDS) are a heterogeneous group of inherited connective tissue disorders characterized by tissue fragility, hyperelasticity of the skin and joint hypermobility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15589118", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Ehlers-Danlos syndrome (EDS), a heterogeneous group of inheritable connective tissue disorders, is attributed to mutations in connective tissue genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16338669", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Ehlers-Danlos syndrome is a heterogeneous group of heritable connective tissue disorders characterized by increased fragility of various non-ossified tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26452443", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "The Ehlers-Danlos syndrome encompasses a group of hereditary disorders of the connective tissue, characterized by hyperextensible skin, joint hypermobility; and varying degrees of vessel and tissue fragility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16638060", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Ehlers-Danlos syndrome is an inherited connective tissue disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2721265", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "The Ehlers-Danlos syndrome is a heritable connective-tissue disorder caused by defects in fibrillar-collagen metabolism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11642233", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 105, "text": "The Ehlers-Danlos syndrome (EDS) comprises a group of hereditary connective tissue disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15994863", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Ehlers-Danlos syndrome type 4, the vascular type, is a rare, life-threatening inherited disorder of the connective tissue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22871544", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 86, "text": "The Ehlers-Danlos syndrome is characterized by abnormal connective tissue ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27084695", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Ehlers-Danlos syndrome is a complex hereditary connective tissue disorder that is characterized by abnormalities of the skin and joints and visceral and neurological manifestation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17621503", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "The Ehlers-Danlos syndromes (EDS) are a group of heritable connective tissue disorders that share the common features of skin hyperextensibility, articular hypermobility, and tissue fragility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8526413", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 193, "text": "The Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders characterised by joint hypermobility, involvement of skin and tissue fragility", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16513057", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 134, "text": "Ehlers-Danlos syndrome (EDS), inherited disorder of connective tissue, frequently leads to impairment of various functional areas,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23405630", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 331, "text": "classic form of Ehlers-Danlos syndrome (cEDS) is an inherited connective tissue disorder, where mutations in type V collagen-encoding genes result in abnormal collagen fibrils. Thus the cEDS patients have pathological connective tissue morphology and low stiffness, but the rate of connective tissue protein turnover is unknown", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25103963", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 244, "text": "Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20847697", "endSection": "abstract"}]}, {"body": "What is Mondor's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1562972", "http://www.ncbi.nlm.nih.gov/pubmed/21855258", "http://www.ncbi.nlm.nih.gov/pubmed/24989360", "http://www.ncbi.nlm.nih.gov/pubmed/25960806", "http://www.ncbi.nlm.nih.gov/pubmed/22421473", "http://www.ncbi.nlm.nih.gov/pubmed/19608071", "http://www.ncbi.nlm.nih.gov/pubmed/6613471", "http://www.ncbi.nlm.nih.gov/pubmed/18385566", "http://www.ncbi.nlm.nih.gov/pubmed/8885560", "http://www.ncbi.nlm.nih.gov/pubmed/21450061", "http://www.ncbi.nlm.nih.gov/pubmed/26803533", "http://www.ncbi.nlm.nih.gov/pubmed/22377612", "http://www.ncbi.nlm.nih.gov/pubmed/25667776", "http://www.ncbi.nlm.nih.gov/pubmed/25530373", "http://www.ncbi.nlm.nih.gov/pubmed/11771217", "http://www.ncbi.nlm.nih.gov/pubmed/23674771", "http://www.ncbi.nlm.nih.gov/pubmed/26971966", "http://www.ncbi.nlm.nih.gov/pubmed/10630059", "http://www.ncbi.nlm.nih.gov/pubmed/22414457", "http://www.ncbi.nlm.nih.gov/pubmed/20579824", "http://www.ncbi.nlm.nih.gov/pubmed/7243138", "http://www.ncbi.nlm.nih.gov/pubmed/25923155", "http://www.ncbi.nlm.nih.gov/pubmed/19629969", "http://www.ncbi.nlm.nih.gov/pubmed/24867818", "http://www.ncbi.nlm.nih.gov/pubmed/15906794"], "ideal_answer": ["Mondor's disease is a rare benign and self-limiting condition characterized by thrombophlebitis of the superficial veins of the anterolateral thoracoabdominal wall and genital area."], "type": "summary", "id": "589a246778275d0c4a00002f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "INTRODUCTION: Mondor's disease is a rare superficial thrombophlebitis, historically involving the thoracic venous system of women. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26971966", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Mondor's disease is a rare benign and self-limiting condition characterized by thrombophlebitis of the superficial veins of the anterolateral thoracoabdominal wall.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24989360", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Mondor's disease is a rare condition characterized by a superficial thrombophlebitis that can occur in the thoracoabdominal and genital areas. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25667776", "endSection": "abstract"}, {"offsetInBeginSection": 1419, "offsetInEndSection": 1680, "text": "CONCLUSION: Penile Mondor disease is a rare complication that can be successfully treated with medical therapy and conservative approach. Our series showed that penile Mondor's disease does not lead to permanent deformation of the penis or erectile dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25530373", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Thrombophlebitis of the thoracoepigastric system of veins is a benign disease and, despite its localized involvement and presentation, the condition is known as Mondor disease (MD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19608071", "endSection": "abstract"}, {"offsetInBeginSection": 400, "offsetInEndSection": 685, "text": "Though penile Mondor's disease involving the dorsal vein of the penis has been reported by many authors, we report a peculiar case of penile Mondor's disease in a 26-year-old sexually active man with thrombophlebitis of the circumflex vein of the penis with sparing of the dorsal vein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24867818", "endSection": "abstract"}, {"offsetInBeginSection": 193, "offsetInEndSection": 348, "text": "Mondor's disease of the penis is an uncommon condition, which usually involves the superficial dorsal veins, it was first described by Braun-Falco in 1955.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15906794", "endSection": "abstract"}, {"offsetInBeginSection": 297, "offsetInEndSection": 404, "text": "Penile Mondor's disease is rare disease that's characterized by thrombosis in the dorsal vein of the penis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18385566", "endSection": "abstract"}]}, {"body": "List metalloenzyme inhibitors.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19949750", "http://www.ncbi.nlm.nih.gov/pubmed/21046516", "http://www.ncbi.nlm.nih.gov/pubmed/21189019", "http://www.ncbi.nlm.nih.gov/pubmed/11551755", "http://www.ncbi.nlm.nih.gov/pubmed/22308350", "http://www.ncbi.nlm.nih.gov/pubmed/17314045", "http://www.ncbi.nlm.nih.gov/pubmed/18666306", "http://www.ncbi.nlm.nih.gov/pubmed/24074025"], "ideal_answer": ["Foscarnet\nVT-1129\nVT-1161 \nBB-3497\nhydroxamate molecules\nsiderophores"], "type": "list", "id": "58ce5c7c1f5fb2b734000001", "snippets": [{"offsetInBeginSection": 123, "offsetInEndSection": 401, "text": " Clinically approved inhibitors were selected as well as several other reported metalloprotein inhibitors in order to represent a broad range of metal binding groups (MBGs), including hydroxamic acid, carboxylate, hydroxypyridinonate, thiol, and N-hydroxyurea functional groups.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24074025", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 293, "text": "A total of 21 different raltegravir-chelator derivative (RCD) compounds were prepared that differed only in the nature of the MBG. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22308350", "endSection": "abstract"}, {"offsetInBeginSection": 863, "offsetInEndSection": 1055, "text": "At least two compounds (RCD-4, RCD-5) containing a hydroxypyrone MBG were found to display superior strand-transfer inhibition when compared to an abbreviated analogue of raltegravir (RCD-1). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22308350", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "By screening a library of metalloenzyme inhibitors, the N-formyl-hydroxylamine derivative BB-3497 was identified as a potent inhibitor of Escherichia coli peptide deformylase with antibacterial activity both in vitro and in vivo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11551755", "endSection": "abstract"}, {"offsetInBeginSection": 984, "offsetInEndSection": 1172, "text": " The 8-hydroxyquinoline represents a promising new chelator scaffold for the development of MMP inhibitors that was discovered by use of a metalloprotein-focused chelator fragment library.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21189019", "endSection": "abstract"}, {"offsetInBeginSection": 568, "offsetInEndSection": 647, "text": " the metalloenzyme inhibitors VT-1129 and VT-1161 (both Viamet Pharmaceuticals)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21046516", "endSection": "abstract"}, {"offsetInBeginSection": 24, "offsetInEndSection": 161, "text": "Based on their ability to chelate metals, hydroxamate molecules and siderophores have been successfully used as metalloenzyme inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19949750", "endSection": "abstract"}, {"offsetInBeginSection": 881, "offsetInEndSection": 1073, "text": " Using this model, we identified two nitrogen donor compounds--2,2'-dipyridylamine (DPA) and triazacyclononane (TACN)--as the most selective ZBGs for zinc metalloenzyme inhibitor development. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18666306", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Foscarnet (phosphonoformate trisodium salt), an antiviral used for the treatment of HIV and herpes virus infections, also acts as an activator or inhibitor of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17314045", "endSection": "abstract"}]}, {"body": "How are immediate early genes (IEG) defined?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8783263", "http://www.ncbi.nlm.nih.gov/pubmed/11222693", "http://www.ncbi.nlm.nih.gov/pubmed/19581597", "http://www.ncbi.nlm.nih.gov/pubmed/15507712"], "ideal_answer": ["this class of genes is experimentally defined by their transcription following primary infection or reactivation in the presence of inhibitors of protein synthesis. Immediate-early (IE) genes are the first class of viral genes expressed after primary infection or reactivation.", "this class of genes is experimentally defined by their transcription following primary infection or reactivation in the presence of inhibitors of protein synthesis.", "Immediate-early (IE) genes are the first class of viral genes expressed after primary infection or reactivation.", "Immediate-early (IE) genes are the first class of viral genes expressed after primary infection or reactivation. this class of genes is experimentally defined by their transcription following primary infection or reactivation in the presence of inhibitors of protein synthesis. . . . ", "Immediate-early (IE) genes are the first class of viral genes expressed after primary infection or reactivation. This class of genes is experimentally defined by their transcription following primary infection or reactivation in the presence of inhibitors of protein synthesis.", "Immediate-early (IE) genes are the first class of viral genes expressed after primary infection or reactivation. this class of genes is experimentally defined by their transcription following primary infection or reactivation in the presence of inhibitors of protein synthesis."], "type": "summary", "id": "58c2556302b8c6095300001f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Immediate-early (IE) genes are the first class of viral genes expressed after primary infection or reactivation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15507712", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 354, "text": "this class of genes is experimentally defined by their transcription following primary infection or reactivation in the presence of inhibitors of protein synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15507712", "endSection": "abstract"}]}, {"body": "Which proteins remove H2A.Z in the yeast Saccharomyces cerevisiae?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26982580", "http://www.ncbi.nlm.nih.gov/pubmed/26142279"], "ideal_answer": ["Removal of H2A.Z by INO80 promotes homologous recombination Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. Here, we show that H2A.Z in human cells is indeed rapidly removed from chromatin flanking DNA damage by INO80.", "Here, we show that H2A.Z in human cells is indeed rapidly removed from chromatin flanking DNA damage by INO80. We also report that the histone chaperone ANP32E, which is implicated in removing H2AZ from chromatin, similarly promotes HR and appears to work on the same pathway as INO80 in these assays. Importantly, we demonstrate that the HR defect in cells depleted of INO80 or ANP32E can be rescued by H2A.Z co-depletion, suggesting that H2A.Z removal from chromatin is the primary function of INO80 and ANP32E in promoting homologous recombination.", "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. Here, we show that H2A.Z in human cells is indeed rapidly removed from chromatin flanking DNA damage by INO80. We also report that the histone chaperone ANP32E, which is implicated in removing H2AZ from chromatin, similarly promotes HR and appears to work on the same pathway as INO80 in these assays.", "we also report that the histone chaperone anp32e, which is implicated in removing h2az from chromatin, similarly promotes hr and appears to work on the same pathway as ino80 in these assays.", "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. Removal of H2A.Z by INO80 promotes homologous recombination H2A.Z removal from chromatin is the primary function of INO80 and ANP32E in promoting homologous recombination.", "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. Removal of H2A.Z by INO80 promotes homologous recombination", "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers. H2A.Z removal from chromatin is the primary function of INO80 and ANP32E in promoting homologous recombination."], "type": "list", "id": "58de71fa8acda3452900002c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Removal of H2A.Z by INO80 promotes homologous recombination", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "title"}, {"offsetInBeginSection": 135, "offsetInEndSection": 235, "text": "Budding yeast INO80 can remove H2A.Z/H2B dimers from chromatin and replace them with H2A/H2B dimers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "abstract"}, {"offsetInBeginSection": 403, "offsetInEndSection": 513, "text": "Here, we show that H2A.Z in human cells is indeed rapidly removed from chromatin flanking DNA damage by INO80.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "abstract"}, {"offsetInBeginSection": 514, "offsetInEndSection": 704, "text": "We also report that the histone chaperone ANP32E, which is implicated in removing H2AZ from chromatin, similarly promotes HR and appears to work on the same pathway as INO80 in these assays.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "abstract"}, {"offsetInBeginSection": 843, "offsetInEndSection": 954, "text": "H2A.Z removal from chromatin is the primary function of INO80 and ANP32E in promoting homologous recombination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26142279", "endSection": "abstract"}, {"offsetInBeginSection": 891, "offsetInEndSection": 1011, "text": "Instead, the INO80 complex, which removes H2A.Z(Htz1) from nucleosomes, promotes the ectopic deposition of CENP-A(Cse4).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26982580", "endSection": "abstract"}]}, {"body": "Which library is used for fixed-length approximate string matching?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27832739"], "ideal_answer": ["libFLASM is a free open-source C++ software library for solving fixed-length approximate string matching under both the edit and the Hamming distance models."], "type": "factoid", "id": "587f7a69d8d850a152000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "libFLASM: a software library for fixed-length approximate string matching.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27832739", "endSection": "title"}, {"offsetInBeginSection": 862, "offsetInEndSection": 1737, "text": "We present and make available libFLASM, a free open-source C++ software library for solving fixed-length approximate string matching under both the edit and the Hamming distance models. Moreover we describe how fixed-length approximate string matching is applied to solve real problems by incorporating libFLASM into established applications for multiple circular sequence alignment as well as single and structured motif extraction. Specifically, we describe how it can be used to improve the accuracy of multiple circular sequence alignment in terms of the inferred likelihood-based phylogenies; and we also describe how it is used to efficiently find motifs in molecular sequences representing regulatory or functional regions. The comparison of the performance of the library to other algorithms show how it is competitive, especially with increasing distance thresholds.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27832739", "endSection": "abstract"}, {"offsetInBeginSection": 1750, "offsetInEndSection": 2164, "text": "Fixed-length approximate string matching is a generalisation of the classic approximate string matching problem. We present libFLASM, a free open-source C++ software library for solving fixed-length approximate string matching. The extensive experimental results presented here suggest that other applications could benefit from using libFLASM, and thus further maintenance and development of libFLASM is desirable", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27832739", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "libFLASM: a software library for fixed-length approximate string matching.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27832739", "endSection": "title"}, {"offsetInBeginSection": 1832, "offsetInEndSection": 1946, "text": "We present libFLASM, a free open-source C++ software library for solving fixed-length approximate string matching.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27832739", "endSection": "abstract"}, {"offsetInBeginSection": 843, "offsetInEndSection": 1028, "text": "We present and make available libFLASM, a free open-source C++ software library for solving fixed-length approximate string matching under both the edit and the Hamming distance models.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27832739", "endSection": "abstract"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1276, "text": "Moreover we describe how fixed-length approximate string matching is applied to solve real problems by incorporating libFLASM into established applications for multiple circular sequence alignment as well as single and structured motif extraction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27832739", "endSection": "abstract"}]}, {"body": "Are there methods for generating highly multiplexed ChIP-seq libraries?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24885602"], "ideal_answer": ["Yes. There are methods for generating highly multiplexed ChIP-seq libraries."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015698", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D047369", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056656"], "type": "yesno", "id": "589206fc49702f2e01000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "A method for generating highly multiplexed ChIP-seq libraries.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24885602", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 817, "text": "The barcoding of next generation sequencing libraries has become an essential part of the experimental design. Barcoding not only allows the sequencing of more than one sample per lane, but also reduces technical bias. However, current barcoding strategies impose significant limitations and/or technical barriers in their implementation for ChIP-sequencing.FINDINGS: Converting Y-shaped sequencing adapters to double stranded DNA prior to agarose gel size selection reduces adapter dimer contamination and quantitating the number of cycles required for amplification of the library with qPCR prior to library amplification eliminates library over-amplification.CONCLUSIONS: We describe an efficient and cost effective method for making barcoded ChIP-seq libraries for sequencing on the Illumina platform.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24885602", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "A method for generating highly multiplexed ChIP-seq libraries", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24885602", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "A method for generating highly multiplexed ChIP-seq libraries.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24885602", "endSection": "title"}, {"offsetInBeginSection": 654, "offsetInEndSection": 785, "text": "We describe an efficient and cost effective method for making barcoded ChIP-seq libraries for sequencing on the Illumina platform..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24885602", "endSection": "abstract"}]}, {"body": "Is Doxorubicin cardiotoxic?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24382354", "http://www.ncbi.nlm.nih.gov/pubmed/25885550", "http://www.ncbi.nlm.nih.gov/pubmed/21057569", "http://www.ncbi.nlm.nih.gov/pubmed/19103993", "http://www.ncbi.nlm.nih.gov/pubmed/6734434", "http://www.ncbi.nlm.nih.gov/pubmed/6407163", "http://www.ncbi.nlm.nih.gov/pubmed/9923553", "http://www.ncbi.nlm.nih.gov/pubmed/12679799", "http://www.ncbi.nlm.nih.gov/pubmed/12865930", "http://www.ncbi.nlm.nih.gov/pubmed/23843850", "http://www.ncbi.nlm.nih.gov/pubmed/24714774", "http://www.ncbi.nlm.nih.gov/pubmed/20060872", "http://www.ncbi.nlm.nih.gov/pubmed/19660469", "http://www.ncbi.nlm.nih.gov/pubmed/26507774", "http://www.ncbi.nlm.nih.gov/pubmed/24484915", "http://www.ncbi.nlm.nih.gov/pubmed/17875725", "http://www.ncbi.nlm.nih.gov/pubmed/25660617", "http://www.ncbi.nlm.nih.gov/pubmed/22343424", "http://www.ncbi.nlm.nih.gov/pubmed/24902966", "http://www.ncbi.nlm.nih.gov/pubmed/8647872", "http://www.ncbi.nlm.nih.gov/pubmed/26164096", "http://www.ncbi.nlm.nih.gov/pubmed/24916696", "http://www.ncbi.nlm.nih.gov/pubmed/8402643", "http://www.ncbi.nlm.nih.gov/pubmed/3029137", "http://www.ncbi.nlm.nih.gov/pubmed/15515283", "http://www.ncbi.nlm.nih.gov/pubmed/1531780", "http://www.ncbi.nlm.nih.gov/pubmed/27735842"], "ideal_answer": ["Doxorubicin (DOXO) is widely used to treat solid tumors. However, its clinical use is limited by side effects including serious cardiotoxicity due to cardiomyocyte damage", "Doxorubicin (DOXO) is widely used to treat solid tumors. However, its clinical use is limited by side effects including serious cardiotoxicity due to cardiomyocyte damage. "], "concepts": ["http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4269440", "http://www.biosemantics.org/jochem#4085749", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004317", "http://www.biosemantics.org/jochem#4269440", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054715", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D066126"], "type": "yesno", "id": "58cdb80302b8c60953000043", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Doxorubicin (DOXO) is widely used to treat solid tumors. However, its clinical use is limited by side effects including serious cardiotoxicity due to cardiomyocyte damage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27735842", "endSection": "abstract"}, {"offsetInBeginSection": 1366, "offsetInEndSection": 1464, "text": "The results provide direct evidence for the role of catalase in doxorubicin cardiotoxic responses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8647872", "endSection": "abstract"}, {"offsetInBeginSection": 582, "offsetInEndSection": 710, "text": "These results do not support the possibility that mitomycin C potentiates the acute cardiotoxic effects produced by doxorubicin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6407163", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "The anthracycline chemotherapeutic agent doxorubicin is converted by the enzyme carbonyl reductase 1 (CBR1) into its cardiotoxic metabolite doxorubicinol", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22343424", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "The clinical efficiency of the highly potent antitumor agent doxorubicin is limited by cardiotoxic effects", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25660617", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Doxorubicin (DOX), a highly active chemotherapeutic drug, faces limitations in clinical application due to severe cardiotoxic effects (mainly through increased oxidative stress)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25885550", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Clinical uses of doxorubicin (DOX), a highly active anticancer agent, are limited by its severe cardiotoxic side effects associated with increased oxidative stress and apoptosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20060872", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Doxorubicin (DOX) and trastuzumab (TRZ) are highly effective chemotherapeutic agents in the breast cancer setting, limited by their cardiotoxic side effects", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24484915", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24916696", "endSection": "title"}, {"offsetInBeginSection": 2666, "offsetInEndSection": 2769, "text": "Cardiotoxic effects were reported in 15 (5%) of 291 children receiving treatment including doxorubicin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26164096", "endSection": "abstract"}, {"offsetInBeginSection": 1857, "offsetInEndSection": 2173, "text": "On the other hand, pretreatment of rats with hesperidin protected cardiac tissues against the cardiotoxic effects of doxorubicin as evidenced from amelioration of histopathological changes and normalization of cardiac biochemical parameters.Hesperidin may have a protective effect against DOX-induced cardiotoxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21057569", "endSection": "abstract"}, {"offsetInBeginSection": 103, "offsetInEndSection": 233, "text": "However, with cumulative doses, doxorubicin also is known to have cardiotoxic effects, including cardiomyopathy and heart failure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15515283", "endSection": "abstract"}, {"offsetInBeginSection": 196, "offsetInEndSection": 363, "text": "Methods of reducing or preventing doxorubicin-induced cardiotoxicity have been suggested, including an investigational doxorubicin analog, mitoxantrone ( Novantrone ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6734434", "endSection": "abstract"}, {"offsetInBeginSection": 777, "offsetInEndSection": 972, "text": "The most cardiotoxic drug, doxorubicin, is the most potent inducer of superoxide generation, while epirubicin, which is less cardiotoxic, has a relatively limited effect on superoxide production.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3029137", "endSection": "abstract"}, {"offsetInBeginSection": 164, "offsetInEndSection": 330, "text": "The mechanism of doxorubicin cardiotoxicity is likely multifactorial and most importantly, the genetic factors predisposing to doxorubicin cardiotoxicity are unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24714774", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "As doxorubicin cardiotoxicity is considered irreversible, early detection of cardiotoxicity and prevention of overt heart failure is essential.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23843850", "endSection": "abstract"}, {"offsetInBeginSection": 144, "offsetInEndSection": 299, "text": "Although there are monitoring guidelines for cardiotoxicity, optimal timing for early detection of subclinical doxorubicin cardiotoxicity is still obscure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23843850", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24902966", "endSection": "title"}, {"offsetInBeginSection": 85, "offsetInEndSection": 171, "text": "However, doxorubicin cardiotoxicity of the heart has largely limited its clinical use.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26507774", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24714774", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Doxorubicin-based chemotherapy induces cardiotoxicity, which limits its clinical application.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24902966", "endSection": "abstract"}, {"offsetInBeginSection": 21, "offsetInEndSection": 166, "text": "he clinical use of doxorubicin (DOX) and other anthracyclines is limited by a dosage-dependent cardiotoxicity, which can lead to cardiomyopathy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17888722", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "Besides its cardiotoxic effect, doxorubicin also elicits inflammatory effects in vivo. 7-Monohydroxyethylrutoside (monoHER) has recently been used as a protector against doxorubicin-induced cardiotoxicity in vivo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12865930", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Doxorubicin is an effective antineoplastic agent, but it frequently causes dose-related cardiotoxic effects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1531780", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 305, "text": "Among these analogs, idarubicin (4-demethoxy-daunorubicin) was shown to be less cardiotoxic than doxorubicin i", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10507317", "endSection": "abstract"}, {"offsetInBeginSection": 177, "offsetInEndSection": 260, "text": "Verapamil has also been suggested to potentiate the cardiotoxicity of doxorubicin. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8402643", "endSection": "abstract"}, {"offsetInBeginSection": 69, "offsetInEndSection": 149, "text": "Doxorubicin treatment is associated with both acute and chronic cardiotoxicity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19103993", "endSection": "abstract"}, {"offsetInBeginSection": 247, "offsetInEndSection": 329, "text": "cardiac effects of diclofenac sodium on doxorubicin-induced cardiomyopathy in rats", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920767", "endSection": "abstract"}]}, {"body": "Which diseases are associated with Primary intestinal lymphangiectasia (PIL)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26934740", "http://www.ncbi.nlm.nih.gov/pubmed/22110841", "http://www.ncbi.nlm.nih.gov/pubmed/23626516", "http://www.ncbi.nlm.nih.gov/pubmed/26405709", "http://www.ncbi.nlm.nih.gov/pubmed/15229406", "http://www.ncbi.nlm.nih.gov/pubmed/16292099", "http://www.ncbi.nlm.nih.gov/pubmed/20812055", "http://www.ncbi.nlm.nih.gov/pubmed/17900962", "http://www.ncbi.nlm.nih.gov/pubmed/18294365", "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "http://www.ncbi.nlm.nih.gov/pubmed/26908672", "http://www.ncbi.nlm.nih.gov/pubmed/26027272"], "ideal_answer": ["Primary intestinal lymphangiectasia (PIL) is associated with:\n1) Waldmann's disease and\n2) Hennekam syndrome (HS)."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:4", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008201", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008200", "http://www.disease-ontology.org/api/metadata/DOID:2402", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007413", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007410", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194"], "type": "list", "id": "58ca6d3902b8c6095300002c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is an exudative enteropathy resulting from morphologic abnormalities in the intestinal lymphatics. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908672", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Secondary hypogammaglobulinemia in Waldmann's disease treated with subcutaneous immunoglobulins.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26934740", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Octreotide in Hennekam syndrome-associated intestinal lymphangiectasia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "endSection": "title"}, {"offsetInBeginSection": 97, "offsetInEndSection": 250, "text": "Primary intestinal lymphangiectasia (PIL) is one mechanism leading to PLE. Few syndromes are associated with PIL; Hennekam syndrome (HS) is one of them. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "endSection": "abstract"}, {"offsetInBeginSection": 530, "offsetInEndSection": 617, "text": "There are no publications on the treatment of PIL with octreotide in patients with HS. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "endSection": "abstract"}, {"offsetInBeginSection": 1169, "offsetInEndSection": 1275, "text": "To the best of our knowledge, this is the first case report on the use of octreotide in HS-associated PIL.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is a rare disorder characterized by dilated intestinal lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20812055", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Primary intestinal lymphangiectasia (Waldmann's disease).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18294365", "endSection": "title"}, {"offsetInBeginSection": 1, "offsetInEndSection": 101, "text": "Limb lymphedema as a first manifestation of primary intestinal lymphangiectasia (Waldmann's disease)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15229406", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Primary intestinal lymphangiectasia (Waldmann's disease) is characterized by protein-losing enteropathy occurring more frequently in childhood. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15229406", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is an exudative enteropathy resulting from morphologic abnormalities in the intestinal lymphatics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908672", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "Primary intestinal lymphangiectasia (PIL), so-called Waldmann's disease, is an uncommon condition, characterized by dilated intestinal submucosal and subserosal lymphatics of the gastrointestinal tract.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16292099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Primary intestinal lymphangiectasia (PIL) or Waldmann's disease is a rare protein-losing gastroenteropathy of unknown etiology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23626516", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 306, "text": "Primary intestinal lymphangiectasia (PIL), also known as Waldmanns disease, is a rare disorder characterized by dilated intestinal lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20812055", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Primary intestinal lymphangiectasia (PIL) or Waldmanns disease is a rare protein-losing gastroenteropathy of unknown etiology", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23626516", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "Primary intestinal lymphangiectasia (PIL), so-called Waldmanns disease, is an uncommon condition, characterized by dilated intestinal submucosal and subserosal lymphatics of the gastrointestinal tract", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16292099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 361, "text": "Primary intestinal lymphangiectasia (Waldmanns disease) is a rare disease characterized by dilated lymphatics in the small bowel leading to an exudative enteropathy with lymphopenia, hypoalbuminemia and hypogammaglobulinemia.We report the case of a 23 year-old male who presented with chronic anemia and in whom primary intestinal lymphangiectasia was diagnosed", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26405709", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Primary intestinal lymphangiectasis (PIL), also known as Waldmanns disease, is a rare protein-losing enteropathy characterized by abnormal enlargement of the lymphatic ducts in the bowel wall", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17900962", "endSection": "abstract"}, {"offsetInBeginSection": 172, "offsetInEndSection": 250, "text": "Few syndromes are associated with PIL; Hennekam syndrome (HS) is one of them. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 309, "text": "Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is a rare disorder characterized by dilated intestinal lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20812055", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Primary intestinal lymphangiectasia (Waldmann's disease) is characterized by protein-losing enteropathy occurring more frequently in childhood.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15229406", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Primary intestinal lymphangiectasia (Waldmann's disease).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18294365", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Octreotide in Hennekam syndrome-associated intestinal lymphangiectasia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "endSection": "title"}]}, {"body": "Is the mouse Sry gene locus free of repetitive sequences?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10410901", "http://www.ncbi.nlm.nih.gov/pubmed/20851541", "http://www.ncbi.nlm.nih.gov/pubmed/24228692", "http://www.ncbi.nlm.nih.gov/pubmed/8747544", "http://www.ncbi.nlm.nih.gov/pubmed/1518820", "http://www.ncbi.nlm.nih.gov/pubmed/9369180", "http://www.ncbi.nlm.nih.gov/pubmed/8566785"], "ideal_answer": ["We demonstrate that the presence of long inverted repeats (IR) flanking the mouse Sry gene leads to the formation of the Sry circular transcript in cultured cells. We have found that in an in vitro assay, the SRY protein binds to several sites of the Sry gene and especially to a (CA)25 sequence and to a (CAG)30 repeat.", "The presence of long inverted repeats (IR) flanking the mouse Sry gene leads to the formation of the Sry circular transcript in cultured cells.", "We demonstrate that the presence of long inverted repeats (IR) flanking the mouse Sry gene leads to the formation of the Sry circular transcript in cultured cells Circularization requires the presence of both IR.", "We demonstrate that the presence of long inverted repeats (IR) flanking the mouse Sry gene leads to the formation of the Sry circular transcript in cultured cells We have found that in an in vitro assay, the SRY protein binds to several sites of the Sry gene and especially to a (CA)25 sequence and to a (CAG)30 repeat", "We demonstrate that the presence of long inverted repeats (IR) flanking the mouse Sry gene leads to the formation of the Sry circular transcript in cultured cells"], "type": "yesno", "id": "58de34608acda3452900002b", "snippets": [{"offsetInBeginSection": 446, "offsetInEndSection": 608, "text": "We demonstrate that the presence of long inverted repeats (IR) flanking the mouse Sry gene leads to the formation of the Sry circular transcript in cultured cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8566785", "endSection": "abstract"}, {"offsetInBeginSection": 610, "offsetInEndSection": 721, "text": "Circularization requires the presence of both IR. As few as 400 complementary nt are necessary for this process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8566785", "endSection": "abstract"}, {"offsetInBeginSection": 723, "offsetInEndSection": 830, "text": "The presence of the IR does not significantly stimulate intermolecular annealing and trans-splicing in vivo", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8566785", "endSection": "abstract"}, {"offsetInBeginSection": 397, "offsetInEndSection": 552, "text": "We have found that in an in vitro assay, the SRY protein binds to several sites of the Sry gene and especially to a (CA)25 sequence and to a (CAG)30 repeat", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8747544", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "The Q-rich domain of the mouse sex determining gene, Sry, is encoded by an in-frame insertion of a repetitive sequence composed of mostly CAG repeats.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10410901", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "Inverted repeat structure of the Sry locus in mice.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1518820", "endSection": "title"}, {"offsetInBeginSection": 442, "offsetInEndSection": 616, "text": "We performed separate amplifications of DXZ4 repetitive satellite sequences on the X chromosome, and SRY gene - testis determined factor on the Y chromosome, using nested PCR", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851541", "endSection": "abstract"}, {"offsetInBeginSection": 223, "offsetInEndSection": 423, "text": "Detailed analysis of the Sry genomic locus reveals a further difference in that the mouse Sry open reading frame lies within 2.8 kilobases of unique sequence at the center of a large inverted repeat. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1518820", "endSection": "abstract"}, {"offsetInBeginSection": 223, "offsetInEndSection": 422, "text": "Detailed analysis of the Sry genomic locus reveals a further difference in that the mouse Sry open reading frame lies within 2.8 kilobases of unique sequence at the center of a large inverted repeat.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1518820", "endSection": "abstract"}, {"offsetInBeginSection": 269, "offsetInEndSection": 478, "text": "The mouse genomic Sry locus is characterized by two arms of a large inverted repeat, flanking a unique region that, between an acceptor and a donor splice site, contains a single exon encoding the Sry protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9369180", "endSection": "abstract"}, {"offsetInBeginSection": 563, "offsetInEndSection": 697, "text": "Recombination involving the repeat region may have led to an 11-kilobase deletion, precisely excising Sry in a line of XY female mice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1518820", "endSection": "abstract"}, {"offsetInBeginSection": 792, "offsetInEndSection": 914, "text": "Repetitive element analysis revealed numerous LINE-L1 elements at regions where conservation is lost among the Sry copies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24228692", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Inverted repeat structure of the Sry locus in mice.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1518820", "endSection": "title"}]}, {"body": "Is Meis1 implicated in microphthalmia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26253404"], "ideal_answer": ["Yes. Meis1 coordinates a network of genes implicated in eye development and microphthalmia. Haploinsufficiency of Meis1, which encodes a transcription factor with evolutionarily conserved expression in the embryonic trunk, brain and sensory organs, including the eye, causes microphthalmic traits and visual impairment in adult mice."], "concepts": ["http://www.uniprot.org/uniprot/MEIS1_HUMAN", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008850", "http://www.uniprot.org/uniprot/MITF_MOUSE", "http://www.uniprot.org/uniprot/MITF_RAT", "http://www.disease-ontology.org/api/metadata/DOID:10629", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051739", "http://www.uniprot.org/uniprot/MEIS1_XENLA", "http://www.uniprot.org/uniprot/MEIS1_MOUSE", "http://www.uniprot.org/uniprot/MITF_HUMAN"], "type": "yesno", "id": "5892783d49702f2e01000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Meis1 coordinates a network of genes implicated in eye development and microphthalmia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "title"}, {"offsetInBeginSection": 328, "offsetInEndSection": 587, "text": "Here we show that haploinsufficiency of Meis1, which encodes a transcription factor with evolutionarily conserved expression in the embryonic trunk, brain and sensory organs, including the eye, causes microphthalmic traits and visual impairment in adult mice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "abstract"}, {"offsetInBeginSection": 1310, "offsetInEndSection": 1502, "text": "We propose that Meis1 is at the core of a genetic network implicated in eye patterning/microphthalmia, and represents an additional candidate for syndromic cases of these ocular malformations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "abstract"}, {"offsetInBeginSection": 1303, "offsetInEndSection": 1495, "text": "We propose that Meis1 is at the core of a genetic network implicated in eye patterning/microphthalmia, and represents an additional candidate for syndromic cases of these ocular malformations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "abstract"}, {"offsetInBeginSection": 868, "offsetInEndSection": 1083, "text": "In the eye primordium, Meis1 coordinates, in a dose-dependent manner, retinal proliferation and differentiation by regulating genes responsible for human microphthalmia and components of the Notch signaling pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Meis1 coordinates a network of genes implicated in eye development and microphthalmia", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "title"}, {"offsetInBeginSection": 1310, "offsetInEndSection": 1531, "text": "We propose that Meis1 is at the core of a genetic network implicated in eye patterning/microphthalmia, and represents an additional candidate for syndromic cases of these ocular malformations. <CopyrightInformation>\u00a9 2015", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "abstract"}, {"offsetInBeginSection": 873, "offsetInEndSection": 1087, "text": "In the eye primordium, Meis1 coordinates, in a dose-dependent manner, retinal proliferation and differentiation by regulating genes responsible for human microphthalmia and components of the Notch signaling pathway", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "abstract"}, {"offsetInBeginSection": 1310, "offsetInEndSection": 1532, "text": "We propose that Meis1 is at the core of a genetic network implicated in eye patterning/microphthalmia, and represents an additional candidate for syndromic cases of these ocular malformations. <CopyrightInformation>\u00a9 2015.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "abstract"}, {"offsetInBeginSection": 873, "offsetInEndSection": 1088, "text": "In the eye primordium, Meis1 coordinates, in a dose-dependent manner, retinal proliferation and differentiation by regulating genes responsible for human microphthalmia and components of the Notch signaling pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Meis1 coordinates a network of genes implicated in eye development and microphthalmia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253404", "endSection": "title"}]}, {"body": "Can Pentraxin 3 predict outcomes of sepsis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15977234", "http://www.ncbi.nlm.nih.gov/pubmed/25001601", "http://www.ncbi.nlm.nih.gov/pubmed/25227610", "http://www.ncbi.nlm.nih.gov/pubmed/26982005", "http://www.ncbi.nlm.nih.gov/pubmed/27864924", "http://www.ncbi.nlm.nih.gov/pubmed/26872435", "http://www.ncbi.nlm.nih.gov/pubmed/24958171", "http://www.ncbi.nlm.nih.gov/pubmed/23341967", "http://www.ncbi.nlm.nih.gov/pubmed/20119647", "http://www.ncbi.nlm.nih.gov/pubmed/22278372", "http://www.ncbi.nlm.nih.gov/pubmed/26717657", "http://www.ncbi.nlm.nih.gov/pubmed/11445697", "http://www.ncbi.nlm.nih.gov/pubmed/25530683", "http://www.ncbi.nlm.nih.gov/pubmed/25048752", "http://www.ncbi.nlm.nih.gov/pubmed/25591437", "http://www.ncbi.nlm.nih.gov/pubmed/24039869", "http://www.ncbi.nlm.nih.gov/pubmed/21423699"], "ideal_answer": ["Yes, Pentraxin 3 s an objective biochemical marker in diagnosis of sepsis; it is helpful in assessment of severity and prognosis of sepsis; it also has a certain clinical value in the assessment of sepsis cardiovascular function damage."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018805", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000066891", "http://www.biosemantics.org/jochem#4264880"], "type": "yesno", "id": "5890eb22621ea6ff7e000006", "snippets": [{"offsetInBeginSection": 1447, "offsetInEndSection": 1708, "text": "As compared with low serum PTX3and sTWEAK cases, cirrhotic patients with high serum PTX3/sTWEAK levels a have higher probability of new severe infections, severe sepsis, septic shock, type 1 hepatorenal syndrome, in-hospital, and 3-month follow-up mortalities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26872435", "endSection": "abstract"}, {"offsetInBeginSection": 1350, "offsetInEndSection": 1543, "text": "Neonates with high nPTX3 concentrations also have lowered APGAR scores, increased rate of respiratory distress syndrome, clinical sepsis, IVH, necrotizing enterocolitis and prolonged NICU stay.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25048752", "endSection": "abstract"}, {"offsetInBeginSection": 3688, "offsetInEndSection": 4106, "text": "In terms of predicting the prognosis of sepsis with heart failure complications, the PTX3 value's area under ROC curve was larger than that of BNP (respectively 0. 844, 0. 472).CONCLUSION: The PTX3 is an objective biochemical marker in diagnosis of sepsis; it is helpful in assessment of severity and prognosis of sepsis; it also has a certain clinical value in the assessment of sepsis cardiovascular function damage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26717657", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Severe Acinetobacter baumannii sepsis is associated with elevation of pentraxin 3.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25001601", "endSection": "title"}, {"offsetInBeginSection": 1636, "offsetInEndSection": 1755, "text": "Together, these results suggest that elevation of PTX3 is associated with fulminant disease during A. baumannii sepsis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25001601", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20119647", "endSection": "title"}, {"offsetInBeginSection": 231, "offsetInEndSection": 332, "text": "PTX3, as a mediator of inflammation, may represent an early marker of severity and outcome in sepsis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20119647", "endSection": "abstract"}, {"offsetInBeginSection": 1413, "offsetInEndSection": 1645, "text": "CONCLUSIONS: Persisting high levels of circulating PTX3 over the first days from sepsis onset may be associated with mortality. PTX3 correlates with severity of sepsis and with sepsis-associated coagulation/fibrinolysis dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20119647", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27864924", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Pentraxin 3: an immune modulator of infection and useful marker for disease severity assessment in sepsis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26982005", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Redox state of pentraxin 3 as a novel biomarker for resolution of inflammation and survival in sepsis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24958171", "endSection": "title"}, {"offsetInBeginSection": 270, "offsetInEndSection": 504, "text": "The prototypic long pentraxin, pentraxin 3, is an acute phase protein that is structurally related but distinct from C-reactive protein which has proven to correlate with the severity of bacterial infection in critically ill patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15977234", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11445697", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: a prospective cohort study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23341967", "endSection": "title"}, {"offsetInBeginSection": 1074, "offsetInEndSection": 1278, "text": "In addition, high levels of PTX3 were associated with unfavorable outcome.CONCLUSIONS: The long pentraxin PTX3 is elevated in critically ill patients and correlates with severity of disease and infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11445697", "endSection": "abstract"}, {"offsetInBeginSection": 222, "offsetInEndSection": 323, "text": "PTX3, as a mediator of inflammation, may represent an early marker of severity and outcome in sepsis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20119647", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Redox state of pentraxin 3 as a novel biomarker for resolution of inflammation and survival in sepsis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24958171", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20119647", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: a prospective cohort study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23341967", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The proteomic profile of circulating pentraxin 3 (PTX3) complex in sepsis demonstrates the interaction with azurocidin 1 and other components of neutrophil extracellular traps.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22278372", "endSection": "title"}]}, {"body": "Which polymerase transcribes pri-miRNAs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18042145", "http://www.ncbi.nlm.nih.gov/pubmed/26473486", "http://www.ncbi.nlm.nih.gov/pubmed/18829588", "http://www.ncbi.nlm.nih.gov/pubmed/26119101", "http://www.ncbi.nlm.nih.gov/pubmed/20144951", "http://www.ncbi.nlm.nih.gov/pubmed/21702984", "http://www.ncbi.nlm.nih.gov/pubmed/20655920", "http://www.ncbi.nlm.nih.gov/pubmed/26149087", "http://www.ncbi.nlm.nih.gov/pubmed/19398578", "http://www.ncbi.nlm.nih.gov/pubmed/20129062", "http://www.ncbi.nlm.nih.gov/pubmed/15525708", "http://www.ncbi.nlm.nih.gov/pubmed/21178961", "http://www.ncbi.nlm.nih.gov/pubmed/21685453", "http://www.ncbi.nlm.nih.gov/pubmed/25730776", "http://www.ncbi.nlm.nih.gov/pubmed/15589161", "http://www.ncbi.nlm.nih.gov/pubmed/22499686", "http://www.ncbi.nlm.nih.gov/pubmed/15372072"], "ideal_answer": ["Recent evidence indicates that miRNA genes are transcribed by RNA polymerase II (Pol II) we have established a robust in vivo system in which pri-miRNA is transcribed by RNAP II and processed to pre-miRNA in HeLa cell nuclear extracts.", "Previous studies in vivo reported that processing of primary microRNA (pri-miRNA) is coupled to transcription by RNA polymerase II (RNAP II) and can occur co-transcriptionally. ", "The non-protein-encoding pri-miRNAs are synthesized by RNA polymerase II and post-transcriptionally modified by addition of a 5'-cap and a 3'-poly (A) tail.", " Analogously to mRNAs, the non-protein-encoding pri-miRNAs are synthesized by RNA polymerase II and post-transcriptionally modified by addition of a 5'-cap and a 3'-poly (A) tail. Recent evidence indicates that miRNA genes are transcribed by RNA polymerase II (Pol II)", "Previous studies in vivo reported that processing of primary microRNA (pri-miRNA) is coupled to transcription by RNA polymerase II (RNAP II) and can occur co-transcriptionally. we have established a robust in vivo system in which pri-miRNA is transcribed by RNAP II and processed to pre-miRNA in HeLa cell nuclear extracts.", "Because the transcripts of most miRNA genes are the products of type-II RNA polymerase, pri-miRNA has a poly(A) tail and appears in expressed sequence tags (EST). Analogously to mRNAs, the non-protein-encoding pri-miRNAs are synthesized by RNA polymerase II and post-transcriptionally modified by addition of a 5'-cap and a 3'-poly (A) tail."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:1902893", "http://amigo.geneontology.org/amigo/term/GO:1902895", "http://amigo.geneontology.org/amigo/term/GO:1902894", "http://amigo.geneontology.org/amigo/term/GO:0061614", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012319"], "type": "factoid", "id": "589d965a78275d0c4a000049", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Previous studies in vivo reported that processing of primary microRNA (pri-miRNA) is coupled to transcription by RNA polymerase II (RNAP II) and can occur co-transcriptionally. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26149087", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 328, "text": "we have established a robust in vivo system in which pri-miRNA is transcribed by RNAP II and processed to pre-miRNA in HeLa cell nuclear extracts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26149087", "endSection": "abstract"}, {"offsetInBeginSection": 628, "offsetInEndSection": 873, "text": "In addition, obvious enrichments of three histone modifications (H2BK5me1, H3K36me3 and H4K20me1) as well as RNA Polymerase II (RNAPII) were observed on pre-miRNA genomic sequences corresponding to the active-promoter miRNAs and expressed miRNAs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21702984", "endSection": "abstract"}, {"offsetInBeginSection": 252, "offsetInEndSection": 413, "text": "Because the transcripts of most miRNA genes are the products of type-II RNA polymerase, pri-miRNA has a poly(A) tail and appears in expressed sequence tags (EST)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20655920", "endSection": "abstract"}, {"offsetInBeginSection": 310, "offsetInEndSection": 398, "text": "Recent evidence indicates that miRNA genes are transcribed by RNA polymerase II (Pol II)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18829588", "endSection": "abstract"}, {"offsetInBeginSection": 400, "offsetInEndSection": 688, "text": "Since Pol II transcripts are capped, we hypothesized that CBP (cap-binding protein) 20 and 80 may bind to capped primary miRNA (pri-miRNA) transcripts and play a role in their processing. Here, we show that cbp20 and cbp80 mutants have reduced miRNA levels and increased pri-miRNA levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18829588", "endSection": "abstract"}, {"offsetInBeginSection": 120, "offsetInEndSection": 299, "text": " Analogously to mRNAs, the non-protein-encoding pri-miRNAs are synthesized by RNA polymerase II and post-transcriptionally modified by addition of a 5'-cap and a 3'-poly (A) tail.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18042145", "endSection": "abstract"}, {"offsetInBeginSection": 112, "offsetInEndSection": 279, "text": "Plant miRNAs are first transcribed as stem-loop primary miRNAs (pri-miRNAs) by RNA polymerase II,then cleaved in the nucleus into mature miRNAs by Dicer-like 1 (DCL1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26473486", "endSection": "abstract"}, {"offsetInBeginSection": 300, "offsetInEndSection": 453, "text": "miRNAs are excised in a stepwise process from double-stranded RNA precursors that are embedded in long RNA polymerase II primary transcripts (pri-miRNA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15589161", "endSection": "abstract"}, {"offsetInBeginSection": 462, "offsetInEndSection": 795, "text": "Plant pri-miRNAs are transcribed by DNA-dependent RNA polymerase II (Pol II) and their levels are determined through transcription and degradation, whereas pri-miRNA processing is affected by its structure, splicing, alternative splicing, loading to the processor and the processor activity, which involve in many accessory proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26119101", "endSection": "abstract"}, {"offsetInBeginSection": 589, "offsetInEndSection": 716, "text": "Specifically, MHV68 miRNAs are transcribed from RNA polymerase III promoters located within adjacent viral tRNA-like sequences.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20129062", "endSection": "abstract"}, {"offsetInBeginSection": 96, "offsetInEndSection": 234, "text": "Mammalian miRNA biogenesis begins with cotranscriptional cleavage of RNA polymerase II (Pol II) transcripts by the Microprocessor complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25730776", "endSection": "abstract"}, {"offsetInBeginSection": 302, "offsetInEndSection": 455, "text": "miRNAs are excised in a stepwise process from double-stranded RNA precursors that are embedded in long RNA polymerase II primary transcripts (pri-miRNA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15589161", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "Canonical primary microRNA (pri-miRNA) precursors are transcribed by RNA polymerase II and then processed by the Drosha endonuclease to generate approximately 60 nt pre-miRNA hairpins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20129062", "endSection": "abstract"}, {"offsetInBeginSection": 520, "offsetInEndSection": 751, "text": "Treatment of cells overexpressing NF90 and NF45 with an RNA polymerase II inhibitor, alpha-amanitin, did not reduce the amounts of pri-miRNAs, suggesting that the accumulation of pri-miRNAs is not due to transcriptional activation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19398578", "endSection": "abstract"}, {"offsetInBeginSection": 113, "offsetInEndSection": 279, "text": "Plant miRNAs are first transcribed as stem-loop primary miRNAs (pri-miRNAs) by RNA polymerase II,then cleaved in the nucleus into mature miRNAs by Dicer-like 1 (DCL1)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26473486", "endSection": "abstract"}, {"offsetInBeginSection": 465, "offsetInEndSection": 797, "text": "Plant pri-miRNAs are transcribed by DNA-dependent RNA polymerase II (Pol II) and their levels are determined through transcription and degradation, whereas pri-miRNA processing is affected by its structure, splicing, alternative splicing, loading to the processor and the processor activity, which involve in many accessory proteins", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26119101", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "The majority of human miRNA genes is transcribed by polymerase II and can be classified as class II genes similar to protein-coding genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20144951", "endSection": "abstract"}, {"offsetInBeginSection": 465, "offsetInEndSection": 798, "text": "Plant pri-miRNAs are transcribed by DNA-dependent RNA polymerase II (Pol II) and their levels are determined through transcription and degradation, whereas pri-miRNA processing is affected by its structure, splicing, alternative splicing, loading to the processor and the processor activity, which involve in many accessory proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26119101", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "In plant, primary transcripts (pri-miRNAs) transcribed from miRNA genes by RNA polymerase II are first processed into stem-loop pre-miRNAs and further chopped into \u223c21\u2009nt long miRNAs by RNase III-like enzyme DCL1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21685453", "endSection": "abstract"}, {"offsetInBeginSection": 888, "offsetInEndSection": 1050, "text": "These small RNAs are first transcribed by RNA polymerase II as a primary miRNA (pri-miRNA) transcript, which is then cleaved into the precursor miRNA (pre-miRNA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21178961", "endSection": "abstract"}, {"offsetInBeginSection": 276, "offsetInEndSection": 381, "text": "Here we present the first direct evidence that miRNA genes are transcribed by RNA polymerase II (pol II).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15372072", "endSection": "abstract"}, {"offsetInBeginSection": 113, "offsetInEndSection": 280, "text": "Plant miRNAs are first transcribed as stem-loop primary miRNAs (pri-miRNAs) by RNA polymerase II,then cleaved in the nucleus into mature miRNAs by Dicer-like 1 (DCL1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26473486", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "MicroRNA genes are transcribed by RNA polymerase II.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15372072", "endSection": "title"}, {"offsetInBeginSection": 177, "offsetInEndSection": 328, "text": "Here we have established a robust in vivo system in which pri-miRNA is transcribed by RNAP II and processed to pre-miRNA in HeLa cell nuclear extracts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26149087", "endSection": "abstract"}, {"offsetInBeginSection": 769, "offsetInEndSection": 1012, "text": "Although it is assumed that miRNA promoters are similar in structure to gene promoters, since both are transcribed by RNA polymerase II (Pol II), computational validations exhibit poor performance of gene promoter prediction methods on miRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22499686", "endSection": "abstract"}]}, {"body": "Which mutated enzyme is responsible for oculocutaneous 1 (OCA1)-type albinism?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22088535", "http://www.ncbi.nlm.nih.gov/pubmed/21968110", "http://www.ncbi.nlm.nih.gov/pubmed/9170158", "http://www.ncbi.nlm.nih.gov/pubmed/8651291", "http://www.ncbi.nlm.nih.gov/pubmed/12829739", "http://www.ncbi.nlm.nih.gov/pubmed/27775880", "http://www.ncbi.nlm.nih.gov/pubmed/24934919", "http://www.ncbi.nlm.nih.gov/pubmed/23112997", "http://www.ncbi.nlm.nih.gov/pubmed/11574907", "http://www.ncbi.nlm.nih.gov/pubmed/15381243", "http://www.ncbi.nlm.nih.gov/pubmed/16767664", "http://www.ncbi.nlm.nih.gov/pubmed/23242301", "http://www.ncbi.nlm.nih.gov/pubmed/7886000", "http://www.ncbi.nlm.nih.gov/pubmed/10571953", "http://www.ncbi.nlm.nih.gov/pubmed/15760344", "http://www.ncbi.nlm.nih.gov/pubmed/10713140", "http://www.ncbi.nlm.nih.gov/pubmed/25577957", "http://www.ncbi.nlm.nih.gov/pubmed/16907708", "http://www.ncbi.nlm.nih.gov/pubmed/10671067", "http://www.ncbi.nlm.nih.gov/pubmed/1905879", "http://www.ncbi.nlm.nih.gov/pubmed/24721949", "http://www.ncbi.nlm.nih.gov/pubmed/20447099", "http://www.ncbi.nlm.nih.gov/pubmed/9242509", "http://www.ncbi.nlm.nih.gov/pubmed/27829221", "http://www.ncbi.nlm.nih.gov/pubmed/11641241", "http://www.ncbi.nlm.nih.gov/pubmed/25216246", "http://www.ncbi.nlm.nih.gov/pubmed/19208379", "http://www.ncbi.nlm.nih.gov/pubmed/15146472", "http://www.ncbi.nlm.nih.gov/pubmed/22875490", "http://www.ncbi.nlm.nih.gov/pubmed/15937636", "http://www.ncbi.nlm.nih.gov/pubmed/11284711", "http://www.ncbi.nlm.nih.gov/pubmed/17355913", "http://www.ncbi.nlm.nih.gov/pubmed/11041207", "http://www.ncbi.nlm.nih.gov/pubmed/15635296", "http://www.ncbi.nlm.nih.gov/pubmed/26763160", "http://www.ncbi.nlm.nih.gov/pubmed/11153699", "http://www.ncbi.nlm.nih.gov/pubmed/10094567", "http://www.ncbi.nlm.nih.gov/pubmed/22097729", "http://www.ncbi.nlm.nih.gov/pubmed/12753405", "http://www.ncbi.nlm.nih.gov/pubmed/25919014", "http://www.ncbi.nlm.nih.gov/pubmed/25093188", "http://www.ncbi.nlm.nih.gov/pubmed/10671066", "http://www.ncbi.nlm.nih.gov/pubmed/27537549", "http://www.ncbi.nlm.nih.gov/pubmed/24392141"], "ideal_answer": ["Mutations in the gene for tyrosinase (TYR), the key enzyme in melanin synthesis, are responsible for oculocutaneous 1 (OCA1)-type albinism."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:0050632", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016115", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000417"], "type": "factoid", "id": "58cbb98c02b8c60953000034", "snippets": [{"offsetInBeginSection": 1, "offsetInEndSection": 89, "text": "An overview of oculocutaneous albinism: TYR gene mutations in five Colombian individuals", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23242301", "endSection": "title"}, {"offsetInBeginSection": 173, "offsetInEndSection": 385, "text": "To date, 230 mutations in the TYR gene have been reported as responsible for oculocutaneus albinism type 1 worldwide. TYR gene encodes the enzyme tyrosinase involved in the metabolic pathway of melanin synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23242301", "endSection": "abstract"}, {"offsetInBeginSection": 397, "offsetInEndSection": 644, "text": "Mutations were identified in the TYR gene as responsible for oculocutaneous albinism type 1 in five Colombian individuals, and a new ophthalmic system was tested that corrected visual defects and symptoms in a patient with oculocutaneous albinism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23242301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Mutations in the gene for tyrosinase, the key enzyme in melanin synthesis, are responsible for oculocutaneous albinism type 1, and more than 100 mutations of this gene have been identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19208379", "endSection": "abstract"}, {"offsetInBeginSection": 346, "offsetInEndSection": 522, "text": "The Q402 allele has been associated with autosomal recessive ocular albinism when it is in trans with a tyrosinase gene mutation associated with oculocutaneous albinism type 1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19208379", "endSection": "abstract"}, {"offsetInBeginSection": 353, "offsetInEndSection": 503, "text": "The disruption of tyrosinase trafficking occurs at the level of the endoplasmic reticulum (ER) in OCA1 and OCA3, but at the post-Golgi level in OCA2. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12829739", "endSection": "abstract"}, {"offsetInBeginSection": 89, "offsetInEndSection": 308, "text": "Mutations at a single N-glycosylation sequon of tyrosinase have been reported to be responsible for oculocutaneous albinism type IA in humans, characterized by inactive tyrosinase and the total absence of pigmentation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10713140", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Mutations of the human tyrosinase gene associated with tyrosinase related oculocutaneous albinism (OCA1). ", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10671066", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 582, "text": "Mutations in the human tyrosinase gene produce tyrosinase-related oculocutaneous albinism (OCA1, MIM #203100). Tyrosinase is a copper containing enzyme and is responsible for catalyzing the rate limiting step in melanin biosynthesis, the hydroxylation of tyrosine to dopaquinone. We report 13 new mutations in the tyrosinase gene associated with OCA1A (without pigment) and OCA1B (with pigment) including 9 missense mutations (H19Q, R521, R77C, G97R, C289R, L312V, P313R, F340L and H404P), two nonsense mutations (W80X and R116X) and two frameshift mutations (53delG and 223 delG). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10671066", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 671, "text": "Mutations of the TYR gene lead to Oculocutaneous Albinism type 1 (OCA1), the most common type of albinism in humans (OMIM accession number 203100).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11153699", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Mutations of the tyrosinase gene associated with a partial or complete loss of enzymatic activity are responsible for tyrosinase related oculocutaneous albinism (OCA1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7886000", "endSection": "abstract"}, {"offsetInBeginSection": 609, "offsetInEndSection": 767, "text": "Oculocutaneous albinism type 1 (OCA1), resulting from mutations of the tyrosinase gene, is genetically and biochemically the best understood type of albinism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12753405", "endSection": "abstract"}, {"offsetInBeginSection": 476, "offsetInEndSection": 945, "text": "Mutations in six genes have been reported to be responsible for different types of oculocutaneous and ocular albinism, including the tyrosinase gene (TYR) and OCA1 (MIM# 203100), the OCA2 gene and OCA2 (MIM# 203200), the tyrosinase-related protein-1 gene (TYRP1) and OCA3 (MIM# 203290), the HPS gene and Hermansky-Pudlak syndrome (MIM# 203300), the CHS gene (CHS1), and Chediak-Higashi syndrome (MIM# 214500), and the X-linked ocular albinism gene and OA1 (MIM#300500).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10094567", "endSection": "abstract"}, {"offsetInBeginSection": 236, "offsetInEndSection": 348, "text": "Defects in the tyrosinase gene (TYR) cause a common type of OCA, known as oculocutaneous albinism type 1 (OCA1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16907708", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Oculocutaneous albinism (OCA) in man may be caused by mutations within the tyrosinase gene (TYR) resulting in OCA1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15146472", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Two novel tyrosinase (TYR) gene mutations with pathogenic impact on oculocutaneous albinism type 1 (OCA1).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25216246", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "BACKGROUND: Tyrosinase (TYR) catalyzes the rate-limiting, first step in melanin production and its gene (TYR) is mutated in many cases of oculocutaneous albinism (OCA1), an autosomal recessive cause of childhood blindness.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392141", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 469, "text": "Mutation analysis and prenatal gene diagnosis for the mutated tyrosinase (TYR) gene in two families with oculocutaneous albinism type I (OCA1).To define the fetus genotypes and gene mutation sites, the PCR and sequencing techniques were applied to amplify and analyze the regions of exon, exon-intron and promoter of TYR gene in probands and their parents of 2 families.The patient or proband of family 1 showed as a compound heterozygote with mutants R278X and 929insC", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16767664", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "Mutations in the gene for tyrosinase, the key enzyme in melanin synthesis, are responsible for oculocutaneous albinism type 1, and more than 100 mutations of this gene have been identified", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19208379", "endSection": "abstract"}, {"offsetInBeginSection": 277, "offsetInEndSection": 752, "text": "TYR gene encodes the enzyme tyrosinase involved in the metabolic pathway of melanin synthesis.Mutations were identified in the TYR gene as responsible for oculocutaneous albinism type 1 in five Colombian individuals, and a new ophthalmic system was tested that corrected visual defects and symptoms in a patient with oculocutaneous albinism.Samples were taken from 5 individuals, four of whom belong to a single family, along with a fifth individual not related to the family", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23242301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Oculocutaneous albinism type 1 (OCA1) results from mutations in the tyrosinase gene, which lead to partial or complete loss of activity of the corresponding enzyme", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15937636", "endSection": "abstract"}, {"offsetInBeginSection": 230, "offsetInEndSection": 385, "text": "Disrupting mutations in the tyrosinase (TYR) gene are known to cause recessive albinisms in humans (oculocutaneous albinism Type 1; OCA1) and other species", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26763160", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 376, "text": "To explore the patients genotypes and the mutation spectrum of Tyrosinase (TYR) gene and the effects on protein structure and function in oculocutaneous albinism type 1 (OCA1).The polymerase chain reaction (PCR) and sequencing techniques were applied to amplify and analyze the regions of exon, exonintron and promoter of TYR gene of 15 OCA1 probands and some of their parents", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22097729", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Genetic analysis of oculocutaneous albinism type 1 (OCA1) in Indian families: two novel frameshift mutations in the TYR Gene", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15635296", "endSection": "title"}, {"offsetInBeginSection": 529, "offsetInEndSection": 677, "text": "Mutations of the TYR gene lead to Oculocutaneous Albinism type 1 (OCA1), the most common type of albinism in humans (OMIM accession number 203100). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11153699", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Mutations of the tyrosinase gene associated with a partial or complete loss of enzymatic activity are responsible for tyrosinase related oculocutaneous albinism (OCA1). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7886000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 301, "text": "Oculocutaneous albinism (OCA) is a heterogeneous group of autosomal recessive disorders resulting from mutations of the tyrosinase (TYR) gene and presents with either complete or partial absence of pigment in the skin, hair and eyes due to a defect in an enzyme involved in the production of melanin. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25216246", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Oculocutaneous albinism type 1 (OCA1) results from mutations in the tyrosinase gene, which lead to partial or complete loss of activity of the corresponding enzyme. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15937636", "endSection": "abstract"}, {"offsetInBeginSection": 429, "offsetInEndSection": 629, "text": "OCA1 (MIM 203100) is associated with mutations of the TYR gene encoding tyrosinase (the rate-limiting enzyme in the production of melanin pigment) and accounts for approximately 40% of OCA worldwide. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11574907", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "Tyrosinase (EC 1.14.18.1) is a copper-containing enzyme that catalyzes several reactions in the biosynthesis of melanin pigments and is deficient in patients with type I oculocutaneous albinism (OCA1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9242509", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Oculocutaneous albinism type 1 (OCA1) results from mutations in the tyrosinase gene, which lead to partial or complete loss of activity of the corresponding enzyme.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15937636", "endSection": "abstract"}, {"offsetInBeginSection": 529, "offsetInEndSection": 676, "text": "Mutations of the TYR gene lead to Oculocutaneous Albinism type 1 (OCA1), the most common type of albinism in humans (OMIM accession number 203100).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11153699", "endSection": "abstract"}, {"offsetInBeginSection": 63, "offsetInEndSection": 224, "text": "In humans mutations in the TYR gene are associated with type 1 oculocutaneous albinism (OCA1) that leads to reduced or absent pigmentation of skin, hair and eye.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15760344", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Oculocutaneous albinism type 1 (OCA1) is an autosomal recessive disease resulting from mutations of the tyrosinase gene (TYR).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11284711", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "Tyrosinase (TYR) catalyzes the rate-limiting, first step in melanin production and its gene (TYR) is mutated in many cases of oculocutaneous albinism (OCA1), an autosomal recessive cause of childhood blindness.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392141", "endSection": "abstract"}, {"offsetInBeginSection": 479, "offsetInEndSection": 948, "text": "Mutations in six genes have been reported to be responsible for different types of oculocutaneous and ocular albinism, including the tyrosinase gene (TYR) and OCA1 (MIM# 203100), the OCA2 gene and OCA2 (MIM# 203200), the tyrosinase-related protein-1 gene (TYRP1) and OCA3 (MIM# 203290), the HPS gene and Hermansky-Pudlak syndrome (MIM# 203300), the CHS gene (CHS1), and Chediak-Higashi syndrome (MIM# 214500), and the X-linked ocular albinism gene and OA1 (MIM#300500).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10094567", "endSection": "abstract"}, {"offsetInBeginSection": 319, "offsetInEndSection": 656, "text": "Therapeutic research for OCA1 has been hampered, in part, by the absence of purified, active, recombinant wild-type and mutant human enzymes.The intra-melanosomal domain of human tyrosinase (residues 19-469) and two OCA1B related temperature-sensitive mutants, R422Q and R422W were expressed in insect cells and produced in T. ni larvae.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392141", "endSection": "abstract"}, {"offsetInBeginSection": 1654, "offsetInEndSection": 1863, "text": "The tyrosinase gene family of proteins (tyrosinase, TRP1, and TRP2) regulate the type of eumelanin synthesized and mutations affecting them result in OCA1, OCA3, and slaty (in the murine system), respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9170158", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Genetic analysis of oculocutaneous albinism type 1 (OCA1) in Indian families: two novel frameshift mutations in the TYR Gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15635296", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 300, "text": "Oculocutaneous albinism (OCA) is a heterogeneous group of autosomal recessive disorders resulting from mutations of the tyrosinase (TYR) gene and presents with either complete or partial absence of pigment in the skin, hair and eyes due to a defect in an enzyme involved in the production of melanin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25216246", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Mutation analysis and prenatal gene diagnosis for the mutated tyrosinase (TYR) gene in two families with oculocutaneous albinism type I (OCA1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16767664", "endSection": "abstract"}, {"offsetInBeginSection": 614, "offsetInEndSection": 772, "text": "Oculocutaneous albinism type 1 (OCA1), resulting from mutations of the tyrosinase gene, is genetically and biochemically the best understood type of albinism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12753405", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Two novel tyrosinase (TYR) gene mutations with pathogenic impact on oculocutaneous albinism type 1 (OCA1).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25216246", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Oculocutaneous albinism Type 1 (OCA1) is an autosomal recessive disorder caused by mutations in the tyrosinase gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27775880", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "The mutation of the tyrosinase (TYR) gene results in oculocutaneous albinism type 1 (OCA1), an autosomal recessive genetic disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22088535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "The tyrosinase gene and oculocutaneous albinism type 1 (OCA1): A model for understanding the molecular biology of melanin formation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11041207", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Genetic analysis of oculocutaneous albinism type 1 (OCA1) in Indian families: two novel frameshift mutations in the TYR Gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15635296", "endSection": "title"}]}, {"body": "Please list 2 treatments for a torn rotator cuff", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26564215", "http://www.ncbi.nlm.nih.gov/pubmed/26912284", "http://www.ncbi.nlm.nih.gov/pubmed/21351612", "http://www.ncbi.nlm.nih.gov/pubmed/20621893", "http://www.ncbi.nlm.nih.gov/pubmed/26847487", "http://www.ncbi.nlm.nih.gov/pubmed/22004636", "http://www.ncbi.nlm.nih.gov/pubmed/8496210", "http://www.ncbi.nlm.nih.gov/pubmed/27157656", "http://www.ncbi.nlm.nih.gov/pubmed/26254089"], "ideal_answer": ["to compare clinical outcomes between conventional en masse repair and separate double-layer double-row repair for the treatment of delaminated rotator cuff tears.", "Surgical repair earlier or later than 3 months after injury may result in similar outcomes and patient satisfaction."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:12702", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000070656", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000070636", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017006"], "type": "list", "id": "58c99acf02b8c60953000028", "snippets": [{"offsetInBeginSection": 408, "offsetInEndSection": 569, "text": "To compare clinical outcomes between conventional en masse repair and separate double-layer double-row repair for the treatment of delaminated rotator cuff tears", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26912284", "endSection": "abstract"}, {"offsetInBeginSection": 467, "offsetInEndSection": 594, "text": " To systematically review and evaluate the effectiveness of grafts in the augmentation of large-to-massive rotator cuff repairs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26847487", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 150, "text": "To evaluate the effectiveness of arthroscopic debridement (DB), partial (PR), and complete repair (CR) for massive rotator cuff tears (mRCT) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26254089", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 163, "text": "The purpose was to investigate whether surgical repair earlier or later than 3\u00a0months after injury may result in similar outcomes and patient satisfaction", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26564215", "endSection": "abstract"}, {"offsetInBeginSection": 94, "offsetInEndSection": 155, "text": "double-row (DR) and knotless transosseous-equivalent (KL-TOE)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27157656", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 255, "text": " arthroscopic subacromial decompression and rotator-cuff debridement; the other comparable group of 23 patients had open repair and acromioplasty", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8496210", "endSection": "abstract"}]}, {"body": "What is the role of Laser Interstitial Thermal Therapy in glioma treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26722845", "http://www.ncbi.nlm.nih.gov/pubmed/26384598", "http://www.ncbi.nlm.nih.gov/pubmed/27861323", "http://www.ncbi.nlm.nih.gov/pubmed/27838155", "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "http://www.ncbi.nlm.nih.gov/pubmed/27690658", "http://www.ncbi.nlm.nih.gov/pubmed/22044371", "http://www.ncbi.nlm.nih.gov/pubmed/25727222", "http://www.ncbi.nlm.nih.gov/pubmed/26113069", "http://www.ncbi.nlm.nih.gov/pubmed/18838327", "http://www.ncbi.nlm.nih.gov/pubmed/25434378", "http://www.ncbi.nlm.nih.gov/pubmed/27861322", "http://www.ncbi.nlm.nih.gov/pubmed/24056317", "http://www.ncbi.nlm.nih.gov/pubmed/24810945", "http://www.ncbi.nlm.nih.gov/pubmed/24994550", "http://www.ncbi.nlm.nih.gov/pubmed/27659837", "http://www.ncbi.nlm.nih.gov/pubmed/27690657"], "ideal_answer": ["Laser Interstitial Thermal Therapy (LITT) is used in treatment of gliomas. LITT can be used effectively for treatment of difficult-to-access high-grade gliomas. More complete coverage of tumor improves progression free survival which can be translated as the extent of resection concept for surgery."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005910", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053685", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812"], "type": "summary", "id": "5890f4ab621ea6ff7e000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "OBJECTIVE MR-guided laser-induced thermal therapy (MRgLITT) can be used to treat intracranial tumors, epilepsy, and chronic pain syndromes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26722845", "endSection": "abstract"}, {"offsetInBeginSection": 1201, "offsetInEndSection": 1346, "text": "Eight patients had glioblastoma multiforme (GBM), 1 had a previously treated GBM with radiation necrosis, and 1 had a melanoma brain metastasis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690658", "endSection": "abstract"}, {"offsetInBeginSection": 1878, "offsetInEndSection": 2087, "text": "CONCLUSIONS Laser interstitial thermal therapy followed by minimally invasive transsulcal resection, reported here for the first time, is a novel option for patients with large, DTA, malignant brain neoplasms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690658", "endSection": "abstract"}, {"offsetInBeginSection": 577, "offsetInEndSection": 739, "text": "MRI-guided laser interstitial thermal therapy is currently used as a minimally invasive treatment for brain metastases, radiation necrosis, glioma, and epilepsy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26113069", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24810945", "endSection": "title"}, {"offsetInBeginSection": 262, "offsetInEndSection": 594, "text": "We report our multicenter results of laser interstitial thermal therapy (LITT) in DTA-HGGs. We retrospectively reviewed 34 consecutive DTA-HGG patients (24 glioblastoma, 10 anaplastic) who underwent LITT at Cleveland Clinic, Washington University, and Wake Forest University (May 2011-December 2012) using the NeuroBlate(\u00ae) System. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24810945", "endSection": "abstract"}, {"offsetInBeginSection": 1484, "offsetInEndSection": 1669, "text": "LITT can be used effectively for treatment of DTA-HGGs. More complete coverage of tumor by TDT lines improves PFS which can be translated as the extent of resection concept for surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24810945", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Stereotactic laser ablation of high-grade gliomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25434378", "endSection": "title"}, {"offsetInBeginSection": 171, "offsetInEndSection": 438, "text": "Recent advances in intraoperative imaging have spurred the use of stereotactic laser ablation (laser interstitial thermal therapy [LITT]) for intracranial lesions. Among other targets, laser ablation has been used in the focal treatment of high-grade gliomas (HGGs). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25434378", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "OBJECT: Laser interstitial thermal therapy has been used as an ablative treatment for glioma; however, its development was limited due to technical issues. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "abstract"}, {"offsetInBeginSection": 1779, "offsetInEndSection": 1943, "text": "CONCLUSIONS: NeuroBlate represents new technology for delivering laser interstitial thermal therapy, allowing controlled thermal ablation of deep hemispheric rGBM. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "abstract"}, {"offsetInBeginSection": 818, "offsetInEndSection": 1118, "text": "Ongoing researches concern the adjunction of local treatments within the surgical field (photodynamic therapy, chemotherapy, convection immunotherapy...), but also the development of minimal invasive procedures (radiosurgery, high intensity focalized ultrasounds, laser interstitial thermal therapy).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18838327", "endSection": "abstract"}, {"offsetInBeginSection": 760, "offsetInEndSection": 1066, "text": "Current commercially available LITT systems have been used for the treatment of neurosurgical soft-tissue lesions, including difficult to access brain tumors, malignant gliomas, and radiosurgery-resistant metastases, as well as for the ablation of such lesions as epileptogenic foci and radiation necrosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25727222", "endSection": "abstract"}, {"offsetInBeginSection": 250, "offsetInEndSection": 403, "text": " The authors report a Phase I, thermal dose-escalation trial assessing the safety and efficacy of NeuroBlate in recurrent glioblastoma multiforme (rGBM).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "abstract"}, {"offsetInBeginSection": 573, "offsetInEndSection": 734, "text": "MRI-guided laser interstitial thermal therapy is currently used as a minimally invasive treatment for brain metastases, radiation necrosis, glioma, and epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26113069", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Laser interstitial thermal therapy has been used as an ablative treatment for glioma; however, its development was limited due to technical issues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "MRI-guided laser interstitial thermal therapy for the treatment of low-grade gliomas in children: a case-series review, description of the current technologies and perspectives.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27659837", "endSection": "title"}, {"offsetInBeginSection": 577, "offsetInEndSection": 737, "text": "MRI-guided laser interstitial thermal therapy is currently used as a minimally invasive treatment for brain metastases, radiation necrosis, glioma, and epilepsy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26113069", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Laser interstitial thermal therapy has been used as an ablative treatment for glioma; however, its development was limited due to technical issues", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "Thermal ablation (radiofrequency, microwave, cryosurgery, laser interstitial thermal therapy) is being used more frequently as a local treatment of secondary but also primary cancers and benign lesions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26384598", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24810945", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Current Applications of MRI-Guided Laser Interstitial Thermal Therapy in the Treatment of Brain Neoplasms and Epilepsy: A Radiologic and Neurosurgical Overview", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26113069", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Magnetic resonance imaging-guided laser interstitial thermal therapy (LITT) is a minimally invasive treatment modality with recent increasing use to ablate brain tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24994550", "endSection": "abstract"}, {"offsetInBeginSection": 1755, "offsetInEndSection": 1871, "text": "Further study is needed to assess the role of laser-induced thermal therapy for the treatment of intracranial tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044371", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "OBJECT: Laser interstitial thermal therapy has been used as an ablative treatment for glioma; however, its development was limited due to technical issues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "abstract"}, {"offsetInBeginSection": 1726, "offsetInEndSection": 1942, "text": "Three had Grade 3 adverse events at the highest dose.CONCLUSIONS: NeuroBlate represents new technology for delivering laser interstitial thermal therapy, allowing controlled thermal ablation of deep hemispheric rGBM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24810945", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Stereotactic Laser Interstitial Thermal Therapy for Recurrent High-Grade Gliomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27861323", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "MRI-guided laser interstitial thermal therapy for the treatment of low-grade gliomas in children: a case-series review, description of the current technologies and perspectives.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27659837", "endSection": "title"}, {"offsetInBeginSection": 577, "offsetInEndSection": 738, "text": "MRI-guided laser interstitial thermal therapy is currently used as a minimally invasive treatment for brain metastases, radiation necrosis, glioma, and epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26113069", "endSection": "abstract"}, {"offsetInBeginSection": 1756, "offsetInEndSection": 1906, "text": "NeuroBlate represents new technology for delivering laser interstitial thermal therapy, allowing controlled thermal ablation of deep hemispheric rGBM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560574", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Laser interstitial thermal therapy followed by minimal-access transsulcal resection for the treatment of large and difficult to access brain tumors.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690658", "endSection": "title"}]}, {"body": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20711347", "http://www.ncbi.nlm.nih.gov/pubmed/15045029", "http://www.ncbi.nlm.nih.gov/pubmed/23816883", "http://www.ncbi.nlm.nih.gov/pubmed/17470967", "http://www.ncbi.nlm.nih.gov/pubmed/21111233", "http://www.ncbi.nlm.nih.gov/pubmed/24507717", "http://www.ncbi.nlm.nih.gov/pubmed/22910211", "http://www.ncbi.nlm.nih.gov/pubmed/19910462", "http://www.ncbi.nlm.nih.gov/pubmed/23580526", "http://www.ncbi.nlm.nih.gov/pubmed/17289584", "http://www.ncbi.nlm.nih.gov/pubmed/26116819", "http://www.ncbi.nlm.nih.gov/pubmed/16299513", "http://www.ncbi.nlm.nih.gov/pubmed/19966225", "http://www.ncbi.nlm.nih.gov/pubmed/27463665", "http://www.ncbi.nlm.nih.gov/pubmed/18726008", "http://www.ncbi.nlm.nih.gov/pubmed/17142478", "http://www.ncbi.nlm.nih.gov/pubmed/19088068"], "ideal_answer": ["Saccharomyces cerevisiae Swr1, a Swi2/Snf2-related ATPase, is the catalytic core of a multisubunit chromatin remodeling enzyme, called the SWR1 complex, that efficiently replaces conventional histone H2A in nucleosomes with histone H2A.Z. We identified a complex containing 13 different polypeptides associated with a soluble pool of H2A.Z in Saccharomyces cerevisiae.", "The multisubunit nucleosome-remodeling enzyme complex SWR1, conserved from yeast to mammals, catalyzes the ATP-dependent replacement of histone H2A in canonical nucleosomes with H2A.Z. The SWR1 complex replaces the canonical histone H2A with the variant H2A.Z (Htz1 in yeast) at specific chromatin regions.", "The multisubunit nucleosome-remodeling enzyme complex SWR1, conserved from yeast to mammals, catalyzes the ATP-dependent replacement of histone H2A in canonical nucleosomes with H2A.Z.", "The chromatin remodeler SWR1 mediates site-specific incorporation of H2A.Z by a multi-step histone replacement reaction, evicting histone H2A-H2B from the canonical nucleosome and depositing the H2A.Z-H2B dimer", "The multisubunit nucleosome-remodeling enzyme complex SWR1, conserved from yeast to mammals, catalyzes the ATP-dependent replacement of histone H2A in canonical nucleosomes with H2A.Z. Saccharomyces cerevisiae Swr1, a Swi2/Snf2-related ATPase, is the catalytic core of a multisubunit chromatin remodeling enzyme, called the SWR1 complex, that efficiently replaces conventional histone H2A in nucleosomes with histone H2A.Z."], "type": "factoid", "id": "58a6db8660087bc10a00002c", "snippets": [{"offsetInBeginSection": 125, "offsetInEndSection": 335, "text": "The chromatin remodeler SWR1 mediates site-specific incorporation of H2A.Z by a multi-step histone replacement reaction, evicting histone H2A-H2B from the canonical nucleosome and depositing the H2A.Z-H2B dimer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26116819", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 333, "text": "he multisubunit nucleosome-remodeling enzyme complex SWR1, conserved from yeast to mammals, catalyzes the ATP-dependent replacement of histone H2A in canonical nucleosomes with H2A.Z.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507717", "endSection": "abstract"}, {"offsetInBeginSection": 741, "offsetInEndSection": 899, "text": "Our results show that the Swr1-Z domain can deliver the H2A.Z-H2B dimer to the DNA-(H3-H4)2 tetrasome to form the nucleosome by a histone chaperone mechanism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507717", "endSection": "abstract"}, {"offsetInBeginSection": 616, "offsetInEndSection": 801, "text": "H2A.Z is deposited into chromatin by the SWR1 complex and is subject to acetylation of its four N-terminal tail lysine residues by the NuA4 and SAGA histone acetyltransferase complexes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23816883", "endSection": "abstract"}, {"offsetInBeginSection": 99, "offsetInEndSection": 236, "text": "H2A.Z deposition is controlled by SWR-C chromatin remodeling enzymes that catalyze the nucleosomal exchange of canonical H2A with H2A.Z. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23580526", "endSection": "abstract"}, {"offsetInBeginSection": 185, "offsetInEndSection": 423, "text": "Saccharomyces cerevisiae Swr1, a Swi2/Snf2-related ATPase, is the catalytic core of a multisubunit chromatin remodeling enzyme, called the SWR1 complex, that efficiently replaces conventional histone H2A in nucleosomes with histone H2A.Z.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22910211", "endSection": "abstract"}, {"offsetInBeginSection": 749, "offsetInEndSection": 886, "text": "The system demonstrates ATP- and SWR1-complex-dependent replacement of histone H2A for histone H2A.Z on a preassembled nucleosome array. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22910211", "endSection": "abstract"}, {"offsetInBeginSection": 192, "offsetInEndSection": 414, "text": "We identified a complex containing 13 different polypeptides associated with a soluble pool of H2A.Z in Saccharomyces cerevisiae. This complex was designated SWR1-Com in reference to the Swr1p subunit, a Swi2/Snf2-paralog.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15045029", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "The SWR1 complex replaces the canonical histone H2A with the variant H2A.Z (Htz1 in yeast) at specific chromatin regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20711347", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 302, "text": "In Saccharomyces cerevisiae, deposition of histone H2AZ is mediated by the multiprotein SWR1 complex, which catalyzes ATP-dependent exchange of nucleosomal histone H2A for H2AZ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16299513", "endSection": "abstract"}, {"offsetInBeginSection": 95, "offsetInEndSection": 286, "text": "In Saccharomyces cerevisiae, chromatin deposition of histone H2AZ is mediated by the fourteen-subunit SWR1 complex, which catalyzes ATP-dependent exchange of nucleosomal histone H2A for H2AZ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19088068", "endSection": "abstract"}, {"offsetInBeginSection": 92, "offsetInEndSection": 245, "text": "This incorporation is mediated by the conserved SWR1 complex, which replaces histone H2A in canonical nucleosomes with H2A.Z in an ATP-dependent manner. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21111233", "endSection": "abstract"}, {"offsetInBeginSection": 185, "offsetInEndSection": 424, "text": "Saccharomyces cerevisiae Swr1, a Swi2/Snf2-related ATPase, is the catalytic core of a multisubunit chromatin remodeling enzyme, called the SWR1 complex, that efficiently replaces conventional histone H2A in nucleosomes with histone H2A.Z. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22910211", "endSection": "abstract"}, {"offsetInBeginSection": 95, "offsetInEndSection": 287, "text": "In Saccharomyces cerevisiae, chromatin deposition of histone H2AZ is mediated by the fourteen-subunit SWR1 complex, which catalyzes ATP-dependent exchange of nucleosomal histone H2A for H2AZ. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19088068", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 303, "text": "In Saccharomyces cerevisiae, deposition of histone H2AZ is mediated by the multiprotein SWR1 complex, which catalyzes ATP-dependent exchange of nucleosomal histone H2A for H2AZ. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16299513", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "The Swc4p protein, encoded by an essential gene, is shared by two chromatin-remodeling complexes in Saccharomyces cerevisiae cells: NuA4 (nucleosome acetyltransferase of H4) and SWR1. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18726008", "endSection": "abstract"}, {"offsetInBeginSection": 139, "offsetInEndSection": 368, "text": "The Saccharomyces cerevisiae protein Yaf9 is a subunit of both the essential histone acetyltransferase complex NuA4 and the ATP-dependent chromatin remodeling complex SWR1-C, which deposits histone variant H2A.Z into euchromatin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19966225", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 398, "text": "Here, we identify and characterize SERRATED LEAVES AND EARLY FLOWERING (SEF), an Arabidopsis (Arabidopsis thaliana) homolog of the yeast SWC6 protein, a conserved subunit of the SWR1/SRCAP complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17142478", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "The SWR1/SRCAP complex is a chromatin-remodeling complex that has been shown to be involved in substitution of histone H2A by the histone variant H2A.Z in yeast (Saccharomyces cerevisiae) and animals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17142478", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "The Swc4p protein, encoded by an essential gene, is shared by two chromatin-remodeling complexes in Saccharomyces cerevisiae cells: NuA4 (nucleosome acetyltransferase of H4) and SWR1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18726008", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "The SWR1 complex (SWR1C) in yeast catalyzes the replacement of nucleosomal H2A with the H2AZ variant, which ensures full activation of underlying genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17470967", "endSection": "abstract"}, {"offsetInBeginSection": 934, "offsetInEndSection": 1011, "text": "In addition, H2AZ, a substrate of SWR1C, interacts with both PIE1 and AtSWC2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17470967", "endSection": "abstract"}, {"offsetInBeginSection": 98, "offsetInEndSection": 243, "text": "The incorporation of H2AZ into chromatin is dependent on the SWR1 complex, which catalyses the replacement of conventional histone H2A with H2AZ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17289584", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "H2A histone-fold and DNA elements in nucleosome activate SWR1-mediated H2A.Z replacement in budding yeast.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26116819", "endSection": "title"}, {"offsetInBeginSection": 177, "offsetInEndSection": 301, "text": "They report that reversal of H2A.Z replacement is mediated by SWR1 and related INO80 on an H2A.Z nucleosome carrying H3K56Q.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27463665", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 336, "text": "The chromatin remodeler SWR1 mediates site-specific incorporation of H2A.Z by a multi-step histone replacement reaction, evicting histone H2A-H2B from the canonical nucleosome and depositing the H2A.Z-H2B dimer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26116819", "endSection": "abstract"}, {"offsetInBeginSection": 92, "offsetInEndSection": 244, "text": "This incorporation is mediated by the conserved SWR1 complex, which replaces histone H2A in canonical nucleosomes with H2A.Z in an ATP-dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21111233", "endSection": "abstract"}, {"offsetInBeginSection": 278, "offsetInEndSection": 473, "text": "Here, we show that the JmjC domain protein Msc1 is a novel component of the fission yeast Swr1 complex and is required for Swr1-mediated incorporation of H2A.Z into nucleosomes at gene promoters.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19910462", "endSection": "abstract"}]}, {"body": "Which are the key players on radial glial specification to ependymal cells?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26395491", "http://www.ncbi.nlm.nih.gov/pubmed/27606337"], "ideal_answer": ["Mcidas and GemC1/Lynkeas specify embryonic radial glial cells. Both proteins were initially described as cell cycle regulators revealing sequence similarity to Geminin. They are expressed in radial glial cells committed to the ependymal cell lineage during embryogenesis, while overexpression and knock down experiments showed that are sufficient and necessary for ependymal cell generation."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063928", "http://amigo.geneontology.org/amigo/term/GO:0090213", "http://amigo.geneontology.org/amigo/term/GO:0009956", "http://amigo.geneontology.org/amigo/term/GO:0021531", "http://amigo.geneontology.org/amigo/term/GO:0021861", "http://amigo.geneontology.org/amigo/term/GO:0021812"], "type": "list", "id": "58948cb47d9090f353000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Mcidas and GemC1/Lynkeas specify embryonic radial glial cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27606337", "endSection": "title"}, {"offsetInBeginSection": 655, "offsetInEndSection": 1358, "text": "Here we discuss recent findings suggesting that 2 novel molecules, Mcidas and GemC1/Lynkeas are key players on radial glial specification to ependymal cells. Both proteins were initially described as cell cycle regulators revealing sequence similarity to Geminin. They are expressed in radial glial cells committed to the ependymal cell lineage during embryogenesis, while overexpression and knock down experiments showed that are sufficient and necessary for ependymal cell generation. We propose that Mcidas and GemC1/Lynkeas are key components of the molecular cascade that promotes radial glial cells fate commitment toward multiciliated ependymal cell lineage operating upstream of c-Myb and FoxJ1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27606337", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 809, "text": "Here we discuss recent findings suggesting that 2 novel molecules, Mcidas and GemC1/Lynkeas are key players on radial glial specification to ependymal cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27606337", "endSection": "abstract"}, {"offsetInBeginSection": 657, "offsetInEndSection": 853, "text": "Overexpression and knockdown experiments show that Mcidas and GemC1 are sufficient and necessary for cell fate commitment and differentiation of radial glial cells to multiciliated ependymal cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26395491", "endSection": "abstract"}, {"offsetInBeginSection": 655, "offsetInEndSection": 812, "text": "Here we discuss recent findings suggesting that 2 novel molecules, Mcidas and GemC1/Lynkeas are key players on radial glial specification to ependymal cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27606337", "endSection": "abstract"}, {"offsetInBeginSection": 1098, "offsetInEndSection": 1237, "text": "Our results suggest that Mcidas and GemC1 are key players in the generation of multiciliated ependymal cells of the adult neurogenic niche.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26395491", "endSection": "abstract"}, {"offsetInBeginSection": 1142, "offsetInEndSection": 1358, "text": "We propose that Mcidas and GemC1/Lynkeas are key components of the molecular cascade that promotes radial glial cells fate commitment toward multiciliated ependymal cell lineage operating upstream of c-Myb and FoxJ1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27606337", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Mcidas and GemC1 are key regulators for the generation of multiciliated ependymal cells in the adult neurogenic niche.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26395491", "endSection": "title"}]}, {"body": "Is ocular melanosis a risk factor for uveal melanoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21670341", "http://www.ncbi.nlm.nih.gov/pubmed/12647250", "http://www.ncbi.nlm.nih.gov/pubmed/9442799", "http://www.ncbi.nlm.nih.gov/pubmed/8292886", "http://www.ncbi.nlm.nih.gov/pubmed/23681424", "http://www.ncbi.nlm.nih.gov/pubmed/6677847", "http://www.ncbi.nlm.nih.gov/pubmed/1520683"], "ideal_answer": ["Yes, ocular melanosis (melanosis oculi) is a risk factor for uveal melanoma."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008545", "http://www.disease-ontology.org/api/metadata/DOID:1909", "http://www.disease-ontology.org/api/metadata/DOID:6566", "http://www.disease-ontology.org/api/metadata/DOID:6039", "http://www.disease-ontology.org/api/metadata/DOID:1752", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012306"], "type": "yesno", "id": "58b5320e22d3005309000002", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 201, "text": "Ocular/oculodermal (oculo[dermal]) melanocytosis is a congenital periocular pigmentary condition that can lead to the development of uveal melanoma, estimated at 1 in 400 affected patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681424", "endSection": "abstract"}, {"offsetInBeginSection": 352, "offsetInEndSection": 582, "text": "Melanosis oculi is often underestimated as a risk factor for uveal melanoma and glaucoma. Ophthalmic surveillance, every 6 or 12 months is important, in patients with ocular melanocytosis for early detection of high risk diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12647250", "endSection": "abstract"}, {"offsetInBeginSection": 992, "offsetInEndSection": 1520, "text": " One of about 400 patients with ODM followed for life is estimated to develop uveal melanoma. Excessive melanocytes in the uveal tract in ODM may provide the biologic basis for susceptibility to the development of uveal melanoma. Patients with ODM should be monitored ophthalmoscopically, especially during the susceptible period, for the development of uveal melanoma. The authors suggest that a national registry of ODM patients be created and prospective data collected to better assess the risk of developing uveal melanoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9442799", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 132, "text": "In the white population, an association between oculo(dermal) melanocytosis (ODM) and uveal melanoma is well recognized. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9442799", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 325, "text": "Malignant melanomas may arise in the uveal tract, the conjunctiva, the skin of the eyelid, or the orbit. Risk factors so far identified include pre-existing choroidal naevi for uveal melanomas, primary acquired melanosis (PAM) for conjunctival tumours, and ocular and oculodermal melanocytosis for uveal and orbital lesions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8292886", "endSection": "abstract"}, {"offsetInBeginSection": 104, "offsetInEndSection": 323, "text": "Risk factors so far identified include pre-existing choroidal naevi for uveal melanomas, primary acquired melanosis (PAM) for conjunctival tumours, and ocular and oculodermal melanocytosis for uveal and orbital lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8292886", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "Phacomatosis pigmentovascularis of cesioflammea type in 7 patients: combination of ocular pigmentation (melanocytosis or melanosis) and nevus flammeus with risk for melanoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21670341", "endSection": "title"}, {"offsetInBeginSection": 197, "offsetInEndSection": 441, "text": "In the fourth case the melanoma was detected in a routine examination and we were able to apply a preserving treatment with I125 brachytherapy.DISCUSSION: Melanosis oculi is often underestimated as a risk factor for uveal melanoma and glaucoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12647250", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681424", "endSection": "title"}, {"offsetInBeginSection": 105, "offsetInEndSection": 323, "text": "Risk factors so far identified include pre-existing choroidal naevi for uveal melanomas, primary acquired melanosis (PAM) for conjunctival tumours, and ocular and oculodermal melanocytosis for uveal and orbital lesions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8292886", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 421, "text": "In the fourth case the melanoma was detected in a routine examination and we were able to apply a preserving treatment with I125 brachytherapy.Melanosis oculi is often underestimated as a risk factor for uveal melanoma and glaucoma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12647250", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 813, "text": "In this study, patients with melanocytosis who developed uveal melanoma were found to have double the risk for metastasis compared with those without melanocytosis.To determine the relationship of oculo(dermal) melanocytosis to the prognosis of patients with uveal melanoma.Retrospective chart review of 7872 patients with uveal melanoma treated at the Ocular Oncology Service, Wills Eye Institute, from August 25, 1970, through August 27, 2008.Enucleation, plaque radiotherapy, local resection, or thermotherapy.Metastasis and death.Of 7872 patients with uveal melanoma, oculo(dermal) melanocytosis was present in 230 (3%)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681424", "endSection": "abstract"}, {"offsetInBeginSection": 1596, "offsetInEndSection": 1913, "text": "By multivariable analysis, the factors predictive of metastasis in patients harboring uveal melanoma associated with oculo(dermal) melanocytosis were increased tumor thickness (P = .001) and the presence of subretinal fluid (P = .05), and the only factor predictive of death was increased tumor thickness (P = .009). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681424", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 422, "text": "In the fourth case the melanoma was detected in a routine examination and we were able to apply a preserving treatment with I125 brachytherapy.Melanosis oculi is often underestimated as a risk factor for uveal melanoma and glaucoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12647250", "endSection": "abstract"}, {"offsetInBeginSection": 105, "offsetInEndSection": 324, "text": "Risk factors so far identified include pre-existing choroidal naevi for uveal melanomas, primary acquired melanosis (PAM) for conjunctival tumours, and ocular and oculodermal melanocytosis for uveal and orbital lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8292886", "endSection": "abstract"}, {"offsetInBeginSection": 1900, "offsetInEndSection": 2077, "text": "CONCLUSIONS AND RELEVANCE Patients with uveal melanoma associated with oculo(dermal) melanocytosis have double the risk for metastasis compared with those with no melanocytosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681424", "endSection": "abstract"}, {"offsetInBeginSection": 1494, "offsetInEndSection": 1810, "text": "By multivariable analysis, the factors predictive of metastasis in patients harboring uveal melanoma associated with oculo(dermal) melanocytosis were increased tumor thickness (P = .001) and the presence of subretinal fluid (P = .05), and the only factor predictive of death was increased tumor thickness (P = .009).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681424", "endSection": "abstract"}, {"offsetInBeginSection": 1811, "offsetInEndSection": 1988, "text": "CONCLUSIONS AND RELEVANCE Patients with uveal melanoma associated with oculo(dermal) melanocytosis have double the risk for metastasis compared with those with no melanocytosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681424", "endSection": "abstract"}]}, {"body": "What is known about telomere length shortening and stress?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25393133", "http://www.ncbi.nlm.nih.gov/pubmed/26853993", "http://www.ncbi.nlm.nih.gov/pubmed/25070535", "http://www.ncbi.nlm.nih.gov/pubmed/26919486"], "ideal_answer": ["A significant relationship between more perceived stress and shorter telomere length is consistent with theoretical frameworks positing that stress induces physiological changes that result in shortened telomeres."], "type": "summary", "id": "58cd633c02b8c6095300003a", "snippets": [{"offsetInBeginSection": 781, "offsetInEndSection": 995, "text": "A significant relationship between more perceived stress and shorter telomere length is consistent with theoretical frameworks positing that stress induces physiological changes that result in shortened telomeres. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25393133", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 175, "text": "Psychological stress contributes to numerous diseases and may do so in part through damage to telomeres, protective non-coding segments on the ends of chromosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26853993", "endSection": "abstract"}, {"offsetInBeginSection": 1340, "offsetInEndSection": 1591, "text": "Our results support the hypothesis that depression is associated with accelerated cell aging. Future studies are required to clarify whether the association is mediated through environmental stress, and whether effective treatment can halt cell aging.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26919486", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "Telomere length, a reliable predictor of disease pathogenesis, can be affected by genetics, chronic stress and health behaviors. Cross-sectionally, highly stressed postmenopausal women have shorter telomeres, but only if they are inactive. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25070535", "endSection": "abstract"}]}, {"body": "What fruit causes Jamaican vomiting sickness?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/6488562", "http://www.ncbi.nlm.nih.gov/pubmed/8185109", "http://www.ncbi.nlm.nih.gov/pubmed/26324727", "http://www.ncbi.nlm.nih.gov/pubmed/23259140", "http://www.ncbi.nlm.nih.gov/pubmed/16099087", "http://www.ncbi.nlm.nih.gov/pubmed/3548729", "http://www.ncbi.nlm.nih.gov/pubmed/26328472", "http://www.ncbi.nlm.nih.gov/pubmed/25531872"], "ideal_answer": ["Jamaican Vomiting Sickness is caused by ingestion of the unripe arils of the Ackee fruit, its seeds and husks."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015984", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005638"], "type": "factoid", "id": "5895f7e978275d0c4a000001", "snippets": [{"offsetInBeginSection": 187, "offsetInEndSection": 315, "text": "The aril of the unripe fruit has high concentrations of HGA, the cause of Jamaican vomiting sickness, which is very often fatal.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25531872", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 315, "text": "In 1976, over 100 years after Jamaican vomiting sickness (JVS) was first reported, the cause of JVS was linked to the ingestion of the toxin hypoglycin A produced by ackee fruit. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26328472", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Ackee apple fruit is a native fruit to Jamaica and some parts of west Africa. Its toxicity known as \"Jamaican vomiting sickness\" dates back to the nineteenth century.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26324727", "endSection": "abstract"}, {"offsetInBeginSection": 172, "offsetInEndSection": 282, "text": "Jamaican Vomiting Sickness is caused by ingestion of the unripe arils of the Ackee fruit, its seeds and husks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259140", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "An acute illness (Jamaican vomiting sickness) which affected two adults after eating unripe ackee fruit was investigated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6488562", "endSection": "abstract"}, {"offsetInBeginSection": 171, "offsetInEndSection": 281, "text": "Jamaican Vomiting Sickness is caused by ingestion of the unripe arils of the Ackee fruit, its seeds and husks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259140", "endSection": "abstract"}, {"offsetInBeginSection": 186, "offsetInEndSection": 314, "text": "The aril of the unripe fruit has high concentrations of HGA, the cause of Jamaican vomiting sickness, which is very often fatal.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25531872", "endSection": "abstract"}, {"offsetInBeginSection": 135, "offsetInEndSection": 313, "text": "In 1976, over 100 years after Jamaican vomiting sickness (JVS) was first reported, the cause of JVS was linked to the ingestion of the toxin hypoglycin A produced by ackee fruit.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26328472", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "Hypoglycin A, the toxin found in the ackee fruit, has been reported in the literature as the causative agent in incidences of acute toxicity termed Jamaican vomiting sickness or toxic hypoglycemic syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16099087", "endSection": "abstract"}, {"offsetInBeginSection": 172, "offsetInEndSection": 281, "text": "Jamaican Vomiting Sickness is caused by ingestion of the unripe arils of the Ackee fruit, its seeds and husks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259140", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "An acute illness (Jamaican vomiting sickness) which affected two adults after eating unripe ackee fruit was investigated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6488562", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "Hypoglycin A, the toxin found in the ackee fruit, has been reported in the literature as the causative agent in incidences of acute toxicity termed Jamaican vomiting sickness or toxic hypoglycemic syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16099087", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Hypoglycin A, the toxin found in the ackee fruit, has been reported in the literature as the causative agent in incidences of acute toxicity termed Jamaican vomiting sickness or toxic hypoglycemic syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16099087", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "An acute illness (Jamaican vomiting sickness) which affected two adults after eating unripe ackee fruit was investigated. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6488562", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 314, "text": "In 1976, over 100 years after Jamaican vomiting sickness (JVS) was first reported, the cause of JVS was linked to the ingestion of the toxin hypoglycin A produced by ackee fruit.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26328472", "endSection": "abstract"}]}, {"body": "Which gene is mutated in the Karak syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16783378", "http://www.ncbi.nlm.nih.gov/pubmed/26001724", "http://www.ncbi.nlm.nih.gov/pubmed/20938027", "http://www.ncbi.nlm.nih.gov/pubmed/27884548", "http://www.ncbi.nlm.nih.gov/pubmed/18443314", "http://www.ncbi.nlm.nih.gov/pubmed/24130795"], "ideal_answer": ["PLA2G6 gene is mutated in the Karak syndrome."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "http://www.disease-ontology.org/api/metadata/DOID:225"], "type": "factoid", "id": "588f9950ed9bbee70d000002", "snippets": [{"offsetInBeginSection": 163, "offsetInEndSection": 333, "text": "Mutations in PLA2G6 have been associated with disorders such as infantile neuroaxonal dystrophy, neurodegeneration with brain iron accumulation type II and Karak syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26001724", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "Mutations in PLA2G6 gene have variable phenotypic outcome including infantile neuroaxonal dystrophy, atypical neuroaxonal dystrophy, idiopathic neurodegeneration with brain iron accumulation and Karak syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24130795", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "BACKGROUND: PLA2G6 is the causative gene for infantile neuroaxonal dystrophy, neurodegeneration associated with brain iron accumulation, and Karak syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20938027", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "PLA2G6 is the causative gene for infantile neuroaxonal dystrophy, neurodegeneration associated with brain iron accumulation, and Karak syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20938027", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "Mutations in PLA2G6 gene have variable phenotypic outcome including infantile neuroaxonal dystrophy, atypical neuroaxonal dystrophy, idiopathic neurodegeneration with brain iron accumulation and Karak syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24130795", "endSection": "abstract"}, {"offsetInBeginSection": 181, "offsetInEndSection": 474, "text": "Recessively inherited mutations of the PLA2G6 gene are causative of infantile neuroaxonal dystrophy and other PLA2G6-associated neurodegeneration, which includes conditions known as atypical neuroaxonal dystrophy, Karak syndrome and early-onset dystonia-parkinsonism with cognitive impairment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27884548", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 333, "text": "Mutations in PLA2G6 have been associated with disorders such as infantile neuroaxonal dystrophy, neurodegeneration with brain iron accumulation type II and Karak syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26001724", "endSection": "abstract"}, {"offsetInBeginSection": 173, "offsetInEndSection": 455, "text": "We mapped a locus for infantile neuroaxonal dystrophy (INAD) and neurodegeneration with brain iron accumulation (NBIA) to chromosome 22q12-q13 and identified mutations in PLA2G6, encoding a calcium-independent group VI phospholipase A2, in NBIA, INAD and the related Karak syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16783378", "endSection": "abstract"}, {"offsetInBeginSection": 174, "offsetInEndSection": 457, "text": "We mapped a locus for infantile neuroaxonal dystrophy (INAD) and neurodegeneration with brain iron accumulation (NBIA) to chromosome 22q12-q13 and identified mutations in PLA2G6, encoding a calcium-independent group VI phospholipase A2, in NBIA, INAD and the related Karak syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16783378", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 335, "text": "Mutations in PLA2G6 have been associated with disorders such as infantile neuroaxonal dystrophy, neurodegeneration with brain iron accumulation type II and Karak syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26001724", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 475, "text": "Recessively inherited mutations of the PLA2G6 gene are causative of infantile neuroaxonal dystrophy and other PLA2G6-associated neurodegeneration, which includes conditions known as atypical neuroaxonal dystrophy, Karak syndrome and early-onset dystonia-parkinsonism with cognitive impairment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27884548", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 334, "text": "Mutations in PLA2G6 have been associated with disorders such as infantile neuroaxonal dystrophy, neurodegeneration with brain iron accumulation type II and Karak syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26001724", "endSection": "abstract"}, {"offsetInBeginSection": 174, "offsetInEndSection": 456, "text": "We mapped a locus for infantile neuroaxonal dystrophy (INAD) and neurodegeneration with brain iron accumulation (NBIA) to chromosome 22q12-q13 and identified mutations in PLA2G6, encoding a calcium-independent group VI phospholipase A2, in NBIA, INAD and the related Karak syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16783378", "endSection": "abstract"}]}, {"body": "What is LedPred?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26628586"], "ideal_answer": ["LedPred is an R/bioconductor package to predict regulatory sequences using support vector machines. LedPred is provided as an R/Bioconductor package connected to an online server to avoid installation of non-R software. Due to the heterogeneous CRM feature integration, LedPred excels at the prediction of regulatory sequences in Drosophila and mouse datasets compared with similar SVM-based software."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D060388", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012045"], "type": "summary", "id": "587e392d2420191125000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "LedPred: an R/bioconductor package to predict regulatory sequences using support vector machines", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26628586", "endSection": "title"}, {"offsetInBeginSection": 316, "offsetInEndSection": 803, "text": "Here, we present LedPred, a flexible SVM workflow that predicts new regulatory sequences based on the annotation of known CRMs, which are associated to a large variety of feature types. LedPred is provided as an R/Bioconductor package connected to an online server to avoid installation of non-R software. Due to the heterogeneous CRM feature integration, LedPred excels at the prediction of regulatory sequences in Drosophila and mouse datasets compared with similar SVM-based software.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26628586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "LedPred: an R/bioconductor package to predict regulatory sequences using support vector machines.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26628586", "endSection": "title"}, {"offsetInBeginSection": 606, "offsetInEndSection": 787, "text": "Due to the heterogeneous CRM feature integration, LedPred excels at the prediction of regulatory sequences in Drosophila and mouse datasets compared with similar SVM-based software.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26628586", "endSection": "abstract"}, {"offsetInBeginSection": 302, "offsetInEndSection": 487, "text": "Here, we present LedPred, a flexible SVM workflow that predicts new regulatory sequences based on the annotation of known CRMs, which are associated to a large variety of feature types.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26628586", "endSection": "abstract"}, {"offsetInBeginSection": 610, "offsetInEndSection": 1085, "text": "Due to the heterogeneous CRM feature integration, LedPred excels at the prediction of regulatory sequences in Drosophila and mouse datasets compared with similar SVM-based software.LedPred is available on GitHub: https://github.com/aitgon/LedPred and Bioconductor: http://bioconductor.org/packages/release/bioc/html/LedPred.html under the MIT license.aitor.gonzalez@univ-amu.frSupplementary data are available at Bioinformatics online.<CopyrightInformation>\u00a9 The Author 2015.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26628586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "LedPred: an R/bioconductor package to predict regulatory sequences using support vector machines.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26628586", "endSection": "title"}, {"offsetInBeginSection": 610, "offsetInEndSection": 791, "text": "Due to the heterogeneous CRM feature integration, LedPred excels at the prediction of regulatory sequences in Drosophila and mouse datasets compared with similar SVM-based software.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26628586", "endSection": "abstract"}, {"offsetInBeginSection": 304, "offsetInEndSection": 489, "text": "Here, we present LedPred, a flexible SVM workflow that predicts new regulatory sequences based on the annotation of known CRMs, which are associated to a large variety of feature types.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26628586", "endSection": "abstract"}]}, {"body": "Is siltuximab effective for Castleman disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25310208", "http://www.ncbi.nlm.nih.gov/pubmed/26124203", "http://www.ncbi.nlm.nih.gov/pubmed/26749192", "http://www.ncbi.nlm.nih.gov/pubmed/25601959", "http://www.ncbi.nlm.nih.gov/pubmed/26634298", "http://www.ncbi.nlm.nih.gov/pubmed/25110138", "http://www.ncbi.nlm.nih.gov/pubmed/25042199", "http://www.ncbi.nlm.nih.gov/pubmed/23659971", "http://www.ncbi.nlm.nih.gov/pubmed/26327301", "http://www.ncbi.nlm.nih.gov/pubmed/25784388", "http://www.ncbi.nlm.nih.gov/pubmed/25873122", "http://www.ncbi.nlm.nih.gov/pubmed/20625121", "http://www.ncbi.nlm.nih.gov/pubmed/27152394", "http://www.ncbi.nlm.nih.gov/pubmed/25685858", "http://www.ncbi.nlm.nih.gov/pubmed/26394632", "http://www.ncbi.nlm.nih.gov/pubmed/26869762", "http://www.ncbi.nlm.nih.gov/pubmed/25736164", "http://www.ncbi.nlm.nih.gov/pubmed/25884809"], "ideal_answer": ["Yes, siltuximab , a chimeric human-mouse monoclonal antibody to IL6, is approved for the treatment of patients with multicentric Castleman disease who are human immunodeficiency virus negative and human herpesvirus-8 negative."], "type": "yesno", "id": "5896d3e278275d0c4a000012", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26634298", "endSection": "title"}, {"offsetInBeginSection": 317, "offsetInEndSection": 680, "text": "The recent approvals in North America, Europe and Brazil of siltuximab, a monoclonal antibody against IL-6, for iMCD now provide a safe and effective therapy that targets a key aspect of pathogenesis. In the first ever randomized, placebo-controlled trial in iMCD, siltuximab significantly reduced disease burden and symptoms in a large portion (34%) of patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26634298", "endSection": "abstract"}, {"offsetInBeginSection": 601, "offsetInEndSection": 854, "text": "Despite recent significant advances in our understanding of this disease and the increasing therapeutic experience with rituximab, tocilizumab and siltuximab, there are still difficult questions concerning its aetiology, prognosis and optimal treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26749192", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Emerging treatments in Castleman disease - a critical appraisal of siltuximab.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26869762", "endSection": "title"}, {"offsetInBeginSection": 284, "offsetInEndSection": 793, "text": " Siltuximab, a chimeric monoclonal antibody to IL-6, has thus emerged as a promising treatment option in a disease lacking efficacious therapy. Here, we review the findings of recent studies evaluating single-agent siltuximab treatment in CD, including the first-ever randomized clinical trial in this disease. Although much more work is needed to establish a standardized treatment approach, siltuximab appears to be a safe and effective treatment for patients with newly diagnosed and previously treated CD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26869762", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601959", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 328, "text": "On April 22, 2014, the FDA granted full approval to siltuximab (SYLVANT for injection; Janssen Biotech, Inc.), a chimeric human-mouse monoclonal antibody to IL6, for the treatment of patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601959", "endSection": "abstract"}, {"offsetInBeginSection": 1460, "offsetInEndSection": 1757, "text": "Currently, there are more effective therapeutic alternatives in multicentric Castleman disease: treatment with monotherapy of rituximab or in combination therapy with immunomodulatory drugs (thalidomide or lenalidomide, treatment with anti-IL-6 (siltuximab) or against its receptor (tocilizumab). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873122", "endSection": "abstract"}, {"offsetInBeginSection": 1448, "offsetInEndSection": 1744, "text": "Currently, there are more effective therapeutic alternatives in multicentric Castleman disease: treatment with monotherapy of rituximab or in combination therapy with immunomodulatory drugs (thalidomide or lenalidomide, treatment with anti-IL-6 (siltuximab) or against its receptor (tocilizumab).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873122", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "Siltuximab for multicentric Castleman disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110138", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26394632", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Siltuximab (IL6 antibody) is approved for the treatment of multicentric Castleman disease (MCD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26124203", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26327301", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659971", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26124203", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27152394", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Siltuximab: a new option for the management of Castleman's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685858", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625121", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 445, "text": "PURPOSE: To evaluate the safety and pharmacokinetics of siltuximab, an anti-interleukin-6 chimeric monoclonal antibody (mAb) in patients with B-cell non-Hodgkin lymphoma (NHL), multiple myeloma, or Castleman disease.EXPERIMENTAL DESIGN: In an open-label, dose-finding, 7 cohort, phase I study, patients with NHL, multiple myeloma, or symptomatic Castleman disease received siltuximab 3, 6, 9, or 12 mg/kg weekly, every 2 weeks, or every 3 weeks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659971", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Dose selection of siltuximab for multicentric Castleman's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784388", "endSection": "title"}, {"offsetInBeginSection": 243, "offsetInEndSection": 690, "text": "Here, modeling and simulation of the pharmacokinetic (PK)/pharmacodynamic (PD) relationship between siltuximab and CRP were used to support dose selection for multicentric Castleman's disease (CD).METHODS: PK/PD modeling was applied to explore the relationship between siltuximab PK and CRP suppression following intravenous siltuximab infusion in 47 patients with B cell non-Hodgkin's lymphoma (n\u00a0=\u00a017), multiple myeloma (n\u00a0=\u00a013), or CD (n\u00a0=\u00a017).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784388", "endSection": "abstract"}, {"offsetInBeginSection": 1459, "offsetInEndSection": 1754, "text": "Currently, there are more effective therapeutic alternatives in multicentric Castleman disease: treatment with monotherapy of rituximab or in combination therapy with immunomodulatory drugs (thalidomide or lenalidomide, treatment with anti-IL-6 (siltuximab) or against its receptor (tocilizumab)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873122", "endSection": "abstract"}, {"offsetInBeginSection": 1916, "offsetInEndSection": 2260, "text": "Three (6%) of 53 patients had serious adverse events judged reasonably related to siltuximab (lower respiratory tract infection, anaphylactic reaction, sepsis).Siltuximab plus best supportive care was superior to best supportive care alone for patients with symptomatic multicentric Castlemans disease and well tolerated with prolonged exposure", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042199", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 557, "text": "Siltuximab, an anti-IL-6 monoclonal antibody, has demonstrated durable tumor and symptomatic responses in a multinational, randomized, placebo-controlled study of MCD.This preplanned safety analysis was conducted to evaluate the long-term safety of siltuximab treatment among 19 patients with MCD who had stable disease or better and were enrolled in a phase-1 study and subsequent ongoing, open-label, phase-2 extension study", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26327301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26124203", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Siltuximab (IL6 antibody) is approved for the treatment of multicentric Castleman disease (MCD)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26124203", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 45, "text": "Siltuximab for multicentric Castleman disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110138", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601959", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 326, "text": "On April 22, 2014, the FDA granted full approval to siltuximab (SYLVANT for injection; Janssen Biotech, Inc.), a chimeric human-mouse monoclonal antibody to IL6, for the treatment of patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601959", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042199", "endSection": "title"}, {"offsetInBeginSection": 217, "offsetInEndSection": 447, "text": "EXPERIMENTAL DESIGN: In an open-label, dose-finding, 7 cohort, phase I study, patients with NHL, multiple myeloma, or symptomatic Castleman disease received siltuximab 3, 6, 9, or 12 mg/kg weekly, every 2 weeks, or every 3 weeks. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659971", "endSection": "abstract"}, {"offsetInBeginSection": 1460, "offsetInEndSection": 1756, "text": "Currently, there are more effective therapeutic alternatives in multicentric Castleman disease: treatment with monotherapy of rituximab or in combination therapy with immunomodulatory drugs (thalidomide or lenalidomide, treatment with anti-IL-6 (siltuximab) or against its receptor (tocilizumab).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873122", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 415, "text": "To evaluate the safety and pharmacokinetics of siltuximab, an anti-interleukin-6 chimeric monoclonal antibody (mAb) in patients with B-cell non-Hodgkin lymphoma (NHL), multiple myeloma, or Castleman disease.In an open-label, dose-finding, 7 cohort, phase I study, patients with NHL, multiple myeloma, or symptomatic Castleman disease received siltuximab 3, 6, 9, or 12 mg/kg weekly, every 2 weeks, or every 3 weeks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659971", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 327, "text": "On April 22, 2014, the FDA granted full approval to siltuximab (SYLVANT for injection; Janssen Biotech, Inc.), a chimeric human-mouse monoclonal antibody to IL6, for the treatment of patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601959", "endSection": "abstract"}, {"offsetInBeginSection": 460, "offsetInEndSection": 767, "text": "Clinical benefit response (CBR; composite of hemoglobin, fatigue, anorexia, fever/night sweats, weight, largest lymph node size) was also evaluated in Castleman disease.Sixty-seven patients received a median of 16 siltuximab doses for a median of 8.5 (maximum 60.5) months; 29 were treated 1 year or longer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659971", "endSection": "abstract"}, {"offsetInBeginSection": 317, "offsetInEndSection": 517, "text": "The recent approvals in North America, Europe and Brazil of siltuximab, a monoclonal antibody against IL-6, for iMCD now provide a safe and effective therapy that targets a key aspect of pathogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26634298", "endSection": "abstract"}, {"offsetInBeginSection": 595, "offsetInEndSection": 793, "text": "Although much more work is needed to establish a standardized treatment approach, siltuximab appears to be a safe and effective treatment for patients with newly diagnosed and previously treated CD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26869762", "endSection": "abstract"}, {"offsetInBeginSection": 1304, "offsetInEndSection": 1594, "text": "No dose-limiting toxicity was reported, and only three patients had grade 3 or higher adverse events after a median exposure of 331 days (range, 1 to 1,148 days).These interim results strongly suggest that siltuximab is an effective treatment with favorable safety for the management of CD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625121", "endSection": "abstract"}, {"offsetInBeginSection": 149, "offsetInEndSection": 492, "text": "Siltuximab is a new anti-IL-6, chimeric monoclonal antibody with potential therapeutic benefit in patients with CD.METHODS: We report interim results from an open-label, dose-finding, seven-cohort, phase I study in which patients with symptomatic, multicentric or unresectable, unicentric CD received siltuximab at 1-, 2-, or 3-week intervals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625121", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "Siltuximab for multicentric Castleman disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110138", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26634298", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Emerging treatments in Castleman disease - a critical appraisal of siltuximab.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26869762", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27152394", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Siltuximab: a new option for the management of Castleman's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685858", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042199", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26394632", "endSection": "title"}]}, {"body": "What are Degrons?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7731961", "http://www.ncbi.nlm.nih.gov/pubmed/23960079", "http://www.ncbi.nlm.nih.gov/pubmed/10545113", "http://www.ncbi.nlm.nih.gov/pubmed/20924402", "http://www.ncbi.nlm.nih.gov/pubmed/16606826", "http://www.ncbi.nlm.nih.gov/pubmed/22577142", "http://www.ncbi.nlm.nih.gov/pubmed/21190544", "http://www.ncbi.nlm.nih.gov/pubmed/26732515", "http://www.ncbi.nlm.nih.gov/pubmed/25157437", "http://www.ncbi.nlm.nih.gov/pubmed/23431188", "http://www.ncbi.nlm.nih.gov/pubmed/19878048", "http://www.ncbi.nlm.nih.gov/pubmed/26456660"], "ideal_answer": ["Specific signals (degrons) regulate protein turnover mediated by the ubiquitin-proteasome system.", "Portable degradation sequences, or degrons, have the ability to bind to E3 ligases and promote substrate ubiquitination when the sequence is presented in isolation or appended to other entities such as fluorescent peptide-based reporters.", "portable degradation sequences, or degrons, have the ability to bind to e3 ligases and promote substrate ubiquitination when the sequence is presented in isolation or appended to other entities such as fluorescent peptide-based reporters."], "type": "summary", "id": "58cdbaf302b8c60953000044", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Specific signals (degrons) regulate protein turnover mediated by the ubiquitin-proteasome system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732515", "endSection": "abstract"}, {"offsetInBeginSection": 672, "offsetInEndSection": 911, "text": "Portable degradation sequences, or degrons, have the ability to bind to E3 ligases and promote substrate ubiquitination when the sequence is presented in isolation or appended to other entities such as fluorescent peptide-based reporters. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26456660", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "The N-degrons, a set of degradation signals recognized by the N-end rule pathway, comprise a protein's destabilizing N-terminal residue and an internal lysine residue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10545113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "The ubiquitin-proteasome system degrades an enormous variety of proteins that contain specific degradation signals, or 'degrons'.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18698327", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 375, "text": "Degron refers to an amino acid sequence that encodes a protein degradation signal, which is oftentimes a poly-ubiquitin chain that can be transferred to other proteins. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26435348", "endSection": "abstract"}, {"offsetInBeginSection": 119, "offsetInEndSection": 311, "text": "Degradation signals (degrons) that are targeted by the N-end rule pathway include a set called N-degrons. The main determinant of an N-degron is a destabilizing N-terminal residue of a protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21633985", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "The N-end rule pathway is a proteolytic system in which destabilizing N-terminal amino acids of short lived proteins are recognized by recognition components (N-recognins) as an essential element of degrons, called N-degrons", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22577142", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "The N-end rule pathway is a regulated proteolytic system that targets proteins containing destabilizing N-terminal residues (N-degrons) for ubiquitination and proteasomal degradation in eukaryotes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20835240", "endSection": "abstract"}, {"offsetInBeginSection": 778, "offsetInEndSection": 940, "text": "More than 25 years ago, the first degradation signal was discovered and defined as destabilizing N-terminal amino-acid residue (or N-degron) of protein substrates", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26743630", "endSection": "abstract"}, {"offsetInBeginSection": 428, "offsetInEndSection": 716, "text": "A protein domain called \"degron\", which induces rapid proteolysis by the proteasome, can be used for this purpose. Degron-based technologies for the conditional depletion of POI--degron fusion proteins have been developed by exploiting various pathways leading to proteasomal degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23271452", "endSection": "abstract"}]}, {"body": "Which disease is associated with mutated Sox2?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25542770", "http://www.ncbi.nlm.nih.gov/pubmed/26893459", "http://www.ncbi.nlm.nih.gov/pubmed/26250054", "http://www.ncbi.nlm.nih.gov/pubmed/26130484"], "ideal_answer": ["SOX2 anophthalmia syndrome is an uncommon autosomal dominant syndrome caused by mutations in the SOX2 gene and clinically characterized by severe eye malformations (anophthalmia/microphthalmia) and extraocular anomalies mainly involving brain, esophagus, and genitalia."], "type": "factoid", "id": "58ce9bf1d46b5c2951000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "Anophthalmia and microphthalmia (A/M) are developmental ocular malformations defined as the complete absence or reduction in size of the eye. A/M is a highly heterogeneous disorder with SOX2 and FOXE3 playing major roles in dominant and recessive pedigrees, respectively;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26130484", "endSection": "abstract"}, {"offsetInBeginSection": 45, "offsetInEndSection": 296, "text": "anophthalmia/microphthalmia (AM) or anterior segment dysgenesis (ASD) have an estimated combined prevalence of 3.7 in 10,000 births. Mutations in SOX2 are the most frequent contributors to severe ODA, yet account for a minority of the genetic drivers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26893459", "endSection": "abstract"}, {"offsetInBeginSection": 477, "offsetInEndSection": 548, "text": "Three causative SOX2 mutations were found in subjects with syndromic A.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25542770", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "SOX2 anophthalmia syndrome is an uncommon autosomal dominant syndrome caused by mutations in the SOX2 gene and clinically characterized by severe eye malformations (anophthalmia/microphthalmia) and extraocular anomalies mainly involving brain, esophagus, and genitalia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26250054", "endSection": "abstract"}]}, {"body": "Is the enzyme EPRS phosphorylated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27729295", "http://www.ncbi.nlm.nih.gov/pubmed/21220307", "http://www.ncbi.nlm.nih.gov/pubmed/19647514", "http://www.ncbi.nlm.nih.gov/pubmed/23071094"], "ideal_answer": ["Yes, EPRS is dually phosphorylated by cyclin-dependent kinase 5 (Cdk5) at Ser(886) and then by a Cdk5-dependent-AGC kinase at Ser(999)"], "type": "yesno", "id": "58cd522902b8c60953000038", "snippets": [{"offsetInBeginSection": 368, "offsetInEndSection": 560, "text": "Phosphorylation of glutamyl-prolyl tRNA synthetase (EPRS) has been investigated extensively in our laboratory for more than a decade, and has served as an archetype for studies of other AARSs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729295", "endSection": "abstract"}, {"offsetInBeginSection": 448, "offsetInEndSection": 579, "text": "EPRS is dually phosphorylated by cyclin-dependent kinase 5 (Cdk5) at Ser(886) and then by a Cdk5-dependent-AGC kinase at Ser(999); ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071094", "endSection": "abstract"}, {"offsetInBeginSection": 800, "offsetInEndSection": 997, "text": "Diphosphorylated EPRS is released from its residence in the tRNA multisynthetase complex for immediate binding to NS1-associated protein and subsequent binding to ribosomal protein L13a and GAPDH. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21220307", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Two-site phosphorylation of EPRS coordinates multimodal regulation of noncanonical translational control activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19647514", "endSection": "title"}]}, {"body": "Which disease the skin condition Necrobiosis lipoidica diabeticorum is associated to?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11259927", "http://www.ncbi.nlm.nih.gov/pubmed/24575162", "http://www.ncbi.nlm.nih.gov/pubmed/17429587", "http://www.ncbi.nlm.nih.gov/pubmed/730866", "http://www.ncbi.nlm.nih.gov/pubmed/8261754", "http://www.ncbi.nlm.nih.gov/pubmed/16060710", "http://www.ncbi.nlm.nih.gov/pubmed/18357585", "http://www.ncbi.nlm.nih.gov/pubmed/7851128", "http://www.ncbi.nlm.nih.gov/pubmed/12183729", "http://www.ncbi.nlm.nih.gov/pubmed/18377597", "http://www.ncbi.nlm.nih.gov/pubmed/8733162", "http://www.ncbi.nlm.nih.gov/pubmed/20537071", "http://www.ncbi.nlm.nih.gov/pubmed/7501550", "http://www.ncbi.nlm.nih.gov/pubmed/18092383", "http://www.ncbi.nlm.nih.gov/pubmed/23762652", "http://www.ncbi.nlm.nih.gov/pubmed/3351015", "http://www.ncbi.nlm.nih.gov/pubmed/19715570", "http://www.ncbi.nlm.nih.gov/pubmed/24283101", "http://www.ncbi.nlm.nih.gov/pubmed/27016885", "http://www.ncbi.nlm.nih.gov/pubmed/25266162", "http://www.ncbi.nlm.nih.gov/pubmed/23969033", "http://www.ncbi.nlm.nih.gov/pubmed/2102235", "http://www.ncbi.nlm.nih.gov/pubmed/20524475", "http://www.ncbi.nlm.nih.gov/pubmed/19380665", "http://www.ncbi.nlm.nih.gov/pubmed/18718195", "http://www.ncbi.nlm.nih.gov/pubmed/12180894", "http://www.ncbi.nlm.nih.gov/pubmed/23595890", "http://www.ncbi.nlm.nih.gov/pubmed/26975548"], "ideal_answer": ["Necrobiosis lipoidica diabeticorum (NLD) is a rare, granulomatous inflammatory skin disease of unknown origin, sometimes associated with diabetes mellitus."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009335", "http://www.disease-ontology.org/api/metadata/DOID:4", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", "http://www.disease-ontology.org/api/metadata/DOID:3486"], "type": "factoid", "id": "58bfd8e902b8c60953000018", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "Necrobiosis lipoidica diabeticorum (NLD) is a chronic condition, which is characterized by single or multiple lesions on the legs, and occurs in 0.3% of patients with diabetes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25266162", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 221, "text": "Necrobiosis lipoidica (NL) is a rare chronic granulomatous dermatitis that usually appears in the lower extremities. It affects about 0.3-1.2% of diabetic patients, the majority of whom have type 1 diabetes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24575162", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 244, "text": "A 32-year-old woman with type 2 diabetes mellitus suffering from morbid obesity with BMI 45,14\u2009kg/m(2) was operated on. Not only the type 2DM but also one of its complication known as necrobiosis lipoidica diabeticorum remitted postoperatively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23762652", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 616, "text": "Necrobiosis lipoidica is a granulomatous skin disease of unknown etiology, associated mainly with diabetes mellitus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23762652", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 133, "text": "Necrobiosis lipoidica diabeticorum is a rare disease of unclear etiology, that occurs in about 1% of diabetic patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715570", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 168, "text": "Necrobiosis lipoidica diabeticorum (NLD) is a rare, granulomatous inflammatory skin disease of unknown origin, sometimes associated with diabetes mellitus. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19380665", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Necrobiosis lipoidica diabeticorum (NLD) is a rare skin condition associated with diabetes, which characteristically occurs in the pretibial region of the lower limbs (Boulton et al., 1988).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11259927", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 302, "text": "More than half of the patients with necrobiosis lipoidica diabeticorum have diabetes mellitus, but less than one per cent of diabetes mellitus patients have necrobiosis lipoidica diabeticorum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8733162", "endSection": "abstract"}, {"offsetInBeginSection": 105, "offsetInEndSection": 390, "text": "We describe the unusual case of a woman with diabetes and a history of generalized granuloma annulare who noted leg ulcers that clinically represented ulcerated necrobiosis lipoidica diabeticorum and had histologic features of necrobiosis lipoidica diabeticorum and granuloma annulare.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7851128", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Necrobiosis lipoidica diabeticorum (NLD) is a rare, granulomatous inflammatory skin disease of unknown origin, sometimes associated with diabetes mellitus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19380665", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Necrobiosis lipoidica diabeticorum (NLD) is a rare skin condition associated with diabetes, which characteristically occurs in the pretibial region of the lower limbs (Boulton et al., 1988)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11259927", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Necrobiosis lipoidica is a rare inflammatory granulomatous skin disease of unknown etiology which is associated with diabetes mellitus in about 60\u2009% of the patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23595890", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 615, "text": "Necrobiosis lipoidica is a granulomatous skin disease of unknown etiology, associated mainly with diabetes mellitus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23762652", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Necrobiosis lipoidica is an inflammatory granulomatous skin disease of unknown etiology which is associated with diabetes mellitus in about 60% of the patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17429587", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Necrobiosis lipoidica dibeticum (NLD) is a granulomatous skin disease mostly associated with diabetes mellitus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18092383", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Necrobiosis lipoidica (NL) is a rare chronic granulomatous disease that has historically been associated with diabetes mellitus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23969033", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Necrobiosis lipoidica diabeticorum is an unusual dermatologic condition with a characteristic clinical appearance and a clear association with diabetes mellitus. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3351015", "endSection": "abstract"}, {"offsetInBeginSection": 306, "offsetInEndSection": 447, "text": "However, it has not been associated previously with necrobiosis lipoidica diabeticorum (NBL), a rare skin manifestation of diabetes mellitus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2102235", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Necrobiosis lipoidica diabeticorum (NLD) is a rare, granulomatous inflammatory skin disease of unknown origin, sometimes associated with diabetes mellitus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19380665", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "Necrobiosis lipoidica diabeticorum (NLD) is a rare degenerative connective tissue disorder associated with diabetes mellitus, which usually presents with red papules or plaques with raised edges and occasional ulceration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26975548", "endSection": "abstract"}, {"offsetInBeginSection": 278, "offsetInEndSection": 401, "text": "We describe two children with diabetes who both developed granuloma annulare and later, necrobiosis lipoidica diabeticorum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20537071", "endSection": "abstract"}, {"offsetInBeginSection": 145, "offsetInEndSection": 277, "text": "Granuloma annulare occurs earlier than necrobiosis lipoidica diabeticorum and the association with diabetes mellitus is much weaker.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20537071", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Diabetes mellitus is associated with a range of dermatologic presentations, including granuloma annulare and necrobiosis lipoidica diabeticorum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20537071", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 273, "text": "In this report a patient with diabetes mellitus and generalized necrobiosis lipoidica diabeticorum with localization in surgical scars is described.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/730866", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Necrobiosis lipoidica is an idiopathic dermatological condition that is strongly associated with diabetes mellitus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18718195", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Necrobiosis lipoidica diabeticorum is an unusual dermatologic condition with a characteristic clinical appearance and a clear association with diabetes mellitus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3351015", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Necrobiosis lipoidica diabeticorum is a rare skin disorder, usually considered a marker for diabetes mellitus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8733162", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Recurrent necrobiosis lipoidica diabeticorum associated with venous insufficiency in an adolescent with poorly controlled type 2 diabetes mellitus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12183729", "endSection": "title"}]}, {"body": "What is the role of Lysine 2-hydroxyisobutyrylation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24681537"], "ideal_answer": ["Lysine 2-hydroxyisobutyrylation (Khib) is a widely distributed active histone mark. This histone mark was initially identified by MS and then validated by chemical and biochemical methods. Histone Khib shows distinct genomic distributions from histone Kac or histone Kcr during male germ cell differentiation. In male germ cells, H4K8hib is associated with active gene transcription in meiotic and post-meiotic cells. In addition, H4K8ac-associated genes are included in and constitute only a subfraction of H4K8hib-labeled genes. The histone Khib mark is conserved and widely distributed, has high stoichiometry and induces a large structural change."], "concepts": ["http://www.biosemantics.org/jochem#4005689", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275269", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008239", "http://www.biosemantics.org/jochem#4278518", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4005689", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042421", "http://www.biosemantics.org/jochem#4275268", "http://www.biosemantics.org/jochem#4275269"], "type": "summary", "id": "589474467d9090f353000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Lysine 2-hydroxyisobutyrylation is a widely distributed active histone mark.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24681537", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1048, "text": "We report the identification of a new type of histone mark, lysine 2-hydroxyisobutyrylation (Khib), and identify the mark at 63 human and mouse histone Khib sites, including 27 unique lysine sites that are not known to be modified by lysine acetylation (Kac) and lysine crotonylation (Kcr). This histone mark was initially identified by MS and then validated by chemical and biochemical methods. Histone Khib shows distinct genomic distributions from histone Kac or histone Kcr during male germ cell differentiation. Using chromatin immunoprecipitation sequencing, gene expression analysis and immunodetection, we show that in male germ cells, H4K8hib is associated with active gene transcription in meiotic and post-meiotic cells. In addition, H4K8ac-associated genes are included in and constitute only a subfraction of H4K8hib-labeled genes. The histone Khib mark is conserved and widely distributed, has high stoichiometry and induces a large structural change. These findings suggest its critical role on the regulation of chromatin functions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24681537", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 290, "text": "We report the identification of a new type of histone mark, lysine 2-hydroxyisobutyrylation (Khib), and identify the mark at 63 human and mouse histone Khib sites, including 27 unique lysine sites that are not known to be modified by lysine acetylation (Kac) and lysine crotonylation (Kcr).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24681537", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Lysine 2-hydroxyisobutyrylation is a widely distributed active histone mark", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24681537", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 289, "text": "We report the identification of a new type of histone mark, lysine 2-hydroxyisobutyrylation (Khib), and identify the mark at 63 human and mouse histone Khib sites, including 27 unique lysine sites that are not known to be modified by lysine acetylation (Kac) and lysine crotonylation (Kcr)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24681537", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 291, "text": "We report the identification of a new type of histone mark, lysine 2-hydroxyisobutyrylation (Khib), and identify the mark at 63 human and mouse histone Khib sites, including 27 unique lysine sites that are not known to be modified by lysine acetylation (Kac) and lysine crotonylation (Kcr). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24681537", "endSection": "abstract"}, {"offsetInBeginSection": 845, "offsetInEndSection": 965, "text": "The histone Khib mark is conserved and widely distributed, has high stoichiometry and induces a large structural change.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24681537", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Lysine 2-hydroxyisobutyrylation is a widely distributed active histone mark.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24681537", "endSection": "title"}]}, {"body": "List diseases associated with the  Dopamine Receptor D4 (DRD4).", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22610946", "http://www.ncbi.nlm.nih.gov/pubmed/25659462", "http://www.ncbi.nlm.nih.gov/pubmed/25983551"], "ideal_answer": ["The 5-repeat allele of a common length polymorphism in the gene that encodes the dopamine D4 receptor (DRD4) is robustly associated with the risk of attention deficit hyperactivity disorder (ADHD)."], "type": "list", "id": "58cd59cb02b8c60953000039", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 279, "text": "The 5-repeat allele of a common length polymorphism in the gene that encodes the dopamine D4 receptor (DRD4) is robustly associated with the risk of attention deficit hyperactivity disorder (ADHD) and substantially exists in Asian populations, which have a lower ADHD prevalence.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25659462", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 296, "text": "The variable number of tandem repeats (VNTR) of the dopamine receptor D4 (DRD4) gene among humans may elucidate individual differences in susceptibility to neuropsychiatric diseases. Dopamine dysfunction may be involved with Attention Deficit Hyperactivity Disorder (ADHD) symptoms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25983551", "endSection": "abstract"}, {"offsetInBeginSection": 505, "offsetInEndSection": 720, "text": "This review summarized the ongoing research of DA receptor genes in ADHD pathogenesis and gathered the past published data with meta-analysis and revealed the high risk of DRD5, DRD2, and DRD4 polymorphisms in ADHD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22610946", "endSection": "abstract"}]}, {"body": "Which bacteria cause diphtheria?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8784575", "http://www.ncbi.nlm.nih.gov/pubmed/24403054", "http://www.ncbi.nlm.nih.gov/pubmed/7766139", "http://www.ncbi.nlm.nih.gov/pubmed/23981100", "http://www.ncbi.nlm.nih.gov/pubmed/14532240", "http://www.ncbi.nlm.nih.gov/pubmed/23357389", "http://www.ncbi.nlm.nih.gov/pubmed/812306", "http://www.ncbi.nlm.nih.gov/pubmed/22205447", "http://www.ncbi.nlm.nih.gov/pubmed/21087580", "http://www.ncbi.nlm.nih.gov/pubmed/25578079", "http://www.ncbi.nlm.nih.gov/pubmed/21549738", "http://www.ncbi.nlm.nih.gov/pubmed/1901182", "http://www.ncbi.nlm.nih.gov/pubmed/25887321", "http://www.ncbi.nlm.nih.gov/pubmed/23163039", "http://www.ncbi.nlm.nih.gov/pubmed/21742447", "http://www.ncbi.nlm.nih.gov/pubmed/26607400", "http://www.ncbi.nlm.nih.gov/pubmed/24295558", "http://www.ncbi.nlm.nih.gov/pubmed/22583953", "http://www.ncbi.nlm.nih.gov/pubmed/25320226", "http://www.ncbi.nlm.nih.gov/pubmed/16107839", "http://www.ncbi.nlm.nih.gov/pubmed/22403045", "http://www.ncbi.nlm.nih.gov/pubmed/12661461", "http://www.ncbi.nlm.nih.gov/pubmed/10220818", "http://www.ncbi.nlm.nih.gov/pubmed/12037265", "http://www.ncbi.nlm.nih.gov/pubmed/25297035", "http://www.ncbi.nlm.nih.gov/pubmed/22568715", "http://www.ncbi.nlm.nih.gov/pubmed/10598381", "http://www.ncbi.nlm.nih.gov/pubmed/16406634", "http://www.ncbi.nlm.nih.gov/pubmed/24293345", "http://www.ncbi.nlm.nih.gov/pubmed/22628666", "http://www.ncbi.nlm.nih.gov/pubmed/25587356", "http://www.ncbi.nlm.nih.gov/pubmed/18583986", "http://www.ncbi.nlm.nih.gov/pubmed/24106714", "http://www.ncbi.nlm.nih.gov/pubmed/3112181", "http://www.ncbi.nlm.nih.gov/pubmed/10932611", "http://www.ncbi.nlm.nih.gov/pubmed/24572455", "http://www.ncbi.nlm.nih.gov/pubmed/11568853", "http://www.ncbi.nlm.nih.gov/pubmed/22382258"], "ideal_answer": ["Diphtheria is caused by the bacteria:\n1) Corynebacterium ulcerans and \n2) Corynebacterium diphtheriae."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001419", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003354", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003352", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004167", "http://www.disease-ontology.org/api/metadata/DOID:11405", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004165"], "type": "list", "id": "58b548d722d3005309000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 256, "text": "Corynebacterium ulcerans is a zoonotic pathogen that can produce diphtheria toxin and causes an illness categorized as diphtheria in the European Union because its clinical appearance is similar to that of diphtheria caused by Corynebacterium diphtheriae. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607400", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 444, "text": "The zoonotic bacterium Corynebacterium ulcerans may be pathogenic both in humans and animals: toxigenic strains can cause diphtheria or diphtheria-like disease in humans via diphtheria toxin, while strains producing the dermonecrotic exotoxin phospholipase D may lead to caseous lymphadenitis primarily in wild animals. Diphtheria toxin-positive Corynebacterium ulcerans strains have been isolated mainly from cattle, dogs and cats.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25887321", "endSection": "abstract"}, {"offsetInBeginSection": 523, "offsetInEndSection": 619, "text": "Corynebacterium diphtheriae, a pathogenic bacterium that causes diphtheria, has been performed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106714", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Corynebacterium ulcerans 0102 carries the gene encoding diphtheria toxin on a prophage different from the C. diphtheriae NCTC 13129 prophage.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22583953", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 299, "text": "Corynebacterium ulcerans can cause a diphtheria-like illness, especially when the bacterium is lysogenized with a tox gene-carrying bacteriophage that produces diphtheria toxin. Acquisition of toxigenicity upon phage lysogenization is a common feature of C. ulcerans and C. diphtheriae. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22583953", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 235, "text": "Corynebacterium ulcerans (toxigenic C. ulcerans) produces the diphtheria toxin, which causes pharyngeal and cutaneous diphtheria-like disease in people, and this bacterium is commonly detected in dogs and cats that are reared at home. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25578079", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 454, "text": "This case demonstrates that strains of C. ulcerans that produce diphtheria toxin can cause infections of the skin that completely mimic typical cutaneous diphtheria, thereby potentially providing a source of bacteria capable of causing life-threatening diseases in the patient's environment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568853", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Diphtheria is a serious upper respiratory tract disease caused by the diphtheria toxin (DT) secreted from the bacteria Corynebacterium diphtheriae.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22205447", "endSection": "abstract"}, {"offsetInBeginSection": 104, "offsetInEndSection": 213, "text": "ulcerans produce diphtheria toxin, which can cause life-threatening cardiopathies and neuropathies in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403045", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "A high-density growth approach was utilized to produce mutated diphtheria toxin from two strains of Corynebacterium diphtheria: C7 (beta)(tox-201,tox-9) and C7 (beta)(tox-107).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7766139", "endSection": "abstract"}, {"offsetInBeginSection": 1049, "offsetInEndSection": 1190, "text": "For the primary prevention of disease caused by diphtheria toxin-producing corynebacteria, vaccination with diphtheria toxoid is recommended.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403045", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 455, "text": "ulcerans that produce diphtheria toxin can cause infections of the skin that completely mimic typical cutaneous diphtheria, thereby potentially providing a source of bacteria capable of causing life-threatening diseases in the patient's environment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568853", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "[A case of diphtheria in the Netherlands due to an infection with Corynebacterium ulcerans].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12661461", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Diphtheria is an acute bacterial illness caused by toxigenic strains of Corynebacterium diphtheriae (C. diphtheriae)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22382258", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Diphtheria is caused by diphtheria toxin-producing Corynebacterium species", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22628666", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Diphtheria, an acute infectious condition caused by Corynebacterium diphtheriae, was once a major killer of children", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357389", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "Diphtheria, caused by toxigenic strains of Corynebacterium diphtheriae, is an ancient disease with high incidence and mortality that has always been characterized by epidemic waves of occurrence", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22568715", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Infections caused by Corynebacterium diphtheriae frequently induce situations in which very small doses of antigens injected intradermally can cause strong inflammatory reactions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Corynebacterium diphtheriae is the etiological agent of diphtheria, a potential fatal disease caused by a corynephage toxin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293345", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "[Diphtheria in Denmark 1956-1989. Occurrence of Corynebacterium diphtheriae and other diphtheria toxigenic bacteria].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1901182", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 231, "text": "Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry as a tool for rapid diagnosis of potentially toxigenic Corynebacterium species in the laboratory management of diphtheria-associated bacteria.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21087580", "endSection": "title"}, {"offsetInBeginSection": 164, "offsetInEndSection": 456, "text": "This case demonstrates that strains of C. ulcerans that produce diphtheria toxin can cause infections of the skin that completely mimic typical cutaneous diphtheria, thereby potentially providing a source of bacteria capable of causing life-threatening diseases in the patient's environment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568853", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Detection of differences in the nucleotide and amino acid sequences of diphtheria toxin from Corynebacterium diphtheriae and Corynebacterium ulcerans causing extrapharyngeal infections.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14532240", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Heterogeneity of diphtheria toxin gene, tox, and its regulatory element, dtxR, in Corynebacterium diphtheriae strains causing epidemic diphtheria in Russia and Ukraine.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8784575", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Diphtheria is a serious upper respiratory tract disease caused by the diphtheria toxin (DT) secreted from the bacteria Corynebacterium diphtheriae. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22205447", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Laboratory guidelines for the diagnosis of infections caused by Corynebacterium diphtheriae and C. ulcerans. ", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10598381", "endSection": "title"}, {"offsetInBeginSection": 1139, "offsetInEndSection": 1374, "text": "A possible biological mechanism for a diphtheria effect on hearing ability exists: The toxin produced by the Corynebacterium diphtheriae bacteria can cause damage to cranial nerves and therefore may affect the auditory neural pathway. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12037265", "endSection": "abstract"}, {"offsetInBeginSection": 1094, "offsetInEndSection": 1328, "text": "A possible biological mechanism for a diphtheria effect on hearing ability exists: The toxin produced by the Corynebacterium diphtheriae bacteria can cause damage to cranial nerves and therefore may affect the auditory neural pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12037265", "endSection": "abstract"}, {"offsetInBeginSection": 680, "offsetInEndSection": 848, "text": "In cases of human infection with potentially toxigenic corynebacteria, it is important to determine the species and examine the isolate for diphtheria toxin production.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403045", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 916, "text": "AIM: Study of the apoptogenic effect of Corynebacterium diphtheriae toxigenic strains on mice peritoneal macrophages in vitro.MATERIALS AND METHODS: Evaluation ofapoptosis induced by Corynebacterium diphtheriae, Corynebacterium pseudodiphtheriticum, Staphylococcus aureus, Streptococcus pyogenes strains was performed by characteristic morphological changes in macrophages in smears stained by azure eosin by Romanovsky-Giemsa.RESULTS: Apoptogenic activity of diphtheria infectious agent was established to be determined by diphtheria exotoxin at early (after 1 hour) and surface structures and pathogenicity enzymes at later (3 hours) stages of effect.CONCLUSION: The ability of diphtheria infectious agent to cause macrophage apoptosis is one of the mechanisms of realization of its pathogenic properties determined by the effect of diphtheria exotoxin, as well as its surface structures and pathogenicity enzymes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23163039", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Extrapharyngeal infections caused by Corynebacterium ulcerans have rarely been reported previously, and diphtheria toxin production has usually not been addressed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568853", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Corynebacterium ulcerans may cause diphtheria in humans and caseous lymphadenitis in animals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24572455", "endSection": "abstract"}, {"offsetInBeginSection": 748, "offsetInEndSection": 979, "text": "ulcerans for the first time, we show that related sequence types (STs) might be associated with the presence of the diphtheria toxin gene, which encodes diphtheria toxin (DT), the most important diphtheria-causing virulence factor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25320226", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Human-to-human-transmitted Corynebacterium diphtheriae was historically the main pathogen causing diphtheria and has therefore been studied extensively in the past.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25320226", "endSection": "abstract"}, {"offsetInBeginSection": 671, "offsetInEndSection": 851, "text": "Toxigenic Corynebacterium diphtheriae, the organism causing diphtheria, was thought to have become rare or even have disappeared from previously endemic areas such as South Dakota.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10932611", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Infection of the skin caused by Corynebacterium ulcerans and mimicking classical cutaneous diphtheria.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568853", "endSection": "title"}]}, {"body": "What is the function of calcium-sensing receptor (CaSR)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21566074", "http://www.ncbi.nlm.nih.gov/pubmed/26386835", "http://www.ncbi.nlm.nih.gov/pubmed/23856267", "http://www.ncbi.nlm.nih.gov/pubmed/26608608", "http://www.ncbi.nlm.nih.gov/pubmed/26261299"], "ideal_answer": ["The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis.\nThe CaSR is a key regulator for such diverse processes as hormone secretion, gene expression, inflammation, proliferation, differentiation, and apoptosis. Due to this pleiotropy, the CaSR is able to regulate cell fate and is implicated in the development of many types of benign or malignant tumours of the breast, prostate, parathyroid, and colon."], "type": "factoid", "id": "58cd7fed02b8c6095300003f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26386835", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 261, "text": "The calcium-sensing receptor (CaSR) plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary calcium excretion. The CaSR is ubiquitously expressed, implying a wide range of functions regulated by this receptor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26608608", "endSection": "abstract"}, {"offsetInBeginSection": 689, "offsetInEndSection": 1037, "text": "The CaSR is a key regulator for such diverse processes as hormone secretion, gene expression, inflammation, proliferation, differentiation, and apoptosis. Due to this pleiotropy, the CaSR is able to regulate cell fate and is implicated in the development of many types of benign or malignant tumours of the breast, prostate, parathyroid, and colon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26608608", "endSection": "abstract"}, {"offsetInBeginSection": 168, "offsetInEndSection": 326, "text": "Extracellular calcium-sensing receptor (CaSR) and ovarian cancer gene receptor 1 (OGR1) are two GPCRs that sense extracellular Ca(2+) and H(+), respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26261299", "endSection": "abstract"}, {"offsetInBeginSection": 91, "offsetInEndSection": 179, "text": " The calcium-sensing receptor (CASR) plays a key role in maintaining calcium homeostasis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21566074", "endSection": "abstract"}]}, {"body": "List drug that were evaluated in the CHAMP trial for migraine.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23594025", "http://www.ncbi.nlm.nih.gov/pubmed/27039826", "http://www.ncbi.nlm.nih.gov/pubmed/27788026"], "ideal_answer": ["Childhood and Adolescent Migraine Prevention (CHAMP) trial evaluated effectiveness of amitriptyline and topiramate in the prevention of migraine in children and adolescents."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:6364", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016430"], "type": "list", "id": "589a245a78275d0c4a000026", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 284, "text": "OBJECTIVE: To describe baseline headache characteristics of children and adolescents participating in a multicenter, randomized, double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo for the prevention of migraine (CHAMP Study).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27039826", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "title"}, {"offsetInBeginSection": 651, "offsetInEndSection": 998, "text": "METHODS: CHAMP is a double-blinded, placebo-controlled, multicenter, comparative effectiveness study of amitriptyline and topiramate for the prevention of episodic and chronic migraine, designed to mirror real-world practice, sponsored by the US National Institute of Neurological Disorders and Stroke/National Institutes of Health (U01NS076788). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "abstract"}, {"offsetInBeginSection": 1292, "offsetInEndSection": 1524, "text": "The subjects will be randomized in a 2:2:1 (amitriptyline: topiramate: placebo) ratio. Doses are weight based and will be slowly titrated over an 8-week period to a target dose of 1\u2009mg/kg of amitriptyline and 2\u2009mg/kg of topiramate. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "abstract"}, {"offsetInBeginSection": 1667, "offsetInEndSection": 1850, "text": "CONCLUSIONS: The goal of the CHAMP study is to obtain level 1 evidence for the effectiveness of amitriptyline and topiramate in the prevention of migraine in children and adolescents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "To describe baseline headache characteristics of children and adolescents participating in a multicenter, randomized, double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo for the prevention of migraine (CHAMP Study).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27039826", "endSection": "abstract"}, {"offsetInBeginSection": 490, "offsetInEndSection": 997, "text": "The aim of the Childhood and Adolescent Migraine Prevention (CHAMP) study is to determine the most effective preventive agent to use in children and adolescents.METHODS: CHAMP is a double-blinded, placebo-controlled, multicenter, comparative effectiveness study of amitriptyline and topiramate for the prevention of episodic and chronic migraine, designed to mirror real-world practice, sponsored by the US National Institute of Neurological Disorders and Stroke/National Institutes of Health (U01NS076788).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "title"}, {"offsetInBeginSection": 478, "offsetInEndSection": 975, "text": "The aim of the Childhood and Adolescent Migraine Prevention (CHAMP) study is to determine the most effective preventive agent to use in children and adolescents.CHAMP is a double-blinded, placebo-controlled, multicenter, comparative effectiveness study of amitriptyline and topiramate for the prevention of episodic and chronic migraine, designed to mirror real-world practice, sponsored by the US National Institute of Neurological Disorders and Stroke/National Institutes of Health (U01NS076788)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "abstract"}, {"offsetInBeginSection": 1669, "offsetInEndSection": 1853, "text": "CONCLUSIONS: The goal of the CHAMP study is to obtain level 1 evidence for the effectiveness of amitriptyline and topiramate in the prevention of migraine in children and adolescents. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025", "endSection": "title"}]}, {"body": "What is the role of IL-18BP?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26782741", "http://www.ncbi.nlm.nih.gov/pubmed/26898120", "http://www.ncbi.nlm.nih.gov/pubmed/27914933", "http://www.ncbi.nlm.nih.gov/pubmed/25548255", "http://www.ncbi.nlm.nih.gov/pubmed/25807634", "http://www.ncbi.nlm.nih.gov/pubmed/25692120", "http://www.ncbi.nlm.nih.gov/pubmed/25182570", "http://www.ncbi.nlm.nih.gov/pubmed/26850179"], "ideal_answer": ["IL-18 binding protein (IL-18BP) is a natural inhibitor of IL-18. The balance between IL-18 and IL-18BP has an important role in the inflammatory setting."], "type": "factoid", "id": "58cd90c202b8c60953000040", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Interleukin 18--binding protein ameliorates liver ischemia--reperfusion injury.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850179", "endSection": "title"}, {"offsetInBeginSection": 1549, "offsetInEndSection": 1719, "text": " IL-18BP exhibited anti-inflammatory, antioxidant, and protective effects in I/R-mediated hepatic injury via regulating some liver enzyme activities and cytokine levels. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850179", "endSection": "abstract"}, {"offsetInBeginSection": 308, "offsetInEndSection": 1012, "text": "Because of IL-18's potential pro-inflammatory and tissue destructive effects, its biological activities are tightly controlled in the body by its naturally occurring antagonist called IL-18BP. The antagonist is produced in the body both constitutively and in response to an increased production of IL-18 as a negative feedback mechanism. Under physiological conditions, most of IL-18 in the circulation is bound with IL-18BP and is inactive. However, an imbalance in the production of IL-18 and its antagonist (an increase in the production of IL-18 with a decrease, no increase or an insufficient increase in the production of IL-18BP) has been described in many chronic inflammatory diseases in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26898120", "endSection": "abstract"}, {"offsetInBeginSection": 377, "offsetInEndSection": 441, "text": "L-18 binding protein (IL-18BP) is a natural inhibitor of IL-18. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182570", "endSection": "abstract"}, {"offsetInBeginSection": 681, "offsetInEndSection": 761, "text": "Platelets also contain the IL-18 antagonist, the IL-18-Binding Protein (IL-18BP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914933", "endSection": "abstract"}, {"offsetInBeginSection": 614, "offsetInEndSection": 762, "text": "The natural inhibitor IL-18BP , whose production is enhanced by IFN-\u03b3 and IL-27, further regulates IL-18 activity in the extracellular environment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25548255", "endSection": "abstract"}, {"offsetInBeginSection": 147, "offsetInEndSection": 224, "text": "IL-18 binding protein (IL-18BP) is a naturally occurring inhibitor of IL-18. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25807634", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 374, "text": "IL-18 binding protein (IL-18BP) is a natural inhibitor of IL-18. The balance between IL-18 and IL-18BP has an important role in the inflammatory setting.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25692120", "endSection": "abstract"}]}, {"body": "Which protein mediates gene loop formation in the yeast S. cerevisiae?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24124207", "http://www.ncbi.nlm.nih.gov/pubmed/22081613", "http://www.ncbi.nlm.nih.gov/pubmed/17803944", "http://www.ncbi.nlm.nih.gov/pubmed/21835917", "http://www.ncbi.nlm.nih.gov/pubmed/19602510", "http://www.ncbi.nlm.nih.gov/pubmed/18550805"], "ideal_answer": ["Moreover, looping is dependent upon the general transcription factor TFIIB: the E62K (glutamic acid 62 --> lysine) form of TFIIB adversely affects looping at every gene tested, including BLM10, SAC3, GAL10, SEN1, and HEM3. TFIIB crosslinks to both the promoter and terminator regions of the PMA1 and BLM10 genes, and its association with the terminator, but not the promoter, is adversely affected by E62K and by depletion of the Ssu72 component of the CPF 3' end processing complex, and is independent of TBP.", "Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB. TFIIB crosslinks to both the promoter and terminator regions of the PMA1 and BLM10 genes, and its association with the terminator, but not the promoter, is adversely affected by E62K and by depletion of the Ssu72 component of the CPF 3' end processing complex, and is independent of TBP", "Gene looping, defined as the interaction of the promoter and the terminator regions of a gene during transcription, requires transcription factor IIB (TFIIB).", "A transcription-independent role for TFIIB in gene looping."], "type": "factoid", "id": "58adc1ff9ef3c34033000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "A transcription-independent role for TFIIB in gene looping.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17803944", "endSection": "title"}, {"offsetInBeginSection": 290, "offsetInEndSection": 510, "text": "Moreover, looping is dependent upon the general transcription factor TFIIB: the E62K (glutamic acid 62 -->lysine) form of TFIIB adversely affects looping at every gene tested, including BLM10, SAC3, GAL10, SEN1, and HEM3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17803944", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 798, "text": "TFIIB crosslinks to both the promoter and terminator regions of the PMA1 and BLM10 genes, and its association with the terminator, but not the promoter, is adversely affected by E62K and by depletion of the Ssu72 component of the CPF 3' end processing complex, and is independent of TBP", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17803944", "endSection": "abstract"}, {"offsetInBeginSection": 962, "offsetInEndSection": 1066, "text": "We present a high-resolution genome-wide map of TFIIB locations that implicates 3' NFRs in gene looping.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18550805", "endSection": "abstract"}, {"offsetInBeginSection": 837, "offsetInEndSection": 1107, "text": "Instead, activators physically interacted with the general transcription factor TFIIB when the genes were activated and in a looped configuration. TFIIB cross-linked to both the promoter and the terminator regions during the transcriptionally activated state of a gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19602510", "endSection": "abstract"}, {"offsetInBeginSection": 1292, "offsetInEndSection": 1428, "text": " We propose that the activators facilitate gene looping through their interaction with TFIIB during transcriptional activation of genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19602510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Gene looping, defined as the interaction of the promoter and the terminator regions of a gene during transcription, requires transcription factor IIB (TFIIB).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21835917", "endSection": "abstract"}, {"offsetInBeginSection": 159, "offsetInEndSection": 272, "text": "We have earlier demonstrated association of TFIIB with the distal ends of a gene in an activator-dependent manner", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21835917", "endSection": "abstract"}, {"offsetInBeginSection": 1578, "offsetInEndSection": 1698, "text": "Furthermore, TFIIB interaction with the CF1 complex and Pap1 is crucial for gene looping and transcriptional regulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21835917", "endSection": "abstract"}, {"offsetInBeginSection": 70, "offsetInEndSection": 226, "text": "TFIIB also cross-links to terminator regions and is required for gene loops that juxtapose promoter-terminator elements in a transcription-dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22081613", "endSection": "abstract"}, {"offsetInBeginSection": 1125, "offsetInEndSection": 1252, "text": "These results define a novel, functional interaction between TFIIB and Ssl2 that affects start site selection and gene looping.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22081613", "endSection": "abstract"}, {"offsetInBeginSection": 249, "offsetInEndSection": 361, "text": "Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24124207", "endSection": "abstract"}, {"offsetInBeginSection": 247, "offsetInEndSection": 359, "text": "Gene-loop formation is dependent on regulatory proteins localized at the 5' and 3' ends of genes, such as TFIIB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24124207", "endSection": "abstract"}]}, {"body": "Which two drugs were compared in the ARISTOTLE Trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22277459", "http://www.ncbi.nlm.nih.gov/pubmed/26424386", "http://www.ncbi.nlm.nih.gov/pubmed/25294786", "http://www.ncbi.nlm.nih.gov/pubmed/24657685", "http://www.ncbi.nlm.nih.gov/pubmed/27463942", "http://www.ncbi.nlm.nih.gov/pubmed/25497244", "http://www.ncbi.nlm.nih.gov/pubmed/25498373", "http://www.ncbi.nlm.nih.gov/pubmed/24281250", "http://www.ncbi.nlm.nih.gov/pubmed/22449118", "http://www.ncbi.nlm.nih.gov/pubmed/22933567", "http://www.ncbi.nlm.nih.gov/pubmed/22572202", "http://www.ncbi.nlm.nih.gov/pubmed/22056819", "http://www.ncbi.nlm.nih.gov/pubmed/23036896", "http://www.ncbi.nlm.nih.gov/pubmed/21740079", "http://www.ncbi.nlm.nih.gov/pubmed/25332806", "http://www.ncbi.nlm.nih.gov/pubmed/26839066", "http://www.ncbi.nlm.nih.gov/pubmed/23619028", "http://www.ncbi.nlm.nih.gov/pubmed/23026665", "http://www.ncbi.nlm.nih.gov/pubmed/24561548", "http://www.ncbi.nlm.nih.gov/pubmed/26447668", "http://www.ncbi.nlm.nih.gov/pubmed/22787066", "http://www.ncbi.nlm.nih.gov/pubmed/23859143", "http://www.ncbi.nlm.nih.gov/pubmed/23883416", "http://www.ncbi.nlm.nih.gov/pubmed/25547937", "http://www.ncbi.nlm.nih.gov/pubmed/23796193", "http://www.ncbi.nlm.nih.gov/pubmed/22684583", "http://www.ncbi.nlm.nih.gov/pubmed/25854636", "http://www.ncbi.nlm.nih.gov/pubmed/25173541", "http://www.ncbi.nlm.nih.gov/pubmed/22298161", "http://www.ncbi.nlm.nih.gov/pubmed/27306620", "http://www.ncbi.nlm.nih.gov/pubmed/23869941"], "ideal_answer": ["Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial compared apixaban and warfarin."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017428"], "type": "list", "id": "589a246178275d0c4a00002b", "snippets": [{"offsetInBeginSection": 262, "offsetInEndSection": 465, "text": "METHODS: We analyzed patients from ARISTOTLE, a randomized trial of 18,201 patients with atrial fibrillation comparing the effects of apixaban versus warfarin on the risk of stroke or systemic embolism. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26447668", "endSection": "abstract"}, {"offsetInBeginSection": 138, "offsetInEndSection": 469, "text": " In this study we evaluated the relationship between inflammatory biomarkers at baseline and future risk of cardiovascular events in the Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.METHODS: The ARISTOTLE trial randomised 18,201 patients with AF to apixaban or warfarin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26839066", "endSection": "abstract"}, {"offsetInBeginSection": 1391, "offsetInEndSection": 1562, "text": "Moreover, apixaban was associated with decreased all-cause mortality (RR 0.89, 95% CI 0.81 to 0.99) although this finding was driven by the results of the ARISTOTLE trial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25547937", "endSection": "abstract"}, {"offsetInBeginSection": 671, "offsetInEndSection": 880, "text": "Compared with warfarin, apixaban (in the ARISTOTLE trial) and edoxaban (in the ENGAGE-AF trial) were shown to be superior or non-inferior, respectively, for reduction in stroke or SE risk in patients with AF. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854636", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 434, "text": "METHODS: A decision-analytic Markov model was constructed to assess the cost-effectiveness of apixaban versus warfarin, based on data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF (ARISTOTLE) trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24281250", "endSection": "abstract"}, {"offsetInBeginSection": 851, "offsetInEndSection": 1406, "text": "The following phase 3 randomized trials with novel oral anticoagulants versus warfarin for stroke prevention in AF have been completed: the Randomized Evaluation of Long-term Anticoagulant therapy (RE-LY) trial with dabigatran, the Rivaroxaban Once daily oral direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial with rivaroxaban, and the Apixaban for Reduction of Stroke and Other Thromboembolism Events in Atrial Fibrillation (ARISTOTLE) trial with apixaban.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22684583", "endSection": "abstract"}, {"offsetInBeginSection": 856, "offsetInEndSection": 1410, "text": "The following phase 3 randomized trials with novel oral anticoagulants versus warfarin for stroke prevention in AF have been completed: the Randomized Evaluation of Long-term Anticoagulant therapy (RE-LY) trial with dabigatran, the Rivaroxaban Once daily oral direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial with rivaroxaban, and the Apixaban for Reduction of Stroke and Other Thromboembolism Events in Atrial Fibrillation (ARISTOTLE) trial with apixaban", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22684583", "endSection": "abstract"}, {"offsetInBeginSection": 200, "offsetInEndSection": 880, "text": "We sought to compare the efficacy and safety of the 3 new agents based on data from their published warfarin-controlled randomized trials, using the method of adjusted indirect comparisons.We included findings from 44 535 patients enrolled in 3 trials of the efficacy of dabigatran (Randomized Evaluation of Long-Term Anticoagulation Therapy [RELY]), apixaban (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation [ARISTOTLE]), and rivaroxaban (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation [ROCKET-AF]), each compared with warfarin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787066", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 574, "text": "A comparative analysis of three major clinical trials with factor Xa inhibitor oral anticoagulant (XOAC) drugs versus warfarin in atrial fibrillation-Rocket-AF (rivaroxaban), Aristotle (apixaban) and Engage AF Timi 48 (edoxaban; two different doses and sets of data)-was carried out.Data were extracted from the original reports (study level) and a meta-analysis was carried out.When compared with warfarin, XOAC therapy was associated with a decrease in haemorrhagic stroke, with a similar pattern for all regimens and meta-analysis showing a risk ratio of 0.488 (95% CI 0.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25332806", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22572202", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25173541", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22933567", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 570, "text": "A comparative analysis of three major clinical trials with factor Xa inhibitor oral anticoagulant (XOAC) drugs versus warfarin in atrial fibrillation-Rocket-AF (rivaroxaban), Aristotle (apixaban) and Engage AF Timi 48 (edoxaban; two different doses and sets of data)-was carried out.Data were extracted from the original reports (study level) and a meta-analysis was carried out.When compared with warfarin, XOAC therapy was associated with a decrease in haemorrhagic stroke, with a similar pattern for all regimens and meta-analysis showing a risk ratio of 0.488 (95% C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25332806", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 548, "text": "This study sought to characterize major bleeding on the basis of the components of the major bleeding definition, to explore major bleeding by location, to define 30-day mortality after a major bleeding event, and to identify factors associated with major bleeding.Apixaban was shown to reduce the risk of major hemorrhage among patients with atrial fibrillation in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.All patients who received at least 1 dose of a study drug were included.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24657685", "endSection": "abstract"}, {"offsetInBeginSection": 363, "offsetInEndSection": 786, "text": "Little is known about patients with 1 dose-reduction criterion who received the 5 mg twice daily dose of apixaban.To determine the frequency of 1 dose-reduction criterion and whether the effects of the 5 mg twice daily dose of apixaban on stroke or systemic embolism and bleeding varied among patients with 1 or no dose-reduction criteria.Among 18 201 patients in the ARISTOTLE trial, 17\u202f322 were included in this analysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27463942", "endSection": "abstract"}, {"offsetInBeginSection": 200, "offsetInEndSection": 816, "text": "We sought to compare the efficacy and safety of the 3 new agents based on data from their published warfarin-controlled randomized trials, using the method of adjusted indirect comparisons.We included findings from 44 535 patients enrolled in 3 trials of the efficacy of dabigatran (Randomized Evaluation of Long-Term Anticoagulation Therapy [RELY]), apixaban (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation [ARISTOTLE]), and rivaroxaban (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial i", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787066", "endSection": "abstract"}, {"offsetInBeginSection": 218, "offsetInEndSection": 640, "text": "This study aimed to evaluate the medical cost reductions associated with the use of individual NOACs instead of warfarin from the US payer perspective.Rates for efficacy and safety clinical events for warfarin were estimated as the weighted averages from the RE-LY, ROCKET-AF and ARISTOTLE trials, and event rates for NOACs were determined by applying trial hazard ratios or relative risk ratios to such weighted averages.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22449118", "endSection": "abstract"}, {"offsetInBeginSection": 980, "offsetInEndSection": 1169, "text": "The ARISTOTLE trial showed apixaban was superior to warfarin for stroke prevention, significantly reduced all major bleeding, and resulted in a significant reduction in all-cause mortality.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23859143", "endSection": "abstract"}, {"offsetInBeginSection": 856, "offsetInEndSection": 1411, "text": "The following phase 3 randomized trials with novel oral anticoagulants versus warfarin for stroke prevention in AF have been completed: the Randomized Evaluation of Long-term Anticoagulant therapy (RE-LY) trial with dabigatran, the Rivaroxaban Once daily oral direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial with rivaroxaban, and the Apixaban for Reduction of Stroke and Other Thromboembolism Events in Atrial Fibrillation (ARISTOTLE) trial with apixaban.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22684583", "endSection": "abstract"}, {"offsetInBeginSection": 1828, "offsetInEndSection": 2081, "text": "In the ARISTOTLE trial, apixaban was superior to warfarin in the reduction of stroke or systemic embolism, major bleeding, intracranial hemorrhage, and all-cause mortality, with a similar reduction in the rate of ischemic stroke and better tolerability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22684583", "endSection": "abstract"}, {"offsetInBeginSection": 1967, "offsetInEndSection": 2123, "text": "The results of the ARISTOTLE trial, which is evaluating apixaban against warfarin in \u223c18\u2009000 patients with AF, are expected to be available later this year.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21740079", "endSection": "abstract"}, {"offsetInBeginSection": 972, "offsetInEndSection": 1278, "text": "The Medco data did not contain information for patients receiving apixaban as it was not on the market at the time of analysis.RESULTS: Stroke and MB rates among RW NVAF patients during warfarin exposure were higher compared with event rates in patients treated with warfarin in ARISTOTLE (stroke: 5.29 vs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23796193", "endSection": "abstract"}, {"offsetInBeginSection": 81, "offsetInEndSection": 190, "text": "In the ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death, and bleeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561548", "endSection": "abstract"}, {"offsetInBeginSection": 414, "offsetInEndSection": 535, "text": "The ARISTOTLE trial compared apixaban with warfarin in 18 201 patients with AF and \u2265 1 additional risk factor for stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22056819", "endSection": "abstract"}, {"offsetInBeginSection": 659, "offsetInEndSection": 867, "text": "Compared with warfarin, apixaban (in the ARISTOTLE trial) and edoxaban (in the ENGAGE-AF trial) were shown to be superior or non-inferior, respectively, for reduction in stroke or SE risk in patients with AF.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854636", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24561548", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22572202", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22572202", "endSection": "abstract"}]}, {"body": "What is REVIGO?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21789182"], "ideal_answer": ["REVIGO summarizes and visualizes long lists of gene ontology terms.", "REVIGO is a Web server that summarizes long, unintelligible lists of GO terms by finding a representative subset of the terms using a simple clustering algorithm that relies on semantic similarity measures. Furthermore, REVIGO visualizes this non-redundant GO term set in multiple ways to assist in interpretation: multidimensional scaling and graph-based visualizations accurately render the subdivisions and the semantic relationships in the data, while treemaps and tag clouds are also offered as alternative views. REVIGO is freely available at http://revigo.irb.hr/.", "Outcomes of high-throughput biological experiments are typically interpreted by statistical testing for enriched gene functional categories defined by the Gene Ontology (GO). The resulting lists of GO terms may be large and highly redundant, and thus difficult to interpret.REVIGO is a Web server that summarizes long, unintelligible lists of GO terms by finding a representative subset of the terms using a simple clustering algorithm that relies on semantic similarity measures. Furthermore, REVIGO visualizes this non-redundant GO term set in multiple ways to assist in interpretation: multidimensional scaling and graph-based visualizations accurately render the subdivisions and the semantic relationships in the data, while treemaps and tag clouds are also offered as alternative views. REVIGO is freely available at http://revigo.irb.hr/."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063990"], "type": "summary", "id": "5891c754621ea6ff7e000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "REVIGO summarizes and visualizes long lists of gene ontology terms.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789182", "endSection": "title"}, {"offsetInBeginSection": 274, "offsetInEndSection": 845, "text": "REVIGO is a Web server that summarizes long, unintelligible lists of GO terms by finding a representative subset of the terms using a simple clustering algorithm that relies on semantic similarity measures. Furthermore, REVIGO visualizes this non-redundant GO term set in multiple ways to assist in interpretation: multidimensional scaling and graph-based visualizations accurately render the subdivisions and the semantic relationships in the data, while treemaps and tag clouds are also offered as alternative views. REVIGO is freely available at http://revigo.irb.hr/.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789182", "endSection": "abstract"}, {"offsetInBeginSection": 479, "offsetInEndSection": 790, "text": "Furthermore, REVIGO visualizes this non-redundant GO term set in multiple ways to assist in interpretation: multidimensional scaling and graph-based visualizations accurately render the subdivisions and the semantic relationships in the data, while treemaps and tag clouds are also offered as alternative views.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789182", "endSection": "abstract"}, {"offsetInBeginSection": 174, "offsetInEndSection": 479, "text": "The resulting lists of GO terms may be large and highly redundant, and thus difficult to interpret.REVIGO is a Web server that summarizes long, unintelligible lists of GO terms by finding a representative subset of the terms using a simple clustering algorithm that relies on semantic similarity measures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789182", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "REVIGO summarizes and visualizes long lists of gene ontology terms", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789182", "endSection": "title"}, {"offsetInBeginSection": 175, "offsetInEndSection": 479, "text": "The resulting lists of GO terms may be large and highly redundant, and thus difficult to interpret.REVIGO is a Web server that summarizes long, unintelligible lists of GO terms by finding a representative subset of the terms using a simple clustering algorithm that relies on semantic similarity measures", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789182", "endSection": "abstract"}, {"offsetInBeginSection": 481, "offsetInEndSection": 791, "text": "Furthermore, REVIGO visualizes this non-redundant GO term set in multiple ways to assist in interpretation: multidimensional scaling and graph-based visualizations accurately render the subdivisions and the semantic relationships in the data, while treemaps and tag clouds are also offered as alternative views", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789182", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 480, "text": "The resulting lists of GO terms may be large and highly redundant, and thus difficult to interpret.REVIGO is a Web server that summarizes long, unintelligible lists of GO terms by finding a representative subset of the terms using a simple clustering algorithm that relies on semantic similarity measures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789182", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "REVIGO summarizes and visualizes long lists of gene ontology terms.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789182", "endSection": "title"}, {"offsetInBeginSection": 481, "offsetInEndSection": 792, "text": "Furthermore, REVIGO visualizes this non-redundant GO term set in multiple ways to assist in interpretation: multidimensional scaling and graph-based visualizations accurately render the subdivisions and the semantic relationships in the data, while treemaps and tag clouds are also offered as alternative views.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789182", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of onartuzumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23922054", "http://www.ncbi.nlm.nih.gov/pubmed/22917884", "http://www.ncbi.nlm.nih.gov/pubmed/25806189", "http://www.ncbi.nlm.nih.gov/pubmed/27937096", "http://www.ncbi.nlm.nih.gov/pubmed/25074413", "http://www.ncbi.nlm.nih.gov/pubmed/27349303", "http://www.ncbi.nlm.nih.gov/pubmed/24101053", "http://www.ncbi.nlm.nih.gov/pubmed/27918764", "http://www.ncbi.nlm.nih.gov/pubmed/24687921", "http://www.ncbi.nlm.nih.gov/pubmed/26445503", "http://www.ncbi.nlm.nih.gov/pubmed/23894056", "http://www.ncbi.nlm.nih.gov/pubmed/25522765", "http://www.ncbi.nlm.nih.gov/pubmed/24493831", "http://www.ncbi.nlm.nih.gov/pubmed/25777467", "http://www.ncbi.nlm.nih.gov/pubmed/24258345", "http://www.ncbi.nlm.nih.gov/pubmed/24959087", "http://www.ncbi.nlm.nih.gov/pubmed/27856142", "http://www.ncbi.nlm.nih.gov/pubmed/23882082", "http://www.ncbi.nlm.nih.gov/pubmed/27401892", "http://www.ncbi.nlm.nih.gov/pubmed/27918718", "http://www.ncbi.nlm.nih.gov/pubmed/23063071", "http://www.ncbi.nlm.nih.gov/pubmed/23536720", "http://www.ncbi.nlm.nih.gov/pubmed/25818471", "http://www.ncbi.nlm.nih.gov/pubmed/23810377"], "ideal_answer": ["Onartuzumab is monoclonal antibody targeting MET. It works by inhibiting MET. Onartuzumab was tested for treatment of non-small cell lung carcinoma, adenocarcinoma of the stomach and gastroesophageal Junction, and recurrent glioblastoma."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"], "type": "summary", "id": "5890dcba621ea6ff7e000003", "snippets": [{"offsetInBeginSection": 316, "offsetInEndSection": 503, "text": " In this study, e-training was used to train board-certified pathologists to evaluate non-small cell lung carcinoma for eligibility for treatment with onartuzumab, a MET-inhibiting agent.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27349303", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892", "endSection": "title"}, {"offsetInBeginSection": 238, "offsetInEndSection": 331, "text": "MET immunohistochemistry expression as a biomarker of onartuzumab activity was also examined.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892", "endSection": "abstract"}, {"offsetInBeginSection": 1721, "offsetInEndSection": 2173, "text": "CONCLUSION: The addition of onartuzumab to mFOLFOX6 in gastric cancer did not improve efficacy in an unselected population or in a MET immunohistochemistry-positive population.IMPLICATIONS FOR PRACTICE: The YO28252 study demonstrated that the addition of the anti-MET agent onartuzumab to mFOLFOX6 for treatment of gastric cancer did not improve efficacy in an overall study population or those selected for positive MET status by immunohistochemistry.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892", "endSection": "abstract"}, {"offsetInBeginSection": 251, "offsetInEndSection": 433, "text": " The phase II study GO27819 investigated the monovalent MET inhibitor onartuzumab plus bevacizumab (Ona + Bev) versus placebo plus bevacizumab (Pla + Bev) in recurrent glioblastoma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27918718", "endSection": "abstract"}, {"offsetInBeginSection": 167, "offsetInEndSection": 376, "text": "We report results of METGastric, a phase 3 trial of the MET inhibitor onartuzumab plus standard first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative, MET-positive, advanced GEC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27918764", "endSection": "abstract"}, {"offsetInBeginSection": 1678, "offsetInEndSection": 1872, "text": "Conclusion Onartuzumab plus erlotinib did not improve clinical outcomes, with shorter OS in the onartuzumab arm, compared with erlotinib in patients with MET-positive non-small-cell lung cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27937096", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 657, "text": "A recent example of a failed trial is the Phase III MetLung trial that compared the effects of the c-MET monovalent antibody onartuzumab with erlotinib versus erlotinib alone in late-stage non-small-cell lung cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25818471", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23882082", "endSection": "title"}, {"offsetInBeginSection": 336, "offsetInEndSection": 496, "text": "Because onartuzumab, a monovalent antibody to MET, blocks HGF-induced MET activation, the addition of onartuzumab to erlotinib may improve therapeutic efficacy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25522765", "endSection": "abstract"}, {"offsetInBeginSection": 1118, "offsetInEndSection": 1330, "text": "Because binding of sMET to onartuzumab in circulation resulted in increasing sMET serum concentrations due to reduced clearance, this likely renders sMET unsuitable as a pharmacodynamic biomarker for onartuzumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24258345", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Onartuzumab, a humanized, monovalent monoclonal anti-MET antibody, antagonizes MET signaling by inhibiting binding of its ligand, hepatocyte growth factor (HGF).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24258345", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23882082", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24258345", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Onartuzumab, a recombinant humanized monovalent monoclonal antibody directed against MET, the receptor for the hepatocyte growth factor, has been investigated for the treatment of solid tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26445503", "endSection": "abstract"}, {"offsetInBeginSection": 595, "offsetInEndSection": 943, "text": "Successful therapeutic targeting of the MET/HGF pathway has been achieved using monoclonal antibodies against the MET receptor and its ligand HGF in addition to MET-specific and multitargeted small-molecule tyrosine-kinase inhibitors with several drugs in late-phase clinical trials including onartuzumab, rilotumumab, tivantinib, and cabozantinib.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24959087", "endSection": "abstract"}, {"offsetInBeginSection": 1504, "offsetInEndSection": 2091, "text": "Grade 3-5 adverse events (AEs) were seen in 88.3% of patients receiving onartuzumab and in 78.3% of patients receiving placebo, with serious AEs in 55% and 40%, respectively.The addition of onartuzumab to mFOLFOX6 in gastric cancer did not improve efficacy in an unselected population or in a MET immunohistochemistry-positive population.The YO28252 study demonstrated that the addition of the anti-MET agent onartuzumab to mFOLFOX6 for treatment of gastric cancer did not improve efficacy in an overall study population or those selected for positive MET status by immunohistochemistry.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23882082", "endSection": "title"}]}, {"body": "Is there a relationship between B cells and Multiple Sclerosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25267439", "http://www.ncbi.nlm.nih.gov/pubmed/19996075", "http://www.ncbi.nlm.nih.gov/pubmed/26857494", "http://www.ncbi.nlm.nih.gov/pubmed/26810546", "http://www.ncbi.nlm.nih.gov/pubmed/25666875", "http://www.ncbi.nlm.nih.gov/pubmed/26604134", "http://www.ncbi.nlm.nih.gov/pubmed/26732544", "http://www.ncbi.nlm.nih.gov/pubmed/20558389", "http://www.ncbi.nlm.nih.gov/pubmed/27120609", "http://www.ncbi.nlm.nih.gov/pubmed/24679343", "http://www.ncbi.nlm.nih.gov/pubmed/1839591", "http://www.ncbi.nlm.nih.gov/pubmed/25750917", "http://www.ncbi.nlm.nih.gov/pubmed/23634189", "http://www.ncbi.nlm.nih.gov/pubmed/18474519", "http://www.ncbi.nlm.nih.gov/pubmed/18388801", "http://www.ncbi.nlm.nih.gov/pubmed/18388800", "http://www.ncbi.nlm.nih.gov/pubmed/20970478", "http://www.ncbi.nlm.nih.gov/pubmed/24526661", "http://www.ncbi.nlm.nih.gov/pubmed/26724102", "http://www.ncbi.nlm.nih.gov/pubmed/18388796", "http://www.ncbi.nlm.nih.gov/pubmed/20535037", "http://www.ncbi.nlm.nih.gov/pubmed/25620021", "http://www.ncbi.nlm.nih.gov/pubmed/25895531", "http://www.ncbi.nlm.nih.gov/pubmed/21216828", "http://www.ncbi.nlm.nih.gov/pubmed/15800022"], "ideal_answer": ["MS patients with high neurodegeneration have changes in B cells characterized by down-regulation of B-cell-specific genes and increased activation status"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001402", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009103", "http://www.disease-ontology.org/api/metadata/DOID:2377"], "type": "yesno", "id": "58c0836102b8c6095300001c", "snippets": [{"offsetInBeginSection": 1682, "offsetInEndSection": 1896, "text": "These results suggest that RRMS patients with radiological phenotypes showing high neurodegeneration have changes in B cells characterized by down-regulation of B-cell-specific genes and increased activation status", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26604134", "endSection": "abstract"}, {"offsetInBeginSection": 517, "offsetInEndSection": 744, "text": "Although the exact etiology is still obscure, the leading hypothesis behind MS relapses is acute inflammatory attacks on CNS myelin and axons. This complex process involves B and T cells together with macrophages and microglia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25620021", "endSection": "abstract"}, {"offsetInBeginSection": 545, "offsetInEndSection": 878, "text": "It is currently known that CD24 serves as a costimulatory factor of T cells that regulate their homeostasis and proliferation, while in B cells, CD24 is functionally involved in cell activation and differentiation. CD24 can enhance autoimmune diseases in terms of its protective role in the clonal deletion of autoreactive thymocytes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25666875", "endSection": "abstract"}, {"offsetInBeginSection": 153, "offsetInEndSection": 378, "text": "Multiple B cell-dependent mechanisms contributing to inflammatory demyelination of the CNS have been explored using experimental autoimmune encephalomyelitis (EAE), a CD4 T cell-dependent animal model for multiple sclerosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25895531", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388801", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 365, "text": "Interest in CD8+ T cells and B cells was initially inspired by observations in multiple sclerosis rather than in animal models: CD8+ T cells predominate in multiple sclerosis lesions, oligoclonal immunoglobulin bands in CSF have long been recognised as diagnostic and prognostic markers, and anti-B-cell therapies showed considerable efficacy in multiple sclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26724102", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Differential effects of fingolimod on B-cell populations in multiple sclerosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24526661", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Unaltered regulatory B-cell frequency and function in patients with multiple sclerosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25267439", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "B cells are increasingly recognized as major players in multiple sclerosis pathogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18474519", "endSection": "abstract"}, {"offsetInBeginSection": 583, "offsetInEndSection": 691, "text": "These observations underscore the B cell's contribution to the putative underpinnings of multiple sclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26857494", "endSection": "abstract"}, {"offsetInBeginSection": 222, "offsetInEndSection": 527, "text": "Data suggesting that B cells play a role in the pathogenesis of multiple sclerosis have been accumulating for the past five decades, demonstrating that the cerebrospinal fluid and central nervous system tissues of multiple sclerosis patients contain B cells, plasma cells, antibodies, and immunoglobulins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388801", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388796", "endSection": "title"}, {"offsetInBeginSection": 161, "offsetInEndSection": 425, "text": "Subset composition and cytokine production of B cells derived from peripheral blood mononuclear cells from multiple sclerosis patients under Fingolimod treatment, untreated multiple sclerosis patients and healthy controls were analyzed by flow cytometry and ELISA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25750917", "endSection": "abstract"}, {"offsetInBeginSection": 335, "offsetInEndSection": 598, "text": "In particular, antigen presentation between B cells and T cells, increased trafficking of B cells across the blood-brain barrier, and autoantibodies produced by plasma cells may contribute to the pathophysiology of autoimmune disorders such as multiple sclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388796", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 107, "text": "Accumulating evidence supports a major role of B cells in multiple sclerosis (MS) pathogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19996075", "endSection": "abstract"}, {"offsetInBeginSection": 1148, "offsetInEndSection": 1304, "text": "Further research is needed to elucidate the pathology of B cells and their role in central nervous system autoimmune diseases, including multiple sclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388800", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23634189", "endSection": "title"}, {"offsetInBeginSection": 1, "offsetInEndSection": 184, "text": "phingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24679343", "endSection": "title"}]}, {"body": "Which virus type causes Molluscum contagiosum?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16390992", "http://www.ncbi.nlm.nih.gov/pubmed/23372568", "http://www.ncbi.nlm.nih.gov/pubmed/24155912", "http://www.ncbi.nlm.nih.gov/pubmed/18950398", "http://www.ncbi.nlm.nih.gov/pubmed/18616033", "http://www.ncbi.nlm.nih.gov/pubmed/9275219", "http://www.ncbi.nlm.nih.gov/pubmed/25186152", "http://www.ncbi.nlm.nih.gov/pubmed/9525670", "http://www.ncbi.nlm.nih.gov/pubmed/3814509", "http://www.ncbi.nlm.nih.gov/pubmed/26672647", "http://www.ncbi.nlm.nih.gov/pubmed/22301546", "http://www.ncbi.nlm.nih.gov/pubmed/8938977", "http://www.ncbi.nlm.nih.gov/pubmed/21802105", "http://www.ncbi.nlm.nih.gov/pubmed/22688765", "http://www.ncbi.nlm.nih.gov/pubmed/24491904", "http://www.ncbi.nlm.nih.gov/pubmed/881573", "http://www.ncbi.nlm.nih.gov/pubmed/23598933", "http://www.ncbi.nlm.nih.gov/pubmed/8850036", "http://www.ncbi.nlm.nih.gov/pubmed/24155550", "http://www.ncbi.nlm.nih.gov/pubmed/15284701", "http://www.ncbi.nlm.nih.gov/pubmed/21228810", "http://www.ncbi.nlm.nih.gov/pubmed/22262788", "http://www.ncbi.nlm.nih.gov/pubmed/10500212", "http://www.ncbi.nlm.nih.gov/pubmed/10502526", "http://www.ncbi.nlm.nih.gov/pubmed/25072249", "http://www.ncbi.nlm.nih.gov/pubmed/12552001"], "ideal_answer": ["Molluscum contagiosum virus (MCV) is a human poxvirus that causes tumor-like skin lesions."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:8867", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008977", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008976"], "type": "factoid", "id": "58bfd0db02b8c60953000017", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Molluscum contagiosum virus (MCV), a poxvirus pathogenic for humans, replicates well in human skin in vivo, but not in vitro in standard monolayer cell cultures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22688765", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Molluscum contagiosum virus (MCV) is a poxvirus that causes tumor-like skin lesions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21228810", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Molluscum contagiosum poxvirus (MCV) type 1 and type 2 encode two chemokine-like proteins MC148R1 and MC148R2. I", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21802105", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Molluscum contagiosum virus (MCV) is a common, human poxvirus that causes small papular skin lesions that persist for long periods without signs of inflammation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10500212", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 311, "text": "All poxviruses studied encode a type 1B topoisomerase that introduces transient nicks into DNA and thereby relaxes DNA supercoils. Here we present a study of the protein domains of the topoisomerase of the poxvirus molluscum contagiosum (MCV), which allows us to specify DNA contacts made by different domains. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502526", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Molluscum contagiosum virus (MCV) causes molluscum contagiosum (MC) in both children and adults.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8850036", "endSection": "abstract"}, {"offsetInBeginSection": 165, "offsetInEndSection": 357, "text": "MC54L, the IL-18 binding protein of the human poxvirus that causes molluscum contagiosum, is unique in having a C-terminal tail of nearly 100 amino acids that is dispensable for IL-18 binding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12552001", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Molluscum contagiosum is a common superficial skin infection caused by the poxvirus, Molluscum Contagiosum virus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155912", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Molluscum contagiosum is a common skin and mucosal disease of viral origin, caused by molluscum contagiosum virus (MCV) virus of poxvirus family.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23598933", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Molluscum contagiosum is a benign contagious disease caused by a poxvirus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15284701", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Molluscum contagiosum is a common superficial skin infection caused by the poxvirus, Molluscum Contagiosum virus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155912", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Molluscum contagiosum is a common skin and mucosal disease of viral origin, caused by molluscum contagiosum virus (MCV) virus of poxvirus family", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23598933", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Molluscum contagiosum is a viral infection of the skin and mucous membranes that is caused by infection with the molluscum contagiosum virus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18950398", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Molluscum contagiosum (MC) is a very common benign self-limiting cutaneous viral infection caused by molluscum contagiosum virus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26672647", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 311, "text": "Molluscum contagiosum is caused by the molluscum contagiosum virus (MCV) and is a very common skin disorder mainly involving young children Cryotherapy, curettage or some topical therapies have been applied for MC, but all of these treatments need several sessions, can be somewhat ineffective, and very painful", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155550", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Molluscum contagiosum virus (MCV) causes an innocuous yet persistent skin infection in immunocompetent individuals and is spread by contact with lesions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25072249", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Molluscum contagiosum virus (MCV) is a poxvirus that causes localized papules in healthy persons", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22262788", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Molluscum contagiosum is a virus that causes characteristic pearly lesions on the surface of the skin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18616033", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Molluscum contagiosum virus (MCV) is a poxvirus that causes tumor-like skin lesions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21228810", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Molluscum contagiosum virus is a human and animal dermatotropic pathogen, which causes a severe disease in immunocompromised individuals", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24491904", "endSection": "abstract"}, {"offsetInBeginSection": 984, "offsetInEndSection": 1313, "text": "Given that human diseases caused by poxviruses can be as lethal as smallpox or as benign as Molluscum contagiosum, and that vaccinia virus, the prototypic member of the pox family, persists as a mainstay of vaccine design and has potential as an oncolytic virus for tumor therapy, further research in this area remains important.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23372568", "endSection": "abstract"}, {"offsetInBeginSection": 168, "offsetInEndSection": 358, "text": "These cases support earlier evidence that the molluscum contagiosum virus may act as cases support earlier evidence that the molluscum contagiosum virus may act as an opportunistic pathogen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3814509", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Molluscum contagiosum is a viral infection of the skin and mucous membranes that is caused by infection with the molluscum contagiosum virus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18950398", "endSection": "abstract"}]}, {"body": "Which disease(s) are caused by HEX A deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25606403", "http://www.ncbi.nlm.nih.gov/pubmed/20100466", "http://www.ncbi.nlm.nih.gov/pubmed/7717398", "http://www.ncbi.nlm.nih.gov/pubmed/2220809", "http://www.ncbi.nlm.nih.gov/pubmed/15108204", "http://www.ncbi.nlm.nih.gov/pubmed/9073025"], "ideal_answer": ["Mutations in the HEX A gene, encoding the alpha-subunit of beta-hexosaminidase A (Hex A), are the cause of Tay-Sachs disease as well as of juvenile, chronic, and adult GM2 gangliosidoses."], "type": "summary", "id": "58cea0768acda34529000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Tay-Sachs disease (TSD) is a recessively inherited neurodegenerative disorder due to mutations in the HEXA gene resulting in a beta-hexosaminidase A (Hex A) deficiency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100466", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Rapid identification of HEXA mutations in Tay-Sachs patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100466", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "Tay-Sachs disease (TSD) is a recessively inherited neurodegenerative disorder caused by mutations in the HEXA gene resulting in \u03b2-hexosaminidase A (HEX A) deficiency and neuronal accumulation of GM2 ganglioside.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25606403", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "Tay-Sachs disease is a genetically determined neurodegenerative disorder, resulting from mutations of the hexosaminidase (Hex) A gene coding for the alpha-subunit of beta-D-N-acetyl-hexosaminidase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9073025", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Tay-Sachs disease (TSD) results from mutations in HEXA that cause Hex A deficiency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7717398", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Mutations in the HEX A gene, encoding the alpha-subunit of beta-hexosaminidase A (Hex A), are the cause of Tay-Sachs disease as well as of juvenile, chronic, and adult GM2 gangliosidoses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2220809", "endSection": "abstract"}]}, {"body": "What is Beh\u00e7et's disease", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22041429", "http://www.ncbi.nlm.nih.gov/pubmed/26868128", "http://www.ncbi.nlm.nih.gov/pubmed/22310876", "http://www.ncbi.nlm.nih.gov/pubmed/25447032", "http://www.ncbi.nlm.nih.gov/pubmed/10511031", "http://www.ncbi.nlm.nih.gov/pubmed/26740268", "http://www.ncbi.nlm.nih.gov/pubmed/25610186", "http://www.ncbi.nlm.nih.gov/pubmed/27914129"], "ideal_answer": ["Behet's disease (BD) is a complex chronic relapsing inflammatory disorder of unknown etiology.", "Beh\u00e7et's disease (BD) is a complex chronic relapsing inflammatory disorder of unknown etiology.", "Beh\u00e7et's disease (BD) is a complex chronic relapsing inflammatory disorder of unknown etiology. ", "beh\u00e7et's disease (bd) is a complex chronic relapsing inflammatory disorder of unknown etiology."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:13241", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001528", "http://www.disease-ontology.org/api/metadata/DOID:1670"], "type": "summary", "id": "58cb305c02b8c60953000032", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Beh\u00e7et's disease (BD) is a complex chronic relapsing inflammatory disorder of unknown etiology. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914129", "endSection": "abstract"}, {"offsetInBeginSection": 8, "offsetInEndSection": 227, "text": " Beh\u00e7et disease is a systemic disease of young adults characterized by venous occlusion in both the deep venous and retinal circulations. In severe ocular disease, blindness may occur despite immunosuppressive treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10511031", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Beh\u00e7et disease is a chronic relapsing inflammatory disease affecting many different organs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22310876", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 232, "text": "Beh\u00e7et's disease is a multisystem disease featuring mucocutaneous, ocular, articular, vascular, intestinal, urogenital, and neurologic involvement and occurs with a high prevalence in the Mediterranean including Turkey. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12755969", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 335, "text": "Beh\u00e7et syndrome is a chronic disease hallmarked by inflammation of the blood vessels that is related to an autoimmune reaction caused by inherited susceptibility due to specific genes and environmental factors, probably components of infectious microorganisms, which turn on or get going the disease in genetically susceptible subjects", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25447032", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Beh\u00e7et disease (BD) is a rare relapsing, multisystem vasculitis characterised by recurrent oral and genital ulcers, and uveitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26740268", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Beh\u00e7et's disease, also known as the Silk Road Disease, is a rare systemic vasculitis disorder of unknown etiology. Recurrent attacks of acute inflammation characterize Beh\u00e7et's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26868128", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 224, "text": "Beh\u00e7et's disease is a chronic multisystem vasculitis of unknown etiology that involves skin, mucous membranes, eyes, blood vessels, joints, central nervous system, digestive system, and occasionally other organs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10195724", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 119, "text": "Behcet's disease is a multisystem inflammatory disorder, and its etiology has not been defined clearly yet. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25610186", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Beh\u00e7et's disease is a systemic inflammatory disease presented with recurrent oral aphtha, cutaneous manifestations, uveitis, and genital ulcer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22041429", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 145, "text": "eh\u00e7et's disease is a systemic immunoinflammatory disease of young adults characterized by systemic vasculitis of arteries and veins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14761134", "endSection": "abstract"}]}, {"body": "Does Yersinia pestis causes a respiratory infection?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17041851", "http://www.ncbi.nlm.nih.gov/pubmed/26463167", "http://www.ncbi.nlm.nih.gov/pubmed/16239527", "http://www.ncbi.nlm.nih.gov/pubmed/26123398", "http://www.ncbi.nlm.nih.gov/pubmed/25928467", "http://www.ncbi.nlm.nih.gov/pubmed/25974210", "http://www.ncbi.nlm.nih.gov/pubmed/16714568", "http://www.ncbi.nlm.nih.gov/pubmed/19629028", "http://www.ncbi.nlm.nih.gov/pubmed/12474416", "http://www.ncbi.nlm.nih.gov/pubmed/16964684", "http://www.ncbi.nlm.nih.gov/pubmed/24721571", "http://www.ncbi.nlm.nih.gov/pubmed/25691593"], "ideal_answer": ["Inhalation of Yersinia pestis results in primary pneumonic plague."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015010", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015007", "http://www.disease-ontology.org/api/metadata/DOID:0050069", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015009"], "type": "yesno", "id": "58caf86f02b8c60953000030", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 140, "text": "Inhalation of Yersinia pestis results in primary pneumonic plague, a highly lethal and rapidly progressing necrotizing pneumonia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25691593", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Yersinia pestis causes the fatal respiratory disease pneumonic plague.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26123398", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Pulmonary infection by Yersinia pestis causes pneumonic plague, a rapidly progressing and often fatal disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16714568", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Pulmonary infection with the bacterium Yersinia pestis causes pneumonic plague, an often-fatal disease for which no vaccine is presently available.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16239527", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Yersinia pestis causes the fatal respiratory disease pneumonic plague", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26123398", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Pneumonic plague is a deadly respiratory disease caused by Yersinia pestis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24721571", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "On July 8, 2014, the Colorado Department of Public Health and Environment (CDPHE) laboratory identified Yersinia pestis, the bacterium that causes plague, in a blood specimen collected from a man (patient A) hospitalized with pneumonia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25928467", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Early emergence of Yersinia pestis as a severe respiratory pathogen.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26123398", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "The aerosol form of the bacterium Yersinia pestis causes the pneumonic plague, a rapidly fatal disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17041851", "endSection": "abstract"}, {"offsetInBeginSection": 17, "offsetInEndSection": 331, "text": " plague bacterium, Yersinia pestis, has historically been regarded as one of the deadliest pathogens known to mankind, having caused three major pandemics. After being transmitted by the bite of an infected flea arthropod vector, Y. pestis can cause three forms of human plague: bubonic, septicemic, and pneumonic,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21859946", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 561, "text": "Plague is an infectious disease caused by the Yersinia pestis microorganism, which is transmitted to the human host from a natural reservoir (different rodent species) by a flea bite. Plague is still encountered in humans in the areas of its enzootic prevalence in local rodent populations. Infection by flea bite results in a bubonic or septicemic plague, possibly complicated by secondary pneumonia. The person with pneumonic symptoms may be a source of a droplet-borne inhalatory infection for other people who consequently develop primary pneumonic plague. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12474416", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 166, "text": "uring pneumonic plague, the bacterium Yersinia pestis elicits the development of inflammatory lung lesions that continue to expand throughout infection. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26463167", "endSection": "abstract"}, {"offsetInBeginSection": 385, "offsetInEndSection": 582, "text": "In November 2006, the Uganda Ministry of Health received reports of an increase in bubonic plague cases and a possible outbreak of pneumonic plague among residents in the Arua and Nebbi districts. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19629028", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Pneumonic plague is a fatal disease caused by Yersinia pestis that is associated with a delayed immune response in the lungs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25974210", "endSection": "abstract"}]}, {"body": "List 3 indications for Bupropion", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17227286", "http://www.ncbi.nlm.nih.gov/pubmed/16027765", "http://www.ncbi.nlm.nih.gov/pubmed/16831112", "http://www.ncbi.nlm.nih.gov/pubmed/9554323", "http://www.ncbi.nlm.nih.gov/pubmed/16546007", "http://www.ncbi.nlm.nih.gov/pubmed/12043548", "http://www.ncbi.nlm.nih.gov/pubmed/21274361", "http://www.ncbi.nlm.nih.gov/pubmed/25661549", "http://www.ncbi.nlm.nih.gov/pubmed/18619194", "http://www.ncbi.nlm.nih.gov/pubmed/15155135", "http://www.ncbi.nlm.nih.gov/pubmed/15479310", "http://www.ncbi.nlm.nih.gov/pubmed/27038550", "http://www.ncbi.nlm.nih.gov/pubmed/26137782", "http://www.ncbi.nlm.nih.gov/pubmed/25223901", "http://www.ncbi.nlm.nih.gov/pubmed/25895022", "http://www.ncbi.nlm.nih.gov/pubmed/18264876", "http://www.ncbi.nlm.nih.gov/pubmed/18219560"], "ideal_answer": ["Bupropion is used to treat Obesity, for smoking cessation and for depression"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016642", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016540", "http://www.biosemantics.org/jochem#4095874", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056687", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061485", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4276121", "http://www.biosemantics.org/jochem#4276121"], "type": "list", "id": "58c1b2f702b8c6095300001e", "snippets": [{"offsetInBeginSection": 407, "offsetInEndSection": 699, "text": " For genotype, genes associated with nicotinic acetylcholine receptors (nAChRs) and related proteins have been found to predict response to first-line medications (e.g. nicotine replacement therapy [NRT], bupropion, or varenicline) or quitting over time without a controlled treatment trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25895022", "endSection": "abstract"}, {"offsetInBeginSection": 1633, "offsetInEndSection": 1851, "text": "The approval of drug combinations, such as phentermine/topiramate and bupropion/naltrexone are also noteworthy, the components of which have been previously approved, but not necessarily for obesity as main indication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137782", "endSection": "abstract"}, {"offsetInBeginSection": 148, "offsetInEndSection": 374, "text": "Two drugs, phentermine plus topiramate and lorcaserin, have recently been approved by the US Food and Drug Administration for the indication of obesity; a third, bupropion plus naltrexone, is under consideration for approval. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25223901", "endSection": "abstract"}, {"offsetInBeginSection": 1010, "offsetInEndSection": 1312, "text": "Bupropion SR is preferred to subjects with depression or smokers who have failed with the previous two agents, due to the many contra-indications and side effects of bupropion SR. With one of the 3 agents combined with follow-up visits with counselling, one can expect a 1-year quit rate around 20-25%.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18619194", "endSection": "abstract"}, {"offsetInBeginSection": 883, "offsetInEndSection": 1211, "text": "In vitro intrinsic clearances were likewise different for bupropion enantiomers.CONCLUSIONS: Stereoselective bupropion hydroxylation may have implications for the therapeutic efficacy of bupropion as an antidepressant or smoking cessation therapy, and for the use of bupropion as an in vivo phenotypic probe for CYP2B6 activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18219560", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "PURPOSE: Hydroxylation of the antidepressant and smoking deterrent drug bupropion is a clinically important bioactivation and elimination pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18219560", "endSection": "abstract"}, {"offsetInBeginSection": 1559, "offsetInEndSection": 2003, "text": "Although not U.S. Food and Drug Administration approved for these indications, bupropion has also been used as an adjunctive treatment to reverse antidepressant-induced sexual dysfunction and to augment anti-depressant efficacy in partial responders and non-responders to other agents.Bupropion has played and will continue to play an important role as a treatment for major depressive disorder in adults, as well as for other related disorders", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16027765", "endSection": "abstract"}, {"offsetInBeginSection": 1191, "offsetInEndSection": 1358, "text": "Clinically, bupropion is used as a treatment for two indications, as an antidepressant, the indication for which it was developed, and as a tobacco use cessation agent", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17227286", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 129, "text": "Sustained release bupropion (amfebutamone) is a non-nicotine agent that is indicated as an aid to smoking cessation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10804045", "endSection": "abstract"}, {"offsetInBeginSection": 21, "offsetInEndSection": 215, "text": "Bupropion was introduced for smoking cessation following a pivotal trial showing that it gave improved efficacy over the nicotine patch and also suggesting combination treatment was beneficial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23859696", "endSection": "abstract"}, {"offsetInBeginSection": 200, "offsetInEndSection": 285, "text": "Compared with a placebo control, bupropion approximately doubles smoking quit rates. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16831112", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "Over the past decade, bupropion has become a major pharmacotherapy for smoking cessation in the Western world. Unlike other smoking cessation pharmacotherapies, bupropion is a non-nicotine treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16831112", "endSection": "abstract"}, {"offsetInBeginSection": 2079, "offsetInEndSection": 2247, "text": "Bupropion has been tested in over 40 controlled clinical trials and has been associated with higher rates of treatment discontinuation due to adverse events than NRTs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21142259", "endSection": "abstract"}, {"offsetInBeginSection": 782, "offsetInEndSection": 875, "text": "Bupropion SR is a useful oral and non-nicotine form of pharmacotherapy for smoking cessation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12043548", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 549, "text": "everal new drugs for the treatment of obesity are either licensed in some parts of the world, submitted for registration, or completing phase III trials. These include combinations (at low dose) of existing drugs, e.g., bupropion + naltrexone (Contrave),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25661549", "endSection": "abstract"}]}, {"body": "What is the function of BAX", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19138672", "http://www.ncbi.nlm.nih.gov/pubmed/12732850", "http://www.ncbi.nlm.nih.gov/pubmed/17494694", "http://www.ncbi.nlm.nih.gov/pubmed/24712408", "http://www.ncbi.nlm.nih.gov/pubmed/27164337", "http://www.ncbi.nlm.nih.gov/pubmed/8798665", "http://www.ncbi.nlm.nih.gov/pubmed/23744350", "http://www.ncbi.nlm.nih.gov/pubmed/24503763", "http://www.ncbi.nlm.nih.gov/pubmed/21069436", "http://www.ncbi.nlm.nih.gov/pubmed/11932420", "http://www.ncbi.nlm.nih.gov/pubmed/22442658", "http://www.ncbi.nlm.nih.gov/pubmed/11340567", "http://www.ncbi.nlm.nih.gov/pubmed/17074758", "http://www.ncbi.nlm.nih.gov/pubmed/16679323", "http://www.ncbi.nlm.nih.gov/pubmed/23784543", "http://www.ncbi.nlm.nih.gov/pubmed/20885444", "http://www.ncbi.nlm.nih.gov/pubmed/19680558", "http://www.ncbi.nlm.nih.gov/pubmed/24269152", "http://www.ncbi.nlm.nih.gov/pubmed/8600029", "http://www.ncbi.nlm.nih.gov/pubmed/8887678", "http://www.ncbi.nlm.nih.gov/pubmed/20723427", "http://www.ncbi.nlm.nih.gov/pubmed/9565621", "http://www.ncbi.nlm.nih.gov/pubmed/25497728", "http://www.ncbi.nlm.nih.gov/pubmed/26395559", "http://www.ncbi.nlm.nih.gov/pubmed/15642728", "http://www.ncbi.nlm.nih.gov/pubmed/18547146", "http://www.ncbi.nlm.nih.gov/pubmed/26252372", "http://www.ncbi.nlm.nih.gov/pubmed/10669738"], "ideal_answer": ["BAX is a central death regulator that controls apoptosis in normal and cancer cells", "pro-apoptotic protein Bax"], "concepts": ["http://www.uniprot.org/uniprot/BAX_ECOLI", "http://amigo.geneontology.org/amigo/term/GO:0065009", "http://www.uniprot.org/uniprot/BAX_BOVIN", "http://www.uniprot.org/uniprot/BAX_RAT", "http://www.uniprot.org/uniprot/BAX_HUMAN", "http://www.uniprot.org/uniprot/BAX_MOUSE"], "type": "factoid", "id": "58bde18b02b8c60953000014", "snippets": [{"offsetInBeginSection": 545, "offsetInEndSection": 570, "text": "pro-apoptotic protein Bax", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252372", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "Bax, a central cell death regulator, is an indispensable gateway to mitochondrial dysfunction and a major proapoptotic member of the B-cell lymphoma 2 (Bcl-2) family proteins that control apoptosis in normal and cancer cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26395559", "endSection": "abstract"}, {"offsetInBeginSection": 1470, "offsetInEndSection": 1620, "text": "Thus, PP2A may function as a physiological Bax regulatory phosphatase that not only dephosphorylates Bax but also activates its proapoptotic function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16679323", "endSection": "abstract"}, {"offsetInBeginSection": 435, "offsetInEndSection": 769, "text": "The ability of the mutants to protect against Bax-mediated cell death is divided into three groups: (1) group I, retention of anti-Bax function in both the Val129 and Met129 mutants; (2) group II, retention of anti-Bax function only in Val129 mutants; and (3) group III, reduction or no anti-Bax function in Val129 and Met129 mutants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17494694", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "A popular model of BCL-2 and BAX involvement in apoptosis suggests that upon apoptosis induction cytosolic BAX translocates to the mitochondria, where it displays the pro-apoptotic function, which involves its homodimerization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11340567", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 572, "text": "The purpose of this study was to investigate the expression of the gene coding for the antiapoptotic molecule Bcl-2, the proapoptotic molecule Bax, and the apoptosis executor enzyme caspase-3 in preimplantation renal biopsies (PIB) as markers for delayed graft function.In this prospective single-center study, gene expression levels were evaluated using real-time TaqMan polymerase chain reaction in PIB of kidneys from 72 deceased donors (DDs) and 18 living donors (LDs).CASP3 and BAX expression levels were higher, whereas those of BCL2 were lower, in DD than in LD PIB", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24503763", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "The function Bax and/or Bak in constituting a gateway for mitochondrial apoptosis in response to apoptotic stimuli has been unequivocally demonstrated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23784543", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Bax is a major proapoptotic member of the Bcl2 family that is required for apoptotic cell death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16679323", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Bax is a proapoptotic member of the Bcl-2 family of proteins which localizes to and uses mitochondria as its major site of action.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10669738", "endSection": "abstract"}, {"offsetInBeginSection": 94, "offsetInEndSection": 121, "text": "death-promoting Bax protein", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8600029", "endSection": "title"}, {"offsetInBeginSection": 97, "offsetInEndSection": 178, "text": "The suppressors function through heterodimerization with the death promoters, Bax", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8798665", "endSection": "abstract"}, {"offsetInBeginSection": 953, "offsetInEndSection": 1024, "text": "Bax- and Bak-mediated apoptosis severely limits adenoviral replication,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11932420", "endSection": "abstract"}, {"offsetInBeginSection": 132, "offsetInEndSection": 275, "text": "Bax a pro-apoptotic member localizes as monomers in the cytosol of healthy cells and accumulates as oligomers in mitochondria of apoptotic cell", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17519046", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "Bax and Bak (Bax/Bak) are essential pro-apoptotic proteins of the Bcl-2 family that trigger mitochondrial outer membrane permeabilization (MOMP) in a Bcl-2/Bcl-xL-inhibitable manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23475110", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "BAX protein plays a key role in the mitochondria-mediated apoptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25497728", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "The multi-BCL-2 homology domain pro-apoptotic BCL-2 family members BAK and BAX have critical roles in apoptosis. They are essential for mitochondrial outer-membrane permeabili", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23744350", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Members of the Bcl-2 family play key roles as proapoptotic (e.g., Bax) and antiapoptotic (e.g., Bcl-x(L)) regulators of programmed cell death", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20885444", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 138, "text": "The Bcl-2 associated X protein (Bax), belonging to the Bcl-2 family, plays a pivotal role in mitochondria-dependent apoptosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20723427", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 36, "text": "The murine proapoptotic protein Bax ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12213925", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Bax is a pro-apoptotic member of the Bcl-2 family proteins involved in the release of apoptogenic factors from mitochondria to the cytosol.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19138672", "endSection": "abstract"}, {"offsetInBeginSection": 50, "offsetInEndSection": 176, "text": "activated Bax forms large oligomers that permeabilize the outer mitochondrial membrane, thereby committing cells to apoptosis,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18547146", "endSection": "abstract"}]}, {"body": "What is the link between Ctf4 and Chl1 in cohesion establishment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23334284", "http://www.ncbi.nlm.nih.gov/pubmed/17222391", "http://www.ncbi.nlm.nih.gov/pubmed/15226378", "http://www.ncbi.nlm.nih.gov/pubmed/27397686", "http://www.ncbi.nlm.nih.gov/pubmed/23036200"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_513031343534001D", "o": "CTF4"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1427963", "o": "http://linkedlifedata.com/resource/umls/label/A20695577"}, {"p": "http://www.w3.org/2004/02/skos/core#exactMatch", "s": "http://purl.uniprot.org/uniprot/Q01454", "o": "http://purl.uniprot.org/uniprot/Q01454"}, {"p": "http://purl.uniprot.org/core/encodedBy", "s": "http://purl.uniprot.org/uniprot/Q01454", "o": "http://linkedlifedata.com/resource/#_513031343534001D"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://purl.uniprot.org/uniprot/Q01454", "o": "CTF4_YEAST"}], "ideal_answer": ["Ctf4 links DNA replication with sister chromatid cohesion establishment by recruiting the Chl1 helicase to the replisome. The Eco1 acetyltransferase, helped by factors including Ctf4 and Chl1, concomitantly acetylates the chromosomal cohesin complex to stabilize its cohesive links.", "Genetic analyses revealed that Rmi1 promoted sister chromatid cohesion in a process that was distinct from both the cohesion establishment pathway involving Ctf4, Csm3, and Chl1 and the pathway involving the acetylation of Smc3. Thus, Ctf4 and Chl1 delineate an additional acetylation-independent pathway that might hold important clues as to the mechanism of sister chromatid cohesion establishment."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0034089", "http://www.biosemantics.org/jochem#4264134", "http://amigo.geneontology.org/amigo/term/GO:0034085", "http://amigo.geneontology.org/amigo/term/GO:0034087", "http://www.biosemantics.org/jochem#4265011"], "type": "summary", "id": "587f8324d8d850a152000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Ctf4 Links DNA Replication with Sister Chromatid Cohesion Establishment by Recruiting the Chl1 Helicase to the Replisome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27397686", "endSection": "title"}, {"offsetInBeginSection": 135, "offsetInEndSection": 441, "text": "The Eco1 acetyltransferase, helped by factors including Ctf4 and Chl1, concomitantly acetylates the chromosomal cohesin complex to stabilize its cohesive links. Here we show that Ctf4 recruits the Chl1 helicase to the replisome via a conserved interaction motif that Chl1 shares with GINS and polymerase \u03b1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27397686", "endSection": "abstract"}, {"offsetInBeginSection": 526, "offsetInEndSection": 1079, "text": "The Chl1 helicase facilitates replication fork progression under conditions of nucleotide depletion, partly independently of Ctf4 interaction. Conversely, Ctf4 interaction, but not helicase activity, is required for Chl1's role in sister chromatid cohesion. A physical interaction between Chl1 and the cohesin complex during S phase suggests that Chl1 contacts cohesin to facilitate its acetylation. Our results reveal how Ctf4 forms a replisomal interaction hub that coordinates replication fork progression and sister chromatid cohesion establishment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27397686", "endSection": "abstract"}, {"offsetInBeginSection": 630, "offsetInEndSection": 858, "text": "Genetic analyses revealed that Rmi1 promoted sister chromatid cohesion in a process that was distinct from both the cohesion establishment pathway involving Ctf4, Csm3, and Chl1 and the pathway involving the acetylation of Smc3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23036200", "endSection": "abstract"}, {"offsetInBeginSection": 1319, "offsetInEndSection": 1490, "text": "Thus, Ctf4 and Chl1 delineate an additional acetylation-independent pathway that might hold important clues as to the mechanism of sister chromatid cohesion establishment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334284", "endSection": "abstract"}, {"offsetInBeginSection": 430, "offsetInEndSection": 629, "text": "We show here that CTF8, CTF4 and a helicase encoded by CHL1 are required for efficient sister chromatid cohesion in unperturbed mitotic cells, and provide evidence that Chl1 functions during S-phase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226378", "endSection": "abstract"}, {"offsetInBeginSection": 825, "offsetInEndSection": 1002, "text": "Our results suggest that Chl1 and Ctf4 are directly involved in homologous recombination repair rather than acting indirectly via the establishment of sister chromatid cohesion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17222391", "endSection": "abstract"}, {"offsetInBeginSection": 1328, "offsetInEndSection": 1499, "text": "Thus, Ctf4 and Chl1 delineate an additional acetylation-independent pathway that might hold important clues as to the mechanism of sister chromatid cohesion establishment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334284", "endSection": "abstract"}, {"offsetInBeginSection": 1327, "offsetInEndSection": 1497, "text": "Thus, Ctf4 and Chl1 delineate an additional acetylation-independent pathway that might hold important clues as to the mechanism of sister chromatid cohesion establishment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334284", "endSection": "abstract"}, {"offsetInBeginSection": 432, "offsetInEndSection": 630, "text": "We show here that CTF8, CTF4 and a helicase encoded by CHL1 are required for efficient sister chromatid cohesion in unperturbed mitotic cells, and provide evidence that Chl1 functions during S-phase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226378", "endSection": "abstract"}, {"offsetInBeginSection": 633, "offsetInEndSection": 860, "text": "Genetic analyses revealed that Rmi1 promoted sister chromatid cohesion in a process that was distinct from both the cohesion establishment pathway involving Ctf4, Csm3, and Chl1 and the pathway involving the acetylation of Smc3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23036200", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "Sister-chromatid cohesion mediated by the alternative RF-CCtf18/Dcc1/Ctf8, the helicase Chl1 and the polymerase-alpha-associated protein Ctf4 is essential for chromatid disjunction during meiosis II.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226378", "endSection": "title"}, {"offsetInBeginSection": 633, "offsetInEndSection": 862, "text": "Genetic analyses revealed that Rmi1 promoted sister chromatid cohesion in a process that was distinct from both the cohesion establishment pathway involving Ctf4, Csm3, and Chl1 and the pathway involving the acetylation of Smc3. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23036200", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Ctf4 Links DNA Replication with Sister Chromatid Cohesion Establishment by Recruiting the Chl1 Helicase to the Replisome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27397686", "endSection": "title"}, {"offsetInBeginSection": 1328, "offsetInEndSection": 1500, "text": "Thus, Ctf4 and Chl1 delineate an additional acetylation-independent pathway that might hold important clues as to the mechanism of sister chromatid cohesion establishment..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334284", "endSection": "abstract"}, {"offsetInBeginSection": 829, "offsetInEndSection": 1007, "text": "Our results suggest that Chl1 and Ctf4 are directly involved in homologous recombination repair rather than acting indirectly via the establishment of sister chromatid cohesion..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17222391", "endSection": "abstract"}]}, {"body": "How is primary intestinal lymphangiectasia (PIL) caused?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19853733", "http://www.ncbi.nlm.nih.gov/pubmed/26217101", "http://www.ncbi.nlm.nih.gov/pubmed/26962779", "http://www.ncbi.nlm.nih.gov/pubmed/8650761", "http://www.ncbi.nlm.nih.gov/pubmed/23229460", "http://www.ncbi.nlm.nih.gov/pubmed/23316917", "http://www.ncbi.nlm.nih.gov/pubmed/24449480", "http://www.ncbi.nlm.nih.gov/pubmed/23626516", "http://www.ncbi.nlm.nih.gov/pubmed/26405709", "http://www.ncbi.nlm.nih.gov/pubmed/18855225", "http://www.ncbi.nlm.nih.gov/pubmed/16292099", "http://www.ncbi.nlm.nih.gov/pubmed/22110841", "http://www.ncbi.nlm.nih.gov/pubmed/19887697", "http://www.ncbi.nlm.nih.gov/pubmed/18294365", "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "http://www.ncbi.nlm.nih.gov/pubmed/26908672", "http://www.ncbi.nlm.nih.gov/pubmed/25943403", "http://www.ncbi.nlm.nih.gov/pubmed/20812055", "http://www.ncbi.nlm.nih.gov/pubmed/26169531"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1418580", "o": "http://linkedlifedata.com/resource/umls/label/A12036259"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12036259", "o": "PIL"}], "ideal_answer": ["Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized by diffuse or localized dilation and eventual rupture of the enteric lymphatic vessels in mucosa, submucosa, and/or subserosa. Lymph, rich in all kinds of proteins and lymphocytes, leaks into the gastrointestinal tract via the affected lymphatic vessels causing hypoproteinemia and lymphopenia."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008201", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008200", "http://www.disease-ontology.org/api/metadata/DOID:2402", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007413", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007410", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007422", "http://www.disease-ontology.org/api/metadata/DOID:5295"], "type": "summary", "id": "58ca5cba02b8c6095300002b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 390, "text": "Primary intestinal lymphangiectasia (PIL) is a rare disorder of unknown etiology characterized by diffuse or localized dilation and eventual rupture of the enteric lymphatic vessels in mucosa, submucosa, and/or subserosa. Lymph, rich in all kinds of proteins and lymphocytes, leaks into the gastrointestinal tract via the affected lymphatic vessels causing hypoproteinemia and lymphopenia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962779", "endSection": "abstract"}, {"offsetInBeginSection": 1778, "offsetInEndSection": 1879, "text": "PIL, effusions, and lymphedema can be the features of multisegmental generalized lymphatic dysplasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962779", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "A number of disorders have been described to cause protein losing enteropathy (PLE) in children. Primary intestinal lymphangiectasia (PIL) is one mechanism leading to PLE.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23180957", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 286, "text": "Primary intestinal lymphangiectasia is a rare cause of protein-losing enteropathy and usually presents with intermittent diarrhea or malnutrition. Diagnosis depends largely on its pathologic condition demonstrating greatly dilated lymphatics mainly in the lamina propria of the mucosa. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19853733", "endSection": "abstract"}, {"offsetInBeginSection": 592, "offsetInEndSection": 762, "text": "The histopathologic condition of the resected small intestine showed lymphatic dilation limited mainly to the subserosa and mesentery but was not prominent in the mucosa.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19853733", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized by dilated intestinal lymphatics and the development of protein-losing enteropathy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22110841", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is an exudative enteropathy resulting from morphologic abnormalities in the intestinal lymphatics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908672", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "Primary intestinal lymphangiectasia (PIL), so-called Waldmann's disease, is an uncommon condition, characterized by dilated intestinal submucosal and subserosal lymphatics of the gastrointestinal tract.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16292099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized by dilated intestinal lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18294365", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is a rare disorder characterized by dilated intestinal lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20812055", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Primary intestinal lymphangiectasia (PIL) is a protein-losing, exsudative gastroenteropathy causing lymphatic obstruction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229460", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Primary intestinal lymphangiectasia (PIL) is a protein-losing enteropathy characterized by tortuous and dilated lymph channels of the small bowel.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24449480", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Primary intestinal lymphangiectasia (PIL) is a rare disease of intestinal lymphatics presenting with hypoproteinemia, bilateral lower limb edema, ascites, and protein losing enteropathy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19887697", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "Exudative enteropathy secondary to primary intestinal lymphangiectasia (PIL) is characterized by lymphopenia, hypogammaglobulinemia and hypoalbuminemia resulting from leakage of lymph fluid into the intestinal tract", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18855225", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Primary intestinal lymphangiectasia (PIL) is a rare protein-losing enteropathy with lymphatic leakage into the small intestine", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26217101", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Primary intestinal lymphangiectasia (PIL) is a protein-losing enteropathy characterized by tortuous and dilated lymph channels of the small bowel", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24449480", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Primary intestinal lymphangiectasia (PIL) is a rare disease of intestinal lymphatics presenting with hypoproteinemia, bilateral lower limb edema, ascites, and protein losing enteropathy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19887697", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "Primary intestinal lymphangiectasia (PIL), so-called Waldmanns disease, is an uncommon condition, characterized by dilated intestinal submucosal and subserosal lymphatics of the gastrointestinal tract", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16292099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 361, "text": "Primary intestinal lymphangiectasia (Waldmanns disease) is a rare disease characterized by dilated lymphatics in the small bowel leading to an exudative enteropathy with lymphopenia, hypoalbuminemia and hypogammaglobulinemia.We report the case of a 23 year-old male who presented with chronic anemia and in whom primary intestinal lymphangiectasia was diagnosed", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26405709", "endSection": "abstract"}, {"offsetInBeginSection": 187, "offsetInEndSection": 367, "text": "We report a series of 4 children from Chennai, India presenting with anasarca, recurrent diarrhea, hypoproteinemia and confirmatory features of PIL on endoscopy and histopathology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19887697", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Primary intestinal lymphangiectasia (PIL) is a protein-losing, exsudative gastroenteropathy causing lymphatic obstruction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229460", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Primary intestinal lymphangiectasia (PIL) is a rare protein-losing enteropathy characterized by a congenital malformation of the lymphatic vessels of the small intestine causing insufficient drainage and leakage of lymph fluid.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25943403", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Primary intestinal lymphangiectasia (PIL) is a rare protein-losing enteropathy with lymphatic leakage into the small intestine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26217101", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Primary intestinal lymphangiectasia (PIL) or Waldmann's disease is a rare protein-losing gastroenteropathy of unknown etiology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23626516", "endSection": "abstract"}]}, {"body": "What are congenital disorders of glycosylation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26873821", "http://www.ncbi.nlm.nih.gov/pubmed/27725718", "http://www.ncbi.nlm.nih.gov/pubmed/25840006", "http://www.ncbi.nlm.nih.gov/pubmed/26238249", "http://www.ncbi.nlm.nih.gov/pubmed/24157261"], "ideal_answer": ["Congenital disorders of glycosylation (CDG) are a growing group of inherited metabolic disorders where enzymatic defects in the formation or processing of glycolipids and/or glycoproteins lead to variety of different diseases.\nMore than 100 rare human genetic disorders that result from deficiencies in the different glycosylation pathways are known today.\t\nThe patients have hundreds of misglycosylated products, which afflict a myriad of processes, including cell signaling, cell-cell interaction, and cell migration."], "type": "summary", "id": "58e115d66fddd3e83e00000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Congenital disorder of glycosylation (CDG), formerly representing a group of diseases due to defects in the biosynthetic pathway of protein N-glycosylation, currently covers a wide range of disorders affecting glycoconjugates. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26873821", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "Congenital disorders of glycosylation form a rapidly growing group of inherited metabolic diseases. As glycosylation affects proteins all over the organism, a mutation in a single gene leads to a multisystemic disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26238249", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 539, "text": "Glycosylation is an integral part in health and disease, as emphasized by the growing number of identified glycosylation defects. In humans, proteins are modified with a diverse range of glycoforms synthesized in complex biosynthetic pathways. Glycosylation disorders have been described in congenital disorders of glycosylation (CDG) as well as in acquired disease conditions such and non-alcoholic fatty liver disease (NAFLD). A hallmark in a subset of CDG cases is the reduced glycosylation site occupancy of asparagine-linked glycans. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725718", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "Congenital disorders of glycosylation (CDG) are a growing group of inherited metabolic disorders where enzymatic defects in the formation or processing of glycolipids and/or glycoproteins lead to variety of different diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24157261", "endSection": "abstract"}, {"offsetInBeginSection": 223, "offsetInEndSection": 354, "text": " More than 100 rare human genetic disorders that result from deficiencies in the different glycosylation pathways are known today. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840006", "endSection": "abstract"}, {"offsetInBeginSection": 719, "offsetInEndSection": 880, "text": "The patients have hundreds of misglycosylated products, which afflict a myriad of processes, including cell signaling, cell-cell interaction, and cell migration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840006", "endSection": "abstract"}]}, {"body": "Which are the additions of the JASPAR 2016 open-access database of transcription factor binding profiles?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26531826"], "ideal_answer": ["Compared to the JASPAR CORE collection, JASPAR 2016 has been expanded with 494 new TF binding profiles (315 in vertebrates, 11 in nematodes, 3 in insects, 1 in fungi and 164 in plants) and 59 profiles (58 in vertebrates and 1 in fungi) have been updated. The introduced profiles represent an 83% expansion and 10% update when compared to the previous release. The structural annotation of the TF DNA binding domains (DBDs) has been updated following a published hierarchical structural classification. In addition, 130 transcription factor flexible models trained on ChIP-seq data for vertebrates, which capture dinucleotide dependencies within TF binding sites were introduced . The new JASPAR release is accompanied by a new web tool to infer JASPAR TF binding profiles recognized by a given TF protein sequence. Moreover, users are provided with a Ruby module complementing the JASPAR API to ease programmatic access and use of the JASPAR collection of profiles. JASPAR2016 R/Bioconductor data package is also provided with the data of this release."], "type": "list", "id": "587d2b7efe8a08052f000003", "snippets": [{"offsetInBeginSection": 267, "offsetInEndSection": 1301, "text": "For this 2016 release, we expanded the JASPAR CORE collection with 494 new TF binding profiles (315 in vertebrates, 11 in nematodes, 3 in insects, 1 in fungi and 164 in plants) and updated 59 profiles (58 in vertebrates and 1 in fungi). The introduced profiles represent an 83% expansion and 10% update when compared to the previous release. We updated the structural annotation of the TF DNA binding domains (DBDs) following a published hierarchical structural classification. In addition, we introduced 130 transcription factor flexible models trained on ChIP-seq data for vertebrates, which capture dinucleotide dependencies within TF binding sites. This new JASPAR release is accompanied by a new web tool to infer JASPAR TF binding profiles recognized by a given TF protein sequence. Moreover, we provide the users with a Ruby module complementing the JASPAR API to ease programmatic access and use of the JASPAR collection of profiles. Finally, we provide the JASPAR2016 R/Bioconductor data package with the data of this release", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26531826", "endSection": "abstract"}]}, {"body": "What is the function of the protein tafazzin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24318983", "http://www.ncbi.nlm.nih.gov/pubmed/25598000", "http://www.ncbi.nlm.nih.gov/pubmed/25118650", "http://www.ncbi.nlm.nih.gov/pubmed/26415690", "http://www.ncbi.nlm.nih.gov/pubmed/21068380", "http://www.ncbi.nlm.nih.gov/pubmed/25941633", "http://www.ncbi.nlm.nih.gov/pubmed/24714493", "http://www.ncbi.nlm.nih.gov/pubmed/24858921", "http://www.ncbi.nlm.nih.gov/pubmed/25688091", "http://www.ncbi.nlm.nih.gov/pubmed/19700766", "http://www.ncbi.nlm.nih.gov/pubmed/25919711", "http://www.ncbi.nlm.nih.gov/pubmed/16794186", "http://www.ncbi.nlm.nih.gov/pubmed/25247053", "http://www.ncbi.nlm.nih.gov/pubmed/17082194"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0031843", "o": "function"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0031843", "o": "http://linkedlifedata.com/resource/umls/label/A3879881"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A3879881", "o": "function"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1336578", "o": "http://linkedlifedata.com/resource/umls/label/A12030635"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12030635", "o": "TAFAZZIN"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1336578", "o": "TAZ"}], "ideal_answer": ["Tafazzin is a phospholipid transacylase that transfers acyl chains with unsaturated fatty acids from phospholipids to monolysocardiolipin to generate cardiolipin with unsaturated fatty acids on mitochondrial membrane."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011506", "http://www.disease-ontology.org/api/metadata/DOID:0050476", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056889"], "type": "summary", "id": "58d90b968acda3452900000e", "snippets": [{"offsetInBeginSection": 104, "offsetInEndSection": 282, "text": "Tafazzin is a transacylase that transfers acyl chains with unsaturated fatty acids from phospholipids to monolysocardiolipin to generate cardiolipin with unsaturated fatty acids.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25688091", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Tafazzin (EC 2.3.1.23) is a Phospholipid Transacylase involved in Cardiolipin remodeling on mitochondrial membrane and coded by TAZ gene (Cytogenetic Location: Xq28) in human.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25118650", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Tafazzin is a transacylase that affects cardiolipin fatty acid composition and mitochondrial function. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25598000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Tafazzin is a mitochondrial phospholipid transacylase, and its mutations cause Barth syndrome (BTHS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941633", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Tafazzin (TAZ) is a phospholipid transacylase that catalyzes the remodeling of cardiolipin, a mitochondrial phospholipid required for oxidative phosphorylation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25919711", "endSection": "abstract"}, {"offsetInBeginSection": 303, "offsetInEndSection": 479, "text": "Tafazzin expression induced a new enzymatic function in Sf9 cell mitochondria, namely 1-palmitoyl-2-[14C]linoleoyl-phosphatidylcholine:monolysocardiolipin linoleoyltransferase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17082194", "endSection": "abstract"}, {"offsetInBeginSection": 605, "offsetInEndSection": 897, "text": "Among the human isoforms, only full-length tafazzin (FL) and tafazzin lacking exon 5 (Delta5) had transacylase activity, and only these two isoforms were able to restore a normal cardiolipin pattern, normal respiratory activity of mitochondria, and male fertility in tafazzin-deficient flies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700766", "endSection": "abstract"}, {"offsetInBeginSection": 211, "offsetInEndSection": 288, "text": "Tafazzin is a mitochondrial transacylase required for cardiolipin remodeling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21068380", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Tafazzin is a putative enzyme that is involved in cardiolipin metabolism, it may carry mutations responsible for Barth syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17082194", "endSection": "abstract"}, {"offsetInBeginSection": 563, "offsetInEndSection": 790, "text": "Tafazzin is an enzyme that remodels saturated fatty acyl chains within CL to unsaturated fatty acyl chains, loss of function mutations in the TAZ gene encoding tafazzin are causal for the inherited cardiomyopathy Barth syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415690", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "The tafazzin gene encodes a phospholipid-lysophospholipid transacylase involved in cardiolipin metabolism, but it is not known why it forms multiple transcripts as a result of alternative splicing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700766", "endSection": "abstract"}, {"offsetInBeginSection": 1435, "offsetInEndSection": 1684, "text": "Furthermore, the data show that the expression of human tafazzin in flies creates cardiolipin with a Drosophila pattern, suggesting that the characteristic fatty acid profile of cardiolipin is not determined by the substrate specificity of tafazzin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700766", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Tafazzin is a transacylase that affects cardiolipin fatty acid composition and mitochondrial function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25598000", "endSection": "abstract"}]}, {"body": "What are assassin bugs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25996956", "http://www.ncbi.nlm.nih.gov/pubmed/24438295", "http://www.ncbi.nlm.nih.gov/pubmed/25689825", "http://www.ncbi.nlm.nih.gov/pubmed/26249492", "http://www.ncbi.nlm.nih.gov/pubmed/27058599", "http://www.ncbi.nlm.nih.gov/pubmed/24884699"], "ideal_answer": ["The family Reduviidae (Hemiptera: Heteroptera), or assassin bugs, is among the most diverse families of the true bugs, with more than 6,000 species."], "type": "summary", "id": "58e12ea66fddd3e83e00000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "The complete mitochondrial genome of an assassin bug Peirates arcuatus (Hemiptera: Reduviidae).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24438295", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "First complete mitochondrial genome sequence from the tribelocephaline assassin bugs (Hemiptera: Reduviidae).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996956", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "The complete mitochondrial genome (mitogenome) of Opistoplatys sp. was determined, which was the first representation from the assassin bug subfamily Tribelocephalinae. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996956", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 160, "text": "The family Reduviidae (Hemiptera: Heteroptera), or assassin bugs, is among the most diverse families of the true bugs, with more than 6,000 species.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27058599", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Comparative mitogenomics of the assassin bug genus Peirates (Hemiptera: Reduviidae: Peiratinae) ", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25689825", "endSection": "title"}]}, {"body": "Are the genes for marneral biosynthesis scattered in the genome of A. thaliana?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21876149"], "ideal_answer": ["These clusters are unlikely to have arisen by horizontal gene transfer, and the mechanisms behind their formation are poorly understood. Here we characterize a second operon-like triterpene cluster (the marneral cluster) from A. thaliana, compare the features of these two clusters, and investigate the evolutionary events that have led to cluster formation.", "Here we characterize a second operon-like triterpene cluster (the marneral cluster) from A. thaliana, compare the features of these two clusters, and investigate the evolutionary events that have led to cluster formation. ", "Genes for marneral synthesis are organized in an operon-like gene cluster in thale cress (A. thaliana)."], "type": "yesno", "id": "58eb7898eda5a57672000006", "snippets": [{"offsetInBeginSection": 1064, "offsetInEndSection": 1284, "text": "Here we characterize a second operon-like triterpene cluster (the marneral cluster) from A. thaliana, compare the features of these two clusters, and investigate the evolutionary events that have led to cluster formation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876149", "endSection": "abstract"}, {"offsetInBeginSection": 1057, "offsetInEndSection": 1278, "text": "Here we characterize a second operon-like triterpene cluster (the marneral cluster) from A. thaliana, compare the features of these two clusters, and investigate the evolutionary events that have led to cluster formation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876149", "endSection": "abstract"}, {"offsetInBeginSection": 892, "offsetInEndSection": 1063, "text": "Previously in thale cress (Arabidopsis thaliana) we identified an operon-like gene cluster that is required for the synthesis and modification of the triterpene thalianol.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876149", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Prediction of operon-like gene clusters in the Arabidopsis thaliana genome based on co-expression analysis of neighboring genes", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561113", "endSection": "title"}, {"offsetInBeginSection": 1064, "offsetInEndSection": 1286, "text": "Here we characterize a second operon-like triterpene cluster (the marneral cluster) from A. thaliana, compare the features of these two clusters, and investigate the evolutionary events that have led to cluster formation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876149", "endSection": "abstract"}, {"offsetInBeginSection": 1064, "offsetInEndSection": 1155, "text": "Here we characterize a second operon-like triterpene cluster (the marneral cluster) from A.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876149", "endSection": "abstract"}, {"offsetInBeginSection": 258, "offsetInEndSection": 447, "text": "the cyclic hydroxamic acid pathways in maize, the avenacin biosynthesis gene clusters in oat, the thalianol pathway in Arabidopsis thaliana, and the diterpenoid momilactone cluster in rice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Prediction of operon-like gene clusters in the Arabidopsis thaliana genome based on co-expression analysis of neighboring genes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561113", "endSection": "title"}]}, {"body": "Is Dupilumab used for treatment of atopic dermatitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27334730", "http://www.ncbi.nlm.nih.gov/pubmed/27690741", "http://www.ncbi.nlm.nih.gov/pubmed/26428945", "http://www.ncbi.nlm.nih.gov/pubmed/25006719", "http://www.ncbi.nlm.nih.gov/pubmed/26836729", "http://www.ncbi.nlm.nih.gov/pubmed/27497276", "http://www.ncbi.nlm.nih.gov/pubmed/26598956", "http://www.ncbi.nlm.nih.gov/pubmed/27906698"], "ideal_answer": ["Yes, patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity."], "type": "yesno", "id": "58df3e408acda3452900002d", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 149, "text": "Dupilumab has demonstrated efficacy in patients with asthma and atopic dermatitis, which are both type 2 helper T-cell-mediated diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836729", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", "endSection": "title"}, {"offsetInBeginSection": 1023, "offsetInEndSection": 1161, "text": "Dupilumab is a biologic agent targeted at TH2 cytokines, but indirectly impacts IgE and is an important biologic agent for atopic disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906698", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Dupilumab for the treatment of atopic dermatitis: A clinical trial review.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945", "endSection": "title"}, {"offsetInBeginSection": 143, "offsetInEndSection": 255, "text": "Dupilumab is a novel monoclonal antibody that was recently studied in adult patients with moderate-to-severe AD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945", "endSection": "abstract"}, {"offsetInBeginSection": 2339, "offsetInEndSection": 2472, "text": "Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25006719", "endSection": "abstract"}, {"offsetInBeginSection": 746, "offsetInEndSection": 978, "text": "The robust effects of dupilumab on skin inflammation and pruritus confirm the pathogenic role of IL-4 and IL-13 signaling in adult AD, and further support the application of Th2 cytokine antagonists in the treatment of this disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", "endSection": "abstract"}]}, {"body": "Where is base J found in the genome of Leishmania tarentolae?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25662217", "http://www.ncbi.nlm.nih.gov/pubmed/17329373", "http://www.ncbi.nlm.nih.gov/pubmed/19114062", "http://www.ncbi.nlm.nih.gov/pubmed/10562569", "http://www.ncbi.nlm.nih.gov/pubmed/25104019", "http://www.ncbi.nlm.nih.gov/pubmed/20215442"], "ideal_answer": ["Base J (\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops. Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes in Trypanosoma brucei.", "Base J (-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops. Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes in Trypanosoma brucei. J is enriched at sites involved in RNA polymerase (RNAP) II initiation and termination. ", "Base J (\u00ce\u00b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops. Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes in Trypanosoma brucei.", "Base J (\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops.", "j (\u03b2-d-glucosyl-hydroxymethyluracil) replaces 1% of t in the leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops. . j is found predominantly in repetitive dna and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes in trypanosoma brucei. . ", "base j (\u03b2-d-glucosyl-hydroxymethyluracil) replaces 1% of t in the leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops."], "type": "factoid", "id": "58cf5c5a8acda34529000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Base J (\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25662217", "endSection": "abstract"}, {"offsetInBeginSection": 107, "offsetInEndSection": 266, "text": "Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes in Trypanosoma brucei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10562569", "endSection": "abstract"}, {"offsetInBeginSection": 155, "offsetInEndSection": 242, "text": "J is enriched at sites involved in RNA polymerase (RNAP) II initiation and termination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25104019", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "Base J (\u03b2-D-glucosyl-hydroxymethyluracil) replaces 1% of T in the Leishmania genome and is only found in telomeric repeats (99%) and in regions where transcription starts and stops", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25662217", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Telomeric localization of the modified DNA base J in the genome of the protozoan parasite Leishmania", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17329373", "endSection": "title"}, {"offsetInBeginSection": 107, "offsetInEndSection": 267, "text": "Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes in Trypanosoma brucei. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10562569", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Base J is a hypermodified DNA base localized primarily to telomeric regions of the genome of Trypanosoma brucei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20215442", "endSection": "abstract"}]}, {"body": "Which tool is available for predicting regulatory interactions from ChIP-seq data?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27924029"], "ideal_answer": ["CisMapper predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene across a panel of tissues. CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical of tissue-specific gene expression. CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can predict which transcription start site of a gene is regulated by a particular binding site of the TF."], "type": "factoid", "id": "587e0116ae05ffb474000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", "endSection": "title"}, {"offsetInBeginSection": 546, "offsetInEndSection": 741, "text": "We present CisMapper, which predicts the regulatory targets of a TF using the correlation between a histone mark at the TF's bound sites and the expression of each gene across a panel of tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", "endSection": "abstract"}, {"offsetInBeginSection": 742, "offsetInEndSection": 1077, "text": "Using both chromatin conformation capture and differential expression data, we show that CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical of tissue-specific gene expression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", "endSection": "abstract"}, {"offsetInBeginSection": 1078, "offsetInEndSection": 1338, "text": " CisMapper also predicts which TF binding sites regulate a given gene more accurately than using genomic distance. Unlike distance-based methods, CisMapper can predict which transcription start site of a gene is regulated by a particular binding site of the TF", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "CisMapper: predicting regulatory interactions from transcription factor ChIP-seq data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", "endSection": "title"}, {"offsetInBeginSection": 742, "offsetInEndSection": 1078, "text": "Using both chromatin conformation capture and differential expression data, we show that CisMapper is more accurate at predicting the target genes of a TF than the distance-based approaches currently used, and is particularly advantageous for predicting the long-range regulatory interactions typical of tissue-specific gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924029", "endSection": "abstract"}]}, {"body": "Where are the unipolar brush cells localized?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7978355", "http://www.ncbi.nlm.nih.gov/pubmed/11457596", "http://www.ncbi.nlm.nih.gov/pubmed/8177517", "http://www.ncbi.nlm.nih.gov/pubmed/9923978", "http://www.ncbi.nlm.nih.gov/pubmed/14614902", "http://www.ncbi.nlm.nih.gov/pubmed/8059339", "http://www.ncbi.nlm.nih.gov/pubmed/19409228", "http://www.ncbi.nlm.nih.gov/pubmed/10891606", "http://www.ncbi.nlm.nih.gov/pubmed/9193142", "http://www.ncbi.nlm.nih.gov/pubmed/11396855", "http://www.ncbi.nlm.nih.gov/pubmed/11044898", "http://www.ncbi.nlm.nih.gov/pubmed/12655510", "http://www.ncbi.nlm.nih.gov/pubmed/17223277", "http://www.ncbi.nlm.nih.gov/pubmed/8300904", "http://www.ncbi.nlm.nih.gov/pubmed/16289944", "http://www.ncbi.nlm.nih.gov/pubmed/16344141", "http://www.ncbi.nlm.nih.gov/pubmed/8821458", "http://www.ncbi.nlm.nih.gov/pubmed/17409247", "http://www.ncbi.nlm.nih.gov/pubmed/7673463", "http://www.ncbi.nlm.nih.gov/pubmed/9023728", "http://www.ncbi.nlm.nih.gov/pubmed/15940501", "http://www.ncbi.nlm.nih.gov/pubmed/12814190", "http://www.ncbi.nlm.nih.gov/pubmed/20937306", "http://www.ncbi.nlm.nih.gov/pubmed/7472327", "http://www.ncbi.nlm.nih.gov/pubmed/21190007"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0392752", "o": "Localized"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0392752", "o": "http://linkedlifedata.com/resource/umls/label/A0428112"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0428112", "o": "LOCALIZED"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0392752", "o": "http://linkedlifedata.com/resource/umls/label/A7581226"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7581226", "o": "Localized"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0392752", "o": "http://linkedlifedata.com/resource/umls/label/A6833253"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A6833253", "o": "Localized"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0392752", "o": "http://linkedlifedata.com/resource/umls/label/A18656681"}], "ideal_answer": ["Unipolar brush cells (UBCs) are glutamatergic interneurons localized in granule cell regions of the cochlear nucleus and the vestibulocerebellum of cerebellum."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002477"], "type": "summary", "id": "58c67bf302b8c60953000026", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Cerebellar unipolar brush cells (UBCs) are glutamatergic interneurons that receive direct input from vestibular afferents in the form of a unique excitatory synapse on their dendritic brush. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17409247", "endSection": "abstract"}, {"offsetInBeginSection": 552, "offsetInEndSection": 677, "text": "Immunostained unipolar brush cells were observed in granule cell regions of the cochlear nucleus and the vestibulocerebellum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8821458", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Postsynaptic enrichment of Eps8 at dendritic shaft synapses of unipolar brush cells in rat cerebellum.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17223277", "endSection": "title"}, {"offsetInBeginSection": 749, "offsetInEndSection": 874, "text": "In cerebellum, unipolar brush cells (UBCs) were densely Eps8 immunopositive and granule cells were moderately immunostained. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17223277", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Postnatal differentiation of unipolar brush cells and mossy fiber-unipolar brush cell synapses in rat cerebellum.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11457596", "endSection": "title"}, {"offsetInBeginSection": 485, "offsetInEndSection": 725, "text": "Knowledge of the ultrastructure of the unipolar brush cell terminals and of the cellular identity of its postsynaptic targets is required to understand how unipolar brush cells contribute to information processing in the cerebellar circuit.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", "endSection": "abstract"}, {"offsetInBeginSection": 725, "offsetInEndSection": 1001, "text": "To investigate the unipolar brush cell axon and its targets, unipolar brush cells were patch-clamped in fresh parasagittal slices from rat cerebellar vermis with electrodes filled with Lucifer Yellow and Biocytin, and examined by confocal fluorescence and electron microscopy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Calretinin-immunoreactive unipolar brush cells in the developing human cerebellum.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16289944", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Unipolar brush cell: a potential feedforward excitatory interneuron of the cerebellum.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", "endSection": "title"}, {"offsetInBeginSection": 1100, "offsetInEndSection": 1160, "text": "Unipolar brush cells are also found in the cochlear nucleus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7978355", "endSection": "abstract"}, {"offsetInBeginSection": 1783, "offsetInEndSection": 1856, "text": "The unipolar brush cells reside nearly exclusively in the granular layer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7978355", "endSection": "abstract"}, {"offsetInBeginSection": 1109, "offsetInEndSection": 1249, "text": "In the monkey cerebellum, unipolar brush cells, localized in the granular layer, were heavily labeled, whereas Golgi cells were devoid of NG", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12655510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Unipolar brush cells (UBC) are small, glutamatergic neurons residing in the granular layer of the cerebellar cortex and the granule cell domain of the cochlear nuclear complex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20937306", "endSection": "abstract"}, {"offsetInBeginSection": 488, "offsetInEndSection": 727, "text": "Knowledge of the ultrastructure of the unipolar brush cell terminals and of the cellular identity of its postsynaptic targets is required to understand how unipolar brush cells contribute to information processing in the cerebellar circuit", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", "endSection": "abstract"}, {"offsetInBeginSection": 729, "offsetInEndSection": 1004, "text": "To investigate the unipolar brush cell axon and its targets, unipolar brush cells were patch-clamped in fresh parasagittal slices from rat cerebellar vermis with electrodes filled with Lucifer Yellow and Biocytin, and examined by confocal fluorescence and electron microscopy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", "endSection": "abstract"}, {"offsetInBeginSection": 320, "offsetInEndSection": 521, "text": "While granule cells express solely VGLUT1, there is no report about the VGLUT(s) of the unipolar brush cell (UBC), the second type of glutamatergic interneuron residing in the cerebellar granular layer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14614902", "endSection": "abstract"}, {"offsetInBeginSection": 484, "offsetInEndSection": 759, "text": "Large clusters of labeled nuclei consisting mainly of granule cells and calretinin-positive unipolar brush cells were present in the granular layer, whereas Purkinje cell nuclei were unlabeled, and labeled basket and stellate cell nuclei were scattered in the molecular layer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15940501", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Unipolar brush cells (UBCs) are a class of excitatory interneuron found in the granule cell layer of the vestibulocerebellum", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19409228", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "TBR2-immunopsitive unipolar brush cells are associated with ectopic zebrin II-immunoreactive Purkinje cell clusters in the cerebellum of scrambler mice", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21190007", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Glutamate receptor subunits at mossy fiber-unipolar brush cell synapses: light and electron microscopic immunocytochemical study in cerebellar cortex of rat and cat.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7673463", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Properties of transmission at a giant glutamatergic synapse in cerebellum: the mossy fiber-unipolar brush cell synapse.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7472327", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Metabotropic glutamate receptors are associated with non-synaptic appendages of unipolar brush cells in rat cerebellar cortex and cochlear nuclear complex.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9923978", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "The unipolar brush cells of the rat cerebellar cortex and cochlear nucleus are calretinin-positive: a study by light and electron microscopic immunocytochemistry.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7978355", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Cerebellar choline acetyltransferase positive mossy fibres and their granule and unipolar brush cell targets: a model for central cholinergic nicotinic neurotransmission.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9023728", "endSection": "title"}, {"offsetInBeginSection": 749, "offsetInEndSection": 873, "text": "In cerebellum, unipolar brush cells (UBCs) were densely Eps8 immunopositive and granule cells were moderately immunostained.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17223277", "endSection": "abstract"}, {"offsetInBeginSection": 1109, "offsetInEndSection": 1250, "text": "In the monkey cerebellum, unipolar brush cells, localized in the granular layer, were heavily labeled, whereas Golgi cells were devoid of NG.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12655510", "endSection": "abstract"}, {"offsetInBeginSection": 2164, "offsetInEndSection": 2415, "text": "The results indicate that synaptic excitation of unipolar brush cells by mossy fibers will drive a large population of granule cells, and thus will contribute a powerful form of distributed excitation within the basic circuit of the cerebellar cortex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", "endSection": "abstract"}, {"offsetInBeginSection": 227, "offsetInEndSection": 339, "text": "These neurons, here termed unipolar brush cells, are intermediate in size between granule cells and Golgi cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8300904", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Extraordinary synapses of the unipolar brush cell: an electron microscopic study in the rat cerebellum.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8059339", "endSection": "title"}, {"offsetInBeginSection": 488, "offsetInEndSection": 728, "text": "Knowledge of the ultrastructure of the unipolar brush cell terminals and of the cellular identity of its postsynaptic targets is required to understand how unipolar brush cells contribute to information processing in the cerebellar circuit.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "The unipolar brush cell: a neglected neuron of the mammalian cerebellar cortex.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8300904", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Postnatal differentiation of unipolar brush cells and mossy fiber-unipolar brush cell synapses in rat cerebellum.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11457596", "endSection": "title"}, {"offsetInBeginSection": 729, "offsetInEndSection": 1005, "text": "To investigate the unipolar brush cell axon and its targets, unipolar brush cells were patch-clamped in fresh parasagittal slices from rat cerebellar vermis with electrodes filled with Lucifer Yellow and Biocytin, and examined by confocal fluorescence and electron microscopy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10891606", "endSection": "abstract"}]}, {"body": "Which driver mutations have been identified for Diffuse Intrinsic Pontine Glioma (DIPG)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26727948", "http://www.ncbi.nlm.nih.gov/pubmed/27048880", "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "http://www.ncbi.nlm.nih.gov/pubmed/25182241", "http://www.ncbi.nlm.nih.gov/pubmed/27251074", "http://www.ncbi.nlm.nih.gov/pubmed/24297113", "http://www.ncbi.nlm.nih.gov/pubmed/25773741"], "ideal_answer": ["We found conservation of heterozygous K27M mutations in H3F3A (n\u2009=\u20094) or HIST1H3B (n\u2009=\u20093) across all primary, contiguous, and metastatic tumor sites in all DIPGs", "found conservation of heterozygous k27m mutations in h3f3a (n\u2009=\u20094) or hist1h3b (n\u2009=\u20093) across all primary , contiguous , and metastatic tumor sites in all dipgs . h3k27m ubiquitously-associated mutations involve alterations in tp53 cell-cycle (tp53/ppm1d) or specific growth factor pathways (acvr1/pik3r1) . reconstruction indicates histone 3 (h3) k27m--including h3.2k27m--mutations potentially arise first and are invariably associated with specific , high-fidelity obligate partners throughout the tumour and its spread , from diagnosis to end-stage disease , suggesting mutual need for tumorigenesis. . aberrations (n\u2009=\u20093 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved. . ", "We found conservation of heterozygous K27M mutations in H3F3A (n\u00e2\u0080\u0089=\u00e2\u0080\u00894) or HIST1H3B (n\u00e2\u0080\u0089=\u00e2\u0080\u00893) across all primary, contiguous, and metastatic tumor sites in all DIPGs. Evolutionary reconstruction indicates histone 3 (H3) K27M--including H3.2K27M--mutations potentially arise first and are invariably associated with specific, high-fidelity obligate partners throughout the tumour and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis. These H3K27M ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1).", "We found conservation of heterozygous K27M mutations in H3F3A (n=4) or HIST1H3B (n=3) across all primary, contiguous, and metastatic tumor sites in all DIPGs. ACVR1 (n=2), PIK3CA (n=2), FGFR1 (n=2), and MET (n=1) were also intra-tumorally conserved. TP53 aberrations (n=3 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved. Evolutionary reconstruction indicates histone 3 (H3) K27M--including H3.2K27M--mutations potentially arise first and are invariably associated with specific, high-fidelity obligate partners throughout the tumour and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis. These H3K27M ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1). ", "Recurrent mutations within the histone H3 genes H3F3A and HIST1H3B that convert K27 to methionine (H3K27M) and disrupt the global H3K27 methylation landscape and PRC2-dependent silencing, have recently been identified in pediatric high-grade gliomas including Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma multiforme (GBM; Type IV glioma). The spatial and temporal homogeneity of main driver mutations in DIPG implies they will be captured by limited biopsies and emphasizes the need to develop therapies specifically targeting obligate oncohistone partnerships. TP53 aberrations (n\u2009=\u20093 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved.Spatial conservation of prognostically-relevant and therapeutically-targetable somatic mutations in DIPG and mHGG contrasts the significant heterogeneity of driver mutations seen in adult HGG and supports uniform implementation of diagnostic biopsy in DIPG and mHGG to classify molecular risk groups and guide therapeutic strategy. Recently, a subset of these same mutations of ACVR1 have been identified in diffuse intrinsic pontine glioma (DIPG) tumors. Sequencing analysis showed c.83A>T mutations in the H3F3A or HIST1H3B gene in 77\u00a0% of our DIPG cohort. Protein profiling identified 2,305 unique proteins indicating distinct DIPG protein expression patterns compared to other pediatric brain tumors. Two distinct subgroups of DIPG were identified.", "We found conservation of heterozygous K27M mutations in H3F3A (n\u2009=\u20094) or HIST1H3B (n\u2009=\u20093) across all primary, contiguous, and metastatic tumor sites in all DIPGs ACVR1 (n\u2009=\u20092), PIK3CA (n\u2009=\u20092), FGFR1 (n\u2009=\u20092), and MET (n\u2009=\u20091) were also intra-tumorally conserved  TP53 aberrations (n\u2009=\u20093 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved.", "Evolutionary reconstruction indicates histone 3 (H3) K27M--including H3.2K27M--mutations potentially arise first and are invariably associated with specific, high-fidelity obligate partners throughout the tumour and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis. Conservation of heterozygous K27M mutations in H3F3A (n\u2009=\u20094) or HIST1H3B (n\u2009=\u20093) was observed across all primary, contiguous, and metastatic tumor sites in all DIPGs. ACVR1 (n\u2009=\u20092), PIK3CA (n\u2009=\u20092), FGFR1 (n\u2009=\u20092), and MET (n\u2009=\u20091) were also intra-tumorally conserved.  TP53 aberrations (n\u2009=\u20093 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved.", "We found conservation of heterozygous K27M mutations in H3F3A (n\u2009=\u20094) or HIST1H3B (n\u2009=\u20093) across all primary, contiguous, and metastatic tumor sites in all DIPGs  TP53 aberrations (n\u2009=\u20093 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved. These H3K27M ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1).", "We found conservation of heterozygous K27M mutations in H3F3A (n=4) or HIST1H3B (n=3) across all primary, contiguous, and metastatic tumor sites in all DIPGs. Evolutionary reconstruction indicates histone 3 (H3) K27M--including H3.2K27M--mutations potentially arise first and are invariably associated with specific, high-fidelity obligate partners throughout the tumour and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis. These H3K27M ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1). TP53 aberrations (n=3 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved. ACVR1 (n=2), PIK3CA (n=2), FGFR1 (n=2), and MET (n=1) were also intra-tumorally conserved. ", "We found conservation of heterozygous K27M mutations in H3F3A (n\u2009=\u20094) or HIST1H3B (n\u2009=\u20093) across all primary, contiguous, and metastatic tumor sites in all DIPGs These H3K27M ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1). "], "type": "list", "id": "58add1d79ef3c34033000008", "snippets": [{"offsetInBeginSection": 1101, "offsetInEndSection": 1262, "text": "We found conservation of heterozygous K27M mutations in H3F3A (n\u2009=\u20094) or HIST1H3B (n\u2009=\u20093) across all primary, contiguous, and metastatic tumor sites in all DIPGs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26727948", "endSection": "abstract"}, {"offsetInBeginSection": 1264, "offsetInEndSection": 1361, "text": "ACVR1 (n\u2009=\u20092), PIK3CA (n\u2009=\u20092), FGFR1 (n\u2009=\u20092), and MET (n\u2009=\u20091) were also intra-tumorally conserved", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26727948", "endSection": "abstract"}, {"offsetInBeginSection": 1549, "offsetInEndSection": 1691, "text": " TP53 aberrations (n\u2009=\u20093 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26727948", "endSection": "abstract"}, {"offsetInBeginSection": 298, "offsetInEndSection": 604, "text": "Evolutionary reconstruction indicates histone 3 (H3) K27M--including H3.2K27M--mutations potentially arise first and are invariably associated with specific, high-fidelity obligate partners throughout the tumour and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048880", "endSection": "abstract"}, {"offsetInBeginSection": 605, "offsetInEndSection": 755, "text": "These H3K27M ubiquitously-associated mutations involve alterations in TP53 cell-cycle (TP53/PPM1D) or specific growth factor pathways (ACVR1/PIK3R1). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048880", "endSection": "abstract"}, {"offsetInBeginSection": 397, "offsetInEndSection": 648, "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", "endSection": "abstract"}, {"offsetInBeginSection": 1238, "offsetInEndSection": 1379, "text": "Moreover, in diffuse intrinsic pontine gliomas (DIPG), recurrent somatic mutations of ACVR1 were found in association with HIST1H3B mutations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182241", "endSection": "abstract"}, {"offsetInBeginSection": 400, "offsetInEndSection": 650, "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "endSection": "title"}, {"offsetInBeginSection": 318, "offsetInEndSection": 668, "text": "Recurrent mutations within the histone H3 genes H3F3A and HIST1H3B that convert K27 to methionine (H3K27M) and disrupt the global H3K27 methylation landscape and PRC2-dependent silencing, have recently been identified in pediatric high-grade gliomas including Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma multiforme (GBM; Type IV glioma).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27251074", "endSection": "abstract"}, {"offsetInBeginSection": 1137, "offsetInEndSection": 1239, "text": "Sequencing analysis showed c.83A>T mutations in the H3F3A or HIST1H3B gene in 77\u00a0% of our DIPG cohort.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24297113", "endSection": "abstract"}, {"offsetInBeginSection": 400, "offsetInEndSection": 651, "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "endSection": "title"}]}, {"body": "Does Jarid2 play a role in early embryo development?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20075857", "http://www.ncbi.nlm.nih.gov/pubmed/26190104", "http://www.ncbi.nlm.nih.gov/pubmed/17521633", "http://www.ncbi.nlm.nih.gov/pubmed/24374312"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1416528", "o": "JARID2"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_5139323833330020", "o": "JARID2"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1416528", "o": "http://linkedlifedata.com/resource/umls/label/A20738817"}], "ideal_answer": ["Yes. Jarid2 coordinates Nanog expression and PCP/Wnt signaling required for efficient ESC differentiation and early embryo development."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0009790", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D047108", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005314", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063146"], "type": "yesno", "id": "5883781b2305cd7e21000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Jarid2 Coordinates Nanog Expression and PCP/Wnt Signaling Required for Efficient ESC Differentiation and Early Embryo Development", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26190104", "endSection": "title"}, {"offsetInBeginSection": 107, "offsetInEndSection": 1159, "text": "Unlike other PRC2-deficient embryonic stem cells (ESCs), however, Jarid2-deficient ESCs show a severe differentiation block, altered colony morphology, and distinctive patterns of deregulated gene expression. Here, we show that Jarid2(-/-) ESCs express constitutively high levels of Nanog but reduced PCP signaling components Wnt9a, Prickle1, and Fzd2 and lowered \u03b2-catenin activity. Depletion of Wnt9a/Prickle1/Fzd2 from wild-type ESCs or overexpression of Nanog largely phenocopies these cellular defects. Co-culture of Jarid2(-/-) with wild-type ESCs restores variable Nanog expression and \u03b2-catenin activity and can partially rescue the differentiation block of mutant cells. In addition, we show that ESCs lacking Jarid2 or Wnt9a/Prickle1/Fzd2 or overexpressing Nanog induce multiple ICM formation when injected into normal E3.5 blastocysts. These data describe a previously unrecognized role for Jarid2 in regulating a core pluripotency and Wnt/PCP signaling circuit that is important for ESC differentiation and for pre-implantation development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26190104", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Jarid2 Coordinates Nanog Expression and PCP/Wnt Signaling Required for Efficient ESC Differentiation and Early Embryo Development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26190104", "endSection": "title"}, {"offsetInBeginSection": 909, "offsetInEndSection": 1075, "text": "Consistent with an essential role for PcG proteins in early development, we demonstrate that JARID2 is required for the differentiation of mouse embryonic stem cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20075857", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Jumonij (JMJ)/Jarid2 plays important roles in embryonic development and functions as a transcriptional repressor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17521633", "endSection": "abstract"}, {"offsetInBeginSection": 1083, "offsetInEndSection": 1293, "text": "Thus, these results demonstrate that JARID2 is essential for the binding of PcG proteins to target genes and, consistent with this, for the proper differentiation of embryonic stem cells and normal development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20075857", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "JARID2 is an accessory component of Polycomb repressive complex-2 (PRC2) required for the differentiation of embryonic stem cells (ESCs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24374312", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Jarid2 Coordinates Nanog Expression and PCP/Wnt Signaling Required for Efficient ESC Differentiation and Early Embryo Development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26190104", "endSection": "title"}, {"offsetInBeginSection": 954, "offsetInEndSection": 1160, "text": "These data describe a previously unrecognized role for Jarid2 in regulating a core pluripotency and Wnt/PCP signaling circuit that is important for ESC differentiation and for pre-implantation development..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26190104", "endSection": "abstract"}]}, {"body": "Is PUVA therapy indicated for eczema treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3903677", "http://www.ncbi.nlm.nih.gov/pubmed/23420314", "http://www.ncbi.nlm.nih.gov/pubmed/14699368", "http://www.ncbi.nlm.nih.gov/pubmed/17254029", "http://www.ncbi.nlm.nih.gov/pubmed/708596", "http://www.ncbi.nlm.nih.gov/pubmed/10321515", "http://www.ncbi.nlm.nih.gov/pubmed/19292787", "http://www.ncbi.nlm.nih.gov/pubmed/9640882", "http://www.ncbi.nlm.nih.gov/pubmed/18712324", "http://www.ncbi.nlm.nih.gov/pubmed/15611423", "http://www.ncbi.nlm.nih.gov/pubmed/7662576", "http://www.ncbi.nlm.nih.gov/pubmed/17673386", "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "http://www.ncbi.nlm.nih.gov/pubmed/8088142", "http://www.ncbi.nlm.nih.gov/pubmed/22738245", "http://www.ncbi.nlm.nih.gov/pubmed/11499537", "http://www.ncbi.nlm.nih.gov/pubmed/8445063"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0034172", "o": "PUVA Therapy"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0034172", "o": "http://linkedlifedata.com/resource/umls/label/A0444272"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0444272", "o": "PUVA therapy"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1704892", "o": "PUVA therapy"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0034172", "o": "http://linkedlifedata.com/resource/umls/label/A0107279"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0107279", "o": "Psoralen Ultraviolet A Therapy"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0034172", "o": "http://linkedlifedata.com/resource/umls/label/A20221619"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A20221619", "o": "Psoralen Ultraviolet A Therapy"}], "ideal_answer": ["Yes, PUVA (psoralen plus UVA) therapy is effective for eczema treatment and has relatively few side effects."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004485", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011701"], "type": "yesno", "id": "58bfe70e02b8c60953000019", "snippets": [{"offsetInBeginSection": 719, "offsetInEndSection": 960, "text": "With bath PUVA treatment, the best results were found in patients with hyperkeratotic eczema (17/22; 77% good clinical response) followed by patients with palmoplantar psoriasis (26/41; 63%) and patients with dyshidrotic eczema (8/16; 50%). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22738245", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 148, "text": "Both oral and bath PUVA with 8-methoxypsoralen (8-MOP) have been shown to be effective in the treatment of chronic palmoplantar eczema. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", "endSection": "abstract"}, {"offsetInBeginSection": 1175, "offsetInEndSection": 1290, "text": "Oral PUVA is preferable for patients with hyperkeratotic eczema and bath PUVA for patients with dyshidrotic eczema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 301, "text": "Treatment of hand eczema is dominated by the administration of topical glucocorticosteriods. If topical treatment fails, the best second-line option is ultraviolet (UV) therapy alone or as combination therapy. UVB and PUVA (psoralen plus UVA) therapy is effective and has relatively few side effects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18712324", "endSection": "abstract"}, {"offsetInBeginSection": 111, "offsetInEndSection": 301, "text": "Although local PUVA has been proven to be effective in the treatment of chronic hand eczema, little is known about the efficacy and safety of local narrowband UVB (TL-01) for this condition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17254029", "endSection": "abstract"}, {"offsetInBeginSection": 1869, "offsetInEndSection": 2015, "text": "Local narrowband UVB phototherapy regimen is as effective as paint-PUVA therapy in patients with chronic hand eczema of dry and dyshidrotic types.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17254029", "endSection": "abstract"}, {"offsetInBeginSection": 1631, "offsetInEndSection": 1859, "text": "Smoking is likely to be a reason for the failure of bath-PUVA therapy in the treatment of chronic palmoplantar eczema, in particular regarding smokers with eczema of the dyshidrotic type where no complete remission was achieved.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Treatment of chronic palmoplantar eczema with local bath-PUVA therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Bath-PUVA therapy has been described as successful treatment for palmoplantar eczema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Systemic PUVA therapy may be useful in the treatment of chronic palmoplantar eczema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "A new psoralen-containing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque-type psoriasis, and hyperkeratotic eczema.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7662576", "endSection": "title"}, {"offsetInBeginSection": 829, "offsetInEndSection": 1076, "text": "These results indicate that topical PUVA therapy with psoralen in aqueous gel is a useful therapeutic modality for treatment of psoriasis patients, and patients with recalcitrant dermatoses such as palmoplantar psoriasis and hyperkeratotic eczema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7662576", "endSection": "abstract"}, {"offsetInBeginSection": 249, "offsetInEndSection": 458, "text": "In order to evaluate environmental influences possibly having an impact on the efficacy of this therapy, smokers and non-smokers suffering from palmoplantar eczema treated with bath-PUVA therapy were compared.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Does smoking influence the efficacy of bath-PUVA therapy in chronic palmoplantar eczema?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "endSection": "title"}, {"offsetInBeginSection": 158, "offsetInEndSection": 210, "text": "PUVA therapy caused acute aggravation of the eczema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8088142", "endSection": "abstract"}, {"offsetInBeginSection": 1073, "offsetInEndSection": 1290, "text": "Hyperkeratotic eczema cleared significantly better with oral than with bath PUVA (P=0.03).CONCLUSION: Oral PUVA is preferable for patients with hyperkeratotic eczema and bath PUVA for patients with dyshidrotic eczema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "BACKGROUND: Systemic PUVA therapy may be useful in the treatment of chronic palmoplantar eczema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}, {"offsetInBeginSection": 835, "offsetInEndSection": 1082, "text": "These results indicate that topical PUVA therapy with psoralen in aqueous gel is a useful therapeutic modality for treatment of psoriasis patients, and patients with recalcitrant dermatoses such as palmoplantar psoriasis and hyperkeratotic eczema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7662576", "endSection": "abstract"}, {"offsetInBeginSection": 819, "offsetInEndSection": 1026, "text": "Vitiligo (60.9%) was the commonest skin disorder treated with PUVA, followed by psoriasis (20.9%), endogenous eczema (11.3%), mycosis fungoides (3.5%), lichen amyloidosis (2.6%) and prurigo nodularis (0.9%).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11499537", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 75, "text": "bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "A 36-year-old female patient was treated with PUVA for dyshidrotic eczema that had not shown sufficient response to topical therapy over the previous months.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8088142", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "BACKGROUND: Both oral and bath PUVA with 8-methoxypsoralen (8-MOP) have been shown to be effective in the treatment of chronic palmoplantar eczema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", "endSection": "abstract"}, {"offsetInBeginSection": 909, "offsetInEndSection": 1179, "text": "One patient with hand eczema consistently had detectable 8-MOP levels 1 hour after topical PUVA treatments.CONCLUSION: This report indicates that there is minimal, if any, systemic absorption of 8-MOP after topical PUVA treatment of patients with palmoplantar psoriasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8445063", "endSection": "abstract"}, {"offsetInBeginSection": 1608, "offsetInEndSection": 1963, "text": "In the narrowband UVB-treated side, the tolerance of all the patients to the treatment was good all patients well-tolerated the treatment with the exception of mild xerosis that responded to topical emollients.Local narrowband UVB phototherapy regimen is as effective as paint-PUVA therapy in patients with chronic hand eczema of dry and dyshidrotic types", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17254029", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Bath-PUVA therapy has been described as successful treatment for palmoplantar eczema", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "endSection": "abstract"}, {"offsetInBeginSection": 1648, "offsetInEndSection": 1875, "text": "Smoking is likely to be a reason for the failure of bath-PUVA therapy in the treatment of chronic palmoplantar eczema, in particular regarding smokers with eczema of the dyshidrotic type where no complete remission was achieved", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Systemic PUVA therapy may be useful in the treatment of chronic palmoplantar eczema", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}, {"offsetInBeginSection": 253, "offsetInEndSection": 710, "text": "However, few data are available on the effectiveness of local bath-PUVA therapy in palmoplantar eczema.Our purpose was to assess the effectiveness of local bath-PUVA therapy in 28 patients with chronic palmar or plantar eczema or both who were resistant to conventional topical treatment.After fungal or bacterial infection had been excluded in all patients, hands or feet or both were soaked for 15 minutes in warm water containing 1 mg/L 8-methoxypsoralen", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}, {"offsetInBeginSection": 1333, "offsetInEndSection": 1504, "text": "No phototoxic reactions were observed.Local bath-PUVA therapy is of value in the management of chronic palmoplantar eczema resistant to standard modes of topical treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Treatment of chronic palmoplantar eczema with local bath-PUVA therapy", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Bath-PUVA therapy has been described as successful treatment for palmoplantar eczema. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "endSection": "abstract"}, {"offsetInBeginSection": 1642, "offsetInEndSection": 1870, "text": "Smoking is likely to be a reason for the failure of bath-PUVA therapy in the treatment of chronic palmoplantar eczema, in particular regarding smokers with eczema of the dyshidrotic type where no complete remission was achieved.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "endSection": "abstract"}, {"offsetInBeginSection": 369, "offsetInEndSection": 566, "text": "OBJECTIVE: Our purpose was to assess the effectiveness of local bath-PUVA therapy in 28 patients with chronic palmar or plantar eczema or both who were resistant to conventional topical treatment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}, {"offsetInBeginSection": 1416, "offsetInEndSection": 1563, "text": "CONCLUSION: Local bath-PUVA therapy is of value in the management of chronic palmoplantar eczema resistant to standard modes of topical treatment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 45, "text": "Topical PUVA therapy for chronic hand eczema.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9640882", "endSection": "title"}, {"offsetInBeginSection": 253, "offsetInEndSection": 711, "text": "However, few data are available on the effectiveness of local bath-PUVA therapy in palmoplantar eczema.Our purpose was to assess the effectiveness of local bath-PUVA therapy in 28 patients with chronic palmar or plantar eczema or both who were resistant to conventional topical treatment.After fungal or bacterial infection had been excluded in all patients, hands or feet or both were soaked for 15 minutes in warm water containing 1 mg/L 8-methoxypsoralen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}, {"offsetInBeginSection": 1333, "offsetInEndSection": 1505, "text": "No phototoxic reactions were observed.Local bath-PUVA therapy is of value in the management of chronic palmoplantar eczema resistant to standard modes of topical treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}, {"offsetInBeginSection": 1648, "offsetInEndSection": 1876, "text": "Smoking is likely to be a reason for the failure of bath-PUVA therapy in the treatment of chronic palmoplantar eczema, in particular regarding smokers with eczema of the dyshidrotic type where no complete remission was achieved.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "endSection": "abstract"}, {"offsetInBeginSection": 86, "offsetInEndSection": 250, "text": "However, our own observations showed that patients with palmoplantar eczema of the dyshidrotic or hyperkeratotic type responded only partially to bath-PUVA therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "endSection": "abstract"}, {"offsetInBeginSection": 1608, "offsetInEndSection": 1964, "text": "In the narrowband UVB-treated side, the tolerance of all the patients to the treatment was good all patients well-tolerated the treatment with the exception of mild xerosis that responded to topical emollients.Local narrowband UVB phototherapy regimen is as effective as paint-PUVA therapy in patients with chronic hand eczema of dry and dyshidrotic types.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17254029", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14699368", "endSection": "title"}, {"offsetInBeginSection": 1374, "offsetInEndSection": 1558, "text": "No phototoxic reactions were observed.CONCLUSION: Local bath-PUVA therapy is of value in the management of chronic palmoplantar eczema resistant to standard modes of topical treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}, {"offsetInBeginSection": 835, "offsetInEndSection": 1083, "text": "These results indicate that topical PUVA therapy with psoralen in aqueous gel is a useful therapeutic modality for treatment of psoriasis patients, and patients with recalcitrant dermatoses such as palmoplantar psoriasis and hyperkeratotic eczema..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7662576", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Treatment of chronic palmoplantar eczema with local bath-PUVA therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "title"}, {"offsetInBeginSection": 1132, "offsetInEndSection": 1248, "text": "Oral PUVA is preferable for patients with hyperkeratotic eczema and bath PUVA for patients with dyshidrotic eczema..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292787", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Does smoking influence the efficacy of bath-PUVA therapy in chronic palmoplantar eczema?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "endSection": "title"}, {"offsetInBeginSection": 1375, "offsetInEndSection": 1509, "text": "Local bath-PUVA therapy is of value in the management of chronic palmoplantar eczema resistant to standard modes of topical treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}, {"offsetInBeginSection": 253, "offsetInEndSection": 356, "text": "However, few data are available on the effectiveness of local bath-PUVA therapy in palmoplantar eczema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "A new psoralen-containing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque-type psoriasis, and hyperkeratotic eczema.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7662576", "endSection": "title"}, {"offsetInBeginSection": 1642, "offsetInEndSection": 1871, "text": "Smoking is likely to be a reason for the failure of bath-PUVA therapy in the treatment of chronic palmoplantar eczema, in particular regarding smokers with eczema of the dyshidrotic type where no complete remission was achieved..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721861", "endSection": "abstract"}, {"offsetInBeginSection": 114, "offsetInEndSection": 445, "text": "In order to investigate the effectiveness of topical PUVA-bath therapy (PUVA-soak therapy) on chronic palmoplantar dermatoses, 30 patients with plaque-type psoriasis, pustular psoriasis, endogenous eczema, dyshidrotic eczema and hyperkeratotic dermatitis of the palms and soles were treated over 8 weeks with PUVA-soak using 8-MOP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10321515", "endSection": "abstract"}, {"offsetInBeginSection": 357, "offsetInEndSection": 542, "text": "Our purpose was to assess the effectiveness of local bath-PUVA therapy in 28 patients with chronic palmar or plantar eczema or both who were resistant to conventional topical treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9146535", "endSection": "abstract"}]}, {"body": "What is DECKO?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26493208"], "ideal_answer": ["DECKO (Double Excision CRISPR Knockout) is a dual CRISPR tool, which is cloned using a single starting oligonucleotide, thereby affording simplicity and scalability to CRISPR knockout studies of non-coding genomic elements, including long non-coding RNAs."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064113"], "type": "summary", "id": "58837ba62305cd7e21000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "DECKO: Single-oligo, dual-CRISPR deletion of genomic elements including long non-coding RNAs", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "title"}, {"offsetInBeginSection": 1213, "offsetInEndSection": 1443, "text": "We present a dual CRISPR tool, DECKO, which is cloned using a single starting oligonucleotide, thereby affording simplicity and scalability to CRISPR knockout studies of non-coding genomic elements, including long non-coding RNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "abstract"}, {"offsetInBeginSection": 132, "offsetInEndSection": 559, "text": " We present a vector system adapted for this purpose called DECKO (Double Excision CRISPR Knockout), which applies a simple two-step cloning to generate lentiviral vectors expressing two guide RNAs (gRNAs) simultaneously. The key feature of DECKO is its use of a single 165 bp starting oligonucleotide carrying the variable sequences of both gRNAs, making it fully scalable from single-locus studies to complex library cloning.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "DECKO: Single-oligo, dual-CRISPR deletion of genomic elements including long non-coding RNAs.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "title"}, {"offsetInBeginSection": 120, "offsetInEndSection": 340, "text": "We present a vector system adapted for this purpose called DECKO (Double Excision CRISPR Knockout), which applies a simple two-step cloning to generate lentiviral vectors expressing two guide RNAs (gRNAs) simultaneously.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "abstract"}, {"offsetInBeginSection": 340, "offsetInEndSection": 545, "text": "The key feature of DECKO is its use of a single 165 bp starting oligonucleotide carrying the variable sequences of both gRNAs, making it fully scalable from single-locus studies to complex library cloning.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "abstract"}, {"offsetInBeginSection": 121, "offsetInEndSection": 340, "text": "We present a vector system adapted for this purpose called DECKO (Double Excision CRISPR Knockout), which applies a simple two-step cloning to generate lentiviral vectors expressing two guide RNAs (gRNAs) simultaneously", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "abstract"}, {"offsetInBeginSection": 342, "offsetInEndSection": 748, "text": "The key feature of DECKO is its use of a single 165 bp starting oligonucleotide carrying the variable sequences of both gRNAs, making it fully scalable from single-locus studies to complex library cloning.We apply DECKO to deleting the promoters of one protein-coding gene and two oncogenic lncRNAs, UCA1 and the highly-expressed MALAT1, focus of many previous studies employing RNA interference approaches", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "abstract"}, {"offsetInBeginSection": 1062, "offsetInEndSection": 1408, "text": "These clones have reductions in steady-state MALAT1 RNA levels of up to 98 % and display reduced proliferation rates.We present a dual CRISPR tool, DECKO, which is cloned using a single starting oligonucleotide, thereby affording simplicity and scalability to CRISPR knockout studies of non-coding genomic elements, including long non-coding RNAs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "abstract"}, {"offsetInBeginSection": 121, "offsetInEndSection": 341, "text": "We present a vector system adapted for this purpose called DECKO (Double Excision CRISPR Knockout), which applies a simple two-step cloning to generate lentiviral vectors expressing two guide RNAs (gRNAs) simultaneously.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "abstract"}, {"offsetInBeginSection": 342, "offsetInEndSection": 749, "text": "The key feature of DECKO is its use of a single 165 bp starting oligonucleotide carrying the variable sequences of both gRNAs, making it fully scalable from single-locus studies to complex library cloning.We apply DECKO to deleting the promoters of one protein-coding gene and two oncogenic lncRNAs, UCA1 and the highly-expressed MALAT1, focus of many previous studies employing RNA interference approaches.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "abstract"}, {"offsetInBeginSection": 1062, "offsetInEndSection": 1409, "text": "These clones have reductions in steady-state MALAT1 RNA levels of up to 98 % and display reduced proliferation rates.We present a dual CRISPR tool, DECKO, which is cloned using a single starting oligonucleotide, thereby affording simplicity and scalability to CRISPR knockout studies of non-coding genomic elements, including long non-coding RNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "DECKO: Single-oligo, dual-CRISPR deletion of genomic elements including long non-coding RNAs.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "title"}, {"offsetInBeginSection": 1181, "offsetInEndSection": 1412, "text": "We present a dual CRISPR tool, DECKO, which is cloned using a single starting oligonucleotide, thereby affording simplicity and scalability to CRISPR knockout studies of non-coding genomic elements, including long non-coding RNAs..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493208", "endSection": "abstract"}]}, {"body": "List genes associated with hypolipidemia.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22247256", "http://www.ncbi.nlm.nih.gov/pubmed/26546829", "http://www.ncbi.nlm.nih.gov/pubmed/24751931", "http://www.ncbi.nlm.nih.gov/pubmed/22062970"], "ideal_answer": ["PCSK9\nAPOB \nANGPTL3\nANGPTL4\nMTP"], "type": "list", "id": "58dfd83a6fddd3e83e000003", "snippets": [{"offsetInBeginSection": 622, "offsetInEndSection": 788, "text": " Conversely familial hypobetalipoproteinemia is caused by inactivation of the PCSK9 gene which increases the number of LDL receptors and decreases plasma cholesterol.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546829", "endSection": "abstract"}, {"offsetInBeginSection": 789, "offsetInEndSection": 985, "text": "Mutations in the genes APOB, and ANGPTL3 and ANGPTL4 (that encode angiopoietin-like proteins which inhibit lipoprotein lipase activity) can further cause low levels of apoB containing lipoproteins", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546829", "endSection": "abstract"}, {"offsetInBeginSection": 19, "offsetInEndSection": 329, "text": "Several mutations in the apoB, proprotein convertase subtilisin/kexin type 9 (PCSK9), and MTP genes result in low or absent levels of apoB and LDL-cholesterol in plasma, which cause familial hypobetalipoproteinemia and abetalipoproteinemia. Mutations in the ANGPTL3 gene cause familial combined hypolipidemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24751931", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 222, "text": "Mutations of the ANGPTL3 gene have been associated with a novel form of primary hypobetalipoproteinemia, the combined hypolipidemia (cHLP), characterized by low total cholesterol and low HDL-cholesterol levels. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247256", "endSection": "abstract"}, {"offsetInBeginSection": 1189, "offsetInEndSection": 1437, "text": "These results demonstrated that in a cohort of subjects with severe primary hypobetalipoproteinemia the prevalence of ANGPTL3 gene mutations responsible for a combined hypolipidemia phenotype is about 10%, whereas mutations of APOB gene are absent.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22247256", "endSection": "abstract"}, {"offsetInBeginSection": 142, "offsetInEndSection": 354, "text": "Angptl3 knockout mice have marked hypolipidemia, and heterozygous carriers of ANGPLT3, loss-of-function mutations were found among individuals in the lowest quartile of plasma triglycerides in population studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22062970", "endSection": "abstract"}, {"offsetInBeginSection": 1703, "offsetInEndSection": 2022, "text": "Complete ANGPTL3 deficiency caused by loss-of-function mutations of ANGPTL3 is associated with a recessive hypolipidemia characterized by a reduction of apolipoprotein B and apolipoprotein A-I-containing lipoproteins, changes in subclasses of high-density lipoprotein, and reduced cholesterol efflux potential of serum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22062970", "endSection": "abstract"}]}, {"body": "What is the enzymatic activity of PARL?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17938163", "http://www.ncbi.nlm.nih.gov/pubmed/21415861", "http://www.ncbi.nlm.nih.gov/pubmed/21355049", "http://www.ncbi.nlm.nih.gov/pubmed/19859837"], "ideal_answer": ["the mitochondrial protease presenilin-associated rhomboid-like (PARL). Rhomboids are a recently discovered family of widely distributed intramembrane serine proteases."], "type": "factoid", "id": "58dfe6b56fddd3e83e000004", "snippets": [{"offsetInBeginSection": 743, "offsetInEndSection": 970, "text": "Here we demonstrate that the mitochondrial protease presenilin-associated rhomboid-like (PARL) can affect the proteolytic processing of PINK1 and that normal PINK1 localization and stability requires PARL's catalytic activity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21355049", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "The mitochondrial rhomboid protease Parl governs apoptosis, morphology, metabolism and might be implicated in Parkinson's disease, but the structural basis of its activity and complex regulation remain unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21415861", "endSection": "abstract"}, {"offsetInBeginSection": 43, "offsetInEndSection": 248, "text": ". In this study, we evaluated the mRNA levels of presenilins-associated rhomboid-like protein (PARL) and mitochondrial content and enzyme activity from skeletal muscle isolated from insulin-resistant rats.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19859837", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Rhomboids are a recently discovered family of widely distributed intramembrane serine proteases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17938163", "endSection": "abstract"}]}, {"body": "Do brown fat cells produce heat?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23834768", "http://www.ncbi.nlm.nih.gov/pubmed/26910308", "http://www.ncbi.nlm.nih.gov/pubmed/22796012", "http://www.ncbi.nlm.nih.gov/pubmed/21196229", "http://www.ncbi.nlm.nih.gov/pubmed/23818608", "http://www.ncbi.nlm.nih.gov/pubmed/6148836", "http://www.ncbi.nlm.nih.gov/pubmed/3083882", "http://www.ncbi.nlm.nih.gov/pubmed/26496384", "http://www.ncbi.nlm.nih.gov/pubmed/26322018", "http://www.ncbi.nlm.nih.gov/pubmed/15058310", "http://www.ncbi.nlm.nih.gov/pubmed/6819159", "http://www.ncbi.nlm.nih.gov/pubmed/21982742", "http://www.ncbi.nlm.nih.gov/pubmed/24567786", "http://www.ncbi.nlm.nih.gov/pubmed/27528872", "http://www.ncbi.nlm.nih.gov/pubmed/8042786", "http://www.ncbi.nlm.nih.gov/pubmed/25642708", "http://www.ncbi.nlm.nih.gov/pubmed/962510", "http://www.ncbi.nlm.nih.gov/pubmed/27528697", "http://www.ncbi.nlm.nih.gov/pubmed/27552974", "http://www.ncbi.nlm.nih.gov/pubmed/1550210", "http://www.ncbi.nlm.nih.gov/pubmed/25068090", "http://www.ncbi.nlm.nih.gov/pubmed/2039657", "http://www.ncbi.nlm.nih.gov/pubmed/21123942", "http://www.ncbi.nlm.nih.gov/pubmed/9277366", "http://www.ncbi.nlm.nih.gov/pubmed/24129212", "http://www.ncbi.nlm.nih.gov/pubmed/5262992", "http://www.ncbi.nlm.nih.gov/pubmed/24046370", "http://www.ncbi.nlm.nih.gov/pubmed/26912151", "http://www.ncbi.nlm.nih.gov/pubmed/6315457", "http://www.ncbi.nlm.nih.gov/pubmed/541897", "http://www.ncbi.nlm.nih.gov/pubmed/25466254", "http://www.ncbi.nlm.nih.gov/pubmed/16594742", "http://www.ncbi.nlm.nih.gov/pubmed/26749900", "http://www.ncbi.nlm.nih.gov/pubmed/22654830", "http://www.ncbi.nlm.nih.gov/pubmed/19641492"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0018837", "o": "Heat"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0018837", "o": "http://linkedlifedata.com/resource/umls/label/A0066521"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0066521", "o": "Heat"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0018837", "o": "http://linkedlifedata.com/resource/umls/label/A18591807"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18591807", "o": "heat"}], "ideal_answer": ["Yes, brown fat cells produce heat."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002477", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002001", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052437", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006359", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005223"], "type": "yesno", "id": "58ca906a02b8c6095300002e", "snippets": [{"offsetInBeginSection": 271, "offsetInEndSection": 512, "text": "WAT and BAT are both involved in energy balance. WAT is mainly involved in the storage and mobilization of energy in the form of triglycerides, whereas BAT specializes in dissipating energy as heat during cold- or diet-induced thermogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24567786", "endSection": "abstract"}, {"offsetInBeginSection": 76, "offsetInEndSection": 288, "text": "Because brown adipose\u00a0tissue (BAT) dissipates energy in the form of heat, increasing energy expenditure by augmenting BAT-mediated thermogenesis may represent an approach to counter obesity and its complications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25466254", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "Classic brown fat and inducible beige fat both dissipate chemical energy in the form of heat through the actions of mitochondrial uncoupling protein 1. This nonshivering thermogenesis is crucial for mammals as a defense against cold and obesity/diabetes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818608", "endSection": "abstract"}, {"offsetInBeginSection": 105, "offsetInEndSection": 245, "text": "Mitochondrial uncoupling protein 1 in brown fat cells produces heat by dissipating the energy generated by fatty acid and glucose oxidation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22654830", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 36, "text": "Brown fat biology and thermogenesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196229", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Brown fat (brown adipose tissue, BAT) primary function is to produce heat. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196229", "endSection": "abstract"}, {"offsetInBeginSection": 165, "offsetInEndSection": 353, "text": "Brown fat cells were classified into 6 types: Type 1 cells are fat-depleted cells filled with granular cytoplasm and are believed to be produced after oxidation of fat for heat production.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", "endSection": "abstract"}, {"offsetInBeginSection": 1226, "offsetInEndSection": 1487, "text": "Calorimetric measurements from cell suspensions showed that ATP increased basal heat production of isolated brown fat cells by approximately 40% but had no effect on the greater than fivefold increase in heat production seen with maximal adrenergic stimulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9277366", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Classic brown fat and inducible beige fat both dissipate chemical energy in the form of heat through the actions of mitochondrial uncoupling protein 1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818608", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "Brown adipocytes oxidize fatty acids to produce heat in response to cold or to excessive energy intake; stimulation of brown fat development and function may thus counteract obesity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21982742", "endSection": "abstract"}, {"offsetInBeginSection": 1032, "offsetInEndSection": 1285, "text": "The occurrence of Types 1 and/or 6 cells that has been revealed in 65 out of the total 180 samples (36%), suggests that the oxidation of fat for the thermogenesis proceeds in the brown fat tissue and that brown fat cells partially undergo fat depletion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 354, "text": "Brown fat cells were classified into 6 types: Type 1 cells are fat-depleted cells filled with granular cytoplasm and are believed to be produced after oxidation of fat for heat production.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", "endSection": "abstract"}, {"offsetInBeginSection": 126, "offsetInEndSection": 333, "text": "In response to cold, both classical brown fat and the newly identified \"beige\" or \"brite\" cells are activated by \u03b2-adrenergic signaling and catabolize stored lipids and carbohydrates to produce heat via UCP1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26322018", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "The ability of brown adipocytes (fat cells) to dissipate energy as heat shows great promise for the treatment of obesity and other metabolic disorders", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26496384", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Inappropriate heat dissipation ignites brown fat thermogenesis in mice with a mutant thyroid hormone receptor \u03b11", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24046370", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "Brown fat and vascular heat dissipation: The new cautionary tail", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25068090", "endSection": "title"}, {"offsetInBeginSection": 255, "offsetInEndSection": 458, "text": "Brown adipose produces heat as a defense against hypothermia and obesity, and the appearance of brown-like adipocytes within white adipose tissue depots is associated with improved metabolic phenotypes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21123942", "endSection": "abstract"}, {"offsetInBeginSection": 1764, "offsetInEndSection": 1902, "text": "In the same manner, marked ability to produce a considerable amount of heat was evidenced in  brown fat tissue of children and teenagers. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 355, "text": "Brown fat cells were classified into 6 types: Type 1 cells are fat-depleted cells filled with granular cytoplasm and are believed to be produced after oxidation of fat for heat production. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", "endSection": "abstract"}, {"offsetInBeginSection": 1616, "offsetInEndSection": 1739, "text": "It is inferred that brown-adipose-tissue heat production is reduced during (and probably also some time after) anesthesia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8042786", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Parallel measurements of heat production and thermogenin content in brown fat cells during cold acclimation of rats.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3083882", "endSection": "title"}, {"offsetInBeginSection": 39, "offsetInEndSection": 287, "text": "The classical white adipose tissue builds up energy in the form of triglycerides and is useful for preventing fatigue during periods of low caloric intake and the brown adipose tissue instead of inducing fat accumulation can produce energy as heat.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27528872", "endSection": "abstract"}, {"offsetInBeginSection": 126, "offsetInEndSection": 334, "text": "In response to cold, both classical brown fat and the newly identified \"beige\" or \"brite\" cells are activated by \u03b2-adrenergic signaling and catabolize stored lipids and carbohydrates to produce heat via UCP1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26322018", "endSection": "abstract"}, {"offsetInBeginSection": 103, "offsetInEndSection": 245, "text": "White adipose tissue stores energy reserves as fat, whereas the metabolic function of brown adipose tissue is lipid oxidation to produce heat.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23834768", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "The main function of brown adipose tissue (BAT) is to produce heat in response to cold.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6148836", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Brown adipocytes oxidize fatty acids to produce heat in response to cold or caloric overfeeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24129212", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Brown fat (brown adipose tissue, BAT) primary function is to produce heat.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196229", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 293, "text": "Adipose tissue plays an active role in energy balance because it is not only a lipid storing and mobilizing tissue but consists of functionally specialized tissues able to produce heat (in brown adipose tissue) and to produce or release a vast number of so called adipokines or adipocytokines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15058310", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Brown adipose tissue (BAT), a specialized fat that dissipates energy to produce heat, plays an important role in the regulation of energy balance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25642708", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Brown adipose cells are specialized to dissipate chemical energy in the form of heat, as a physiological defence against cold and obesity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19641492", "endSection": "abstract"}, {"offsetInBeginSection": 1286, "offsetInEndSection": 1430, "text": "In the present study, the thermogenesis of human brown fat tissue was suggested chiefly with regard to the occurrence of Types 1 and/or 6 cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", "endSection": "abstract"}, {"offsetInBeginSection": 1764, "offsetInEndSection": 1901, "text": "In the same manner, marked ability to produce a considerable amount of heat was evidenced in  brown fat tissue of children and teenagers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/962510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Adult humans have heat-producing and energy-consuming brown adipose tissue in the clavicular region of the neck.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26749900", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Brown and beige adipocytes expend chemical energy to produce heat and are therefore important in regulating body temperature and body weight.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552974", "endSection": "abstract"}, {"offsetInBeginSection": 2005, "offsetInEndSection": 2203, "text": "In human perirenal brown fat tissue, darkly stained fat-depleted cells (D) occupy, with other cell types (CR, CR'), an important part in the reversible heat production cycle of the brown fat tissue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2039657", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Brown fat is a specialized fat depot that can increase energy expenditure and produce heat.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26912151", "endSection": "abstract"}]}, {"body": "What is a mimotope vaccine?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15634921", "http://www.ncbi.nlm.nih.gov/pubmed/16634806", "http://www.ncbi.nlm.nih.gov/pubmed/19344285", "http://www.ncbi.nlm.nih.gov/pubmed/16814270", "http://www.ncbi.nlm.nih.gov/pubmed/19846865", "http://www.ncbi.nlm.nih.gov/pubmed/17597331", "http://www.ncbi.nlm.nih.gov/pubmed/7534789", "http://www.ncbi.nlm.nih.gov/pubmed/24106273", "http://www.ncbi.nlm.nih.gov/pubmed/19695868", "http://www.ncbi.nlm.nih.gov/pubmed/23161490", "http://www.ncbi.nlm.nih.gov/pubmed/19088033", "http://www.ncbi.nlm.nih.gov/pubmed/27622022", "http://www.ncbi.nlm.nih.gov/pubmed/17445956", "http://www.ncbi.nlm.nih.gov/pubmed/25990849", "http://www.ncbi.nlm.nih.gov/pubmed/22936035", "http://www.ncbi.nlm.nih.gov/pubmed/11122460", "http://www.ncbi.nlm.nih.gov/pubmed/21919618", "http://www.ncbi.nlm.nih.gov/pubmed/19111573", "http://www.ncbi.nlm.nih.gov/pubmed/20493257", "http://www.ncbi.nlm.nih.gov/pubmed/20827761", "http://www.ncbi.nlm.nih.gov/pubmed/25379726", "http://www.ncbi.nlm.nih.gov/pubmed/16685414"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/11094", "o": "http://linkedlifedata.com/resource/rxnorm/label/354401"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/354401", "o": "Vaccines"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/11094", "o": "http://linkedlifedata.com/resource/rxnorm/label/3254401"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3254401", "o": "Vaccines"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0042210", "o": "Vaccine"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0042210", "o": "http://linkedlifedata.com/resource/umls/label/A11798658"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11798658", "o": "Vaccine"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/11094", "o": "http://linkedlifedata.com/resource/rxnorm/label/354410"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/354410", "o": "Vaccine"}], "ideal_answer": ["A mimotope vaccine contains peptide mimics of specific antigen epitopes, which alter the antigen presentation and/or T cell activation to increase the expansion of tumor-specific T cells and are able to induce polyclonal antibodies response."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016233", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064166", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014612"], "type": "summary", "id": "58d388958acda34529000006", "snippets": [{"offsetInBeginSection": 1704, "offsetInEndSection": 1980, "text": "These data are proof of principle that by performing affinity selection on neutralizing antibodies, our VLP technology can identify peptide mimics of non-linear epitopes and that these mimotope based VLP vaccines provide protection against pathogens in relevant animal models.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25379726", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 657, "text": "A major hurdle in vaccine development is the difficulty in identifying relevant target epitopes and then presenting them to the immune system in a context that mimics their native conformation. We have engineered novel virus-like-particle (VLP) technology that is able to display complex libraries of random peptide sequences on a surface-exposed loop in the coat protein without disruption of protein folding or VLP assembly. This technology allows us to use the same VLP particle for both affinity selection and immunization, integrating the power of epitope discovery and epitope mimicry of traditional phage display with the high immunogenicity of VLPs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25379726", "endSection": "abstract"}, {"offsetInBeginSection": 1165, "offsetInEndSection": 1630, "text": "Our data suggest that the improved tumor immunity results from the expansion of mimotope-elicited tumor-specific T cells that have increased avidity for the tumor antigen. The enhanced T cells are phenotypically distinct and enriched for T-cell receptors previously correlated with improved antitumor immunity. These results suggest that incorporation of native antigen into clinical mimotope vaccine regimens may improve the efficacy of antitumor T-cell responses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490", "endSection": "abstract"}, {"offsetInBeginSection": 683, "offsetInEndSection": 911, "text": "One strategy for overcoming these mechanisms is vaccination with mimotopes, or peptide mimics of tumor antigens, which alter the antigen presentation and/or T cell activation to increase the expansion of tumor-specific T cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22936035", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 296, "text": "The high molecular weight melanoma-associated antigen (HMW-MAA) is an attractive target for immunotherapy of malignant melanoma. We have recently generated a vaccine based on the HMW-MAA mimotope 225D9.2+ that was able to induce anti-HMW-MAA antibodies with antitumor activity in vitro. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19088033", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 268, "text": "Peptide mimics of a conformational epitope that is recognized by a mAb with antitumor activity are promising candidates for formulations of anticancer vaccines. These mimotope vaccines are able to induce a polyclonal Ab response focused to the determinant of the mAb. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15634921", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 386, "text": "Carbohydrate mimetic peptides of tumor associated carbohydrate antigens (TACA) are T-cell-dependent antigens and, therefore, immunization with these surrogates is predicted to overcome the low immunogenicity of carbohydrate antigens. Consistent with this hypothesis, we show that among the potential immune cells involved, peptide immunization led to an increase in T-cell populations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16685414", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 802, "text": "To explore the mimotope vaccine approach against infectious bursal disease virus (IBDV), five IBDV-specific monoclonal antibodies (mAbs) were prepared and their binding peptides were screened against a phage-displayed 12-mer peptide library. After three rounds of biopanning, 12 phages were selected for each mAbs and their specificity to IBDV was verified by sandwich and competitive inhibition ELISAs. Seven phages per mAb were sequenced and their amino acid sequences were deduced. The five representative sequences of mimotopes corresponding mAbs were determined. An artificial gene, designated 5epis (5 epitopes) and consisting of the five mimotopes arranged in tandem (F1-F7-B34-2B1-2G8) with four GGGS spacers, was chemically synthesized and cloned into a prokaryotic expression plasmid pET28b. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17445956", "endSection": "abstract"}, {"offsetInBeginSection": 729, "offsetInEndSection": 862, "text": "The mimotope vaccine was then generated by coupling the most suitable candidate mimotope to tetanus toxoid as an immunogenic carrier.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15634921", "endSection": "abstract"}, {"offsetInBeginSection": 790, "offsetInEndSection": 973, "text": "We hypothesized that boosting the mimotope vaccine with the native tumor antigen would focus the T-cell response elicited by the mimotope toward high affinity, tumor-specific T cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490", "endSection": "abstract"}, {"offsetInBeginSection": 585, "offsetInEndSection": 672, "text": "Following the mice immunization, phage-based mimotope vaccine induced humoral immunity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25990849", "endSection": "abstract"}, {"offsetInBeginSection": 695, "offsetInEndSection": 796, "text": "In this article we focus on cancer vaccines for antibody production, in particular mimotope vaccines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21919618", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "Vaccines that incorporate peptide mimics of tumor antigens, or mimotope vaccines, are commonly used in cancer immunotherapy and function by eliciting increased numbers of T cells that cross-react with the native tumor antigen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106273", "endSection": "abstract"}, {"offsetInBeginSection": 795, "offsetInEndSection": 978, "text": "We hypothesized that boosting the mimotope vaccine with the native tumor antigen would focus the T-cell response elicited by the mimotope toward high affinity, tumor-specific T cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161490", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17597331", "endSection": "title"}, {"offsetInBeginSection": 161, "offsetInEndSection": 267, "text": "These mimotope vaccines are able to induce a polyclonal Ab response focused to the determinant of the mAb.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15634921", "endSection": "abstract"}, {"offsetInBeginSection": 1501, "offsetInEndSection": 1628, "text": "We therefore suggest that mimotope gene vaccines are potential candidates for epitope-specific immunotherapy of type I allergy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19111573", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Conformational B-cell epitopes on the HCV E2 protein recognized by human antibodies were characterized by the use of a peptide mimotope named K1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20827761", "endSection": "abstract"}, {"offsetInBeginSection": 590, "offsetInEndSection": 677, "text": "Following the mice immunization, phage-based mimotope vaccine induced humoral immunity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25990849", "endSection": "abstract"}, {"offsetInBeginSection": 700, "offsetInEndSection": 801, "text": "In this article we focus on cancer vaccines for antibody production, in particular mimotope vaccines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21919618", "endSection": "abstract"}]}, {"body": "Describe clinical manifestation of the Mal de debarquement syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25570942", "http://www.ncbi.nlm.nih.gov/pubmed/25076935", "http://www.ncbi.nlm.nih.gov/pubmed/26346344", "http://www.ncbi.nlm.nih.gov/pubmed/23219828", "http://www.ncbi.nlm.nih.gov/pubmed/25809585", "http://www.ncbi.nlm.nih.gov/pubmed/26559820", "http://www.ncbi.nlm.nih.gov/pubmed/26252893", "http://www.ncbi.nlm.nih.gov/pubmed/17046477", "http://www.ncbi.nlm.nih.gov/pubmed/27730651", "http://www.ncbi.nlm.nih.gov/pubmed/23202153", "http://www.ncbi.nlm.nih.gov/pubmed/25726862", "http://www.ncbi.nlm.nih.gov/pubmed/23209584", "http://www.ncbi.nlm.nih.gov/pubmed/8336953", "http://www.ncbi.nlm.nih.gov/pubmed/23091536", "http://www.ncbi.nlm.nih.gov/pubmed/3631419", "http://www.ncbi.nlm.nih.gov/pubmed/24594496", "http://www.ncbi.nlm.nih.gov/pubmed/22231864", "http://www.ncbi.nlm.nih.gov/pubmed/25331814"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1608983", "o": "http://linkedlifedata.com/resource/umls/label/A18471215"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18471215", "o": "Mal de debarquement syndrome"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1608983", "o": "Mal de debarquement"}], "ideal_answer": ["Mal de debarquement syndrome (MdDS) is a disorder of chronic self-motion perception that occurs though entrainment to rhythmic background motion, such as from sea voyage, and involves the perception of low-frequency rocking that can last for months or years."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "http://www.disease-ontology.org/api/metadata/DOID:225"], "type": "summary", "id": "588f9b7eed9bbee70d000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 409, "text": "Mal de debarquement (MdD) is a subjective perception of self-motion after exposure to passive motion, in most cases sea travel, hence the name. Mal de debarquement occurs quite frequently in otherwise healthy individuals for a short period of time (several hours). However, in some people symptoms remain for a longer period of time or even persist and this is then called mal de debarquement syndrome (MdDS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559820", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "OBJECTIVE: Mal de debarquement syndrome (MdDS) is a balance disorder that typically starts after an extended exposure to passive motion, such as a boat or plane ride. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27730651", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Mal de debarquement syndrome (MdDS) is a rare and poorly understood condition of perceived continual motion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25809585", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "BACKGROUND: Mal de debarquement syndrome (MdDS) is a disorder of chronic self-motion perception that occurs though entrainment to rhythmic background motion, such as from sea voyage, and involves the perception of low-frequency rocking that can last for months or years. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252893", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 335, "text": "It is characterized by abnormal sensation of motion/balance reported after travel by air, land, and sea; being reexposed to motion/activity relieves it. Symptoms may last from minutes to years. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346344", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Persistent mal de debarquement syndrome: a motion-induced subjective disorder of balance.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3631419", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Mal de debarquement syndrome (MdDS) is a disorder of phantom perception of self-motion of unknown cause. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22231864", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Mal de debarquement (MDD) is a common, benign, and self-limited syndrome suffered by many people after disembarkation from an oceangoing vessel.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17046477", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Persistent mal de debarquement syndrome: a motion-induced subjective disorder of balance.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3631419", "endSection": "title"}]}, {"body": "Is Melioidosis caused by the bacterium\u00a0Burkholderia pseudomallei?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24603493", "http://www.ncbi.nlm.nih.gov/pubmed/26542622", "http://www.ncbi.nlm.nih.gov/pubmed/25653950", "http://www.ncbi.nlm.nih.gov/pubmed/19538822", "http://www.ncbi.nlm.nih.gov/pubmed/22176696", "http://www.ncbi.nlm.nih.gov/pubmed/17582188", "http://www.ncbi.nlm.nih.gov/pubmed/26495852", "http://www.ncbi.nlm.nih.gov/pubmed/12139670", "http://www.ncbi.nlm.nih.gov/pubmed/19156200", "http://www.ncbi.nlm.nih.gov/pubmed/26935879", "http://www.ncbi.nlm.nih.gov/pubmed/27427979", "http://www.ncbi.nlm.nih.gov/pubmed/25803046", "http://www.ncbi.nlm.nih.gov/pubmed/26710411", "http://www.ncbi.nlm.nih.gov/pubmed/9753000", "http://www.ncbi.nlm.nih.gov/pubmed/15191392", "http://www.ncbi.nlm.nih.gov/pubmed/12803798", "http://www.ncbi.nlm.nih.gov/pubmed/27694236", "http://www.ncbi.nlm.nih.gov/pubmed/17563759", "http://www.ncbi.nlm.nih.gov/pubmed/18691413", "http://www.ncbi.nlm.nih.gov/pubmed/22473609", "http://www.ncbi.nlm.nih.gov/pubmed/24736221", "http://www.ncbi.nlm.nih.gov/pubmed/24067292", "http://www.ncbi.nlm.nih.gov/pubmed/27219859", "http://www.ncbi.nlm.nih.gov/pubmed/22442327", "http://www.ncbi.nlm.nih.gov/pubmed/11495298", "http://www.ncbi.nlm.nih.gov/pubmed/15380526", "http://www.ncbi.nlm.nih.gov/pubmed/14604083", "http://www.ncbi.nlm.nih.gov/pubmed/22564963", "http://www.ncbi.nlm.nih.gov/pubmed/20142364", "http://www.ncbi.nlm.nih.gov/pubmed/25689538", "http://www.ncbi.nlm.nih.gov/pubmed/24065633", "http://www.ncbi.nlm.nih.gov/pubmed/17676990", "http://www.ncbi.nlm.nih.gov/pubmed/24962103", "http://www.ncbi.nlm.nih.gov/pubmed/17062053", "http://www.ncbi.nlm.nih.gov/pubmed/20169062", "http://www.ncbi.nlm.nih.gov/pubmed/19276877", "http://www.ncbi.nlm.nih.gov/pubmed/18855560", "http://www.ncbi.nlm.nih.gov/pubmed/26311902", "http://www.ncbi.nlm.nih.gov/pubmed/26607593", "http://www.ncbi.nlm.nih.gov/pubmed/24392083", "http://www.ncbi.nlm.nih.gov/pubmed/27472421", "http://www.ncbi.nlm.nih.gov/pubmed/26526925", "http://www.ncbi.nlm.nih.gov/pubmed/20532233", "http://www.ncbi.nlm.nih.gov/pubmed/19679240", "http://www.ncbi.nlm.nih.gov/pubmed/25943405", "http://www.ncbi.nlm.nih.gov/pubmed/25442759"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0025229", "o": "Melioidosis"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0025229", "o": "http://linkedlifedata.com/resource/umls/label/A0432241"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0432241", "o": "MELIOIDOSIS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0025229", "o": "http://linkedlifedata.com/resource/umls/label/A0084485"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0084485", "o": "Melioidosis"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/1025638", "o": "http://linkedlifedata.com/resource/rxnorm/label/3197303"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3197303", "o": "Melioidosis"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/semanticnetwork/id/T007", "o": "Bacterium"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0004611", "o": "http://linkedlifedata.com/resource/umls/label/A7567988"}], "ideal_answer": ["Burkholderia pseudomallei is the causative agent of melioidosis"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019121", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016957", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008554"], "type": "yesno", "id": "58caf88c02b8c60953000031", "snippets": [{"offsetInBeginSection": 222, "offsetInEndSection": 284, "text": "Burkholderia pseudomallei, the causative agent of melioidosis,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935879", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "What drives the occurrence of the melioidosis bacterium Burkholderia pseudomallei in domestic gardens?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25803046", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Landscape changes influence the occurrence of the melioidosis bacterium Burkholderia pseudomallei in soil in northern Australia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156200", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Out of the ground: aerial and exotic habitats of the melioidosis bacterium Burkholderia pseudomallei in grasses in Australia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22176696", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Melioidosis, caused by the gram-negative bacterium Burkholderia pseudomallei, is a common cause of community-acquired sepsis in Southeast Asia and Northern Australia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27219859", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Melioidosis is a suppurative chronic infection caused by a gramnegative bacterium, Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17582188", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Melioidosis is an infection caused by the gram-negative bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17062053", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Melioidosis is an infectious disease caused by a saprophytic bacterium, Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12803798", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Melioidosis is an infectious disease caused by the Gram-negative bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19679240", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Melioidosis is a pyogenic infection with high mortality caused by the bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24067292", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Melioidosis is a tropical infectious disease caused by the gram-negative bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14604083", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Melioidosis is a potentially fatal disease caused by the bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15380526", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Melioidosis is a rare tropical disease caused by infection with the bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12139670", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "The mechanisms involved in the pathogenesis of melioidosis, caused by the intracellular bacterium Burkholderia pseudomallei, are unclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9753000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Melioidosis is an emerging tropical infection caused by the intracellular bacterium Burkholderia pseudomallei, and is associated with high mortality rates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15191392", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Melioidosis is an increasingly recognised cause of sepsis and death across South East Asia and Northern Australia, caused by the bacterium Burkholderia pseudomallei", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495852", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Melioidosis, an infection caused by the gram-negative bacterium Burkholderia pseudomallei, is an important cause of pneumonia, skin infection, sepsis, and death in Southeast Asia and Australia, but is exceedingly rare in North America", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25943405", "endSection": "abstract"}, {"offsetInBeginSection": 179, "offsetInEndSection": 391, "text": "The Gram-negative bacterium Burkholderia pseudomallei is able to survive and replicate within leukocytes and causes melioidosis, an important cause of pneumonia-derived community-acquired sepsis in Southeast Asia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20142364", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Melioidosis, a lethal tropical infection that is endemic in southeast Asia and northern Australia, is caused by the saprophytic Gram-negative bacterium Burkholderia pseudomallei", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18691413", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Melioidosis is an emerging infectious disease caused by the soil bacterium Burkholderia pseudomallei", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442327", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Melioidosis is a tropical disease of high mortality caused by the environmental bacterium, Burkholderia pseudomallei", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26526925", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Melioidosis is an infectious disease caused by Burkholderia pseudomallei, a bacterium endemic in Southeast Asia and northern Australia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26542622", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Melioidosis is a life-threatening infection caused by the Gram-negative bacterium Burkholderia pseudomallei, mainly found in Southeast Asia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25689538", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Melioidosis, caused by the Gram-negative bacterium Burkholderia pseudomallei, is a dreadful disease common in South-East Asia and Northern Australia and is characterized by chronic suppurative lesions and pneumonia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24962103", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442759", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Melioidosis is an emerging infectious disease of humans and animals in the tropics caused by the soil bacterium Burkholderia pseudomallei. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22176696", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Melioidosis is a potentially fatal disease caused by the bacterium Burkholderia pseudomallei. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22473609", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Melioidosis, infection caused by the Gram-negative bacterium Burkholderia pseudomallei, is a common cause of sepsis in northeast Thailand. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392083", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Melioidosis is a potentially fatal disease caused by the bacterium, Burkholderia pseudomallei. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17563759", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "BACKGROUND: The soil-dwelling saprophyte bacterium Burkholderia pseudomallei is the cause of melioidosis, a severe disease of humans and animals in southeast Asia and northern Australia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156200", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Melioidosis is an endemic disease caused by the bacterium Burkholderia pseudomallei. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24603493", "endSection": "abstract"}, {"offsetInBeginSection": 289, "offsetInEndSection": 424, "text": "Melioidosis is a severe infection caused by the gram-negative bacterium, Burkholderia pseudomallei, that is endemic in Southeast Asia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676990", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Melioidosis, infection caused by the Gram-negative bacterium Burkholderia pseudomallei, is a common cause of sepsis in northeast Thailand.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24392083", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Melioidosis is a clinically diverse disease caused by the facultative intracellular Gram-negative bacterium, Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25653950", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442759", "endSection": "abstract"}, {"offsetInBeginSection": 277, "offsetInEndSection": 411, "text": "Melioidosis is a severe infection caused by the gram-negative bacterium, Burkholderia pseudomallei, that is endemic in Southeast Asia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17676990", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Melioidosis, a lethal tropical infection that is endemic in southeast Asia and northern Australia, is caused by the saprophytic Gram-negative bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18691413", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "Melioidosis, a severe human disease caused by the bacterium Burkholderia pseudomallei, has a wide spectrum of clinical manifestations ranging from acute septicemia to chronic localized illness or latent infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26311902", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Melioidosis, an often fatal infectious disease in Northeast Thailand, is caused by skin inoculation, inhalation or ingestion of the environmental bacterium, Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27472421", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Melioidosis is an infection caused by Gram-negative bacterium, Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26710411", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "Melioidosis, caused by the Gram-negative bacterium Burkholderia pseudomallei, is a dreadful disease common in South-East Asia and Northern Australia and is characterized by chronic suppurative lesions and pneumonia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24962103", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Largely due to its recognition as a biological threat agent, current knowledge on melioidosis, caused by the Gram-negative bacterium Burkholderia pseudomallei, has increased tremendously over the last years.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276877", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Melioidosis is an endemic disease caused by the bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24603493", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Melioidosis is a potentially fatal disease caused by the bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22473609", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Melioidosis is a potentially fatal disease caused by the bacterium, Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17563759", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Melioidosis is a disease of humans and animals that is caused by the saprophytic bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607593", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Melioidosis is an emerging infectious disease of humans and animals in the tropics caused by the soil bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22176696", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "The soil-dwelling saprophyte bacterium Burkholderia pseudomallei is the cause of melioidosis, a severe disease of humans and animals in southeast Asia and northern Australia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156200", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Melioidosis is an often fatal infectious disease affecting humans and animals in tropical regions and is caused by the saprophytic environmental bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25803046", "endSection": "abstract"}, {"offsetInBeginSection": 147, "offsetInEndSection": 352, "text": "We have recently shown that during melioidosis, a severe infection caused by the gram-negative bacterium Burkholderia pseudomallei, TLR2 but not TLR4 impacts the immune response of the intact host in vivo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18855560", "endSection": "abstract"}, {"offsetInBeginSection": 1767, "offsetInEndSection": 1924, "text": "It is caused by the bacterium Burkholderia pseudomallei, which can infect many organs of the body, including the brain, and results in neurological symptoms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24736221", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Melioidosis is a frequent cause of severe sepsis in Southeast Asia caused by the gram-negative bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22564963", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "What drives the occurrence of the melioidosis bacterium Burkholderia pseudomallei in domestic gardens?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25803046", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "The Gram-negative bacterium Burkholderia pseudomallei is the causative agent of melioidosi", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065633", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 175, "text": "The environmental bacterium Burkholderia pseudomallei causes the infectious disease melioidosis with a high case-fatality rate in tropical and subtropical regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27427979", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Burkholderia pseudomallei is a soil-dwelling bacterium and the cause of melioidosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27694236", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Melioidosis, an infectious disease caused by the Gram-negative bacterium Burkholderia pseudomallei,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19538822", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 144, "text": "Melioidosis is a frequently fatal infectious disease caused by the soil dwelling Gram-negative bacterium Burkholderia pseudomallei. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532233", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Burkholderia pseudomallei, an environmental bacterium that causes the deadly disease melioidosis, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27303718", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Melioidosis is an important public health problem in Southeast Asia and Northern Australia. This disease is caused by the gram-negative bacilli, Burkholderia pseudomallei", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11495298", "endSection": "abstract"}, {"offsetInBeginSection": 184, "offsetInEndSection": 301, "text": "Melioidosis, caused by Burkholderia pseudomallei, is an important cause of community-acquired sepsis in Southeast-Asi", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20169062", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Melioidosis is a potentially fatal disease caused by the saprophytic bacterium Burkholderia pseudomallei", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24145517", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Melioidosis is a disease of humans caused by opportunistic infection with the soil and water bacterium Burkholderia pseudomallei.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22624016", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of verubecestat?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27933948", "http://www.ncbi.nlm.nih.gov/pubmed/27023706", "http://www.ncbi.nlm.nih.gov/pubmed/27678025", "http://www.ncbi.nlm.nih.gov/pubmed/27807285", "http://www.ncbi.nlm.nih.gov/pubmed/27934506"], "ideal_answer": ["Verubecestat (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of A\u03b240, A\u03b242, and sAPP\u03b2 (a direct product of BACE1 enzymatic activity)."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504"], "type": "summary", "id": "589a246a78275d0c4a000031", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer's disease patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285", "endSection": "title"}, {"offsetInBeginSection": 301, "offsetInEndSection": 601, "text": "We show that verubecestat (MK-8931) is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of A\u03b240, A\u03b242, and sAPP\u03b2 (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A \u03b2-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 315, "text": "Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27934506", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Verubecestat is an inhibitor of \u03b2-secretase being evaluated for the treatment of Alzheimer's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27934506", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Verubecestat is an inhibitor of \u03b2-secretase being evaluated for the treatment of Alzheimer's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27934506", "endSection": "abstract"}, {"offsetInBeginSection": 1201, "offsetInEndSection": 1446, "text": "After giving an update on the development and current status of new AD therapeutics, this review will focus on BACE inhibitors and, in particular, will discuss the prospects of verubecestat (MK-8931), which has reached phase III clinical trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27023706", "endSection": "abstract"}, {"offsetInBeginSection": 314, "offsetInEndSection": 591, "text": "Although not selective over the closely related aspartyl protease BACE2, verubecestat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain A\u03b2 levels in rats and nonhuman primates and CSF A\u03b2 levels in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", "endSection": "abstract"}, {"offsetInBeginSection": 299, "offsetInEndSection": 599, "text": "We show that verubecestat (MK-8931) is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of A\u03b240, A\u03b242, and sAPP\u03b2 (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 314, "text": "Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", "endSection": "abstract"}, {"offsetInBeginSection": 599, "offsetInEndSection": 938, "text": "Chronic treatment of rats and monkeys with verubecestat achieved exposures >40-fold higher than those being tested in clinical trials in AD patients yet did not elicit many of the adverse effects previously attributed to BACE inhibition, such as reduced nerve myelination, neurodegeneration, altered glucose homeostasis, or hepatotoxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285", "endSection": "abstract"}, {"offsetInBeginSection": 514, "offsetInEndSection": 883, "text": "Expert opinion: Drugs in Phase III clinical development for AD include one inhibitor of the \u03b2-secretase cleaving enzyme (BACE) (verubecestat), three anti-A\u03b2 monoclonal antibodies (solanezumab, gantenerumab, and aducanumab), an inhibitor of receptor for advanced glycation end products (RAGE) (azeliragon) and the combination of cromolyn sodium and ibuprofen (ALZT-OP1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27678025", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27934506", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer's disease patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A \u03b2-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", "endSection": "title"}, {"offsetInBeginSection": 1209, "offsetInEndSection": 1454, "text": "After giving an update on the development and current status of new AD therapeutics, this review will focus on BACE inhibitors and, in particular, will discuss the prospects of verubecestat (MK-8931), which has reached phase III clinical trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27023706", "endSection": "abstract"}, {"offsetInBeginSection": 315, "offsetInEndSection": 592, "text": "Although not selective over the closely related aspartyl protease BACE2, verubecestat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain A\u03b2 levels in rats and nonhuman primates and CSF A\u03b2 levels in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948", "endSection": "abstract"}]}, {"body": "How are triple negative gliomas characterized?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23288644", "http://www.ncbi.nlm.nih.gov/pubmed/22890969", "http://www.ncbi.nlm.nih.gov/pubmed/26989023", "http://www.ncbi.nlm.nih.gov/pubmed/23831947", "http://www.ncbi.nlm.nih.gov/pubmed/26061753", "http://www.ncbi.nlm.nih.gov/pubmed/21889777"], "ideal_answer": ["of these markers - 1p/19q deletions , mgmt methylation status , and mutations in the idh1 gene - are so potent that a new brain tumor subtype , the \"triple negative\" glioma (1p/19q intact , mgmt unmethylated , idh1 non-mutated) has entered common parlance . ", "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis.", "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. ", "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis. Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. On the basis of previous studies of tumor biology, we defined five glioma molecular groups with the use of three alterations: mutations in the TERT promoter, mutations in IDH, and codeletion of chromosome arms 1p and 19q (1p/19q codeletion). Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. (Funded by the National Institutes of Health and others. Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance.", "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis. Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations. Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance. ", "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative (IDH-/p53-/1p19q-), this last subgroup having the worst prognosis.", "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis. Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations. Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance. ", "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis. Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations", "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis. Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance"], "type": "summary", "id": "58bac5e822d3005309000012", "snippets": [{"offsetInBeginSection": 1107, "offsetInEndSection": 1310, "text": "According to IDH, TP53, and 1p19q status, four major subtypes of LGG are recorded: IDH+/p53-/1p19q-, IDH+/p53+/1p19q-, IDH+/p53-/1p19q+ and triple negative, this last subgroup having the worst prognosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21889777", "endSection": "abstract"}, {"offsetInBeginSection": 696, "offsetInEndSection": 878, "text": "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890969", "endSection": "abstract"}, {"offsetInBeginSection": 838, "offsetInEndSection": 1255, "text": "Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26061753", "endSection": "abstract"}, {"offsetInBeginSection": 1026, "offsetInEndSection": 1282, "text": "Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288644", "endSection": "abstract"}, {"offsetInBeginSection": 219, "offsetInEndSection": 513, "text": "Few data are available in the literature regarding the relationship between IDH mutations and HIF expression in low-grade gliomas (LGGs), especially in a recently described aggressive molecular subtype: \"triple negative\" (IDH non mutated, 1p 19q non codeleted, p53 expression negative) gliomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989023", "endSection": "abstract"}, {"offsetInBeginSection": 691, "offsetInEndSection": 872, "text": "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890969", "endSection": "abstract"}, {"offsetInBeginSection": 1021, "offsetInEndSection": 1278, "text": "Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the \"triple negative\" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288644", "endSection": "abstract"}, {"offsetInBeginSection": 696, "offsetInEndSection": 876, "text": "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890969", "endSection": "abstract"}, {"offsetInBeginSection": 696, "offsetInEndSection": 877, "text": "Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53-/1p19q-; group 2, IDH+/p53-/1p19q+; group 3, IDH+/p53+/1p19q-; and group 4, triple negative gliomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22890969", "endSection": "abstract"}, {"offsetInBeginSection": 220, "offsetInEndSection": 514, "text": "Few data are available in the literature regarding the relationship between IDH mutations and HIF expression in low-grade gliomas (LGGs), especially in a recently described aggressive molecular subtype: \"triple negative\" (IDH non mutated, 1p 19q non codeleted, p53 expression negative) gliomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989023", "endSection": "abstract"}]}, {"body": "What is ectopia lentis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25797933", "http://www.ncbi.nlm.nih.gov/pubmed/25939784", "http://www.ncbi.nlm.nih.gov/pubmed/19200529"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0013581", "o": "Ectopia lentis"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0013581", "o": "http://linkedlifedata.com/resource/umls/label/A0052649"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0052649", "o": "Ectopia Lentis"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/1026597", "o": "http://linkedlifedata.com/resource/rxnorm/label/3153153"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3153153", "o": "Ectopia Lentis"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0013581", "o": "http://linkedlifedata.com/resource/umls/label/A12012342"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12012342", "o": "Ectopia lentis"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0013581", "o": "http://linkedlifedata.com/resource/umls/label/A0078970"}], "ideal_answer": ["Ectopia Lentis is dislocation of the optic lens in the eye."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004479"], "type": "summary", "id": "58dc2c698acda3452900001f", "snippets": [{"offsetInBeginSection": 242, "offsetInEndSection": 268, "text": "bilateral lens dislocation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25797933", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 239, "text": "Clinical manifestations include mental retardation, dislocation of the optic lens (ectopia lentis)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25939784", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Ectopia lentis is a genetically heterogeneous condition that is characterized by the subluxation of the lens resulting from the disruption of the zonular fibers. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19200529", "endSection": "abstract"}]}, {"body": "Can glyburide reduce cerebral edema?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24193798", "http://www.ncbi.nlm.nih.gov/pubmed/25422710", "http://www.ncbi.nlm.nih.gov/pubmed/26463916", "http://www.ncbi.nlm.nih.gov/pubmed/24072459", "http://www.ncbi.nlm.nih.gov/pubmed/24552576", "http://www.ncbi.nlm.nih.gov/pubmed/24671831", "http://www.ncbi.nlm.nih.gov/pubmed/23633925", "http://www.ncbi.nlm.nih.gov/pubmed/17673715", "http://www.ncbi.nlm.nih.gov/pubmed/26268138"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0017628", "o": "glyburide"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0017628", "o": "http://linkedlifedata.com/resource/umls/label/A10769058"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A10769058", "o": "GLYBURIDE"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/4815", "o": "http://linkedlifedata.com/resource/rxnorm/label/3163336"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3163336", "o": "GLYBURIDE"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0017628", "o": "http://linkedlifedata.com/resource/umls/label/A0064005"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0064005", "o": "Glyburide"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/4815", "o": "http://linkedlifedata.com/resource/rxnorm/label/1842549"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/1842549", "o": "Glyburide"}], "ideal_answer": ["Yes. Glyburide, a selective inhibitor of sulfonylurea receptor 1-transient receptor potential melastatin 4, is effective in preventing and attenuating cerebral edema."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001929", "http://www.biosemantics.org/jochem#4275786", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275786", "http://www.disease-ontology.org/api/metadata/DOID:4724", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005905"], "type": "yesno", "id": "588482f5e56acf517600000a", "snippets": [{"offsetInBeginSection": 137, "offsetInEndSection": 411, "text": "Preclinical studies have shown that a continuous infusion of glyburide blocks edema formation and improves outcome. We hypothesize that treatment with RP-1127 (Glyburide for Injection) reduces formation of brain edema in patients after large anterior circulation infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26268138", "endSection": "abstract"}, {"offsetInBeginSection": 1298, "offsetInEndSection": 1486, "text": "CONCLUSIONS: GAMES-RP was designed to provide critical information regarding glyburide for injection in patients with large hemispheric stroke and will inform the design of future studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26268138", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Glyburide is associated with attenuated vasogenic edema in stroke patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", "endSection": "title"}, {"offsetInBeginSection": 134, "offsetInEndSection": 382, "text": "Glyburide is reported to prevent brain swelling in preclinical rodent models of ischemic stroke through inhibition of a non-selective channel composed of sulfonylurea receptor 1 and transient receptor potential cation channel subfamily M member 4. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", "endSection": "abstract"}, {"offsetInBeginSection": 936, "offsetInEndSection": 1323, "text": "RESULTS: We report that IV glyburide was associated with T2 fluid-attenuated inversion recovery signal intensity ratio on brain MRI, diminished the lesional water diffusivity between days 1 and 2 (pseudo-normalization), and reduced blood MMP-9 level.CONCLUSIONS: Several surrogate markers of vasogenic edema appear to be reduced in the setting of IV glyburide treatment in human stroke. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Pilot study of intravenous glyburide in patients with a large ischemic stroke.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193798", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 262, "text": "BACKGROUND AND PURPOSE: Preclinical and retrospective clinical data indicate that glyburide, a selective inhibitor of sulfonylurea receptor 1-transient receptor potential melastatin 4, is effective in preventing edema and improving outcome after focal ischemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193798", "endSection": "abstract"}, {"offsetInBeginSection": 120, "offsetInEndSection": 222, "text": "Preclinical data suggest that glyburide, an inhibitor of SUR1-TRPM4, is effective in preventing edema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24671831", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Glyburide in Treating Malignant Cerebral Edema. ", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25422710", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Glyburide in Treating Malignant Cerebral Edema. Blocking Sulfonyl Urea One (SUR1) Receptors.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25422710", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "The sulfonylurea receptor 1-regulated NC(Ca-ATP) channel is upregulated in rodent models of stroke with block of the channel by the sulfonylurea, glibenclamide (glyburide), significantly reducing mortality, cerebral edema, and infarct volume.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17673715", "endSection": "abstract"}, {"offsetInBeginSection": 1534, "offsetInEndSection": 1678, "text": "Glyburide is a safe, inexpensive, and efficacious alternative to dexamethasone for the treatment of cerebral metastasis-related vasogenic edema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633925", "endSection": "abstract"}, {"offsetInBeginSection": 552, "offsetInEndSection": 901, "text": "In this focused review, we explore preclinical data linking Sur1 channel formation to development of edema and reference evidence suggesting that the antidiabetic sulfonylurea drug glyburide (a Sur1 inhibitor) is an inexpensive and well-tolerated agent that can be clinically tested to reduce or prevent malignancy and/or treatment-associated edema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24552576", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Potential of glyburide to reduce intracerebral edema in brain metastases.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24552576", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26268138", "endSection": "title"}, {"offsetInBeginSection": 107, "offsetInEndSection": 209, "text": "Preclinical data suggest that glyburide, an inhibitor of SUR1-TRPM4, is effective in preventing edema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24671831", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Inhibition of sulfonylurea receptor 1 (SUR1) by glyburide has been shown to decrease edema after subarachnoid hemorrhage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633925", "endSection": "abstract"}, {"offsetInBeginSection": 1563, "offsetInEndSection": 1706, "text": "Glyburide is a safe, inexpensive, and efficacious alternative to dexamethasone for the treatment of cerebral metastasis-related vasogenic edema", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633925", "endSection": "abstract"}, {"offsetInBeginSection": 938, "offsetInEndSection": 1189, "text": "RESULTS: We report that IV glyburide was associated with T2 fluid-attenuated inversion recovery signal intensity ratio on brain MRI, diminished the lesional water diffusivity between days 1 and 2 (pseudo-normalization), and reduced blood MMP-9 level. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", "endSection": "abstract"}, {"offsetInBeginSection": 120, "offsetInEndSection": 223, "text": "Preclinical data suggest that glyburide, an inhibitor of SUR1-TRPM4, is effective in preventing edema. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24671831", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Exploratory analysis of glyburide as a novel therapy for preventing brain swelling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24671831", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Inhibition of sulfonylurea receptor 1 (SUR1) by glyburide has been shown to decrease edema after subarachnoid hemorrhage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633925", "endSection": "abstract"}, {"offsetInBeginSection": 555, "offsetInEndSection": 904, "text": "In this focused review, we explore preclinical data linking Sur1 channel formation to development of edema and reference evidence suggesting that the antidiabetic sulfonylurea drug glyburide (a Sur1 inhibitor) is an inexpensive and well-tolerated agent that can be clinically tested to reduce or prevent malignancy and/or treatment-associated edema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24552576", "endSection": "abstract"}, {"offsetInBeginSection": 1531, "offsetInEndSection": 1675, "text": "Glyburide is a safe, inexpensive, and efficacious alternative to dexamethasone for the treatment of cerebral metastasis-related vasogenic edema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633925", "endSection": "abstract"}, {"offsetInBeginSection": 134, "offsetInEndSection": 381, "text": "Glyburide is reported to prevent brain swelling in preclinical rodent models of ischemic stroke through inhibition of a non-selective channel composed of sulfonylurea receptor 1 and transient receptor potential cation channel subfamily M member 4.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", "endSection": "abstract"}, {"offsetInBeginSection": 1159, "offsetInEndSection": 1282, "text": "Several surrogate markers of vasogenic edema appear to be reduced in the setting of IV glyburide treatment in human stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", "endSection": "abstract"}, {"offsetInBeginSection": 241, "offsetInEndSection": 399, "text": "We hypothesize that treatment with RP-1127 (Glyburide for Injection) reduces formation of brain edema in patients after large anterior circulation infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26268138", "endSection": "abstract"}, {"offsetInBeginSection": 1545, "offsetInEndSection": 1690, "text": "Glyburide is a safe, inexpensive, and efficacious alternative to dexamethasone for the treatment of cerebral metastasis-related vasogenic edema..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633925", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Glyburide is associated with attenuated vasogenic edema in stroke patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24072459", "endSection": "title"}]}, {"body": "What is the function of gasdermin D?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26482951", "http://www.ncbi.nlm.nih.gov/pubmed/27932073", "http://www.ncbi.nlm.nih.gov/pubmed/27281216", "http://www.ncbi.nlm.nih.gov/pubmed/26611636"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1539620", "o": "http://linkedlifedata.com/resource/umls/label/A20719561"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A20719561", "o": "gasdermin D"}], "ideal_answer": ["The gasdermin-N domains of the gasdermin proteins can bind membrane lipids, phosphoinositides and cardiolipin to produce membrane-disrupting cytotoxicity."], "concepts": ["http://www.uniprot.org/uniprot/GSDMD_MOUSE", "http://www.uniprot.org/uniprot/GSDMD_HUMAN"], "type": "summary", "id": "58e2467a6fddd3e83e000012", "snippets": [{"offsetInBeginSection": 33, "offsetInEndSection": 161, "text": "gasdermin D (GSDMD) protein to trigger pyroptosis, a lytic form of cell death that is crucial for immune defences and diseases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27281216", "endSection": "abstract"}, {"offsetInBeginSection": 329, "offsetInEndSection": 584, "text": "Here we show that the gasdermin-N domains of the gasdermin proteins GSDMD, GSDMA3 and GSDMA can bind membrane lipids, phosphoinositides and cardiolipin, and exhibit membrane-disrupting cytotoxicity in mammalian cells and artificially transformed bacteria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27281216", "endSection": "abstract"}]}, {"body": "What is TOPAZ1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26358182", "http://www.ncbi.nlm.nih.gov/pubmed/22069478"], "ideal_answer": ["TOPAZ1 is a novel germ cell-specific expressed gene conserved during evolution across vertebrates. Its PAZ-domain protein is abundantly expressed in the gonads during germ cell meiosis. The expression pattern of TOPAZ1, and its high degree of conservation, suggests that it may play an important role in germ cell development. Further characterization of TOPAZ1 may elucidate the mechanisms involved in gametogenesis, and particularly in the RNA silencing process in the germ line.", "TOPAZ1 (Testis and Ovary-specific PAZ domain gene 1) is a germ cell specific factor that is essential for male meiotic progression. Topaz1 is supposed to have a role during gametogenesis and may be involved in the piRNA pathway and contribute to silencing of transposable elements and maintenance of genome integrity. It is highly conserved in vertebrates."], "concepts": ["http://www.uniprot.org/uniprot/TOPZ1_BOVIN", "http://www.uniprot.org/uniprot/TOPZ1_RAT", "http://www.uniprot.org/uniprot/TOPZ1_MOUSE", "http://www.uniprot.org/uniprot/TOPZ1_MACFA", "http://www.uniprot.org/uniprot/TOPZ1_CALJA", "http://www.uniprot.org/uniprot/TOPZ1_MACMU", "http://www.uniprot.org/uniprot/TOPZ1_SHEEP", "http://www.uniprot.org/uniprot/TOPZ1_HUMAN"], "type": "summary", "id": "587d016ed673c3eb14000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "TOPAZ1, a germ cell specific factor, is essential for male meiotic progression", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358182", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Topaz1 (Testis and Ovary-specific PAZ domain gene 1) is a germ cell specific gene highly conserved in vertebrates", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358182", "endSection": "abstract"}, {"offsetInBeginSection": 239, "offsetInEndSection": 423, "text": "Topaz1 is supposed to have a role during gametogenesis and may be involved in the piRNA pathway and contribute to silencing of transposable elements and maintenance of genome integrity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26358182", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "TOPAZ1, a novel germ cell-specific expressed gene conserved during evolution across vertebrates", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22069478", "endSection": "title"}]}, {"body": "Which are the symptoms of glucose-6-phosphate dehydrogenase (G6PD) deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24865682", "http://www.ncbi.nlm.nih.gov/pubmed/24372186", "http://www.ncbi.nlm.nih.gov/pubmed/11233775", "http://www.ncbi.nlm.nih.gov/pubmed/20684792", "http://www.ncbi.nlm.nih.gov/pubmed/21336800", "http://www.ncbi.nlm.nih.gov/pubmed/16450734", "http://www.ncbi.nlm.nih.gov/pubmed/19086137", "http://www.ncbi.nlm.nih.gov/pubmed/25079187", "http://www.ncbi.nlm.nih.gov/pubmed/25116429", "http://www.ncbi.nlm.nih.gov/pubmed/25949934", "http://www.ncbi.nlm.nih.gov/pubmed/23188", "http://www.ncbi.nlm.nih.gov/pubmed/21302115", "http://www.ncbi.nlm.nih.gov/pubmed/23961874", "http://www.ncbi.nlm.nih.gov/pubmed/23640458", "http://www.ncbi.nlm.nih.gov/pubmed/10745013", "http://www.ncbi.nlm.nih.gov/pubmed/24891465", "http://www.ncbi.nlm.nih.gov/pubmed/18094574", "http://www.ncbi.nlm.nih.gov/pubmed/21784438", "http://www.ncbi.nlm.nih.gov/pubmed/12737943", "http://www.ncbi.nlm.nih.gov/pubmed/26275698", "http://www.ncbi.nlm.nih.gov/pubmed/22829586", "http://www.ncbi.nlm.nih.gov/pubmed/24636884", "http://www.ncbi.nlm.nih.gov/pubmed/18450407", "http://www.ncbi.nlm.nih.gov/pubmed/11271380", "http://www.ncbi.nlm.nih.gov/pubmed/26840990", "http://www.ncbi.nlm.nih.gov/pubmed/20194698", "http://www.ncbi.nlm.nih.gov/pubmed/9088998", "http://www.ncbi.nlm.nih.gov/pubmed/10698963", "http://www.ncbi.nlm.nih.gov/pubmed/25807896", "http://www.ncbi.nlm.nih.gov/pubmed/22139979", "http://www.ncbi.nlm.nih.gov/pubmed/11793482", "http://www.ncbi.nlm.nih.gov/pubmed/23874768", "http://www.ncbi.nlm.nih.gov/pubmed/11261779", "http://www.ncbi.nlm.nih.gov/pubmed/10980404", "http://www.ncbi.nlm.nih.gov/pubmed/750548", "http://www.ncbi.nlm.nih.gov/pubmed/24711919", "http://www.ncbi.nlm.nih.gov/pubmed/20065266", "http://www.ncbi.nlm.nih.gov/pubmed/19769422", "http://www.ncbi.nlm.nih.gov/pubmed/11842483"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#exactMatch", "s": "http://purl.uniprot.org/uniprot/P11413", "o": "http://purl.uniprot.org/uniprot/P11413"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0017757", "o": "G6PD"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_503131343133004B", "o": "G6PD"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0017757", "o": "http://linkedlifedata.com/resource/umls/label/A8256485"}, {"p": "http://www.w3.org/2004/02/skos/core#exactMatch", "s": "http://linkedlifedata.com/resource/drugbank/molecule/1799", "o": "http://purl.uniprot.org/uniprot/P11413"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/drugbank/molecule/1799", "o": "Glucose-6-phosphate 1-dehydrogenase"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://purl.uniprot.org/uniprot/P11413", "o": "G6PD_HUMAN"}], "ideal_answer": ["Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) is the most common red blood cell (RBC) enzyme disorder. The decrease as well as the absence of the enzyme increase RBC vulnerability to oxidative stress caused by exposure to certain medications or intake of fava beans. Among the most common symptoms of this condition are:\n1) acute hemolysis, \n2) chronic hemolysis, \n3) neonatal hyperbilirubinemia."], "concepts": ["http://www.uniprot.org/uniprot/G6PD_BUCAI", "http://www.disease-ontology.org/api/metadata/DOID:2862", "http://www.uniprot.org/uniprot/G6PD_CERCA", "http://www.uniprot.org/uniprot/G6PD_CRIGR", "http://www.uniprot.org/uniprot/G6PD_ECOLI", "http://www.uniprot.org/uniprot/G6PD_EMENI", "http://www.uniprot.org/uniprot/G6PD_BUCAP", "http://www.uniprot.org/uniprot/G6PD_HUMAN", "http://www.uniprot.org/uniprot/G6PD_ZYMMO", "http://www.uniprot.org/uniprot/G6PD_MACRO", "http://amigo.geneontology.org/amigo/term/GO:0004345", "http://www.uniprot.org/uniprot/G6PD_ENCCU", "http://www.uniprot.org/uniprot/G6PD_TAKRU", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005954", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005955", "http://www.uniprot.org/uniprot/G6PD_HAEIN", "http://www.uniprot.org/uniprot/G6PD_CYBJA", "http://www.uniprot.org/uniprot/G6PD_ECO57", "http://www.uniprot.org/uniprot/G6PD_DIDVI", "http://www.uniprot.org/uniprot/G6PD_AGGAC", "http://www.uniprot.org/uniprot/G6PD_HELPY", "http://www.uniprot.org/uniprot/G6PD_BOSIN", "http://www.uniprot.org/uniprot/G6PD_GLUOX", "http://www.uniprot.org/uniprot/G6PD_HELPJ", "http://www.uniprot.org/uniprot/G6PD_NOSP7"], "type": "list", "id": "58c6665602b8c60953000024", "snippets": [{"offsetInBeginSection": 14, "offsetInEndSection": 466, "text": "Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) is the most common red blood cell (RBC) enzyme disorder. The decrease as well as the absence of the enzyme increase RBC vulnerability to oxidative stress caused by exposure to certain medications or intake of fava beans. Among the most common clinical manifestations of this condition, acute hemolysis, chronic hemolysis, neonatal hyperbilirubinemia, and an asymptomatic form are observed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25079187", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 330, "text": "Red blood cells carry oxygen in the body and Glucose-6-Phosphate Dehydrogenase protects these cells from oxidative chemicals. If there is a lack of Glucose-6-Phosphate Dehydrogenase, red blood cells can go acute hemolysis. Convulsion is a rare presentation for acute hemolysis due to Glucose-6-Phosphate Dehydrogenase deficiency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24711919", "endSection": "abstract"}, {"offsetInBeginSection": 376, "offsetInEndSection": 851, "text": "By far the most common form worldwide is the Glucose-6-phosphate deficiency. In the most frequent variants of this disease hemolysis occurs only during stress, imposed for example by infection, \"oxidative\" drugs or after ingestion of fava beans. The most serious clinical complication of the Glucose-6-phosphate deficiency is the rarely observed neonatal icterus. Some enzyme variants can cause chronic hemolysis which is described as chronic nonsperocytic hemolytic anemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16450734", "endSection": "abstract"}, {"offsetInBeginSection": 194, "offsetInEndSection": 367, "text": "One limitation of primaquine is that, at certain doses, primaquine can cause hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24891465", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common human enzymopathy that affects cellular redox status and may lower flux into nonoxidative pathways of glucose metabolism", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22829586", "endSection": "abstract"}, {"offsetInBeginSection": 279, "offsetInEndSection": 505, "text": "The 6PGD deficiency was associated with a variable reticulocyte count and recurrent increased unconjugated bilirubinemia without anemia in the propositus, while no clinical or hematological symptoms were evident in her mother.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11233775", "endSection": "abstract"}, {"offsetInBeginSection": 2121, "offsetInEndSection": 2644, "text": "The authors of this article make 5 particular recommendations: (1) Anyone suspected of G6PD deficiency should be screened; (2) exposure to oxidative stressors in these individuals should be avoided; (3) these patients should be informed of risks along with signs and symptoms of an acute hemolytic crisis; (4) the clinician should be able to identify both laboratory and clinical signs of hemolysis; and finally, (5) if an acute hemolytic crisis is identified, the patient should be admitted for close observation and care.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19769422", "endSection": "abstract"}, {"offsetInBeginSection": 639, "offsetInEndSection": 816, "text": "None of the patients with or without G6PD deficiency showed symptoms, signs, or laboratory findings indicating hemolysis before administration of the drug and 4 days thereafter.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9088998", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "Kinetic and electrophoretic properties of 230--300 fold purified preparations of glucose-6-phosphate dehydrogenase (G6PD) from red cells of donors and patients with acute drug hemolytic anemia due to G6PD deficiency were studied.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23188", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive disorder in which haemolytic anaemia is the major symptom.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11271380", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive genetic defect that can cause hemolytic crisis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25116429", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 245, "text": "However, its use is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk for haemolytic anaemia).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25807896", "endSection": "abstract"}, {"offsetInBeginSection": 61, "offsetInEndSection": 192, "text": "The role of glucose-6-phosphate dehydrogenase (G6PD) deficiency in the development of stroke in children with SCA is controversial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26840990", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive hemolytic anemia caused by a mutation in the G6PD gene on Xq28.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275698", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25807896", "endSection": "title"}]}, {"body": "Has the gorilla genome been determined?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11592477", "http://www.ncbi.nlm.nih.gov/pubmed/27034376", "http://www.ncbi.nlm.nih.gov/pubmed/22398555", "http://www.ncbi.nlm.nih.gov/pubmed/27435933"], "ideal_answer": ["Yes, the gorilla genome has been sequenced."], "type": "yesno", "id": "58dfec676fddd3e83e000006", "snippets": [{"offsetInBeginSection": 494, "offsetInEndSection": 638, "text": "Starting with human, chimpanzee, gorilla, and orangutan genomes, our software generated an exhaustive data set of 292 ALs (\u223c1 kb each) in \u223c3 h. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27435933", "endSection": "abstract"}, {"offsetInBeginSection": 101, "offsetInEndSection": 258, "text": "We generated a high-quality assembly of the gorilla genome using single-molecule, real-time sequence technology and a string graph de novo assembly algorithm", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27034376", "endSection": "abstract"}, {"offsetInBeginSection": 144, "offsetInEndSection": 301, "text": "Here we present the assembly and analysis of a genome sequence for the western lowland gorilla, and compare the whole genomes of all extant great ape genera.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22398555", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "DNA sequencing reveals that the genomes of the human, gorilla and chimpanzee share more than 98% homology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592477", "endSection": "abstract"}]}, {"body": "Is vemurafenib used for thyroid cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27460442", "http://www.ncbi.nlm.nih.gov/pubmed/27554612", "http://www.ncbi.nlm.nih.gov/pubmed/27754804", "http://www.ncbi.nlm.nih.gov/pubmed/24987354", "http://www.ncbi.nlm.nih.gov/pubmed/23489023", "http://www.ncbi.nlm.nih.gov/pubmed/26751190", "http://www.ncbi.nlm.nih.gov/pubmed/27127178", "http://www.ncbi.nlm.nih.gov/pubmed/26735176", "http://www.ncbi.nlm.nih.gov/pubmed/25353071", "http://www.ncbi.nlm.nih.gov/pubmed/25467940", "http://www.ncbi.nlm.nih.gov/pubmed/26284586", "http://www.ncbi.nlm.nih.gov/pubmed/22649416", "http://www.ncbi.nlm.nih.gov/pubmed/26176686", "http://www.ncbi.nlm.nih.gov/pubmed/26636651", "http://www.ncbi.nlm.nih.gov/pubmed/24262022", "http://www.ncbi.nlm.nih.gov/pubmed/27432558", "http://www.ncbi.nlm.nih.gov/pubmed/24756795"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/rxnorm/id/1147220", "o": "VEMURAFENIB"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C3192263", "o": "http://linkedlifedata.com/resource/umls/label/A20020623"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A20020623", "o": "VEMURAFENIB"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/1147220", "o": "http://linkedlifedata.com/resource/rxnorm/label/4224011"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/4224011", "o": "VEMURAFENIB"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/chembl/synonym/691867_Vemurafenib_USAN", "o": "Vemurafenib"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C3192263", "o": "http://linkedlifedata.com/resource/umls/label/A19613644"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A19613644", "o": "Vemurafenib"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C3192263", "o": "http://linkedlifedata.com/resource/umls/label/A19649207"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A19649207", "o": "Vemurafenib"}], "ideal_answer": ["Yes. Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:3963", "http://www.disease-ontology.org/api/metadata/DOID:1781", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013964"], "type": "yesno", "id": "58848ea5e56acf517600000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27460442", "endSection": "title"}, {"offsetInBeginSection": 117, "offsetInEndSection": 314, "text": "Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF-positive melanoma, showed clinical benefit in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27460442", "endSection": "abstract"}, {"offsetInBeginSection": 2338, "offsetInEndSection": 2559, "text": "INTERPRETATION: Vemurafenib showed antitumour activity in patients with progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a multikinase inhibitor. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27460442", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", "endSection": "title"}, {"offsetInBeginSection": 1685, "offsetInEndSection": 1840, "text": "CONCLUSIONS: Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAF(V600E) mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 459, "text": "The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in patients with progressive, radioactive iodine-refractory BRAF-mutant papillary thyroid cancer suggest response rates of approximately 30-40%.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25467940", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Use of vemurafenib in anaplastic thyroid carcinoma: a case report.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176686", "endSection": "title"}, {"offsetInBeginSection": 1212, "offsetInEndSection": 1361, "text": "Finally, we found that propranolol can amplify the cytotoxicity of vemurafenib and sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432558", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 399, "text": "CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.OBJECTIVE: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.DESIGN: A retrospective review at MD Anderson Cancer Center.METHODS: The best responses were evaluated using RECIST v1.1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 361, "text": "Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.A retrospective review at MD Anderson Cancer Center.The best responses were evaluated using RECIST v1.1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 400, "text": "CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.OBJECTIVE: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.DESIGN: A retrospective review at MD Anderson Cancer Center.METHODS: The best responses were evaluated using RECIST v1.1. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", "endSection": "abstract"}, {"offsetInBeginSection": 1220, "offsetInEndSection": 1369, "text": "Finally, we found that propranolol can amplify the cytotoxicity of vemurafenib and sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432558", "endSection": "abstract"}, {"offsetInBeginSection": 1237, "offsetInEndSection": 1415, "text": "Metformin or rapamycin adjuvant treatment may provide clinical benefits with minimal side effects to BRAFV600E-positive advanced thyroid cancer patients treated with vemurafenib.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 362, "text": "Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.A retrospective review at MD Anderson Cancer Center.The best responses were evaluated using RECIST v1.1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071", "endSection": "abstract"}, {"offsetInBeginSection": 1515, "offsetInEndSection": 1727, "text": "Our data demonstrate that vemurafenib induces ER stress response-mediated autophagy in thyroid cancer and autophagy inhibition may be a beneficial strategy to sensitize BRAF-mutant thyroid cancer to vemurafenib..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754804", "endSection": "abstract"}, {"offsetInBeginSection": 552, "offsetInEndSection": 729, "text": "Combination of vemurafenib and metformin decreased cell viability and increased apoptosis in both BCPAP papillary thyroid cancer cells and 8505c anaplastic thyroid cancer cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754804", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432558", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284586", "endSection": "title"}, {"offsetInBeginSection": 1010, "offsetInEndSection": 1092, "text": "Vemurafenib induced a high level of autophagy in BRAF-mutant thyroid cancer cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754804", "endSection": "abstract"}]}, {"body": "Are mutations in the C9orf72  gene associated with macular degeneration?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26303227", "http://www.ncbi.nlm.nih.gov/pubmed/24521566", "http://www.ncbi.nlm.nih.gov/pubmed/27632209", "http://www.ncbi.nlm.nih.gov/pubmed/22892647", "http://www.ncbi.nlm.nih.gov/pubmed/22300873", "http://www.ncbi.nlm.nih.gov/pubmed/22366791", "http://www.ncbi.nlm.nih.gov/pubmed/24442578", "http://www.ncbi.nlm.nih.gov/pubmed/23934648", "http://www.ncbi.nlm.nih.gov/pubmed/27619540", "http://www.ncbi.nlm.nih.gov/pubmed/22673113", "http://www.ncbi.nlm.nih.gov/pubmed/23053135", "http://www.ncbi.nlm.nih.gov/pubmed/24064469"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1428691", "o": "C9orf72"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1428691", "o": "http://linkedlifedata.com/resource/umls/label/A20715582"}], "ideal_answer": ["Amyotrophic lateral sclerosis (ALS) is characterized by motor neurone loss resulting in muscle weakness, spasticity and ultimately death. 5-10% are caused by inherited mutations, most commonly C9ORF72, SOD1, TARDBP and FUS."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012162", "http://www.disease-ontology.org/api/metadata/DOID:4448", "http://www.disease-ontology.org/api/metadata/DOID:10871", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057135", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008268", "http://www.disease-ontology.org/api/metadata/DOID:14245", "http://www.disease-ontology.org/api/metadata/DOID:8466"], "type": "yesno", "id": "58e11bf76fddd3e83e00000c", "snippets": [{"offsetInBeginSection": 296, "offsetInEndSection": 710, "text": "Over the years, however, growing evidence from clinical, pathological and genetic findings has suggested that ALS and FTD belong to the same clinic-pathological spectrum disorder. This concept has been further supported by the identification of the most common genetic cause for both diseases, an aberrantly expanded hexanucleotide repeat GGGGCC/ CCCCGG sequence located in a non-coding region of the gene C9orf72.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27619540", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 223, "text": "Amyotrophic lateral sclerosis (ALS) is characterized by motor neurone loss resulting in muscle weakness, spasticity and ultimately death. 5-10% are caused by inherited mutations, most commonly C9ORF72, SOD1, TARDBP and FUS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26303227", "endSection": "abstract"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1125, "text": "In this article, we will review the brief characterizations of the C9ORF72 gene, the expansion mutations, the related disorders, and their features, followed by a discussion of the deficiency knowledge of C9ORF72 mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23934648", "endSection": "abstract"}, {"offsetInBeginSection": 2374, "offsetInEndSection": 2520, "text": "Mutations in the C9ORF72 gene may be a major cause not only of frontotemporal dementia with motor neuron disease but also of late onset psychosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300873", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Frontotemporal lobar degeneration (FTLD) is a genetically heterogenous syndrome and has been associated most recently with a hexanucleotide repeat expansion within the C9ORF72 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22892647", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "An expanded GGGGCC hexanucleotide repeat in C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal lobar degeneration associated with TDP-43 pathology (FTLD-TDP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23053135", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Novel TARDBP sequence variant and C9ORF72 repeat expansion in a family with frontotemporal dementia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22892647", "endSection": "title"}, {"offsetInBeginSection": 914, "offsetInEndSection": 1027, "text": "There was, as expected, a significant association between C9ORF72 mutations and presence of motor neuron disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300873", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Expansion of a hexanucleotide repeat in the C9ORF72 gene has been identified as the most common pathogenic mutation in families with autosomal dominant frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24064469", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "C9ORF72 hexanucleotide repeat number in frontotemporal lobar degeneration: a genotype-phenotype correlation study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24064469", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 262, "text": "Hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9orf72) have recently been linked to frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis, and may be the most common genetic cause of both neurodegenerative diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24442578", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 260, "text": "studies recently identified a GGGGCC hexanucleotide repeat expansion in a non-coding region of the chromosome 9 open-reading frame 72 gene (C9ORF72) as the cause of chromosome 9p-linked amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22228244", "endSection": "abstract"}, {"offsetInBeginSection": 2, "offsetInEndSection": 208, "text": "GGGGCC hexanucleotide repeat expansion in the C9ORF72 gene was recently identified as an important cause of familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia in Caucasian populations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22673113", "endSection": "abstract"}]}, {"body": "What is the Genome 10K Project?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25689317", "http://www.ncbi.nlm.nih.gov/pubmed/22897955"], "ideal_answer": ["The Genome 10K Project was established in 2009 by a consortium of biologists and genome scientists determined to facilitate the sequencing and analysis of the complete genomes of 10,000 vertebrate species."], "type": "summary", "id": "58dff3f06fddd3e83e000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "The Genome 10K Project was established in 2009 by a consortium of biologists and genome scientists determined to facilitate the sequencing and analysis of the complete genomes of 10,000 vertebrate species.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25689317", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "The Genome 10K project aims to sequence the genomes of 10,000 vertebrates, representing approximately one genome for each vertebrate genus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22897955", "endSection": "abstract"}]}, {"body": "Which gene controls the expression of GATA-1 isoforms?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12202480", "http://www.ncbi.nlm.nih.gov/pubmed/24453067", "http://www.ncbi.nlm.nih.gov/pubmed/20304827"], "ideal_answer": ["In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development.  This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript.", "A transcriptional network has been reported, in which PU.1 positively regulates GATA-1 expression in mast cell development.", "In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation.", "Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development.", "Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript. Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation. ", "Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation. Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s."], "type": "factoid", "id": "58e75d483e8b6dc87c000005", "snippets": [{"offsetInBeginSection": 127, "offsetInEndSection": 272, "text": "Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24453067", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 320, "text": "In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20304827", "endSection": "abstract"}, {"offsetInBeginSection": 454, "offsetInEndSection": 611, "text": "This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20304827", "endSection": "abstract"}, {"offsetInBeginSection": 1035, "offsetInEndSection": 1186, "text": "Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20304827", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12202480", "endSection": "title"}, {"offsetInBeginSection": 886, "offsetInEndSection": 1034, "text": "Furthermore, we observe that in PU.1(-/-) fetal liver cells, low levels of the IE GATA-1 isoform is expressed, but the variant IB isoform is absent.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20304827", "endSection": "abstract"}, {"offsetInBeginSection": 1587, "offsetInEndSection": 1813, "text": "Our findings identify novel combinatorial protein-protein interactions for GATA-1, PU.1, and C/EBPepsilon isoforms in eosinophil gene transcription that include GATA-1/PU.1 synergy and repressor activity for C/EBPepsilon(27)..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12202480", "endSection": "abstract"}]}, {"body": "What is MIRA-seq?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25881900", "http://www.ncbi.nlm.nih.gov/pubmed/26384656", "http://www.ncbi.nlm.nih.gov/pubmed/27009155", "http://www.ncbi.nlm.nih.gov/pubmed/25623529"], "ideal_answer": ["MIRA-seq is a reliable, genome-scale DNA methylation analysis platform for scoring DNA methylation differences at CpG-rich genomic regions. The method is not limited by primer or probe design and is cost effective."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:1905642", "http://amigo.geneontology.org/amigo/term/GO:0044029", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019175", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018899", "http://amigo.geneontology.org/amigo/term/GO:0044027", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000070593", "http://amigo.geneontology.org/amigo/term/GO:0044728"], "type": "summary", "id": "588fd7cded9bbee70d000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "MIRA-seq for DNA methylation analysis of CpG islands.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25881900", "endSection": "title"}, {"offsetInBeginSection": 620, "offsetInEndSection": 834, "text": "MIRA-seq is a reliable, genome-scale DNA methylation analysis platform for scoring DNA methylation differences at CpG-rich genomic regions. The method is not limited by primer or probe design and is cost effective.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25881900", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Using MIRA-seq, we have characterized the DNA methylome of metastatic melanoma and normal melanocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26384656", "endSection": "abstract"}, {"offsetInBeginSection": 353, "offsetInEndSection": 538, "text": "Global gene expression was measured by RNA-Seq, while an epigenetic basis for expression differences was examined by methylated CpG island recovery assay sequencing (MIRA-Seq) analysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009155", "endSection": "abstract"}, {"offsetInBeginSection": 355, "offsetInEndSection": 540, "text": "Global gene expression was measured by RNA-Seq, while an epigenetic basis for expression differences was examined by methylated CpG island recovery assay sequencing (MIRA-Seq) analysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009155", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "MIRA-seq for DNA methylation analysis of CpG islands.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25881900", "endSection": "title"}, {"offsetInBeginSection": 576, "offsetInEndSection": 715, "text": "MIRA-seq is a reliable, genome-scale DNA methylation analysis platform for scoring DNA methylation differences at CpG-rich genomic regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25881900", "endSection": "abstract"}, {"offsetInBeginSection": 928, "offsetInEndSection": 1129, "text": "Despite extensive breed differences in the transcriptome, MIRA-Seq unveiled relatively similar patterns of genome-wide DNA methylation between breeds, with an overall hypomethylation of gene promoters.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009155", "endSection": "abstract"}, {"offsetInBeginSection": 1141, "offsetInEndSection": 1470, "text": "Methylated CpG island recovery assay sequencing (MIRA-Seq) revealed numerous methylation peaks spread across the genome, combined with an overall hypomethylation of gene promoter regions, and a remarkable similarity, except for 20 regions along the genome, between the fibroblasts collected at the two ages from the same animals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25623529", "endSection": "abstract"}]}, {"body": "How does Ssu72 mediate gene looping?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24945319", "http://www.ncbi.nlm.nih.gov/pubmed/19188448", "http://www.ncbi.nlm.nih.gov/pubmed/17803944", "http://www.ncbi.nlm.nih.gov/pubmed/16319194", "http://www.ncbi.nlm.nih.gov/pubmed/26119342", "http://www.ncbi.nlm.nih.gov/pubmed/12704082"], "ideal_answer": ["Investigation of chromosome folding in mutants confirms roles for RSC, \"gene looping\" factor Ssu72, Mediator, H3K56 acetyltransferase Rtt109, and the N-terminal tail of H4 in folding of the yeast genome. The essential N terminus of the Pta1 scaffold protein is required for snoRNA transcription termination and Ssu72 function but is dispensable for pre-mRNA 3'-end processing. TFIIB crosslinks to both the promoter and terminator regions of the PMA1 and BLM10 genes, and its association with the terminator, but not the promoter, is adversely affected by E62K and by depletion of the Ssu72 component of the CPF 3' end processing complex, and is independent of TBP. We propose a model for RNAP II transcription in which promoter and terminator regions are juxtaposed, and that the resulting gene loops facilitate transcription reinitiation by the same molecule of RNAP II in a manner dependent upon Ssu72-mediated CTD dephosphorylation. The first 300 amino acids of Pta1 are sufficient for interactions with Ssu72, which is needed for pre-mRNA cleavage. ", "In RNAP II transcription, promoter and terminator regions are juxtaposed and the resulting gene loops facilitate transcription reinitiation by the same molecule of RNAP II in a manner dependent upon Ssu72-mediated CTD dephosphorylation. These interactions are transcription-dependent, require the Ssu72 and Pta1 components of the CPF 3'-end processing complex, and require the phosphatase activity of Ssu72.", "tfiib crosslinks to both the promoter and terminator regions of the pma1 and blm10 genes, and its association with the terminator, but not the promoter, is adversely affected by e62k and by depletion of the ssu72 component of the cpf 3' end processing complex, and is independent of tbp.", "Investigation of chromosome folding in mutants confirms roles for RSC, \"gene looping\" factor Ssu72, Mediator, H3K56 acetyltransferase Rtt109, and the N-terminal tail of H4 in folding of the yeast genome. TFIIB crosslinks to both the promoter and terminator regions of the PMA1 and BLM10 genes, and its association with the terminator, but not the promoter, is adversely affected by E62K and by depletion of the Ssu72 component of the CPF 3' end processing complex, and is independent of TBP. We propose a model for RNAP II transcription in which promoter and terminator regions are juxtaposed, and that the resulting gene loops facilitate transcription reinitiation by the same molecule of RNAP II in a manner dependent upon Ssu72-mediated CTD dephosphorylation. The essential N terminus of the Pta1 scaffold protein is required for snoRNA transcription termination and Ssu72 function but is dispensable for pre-mRNA 3'-end processing  These interactions are transcription-dependent, require the Ssu72 and Pta1 components of the CPF 3'-end processing complex, and require the phosphatase activity of Ssu72. Furthermore, different regions of Pta1 interact with the CPF subunits Ssu72, Pti1, and Ysh1, supporting the idea that Pta1 acts as a scaffold to organize CPF.", "The essential N terminus of the Pta1 scaffold protein is required for snoRNA transcription termination and Ssu72 function but is dispensable for pre-mRNA 3'-end processing"], "type": "summary", "id": "58af14ae717cd3f655000001", "snippets": [{"offsetInBeginSection": 688, "offsetInEndSection": 891, "text": "Investigation of chromosome folding in mutants confirms roles for RSC, \"gene looping\" factor Ssu72, Mediator, H3K56 acetyltransferase Rtt109, and the N-terminal tail of H4 in folding of the yeast genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26119342", "endSection": "abstract"}, {"offsetInBeginSection": 661, "offsetInEndSection": 819, "text": "Furthermore, different regions of Pta1 interact with the CPF subunits Ssu72, Pti1, and Ysh1, supporting the idea that Pta1 acts as a scaffold to organize CPF.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "The essential N terminus of the Pta1 scaffold protein is required for snoRNA transcription termination and Ssu72 function but is dispensable for pre-mRNA 3'-end processing", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", "endSection": "title"}, {"offsetInBeginSection": 820, "offsetInEndSection": 937, "text": "The first 300 amino acids of Pta1 are sufficient for interactions with Ssu72, which is needed for pre-mRNA cleavage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", "endSection": "abstract"}, {"offsetInBeginSection": 1237, "offsetInEndSection": 1392, "text": "These findings suggest that the amino terminus of Pta1 has an inhibitory effect and that this effect can be neutralized through the interaction with Ssu72.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 799, "text": "TFIIB crosslinks to both the promoter and terminator regions of the PMA1 and BLM10 genes, and its association with the terminator, but not the promoter, is adversely affected by E62K and by depletion of the Ssu72 component of the CPF 3' end processing complex, and is independent of TBP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17803944", "endSection": "abstract"}, {"offsetInBeginSection": 585, "offsetInEndSection": 756, "text": " These interactions are transcription-dependent, require the Ssu72 and Pta1 components of the CPF 3'-end processing complex, and require the phosphatase activity of Ssu72.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16319194", "endSection": "abstract"}, {"offsetInBeginSection": 757, "offsetInEndSection": 1027, "text": "We propose a model for RNAP II transcription in which promoter and terminator regions are juxtaposed, and that the resulting gene loops facilitate transcription reinitiation by the same molecule of RNAP II in a manner dependent upon Ssu72-mediated CTD dephosphorylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16319194", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "The essential N terminus of the Pta1 scaffold protein is required for snoRNA transcription termination and Ssu72 function but is dispensable for pre-mRNA 3'-end processing.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", "endSection": "title"}, {"offsetInBeginSection": 469, "offsetInEndSection": 661, "text": "The pta1-Delta75 mutant is defective for snoRNA termination, RNA polymerase II C-terminal domain Ser5-P dephosphorylation, and gene looping but is fully functional for mRNA 3'-end processing. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", "endSection": "abstract"}, {"offsetInBeginSection": 1168, "offsetInEndSection": 1325, "text": "We conclude that Swd2.2 opposes condensin-mediated chromosome condensation by facilitating the function of the two CPF-associated phosphatases PP1 and Ssu72.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24945319", "endSection": "abstract"}, {"offsetInBeginSection": 983, "offsetInEndSection": 1286, "text": "Based on the interactions of Ssu72 and Sub1 with both the Pta1 of CPF and the TFIIB component of the initiation complex, we present a model describing how these novel connections between the transcription and 3' end processing machineries might facilitate transitions in the RNAP II transcription cycle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12704082", "endSection": "abstract"}, {"offsetInBeginSection": 937, "offsetInEndSection": 1128, "text": "By the degron-mediated depletion of Pta1, we show that the removal of this essential region leads to a loss of Ssu72, yet surprisingly, in vitro cleavage and polyadenylation remain efficient.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", "endSection": "abstract"}, {"offsetInBeginSection": 469, "offsetInEndSection": 660, "text": "The pta1-Delta75 mutant is defective for snoRNA termination, RNA polymerase II C-terminal domain Ser5-P dephosphorylation, and gene looping but is fully functional for mRNA 3'-end processing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19188448", "endSection": "abstract"}]}, {"body": "Is the number of described human nuclear mutations less than 50000?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22948725", "http://www.ncbi.nlm.nih.gov/pubmed/20569258", "http://www.ncbi.nlm.nih.gov/pubmed/24077912"], "ideal_answer": ["No, The number of known mutations in human nuclear genes, underlying or associated with human inherited disease, has now exceeded 100,000 in more than 3700 different genes (Human Gene Mutation Database)."], "type": "yesno", "id": "58e26ede6fddd3e83e000015", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "The number of known mutations in human nuclear genes, underlying or associated with human inherited disease, has now exceeded 100,000 in more than 3700 different genes (Human Gene Mutation Database).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20569258", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 368, "text": "The Human Gene Mutation Database (HGMD\u00ae) is a comprehensive collection of germline mutations in nuclear genes that underlie, or are associated with, human inherited disease. By June 2013, the database contained over 141,000 different lesions detected in over 5,700 different genes, with new mutation entries currently accumulating at a rate exceeding 10,000 per annum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24077912", "endSection": "abstract"}, {"offsetInBeginSection": 607, "offsetInEndSection": 778, "text": "By March 2012, the database contained in excess of 123,600 different lesions (HGMD Professional release 2012.1) detected in 4,514 different nuclear genes, with new entries", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22948725", "endSection": "abstract"}]}, {"body": "What is the role of peptide aptamers?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21224349", "http://www.ncbi.nlm.nih.gov/pubmed/22949372", "http://www.ncbi.nlm.nih.gov/pubmed/25966787", "http://www.ncbi.nlm.nih.gov/pubmed/21838684", "http://www.ncbi.nlm.nih.gov/pubmed/25238402", "http://www.ncbi.nlm.nih.gov/pubmed/18186614", "http://www.ncbi.nlm.nih.gov/pubmed/23785412", "http://www.ncbi.nlm.nih.gov/pubmed/11071782", "http://www.ncbi.nlm.nih.gov/pubmed/8755498", "http://www.ncbi.nlm.nih.gov/pubmed/17189388", "http://www.ncbi.nlm.nih.gov/pubmed/25801767", "http://www.ncbi.nlm.nih.gov/pubmed/19377984", "http://www.ncbi.nlm.nih.gov/pubmed/15037656", "http://www.ncbi.nlm.nih.gov/pubmed/19295259", "http://www.ncbi.nlm.nih.gov/pubmed/17574575", "http://www.ncbi.nlm.nih.gov/pubmed/16581027", "http://www.ncbi.nlm.nih.gov/pubmed/19895821", "http://www.ncbi.nlm.nih.gov/pubmed/18195017", "http://www.ncbi.nlm.nih.gov/pubmed/16751801", "http://www.ncbi.nlm.nih.gov/pubmed/12842895", "http://www.ncbi.nlm.nih.gov/pubmed/11641783", "http://www.ncbi.nlm.nih.gov/pubmed/18314488", "http://www.ncbi.nlm.nih.gov/pubmed/23579184", "http://www.ncbi.nlm.nih.gov/pubmed/18243349", "http://www.ncbi.nlm.nih.gov/pubmed/25699094", "http://www.ncbi.nlm.nih.gov/pubmed/9222505", "http://www.ncbi.nlm.nih.gov/pubmed/24478452", "http://www.ncbi.nlm.nih.gov/pubmed/12530529", "http://www.ncbi.nlm.nih.gov/pubmed/20653933", "http://www.ncbi.nlm.nih.gov/pubmed/18265211", "http://www.ncbi.nlm.nih.gov/pubmed/25963836", "http://www.ncbi.nlm.nih.gov/pubmed/25230811", "http://www.ncbi.nlm.nih.gov/pubmed/22503683", "http://www.ncbi.nlm.nih.gov/pubmed/19377987", "http://www.ncbi.nlm.nih.gov/pubmed/19320493", "http://www.ncbi.nlm.nih.gov/pubmed/10439043", "http://www.ncbi.nlm.nih.gov/pubmed/15231297", "http://www.ncbi.nlm.nih.gov/pubmed/15952909", "http://www.ncbi.nlm.nih.gov/pubmed/19377988", "http://www.ncbi.nlm.nih.gov/pubmed/18336207", "http://www.ncbi.nlm.nih.gov/pubmed/16731923"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/595798", "o": "http://linkedlifedata.com/resource/rxnorm/label/3218865"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3218865", "o": "Peptide Aptamers"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1567956", "o": "Aptamers, Peptide"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1567956", "o": "http://linkedlifedata.com/resource/umls/label/A17937093"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17937093", "o": "Aptamers, Peptide"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/595798", "o": "http://linkedlifedata.com/resource/rxnorm/label/3111176"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3111176", "o": "Aptamers, Peptide"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1567956", "o": "http://linkedlifedata.com/resource/umls/label/A17888724"}], "ideal_answer": ["Peptide aptamers are artificial short peptides which are able to specifically bind to defined functional domains, track, and inhibit a given target molecule with high affinity, even molecules with poor immunogenicity or high toxicity. They represent a remarkable alternative to antibodies in many different applications."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052158", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012380", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010455"], "type": "summary", "id": "58d131218acda34529000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Peptide aptamers: The versatile role of specific protein function inhibitors in plant biotechnology.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966787", "endSection": "title"}, {"offsetInBeginSection": 215, "offsetInEndSection": 485, "text": " These artificial short peptides are able to specifically bind, track, and inhibit a given target molecule with high affinity, even molecules with poor immunogenicity or high toxicity, and represent a remarkable alternative to antibodies in many different applications. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966787", "endSection": "abstract"}, {"offsetInBeginSection": 488, "offsetInEndSection": 696, "text": "To inhibit the oncogenic action of Stat3 in tumor cells, we have selected short peptides, so-called peptide aptamers, which specifically interact with defined functional domains of this transcription factor. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15037656", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 347, "text": "Aptasensors utilize aptamers as bioreceptors. Aptamers are highly efficient, have a high specificity and are reusable. Within the biosensor the aptamers are immobilized to maximize their access to target molecules. Knowledge of the orientation and location of the aptamer and peptide during binding could be gained through computational modeling. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25963836", "endSection": "abstract"}, {"offsetInBeginSection": 607, "offsetInEndSection": 743, "text": "Understanding orientation and location of the binding region for a peptide-aptamer complex is critical in their biosensor applicability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25963836", "endSection": "abstract"}, {"offsetInBeginSection": 2171, "offsetInEndSection": 2435, "text": " Our study clearly demonstrates the ability of MD simulations to obtain molecular insights for peptide-aptamer binding, and to provide details on the orientation and location of binding between the peptide-aptamer that can be instrumental in biosensor development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25963836", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "Peptide aptamers are artificial short peptides that potentially interfere with the biological roles of their target proteins; however, this technology has not yet been applied to plant functional genomics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230811", "endSection": "abstract"}, {"offsetInBeginSection": 252, "offsetInEndSection": 436, "text": "To extend such strategies we selected peptide aptamers binding to PrP from a combinatorial peptide library presented on the Escherichia coli thioredoxin A (trxA) protein as a scaffold.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17574575", "endSection": "abstract"}, {"offsetInBeginSection": 1064, "offsetInEndSection": 1277, "text": "These peptide aptamers retained their binding properties to PrPc and, depending on peptide sequence and C-terminal modification, interfered with endogenous PrPSc conversion upon expression in prion-infected cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17574575", "endSection": "abstract"}, {"offsetInBeginSection": 566, "offsetInEndSection": 706, "text": "Binding to the nonfarnesylated peptide was at least 10-fold weaker, showing that the aptamers can recognize the hydrophobic farnesyl moiety.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9222505", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Peptide aptamers: exchange of the thioredoxin-A scaffold by alternative platform proteins and its influence on target protein binding.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12530529", "endSection": "title"}, {"offsetInBeginSection": 190, "offsetInEndSection": 351, "text": "Typically, peptide aptamers are generated by screening a randomized peptide expression library, displayed from the Escherichia coli thioredoxin A (TrxA) protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12530529", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Peptide aptamers define distinct EB1- and EB3-binding motifs and interfere with microtubule dynamics.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24478452", "endSection": "title"}, {"offsetInBeginSection": 222, "offsetInEndSection": 382, "text": "Reverse analysis with peptide aptamers involves isolating aptamers that interact with a specific protein and monitoring the resulting aptamer-induced phenotype.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18265211", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 504, "text": "Peptide aptamers are combinatorial protein reagents that bind to targets with a high specificity and a strong affinity thus providing a molecular tool kit for modulating the function of their targets in vivo.Here we report the isolation of a peptide aptamer named swiggle that interacts with the very short (21 amino acid long) intracellular domain of membrane type 1-metalloproteinase (MT1-MMP), a key cell surface protease involved in numerous and crucial physiological and pathological cellular events", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20653933", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Peptide aptamers are simple structures, often made up of a single-variable peptide loop constrained within a constant scaffold protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19895821", "endSection": "abstract"}, {"offsetInBeginSection": 286, "offsetInEndSection": 461, "text": "Peptide aptamers are small peptide sequences that have been selected to recognise a predetermined target protein domain and are potentially able to interfere with its function", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15952909", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Aptamers, including DNA, RNA and peptide aptamers, are a group of promising recognition units that can specifically bind to target molecules and cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25699094", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Aptamers are a group of molecules, which can specifically bind, track, and inhibit target molecules, comprising DNA aptamers, RNA aptamers, and peptide aptamers", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949372", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Peptide aptamers: The versatile role of specific protein function inhibitors in plant biotechnology", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966787", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Peptide aptamers are small proteins containing a randomized peptide sequence embedded into a stable protein scaffold, such as Thioredoxin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23785412", "endSection": "abstract"}, {"offsetInBeginSection": 534, "offsetInEndSection": 822, "text": "Peptide aptamers can subsequently be used to guide the discovery of small molecule drugs specific for these molecular surfaces.Here, we present a high-throughput screening assay that identifies small molecules that displace interactions between proteins and their cognate peptide aptamers", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19377984", "endSection": "abstract"}, {"offsetInBeginSection": 154, "offsetInEndSection": 443, "text": "These peptide aptamers are target-specific peptides expressed within a protein scaffold engineered from the human protease inhibitor stefin A. The scaffold provides stability to the inserted peptides and increases their binding affinity owing to the resulting three-dimensional constraints", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18186614", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Isolation of Peptide aptamers to target protein function.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19377987", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17189388", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21224349", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11641783", "endSection": "title"}, {"offsetInBeginSection": 1590, "offsetInEndSection": 1776, "text": "These data highlight the utility of peptide aptamers to identify novel binding interfaces and highlight a role for MAP1B in DAPK-1-dependent signaling in autophagy and membrane blebbing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18195017", "endSection": "abstract"}, {"offsetInBeginSection": 399, "offsetInEndSection": 588, "text": "Therapeutic application depends on binding specificities and affinities, as well as on the production and purification characteristics of the peptide aptamers and their delivery into cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18314488", "endSection": "abstract"}, {"offsetInBeginSection": 209, "offsetInEndSection": 407, "text": "While antibodies are known to recognize the sequence and conformation of protein surface features (epitopes), very little is known about the precise interactions between aptamers and their epitopes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8755498", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18314488", "endSection": "title"}, {"offsetInBeginSection": 423, "offsetInEndSection": 575, "text": "The use of small peptide aptamers to competitively inhibit protein interaction and function is becoming increasingly recognized as a powerful technique.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24478452", "endSection": "abstract"}, {"offsetInBeginSection": 1373, "offsetInEndSection": 1533, "text": "For the first time, we show that trxA-based peptide aptamers can be targeted to the secretory pathway, thereby not losing the affinity for their target protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17574575", "endSection": "abstract"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1047, "text": "Moreover, the aptamers appeared to be able to bind peptides with different solution conformations, implying an induced fit mechanism for binding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8755498", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Peptide aptamers are small proteins containing a randomized peptide sequence embedded into a stable protein scaffold, such as Thioredoxin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23785412", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Peptide aptamers are the newest in the class of \"genetic\" agents that aid in the analysis of cellular processes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18265211", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Peptide aptamers: The versatile role of specific protein function inhibitors in plant biotechnology.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966787", "endSection": "title"}, {"offsetInBeginSection": 637, "offsetInEndSection": 892, "text": "Here we present a detailed protocol for the creation of a peptide aptamer plasmid library, selection of peptide aptamers using the LiRP scaffold in a yeast two-hybrid system, and the screening of those peptide aptamers for a ligand-regulated interaction..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19377988", "endSection": "abstract"}]}, {"body": "Which are the clinical symptoms of left ventricular noncompaction?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27274374", "http://www.ncbi.nlm.nih.gov/pubmed/15458689", "http://www.ncbi.nlm.nih.gov/pubmed/11858389", "http://www.ncbi.nlm.nih.gov/pubmed/19218740", "http://www.ncbi.nlm.nih.gov/pubmed/24231893", "http://www.ncbi.nlm.nih.gov/pubmed/20347493", "http://www.ncbi.nlm.nih.gov/pubmed/23258208", "http://www.ncbi.nlm.nih.gov/pubmed/20860157", "http://www.ncbi.nlm.nih.gov/pubmed/23633270", "http://www.ncbi.nlm.nih.gov/pubmed/22949776", "http://www.ncbi.nlm.nih.gov/pubmed/23196658", "http://www.ncbi.nlm.nih.gov/pubmed/17479651", "http://www.ncbi.nlm.nih.gov/pubmed/9005281", "http://www.ncbi.nlm.nih.gov/pubmed/21987083", "http://www.ncbi.nlm.nih.gov/pubmed/24132556", "http://www.ncbi.nlm.nih.gov/pubmed/10824732", "http://www.ncbi.nlm.nih.gov/pubmed/23843353", "http://www.ncbi.nlm.nih.gov/pubmed/25290726", "http://www.ncbi.nlm.nih.gov/pubmed/23117287", "http://www.ncbi.nlm.nih.gov/pubmed/24826276", "http://www.ncbi.nlm.nih.gov/pubmed/22009732", "http://www.ncbi.nlm.nih.gov/pubmed/22773171", "http://www.ncbi.nlm.nih.gov/pubmed/22235038", "http://www.ncbi.nlm.nih.gov/pubmed/23914034"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1457887", "o": "Symptoms"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1457887", "o": "http://linkedlifedata.com/resource/umls/label/A0788385"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0788385", "o": "SYMPTOMS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1457887", "o": "http://linkedlifedata.com/resource/umls/label/A11838788"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11838788", "o": "Symptoms"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1457887", "o": "http://linkedlifedata.com/resource/umls/label/A7164206"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7164206", "o": "Symptoms"}], "ideal_answer": ["The clinical symptoms of left ventricular noncompaction are:\n1) heart failure, \n2) systemic thromboembolic events, \n3) ventricular arrhythmias and\n4) sudden cardiac death."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016277", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018754", "http://www.disease-ontology.org/api/metadata/DOID:0060480", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018487"], "type": "list", "id": "58d8e9bd8acda3452900000b", "snippets": [{"offsetInBeginSection": 188, "offsetInEndSection": 377, "text": "Perioperative management of the patient with LVNC might be challenging due to the clinical symptoms of heart failure, systemic thromboembolic events, and fatal left ventricular arrhythmias.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27274374", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "Left ventricular noncompaction cardiomyopathy is a rare type of congenital cardiomyopathy characterized by prematurely arrested compaction of the endocardial and myocardial fibers and the progressive deterioration of left ventricular contractility. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196658", "endSection": "abstract"}, {"offsetInBeginSection": 313, "offsetInEndSection": 590, "text": "Clinical features associated with LVNC vary in asymptomatic and symptomatic patients, and include the potential for heart failure, conduction defects (eg, left bundle branch block), supraventricular and ventricular arrhythmias, thromboembolic events, and sudden cardiac death. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25290726", "endSection": "abstract"}, {"offsetInBeginSection": 1146, "offsetInEndSection": 1328, "text": "The clinical presentations are variable ranging from asymptomatic patients to patients who develop ventricular arrhythmias, thromboembolism, heart failure, and sudden cardiac death. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24132556", "endSection": "abstract"}, {"offsetInBeginSection": 372, "offsetInEndSection": 546, "text": "The clinical presentation and the natural history of LVNC are highly variable, ranging from no symptoms to congestive heart failure, arrhythmias, and systemic thromboemboli. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23117287", "endSection": "abstract"}, {"offsetInBeginSection": 451, "offsetInEndSection": 606, "text": "The clinical manifestations of the disease are variable, ranging from no symptoms to signs of heart failure, systemic emboli, and ventricular arrhythmias. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22773171", "endSection": "abstract"}, {"offsetInBeginSection": 281, "offsetInEndSection": 414, "text": "We describe the case of a 62-year-old woman who presented with symptoms of heart failure secondary to left ventricular noncompaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Multiple left ventricular thrombi in a patient with left ventricular noncompaction.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949776", "endSection": "title"}, {"offsetInBeginSection": 146, "offsetInEndSection": 578, "text": "We present three children with myocardial noncompaction: one male with isolated left ventricular noncompaction, another with right ventricular noncompaction and dysplastic tricuspid valve, and the last with left ventricular noncompaction, ventricular septal defect and coarctation of aorta, to stress especially the different clinical forms of the disorder and the importance of early diagnosis, as it may result in a fatal outcome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17479651", "endSection": "abstract"}, {"offsetInBeginSection": 172, "offsetInEndSection": 443, "text": "Left ventricular noncompaction has a heterogeneous clinical presentation that includes arrhythmia and sudden cardiac death.We retrospectively reviewed all children diagnosed with left ventricular noncompaction at Texas Childrens Hospital from January 1990 to January 2009", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633270", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Left ventricular noncompaction is a cardiomyopathy characterized by excessive trabeculation of the left ventricle, progressive myocardial dysfunction, and early mortality", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633270", "endSection": "abstract"}, {"offsetInBeginSection": 283, "offsetInEndSection": 417, "text": "We describe the case of a 62-year-old woman who presented with symptoms of heart failure secondary to left ventricular noncompaction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949776", "endSection": "abstract"}, {"offsetInBeginSection": 1094, "offsetInEndSection": 1273, "text": "Left ventricular noncompaction (LVNC) and dilated CMP are the most common cardiac phenotypes reported and can lead to symptoms of heart failure as well as ventricular arrhythmias.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23843353", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Multiple left ventricular thrombi in a patient with left ventricular noncompaction.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949776", "endSection": "title"}, {"offsetInBeginSection": 172, "offsetInEndSection": 295, "text": "Left ventricular noncompaction has a heterogeneous clinical presentation that includes arrhythmia and sudden cardiac death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633270", "endSection": "abstract"}, {"offsetInBeginSection": 360, "offsetInEndSection": 513, "text": "Clinical symptoms include signs of left ventricular systolic dysfunction even to the point of heart failure, ventricular arrhythmias, and embolic events.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10824732", "endSection": "abstract"}]}, {"body": "What is the Glasgow Coma score?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25834958", "http://www.ncbi.nlm.nih.gov/pubmed/26295284", "http://www.ncbi.nlm.nih.gov/pubmed/23022643", "http://www.ncbi.nlm.nih.gov/pubmed/11332457"], "ideal_answer": ["Glasgow coma sore is used to determine injury severity on admission to a hospital emergency department or by the duration of unconsciousness."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015600"], "type": "summary", "id": "58cdbbd102b8c60953000045", "snippets": [{"offsetInBeginSection": 423, "offsetInEndSection": 543, "text": " Injury severity was determined by the Glasgow Coma Scale (GCS) score on admission or by the duration of unconsciousness", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26295284", "endSection": "abstract"}, {"offsetInBeginSection": 600, "offsetInEndSection": 678, "text": "Severity analysis was based on the Glasgow Coma Scale and Injury Severity Scor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25834958", "endSection": "abstract"}, {"offsetInBeginSection": 663, "offsetInEndSection": 775, "text": "The strongest correlations were found between the Glasgow coma score and quality of life (r\u00a0= 0.236, P\u00a0= 0.0001)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23022643", "endSection": "abstract"}, {"offsetInBeginSection": 1245, "offsetInEndSection": 1420, "text": "By accepting the Glasgow Coma Scale as a gold standard for classification of the level of coma, we can confirm satisfactory measuring qualities for the Vienna Vigilance Score.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11332457", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 399, "text": "Our aim in this study was to assess whether the new Glasgow Coma Scale, Age, and Systolic Blood Pressure (GAP) scoring system, which is a modification of the Mechanism, Glasgow Coma Scale, Age, and Arterial Pressure (MGAP) scoring system, better predicts in-hospital mortality and can be applied more easily than previous trauma scores among trauma patients in the emergency department", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21831280", "endSection": "abstract"}]}, {"body": "Andexanet Alfa is an antidote of which clotting factor inhibitors?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27147456", "http://www.ncbi.nlm.nih.gov/pubmed/26449414", "http://www.ncbi.nlm.nih.gov/pubmed/27082776", "http://www.ncbi.nlm.nih.gov/pubmed/26559317", "http://www.ncbi.nlm.nih.gov/pubmed/27575436", "http://www.ncbi.nlm.nih.gov/pubmed/25516695", "http://www.ncbi.nlm.nih.gov/pubmed/27399455", "http://www.ncbi.nlm.nih.gov/pubmed/25494843", "http://www.ncbi.nlm.nih.gov/pubmed/25816811", "http://www.ncbi.nlm.nih.gov/pubmed/27895055", "http://www.ncbi.nlm.nih.gov/pubmed/27789605", "http://www.ncbi.nlm.nih.gov/pubmed/27659071", "http://www.ncbi.nlm.nih.gov/pubmed/25431993", "http://www.ncbi.nlm.nih.gov/pubmed/26069913", "http://www.ncbi.nlm.nih.gov/pubmed/27913536", "http://www.ncbi.nlm.nih.gov/pubmed/26627486", "http://www.ncbi.nlm.nih.gov/pubmed/26872887", "http://www.ncbi.nlm.nih.gov/pubmed/27697443", "http://www.ncbi.nlm.nih.gov/pubmed/26686866", "http://www.ncbi.nlm.nih.gov/pubmed/26519420", "http://www.ncbi.nlm.nih.gov/pubmed/25387210"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0003295", "o": "antidote"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0003295", "o": "http://linkedlifedata.com/resource/umls/label/A17973253"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17973253", "o": "Antidote"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/930", "o": "http://linkedlifedata.com/resource/rxnorm/label/30155"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/30155", "o": "Antidote"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/rxnorm/id/99104", "o": "Coagulation factor inhibitor"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/99104", "o": "http://linkedlifedata.com/resource/rxnorm/label/743388"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0003295", "o": "http://linkedlifedata.com/resource/umls/label/A17925206"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17925206", "o": "Antidote [EPC]"}], "ideal_answer": ["Andexanet alfa is a specific reversal agent for Factor Xa inhibitors.", "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. Idarucizumab and andexanet alfa are NOAC-specific reversal agents designed to reverse dabigatran and factor Xa inhibitors accordingly. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. ", "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin.", "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. Idarucizumab and andexanet alfa are NOAC-specific reversal agents designed to reverse dabigatran and factor Xa inhibitors accordingly. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) was able to dose-dependently reverse Factor Xa inhibition and restore thrombin generation for the duration of drug administration. ", "andexanet alfa is a factor xa (fxa) decoy that binds to direct and indirect inhibitors in phase iii trials in healthy volunteers , andexanet alfa reduced anti-fxa activity by more than 90% , reduced the concentration of unbound direct fxa inhibitor , and inhibited thrombin generation . andexanet is an antidote targeted to reverse the oral direct factor xa inhibitors as well as the indirect inhibitor enoxaparin. . ", "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. In Phase III trials in healthy volunteers, andexanet alfa reduced anti-FXa activity by more than 90%, reduced the concentration of unbound direct FXa inhibitor, and inhibited thrombin generation. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) was able to dose-dependently reverse Factor Xa inhibition and restore thrombin generation for the duration of drug administration. ", "Andexanet alfa (r-Antidote, PRT064445; Portola Pharmaceuticals) is a truncated form of enzymatically inactive factor Xa, which binds and reverses the anticoagulant action of the factor Xa inhibitors (e.g.: rivaroxaban, apixaban and edoxaban). Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. Andexanet alfa (AnXa), a recombinant modified FXa, is an investigational specific antidote for FXa inhibitors. Antidotes that experimentally reverse the anti-coagulant effect of dabigatran (Idarucizumab; BI 655075; Boehringer Ingelheim); of rivaroxaban, apixaban, or edoxaban (Andexanet alfa, r-Antidote, PRT064445; Portola Pharmaceuticals) or of all DOACs (Aripazine, PER-977, ciraparantag; Perosphere Inc.) are discussed. Idarucizumab and andexanet alfa are NOAC-specific reversal agents designed to reverse dabigatran and factor Xa inhibitors accordingly. Andexanet alfa (PRT064445), a specific reversal agent against factor Xa inhibitors, showed a complete reversal of anticoagulant activity of apixaban and rivaroxaban within minutes after administration without adverse effects in two recently completed parallel phase III trials ANNEXA-A and ANNEXA-R respectively.", "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. Idarucizumab and andexanet alfa are NOAC-specific reversal agents designed to reverse dabigatran and factor Xa inhibitors accordingly.", "Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin.", "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. Andexanet alfa is a factor Xa (FXa) decoy that binds to direct and indirect FXa inhibitors."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000925", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000931", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019774"], "type": "factoid", "id": "5880b073c872c95565000003", "snippets": [{"offsetInBeginSection": 642, "offsetInEndSection": 789, "text": "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26449414", "endSection": "abstract"}, {"offsetInBeginSection": 1095, "offsetInEndSection": 1229, "text": "Idarucizumab and andexanet alfa are NOAC-specific reversal agents designed to reverse dabigatran and factor Xa inhibitors accordingly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26627486", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26686866", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Andexanet alfa is a specific reversal agent for Factor Xa inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26686866", "endSection": "abstract"}, {"offsetInBeginSection": 238, "offsetInEndSection": 440, "text": "In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) was able to dose-dependently reverse Factor Xa inhibition and restore thrombin generation for the duration of drug administration. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26686866", "endSection": "abstract"}, {"offsetInBeginSection": 1198, "offsetInEndSection": 1330, "text": "Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26872887", "endSection": "abstract"}, {"offsetInBeginSection": 746, "offsetInEndSection": 1034, "text": "Andexanet alfa is a factor Xa (FXa) decoy that binds to direct and indirect FXa inhibitors. In Phase III trials in healthy volunteers, andexanet alfa reduced anti-FXa activity by more than 90%, reduced the concentration of unbound direct FXa inhibitor, and inhibited thrombin generation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27147456", "endSection": "abstract"}, {"offsetInBeginSection": 734, "offsetInEndSection": 938, "text": "Andexanet alfa (r-Antidote, PRT064445; Portola Pharmaceuticals) is a truncated form of enzymatically inactive factor Xa, which binds and reverses the anticoagulant action of the factor Xa inhibitors (e.g.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25494843", "endSection": "abstract"}, {"offsetInBeginSection": 1308, "offsetInEndSection": 1601, "text": "Recent results from phase 3/4 studies demonstrate efficacy for an antidote to dabigatran (idarucizumab, a monoclonal antibody fragment with specificity for dabigatran) and an antidote to factor Xa inhibitors (andexanet alfa, a recombinant and inactive form of factor Xa that binds inhibitors).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27913536", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "176\u2003Andexanet Alfa: An Investigational Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399455", "endSection": "title"}, {"offsetInBeginSection": 1190, "offsetInEndSection": 1322, "text": "Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26872887", "endSection": "abstract"}, {"offsetInBeginSection": 638, "offsetInEndSection": 785, "text": "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26449414", "endSection": "abstract"}, {"offsetInBeginSection": 172, "offsetInEndSection": 282, "text": "Andexanet alfa (AnXa), a recombinant modified FXa, is an investigational specific antidote for FXa inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399455", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 352, "text": "With Idarucizumab and Andexanet Alfa, specific antidotes have been developed against both, direct thrombin inhibitors as well as direct Factor Xa inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26069913", "endSection": "abstract"}, {"offsetInBeginSection": 197, "offsetInEndSection": 354, "text": "With Idarucizumab and Andexanet Alfa, specific antidotes have been developed against both, direct thrombin inhibitors as well as direct Factor Xa inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26069913", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559317", "endSection": "title"}, {"offsetInBeginSection": 959, "offsetInEndSection": 1212, "text": "Specific reversal agents are currently under development (idarucizumab for dabigatran, andexanet alfa for Xa inhibitors, and PER977 for both Xa- and thrombin inhibitors), which will facilitate clinical management of severe bleeding and emergency surgery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25431993", "endSection": "abstract"}, {"offsetInBeginSection": 197, "offsetInEndSection": 355, "text": "With Idarucizumab and Andexanet Alfa, specific antidotes have been developed against both, direct thrombin inhibitors as well as direct Factor Xa inhibitors. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26069913", "endSection": "abstract"}, {"offsetInBeginSection": 739, "offsetInEndSection": 981, "text": "Andexanet alfa (r-Antidote, PRT064445; Portola Pharmaceuticals) is a truncated form of enzymatically inactive factor Xa, which binds and reverses the anticoagulant action of the factor Xa inhibitors (e.g.: rivaroxaban, apixaban and edoxaban).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25494843", "endSection": "abstract"}, {"offsetInBeginSection": 174, "offsetInEndSection": 284, "text": "Andexanet alfa (AnXa), a recombinant modified FXa, is an investigational specific antidote for FXa inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399455", "endSection": "abstract"}, {"offsetInBeginSection": 1077, "offsetInEndSection": 1389, "text": "Andexanet alfa (PRT064445), a specific reversal agent against factor Xa inhibitors, showed a complete reversal of anticoagulant activity of apixaban and rivaroxaban within minutes after administration without adverse effects in two recently completed parallel phase III trials ANNEXA-A and ANNEXA-R respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27082776", "endSection": "abstract"}, {"offsetInBeginSection": 1673, "offsetInEndSection": 1968, "text": "New antidotes are being explored, including a mouse monoclonal antibody to dabigatran; andexanet alfa, a potential universal factor Xa inhibitor reversal agent; and a synthetic small molecule (PER977) that may be effective for the reversal of factor Xa inhibitors and direct thrombin inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516695", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559317", "endSection": "title"}, {"offsetInBeginSection": 699, "offsetInEndSection": 857, "text": "Currently, two potential reversal agents for oral direct factor Xa inhibitors (andexanet alfa and ciraparantag) are at various stages of clinical development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27895055", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "176\u2003Andexanet Alfa: An Investigational Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399455", "endSection": "title"}, {"offsetInBeginSection": 1315, "offsetInEndSection": 1608, "text": "Recent results from phase 3/4 studies demonstrate efficacy for an antidote to dabigatran (idarucizumab, a monoclonal antibody fragment with specificity for dabigatran) and an antidote to factor Xa inhibitors (andexanet alfa, a recombinant and inactive form of factor Xa that binds inhibitors).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27913536", "endSection": "abstract"}]}, {"body": "Which is the main cause of the Patau syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11885075", "http://www.ncbi.nlm.nih.gov/pubmed/23613355", "http://www.ncbi.nlm.nih.gov/pubmed/17603803", "http://www.ncbi.nlm.nih.gov/pubmed/14506431", "http://www.ncbi.nlm.nih.gov/pubmed/6458983", "http://www.ncbi.nlm.nih.gov/pubmed/18467377", "http://www.ncbi.nlm.nih.gov/pubmed/12762245", "http://www.ncbi.nlm.nih.gov/pubmed/24993362", "http://www.ncbi.nlm.nih.gov/pubmed/18253026", "http://www.ncbi.nlm.nih.gov/pubmed/12393964", "http://www.ncbi.nlm.nih.gov/pubmed/20537076", "http://www.ncbi.nlm.nih.gov/pubmed/19408854", "http://www.ncbi.nlm.nih.gov/pubmed/24564826", "http://www.ncbi.nlm.nih.gov/pubmed/20641042", "http://www.ncbi.nlm.nih.gov/pubmed/23949924", "http://www.ncbi.nlm.nih.gov/pubmed/24340511", "http://www.ncbi.nlm.nih.gov/pubmed/26034714", "http://www.ncbi.nlm.nih.gov/pubmed/2325123", "http://www.ncbi.nlm.nih.gov/pubmed/23622175", "http://www.ncbi.nlm.nih.gov/pubmed/20584846", "http://www.ncbi.nlm.nih.gov/pubmed/25459971", "http://www.ncbi.nlm.nih.gov/pubmed/21344634", "http://www.ncbi.nlm.nih.gov/pubmed/2348978"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0152095", "o": "http://linkedlifedata.com/resource/umls/label/A18670259"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18670259", "o": "syndrome patau"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0152095", "o": "http://linkedlifedata.com/resource/umls/label/A0574493"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0574493", "o": "Patau syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0152095", "o": "http://linkedlifedata.com/resource/umls/label/A18474937"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18474937", "o": "Patau syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0152095", "o": "http://linkedlifedata.com/resource/umls/label/A18577308"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0152095", "o": "Trisomy 13"}], "ideal_answer": ["Patau syndrome is caused by trisomy 13."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002882", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "http://www.disease-ontology.org/api/metadata/DOID:11665"], "type": "factoid", "id": "58da111c8acda34529000010", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Trisomy 13, or Patau syndrome is a rare chromosomal disorder characterized by a triad of cleft lip and palate, postaxial polydactyly and microcephaly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21344634", "endSection": "abstract"}, {"offsetInBeginSection": 213, "offsetInEndSection": 308, "text": "Mosaic trisomy 13 is very rare, it occurs in only 5% of all patients with trisomy 13 phenotype.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21344634", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Among full autosomal trisomies, only trisomies of chromosome 21 (Down syndrome), 18 (Edwards syndrome) and 13 (Patau syndrome) are compatible with postnatal survival. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18253026", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "We describe the management of the eyelid anomaly associated with Patau syndrome. Trisomy 13 is the genotype of the syndrome's phenotype. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14506431", "endSection": "abstract"}, {"offsetInBeginSection": 226, "offsetInEndSection": 400, "text": "This article identifies the causes and manifestations of most of these trisomies: trisomy 13 (Patau syndrome), trisomy 18 (Edwards syndrome), and trisomy 21 (Down syndrome). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11885075", "endSection": "abstract"}, {"offsetInBeginSection": 128, "offsetInEndSection": 248, "text": "WHS is caused by a deletion of 4p16, while Patau syndrome is caused by trisomy for some or all regions of chromosome 13.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12393964", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Patau syndrome is a chromosomal disorder associated with multiple malformations caused by inheritance of an extra chromosome (trisomy 13).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20537076", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Survival of trisomy 18 (Edwards syndrome) and trisomy 13 (Patau Syndrome) in England and Wales: 2004-2011", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23949924", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 640, "text": "To determine whether older paternal age increases the risk of fathering a pregnancy with Patau (trisomy 13), Edwards (trisomy 18), Klinefelter (XXY) or XYY syndrome.Case-control: cases with each of these syndromes were matched to four controls with Down syndrome from within the same congenital anomaly register and with maternal age within 6 months.Data from 22 EUROCAT congenital anomaly registers in 12 European countries.Diagnoses with observed or (for terminations) predicted year of birth from 1980 to 2005, comprising live births, fetal deaths with gestational age \u2265 20 weeks and terminations after prenatal diagnosis of the anomaly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20584846", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 231, "text": "Congenital diaphragmatic hernia (CDH) occurs in 5-10% associated with chromosomal abnormalities like, Pallister Killian syndrome, Trisomy 18, and certain deletions.. Association of CDH with trisomy 13 (Patau syndromes) is very rare", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26034714", "endSection": "abstract"}, {"offsetInBeginSection": 129, "offsetInEndSection": 250, "text": "WHS is caused by a deletion of 4p16, while Patau syndrome is caused by trisomy for some or all regions of chromosome 13. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12393964", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Patau syndrome is a chromosomal disorder associated with multiple malformations caused by inheritance of an extra chromosome (trisomy 13). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20537076", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Ocular abnormalities in Patau syndrome (chromosome 13 trisomy syndrome).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2348978", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Trisomy 13 (Patau's syndrome): a rare case of survival into adulthood.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2325123", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "BACKGROUND: Whilst maternal age is an established risk factor for Patau syndrome (trisomy 13), Edwards syndrome (trisomy 18) and Down syndrome (trisomy 21), the aetiology and contribution of genetic and environmental factors remains unclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18467377", "endSection": "abstract"}, {"offsetInBeginSection": 129, "offsetInEndSection": 249, "text": "WHS is caused by a deletion of 4p16, while Patau syndrome is caused by trisomy for some or all regions of chromosome 13.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12393964", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Patau syndrome, trisomy 13, is the third commonest autosomal trisomy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459971", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Patau syndrome (trisomy 13) is very rare in live-born babies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17603803", "endSection": "abstract"}]}, {"body": "Which is the main abnormality that arises with Sox9 locus duplication?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10588843", "http://www.ncbi.nlm.nih.gov/pubmed/18391513", "http://www.ncbi.nlm.nih.gov/pubmed/22678921", "http://www.ncbi.nlm.nih.gov/pubmed/25010117", "http://www.ncbi.nlm.nih.gov/pubmed/24040047", "http://www.ncbi.nlm.nih.gov/pubmed/25077096", "http://www.ncbi.nlm.nih.gov/pubmed/18056774", "http://www.ncbi.nlm.nih.gov/pubmed/11420125"], "ideal_answer": ["The 46,XX testicular disorder of sex development (DSD), also known as 46,XX male syndrome, is a rare form of DSD and clinical phenotype shows complete sex reversal from female to male. A complex network of genes determines sex in mammals. Differentiation of testicular tissue in 46,XX individuals is seen either in XX males, the majority of them with SRY gene, or in individuals, usually SRY(-), with ovotesticular disorder of sex development (OT-DSD). SOX9 is one of the genes that play critical roles in male sexual differentiation.", "Thus, SOX9 duplication is the most likely cause for the sex reversal in this case because it plays an important role in male sex determination and differentiation. The SRY-box 9 (SOX9) gene has several important functions during testis development and differentiation in males, and overexpression of SOX9 leads to the male development of 46,XX gonads in the absence of SRY.", "Autosomal XX sex reversal caused by duplication of SOX9. Mutations of SOX9 leading to haploinsufficiency can cause campomelic dysplasia and XY sex reversal. We report here evidence supporting that SOX9 duplication can cause XX sex reversal. Fluorescent in situ hybridization (FISH) with a BAC clone containing the SOX9 gene demonstrated that the SOX9 gene is duplicated on the rearranged chromosome 17. SOX9 duplication linked to intersex in deer. ", "SOX9 duplication can cause XX sex reversal.  SOX9 duplication has been found to be a rare cause of 46,XX testicular DSD in humans.", "Mutations of SOX9 leading to haploinsufficiency can cause campomelic dysplasia and XY sex reversal. In addition, SOX9 duplication has been found to be a rare cause of 46,XX testicular DSD in humans.", "Autosomal XX sex reversal caused by duplication of SOX9"], "type": "factoid", "id": "58af1cb3717cd3f655000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Autosomal XX sex reversal caused by duplication of SOX9", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", "endSection": "title"}, {"offsetInBeginSection": 82, "offsetInEndSection": 180, "text": "Mutations of SOX9 leading to haploinsufficiency can cause campomelic dysplasia and XY sex reversal", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 264, "text": "We report here evidence supporting that SOX9 duplication can cause XX sex reversal", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", "endSection": "abstract"}, {"offsetInBeginSection": 531, "offsetInEndSection": 691, "text": "Fluorescent in situ hybridization (FISH) with a BAC clone containing the SOX9 gene demonstrated that the SOX9 gene is duplicated on the rearranged chromosome 17", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 43, "text": "SOX9 duplication linked to intersex in deer", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24040047", "endSection": "title"}, {"offsetInBeginSection": 193, "offsetInEndSection": 358, "text": "Whole genome sequencing and quantitative real-time PCR analyses revealed a triple dose of the SOX9 gene, allowing insights into a new genetic defect in a wild animal", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24040047", "endSection": "abstract"}, {"offsetInBeginSection": 575, "offsetInEndSection": 672, "text": "In addition, SOX9 duplication has been found to be a rare cause of 46,XX testicular DSD in humans", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25077096", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Extended pedigree with multiple cases of XX sex reversal in the absence of SRY and of a mutation at the SOX9 locus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18391513", "endSection": "title"}, {"offsetInBeginSection": 1152, "offsetInEndSection": 1307, "text": "Together, these findings implicate a mutation at a sex-determining locus other than SRY and SOX9 as the cause for the XX sex reversal trait in this family.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18391513", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Autosomal XX sex reversal caused by duplication of SOX9.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Sox9 duplications are a relevant cause of Sry-negative XX sex reversal dogs.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010117", "endSection": "title"}, {"offsetInBeginSection": 182, "offsetInEndSection": 265, "text": "We report here evidence supporting that SOX9 duplication can cause XX sex reversal.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", "endSection": "abstract"}, {"offsetInBeginSection": 82, "offsetInEndSection": 181, "text": "Mutations of SOX9 leading to haploinsufficiency can cause campomelic dysplasia and XY sex reversal.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10588843", "endSection": "abstract"}, {"offsetInBeginSection": 916, "offsetInEndSection": 1081, "text": "Duplications of the locus DSS can lead to a failure of testicular development and a duplication of the region containing SOX9 has been implicated in XX sex reversal.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11420125", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Extended pedigree with multiple cases of XX sex reversal in the absence of SRY and of a mutation at the SOX9 locus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18391513", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "XX male sex reversal with genital abnormalities associated with a de novo SOX3 gene duplication.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22678921", "endSection": "title"}]}, {"body": "Is Musclin a secretory peptide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19244276", "http://www.ncbi.nlm.nih.gov/pubmed/26449458", "http://www.ncbi.nlm.nih.gov/pubmed/17189616", "http://www.ncbi.nlm.nih.gov/pubmed/24734231", "http://www.ncbi.nlm.nih.gov/pubmed/23940802"], "ideal_answer": ["Yes, musclin has been described as a muscle-derived secretory peptide."], "type": "yesno", "id": "58df779d6fddd3e83e000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "Musclin is a novel skeletal muscle-derived secretory factor,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17950246", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Musclin has been described as a muscle-derived secretory peptide, responsive to insulin in vivo, and inducing insulin resistance in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17189616", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Musclin is a type of muscle-secreted cytokine and its increased gene expression induces insulin resistance in type 2 diabetes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26449458", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Musclin is a novel skeletal muscle-derived factor found in the signal sequence trap of mouse skeletal muscle cDNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24734231", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Musclin is a novel skeletal muscle-derived secretory factor found in the signal sequence trap of mouse skeletal muscle cDNAs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23940802", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Musclin is a novel skeletal muscle-derived secretory factor that was isolated by our group. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19244276", "endSection": "abstract"}]}, {"body": "What tissue is commonly affected in Marfan's syndrome", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23304566", "http://www.ncbi.nlm.nih.gov/pubmed/26494287", "http://www.ncbi.nlm.nih.gov/pubmed/21723458", "http://www.ncbi.nlm.nih.gov/pubmed/21308160", "http://www.ncbi.nlm.nih.gov/pubmed/17620463", "http://www.ncbi.nlm.nih.gov/pubmed/26272787", "http://www.ncbi.nlm.nih.gov/pubmed/16400220", "http://www.ncbi.nlm.nih.gov/pubmed/14304236", "http://www.ncbi.nlm.nih.gov/pubmed/9401003", "http://www.ncbi.nlm.nih.gov/pubmed/19554831", "http://www.ncbi.nlm.nih.gov/pubmed/8240311", "http://www.ncbi.nlm.nih.gov/pubmed/21866385", "http://www.ncbi.nlm.nih.gov/pubmed/9068910", "http://www.ncbi.nlm.nih.gov/pubmed/9316048", "http://www.ncbi.nlm.nih.gov/pubmed/26281765", "http://www.ncbi.nlm.nih.gov/pubmed/10050736"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0024796", "o": "Marfan Syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0024796", "o": "http://linkedlifedata.com/resource/umls/label/A0431931"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0431931", "o": "MARFAN SYNDROME"}], "ideal_answer": ["Marfan syndrome (MS) is a connective tissue disorder that affects thousands of adolescents ", "Marfan syndrome (MS) is a connective tissue disorder that affects thousands of adolescents", "Marfan syndrome (MS) is a connective tissue disorder that affects thousands of adolescents. ", "Marfan syndrome (MS) is a connective tissue disorder that affects thousands of adolescents.", "marfan syndrome (ms) is a connective tissue disorder that affects thousands of adolescents ."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008382", "http://www.disease-ontology.org/api/metadata/DOID:14323"], "type": "factoid", "id": "58dd0dde8acda34529000027", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Marfan syndrome (MS) is a connective tissue disorder that affects thousands of adolescents ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26272787", "endSection": "abstract"}, {"offsetInBeginSection": 357, "offsetInEndSection": 636, "text": "Fibrillin-1 mutations have also been found in several other related connective tissue disorders, such as severe neonatal Marfan syndrome, dominant ectopia lentis, familial ascending aortic aneurysm, isolated skeletal features of Marfan syndrome, and Shprintzen-Goldberg syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401003", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Marfans syndrome is an Autosomal dominant disorder of the connective tissues resulting in abnormalities of the musculoskeletal system, cardiovascular system and eyes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16400220", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "Marfan syndrome (MFS) is a systemic disorder of the connective tissue with pleiotropic manifestations due to heterozygous FBN1 mutations and consequent upregulation of TGF\u03b2 signaling in affected tissues", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21866385", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "Marfan syndrome (MFS) is an autosomal dominant disorder of connective tissue, caused by mutations of the microfibrillar protein fibrillin-1, that predisposes affected individuals to aortic aneurysm and rupture and is associated with increased TGF\u03b2 signaling", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26494287", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 262, "text": "Marfan syndrome is an autosomal dominant connective tissue disorder commonly due to mutation of the fibrillin-1 (FBN-1) gene that causes disruption of elastic fibers in large- and medium-size arteries and predisposes to aneurysm formation and arterial dissection", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21723458", "endSection": "abstract"}, {"offsetInBeginSection": 85, "offsetInEndSection": 236, "text": "Children affected by the Marfan syndrome carry a mutation in one of their two copies of the gene that encodes the connective tissue protein fibrillin-1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23304566", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Marfan's syndrome is an autosomal dominant disorder of connective tissue, commonly involving the cardiovascular, ocular, and skeletal systems. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10050736", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "Marfan syndrome is an autosomal dominant connective tissue disorder commonly due to mutation of the fibrillin-1 (FBN-1) gene that causes disruption of elastic fibers in large- and medium-size arteries and predisposes to aneurysm formation and arterial dissection. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21723458", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Marfan's syndrome is an autosomal dominant disorder of connective tissue, commonly involving the cardiovascular, ocular, and skeletal systems.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10050736", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Marfan's syndrome is a heritable connective tissue disorder that has been associated with intracranial aneurysms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9316048", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Marfan's syndrome is an inherited disorder of connective tissue associated with characteristic abnormalities of the skeletal, ocular, and cardiovascular systems.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9068910", "endSection": "abstract"}, {"offsetInBeginSection": 785, "offsetInEndSection": 939, "text": "Therefore, Marfan's syndrome is termed a fibrillinopathy, along with other connective tissue disorders with subtle differences in clinical manifestations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21308160", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "The Marfan syndrome is an inherited disorder of the connective tissue which is mainly caused by a mutation in the fibrillin-1 gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19554831", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Marfan syndrome is an inherited multisystemic connective-tissue disease that is caused by a mutation of the fibrillin-1 gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17620463", "endSection": "abstract"}, {"offsetInBeginSection": 311, "offsetInEndSection": 497, "text": " Mutations in the fibrillin-1 gene give rise to Marfan syndrome, a connective tissue disorder with clinical complications in the cardiovascular, skeletal, ocular and other organ systems.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26281765", "endSection": "abstract"}]}, {"body": "To which disease does the loss of CD28 expression by liver-infiltrating T cells contribute?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24726754"], "ideal_answer": ["Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis.", "Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. ", "loss of cd28 expression by liver-infiltrating t cells contributes to pathogenesis of primary sclerosing cholangitis."], "concepts": ["http://www.uniprot.org/uniprot/CD28_RABIT", "http://www.uniprot.org/uniprot/CD28_RAT", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008107", "http://www.uniprot.org/uniprot/CD28_HUMAN", "http://www.uniprot.org/uniprot/CD28_CHICK", "http://www.uniprot.org/uniprot/CD28_FELCA", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058625", "http://www.uniprot.org/uniprot/CD28_BOVIN", "http://www.uniprot.org/uniprot/CD28_MOUSE"], "type": "factoid", "id": "58853922e56acf5176000016", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726754", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726754", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726754", "endSection": "title"}]}, {"body": "Are cutaneous porphyrias inherited with a recessive pattern?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15868463", "http://www.ncbi.nlm.nih.gov/pubmed/11202049", "http://www.ncbi.nlm.nih.gov/pubmed/12859407"], "ideal_answer": ["No, cutaneous porphyrias are inherited in a dominant (not recessive) pattern."], "type": "yesno", "id": "58e11b9b6fddd3e83e00000b", "snippets": [{"offsetInBeginSection": 464, "offsetInEndSection": 728, "text": "Five of the porphyrias are low-penetrance autosomal dominant conditions in which clinical expression results from additional factors that act by increasing demand for haem or by causing an additional decrease in enzyme activity or by a combination of these effects", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15868463", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Molecular mechanisms of dominant expression in porphyria.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15868463", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 262, "text": "Variegate porphyria (VP) is an autosomal-dominant disorder that is caused by inheritance of a partial deficiency of the enzyme protoporphyrinogen oxidase (EC 1.3.3.4). It is characterized by cutaneous photosensitivity and/or various neurological manifestations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12859407", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "The acute porphyrias constitute a group of metabolic disorders engaging enzymes in the haem synthetic chain and generally following dominant inheritance patterns.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11202049", "endSection": "abstract"}]}, {"body": "Which disease is treated with ZMapp?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25694097", "http://www.ncbi.nlm.nih.gov/pubmed/25171469", "http://www.ncbi.nlm.nih.gov/pubmed/27274814", "http://www.ncbi.nlm.nih.gov/pubmed/26311869", "http://www.ncbi.nlm.nih.gov/pubmed/25404321", "http://www.ncbi.nlm.nih.gov/pubmed/26962157", "http://www.ncbi.nlm.nih.gov/pubmed/27279622", "http://www.ncbi.nlm.nih.gov/pubmed/25648233", "http://www.ncbi.nlm.nih.gov/pubmed/26798032", "http://www.ncbi.nlm.nih.gov/pubmed/26861827", "http://www.ncbi.nlm.nih.gov/pubmed/27683818", "http://www.ncbi.nlm.nih.gov/pubmed/25465382", "http://www.ncbi.nlm.nih.gov/pubmed/26191408", "http://www.ncbi.nlm.nih.gov/pubmed/26946569", "http://www.ncbi.nlm.nih.gov/pubmed/25414384", "http://www.ncbi.nlm.nih.gov/pubmed/27521366", "http://www.ncbi.nlm.nih.gov/pubmed/25760722", "http://www.ncbi.nlm.nih.gov/pubmed/25648530", "http://www.ncbi.nlm.nih.gov/pubmed/25352204", "http://www.ncbi.nlm.nih.gov/pubmed/27067649", "http://www.ncbi.nlm.nih.gov/pubmed/27676206", "http://www.ncbi.nlm.nih.gov/pubmed/25260583", "http://www.ncbi.nlm.nih.gov/pubmed/27465308", "http://www.ncbi.nlm.nih.gov/pubmed/25387576", "http://www.ncbi.nlm.nih.gov/pubmed/27732819"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0012634", "o": "http://linkedlifedata.com/resource/umls/label/A0049608"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0049608", "o": "Disease"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/1022004", "o": "http://linkedlifedata.com/resource/rxnorm/label/3147522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3147522", "o": "Disease"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0012634", "o": "http://linkedlifedata.com/resource/umls/label/A18683747"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18683747", "o": "disease"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0012634", "o": "http://linkedlifedata.com/resource/umls/label/A0015569"}], "ideal_answer": ["ZMapp is a combination of antibodies for treatment of Ebola virus disease."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:4", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"], "type": "factoid", "id": "5880e417713cbdfd3d000001", "snippets": [{"offsetInBeginSection": 424, "offsetInEndSection": 691, "text": "This includes agents belonging to various therapeutic classes, namely direct antiviral agents (favipiravir and BCX4430), a combination of antibodies (ZMapp), type I interferons, RNA interference-based drugs (TKM-Ebola and AVI-7537), and anticoagulant drugs (rNAPc2). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798032", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26861827", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Recent successes with monoclonal antibody cocktails ZMapp(TM) and MIL77 against Ebola virus (EBOV) infections have reignited interest in antibody-based therapeutics. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067649", "endSection": "abstract"}, {"offsetInBeginSection": 147, "offsetInEndSection": 708, "text": "The human-mouse chimeric monoclonal antibody (mAb) cocktail ZMapp, previously shown to be efficacious in EBOV (variant Kikwit) lethally infected nonhuman primates (NHPs) when administration was initiated up to 5 days, was used in some patients during the outbreak. We show that a two-antibody cocktail, MIL77E, is fully protective in NHPs when administered at 50 mg/kg 3 days after challenge with a lethal dose of EBOV variant Makona, the virus responsible for the ongoing 2014-2015 outbreak, whereas a similar formulation of ZMapp protected two of three NHPs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962157", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "The growing promise of plant-made biologics is highlighted by the success story of ZMapp\u2122 as a potentially life-saving drug during the Ebola outbreak of 2014-2016. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27274814", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25171469", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Background Data from studies in nonhuman primates suggest that the triple monoclonal antibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27732819", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Several patients with Ebola virus disease (EVD) managed in the United States have received ZMapp monoclonal antibodies, TKM-Ebola small interfering RNA, brincidofovir, and/or convalescent plasma as investigational therapeutics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27521366", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 838, "text": "Also there is no specific vaccine and treatment for Ebola virus; however, many candidate vaccines and antiviral-drugs such as ZMapp and TKM-Ebola are being developed for Ebola virus disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648530", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27732819", "endSection": "title"}, {"offsetInBeginSection": 757, "offsetInEndSection": 869, "text": "ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25171469", "endSection": "abstract"}, {"offsetInBeginSection": 1233, "offsetInEndSection": 1489, "text": "Going forward, this work now provides a basis for strategic selection of next-generation antibody cocktails against Ebola and related viruses and a model for predicting the impact of ZMapp on potential escape mutations in ongoing or future Ebola outbreaks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404321", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 742, "text": "Some potential therapeutic materials including ZMapp were supplied and the treated people got over the EVD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648233", "endSection": "abstract"}, {"offsetInBeginSection": 1580, "offsetInEndSection": 1876, "text": "Cocktails of inhibitory monoclonal antibodies (MAbs), such as ZMAb, MB-003, and in particular ZMapp, have demonstrated in animal models some of the most significant therapeutic potential for treating EVD, and in 2014, 15 patients were treated with ZMapp or ZMAb under compassionate-use protocols.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26311869", "endSection": "abstract"}, {"offsetInBeginSection": 426, "offsetInEndSection": 666, "text": "This review explores some of the more prominent recent advances in the biofarming of viral vaccines and therapies, including the recent use of ZMapp for Ebolavirus infection, and explores some possible future applications of the technology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25465382", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26861827", "endSection": "abstract"}, {"offsetInBeginSection": 757, "offsetInEndSection": 868, "text": "ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25171469", "endSection": "abstract"}, {"offsetInBeginSection": 1581, "offsetInEndSection": 1877, "text": "Cocktails of inhibitory monoclonal antibodies (MAbs), such as ZMAb, MB-003, and in particular ZMapp, have demonstrated in animal models some of the most significant therapeutic potential for treating EVD, and in 2014, 15 patients were treated with ZMapp or ZMAb under compassionate-use protocols.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26311869", "endSection": "abstract"}, {"offsetInBeginSection": 176, "offsetInEndSection": 369, "text": "For example, several patients of the present Ebola virus outbreak in West Africa were treated with ZMapp, a cocktail of three monoclonal antibodies which are expressed in Nicotiana benthamiana.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26191408", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25171469", "endSection": "title"}]}, {"body": "Can methylenetetrahydrofolate reductase (MTHFR) gene mutations cause homocystinuria?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16629766", "http://www.ncbi.nlm.nih.gov/pubmed/27130656", "http://www.ncbi.nlm.nih.gov/pubmed/10980581", "http://www.ncbi.nlm.nih.gov/pubmed/23095199", "http://www.ncbi.nlm.nih.gov/pubmed/10923034", "http://www.ncbi.nlm.nih.gov/pubmed/21626167", "http://www.ncbi.nlm.nih.gov/pubmed/2629632", "http://www.ncbi.nlm.nih.gov/pubmed/17457696", "http://www.ncbi.nlm.nih.gov/pubmed/12673793", "http://www.ncbi.nlm.nih.gov/pubmed/11592438", "http://www.ncbi.nlm.nih.gov/pubmed/9490685", "http://www.ncbi.nlm.nih.gov/pubmed/23533858", "http://www.ncbi.nlm.nih.gov/pubmed/20532821", "http://www.ncbi.nlm.nih.gov/pubmed/9453374", "http://www.ncbi.nlm.nih.gov/pubmed/10679944", "http://www.ncbi.nlm.nih.gov/pubmed/24461181", "http://www.ncbi.nlm.nih.gov/pubmed/14656017", "http://www.ncbi.nlm.nih.gov/pubmed/20236116", "http://www.ncbi.nlm.nih.gov/pubmed/22521626", "http://www.ncbi.nlm.nih.gov/pubmed/9781030", "http://www.ncbi.nlm.nih.gov/pubmed/11181567", "http://www.ncbi.nlm.nih.gov/pubmed/17349292", "http://www.ncbi.nlm.nih.gov/pubmed/8124871"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0066357", "o": "MTHFR"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_5034323839380027", "o": "MTHFR"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_5135534E573500F", "o": "MTHFR"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/drugbank/molecule/3917", "o": "Methylenetetrahydrofolate reductase"}, {"p": "http://www.w3.org/2004/02/skos/core#exactMatch", "s": "http://linkedlifedata.com/resource/drugbank/molecule/3917", "o": "http://purl.uniprot.org/uniprot/P42898"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://purl.uniprot.org/uniprot/P42898", "o": "MTHR_HUMAN"}, {"p": "http://www.w3.org/2004/02/skos/core#exactMatch", "s": "http://purl.uniprot.org/uniprot/P42898", "o": "http://purl.uniprot.org/uniprot/P42898"}], "ideal_answer": ["Yes, several methylenetetrahydrofolate reductase (MTHFR) gene mutations can cause homocystinuria and hyperhomocysteinemia."], "concepts": ["http://www.uniprot.org/uniprot/MTHR_MOUSE", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006712", "http://www.uniprot.org/uniprot/MTHR_BOVIN", "http://www.disease-ontology.org/api/metadata/DOID:9263", "http://www.uniprot.org/uniprot/MTHR_MACFA", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154", "http://www.uniprot.org/uniprot/MTHR_HUMAN"], "type": "yesno", "id": "58d8d0cc8acda34529000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Methylenetetrahydrofolate reductase (MTHFR) deficiency is a rare autosomal recessive disorder. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461181", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 391, "text": "Several mutations seen in methylenetetrahydrofolate reductase (MTHFR) give rise to the formation of hyperhomocysteinemia and homocystinuria, a considerable risk factor for cardiovascular and cerebrovascular disorders, by leading to enzymatic inactivation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533858", "endSection": "abstract"}, {"offsetInBeginSection": 551, "offsetInEndSection": 764, "text": "At admission, he had significantly elevated plasma and urine levels of total homocysteine, significantly decreased levels of folate in serum and cerebrospinal fluid, and a normal blood concentration of methionine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461181", "endSection": "abstract"}, {"offsetInBeginSection": 529, "offsetInEndSection": 814, "text": "Response to treatment demonstrated B(6)-non-responsive homocystinuria. Molecular study showed compound heterozygous T353\u00a0N and D444\u00a0N mutations of the cystathionine beta-synthase (CBS) gene, and also a C667T homozygous mutation of the methylenetetrahydrofolate-reductase (MTHFR) gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21626167", "endSection": "abstract"}, {"offsetInBeginSection": 1121, "offsetInEndSection": 1374, "text": "Our case is atypical because of the absence of thromboembolism and the mild phenotype, in spite of being B(6)-non-responsive, and the association of a rare compound heterozygous mutation of the CBS gene and also an homozygous mutation of the MTHFR gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21626167", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Molecular characterization of five patients with homocystinuria due to severe methylenetetrahydrofolate reductase deficiency.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236116", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 457, "text": "Methylenetetrahydrofolate reductase (MTHFR) is a key regulatory enzyme in folate and homocysteine metabolism. Research performed during the past decade has clarified our understanding of MTHFR deficiencies that cause homocystinuria or mild hyperhomocysteinemia. Our cloning of the MTHFR coding sequence was initially followed by the identification of the first deleterious mutations in MTHFR, in patients with homocystinuria and marked hyperhomocysteinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349292", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 320, "text": "Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the regulation of plasma homocysteine levels. MTHFR deficiency, an autosomal recessive disorder, results in homocystinuria and hypomethioninaemia and presents with highly variable symptoms affecting many organs but predominantly the central nervous system. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17457696", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Some methylenetetrahydrofolate reductase (MTHFR) gene mutations cause hyperhomocysteinemia and homocystinuria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16629766", "endSection": "abstract"}, {"offsetInBeginSection": 309, "offsetInEndSection": 431, "text": "Rare mutations in the MTHFR gene have been associated with autosomal recessive MTHFR deficiency leading to homocystinuria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130656", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679944", "endSection": "title"}, {"offsetInBeginSection": 227, "offsetInEndSection": 414, "text": "Five patients suspected of having non-classical homocystinuria due to MTHFR deficiency were examined with respect to their symptoms, MTHFR enzyme activity and genotypes of the MTHFR gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236116", "endSection": "abstract"}, {"offsetInBeginSection": 1171, "offsetInEndSection": 1417, "text": "The results of our study render the full-length characterisation of affected alleles in severe homocystinuria and moderate hyperhomocysteinaemia due to MTHFR deficiency and provide a basis for investigating the regulation of the human MTHFR gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10980581", "endSection": "abstract"}, {"offsetInBeginSection": 260, "offsetInEndSection": 455, "text": "Our cloning of the MTHFR coding sequence was initially followed by the identification of the first deleterious mutations in MTHFR, in patients with homocystinuria and marked hyperhomocysteinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349292", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 385, "text": "Different MTHFR mutations lead either to severe homocystinuria as a multisystem disorder or to moderate hyperhomocysteinaemia, which is a common risk factor for disorders ranging from cardiovasculopathy to spina bifida.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10980581", "endSection": "abstract"}, {"offsetInBeginSection": 435, "offsetInEndSection": 712, "text": "We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685", "endSection": "abstract"}, {"offsetInBeginSection": 807, "offsetInEndSection": 1094, "text": "On the contrary, thermolabile MTHFR caused by the 677C-->T mutation, was frequently observed among homocystinuria patients, especially among those with thromboembolic complications: three of six homocystinuria patients who had suffered from a thromboembolic event had thermolabile MTHFR.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685", "endSection": "abstract"}, {"offsetInBeginSection": 438, "offsetInEndSection": 715, "text": "We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Some methylenetetrahydrofolate reductase (MTHFR) gene mutations cause hyperhomocysteinemia and homocystinuria", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16629766", "endSection": "abstract"}, {"offsetInBeginSection": 438, "offsetInEndSection": 714, "text": "We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679944", "endSection": "title"}, {"offsetInBeginSection": 144, "offsetInEndSection": 278, "text": "The most common genetic cause of hyperhomocysteinemia is the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11181567", "endSection": "abstract"}, {"offsetInBeginSection": 237, "offsetInEndSection": 444, "text": "The 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinemia, but this polymorphism does not seem to be a risk factor for venous thrombosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592438", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) gene mutation have been postulated as a possible cause of recurrent miscarriage (RM)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23095199", "endSection": "abstract"}, {"offsetInBeginSection": 276, "offsetInEndSection": 403, "text": "The 677C>T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinaemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14656017", "endSection": "abstract"}, {"offsetInBeginSection": 438, "offsetInEndSection": 716, "text": "We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "AIM: Some methylenetetrahydrofolate reductase (MTHFR) gene mutations cause hyperhomocysteinemia and homocystinuria. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16629766", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2629632", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 216, "text": "Severe deficiency of methylenetetrahydrofolate reductase (MTHFR) with homocystinuria can result in early demise or later-onset neurological impairment, including developmental delay, motor dysfunction, and seizures. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532821", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Deficiency of 5,10-methylenetetrahydrofolate reductase (MTHFR) leads to deficient remethylation of homocysteine and is one of the causes of homocystinuria. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8124871", "endSection": "abstract"}, {"offsetInBeginSection": 270, "offsetInEndSection": 369, "text": "Neurological disturbances have been described in homocystinuria caused by severe MTHFR deficiency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22521626", "endSection": "abstract"}, {"offsetInBeginSection": 237, "offsetInEndSection": 445, "text": "The 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinemia, but this polymorphism does not seem to be a risk factor for venous thrombosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592438", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 261, "text": "Research performed during the past decade has clarified our understanding of MTHFR deficiencies that cause homocystinuria or mild hyperhomocysteinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349292", "endSection": "abstract"}, {"offsetInBeginSection": 276, "offsetInEndSection": 404, "text": "The 677C>T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinaemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14656017", "endSection": "abstract"}, {"offsetInBeginSection": 144, "offsetInEndSection": 279, "text": "The most common genetic cause of hyperhomocysteinemia is the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11181567", "endSection": "abstract"}, {"offsetInBeginSection": 262, "offsetInEndSection": 457, "text": "Our cloning of the MTHFR coding sequence was initially followed by the identification of the first deleterious mutations in MTHFR, in patients with homocystinuria and marked hyperhomocysteinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349292", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679944", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Molecular characterization of five patients with homocystinuria due to severe methylenetetrahydrofolate reductase deficiency.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236116", "endSection": "title"}, {"offsetInBeginSection": 812, "offsetInEndSection": 1099, "text": "On the contrary, thermolabile MTHFR caused by the 677C-->T mutation, was frequently observed among homocystinuria patients, especially among those with thromboembolic complications: three of six homocystinuria patients who had suffered from a thromboembolic event had thermolabile MTHFR.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685", "endSection": "abstract"}]}, {"body": "What happens to H2AX upon DNA bouble strand breaks?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24682951", "http://www.ncbi.nlm.nih.gov/pubmed/27158526", "http://www.ncbi.nlm.nih.gov/pubmed/22704343", "http://www.ncbi.nlm.nih.gov/pubmed/21511815"], "ideal_answer": [" Phosphorylated H2AX (\u03b3H2AX) is rapidly concentrated in chromatin domains around DNA double-strand breaks (DSBs) after the action of ionizing radiation or chemical agents and at stalled replication forks during replication stress The nuclear foci of phosphorylated histone H2AX (\u03b3H2AX) are frequently used as a marker for DNA double-strand breaks (DSBs) following ionizing radiation (IR)", " phosphorylated h2ax (\u03b3h2ax) is rapidly concentrated in chromatin domains around dna double-strand breaks (dsbs) after the action of ionizing radiation or chemical agents and at stalled replication forks during replication stress.", "Defective or inefficient DNA double-strand break (DSB) repair results in failure to preserve genomic integrity leading to apoptotic cell death, a hallmark of systemic lupus erythematosus (SLE). Phosphorylated H2AX (\u00ce\u00b3H2AX) is rapidly concentrated in chromatin domains around DNA double-strand breaks (DSBs) after the action of ionizing radiation or chemical agents and at stalled replication forks during replication stress.", "The nuclear foci of phosphorylated histone H2AX (\u03b3H2AX) are frequently used as a marker for DNA double-strand breaks (DSBs) following ionizing radiation (IR).  Phosphorylated H2AX (\u03b3H2AX) is rapidly concentrated in chromatin domains around DNA double-strand breaks (DSBs) after the action of ionizing radiation or chemical agents and at stalled replication forks during replication stress. DNA double-strand breaks in heterochromatin elicit fast repair protein recruitment, histone H2AX phosphorylation and relocation to euchromatin", "Histone H2AX phosphorylation as a measure of DNA double-strand breaks and a marker of environmental stress and disease activity in lupus. DSBs were quantified in peripheral blood mononuclear cell subsets from patients with SLE, healthy controls, and patients with rheumatoid arthritis (RA) by measuring phosphorylated H2AX (phospho-H2AX) levels with flow cytometry. Most hydrogen peroxide-induced histone H2AX phosphorylation is mediated by ATR and is not dependent on DNA double-strand breaks. The nuclear foci of phosphorylated histone H2AX (H2AX) are frequently used as a marker for DNA double-strand breaks (DSBs) following ionizing radiation (IR). These results suggest that a major fraction of H2AX induced by oxidative stress is not associated with DSBs. ", "Defective or inefficient DNA double-strand break (DSB) repair results in failure to preserve genomic integrity leading to apoptotic cell death, a hallmark of systemic lupus erythematosus (SLE). The nuclear foci of phosphorylated histone H2AX (\u03b3H2AX) are frequently used as a marker for DNA double-strand breaks (DSBs) following ionizing radiation (IR). A sequence variant of histone H2A called H2AX is one of the key components of chromatin involved in DNA damage response induced by different genotoxic stresses. DNA double-strand breaks (DSBs) can induce chromosomal aberrations and carcinogenesis and their correct repair is crucial for genetic stability.", "DSBs were quantified in peripheral blood mononuclear cell subsets from patients with SLE, healthy controls, and patients with rheumatoid arthritis (RA) by measuring phosphorylated H2AX (phospho-H2AX) levels with flow cytometry DNA double-strand breaks in heterochromatin elicit fast repair protein recruitment, histone H2AX phosphorylation and relocation to euchromatin"], "type": "factoid", "id": "58af16ea717cd3f655000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Histone H2AX phosphorylation as a measure of DNA double-strand breaks and a marker of environmental stress and disease activity in lupus", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27158526", "endSection": "title"}, {"offsetInBeginSection": 542, "offsetInEndSection": 768, "text": "DSBs were quantified in peripheral blood mononuclear cell subsets from patients with SLE, healthy controls, and patients with rheumatoid arthritis (RA) by measuring phosphorylated H2AX (phospho-H2AX) levels with flow cytometry", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27158526", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Most hydrogen peroxide-induced histone H2AX phosphorylation is mediated by ATR and is not dependent on DNA double-strand breaks.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24682951", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "The nuclear foci of phosphorylated histone H2AX (\u03b3H2AX) are frequently used as a marker for DNA double-strand breaks (DSBs) following ionizing radiation (IR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24682951", "endSection": "abstract"}, {"offsetInBeginSection": 1030, "offsetInEndSection": 1243, "text": "These results suggest that a major fraction of \u03b3H2AX induced by oxidative stress is not associated with DSBs. Single-stranded DNA arisen from stalled replication forks can cause the ATR-mediated induction of \u03b3H2AX", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24682951", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704343", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "A sequence variant of histone H2A called H2AX is one of the key components of chromatin involved in DNA damage response induced by different genotoxic stresses", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704343", "endSection": "abstract"}, {"offsetInBeginSection": 160, "offsetInEndSection": 389, "text": " Phosphorylated H2AX (\u03b3H2AX) is rapidly concentrated in chromatin domains around DNA double-strand breaks (DSBs) after the action of ionizing radiation or chemical agents and at stalled replication forks during replication stress", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22704343", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "DNA double-strand breaks in heterochromatin elicit fast repair protein recruitment, histone H2AX phosphorylation and relocation to euchromatin", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21511815", "endSection": "title"}, {"offsetInBeginSection": 146, "offsetInEndSection": 583, "text": "he cellular response to DSBs depends on damage signaling including the phosphorylation of the histone H2AX (\u03b3H2AX). However, a lack of \u03b3H2AX formation in heterochromatin (HC) is generally observed after DNA damage induction. Here, we examine \u03b3H2AX and repair protein foci along linear ion tracks traversing heterochromatic regions in human or murine cells and find the DSBs and damage signal streaks bending around highly compacted DNA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21511815", "endSection": "abstract"}]}, {"body": "Can valproic acid prolong survival of glioblastoma patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26786929", "http://www.ncbi.nlm.nih.gov/pubmed/26976976", "http://www.ncbi.nlm.nih.gov/pubmed/26194676", "http://www.ncbi.nlm.nih.gov/pubmed/25648357", "http://www.ncbi.nlm.nih.gov/pubmed/22168970", "http://www.ncbi.nlm.nih.gov/pubmed/25066904", "http://www.ncbi.nlm.nih.gov/pubmed/21880994", "http://www.ncbi.nlm.nih.gov/pubmed/26420896", "http://www.ncbi.nlm.nih.gov/pubmed/26925628", "http://www.ncbi.nlm.nih.gov/pubmed/24328881", "http://www.ncbi.nlm.nih.gov/pubmed/27889835", "http://www.ncbi.nlm.nih.gov/pubmed/18751431", "http://www.ncbi.nlm.nih.gov/pubmed/23523186"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0042291", "o": "valproic acid"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0042291", "o": "http://linkedlifedata.com/resource/umls/label/A10769673"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A10769673", "o": "VALPROIC ACID"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/11118", "o": "http://linkedlifedata.com/resource/rxnorm/label/3253230"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3253230", "o": "VALPROIC ACID"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0042291", "o": "http://linkedlifedata.com/resource/umls/label/A0131324"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0131324", "o": "Valproic Acid"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/11118", "o": "http://linkedlifedata.com/resource/rxnorm/label/3254597"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3254597", "o": "Valproic Acid"}], "ideal_answer": ["Yes, there is evidence to suggest that valproic acid (VPA) is associated with prolonged survival of glioblastoma patients. Several studies have indicated that VPA has radiosensitizing effects for gliomas and radioprotective influence on normal brain tissue or hippocampal neurons."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016019", "http://www.disease-ontology.org/api/metadata/DOID:3073", "http://www.disease-ontology.org/api/metadata/DOID:3068", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013534", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005909", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4271063", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015996", "http://www.biosemantics.org/jochem#4271063", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014635"], "type": "yesno", "id": "5884755ce56acf5176000007", "snippets": [{"offsetInBeginSection": 978, "offsetInEndSection": 1152, "text": "For patients who presented with epilepsy, the use of the antiepileptic drug VPA did not associate with survival when compared with patients who did not receive VPA treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26420896", "endSection": "abstract"}, {"offsetInBeginSection": 1255, "offsetInEndSection": 1372, "text": "This prognostic effect is not solely explained by early diagnosis, and survival is not associated with VPA treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26420896", "endSection": "abstract"}, {"offsetInBeginSection": 571, "offsetInEndSection": 1042, "text": "Several in vivo and in vitro studies have indicated that VPA has radiosensitizing effects for gliomas and radioprotective influence on normal brain tissue or hippocampal neurons. The results of several retrospective studies have also indicated potential benefit to improve survival of patients with GBM. Moreover, the promising treatment results of a phase 2 trial of concurrent radiation therapy, temozolomide, and VPA for patients with GBM have been recently reported. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26925628", "endSection": "abstract"}, {"offsetInBeginSection": 102, "offsetInEndSection": 368, "text": "While there have not been any novel anti-GBM therapeutics approved for many years, there has been the gradual accumulation of clinical data suggesting that the widely used anti-convulsant agent, valproic acid (VPA) may significantly prolong survival in GBM patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648357", "endSection": "abstract"}, {"offsetInBeginSection": 1851, "offsetInEndSection": 1955, "text": " Additionally, VPA may result in improved outcomes compared to historical data and merits further study.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26194676", "endSection": "abstract"}, {"offsetInBeginSection": 1015, "offsetInEndSection": 1247, "text": "Several retrospective studies in seizure patients with glioblastoma treated with chemotherapy have provided evidence for a moderately improved survival with the use of valproic acid, possibly due to inhibition of histone deacetylase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881", "endSection": "abstract"}, {"offsetInBeginSection": 239, "offsetInEndSection": 335, "text": "Several clinical studies have reported that valproic acid could prolong survival of GBM patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25066904", "endSection": "abstract"}, {"offsetInBeginSection": 102, "offsetInEndSection": 367, "text": "While there have not been any novel anti-GBM therapeutics approved for many years, there has been the gradual accumulation of clinical data suggesting that the widely used anti-convulsant agent, valproic acid (VPA) may significantly prolong survival in GBM patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648357", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Valproic acid use during radiation therapy for glioblastoma associated with improved survival.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523186", "endSection": "title"}, {"offsetInBeginSection": 1032, "offsetInEndSection": 1333, "text": "Patients receiving VPA alone (97 [16.9%]) appeared to derive more survival benefit from TMZ/RT (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.24-0.63) than patients receiving an EIAED only (252 [44%]) (HR 0.69, 95% CI 0.53-0.90) or patients not receiving any AED (HR 0.67, 95% CI 0.49-0.93). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994", "endSection": "abstract"}, {"offsetInBeginSection": 1016, "offsetInEndSection": 1249, "text": "Several retrospective studies in seizure patients with glioblastoma treated with chemotherapy have provided evidence for a moderately improved survival with the use of valproic acid, possibly due to inhibition of histone deacetylase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328881", "endSection": "abstract"}, {"offsetInBeginSection": 92, "offsetInEndSection": 740, "text": "Several uncontrolled retrospective case series and a post hoc analysis of the registration trial for temozolomide indicated an association between valproic acid (VPA) use and improved survival outcomes in patients with newly diagnosed glioblastoma.To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation T", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786929", "endSection": "abstract"}, {"offsetInBeginSection": 239, "offsetInEndSection": 336, "text": "Several clinical studies have reported that valproic acid could prolong survival of GBM patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25066904", "endSection": "abstract"}, {"offsetInBeginSection": 1001, "offsetInEndSection": 1420, "text": "Patients receiving VPA alone (97 [16.9%]) appeared to derive more survival benefit from TMZ/RT (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.24-0.63) than patients receiving an EIAED only (252 [44%]) (HR 0.69, 95% CI 0.53-0.90) or patients not receiving any AED (HR 0.67, 95% CI 0.49-0.93).VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 537, "text": "The combination of radiotherapy, temozolomide and valproic acid (VPA) has shown some promise in retrospective analyses of patients with glioblastoma, although their mechanisms of action remain unknown.We investigated the in vitro and in vivo effects of pretreating glioma cells with temozolomide and VPA as an immunization strategy to boost an adaptive immune response in a syngeneic mouse model.Temozolomide and VPA induced autophagy in GL261 glioma cells, and caused tumor antigen-specific T-cells to become activated effector T-cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976976", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880994", "endSection": "title"}]}, {"body": "What is the effect of the direct interaction of Ikaros and Foxp1 in B-lymphocytes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27588474"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1825588", "o": "http://linkedlifedata.com/resource/umls/label/A20756491"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A20756491", "o": "IKAROS"}], "ideal_answer": ["Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia.", "The effect of the direct interaction of Ikaros and Foxp1 in B-lymphocytesis is modulation of expression of the G protein-coupled receptor G2A."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001402", "http://www.uniprot.org/uniprot/FOXP1_RAT", "http://www.uniprot.org/uniprot/FOXP1_MOUSE", "http://www.biosemantics.org/jochem#4250484", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D060151", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051740"], "type": "factoid", "id": "58853667e56acf5176000015", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27588474", "endSection": "title"}, {"offsetInBeginSection": 114, "offsetInEndSection": 555, "text": "We describe a novel physical and functional interaction between the proteins, which requires the central zinc finger domain of Ikaros. The Ikaros-Foxp1 interaction is abolished by deletion of this region, which corresponds to the IK6 isoform that is commonly associated with high-risk acute lymphoblastic leukemia (ALL). We also identify the Gpr132 gene, which encodes the orphan G protein-coupled receptor G2A, as a novel target for Foxp1. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27588474", "endSection": "abstract"}, {"offsetInBeginSection": 1047, "offsetInEndSection": 1216, "text": "Our results reveal a novel effect of Ikaros haploinsufficiency on Foxp1 functioning, and identify G2A as a potential modulator of the cell cycle in Ikaros-deleted B-ALL.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27588474", "endSection": "abstract"}, {"offsetInBeginSection": 1040, "offsetInEndSection": 1209, "text": "Our results reveal a novel effect of Ikaros haploinsufficiency on Foxp1 functioning, and identify G2A as a potential modulator of the cell cycle in Ikaros-deleted B-ALL.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27588474", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27588474", "endSection": "title"}, {"offsetInBeginSection": 1047, "offsetInEndSection": 1217, "text": "Our results reveal a novel effect of Ikaros haploinsufficiency on Foxp1 functioning, and identify G2A as a potential modulator of the cell cycle in Ikaros-deleted B-ALL..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27588474", "endSection": "abstract"}]}, {"body": "Which syndrome is caused by deletion of Pds5b in mice?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17652350", "http://www.ncbi.nlm.nih.gov/pubmed/19412548"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1442161", "o": "Gene Deletion"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0039082", "o": "Syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0039082", "o": "http://linkedlifedata.com/resource/umls/label/A0121946"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0121946", "o": "Syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/989712", "o": "http://linkedlifedata.com/resource/rxnorm/label/3242053"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3242053", "o": "Syndrome"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1511760", "o": "Deletion"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1442161", "o": "http://linkedlifedata.com/resource/umls/label/A10802767"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A10802767", "o": "Deletion"}], "ideal_answer": ["mice lacking sister chromatid cohesion protein pds5b exhibit developmental abnormalities reminiscent of cornelia de lange syndrome.", "Mice lacking sister chromatid cohesion protein PDS5B exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome. ", "Mice lacking sister chromatid cohesion protein PDS5B exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome.", "Mice lacking sister chromatid cohesion protein PDS5B exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome", "Mice lacking sister chromatid cohesion protein Pds5b exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0090695", "http://www.uniprot.org/uniprot/PDS5B_RAT", "http://www.uniprot.org/uniprot/PDS5B_MOUSE"], "type": "factoid", "id": "5889eb503b87a8a73800000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Mice lacking sister chromatid cohesion protein PDS5B exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652350", "endSection": "title"}, {"offsetInBeginSection": 298, "offsetInEndSection": 364, "text": "Pds5B mutant mice have developmental abnormalities resembling CdLS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Mice lacking sister chromatid cohesion protein PDS5B exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652350", "endSection": "title"}, {"offsetInBeginSection": 296, "offsetInEndSection": 460, "text": "Pds5B mutant mice have developmental abnormalities resembling CdLS; however the role of Pds5A in mammals and the association of PDS5 proteins with CdLS are unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412548", "endSection": "abstract"}, {"offsetInBeginSection": 298, "offsetInEndSection": 462, "text": "Pds5B mutant mice have developmental abnormalities resembling CdLS; however the role of Pds5A in mammals and the association of PDS5 proteins with CdLS are unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Mice lacking sister chromatid cohesion protein PDS5B exhibit developmental abnormalities reminiscent of Cornelia de Lange syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652350", "endSection": "title"}]}, {"body": "What is the inheritance of Barth syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9345098", "http://www.ncbi.nlm.nih.gov/pubmed/21932011", "http://www.ncbi.nlm.nih.gov/pubmed/12749056", "http://www.ncbi.nlm.nih.gov/pubmed/16847078", "http://www.ncbi.nlm.nih.gov/pubmed/24751896", "http://www.ncbi.nlm.nih.gov/pubmed/24342716", "http://www.ncbi.nlm.nih.gov/pubmed/8884581", "http://www.ncbi.nlm.nih.gov/pubmed/21068380", "http://www.ncbi.nlm.nih.gov/pubmed/24093814", "http://www.ncbi.nlm.nih.gov/pubmed/11975944", "http://www.ncbi.nlm.nih.gov/pubmed/12112112", "http://www.ncbi.nlm.nih.gov/pubmed/16857210", "http://www.ncbi.nlm.nih.gov/pubmed/21987083", "http://www.ncbi.nlm.nih.gov/pubmed/23523468", "http://www.ncbi.nlm.nih.gov/pubmed/25776009", "http://www.ncbi.nlm.nih.gov/pubmed/8487269", "http://www.ncbi.nlm.nih.gov/pubmed/23031367", "http://www.ncbi.nlm.nih.gov/pubmed/8434619", "http://www.ncbi.nlm.nih.gov/pubmed/17353728", "http://www.ncbi.nlm.nih.gov/pubmed/19037987", "http://www.ncbi.nlm.nih.gov/pubmed/25185984"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0574083", "o": "Barth Syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0574083", "o": "http://linkedlifedata.com/resource/umls/label/A12001922"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12001922", "o": "BARTH SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1336578", "o": "http://linkedlifedata.com/resource/umls/label/A20801255"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A20801255", "o": "Barth syndrome"}, {"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name", "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/137", "o": "Barth_syndrome"}], "ideal_answer": ["Barth syndrome (BTHS) has an X-linked recessive pattern of inheritance."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "http://www.disease-ontology.org/api/metadata/DOID:0050476", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040582", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056889"], "type": "factoid", "id": "58d900428acda3452900000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Barth syndrome (BTHS) is an X-linked recessive disease primarily affecting males.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25776009", "endSection": "abstract"}, {"offsetInBeginSection": 974, "offsetInEndSection": 1097, "text": "The results of our study should not only be applicable to BTHS families, but also to families with other X-linked diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25776009", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 256, "text": "Barth syndrome, an X-linked disorder that is characterized by cardiomyopathy, neutropenia, skeletal myopathy, and growth delay, is caused by mutations in the taffazin gene at Xq28 that result in cardiolipin deficiency and abnormal mitochondria. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847078", "endSection": "abstract"}, {"offsetInBeginSection": 2300, "offsetInEndSection": 2553, "text": "Barth syndrome should be considered when boys present with cardiomyopathy, especially when associated with increased left ventricular trabeculations, neutropenia, skeletal muscle weakness, or family history indicating an X-linked pattern of inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847078", "endSection": "abstract"}, {"offsetInBeginSection": 247, "offsetInEndSection": 418, "text": "Mutations in the G4.5 gene result in a wide spectrum of severe infantile X-linked cardiomyopathic phenotypes including Barth syndrome with dilated cardiomyopathy and INVM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12749056", "endSection": "abstract"}, {"offsetInBeginSection": 600, "offsetInEndSection": 755, "text": "X-linked mode of inheritance is seen in Menkes disease, Barth syndrome, and in deficiencies of the E1 alpha subunit of the pyruvate dehydrogenase complex. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8884581", "endSection": "abstract"}, {"offsetInBeginSection": 595, "offsetInEndSection": 749, "text": "X-linked mode of inheritance is seen in Menkes disease, Barth syndrome, and in deficiencies of the E1 alpha subunit of the pyruvate dehydrogenase complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8884581", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "OBJECTIVE: Barth syndrome is a rare, X-linked recessive disorder that affects only boys.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17353728", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 236, "text": "Barth syndrome, an X-linked mitochondrial cardioskeletal myopathy, was diagnosed by genetic testing at autopsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19037987", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Barth syndrome is an X-linked cardiomyopathy with neutropenia and 3-methylglutaconic aciduria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9345098", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Barth syndrome is an X-linked cardiac and skeletal mitochondrial myopathy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12112112", "endSection": "abstract"}, {"offsetInBeginSection": 2265, "offsetInEndSection": 2517, "text": "Barth syndrome should be considered when boys present with cardiomyopathy, especially when associated with increased left ventricular trabeculations, neutropenia, skeletal muscle weakness, or family history indicating an X-linked pattern of inheritance", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847078", "endSection": "abstract"}, {"offsetInBeginSection": 600, "offsetInEndSection": 753, "text": "X-linked mode of inheritance is seen in Menkes disease, Barth syndrome, and in deficiencies of the E1 alpha subunit of the pyruvate dehydrogenase complex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8884581", "endSection": "abstract"}, {"offsetInBeginSection": 530, "offsetInEndSection": 685, "text": "Although the cardiomyopathy was familial in two siblings, two of three cases were female, ruling out Barth syndrome (with sex-linked recessive inheritance)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11975944", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "Barth syndrome is an X-linked genetic disorder caused by mutations in the tafazzin (taz) gene and characterized by dilated cardiomyopathy, exercise intolerance, chronic fatigue, delayed growth, and neutropenia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21068380", "endSection": "abstract"}, {"offsetInBeginSection": 2265, "offsetInEndSection": 2518, "text": "Barth syndrome should be considered when boys present with cardiomyopathy, especially when associated with increased left ventricular trabeculations, neutropenia, skeletal muscle weakness, or family history indicating an X-linked pattern of inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847078", "endSection": "abstract"}, {"offsetInBeginSection": 600, "offsetInEndSection": 754, "text": "X-linked mode of inheritance is seen in Menkes disease, Barth syndrome, and in deficiencies of the E1 alpha subunit of the pyruvate dehydrogenase complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8884581", "endSection": "abstract"}, {"offsetInBeginSection": 530, "offsetInEndSection": 686, "text": "Although the cardiomyopathy was familial in two siblings, two of three cases were female, ruling out Barth syndrome (with sex-linked recessive inheritance).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11975944", "endSection": "abstract"}, {"offsetInBeginSection": 531, "offsetInEndSection": 687, "text": "Although the cardiomyopathy was familial in two siblings, two of three cases were female, ruling out Barth syndrome (with sex-linked recessive inheritance).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11975944", "endSection": "abstract"}, {"offsetInBeginSection": 2265, "offsetInEndSection": 2519, "text": "Barth syndrome should be considered when boys present with cardiomyopathy, especially when associated with increased left ventricular trabeculations, neutropenia, skeletal muscle weakness, or family history indicating an X-linked pattern of inheritance..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847078", "endSection": "abstract"}]}, {"body": "Is Cryptococcus neoformans a frequent cause of isolated skin infections in immunocompromised individuals", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26246081", "http://www.ncbi.nlm.nih.gov/pubmed/12602722", "http://www.ncbi.nlm.nih.gov/pubmed/27852678", "http://www.ncbi.nlm.nih.gov/pubmed/12219115"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0010414", "o": "http://linkedlifedata.com/resource/umls/label/A18683550"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18683550", "o": "cryptococcus neoformans"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0010416", "o": "Cryptococcus neoformans"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0010416", "o": "http://linkedlifedata.com/resource/umls/label/A0043970"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0010414", "o": "http://linkedlifedata.com/resource/umls/label/A8355137"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8355137", "o": "Infection by Cryptococcus neoformans"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0010414", "o": "http://linkedlifedata.com/resource/umls/label/A0560486"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0560486", "o": "Infection by Cryptococcus neoformans"}], "ideal_answer": ["Primary cutaneous cryptococcosis (PCC) without systemic infection is rare."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003453", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012874", "http://www.disease-ontology.org/api/metadata/DOID:12053", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003455", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003454"], "type": "yesno", "id": "58e120036fddd3e83e00000d", "snippets": [{"offsetInBeginSection": 10, "offsetInEndSection": 284, "text": " Cryptococcus is an opportunistic yeast with a worldwide distribution that primarily causes significant infections in immunocompromised individuals, generally by affecting the respiratory tract. But primary cutaneous cryptococcosis (PCC) without systemic infection is rare. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26246081", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Cryptococcus is a ubiquitous fungus and is known for causing meningitis and cutaneous infections in immunocompromised individuals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27852678", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "Cryptococcus neoformans is an encapsulated yeast that can cause primary pulmonary infections or disseminate and cause infections of the central nervous system, meninges, skin, and bone in the immunocompromised host.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12602722", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "The authors report a male patient, a seller with no detected immunosuppression, with an extensive ulcerated skin lesion localized on the left forearm, caused by Cryptococcus neoformans var.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12219115", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of Pictilisib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27044711", "http://www.ncbi.nlm.nih.gov/pubmed/25370471", "http://www.ncbi.nlm.nih.gov/pubmed/27573562", "http://www.ncbi.nlm.nih.gov/pubmed/26830312", "http://www.ncbi.nlm.nih.gov/pubmed/27565810", "http://www.ncbi.nlm.nih.gov/pubmed/26733612", "http://www.ncbi.nlm.nih.gov/pubmed/26965285", "http://www.ncbi.nlm.nih.gov/pubmed/27489350", "http://www.ncbi.nlm.nih.gov/pubmed/27012832", "http://www.ncbi.nlm.nih.gov/pubmed/24754926", "http://www.ncbi.nlm.nih.gov/pubmed/27155741", "http://www.ncbi.nlm.nih.gov/pubmed/27048952", "http://www.ncbi.nlm.nih.gov/pubmed/27529512", "http://www.ncbi.nlm.nih.gov/pubmed/26976426"], "ideal_answer": ["Pictilisib acts by inhibiting PI3K. It is used for breast cancer treatment."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"], "type": "summary", "id": "5884fed0e56acf5176000011", "snippets": [{"offsetInBeginSection": 367, "offsetInEndSection": 696, "text": "EXPERIMENTAL DESIGN: Antiestrogen-sensitive and antiestrogen-resistant ER(+) human breast cancer cell lines and mice bearing PIK3CA-mutant xenografts were treated with the antiestrogen fulvestrant, the PI3K inhibitor GDC-0941 (pictilisib; varied doses/schedules that provided similar amounts of drug each week), or combinations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733612", "endSection": "abstract"}, {"offsetInBeginSection": 1383, "offsetInEndSection": 1834, "text": "These strategies include first-line therapy with high-dose fulvestrant or everolimus (in combination with exemestane or letrozole or with other endocrine therapies), use of the PI3K inhibitors (e.g., buparlisib, alpelisib, pictilisib, taselisib), entinostat, CDK 4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib), and novel selective estrogen receptor degradation agents that may enhance the targeting of acquired mutations in the ESR1 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26830312", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976426", "endSection": "title"}, {"offsetInBeginSection": 201, "offsetInEndSection": 458, "text": "This preoperative window study assessed whether adding the PI3K inhibitor pictilisib (GDC-0941) can increase the antitumor effects of anastrozole in primary breast cancer and aimed to identify the most appropriate patient population for combination therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26976426", "endSection": "abstract"}, {"offsetInBeginSection": 894, "offsetInEndSection": 1100, "text": "In contrast to parental cells, resistant cells were sensitive to growth inhibition and apoptosis induced by the class I PI3K inhibitor, GDC-0941 (pictilisib), which also induced FOXO1 nuclear translocation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27044711", "endSection": "abstract"}, {"offsetInBeginSection": 57, "offsetInEndSection": 429, "text": "Using a mass spectrometry-based metabolomics platform, we discovered that plasma concentrations of 26 metabolites, including amino acids, acylcarnitines, and phosphatidylcholines, were decreased in mice bearing PTEN-deficient tumors compared with non-tumor-bearing controls and in addition were increased following dosing with class I PI3K inhibitor pictilisib (GDC-0941).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048952", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "The PI3K inhibitor pictilisib plus anastrozole suppresses luminal B breast cancer proliferation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27012832", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 194, "text": "Pictilisib is an oral inhibitor of multiple PI3K isoforms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27155741", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Pictilisib (GDC-0941) is an oral class I phosphatidylinositol-3-phosphate kinase inhibitor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27565810", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24754926", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25370471", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 563, "text": "PURPOSE: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K).PATIENTS AND METHODS: Sixty patients with solid tumors received pictilisib at 14 dose levels from 15 to 450 mg once-daily, initially on days 1 to 21 every 28 days and later, using continuous dosing for selected dose levels. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25370471", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "The PI3K inhibitor pictilisib plus anastrozole suppresses luminal B breast cancer proliferation. <CopyrightInformation>\u00a92016 American Association for Cancer Research.</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27012832", "endSection": "abstract"}, {"offsetInBeginSection": 172, "offsetInEndSection": 665, "text": "Understanding the temporal response and pharmacodynamic effects of PI3K inhibition in ER(+) breast cancer will provide a rationale for treatment scheduling to maximize therapeutic index.Antiestrogen-sensitive and antiestrogen-resistant ER(+) human breast cancer cell lines and mice bearing PIK3CA-mutant xenografts were treated with the antiestrogen fulvestrant, the PI3K inhibitor GDC-0941 (pictilisib; varied doses/schedules that provided similar amounts of drug each week), or combinations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26733612", "endSection": "abstract"}, {"offsetInBeginSection": 352, "offsetInEndSection": 926, "text": "The objectives of these studies were to visualize and compare by matrix-assisted laser desorption ionization (MALDI) imaging mass spectrometry the brain and tumor distribution of the phosphatidylinositol 3-kinase (PI3K) inhibitors pictilisib (GDC-0941, 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine) and GNE-317 [5-(6-(3-methoxyoxetan-3-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-2-yl)pyrimidin-2-amine] in U87 and GS2 orthotopic models of GBM, models that exhibit differing blood-brain barrier characteristics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24754926", "endSection": "abstract"}, {"offsetInBeginSection": 707, "offsetInEndSection": 918, "text": "Treating Mx1-Cre, Kras(D12) mice with GDC-0941 (also referred to as pictilisib), an orally bioavailable inhibitor of class I PI3K isoforms, reduced leukocytosis, anemia and splenomegaly while extending survival.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26965285", "endSection": "abstract"}, {"offsetInBeginSection": 1383, "offsetInEndSection": 1874, "text": "These strategies include first-line therapy with high-dose fulvestrant or everolimus (in combination with exemestane or letrozole or with other endocrine therapies), use of the PI3K inhibitors (e.g., buparlisib, alpelisib, pictilisib, taselisib), entinostat, CDK 4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib), and novel selective estrogen receptor degradation agents that may enhance the targeting of acquired mutations in the ESR1 gene. <CopyrightInformation>Copyright \u00a9 2015.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26830312", "endSection": "abstract"}, {"offsetInBeginSection": 137, "offsetInEndSection": 195, "text": "Pictilisib is an oral inhibitor of multiple PI3K isoforms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27155741", "endSection": "abstract"}]}, {"body": "What are sirtuins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26463981", "http://www.ncbi.nlm.nih.gov/pubmed/26961318", "http://www.ncbi.nlm.nih.gov/pubmed/26796034"], "ideal_answer": ["Seven sirtuins have been identified in humans, and their functions currently surpass their originally identified role as histone deacetylase and chromatin silencers to encompass nutrient sensing and metabolic function. All seven sirtuins require NAD(+) in order to carry out their enzymatic activity, and thus become activated in conditions of nutrient depletion, starvation, and cellular stress."], "type": "summary", "id": "58e2651c6fddd3e83e000013", "snippets": [{"offsetInBeginSection": 179, "offsetInEndSection": 577, "text": " seven sirtuins have been identified in humans, and their functions currently surpass their originally identified role as histone deacetylase and chromatin silencers to encompass nutrient sensing and metabolic function. All seven sirtuins require NAD(+) in order to carry out their enzymatic activity, and thus become activated in conditions of nutrient depletion, starvation, and cellular stress. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26463981", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Sirtuins are NAD-dependent lysine deacylases that play critical roles in cellular regulation and are implicated in human diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26796034", "endSection": "abstract"}, {"offsetInBeginSection": 92, "offsetInEndSection": 160, "text": "Sirtuins are NAD+ -dependent class III histone deacetylases (HDACs) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26961318", "endSection": "abstract"}]}, {"body": "Which miRNA is targeted by SRY/Sox9?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23446346", "http://www.ncbi.nlm.nih.gov/pubmed/23389731", "http://www.ncbi.nlm.nih.gov/pubmed/25580223"], "ideal_answer": ["The testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon", "Does the linear Sry transcript function as a ceRNA for miR-138?. Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138. Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1 (HIF-1), and overexpression of SOX4 and HIF-1 effectively reversed the miR-138-mediated suppression of cell invasion. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. ", ", the sex determining region y ( sry) and the cerebellar degeneration-related protein 1 ( cdr1as) rna transcripts have been described to function as a new class of post-transcriptional regulatory rnas that behave as circular endogenous rna sponges for the micro rnas (mirnas) mir-138 and mir-7 , respectively . ", "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively.  it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138.", "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively.", "Does the linear Sry transcript function as a ceRNA for miR-138?. Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1 (HIF-1), and overexpression of SOX4 and HIF-1 effectively reversed the miR-138-mediated suppression of cell invasion. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138. Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. ", "recently, the sex determining region y ( sry) and the cerebellar degeneration-related protein 1 ( cdr1as) rna transcripts have been described to function as a new class of post-transcriptional regulatory rnas that behave as circular endogenous rna sponges for the micro rnas (mirnas) mir-138 and mir-7, respectively.", "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. Metastasis is the major factor affecting patient survival in ovarian cancer. MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by direct base pairing to target sites within untranslated regions of messenger RNAs.", "Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1\u00ce\u00b1 (HIF-1\u00ce\u00b1), and overexpression of SOX4 and HIF-1\u00ce\u00b1 effectively reversed the miR-138-mediated suppression of cell invasion. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon.", "Does the linear Sry transcript function as a ceRNA for miR-138? Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively.", "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. Epidermal growth factor receptor acted as the downstream molecule of SOX4 by way of direct transcriptional control, whereas Slug was the downstream molecule of HIF-1\u00ce\u00b1 by way of proteasome-mediated degradation.", "Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), and overexpression of SOX4 and HIF-1\u03b1 effectively reversed the miR-138-mediated suppression of cell invasion. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. "], "type": "factoid", "id": "58de18e48acda3452900002a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Does the linear Sry transcript function as a ceRNA for miR-138?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25580223", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 317, "text": "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25580223", "endSection": "abstract"}, {"offsetInBeginSection": 682, "offsetInEndSection": 834, "text": " it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25580223", "endSection": "abstract"}, {"offsetInBeginSection": 497, "offsetInEndSection": 742, "text": "Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), and overexpression of SOX4 and HIF-1\u03b1 effectively reversed the miR-138-mediated suppression of cell invasion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23389731", "endSection": "abstract"}, {"offsetInBeginSection": 1105, "offsetInEndSection": 1308, "text": "We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "endSection": "abstract"}]}, {"body": "Which technique led to the elucidation of the role of HOXD10 in regulating lymphatic endothelial responses to VEGF-C?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27199372"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1415684", "o": "HOXD10"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_5032383335380014", "o": "HOXD10"}], "ideal_answer": ["DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C.", "DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C", "DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C. "], "concepts": ["http://www.uniprot.org/uniprot/VEGFC_MOUSE", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040262", "http://www.uniprot.org/uniprot/HXD10_SAGLB", "http://www.uniprot.org/uniprot/HXD10_HUMAN", "http://www.uniprot.org/uniprot/HXD10_HETFR", "http://www.uniprot.org/uniprot/HXD10_LAGLA", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004729", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042582", "http://www.uniprot.org/uniprot/VEGFC_RAT", "http://www.biosemantics.org/jochem#4263666", "http://www.uniprot.org/uniprot/VEGFC_HUMAN", "http://www.uniprot.org/uniprot/HXD10_CHICK", "http://www.uniprot.org/uniprot/HXD10_PANTR", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042442", "http://amigo.geneontology.org/amigo/term/GO:0036328"], "type": "factoid", "id": "5881f627713cbdfd3d000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27199372", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27199372", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "DeepCAGE transcriptomics identify HOXD10 as a transcription factor regulating lymphatic endothelial responses to VEGF-C.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27199372", "endSection": "title"}]}, {"body": "Is Obeticholic Acid used for treatment of Primary Biliary Cholangitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27406083", "http://www.ncbi.nlm.nih.gov/pubmed/27906472", "http://www.ncbi.nlm.nih.gov/pubmed/27532829", "http://www.ncbi.nlm.nih.gov/pubmed/27621676", "http://www.ncbi.nlm.nih.gov/pubmed/27700211", "http://www.ncbi.nlm.nih.gov/pubmed/27825634", "http://www.ncbi.nlm.nih.gov/pubmed/27468093", "http://www.ncbi.nlm.nih.gov/pubmed/26312413", "http://www.ncbi.nlm.nih.gov/pubmed/27589928"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C2825352", "o": "Obeticholic Acid"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2825352", "o": "http://linkedlifedata.com/resource/umls/label/A17691068"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17691068", "o": "OBETICHOLIC ACID"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0087111", "o": "http://linkedlifedata.com/resource/umls/label/A10762572"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A10762572", "o": "Treatment"}], "ideal_answer": ["Yes, obeticholic acid is a farnesoid-X receptor agonist that is approved for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:0060643", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019468"], "type": "yesno", "id": "5884722ee56acf5176000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Obeticholic acid in primary biliary cholangitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825634", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 330, "text": "In a double-blind, randomized, placebo-controlled study including 217 patients with primary biliary cholangitis, the authors show that obeticholic acid (a potent farnesoid X agonist) administered with ursodeoxycholic acid or as monotherapy significantly decreases serum alkaline phosphatase and bilirubin when compared to placebo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825634", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 453, "text": "Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27406083", "endSection": "abstract"}, {"offsetInBeginSection": 238, "offsetInEndSection": 400, "text": "Obeticholic Acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second line therapy in PBC and has recently been licenced by the FDA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27589928", "endSection": "abstract"}, {"offsetInBeginSection": 1142, "offsetInEndSection": 1363, "text": "OCA will be the first stratified therapy introduced in PBC, however confirmatory trial and real life data are needed to confirm that suggestive biochemical improvements are matched by improvement in key clinical outcomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27589928", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27621676", "endSection": "title"}, {"offsetInBeginSection": 972, "offsetInEndSection": 1466, "text": "A series of clinical trials of OCA in PBC, primarily in combination with UDCA, have established that OCA leads to significant reductions in serum alkaline phosphatase that are predicted to lead to improved clinical outcomes, while dose-dependent pruritus has been the most common adverse effect. On the basis of these studies, OCA was given conditional approval by the US Food and Drug Administration with plans to establish the long-term clinical efficacy of OCA in patients with advanced PBC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27621676", "endSection": "abstract"}, {"offsetInBeginSection": 1246, "offsetInEndSection": 1394, "text": "Although obeticholic acid was approved by the FDA for the treatment of PBC in May 2016, this development occurred after the symposium presentation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27700211", "endSection": "abstract"}, {"offsetInBeginSection": 2330, "offsetInEndSection": 2511, "text": "While several agents are being studied in combination with UDCA, monotherapy with the novel agent obeticholic acid, a farnesoid X receptor agonist, has also shown promising results.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27700211", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 452, "text": "Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27406083", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Obeticholic acid for the treatment of primary biliary cholangitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468093", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906472", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532829", "endSection": "title"}, {"offsetInBeginSection": 513, "offsetInEndSection": 654, "text": "This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27406083", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Obeticholic acid for the treatment of primary biliary cholangitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468093", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Long-term Clinical Impact and Cost-Effectiveness of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906472", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "Obeticholic acid in primary biliary cholangitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825634", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532829", "endSection": "title"}, {"offsetInBeginSection": 515, "offsetInEndSection": 656, "text": "This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27406083", "endSection": "abstract"}]}, {"body": "What alternate indication has Vanoxerine been repositioned for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21615815", "http://www.ncbi.nlm.nih.gov/pubmed/27108936", "http://www.ncbi.nlm.nih.gov/pubmed/19817928", "http://www.ncbi.nlm.nih.gov/pubmed/19817929", "http://www.ncbi.nlm.nih.gov/pubmed/25684233", "http://www.ncbi.nlm.nih.gov/pubmed/26616666"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0164200", "o": "vanoxerine"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0164200", "o": "http://linkedlifedata.com/resource/umls/label/A17685361"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17685361", "o": "VANOXERINE"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0164200", "o": "http://linkedlifedata.com/resource/umls/label/A0294723"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0294723", "o": "vanoxerine"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0556030", "o": "repositioning"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0556030", "o": "http://linkedlifedata.com/resource/umls/label/A15558315"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A15558315", "o": "Repositioned"}], "ideal_answer": ["Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter. Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy.", "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy. Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter. ", "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction and can potential treat atrial fibrillation", "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy. Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", "vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", "Vanoxerine 's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", "vanoxerine's were strongly frequency-dependent and repositioned it for treatment of atrial fibrillation and flutter. . has been in clinical trials for parkinsonism , depression and cocaine addiction but lacked efficacy. . "], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056687", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4001200", "http://www.biosemantics.org/jochem#4001200", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4258722", "http://www.biosemantics.org/jochem#4151584", "http://www.biosemantics.org/jochem#4258722", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4151584", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001145"], "type": "factoid", "id": "58c9a8fe02b8c6095300002a", "snippets": [{"offsetInBeginSection": 272, "offsetInEndSection": 399, "text": "Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616666", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Vanoxerine: cellular mechanism of a new antiarrhythmic.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817928", "endSection": "title"}, {"offsetInBeginSection": 231, "offsetInEndSection": 294, "text": "Therefore, we proposed that vanoxerine might be antiarrhythmic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817929", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Vanoxerine is a promising, new, investigational antiarrhythmic drug.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615815", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615815", "endSection": "title"}, {"offsetInBeginSection": 269, "offsetInEndSection": 396, "text": "Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616666", "endSection": "abstract"}, {"offsetInBeginSection": 245, "offsetInEndSection": 308, "text": "Therefore, we proposed that vanoxerine might be antiarrhythmic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817929", "endSection": "abstract"}, {"offsetInBeginSection": 1592, "offsetInEndSection": 1674, "text": "Vanoxerine has characteristics of a potentially effective and safe antiarrhythmic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817928", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "BACKGROUND: Vanoxerine is a promising, new, investigational antiarrhythmic drug.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615815", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615815", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Vanoxerine, a new drug for terminating atrial fibrillation and flutter.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817929", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 164, "text": "Vanoxerine is an oral, 1,4-dialkylpiperazine derivative antiarrhythmic drug being evaluated for pharmacological cardioversion of atrial fibrillation (AF", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27108936", "endSection": "abstract"}, {"offsetInBeginSection": 1420, "offsetInEndSection": 1535, "text": "Oral vanoxerine converted AF/AFL to SR at a high rate, was well tolerated, and caused no ventricular proarrhythmia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25684233", "endSection": "abstract"}]}, {"body": "What is the applicability of the No Promoter Left Behind method?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26530723"], "ideal_answer": ["No Promoter Left Behind (NPLB) is an efficient, organism-independent method for characterizing promoter architectures directly from experimentally identified genome-wide TSSs, without relying on known promoter elements.", "Promoters have diverse regulatory architectures and thus activate genes differently. No Promoter Left Behind (NPLB) is an efficient, organism-independent method for characterizing such diverse architectures directly from experimentally identified genome-wide TSSs, without relying on known promoter elements."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011401", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005786", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015870", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018507"], "type": "factoid", "id": "588f341594c1512c50000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "No Promoter Left Behind (NPLB): learn de novo promoter architectures from genome-wide transcription start sites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", "endSection": "title"}, {"offsetInBeginSection": 249, "offsetInEndSection": 472, "text": "No Promoter Left Behind (NPLB) is an efficient, organism-independent method for characterizing such diverse architectures directly from experimentally identified genome-wide TSSs, without relying on known promoter elements.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", "endSection": "abstract"}, {"offsetInBeginSection": 234, "offsetInEndSection": 457, "text": "No Promoter Left Behind (NPLB) is an efficient, organism-independent method for characterizing such diverse architectures directly from experimentally identified genome-wide TSSs, without relying on known promoter elements.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", "endSection": "abstract"}, {"offsetInBeginSection": 237, "offsetInEndSection": 459, "text": "No Promoter Left Behind (NPLB) is an efficient, organism-independent method for characterizing such diverse architectures directly from experimentally identified genome-wide TSSs, without relying on known promoter elements", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "No Promoter Left Behind (NPLB): learn de novo promoter architectures from genome-wide transcription start sites", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "No Promoter Left Behind (NPLB): learn de novo promoter architectures from genome-wide transcription start sites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", "endSection": "title"}, {"offsetInBeginSection": 237, "offsetInEndSection": 460, "text": "No Promoter Left Behind (NPLB) is an efficient, organism-independent method for characterizing such diverse architectures directly from experimentally identified genome-wide TSSs, without relying on known promoter elements.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530723", "endSection": "abstract"}]}, {"body": "Which mutated genes are associated with isolated ectopia lentis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20702823", "http://www.ncbi.nlm.nih.gov/pubmed/16765689", "http://www.ncbi.nlm.nih.gov/pubmed/20082464", "http://www.ncbi.nlm.nih.gov/pubmed/24406422", "http://www.ncbi.nlm.nih.gov/pubmed/22871183", "http://www.ncbi.nlm.nih.gov/pubmed/18079676", "http://www.ncbi.nlm.nih.gov/pubmed/22539873", "http://www.ncbi.nlm.nih.gov/pubmed/19390640", "http://www.ncbi.nlm.nih.gov/pubmed/26653794", "http://www.ncbi.nlm.nih.gov/pubmed/21989719", "http://www.ncbi.nlm.nih.gov/pubmed/25975359", "http://www.ncbi.nlm.nih.gov/pubmed/25900864", "http://www.ncbi.nlm.nih.gov/pubmed/22950452", "http://www.ncbi.nlm.nih.gov/pubmed/25654236", "http://www.ncbi.nlm.nih.gov/pubmed/23426735", "http://www.ncbi.nlm.nih.gov/pubmed/17679947", "http://www.ncbi.nlm.nih.gov/pubmed/21051722", "http://www.ncbi.nlm.nih.gov/pubmed/22219643", "http://www.ncbi.nlm.nih.gov/pubmed/22736615", "http://www.ncbi.nlm.nih.gov/pubmed/20141359", "http://www.ncbi.nlm.nih.gov/pubmed/19200529"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1705285", "o": "http://linkedlifedata.com/resource/umls/label/A19043125"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A19043125", "o": "Mutated"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1851286", "o": "Ectopia lentis isolated"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1851286", "o": "http://linkedlifedata.com/resource/umls/label/A18467573"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1705285", "o": "mutation"}], "ideal_answer": ["Isolated ectopia lentis (EL) is caused by mutation in genes:\n1) ADAMTSL4 and \n2) Fibrillin-1 (FBN1)."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004479"], "type": "list", "id": "58d8d8108acda34529000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "A founder mutation in ADAMTSL4 causes early-onset bilateral ectopia lentis among Jews of Bukharian origin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26653794", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 421, "text": "The term isolated ectopia lentis (EL; subluxation or dislocation of the human crystalline lens) is applied to patients with EL, without skeletal features and in the absence of aortic root dilatation. To date, the only gene shown to cause autosomal-recessive isolated EL is ADAMTSL4. Here we report a novel founder mutation in ADAMTSL4 gene in children of Bukharian Jewish origin presenting with early-onset bilateral EL. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26653794", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Early onset ectopia lentis due to a FBN1 mutation with non-penetrance.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25900864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Isolated ectopia lentis is usually autosomal dominant and commonly due to the mutations of FBN1 gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25900864", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 810, "text": "In conclusion, we report on a case of early-onset autosomal dominant isolated ectopia lentis caused by FBN1 mutation that has previously been reported only in Marfan syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25900864", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "ADAMTSL4-associated isolated ectopia lentis: Further patients, novel mutations and a detailed phenotype description.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25975359", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "ADAMTSL4 mutations seem to be the most common cause of isolated ectoplia lentis (EL) and thus are important concerning the differential diagnosis of connective tissue syndromes with EL as main feature. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25975359", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "A genotype-phenotype comparison of ADAMTSL4 and FBN1 in isolated ectopia lentis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736615", "endSection": "title"}, {"offsetInBeginSection": 9, "offsetInEndSection": 168, "text": "To describe the genotype-phenotype relationship of a cohort of consecutive patients with isolated ectopia lentis (EL) secondary to ADAMTSL4 and FBN1 mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736615", "endSection": "abstract"}, {"offsetInBeginSection": 1389, "offsetInEndSection": 1769, "text": "ADAMTSL4 is the most important known causative gene in isolated EL. Mutations in ADAMTSL4 appear to cause earlier manifestation of EL and are associated with increased axial length as compared to FBN1. We suggest that ADAMTSL4 be screened in all patients with isolated EL and that physicians be vigilant for the more severe ocular phenotype associated with mutations in this gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736615", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "A novel FBN1 mutation in a Chinese family with isolated ectopia lentis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22539873", "endSection": "title"}, {"offsetInBeginSection": 9, "offsetInEndSection": 101, "text": "To identify the genetic defect in an autosomal dominant isolated ectopia lentis (EL) family.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22539873", "endSection": "abstract"}, {"offsetInBeginSection": 974, "offsetInEndSection": 1144, "text": "A novel mutation of FBN1 results in an arginine to cysteine residue (p.R974C) substitution, which is responsible for the patients with isolated EL in this Chinese family.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22539873", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "A homozygous mutation in ADAMTSL4 causes autosomal-recessive isolated ectopia lentis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19200529", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Isolated ectopia lentis is usually autosomal dominant and commonly due to the mutations of FBN1 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25900864", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "To examine the fibrillin-1 (FBN1) gene for mutations in members of a Chinese family with isolated ectopia lentis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16765689", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Ophthalmic findings in a family with early-onset isolated ectopia lentis and the p.Arg62Cys mutation of the fibrillin-1 gene (FBN1).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22950452", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Craniosynostosis with ectopia lentis and a homozygous 20-base deletion in ADAMTSL4.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22871183", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "ADAMTSL4-associated isolated ectopia lentis: Further patients, novel mutations and a detailed phenotype description", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25975359", "endSection": "title"}, {"offsetInBeginSection": 1200, "offsetInEndSection": 1509, "text": "Our study presented detailed clinical manifestations, including some novel ophthalmic findings, such as pupillary abnormality, different types of glaucoma, and progressive hyperopia.Ophthalmic findings and the p.Arg62Cys mutation of FBN1 gene were reported in a family with early-onset isolated ectopia lentis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22950452", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "To examine the fibrillin-1 (FBN1) gene for mutations in members of a Chinese family with isolated ectopia lentis.Clinically relevant laboratory investigation.Family members underwent clinical examinations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16765689", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Ophthalmic findings in a family with early-onset isolated ectopia lentis and the p.Arg62Cys mutation of the fibrillin-1 gene (FBN1)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22950452", "endSection": "title"}, {"offsetInBeginSection": 335, "offsetInEndSection": 920, "text": "The 65 exons of FBN1 were amplified by polymerase chain reaction and screened for mutations by a combination of denaturing high-performance liquid chromatography analysis and direct DNA sequencing.A mutation, c.184C-->T in exon 2 of FBN1, which results in substitution of arginine by cysteine at position 62 of the fibrillin-1 protein (p.R62C) in all affected family members but in none of the unaffected individuals.A recurrent mutation of FBN1 gene resulted in an arginine-to-cysteine residue (p.R62C), is responsible for the patients with isolated ectopia lentis in a Chinese family", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16765689", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Isolated ectopia lentis is usually autosomal dominant and commonly due to the mutations of FBN1 gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25900864", "endSection": "abstract"}, {"offsetInBeginSection": 672, "offsetInEndSection": 846, "text": "CONCLUSIONS: The results emphasize the association of ADAMTSL4 null mutations with isolated ectopia lentis and the presence of a founder mutation in the European population. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21051722", "endSection": "abstract"}, {"offsetInBeginSection": 740, "offsetInEndSection": 1052, "text": "Herein we show a consanguineous family that carries a novel homozygous splice mutation IVS4-1G>A/IVS4-1G>A in ADAMTSL4 responsible for isolated autosomal recessive EL, thus confirming the involvement of this gene in this condition and underlining the major role of ADAMTS proteases in zonular fibers homeostasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20141359", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Two novel FBN1 mutations associated with ectopia lentis and marfanoid habitus in two Chinese families.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19390640", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Novel FBN1 mutations associated with predominant ectopia lentis and marfanoid habitus in Chinese patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17679947", "endSection": "title"}, {"offsetInBeginSection": 203, "offsetInEndSection": 402, "text": "FBN1 mutations are associated with multiple clinical phenotypes, including Marfan syndrome (MFS), MASS phenotype, and familial ectopia lentis, but rarely with isolated aortic aneurysm and dissection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20082464", "endSection": "abstract"}, {"offsetInBeginSection": 237, "offsetInEndSection": 387, "text": "This was correlated with Sanger sequencing of ADAMTSL4 and FBN1 genes.Seventeen patients were examined, including one with ectopia lentis et pupillae.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736615", "endSection": "abstract"}, {"offsetInBeginSection": 619, "offsetInEndSection": 739, "text": "Recently, ADAMTSL4 has been shown to be responsible for isolated autosomal recessive ectopia lentis in an inbred family.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20141359", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Confirmation of ADAMTSL4 mutations for autosomal recessive isolated bilateral ectopia lentis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20141359", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "A recurrent FBN1 mutation in an autosomal dominant ectopia lentis family of Indian origin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18079676", "endSection": "title"}, {"offsetInBeginSection": 1558, "offsetInEndSection": 1737, "text": "We suggest that ADAMTSL4 be screened in all patients with isolated EL and that physicians be vigilant for the more severe ocular phenotype associated with mutations in this gene..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736615", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "A homozygous mutation in ADAMTSL4 causes autosomal-recessive isolated ectopia lentis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19200529", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Recurrent FBN1 mutation (R62C) in a Chinese family with isolated ectopia lentis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16765689", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "A genotype-phenotype comparison of ADAMTSL4 and FBN1 in isolated ectopia lentis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22736615", "endSection": "title"}, {"offsetInBeginSection": 1385, "offsetInEndSection": 1514, "text": "Ophthalmic findings and the p.Arg62Cys mutation of FBN1 gene were reported in a family with early-onset isolated ectopia lentis..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22950452", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Ophthalmic findings in a family with early-onset isolated ectopia lentis and the p.Arg62Cys mutation of the fibrillin-1 gene (FBN1).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22950452", "endSection": "title"}, {"offsetInBeginSection": 756, "offsetInEndSection": 926, "text": "A recurrent mutation of FBN1 gene resulted in an arginine-to-cysteine residue (p.R62C), is responsible for the patients with isolated ectopia lentis in a Chinese family..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16765689", "endSection": "abstract"}]}, {"body": "Does the word ovine refers to goats?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23903827", "http://www.ncbi.nlm.nih.gov/pubmed/25755186", "http://www.ncbi.nlm.nih.gov/pubmed/11578130"], "ideal_answer": ["Ovine refers to sheep."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012756", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D034561"], "type": "yesno", "id": "58e186fd6fddd3e83e00000f", "snippets": [{"offsetInBeginSection": 147, "offsetInEndSection": 320, "text": "Jaagsiekte sheep retrovirus (JSRV) is the causative agent of ovine pulmonary adenocarcinoma (OPA), a transmissible lung cancer of sheep that has rarely been found in goats. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903827", "endSection": "abstract"}, {"offsetInBeginSection": 138, "offsetInEndSection": 304, "text": "In sheep, a bronchiolo-alveolar carcinoma, known as ovine pulmonary carcinoma (OPC), is caused by jaagsiekte sheep retrovirus (JSRV), an exogenous type D retrovirus. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11578130", "endSection": "abstract"}]}, {"body": "Does GATA-1 regulate ribosomal protein genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19587786", "http://www.ncbi.nlm.nih.gov/pubmed/10224082", "http://www.ncbi.nlm.nih.gov/pubmed/24453067"], "ideal_answer": ["Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins. Sixteen of the corresponding transcription factors are of particular interest, as they are housekeeping genes or show a direct link to hematopoiesis, tumorigenesis or leukemia (e.g. GATA-1/2, PU.1, MZF-1). ", "in exon 2 interfere with the synthesis of the full-length isoform of gata-1 and lead to the production of a shortened isoform , gata-1s these mutations have been found in patients with diamond-blackfan anemia (dba) , a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins. . of the corresponding transcription factors are of particular interest , as they are housekeeping genes or show a direct link to hematopoiesis , tumorigenesis or leukemia (e.g gata-1/2 , pu.1 , mzf-1). . ", "These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins. Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. Sixteen of the corresponding transcription factors are of particular interest, as they are housekeeping genes or show a direct link to hematopoiesis, tumorigenesis or leukemia (e.g. GATA-1/2, PU.1, MZF-1). ", "These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins. Sixteen of the corresponding transcription factors are of particular interest, as they are housekeeping genes or show a direct link to hematopoiesis, tumorigenesis or leukemia (e.g.", "These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins. The Ribosomal protein S19 gene locus (RPS19) has been linked to two kinds of red cell aplasia, Diamond-Blackfan Anemia (DBA) and Transient Erythroblastopenia in Childhood (TEC).", "Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins.", "mutations in exon 2 interfere with the synthesis of the full-length isoform of gata-1 and lead to the production of a shortened isoform, gata-1s.", "yes", "Sixteen of the corresponding transcription factors are of particular interest, as they are housekeeping genes or show a direct link to hematopoiesis, tumorigenesis or leukemia (e.g. GATA-1/2, PU.1, MZF-1). Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins."], "type": "yesno", "id": "58e782fd3e8b6dc87c000006", "snippets": [{"offsetInBeginSection": 127, "offsetInEndSection": 451, "text": "Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24453067", "endSection": "abstract"}, {"offsetInBeginSection": 1248, "offsetInEndSection": 1453, "text": "Sixteen of the corresponding transcription factors are of particular interest, as they are housekeeping genes or show a direct link to hematopoiesis, tumorigenesis or leukemia (e.g. GATA-1/2, PU.1, MZF-1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587786", "endSection": "abstract"}, {"offsetInBeginSection": 885, "offsetInEndSection": 1028, "text": "Deletion of PKC1 relieves the repression of both ribosomal protein and rRNA genes that occurs in response to a defect in the secretory pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10224082", "endSection": "abstract"}, {"offsetInBeginSection": 1197, "offsetInEndSection": 1360, "text": "This stress is monitored by Pkc1p, which initiates a signal transduction pathway that leads to repression of transcription of the rRNA and ribosomal protein genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10224082", "endSection": "abstract"}, {"offsetInBeginSection": 1361, "offsetInEndSection": 1578, "text": "The importance of the transcription of the 137 ribosomal protein genes to the economy of the cell is apparent from the existence of at least three distinct pathways that can effect the repression of this set of genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10224082", "endSection": "abstract"}]}, {"body": "Which gene mutations cause the Marfan syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3354620", "http://www.ncbi.nlm.nih.gov/pubmed/8841521", "http://www.ncbi.nlm.nih.gov/pubmed/7611299", "http://www.ncbi.nlm.nih.gov/pubmed/22221020", "http://www.ncbi.nlm.nih.gov/pubmed/9649943", "http://www.ncbi.nlm.nih.gov/pubmed/1569206", "http://www.ncbi.nlm.nih.gov/pubmed/12511552", "http://www.ncbi.nlm.nih.gov/pubmed/20538085", "http://www.ncbi.nlm.nih.gov/pubmed/19353630", "http://www.ncbi.nlm.nih.gov/pubmed/19839986", "http://www.ncbi.nlm.nih.gov/pubmed/19328768", "http://www.ncbi.nlm.nih.gov/pubmed/8008028", "http://www.ncbi.nlm.nih.gov/pubmed/24668922", "http://www.ncbi.nlm.nih.gov/pubmed/23684891", "http://www.ncbi.nlm.nih.gov/pubmed/26503076", "http://www.ncbi.nlm.nih.gov/pubmed/19159394", "http://www.ncbi.nlm.nih.gov/pubmed/15287423", "http://www.ncbi.nlm.nih.gov/pubmed/18388785", "http://www.ncbi.nlm.nih.gov/pubmed/21909107", "http://www.ncbi.nlm.nih.gov/pubmed/9401003", "http://www.ncbi.nlm.nih.gov/pubmed/23653584", "http://www.ncbi.nlm.nih.gov/pubmed/7870075", "http://www.ncbi.nlm.nih.gov/pubmed/17701892", "http://www.ncbi.nlm.nih.gov/pubmed/27906200", "http://www.ncbi.nlm.nih.gov/pubmed/11251996", "http://www.ncbi.nlm.nih.gov/pubmed/18377530", "http://www.ncbi.nlm.nih.gov/pubmed/12413333", "http://www.ncbi.nlm.nih.gov/pubmed/25812041", "http://www.ncbi.nlm.nih.gov/pubmed/10633129", "http://www.ncbi.nlm.nih.gov/pubmed/18435798", "http://www.ncbi.nlm.nih.gov/pubmed/11826022", "http://www.ncbi.nlm.nih.gov/pubmed/8941093", "http://www.ncbi.nlm.nih.gov/pubmed/8180508", "http://www.ncbi.nlm.nih.gov/pubmed/1406753", "http://www.ncbi.nlm.nih.gov/pubmed/10721679", "http://www.ncbi.nlm.nih.gov/pubmed/18412115", "http://www.ncbi.nlm.nih.gov/pubmed/12402346", "http://www.ncbi.nlm.nih.gov/pubmed/21034599", "http://www.ncbi.nlm.nih.gov/pubmed/10441700", "http://www.ncbi.nlm.nih.gov/pubmed/19161152", "http://www.ncbi.nlm.nih.gov/pubmed/8882780", "http://www.ncbi.nlm.nih.gov/pubmed/24078565", "http://www.ncbi.nlm.nih.gov/pubmed/21211293", "http://www.ncbi.nlm.nih.gov/pubmed/12651868", "http://www.ncbi.nlm.nih.gov/pubmed/10189088", "http://www.ncbi.nlm.nih.gov/pubmed/8405806", "http://www.ncbi.nlm.nih.gov/pubmed/16799921", "http://www.ncbi.nlm.nih.gov/pubmed/11175294", "http://www.ncbi.nlm.nih.gov/pubmed/10694921", "http://www.ncbi.nlm.nih.gov/pubmed/21883168", "http://www.ncbi.nlm.nih.gov/pubmed/23121584", "http://www.ncbi.nlm.nih.gov/pubmed/10756346", "http://www.ncbi.nlm.nih.gov/pubmed/10766875", "http://www.ncbi.nlm.nih.gov/pubmed/15861007", "http://www.ncbi.nlm.nih.gov/pubmed/23552953"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0596611", "o": "Gene Mutation"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0596611", "o": "http://linkedlifedata.com/resource/umls/label/A7647895"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7647895", "o": "Gene Mutation"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0596611", "o": "http://linkedlifedata.com/resource/umls/label/A7850263"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7850263", "o": "Gene Mutation"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0024796", "o": "Marfan Syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0024796", "o": "http://linkedlifedata.com/resource/umls/label/A0431931"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0596611", "o": "http://linkedlifedata.com/resource/umls/label/A18566680"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18566680", "o": "gene mutations"}], "ideal_answer": ["Marfan syndrome (MFS) is an autosomal dominant disorder caused by mutations in the fibrillin 1 gene (FBN1)."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008382", "http://www.disease-ontology.org/api/metadata/DOID:14323"], "type": "factoid", "id": "58d8e6818acda3452900000a", "snippets": [{"offsetInBeginSection": 9, "offsetInEndSection": 126, "text": "The diagnostic criteria of Marfan syndrome (MFS) highlight the importance of a FBN1 mutation test in diagnosing MFS. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25812041", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "A marked decrease in heart rate variability in Marfan syndrome patients with confirmed FBN1 mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503076", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 199, "text": "The studies on heart rate variability (HRV), a key predictor of all-cause mortality, in Marfan syndrome (MS), up to now have not been reported, especially in patients with FBN1 mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503076", "endSection": "abstract"}, {"offsetInBeginSection": 208, "offsetInEndSection": 315, "text": "Among 18 MS patients with the phenotype of MS meeting inclusion criteria 15 have had a FBN1 gene mutation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503076", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 637, "text": "Heart rates in MS patients with the FBN1 mutation were increased in both the supine position and orthostatic test (p<0.001).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503076", "endSection": "abstract"}, {"offsetInBeginSection": 847, "offsetInEndSection": 985, "text": "A marked decrease in HRV, documented in the study, may be an important clinical feature in MS patients with confirmed FBN1 gene mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503076", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Evaluating the quality of Marfan genotype-phenotype correlations in existing FBN1 databases.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906200", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 102, "text": "Genetic FBN1 testing is pivotal for confirming the clinical diagnosis of Marfan syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906200", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Novel FBN1 gene mutation and maternal germinal mosaicism as the cause of neonatal form of Marfan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24668922", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Marfan syndrome (MFS) is an autosomal dominant disorder caused by mutations in the fibrillin 1 gene (FBN1). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24668922", "endSection": "abstract"}, {"offsetInBeginSection": 227, "offsetInEndSection": 491, "text": "While mutations causing classic manifestations of Marfan syndrome have been identified throughout the FBN1 gene, the six previously characterized mutations resulting in the severe, perinatal lethal form of Marfan syndrome have clustered in exons 24-32 of the gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882780", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "[Screening of FBN1 gene mutations in a family with Marfan syndrome].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211293", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "To identify FBN1 gene mutations in a Chinese family with Marfan syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211293", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Identification of fibrillin-1 gene mutations in Marfan syndrome by high-resolution melting analysis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19328768", "endSection": "title"}, {"offsetInBeginSection": 51, "offsetInEndSection": 458, "text": "Three diagnostic classifications comprising first, Marfan genotype with a causative FBN1 gene mutation; second, Marfan phenotype with clinical criteria of the original Ghent nosology (Ghent-1); and third, phenotype with clinical criteria of its current revision (Ghent-2) in 300 consecutive persons referred for confirmation or exclusion of Marfan syndrome (150 men, 150 women aged 35 \u00b1 13 years) were used.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21883168", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Prevalence of dural ectasia in 63 gene-mutation-positive patients with features of Marfan syndrome type 1 and Loeys-Dietz syndrome and report of 22 novel FBN1 mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19159394", "endSection": "title"}, {"offsetInBeginSection": 85, "offsetInEndSection": 155, "text": "Marfan syndrome type 1 (MFS1) is caused by mutations in the FBN1 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19159394", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Fibrillin gene (FBN1) mutations in Japanese patients with Marfan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10721679", "endSection": "title"}, {"offsetInBeginSection": 116, "offsetInEndSection": 222, "text": "Mutations in FBN1, TGFBR1, TGFBR2 are known to cause Marfan syndrome (MIM 154700), a pleiotropic disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20538085", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24-40.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11175294", "endSection": "title"}, {"offsetInBeginSection": 1088, "offsetInEndSection": 1345, "text": "We conclude that fibrillin gene defects cause familial Marfan syndrome, that mutations in the EGF-like motif of the fibrillin gene are not uniformly associated with severe disease, and that fibrillin genotype is not the sole determinant of Marfan phenotype.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1569206", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Mutations of the fibrillin gene (FBN1) are known to cause classical Marfan's syndrome, ectopia lentis and neonatal Marfan's syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7870075", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Severe Marfan syndrome due to FBN1 exon deletions.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18412115", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "BACKGROUND: Mutations in the FBN1 gene are the cause of the Marfan syndrome, an autosomal dominant disorder with skeletal, ocular, and cardiovascular complications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8941093", "endSection": "abstract"}, {"offsetInBeginSection": 454, "offsetInEndSection": 696, "text": "It is still difficult to use modern genetic testing for diagnosis because Marfan syndrome can be caused by many different mutations in FBN1, a large gene with 65 coding segments, while mutations in other genes can cause overlapping phenotypes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121584", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 292, "text": "The studies on heart rate variability (HRV), a key predictor of all-cause mortality, in Marfan syndrome (MS), up to now have not been reported, especially in patients with FBN1 mutations.Among 18 MS patients with the phenotype of MS meeting inclusion criteria 15 have had a FBN1 gene mutation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503076", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Mutations in the gene encoding fibrillin-1 (FBN1), a component of the extracellular microfibril, cause Marfan syndrome (MFS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22221020", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Mutations in the fibrillin-1 (FBN1) gene cause Marfan syndrome (MFS) and have been associated with a wide range of overlapping phenotypes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17701892", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Mutations in the gene encoding fibrillin-1 (FBN1) cause Marfan syndrome (MFS) and other related connective tissue disorders", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12402346", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Mutations in the FBN1 gene cause Marfan syndrome (MFS) and have been associated with a wide range of milder overlapping phenotypes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19353630", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "The aim of this study was to establish a national database of mutations in the fibrillin-1 (FBN1) gene that cause Marfan syndrome (MFS) in the Taiwanese population", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19839986", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Fibrillin-1 gene (FBN1) mutations cause Marfan syndrome (MFS), an inherited connective tissue disorder with autosomal dominant transmission", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18435798", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Mutations in the gene encoding fibrillin 1 (FBN1) cause Marfan syndrome (MFS), and related connective tissue disorders", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19161152", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Acute mitral regurgitation due to chordal rupture in a patient with neonatal Marfan syndrome caused by a deletion in exon 29 of the FBN1 gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441700", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Neonatal Marfan syndrome caused by an exon 25 mutation of the fibrillin-1 gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15287423", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Functional pulmonary atresia in a patient with neonatal Marfan syndrome caused by a c.3602G>A mutation in exon 29 of the FBN1 gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18388785", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "Mutations in the gene for fibrillin-1 (FBN1) cause Marfan syndrome, an autosomal dominant disorder of connective tissue with prominent manifestations in the skeletal, ocular, and cardiovascular system. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11175294", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "It has been firmly established that mutations in the gene for fibrillin 1, FBN1, cause Marfan syndrome (MFS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11826022", "endSection": "abstract"}, {"offsetInBeginSection": 118, "offsetInEndSection": 282, "text": "Mutations in the fibrillin-1 gene (FBN1) cause Marfan syndrome and related connective tissue disorders (fibrillinopathies) that show autosomal dominant inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12651868", "endSection": "abstract"}, {"offsetInBeginSection": 394, "offsetInEndSection": 623, "text": "It is known that mutations in the fibrillin gene cause a heterogenous connective tissue disease called Marfan syndrome [2], so information on mechanical properties of microfibrils or their role in tissue function would be useful.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8841521", "endSection": "abstract"}, {"offsetInBeginSection": 1727, "offsetInEndSection": 1856, "text": "Mutations in the fibrillin gene located on human chromosome 15 have been strongly implicated as the cause of the Marfan syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8405806", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Mutations in the FBN1 gene cause Marfan syndrome (MFS) and have been associated with a wide range of milder overlapping phenotypes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19353630", "endSection": "abstract"}, {"offsetInBeginSection": 153, "offsetInEndSection": 261, "text": "Mutations within the fibrillin-1 gene cause Marfan syndrome (MFS), a heritable disease of connective tissue.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12511552", "endSection": "abstract"}, {"offsetInBeginSection": 878, "offsetInEndSection": 1013, "text": "These data speak against the hypothesis that mutations in one or more of these 3 fibrillar collagens cause the classic Marfan syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3354620", "endSection": "abstract"}, {"offsetInBeginSection": 777, "offsetInEndSection": 1074, "text": "By WES and filtering with a mining tool, a novel FBN1 missense variant was found in patient 1 and his mother, who both showed clinical features of Marfan syndrome by thorough anthropometric assessment, and a novel EYA1 missense variant as a probable cause of the renal malformation in the patient.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23552953", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Mutations in the fibrillin-1 (FBN1) gene cause Marfan syndrome (MFS) and have been associated with a wide range of overlapping phenotypes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17701892", "endSection": "abstract"}, {"offsetInBeginSection": 695, "offsetInEndSection": 781, "text": "FBN1 mutations cause Marfan syndrome, whose major cardiovascular complication is TAAD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21909107", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Marfan syndrome is a multisystem disorder of connective tissue that is inherited in an autosomal dominant fashion, and results from mutation of the FBN1 gene on human chromosome 15.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121584", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "Mutations in the gene for fibrillin-1 (FBN1) cause Marfan syndrome, an autosomal dominant disorder of connective tissue with prominent manifestations in the skeletal, ocular, and cardiovascular system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11175294", "endSection": "abstract"}, {"offsetInBeginSection": 537, "offsetInEndSection": 661, "text": "We here report 22 novel and 9 recurrent mutations in the FBN1 gene in 36 patients with clinical features of Marfan syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19159394", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 195, "text": "The fibrillin gene is the site of mutations causing Marfan's syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8008028", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Fibrillin-1 gene (FBN1) mutations cause Marfan syndrome (MFS), an inherited connective tissue disorder with autosomal dominant transmission.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18435798", "endSection": "abstract"}, {"offsetInBeginSection": 198, "offsetInEndSection": 344, "text": "FBN1 at 15q21.1 was found to cause Marfan syndrome in 1991, and in 2004 TGFBR2 at 3p24.1 was newly identified as the Marfan syndrome type II gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15861007", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7611299", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Mutations in the gene encoding fibrillin-1 (FBN1) cause Marfan syndrome (MFS) and other related connective tissue disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12402346", "endSection": "abstract"}, {"offsetInBeginSection": 399, "offsetInEndSection": 540, "text": "Mutations in the gene coding for fibrillin-1, FBN1, are known to cause Marfan syndrome, and have been identified in almost all exons of FBN1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10189088", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Mutations in the gene encoding fibrillin-1 (FBN1), a component of the extracellular microfibril, cause the Marfan syndrome (MFS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7611299", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "The aim of this study was to establish a national database of mutations in the fibrillin-1 (FBN1) gene that cause Marfan syndrome (MFS) in the Taiwanese population.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19839986", "endSection": "abstract"}, {"offsetInBeginSection": 229, "offsetInEndSection": 493, "text": "While mutations causing classic manifestations of Marfan syndrome have been identified throughout the FBN1 gene, the six previously characterized mutations resulting in the severe, perinatal lethal form of Marfan syndrome have clustered in exons 24-32 of the gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882780", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 358, "text": "Mutations in the fibrillin-1 (FBN1) gene, on chromosome 15q21.1, have been found to cause Marfan syndrome, a dominantly inherited disorder characterised by clinically variable skeletal, ocular, and cardiovascular abnormalities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401003", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "Mutations in the gene for fibrillin-1 (FBN1) have been shown to cause Marfan syndrome, an autosomal dominant disorder of connective tissue characterised by pleiotropic manifestations involving primarily the ocular, skeletal, and cardiovascular systems.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10633129", "endSection": "abstract"}, {"offsetInBeginSection": 149, "offsetInEndSection": 332, "text": "Through a number of investigational approaches, the gene encoding for fibrillin, the FBN1 gene on chromosome 15, has been identified as the defective gene causing the Marfan syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8180508", "endSection": "abstract"}]}, {"body": "What is the indication of ARCALYST?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22096352", "http://www.ncbi.nlm.nih.gov/pubmed/19707454", "http://www.ncbi.nlm.nih.gov/pubmed/19649332"], "ideal_answer": ["In February 2008, Regeneron received Orphan Drug approval from the Food and Drug Administration for rilonacept in the treatment of two cryopyrin-associated periodic syndromes (CAPS) disorders, namely, familial cold-induced autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), for children and adults 12 years and older."], "type": "factoid", "id": "58df47f08acda3452900002f", "snippets": [{"offsetInBeginSection": 526, "offsetInEndSection": 775, "text": "Rilonacept (Arcalyst(TM); Regeneron) is the first us Food and Drug Administration-approved treatment for familial cold autoinflammatory syndrome and Muckle-Wells syndrome and the first in a new line of drugs designed for longer-acting IL-1 blockade.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22096352", "endSection": "abstract"}, {"offsetInBeginSection": 401, "offsetInEndSection": 735, "text": " In February 2008, Regeneron received Orphan Drug approval from the Food and Drug Administration for rilonacept in the treatment of two cryopyrin-associated periodic syndromes (CAPS) disorders, namely, familial cold-induced autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), for children and adults 12 years and older. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19649332", "endSection": "abstract"}, {"offsetInBeginSection": 1271, "offsetInEndSection": 1605, "text": "In February, 2008, 'Orphan Drug' approval from the Food and Drug Administration (FDA) for rilonacept (IL-1 Trap/Arcalyst(), Regeneron Pharmaceuticals, Inc) was given for the treatment of two CAPS disorders, FCAS and MWS in adults and children 12 years and older, making rilonacept the first therapy approved for the treatment of CAPS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19707454", "endSection": "abstract"}]}, {"body": "What is ChIPpeakAnno?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20459804"], "ideal_answer": ["ChIPpeakAnno is a Bioconductor package within the statistical programming environment R that facilitates batch annotation of enriched peaks identified from ChIP-seq, ChIP-chip, cap analysis of gene expression (CAGE) or any experiments resulting in a large number of enriched genomic regions."], "type": "summary", "id": "587d13c0d673c3eb14000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459804", "endSection": "title"}, {"offsetInBeginSection": 706, "offsetInEndSection": 1011, "text": "We have developed ChIPpeakAnno as a Bioconductor package within the statistical programming environment R to facilitate batch annotation of enriched peaks identified from ChIP-seq, ChIP-chip, cap analysis of gene expression (CAGE) or any experiments resulting in a large number of enriched genomic regions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459804", "endSection": "abstract"}, {"offsetInBeginSection": 1719, "offsetInEndSection": 2187, "text": "ChIPpeakAnno enables batch annotation of the binding sites identified from ChIP-seq, ChIP-chip, CAGE or any technology that results in a large number of enriched genomic regions within the statistical programming environment R. Allowing users to pass their own annotation data such as a different Chromatin immunoprecipitation (ChIP) preparation and a dataset from literature, or existing annotation packages, such as GenomicFeatures and BSgenome, provides flexibility", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459804", "endSection": "abstract"}]}, {"body": "Signaling of which pathways is inhibited by Dupilumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27130691", "http://www.ncbi.nlm.nih.gov/pubmed/25482871", "http://www.ncbi.nlm.nih.gov/pubmed/25006719", "http://www.ncbi.nlm.nih.gov/pubmed/26454361", "http://www.ncbi.nlm.nih.gov/pubmed/26598956", "http://www.ncbi.nlm.nih.gov/pubmed/27334730", "http://www.ncbi.nlm.nih.gov/pubmed/26440137", "http://www.ncbi.nlm.nih.gov/pubmed/27690741", "http://www.ncbi.nlm.nih.gov/pubmed/25214796", "http://www.ncbi.nlm.nih.gov/pubmed/25645542", "http://www.ncbi.nlm.nih.gov/pubmed/26308331", "http://www.ncbi.nlm.nih.gov/pubmed/27525671", "http://www.ncbi.nlm.nih.gov/pubmed/27637004", "http://www.ncbi.nlm.nih.gov/pubmed/25542094", "http://www.ncbi.nlm.nih.gov/pubmed/27497276", "http://www.ncbi.nlm.nih.gov/pubmed/26967382", "http://www.ncbi.nlm.nih.gov/pubmed/27223113", "http://www.ncbi.nlm.nih.gov/pubmed/26457448", "http://www.ncbi.nlm.nih.gov/pubmed/26428945", "http://www.ncbi.nlm.nih.gov/pubmed/26836729", "http://www.ncbi.nlm.nih.gov/pubmed/23688323", "http://www.ncbi.nlm.nih.gov/pubmed/24275927"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0037083", "o": "http://linkedlifedata.com/resource/umls/label/A7662356"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7662356", "o": "Signaling"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1710082", "o": "http://linkedlifedata.com/resource/umls/label/A17472893"}], "ideal_answer": ["Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling. It is used for treatment of atopic or allergic diseases."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0023052", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015398"], "type": "list", "id": "5880b2a6c872c95565000004", "snippets": [{"offsetInBeginSection": 724, "offsetInEndSection": 1170, "text": "This study reviewed all studies about any roles of IL-4 that can directly and indirectly be played in the development of pemphigus and IL-4 inhibition with interferons and dupilumab therapy were introduced as a novel pemphigus treatment for patients who are in relapse phase of the disease. Dupilumab was also introduced as a possible treatment for patients with severe pemphigus. It can directly inhibit IL-4 by targeting IL-4 \u03b1-chain receptor. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440137", "endSection": "abstract"}, {"offsetInBeginSection": 149, "offsetInEndSection": 276, "text": "OBJECTIVE: To assess inhibition of interleukins 4 and 13 with dupilumab in patients with chronic sinusitis and nasal polyposis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836729", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "BACKGROUND: Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130691", "endSection": "abstract"}, {"offsetInBeginSection": 936, "offsetInEndSection": 1158, "text": "Anti-IL-4 and IL-13 agents (dupilumab, lebrikizumab, and tralokinumab) which block different Th-2 inflammatory pathways and agents targeting the Th-17 inflammatory pathway in severe refractory asthma are under development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27334730", "endSection": "abstract"}, {"offsetInBeginSection": 1051, "offsetInEndSection": 1337, "text": "Best evidence of the clinical efficacy of novel immunologic approaches using biological agents in patients with AD is available for the anti-IL-4 receptor \u03b1-chain antibody dupilumab, but a number of studies are currently ongoing with other specific antagonists to immune system players.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27497276", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", "endSection": "abstract"}, {"offsetInBeginSection": 450, "offsetInEndSection": 614, "text": "The world's first prospective controlled studies with the biologic human anti-IL4R antibody dupilumab for the indication \"atopic dermatitis\" were published in 2014.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25645542", "endSection": "abstract"}, {"offsetInBeginSection": 708, "offsetInEndSection": 803, "text": "An IL-4R antagonist, dupilumab, is the first drug that shows great promise in phase II trials. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25542094", "endSection": "abstract"}, {"offsetInBeginSection": 625, "offsetInEndSection": 818, "text": "Dupilumab, a humanized monoclonal antibody to the interteukin-4R is the first antibody (i.e. 'biological') with published efficacy shown in controlled prospective studies in atopic dermatitis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26308331", "endSection": "abstract"}, {"offsetInBeginSection": 90, "offsetInEndSection": 271, "text": "Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", "endSection": "abstract"}, {"offsetInBeginSection": 240, "offsetInEndSection": 368, "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are requisite drivers of atopic dermatitis, evidenced by marked improvement after treatment with dupilumab, a fully-human monoclonal antibody that blocks both pathways.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26454361", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", "endSection": "abstract"}, {"offsetInBeginSection": 742, "offsetInEndSection": 974, "text": "The robust effects of dupilumab on skin inflammation and pruritus confirm the pathogenic role of IL-4 and IL-13 signaling in adult AD, and further support the application of Th2 cytokine antagonists in the treatment of this disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130691", "endSection": "abstract"}, {"offsetInBeginSection": 91, "offsetInEndSection": 271, "text": "Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", "endSection": "abstract"}, {"offsetInBeginSection": 101, "offsetInEndSection": 684, "text": "In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor \ufffd, markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the molecular level has not been characterized.OBJECTIVES: We sought to evaluate dupilumab modulation of the AD molecular signature.METHODS: We performed transcriptomic analyses of pretreatment and posttreatment skin biopsy specimens from patients with moderate-to-severe AD treated weekly with 150 or 300 mg of dupilumab or placebo.RESULTS: Exacerbation of the AD transcriptome was observed in placebo-treated patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25482871", "endSection": "abstract"}, {"offsetInBeginSection": 91, "offsetInEndSection": 272, "text": "Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", "endSection": "abstract"}, {"offsetInBeginSection": 242, "offsetInEndSection": 370, "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945", "endSection": "abstract"}, {"offsetInBeginSection": 746, "offsetInEndSection": 978, "text": "The robust effects of dupilumab on skin inflammation and pruritus confirm the pathogenic role of IL-4 and IL-13 signaling in adult AD, and further support the application of Th2 cytokine antagonists in the treatment of this disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", "endSection": "abstract"}, {"offsetInBeginSection": 101, "offsetInEndSection": 683, "text": "In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor \u00e1, markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the molecular level has not been characterized.OBJECTIVES: We sought to evaluate dupilumab modulation of the AD molecular signature.METHODS: We performed transcriptomic analyses of pretreatment and posttreatment skin biopsy specimens from patients with moderate-to-severe AD treated weekly with 150 or 300 mg of dupilumab or placebo.RESULTS: Exacerbation of the AD transcriptome was observed in placebo-treated patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25482871", "endSection": "abstract"}]}, {"body": "Does the TOP2B/TOP2A expression ratio affect the response to AML chemotherapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22627319"], "ideal_answer": ["High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype.", "High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia. Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype. Another interesting finding is that high ratios of TOP2B/RRM2 and TOP2B/TOP2 alpha (TOP2A) in a combined analysis were also shown to have a prognostic impact for longer survival with improved accuracy. Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P=0.002) and overall survival (HR, 0.29; P=0.005). ", "Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P=0.002) and overall survival (HR, 0.29; P=0.005). Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype.", "among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the top2b/top2a ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (hr, 0.24; p=0.002) and overall survival (hr, 0.29; p=0.005).", "yes", "Another interesting finding is that high ratios of TOP2B/RRM2 and TOP2B/TOP2 alpha (TOP2A) in a combined analysis were also shown to have a prognostic impact for longer survival with improved accuracy. Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype.", "High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia"], "type": "yesno", "id": "58b67fae22d3005309000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", "endSection": "title"}, {"offsetInBeginSection": 1292, "offsetInEndSection": 1496, "text": "Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", "endSection": "abstract"}, {"offsetInBeginSection": 763, "offsetInEndSection": 964, "text": "Another interesting finding is that high ratios of TOP2B/RRM2 and TOP2B/TOP2 alpha (TOP2A) in a combined analysis were also shown to have a prognostic impact for longer survival with improved accuracy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", "endSection": "abstract"}, {"offsetInBeginSection": 965, "offsetInEndSection": 1279, "text": "Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P=0.002) and overall survival (HR, 0.29; P=0.005)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", "endSection": "title"}, {"offsetInBeginSection": 935, "offsetInEndSection": 1453, "text": "Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P=0.002) and overall survival (HR, 0.29; P=0.005).Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", "endSection": "abstract"}, {"offsetInBeginSection": 1283, "offsetInEndSection": 1499, "text": "CONCLUSION: Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", "endSection": "abstract"}, {"offsetInBeginSection": 1253, "offsetInEndSection": 1458, "text": "Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", "endSection": "title"}, {"offsetInBeginSection": 937, "offsetInEndSection": 1252, "text": "Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P=0.002) and overall survival (HR, 0.29; P=0.005).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", "endSection": "abstract"}, {"offsetInBeginSection": 735, "offsetInEndSection": 936, "text": "Another interesting finding is that high ratios of TOP2B/RRM2 and TOP2B/TOP2 alpha (TOP2A) in a combined analysis were also shown to have a prognostic impact for longer survival with improved accuracy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22627319", "endSection": "abstract"}]}, {"body": "List the three main structures of the cytoskeleton.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26498781"], "ideal_answer": ["Fibrillar polymers-actin filaments, microtubules, and intermediate filaments-are major constituents of the cytoskeleton."], "type": "list", "id": "58e0035f6fddd3e83e000009", "snippets": [{"offsetInBeginSection": 177, "offsetInEndSection": 297, "text": "Fibrillar polymers-actin filaments, microtubules, and intermediate filaments-are major constituents of the cytoskeleton,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26498781", "endSection": "abstract"}]}, {"body": "What is the genus for the common European honey bee?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18941909", "http://www.ncbi.nlm.nih.gov/pubmed/26990560", "http://www.ncbi.nlm.nih.gov/pubmed/27518068", "http://www.ncbi.nlm.nih.gov/pubmed/27447542", "http://www.ncbi.nlm.nih.gov/pubmed/27705831", "http://www.ncbi.nlm.nih.gov/pubmed/19909977", "http://www.ncbi.nlm.nih.gov/pubmed/21960435", "http://www.ncbi.nlm.nih.gov/pubmed/17897670"], "ideal_answer": ["The genus and species of the European honey bee is Apis mellifera."], "type": "factoid", "id": "58e23ec66fddd3e83e000010", "snippets": [{"offsetInBeginSection": 52, "offsetInEndSection": 87, "text": "European honey bee (Apis mellifera)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27447542", "endSection": "abstract"}, {"offsetInBeginSection": 69, "offsetInEndSection": 106, "text": " European honey bees (Apis mellifera)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18941909", "endSection": "title"}, {"offsetInBeginSection": 63, "offsetInEndSection": 99, "text": " European honey bees (Apis mellifera", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17897670", "endSection": "title"}, {"offsetInBeginSection": 56, "offsetInEndSection": 92, "text": " European honey bees, Apis mellifera", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17897670", "endSection": "abstract"}]}, {"body": "Where is the TAZ (G4.5) is located in humans?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9345098", "http://www.ncbi.nlm.nih.gov/pubmed/25118650", "http://www.ncbi.nlm.nih.gov/pubmed/23398819", "http://www.ncbi.nlm.nih.gov/pubmed/12032589", "http://www.ncbi.nlm.nih.gov/pubmed/23606313", "http://www.ncbi.nlm.nih.gov/pubmed/19261493", "http://www.ncbi.nlm.nih.gov/pubmed/11735032", "http://www.ncbi.nlm.nih.gov/pubmed/23031367", "http://www.ncbi.nlm.nih.gov/pubmed/10407787"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1336578", "o": "http://linkedlifedata.com/resource/umls/label/A20729485"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A20729485", "o": "TAZ gene"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1336578", "o": "http://linkedlifedata.com/resource/umls/label/A6916046"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A6916046", "o": "TAZ gene"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0086418", "o": "http://linkedlifedata.com/resource/umls/label/A6958822"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1336578", "o": "http://linkedlifedata.com/resource/umls/label/A20747487"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A20747487", "o": "G4.5"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1336578", "o": "TAZ"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0086418", "o": "Man"}], "ideal_answer": ["TAZ gene (G4.5) is located on Xq28 in humans."], "concepts": ["http://www.uniprot.org/uniprot/TAZ_MACMU", "http://www.uniprot.org/uniprot/TAZ_HUMAN", "http://www.uniprot.org/uniprot/TAZ_SAISC", "http://www.uniprot.org/uniprot/TAZ_PONPY", "http://www.uniprot.org/uniprot/TAZ_ERYPA", "http://www.uniprot.org/uniprot/TAZ_PANTR", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006801"], "type": "factoid", "id": "58d906b28acda3452900000d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Tafazzin (EC 2.3.1.23) is a Phospholipid Transacylase involved in Cardiolipin remodeling on mitochondrial membrane and coded by TAZ gene (Cytogenetic Location: Xq28) in human.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25118650", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "Barth syndrome is an X-linked cardiomyopathy with neutropenia and 3-methylglutaconic aciduria. Recently, mutations in the G4.5 gene, located in Xq28, have been described in four probands with Barth syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9345098", "endSection": "abstract"}, {"offsetInBeginSection": 210, "offsetInEndSection": 294, "text": "The disorder is caused by mutations in the tafazzin (TAZ/G4.5) gene located on Xq28.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23606313", "endSection": "abstract"}, {"offsetInBeginSection": 1506, "offsetInEndSection": 1702, "text": "Disabling mutations or deletions of the tafazzin (TAZ) gene, located at Xq28, cause the disorder by reducing remodeling of cardiolipin, a principal phospholipid of the inner mitochondrial membrane", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23398819", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "The tafazzin gene (TAZ) is located at Xq28 and encodes a protein involved in the transacylation of cardiolipin, an essential mitochondrial phospholipid", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23031367", "endSection": "abstract"}, {"offsetInBeginSection": 211, "offsetInEndSection": 294, "text": "The disorder is caused by mutations in the tafazzin (TAZ/G4.5) gene located on Xq28", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23606313", "endSection": "abstract"}, {"offsetInBeginSection": 211, "offsetInEndSection": 295, "text": "The disorder is caused by mutations in the tafazzin (TAZ/G4.5) gene located on Xq28.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23606313", "endSection": "abstract"}, {"offsetInBeginSection": 95, "offsetInEndSection": 207, "text": "Recently, mutations in the G4.5 gene, located in Xq28, have been described in four probands with Barth syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9345098", "endSection": "abstract"}]}, {"body": "What do nerve-associated peripheral glial progenitors give rise to?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24925909"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0027757", "o": "NERVE"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0027757", "o": "http://linkedlifedata.com/resource/umls/label/A20241247"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A20241247", "o": "NERVE"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0027740", "o": "http://linkedlifedata.com/resource/umls/label/A0006429"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0006429", "o": "Nerve"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0027740", "o": "http://linkedlifedata.com/resource/umls/label/A0006426"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0006426", "o": "Nerve"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0205100", "o": "Peripheral"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0205100", "o": "http://linkedlifedata.com/resource/umls/label/A20244302"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0027740", "o": "Nerves"}], "ideal_answer": ["Nerve-associated peripheral glial progenitors give rise to parasympathetic neurons. The parasympathetic system in mice--including trunk ganglia and the cranial ciliary, pterygopalatine, lingual, submandibular, and otic ganglia--arise from glial cells in nerves, not neural crest cells. The parasympathetic fate is induced in nerve-associated Schwann cell precursors at distal peripheral sites.", "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors. The parasympathetic fate is induced in nerve-associated Schwann cell precursors at distal peripheral sites.", "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009457", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009417", "http://amigo.geneontology.org/amigo/term/GO:0010001", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009474"], "type": "factoid", "id": "5881f9b65bf093691f000001", "snippets": [{"offsetInBeginSection": 18, "offsetInEndSection": 103, "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909", "endSection": "title"}, {"offsetInBeginSection": 156, "offsetInEndSection": 478, "text": "We show that the parasympathetic system in mice--including trunk ganglia and the cranial ciliary, pterygopalatine, lingual, submandibular, and otic ganglia--arise from glial cells in nerves, not neural crest cells. The parasympathetic fate is induced in nerve-associated Schwann cell precursors at distal peripheral sites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Neurodevelopment. Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909", "endSection": "title"}, {"offsetInBeginSection": 18, "offsetInEndSection": 102, "text": "Parasympathetic neurons originate from nerve-associated peripheral glial progenitors", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Neurodevelopment. Parasympathetic neurons originate from nerve-associated peripheral glial progenitors.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925909", "endSection": "title"}]}, {"body": "How many topological associated domains are contained in the human Hox cluster?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24843030"], "ideal_answer": ["transcriptional activation is associated with a dynamic bi-modal 3d organization, whereby the genes switch autonomously from an inactive to an active compartment.", "Initially, Hox clusters are organized as single chromatin compartments containing all genes and bivalent chromatin marks. Transcriptional activation is associated with a dynamic bi-modal 3D organization, whereby the genes switch autonomously from an inactive to an active compartment. ", ", hox clusters are organized as single chromatin compartments containing all genes and bivalent chromatin marks. . activation is associated with a dynamic bi-modal 3d organization , whereby the genes switch autonomously from an inactive to an active compartment. . ", "Initially, Hox clusters are organized as single chromatin compartments containing all genes and bivalent chromatin marks. Transcriptional activation is associated with a dynamic bi-modal 3D organization, whereby the genes switch autonomously from an inactive to an active compartment."], "type": "factoid", "id": "58e793f53e8b6dc87c000008", "snippets": [{"offsetInBeginSection": 422, "offsetInEndSection": 543, "text": "Initially, Hox clusters are organized as single chromatin compartments containing all genes and bivalent chromatin marks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24843030", "endSection": "abstract"}, {"offsetInBeginSection": 544, "offsetInEndSection": 706, "text": "Transcriptional activation is associated with a dynamic bi-modal 3D organization, whereby the genes switch autonomously from an inactive to an active compartment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24843030", "endSection": "abstract"}]}, {"body": "Is Lennox-Gastaut Syndrome usually diagnosed in older adults?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22576075", "http://www.ncbi.nlm.nih.gov/pubmed/8029151", "http://www.ncbi.nlm.nih.gov/pubmed/26166587", "http://www.ncbi.nlm.nih.gov/pubmed/24659735", "http://www.ncbi.nlm.nih.gov/pubmed/20542434", "http://www.ncbi.nlm.nih.gov/pubmed/26945476", "http://www.ncbi.nlm.nih.gov/pubmed/9400037", "http://www.ncbi.nlm.nih.gov/pubmed/20518600"], "ideal_answer": ["Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3 Hz) spike wave discharges on electroencephalography.", "lennox-gastaut syndrome (lgs) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3 hz) spike wave discharges on electroencephalography.", " children with Lennox-Gastaut syndrome Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3 Hz) spike wave discharges on electroencephalography"], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:0050561", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065768"], "type": "yesno", "id": "58dbb4f08acda3452900001a", "snippets": [{"offsetInBeginSection": 583, "offsetInEndSection": 729, "text": "We studied 15 LGS patients (mean age \u00b1 1 standard deviation [SD] = 28.7 \u00b1 10.6 years) and 17 healthy controls (mean age \u00b1 1 SD = 27.6 \u00b1 6.6 years)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26945476", "endSection": "abstract"}, {"offsetInBeginSection": 91, "offsetInEndSection": 129, "text": " children with Lennox-Gastaut syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24659735", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by mixed seizures, cognitive decline, and generalized slow (<3 Hz) spike wave discharges on electroencephalography", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26166587", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Clinical course and results of therapy were analysed in the group of 92 children, aged between 3 and 9 years, with diagnosed Lennox-Gastaut syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8029151", "endSection": "abstract"}, {"offsetInBeginSection": 427, "offsetInEndSection": 659, "text": "We report the case of a 27-year-old man with a neurodevelopmental syndrome due to a 15q duplication, with intellectual disability, psychiatric disturbances, and an epileptic phenotype diagnosed as late-onset Lennox-Gastaut syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22576075", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "Lennox-Gastaut syndrome is a relatively rare epilepsy syndrome that usually begins in early-mid childhood and is characterized by multiple seizure types, particularly generalized seizures, which are often resistant to antiepileptic drug medication", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20518600", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "Lennox-Gastaut Syndrome is a severe childhood epilepsy syndrome characterised by the diagnostic triad of a slow spike and wave pattern on electroencephalogram, multiple seizure types and developmental delay", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20542434", "endSection": "abstract"}, {"offsetInBeginSection": 427, "offsetInEndSection": 660, "text": "We report the case of a 27-year-old man with a neurodevelopmental syndrome due to a 15q duplication, with intellectual disability, psychiatric disturbances, and an epileptic phenotype diagnosed as late-onset Lennox-Gastaut syndrome..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22576075", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "The Lennox-Gastaut syndrome, a severe form of epilepsy that usually begins in early childhood, is difficult to treat.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9400037", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Lennox-Gastaut syndrome is a relatively rare epilepsy syndrome that usually begins in early-mid childhood and is characterized by multiple seizure types, particularly generalized seizures, which are often resistant to antiepileptic drug medication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20518600", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 400, "text": "The Lennox-Gastaut syndrome is an age-specific disorder, characterised by epileptic seizures, a characteristic electroencephalogram (EEG), psychomotor delay and behaviour disorders. It occurs more frequently in males and onset is usually before the age of eight, with a peak between three and five years. Late cases occurring in adolescence and early adulthood have rarely been reported. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19588340", "endSection": "abstract"}]}, {"body": "Which treatment methods were compared in the EXCEL Trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21547994", "http://www.ncbi.nlm.nih.gov/pubmed/25983143", "http://www.ncbi.nlm.nih.gov/pubmed/26159652", "http://www.ncbi.nlm.nih.gov/pubmed/25583761", "http://www.ncbi.nlm.nih.gov/pubmed/21796086", "http://www.ncbi.nlm.nih.gov/pubmed/22941121", "http://www.ncbi.nlm.nih.gov/pubmed/22075415", "http://www.ncbi.nlm.nih.gov/pubmed/27639738", "http://www.ncbi.nlm.nih.gov/pubmed/22511269", "http://www.ncbi.nlm.nih.gov/pubmed/23995725"], "ideal_answer": ["EXCEL trial compared Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017428", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002986", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016430", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017326"], "type": "list", "id": "5880b583c872c95565000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25583761", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "AIMS: To prospectively validate the SYNTAX Score II and forecast the outcomes of the randomized Evaluation of the Xience Everolimus-Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) Trial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25583761", "endSection": "abstract"}, {"offsetInBeginSection": 1385, "offsetInEndSection": 1665, "text": "Based on 4-year mortality predictions in EXCEL, clinical characteristics shifted long-term mortality predictions either in favour of PCI (older age, male gender and COPD) or CABG (younger age, lower creatinine clearance, female gender, reduced left ventricular ejection fraction).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25583761", "endSection": "abstract"}, {"offsetInBeginSection": 463, "offsetInEndSection": 797, "text": "Given that the completed randomized trials did not include contemporary DESs, the upcoming results of the ongoing trials evaluating the performance of new-generation DES compared with CABG (such as the EXCEL trial), may further help to clarify the current role and future recommendations of PCI for left main coronary artery disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26159652", "endSection": "abstract"}, {"offsetInBeginSection": 531, "offsetInEndSection": 686, "text": "The ongoing EXCEL trial will help elucidate the role of ULMCA PCI in the treatment of left main disease compared with coronary artery bypass graft surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23995725", "endSection": "abstract"}, {"offsetInBeginSection": 1151, "offsetInEndSection": 1412, "text": "The ongoing Evaluation of XIENCE V Everolimus Eluting Stent System Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial is expected to provide a better answer on the optimal treatment strategy for LMCAD patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22941121", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 496, "text": "The Evaluation of Xience Prime or Xience V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial is a multicenter, ongoing trial conducted in patients with left main disease and SYNTAX score \u2264 32 to establish the presumptive advantage of percutaneous coronary intervention (PCI) versus bypass surgery in patients with less complex coronary artery disease than those enrolled in the Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22075415", "endSection": "abstract"}, {"offsetInBeginSection": 965, "offsetInEndSection": 1095, "text": "The EXCEL trial will address the value of PCI in relation to CABG for the treatment of ULMCA stenosis in more than 2000 patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22511269", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 478, "text": "OBJECTIVES: The aim of this study is to verify the study hypothesis of the EXCEL trial by comparing percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) in an EXCEL-like population of patients.BACKGROUND: The upcoming EXCEL trial will test the hypothesis that left main patients with SYNTAX score \u2264 32 experience similar rates of 3-year death, myocardial infarction (MI), or cerebrovascular accidents (CVA) following revascularization by PCI or CABG.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21547994", "endSection": "abstract"}, {"offsetInBeginSection": 1403, "offsetInEndSection": 1562, "text": "CONCLUSIONS: In an EXCEL-like cohort of patients with left main disease, there seems to be a clinical equipoise between PCI and CABG in terms of death/MI/CVA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21547994", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "The aim of this study is to verify the study hypothesis of the EXCEL trial by comparing percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) in an EXCEL-like population of patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21547994", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 730, "text": "To prospectively validate the SYNTAX Score II and forecast the outcomes of the randomized Evaluation of the Xience Everolimus-Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) Trial.Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization is a prospective, randomized multicenter trial designed to establish the efficacy and safety of percutaneous coronary intervention (PCI) with the everolimus-eluting stent compared with coronary artery bypass graft (CABG) surgery in subjects with unprotected left-main coronary artery (ULMCA) disease and low-intermediate anatomical SYNTAX scores (&lt;33).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25583761", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 326, "text": "OBJECTIVES: The aim of this study is to verify the study hypothesis of the EXCEL trial by comparing percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) in an EXCEL-like population of patients.BACKGROUND: The upcoming EXCEL trial will test the hypothesis that left main patients with SYNTAX score ?", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21547994", "endSection": "abstract"}, {"offsetInBeginSection": 679, "offsetInEndSection": 902, "text": "The results of the ongoing EXCEL trial, which compares left main percutaneous coronary intervention with drug-eluting stents and CABG, will provide insight regarding the ideal revascularization strategy for these patients..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21796086", "endSection": "abstract"}, {"offsetInBeginSection": 463, "offsetInEndSection": 796, "text": "Given that the completed randomized trials did not include contemporary DESs, the upcoming results of the ongoing trials evaluating the performance of new-generation DES compared with CABG (such as the EXCEL trial), may further help to clarify the current role and future recommendations of PCI for left main coronary artery disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26159652", "endSection": "abstract"}, {"offsetInBeginSection": 363, "offsetInEndSection": 904, "text": "The introduction of the newer-generation drug-eluting stents (DES) -with documented improvements in both safety and efficacy- has prompted the interventional community to design two new dedicated randomised trials comparing CABG and PCI: the NOBLE (Coronary Artery Bypass Grafting Vs Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis) and EXCEL (Evaluation of XIENCE Everolimus Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25983143", "endSection": "abstract"}, {"offsetInBeginSection": 965, "offsetInEndSection": 1094, "text": "The EXCEL trial will address the value of PCI in relation to CABG for the treatment of ULMCA stenosis in more than 2000 patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22511269", "endSection": "abstract"}, {"offsetInBeginSection": 1108, "offsetInEndSection": 1368, "text": "The ongoing Evaluation of XIENCE V Everolimus Eluting Stent System Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial is expected to provide a better answer on the optimal treatment strategy for LMCAD patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22941121", "endSection": "abstract"}]}, {"body": "Describe ATR-16 syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9375730", "http://www.ncbi.nlm.nih.gov/pubmed/24631100", "http://www.ncbi.nlm.nih.gov/pubmed/10631133", "http://www.ncbi.nlm.nih.gov/pubmed/8606626", "http://www.ncbi.nlm.nih.gov/pubmed/17598130", "http://www.ncbi.nlm.nih.gov/pubmed/10872473", "http://www.ncbi.nlm.nih.gov/pubmed/8460633", "http://www.ncbi.nlm.nih.gov/pubmed/15921166", "http://www.ncbi.nlm.nih.gov/pubmed/18076105"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0795917", "o": "http://linkedlifedata.com/resource/umls/label/A11992244"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11992244", "o": "ATR-16 SYNDROME"}], "ideal_answer": ["ATR-16 syndrome is due to alterations on chromosome 16p13.3, and is usually accompanied by alpha-thalassemia, mild-moderate mental retardation, dysmorphic facial features, skeletal and genitourinary malformations."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "http://www.disease-ontology.org/api/metadata/DOID:225"], "type": "summary", "id": "588623153b87a8a738000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "ATR-16 syndrome is due to alterations on chromosome 16p13.3, and is usually accompanied by alpha-thalassemia, mild-moderate mental retardation, dysmorphic facial features, skeletal and genitourinary malformations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24631100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "Alpha thalassemia retardation associated with chromosome16 (ATR-16 syndrome) is defined as a contiguous gene syndrome resulting from haploinsufficiency of the alpha-globin gene cluster and genes involved in mental retardation (MR). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17598130", "endSection": "abstract"}, {"offsetInBeginSection": 498, "offsetInEndSection": 652, "text": "This is the fifth reported case of the ATR-16 syndrome (alpha-thalassemia retardation-16) not complicated by duplication or deletion of other chromosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9375730", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Familial mental retardation syndrome ATR-16 due to an inherited cryptic subtelomeric translocation, t(3;16)(q29;p13.3).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10631133", "endSection": "title"}]}, {"body": "What is the results of inactivated ANGPLT3?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24798233", "http://www.ncbi.nlm.nih.gov/pubmed/22062970"], "ideal_answer": ["Complete ANGPTL3 deficiency caused by loss-of-function mutations of ANGPTL3 is associated with a recessive hypolipidemia"], "type": "factoid", "id": "58dfd70c6fddd3e83e000002", "snippets": [{"offsetInBeginSection": 681, "offsetInEndSection": 895, "text": "Although it appears by now that the main lipid pathways have been uncovered, and that only modulators or adaptor proteins such as those encoded by LDLRAP1, APOA5, ANGPLT3/4, and PCSK9 are currently being discovered", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24798233", "endSection": "abstract"}, {"offsetInBeginSection": 142, "offsetInEndSection": 355, "text": "Angptl3 knockout mice have marked hypolipidemia, and heterozygous carriers of ANGPLT3, loss-of-function mutations were found among individuals in the lowest quartile of plasma triglycerides in population studies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22062970", "endSection": "abstract"}, {"offsetInBeginSection": 364, "offsetInEndSection": 493, "text": " 4 related individuals with primary hypolipidemia were found to be compound heterozygotes for ANGPTL3 loss-of-function mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22062970", "endSection": "abstract"}, {"offsetInBeginSection": 1703, "offsetInEndSection": 1823, "text": "Complete ANGPTL3 deficiency caused by loss-of-function mutations of ANGPTL3 is associated with a recessive hypolipidemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22062970", "endSection": "abstract"}]}, {"body": "What percentage of rheumatoid arthritis patients are responsive to anti-TNF therapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22044414", "http://www.ncbi.nlm.nih.gov/pubmed/24040234"], "ideal_answer": ["Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies. Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients. ", "The introduction of anti-TNF therapy has dramatically improved the outlook for patients suffering from a number of inflammatory conditions including rheumatoid arthritis and inflammatory bowel disease. Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients.", "Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients. A substantial proportion of Rheumatoid Arthritis patients (approximately 30-40%) fail to respond to anti-TNF therapies.", "Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies. Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients.", "Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients. Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies. ", "strategies blocking tumor necrosis factor (anti-tnf) have proven very successful in patients with rheumatoid arthritis (ra) , showing beneficial effects in approximately 50-60% of the patients. . this , a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies . ", "Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients. The introduction of anti-TNF therapy has dramatically improved the outlook for patients suffering from a number of inflammatory conditions including rheumatoid arthritis and inflammatory bowel disease.", "treatment strategies blocking tumor necrosis factor (anti-tnf) have proven very successful in patients with rheumatoid arthritis (ra), showing beneficial effects in approximately 50-60% of the patients.", "Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies. ", "Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies.  Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients.", "Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients. Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies."], "type": "factoid", "id": "58e79e703e8b6dc87c00000a", "snippets": [{"offsetInBeginSection": 202, "offsetInEndSection": 344, "text": "Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22044414", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very successful in patients with rheumatoid arthritis (RA), showing beneficial effects in approximately 50-60% of the patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24040234", "endSection": "abstract"}]}, {"body": "Which disease is treated with semaglutide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25475122", "http://www.ncbi.nlm.nih.gov/pubmed/22675341", "http://www.ncbi.nlm.nih.gov/pubmed/26308095", "http://www.ncbi.nlm.nih.gov/pubmed/27432074", "http://www.ncbi.nlm.nih.gov/pubmed/27817160", "http://www.ncbi.nlm.nih.gov/pubmed/27863704", "http://www.ncbi.nlm.nih.gov/pubmed/27921428", "http://www.ncbi.nlm.nih.gov/pubmed/27042424", "http://www.ncbi.nlm.nih.gov/pubmed/27835045", "http://www.ncbi.nlm.nih.gov/pubmed/27633186", "http://www.ncbi.nlm.nih.gov/pubmed/27183953", "http://www.ncbi.nlm.nih.gov/pubmed/26642233", "http://www.ncbi.nlm.nih.gov/pubmed/26358288", "http://www.ncbi.nlm.nih.gov/pubmed/26694823"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0012634", "o": "http://linkedlifedata.com/resource/umls/label/A0049608"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0049608", "o": "Disease"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/1022004", "o": "http://linkedlifedata.com/resource/rxnorm/label/3147522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3147522", "o": "Disease"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0012634", "o": "http://linkedlifedata.com/resource/umls/label/A18683747"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18683747", "o": "disease"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0012634", "o": "http://linkedlifedata.com/resource/umls/label/A0015569"}], "ideal_answer": ["Semaglutide is glucagon-like peptide-1 receptor agonist that is being used for the treatment of type 2 diabetes mellitus."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:4", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019468"], "type": "factoid", "id": "5880c42fc872c95565000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 741, "text": "INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly being used for the treatment of type 2 diabetes mellitus, but consideration of benefits and potential adverse events is required. This review examines the state of glycemic control, weight loss, blood pressure, and tolerability, as well as the current debate about the safety of GLP-1 RAs, including risk of pancreatitis, pancreatic cancer, and thyroid cancer.METHODS: A MEDLINE search (2010-2015) identified publications that discussed longer-acting GLP-1 RAs. Search terms included GLP-1 receptor agonists, liraglutide, exenatide, lixisenatide, semaglutide, dulaglutide, albiglutide, efficacy, safety, pancreatitis, pancreatic cancer, and thyroid cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26694823", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 872, "text": " Seven trials have been published that have established CV safety for three DPP-4 inhibitors (alogliptin, saxagliptin, and sitagliptin), three GLP-1 receptor agonists (liraglutide, lixisenatide, and semaglutide), and one sodium-glucose cotransporter-2 inhibitor (empagliflozin). Three of those studies also established superiority with liraglutide, empagliflozin, and semaglutide at reducing the composite primary endpoint of major CV events (CV death, nonfatal myocardial infarction, and nonfatal stroke). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27835045", "endSection": "abstract"}, {"offsetInBeginSection": 137, "offsetInEndSection": 727, "text": "RECENT FINDINGS: In response to guidance issued by the Food and Drug Administration, thousands of patients have been enrolled in large randomized trials evaluating the cardiovascular effects of the three newest diabetes drug classes: glucagon-like peptide-1 (GLP-1) receptor agonists, sodium glucose cotransporter 2 (SGLT-2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors. Two studies of GLP-1 receptor agonists-one of liraglutide and one of semaglutide-have shown cardiovascular benefit relative to placebo, and one study of the SGLT-2 inhibitor empagliflozin has shown benefit.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27817160", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "New antidiabetic drugs are being developed today that expand the range of pharmacological intervention, in particular for patients with type 2 diabetes (imeglimin, semaglutide, dulaglutide, FGF 21 analogue).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27921428", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "The effect of semaglutide, a once-weekly human glucagon-like peptide-1 (GLP-1) analog in development for type 2 diabetes (T2D), on the bioavailability of a combined oral contraceptive was investigated. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25475122", "endSection": "abstract"}, {"offsetInBeginSection": 2040, "offsetInEndSection": 2365, "text": "Conclusions In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27633186", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 526, "text": "Postmenopausal women with T2D (n\u2009=\u200943) on diet/exercise\u2009\u00b1\u2009metformin received ethinylestradiol (0.03\u2009mg)/levonorgestrel (0.15\u2009mg) once daily for 8 days before (semaglutide-free) and during (steady-state 1.0\u2009mg) semaglutide treatment (subcutaneous once weekly; dose escalation: 0.25\u2009mg 4 weeks; 0.5\u2009mg 4 weeks; 1.0\u2009mg 5 weeks).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25475122", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27633186", "endSection": "title"}]}, {"body": "What condition is usually represented by the acronym SUDEP?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19623466", "http://www.ncbi.nlm.nih.gov/pubmed/25323494", "http://www.ncbi.nlm.nih.gov/pubmed/23099115", "http://www.ncbi.nlm.nih.gov/pubmed/19713869", "http://www.ncbi.nlm.nih.gov/pubmed/22042178", "http://www.ncbi.nlm.nih.gov/pubmed/25499158", "http://www.ncbi.nlm.nih.gov/pubmed/22191982", "http://www.ncbi.nlm.nih.gov/pubmed/19666211", "http://www.ncbi.nlm.nih.gov/pubmed/15824334", "http://www.ncbi.nlm.nih.gov/pubmed/19909334", "http://www.ncbi.nlm.nih.gov/pubmed/25253292", "http://www.ncbi.nlm.nih.gov/pubmed/17433051", "http://www.ncbi.nlm.nih.gov/pubmed/24348119", "http://www.ncbi.nlm.nih.gov/pubmed/25600783", "http://www.ncbi.nlm.nih.gov/pubmed/23962523", "http://www.ncbi.nlm.nih.gov/pubmed/26387918", "http://www.ncbi.nlm.nih.gov/pubmed/27131289", "http://www.ncbi.nlm.nih.gov/pubmed/19232547", "http://www.ncbi.nlm.nih.gov/pubmed/26038597", "http://www.ncbi.nlm.nih.gov/pubmed/12862502", "http://www.ncbi.nlm.nih.gov/pubmed/26924854", "http://www.ncbi.nlm.nih.gov/pubmed/19130900", "http://www.ncbi.nlm.nih.gov/pubmed/24236903", "http://www.ncbi.nlm.nih.gov/pubmed/16421121", "http://www.ncbi.nlm.nih.gov/pubmed/21737136", "http://www.ncbi.nlm.nih.gov/pubmed/15129839"], "ideal_answer": ["The acronym SUDEP refers to  Sudden Unexpected Death in Epilepsy", " sudden unexpected death in epilepsy (SUDEP), Sudden Unexpected Death in Epilepsy (SUDEP)", "Sudden Unexpected Death in Epilepsy (SUDEP)", "Sudden Unexpected Death in Epilepsy (SUDEP). sudden unexpected death in epilepsy (SUDEP),. "], "type": "factoid", "id": "58dbb8968acda3452900001b", "snippets": [{"offsetInBeginSection": 117, "offsetInEndSection": 160, "text": "Sudden Unexpected Death in Epilepsy (SUDEP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26038597", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 211, "text": " sudden unexpected death in epilepsy (SUDEP),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26387918", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Sudden unexpected death in epilepsy (SUDEP) is the most important direct seizure-related cause of death, and most cases usually occur in patients with intractable, longstanding epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19232547", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Sudden unexpected death in epilepsy (SUDEP): what do patients think?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25499158", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "OBJECTIVES: Sudden unexpected death in epilepsy (SUDEP) is a major cause of mortality in epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25499158", "endSection": "abstract"}, {"offsetInBeginSection": 504, "offsetInEndSection": 582, "text": "In 11 patients cause of death was sudden unexpected death in epilepsy (SUDEP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22042178", "endSection": "abstract"}, {"offsetInBeginSection": 124, "offsetInEndSection": 334, "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may reflect the mistaken belief that epilepsy is a benign condition", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23962523", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Risk factors in sudden death in epilepsy (SUDEP): the quest for mechanisms", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17433051", "endSection": "title"}, {"offsetInBeginSection": 89, "offsetInEndSection": 296, "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably heterogeneous - condition where patients with epilepsy die suddenly, almost certainly during a seizure and with no other identified cause of death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24236903", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Epilepsy, the commonest serious neurological condition, is associated with an increased risk in premature deaths, including an estimated 500 sudden unexpected deaths (SUDEP) per year in the UK.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15129839", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy-related cause of death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19666211", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy-related cause of death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19623466", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally difficult condition to study in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24348119", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Sudden unexpected death in epilepsy (SUDEP): don't ask, don't tell?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16421121", "endSection": "title"}, {"offsetInBeginSection": 121, "offsetInEndSection": 276, "text": "Many individuals with epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy (SUDEP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19909334", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "The baboon represents a natural model for genetic generalized epilepsy and sudden unexpected death in epilepsy (SUDEP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26924854", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Sudden unexpected death in epilepsy (SUDEP) refers to the sudden death of a seemingly healthy individual with epilepsy, usually occurring during, or immediately after, a tonic-clonic seizure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21737136", "endSection": "abstract"}, {"offsetInBeginSection": 90, "offsetInEndSection": 236, "text": "This condition is called sudden unexpected death in epilepsy (SUDEP), and it accounts for a large proportion of deaths among people with epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19713869", "endSection": "abstract"}, {"offsetInBeginSection": 124, "offsetInEndSection": 335, "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may reflect the mistaken belief that epilepsy is a benign condition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23962523", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 45, "text": "Sudden unexpected death in epilepsy (SUDEP) i", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22191982", "endSection": "abstract"}, {"offsetInBeginSection": 86, "offsetInEndSection": 130, "text": " sudden unexpected death in epilepsy (SUDEP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19130900", "endSection": "abstract"}, {"offsetInBeginSection": 25, "offsetInEndSection": 70, "text": "sudden unexpected death in epilepsy (SUDEP) f", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600783", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 44, "text": "udden unexpected death in epilepsy (SUDEP) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12862502", "endSection": "abstract"}, {"offsetInBeginSection": 40, "offsetInEndSection": 88, "text": "sudden and unexpected death in epilepsy (SUDEP) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17178458", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 53, "text": "Sudden unexpected death in epilepsy (SUDEP) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25647769", "endSection": "abstract"}, {"offsetInBeginSection": 70, "offsetInEndSection": 113, "text": "sudden unexpected death in epilepsy (SUDEP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15824334", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 45, "text": "udden unexpected death in epilepsy (SUDEP) i", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25323494", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 53, "text": "Sudden unexplained death in epilepsy (SUDEP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099115", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 44, "text": "udden unexpected death in epilepsy (SUDEP) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24139807", "endSection": "abstract"}, {"offsetInBeginSection": 157, "offsetInEndSection": 201, "text": " sudden unexpected death in epilepsy (SUDEP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109241", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 105, "text": "udden unexpected death in epilepsy (SUDEP) is the leading cause for death in individuals with epilepsy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27131289", "endSection": "abstract"}]}, {"body": "Which proteins does the yeast Cleavage and Polyadenylation Complex contain?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19049464", "http://www.ncbi.nlm.nih.gov/pubmed/23514951", "http://www.ncbi.nlm.nih.gov/pubmed/25877920", "http://www.ncbi.nlm.nih.gov/pubmed/20226668", "http://www.ncbi.nlm.nih.gov/pubmed/18951092"], "ideal_answer": ["The proteins Nrd1, Rap1, Trf4, Rrp6, Ssu72, Cstf64, Pcf11 and PAP are the major components of the 3' cleavage and polyadenylation complex."], "type": "list", "id": "58add7699ef3c34033000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "Gene loops have been described in different organisms from yeast to human and form through interaction between components of the transcription pre-initiation complex and Ssu72, a member of the 3' end cleavage and polyadenylation complex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23514951", "endSection": "abstract"}, {"offsetInBeginSection": 90, "offsetInEndSection": 364, "text": "A large cleavage and polyadenylation complex containing the major poly(A) polymerase Pap1 produces mRNA 3' ends, whereas those of nonpolyadenylated snoRNAs in yeast are formed either by endonucleolytic cleavage or by termination, followed by trimming by the nuclear exosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18951092", "endSection": "abstract"}, {"offsetInBeginSection": 582, "offsetInEndSection": 814, "text": "Poly(A) tails are added by Pap1 to both forms, whereas the alternative poly(A) polymerase Tfr4 adenylates major precursors and processing intermediates to facilitate further polyadenylation by Pap1 and maturation by the exosome/Rrp6", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18951092", "endSection": "abstract"}, {"offsetInBeginSection": 816, "offsetInEndSection": 911, "text": "A more important role of Trf4/TRAMP, however, is to enhance Nrd1 association with snoRNA genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18951092", "endSection": "abstract"}, {"offsetInBeginSection": 551, "offsetInEndSection": 844, "text": "Screening crude natural product extracts with this technology has resulted in the identification of a novel family of antifungal natural products, named the parnafungins, which inhibit the enzyme polyadenosine polymerase (PAP), a key component of the mRNA cleavage and polyadenylation complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19049464", "endSection": "abstract"}, {"offsetInBeginSection": 717, "offsetInEndSection": 884, "text": "We show that phosphorylation of TFIIB at serine 65 regulates the interaction between TFIIB and the CstF-64 component of the CstF 3' cleavage and polyadenylation comple", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20226668", "endSection": "abstract"}, {"offsetInBeginSection": 167, "offsetInEndSection": 400, "text": "We now show that Pcf11, a component of the cleavage and polyadenylation complex (CPAC), is also generally required for NRD-dependent transcription termination through the action of its C-terminal domain (CTD)-interacting domain (CID)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25877920", "endSection": "abstract"}, {"offsetInBeginSection": 398, "offsetInEndSection": 560, "text": "Like the yeast counterpart, mammalian Ssu72 associates with TFIIB and the yeast cleavage/polyadenylation factor Pta1, and exhibits intrinsic phosphatase activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15659578", "endSection": "abstract"}, {"offsetInBeginSection": 560, "offsetInEndSection": 772, "text": "We also provide evidence that Pti1p probably acts by uncoupling cleavage and polyadenylation, and functions in coordination with the Nrd1p-dependent pathway for 3' end formation of non-polyadenylated transcripts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12773397", "endSection": "abstract"}, {"offsetInBeginSection": 400, "offsetInEndSection": 562, "text": "Like the yeast counterpart, mammalian Ssu72 associates with TFIIB and the yeast cleavage/polyadenylation factor Pta1, and exhibits intrinsic phosphatase activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15659578", "endSection": "abstract"}]}, {"body": "Which disease can be categorized using the Koos grading system?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26967786", "http://www.ncbi.nlm.nih.gov/pubmed/25811349", "http://www.ncbi.nlm.nih.gov/pubmed/26606668", "http://www.ncbi.nlm.nih.gov/pubmed/25181431", "http://www.ncbi.nlm.nih.gov/pubmed/27513938", "http://www.ncbi.nlm.nih.gov/pubmed/24797568", "http://www.ncbi.nlm.nih.gov/pubmed/15179293", "http://www.ncbi.nlm.nih.gov/pubmed/21665381", "http://www.ncbi.nlm.nih.gov/pubmed/23160632", "http://www.ncbi.nlm.nih.gov/pubmed/27453796", "http://www.ncbi.nlm.nih.gov/pubmed/24987677"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0012634", "o": "http://linkedlifedata.com/resource/umls/label/A0049608"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0049608", "o": "Disease"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/1022004", "o": "http://linkedlifedata.com/resource/rxnorm/label/3147522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3147522", "o": "Disease"}], "ideal_answer": ["Koos grading system is used for vestibular schwannoma."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:4", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"], "type": "factoid", "id": "5886519c3b87a8a738000007", "snippets": [{"offsetInBeginSection": 636, "offsetInEndSection": 789, "text": "The patients had Koos Grade I or II tumors and American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) Class D hearing status preoperatively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26967786", "endSection": "abstract"}, {"offsetInBeginSection": 250, "offsetInEndSection": 378, "text": "METHODS: This is a retrospective review of 22 patients with VS Koos grade III and IV who were treated with STR followed by SRS. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27513938", "endSection": "abstract"}, {"offsetInBeginSection": 483, "offsetInEndSection": 585, "text": " VS was characterized by its size (Koos classification) and the presence or not of a cystic component.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25811349", "endSection": "abstract"}, {"offsetInBeginSection": 624, "offsetInEndSection": 788, "text": "MAIN OUTCOME MEASURES: All data recorded were reviewed to access age, sex, tumor type, and tumor size according to the Koos classification and presenting symptoms. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24797568", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Facial nerve preservation surgery for koos grade 3 and 4 vestibular schwannomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25181431", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Safety and Efficacy of Gamma Knife Radiosurgery for the Management of Koos Grade 4 Vestibular Schwannomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26606668", "endSection": "title"}, {"offsetInBeginSection": 368, "offsetInEndSection": 509, "text": "In all 333 patients microsurgical vestibular schwannoma (Koos grade 1: 12, grade 2: 34, grade 3: 62, and grade 4: 225) removal was performed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24987677", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Facial nerve preservation surgery for koos grade 3 and 4 vestibular schwannomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25181431", "endSection": "title"}, {"offsetInBeginSection": 195, "offsetInEndSection": 293, "text": "To report, in a retrospective study, outcomes for large Koos grade 3 and 4 vestibular schwannomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25181431", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Safety and Efficacy of Gamma Knife Radiosurgery for the Management of Koos Grade 4 Vestibular Schwannomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26606668", "endSection": "title"}]}, {"body": "What is the inheritance of the glucose-6-phosphate dehydrogenase (G6PD) deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1188317", "http://www.ncbi.nlm.nih.gov/pubmed/6350992", "http://www.ncbi.nlm.nih.gov/pubmed/15226563", "http://www.ncbi.nlm.nih.gov/pubmed/26275698", "http://www.ncbi.nlm.nih.gov/pubmed/12169625", "http://www.ncbi.nlm.nih.gov/pubmed/24460025", "http://www.ncbi.nlm.nih.gov/pubmed/631693", "http://www.ncbi.nlm.nih.gov/pubmed/24865682", "http://www.ncbi.nlm.nih.gov/pubmed/11261779", "http://www.ncbi.nlm.nih.gov/pubmed/11271380", "http://www.ncbi.nlm.nih.gov/pubmed/10066026", "http://www.ncbi.nlm.nih.gov/pubmed/1634454", "http://www.ncbi.nlm.nih.gov/pubmed/10698963", "http://www.ncbi.nlm.nih.gov/pubmed/24943486", "http://www.ncbi.nlm.nih.gov/pubmed/25116429", "http://www.ncbi.nlm.nih.gov/pubmed/1953691", "http://www.ncbi.nlm.nih.gov/pubmed/12737943"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#exactMatch", "s": "http://purl.uniprot.org/uniprot/P11413", "o": "http://purl.uniprot.org/uniprot/P11413"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0017757", "o": "G6PD"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_503131343133004B", "o": "G6PD"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0017757", "o": "http://linkedlifedata.com/resource/umls/label/A8256485"}, {"p": "http://www.w3.org/2004/02/skos/core#exactMatch", "s": "http://linkedlifedata.com/resource/drugbank/molecule/1799", "o": "http://purl.uniprot.org/uniprot/P11413"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/drugbank/molecule/1799", "o": "Glucose-6-phosphate 1-dehydrogenase"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://purl.uniprot.org/uniprot/P11413", "o": "G6PD_HUMAN"}], "ideal_answer": ["Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the commonest red cell enzymopathy in humans and has a recessive X-linked inheritance."], "concepts": ["http://www.uniprot.org/uniprot/G6PD_BUCAI", "http://www.disease-ontology.org/api/metadata/DOID:2862", "http://www.uniprot.org/uniprot/G6PD_CERCA", "http://www.uniprot.org/uniprot/G6PD_CRIGR", "http://www.uniprot.org/uniprot/G6PD_EMENI", "http://www.uniprot.org/uniprot/G6PD_BUCAP", "http://www.uniprot.org/uniprot/G6PD_HUMAN", "http://www.uniprot.org/uniprot/G6PD_ZYMMO", "http://www.uniprot.org/uniprot/G6PD_MACRO", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042843", "http://www.uniprot.org/uniprot/G6PD_ENCCU", "http://www.uniprot.org/uniprot/G6PD_TAKRU", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005954", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005955", "http://www.uniprot.org/uniprot/G6PD_HAEIN", "http://www.uniprot.org/uniprot/G6PD_CYBJA", "http://www.uniprot.org/uniprot/G6PD_DIDVI", "http://www.uniprot.org/uniprot/G6PD_AGGAC", "http://www.uniprot.org/uniprot/G6PD_HELPY", "http://www.uniprot.org/uniprot/G6PD_BOSIN", "http://www.uniprot.org/uniprot/G6PD_GLUOX", "http://www.uniprot.org/uniprot/G6PD_HELPJ", "http://www.uniprot.org/uniprot/G6PD_NOSP7"], "type": "factoid", "id": "58c6635f02b8c60953000023", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the commonest red cell enzymopathy in humans and has an X-linked inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226563", "endSection": "abstract"}, {"offsetInBeginSection": 1050, "offsetInEndSection": 1317, "text": " The high manifestation of G6PD deficiency in women may be due to the preferential expression of the G6PD-deficient gene and X-inactivation of the normal gene, and/or to the presence of an 'enhancer' gene that makes the expression of the G6PD deficiency more likely. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10066026", "endSection": "abstract"}, {"offsetInBeginSection": 461, "offsetInEndSection": 605, "text": "Study of the deficiency pattern amongst family members of the enzyme deficient subjects confirmed the X-linked inheritance of G-6-PD deficiency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1634454", "endSection": "abstract"}, {"offsetInBeginSection": 517, "offsetInEndSection": 639, "text": " The investigation of the patient's whole family showed the typical recessive X-linked inheritance of this enzyme-defect. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6350992", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 297, "text": "After having described in detail the pathophysiology, symptomatology, X-chromosomal inheritance and some laboratory methods in detecting G-6-PD-deficiency by demonstrating a case of favism (Schulz et al. 1977), the authors now discuss the particularities of the enzyme deficiency in the newborn. T", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/631693", "endSection": "abstract"}, {"offsetInBeginSection": 185, "offsetInEndSection": 327, "text": "The genetic pattern is consistent with x-linked recessive inheritance and the defect is associated with drug (primaquine) induced haemolysis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1188317", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "UNLABELLED: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive disorder in which haemolytic anaemia is the major symptom.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11271380", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common human genetic abnormalities, and it has a significant prevalence in the male population (X chromosome linked).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24865682", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the commonest red cell enzymopathy in humans and has an X-linked inheritance", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15226563", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive genetic defect that can cause hemolytic crisis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25116429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive hemolytic anemia caused by a mutation in the G6PD gene on Xq28.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275698", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 297, "text": "Glucose-6-phosphate dehydrogenase deficiency is an X-linked recessive hereditary disease characterised by abnormally low levels of G6PD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24943486", "endSection": "abstract"}]}, {"body": "Which deep learning-based algorithms are used for enhancer prediction?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25378307", "http://www.ncbi.nlm.nih.gov/pubmed/27929098", "http://www.ncbi.nlm.nih.gov/pubmed/26091399", "http://www.ncbi.nlm.nih.gov/pubmed/27490187", "http://www.ncbi.nlm.nih.gov/pubmed/27329130"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0086222", "o": "Enhancer"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0086222", "o": "http://linkedlifedata.com/resource/umls/label/A7570315"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7570315", "o": "Enhancer"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0205125", "o": "DEEP"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0205125", "o": "http://linkedlifedata.com/resource/umls/label/A20250446"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A20250446", "o": "DEEP"}], "ideal_answer": ["EP-DNN and DEEP."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000069550"], "type": "list", "id": "587d30fb31b33e8760000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "EP-DNN: A Deep Neural Network-Based Global Enhancer Prediction Algorithm", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27929098", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "We present EP-DNN, a protocol for predicting enhancers based on chromatin features, in different cell types", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27929098", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "DEEP: a general computational framework for predicting enhancers", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25378307", "endSection": "title"}, {"offsetInBeginSection": 671, "offsetInEndSection": 1145, "text": " In this study we developed DEEP, a novel ensemble prediction framework. DEEP integrates three components with diverse characteristics that streamline the analysis of enhancer's properties in a great variety of cellular conditions. In our method we train many individual classification models that we combine to classify DNA regions as enhancers or non-enhancers. DEEP uses features derived from histone modification marks or attributes coming from sequence characteristics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25378307", "endSection": "abstract"}, {"offsetInBeginSection": 869, "offsetInEndSection": 1080, "text": " in this paper, we use recent state-of-the-art Deep Learning methods and develop a deep neural network (DNN)-based architecture, called EP-DNN, to predict the presence and types of enhancers in the human genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490187", "endSection": "abstract"}, {"offsetInBeginSection": 2349, "offsetInEndSection": 2583, "text": "In this paper, we developed EP-DNN, which has high accuracy of prediction, with validation rates above 90\u00a0% for the operational region of enhancer prediction for all four cell lines that we studied, outperforming DEEP-ENCODE and RFECS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490187", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 307, "text": "We present EP-DNN, a protocol for predicting enhancers based on chromatin features, in different cell types. Specifically, we use a deep neural network (DNN)-based architecture to extract enhancer signatures in a representative human embryonic stem cell type (H1) and a differentiated lung cell type (IMR90)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27929098", "endSection": "abstract"}, {"offsetInBeginSection": 570, "offsetInEndSection": 810, "text": "We find that EP-DNN has superior accuracy with a validation rate of 91.6%, relative to 85.3% for DEEP-ENCODE and 85.5% for RFECS, for a given number of enhancer predictions and also scales better for a larger number of enhancer predictions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27929098", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "PEDLA: predicting enhancers with a deep learning-based algorithmic framework.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329130", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "DEEP: a general computational framework for predicting enhancers.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25378307", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "PEDLA: predicting enhancers with a deep learning-based algorithmic framework.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329130", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "EP-DNN: A Deep Neural Network-Based Global Enhancer Prediction Algorithm.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27929098", "endSection": "title"}, {"offsetInBeginSection": 342, "offsetInEndSection": 616, "text": "We developed a deep learning-based algorithmic framework named PEDLA (https://github.com/wenjiegroup/PEDLA), which can directly learn an enhancer predictor from massively heterogeneous data and generalize in ways that are mostly consistent across various cell types/tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329130", "endSection": "abstract"}]}, {"body": "Is Beta-Thalassemia is associated with a mutation or deletion of the gene that codes for alpha globin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25230702"], "ideal_answer": ["Beta-thalassemia, one of the most common single-gene disorders, is the result of reduced or absent production of \u03b2-globin chains", "beta-thalassemia, one of the most common single-gene disorders, is the result of reduced or absent production of \u03b2-globin chains.", "Beta-thalassemia, one of the most common single-gene disorders, is the result of reduced or absent production of -globin chains. ", "Beta-thalassemia, one of the most common single-gene disorders, is the result of reduced or absent production of \u03b2-globin chains."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055544", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017086"], "type": "yesno", "id": "58dbbbf08acda3452900001d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Beta-thalassemia, one of the most common single-gene disorders, is the result of reduced or absent production of \u03b2-globin chains", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230702", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "The beta-thalassemia syndromes are a heterogeneous group of genetic disorders characterized by reduced or absent expression of the beta-globin gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9056561", "endSection": "abstract"}]}, {"body": "Is diphosphatidylglycerol (cardiolipin) a phospholipid of the mitochondrial membranes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21599656", "http://www.ncbi.nlm.nih.gov/pubmed/26028302", "http://www.ncbi.nlm.nih.gov/pubmed/24905496", "http://www.ncbi.nlm.nih.gov/pubmed/7378435", "http://www.ncbi.nlm.nih.gov/pubmed/4322761", "http://www.ncbi.nlm.nih.gov/pubmed/2397096", "http://www.ncbi.nlm.nih.gov/pubmed/24007978", "http://www.ncbi.nlm.nih.gov/pubmed/7794966", "http://www.ncbi.nlm.nih.gov/pubmed/3668386", "http://www.ncbi.nlm.nih.gov/pubmed/8143741", "http://www.ncbi.nlm.nih.gov/pubmed/23200781", "http://www.ncbi.nlm.nih.gov/pubmed/26301254", "http://www.ncbi.nlm.nih.gov/pubmed/6257342", "http://www.ncbi.nlm.nih.gov/pubmed/6509920", "http://www.ncbi.nlm.nih.gov/pubmed/26396268", "http://www.ncbi.nlm.nih.gov/pubmed/6807345", "http://www.ncbi.nlm.nih.gov/pubmed/16971584", "http://www.ncbi.nlm.nih.gov/pubmed/9370332", "http://www.ncbi.nlm.nih.gov/pubmed/20336283", "http://www.ncbi.nlm.nih.gov/pubmed/1213878", "http://www.ncbi.nlm.nih.gov/pubmed/9843887", "http://www.ncbi.nlm.nih.gov/pubmed/7459841", "http://www.ncbi.nlm.nih.gov/pubmed/3548756", "http://www.ncbi.nlm.nih.gov/pubmed/22634369", "http://www.ncbi.nlm.nih.gov/pubmed/6717095", "http://www.ncbi.nlm.nih.gov/pubmed/25182746", "http://www.ncbi.nlm.nih.gov/pubmed/3718705", "http://www.ncbi.nlm.nih.gov/pubmed/15460113", "http://www.ncbi.nlm.nih.gov/pubmed/25843549", "http://www.ncbi.nlm.nih.gov/pubmed/1550861", "http://www.ncbi.nlm.nih.gov/pubmed/24443516", "http://www.ncbi.nlm.nih.gov/pubmed/20637181", "http://www.ncbi.nlm.nih.gov/pubmed/8977117", "http://www.ncbi.nlm.nih.gov/pubmed/1247555", "http://www.ncbi.nlm.nih.gov/pubmed/24769127"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0202177", "o": "Phospholipid"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0007188", "o": "http://linkedlifedata.com/resource/umls/label/A17997459"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17997459", "o": "Cardiolipins"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/2083", "o": "http://linkedlifedata.com/resource/rxnorm/label/3130515"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3130515", "o": "Cardiolipins"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0007188", "o": "cardiolipin"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/2083", "o": "http://linkedlifedata.com/resource/rxnorm/label/3130514"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3130514", "o": "Cardiolipin"}], "ideal_answer": ["Yes, diphosphatidylglycerol (cardiolipin) is a phospholipid of the mitochondrial membranes."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002308", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008566", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008563", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4244279", "http://www.biosemantics.org/jochem#4001026", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008928", "http://www.biosemantics.org/jochem#4244279", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051336"], "type": "yesno", "id": "58d90f228acda3452900000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 341, "text": "A unique organelle for studying membrane biochemistry is the mitochondrion whose functionality depends on a coordinated supply of proteins and lipids. Mitochondria are capable of synthesizing several lipids autonomously such as phosphatidylglycerol, cardiolipin and in part phosphatidylethanolamine, phosphatidic acid and CDP-diacylglycerol.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24007978", "endSection": "abstract"}, {"offsetInBeginSection": 372, "offsetInEndSection": 474, "text": "A small decrease of diphosphatidylglycerol also occurred in the hepatoma mitochondria inner membrane. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7459841", "endSection": "abstract"}, {"offsetInBeginSection": 492, "offsetInEndSection": 624, "text": "Diphosphatidylglycerol was confined to the mitochondrial fraction, where it represented about 7% of the total phosphoacylglycerols. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6807345", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 401, "text": "Mitochondrial membranes were isolated from the myocardium of young (4-month-old) and aged (33-month-old) male Long-Evans rats and compared in terms of cholesterol content and phospholipid and fatty acid composition. In aged rats, as compared to young, the major observations include: markedly higher cholesterol content; increased percentage of sphingomyelin and diphosphatidylglycerol (cardiolipin); ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6717095", "endSection": "abstract"}, {"offsetInBeginSection": 445, "offsetInEndSection": 632, "text": "The polyglycerophosphatides (typified by diphosphatidylglycerol) were apparently synthesized in situ by intramitochondrial membrane-bound enzymes using CDP-diglycerides as intermediates. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3548756", "endSection": "abstract"}, {"offsetInBeginSection": 538, "offsetInEndSection": 875, "text": "Both the mitochondrial and microsomal fractions contained significant proportions of solvent front phospholipid (SFP) and whereas the mitochondrial SFP displayed the relatively unsaturated fatty acid composition characteristic of diphosphatidylglycerol (cardiolipin), the fatty acids of the microsomal SFP were distinctly more saturated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6509920", "endSection": "abstract"}, {"offsetInBeginSection": 456, "offsetInEndSection": 764, "text": "Ten to 15% of microsomal radioactive CDP-diglycerides was transferred to mitochondrial membranes and incorporated into mitochondrial radioactive lipids identified as phosphatidylglycerol, phosphatidylglycerophosphate, and, when [14C]linoleoyl CDP-diglycerides were used, diphosphatidylglycerol (cardiolipin).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3718705", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 295, "text": "The enzyme responsible for the conversion of phosphatidylglycerol to diphosphatidylglycerol (cardiolipin) in the presence of cytidine diphosphate diacylglycerol is firmly associated with mitochondrial membranes and is not extracted with hypotonic or hypertonic media or with nonionic detergents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6257342", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 347, "text": "The mechanism of cardiolipin (diphosphatidylglycerol) biosynthesis was examined in mitochondria and outer and inner mitochondrial membranes prepared from guinea pig and rat livers to determine whether this formation from phosphatidylglycerol was absolutely dependent on cytidinediphosphodiglyceride, as previously reported for intact mitochondria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2397096", "endSection": "abstract"}, {"offsetInBeginSection": 454, "offsetInEndSection": 597, "text": "In isolated mitochondrial outer membranes, cardiolipin (diphosphatidylglycerol) increased CPT1 activity 4-fold and the Km for carnitine 6-fold.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21599656", "endSection": "abstract"}, {"offsetInBeginSection": 457, "offsetInEndSection": 765, "text": "Ten to 15% of microsomal radioactive CDP-diglycerides was transferred to mitochondrial membranes and incorporated into mitochondrial radioactive lipids identified as phosphatidylglycerol, phosphatidylglycerophosphate, and, when [14C]linoleoyl CDP-diglycerides were used, diphosphatidylglycerol (cardiolipin).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3718705", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 615, "text": "90% or more of the phospholipid, cardiolipin was found in the mitochondrial membranes of wild type and petite yeast.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4322761", "endSection": "abstract"}, {"offsetInBeginSection": 629, "offsetInEndSection": 760, "text": "Furthermore, the same mechanism for the biosynthesis of cardiolipin was operational in the outer and inner mitochondrial membranes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2397096", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 346, "text": "The mechanism of cardiolipin (diphosphatidylglycerol) biosynthesis was examined in mitochondria and outer and inner mitochondrial membranes prepared from guinea pig and rat livers to determine whether this formation from phosphatidylglycerol was absolutely dependent on cytidinediphosphodiglyceride, as previously reported for intact mitochondria", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2397096", "endSection": "abstract"}, {"offsetInBeginSection": 65, "offsetInEndSection": 246, "text": "Cardiolipin (CL) is a key phospholipid in mitochondrial membranes, playing important roles in maintaining the functional integrity and dynamics of mitochondria in animals and yeasts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24443516", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Cardiolipin, the specific phospholipid of mitochondria, is involved in the biogenesis, the dynamics, and the supramolecular organization of mitochondrial membranes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200781", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Cardiolipin (CL), the signature phospholipid of mitochondrial membranes, is crucial for both mitochondrial function and cellular processes outside of the mitochondria", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26301254", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 231, "text": "Since it has been recognized that mitochondria are crucial not only for energy metabolism but also for other cellular functions, there has been a growing interest in cardiolipin, the specific phospholipid of mitochondrial membranes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24769127", "endSection": "abstract"}, {"offsetInBeginSection": 72, "offsetInEndSection": 259, "text": "Cardiolipin, the main anionic phospholipid in mitochondrial membranes, is expected to be a determinant in this adaptive mechanism since it modulates the activity of most membrane proteins", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25843549", "endSection": "abstract"}, {"offsetInBeginSection": 457, "offsetInEndSection": 764, "text": "Ten to 15% of microsomal radioactive CDP-diglycerides was transferred to mitochondrial membranes and incorporated into mitochondrial radioactive lipids identified as phosphatidylglycerol, phosphatidylglycerophosphate, and, when [14C]linoleoyl CDP-diglycerides were used, diphosphatidylglycerol (cardiolipin)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3718705", "endSection": "abstract"}, {"offsetInBeginSection": 247, "offsetInEndSection": 530, "text": "Cardiolipin is normally localized to the inner mitochondrial membrane; however, when cardiolipin becomes externalized to the surface of dysregulated mitochondria, it promotes inflammasome activation and stimulates the elimination of damaged or nonfunctional mitochondria by mitophagy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26396268", "endSection": "abstract"}, {"offsetInBeginSection": 454, "offsetInEndSection": 598, "text": "In isolated mitochondrial outer membranes, cardiolipin (diphosphatidylglycerol) increased CPT1 activity 4-fold and the Km for carnitine 6-fold. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21599656", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Increasing levels of cardiolipin differentially influence packing of phospholipids found in the mitochondrial inner membrane.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24905496", "endSection": "title"}, {"offsetInBeginSection": 261, "offsetInEndSection": 440, "text": "Here, we used Saccharomyces cerevisiae subjected to conditions that affect mitochondrial metabolism as a model to determine the possible role of cardiolipin in stress adaptation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25843549", "endSection": "abstract"}, {"offsetInBeginSection": 290, "offsetInEndSection": 684, "text": "This decline of respiration was attributed to a progressive diminution of the number of mitochondria in copper-treated cells, based on the demonstration of the concomitant decline of (1) cardiolipin (diphosphatidylglycerol) and cytochrome aa3 (cytochrome oxidase), two specific markers of mitochondrial inner membrane, and (2) fumarase activity, a specific marker of mitochondrial matrix space.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8977117", "endSection": "abstract"}, {"offsetInBeginSection": 327, "offsetInEndSection": 477, "text": "Diphosphatidylglycerol (DPG) or cardiolipin, a specific component of the inner mitochondrial membrane, represents about 4% of the total lipid content.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15460113", "endSection": "abstract"}, {"offsetInBeginSection": 348, "offsetInEndSection": 628, "text": "Experimental results confirmed that the biosynthesis of cardiolipin, from the membrane-bound radioactive phosphatidylglycerol in intact mitochondria isolated from guinea pig and rat liver, was absolutely dependent on CDP-diglycerides and required the addition of divalent cations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2397096", "endSection": "abstract"}, {"offsetInBeginSection": 561, "offsetInEndSection": 776, "text": "We have shown that decrease of cardiolipin in mitochondrial membrane occurs early during ischemia, and only during the irreversible phase of ischemia are phosphatidylethanolamine and phosphatidylcholine broken down.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7378435", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Partial purification of diphosphatidylglycerol synthetase from liver mitochondrial membranes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6257342", "endSection": "title"}, {"offsetInBeginSection": 372, "offsetInEndSection": 473, "text": "A small decrease of diphosphatidylglycerol also occurred in the hepatoma mitochondria inner membrane.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7459841", "endSection": "abstract"}]}, {"body": "Have studies shown that there is no link between DNA methylation patterns and Post Traumatic Stress Disorder?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27886370", "http://www.ncbi.nlm.nih.gov/pubmed/21508515", "http://www.ncbi.nlm.nih.gov/pubmed/25065861", "http://www.ncbi.nlm.nih.gov/pubmed/21714072", "http://www.ncbi.nlm.nih.gov/pubmed/26361058", "http://www.ncbi.nlm.nih.gov/pubmed/22332656", "http://www.ncbi.nlm.nih.gov/pubmed/21306736", "http://www.ncbi.nlm.nih.gov/pubmed/26305478", "http://www.ncbi.nlm.nih.gov/pubmed/26447678", "http://www.ncbi.nlm.nih.gov/pubmed/19793403"], "ideal_answer": ["Studies do show a correlation of PTSD-related accelerated aging in DNA methylation patterns."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040921", "http://www.disease-ontology.org/api/metadata/DOID:2055", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013313", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019175"], "type": "yesno", "id": "58e2422c6fddd3e83e000011", "snippets": [{"offsetInBeginSection": 918, "offsetInEndSection": 1502, "text": "Using pre-deployment SKA2 methylation levels and childhood trauma exposure, we found that the previously published suicide prediction rule significantly predicted post-deployment PTSD symptoms (AUC=0.66, 95% CI: 0.53-0.79) with an optimal sensitivity of 0.81 and specificity of 0.91. Permutation analysis using random methylation loci supported these findings. Together, these data establish the importance of SKA2 for cortisol stress responsivity and the development of PTSD and provide further evidence that SKA2 is a promising biomarker for stress-related disorders including PTSD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26361058", "endSection": "abstract"}, {"offsetInBeginSection": 1126, "offsetInEndSection": 1307, "text": " Results provide novel support for PTSD-related accelerated aging in DNAm and extend the evidence base of known DNAm age correlates to the domains of neural integrity and cognition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26447678", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "We investigated serum DNA methylation patterns in genomic repetitive elements, LINE-1 and Alu, for post-traumatic stress disorder (PTSD) cases and controls who were US military service members recently deployed to Afghanistan or Iraq.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332656", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 321, "text": "In light of its role in glucocorticoid receptor transactivation, we investigated whether SKA2 DNA methylation influences cortisol stress reactivity and is involved in the development of post-traumatic stress disorder (PTSD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26361058", "endSection": "abstract"}, {"offsetInBeginSection": 1398, "offsetInEndSection": 1579, "text": "These results suggest that alterations in global methylation pattern are involved in behavioural adaptation to environmental stress and pinpoint Dlgap2 as a possible target in PTSD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19793403", "endSection": "abstract"}, {"offsetInBeginSection": 146, "offsetInEndSection": 286, "text": "Here we examined whether there was a link between an established rat model of post-traumatic stress disorder (PTSD) and Bdnf DNA methylation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21306736", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 287, "text": "We investigated serum DNA methylation patterns in genomic repetitive elements, LINE-1 and Alu, for post-traumatic stress disorder (PTSD) cases and controls who were US military service members recently deployed to Afghanistan or Iraq.Cases (n = 75) had a postdeployment diagnosis of PTSD", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332656", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "DNA methylation in repetitive elements and post-traumatic stress disorder: a case-control study of US military service members", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332656", "endSection": "title"}, {"offsetInBeginSection": 146, "offsetInEndSection": 288, "text": "Here we examined whether there was a link between an established rat model of post-traumatic stress disorder (PTSD) and Bdnf DNA methylation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21306736", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "DNA methylation in repetitive elements and post-traumatic stress disorder: a case-control study of US military service members.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332656", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "AIM: We investigated serum DNA methylation patterns in genomic repetitive elements, LINE-1 and Alu, for post-traumatic stress disorder (PTSD) cases and controls who were US military service members recently deployed to Afghanistan or Iraq. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332656", "endSection": "abstract"}, {"offsetInBeginSection": 1221, "offsetInEndSection": 1398, "text": "Together, these results suggest that psychosocial stress may alter global and gene-specific DNA methylation patterns potentially associated with peripheral immune dysregulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21714072", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "DNA methylation in vulnerability to post-traumatic stress in rats: evidence for the role of the post-synaptic density protein Dlgap2.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19793403", "endSection": "title"}, {"offsetInBeginSection": 763, "offsetInEndSection": 885, "text": "Subjects with PTSD showed a higher DNA methylation of four CpG sites at the BDNF promoter compared with those without PTSD", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27886370", "endSection": "abstract"}, {"offsetInBeginSection": 1427, "offsetInEndSection": 1606, "text": "Cumulatively, the data suggest that epigenetic variation at SKA2 mediates vulnerability to suicidal behaviors and PTSD through dysregulation of the HPA axis in response to stress.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26305478", "endSection": "abstract"}]}, {"body": "Is POLD3 essential for mouse development?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27524497"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1427199", "o": "POLD3"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_5131353035340028", "o": "POLD3"}], "ideal_answer": ["Yes. The Pold3 gene encodes a subunit of the Pol\u03b4 DNA polymerase complex. Pold3 orthologs are not essential in Saccharomyces cerevisiae or chicken DT40 cells, but the Schizosaccharomyces pombe ortholog is essential. POLD3 also has a specialized role in the repair of broken replication forks, suggesting that POLD3 activity could be particularly relevant for cancer cells enduring high levels of DNA replication stress. In mouse, POLD3 is essential for development and is also required for viability in adult animals.", "yes"], "type": "yesno", "id": "5883b8e6e56acf5176000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 528, "text": "The Pold3 gene encodes a subunit of the Pol\u03b4 DNA polymerase complex. Pold3 orthologs are not essential in Saccharomyces cerevisiae or chicken DT40 cells, but the Schizosaccharomyces pombe ortholog\u00a0is essential. POLD3 also has a specialized role in the repair of broken replication forks, suggesting that POLD3 activity could be particularly relevant for cancer cells enduring high levels of DNA replication stress. We report here that POLD3 is essential for mouse development and is also required for viability in adult animals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27524497", "endSection": "abstract"}, {"offsetInBeginSection": 412, "offsetInEndSection": 525, "text": "We report here that POLD3 is essential for mouse development and is also required for viability in adult animals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27524497", "endSection": "abstract"}, {"offsetInBeginSection": 415, "offsetInEndSection": 528, "text": "We report here that POLD3 is essential for mouse development and is also required for viability in adult animals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27524497", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of Romosozumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26768288", "http://www.ncbi.nlm.nih.gov/pubmed/25432357", "http://www.ncbi.nlm.nih.gov/pubmed/26232375", "http://www.ncbi.nlm.nih.gov/pubmed/24272917", "http://www.ncbi.nlm.nih.gov/pubmed/26277199", "http://www.ncbi.nlm.nih.gov/pubmed/27487526", "http://www.ncbi.nlm.nih.gov/pubmed/26557374", "http://www.ncbi.nlm.nih.gov/pubmed/26529924", "http://www.ncbi.nlm.nih.gov/pubmed/26451332", "http://www.ncbi.nlm.nih.gov/pubmed/24433088", "http://www.ncbi.nlm.nih.gov/pubmed/24382002", "http://www.ncbi.nlm.nih.gov/pubmed/24870844", "http://www.ncbi.nlm.nih.gov/pubmed/27510350", "http://www.ncbi.nlm.nih.gov/pubmed/27569204", "http://www.ncbi.nlm.nih.gov/pubmed/26082665", "http://www.ncbi.nlm.nih.gov/pubmed/27641143", "http://www.ncbi.nlm.nih.gov/pubmed/24665957", "http://www.ncbi.nlm.nih.gov/pubmed/26989807", "http://www.ncbi.nlm.nih.gov/pubmed/25799662", "http://www.ncbi.nlm.nih.gov/pubmed/24835636", "http://www.ncbi.nlm.nih.gov/pubmed/24490672", "http://www.ncbi.nlm.nih.gov/pubmed/25669441", "http://www.ncbi.nlm.nih.gov/pubmed/24842796"], "ideal_answer": ["Romosozumab is humanized monoclonal antibody to sclerostin. It inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. This dual effect of romosozumab leads to rapid and substantial increases in areal bone mineral density as measured by dual-energy X-ray absorptiometry. It is developed for osteoporosis treatment."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"], "type": "summary", "id": "5880e089c872c9556500000b", "snippets": [{"offsetInBeginSection": 416, "offsetInEndSection": 681, "text": "The current review will focus on emerging treatments of osteoporosis with the potential of enhanced anabolic effects (romosozumab and abaloparatide) or uncoupling of resorption and formation (odanacatib and romosozumab) as well as the effect of combination therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26989807", "endSection": "abstract"}, {"offsetInBeginSection": 1245, "offsetInEndSection": 1443, "text": "Newer anabolic agents are imminent and include an analogue of parathyroid hormone-related protein, abaloparatide, and a humanised monoclonal antibody to an inhibitor of bone formation, romosozumab. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27510350", "endSection": "abstract"}, {"offsetInBeginSection": 895, "offsetInEndSection": 1022, "text": " Several humanized monoclonal antibodies to sclerostin, including romosozumab and blosozumab, are now in clinical development. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25669441", "endSection": "abstract"}, {"offsetInBeginSection": 129, "offsetInEndSection": 216, "text": "Romosozumab, an antibody raised against sclerostin, is a promising bone anabolic agent.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25799662", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "Romosozumab inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. This dual effect of romosozumab leads to rapid and substantial increases in areal bone mineral density (aBMD) as measured by dual-energy X-ray absorptiometry (DXA). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26232375", "endSection": "abstract"}, {"offsetInBeginSection": 976, "offsetInEndSection": 1146, "text": "Phase I and II studies of the two humanized sclerostin monoclonal antibodies, romosozumab and blosozumab, both of which have had positive effects on bone mineral density.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26082665", "endSection": "abstract"}, {"offsetInBeginSection": 1142, "offsetInEndSection": 1368, "text": "Romosozumab, an anti-sclerosin antibody, and abaloparatide, a PTH-related peptide analog, are at present in advanced stages of clinical evaluation, so far demonstrating efficaciousness together with a favorable safety profile.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26277199", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Romosozumab is a humanized immunoglobulin G2 monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569204", "endSection": "abstract"}, {"offsetInBeginSection": 277, "offsetInEndSection": 621, "text": "Advances in understanding the mechanisms of action of this signaling molecule have led to the development of a pharmacological inhibitor of sclerostin with potential clinical applications as an osteoanabolic drug for the treatment of osteoporosis.Romosozumab is the first humanized monoclonal sclerostin antibody to be tested in clinical trials", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Update on romosozumab : a humanized monoclonal antibody to sclerostin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24272917", "endSection": "title"}, {"offsetInBeginSection": 539, "offsetInEndSection": 653, "text": "AREAS COVERED: Romosozumab is the first humanized monoclonal sclerostin antibody to be tested in clinical trials. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", "endSection": "abstract"}, {"offsetInBeginSection": 81, "offsetInEndSection": 167, "text": "The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24382002", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Romosozumab (formerly AMG 785/CDP7851) is a monoclonal antibody that blocks sclerostin from inhibiting osteoblast maturation and function. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24272917", "endSection": "abstract"}, {"offsetInBeginSection": 129, "offsetInEndSection": 217, "text": "Romosozumab, an antibody raised against sclerostin, is a promising bone anabolic agent. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25799662", "endSection": "abstract"}, {"offsetInBeginSection": 606, "offsetInEndSection": 775, "text": "Phase II clinical trials with anti-sclerostin antibodies, romosozumab and blosozumab, demonstrated a marked increase in bone mineral density after one year of treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26529924", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 1022, "text": "Similar to preclinical animal studies with sclerostin antibodies, initial clinical studies show that romosozumab increases bone formation and bone mineral density.EXPERT OPINION: Blocking sclerostin action with romosozumab is a promising new therapeutic approach to osteoanabolic therapy of osteoporosis; efficacy and safety data on large controlled studies are awaited.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", "endSection": "abstract"}, {"offsetInBeginSection": 291, "offsetInEndSection": 651, "text": "Advances in understanding the mechanisms of action of this signaling molecule have led to the development of a pharmacological inhibitor of sclerostin with potential clinical applications as an osteoanabolic drug for the treatment of osteoporosis.AREAS COVERED: Romosozumab is the first humanized monoclonal sclerostin antibody to be tested in clinical trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Romosozumab (formerly AMG 785/CDP7851) is a monoclonal antibody that blocks sclerostin from inhibiting osteoblast maturation and function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24272917", "endSection": "abstract"}, {"offsetInBeginSection": 81, "offsetInEndSection": 564, "text": "The monoclonal antibody romosozumab binds to sclerostin and increases bone formation.METHODS: In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24382002", "endSection": "abstract"}, {"offsetInBeginSection": 788, "offsetInEndSection": 980, "text": "Blocking sclerostin action with romosozumab is a promising new therapeutic approach to osteoanabolic therapy of osteoporosis; efficacy and safety data on large controlled studies are awaited..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Romosozumab is a humanized immunoglobulin G  monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569204", "endSection": "abstract"}]}, {"body": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16600574", "http://www.ncbi.nlm.nih.gov/pubmed/25049338", "http://www.ncbi.nlm.nih.gov/pubmed/19268914", "http://www.ncbi.nlm.nih.gov/pubmed/26502199", "http://www.ncbi.nlm.nih.gov/pubmed/9122295", "http://www.ncbi.nlm.nih.gov/pubmed/17224720", "http://www.ncbi.nlm.nih.gov/pubmed/27418378", "http://www.ncbi.nlm.nih.gov/pubmed/11891997", "http://www.ncbi.nlm.nih.gov/pubmed/21034691", "http://www.ncbi.nlm.nih.gov/pubmed/23212598", "http://www.ncbi.nlm.nih.gov/pubmed/25763455", "http://www.ncbi.nlm.nih.gov/pubmed/22209270", "http://www.ncbi.nlm.nih.gov/pubmed/19282141", "http://www.ncbi.nlm.nih.gov/pubmed/18436427", "http://www.ncbi.nlm.nih.gov/pubmed/16324899", "http://www.ncbi.nlm.nih.gov/pubmed/11552771", "http://www.ncbi.nlm.nih.gov/pubmed/23103549", "http://www.ncbi.nlm.nih.gov/pubmed/23706842", "http://www.ncbi.nlm.nih.gov/pubmed/12798257", "http://www.ncbi.nlm.nih.gov/pubmed/19506776", "http://www.ncbi.nlm.nih.gov/pubmed/25007537", "http://www.ncbi.nlm.nih.gov/pubmed/25709077", "http://www.ncbi.nlm.nih.gov/pubmed/18396192", "http://www.ncbi.nlm.nih.gov/pubmed/24216181", "http://www.ncbi.nlm.nih.gov/pubmed/15076016", "http://www.ncbi.nlm.nih.gov/pubmed/11555345", "http://www.ncbi.nlm.nih.gov/pubmed/10954063", "http://www.ncbi.nlm.nih.gov/pubmed/22475888", "http://www.ncbi.nlm.nih.gov/pubmed/16317314", "http://www.ncbi.nlm.nih.gov/pubmed/19016483", "http://www.ncbi.nlm.nih.gov/pubmed/15915097", "http://www.ncbi.nlm.nih.gov/pubmed/27111262"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1457887", "o": "Symptoms"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1457887", "o": "http://linkedlifedata.com/resource/umls/label/A0788385"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0788385", "o": "SYMPTOMS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1457887", "o": "http://linkedlifedata.com/resource/umls/label/A11838788"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11838788", "o": "Symptoms"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1457887", "o": "http://linkedlifedata.com/resource/umls/label/A7164206"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7164206", "o": "Symptoms"}], "ideal_answer": ["Davidson Trauma Scale is used for evaluation of post-traumatic stress disorder."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:4", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013568", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012816"], "type": "factoid", "id": "58861d413b87a8a738000002", "snippets": [{"offsetInBeginSection": 539, "offsetInEndSection": 1221, "text": "Besides, to study its scores' evidence of convergent, discriminant, and predictive validity in relation to other resilience questionnaires (Connor Davidson Resilience Scale 10-item version, Situated Subjective Resilience Questionnaire for Adults and Resiliency Questionnaire for Adults) and to variables such as emotions (Modified Differential Emotions Scale), coping (Person-situation Coping Questionnaire for Adults), anxiety and depression (Hospital Anxiety and Depression Scale), posttraumatic growth (Posttraumatic Growth Inventory), perceived stress (Perceived Stress Scale) and posttraumatic stress (Davidson Trauma Scale), correlation and regression analyses were conducted.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26502199", "endSection": "abstract"}, {"offsetInBeginSection": 1441, "offsetInEndSection": 1796, "text": "Using the normalized population mean of 50 on the SF-36 MH domain score as a cut-off, positive predictive values were 16 and 55% for substantial depression; 20 and 68% for substantial anxiety (Depression Anxiety Stress Scales and HADS, respectively); and 40, 44, and 67% for substantial PTSD symptoms (IES-R, IES, and Davidson Trauma Scale, respectively).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111262", "endSection": "abstract"}, {"offsetInBeginSection": 248, "offsetInEndSection": 714, "text": "METHOD: A randomly selected representative sample of inmates in the Puerto Rico correctional system (N = 1,179) was assessed with the Spanish-language Wender Utah Rating Scale (WURS); the Composite International Diagnostic Interview (CIDI) modules for lifetime/current major depression disorder (MDD), generalized anxiety disorder (GAD), and SUD; the Davidson Trauma Scale (DTS; posttraumatic stress disorder [PTSD]); and self-reports of in-site high-risk behaviors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23212598", "endSection": "abstract"}, {"offsetInBeginSection": 662, "offsetInEndSection": 1295, "text": "After correcting for multiple comparisons, no significant effects were observed on any of the outcomes among the NHW sample; however, within the NHB sample, significant gene \u00d7 environment (G \u00d7 E) interactions were observed for lifetime PTSD (P = .0029) and PTSD symptom severity (P = .0009). In each case, the APOE \u03b54 allele had no effect on the outcomes when combat exposure was low; however, when combat exposure was high, an additive effect was observed such that \u03b54 homozygotes exposed to high levels of combat reported the highest rates of PTSD (92%) and the worst symptom severity scores on the Davidson Trauma Scale (M = 79.5)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709077", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Early prognostic screening for posttraumatic stress disorder with the Davidson Trauma Scale and the SPAN.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19016483", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "The Davidson Trauma Scale (DTS) was developed as a self-rating for use in diagnosing and measuring symptom severity and treatment outcome in post-traumatic stress disorder (PTSD); 630 subjects were identified by random digit dialing and evaluated for a history of trauma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11891997", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 404, "text": "The purpose of this paper is to assess the reliability and validity of the Spanish version of the Davidson trauma scale (DTS-S) and to determine the prevalence and correlates of post-traumatic stress disorder (PTSD) symptoms in a non-clinical random sample of prison inmates.Probabilistic samples of 1,179 inmates from 26 penal institutions in Puerto Rico were selected using a multistage sampling design", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25763455", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15076016", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "The Davidson Trauma Scale (DTS) was developed as a self-rating for use in diagnosing and measuring symptom severity and treatment outcome in post-traumatic stress disorder (PTSD); 630 subjects were identified by random digit dialing and evaluated for a history of trauma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11891997", "endSection": "abstract"}, {"offsetInBeginSection": 527, "offsetInEndSection": 718, "text": "Symptoms were assessed at sequential time points by the Structured Interview for PTSD (SIP), a clinician interview based assessment, and a self-report scale, the Davidson Trauma Scale (DTS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10954063", "endSection": "abstract"}, {"offsetInBeginSection": 117, "offsetInEndSection": 427, "text": "The present study focused on platelet serotonin (5-HT) concentration and symptoms of comorbid depression in war veterans with or without PTSD.PTSD and depression were evaluated using Clinician Administered PTSD Scale, Davidson Trauma Scale, Montgomery-Asberg Depression Rating Scale and Hamilton Anxiety Scale.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12798257", "endSection": "abstract"}, {"offsetInBeginSection": 346, "offsetInEndSection": 768, "text": "Although rates of trauma and PTSD are higher in those with bipolar disorder than in the general population, little is known about differences across bipolar subtypes.Using the NIMH STEP-BD dataset (N=3158), this study evaluated whether there were baseline differences in the prevalence of PTSD between participants with bipolar disorder I (BDI) and bipolar disorder II (BDII), using the MINI and the Davidson Trauma Scale.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23706842", "endSection": "abstract"}, {"offsetInBeginSection": 213, "offsetInEndSection": 542, "text": "We also investigated the interaction between the genetic variants to determine whether these variables and the interactions between the variables influenced the severity of PTSD symptoms.PTSD symptoms were quantitatively assessed using the Davidson Trauma Scale (DTS) in 150 participants from an at-risk South African population.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103549", "endSection": "abstract"}, {"offsetInBeginSection": 1378, "offsetInEndSection": 1733, "text": "Using the normalized population mean of 50 on the SF-36 MH domain score as a cut-off, positive predictive values were 16 and 55% for substantial depression; 20 and 68% for substantial anxiety (Depression Anxiety Stress Scales and HADS, respectively); and 40, 44, and 67% for substantial PTSD symptoms (IES-R, IES, and Davidson Trauma Scale, respectively).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27111262", "endSection": "abstract"}, {"offsetInBeginSection": 526, "offsetInEndSection": 672, "text": "The Davidson Trauma Scale was completed at 1 (n = 145), 6 (n = 106), 12 (n = 94), and 24 (n = 66) months postdischarge to assess symptoms of PTSD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21034691", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "The Davidson Trauma Scale (DTS) is a validated, 17-item, brief global assessment scale for posttraumatic stress disorder (PTSD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18396192", "endSection": "abstract"}, {"offsetInBeginSection": 177, "offsetInEndSection": 423, "text": "Evaluation of PTSD symptoms using the Davidson Trauma Scale (DTS) and General Health Questionnaire (GHQ) in a sample of 56 patients admitted to an emergency room of a general hospital, and assessment of PTSD symptoms in relatives of the patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16600574", "endSection": "abstract"}]}, {"body": "What is the function of the Mis18 protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25569776", "http://www.ncbi.nlm.nih.gov/pubmed/24774534", "http://www.ncbi.nlm.nih.gov/pubmed/22540025", "http://www.ncbi.nlm.nih.gov/pubmed/24789708", "http://www.ncbi.nlm.nih.gov/pubmed/27239045", "http://www.ncbi.nlm.nih.gov/pubmed/15369671", "http://www.ncbi.nlm.nih.gov/pubmed/22516971", "http://www.ncbi.nlm.nih.gov/pubmed/21911481", "http://www.ncbi.nlm.nih.gov/pubmed/26343758", "http://www.ncbi.nlm.nih.gov/pubmed/27670610", "http://www.ncbi.nlm.nih.gov/pubmed/19217403", "http://www.ncbi.nlm.nih.gov/pubmed/24269809", "http://www.ncbi.nlm.nih.gov/pubmed/25202874", "http://www.ncbi.nlm.nih.gov/pubmed/21768289"], "ideal_answer": ["Kinetochores assemble on a specialized chromosomal locus termed the centromere, which is characterized by the replacement of histone H3 in centromeric nucleosomes with the essential histone H3 variant CENP-A (centromere protein A). The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome. Further, we demonstrate Mis18\u00ce\u00b1's crucial role for epigenetic regulation of centromeric chromatin by reinforcing centromeric localization of DNMT3A/3B. Mis18\u00ce\u00b1 interacts with DNMT3A/3B, and this interaction is critical for maintaining DNA methylation and hence regulating epigenetic states of centromeric chromatin. Together, our findings uncover the functional mechanism of Mis18\u00ce\u00b1 and its pivotal role in mammalian cell cycle. The Mis18 complex is a critical player in determining when and where centromeres are built.", "Mis16 and Mis18 are required for CENP-A loading and histone deacetylation at centromeres Here we report identification of five fission yeast centromere proteins, Mis14-18. Mis14 is recruited to kinetochores independently of CENP-A, and, conversely, CENP-A does not require Mis14 to associate with centromeres. In contrast, Mis15, Mis16 (strong similarity with human RbAp48 and RbAp46), Mis17, and Mis18 are all part of the CENP-A recruitment pathway. Mis16 and Mis18 form a complex and maintain the deacetylated state of histones specifically in the central core of centromeres. Mis16 and Mis18 are the most upstream factors in kinetochore assembly as they can associate with kinetochores in all kinetochore mutants except for mis18 and mis16, respectively.", "The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome.", "Mis16 and Mis18 form a complex and maintain the deacetylated state of histones specifically in the central core of centromeres. A fundamental process in centromere establishment is the incorporation of the histone variant CENP-A into centromeric chromatin, which provides a binding platform for the other centromeric proteins. CENP-A nucleosome assembly requires the Mis18 complex and the CENP-A chaperone HJURP. Thus, CENP-C provides a link between existing CENP-A chromatin and the proteins required for new CENP-A nucleosome assembly. The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome. This is a critical step that is essential for proper centromere function and maintaining the integrity of the genome.", "The Mis18 complex is a critical player in determining when and where centromeres are built. The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome. Eukaryotic chromosomes segregate by attaching to microtubules of the mitotic spindle through a chromosomal microtubule binding site called the kinetochore. Centromeres are important structural constituents of chromosomes that ensure proper chromosome segregation during mitosis by providing defined sites for kinetochore attachment. Centromeres contain specialized chromatin that includes the centromere-specific histone H3 variant, spCENP-A/Cnp1.", "Together, our findings uncover the functional mechanism of Mis18\u03b1 and its pivotal role in mammalian cell cycle. The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome.", "the mis18 complex has been identified as a critical factor for the centromeric localization of a histone h3 variant, centromeric protein a (cenp-a), which is responsible for the specification of centromere identity in the chromosome."], "type": "summary", "id": "58af11e67125859353000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Mis16 and Mis18 are required for CENP-A loading and histone deacetylation at centromeres", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", "endSection": "title"}, {"offsetInBeginSection": 115, "offsetInEndSection": 335, "text": "Here we report identification of five fission yeast centromere proteins, Mis14-18. Mis14 is recruited to kinetochores independently of CENP-A, and, conversely, CENP-A does not require Mis14 to associate with centromeres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", "endSection": "abstract"}, {"offsetInBeginSection": 336, "offsetInEndSection": 476, "text": "In contrast, Mis15, Mis16 (strong similarity with human RbAp48 and RbAp46), Mis17, and Mis18 are all part of the CENP-A recruitment pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", "endSection": "abstract"}, {"offsetInBeginSection": 559, "offsetInEndSection": 866, "text": "Mis16 and Mis18 form a complex and maintain the deacetylated state of histones specifically in the central core of centromeres. Mis16 and Mis18 are the most upstream factors in kinetochore assembly as they can associate with kinetochores in all kinetochore mutants except for mis18 and mis16, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", "endSection": "abstract"}, {"offsetInBeginSection": 508, "offsetInEndSection": 640, "text": "The Mis18 complex, and, in particular, its member M18BP1 was shown to be essential for both incorporation and maintenance of CENP-A.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22540025", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 599, "text": " CENP-A nucleosome assembly requires the Mis18 complex and the CENP-A chaperone HJURP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911481", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Roles of Mis18\u03b1 in epigenetic regulation of centromeric chromatin and CENP-A loading", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "The Mis18 complex has been identified as a critical factor for the centromeric localization of a histone H3 variant, centromeric protein A (CENP-A), which is responsible for the specification of centromere identity in the chromosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", "endSection": "abstract"}, {"offsetInBeginSection": 300, "offsetInEndSection": 514, "text": "Here, we generated Mis18\u03b1 conditional knockout mice and found that Mis18\u03b1 deficiency resulted in lethality at early embryonic stage with severe defects in chromosome segregation caused by mislocalization of CENP-A.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", "endSection": "abstract"}, {"offsetInBeginSection": 515, "offsetInEndSection": 664, "text": "Further, we demonstrate Mis18\u03b1's crucial role for epigenetic regulation of centromeric chromatin by reinforcing centromeric localization of DNMT3A/3B", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", "endSection": "abstract"}, {"offsetInBeginSection": 666, "offsetInEndSection": 827, "text": "Mis18\u03b1 interacts with DNMT3A/3B, and this interaction is critical for maintaining DNA methylation and hence regulating epigenetic states of centromeric chromatin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", "endSection": "abstract"}, {"offsetInBeginSection": 829, "offsetInEndSection": 1003, "text": "Mis18\u03b1 deficiency led to reduced DNA methylation, altered histone modifications, and uncontrolled noncoding transcripts in centromere region by decreased DNMT3A/3B enrichment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", "endSection": "abstract"}, {"offsetInBeginSection": 1005, "offsetInEndSection": 1116, "text": "Together, our findings uncover the functional mechanism of Mis18\u03b1 and its pivotal role in mammalian cell cycle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22516971", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "Centromere licensing: Mis18 is required to Polo-ver", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25202874", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "The Mis18 complex is a critical player in determining when and where centromeres are built", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25202874", "endSection": "abstract"}, {"offsetInBeginSection": 793, "offsetInEndSection": 972, "text": "Its nearest relatives are yippee, a highly conserved eukaryotic protein of unknown function, and Mis18, a protein involved in the priming of centromeres for recruitment of CENP-A.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25569776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Mis16 and Mis18 are subunits of a protein complex required for incorporation of the histone H3 variant CenH3 (Cnp1/CENP-A) into centromeric chromatin in Schizosaccharomyces pombe and mammals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19217403", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "The Mis18 proteins (Mis18\u03b1, Mis18\u03b2, and M18BP1) are pivotal to the deposition of CENP-A at the centromere during cell cycle progression and are indispensable for embryonic development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27670610", "endSection": "abstract"}, {"offsetInBeginSection": 265, "offsetInEndSection": 471, "text": "Although Mis18\u03b1 and Mis18\u03b2 are highly homologous proteins, we find that their conserved YIPPEE domains mediate distinct interactions that are essential to link new CENP-A deposition to existing centromeres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27239045", "endSection": "abstract"}, {"offsetInBeginSection": 796, "offsetInEndSection": 975, "text": "Its nearest relatives are yippee, a highly conserved eukaryotic protein of unknown function, and Mis18, a protein involved in the priming of centromeres for recruitment of CENP-A.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25569776", "endSection": "abstract"}, {"offsetInBeginSection": 335, "offsetInEndSection": 651, "text": "Ectopically targeted CENP-A chromatin at the LacO array was sufficient to direct the assembly of a functional centromere as indicated by the recruitment of the constitutive centromere-associated network proteins, the microtubule-binding protein NDC80, and the formation of stable kinetochore-microtubule attachments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21768289", "endSection": "abstract"}, {"offsetInBeginSection": 64, "offsetInEndSection": 208, "text": "Replication-independent incorporation of CENP-A at centromeres depends on its chaperone HJURP(Scm3), and Mis18 in vertebrates and fission yeast.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789708", "endSection": "abstract"}, {"offsetInBeginSection": 932, "offsetInEndSection": 1261, "text": "Our findings suggest that Eic1 serves a function analogous to that of Mis18BP1(KNL2), thus representing the functional counterpart of Mis18BP1(KNL2) in fission yeast that connects with a module within the CCAN/Mis6/Ctf19 complex to allow the temporally regulated recruitment of the Mis18/Scm3(HJURP) Cnp1(CENP-A) loading factors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789708", "endSection": "abstract"}, {"offsetInBeginSection": 77, "offsetInEndSection": 215, "text": "Here, we show that Mis18\u00e2, a component of Mis18 complex governing CENP-A localization, is a new substrate of \u00e2TrCP-containing SCF complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24269809", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Schizosaccharomyces pombe centromere protein Mis19 links Mis16 and Mis18 to recruit CENP-A through interacting with NMD factors and the SWI/SNF complex.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24774534", "endSection": "title"}, {"offsetInBeginSection": 108, "offsetInEndSection": 245, "text": "The fission yeast Schizosaccharomyces pombe and mammalian Mis16 and Mis18 form a complex essential for CENP-A recruitment to centromeres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24774534", "endSection": "abstract"}, {"offsetInBeginSection": 796, "offsetInEndSection": 1227, "text": "Its nearest relatives are yippee, a highly conserved eukaryotic protein of unknown function, and Mis18, a protein involved in the priming of centromeres for recruitment of CENP-A. Searches for distant homologs point to an evolutionary relationship of CULT, yippee, and Mis18 to proteins sharing a common fold, which consists of two four-stranded \u03b2-meanders packing at a roughly right angle and coordinating a zinc ion at their apex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25569776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Schizosaccharomyces pombe centromere protein Mis19 links Mis16 and Mis18 to recruit CENP-A through interacting with NMD factors and the SWI/SNF complex", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24774534", "endSection": "title"}, {"offsetInBeginSection": 336, "offsetInEndSection": 475, "text": "In contrast, Mis15, Mis16 (strong similarity with human RbAp48 and RbAp46), Mis17, and Mis18 are all part of the CENP-A recruitment pathway", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Eic1 links Mis18 with the CCAN/Mis6/Ctf19 complex to promote CENP-A assembly.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789708", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Mis16 and Mis18 are required for CENP-A loading and histone deacetylation at centromeres.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", "endSection": "title"}, {"offsetInBeginSection": 773, "offsetInEndSection": 932, "text": "No Mis18BP1(KNL2) orthologue has been identified in fission yeast, consequently it remains unknown how the key Cnp1(CENP-A) loading factor Mis18 is recruited. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789708", "endSection": "abstract"}, {"offsetInBeginSection": 336, "offsetInEndSection": 477, "text": "In contrast, Mis15, Mis16 (strong similarity with human RbAp48 and RbAp46), Mis17, and Mis18 are all part of the CENP-A recruitment pathway. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15369671", "endSection": "abstract"}, {"offsetInBeginSection": 213, "offsetInEndSection": 451, "text": "In fission yeast, Scm3sp and the Mis18 complex, composed of Mis16, Eic1, and Mis18, function as a CENP-A(Cnp1)-specific chaperone and a recruiting factor, respectively, and together ensure accurate delivery of CENP-A(Cnp1) to centromeres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26343758", "endSection": "abstract"}, {"offsetInBeginSection": 796, "offsetInEndSection": 1228, "text": "Its nearest relatives are yippee, a highly conserved eukaryotic protein of unknown function, and Mis18, a protein involved in the priming of centromeres for recruitment of CENP-A. Searches for distant homologs point to an evolutionary relationship of CULT, yippee, and Mis18 to proteins sharing a common fold, which consists of two four-stranded \u03b2-meanders packing at a roughly right angle and coordinating a zinc ion at their apex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25569776", "endSection": "abstract"}, {"offsetInBeginSection": 773, "offsetInEndSection": 931, "text": "No Mis18BP1(KNL2) orthologue has been identified in fission yeast, consequently it remains unknown how the key Cnp1(CENP-A) loading factor Mis18 is recruited.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789708", "endSection": "abstract"}, {"offsetInBeginSection": 514, "offsetInEndSection": 599, "text": "CENP-A nucleosome assembly requires the Mis18 complex and the CENP-A chaperone HJURP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911481", "endSection": "abstract"}, {"offsetInBeginSection": 474, "offsetInEndSection": 716, "text": "We find that Mis18\u03b1 directly interacts with the N terminus of Mis18BP1, whereas Mis18\u03b2 directly interacts with CENP-C during G1 phase, revealing that these proteins have evolved to serve distinct functions in centromeres of higher eukaryotes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27239045", "endSection": "abstract"}]}, {"body": "Are hepadnaviral minichromosomes free of nucleosomes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3023620", "http://www.ncbi.nlm.nih.gov/pubmed/8649399", "http://www.ncbi.nlm.nih.gov/pubmed/1337883", "http://www.ncbi.nlm.nih.gov/pubmed/22787202", "http://www.ncbi.nlm.nih.gov/pubmed/8380890", "http://www.ncbi.nlm.nih.gov/pubmed/21331901"], "ideal_answer": ["Nucleosomes along viral cccDNA in the minichromosomes are not random but sequence-specifically positioned.", "In vitro assembled minichromosomes were able to replicate efficiently in vitro, when the DNA was preincubated with T-antigen, a cytosolic S100 extract and three deoxynucleoside triphosphates prior to chromatin assembly, indicating that the origin has to be free of nucleosomes for replication initiation. The transcriptionally inactive locus is covered by an array of positioned nucleosomes extending over 1,400 bp. In minichromosomes with a (mu)LCR or DNase I-hypersensitive site 2 (HS2) which actively transcribe the epsilon-globin gene, the nucleosome at the promoter is altered or disrupted while positioning of nucleosomes in the rest of the locus is retained. Viral minichromosomes were found to exist in at least two defined structures covered with 11 or 12 nucleosomes, leaving open gaps accessible for interactions with other host factors. Minichromosomes from both preparations contain the full complement of nucleosomes, but salt treatment removes histone H1 and a fraction of nonhistone chromatin proteins. This double-stranded DNA serves as a template for replication as well as transcription and is assembled into host nucleosomes, yielding circular viral minichromosomes. In contrast, the replicated untreated minichromosomes were found to be densely packed with nucleosomes, indicating that an assembly of new nucleosomes occurred during in vitro replication.", "Several nucleosome-protected sites in a region of the DHBV genome [nucleotides (nt) 2000 to 2700], known to harbor various cis transcription regulatory elements, were consistently identified in all DHBV-positive liver samples. In addition, we observed other nucleosome protection sites in DHBV minichromosomes that may vary among individual ducks, but the pattern of MNase mapping in those regions is transmittable from the adult ducks to the newly infected ducklings.", "nucleosomes along viral cccDNA in the minichromosomes are not random but sequence-specifically positioned. In addition, we observed other nucleosome protection sites in DHBV minichromosomes that may vary among individual ducks, but the pattern of MNase mapping in those regions is transmittable from the adult ducks to the newly infected ducklings."], "type": "yesno", "id": "58e3d1743e8b6dc87c000001", "snippets": [{"offsetInBeginSection": 556, "offsetInEndSection": 782, "text": "Several nucleosome-protected sites in a region of the DHBV genome [nucleotides (nt) 2000 to 2700], known to harbor various cis transcription regulatory elements, were consistently identified in all DHBV-positive liver samples.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", "endSection": "abstract"}, {"offsetInBeginSection": 783, "offsetInEndSection": 1024, "text": "In addition, we observed other nucleosome protection sites in DHBV minichromosomes that may vary among individual ducks, but the pattern of MNase mapping in those regions is transmittable from the adult ducks to the newly infected ducklings.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", "endSection": "abstract"}, {"offsetInBeginSection": 1054, "offsetInEndSection": 1160, "text": "nucleosomes along viral cccDNA in the minichromosomes are not random but sequence-specifically positioned.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", "endSection": "abstract"}, {"offsetInBeginSection": 232, "offsetInEndSection": 593, "text": "Investigators studying the structure and function of hepadnaviral CCC DNA (3) have provided evidence that suggests that this structure exists in the nucleus of infected hepatocytes as a heterogeneous population of viral minichromosomes, which range from half to fully chromatinized, thought to be owing to their association with variable numbers of nucleosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331901", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Characterization of nucleosome positioning in hepadnaviral covalently closed circular DNA minichromosomes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", "endSection": "title"}, {"offsetInBeginSection": 212, "offsetInEndSection": 554, "text": "To obtain insight on the structure of hepadnaviral cccDNA minichromosomes, we utilized ducks infected with the duck hepatitis B virus (DHBV) as a model and determined the in vivo nucleosome distribution pattern on viral cccDNA by the micrococcal nuclease (MNase) mapping and genome-wide PCR amplification of isolated mononucleosomal DHBV DNA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", "endSection": "abstract"}, {"offsetInBeginSection": 291, "offsetInEndSection": 497, "text": "Mature SV40 minichromosomes are estimated to contain about 27 nucleosomes (error +/- 2), except for those molecules with a nucleosome-free gap, which are interpreted to contain 25 nucleosomes (error +/- 2).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3023620", "endSection": "abstract"}, {"offsetInBeginSection": 591, "offsetInEndSection": 791, "text": "In vitro replication in the presence of protein-free competitor DNA shows that replicating trypsinized minichromosomes do not lose nucleosomes and replicating competitor DNA does not gain nucleosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8649399", "endSection": "abstract"}, {"offsetInBeginSection": 595, "offsetInEndSection": 795, "text": "In vitro replication in the presence of protein-free competitor DNA shows that replicating trypsinized minichromosomes do not lose nucleosomes and replicating competitor DNA does not gain nucleosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8649399", "endSection": "abstract"}, {"offsetInBeginSection": 599, "offsetInEndSection": 793, "text": "We conclude that in both cases parental nucleosomes are transferred to progeny DNA, and, in addition, that an assembly of new nucleosomes occurs during the replication of native minichromosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1337883", "endSection": "abstract"}, {"offsetInBeginSection": 657, "offsetInEndSection": 845, "text": "In contrast, the replicated untreated minichromosomes were found to be densely packed with nucleosomes, indicating that an assembly of new nucleosomes occurred during in vitro replication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8380890", "endSection": "abstract"}, {"offsetInBeginSection": 233, "offsetInEndSection": 593, "text": "Investigators studying the structure and function of hepadnaviral CCC DNA (3) have provided evidence that suggests that this structure exists in the nucleus of infected hepatocytes as a heterogeneous population of viral minichromosomes, which range from half to fully chromatinized, thought to be owing to their association with variable numbers of nucleosomes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331901", "endSection": "abstract"}, {"offsetInBeginSection": 213, "offsetInEndSection": 554, "text": "To obtain insight on the structure of hepadnaviral cccDNA minichromosomes, we utilized ducks infected with the duck hepatitis B virus (DHBV) as a model and determined the in vivo nucleosome distribution pattern on viral cccDNA by the micrococcal nuclease (MNase) mapping and genome-wide PCR amplification of isolated mononucleosomal DHBV DNA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Characterization of nucleosome positioning in hepadnaviral covalently closed circular DNA minichromosomes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", "endSection": "title"}, {"offsetInBeginSection": 213, "offsetInEndSection": 555, "text": "To obtain insight on the structure of hepadnaviral cccDNA minichromosomes, we utilized ducks infected with the duck hepatitis B virus (DHBV) as a model and determined the in vivo nucleosome distribution pattern on viral cccDNA by the micrococcal nuclease (MNase) mapping and genome-wide PCR amplification of isolated mononucleosomal DHBV DNA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22787202", "endSection": "abstract"}, {"offsetInBeginSection": 233, "offsetInEndSection": 595, "text": "Investigators studying the structure and function of hepadnaviral CCC DNA (3) have provided evidence that suggests that this structure exists in the nucleus of infected hepatocytes as a heterogeneous population of viral minichromosomes, which range from half to fully chromatinized, thought to be owing to their association with variable numbers of nucleosomes..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331901", "endSection": "abstract"}]}, {"body": "Is Cri Du Chat associated with an expansion of a repeat with in the gene found on chromosome 5?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7896290", "http://www.ncbi.nlm.nih.gov/pubmed/11810654", "http://www.ncbi.nlm.nih.gov/pubmed/24556499", "http://www.ncbi.nlm.nih.gov/pubmed/2988137", "http://www.ncbi.nlm.nih.gov/pubmed/9464278", "http://www.ncbi.nlm.nih.gov/pubmed/995018", "http://www.ncbi.nlm.nih.gov/pubmed/9718678", "http://www.ncbi.nlm.nih.gov/pubmed/7713510", "http://www.ncbi.nlm.nih.gov/pubmed/7757083", "http://www.ncbi.nlm.nih.gov/pubmed/21045963", "http://www.ncbi.nlm.nih.gov/pubmed/1606717", "http://www.ncbi.nlm.nih.gov/pubmed/23455788", "http://www.ncbi.nlm.nih.gov/pubmed/9284926", "http://www.ncbi.nlm.nih.gov/pubmed/27144168", "http://www.ncbi.nlm.nih.gov/pubmed/7762563", "http://www.ncbi.nlm.nih.gov/pubmed/16953888"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0008668", "o": "http://linkedlifedata.com/resource/umls/label/A18590602"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18590602", "o": "5 chromosome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0008668", "o": "http://linkedlifedata.com/resource/umls/label/A7569590"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7569590", "o": "Chromosome 5"}], "ideal_answer": ["Cri-du-chat syndrome is a chromosomal disorder caused by a deletion of the short arm of chromosome 5", "Cri-du-chat syndrome is a chromosomal disorder caused by a deletion of the short arm of chromosome 5. ", "syndrome is a chromosomal disorder caused by a deletion of the short arm of chromosome 5 . ", "cri-du-chat syndrome is a chromosomal disorder caused by a deletion of the short arm of chromosome 5.", "Cri-du-chat syndrome is a chromosomal disorder caused by a deletion of the short arm of chromosome 5."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:12580", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003410"], "type": "yesno", "id": "58dbba438acda3452900001c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Cri-du-chat syndrome is a chromosomal disorder caused by a deletion of the short arm of chromosome 5", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27144168", "endSection": "abstract"}, {"offsetInBeginSection": 192, "offsetInEndSection": 571, "text": "The typical cri du chat syndrome, due to 5p15.2 deletion, includes severe intellectual disability, facial dysmorphisms, neonatal hypotonia and pre- and post-natal growth retardation, whereas more distal deletions in 5p15.3 lead to cat-like cry and speech delay and produce the clinical picture of the atypical cri du chat syndrome, with minimal or absent intellectual impairment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24556499", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Cri-du-chat is a human contiguous gene deletion syndrome resulting from hemizygous deletions of chromosome 5p.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9464278", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Cri-du-chat is a chromosomal deletion syndrome characterized by partial deletion of the short arm of chromosome 5.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7896290", "endSection": "abstract"}, {"offsetInBeginSection": 188, "offsetInEndSection": 322, "text": "The karyotype showed a terminal deletion of the short arm of chromosome 5 including the critical region 5p15 for cri du chat syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11810654", "endSection": "abstract"}, {"offsetInBeginSection": 804, "offsetInEndSection": 938, "text": "Fewer than 1 in 200 of cri du chat syndrome cases are due to recombination aneusomy arising from a parental inversion of chromosome 5.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1606717", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Molecular approach to analyzing the human 5p deletion syndrome, cri du chat.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2988137", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Cri-du-chat is a human contiguous gene deletion syndrome resulting from hemizygous deletions of chromosome 5p", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9464278", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "The cri du chat syndrome (CdCS) is a chromosomal deletion syndrome associated with a partial deletion of the short (p) arm of chromosome 5", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23455788", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "The cri-du-chat syndrome is a contiguous gene syndrome that results from a deletion of the short arm of chromosome 5 (5p).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7762563", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Cri-du-chat syndrome is associated with a deletion of the short arm of chromosome 5.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9284926", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "The deletion of the short arm of chromosome 5 is associated with the cri-du-chat syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7713510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "The Cri du Chat syndrome (CdCS) is a genetic disease resulting from a deletion of variable size occurring on the short arm of chromosome 5 (5p-).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16953888", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Cri-du-chat is a well described partial aneusomy resulting from deletion of the short arm of chromosome 5.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7757083", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "Cri-du-chat syndrome is caused by haploinsufficiency of the genes on the distal part of the short arm of chromosome 5, and characteristic features include microcephaly, developmental delays, and a distinctive high-pitched mewing cry.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21045963", "endSection": "abstract"}, {"offsetInBeginSection": 461, "offsetInEndSection": 578, "text": "The pathological condition of cri du chat syndrome is due to the cytogenetic deletion of band p15.2 of chromosome 5. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9718678", "endSection": "abstract"}, {"offsetInBeginSection": 695, "offsetInEndSection": 875, "text": " Karyotype analysis indicated that the patient has carried a terminal deletion in 5p. FISH with Cri du Chat syndrome region probe confirmed that D5S23 and D5S721 loci are deleted. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450488", "endSection": "abstract"}]}, {"body": "What are the roles of Smyd3 in zebrafish?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27377701", "http://www.ncbi.nlm.nih.gov/pubmed/21887258", "http://www.ncbi.nlm.nih.gov/pubmed/25997738"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0043457", "o": "Danio rerio"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0043457", "o": "http://linkedlifedata.com/resource/umls/label/A7574572"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7574572", "o": "Zebrafish"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0043457", "o": "http://linkedlifedata.com/resource/umls/label/A0134867"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0134867", "o": "Zebrafish"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0043457", "o": "http://linkedlifedata.com/resource/umls/label/A18687609"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18687609", "o": "zebrafish"}], "ideal_answer": ["Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish. Transcripts of smyd3 are expressed in zebrafish embryos at all developmental stages and knockdown of smyd3 in embryos resulted in pericardial edema and defects in the trunk structure. In addition, these phenotypes are associated with abnormal expression of three heart-chamber markers including cmlc2, amhc and vmhc, and abnormal expression of myogenic regulatory factors including myod and myog."], "concepts": ["http://www.uniprot.org/uniprot/SMYD3_HUMAN", "http://www.uniprot.org/uniprot/SMYD3_MOUSE", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018482", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D029961", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011495", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015027"], "type": "list", "id": "5883a25d7ffa0d4374000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21887258", "endSection": "title"}, {"offsetInBeginSection": 704, "offsetInEndSection": 1237, "text": "We here show that transcripts of smyd3 were expressed in zebrafish embryos at all developmental stages examined and that knockdown of smyd3 in embryos resulted in pericardial edema and defects in the trunk structure. In addition, these phenotypes were associated with abnormal expression of three heart-chamber markers including cmlc2, amhc and vmhc, and abnormal expression of myogenic regulatory factors including myod and myog. These data suggest that Smyd3 plays an important role in the development of heart and skeletal muscle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21887258", "endSection": "abstract"}, {"offsetInBeginSection": 700, "offsetInEndSection": 916, "text": "We here show that transcripts of smyd3 were expressed in zebrafish embryos at all developmental stages examined and that knockdown of smyd3 in embryos resulted in pericardial edema and defects in the trunk structure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21887258", "endSection": "abstract"}, {"offsetInBeginSection": 465, "offsetInEndSection": 717, "text": "We find both smyd3 and setd7 are highly expressed within developing zebrafish heart and knock-down of these genes led to severe defects in cardiac morphogenesis without altering the expressions pattern of heart markers, including cmlc2, vmhc, and amhc.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25997738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21887258", "endSection": "title"}, {"offsetInBeginSection": 238, "offsetInEndSection": 378, "text": "SMYD1, SMYD2, SMYD3, and SMYD4 have been found to play critical roles in carcinogenesis and/or the development of heart and skeletal muscle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377701", "endSection": "abstract"}, {"offsetInBeginSection": 240, "offsetInEndSection": 380, "text": "SMYD1, SMYD2, SMYD3, and SMYD4 have been found to play critical roles in carcinogenesis and/or the development of heart and skeletal muscle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377701", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21887258", "endSection": "title"}, {"offsetInBeginSection": 1135, "offsetInEndSection": 1238, "text": "These data suggest that Smyd3 plays an important role in the development of heart and skeletal muscle..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21887258", "endSection": "abstract"}]}, {"body": "Which enzyme is inhibited by ribociclib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26303211", "http://www.ncbi.nlm.nih.gov/pubmed/27729458", "http://www.ncbi.nlm.nih.gov/pubmed/27017286", "http://www.ncbi.nlm.nih.gov/pubmed/25941111", "http://www.ncbi.nlm.nih.gov/pubmed/26642065", "http://www.ncbi.nlm.nih.gov/pubmed/27030077", "http://www.ncbi.nlm.nih.gov/pubmed/27493615", "http://www.ncbi.nlm.nih.gov/pubmed/27496135", "http://www.ncbi.nlm.nih.gov/pubmed/26830312", "http://www.ncbi.nlm.nih.gov/pubmed/27717303", "http://www.ncbi.nlm.nih.gov/pubmed/25848011", "http://www.ncbi.nlm.nih.gov/pubmed/26053278", "http://www.ncbi.nlm.nih.gov/pubmed/27810861", "http://www.ncbi.nlm.nih.gov/pubmed/27542767", "http://www.ncbi.nlm.nih.gov/pubmed/27087139", "http://www.ncbi.nlm.nih.gov/pubmed/26995305", "http://www.ncbi.nlm.nih.gov/pubmed/27336726", "http://www.ncbi.nlm.nih.gov/pubmed/26390342", "http://www.ncbi.nlm.nih.gov/pubmed/25876993", "http://www.ncbi.nlm.nih.gov/pubmed/26896604"], "ideal_answer": ["Ribociclib is inhibitor of cyclin D-cyclin-dependent kinase 4/6 (CDK 4/6). It is used for breast cancer treatment."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798"], "type": "factoid", "id": "5880dba9c872c95565000009", "snippets": [{"offsetInBeginSection": 411, "offsetInEndSection": 587, "text": "Three CDK 4/6 inhibitors have been investigated for the treatment of HR(+) breast cancer, including palbociclib (PD 0332991), ribociclib (LEE011), and abemaciclib (LY2835219). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26303211", "endSection": "abstract"}, {"offsetInBeginSection": 472, "offsetInEndSection": 761, "text": "The CDK 4/6 inhibitors are a novel class of therapeutics that target the CDK 4/6 kinases that promote transition through the cell cycle. Currently, palbociclib (PD0332991, Pfizer), abemaciclib (LY2835219, Lilly) and ribociclib (LEE011, Novartis) are being investigated in clinical trials. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065", "endSection": "abstract"}, {"offsetInBeginSection": 1054, "offsetInEndSection": 1405, "text": "SUMMARY: Palbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma. Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065", "endSection": "abstract"}, {"offsetInBeginSection": 1339, "offsetInEndSection": 1512, "text": "Currently, three selective CDK4/6 inhibitors have been approved or are in late-stage development: palbociclib (PD-0332991), ribociclib (LEE011), and abemaciclib (LY2835219).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27017286", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 276, "text": "The combination of antiestrogen therapy and ribociclib, an investigational CDK4/6 inhibitor, led to improved outcomes in women with metastatic HR-positive, HER2-negative breast cancer, according to findings presented at a meeting of the European Society for Medical Oncology. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27810861", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 353, "text": "OBJECTIVES: Cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of CDK4/6-retinoblastoma (Rb) pathway hyperactivation is associated with hormone receptor-positive (HR+) breast cancer (BC). This study assessed the biological activity of ribociclib (LEE011; CDK4/6 inhibitor) plus letrozole compared with single-agent letrozole in the presurgical setting", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336726", "endSection": "abstract"}, {"offsetInBeginSection": 406, "offsetInEndSection": 559, "text": "Importantly, 2 other CDK4/6 inhibitors, abemaciclib (LY2835219; Lilly) and ribociclib (LEE011; Novartis), are in the late stage of clinical development. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493615", "endSection": "abstract"}, {"offsetInBeginSection": 547, "offsetInEndSection": 803, "text": "After noting an inverse correlation with sensitivity to ribociclib (CDK4/6 inhibitor), we studied the combinatorial effect of these two agents using proliferation assays, cell cycle analysis, Ki67 immunostaining, timelapse microscopy and xenograft studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729458", "endSection": "abstract"}, {"offsetInBeginSection": 274, "offsetInEndSection": 635, "text": "Methods In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy and safety of the selective CDK4/6 inhibitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal women with HR-positive, HER2-negative recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27717303", "endSection": "abstract"}, {"offsetInBeginSection": 522, "offsetInEndSection": 795, "text": "Three selective CDK4/6 inhibitors, palbociclib (Ibrance; Pfizer), ribociclib (Novartis), and abemaciclib (Lilly), are in various stages of development in a variety of pRb-positive tumor types, including breast cancer, melanoma, liposarcoma, and non-small cell lung cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941111", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493615", "endSection": "title"}, {"offsetInBeginSection": 874, "offsetInEndSection": 1102, "text": "Targeted inhibition of CDK4/6 pathway by small-molecule inhibitors palbociclib (PD-0332991) and ribociclib (LEE011) resulted in inhibition of cell-cycle progression, amelioration of kidney injury, and improved overall survival. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848011", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493615", "endSection": "title"}]}, {"body": "Which histone mutations have been associated with pediatric gliomas?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27135271", "http://www.ncbi.nlm.nih.gov/pubmed/27444975", "http://www.ncbi.nlm.nih.gov/pubmed/23429371", "http://www.ncbi.nlm.nih.gov/pubmed/27048880", "http://www.ncbi.nlm.nih.gov/pubmed/27622066", "http://www.ncbi.nlm.nih.gov/pubmed/23715325", "http://www.ncbi.nlm.nih.gov/pubmed/23907119", "http://www.ncbi.nlm.nih.gov/pubmed/23603901", "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "http://www.ncbi.nlm.nih.gov/pubmed/26376656", "http://www.ncbi.nlm.nih.gov/pubmed/25200322", "http://www.ncbi.nlm.nih.gov/pubmed/24285547", "http://www.ncbi.nlm.nih.gov/pubmed/23539183", "http://www.ncbi.nlm.nih.gov/pubmed/25170156", "http://www.ncbi.nlm.nih.gov/pubmed/25773741", "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "http://www.ncbi.nlm.nih.gov/pubmed/23417712", "http://www.ncbi.nlm.nih.gov/pubmed/25401693"], "ideal_answer": ["About 80% of Diffuse intrinsic pontine glioma (DIPG) cases and 70% of midline glioblastomas contain a mutation at one allele of the H3F3A gene (encoding histone H3 variant H3.3), replacing the lysine 27 with methionine (K27M). Moreover, approximately 30% of pediatric high grade gliomas (pedHGG) including GBM and DIPG harbor a lysine 27 mutation (K27M) in histone 3.3 (H3.3) which is correlated with poor outcome. Recent studies on high-grade pediatric GBM have identified two recurrent mutations (K27M and G34R/V) in genes encoding histone H3 (H3F3A for H3.3 and HIST1H3B for H3.1)", "Moreover, approximately 30% of pediatric high grade gliomas (pedHGG) including GBM and DIPG harbor a lysine 27 mutation (K27M) in histone 3.3 (H3.3) which is correlated with poor outcome and was shown to influence EZH2 function Recent studies on high-grade pediatric GBM have identified two recurrent mutations (K27M and G34R/V) in genes encoding histone H3 (H3F3A for H3.3 and HIST1H3B for H3.1) Recent studies have identified a Lys 27-to-methionine (K27M) mutation at one allele of H3F3A, one of the two genes encoding histone H3 variant H3.3, in 60% of high-grade pediatric glioma cases.", "Recent studies on high-grade pediatric GBM have identified two recurrent mutations (K27M and G34R/V) in genes encoding histone H3 (H3F3A for H3.3 and HIST1H3B for H3.1). Two new studies show that the known histone H3 alteration p.Lys27Met in pediatric glioma leads to globally diminished trimethylation at histone H3 lysine 27. These results indicate that H3.3K27M mutation reprograms epigenetic landscape and gene expression, which may drive tumorigenesis.", ", approximately 30% of pediatric high grade gliomas (pedhgg) including gbm and dipg harbor a lysine 27 mutation (k27m) in histone 3.3 (h3.3) which is correlated with poor outcome and was shown to influence ezh2 function . the h3f3a mutant allele found in high-grade pediatric glioma by real-time pcr . studies on high-grade pediatric gbm have identified two recurrent mutations (k27m and g34r/v) in genes encoding histone h3 (h3f3a for h3.3 and hist1h3b for h3.1) . has been reported recently that about 80% of dipg cases and 70% of midline glioblastomas contain a mutation at one allele of the h3f3a gene (encoding histone h3 variant h3.3) , replacing the lysine 27 with methionine (k27m). . , discuss vaccine treatment for children diagnosed with malignant glioma , through targeting epha2 , il-13r\u03b12 and/or histone h3 k27m , while in adults , treatments with rintega , prophage series g-100 and dendritic cells are explored. . studies have identified a lys 27-to-methionine (k27m) mutation at one allele of h3f3a , one of the two genes encoding histone h3 variant h3.3 , in 60% of high-grade pediatric glioma cases. . new studies show that the known histone h3 alteration p.lys27met in pediatric glioma leads to globally diminished trimethylation at histone h3 lysine 27 . were able to discern the h3f3a k27m mutation in a newly obtained pediatric brainstem glioblastoma sample whose h3.3 status was not known previously , and in three other dipg samples as well as paraffin embedded samples these results demonstrate that have developed a new reliable procedure for detecting the h3f3a k27m mutation in pediatric glioblastoma patient samples. . "], "type": "list", "id": "58a6c94860087bc10a00002a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376656", "endSection": "title"}, {"offsetInBeginSection": 128, "offsetInEndSection": 355, "text": " It has been reported recently that about 80% of DIPG cases and 70% of midline glioblastomas contain a mutation at one allele of the H3F3A gene (encoding histone H3 variant H3.3), replacing the lysine 27 with methionine (K27M).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376656", "endSection": "abstract"}, {"offsetInBeginSection": 356, "offsetInEndSection": 481, "text": "In order to facilitate diagnosis of DIPG patients, a quick and reliable method to identify the H3F3A K27M mutation is needed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376656", "endSection": "abstract"}, {"offsetInBeginSection": 1040, "offsetInEndSection": 1240, "text": "Using this optimized real-time PCR assay, we analyzed eleven samples, two of which containing H3F3A K27M mutation, and found that these two samples were differentially amplified from the nine others. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376656", "endSection": "abstract"}, {"offsetInBeginSection": 1253, "offsetInEndSection": 1629, "text": "we were able to discern the H3F3A K27M mutation in a newly obtained pediatric brainstem glioblastoma sample whose H3.3 status was not known previously, and in three other DIPG samples as well as paraffin embedded samples. These results demonstrate that we have developed a new reliable procedure for detecting the H3F3A K27M mutation in pediatric glioblastoma patient samples.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376656", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 739, "text": "Moreover, approximately 30% of pediatric high grade gliomas (pedHGG) including GBM and DIPG harbor a lysine 27 mutation (K27M) in histone 3.3 (H3.3) which is correlated with poor outcome and was shown to influence EZH2 function", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27135271", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907119", "endSection": "title"}, {"offsetInBeginSection": 72, "offsetInEndSection": 240, "text": "Recent studies on high-grade pediatric GBM have identified two recurrent mutations (K27M and G34R/V) in genes encoding histone H3 (H3F3A for H3.3 and HIST1H3B for H3.1)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907119", "endSection": "abstract"}, {"offsetInBeginSection": 504, "offsetInEndSection": 620, "text": "Genome-wide studies using ChIP-seq on H3.3K27M patient samples indicate a global reduction of H3K27me3 on chromatin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907119", "endSection": "abstract"}, {"offsetInBeginSection": 621, "offsetInEndSection": 788, "text": "Remarkably, we also found a dramatic enrichment of H3K27me3 and EZH2 (the catalytic subunit H3K27 methyltransferase) at hundreds of gene loci in H3.3K27M patient cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907119", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Two new studies show that the known histone H3 alteration p.Lys27Met in pediatric glioma leads to globally diminished trimethylation at histone H3 lysine 27. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23715325", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Recent studies have identified a Lys 27-to-methionine (K27M) mutation at one allele of H3F3A, one of the two genes encoding histone H3 variant H3.3, in 60% of high-grade pediatric glioma cases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", "endSection": "abstract"}, {"offsetInBeginSection": 795, "offsetInEndSection": 924, "text": "These results indicate that H3.3K27M mutation reprograms epigenetic landscape and gene expression, which may drive tumorigenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", "endSection": "abstract"}, {"offsetInBeginSection": 332, "offsetInEndSection": 568, "text": "Here, we discuss vaccine treatment for children diagnosed with malignant glioma, through targeting EphA2, IL-13R\u03b12 and/or histone H3 K27M, while in adults, treatments with RINTEGA, Prophage Series G-100 and dendritic cells are explored.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27622066", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Histone H3 lysine(27)-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25170156", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Sequencing of pediatric gliomas has identified missense mutations Lys27Met (K27M) and Gly34Arg/Val (G34R/V) in genes encoding histone H3.3 (H3F3A) and H3.1 (HIST3H1B).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23539183", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "abstract"}, {"offsetInBeginSection": 397, "offsetInEndSection": 648, "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "title"}, {"offsetInBeginSection": 146, "offsetInEndSection": 455, "text": "Exon sequencing has identified a mutation in K27M of the histone H3.3 gene (H3F3A K27M and G34R/V) in about 20% of pediatric glioblastomas, but it remains to be seen whether these mutations can be considered specific for pediatric diffuse high-grade astrocytomas or also occur in other pediatric brain tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23429371", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "endSection": "title"}, {"offsetInBeginSection": 400, "offsetInEndSection": 650, "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", "endSection": "abstract"}, {"offsetInBeginSection": 71, "offsetInEndSection": 253, "text": "Recent sequencing studies have shown that ~30\u00a0% of pediatric GBM and ~80\u00a0% of diffuse intrinsic pontine gliomas show K27M mutations in the H3F3A gene, a variant encoding histone H3.3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25200322", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Histone H3 lysine(27)-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25170156", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Sequencing of pediatric gliomas has identified missense mutations Lys27Met (K27M) and Gly34Arg/Val (G34R/V) in genes encoding histone H3.3 (H3F3A) and H3.1 (HIST3H1B)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23539183", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "abstract"}, {"offsetInBeginSection": 146, "offsetInEndSection": 454, "text": "Exon sequencing has identified a mutation in K27M of the histone H3.3 gene (H3F3A K27M and G34R/V) in about 20% of pediatric glioblastomas, but it remains to be seen whether these mutations can be considered specific for pediatric diffuse high-grade astrocytomas or also occur in other pediatric brain tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23429371", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Pediatric brainstem gliomas often harbor oncogenic K27M mutation of histone H3.3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25401693", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "Recent studies have identified a Lys 27-to-methionine (K27M) mutation at one allele of H3F3A, one of the two genes encoding histone H3 variant H3.3, in 60% of high-grade pediatric glioma cases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", "endSection": "abstract"}, {"offsetInBeginSection": 118, "offsetInEndSection": 386, "text": "We established a Drosophila animal model for the pathogenic histone H3K27M mutation and show that its overexpression resembles polycomb repressive complex 2 (PRC2) loss-of-function phenotypes, causing derepression of PRC2 target genes and developmental perturbations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25170156", "endSection": "abstract"}, {"offsetInBeginSection": 71, "offsetInEndSection": 254, "text": "Recent sequencing studies have shown that ~30\u00a0% of pediatric GBM and ~80\u00a0% of diffuse intrinsic pontine gliomas show K27M mutations in the H3F3A gene, a variant encoding histone H3.3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25200322", "endSection": "abstract"}, {"offsetInBeginSection": 298, "offsetInEndSection": 604, "text": "Evolutionary reconstruction indicates histone 3 (H3) K27M--including H3.2K27M--mutations potentially arise first and are invariably associated with specific, high-fidelity obligate partners throughout the tumour and its spread, from diagnosis to end-stage disease, suggesting mutual need for tumorigenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048880", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 1070, "text": "Moreover, approximately 30% of pediatric high grade gliomas (pedHGG) including GBM and DIPG harbor a lysine 27 mutation (K27M) in histone 3.3 (H3.3) which is correlated with poor outcome and was shown to influence EZH2 function.The present study investigated the correlation of expression of EZH2 and other PRC2 genes (EZH1, SUZ12, EED) with overall survival of pediatric GBM patients and the cytotoxic impact of EZH2 inhibition by the novel agent Tazemetostat in pediatric GBM/DIPG cells harboring either a H3.3 mutation or a H3 wildtype.EZH2 gene expression does not c", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27135271", "endSection": "abstract"}, {"offsetInBeginSection": 400, "offsetInEndSection": 651, "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", "endSection": "abstract"}, {"offsetInBeginSection": 940, "offsetInEndSection": 1352, "text": "Important insights have also been uncovered in the field of pediatric glioma, including the identification of recurrent mutation, fusion, and/or duplication events of the BRAF, FGFR1, MYB, and MYBL1 genes in pediatric low-grade gliomas, mutations affecting histone components (H3F3A p.K27M or p.G34) in pediatric high-grade gliomas, and aggressive subsets developing in midline central nervous system structures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27444975", "endSection": "abstract"}, {"offsetInBeginSection": 1139, "offsetInEndSection": 1261, "text": "K27M-H3.3 is universally associated with short survival in DIPG, while patients wild-type for H3.3 show improved survival.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "endSection": "abstract"}, {"offsetInBeginSection": 1481, "offsetInEndSection": 1704, "text": "Taken together, our results suggest that mutations disrupting the histone code at H3K36, including H3.3 G34R/V, IDH1 and/or SETD2 mutations, are central to the genesis of hemispheric HGGs in older children and young adults.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23417712", "endSection": "abstract"}, {"offsetInBeginSection": 1168, "offsetInEndSection": 1284, "text": "Gliomas with H3F3A K27M from pediatric or young adult patients had similar, characteristic DNA methylation profiles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285547", "endSection": "abstract"}, {"offsetInBeginSection": 1141, "offsetInEndSection": 1263, "text": "K27M-H3.3 is universally associated with short survival in DIPG, while patients wild-type for H3.3 show improved survival.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "endSection": "abstract"}, {"offsetInBeginSection": 656, "offsetInEndSection": 794, "text": "Moreover, the gain of H3K27me3 and Ezh2 at gene promoters alters the expression of genes that are associated with various cancer pathways.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907119", "endSection": "title"}]}, {"body": "Is it feasible to obtain DNA read lengths that exceed 30 Kb?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25977818", "http://www.ncbi.nlm.nih.gov/pubmed/27712583", "http://www.ncbi.nlm.nih.gov/pubmed/27587671"], "ideal_answer": ["The emergence and development of so called third generation sequencing platforms such as PacBio has permitted exceptionally long reads (over 20\u2009kb) to be generated but not yet read length >30 Kb."], "type": "yesno", "id": "58dff5776fddd3e83e000008", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 368, "text": "Single-molecule, real-time sequencing (SMRT) developed by Pacific BioSciences produces longer reads than secondary generation sequencing technologies such as Illumina. The long read length enables PacBio sequencing to close gaps in genome assembly, reveal structural variations, and identify gene isoforms with higher accuracy in transcriptomic sequencing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27587671", "endSection": "abstract"}, {"offsetInBeginSection": 214, "offsetInEndSection": 513, "text": " Third-generation sequencing, with read lengths>10 kb, will improve the assembly of complex genomes, but these techniques require high-molecular-weight genomic DNA (gDNA), and gDNA extraction protocols used for obtaining smaller fragments for short-read sequencing are not suitable for this purpose.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27712583", "endSection": "abstract"}, {"offsetInBeginSection": 219, "offsetInEndSection": 383, "text": "The emergence and development of so called third generation sequencing platforms such as PacBio has permitted exceptionally long reads (over 20\u2009kb) to be generated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25977818", "endSection": "abstract"}]}, {"body": "Is osteocrin expressed exclusively in the bone?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15923362", "http://www.ncbi.nlm.nih.gov/pubmed/14523025", "http://www.ncbi.nlm.nih.gov/pubmed/27830782", "http://www.ncbi.nlm.nih.gov/pubmed/17951249"], "ideal_answer": ["No, Osteocrin (Ostn) has been detected in the bones and the brain."], "type": "yesno", "id": "58df73bd38f7f3e93a000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Evolution of Osteocrin as an activity-regulated factor in the primate brain.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27830782", "endSection": "title"}, {"offsetInBeginSection": 390, "offsetInEndSection": 601, "text": "Here we use transcriptional profiling of human fetal brain cultures to identify an activity-dependent secreted factor, Osteocrin (OSTN), that is induced by membrane depolarization of human but not mouse neurons.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27830782", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Osteocrin (Ostn) is a recently discovered secreted protein produced by cells of the osteoblast lineage that shows a well conserved homology with members of the natriuretic peptide (NP) family. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17951249", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Osteocrin (Ostn), a bone-active molecule, has been shown in animals to be highly expressed in cells of the osteoblast lineage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15923362", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Osteocrin, a novel bone-specific secreted protein that modulates the osteoblast phenotype.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14523025", "endSection": "title"}]}, {"body": "What is  Achondroplasia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20624921", "http://www.ncbi.nlm.nih.gov/pubmed/24365319", "http://www.ncbi.nlm.nih.gov/pubmed/25823796"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0001080", "o": "Achondroplasia"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0001080", "o": "http://linkedlifedata.com/resource/umls/label/A0385394"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0385394", "o": "ACHONDROPLASIA"}, {"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name", "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/21", "o": "Achondroplasia"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0001080", "o": "http://linkedlifedata.com/resource/umls/label/A0018520"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0018520", "o": "Achondroplasia"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/1024318", "o": "http://linkedlifedata.com/resource/rxnorm/label/3105017"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3105017", "o": "Achondroplasia"}], "ideal_answer": ["Achondrogenesis type II also known as  Achondroplasia  is an autosomal-dominant disease leading to severe micromelic dwarfism", "Achondrogenesis type II is an autosomal-dominant disease leading to severe micromelic dwarfism. ", "Achondrogenesis type II is an autosomal-dominant disease leading to severe micromelic dwarfism.", "achondrogenesis type ii is an autosomal-dominant disease leading to severe micromelic dwarfism.", "achondrogenesis type ii is an autosomal-dominant disease to severe micromelic dwarfism. . "], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:4480", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000130"], "type": "factoid", "id": "58cefcfb8acda34529000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Achondrogenesis type II is an autosomal-dominant disease leading to severe micromelic dwarfism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25823796", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Physical basis behind achondroplasia, the most common form of human dwarfism", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20624921", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Achondroplasia is the best described and most common form of the congenital short-limbed dwarfing conditions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24365319", "endSection": "abstract"}]}, {"body": "What is the indication for Mirabegron?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26908514", "http://www.ncbi.nlm.nih.gov/pubmed/24127366", "http://www.ncbi.nlm.nih.gov/pubmed/24078498", "http://www.ncbi.nlm.nih.gov/pubmed/24610862", "http://www.ncbi.nlm.nih.gov/pubmed/23757386", "http://www.ncbi.nlm.nih.gov/pubmed/26665779", "http://www.ncbi.nlm.nih.gov/pubmed/26422675", "http://www.ncbi.nlm.nih.gov/pubmed/23063375", "http://www.ncbi.nlm.nih.gov/pubmed/25521658", "http://www.ncbi.nlm.nih.gov/pubmed/23089348", "http://www.ncbi.nlm.nih.gov/pubmed/23850394", "http://www.ncbi.nlm.nih.gov/pubmed/23182126", "http://www.ncbi.nlm.nih.gov/pubmed/26501573", "http://www.ncbi.nlm.nih.gov/pubmed/22981677", "http://www.ncbi.nlm.nih.gov/pubmed/25791612", "http://www.ncbi.nlm.nih.gov/pubmed/27124860", "http://www.ncbi.nlm.nih.gov/pubmed/24602031", "http://www.ncbi.nlm.nih.gov/pubmed/26663687", "http://www.ncbi.nlm.nih.gov/pubmed/26493129", "http://www.ncbi.nlm.nih.gov/pubmed/20878594", "http://www.ncbi.nlm.nih.gov/pubmed/22384458", "http://www.ncbi.nlm.nih.gov/pubmed/24458878"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/chebi/id/CHEBI:65349", "o": "mirabegron"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2983812", "o": "http://linkedlifedata.com/resource/umls/label/A19588156"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A19588156", "o": "mirabegron"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2983812", "o": "http://linkedlifedata.com/resource/umls/label/A20837597"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A20837597", "o": "mirabegron"}], "ideal_answer": ["Mirabegron, the first \u5c3e3-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms.", "mirabegron, the first \u03b23-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (oab) syndrome symptoms.", "Mirabegron, the first \u03b23-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms.", "Mirabegron, the first \ufffd3-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms.", "Mirabegron, the first 3-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms. "], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053201"], "type": "factoid", "id": "58f4b2f070f9fc6f0f000012", "snippets": [{"offsetInBeginSection": 9, "offsetInEndSection": 149, "text": "Mirabegron, the first \u03b23-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26422675", "endSection": "abstract"}, {"offsetInBeginSection": 344, "offsetInEndSection": 529, "text": "The clinical indication for mirabegron is overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency and other storage symptoms in both men and women.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26665779", "endSection": "abstract"}, {"offsetInBeginSection": 450, "offsetInEndSection": 685, "text": "Mirabegron has been approved in Japan for the indication of urgency, urinary frequency and urge urinary incontinence associated with OAB, and was recently submitted for approval to U.S. and European authorities for the same indication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22384458", "endSection": "abstract"}, {"offsetInBeginSection": 1386, "offsetInEndSection": 1603, "text": "Mirabegron was well tolerated.The early onset of action and good overall efficacy and tolerability balance that mirabegron offers may lead to high rates of persistence with mirabegron in the long-term treatment of OAB", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24458878", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 461, "text": "Mirabegron, the selective \u03b23-adrenoceptor agonist, heralds the latest development for the treatment of overactive bladder (OAB).To present the evidence available on the efficacy and tolerability of mirabegron and to discuss this treatments potential in our setting.We reviewed 11 studies conducted with mirabegron in patients with OAB (2 phase II, 9 phase III), all studies were compared to placebo with 6 studies also including tolterodine as an additional arm", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23850394", "endSection": "abstract"}, {"offsetInBeginSection": 864, "offsetInEndSection": 1386, "text": "More than 50% of patients had previously discontinued anticholinergics medication for OAB, thus allowing us to obtain data on the effectiveness of mirabegron in patients already treated with anticholinergics.Mirabegron is an efficacious drug which presents a statistically significant reduction in the number of incontinence episodes and in urinary frequency as of 4 weeks, with a higher percentage of dry patients and a higher percentage of patients with reduction \u226550% in the number of incontinence episodes than placebo", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23850394", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 657, "text": "Mirabegron, a \u03b2(3)-adrenoceptor agonist, has been developed for the treatment of overactive bladder (OAB).To assess the efficacy and tolerability of mirabegron versus placebo.Multicenter randomised double-blind, parallel-group placebo- and tolterodine-controlled phase 3 trial conducted in 27 countries in Europe and Australia in patients \u2265 18 yr of age with symptoms of OAB for \u2265 3 mo.After a 2-wk single-blind placebo run-in period, patients were randomised to receive placebo, mirabegron 50mg, mirabegron 100mg, or tolterodine extended release 4 mg orally once daily for 12 wk.Patients completed a micturition diary and quality-of-life (QoL) assessments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 334, "text": "Mirabegron is the first \u03b23-adrenoceptor agonist that is clinically effective for overactive bladder.The effects of mirabegron on primary bladder mechanosensitive single-unit afferent activities (SAAs) and bladder microcontractions were evaluated and compared with the effects of oxybutynin.Female Sprague-Dawley rats were anesthetized", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22981677", "endSection": "abstract"}, {"offsetInBeginSection": 1247, "offsetInEndSection": 1538, "text": "Mirabegron exhibits a novel mode of action in targeting the \u03b2\u2083-AR for bladder relaxation, and the studies and trials conducted to date suggest mirabegron as a promising new treatment in the management of OAB symptoms, such as increased urinary urgency and frequency, and urgency incontinence", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20878594", "endSection": "abstract"}, {"offsetInBeginSection": 452, "offsetInEndSection": 686, "text": "Mirabegron has been approved in Japan for the indication of urgency, urinary frequency and urge urinary incontinence associated with OAB, and was recently submitted for approval to U.S. and European authorities for the same indication", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22384458", "endSection": "abstract"}, {"offsetInBeginSection": 347, "offsetInEndSection": 532, "text": "The clinical indication for mirabegron is overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency and other storage symptoms in both men and women.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26665779", "endSection": "abstract"}, {"offsetInBeginSection": 237, "offsetInEndSection": 371, "text": "Mirabegron's efficacy on frequency, urgency, and urge incontinence was tested in several trials before its wide clinical introduction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26501573", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 540, "text": "To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-in class novel \u03b23 receptor agonist drug recently approved by the food and drug administration (FDA) for the treatment of overactive bladder (OAB).We conducted a computerized search of the MEDLINE/PUBMED databases with the word Mirabegron, \u03b23 receptor agonist and overactive bladder.Effect of Mirabegron on \u03b23 adrenergic receptor purportedly releases nitric oxide(NO) by an increase in intracellular Ca2+ through accumulation of cyclic adenosine monophosphate (cAMP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078498", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Mirabegron for the treatment of overactive bladder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22384458", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Mirabegron: a Beta-3 agonist for overactive bladder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25521658", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "[MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26665779", "endSection": "title"}, {"offsetInBeginSection": 399, "offsetInEndSection": 650, "text": "Phase III clinical trials in patients with overactive bladder (OAB), mirabegron at daily doses of 25, 50, and 100\u2009mg demonstrated significant efficacy in treating the symptoms of OAB, including micturition frequency, urgency incontinence, and urgency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24127366", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 144, "text": "To review the place in therapy of mirabegron, a new oral \u03b23-adrenergic receptor agonist, for the treatment of overactive bladder (OAB", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23757386", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 108, "text": "Mirabegron (YM178) is a \u03b2(3)-adrenoceptor agonist for the treatment of overactive bladder (OAB).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23063375", "endSection": "abstract"}, {"offsetInBeginSection": 586, "offsetInEndSection": 666, "text": "Two new therapies have emerged for treating overactive bladder (OAB): Mirabegron", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089348", "endSection": "abstract"}, {"offsetInBeginSection": 8, "offsetInEndSection": 134, "text": " OnabotulinumtoxinA and mirabegron have recently gained marketing authorisation to treat symptoms of overactive bladder (OAB).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908514", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 188, "text": "irabegron (YM-178), currently in development by Astellas Pharma Inc, is an orally active \u03b2\u2083-adrenoceptor (AR) agonist for the potential symptomatic treatment of overactive bladder (OAB). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20878594", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 166, "text": "To evaluate the efficacy and safety of the \u03b23 -adrenoceptor agonist, mirabegron, compared with placebo in Japanese patients with overactive bladder (OAB).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26663687", "endSection": "abstract"}, {"offsetInBeginSection": 180, "offsetInEndSection": 284, "text": "Mirabegron is the first \u03b23 -adrenoceptor agonist approved for treatment of overactive bladder syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26493129", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 162, "text": "To examine the effects of mirabegron, a selective \u03b23 -adrenoceptor agonist that has recently been approved for the treatment of overactive bladder (OAB", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27124860", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 122, "text": "mirabegron is a \u03b23-adrenoceptor agonist developed for the treatment of symptoms of overactive bladder (OAB).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24610862", "endSection": "abstract"}, {"offsetInBeginSection": 113, "offsetInEndSection": 191, "text": "mirabegron, a \u03b23-adrenoceptor agonist for the treatment of overactive bladder,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25791612", "endSection": "abstract"}, {"offsetInBeginSection": 3, "offsetInEndSection": 237, "text": "critically analyse available phase II and III randomised control trials (RCTs) reporting clinical data about the efficacy and tolerability of Mirabegron (a \u03b2\u2083-adrenoceptor agonist) in the treatment of overactive bladder (OAB) syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24602031", "endSection": "abstract"}]}, {"body": "What is the cause of Tardive dyskinesia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26979525", "http://www.ncbi.nlm.nih.gov/pubmed/24747871", "http://www.ncbi.nlm.nih.gov/pubmed/20818603", "http://www.ncbi.nlm.nih.gov/pubmed/23157631", "http://www.ncbi.nlm.nih.gov/pubmed/24310603"], "ideal_answer": ["Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications."], "type": "factoid", "id": "58efa36d70f9fc6f0f000004", "snippets": [{"offsetInBeginSection": 9, "offsetInEndSection": 89, "text": ": Free radicals may be involved in the pathogenesis of tardive dyskinesia (TD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26979525", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Tardive dyskinesia (TD) is a serious, often disabling, movement disorder that is caused by medications that block dopamine receptors (i.e., neuroleptics, anti-emetics). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24310603", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Antipsychotics may cause tardive dyskinesia in humans and orofacial dyskinesia in rodents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24747871", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23157631", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "The objective of this report is to draw attention to tardive dyskinesia (TD) caused by aripiprazole, a third generation antipsychotic. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20818603", "endSection": "abstract"}]}, {"body": "Are alterations in ultraconserved elements associated with colorectal adenocarcinoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22318908", "http://www.ncbi.nlm.nih.gov/pubmed/22328099", "http://www.ncbi.nlm.nih.gov/pubmed/22673945"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1319315", "o": "Colorectal Adenocarcinoma"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1319315", "o": "http://linkedlifedata.com/resource/umls/label/A18681147"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18681147", "o": "colorectal adenocarcinoma"}], "ideal_answer": ["yes", "Yes. SNPs within ultraconserved elements (UCEs) may be valuable prognostic biomarkers for patients with locally advanced CRC who receive 5-fluorouracil-based chemotherapy."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:0050861", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050436", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015179"], "type": "yesno", "id": "587e1e57fc7e8dd84f000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22318908", "endSection": "title"}, {"offsetInBeginSection": 1481, "offsetInEndSection": 1684, "text": "Our results strongly suggest that several genetic variants in the UCEs may contribute to CRC susceptibility, individually and jointly, and that different genetic etiology may be involved in RCRC and LCRC", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22318908", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22673945", "endSection": "title"}, {"offsetInBeginSection": 1786, "offsetInEndSection": 2099, "text": "To the authors' knowledge, this is the first study to evaluate the association between SNPs within UCEs and clinical outcome in patients with CRC. The results suggested that SNPs within UCEs may be valuable prognostic biomarkers for patients with locally advanced CRC who receive 5-fluorouracil-based chemotherapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22673945", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22673945", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22318908", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "We investigated whether single nucleotide polymorphisms within ultraconserved elements (UCEs) are associated with susceptibility to overall colorectal cancer (CRC) and susceptibility to tumor site-specific CRC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22318908", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "We investigated whether single nucleotide polymorphisms within ultraconserved elements (UCEs) are associated with susceptibility to overall colorectal cancer (CRC) and susceptibility to tumor site-specific CRC", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22318908", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22673945", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22318908", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Expression levels of transcribed ultraconserved regions uc.73 and uc.388 are altered in colorectal cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22328099", "endSection": "title"}]}, {"body": "What is PANTHER-PSEP?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27193693"], "ideal_answer": ["PANTHER-PSEP is a new software tool for predicting non-synonymous genetic variants that may play a causal role in human disease. Several previous variant pathogenicity prediction methods have been proposed that quantify evolutionary conservation among homologous proteins from different organisms. PANTHER-PSEP employs a related but distinct metric based on 'evolutionary preservation': homologous proteins are used to reconstruct the likely sequences of ancestral proteins at nodes in a phylogenetic tree, and the history of each amino acid can be traced back in time from its current state to estimate how long that state has been preserved in its ancestors. ", "PANTHER-PSEP is a software tool for predicting non-synonymous genetic variants that may play a causal role in human disease. PANTHER-PSEP employs a related but distinct metric based on 'evolutionary preservation': homologous proteins are used to reconstruct the likely sequences of ancestral proteins at nodes in a phylogenetic tree, and the history of each amino acid can be traced back in time from its current state to estimate how long that state has been preserved in its ancestors.", "PANTHER-PSEP is a new software tool for predicting non-synonymous genetic variants that may play a causal role in human disease."], "type": "summary", "id": "58965c5578275d0c4a00000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "PANTHER-PSEP: predicting disease-causing genetic variants using position-specific evolutionary preservation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193693", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 673, "text": "PANTHER-PSEP is a new software tool for predicting non-synonymous genetic variants that may play a causal role in human disease. Several previous variant pathogenicity prediction methods have been proposed that quantify evolutionary conservation among homologous proteins from different organisms. PANTHER-PSEP employs a related but distinct metric based on 'evolutionary preservation': homologous proteins are used to reconstruct the likely sequences of ancestral proteins at nodes in a phylogenetic tree, and the history of each amino acid can be traced back in time from its current state to estimate how long that state has been preserved in its ancestors. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193693", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "PANTHER-PSEP is a new software tool for predicting non-synonymous genetic variants that may play a causal role in human disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193693", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 658, "text": "PANTHER-PSEP employs a related but distinct metric based on 'evolutionary preservation': homologous proteins are used to reconstruct the likely sequences of ancestral proteins at nodes in a phylogenetic tree, and the history of each amino acid can be traced back in time from its current state to estimate how long that state has been preserved in its ancestors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193693", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "PANTHER-PSEP: predicting disease-causing genetic variants using position-specific evolutionary preservation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193693", "endSection": "title"}, {"offsetInBeginSection": 298, "offsetInEndSection": 660, "text": "PANTHER-PSEP employs a related but distinct metric based on 'evolutionary preservation': homologous proteins are used to reconstruct the likely sequences of ancestral proteins at nodes in a phylogenetic tree, and the history of each amino acid can be traced back in time from its current state to estimate how long that state has been preserved in its ancestors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27193693", "endSection": "abstract"}]}, {"body": "What is MPE-seq?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26080409"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0004793", "o": "nucleic acid sequencing"}], "ideal_answer": ["MPE-seq (methidiumpropyl-EDTA sequencing) is a new method for the genome-wide characterization of chromatin that involves the digestion of nuclei with MPE-Fe(II) followed by massively parallel sequencing. Like micrococcal nuclease (MNase), MPE-Fe(II) preferentially cleaves the linker DNA between nucleosomes. However, there are differences in the cleavage of nuclear chromatin by MPE-Fe(II) relative to MNase. MPE-seq provides a unique and straightforward means for the genome-wide analysis of chromatin structure with minimal DNA sequence bias. In particular, the combined use of MPE-seq and MNase-seq enables the identification of noncanonical chromatin structures that are likely to be important for the regulation of gene expression."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017422", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020411"], "type": "summary", "id": "58946d6e7d9090f353000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "MPE-seq, a new method for the genome-wide analysis of chromatin structure.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1021, "text": "The analysis of chromatin structure is essential for the understanding of transcriptional regulation in eukaryotes. Here we describe methidiumpropyl-EDTA sequencing (MPE-seq), a method for the genome-wide characterization of chromatin that involves the digestion of nuclei withMPE-Fe(II) followed by massively parallel sequencing. Like micrococcal nuclease (MNase), MPE-Fe(II) preferentially cleaves the linker DNA between nucleosomes. However, there are differences in the cleavage of nuclear chromatin by MPE-Fe(II) relative to MNase. Most notably, immediately upstream of the transcription start site of active promoters, we frequently observed nucleosome-sized (141-190 bp) and subnucleosome-sized (such as 101-140 bp) peaks of digested chromatin fragments with MPE-seq but not with MNase-seq. These peaks also correlate with the presence of core histones and could thus be due, at least in part, to noncanonical chromatin structures such as labile nucleosome-like particles that have been observed in other contexts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409", "endSection": "abstract"}, {"offsetInBeginSection": 1423, "offsetInEndSection": 1792, "text": "These findings collectively indicate that MPE-seq provides a unique and straightforward means for the genome-wide analysis of chromatin structure with minimal DNA sequence bias. In particular, the combined use of MPE-seq and MNase-seq enables the identification of noncanonical chromatin structures that are likely to be important for the regulation of gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409", "endSection": "abstract"}, {"offsetInBeginSection": 1413, "offsetInEndSection": 1590, "text": "These findings collectively indicate that MPE-seq provides a unique and straightforward means for the genome-wide analysis of chromatin structure with minimal DNA sequence bias.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409", "endSection": "abstract"}, {"offsetInBeginSection": 1590, "offsetInEndSection": 1781, "text": "In particular, the combined use of MPE-seq and MNase-seq enables the identification of noncanonical chromatin structures that are likely to be important for the regulation of gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409", "endSection": "abstract"}, {"offsetInBeginSection": 115, "offsetInEndSection": 329, "text": "Here we describe methidiumpropyl-EDTA sequencing (MPE-seq), a method for the genome-wide characterization of chromatin that involves the digestion of nuclei withMPE-Fe(II) followed by massively parallel sequencing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409", "endSection": "abstract"}, {"offsetInBeginSection": 1601, "offsetInEndSection": 1792, "text": "In particular, the combined use of MPE-seq and MNase-seq enables the identification of noncanonical chromatin structures that are likely to be important for the regulation of gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "MPE-seq, a new method for the genome-wide analysis of chromatin structure.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409", "endSection": "title"}, {"offsetInBeginSection": 1423, "offsetInEndSection": 1600, "text": "These findings collectively indicate that MPE-seq provides a unique and straightforward means for the genome-wide analysis of chromatin structure with minimal DNA sequence bias.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409", "endSection": "abstract"}, {"offsetInBeginSection": 116, "offsetInEndSection": 330, "text": "Here we describe methidiumpropyl-EDTA sequencing (MPE-seq), a method for the genome-wide characterization of chromatin that involves the digestion of nuclei withMPE-Fe(II) followed by massively parallel sequencing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26080409", "endSection": "abstract"}]}, {"body": "Describe the mechanism of action of Bezlotoxumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27905086", "http://www.ncbi.nlm.nih.gov/pubmed/27753689", "http://www.ncbi.nlm.nih.gov/pubmed/25385797", "http://www.ncbi.nlm.nih.gov/pubmed/25486992", "http://www.ncbi.nlm.nih.gov/pubmed/24821719", "http://www.ncbi.nlm.nih.gov/pubmed/27527088", "http://www.ncbi.nlm.nih.gov/pubmed/25451052", "http://www.ncbi.nlm.nih.gov/pubmed/27757389"], "ideal_answer": ["Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B (TcdB). It is used for prevention of  recurrent C. difficile infections."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"], "type": "summary", "id": "588fa24fed9bbee70d000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck&Co. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27905086", "endSection": "abstract"}, {"offsetInBeginSection": 86, "offsetInEndSection": 320, "text": "Circulating neutralizing antitoxin antibodies are protective in C. difficile infection (CDI), as demonstrated, in part, by the protective effects of actoxumab and bezlotoxumab, which bind to and neutralize TcdA and TcdB, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385797", "endSection": "abstract"}, {"offsetInBeginSection": 155, "offsetInEndSection": 295, "text": "Actoxumab and bezlotoxumab are human monoclonal antibodies that neutralize the cytotoxic/cytopathic effects of TcdA and TcdB, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451052", "endSection": "abstract"}, {"offsetInBeginSection": 1242, "offsetInEndSection": 1542, "text": "We compared the bezlotoxumab epitopes in the TcdB receptor binding domain across known TcdB sequences and found that key substitutions within the bezlotoxumab epitopes correlated with the relative differences in potencies of bezlotoxumab against TcdB of some strains, including ribotypes 027 and 078.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451052", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", "endSection": "title"}, {"offsetInBeginSection": 245, "offsetInEndSection": 578, "text": "A combination of the anti-TcdA antibody actoxumab and the anti-TcdB antibody bezlotoxumab is currently under development for the prevention of recurrent C. difficile infections. We demonstrate here through various biophysical approaches that bezlotoxumab binds to specific regions within the N-terminal half of the TcdB CROP domain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", "endSection": "abstract"}, {"offsetInBeginSection": 999, "offsetInEndSection": 1411, "text": "We also show that bezlotoxumab neutralizes TcdB by blocking binding of TcdB to mammalian cells. Overall, our data are consistent with a model wherein a single molecule of bezlotoxumab neutralizes TcdB by binding via its two Fab regions to two epitopes within the N-terminal half of the TcdB CROP domain, partially blocking the carbohydrate binding pockets of the toxin and preventing toxin binding to host cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", "endSection": "abstract"}, {"offsetInBeginSection": 1235, "offsetInEndSection": 1535, "text": "We compared the bezlotoxumab epitopes in the TcdB receptor binding domain across known TcdB sequences and found that key substitutions within the bezlotoxumab epitopes correlated with the relative differences in potencies of bezlotoxumab against TcdB of some strains, including ribotypes 027 and 078.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451052", "endSection": "abstract"}, {"offsetInBeginSection": 994, "offsetInEndSection": 1089, "text": "We also show that bezlotoxumab neutralizes TcdB by blocking binding of TcdB to mammalian cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Bezlotoxumab (Zinplava\u2122) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck & Co.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27905086", "endSection": "abstract"}, {"offsetInBeginSection": 154, "offsetInEndSection": 293, "text": "Actoxumab and bezlotoxumab are human monoclonal antibodies that neutralize the cytotoxic/cytopathic effects of TcdA and TcdB, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451052", "endSection": "abstract"}, {"offsetInBeginSection": 522, "offsetInEndSection": 674, "text": "The monoclonal antitoxin antibodies actoxumab (anti-TcdA) and bezlotoxumab (anti-TcdB) are currently in development for the prevention of recurrent CDI.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27527088", "endSection": "abstract"}, {"offsetInBeginSection": 485, "offsetInEndSection": 708, "text": "A combination of human monoclonal antibodies, actoxumab and bezlotoxumab, directed against TcdA and TcdB, respectively, has been shown to decrease the rate of recurrence in patients treated with standard-of-care antibiotics", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25486992", "endSection": "abstract"}, {"offsetInBeginSection": 86, "offsetInEndSection": 319, "text": "Circulating neutralizing antitoxin antibodies are protective in C. difficile infection (CDI), as demonstrated, in part, by the protective effects of actoxumab and bezlotoxumab, which bind to and neutralize TcdA and TcdB, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385797", "endSection": "abstract"}, {"offsetInBeginSection": 423, "offsetInEndSection": 577, "text": "We demonstrate here through various biophysical approaches that bezlotoxumab binds to specific regions within the N-terminal half of the TcdB CROP domain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", "endSection": "abstract"}, {"offsetInBeginSection": 578, "offsetInEndSection": 721, "text": "Based on this information, we solved the x-ray structure of the N-terminal half of the TcdB CROP domain bound to Fab fragments of bezlotoxumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", "endSection": "abstract"}, {"offsetInBeginSection": 722, "offsetInEndSection": 998, "text": "The structure reveals that the TcdB CROP domain adopts a \u03b2-solenoid fold consisting of long and short repeats and that bezlotoxumab binds to two homologous sites within the CROP domain, partially occluding two of the four putative carbohydrate binding pockets located in TcdB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", "endSection": "abstract"}, {"offsetInBeginSection": 1095, "offsetInEndSection": 1512, "text": "Overall, our data are consistent with a model wherein a single molecule of bezlotoxumab neutralizes TcdB by binding via its two Fab regions to two epitopes within the N-terminal half of the TcdB CROP domain, partially blocking the carbohydrate binding pockets of the toxin and preventing toxin binding to host cells. <CopyrightInformation>\u00a9 2014 by The American Society for Biochemistry and Molecular Biology, Inc.</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", "endSection": "title"}, {"offsetInBeginSection": 999, "offsetInEndSection": 1094, "text": "We also show that bezlotoxumab neutralizes TcdB by blocking binding of TcdB to mammalian cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24821719", "endSection": "abstract"}]}, {"body": "Is apremilast effective for psoriasis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27376729", "http://www.ncbi.nlm.nih.gov/pubmed/26923915", "http://www.ncbi.nlm.nih.gov/pubmed/26220911", "http://www.ncbi.nlm.nih.gov/pubmed/22712800", "http://www.ncbi.nlm.nih.gov/pubmed/26243735", "http://www.ncbi.nlm.nih.gov/pubmed/26644232", "http://www.ncbi.nlm.nih.gov/pubmed/26806620", "http://www.ncbi.nlm.nih.gov/pubmed/26549249", "http://www.ncbi.nlm.nih.gov/pubmed/27486641", "http://www.ncbi.nlm.nih.gov/pubmed/23663752", "http://www.ncbi.nlm.nih.gov/pubmed/24595547", "http://www.ncbi.nlm.nih.gov/pubmed/26954311", "http://www.ncbi.nlm.nih.gov/pubmed/26357944", "http://www.ncbi.nlm.nih.gov/pubmed/20419594", "http://www.ncbi.nlm.nih.gov/pubmed/26267722", "http://www.ncbi.nlm.nih.gov/pubmed/26089047", "http://www.ncbi.nlm.nih.gov/pubmed/23569359", "http://www.ncbi.nlm.nih.gov/pubmed/26892034", "http://www.ncbi.nlm.nih.gov/pubmed/26783350", "http://www.ncbi.nlm.nih.gov/pubmed/27538241", "http://www.ncbi.nlm.nih.gov/pubmed/26660203", "http://www.ncbi.nlm.nih.gov/pubmed/26820148", "http://www.ncbi.nlm.nih.gov/pubmed/26837052", "http://www.ncbi.nlm.nih.gov/pubmed/27021239", "http://www.ncbi.nlm.nih.gov/pubmed/23030767", "http://www.ncbi.nlm.nih.gov/pubmed/26792812"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0033860", "o": "psoriasis"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0033860", "o": "http://linkedlifedata.com/resource/umls/label/A0487662"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0487662", "o": "psoriasis"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1678805", "o": "APREMILAST"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1678805", "o": "http://linkedlifedata.com/resource/umls/label/A15589751"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A15589751", "o": "apremilast"}], "ideal_answer": ["Yes, apremilast is effective for treatment of psoriasis."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:8893", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011565"], "type": "yesno", "id": "589a246d78275d0c4a000033", "snippets": [{"offsetInBeginSection": 1630, "offsetInEndSection": 1698, "text": "CONCLUSION: Apremilast reduces the severity of nail/scalp psoriasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26549249", "endSection": "abstract"}, {"offsetInBeginSection": 1638, "offsetInEndSection": 1834, "text": "CONCLUSIONS: Apremilast demonstrated clinically meaningful improvements in psoriatic arthritis and psoriasis at week 16; sustained improvements were seen with continued treatment through 52\u2005weeks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26792812", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350", "endSection": "title"}, {"offsetInBeginSection": 634, "offsetInEndSection": 910, "text": "In those that involved doses of 30 mg twice daily, a significantly greater percentage of patients receiving apremilast (28.8% to 40.9%) compared with placebo (5.3% to 5.8%) achieved at least 75% improvement from baseline in Psoriasis Area and Severity Index score at 16 weeks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350", "endSection": "abstract"}, {"offsetInBeginSection": 1356, "offsetInEndSection": 1605, "text": "CONCLUSIONS: Apremilast has a novel mechanism of action and is safe and effective for the management of psoriasis and psoriatic arthritis. At this time, apremilast should be reserved for patients unable to take disease-modifying antirheumatic drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089047", "endSection": "title"}, {"offsetInBeginSection": 938, "offsetInEndSection": 1338, "text": "More recently, three larger double-blinded, and randomized multicenter studies demonstrate that apremilast is efficacious in the treatment of psoriasis and PsA, with significantly higher numbers of apremilast-treated patients achieving endpoints of a 75% reduction compared to baseline in Psoriasis Area and Severity Index (PASI-75) or American College of Rheumatology-20 scores, relative to placebo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23569359", "endSection": "abstract"}, {"offsetInBeginSection": 1284, "offsetInEndSection": 1664, "text": "No new significant adverse events emerged with continued apremilast exposure versus the placebo-controlled period.Data were limited to 52 weeks and may not generalize to nonplaque psoriasis.Apremilast was effective in moderate to severe plaque psoriasis.<CopyrightInformation>Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.</", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089047", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 596, "text": "Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediator production.Assess apremilast efficacy and safety in moderate to severe plaque psoriasis.Phase II, 12-week, multicenter, double-blind, placebo-controlled, parallel-group, dose-comparison study of 259 subjects randomized 1 : 1 : 1 to placebo, apremilast 20 mg QD or apremilast 20 mg BID.More subjects receiving apremilast 20 mg BID achieved \u2265 75% reduction in Psoriasis Area and Severity Index (PASI-75) vs. placebo (24.4% vs. 10.3%; P = 0.023)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030767", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 449, "text": "Apremilast, a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-inflammatory cytokine production.Apremilasts effect on patient-reported outcomes (PROs) in patients with moderate to severe psoriasis was evaluated in a phase IIb randomized, controlled trial (NCT00773734).In this 16-week, placebo-controlled study, 352 patients with moderate to severe plaque psoriasis received placebo or apremilast (10, 20, or 30 mg BID)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23663752", "endSection": "abstract"}, {"offsetInBeginSection": 1278, "offsetInEndSection": 1517, "text": "Although further longer-term and comparative efficacy and tolerability data would be beneficial, the current clinical data indicate that apremilast is an effective and well tolerated option for the management of psoriasis and PsA in adults", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26220911", "endSection": "abstract"}, {"offsetInBeginSection": 944, "offsetInEndSection": 1343, "text": "More recently, three larger double-blinded, and randomized multicenter studies demonstrate that apremilast is efficacious in the treatment of psoriasis and PsA, with significantly higher numbers of apremilast-treated patients achieving endpoints of a 75% reduction compared to baseline in Psoriasis Area and Severity Index (PASI-75) or American College of Rheumatology-20 scores, relative to placebo", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23569359", "endSection": "abstract"}, {"offsetInBeginSection": 1601, "offsetInEndSection": 1813, "text": "No deaths or opportunistic infections were reported.Apremilast 20 mg BID for 12 weeks was effective and well tolerated in subjects with moderate to severe plaque psoriasis.<CopyrightInformation>\u00a9 2012 The Authors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030767", "endSection": "abstract"}, {"offsetInBeginSection": 686, "offsetInEndSection": 934, "text": "In addition, GlaxoSmithKline plc is developing 256066, an inhaled formulation of a PDE4 inhibitor that has demonstrated efficacy in trials in asthma, and apremilast from Celgene Corp has been reported to be effective for the treatment of psoriasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20419594", "endSection": "abstract"}, {"offsetInBeginSection": 1278, "offsetInEndSection": 1518, "text": "Although further longer-term and comparative efficacy and tolerability data would be beneficial, the current clinical data indicate that apremilast is an effective and well tolerated option for the management of psoriasis and PsA in adults.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26220911", "endSection": "abstract"}, {"offsetInBeginSection": 1284, "offsetInEndSection": 1665, "text": "No new significant adverse events emerged with continued apremilast exposure versus the placebo-controlled period.Data were limited to 52 weeks and may not generalize to nonplaque psoriasis.Apremilast was effective in moderate to severe plaque psoriasis.<CopyrightInformation>Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089047", "endSection": "abstract"}, {"offsetInBeginSection": 1161, "offsetInEndSection": 1344, "text": "Several drug peculiarities, such as the low frequency of adverse events and the oral route of administration, make apremilast an innovative treatment for moderate-to-severe psoriasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26243735", "endSection": "abstract"}, {"offsetInBeginSection": 244, "offsetInEndSection": 673, "text": "Two new oral medications, apremilast and tofacitinib, have been developed for their immunomodulatory properties, and their potential efficacy in treating psoriasis is being evaluated.We reviewed phase III randomized, placebo-controlled clinical trial results for apremilast and tofacitinib for efficacy and safety in psoriasis.Psoriasis Area and Severity Index (PASI) 75 after 16 weeks for apremilast was between 28.8% and 33.1%.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722", "endSection": "abstract"}, {"offsetInBeginSection": 1476, "offsetInEndSection": 1541, "text": "Apremilast was effective in moderate to severe plaque psoriasis..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089047", "endSection": "abstract"}, {"offsetInBeginSection": 1009, "offsetInEndSection": 1109, "text": "Both new oral medications, apremilast and tofacitinib, appear to be effective in treating psoriasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722", "endSection": "abstract"}, {"offsetInBeginSection": 1516, "offsetInEndSection": 1612, "text": "Apremilast was effective in the treatment of moderate-to-severe plaque psoriasis over 52\u00a0weeks..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357944", "endSection": "abstract"}, {"offsetInBeginSection": 963, "offsetInEndSection": 1064, "text": "Apremilast is an effective and well-tolerated option in treating moderate-to-severe plaque psoriasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27376729", "endSection": "abstract"}, {"offsetInBeginSection": 1282, "offsetInEndSection": 1407, "text": "Apremilast has a novel mechanism of action and is safe and effective for the management of psoriasis and psoriatic arthritis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350", "endSection": "abstract"}, {"offsetInBeginSection": 1651, "offsetInEndSection": 1772, "text": "Apremilast 20 mg BID for 12 weeks was effective and well tolerated in subjects with moderate to severe plaque psoriasis..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030767", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 43, "text": "Apremilast for the treatment of psoriasis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26243735", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 309, "text": "Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27021239", "endSection": "title"}]}, {"body": "Is skin color affected by variations of the SLC24A5 gene?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25370040", "http://www.ncbi.nlm.nih.gov/pubmed/26918427"], "ideal_answer": ["Yes. The alleles of single-nucleotide polymorphisms rs1426654 and rs1834640 (SLC24A5) are associated with light skin pigmentation in Eurasian population."], "type": "yesno", "id": "58ef9ff170f9fc6f0f000002", "snippets": [{"offsetInBeginSection": 1494, "offsetInEndSection": 1635, "text": "the alleles of single-nucleotide polymorphisms rs1426654 and rs1834640 (SLC24A5) associated with light skin pigmentation in Eurasian populati", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25370040", "endSection": "abstract"}, {"offsetInBeginSection": 520, "offsetInEndSection": 816, "text": "Associations between five single nucleotide polymorphisms (SNPs) known to play a role in pigmentation (rs1426654-SLC24A5, rs1042602-TYR, rs16891982-SLC45A2, rs6058017-ASIP, and rs642742-KITLG) and MI measures were tested using standard one-way analysis of variance (ANOVA) within each population.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26918427", "endSection": "abstract"}]}, {"body": "How are Arboviruses transmitted?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26141429", "http://www.ncbi.nlm.nih.gov/pubmed/10488638", "http://www.ncbi.nlm.nih.gov/pubmed/21658241", "http://www.ncbi.nlm.nih.gov/pubmed/26925368", "http://www.ncbi.nlm.nih.gov/pubmed/16893487", "http://www.ncbi.nlm.nih.gov/pubmed/25597441", "http://www.ncbi.nlm.nih.gov/pubmed/27220616", "http://www.ncbi.nlm.nih.gov/pubmed/1973949", "http://www.ncbi.nlm.nih.gov/pubmed/26363996", "http://www.ncbi.nlm.nih.gov/pubmed/1297177", "http://www.ncbi.nlm.nih.gov/pubmed/27869394", "http://www.ncbi.nlm.nih.gov/pubmed/24941331", "http://www.ncbi.nlm.nih.gov/pubmed/26283013", "http://www.ncbi.nlm.nih.gov/pubmed/8158611", "http://www.ncbi.nlm.nih.gov/pubmed/25053841"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0003725", "o": "Arboviruses"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0003725", "o": "http://linkedlifedata.com/resource/umls/label/A18608581"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18608581", "o": "arboviruses"}], "ideal_answer": ["Arboviruses are transmitted by arthropods."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007303", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018562", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001103", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001102"], "type": "factoid", "id": "58f4b85f70f9fc6f0f000015", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Epizootic congenital abnormalities, encephalomyelitis and febrile illnesses in cattle caused by arthropod-borne viruses (arboviruses) are prevalent in Japan", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25597441", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 97, "text": " Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) transmitted by mosquitoes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26283013", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "Nine different arboviruses are known to be transmitted by, or associated with, mosquitoes in Europe, and several (West Nile, Sindbis and Tahyna viruses) are reported to cause outbreaks of human disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16893487", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Arthropod-borne viruses (arboviruses) are transmitted to humans primarily through the bites of infected mosquitoes and ticks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24941331", "endSection": "abstract"}, {"offsetInBeginSection": 114, "offsetInEndSection": 207, "text": "Arboviruses are transmitted among vertebrates by biting insects, chiefly mosquitoes and ticks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21658241", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Arboviruses are transmitted by distantly related arthropod vectors such as mosquitoes (class Insecta) and ticks (class Arachnida)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25053841", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "Mosquito-transmitted arthropod-borne viruses (arboviruses) such as dengue virus, chikungunya virus, and West Nile virus constitute a major public health burden and are increasing in severity and frequency worldwide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26363996", "endSection": "abstract"}, {"offsetInBeginSection": 263, "offsetInEndSection": 564, "text": "Malaria and Japanese encephalitis are the two most serious human diseases transmitted by riceland mosquitoes, but they have been incriminated as vectors of dozens of arboviruses and other parasites and pathogens including the causal agents of West Nile and Rift Valley Fevers and lymphatic filariasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1973949", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Arboviruses are transmitted by distantly related arthropod vectors such as mosquitoes (class Insecta) and ticks (class Arachnida).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25053841", "endSection": "abstract"}, {"offsetInBeginSection": 594, "offsetInEndSection": 786, "text": "Many of them are transmitted by insects (arboviruses, e.g. yellow fever virus) or by rodents (e.g. Hanta viruses), others by contact with patients and nosocomial infections (e.g. Ebola virus).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10488638", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Arboviruses - viruses transmitted by haematophagous arthropods - are responsible for febrile syndromes, which sometimes include haemorrhagic or neurological symptoms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26141429", "endSection": "abstract"}, {"offsetInBeginSection": 168, "offsetInEndSection": 289, "text": "Arboviruses are transmitted to vertebral hosts during blood feedings by mosquitoes, ticks, biting flies, mites, and nits.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27220616", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Arboviruses transmitted by mosquitoes are a major cause of human disease worldwide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26925368", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Diseases caused by arboviruses transmitted by Aedes aegypti, such as dengue, chikungunya and Zika, continue to rise in annual incidence and geographic expansion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27869394", "endSection": "abstract"}, {"offsetInBeginSection": 223, "offsetInEndSection": 414, "text": "Arboviruses transmitted by ticks must adapt to the peculiar physiological and behavioral characteristics of ticks, particularly with regard to blood feeding, bloodmeal digestion, and molting.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8158611", "endSection": "abstract"}, {"offsetInBeginSection": 330, "offsetInEndSection": 532, "text": "The last decade has seen significant changes in the epidemiology of arboviruses transmitted by mosquitoes of the genus Aedes, particularly in relation to the intercontinental spread of Aedes albopictus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26141429", "endSection": "abstract"}, {"offsetInBeginSection": 381, "offsetInEndSection": 687, "text": "This technique enables the detection of 70 of the 80 arboviruses transmitted by mosquitoes in Africa and very easily detects arbovirus associations by using either monospecific or monoclonal immune ascitic fluids (dengue-1-2-3-4 and yellow fever viruses) used in the indirect immunofluorescence technique..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1297177", "endSection": "abstract"}]}, {"body": "Which bacterium has the smallest genome in base pairs yet found?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23918810"], "ideal_answer": ["Our results reveal that Nasuia-ALF has the smallest bacterial genome yet sequenced (112 kb), and that the Sulcia-ALF genome (190 kb) is smaller than that of Sulcia in other insect lineages. Both regions exhibit a significant reduction in length and gene number in B. aphidicola BCc, as it could be expected since it possess the smallest bacterial genome. We sequenced genomes of the obligate symbionts, Sulcia muelleri and Nasuia deltocephalinicola, of the phloem-feeding pest insect, Macrosteles quadrilineatus (Auchenorrhyncha: Cicadellidae). ", "Nasuia deltocephalinicola, of the phloem-feeding pest insect, Macrosteles quadrilineatus has the smallest bacterial genome yet sequenced (112 kb).", "Our results reveal that Nasuia-ALF has the smallest bacterial genome yet sequenced (112 kb), and that the Sulcia-ALF genome (190 kb) is smaller than that of Sulcia in other insect lineages. We sequenced genomes of the obligate symbionts, Sulcia muelleri and Nasuia deltocephalinicola, of the phloem-feeding pest insect, Macrosteles quadrilineatus (Auchenorrhyncha: Cicadellidae).", "sequenced genomes of the obligate symbionts , sulcia muelleri and nasuia deltocephalinicola , of the phloem-feeding pest insect , macrosteles quadrilineatus (auchenorrhyncha: cicadellidae). . regions exhibit a significant reduction in length and gene number in b aphidicola bcc , as it could be expected since it possess the smallest bacterial genome. . results reveal that nasuia-alf has the smallest bacterial genome yet sequenced (112 kb) , and that the sulcia-alf genome (190 kb) is smaller than that of sulcia in other insect lineages. . ", "Our results reveal that Nasuia-ALF has the smallest bacterial genome yet sequenced (112 kb), and that the Sulcia-ALF genome (190 kb) is smaller than that of Sulcia in other insect lineages. Both regions exhibit a significant reduction in length and gene number in B. aphidicola BCc, as it could be expected since it possess the smallest bacterial genome.", "Our results reveal that Nasuia-ALF has the smallest bacterial genome yet sequenced (112 kb), and that the Sulcia-ALF genome (190 kb) is smaller than that of Sulcia in other insect lineages.", "our results reveal that nasuia-alf has the smallest bacterial genome yet sequenced (112 kb), and that the sulcia-alf genome (190 kb) is smaller than that of sulcia in other insect lineages."], "type": "factoid", "id": "58e9f0ba3e8b6dc87c00000e", "snippets": [{"offsetInBeginSection": 685, "offsetInEndSection": 874, "text": "Our results reveal that Nasuia-ALF has the smallest bacterial genome yet sequenced (112 kb), and that the Sulcia-ALF genome (190 kb) is smaller than that of Sulcia in other insect lineages.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918810", "endSection": "abstract"}, {"offsetInBeginSection": 495, "offsetInEndSection": 684, "text": "We sequenced genomes of the obligate symbionts, Sulcia muelleri and Nasuia deltocephalinicola, of the phloem-feeding pest insect, Macrosteles quadrilineatus (Auchenorrhyncha: Cicadellidae).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918810", "endSection": "abstract"}]}, {"body": "Which are the triad symptoms of pheochromocytoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23513638", "http://www.ncbi.nlm.nih.gov/pubmed/8302154", "http://www.ncbi.nlm.nih.gov/pubmed/12584992", "http://www.ncbi.nlm.nih.gov/pubmed/27034920", "http://www.ncbi.nlm.nih.gov/pubmed/24059371", "http://www.ncbi.nlm.nih.gov/pubmed/1988766", "http://www.ncbi.nlm.nih.gov/pubmed/19497985", "http://www.ncbi.nlm.nih.gov/pubmed/17102071", "http://www.ncbi.nlm.nih.gov/pubmed/12002199", "http://www.ncbi.nlm.nih.gov/pubmed/20169139", "http://www.ncbi.nlm.nih.gov/pubmed/12814824", "http://www.ncbi.nlm.nih.gov/pubmed/21125743", "http://www.ncbi.nlm.nih.gov/pubmed/24382904", "http://www.ncbi.nlm.nih.gov/pubmed/22980466", "http://www.ncbi.nlm.nih.gov/pubmed/18206604", "http://www.ncbi.nlm.nih.gov/pubmed/1867186", "http://www.ncbi.nlm.nih.gov/pubmed/22953071", "http://www.ncbi.nlm.nih.gov/pubmed/26998444", "http://www.ncbi.nlm.nih.gov/pubmed/21226896", "http://www.ncbi.nlm.nih.gov/pubmed/16789642"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0076994", "o": "http://linkedlifedata.com/resource/umls/label/A18632370"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18632370", "o": "triad"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0076994", "o": "triad"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0031511", "o": "Pheochromocytoma"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0031511", "o": "http://linkedlifedata.com/resource/umls/label/A0486392"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0486392", "o": "pheochromocytoma"}], "ideal_answer": ["The classic triad of symptoms are episodic headache, excessive sweating (diaphoresis) and palpitation."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010673"], "type": "list", "id": "58da5b588acda34529000015", "snippets": [{"offsetInBeginSection": 2236, "offsetInEndSection": 2403, "text": "Diaphoresis (LR+ 2.2, LR- 0.45), Palpitation (LR+ 1.9, LR- 0.52) and headache (LR+ 1.6, LR- 0.24) were significant symptoms in clinical diagnosis of pheochromocytoma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27034920", "endSection": "abstract"}, {"offsetInBeginSection": 723, "offsetInEndSection": 931, "text": "In the 52 cases analyzed, 40 of the patients had symptoms: 31 patients had hypertension; 10 had the triad of palpitations, diaphoresis, and headaches; and all had elevated urinary metanephrine concentrations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24059371", "endSection": "abstract"}, {"offsetInBeginSection": 192, "offsetInEndSection": 322, "text": " The symptoms and signs of pheochromocytoma include the classic triad of episodic headache, increased sweating, and palpitations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23513638", "endSection": "abstract"}, {"offsetInBeginSection": 411, "offsetInEndSection": 543, "text": "Among the presenting symptoms, episodes of palpitations, headaches, and profuse sweating are typical and constitute a classic triad.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22953071", "endSection": "abstract"}, {"offsetInBeginSection": 94, "offsetInEndSection": 183, "text": "The classic triad of symptoms are episodic headache, excessive sweating and palpitation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125743", "endSection": "abstract"}, {"offsetInBeginSection": 192, "offsetInEndSection": 320, "text": "The symptoms and signs of pheochromocytoma include the classic triad of episodic headache, increased sweating, and palpitations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23513638", "endSection": "abstract"}, {"offsetInBeginSection": 830, "offsetInEndSection": 1065, "text": "Combinations of symptoms can be of value: 2 or more symptoms from the triad of headache, palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non-pheochromocytoma patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1988766", "endSection": "abstract"}, {"offsetInBeginSection": 193, "offsetInEndSection": 320, "text": "The symptoms and signs of pheochromocytoma include the classic triad of episodic headache, increased sweating, and palpitations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23513638", "endSection": "abstract"}, {"offsetInBeginSection": 67, "offsetInEndSection": 411, "text": "Pheochromocytoma in pregnancy is rare, and if unrecognized, can cause serious perinatal morbidity and mortality.A patient with severe hypertension, postpartum pulmonary edema, and a recognized pheochromocytoma is described.Abdominal palpation after vaginal childbirth reproduced the diagnostic triad of hypertension, headaches, and palpitations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12002199", "endSection": "abstract"}, {"offsetInBeginSection": 836, "offsetInEndSection": 1070, "text": "Combinations of symptoms can be of value: 2 or more symptoms from the triad of headache, palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non-pheochromocytoma patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1988766", "endSection": "abstract"}, {"offsetInBeginSection": 289, "offsetInEndSection": 457, "text": "Although hypertension, headache, and diaphoresis are common symptoms in a dialyzed patient, pheochromocytoma has to be eliminated in the presence of this clinical triad", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1867186", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 538, "text": "Pheochromocytomas are catecholamine producing tumors that classically present with the triad of sweating, palpitations and headache.9-year-old boy whose only presenting complaints were polyuria and polydipsia for 2 years.Routine measurement of blood pressure detected mild hypertension, and subsequent investigations revealed bilateral pheochromocytoma.Surgical removal of the tumors resulted in complete resolution of polyuria and polydipsia.The case highlights the importance of measuring BP for children as part of physical examination", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24382904", "endSection": "abstract"}, {"offsetInBeginSection": 193, "offsetInEndSection": 321, "text": "The symptoms and signs of pheochromocytoma include the classic triad of episodic headache, increased sweating, and palpitations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23513638", "endSection": "abstract"}, {"offsetInBeginSection": 289, "offsetInEndSection": 458, "text": "Although hypertension, headache, and diaphoresis are common symptoms in a dialyzed patient, pheochromocytoma has to be eliminated in the presence of this clinical triad.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1867186", "endSection": "abstract"}, {"offsetInBeginSection": 836, "offsetInEndSection": 1071, "text": "Combinations of symptoms can be of value: 2 or more symptoms from the triad of headache, palpitations, and diaphoresis were present in the majority of pheochromocytoma patients, but in a smaller number of non-pheochromocytoma patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1988766", "endSection": "abstract"}, {"offsetInBeginSection": 680, "offsetInEndSection": 888, "text": "In the 52 cases analyzed, 40 of the patients had symptoms: 31 patients had hypertension; 10 had the triad of palpitations, diaphoresis, and headaches; and all had elevated urinary metanephrine concentrations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24059371", "endSection": "abstract"}, {"offsetInBeginSection": 94, "offsetInEndSection": 182, "text": "The classic triad of symptoms are episodic headache, excessive sweating and palpitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125743", "endSection": "abstract"}, {"offsetInBeginSection": 857, "offsetInEndSection": 1149, "text": "The clinical symptoms of these tumors vary from isolated hypertension or hypertension accompanied by paroxysmal episodes -including the classical triad of headache, palpitations and diaphoresis-to potentially serious manifestations such as acute pulmonary edema, arrhythmias and sudden death.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22980466", "endSection": "abstract"}, {"offsetInBeginSection": 706, "offsetInEndSection": 841, "text": "A very few symptoms were specific, like the triad \"headaches, sweating, palpitations\" whose onlyone third of patients was concerned by.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12814824", "endSection": "abstract"}, {"offsetInBeginSection": 63, "offsetInEndSection": 142, "text": "Classically, a triad of symptoms includes sweating, palpitations, and headache.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17102071", "endSection": "abstract"}, {"offsetInBeginSection": 307, "offsetInEndSection": 425, "text": "The triad of diaphoresis, tachycardia, and headache in hypertensive patients is highly suggestive of pheochromocytoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8302154", "endSection": "abstract"}, {"offsetInBeginSection": 708, "offsetInEndSection": 843, "text": "A very few symptoms were specific, like the triad \"headaches, sweating, palpitations\" whose onlyone third of patients was concerned by.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12814824", "endSection": "abstract"}, {"offsetInBeginSection": 3501, "offsetInEndSection": 3696, "text": "We noticed, like others, when the triad of headache, sweating and palpitations is accompanied by hypertension, the diagnosis of pheochromocytoma can be made with specify and sensitivity over 93%.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12584992", "endSection": "abstract"}]}, {"body": "List the types of the Cardiorenal syndrome (CRS) according to the five-part classification system.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21259069", "http://www.ncbi.nlm.nih.gov/pubmed/22493598", "http://www.ncbi.nlm.nih.gov/pubmed/19169027", "http://www.ncbi.nlm.nih.gov/pubmed/24656104", "http://www.ncbi.nlm.nih.gov/pubmed/25254030", "http://www.ncbi.nlm.nih.gov/pubmed/21234092", "http://www.ncbi.nlm.nih.gov/pubmed/26483371", "http://www.ncbi.nlm.nih.gov/pubmed/20037146", "http://www.ncbi.nlm.nih.gov/pubmed/19007588", "http://www.ncbi.nlm.nih.gov/pubmed/26411911", "http://www.ncbi.nlm.nih.gov/pubmed/21647318", "http://www.ncbi.nlm.nih.gov/pubmed/23265597", "http://www.ncbi.nlm.nih.gov/pubmed/22718456", "http://www.ncbi.nlm.nih.gov/pubmed/20653717", "http://www.ncbi.nlm.nih.gov/pubmed/20427991", "http://www.ncbi.nlm.nih.gov/pubmed/24402629", "http://www.ncbi.nlm.nih.gov/pubmed/20427956", "http://www.ncbi.nlm.nih.gov/pubmed/19554920", "http://www.ncbi.nlm.nih.gov/pubmed/23689657", "http://www.ncbi.nlm.nih.gov/pubmed/21921607", "http://www.ncbi.nlm.nih.gov/pubmed/27165977"], "ideal_answer": ["Cardiorenal syndromes (CRS) have been recently classified into five distinct entities, each with different major pathophysiologic mechanisms. \nCRS type 1: acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction. \nCRS type 2: chronic abnormalities in heart function (CHF-CHD) leading to kidney injury or dysfunction. \nCRS type 3: acute worsening of kidney function (AKI) leading to heart injury and/or dysfunction. \nCRS type 4: chronic kidney disease (CKD) leading to heart injury, disease and/or dysfunction. \nCRS type 5: systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002965", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "http://www.disease-ontology.org/api/metadata/DOID:225", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059347"], "type": "list", "id": "58da5dc58acda34529000016", "snippets": [{"offsetInBeginSection": 693, "offsetInEndSection": 1368, "text": "The general definition has been expanded into five subtypes: CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome) leading to kidney injury and/or dysfunction; CRS type 2 = chronic abnormalities in heart function (chronic heart failure-chronic heart disease) leading to kidney injury or dysfunction; CRS type 3 = acute worsening of kidney function (acute kidney injury) leading to heart injury and/or dysfunction; CRS type 4 = chronic kidney disease (chronic kidney disease) leading to heart injury, disease and/or dysfunction; and CRS type 5 = systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21921607", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 387, "text": "Cardiorenal syndromes (CRS) have been recently classified into five distinct entities, each with different major pathophysiologic mechanisms. CRS type 1 most commonly occurs in the setting of acutely decompensated heart failure where approximately 25% of patients develop a rise in serum creatinine and a reduction of urine output after the first several doses of intravenous diuretics. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23689657", "endSection": "abstract"}, {"offsetInBeginSection": 492, "offsetInEndSection": 604, "text": "CRS type 2 is the hastened progression of chronic kidney disease (CKD) in the setting of chronic heart failure. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23689657", "endSection": "abstract"}, {"offsetInBeginSection": 706, "offsetInEndSection": 829, "text": "CRS type 3 is acutely decompensated heart failure after acute kidney injury from inflammatory, toxic, or ischemic insults. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23689657", "endSection": "abstract"}, {"offsetInBeginSection": 954, "offsetInEndSection": 1326, "text": "CRS type 4 is manifested by the acceleration of the progression of chronic heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called 'CKD cardiomyopathy', is believed to be the predominant pathophysiologic mechanism. Type 5 CRS is simultaneous acute cardiac and renal injury in the setting of an overwhelming systemic insult such as sepsis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23689657", "endSection": "abstract"}, {"offsetInBeginSection": 392, "offsetInEndSection": 894, "text": "CRS type I: acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction. CRS type II: chronic abnormalities in heart function (CHF-CHD) leading to kidney injury or dysfunction. CRS type III: acute worsening of kidney function (AKI) leading to heart injury and/or dysfunction. CRS type IV: chronic kidney disease (CKD) leading to heart injury, disease and/or dysfunction. CRS type V: systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21259069", "endSection": "abstract"}, {"offsetInBeginSection": 703, "offsetInEndSection": 1302, "text": "Acute CRS (type 1): acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction. Chronic cardio-renal syndrome (type 2): chronic abnormalities in heart function (CHF-CHD) leading to kidney injury and/or dysfunction. Acute reno-cardiac syndrome (type 3): acute worsening of kidney function (AKI) leading to heart injury and/or dysfunction. Chronic reno-cardiac syndrome (type 4): chronic kidney disease leading to heart injury, disease, and/or dysfunction. Secondary CRS (type 5): systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20037146", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 802, "text": "For mentioning the interaction of cardiovascular and renal diseases the cardiorenal syndrome (CRS) term was introduced, with its classification on 5 types, according to the presence of acute/chronic heart failure and primary/secondary origination of heart and kidney injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26483371", "endSection": "abstract"}, {"offsetInBeginSection": 532, "offsetInEndSection": 805, "text": "For mentioning the interaction of cardiovascular and renal diseases the cardiorenal syndrome (CRS) term was introduced, with its classification on 5 types, according to the presence of acute/chronic heart failure and primary/secondary origination of heart and kidney injury", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26483371", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 391, "text": "The most recent classification recognizes five types of CRS: types I and II originate from heart failure (acute and chronic, respectively), type III and IV from kidney failure (again acute and chronic), while type V originates from a range of systemic diseases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22718456", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 392, "text": "The most recent classification recognizes five types of CRS: types I and II originate from heart failure (acute and chronic, respectively), type III and IV from kidney failure (again acute and chronic), while type V originates from a range of systemic diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22718456", "endSection": "abstract"}, {"offsetInBeginSection": 532, "offsetInEndSection": 806, "text": "For mentioning the interaction of cardiovascular and renal diseases the cardiorenal syndrome (CRS) term was introduced, with its classification on 5 types, according to the presence of acute/chronic heart failure and primary/secondary origination of heart and kidney injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26483371", "endSection": "abstract"}, {"offsetInBeginSection": 156, "offsetInEndSection": 425, "text": "Based on the pathophysiological primum movens, the actual classification recognizes five CRS types: in type I and II CRS, the initiating event is heart failure (acute or chronic), while it is kidney failure in type III and IV CRS; type V is linked to systemic diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22493598", "endSection": "abstract"}, {"offsetInBeginSection": 143, "offsetInEndSection": 425, "text": "An effective classification of CRS in 2008 essentially divides CRS in two main groups, cardiorenal and renocardiac CRS, based on primum movens of disease (cardiac or renal); both cardiorenal and renocardiac CRS are then divided into acute and chronic, according to onset of disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24656104", "endSection": "abstract"}, {"offsetInBeginSection": 581, "offsetInEndSection": 720, "text": "Of particular interest to the critical care specialist are CRS type 1 (acute cardiorenal syndrome) and type 3 (acute renocardiac syndrome).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23265597", "endSection": "abstract"}, {"offsetInBeginSection": 128, "offsetInEndSection": 403, "text": "At present, the classification of the syndrome includes five types of CRS: types I and II which are strictly related to initial heart failure (both acute and chronic), types III and IV which include initial kidney failure, and type V which includes several systemic diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24402629", "endSection": "abstract"}, {"offsetInBeginSection": 693, "offsetInEndSection": 1367, "text": "The general definition has been expanded into five subtypes: CRS type 1 = acute worsening of heart function (acute heart failure-acute coronary syndrome) leading to kidney injury and/or dysfunction; CRS type 2 = chronic abnormalities in heart function (chronic heart failure-chronic heart disease) leading to kidney injury or dysfunction; CRS type 3 = acute worsening of kidney function (acute kidney injury) leading to heart injury and/or dysfunction; CRS type 4 = chronic kidney disease (chronic kidney disease) leading to heart injury, disease and/or dysfunction; and CRS type 5 = systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21921607", "endSection": "abstract"}, {"offsetInBeginSection": 174, "offsetInEndSection": 788, "text": "The general definition has been expanded into five subtypes reflecting the primacy of organ dysfunction and the time-frame of the syndrome: CRS type 1 = acute worsening of heart function leading to kidney injury and/or dysfunction; CRS type 2 = chronic abnormalities in heart function leading to kidney injury or dysfunction; CRS type 3 = acute worsening of kidney function leading to heart injury and/or dysfunction; CRS type 4 = chronic kidney disease leading to heart injury, disease and/or dysfunction, and CRS type 5 = systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20427956", "endSection": "abstract"}]}, {"body": "What is a miR?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27814624", "http://www.ncbi.nlm.nih.gov/pubmed/27924483", "http://www.ncbi.nlm.nih.gov/pubmed/27734397", "http://www.ncbi.nlm.nih.gov/pubmed/27586262"], "ideal_answer": ["The discovery of microRNAs (miRNAs) has opened an entire new avenue for drug development. These short (15-22 nucleotides) noncoding RNAs, which function in RNA silencing and posttranscriptional regulation of gene expression, have been shown to critically affect numerous pathways in both development and disease progression."], "type": "factoid", "id": "58f0b1d670f9fc6f0f000007", "snippets": [{"offsetInBeginSection": 508, "offsetInEndSection": 634, "text": "As novel molecules, microRNAs (miRs) take part in regulating protein-coding gene expression at the post-transcriptional level,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814624", "endSection": "abstract"}, {"offsetInBeginSection": 399, "offsetInEndSection": 461, "text": "The discovery of microRNA (miRNA) regulation in tumorigenesis ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27586262", "endSection": "abstract"}, {"offsetInBeginSection": 467, "offsetInEndSection": 671, "text": "MiRs are small (~23 nt) noncoding RNAs that regulate gene expression by specifically interacting with the 3' untranslated region (UTR) of target gene mRNA to repress translation or enhance mRNA cleavage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27734397", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 325, "text": "The discovery of microRNAs (miRNAs) has opened an entire new avenue for drug development. These short (15-22 nucleotides) noncoding RNAs, which function in RNA silencing and posttranscriptional regulation of gene expression, have been shown to critically affect numerous pathways in both development and disease progression. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924483", "endSection": "abstract"}]}, {"body": "Do circRNAs remain untranslated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27040791", "http://www.ncbi.nlm.nih.gov/pubmed/25449546", "http://www.ncbi.nlm.nih.gov/pubmed/26204923", "http://www.ncbi.nlm.nih.gov/pubmed/26223268", "http://www.ncbi.nlm.nih.gov/pubmed/26861625", "http://www.ncbi.nlm.nih.gov/pubmed/26442181", "http://www.ncbi.nlm.nih.gov/pubmed/26177684", "http://www.ncbi.nlm.nih.gov/pubmed/26931159", "http://www.ncbi.nlm.nih.gov/pubmed/27606420", "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "http://www.ncbi.nlm.nih.gov/pubmed/26070627", "http://www.ncbi.nlm.nih.gov/pubmed/26472973", "http://www.ncbi.nlm.nih.gov/pubmed/27740630", "http://www.ncbi.nlm.nih.gov/pubmed/27677588"], "ideal_answer": ["The resulting circRNA can be translated to generate functional proteins.", "We demonstrate that the circular RNA circ-Foxo3 was highly expressed in non-cancer cells and were associated with cell cycle progression", "yes"], "type": "yesno", "id": "58dd054c8acda34529000024", "snippets": [{"offsetInBeginSection": 462, "offsetInEndSection": 598, "text": "We demonstrate that the circular RNA circ-Foxo3 was highly expressed in non-cancer cells and were associated with cell cycle progression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26861625", "endSection": "abstract"}, {"offsetInBeginSection": 661, "offsetInEndSection": 944, "text": "Ectopic expression of circ-Foxo3 repressed cell cycle progression by binding to the cell cycle proteins cyclin-dependent kinase 2 (also known as cell division protein kinase 2 or CDK2) and cyclin-dependent kinase inhibitor 1 (or p21), resulting in the formation of a ternary complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26861625", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by direct base pairing to target sites within untranslated regions of messenger RNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "endSection": "abstract"}, {"offsetInBeginSection": 1105, "offsetInEndSection": 1411, "text": "We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. This study serves as the first, to our knowledge, functional analysis of a naturally expressed circRNA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "endSection": "abstract"}, {"offsetInBeginSection": 663, "offsetInEndSection": 803, "text": "Numerous circRNAs were specifically expressed at different lactation stages, and only 1,314 circRNAs were detected at both lactation stages.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26472973", "endSection": "abstract"}, {"offsetInBeginSection": 1054, "offsetInEndSection": 1172, "text": "A significantly positive correlation was observed for the expression profiles of some circRNAs and their parent genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26204923", "endSection": "abstract"}, {"offsetInBeginSection": 792, "offsetInEndSection": 864, "text": "The resulting circRNA can be translated to generate functional proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25449546", "endSection": "abstract"}, {"offsetInBeginSection": 1176, "offsetInEndSection": 1381, "text": "In total, 80 circRNAs were identified from these 4 genes; circRNAs from CSN1S1 had very high abundance, and 3 of them accounted for 36% of all the circRNAs expressed in the mammary gland on lactation d 90.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27040791", "endSection": "abstract"}, {"offsetInBeginSection": 583, "offsetInEndSection": 825, "text": "A total of 4,804 and 4,048 circRNAs were identified in the cow mammary gland on d 90 and 250 postpartum, respectively, of which only 2,231 circRNAs were co-expressed at both lactation stages, suggesting high stage specificity in the circRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27040791", "endSection": "abstract"}, {"offsetInBeginSection": 386, "offsetInEndSection": 514, "text": "Arraystar circRNA Microarray Technology (KANGCHEN, Shanghai, China) was used to analyze the differential expression of circRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27606420", "endSection": "abstract"}, {"offsetInBeginSection": 143, "offsetInEndSection": 332, "text": "The aim of study was to identify circRNA expression in articular cartilage and to explore the function of chondrocyte extracellular matrix (ECM)-related circRNAs (circRNA-CER) in cartilage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26931159", "endSection": "abstract"}, {"offsetInBeginSection": 1766, "offsetInEndSection": 2077, "text": "We also validated that P. falciparum produces circRNAs, which is notable given the lack of RNA interference in the organism, and discovered that a highly expressed, five-exon antisense RNA is poised to regulate P. falciparum gametocyte development 1 (PfGDV1), a gene required for early sexual commitment events.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26070627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "CircRNA expression pattern and circRNA-miRNA-mRNA network in the pathogenesis of nonalcoholic steatohepatitis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27677588", "endSection": "title"}, {"offsetInBeginSection": 515, "offsetInEndSection": 587, "text": "CircRNAs are abundantly expressed also in the hematopoietic compartment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27740630", "endSection": "abstract"}]}, {"body": "What is the biological function of the SRY circular RNA (circRNA)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23446346", "http://www.ncbi.nlm.nih.gov/pubmed/25580223", "http://www.ncbi.nlm.nih.gov/pubmed/10027176", "http://www.ncbi.nlm.nih.gov/pubmed/7600978", "http://www.ncbi.nlm.nih.gov/pubmed/26649774", "http://www.ncbi.nlm.nih.gov/pubmed/7684656", "http://www.ncbi.nlm.nih.gov/pubmed/8718689"], "ideal_answer": ["We suggest that the circles arise from normal splicing processes as a consequence of the unusual genomic structure surrounding the Sry locus in the mouse. While this result does not prove a direct interaction between the two genes, it defines the critical period during which Sry must act to initiate Sertoli cell differentiation. We also attempted to make clear whether the equine SRY gene transcript is expressed in the adult testis, and whether the type of transcript is expressed as linear or circular RNA. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon Recent studies have mainly been devoted to the function of the circular RNA sponge for miR-7 (ciRS-7) and sex-determining region Y (SRY) by targeting microRNA-7 (miR-7) and microRNA-138 (miR-138), respectively However, the characteristics and the critical role of circRNA in co-/post-transcriptional regulation were not well recognized until the \"microRNA sponge\" function of circRNA is discovered", "Sox5, Sox6, and Sox13 constitute the group D of sex-determining region (Sry)-related transcription factors. We previously identified a highly expressed circular RNA (circRNA) in human and mouse brain. Here we show that this circRNA acts as a miR-7 sponge; we term this circular transcript ciRS-7 (circular RNA sponge for miR-7). ciRS-7 contains more than 70 selectively conserved miRNA target sites, and it is highly and widely associated with Argonaute (AGO) proteins in a miR-7-dependent manner. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. These observations support the hypothesis that the Q-rich domain may contribute to the biological function(s) of mouse Sry through a protein-protein interactive role(s).", "Recent studies have mainly been devoted to the function of the circular RNA sponge for miR-7 (ciRS-7) and sex-determining region Y (SRY) by targeting microRNA-7 (miR-7) and microRNA-138 (miR-138), respectively However, the characteristics and the critical role of circRNA in co-/post-transcriptional regulation were not well recognized until the \"microRNA sponge\" function of circRNA is discovered", "We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon Recent studies have mainly been devoted to the function of the circular RNA sponge for miR-7 (ciRS-7) and sex-determining region Y (SRY) by targeting microRNA-7 (miR-7) and microRNA-138 (miR-138), respectively We also attempted to make clear whether the equine SRY gene transcript is expressed in the adult testis, and whether the type of transcript is expressed as linear or circular RNA. However, the characteristics and the critical role of circRNA in co-/post-transcriptional regulation were not well recognized until the \"microRNA sponge\" function of circRNA is discovered We suggest that the circles arise from normal splicing processes as a consequence of the unusual genomic structure surrounding the Sry locus in the mouse. While this result does not prove a direct interaction between the two genes, it defines the critical period during which Sry must act to initiate Sertoli cell differentiation.", "The testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon."], "type": "summary", "id": "58dd0c608acda34529000026", "snippets": [{"offsetInBeginSection": 812, "offsetInEndSection": 966, "text": "We suggest that the circles arise from normal splicing processes as a consequence of the unusual genomic structure surrounding the Sry locus in the mouse.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7684656", "endSection": "abstract"}, {"offsetInBeginSection": 1556, "offsetInEndSection": 1731, "text": "While this result does not prove a direct interaction between the two genes, it defines the critical period during which Sry must act to initiate Sertoli cell differentiation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7600978", "endSection": "abstract"}, {"offsetInBeginSection": 217, "offsetInEndSection": 396, "text": "We also attempted to make clear whether the equine SRY gene transcript is expressed in the adult testis, and whether the type of transcript is expressed as linear or circular RNA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10027176", "endSection": "abstract"}, {"offsetInBeginSection": 1105, "offsetInEndSection": 1306, "text": "We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "endSection": "abstract"}, {"offsetInBeginSection": 305, "offsetInEndSection": 514, "text": "Recent studies have mainly been devoted to the function of the circular RNA sponge for miR-7 (ciRS-7) and sex-determining region Y (SRY) by targeting microRNA-7 (miR-7) and microRNA-138 (miR-138), respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26649774", "endSection": "abstract"}, {"offsetInBeginSection": 116, "offsetInEndSection": 303, "text": "However, the characteristics and the critical role of circRNA in co-/post-transcriptional regulation were not well recognized until the \"microRNA sponge\" function of circRNA is discovered", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26649774", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 315, "text": "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25580223", "endSection": "abstract"}, {"offsetInBeginSection": 451, "offsetInEndSection": 746, "text": "Here we show that this circRNA acts as a miR-7 sponge; we term this circular transcript ciRS-7 (circular RNA sponge for miR-7). ciRS-7 contains more than 70 selectively conserved miRNA target sites, and it is highly and widely associated with Argonaute (AGO) proteins in a miR-7-dependent manner", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "endSection": "abstract"}, {"offsetInBeginSection": 451, "offsetInEndSection": 747, "text": "Here we show that this circRNA acts as a miR-7 sponge; we term this circular transcript ciRS-7 (circular RNA sponge for miR-7). ciRS-7 contains more than 70 selectively conserved miRNA target sites, and it is highly and widely associated with Argonaute (AGO) proteins in a miR-7-dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "endSection": "abstract"}, {"offsetInBeginSection": 1105, "offsetInEndSection": 1307, "text": "We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "endSection": "abstract"}, {"offsetInBeginSection": 305, "offsetInEndSection": 515, "text": "Recent studies have mainly been devoted to the function of the circular RNA sponge for miR-7 (ciRS-7) and sex-determining region Y (SRY) by targeting microRNA-7 (miR-7) and microRNA-138 (miR-138), respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26649774", "endSection": "abstract"}, {"offsetInBeginSection": 451, "offsetInEndSection": 578, "text": "Here we show that this circRNA acts as a miR-7 sponge; we term this circular transcript ciRS-7 (circular RNA sponge for miR-7).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446346", "endSection": "abstract"}]}, {"body": "What is Uhl's anomaly?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26054127", "http://www.ncbi.nlm.nih.gov/pubmed/11227837", "http://www.ncbi.nlm.nih.gov/pubmed/26929879", "http://www.ncbi.nlm.nih.gov/pubmed/24784726", "http://www.ncbi.nlm.nih.gov/pubmed/10611917"], "ideal_answer": ["uhl's anomaly is an extremely rare cardiac defect characterized by absence of the myocardium of the right ventricle.", "Uhl's anomaly is an evolutive disease leading to terminal right ventricular failure. Uhl's anomaly is an extremely rare cardiac defect characterized by absence of the myocardium of the right ventricle.", "Uhl's anomaly is an extremely rare cardiac defect characterized by absence of the myocardium of the right ventricle. Uhl's anomaly is an evolutive disease leading to terminal right ventricular failure. ", "Uhl's anomaly is an extremely rare cardiac defect characterized by absence of the myocardium of the right ventricle. Uhl's anomaly is an evolutive disease leading to terminal right ventricular failure", "Uhl's anomaly is an extremely rare cardiac defect characterized by absence of the myocardium of the right ventricle."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006330"], "type": "summary", "id": "58f4c22170f9fc6f0f000018", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 128, "text": "Uhl's anomaly is an extremely rare cardiac defect characterized by absence of the myocardium of the right ventricle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26054127", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Uhl's anomaly is an evolutive disease leading to terminal right ventricular failure", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24784726", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Uhl anomaly is a rare form of congenital hypoplasia of the right ventricular myocardium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26929879", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Uhl's anomaly was first reported by Uhl in 1952 and is characterized by congenital partial or complete absence of right ventricular myocardium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11227837", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Uhls anomaly was first reported by Uhl in 1952 and is characterized by congenital partial or complete absence of right ventricular myocardium", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11227837", "endSection": "abstract"}]}, {"body": "Is autophagy the process where bacteria ingest viral particles?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24906121", "http://www.ncbi.nlm.nih.gov/pubmed/23121192", "http://www.ncbi.nlm.nih.gov/pubmed/27814601", "http://www.ncbi.nlm.nih.gov/pubmed/21946213", "http://www.ncbi.nlm.nih.gov/pubmed/27812870", "http://www.ncbi.nlm.nih.gov/pubmed/21175768", "http://www.ncbi.nlm.nih.gov/pubmed/27027951", "http://www.ncbi.nlm.nih.gov/pubmed/24384599", "http://www.ncbi.nlm.nih.gov/pubmed/24198400"], "ideal_answer": ["Autophagy, a cellular degradation process"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001343"], "type": "yesno", "id": "58dd2cb08acda34529000029", "snippets": [{"offsetInBeginSection": 255, "offsetInEndSection": 296, "text": "Autophagy, a cellular degradation process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27812870", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Autophagy, a form of lysosomal degradation capable of eliminating dysfunctional proteins and organelles, is a cellular process associated with homeostasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814601", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 362, "text": "Autophagy, a programmed process in which cell contents are delivered to lysosomes for degradation, appears to have both tumor-suppressive and tumor-promoting functions; both stimulation and inhibition of autophagy have been reported to induce cancer cell death, and particular genes and proteins have been associated both positively and negatively with autophagy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24906121", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Autophagy is a lysosome-mediated catabolic process involving the degradation of intracellular contents (e.g., proteins and organelles) as well as invading microbes (e.g., parasites, bacteria and viruses).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23388380", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Autophagy is a cellular process that targets proteins, lipids and organelles to lysosomes for degradation, but it has also been shown to combat infection with various pathogenic bacteria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24384599", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Autophagy, an intracellular degradation process highly conserved from yeast to humans, is viewed as an important defence mechanism to clear intracellular bacteria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121192", "endSection": "abstract"}, {"offsetInBeginSection": 89, "offsetInEndSection": 274, "text": "Autophagy has intracellular anti-viral and anti-bacterial functions, and plays a role in the initiation of innate and adaptive immune system responses to viral and bacterial infections.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21175768", "endSection": "abstract"}, {"offsetInBeginSection": 1562, "offsetInEndSection": 1756, "text": "documented abundant autophagy within VZV-infected cells throughout the infectious cycle but also demonstrated that VZV-induced autophagy facilitated VZV glycoprotein biosynthesis and processing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198400", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Autophagy is a highly conserved process by which cells can recycle organelles and proteins by degrading them in the lysosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27027951", "endSection": "abstract"}]}, {"body": "Can aspirin be used in cancer prevention?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26926089", "http://www.ncbi.nlm.nih.gov/pubmed/27817122", "http://www.ncbi.nlm.nih.gov/pubmed/27543497", "http://www.ncbi.nlm.nih.gov/pubmed/26510933", "http://www.ncbi.nlm.nih.gov/pubmed/26712086", "http://www.ncbi.nlm.nih.gov/pubmed/27289249", "http://www.ncbi.nlm.nih.gov/pubmed/26433247", "http://www.ncbi.nlm.nih.gov/pubmed/27268656", "http://www.ncbi.nlm.nih.gov/pubmed/26940135"], "ideal_answer": ["Long-term aspirin use was associated with a modest but significantly reduced risk for overall cancer, especially gastrointestinal tract tumors. Regular aspirin use may prevent a substantial proportion of colorectal cancers and complement the benefits of screening."], "type": "summary", "id": "58efa66070f9fc6f0f000005", "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 165, "text": " Evidence for an association between aspirin or other nonsteroidal antiinflammatory drug (NSAID) use and basal cell carcinoma (BCC) has been inconsistent.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433247", "endSection": "abstract"}, {"offsetInBeginSection": 1374, "offsetInEndSection": 1730, "text": " We report for the first time, in a typical risk US clinical population, a lack of protective association of aspirin for polyps among active smokers. Future prospective studies are recommended to confirm this mitigating effect in order to improve the precision of the growing evidence base about the chemopreventive benefit of aspirin in colorectal cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26510933", "endSection": "abstract"}, {"offsetInBeginSection": 761, "offsetInEndSection": 1047, "text": "The most serious side effect of prolonged aspirin treatment is haemorrhage, especially from the GI tract. This is likely to be less of a problem with chemoprevention at lower doses. One also needs to consider the impact if aspirin resistance, an increasingly recognised clinical entity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27289249", "endSection": "abstract"}, {"offsetInBeginSection": 1208, "offsetInEndSection": 1337, "text": "Overall, our results do support the hypothesis that use of NSAIDs or statins may reduce the odds of developing pancreatic cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27817122", "endSection": "abstract"}, {"offsetInBeginSection": 973, "offsetInEndSection": 1073, "text": "Understanding is growing of the possible mechanisms by which aspirin exerts its anticancer effects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27543497", "endSection": "abstract"}, {"offsetInBeginSection": 2425, "offsetInEndSection": 2689, "text": "Long-term aspirin use was associated with a modest but significantly reduced risk for overall cancer, especially gastrointestinal tract tumors. Regular aspirin use may prevent a substantial proportion of colorectal cancers and complement the benefits of screening.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940135", "endSection": "abstract"}]}, {"body": "Which are the components of the pre-replication complex (pre-RC) in eukaryotes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22421151", "http://www.ncbi.nlm.nih.gov/pubmed/24699916", "http://www.ncbi.nlm.nih.gov/pubmed/15065651", "http://www.ncbi.nlm.nih.gov/pubmed/22412905", "http://www.ncbi.nlm.nih.gov/pubmed/22645314", "http://www.ncbi.nlm.nih.gov/pubmed/16257456", "http://www.ncbi.nlm.nih.gov/pubmed/20705581", "http://www.ncbi.nlm.nih.gov/pubmed/22134836", "http://www.ncbi.nlm.nih.gov/pubmed/23720738", "http://www.ncbi.nlm.nih.gov/pubmed/20097898", "http://www.ncbi.nlm.nih.gov/pubmed/19910535", "http://www.ncbi.nlm.nih.gov/pubmed/22801552", "http://www.ncbi.nlm.nih.gov/pubmed/25374915", "http://www.ncbi.nlm.nih.gov/pubmed/15201046", "http://www.ncbi.nlm.nih.gov/pubmed/23093411", "http://www.ncbi.nlm.nih.gov/pubmed/19531585", "http://www.ncbi.nlm.nih.gov/pubmed/16322558", "http://www.ncbi.nlm.nih.gov/pubmed/19285403", "http://www.ncbi.nlm.nih.gov/pubmed/22250202", "http://www.ncbi.nlm.nih.gov/pubmed/9159120"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0684063", "o": "Eukaryota"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0684063", "o": "http://linkedlifedata.com/resource/umls/label/A18622894"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18622894", "o": "eukaryota"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0449432", "o": "http://linkedlifedata.com/resource/umls/label/A18657821"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18657821", "o": "components"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0684063", "o": "http://linkedlifedata.com/resource/umls/label/A18585798"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18585798", "o": "eukaryotes"}], "ideal_answer": ["The components of the pre-replication complex (pre-RC) in eukaryotes are:\n1) Cdc6/Cdc18, \n2) MCM, \n3) ORC1-6,\n4) Cdt1 and\n5) Sap1/Gi."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0036387", "http://amigo.geneontology.org/amigo/term/GO:0036388", "http://amigo.geneontology.org/amigo/term/GO:1902299", "http://amigo.geneontology.org/amigo/term/GO:1902985", "http://amigo.geneontology.org/amigo/term/GO:0006267", "http://amigo.geneontology.org/amigo/term/GO:0005656"], "type": "list", "id": "58dcecf58acda34529000023", "snippets": [{"offsetInBeginSection": 496, "offsetInEndSection": 915, "text": " The first step of replication initiation is the assembly of pre-replication complex (pre-RC). Since 1973, four proteins, Cdc6/Cdc18, MCM, ORC and Cdt1, have been extensively studied and proved to be pre-RC components. Recently, a novel pre-RC component called Sap1/Girdin was identified. Sap1/Girdin is required for loading Cdc18/Cdc6 to origins for pre-RC assembly in the fission yeast and human cells, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24699916", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 390, "text": "In eukaryotes, the pre-replication complex is composed of the Origin Recognition Complex (ORC), Cdc6 and the MCM replicative helicase in conjunction with Cdt1. Eukaryotic ORC is considered to be composed of six subunits, named Orc1-6, and monomeric Cdc6 is closely related in sequence to Orc1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22412905", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 676, "text": "The sequencing of the Plasmodium genome has also revealed the apparent absence of many key components (e.g. Cdt1, DDK and Cdc45) of the eukaryotic cell cycle machinery that are responsible for the formation of the pre-replication complex (pre-RC). We have characterized the Plasmodium falciparum minichromosome maintenance complex (MCM) that plays a key role in the transition of pre-RC to the RC. Similar to other eukaryotes, the Plasmodium genome encodes six MCM subunits. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16257456", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "During pre-replication complex (pre-RC) formation, origin recognition complex (ORC), Cdc6, and Cdt1 cooperatively load the 6-subunit mini chromosome maintenance (MCM2-7) complex onto DNA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19910535", "endSection": "abstract"}, {"offsetInBeginSection": 99, "offsetInEndSection": 218, "text": "ORC1 is an essential component of the pre-replicative complex (pre-RC) that licenses eukaryote DNA replication origins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801552", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "In higher eukaryotes, the pre-replication complex (pre-RC) component Cdt1 is the major regulator in licensing control for DNA replication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19531585", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 447, "text": "The sequencing of the Plasmodium genome has also revealed the apparent absence of many key components (e.g. Cdt1, DDK and Cdc45) of the eukaryotic cell cycle machinery that are responsible for the formation of the pre-replication complex (pre-RC)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16257456", "endSection": "abstract"}, {"offsetInBeginSection": 702, "offsetInEndSection": 811, "text": "We examined the mRNA expression of the components of pre-replication complex (Pre-RC), CDC6, CDT1, and MCM2-7", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25374915", "endSection": "abstract"}, {"offsetInBeginSection": 107, "offsetInEndSection": 301, "text": "Replication initiation is a multi-step process involving many factors including ORC, Cdt1p, Mcm2-7p and other proteins that bind to replication origins to form a pre-replicative complex (pre-RC)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22250202", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 448, "text": "The sequencing of the Plasmodium genome has also revealed the apparent absence of many key components (e.g. Cdt1, DDK and Cdc45) of the eukaryotic cell cycle machinery that are responsible for the formation of the pre-replication complex (pre-RC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16257456", "endSection": "abstract"}, {"offsetInBeginSection": 271, "offsetInEndSection": 519, "text": "Different components of the ORC complex and Cdc6 stimulated prereplicative complex (pre-RC) formation and replication initiation when fused to the GAL4 DNA-binding domain and recruited to plasmid DNA containing a tandem array of GAL4-binding sites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16322558", "endSection": "abstract"}, {"offsetInBeginSection": 309, "offsetInEndSection": 448, "text": "Cdt1, DDK and Cdc45) of the eukaryotic cell cycle machinery that are responsible for the formation of the pre-replication complex (pre-RC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16257456", "endSection": "abstract"}, {"offsetInBeginSection": 715, "offsetInEndSection": 784, "text": "Recently, a novel pre-RC component called Sap1/Girdin was identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24699916", "endSection": "abstract"}, {"offsetInBeginSection": 155, "offsetInEndSection": 322, "text": "MCM2-7 is a key component of the prereplicative complex (pre-RC), which is loaded onto chromatin by the concerted action of origin recognition complex, Cdc6, and Cdt1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23093411", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "The pre-replicative complex (pre-RC) is formed at all potential origins of replication through the action of the origin recognition complex (ORC), Cdc6, Cdt1, and the Mcm2-7 complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20097898", "endSection": "abstract"}]}, {"body": "What is the inheritance of hypophosphatemic rickets?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17635744", "http://www.ncbi.nlm.nih.gov/pubmed/11200035", "http://www.ncbi.nlm.nih.gov/pubmed/19258716", "http://www.ncbi.nlm.nih.gov/pubmed/20213538", "http://www.ncbi.nlm.nih.gov/pubmed/19007919", "http://www.ncbi.nlm.nih.gov/pubmed/22806288", "http://www.ncbi.nlm.nih.gov/pubmed/23108197", "http://www.ncbi.nlm.nih.gov/pubmed/10720930", "http://www.ncbi.nlm.nih.gov/pubmed/20578943", "http://www.ncbi.nlm.nih.gov/pubmed/2832821", "http://www.ncbi.nlm.nih.gov/pubmed/21747952", "http://www.ncbi.nlm.nih.gov/pubmed/16358214", "http://www.ncbi.nlm.nih.gov/pubmed/443639", "http://www.ncbi.nlm.nih.gov/pubmed/9024275", "http://www.ncbi.nlm.nih.gov/pubmed/16303832"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0733682", "o": "HYP"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0733682", "o": "http://linkedlifedata.com/resource/umls/label/A18679376"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18679376", "o": "hypophosphatemic rickets"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0733682", "o": "http://linkedlifedata.com/resource/umls/label/A18586469"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18586469", "o": "vitamin d resistant rickets"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0020631", "o": "http://linkedlifedata.com/resource/umls/label/A1192422"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A1192422", "o": "familial hypophosphatemia"}], "ideal_answer": ["Hypophosphatemic rickets are transmitted with:\n1) autosomal recessive\n2) autosomal dominant\n3) X-linked recessive and\n4) X-linked dominant inheritance."], "type": "list", "id": "58b6d6f322d300530900000f", "snippets": [{"offsetInBeginSection": 545, "offsetInEndSection": 688, "text": "Among 35 candidate genes in this region, the dentin matrix protein 1 gene (DMP1) was sequenced to reveal a nonsense mutation 250C/T on exon 6. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21747952", "endSection": "abstract"}, {"offsetInBeginSection": 1135, "offsetInEndSection": 1270, "text": "Previous research has shown that mutations in the DMP1 gene are responsible for autosomal recessive hypophosphatemic rickets in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21747952", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "A novel nonsense mutation in the DMP1 gene in a Japanese family with autosomal recessive hypophosphatemic rickets.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20213538", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Autosomal recessive hypophosphatemic rickets (ARHR) is an extremely rare disorder of autosomal recessive inheritance, characterized by hypophosphatemia resulting from renal phosphate wasting. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20213538", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Prenatal diagnosis for a novel splice mutation of PHEX gene in a large Han Chinese family affected with X-linked hypophosphatemic rickets.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20578943", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 214, "text": "X-linked hypophosphatemia (XLH) is the most common form of heritable rickets characterized by X-linked dominant inheritance, renal phosphate wasting, hypophosphatemia, and defective bone mineralization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20578943", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007919", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 299, "text": "We previously demonstrated that the mutations Met1Val (M1V) and the deletion of nucleotides 1484-1490 (1484-1490del) in Dentin matrix protein-1 (DMP1) cause the novel disorder autosomal recessive hypophosphatemic rickets (ARHR), which is associated with elevated fibroblast growth factor-23 (FGF23).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007919", "endSection": "abstract"}, {"offsetInBeginSection": 412, "offsetInEndSection": 517, "text": "First, we examined a kindred with a severe hypophosphatemic rickets phenotype and recessive inheritance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007919", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Discordance for X-linked hypophosphataemic rickets in identical twin girls.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19258716", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 125, "text": "We report monozygotic twin girls with a family history consistent with X-linked hypophosphataemic rickets (XLH). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19258716", "endSection": "abstract"}, {"offsetInBeginSection": 428, "offsetInEndSection": 539, "text": "Microsatellite analysis was performed to confirm monozygosity and bi-parental inheritance of the X chromosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19258716", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 414, "text": "Hypophosphatemia due to isolated renal phosphate wasting is a genetically heterogeneous disease. Two new genes linked to two different forms of hereditary hypophosphatemias have recently been described. Autosomal recessive form of hypophosphatemic rickets was mapped to chromosome 4q21 and identified homozygous mutations in dentin matrix protein 1 (DMP1) gene, which encodes a non-collagenous bone matrix protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17635744", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Somatic and germline mosaicism for a mutation of the PHEX gene can lead to genetic transmission of X-linked hypophosphatemic rickets that mimics an autosomal dominant trait.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16303832", "endSection": "title"}, {"offsetInBeginSection": 9, "offsetInEndSection": 331, "text": "Familial hypophosphatemic rickets is usually transmitted as an X-linked dominant disorder (XLH), although autosomal dominant forms have also been observed. Genetic studies of these disorders have identified mutations in PHEX and FGF23 as the causes of X-linked dominant disorder and autosomal dominant forms, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16303832", "endSection": "abstract"}, {"offsetInBeginSection": 823, "offsetInEndSection": 1051, "text": "Direct nucleotide sequencing of FGF23 and PHEX revealed that the elder daughter was heterozygous for an R567X mutation in PHEX, rather than FGF23, suggesting that the genetic transmission occurred as an X-linked dominant trait. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16303832", "endSection": "abstract"}, {"offsetInBeginSection": 1568, "offsetInEndSection": 1682, "text": "Somatic and germline mosaicism for an X-linked dominant mutation in PHEX may mimic autosomal dominant inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16303832", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "We report two cases of x-linked dominant hypophosphatemic rickets involving a man and his daughter. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11200035", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "X-linked hypophosphatemic rickets--a report of 2 cases and review of literature.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11200035", "endSection": "title"}, {"offsetInBeginSection": 207, "offsetInEndSection": 288, "text": "The study of this family tree strongly suggests an x-linked dominant inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11200035", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9024275", "endSection": "title"}, {"offsetInBeginSection": 304, "offsetInEndSection": 452, "text": "We performed clinical and biochemical evaluations of individuals from a large kindred with autosomal dominant hypophosphatemic rickets/osteomalacia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9024275", "endSection": "abstract"}, {"offsetInBeginSection": 1473, "offsetInEndSection": 1608, "text": " In conclusion, autosomal dominant hypophosphatemic rickets/osteomalacia is an inherited disorder of isolated renal phosphate wasting. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9024275", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "[Scriver type autosomal hypophosphatemic rachitis: a family case].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2832821", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "A familial observation of hypophosphatemic rickets with unusual inheritance and evolution, different from that of X linked hypophosphatemia, is reported. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2832821", "endSection": "abstract"}, {"offsetInBeginSection": 591, "offsetInEndSection": 702, "text": "This observation is quite similar to the 'autosomal hypophosphatemic bone disease' described by Scriver et al. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2832821", "endSection": "abstract"}, {"offsetInBeginSection": 1119, "offsetInEndSection": 1236, "text": "The HHRH is transmitted by autosomal recessive inheritance and is an extremely rare form of hypophosphatemic rickets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22806288", "endSection": "abstract"}, {"offsetInBeginSection": 410, "offsetInEndSection": 514, "text": "First, we examined a kindred with a severe hypophosphatemic rickets phenotype and recessive inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007919", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "A familial observation of hypophosphatemic rickets with unusual inheritance and evolution, different from that of X linked hypophosphatemia, is reported.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2832821", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Autosomal recessive hypophosphatemic rickets (ARHR) is an extremely rare disorder of autosomal recessive inheritance, characterized by hypophosphatemia resulting from renal phosphate wasting.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20213538", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is a rare disorder of autosomal recessive inheritance that was first described in a large consanguineous Bedouin kindred.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16358214", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Autosomal recessive hypophosphatemic rickets (ARHR) is an extremely rare disorder of autosomal recessive inheritance, characterized by hypophosphatemia resulting from renal phosphate wasting", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20213538", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "A familial observation of hypophosphatemic rickets with unusual inheritance and evolution, different from that of X linked hypophosphatemia, is reported", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2832821", "endSection": "abstract"}, {"offsetInBeginSection": 1134, "offsetInEndSection": 1250, "text": "The HHRH is transmitted by autosomal recessive inheritance and is an extremely rare form of hypophosphatemic rickets", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22806288", "endSection": "abstract"}, {"offsetInBeginSection": 412, "offsetInEndSection": 515, "text": "First, we examined a kindred with a severe hypophosphatemic rickets phenotype and recessive inheritance", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007919", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is a rare disorder of autosomal recessive inheritance that was first described in a large consanguineous Bedouin kindred", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16358214", "endSection": "abstract"}, {"offsetInBeginSection": 156, "offsetInEndSection": 636, "text": "Genetic studies of these disorders have identified mutations in PHEX and FGF23 as the causes of X-linked dominant disorder and autosomal dominant forms, respectively.The objective of the study was to describe the molecular genetic findings in a family affected by hypophosphatemic rickets with presumed autosomal dominant inheritance.We studied a family in which the father and the elder of his two daughters, but not the second daughter, were affected by hypophosphatemic rickets", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16303832", "endSection": "abstract"}, {"offsetInBeginSection": 715, "offsetInEndSection": 830, "text": "Hereditary hypophosphatemic rickets with hypercalciuria is another rare disorder of autosomal recessive inheritance", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17635744", "endSection": "abstract"}, {"offsetInBeginSection": 412, "offsetInEndSection": 516, "text": "First, we examined a kindred with a severe hypophosphatemic rickets phenotype and recessive inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007919", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 414, "text": "Autosomal recessive form of hypophosphatemic rickets was mapped to chromosome 4q21 and identified homozygous mutations in dentin matrix protein 1 (DMP1) gene, which encodes a non-collagenous bone matrix protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17635744", "endSection": "abstract"}, {"offsetInBeginSection": 1725, "offsetInEndSection": 2032, "text": "In addition, such CLCN5 mutations that would result in a functional loss have also been demonstrated in Japanese children with idiopathic low molecular weight proteinuria, hypercalciuria and nephrocalcinosis, and an Italian kindred with X-linked recessive hypophosphatemic rickets (XLRH) and hypercalciuria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10720930", "endSection": "abstract"}, {"offsetInBeginSection": 272, "offsetInEndSection": 641, "text": "Inactivating mutations of phosphate-regulating gene with homologies to endopeptidases on the X chromosome, dentin matrix acidic phosphoprotein 1, and ectonucleotide pyrophosphatase/phosphodiesterase 1 are associated with X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets 1, and autosomal recessive hypophosphatemic rickets 2, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23108197", "endSection": "abstract"}, {"offsetInBeginSection": 323, "offsetInEndSection": 491, "text": "The objective of the study was to describe the molecular genetic findings in a family affected by hypophosphatemic rickets with presumed autosomal dominant inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16303832", "endSection": "abstract"}, {"offsetInBeginSection": 1120, "offsetInEndSection": 1237, "text": "The HHRH is transmitted by autosomal recessive inheritance and is an extremely rare form of hypophosphatemic rickets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22806288", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "X-linked familial hypophosphatemic rickets (X.L.F.H.R.) is one of the D resistant rickets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/443639", "endSection": "abstract"}, {"offsetInBeginSection": 738, "offsetInEndSection": 1039, "text": "Iron deficiency may affect autosomal dominant hypophosphatemic rickets phenotype by regulating FGF23 production.Current treatment with activated vitamin D metabolites and oral inorganic phosphate salts may partially correct skeletal lesions and linear growth in patients with hypophosphatemic rickets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23108197", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "[X-linked familial hypophosphatemic rickets report of six cases (author's transl)].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/443639", "endSection": "title"}]}, {"body": "Which mushroom is poisonous, Amanita phalloides or Agaricus Bisporus", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27596390", "http://www.ncbi.nlm.nih.gov/pubmed/26304449", "http://www.ncbi.nlm.nih.gov/pubmed/27389675"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0032346", "o": "http://linkedlifedata.com/resource/umls/label/A18612096"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18612096", "o": "poisons"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0032346", "o": "poison"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0001774", "o": "mushroom"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0001774", "o": "http://linkedlifedata.com/resource/umls/label/A1308163"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A1308163", "o": "mushroom"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0678206", "o": "mushroom"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0997580", "o": "Agaricus bisporus"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0997580", "o": "http://linkedlifedata.com/resource/umls/label/A18588497"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18588497", "o": "agaricus bisporus"}], "ideal_answer": ["The well-known cultivated species Agaricus bisporus is safe to eat while Amanita Phalloides is poisonous."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000363", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000364", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010947", "http://www.uniprot.org/uniprot/ABL_AGABI", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000545", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009145"], "type": "factoid", "id": "58f4b1a170f9fc6f0f000010", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 444, "text": "Seventeen edible mushrooms commercially available in Korea were analysed for their umami taste compounds (5'-nucleotides: AMP, GMP, IMP, UMP, XMP; free amino acids: aspartic, glutamic acid) and subjected to human sensory evaluation and electronic tongue measurements. Amanita virgineoides featured the highest total 5'-nucleotide content (36.9 \u00b1 1.50 mg/g), while monosodium glutamate-like components (42.4 \u00b1 6.90 mg/g) were highest in Agaricus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26304449", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 415, "text": "liver transplantation improves patients' short-term post liver transplantation survival in Amanita phalloides poisoning", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27389675", "endSection": "abstract"}]}, {"body": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25167216", "http://www.ncbi.nlm.nih.gov/pubmed/23819583", "http://www.ncbi.nlm.nih.gov/pubmed/23897011", "http://www.ncbi.nlm.nih.gov/pubmed/20722020", "http://www.ncbi.nlm.nih.gov/pubmed/22532634", "http://www.ncbi.nlm.nih.gov/pubmed/21366908", "http://www.ncbi.nlm.nih.gov/pubmed/22872428", "http://www.ncbi.nlm.nih.gov/pubmed/18781962", "http://www.ncbi.nlm.nih.gov/pubmed/20392289", "http://www.ncbi.nlm.nih.gov/pubmed/25504080", "http://www.ncbi.nlm.nih.gov/pubmed/23434571", "http://www.ncbi.nlm.nih.gov/pubmed/25319955", "http://www.ncbi.nlm.nih.gov/pubmed/22866899", "http://www.ncbi.nlm.nih.gov/pubmed/22719926", "http://www.ncbi.nlm.nih.gov/pubmed/22043277", "http://www.ncbi.nlm.nih.gov/pubmed/21303493", "http://www.ncbi.nlm.nih.gov/pubmed/21803750"], "ideal_answer": ["A five gene type I IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the WB with clinical measurements.R Baseline disease activity measurements correlated with a type I IFN gene signature in the WB of subjects with SLE, PM and SSc, as did various serum autoantibody levels in subjects with SLE and DM.", "Baseline disease activity measurements correlated with a type I IFN gene signature in the WB of subjects. The type I IFN signature negatively predicts the clinical response to rituximab treatment in patients with RA.", "a five gene type i ifn signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type i ifn pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the wb with clinical measurements.", "A five gene type I IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the WB with clinical measurements.R"], "type": "factoid", "id": "58e7902b3e8b6dc87c000007", "snippets": [{"offsetInBeginSection": 601, "offsetInEndSection": 909, "text": "A five gene type I IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the WB with clinical measurements.R", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803750", "endSection": "abstract"}, {"offsetInBeginSection": 1154, "offsetInEndSection": 1467, "text": "Baseline disease activity measurements correlated with a type I IFN gene signature in the WB of subjects with SLE, PM and SSc, as did various serum autoantibody levels in subjects with SLE and DM. This signature was also well correlated between disease-affected tissue and WB in subjects with SLE, DM, PM and SSc.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803750", "endSection": "abstract"}, {"offsetInBeginSection": 888, "offsetInEndSection": 1022, "text": "We identified an arsenic exposure related 51-gene signature at PND1 and PND70 with several hubs of interaction (Hspa8, IgM and Hnf4a).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22719926", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22532634", "endSection": "title"}, {"offsetInBeginSection": 808, "offsetInEndSection": 1018, "text": "A 12-gene transcriptional 'signature' identified RA patients in the training cohort and predicted the subsequent development of RA among UA patients in the validation cohort (sensitivity 68%, specificity 70%). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22532634", "endSection": "abstract"}, {"offsetInBeginSection": 681, "offsetInEndSection": 867, "text": "The involvement of HIF isoforms in generating the angiogenic signature of RA FLS stimulated with hypoxia and/or cytokines was investigated using a DNA-binding assay and RNA interference.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22866899", "endSection": "abstract"}, {"offsetInBeginSection": 189, "offsetInEndSection": 525, "text": "The objective of our study was to characterise the angiogenic gene signature of RA fibroblast-like synoviocytes (FLS) in response to hypoxia, as well as Th1 and T-helper cell 2 (Th2) cytokines, and in particular to dissect out effects of combined hypoxia and cytokines on hypoxia inducible transcription factors (HIFs) and angiogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22866899", "endSection": "abstract"}, {"offsetInBeginSection": 945, "offsetInEndSection": 1400, "text": "Multiple folate metabolism-related genes were consistently and significantly altered between the 3 groups in both cohorts. Concurrent with evidence of an immune-activation gene signature in MTX-naive RA patients, significant up-regulation of the folate-metabolizing enzymes \u03b3-glutamyl hydrolase and dihydrofolate reductase, as well as the MTX/folate efflux transporters ABCC2 and ABCC5, was observed in the MTX-naive RA group compared to healthy controls.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23897011", "endSection": "abstract"}, {"offsetInBeginSection": 286, "offsetInEndSection": 536, "text": "We used microarray profiling of peripheral blood mononuclear cells (PBMCs) in 30 RA patients to assess the effect of different biologic agent (biologics) treatments and to quantify the degree of a type-I interferon (IFN) signature in these patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872428", "endSection": "abstract"}, {"offsetInBeginSection": 1188, "offsetInEndSection": 1310, "text": "The 256 genes identified were used to derive a gene signature score by averaging their log expression within each patient.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25504080", "endSection": "abstract"}, {"offsetInBeginSection": 1232, "offsetInEndSection": 1473, "text": " IL-17A inhibitors produced rapid down-regulation of the psoriasis gene signature and high clinical response rates in patients with moderate-to-severe plaque psoriasis, consistent with an important role for IL-17A in psoriasis pathogenesis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23819583", "endSection": "abstract"}, {"offsetInBeginSection": 1059, "offsetInEndSection": 1304, "text": "We observed that baseline synovial myeloid, but not lymphoid, gene signature expression was higher in patients with good compared with poor European league against rheumatism (EULAR) clinical response to anti-TNF\u03b1 therapy at week 16 (P =0.011). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25167216", "endSection": "abstract"}, {"offsetInBeginSection": 691, "offsetInEndSection": 1072, "text": "Flow cytometry and gene profiling indicated that RA-SF macrophages express pro-inflammatory polarization markers (MMP12, EGLN3, CCR2), lack expression of markers associated with homeostatic and anti-inflammatory polarization (IGF1, HTR2B) and exhibit a transcriptomic profile that resembles the activin A-dependent gene signature of pro-inflammatory in vitro-generated macrophages.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25319955", "endSection": "abstract"}, {"offsetInBeginSection": 1792, "offsetInEndSection": 2097, "text": "Gene expression analyses showed a greater prevalence of significantly upregulated genes in HCs with negative ANA values than in those with significant ANA positivity. Genes upregulated in high ANA HCs included a celiac disease autoantigen and some components of the Type I interferon (IFN) gene signature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21366908", "endSection": "abstract"}, {"offsetInBeginSection": 145, "offsetInEndSection": 513, "text": "We therefore initiated this study to identify signatures that would be of utility in studying rheumatoid arthritis (RA).We used microarray profiling of peripheral blood mononuclear cells (PBMCs) in 30 RA patients to assess the effect of different biologic agent (biologics) treatments and to quantify the degree of a type-I interferon (IFN) signature in these patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22872428", "endSection": "abstract"}, {"offsetInBeginSection": 328, "offsetInEndSection": 544, "text": "Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature similar to but less intense than that seen in patients with lupus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21303493", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "To analyze the relationship between the type I interferon (IFN) signature and clinical response to rituximab in rheumatoid arthritis (RA) patients.Twenty RA patients were treated with rituximab (cohort 1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20722020", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 508, "text": "To validate the presence and demonstrate the clinical value of the type I interferon (IFN)-signature during arthritis development.In 115 seropositive arthralgia patients who were followed for the development of arthritis (Amsterdam Reade cohort), and 25 presymptomatic individuals who developed rheumatoid arthritis (RA) later, and 45 population-based controls (Northern Sweden cohort), the expression levels of 7 type I IFN response genes were determined with multiplex qPCR and an IFN-score was calculated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23434571", "endSection": "abstract"}, {"offsetInBeginSection": 924, "offsetInEndSection": 1190, "text": "Patients with systemic lupus erythematosus, Sj\u00f6gren's syndrome, dermatomyositis, psoriasis, and a fraction of patients with rheumatoid arthritis display a specific expression pattern of interferon-dependent genes in their leukocytes, termed the interferon signature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20392289", "endSection": "abstract"}, {"offsetInBeginSection": 675, "offsetInEndSection": 967, "text": "More recently, large-scale differential gene expression studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature in lupus).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18781962", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20722020", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22043277", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "To analyze the relationship between the type I interferon (IFN) signature and clinical response to rituximab in rheumatoid arthritis (RA) patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20722020", "endSection": "abstract"}]}, {"body": "Which NGS alignment software implement the Burrows-Wheeler Transform?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21724593", "http://www.ncbi.nlm.nih.gov/pubmed/26405948", "http://www.ncbi.nlm.nih.gov/pubmed/19261174", "http://www.ncbi.nlm.nih.gov/pubmed/19451168", "http://www.ncbi.nlm.nih.gov/pubmed/24743329", "http://www.ncbi.nlm.nih.gov/pubmed/23813006", "http://www.ncbi.nlm.nih.gov/pubmed/26839887", "http://www.ncbi.nlm.nih.gov/pubmed/19497933", "http://www.ncbi.nlm.nih.gov/pubmed/20080505"], "ideal_answer": ["The most widely used software belong to the family of the Burrows-Wheeler Aligner (BWA) and its variants for local alignment BWASW, map reduce BWASW-PMR and multi-threaded implementation BWA-MT. Other approaches include Bowtie, SOAP2, BWBBLE, SOAP2 and FANSe2."], "type": "list", "id": "58eb2887eda5a57672000003", "snippets": [{"offsetInBeginSection": 115, "offsetInEndSection": 406, "text": "For the human genome, Burrows-Wheeler indexing allows Bowtie to align more than 25 million reads per CPU hour with a memory footprint of approximately 1.3 gigabytes. Bowtie extends previous Burrows-Wheeler techniques with a novel quality-aware backtracking algorithm that permits mismatches.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19261174", "endSection": "abstract"}, {"offsetInBeginSection": 627, "offsetInEndSection": 914, "text": "We implemented Burrows-Wheeler Alignment tool (BWA), a new read alignment package that is based on backward search with Burrows-Wheeler Transform (BWT), to efficiently align short sequencing reads against a large reference sequence such as the human genome, allowing mismatches and gaps.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451168", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 346, "text": "SOAP2 is a significantly improved version of the short oligonucleotide alignment program that both reduces computer memory usage and increases alignment speed at an unprecedented rate. We used a Burrows Wheeler Transformation (BWT) compression index to substitute the seed strategy for indexing the reference sequence in the main memory.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19497933", "endSection": "abstract"}, {"offsetInBeginSection": 662, "offsetInEndSection": 892, "text": "We designed and implemented a new algorithm, Burrows-Wheeler Aligner's Smith-Waterman Alignment (BWA-SW), to align long sequences up to 1 Mb against a large sequence database (e.g. the human genome) with a few gigabytes of memory.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080505", "endSection": "abstract"}, {"offsetInBeginSection": 772, "offsetInEndSection": 1131, "text": "Here, we propose a new base-calling algorithm, TotalReCaller, to achieve improved performance. A linear error model for the raw intensity data and Burrows-Wheeler transform (BWT) based alignment are combined utilizing a Bayesian score function, which is then globally optimized over all possible genomic locations using an efficient branch-and-bound approach.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21724593", "endSection": "abstract"}, {"offsetInBeginSection": 508, "offsetInEndSection": 1009, "text": "To tackle this problem, a new alignment tool BWBBLE is introduced in this article. We (i) introduce a new compressed representation of a collection of genomes, which explicitly tackles the genomic variation observed at every position, and (ii) design a new alignment algorithm based on the Burrows-Wheeler transform that maps short reads from a newly sequenced genome to an arbitrary collection of two or more (up to millions of) genomes with high accuracy and no inherent bias to one specific genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23813006", "endSection": "abstract"}, {"offsetInBeginSection": 212, "offsetInEndSection": 578, "text": "Seed-based algorithms are generally slow but robust, while Burrows-Wheeler Transform (BWT) based algorithms are fast but less robust. To have both advantages, we developed an algorithm FANSe2 with iterative mapping strategy based on the statistics of real-world sequencing error distribution to substantially accelerate the mapping without compromising the accuracy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24743329", "endSection": "abstract"}, {"offsetInBeginSection": 526, "offsetInEndSection": 693, "text": "Therefore, in this paper, we introduce Burrows-Wheeler Aligner's Smith-Waterman Alignment on Parallel MapReduce (BWASW-PMR) cloud platform for long sequence alignment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26839887", "endSection": "abstract"}, {"offsetInBeginSection": 470, "offsetInEndSection": 797, "text": "In this paper, we propose a BWA-MT tool, evolved from BWA but supporting multi-thread computation, designed to fully utilize the underlying multi-core architecture of computing resources. By using multi-thread computation, BWA-MT can significantly shorten the time needed to generate an alignment for single-end read sequences.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26405948", "endSection": "abstract"}, {"offsetInBeginSection": 492, "offsetInEndSection": 892, "text": "The speed of MAQ is also a concern when the alignment is scaled up to the resequencing of hundreds of individuals.We implemented Burrows-Wheeler Alignment tool (BWA), a new read alignment package that is based on backward search with Burrows-Wheeler Transform (BWT), to efficiently align short sequencing reads against a large reference sequence such as the human genome, allowing mismatches and gaps", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451168", "endSection": "abstract"}, {"offsetInBeginSection": 233, "offsetInEndSection": 468, "text": "Although the Burrows-Wheeler Aligner (BWA) tool is one of the most widely used open-source software tools to align read sequences, it is still limited in that it does not fully support multi-thread mechanisms during the alignment steps", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26405948", "endSection": "abstract"}, {"offsetInBeginSection": 607, "offsetInEndSection": 894, "text": "We implemented Burrows-Wheeler Alignment tool (BWA), a new read alignment package that is based on backward search with Burrows-Wheeler Transform (BWT), to efficiently align short sequencing reads against a large reference sequence such as the human genome, allowing mismatches and gaps.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451168", "endSection": "abstract"}, {"offsetInBeginSection": 643, "offsetInEndSection": 823, "text": "We designed and implemented a new algorithm, Burrows-Wheeler Aligner's Smith-Waterman Alignment (BWA-SW), to align long sequences up to 1 Mb against a large sequence database (e.g.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080505", "endSection": "abstract"}, {"offsetInBeginSection": 233, "offsetInEndSection": 469, "text": "Although the Burrows-Wheeler Aligner (BWA) tool is one of the most widely used open-source software tools to align read sequences, it is still limited in that it does not fully support multi-thread mechanisms during the alignment steps.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26405948", "endSection": "abstract"}]}, {"body": "Is intraoperative radiotherapy used for treatment of glioblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25535398", "http://www.ncbi.nlm.nih.gov/pubmed/8092110", "http://www.ncbi.nlm.nih.gov/pubmed/6328061", "http://www.ncbi.nlm.nih.gov/pubmed/7623073", "http://www.ncbi.nlm.nih.gov/pubmed/26824195", "http://www.ncbi.nlm.nih.gov/pubmed/3014858", "http://www.ncbi.nlm.nih.gov/pubmed/2852827", "http://www.ncbi.nlm.nih.gov/pubmed/25724425", "http://www.ncbi.nlm.nih.gov/pubmed/16044217", "http://www.ncbi.nlm.nih.gov/pubmed/7709332"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0338240", "o": "http://linkedlifedata.com/resource/umls/label/A4352743"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A4352743", "o": "intraoperative radiotherapy"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0017636", "o": "GBM"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0338240", "o": "http://linkedlifedata.com/resource/umls/label/A7582156"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7582156", "o": "radiotherapy, intraoperative"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0338240", "o": "intraoperative radiation therapy"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0017636", "o": "http://linkedlifedata.com/resource/umls/label/A18647416"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18647416", "o": "glioblastoma"}], "ideal_answer": ["Yes, intraoperative radiotherapy (IORT) is being used for treatment of glioblastoma. IORT combined with extensive tumor removal has an acceptable toxicity in previously irradiated patients and can be effective for selected recurrent malignant brain tumors."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005909", "http://www.disease-ontology.org/api/metadata/DOID:3068", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011878", "http://www.disease-ontology.org/api/metadata/DOID:3073", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007430"], "type": "yesno", "id": "589a245478275d0c4a000022", "snippets": [{"offsetInBeginSection": 181, "offsetInEndSection": 294, "text": " 1) Intraoperative radiotherapy ( IOR , 1,000-2,000 rad) was applied in 13 cases; the 2-year survival was 41.6%. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6328061", "endSection": "abstract"}, {"offsetInBeginSection": 588, "offsetInEndSection": 837, "text": "The median survival time after IORT was 12 months for 9 patients with glioblastoma or anaplastic astrocytoma, while it was 51 months for 8 patients with less infiltrative tumors (ependymoma, anaplastic ependymoma, and anaplastic oligodendroglioma). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8092110", "endSection": "abstract"}, {"offsetInBeginSection": 1147, "offsetInEndSection": 1339, "text": "It is concluded that IORT combined with extensive tumor removal has an acceptable toxicity in previously irradiated patients and can be effective for selected recurrent malignant brain tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8092110", "endSection": "abstract"}, {"offsetInBeginSection": 1467, "offsetInEndSection": 1642, "text": "CONCLUSIONS: The results of this study indicate that IORT can contribute to successful tumor treatment while neither increasing peri-operative morbidity nor subacute sequelae.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7709332", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 694, "text": "This review compiles preclinical and clinical evidence for a dedicated treatment of both residual cancer cells and regional microenvironment using intraoperative radiotherapy (IORT).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824195", "endSection": "abstract"}, {"offsetInBeginSection": 380, "offsetInEndSection": 624, "text": " Intraoperative radiotherapy (IORT) is a pragmatic and effective approach to sterilize the margins from persistent tumor cells, abrogate post-injury proliferative stimuli and to bridge the therapeutic gap between surgery and radiochemotherapy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25535398", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "[Surgical treatment and radiation therapy for glioblastoma multiforme, with special reference to intraoperative radiotherapy].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6328061", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Rationale for intraoperative radiotherapy in glioblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824195", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Intraoperative radiotherapy (IORT) was performed in 20 of 36 patients with glioma; 11 glioblastomas, 7 malignant astrocytomas, 2 benign astrocytomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7623073", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "[Surgical treatment and radiation therapy for glioblastoma multiforme, with special reference to intraoperative radiotherapy]", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6328061", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "INTRAGO: intraoperative radiotherapy in glioblastoma multiforme\u2014a phase I/II dose escalation study", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25535398", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Intraoperative cobalt-60 treatment of glioblastoma multiforme", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2852827", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "An intraoperative remote afterloading endocurietherapy (ECT) technique with high-activity 60cobalt (60Co) for the treatment of glioblastoma multiforme (GM) is described", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2852827", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "[Surgical treatment and radiation therapy for glioblastoma multiforme, with special reference to intraoperative radiotherapy].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6328061", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Rationale for intraoperative radiotherapy in glioblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26824195", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Intraoperative cobalt-60 treatment of glioblastoma multiforme.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2852827", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "INTRAGO: intraoperative radiotherapy in glioblastoma multiforme\u2014a phase I/II dose escalation study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25535398", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Intraoperative remote afterloading endocurietherapy with high-activity 60cobalt for treatment of glioblastoma multiforme.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3014858", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25724425", "endSection": "title"}, {"offsetInBeginSection": 1243, "offsetInEndSection": 1378, "text": "The intraoperative use of carmustine wafers in combination with Stupp regimen is a viable first-line treatment option of glioblastomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25724425", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "An intraoperative remote afterloading endocurietherapy (ECT) technique with high-activity 60cobalt (60Co) for the treatment of glioblastoma multiforme (GM) is described.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2852827", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "The study investigated if intraoperative use of carmustine wafers, particularly in combination with Stupp regimen, is a viable and safe first-line treatment option of glioblastomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25724425", "endSection": "abstract"}]}, {"body": "Which server is used for generating modes of pseudo components of DNA, RNA and protein sequences?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25958395"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0002518", "o": "http://linkedlifedata.com/resource/umls/label/A18664122"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18664122", "o": "protein sequences"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0002518", "o": "amino acid sequence"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0002518", "o": "http://linkedlifedata.com/resource/umls/label/A18589792"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18589792", "o": "amino acid sequence"}], "ideal_answer": ["Pse-in-One is a web server for generating various modes of pseudo components of DNA, RNA, and protein sequences. It can, through its 28 different modes, generate nearly all the possible feature vectors for DNA, RNA and protein sequences. Particularly, it can also generate those feature vectors with the properties defined by users themselves. These feature vectors can be easily combined with machine-learning algorithms to develop computational predictors and analysis methods for various tasks in bioinformatics and system biology."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004247", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D030561", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000595", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D021901", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017422", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017421", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012313", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020539"], "type": "factoid", "id": "589317e849702f2e01000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Pse-in-One: a web server for generating various modes of pseudo components of DNA, RNA, and protein sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25958395", "endSection": "title"}, {"offsetInBeginSection": 723, "offsetInEndSection": 1492, "text": "In this article, with a much larger number of built-in properties, we are to propose a much more flexible web server called Pse-in-One (http://bioinformatics.hitsz.edu.cn/Pse-in-One/), which can, through its 28 different modes, generate nearly all the possible feature vectors for DNA, RNA and protein sequences. Particularly, it can also generate those feature vectors with the properties defined by users themselves. These feature vectors can be easily combined with machine-learning algorithms to develop computational predictors and analysis methods for various tasks in bioinformatics and system biology. It is anticipated that the Pse-in-One web server will become a very useful tool in computational proteomics, genomics, as well as biological sequence analysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25958395", "endSection": "abstract"}, {"offsetInBeginSection": 720, "offsetInEndSection": 1032, "text": "In this article, with a much larger number of built-in properties, we are to propose a much more flexible web server called Pse-in-One (http://bioinformatics.hitsz.edu.cn/Pse-in-One/), which can, through its 28 different modes, generate nearly all the possible feature vectors for DNA, RNA and protein sequences.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25958395", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Pse-in-One: a web server for generating various modes of pseudo components of DNA, RNA, and protein sequences", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25958395", "endSection": "title"}, {"offsetInBeginSection": 723, "offsetInEndSection": 1034, "text": "In this article, with a much larger number of built-in properties, we are to propose a much more flexible web server called Pse-in-One (http://bioinformatics.hitsz.edu.cn/Pse-in-One/), which can, through its 28 different modes, generate nearly all the possible feature vectors for DNA, RNA and protein sequences", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25958395", "endSection": "abstract"}, {"offsetInBeginSection": 723, "offsetInEndSection": 1035, "text": "In this article, with a much larger number of built-in properties, we are to propose a much more flexible web server called Pse-in-One (http://bioinformatics.hitsz.edu.cn/Pse-in-One/), which can, through its 28 different modes, generate nearly all the possible feature vectors for DNA, RNA and protein sequences.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25958395", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Pse-in-One: a web server for generating various modes of pseudo components of DNA, RNA, and protein sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25958395", "endSection": "title"}]}, {"body": "What is the link between TB (Turbeculosis) infection and TNFa inhibition?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19176545", "http://www.ncbi.nlm.nih.gov/pubmed/25095612", "http://www.ncbi.nlm.nih.gov/pubmed/24295645", "http://www.ncbi.nlm.nih.gov/pubmed/19075965", "http://www.ncbi.nlm.nih.gov/pubmed/19107015"], "ideal_answer": ["The occurrence of tuberculosis (TB) in patients treated with immunosuppressive drugs (ISD) is an old problem that has been highlighted by cases occurring in patients using anti-TNFalpha drugs."], "type": "summary", "id": "58ea521d3e8b6dc87c00000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "The use of TNFalpha blockers is associated with reactivation of tuberculosis (TB)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25095612", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "We present two patients with inflammatory bowel disease who, despite negative tuberculosis screening, developed a de novo tuberculosis infection after the start of anti tumor necrosis factor alpha treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295645", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 302, "text": "To compare the performance of two interferon gamma release assays (IGRAs) and conventional screening tests in patients with inflammatory arthritis undergoing screening for latent tuberculosis infection (LTBI) before treatment with anti-tumour necrosis factor alpha (anti-TNFalpha) compounds.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19176545", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "The occurrence of tuberculosis (TB) in patients treated with immunosuppressive drugs (ISD) is an old problem that has been highlighted by cases occurring in patients using anti-TNFalpha drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19107015", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "TNFalpha plays a pivotal role not only in the inflammatory process but also in the normal response against pathogens and therefore, interfering with this cytokine may increase the risk of infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19075965", "endSection": "abstract"}]}, {"body": "Which class of genes are mutated in Diamond Blackfan Anemia patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11112378", "http://www.ncbi.nlm.nih.gov/pubmed/20606162", "http://www.ncbi.nlm.nih.gov/pubmed/18768533", "http://www.ncbi.nlm.nih.gov/pubmed/20960466", "http://www.ncbi.nlm.nih.gov/pubmed/22689679", "http://www.ncbi.nlm.nih.gov/pubmed/12393682", "http://www.ncbi.nlm.nih.gov/pubmed/12586610", "http://www.ncbi.nlm.nih.gov/pubmed/18230666", "http://www.ncbi.nlm.nih.gov/pubmed/19191325", "http://www.ncbi.nlm.nih.gov/pubmed/17647292", "http://www.ncbi.nlm.nih.gov/pubmed/20378560", "http://www.ncbi.nlm.nih.gov/pubmed/18781615", "http://www.ncbi.nlm.nih.gov/pubmed/17186470", "http://www.ncbi.nlm.nih.gov/pubmed/24453067", "http://www.ncbi.nlm.nih.gov/pubmed/18535205", "http://www.ncbi.nlm.nih.gov/pubmed/23863123", "http://www.ncbi.nlm.nih.gov/pubmed/21435505", "http://www.ncbi.nlm.nih.gov/pubmed/16990592", "http://www.ncbi.nlm.nih.gov/pubmed/20116044"], "ideal_answer": ["Diamond-Blackfan Anemia (DBA) is characterized by a defect of erythroid progenitors and, clinically, by anemia and malformations. Diamond Blackfan anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes. Diamond-Blackfan anemia (DBA) is a rare congenital disease affecting erythroid precursor differentiation. Diamond-Blackfan anemia (DBA) is a congenital disease characterized by defective erythroid progenitor maturation and physical malformations.", "Currently nine genes, all encoding ribosomal proteins (RP), have been found mutated in approximately 50% of patients.", "In 25% of patients with Diamond-Blackfan anaemia 19q13 gene mutation was detected, and recent findings suggest another gene located on 8p23.3-p22 chromosome. Diamond Blackfan anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes. Currently nine genes, all encoding ribosomal proteins (RP), have been found mutated in approximately 50% of patients. We also report the prevalence of RPS 19 mutations in the Italian DBA population, as shown by an analysis of 56 patients. Experimental evidence supports the hypothesis that DBA is primarily the result of defective ribosome synthesis. ", "blackfan anemia (dba) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes. . genes encoding ribosomal proteins have been associated to dba: after rps19 , mutations in genes rps24 and rps17 were recently identified in a fraction of the patients. . 25% of patients with diamond-blackfan anaemia 19q13 gene mutation was detected , and recent findings suggest another gene located on 8p23.3-p22 chromosome. . transgenic mouse model demonstrates a dominant negative effect of a point mutation in the rps19 gene associated with diamond-blackfan anemia . also report the prevalence of rps 19 mutations in the italian dba population , as shown by an analysis of 56 patients. . in the gene encoding ribosomal protein (rp) s19 have recently been found in 25% of patients with either the dominant or the sporadic form. . ", "Diamond Blackfan anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes.", "three genes encoding ribosomal proteins have been associated to dba: after rps19, mutations in genes rps24 and rps17 were recently identified in a fraction of the patients.", "Small ribosomal subunit genes RPS19, RPS24, and RPS17 are mutated in approximately one-third of patients. Currently two genes are associated with the DBA phenotype--the ribosomal protein (RP) S19 mutated in 25% of DBA patients and RPS24 mutated in approximately 1.4% of DBA patients. As a proof of concept, we designed a multiplex ligation-dependent probe amplification assay targeted to screen the six genes that are most frequently mutated in Diamond-Blackfan anemia patients: RPS17, RPS19, RPS26, RPL5, RPL11, and RPL35A. We sequenced GATA-1 in 23 patients that were negative for mutations in the most frequently mutated DBA genes. Currently nine genes, all encoding ribosomal proteins (RP), have been found mutated in approximately 50% of patients. More than a decade has passed since the initial identification of ribosomal protein gene mutations in patients with Diamond-Blackfan anemia (DBA), a hematologic disorder that became the founding member of a class of diseases known as ribosomopathies. In this study, nine Korean DBA patients were screened for mutations in eight known DBA genes (RPS19, RPS24, RPS17, RPS10, RPS26, RPL35A, RPL5 and RPL11) using the direct sequencing method.", "Diamond Blackfan anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes. Mutation of ribosomal protein RPS24 in Diamond-Blackfan anemia results in a ribosome biogenesis disorder."], "type": "factoid", "id": "58e74bff3e8b6dc87c000004", "snippets": [{"offsetInBeginSection": 250, "offsetInEndSection": 398, "text": "Mutations in the gene encoding ribosomal protein (RP) S19 have recently been found in 25% of patients with either the dominant or the sporadic form.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11112378", "endSection": "abstract"}, {"offsetInBeginSection": 921, "offsetInEndSection": 1041, "text": "We also report the prevalence of RPS 19 mutations in the Italian DBA population, as shown by an analysis of 56 patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11112378", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Mutation of ribosomal protein RPS24 in Diamond-Blackfan anemia results in a ribosome biogenesis disorder.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18230666", "endSection": "title"}, {"offsetInBeginSection": 223, "offsetInEndSection": 395, "text": "Three genes encoding ribosomal proteins have been associated to DBA: after RPS19, mutations in genes RPS24 and RPS17 were recently identified in a fraction of the patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18230666", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "A transgenic mouse model demonstrates a dominant negative effect of a point mutation in the RPS19 gene associated with Diamond-Blackfan anemia", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20606162", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Diamond Blackfan anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20606162", "endSection": "abstract"}, {"offsetInBeginSection": 216, "offsetInEndSection": 333, "text": "Currently nine genes, all encoding ribosomal proteins (RP), have been found mutated in approximately 50% of patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20960466", "endSection": "abstract"}, {"offsetInBeginSection": 334, "offsetInEndSection": 445, "text": "Experimental evidence supports the hypothesis that DBA is primarily the result of defective ribosome synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20960466", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20116044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "A new database for ribosomal protein genes which are mutated in Diamond-Blackfan Anemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18781615", "endSection": "title"}, {"offsetInBeginSection": 530, "offsetInEndSection": 758, "text": "Recently, new genes, all encoding ribosomal proteins, have been found to be mutated in Diamond-Blackfan anemia, adding further support to the concept that ribosome biogenesis plays an important role in regulating erythropoiesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18768533", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "More than a decade has passed since the initial identification of ribosomal protein gene mutations in patients with Diamond-Blackfan anemia (DBA), a hematologic disorder that became the founding member of a class of diseases known as ribosomopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23863123", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "High frequency of ribosomal protein gene deletions in Italian Diamond-Blackfan anemia patients detected by multiplex ligation-dependent probe amplification assay.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22689679", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "The gene encoding ribosomal protein S19 (RPS19) has been shown to be mutated in 25% of the patients affected by Diamond-Blackfan anemia (DBA), a congenital erythroblastopenia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12393682", "endSection": "abstract"}, {"offsetInBeginSection": 273, "offsetInEndSection": 450, "text": "These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24453067", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20116044", "endSection": "title"}, {"offsetInBeginSection": 681, "offsetInEndSection": 930, "text": "The combination of sequencing and multiplex ligation-dependent probe amplification analysis of these six genes allows the genetic characterization of approximately 65% of patients, showing that Diamond-Blackfan anemia is indisputably a ribosomopathy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22689679", "endSection": "abstract"}, {"offsetInBeginSection": 533, "offsetInEndSection": 760, "text": "Recently, new genes, all encoding ribosomal proteins, have been found to be mutated in Diamond-Blackfan anemia, adding further support to the concept that ribosome biogenesis plays an important role in regulating erythropoiesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18768533", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Identification of mutations in the ribosomal protein L5 (RPL5) and ribosomal protein L11 (RPL11) genes in Czech patients with Diamond-Blackfan anemia", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19191325", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "Mutations in the ribosomal protein S19 gene (RPS19) have been found in 25% of patients with Diamond-Blackfan anemia, a rare syndrome of congenital bone marrow failure characterized by erythroblastopenia and various malformations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18768533", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17647292", "endSection": "title"}, {"offsetInBeginSection": 153, "offsetInEndSection": 258, "text": "Small ribosomal subunit genes RPS19, RPS24, and RPS17 are mutated in approximately one-third of patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18535205", "endSection": "abstract"}, {"offsetInBeginSection": 280, "offsetInEndSection": 457, "text": "Currently two genes are associated with the DBA phenotype--the ribosomal protein (RP) S19 mutated in 25% of DBA patients and RPS24 mutated in approximately 1.4% of DBA patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17647292", "endSection": "abstract"}, {"offsetInBeginSection": 236, "offsetInEndSection": 480, "text": "DBA patients exhibit abnormal pre-rRNA maturation patterns and the majority bear mutations in one of several ribosomal protein genes that encode structural components of the ribosome essential for the correct assembly of the ribosomal subunits.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21435505", "endSection": "abstract"}, {"offsetInBeginSection": 681, "offsetInEndSection": 931, "text": "The combination of sequencing and multiplex ligation-dependent probe amplification analysis of these six genes allows the genetic characterization of approximately 65% of patients, showing that Diamond-Blackfan anemia is indisputably a ribosomopathy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22689679", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16990592", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17647292", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "A new database for ribosomal protein genes which are mutated in Diamond-Blackfan Anemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18781615", "endSection": "title"}, {"offsetInBeginSection": 815, "offsetInEndSection": 924, "text": "In total, 12 (27%) of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20378560", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Ribosomal protein S19 (RPS19) is frequently mutated in Diamond-Blackfan anemia (DBA), a rare congenital hypoplastic anemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12586610", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Mutations in the ribosomal protein genes in Japanese patients with Diamond-Blackfan anemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20378560", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17186470", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20116044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "High frequency of ribosomal protein gene deletions in Italian Diamond-Blackfan anemia patients detected by multiplex ligation-dependent probe amplification assay.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22689679", "endSection": "title"}]}, {"body": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15845597", "http://www.ncbi.nlm.nih.gov/pubmed/6163355", "http://www.ncbi.nlm.nih.gov/pubmed/2793186", "http://www.ncbi.nlm.nih.gov/pubmed/23771085", "http://www.ncbi.nlm.nih.gov/pubmed/3463445", "http://www.ncbi.nlm.nih.gov/pubmed/2831495", "http://www.ncbi.nlm.nih.gov/pubmed/25179263", "http://www.ncbi.nlm.nih.gov/pubmed/15284799", "http://www.ncbi.nlm.nih.gov/pubmed/10096024", "http://www.ncbi.nlm.nih.gov/pubmed/20045761", "http://www.ncbi.nlm.nih.gov/pubmed/11330398", "http://www.ncbi.nlm.nih.gov/pubmed/12424707", "http://www.ncbi.nlm.nih.gov/pubmed/8659523", "http://www.ncbi.nlm.nih.gov/pubmed/8010709", "http://www.ncbi.nlm.nih.gov/pubmed/2658738", "http://www.ncbi.nlm.nih.gov/pubmed/12210293", "http://www.ncbi.nlm.nih.gov/pubmed/1478673", "http://www.ncbi.nlm.nih.gov/pubmed/11536270", "http://www.ncbi.nlm.nih.gov/pubmed/527972", "http://www.ncbi.nlm.nih.gov/pubmed/2095460", "http://www.ncbi.nlm.nih.gov/pubmed/15505407", "http://www.ncbi.nlm.nih.gov/pubmed/9865780", "http://www.ncbi.nlm.nih.gov/pubmed/19070179"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0333715", "o": "Robertsonian Translocation"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0333715", "o": "http://linkedlifedata.com/resource/umls/label/A18692913"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18692913", "o": "robertsonian translocation"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0333715", "o": "http://linkedlifedata.com/resource/umls/label/A18618720"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18618720", "o": "robertsonian translocations"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0333715", "o": "http://linkedlifedata.com/resource/umls/label/A18637418"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18637418", "o": "translocation robertsonian"}], "ideal_answer": ["Robertsonian translocations (ROBs) are the most common chromosomal rearrangements in humans. ROBs are whole-arm rearrangements between the acrocentric chromosomes 13, 14, 15, 21, and 22."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002904", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014178", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002877", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006801", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002875"], "type": "list", "id": "58da14178acda34529000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Sperm segregation analysis of a (13;22) Robertsonian translocation carrier by FISH: a comparison of locus-specific probe and whole chromosome painting.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15845597", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 277, "text": "The t(13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric human chromosomes. Most of the meiotic segregation studies of human Robertsonian translocations have been performed on common t(13;14) and t(14;21) translocations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15845597", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 365, "text": "Robertsonian translocations (ROBs) are the most common chromosomal rearrangements in humans. ROBs are whole-arm rearrangements between the acrocentric chromosomes 13-15, 21, and 22. ROBs can be classified into two groups depending on their frequency of occurrence, common (rob(13q14q) and rob(14q21q)), and rare (all remaining possible nonhomologous combinations). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12424707", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 477, "text": "Robertsonian translocations (ROBs) are the most common rearrangements in humans, contributing significantly to genetic imbalance, fetal wastage, mental retardation and birth defects. Rob(14q21q) and rob(13q14q), which are formed predominantly during female meiosis, comprise the majority (approximately 85%) of all ROBs. Previous studies have shown that the breakpoints are consistently located within specific regions of the proximal short arms of chromosomes 13, 14, and 21. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11330398", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 506, "text": "To localize the chAB4 sequences more precisely on the acrocentrics, chAB4-specific probes together with rDNA and a number of satellite sequences were hybridized to metaphase chromosomes of normal probands and of carriers of Robertsonian translocations of the frequent types rob(13q14q) and rob(14q21q). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9865780", "endSection": "abstract"}, {"offsetInBeginSection": 660, "offsetInEndSection": 968, "text": "Chromosome 22, most probably, is the only chromosome where chAB4 is found in the direct neighbourhood of the centromere. Fluorescence in situ hybridization analyses of metaphase chromosomes of carriers of rob(21q22q) revealed breakpoint diversity for this rare type of Robertsonian translocation chromosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9865780", "endSection": "abstract"}, {"offsetInBeginSection": 466, "offsetInEndSection": 793, "text": "This process is suggested for the evolution of an alpha satellite subfamily recently found on chromosomes 13, 14 and 21. The presence of this alpha subfamily may allow pairing between these chromosomes leading to the observed non-random participation of these chromosomes in t(13q14q) and t(14q21q) Robertsonian translocations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2095460", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "The pattern of association of acrocentric chromosomes was examined in ten and five carriers of a 15/21 and a 13/14 Robertsonian translocation, respectively, and was compared with that of the same numbers of relatives with normal karyotypes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/527972", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Homologous alpha satellite sequences on human acrocentric chromosomes with selectivity for chromosomes 13, 14 and 21: implications for recombination between nonhomologues and Robertsonian translocations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2831495", "endSection": "title"}, {"offsetInBeginSection": 955, "offsetInEndSection": 1339, "text": "Out of 21 structural chromosomal anomalies and polymorphic variants, six deletions and microdeletions, four situations with abnormal long \"p\" arm of acrocentric chromosomes, two duplications, two reciprocal translocations, two inversions, two additions, one Robertsonian translocation associating trisomy 13, one 9q heteromorphism and one complex chromosome rearrangement were noticed", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771085", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 414, "text": "The purpose of this study was to search for cytologic evidence of robertsonian translocation formation that involves chromosomes 14q and 21q in human oogenesis with the use of dual color fluorescent in situ hybridization with whole chromosome paints.The oocytes from a chromosomally normal fetus at 23.5 weeks of gestation underwent cohybridization with chromosome specific DNA libraries from chromosomes 14 and 21", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15284799", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "The t(13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric human chromosomes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15845597", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Homologous alpha satellite sequences on human acrocentric chromosomes with selectivity for chromosomes 13, 14 and 21: implications for recombination between nonhomologues and Robertsonian translocations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2831495", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "The t(13;22) Robertsonian translocation constitutes a rare form of rearrangement between acrocentric human chromosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15845597", "endSection": "abstract"}]}, {"body": "Is tirilazad effective for treatment of aneurysmal subarachnoid haemorrhage?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9509802", "http://www.ncbi.nlm.nih.gov/pubmed/8592224", "http://www.ncbi.nlm.nih.gov/pubmed/8592225", "http://www.ncbi.nlm.nih.gov/pubmed/20166088", "http://www.ncbi.nlm.nih.gov/pubmed/9046304", "http://www.ncbi.nlm.nih.gov/pubmed/9773664", "http://www.ncbi.nlm.nih.gov/pubmed/8737119", "http://www.ncbi.nlm.nih.gov/pubmed/7714603", "http://www.ncbi.nlm.nih.gov/pubmed/10350245", "http://www.ncbi.nlm.nih.gov/pubmed/22152574", "http://www.ncbi.nlm.nih.gov/pubmed/10350246", "http://www.ncbi.nlm.nih.gov/pubmed/18810661"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0245179", "o": "TIRILAZAD"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0245179", "o": "http://linkedlifedata.com/resource/umls/label/A10338320"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A10338320", "o": "tirilazad"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/rxnorm/id/72467", "o": "http://linkedlifedata.com/resource/rxnorm/label/3263018"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/rxnorm/label/3263018", "o": "tirilazad"}], "ideal_answer": ["No. Based on meta-analysis, there is no evidence that tirilazad, in addition to nimodipine, reduces mortality or improves poor outcome in patients with aneurysmal subarachnoid haemorrhage."], "concepts": ["http://www.biosemantics.org/jochem#4215434", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4260337", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013345", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", "http://www.biosemantics.org/jochem#4236283", "http://www.biosemantics.org/jochem#4260337", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019468"], "type": "yesno", "id": "58ec72a4eda5a5767200000f", "snippets": [{"offsetInBeginSection": 1776, "offsetInEndSection": 2328, "text": "There was no significant difference between the two groups at the end of follow up for the primary outcome, death (odds ratio (OR) 0.89, 95% confidence interval (CI) 0.74 to 1.06), or in poor outcome (death, vegetative state or severe disability) (OR 1.04, 95% CI 0.90 to 1.21). During the treatment period, fewer patients developed delayed cerebral ischaemia in the tirilazad group than in the control group (OR 0.80, 95% CI 0.69 to 0.93). Subgroup analyses did not demonstrate any significant difference in effects of tirilazad on clinical outcomes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20166088", "endSection": "abstract"}, {"offsetInBeginSection": 2606, "offsetInEndSection": 2767, "text": "AUTHORS' CONCLUSIONS: There is no evidence that tirilazad, in addition to nimodipine, reduces mortality or improves poor outcome in patients with aneurysmal SAH.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20166088", "endSection": "abstract"}, {"offsetInBeginSection": 773, "offsetInEndSection": 926, "text": "This clinical trial suggest that tirilazad mesylate, at a dosage of 6 mg/kg/day, improves overall outcome in aneurysmal subarachnoid hemorrhage patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9773664", "endSection": "abstract"}, {"offsetInBeginSection": 1312, "offsetInEndSection": 1644, "text": "Tirilazad is ineffective.There are many possible successful treatment options for preventing vasospasm, delayed ischemic neurologic deficits, and poor neurologic outcome following aneurysmal subarachnoid hemorrhage; however, further multicenter RCTs need to be performed to determine if there is a significant benefit from their use", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22152574", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 231, "text": "Findings from previous multicenter clinical trials have suggested that tirilazad mesylate, a synthetic nonhormonal 21-aminosteroid, might be effective in preventing delayed cerebral ischemia following subarachnoid hemorrhage (SAH).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10350245", "endSection": "abstract"}, {"offsetInBeginSection": 777, "offsetInEndSection": 930, "text": "This clinical trial suggest that tirilazad mesylate, at a dosage of 6 mg/kg/day, improves overall outcome in aneurysmal subarachnoid hemorrhage patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9773664", "endSection": "abstract"}]}, {"body": "Which protein is the main marker of Cajal bodies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22558428", "http://www.ncbi.nlm.nih.gov/pubmed/11302690", "http://www.ncbi.nlm.nih.gov/pubmed/10806077", "http://www.ncbi.nlm.nih.gov/pubmed/14989147", "http://www.ncbi.nlm.nih.gov/pubmed/10944589", "http://www.ncbi.nlm.nih.gov/pubmed/16079131", "http://www.ncbi.nlm.nih.gov/pubmed/23274112", "http://www.ncbi.nlm.nih.gov/pubmed/24358231", "http://www.ncbi.nlm.nih.gov/pubmed/23064547", "http://www.ncbi.nlm.nih.gov/pubmed/27317682", "http://www.ncbi.nlm.nih.gov/pubmed/24569877", "http://www.ncbi.nlm.nih.gov/pubmed/21920476"], "ideal_answer": ["Coilin is widely known as the protein marker of the Cajal body, a subnuclear domain important to the biogenesis of small nuclear ribonucleoproteins and telomerase, complexes that are crucial to pre-messenger RNA splicing and telomere maintenance, respectively The Cajal body has now regained the interest of biologists, due to the isolation of a protein marker, coilin.", "Coilin is widely known as the protein marker of the Cajal body, a subnuclear domain important to the biogenesis of small nuclear ribonucleoproteins and telomerase, complexes that are crucial to pre-messenger RNA splicing and telomere maintenance, respectively Extensive studies have characterized the interaction between coilin and the various other protein components of CBs and related subnuclear domains; however, only a few have examined interactions between coilin and nucleic acid.", "Coilin is widely known as the protein marker of the Cajal body, a subnuclear domain important to the biogenesis of small nuclear ribonucleoproteins and telomerase, complexes that are crucial to pre-messenger RNA splicing and telomere maintenance, respectively. The Cajal (coiled) body is a discrete nuclear organelle that was first described in mammalian neurons in 1903.", "coilin", "Coilin is widely known as the protein marker of the Cajal body, a subnuclear domain important to the biogenesis of small nuclear ribonucleoproteins and telomerase, complexes that are crucial to pre-messenger RNA splicing and telomere maintenance, respectively", "Coilin, more than a molecular marker of the cajal (coiled) body The Cajal body has now regained the interest of biologists, due to the isolation of a protein marker, coilin.", "Coilin is widely known as the protein marker of the Cajal body, a subnuclear domain important to the biogenesis of small nuclear ribonucleoproteins and telomerase, complexes that are crucial to pre-messenger RNA splicing and telomere maintenance, respectively."], "type": "factoid", "id": "58eb9542eda5a57672000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "Coilin is widely known as the protein marker of the Cajal body, a subnuclear domain important to the biogenesis of small nuclear ribonucleoproteins and telomerase, complexes that are crucial to pre-messenger RNA splicing and telomere maintenance, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23274112", "endSection": "abstract"}, {"offsetInBeginSection": 261, "offsetInEndSection": 488, "text": "Extensive studies have characterized the interaction between coilin and the various other protein components of CBs and related subnuclear domains; however, only a few have examined interactions between coilin and nucleic acid.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23274112", "endSection": "abstract"}, {"offsetInBeginSection": 521, "offsetInEndSection": 735, "text": "coilin is tightly associated with nucleic acid, displays RNase activity in vitro, and is redistributed to the ribosomal RNA (rRNA)-rich nucleoli in cells treated with the DNA-damaging agents cisplatin and etoposide", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23274112", "endSection": "abstract"}, {"offsetInBeginSection": 737, "offsetInEndSection": 1044, "text": "Here, we report a specific in vivo association between coilin and rRNA, U small nuclear RNA (snRNA), and human telomerase RNA, which is altered upon treatment with DNA-damaging agents. Using chromatin immunoprecipitation, we provide evidence of coilin interaction with specific regions of U snRNA gene loci.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23274112", "endSection": "abstract"}, {"offsetInBeginSection": 1191, "offsetInEndSection": 1315, "text": "Additionally, we provide evidence of coilin involvement in the processing of human telomerase RNA both in vitro and in vivo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23274112", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Coilin, more than a molecular marker of the cajal (coiled) body", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10944589", "endSection": "title"}, {"offsetInBeginSection": 278, "offsetInEndSection": 387, "text": "The Cajal body has now regained the interest of biologists, due to the isolation of a protein marker, coilin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10944589", "endSection": "abstract"}, {"offsetInBeginSection": 533, "offsetInEndSection": 733, "text": "Here, I would like to discuss what we have learned about coilin and suggest a possible role for coilin in RNA processing and cellular trafficking, especially in relation to Cajal bodies and nucleoli. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10944589", "endSection": "abstract"}, {"offsetInBeginSection": 174, "offsetInEndSection": 317, "text": "Coilin-p80 is a marker protein for nuclear Cajal bodies (coiled bodies; CBs) which are also involved in snRNP maturation, storage or transport.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11302690", "endSection": "abstract"}, {"offsetInBeginSection": 1075, "offsetInEndSection": 1165, "text": "Coilin is another nuclear SMN binding partner and a marker protein for Cajal bodies (CBs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24358231", "endSection": "abstract"}, {"offsetInBeginSection": 288, "offsetInEndSection": 372, "text": "A limited set of NBs also contained coilin, a marker protein for Cajal bodies (CBs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14989147", "endSection": "abstract"}, {"offsetInBeginSection": 311, "offsetInEndSection": 430, "text": "We performed a genome-wide screen to identify proteins that colocalize with coilin, the marker protein of Cajal bodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24569877", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "Coilin is a marker protein for subnuclear organelles known as Cajal bodies, which are sites of various RNA metabolic processes including the biogenesis of spliceosomal small nuclear ribonucleoprotein particles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317682", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Coilin is a marker protein for the Cajal body, a subnuclear domain acting as a site for assembly and maturation of nuclear RNA-protein complexes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16079131", "endSection": "abstract"}, {"offsetInBeginSection": 313, "offsetInEndSection": 431, "text": "We performed a genome-wide screen to identify proteins that colocalize with coilin, the marker protein of Cajal bodies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24569877", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Cajal bodies (CB) are subnuclear domains that contain various proteins with diverse functions including the CB marker protein coilin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064547", "endSection": "abstract"}, {"offsetInBeginSection": 1083, "offsetInEndSection": 1172, "text": "Coilin is another nuclear SMN binding partner and a marker protein for Cajal bodies (CBs)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24358231", "endSection": "abstract"}, {"offsetInBeginSection": 1088, "offsetInEndSection": 1175, "text": "One of these target proteins is coilin; a basic protein located in nuclear Cajal bodies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21920476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Coilin is known as the marker protein for Cajal bodies (CBs), subnuclear domains important for the biogenesis of small nuclear ribonucleoproteins (snRNPs) which function in pre-mRNA splicing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22558428", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 363, "text": "Cajal bodies (coiled bodies, CBs) are nuclear organelles of unknown function and are characterized by a wide variety of components including various basal transcription and cell cycle proteins, the nucleolar proteins fibrillarin and Nopp140, numerous small nuclear ribonucleoproteins, the survival motor neuron protein complex, and the marker protein, p80 coilin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10806077", "endSection": "abstract"}, {"offsetInBeginSection": 1182, "offsetInEndSection": 1312, "text": "Perturbation of SMN function results in disassembly of Cajal bodies and relocalization of the marker protein, coilin, to nucleoli.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16301532", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 495, "text": "Human coilin interacting nuclear ATPase protein (hCINAP) directly interacts with coilin, a marker protein of Cajal Bodies (CBs), nuclear organelles involved in the maturation of small nuclear ribonucleoproteins UsnRNPs and snoRNPs. hCINAP has previously been designated as an adenylate kinase (AK6), but is very atypical as it exhibits unusually broad substrate specificity, structural features characteristic of ATPase/GTPase proteins (Walker motifs A and B) and also intrinsic ATPase activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038794", "endSection": "abstract"}, {"offsetInBeginSection": 1083, "offsetInEndSection": 1173, "text": "Coilin is another nuclear SMN binding partner and a marker protein for Cajal bodies (CBs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24358231", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Cajal bodies (CB) are subnuclear domains that contain various proteins with diverse functions including the CB marker protein coilin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064547", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "We have found that coilin, the marker protein for Cajal bodies (coiled bodies, CBs), is a self-interacting protein, and we have mapped the domain responsible for this activity to the amino-terminus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11102515", "endSection": "abstract"}, {"offsetInBeginSection": 257, "offsetInEndSection": 405, "text": "Cajal bodies contain a marker protein of unknown function, p80-coilin, and many components involved in transcription and processing of nuclear RNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11031238", "endSection": "abstract"}, {"offsetInBeginSection": 313, "offsetInEndSection": 432, "text": "We performed a genome-wide screen to identify proteins that colocalize with coilin, the marker protein of Cajal bodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24569877", "endSection": "abstract"}, {"offsetInBeginSection": 592, "offsetInEndSection": 704, "text": "A defect in this activity caused a significant accumulation of the Cajal body marker protein coilin in nucleoli.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22250197", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Coilin, more than a molecular marker of the cajal (coiled) body.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10944589", "endSection": "title"}, {"offsetInBeginSection": 300, "offsetInEndSection": 473, "text": "We have constructed a stable HeLa cell line, HeLa(GFP-coilin), that expresses the Cajal body marker protein, p80 coilin, fused to the green fluorescent protein (GFP-coilin).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11134083", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "The Cajal body, originally identified over 100 years ago as a nucleolar accessory body in neurons, has come to be identified with nucleoplasmic structures, often quite tiny, that contain coiled threads of the marker protein, coilin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18755223", "endSection": "abstract"}, {"offsetInBeginSection": 600, "offsetInEndSection": 857, "text": "By immunoprecipitation we find that WRAP53 associates with the Cajal body marker coilin, the splicing regulatory protein SMN, and the nuclear import receptor importin\u03b2, and that WRAP53 is essential for complex formation between SMN-coilin and SMN-importin\u03b2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21072240", "endSection": "abstract"}]}, {"body": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/14599068", "http://www.ncbi.nlm.nih.gov/pubmed/20617205", "http://www.ncbi.nlm.nih.gov/pubmed/25582874", "http://www.ncbi.nlm.nih.gov/pubmed/24521565", "http://www.ncbi.nlm.nih.gov/pubmed/25425525", "http://www.ncbi.nlm.nih.gov/pubmed/22762706", "http://www.ncbi.nlm.nih.gov/pubmed/23521865", "http://www.ncbi.nlm.nih.gov/pubmed/22032885", "http://www.ncbi.nlm.nih.gov/pubmed/18194410", "http://www.ncbi.nlm.nih.gov/pubmed/23615171", "http://www.ncbi.nlm.nih.gov/pubmed/23804531"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0007965", "o": "http://linkedlifedata.com/resource/umls/label/A18609146"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18609146", "o": "chediak-higashi syndrome"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0007965", "o": "CHS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0007965", "o": "http://linkedlifedata.com/resource/umls/label/A18590514"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18590514", "o": "chediak higashi syndrome"}], "ideal_answer": ["Mutation in the lysosomal trafficking regulator (LYST) gene causes the Ch\u00e9diak-Higashi syndrome (CHS)."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002609", "http://www.disease-ontology.org/api/metadata/DOID:2935"], "type": "factoid", "id": "58cbd0d502b8c60953000035", "snippets": [{"offsetInBeginSection": 727, "offsetInEndSection": 921, "text": "We detected a homozygous missense mutation (c.4189T>G, p.F1397V) in the lysosomal trafficking regulator (LYST) gene, which is described as the causative gene for Ch\u00e9diak-Higashi syndrome (CHS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24521565", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "A frameshift mutation in the LYST gene is responsible for the Aleutian color and the associated Ch\u00e9diak-Higashi syndrome in American mink.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22762706", "endSection": "title"}, {"offsetInBeginSection": 363, "offsetInEndSection": 494, "text": "As with forms of CHS in other species, we report that the mink CHS is linked to the lysosomal trafficking regulator ( LYST ) gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22762706", "endSection": "abstract"}, {"offsetInBeginSection": 1137, "offsetInEndSection": 1295, "text": "LYST analysis was performed for 10 patients; seven different mutations were detected in seven patients, whereas no mutation was identified in three patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23804531", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 172, "text": "Ch\u00e9diak-Higashi syndrome (CHS) is a rare autosomal recessive disorder characterized by immunodeficiency, neurological dysfunction, and oculocutaneous albinism. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23804531", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "Mutations in LYST, a gene encoding a putative lysosomal trafficking protein, cause Ch\u00e9diak-Higashi syndrome (CHS), an autosomal recessive disorder typically characterized by infantile-onset hemophagocytic syndrome and immunodeficiency, and oculocutaneous albinism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23521865", "endSection": "abstract"}, {"offsetInBeginSection": 598, "offsetInEndSection": 737, "text": "This phenotype is similar to that reported previously in lvsB mutant cells where the ortholog of the LYST gene, involved in CHS, is mutated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18194410", "endSection": "abstract"}, {"offsetInBeginSection": 731, "offsetInEndSection": 1305, "text": "Rarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the \u03b2-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25582874", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "LYST is a large cytosolic protein that influences the biogenesis of lysosome-related organelles, and mutation of the encoding gene, LYST, can cause Chediak-Higashi syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20617205", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Chediak-Higashi syndrome (CHS) is an autosomal recessive hereditary disorder in Japanese Black cattle, caused by a mutation of the Lyst gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23615171", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Chediak-Higashi syndrome (CHS) is caused by mutations in the gene encoding LYST protein, the function of which remains poorly understood.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25425525", "endSection": "abstract"}, {"offsetInBeginSection": 1522, "offsetInEndSection": 1586, "text": "Mutations of genes other than LYST were suspected in some cases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23804531", "endSection": "abstract"}]}, {"body": "The pathogen Fusarium graminearum affects what type of plant species?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18179606", "http://www.ncbi.nlm.nih.gov/pubmed/26693688", "http://www.ncbi.nlm.nih.gov/pubmed/26585460", "http://www.ncbi.nlm.nih.gov/pubmed/22516221", "http://www.ncbi.nlm.nih.gov/pubmed/26607286", "http://www.ncbi.nlm.nih.gov/pubmed/26305050", "http://www.ncbi.nlm.nih.gov/pubmed/17031651", "http://www.ncbi.nlm.nih.gov/pubmed/22028654", "http://www.ncbi.nlm.nih.gov/pubmed/21639892", "http://www.ncbi.nlm.nih.gov/pubmed/24779355", "http://www.ncbi.nlm.nih.gov/pubmed/12492838", "http://www.ncbi.nlm.nih.gov/pubmed/17222149", "http://www.ncbi.nlm.nih.gov/pubmed/26198851", "http://www.ncbi.nlm.nih.gov/pubmed/26679010", "http://www.ncbi.nlm.nih.gov/pubmed/17555271"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0032098", "o": "http://linkedlifedata.com/resource/umls/label/A18593376"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18593376", "o": "plants"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0032098", "o": "plant"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0032098", "o": "http://linkedlifedata.com/resource/umls/label/A0486695"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0486695", "o": "plant"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0450254", "o": "Pathogenic organism"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0450254", "o": "http://linkedlifedata.com/resource/umls/label/A18639324"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18639324", "o": "pathogenic organism"}], "ideal_answer": ["Fusarium graminearum is a broad host pathogen threatening cereal crops in temperate regions around the world.", "Fusarium graminearum is a broad host pathogen threatening cereal crops in temperate regions around the world. "], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005670", "http://www.biosemantics.org/jochem#4053737", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010945"], "type": "factoid", "id": "58f3ca5c70f9fc6f0f00000d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Fusarium graminearum is a broad host pathogen threatening cereal crops in temperate regions around the world. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26693688", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 342, "text": "Fusarium head blight (FHB) of small cereals is a disease of global importance with regard to economic losses and mycotoxin contamination harmful to human and animal health. In Germany, FHB is predominantly associated with wheat and F. graminearum is recognised as the major causal agent of the disease, but little is known about FHB of barley", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679010", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Fusarium graminearum is a filamentous fungal pathogen that causes wheat Fusarium head blight", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607286", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Disruption of the GABA shunt affects mitochondrial respiration and virulence in the cereal pathogen Fusarium graminearum.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26305050", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Fusarium graminearum is an important plant pathogen that causes head blight of major cereal crops", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22028654", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Fusarium graminearum is a ubiquitous pathogen of cereal crops, including wheat, barley, and maize", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17555271", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Disruption of the GABA shunt affects mitochondrial respiration and virulence in the cereal pathogen Fusarium graminearum.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26305050", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "The Ascomycete pathogen Fusarium graminearum can infect all cereal species and lower grain yield, quality and safety.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18179606", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Arabidopsis is susceptible to the cereal ear blight fungal pathogens Fusarium graminearum and Fusarium culmorum.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12492838", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Fusarium head blight (FHB) is a devastating disease of small grain cereal crops caused by the necrotrophic pathogen Fusarium graminearum and Fusarium culmorum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17031651", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "The cereal pathogen Fusarium graminearum threatens food and feed production worldwide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26305050", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 165, "text": " necrotrophic fungal pathogen Fusarium that cause head blight and crown rot of cereals including wheat also infect a number of alternative host plants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17222149", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 101, "text": "Fusarium species cause Fusarium head blight (FHB) and other important diseases of cereals", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21639892", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 131, "text": "usarium graminearum is a toxigenic fungal pathogen that causes Fusarium head blight (FHB) and crown rot on cereal crops worldwide.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24779355", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 95, "text": "usarium graminearum is the fungal pathogen that causes globally important diseases of cereals ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26882849", "endSection": "abstract"}, {"offsetInBeginSection": 223, "offsetInEndSection": 344, "text": "Fusarium graminearum, the causal agent of head scab disease of small grain cereals which threatens global food security. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26198851", "endSection": "abstract"}]}, {"body": "List viral vectors used in gene therapy.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26611583", "http://www.ncbi.nlm.nih.gov/pubmed/25636961", "http://www.ncbi.nlm.nih.gov/pubmed/26611600", "http://www.ncbi.nlm.nih.gov/pubmed/25962909", "http://www.ncbi.nlm.nih.gov/pubmed/24519667", "http://www.ncbi.nlm.nih.gov/pubmed/26607476"], "ideal_answer": ["adeno-associated viruses\nlentiviruses\nherpes simplex viral vector"], "type": "list", "id": "58ea59273e8b6dc87c000012", "snippets": [{"offsetInBeginSection": 228, "offsetInEndSection": 450, "text": "Not only can some genetically engineered adenoviral vectors achieve remarkably efficient and specific gene delivery to target cells, but they also may act as anticancer agents by selectively replicating within cancer cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26611583", "endSection": "abstract"}, {"offsetInBeginSection": 349, "offsetInEndSection": 503, "text": ". Using these criteria, we then evaluate approaches made to model PD using viral vectors to date, including both adeno-associated viruses and lentiviruses", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26611600", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "Recombinant AAV (rAAV) vectors are a suitable vector for gene therapy studies because of desired characteristics such as low immunogenicity, transfection of non-dividing and dividing cells, and long-term expression of the transgene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 292, "text": "Over the last five years, the number of clinical trials involving AAV (adeno-associated virus) and lentiviral vectors continue to increase by about 150 trials each year. For continued success, AAV and lentiviral expression cassettes need to be designed to meet each disease's specific needs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25636961", "endSection": "abstract"}, {"offsetInBeginSection": 516, "offsetInEndSection": 633, "text": "describes commonly used gene therapeutics (herpes simplex viral vector (HSV) and adeno-associated viral vector (AAV))", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25962909", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "This study examined the efficacy of gene therapy of lung adenocarcinoma using specifically controlled type I herpes simplex virus recombinant vector expressing Gibbon ape leukemia virus membrane fusion glycoprotein gene (GALV.fus)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24519667", "endSection": "abstract"}]}, {"body": "Is dexamethasone recommended for treatment of intracerebral hemorrhage?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19108704", "http://www.ncbi.nlm.nih.gov/pubmed/16034939", "http://www.ncbi.nlm.nih.gov/pubmed/3574383"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0011777", "o": "dexamethasone"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0011777", "o": "http://linkedlifedata.com/resource/umls/label/A0477612"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0477612", "o": "dexamethasone"}], "ideal_answer": ["No. Dexamethasone and other glucocorticoids should be avoided for treatment of intracerebral hemorrhage because they do not improve patient outcome and are associated with increased risk of side effects."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002543", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045506", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4271528", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020299", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003907", "http://www.biosemantics.org/jochem#4271528"], "type": "yesno", "id": "58ec5ffaeda5a5767200000a", "snippets": [{"offsetInBeginSection": 625, "offsetInEndSection": 684, "text": "Dexamethasone and other glucocorticoids should be avoided. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19108704", "endSection": "abstract"}, {"offsetInBeginSection": 582, "offsetInEndSection": 1206, "text": "During the third interim analysis, the death rate at the 21st day was identical in the two groups (dexamethasone vs. placebo, 21 of 46 vs. 21 of 47; chi-square = 0.01, P = 0.93). In contrast, the rate of complications (mostly infections and complications of diabetes) was much higher in the dexamethasone group (chi-square = 10.89, P less than 0.001), leading to early termination of the study. In the light of the absence of a demonstrable beneficial effect and the presence of a significant harmful effect, current practices of using dexamethasone for treatment of primary supratentorial hemorrhage should be reconsidered.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3574383", "endSection": "abstract"}, {"offsetInBeginSection": 977, "offsetInEndSection": 1206, "text": "In the light of the absence of a demonstrable beneficial effect and the presence of a significant harmful effect, current practices of using dexamethasone for treatment of primary supratentorial hemorrhage should be reconsidered.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3574383", "endSection": "abstract"}]}, {"body": "What happens upon disruption of a TAD boundary?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22495304", "http://www.ncbi.nlm.nih.gov/pubmed/25959774"], "ideal_answer": ["rewiring occurred only if the variant disrupted a ctcf-associated boundary domain . of a tad boundary causes ectopic chromosomal contacts and long-range transcriptional misregulation. . of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions . ", "Disruption of a TAD boundary causes ectopic chromosomal contacts and long-range transcriptional misregulation. This rewiring occurred only if the variant disrupted a CTCF-associated boundary domain. Both in mouse limb tissue and patient-derived fibroblasts, disease-relevant structural changes cause ectopic interactions between promoters and non-coding DNA, and a cluster of limb enhancers normally associated with Epha4 is misplaced relative to TAD boundaries and drives ectopic limb expression of another gene in the locus. Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions. ", "This rewiring occurred only if the variant disrupted a CTCF-associated boundary domain.  Disruption of a TAD boundary causes ectopic chromosomal contacts and long-range transcriptional misregulation. Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions Both in mouse limb tissue and patient-derived fibroblasts, disease-relevant structural changes cause ectopic interactions between promoters and non-coding DNA, and a cluster of limb enhancers normally associated with Epha4 is misplaced relative to TAD boundaries and drives ectopic limb expression of another gene in the locus.", "both in mouse limb tissue and patient-derived fibroblasts, disease-relevant structural changes cause ectopic interactions between promoters and non-coding dna, and a cluster of limb enhancers normally associated with epha4 is misplaced relative to tad boundaries and drives ectopic limb expression of another gene in the locus.", "Disruption of a TAD boundary causes ectopic chromosomal contacts and long-range transcriptional misregulation. This rewiring occurred only if the variant disrupted a CTCF-associated boundary domain. ", "Disruption of a TAD boundary causes ectopic chromosomal contacts and long-range transcriptional misregulation. Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions. Both in mouse limb tissue and patient-derived fibroblasts, disease-relevant structural changes cause ectopic interactions between promoters and non-coding DNA, and a cluster of limb enhancers normally associated with Epha4 is misplaced relative to TAD boundaries and drives ectopic limb expression of another gene in the locus. This rewiring occurred only if the variant disrupted a CTCF-associated boundary domain. ", "Disruption of a TAD boundary causes ectopic chromosomal contacts and long-range transcriptional misregulation.", "Disruption of a TAD boundary causes ectopic chromosomal contacts and long-range transcriptional misregulation. In this way, disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions. This rewiring occurred only if the variant disrupted a CTCF-associated boundary domain.", "Disruption of a TAD boundary causes ectopic chromosomal contacts and long-range transcriptional misregulation. Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions Both in mouse limb tissue and patient-derived fibroblasts, disease-relevant structural changes cause ectopic interactions between promoters and non-coding DNA, and a cluster of limb enhancers normally associated with Epha4 is misplaced relative to TAD boundaries and drives ectopic limb expression of another gene in the locus. This rewiring occurred only if the variant disrupted a CTCF-associated boundary domain. "], "type": "summary", "id": "58eb984aeda5a57672000008", "snippets": [{"offsetInBeginSection": 999, "offsetInEndSection": 1109, "text": "Disruption of a TAD boundary causes ectopic chromosomal contacts and long-range transcriptional misregulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22495304", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25959774", "endSection": "title"}, {"offsetInBeginSection": 471, "offsetInEndSection": 798, "text": "Both in mouse limb tissue and patient-derived fibroblasts, disease-relevant structural changes cause ectopic interactions between promoters and non-coding DNA, and a cluster of limb enhancers normally associated with Epha4 is misplaced relative to TAD boundaries and drives ectopic limb expression of another gene in the locus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25959774", "endSection": "abstract"}, {"offsetInBeginSection": 799, "offsetInEndSection": 887, "text": "This rewiring occurred only if the variant disrupted a CTCF-associated boundary domain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25959774", "endSection": "abstract"}, {"offsetInBeginSection": 993, "offsetInEndSection": 1103, "text": "Disruption of a TAD boundary causes ectopic chromosomal contacts and long-range transcriptional misregulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22495304", "endSection": "abstract"}]}, {"body": "List the classical symptoms of the Moschcowitz syndrome (Thrombotic thrombocytopenic purpura).", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/6757857", "http://www.ncbi.nlm.nih.gov/pubmed/10714127", "http://www.ncbi.nlm.nih.gov/pubmed/6752882", "http://www.ncbi.nlm.nih.gov/pubmed/21853406", "http://www.ncbi.nlm.nih.gov/pubmed/21184040", "http://www.ncbi.nlm.nih.gov/pubmed/14727263", "http://www.ncbi.nlm.nih.gov/pubmed/10668344", "http://www.ncbi.nlm.nih.gov/pubmed/2107174", "http://www.ncbi.nlm.nih.gov/pubmed/9036362", "http://www.ncbi.nlm.nih.gov/pubmed/16240903", "http://www.ncbi.nlm.nih.gov/pubmed/7712934", "http://www.ncbi.nlm.nih.gov/pubmed/16388418", "http://www.ncbi.nlm.nih.gov/pubmed/11450586", "http://www.ncbi.nlm.nih.gov/pubmed/7863389", "http://www.ncbi.nlm.nih.gov/pubmed/25168331", "http://www.ncbi.nlm.nih.gov/pubmed/3752426", "http://www.ncbi.nlm.nih.gov/pubmed/12923683"], "ideal_answer": ["The typical manifestations of Moschocowitz syndrome (Thrombotic-thrombocytopenic purpura) are:\n1) thrombocytopenia, \n2) haemolysis, \n3) fever, \n4) coma and \n5) renal failure."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011696", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011697", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "http://www.disease-ontology.org/api/metadata/DOID:225", "http://www.disease-ontology.org/api/metadata/DOID:10772"], "type": "list", "id": "58dd07488acda34529000025", "snippets": [{"offsetInBeginSection": 1439, "offsetInEndSection": 1602, "text": "The combination of neurological symptoms, thrombocytopenia, fever, renal failure and hemolytic anemia in a patient taking ticlopidine points to a diagnosis of TTP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10668344", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "In addition to the typical manifestations of thrombotic-thrombocytopenic purpura like thrombocytopenia, haemolysis, fever, coma and renal failure, signs of a beginning DIC could be seen in a patient after abdominal surgery. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3752426", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Moschcowitz syndrome or thrombotic thrombocytopenic purpura is a rare disorder with a poor prognosis. This syndrome is characterized by a microangiopathic hemolytic anemia with thrombocytopenia, neurologic symptoms and renal disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6752882", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Moschcowitz's syndrome is a rare condition with poor prognosis. It is characterized by a microangiopathic haemolytic anaemia associated with thrombocytopenia, neurological symptoms and renal involvement.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6757857", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 238, "text": "Thrombotic thrombocytopenic purpura (TTP), in 1924 first described by Moschcowitz, is a clinically heterogeneous syndrome associated with thrombocytopenia, Coombs-negative hemolytic anemia, neurologic changes, renal impairment, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11450586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 237, "text": "Thrombotic thrombocytopenic purpura (TTP), in 1924 first described by Moschcowitz, is a clinically heterogeneous syndrome associated with thrombocytopenia, Coombs-negative hemolytic anemia, neurologic changes, renal impairment, and fever", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11450586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Thrombotic thrombocytopenic purpura (TTP, Moschcowitz disease) is characterized by thrombotic microangiopathy leading to microvascular occlusion and ischemic dysfunction of various organs including the brain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25168331", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 337, "text": "Severe deficiency of von Willebrand factor-cleaving protease (ADAMTS-13) activity (<5% of normal) is specific for classical thrombotic thrombocytopenic purpura (TTP), a disorder presenting with thrombocytopenia, microangiopathic haemolytic anaemia and often with organ dysfunction such as neurological symptoms, renal failure, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12923683", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 370, "text": "In a 57-year-old female patient, who was admitted with fluctuating central neurological abnormalities and generalized purpura, was made the diagnosis of a thrombotic thrombocytopenic purpura (TTP, Moschcowitz' syndrome).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10714127", "endSection": "abstract"}, {"offsetInBeginSection": 619, "offsetInEndSection": 862, "text": "Thrombotic thrombocytopenic purpura (TTP) is a syndrome that occurs mainly in adults with multiorgan microvascular thrombosis consisting of thrombocytopenia, microangiopathic hemolytic anemia, neurologic symptoms, renal involvement, and fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2107174", "endSection": "abstract"}]}, {"body": "Is airplane stroke syndrome a common disease.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16128878", "http://www.ncbi.nlm.nih.gov/pubmed/26892280", "http://www.ncbi.nlm.nih.gov/pubmed/26898578", "http://www.ncbi.nlm.nih.gov/pubmed/11914416"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0038454", "o": "Stroke"}], "ideal_answer": ["No. Only 37 cases of stroke during or soon after long-haul flights have been published. A single center study reported that 42 out of 5727 stroke admissions (0.73%) were flight-related strokes."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020521"], "type": "yesno", "id": "58ec613ceda5a5767200000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Only 37 cases of stroke during or soon after long-haul flights have been published to our knowledge. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26898578", "endSection": "abstract"}, {"offsetInBeginSection": 642, "offsetInEndSection": 730, "text": "Our centre admitted 5727 stroke patients, of whom 42 (0.73%) had flight-related strokes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26898578", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "The authors report three cases of ischemic stroke in young adults that occurred during or after an airplane flight.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11914416", "endSection": "abstract"}]}, {"body": "Which R / bioconductor package is used for enrichment analysis of genomic regions?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26508757"], "ideal_answer": ["locus overlap analysis (lola) provides easy and automatable enrichment analysis for genomic region sets, thus facilitating the interpretation of functional genomics and epigenomics data.", "Genomic datasets are often interpreted in the context of large-scale reference databases. Locus Overlap Analysis (LOLA) provides easy and automatable enrichment analysis for genomic region sets, thus facilitating the interpretation of functional genomics and epigenomics data.", "Locus Overlap Analysis (LOLA) provides easy and automatable enrichment analysis for genomic region sets, thus facilitating the interpretation of functional genomics and epigenomics data."], "type": "factoid", "id": "587e3e302420191125000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "LOLA: enrichment analysis for genomic region sets and regulatory elements in R and Bioconductor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26508757", "endSection": "title"}, {"offsetInBeginSection": 281, "offsetInEndSection": 467, "text": "Locus Overlap Analysis (LOLA) provides easy and automatable enrichment analysis for genomic region sets, thus facilitating the interpretation of functional genomics and epigenomics data.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26508757", "endSection": "abstract"}, {"offsetInBeginSection": 269, "offsetInEndSection": 654, "text": "Locus Overlap Analysis (LOLA) provides easy and automatable enrichment analysis for genomic region sets, thus facilitating the interpretation of functional genomics and epigenomics data.R package available in Bioconductor and on the following website: http://lola.computational-epigenetics.org.nsheffield@cemm.oeaw.ac.at or cbock@cemm.oeaw.ac.at.<CopyrightInformation>\u00a9 The Author 2015", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26508757", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "LOLA: enrichment analysis for genomic region sets and regulatory elements in R and Bioconductor", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26508757", "endSection": "title"}, {"offsetInBeginSection": 269, "offsetInEndSection": 655, "text": "Locus Overlap Analysis (LOLA) provides easy and automatable enrichment analysis for genomic region sets, thus facilitating the interpretation of functional genomics and epigenomics data.R package available in Bioconductor and on the following website: http://lola.computational-epigenetics.org.nsheffield@cemm.oeaw.ac.at or cbock@cemm.oeaw.ac.at.<CopyrightInformation>\u00a9 The Author 2015.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26508757", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "LOLA: enrichment analysis for genomic region sets and regulatory elements in R and Bioconductor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26508757", "endSection": "title"}, {"offsetInBeginSection": 269, "offsetInEndSection": 455, "text": "Locus Overlap Analysis (LOLA) provides easy and automatable enrichment analysis for genomic region sets, thus facilitating the interpretation of functional genomics and epigenomics data.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26508757", "endSection": "abstract"}]}, {"body": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24137011", "http://www.ncbi.nlm.nih.gov/pubmed/26656153", "http://www.ncbi.nlm.nih.gov/pubmed/25555396", "http://www.ncbi.nlm.nih.gov/pubmed/17018572", "http://www.ncbi.nlm.nih.gov/pubmed/20886259"], "ideal_answer": ["Adenosine deaminases that act on RNA [adenosine deaminase, RNA specific (ADAR)] catalyze the site-specific conversion of adenosine to inosine in primary mRNA transcripts. The ADAR RNA editing enzyme controls neuronal excitability in Drosophila melanogaster. TIRs were deduced to form dsRNAs as a putative target of ADAR. Genetic Determinants of RNA Editing Levels of ADAR Targets in Drosophila melanogaster. RNA editing usually affects only a fraction of expressed transcripts and there is a vast amount of variation in editing levels of ADAR (adenosine deaminase, RNA-specific) targets. ", "The ADAR (adenosine deaminase, RNA-specific) RNA editing enzyme controls neuronal excitability in Drosophila melanogaster.", "Adenosine deaminases that act on RNA [adenosine deaminase, RNA specific (ADAR)] catalyze the site-specific conversion of adenosine to inosine in primary mRNA transcripts. The ADAR RNA editing enzyme controls neuronal excitability in Drosophila melanogaster. Genetic Determinants of RNA Editing Levels of ADAR Targets in Drosophila melanogaster. TIRs were deduced to form dsRNAs as a putative target of ADAR. we show that expression of the editing enzyme, ADAR (adenosine deaminase acting on RNA), is dramatically decreased at elevated temperatures, partially, but not fully, explaining some target responses to temperature. ", "Adenosine-to-inosine RNA editing is a highly conserved process that post-transcriptionally modifies mRNA, generating proteomic diversity, particularly within the nervous system of metazoans. RNA editing usually affects only a fraction of expressed transcripts and there is a vast amount of variation in editing levels of ADAR (adenosine deaminase, RNA-specific) targets. RNA editing by deamination of specific adenosine bases to inosines during pre-mRNA processing generates edited isoforms of proteins. RNA editing is proposed as a modulator of transcriptomes, but its biological impact has not been fully elucidated. Adenosine deaminases that act on RNA [adenosine deaminase, RNA specific (ADAR)] catalyze the site-specific conversion of adenosine to inosine in primary mRNA transcripts.", "adar", "RNA editing usually affects only a fraction of expressed transcripts and there is a vast amount of variation in editing levels of ADAR (adenosine deaminase, RNA-specific) targets. Adenosine-to-inosine RNA editing is a highly conserved process that post-transcriptionally modifies mRNA, generating proteomic diversity, particularly within the nervous system of metazoans.", "Adenosine deaminases that act on RNA [adenosine deaminase, RNA specific (ADAR)] catalyze the site-specific conversion of adenosine to inosine in primary mRNA transcripts. TIRs were deduced to form dsRNAs as a putative target of ADAR. ", "Adenosine deaminases that act on RNA [adenosine deaminase, RNA specific (ADAR)] catalyze the site-specific conversion of adenosine to inosine in primary mRNA transcripts. TIRs were deduced to form dsRNAs as a putative target of ADAR. The ADAR RNA editing enzyme controls neuronal excitability in Drosophila melanogaster. Genetic Determinants of RNA Editing Levels of ADAR Targets in Drosophila melanogaster. RNA editing usually affects only a fraction of expressed transcripts and there is a vast amount of variation in editing levels of ADAR (adenosine deaminase, RNA-specific) targets. ", "GABA inhibitory signalling is impaired in human epileptic and autistic conditions, and vertebrate ADARs may have a relevant evolutionarily conserved control over neuronal excitability. RNA editing usually affects only a fraction of expressed transcripts and there is a vast amount of variation in editing levels of ADAR (adenosine deaminase, RNA-specific) targets.", "Adenosine deaminases that act on RNA [adenosine deaminase, RNA specific (ADAR)] catalyze the site-specific conversion of adenosine to inosine in primary mRNA transcripts."], "type": "factoid", "id": "58e9e7aa3e8b6dc87c00000d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Adenosine deaminases that act on RNA [adenosine deaminase, RNA specific (ADAR)] catalyze the site-specific conversion of adenosine to inosine in primary mRNA transcripts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17018572", "endSection": "abstract"}, {"offsetInBeginSection": 664, "offsetInEndSection": 727, "text": "TIRs were deduced to form dsRNAs as a putative target of ADAR. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20886259", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "The ADAR RNA editing enzyme controls neuronal excitability in Drosophila melanogaster.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137011", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Genetic Determinants of RNA Editing Levels of ADAR Targets in Drosophila melanogaster.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26656153", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "RNA editing usually affects only a fraction of expressed transcripts and there is a vast amount of variation in editing levels of ADAR (adenosine deaminase, RNA-specific) targets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26656153", "endSection": "abstract"}, {"offsetInBeginSection": 967, "offsetInEndSection": 1183, "text": "we show that expression of the editing enzyme, ADAR (adenosine deaminase acting on RNA), is dramatically decreased at elevated temperatures, partially, but not fully, explaining some target responses to temperature. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25555396", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "The ADAR RNA editing enzyme controls neuronal excitability in Drosophila melanogaster", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137011", "endSection": "title"}, {"offsetInBeginSection": 98, "offsetInEndSection": 421, "text": "In Drosophila, many messenger RNAs involved in neuro-transmission are re-coded at the RNA level by the RNA-editing enzyme, dADAR, leading to the incorporation of amino acids that are not directly encoded by the genome. dADAR also re-codes its own transcript, but the consequences of this auto-regulation in vivo are unclear", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22531175", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "Novel putative nicotinic acetylcholine receptor subunit genes, Dalpha5, Dalpha6 and Dalpha7, in Drosophila melanogaster identify a new and highly conserved target of adenosine deaminase acting on RNA-mediated A-to-I pre-mRNA editing", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11973307", "endSection": "title"}, {"offsetInBeginSection": 268, "offsetInEndSection": 444, "text": "The genome of the fruitfly, Drosophila melanogaster, contains a single gene encoding the enzyme responsible for deamination, termed ADAR (for adenosine deaminase acting on RNA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662845", "endSection": "abstract"}, {"offsetInBeginSection": 293, "offsetInEndSection": 852, "text": "Using these and other available data, we discovered and analyzed thousands of neuronal human and mouse circRNAs. circRNAs were extraordinarily enriched in the mammalian brain, well conserved in sequence, often expressed as circRNAs in both human and mouse, and sometimes even detected in Drosophila brains. circRNAs were overall upregulated during neuronal differentiation, highly enriched in synapses, and often differentially expressed compared to their\u00a0mRNA isoforms. circRNA expression correlated\u00a0negatively with expression of the RNA-editing enzyme ADAR1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25921068", "endSection": "abstract"}, {"offsetInBeginSection": 611, "offsetInEndSection": 913, "text": "While several ADAR enzymes are present in mice, the presence of a single ADAR in Drosophila, combined with the diverse genetic toolkit available to researchers and the wide range of ADAR target mRNAs identified to date, make Drosophila an ideal organism to study the genetic basis of A-to-I RNA editing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662845", "endSection": "abstract"}, {"offsetInBeginSection": 160, "offsetInEndSection": 536, "text": "Aside from their role in generating protein diversity in the central nervous system, ADARs have been implicated in the hypermutation of some RNA viruses, although why this hypermutation occurs is not well understood.Here we describe the hypermutation of adenosines to guanosines in the genome of the sigma virus--a negative sense RNA virus that infects Drosophila melanogaster", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19941656", "endSection": "abstract"}, {"offsetInBeginSection": 268, "offsetInEndSection": 445, "text": "The genome of the fruitfly, Drosophila melanogaster, contains a single gene encoding the enzyme responsible for deamination, termed ADAR (for adenosine deaminase acting on RNA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662845", "endSection": "abstract"}, {"offsetInBeginSection": 644, "offsetInEndSection": 979, "text": "The enzyme has no activity on dsRNA substrates but is a tRNA deaminase with specificity for adenosine 37 of insect alanine tRNA. dADAT1 shows greater similarity to vertebrate ADARs than to yeast Tad1p, supporting the hypothesis of a common evolutionary origin for ADARs and ADATs. dAdat1 transcripts are maternally supplied in the egg.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10629039", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "The ADAR RNA editing enzyme controls neuronal excitability in Drosophila melanogaster.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137011", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Genetic Determinants of RNA Editing Levels of ADAR Targets in Drosophila melanogaster.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26656153", "endSection": "title"}, {"offsetInBeginSection": 377, "offsetInEndSection": 538, "text": "Here we describe the hypermutation of adenosines to guanosines in the genome of the sigma virus--a negative sense RNA virus that infects Drosophila melanogaster.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19941656", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "The RNA editing enzyme ADAR chemically modifies adenosine (A) to inosine (I), which is interpreted by the ribosome as a guanosine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22658416", "endSection": "abstract"}, {"offsetInBeginSection": 98, "offsetInEndSection": 316, "text": "In Drosophila, many messenger RNAs involved in neuro-transmission are re-coded at the RNA level by the RNA-editing enzyme, dADAR, leading to the incorporation of amino acids that are not directly encoded by the genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22531175", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Drosophila melanogaster has a single Adar gene encoding a protein related to mammalian ADAR2 that edits transcripts encoding glutamate receptor subunits.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21761288", "endSection": "abstract"}, {"offsetInBeginSection": 611, "offsetInEndSection": 914, "text": "While several ADAR enzymes are present in mice, the presence of a single ADAR in Drosophila, combined with the diverse genetic toolkit available to researchers and the wide range of ADAR target mRNAs identified to date, make Drosophila an ideal organism to study the genetic basis of A-to-I RNA editing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17662845", "endSection": "abstract"}]}, {"body": "What is the CEGA catalog?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26527719"], "ideal_answer": ["CEGA is a catalog of conserved elements from genomic alignments. Harnessing the power of multiple species comparisons to detect genomic elements under purifying selection, CEGA provides a comprehensive set of CNCs identified at different radiations along the vertebrate lineage. Evolutionary constraint is identified using threshold-free phylogenetic modeling of unbiased and sensitive global alignments of genomic synteny blocks identified using protein orthology. The dynamic CEGA web interface displays alignments, genomic locations, as well as biologically relevant data to help prioritize and select CNCs of interest for further functional investigations."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017124"], "type": "summary", "id": "5880a46d3d0145644d000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "CEGA--a catalog of conserved elements from genomic alignments.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527719", "endSection": "title"}, {"offsetInBeginSection": 712, "offsetInEndSection": 1830, "text": "To facilitate the study of such CNCs/UCEs, we present our resource of Conserved Elements from Genomic Alignments (CEGA), accessible from http://cega.ezlab.org. Harnessing the power of multiple species comparisons to detect genomic elements under purifying selection, CEGA provides a comprehensive set of CNCs identified at different radiations along the vertebrate lineage. Evolutionary constraint is identified using threshold-free phylogenetic modeling of unbiased and sensitive global alignments of genomic synteny blocks identified using protein orthology. We identified CNCs independently for five vertebrate clades, each referring to a different last common ancestor and therefore to an overlapping but varying set of CNCs with 24 488 in vertebrates, 241 575 in amniotes, 709 743 in Eutheria, 642 701 in Boreoeutheria and 612 364 in Euarchontoglires, spanning from 6 Mbp in vertebrates to 119 Mbp in Euarchontoglires. The dynamic CEGA web interface displays alignments, genomic locations, as well as biologically relevant data to help prioritize and select CNCs of interest for further functional investigations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527719", "endSection": "abstract"}, {"offsetInBeginSection": 709, "offsetInEndSection": 868, "text": "To facilitate the study of such CNCs/UCEs, we present our resource of Conserved Elements from Genomic Alignments (CEGA), accessible from http://cega.ezlab.org.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527719", "endSection": "abstract"}, {"offsetInBeginSection": 712, "offsetInEndSection": 870, "text": "To facilitate the study of such CNCs/UCEs, we present our resource of Conserved Elements from Genomic Alignments (CEGA), accessible from http://cega.ezlab.org", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527719", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "CEGA--a catalog of conserved elements from genomic alignments", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527719", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "CEGA--a catalog of conserved elements from genomic alignments.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527719", "endSection": "title"}, {"offsetInBeginSection": 712, "offsetInEndSection": 871, "text": "To facilitate the study of such CNCs/UCEs, we present our resource of Conserved Elements from Genomic Alignments (CEGA), accessible from http://cega.ezlab.org.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527719", "endSection": "abstract"}]}, {"body": "Which protein is associated with hyperemesis gravidarum during pregrancy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25963653", "http://www.ncbi.nlm.nih.gov/pubmed/20735820", "http://www.ncbi.nlm.nih.gov/pubmed/11380287", "http://www.ncbi.nlm.nih.gov/pubmed/21360554"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0020450", "o": "http://linkedlifedata.com/resource/umls/label/A18647822"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18647822", "o": "gravidarum hyperemesis"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0020450", "o": "http://linkedlifedata.com/resource/umls/label/A18610602"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18610602", "o": "excessive vomiting in pregnancy"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0020450", "o": "Hyperemesis Gravidarum"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0020450", "o": "http://linkedlifedata.com/resource/umls/label/A18666384"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18666384", "o": "hyperemesis gravidarum"}], "ideal_answer": ["Human chorionic gonadotropin (hCG) is associated with hyperemesis gravidarum during pregrancy."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014839", "http://www.disease-ontology.org/api/metadata/DOID:1832", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006939", "http://www.disease-ontology.org/api/metadata/DOID:9357", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018997"], "type": "factoid", "id": "58da1aa08acda34529000012", "snippets": [{"offsetInBeginSection": 1105, "offsetInEndSection": 1246, "text": "Maternal smoking, BMI, parity, ethnicity, fetal gender, placental weight and hyperemesis gravidarum symptoms were associated with total hCG. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25963653", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "First trimester maternal serum PAPP-A and free \u03b2-HCG levels in hyperemesis gravidarum.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21360554", "endSection": "title"}, {"offsetInBeginSection": 896, "offsetInEndSection": 1043, "text": "HG is associated with elevated levels of PAPP-A and free \u03b2-hCG, and such changes are independent of serum indicators of thyroid and liver function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21360554", "endSection": "abstract"}, {"offsetInBeginSection": 462, "offsetInEndSection": 1133, "text": "hCG promotes progesterone production by corpus luteal cells; promotes angiogenesis in uterine vasculature; promoted the fusion of cytotrophoblast cell and differentiation to make syncytiotrophoblast cells; causes the blockage of any immune or macrophage action by mother on foreign invading placental cells; causes uterine growth parallel to fetal growth; suppresses any myometrial contractions during the course of pregnancy; causes growth and differentiation of the umbilical cord; signals the endometrium about forthcoming implantation; acts on receptor in mother's brain causing hyperemesis gravidarum, and seemingly promotes growth of fetal organs during pregnancy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735820", "endSection": "abstract"}]}, {"body": "Is hydroxyurea usually used to treated infectious disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21196716", "http://www.ncbi.nlm.nih.gov/pubmed/26275071", "http://www.ncbi.nlm.nih.gov/pubmed/27677923", "http://www.ncbi.nlm.nih.gov/pubmed/15307105", "http://www.ncbi.nlm.nih.gov/pubmed/20008183"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0020402", "o": "hydroxyurea"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0020402", "o": "http://linkedlifedata.com/resource/umls/label/A0481276"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0481276", "o": "hydroxyurea"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0020402", "o": "http://linkedlifedata.com/resource/umls/label/A7996376"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7996376", "o": "hydroxyurea"}], "ideal_answer": ["Hydroxyurea represents the only available disease-modifying therapy for Sickle Cell Anemia (SCA)."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:10923", "http://www.biosemantics.org/jochem#4275774", "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275774", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000755", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006450", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006918"], "type": "yesno", "id": "58dbbdac8acda3452900001e", "snippets": [{"offsetInBeginSection": 156, "offsetInEndSection": 294, "text": "Hydroxyurea represents the only available disease-modifying therapy for SCA, and has proven safety and efficacy in high-resource countries", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275071", "endSection": "abstract"}, {"offsetInBeginSection": 1579, "offsetInEndSection": 1777, "text": "In conclusion, the data here presented suggests that hydroxyurea may prevent priapism attacks in sickle cell disease, probably at higher doses than usually prescribed for painful crisis prevention..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15307105", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196716", "endSection": "title"}, {"offsetInBeginSection": 405, "offsetInEndSection": 546, "text": "t may also attenuate optimal response to hydroxyurea therapy, the only effective and practical treatment option for SCD in sub-Saharan Africa", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27677923", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Hydroxyurea is one of the most successfully used therapies for sickle cell disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15307105", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulating for the past 25 years. The bulk of the current evidence suggests that hydroxyurea is well-tolerated, safe, and efficacious for most patients with SCD", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20008183", "endSection": "abstract"}]}, {"body": "What is magnetoreception?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25551148", "http://www.ncbi.nlm.nih.gov/pubmed/25535848", "http://www.ncbi.nlm.nih.gov/pubmed/26727944", "http://www.ncbi.nlm.nih.gov/pubmed/26953690", "http://www.ncbi.nlm.nih.gov/pubmed/26811445", "http://www.ncbi.nlm.nih.gov/pubmed/27614751", "http://www.ncbi.nlm.nih.gov/pubmed/27216936"], "ideal_answer": ["Magnetoreception is an enigmatic, poorly understood sensory ability, described mainly on the basis of behavioural studies in animals of diverse taxa. The ability to perceive geomagnetic fields (GMFs) represents a fascinating biological phenomenon. Studies on transgenic flies have provided evidence that photosensitive Cryptochromes (Cry) are involved in the response to magnetic fields (MFs). The photoreceptor protein cryptochrome is thought to host, upon light absorption, a radical pair that is sensitive to very weak magnetic fields, endowing migratory birds with a magnetic compass sense."], "type": "summary", "id": "58ea6c3eeda5a57672000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 244, "text": "The ability to perceive geomagnetic fields (GMFs) represents a fascinating biological phenomenon. Studies on transgenic flies have provided evidence that photosensitive Cryptochromes (Cry) are involved in the response to magnetic fields (MFs). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26811445", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Cryptochromes, blue-light absorbing proteins involved in the circadian clock, have been proposed to be the receptor molecules of the avian magnetic compass. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26953690", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 366, "text": "Although it has been known for almost half a century that migratory birds can detect the direction of the Earth's magnetic field, the primary sensory mechanism behind this remarkable feat is still unclear. The leading hypothesis centers on radical pairs-magnetically sensitive chemical intermediates formed by photoexcitation of cryptochrome proteins in the retina. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27216936", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Biogenic magnetic particles have been detected in some migratory insects, which implies the basis of magnetoreception mechanism for orientation and navigation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26727944", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 306, "text": "Magnetoreception is essential for magnetic orientation in animal migration. The molecular basis for magnetoreception has recently been elucidated in fruitfly as complexes between the magnetic receptor magnetoreceptor (MagR) and its ligand cryptochrome (Cry). MagR and Cry are present in the animal kingdom.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27614751", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Magnetoreception is an enigmatic, poorly understood sensory ability, described mainly on the basis of behavioural studies in animals of diverse taxa. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25551148", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "The photoreceptor protein cryptochrome is thought to host, upon light absorption, a radical pair that is sensitive to very weak magnetic fields, endowing migratory birds with a magnetic compass sense.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25535848", "endSection": "abstract"}]}, {"body": "Can acupuncture cause spinal epidural hematoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27651774", "http://www.ncbi.nlm.nih.gov/pubmed/8456713", "http://www.ncbi.nlm.nih.gov/pubmed/25459742", "http://www.ncbi.nlm.nih.gov/pubmed/21289580", "http://www.ncbi.nlm.nih.gov/pubmed/21082060", "http://www.ncbi.nlm.nih.gov/pubmed/24094991"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0394664", "o": "Acupuncture"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0394664", "o": "http://linkedlifedata.com/resource/umls/label/A0472806"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0472806", "o": "acupuncture"}], "ideal_answer": ["Yes, acupuncture can cause spinal epidural hematoma."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D046748", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D026881"], "type": "yesno", "id": "5890e762621ea6ff7e000005", "snippets": [{"offsetInBeginSection": 649, "offsetInEndSection": 939, "text": "RESULTS: A 54-year-old woman, a 38-year-old woman, and a 60-year-old man with hemiplegia by cervical subdural or epidural hematoma after cervical posterior paraspinal muscle needling without direct invasion (intramuscular stimulation, acupuncture, or intramuscular lidocaine) were observed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459742", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Acute spinal subdural hematoma with hemiplegia after acupuncture: a case report and review of the literature.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24094991", "endSection": "title"}, {"offsetInBeginSection": 174, "offsetInEndSection": 482, "text": "Although acupuncture has been a popular method for the management of pain control, we encountered the first case of SDH after acupuncture.PURPOSE: The purpose of this case report was to present the first case of subdural hematoma after acupuncture and the reasons for the risks of blind cervical acupuncture.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24094991", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 317, "text": "SUMMARY OF BACKGROUND DATA: Epidural hematomas after dry needling are quite unusual and only a few cases of epidural hematoma after acupuncture have been reported in the literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21289580", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Spinal epidural hematoma is a rare complication associated with pain control procedures such as facet block, acupuncture, epidural injection, etc. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21082060", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Unintentional acupuncture needling of the thoracic spinal canal produced a spinal epidural hematoma and subarachnoid hemorrhage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8456713", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Spinal epidural hematoma is a rare complication associated with pain control procedures such as facet block, acupuncture, epidural injection, etc.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21082060", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Spinal epidural hematoma with subarachnoid hemorrhage caused by acupuncture.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8456713", "endSection": "title"}, {"offsetInBeginSection": 69, "offsetInEndSection": 199, "text": "However, subarachnoid hemorrhage and spinal epidural hematoma have been reported to occur after acupuncture in the posterior neck.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27651774", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 263, "text": "A retrospective case report.The objective of this article is to report an unusual complication of dry needling.Epidural hematomas after dry needling are quite unusual and only a few cases of epidural hematoma after acupuncture have been reported in the literature", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21289580", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Spinal epidural hematoma with subarachnoid hemorrhage caused by acupuncture", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8456713", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Spinal epidural hematoma is a rare complication associated with pain control procedures such as facet block, acupuncture, epidural injection, etc", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21082060", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Unintentional acupuncture needling of the thoracic spinal canal produced a spinal epidural hematoma and subarachnoid hemorrhage", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8456713", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Spinal epidural hematoma with subarachnoid hemorrhage caused by acupuncture.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8456713", "endSection": "title"}]}, {"body": "Is edema a symptom of nephrotic syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17448310", "http://www.ncbi.nlm.nih.gov/pubmed/20368913", "http://www.ncbi.nlm.nih.gov/pubmed/10884998", "http://www.ncbi.nlm.nih.gov/pubmed/17111701", "http://www.ncbi.nlm.nih.gov/pubmed/10361423", "http://www.ncbi.nlm.nih.gov/pubmed/15852660", "http://www.ncbi.nlm.nih.gov/pubmed/1953084", "http://www.ncbi.nlm.nih.gov/pubmed/9241903", "http://www.ncbi.nlm.nih.gov/pubmed/19556043", "http://www.ncbi.nlm.nih.gov/pubmed/23510630", "http://www.ncbi.nlm.nih.gov/pubmed/21234253", "http://www.ncbi.nlm.nih.gov/pubmed/21302208", "http://www.ncbi.nlm.nih.gov/pubmed/24240509", "http://www.ncbi.nlm.nih.gov/pubmed/21454171", "http://www.ncbi.nlm.nih.gov/pubmed/17009081", "http://www.ncbi.nlm.nih.gov/pubmed/26457719", "http://www.ncbi.nlm.nih.gov/pubmed/26281851", "http://www.ncbi.nlm.nih.gov/pubmed/25722313", "http://www.ncbi.nlm.nih.gov/pubmed/23529637", "http://www.ncbi.nlm.nih.gov/pubmed/11928729", "http://www.ncbi.nlm.nih.gov/pubmed/12508485", "http://www.ncbi.nlm.nih.gov/pubmed/24533195", "http://www.ncbi.nlm.nih.gov/pubmed/10215332", "http://www.ncbi.nlm.nih.gov/pubmed/25400184", "http://www.ncbi.nlm.nih.gov/pubmed/26178548", "http://www.ncbi.nlm.nih.gov/pubmed/19194561", "http://www.ncbi.nlm.nih.gov/pubmed/16247647", "http://www.ncbi.nlm.nih.gov/pubmed/20924604"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0027726", "o": "Nephrotic Syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0027726", "o": "http://linkedlifedata.com/resource/umls/label/A0484584"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0484584", "o": "nephrotic syndrome"}], "ideal_answer": ["Yes, edema is the commonest presenting symptom and sign in nephrotic syndrome."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004487", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009404", "http://www.disease-ontology.org/api/metadata/DOID:1184"], "type": "yesno", "id": "58da270d8acda34529000013", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 192, "text": "Nephrotic syndrome (NS) is a common clinical disease with four main clinical manifestations: hypoalbuminemia (<30 g/L), macro-proteinuria (>3.5 g/24 h), edema, and hyperlipidemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26281851", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Nephrotic syndrome is an unusual manifestation of IgA Nephropathy (IgAN).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19194561", "endSection": "abstract"}, {"offsetInBeginSection": 207, "offsetInEndSection": 355, "text": "Twelve patients with IgAN with steroid-responsive nephrotic syndrome were evaluated and followed up. All patients presented with generalized edema. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19194561", "endSection": "abstract"}, {"offsetInBeginSection": 1212, "offsetInEndSection": 1406, "text": "The clinical features of sudden onset of generalized edema, initial heavy proteinuria and initial severe hypoalbuminemia might help identify the subset of patients, especially in low grade IgAN.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19194561", "endSection": "abstract"}, {"offsetInBeginSection": 608, "offsetInEndSection": 755, "text": "Most patients presented within 3 months duration (61.4%) and the most common symptom was puffiness of face (98.45%) followed by pedal edema (91%). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20368913", "endSection": "abstract"}, {"offsetInBeginSection": 117, "offsetInEndSection": 381, "text": "We analyzed medical records of 290 patients with diagnosis of nephrotic syndrome as defined by International Study of Kidney Disease in Children (ISKDC), between January 1987 and December 2000, at the Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20368913", "endSection": "abstract"}, {"offsetInBeginSection": 222, "offsetInEndSection": 402, "text": "He was admitted because of systemic edema and dyspnea on effort Laboratory data revealed renal failure and nephrotic syndrome, whereas there was no symptom of diabetic retinopathy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15852660", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 42, "text": "Nephrotic syndrome: more than just oedema.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11928729", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Oedema is the commonest presenting symptom and sign in nephrotic syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11928729", "endSection": "abstract"}, {"offsetInBeginSection": 242, "offsetInEndSection": 428, "text": "One of these five clinical syndromes is the nephrotic syndrome, which is characterized by proteinuria > 3.5 g/day accompanied by hypalbuminemia, hyperlipoproteinemia and pronounced edema", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21302208", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Tolvaptan therapy for massive edema in a patient with nephrotic syndrome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240509", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Nephrotic syndrome (NS) is characterized by water and sodium retention, which leads to edema", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240509", "endSection": "abstract"}, {"offsetInBeginSection": 94, "offsetInEndSection": 555, "text": "The non-osmotic stimulation of arginine vasopressin release from the pituitary gland has been implicated as one of the important factors in abnormal water retention in patients with NS.We present the initial description of a patient with massive edema caused by refractory nephrotic syndrome, which was effectively treated with tolvaptan, a selective oral vasopressin V2 receptor antagonist.Tolvaptan is effective for the treatment of massive edema caused by NS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240509", "endSection": "abstract"}, {"offsetInBeginSection": 318, "offsetInEndSection": 487, "text": "We report a child with steroid-resistant nephrotic syndrome with diuretic-resistant nephrotic edema treated successfully using acute peritoneal dialysis as a means of UF", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26178548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Albumin and Furosemide Combination for Management of Edema in Nephrotic Syndrome: A Review of Clinical Studies", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26457719", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "The treatment of edema in patients with nephrotic syndrome is generally managed by dietary sodium restriction and loop diuretics", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26457719", "endSection": "abstract"}, {"offsetInBeginSection": 720, "offsetInEndSection": 858, "text": "Nine months after introduction of tiopronin, the boy manifested generalized edema, oliguria, and biochemical indices of nephrotic syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20924604", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "Blessed were the days when it all made sense and the apparent mechanism for edema formation in nephrotic syndrome was straightforward: the kidneys lost protein in the urine, which lowered the plasma oncotic pressure", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23529637", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "The nephrotic syndrome is characterized by a combination of pathological lab values and clinical symptoms, i. e. pronounced proteinuria (usually more than 3 - 3,5 g protein/24 h), hypoalbuminemia, edema and hyperlipidemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25722313", "endSection": "abstract"}, {"offsetInBeginSection": 212, "offsetInEndSection": 365, "text": "The patient was admitted with edema of both legs, and the nephrotic syndrome was discovered, leading to the diagnosis of AA amyloidosis on kidney biopsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17111701", "endSection": "abstract"}, {"offsetInBeginSection": 714, "offsetInEndSection": 1086, "text": "Linear regression to relate measures.Other signs and symptoms of nephrotic syndrome at baseline (serum albumin < 3.5 g/dL, serum total cholesterol > 260 mg/dL or use of a statin, and edema or use of a loop diuretic); progression of chronic kidney disease during follow-up (doubling of baseline serum creatinine level or requirement for dialysis or kidney transplantation).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19556043", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "A case of interstitial shadows associated with oral cyclophosphamide therapy in a 32-month-old girl with steroid-resistant nephrotic syndrome, who was admitted to the Nishi-Kobe Medical Center with systemic edema, is reported.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9241903", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Nephrotic syndrome represents a constellation of symptoms including hyperalbuminuria, hypoalbuminemia, edema formation, hypercholesterolemia, hypertension, hypercoagulopathy, and increased infection risk.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10884998", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Pathophysiology of edema formation in children with nephrotic syndrome not due to minimal change disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10215332", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "To study the evidence-based therapy of edema in nephrotic syndrome by analyzing the literatures systematically.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17448310", "endSection": "abstract"}, {"offsetInBeginSection": 261, "offsetInEndSection": 362, "text": "Edema is the prominent feature of nephrotic syndrome and initially develops around the eyes and legs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21454171", "endSection": "abstract"}, {"offsetInBeginSection": 439, "offsetInEndSection": 611, "text": "Intussusception should be considered in the differential diagnosis of abdominal pain in patients with nephrotic syndrome, especially in patients exhibiting prolonged edema.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16247647", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Oedema is the commonest presenting symptom and sign in nephrotic syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11928729", "endSection": "abstract"}, {"offsetInBeginSection": 755, "offsetInEndSection": 1090, "text": "Other signs and symptoms of nephrotic syndrome at baseline (serum albumin < 3.5 g/dL, serum total cholesterol > 260 mg/dL or use of a statin, and edema or use of a loop diuretic); progression of chronic kidney disease during follow-up (doubling of baseline serum creatinine level or requirement for dialysis or kidney transplantation).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19556043", "endSection": "abstract"}]}, {"body": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26713299", "http://www.ncbi.nlm.nih.gov/pubmed/1714232", "http://www.ncbi.nlm.nih.gov/pubmed/1985457", "http://www.ncbi.nlm.nih.gov/pubmed/2309781"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0008657", "o": "http://linkedlifedata.com/resource/umls/label/A18664896"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18664896", "o": "chromosome 15"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0008657", "o": "Chromosomes, Human, Pair 15"}], "ideal_answer": ["Prader-Willi syndrome (PWS) results from a deletion of the paternal genes in the region of chromosome 15q11-q13.", " prader-willi syndrome (pws) results from a deletion of the paternal genes in the region of chromosome 15q11-q13.", "Prader-Willi syndrome (PWS) results from a deletion of the paternal genes in the region of chromosome 15q11-q13. ", " Prader-Willi syndrome (PWS) results from a deletion of the paternal genes in the region of chromosome 15q11-q13."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002872", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D025063", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011218", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002901", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017353"], "type": "factoid", "id": "58e3d9ab3e8b6dc87c000002", "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 124, "text": " Prader-Willi syndrome (PWS) results from a deletion of the paternal genes in the region of chromosome 15q11-q13.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26713299", "endSection": "abstract"}, {"offsetInBeginSection": 428, "offsetInEndSection": 575, "text": "In AS, the deletion occurs in the maternally inherited chromosome 15, while in PWS the deletion is found in the paternally inherited chromosome 15.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1985457", "endSection": "abstract"}, {"offsetInBeginSection": 431, "offsetInEndSection": 577, "text": "In AS, the deletion occurs in the maternally inherited chromosome 15, while in PWS the deletion is found in the paternally inherited chromosome 15", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1985457", "endSection": "abstract"}, {"offsetInBeginSection": 431, "offsetInEndSection": 578, "text": "In AS, the deletion occurs in the maternally inherited chromosome 15, while in PWS the deletion is found in the paternally inherited chromosome 15.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1985457", "endSection": "abstract"}, {"offsetInBeginSection": 311, "offsetInEndSection": 452, "text": "However, deletions in AS occur on the maternally inherited chromosome 15, and deletions in PWS occur on the paternally derived chromosome 15.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1714232", "endSection": "abstract"}, {"offsetInBeginSection": 494, "offsetInEndSection": 630, "text": "This contrasts with the Prader-Willi syndrome (PWS) in which a similar deletion of the paternally contributed chromosome 15 is observed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2309781", "endSection": "abstract"}, {"offsetInBeginSection": 443, "offsetInEndSection": 563, "text": "However, in contrast to the paternal inheritance of the deleted chromosome 15 observed in the majority of PWS patients, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2564739", "endSection": "abstract"}]}, {"body": "What is the phenotype of people carrying mutations in the gene PRDM12?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25891934", "http://www.ncbi.nlm.nih.gov/pubmed/26005867", "http://www.ncbi.nlm.nih.gov/pubmed/26549885"], "ideal_answer": ["New therapeutic options have recently been derived from studies of individuals with congenital insensitivity to pain (CIP). Here we identified 10 different homozygous mutations in PRDM12 (encoding PRDI-BF1 and RIZ homology domain-containing protein 12) in subjects with CIP from 11 families."], "type": "factoid", "id": "58ea7248eda5a57672000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "The evolutionarily conserved transcription factor PRDM12 controls sensory neuron development and pain perception.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25891934", "endSection": "title"}, {"offsetInBeginSection": 139, "offsetInEndSection": 396, "text": "Here we show that PRDM12 is a key regulator of sensory neuronal specification in Xenopus. Modeling of human PRDM12 mutations that cause hereditary sensory and autonomic neuropathy (HSAN) revealed remarkable conservation of the mutated residues in evolution.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25891934", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Transcriptional regulator PRDM12 is essential for human pain perception.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26005867", "endSection": "title"}, {"offsetInBeginSection": 276, "offsetInEndSection": 673, "text": " New therapeutic options have recently been derived from studies of individuals with congenital insensitivity to pain (CIP). Here we identified 10 different homozygous mutations in PRDM12 (encoding PRDI-BF1 and RIZ homology domain-containing protein 12) in subjects with CIP from 11 families. Prdm proteins are a family of epigenetic regulators that control neural specification and neurogenesis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26005867", "endSection": "abstract"}, {"offsetInBeginSection": 153, "offsetInEndSection": 592, "text": " However, the study of genetic disorders rendering individuals completely unable to feel pain offers hope. All causes of congenital painlessness affect nociceptors, evolutionarily conserved specialist neurons able to sense all type of tissue damage. The discovery of new genes essential for sensing pain (SCN11A, PRDM12, and CLTCL1) has provided unexpected insights into the biological mechanisms that drive distinct stages of nociception.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26549885", "endSection": "abstract"}]}, {"body": "Is there an association between Histone H3.3 mutations and glioma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24997139", "http://www.ncbi.nlm.nih.gov/pubmed/22286061", "http://www.ncbi.nlm.nih.gov/pubmed/24229707", "http://www.ncbi.nlm.nih.gov/pubmed/25281433", "http://www.ncbi.nlm.nih.gov/pubmed/23429371", "http://www.ncbi.nlm.nih.gov/pubmed/25976256", "http://www.ncbi.nlm.nih.gov/pubmed/27392443", "http://www.ncbi.nlm.nih.gov/pubmed/25219808", "http://www.ncbi.nlm.nih.gov/pubmed/24691963", "http://www.ncbi.nlm.nih.gov/pubmed/23907119", "http://www.ncbi.nlm.nih.gov/pubmed/26517431", "http://www.ncbi.nlm.nih.gov/pubmed/23603901", "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "http://www.ncbi.nlm.nih.gov/pubmed/25200322", "http://www.ncbi.nlm.nih.gov/pubmed/24285547", "http://www.ncbi.nlm.nih.gov/pubmed/24622842", "http://www.ncbi.nlm.nih.gov/pubmed/27864305", "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "http://www.ncbi.nlm.nih.gov/pubmed/23417712", "http://www.ncbi.nlm.nih.gov/pubmed/25773741"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0017638", "o": "Glioma"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0026882", "o": "mutation"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0026882", "o": "http://linkedlifedata.com/resource/umls/label/A18555731"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18555731", "o": "mutation"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0596306", "o": "Association"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0026882", "o": "http://linkedlifedata.com/resource/umls/label/A18667225"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18667225", "o": "mutations"}], "ideal_answer": ["Yes, histone H3.3 mutation in the codon for lysine 27 has been found as driver mutations in pediatric glioblastoma and has been suggested to play critical roles in the pathogenesis of thalamic gliomas and diffuse intrinsic pontine gliomas."], "concepts": ["http://www.uniprot.org/uniprot/H33_SPISO", "http://www.uniprot.org/uniprot/H33_VITVI", "http://www.uniprot.org/uniprot/H33_BOVIN", "http://www.uniprot.org/uniprot/H33_TETTS", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005910", "http://www.uniprot.org/uniprot/H33_LOLMU", "http://www.uniprot.org/uniprot/H33_CHICK", "http://www.uniprot.org/uniprot/H33_MEDSA", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154", "http://www.uniprot.org/uniprot/H33_TRIPS", "http://www.uniprot.org/uniprot/H33_TOBAC", "http://www.uniprot.org/uniprot/H33_TETPY", "http://www.uniprot.org/uniprot/H33_XENLA", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001244", "http://www.uniprot.org/uniprot/H33_ARATH", "http://www.uniprot.org/uniprot/H33_XENTR"], "type": "yesno", "id": "5890ede0621ea6ff7e000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 522, "text": "PURPOSE: Histone H3.3 (H3F3A) mutation in the codon for lysine 27 (K27M) has been found as driver mutations in pediatric glioblastoma and has been suggested to play critical roles in the pathogenesis of thalamic gliomas and diffuse intrinsic pontine gliomas. We report a case of thalamic glioma with H3F3A K27M mutation, which was detected in both the primary tumor diagnosed as diffuse astrocytoma obtained during the first surgery and also in the tumor diagnosed as anaplastic astrocytoma obtained at the second surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27392443", "endSection": "abstract"}, {"offsetInBeginSection": 1298, "offsetInEndSection": 1470, "text": "CONCLUSION: This report demonstrates minute neuroradiological and pathological features of malignant transformation from thalamic low grade glioma with H3F3A K27M mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27392443", "endSection": "abstract"}, {"offsetInBeginSection": 400, "offsetInEndSection": 651, "text": "Recently, sequencing of tumor cells revealed that histone H3 is frequently mutated in pediatric HGG, with up to 78\u00a0% of diffuse intrinsic pontine gliomas (DIPGs) carrying K27M and 36\u00a0% of non-brainstem gliomas carrying either K27M or G34R/V mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773741", "endSection": "abstract"}, {"offsetInBeginSection": 623, "offsetInEndSection": 751, "text": "The pathological diagnosis was anaplastic oligodendroglioma, and we identified a mutation in histone H3.3 in the tumor specimen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25281433", "endSection": "abstract"}, {"offsetInBeginSection": 1121, "offsetInEndSection": 1301, "text": "CONCLUSIONS: Pediatric brainstem oligodendroglial tumors can include histone H3.3-mutated tumors and have a tendency to disseminate throughout the neuroaxis at the time of relapse.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25281433", "endSection": "abstract"}, {"offsetInBeginSection": 441, "offsetInEndSection": 765, "text": "We highlight the genetic aberrations recently discovered in isocitrate dehydrogenase, alpha thalassemia/mental retardation syndrome X-linked, death-domain-associated protein, histone H3.3, and telomerase reverse transcriptase and discuss how these mutations lead to unexpected changes in the epigenetic landscape in gliomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25976256", "endSection": "abstract"}, {"offsetInBeginSection": 1024, "offsetInEndSection": 1194, "text": "Particularly striking is the discovery of frequent histone H3.3 mutations in pediatric glioma, a particularly aggressive neoplasm that has long remained poorly understood", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24622842", "endSection": "abstract"}, {"offsetInBeginSection": 146, "offsetInEndSection": 454, "text": "Exon sequencing has identified a mutation in K27M of the histone H3.3 gene (H3F3A K27M and G34R/V) in about 20% of pediatric glioblastomas, but it remains to be seen whether these mutations can be considered specific for pediatric diffuse high-grade astrocytomas or also occur in other pediatric brain tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23429371", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603901", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907119", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Pediatric glioblastoma multiforme (GBM) is rare, and there is a single study, a seminal discovery showing association of histone H3.3 and isocitrate dehydrogenase (IDH)1 mutation with a DNA methylation signature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24997139", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "Over 70% of diffuse intrinsic pediatric gliomas, an aggressive brainstem tumor, harbor heterozygous mutations that create a K27M amino acid substitution (methionine replaces lysine 27) in the tail of histone H3.3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Mutations in H3F3A, which encodes histone H3.3, commonly occur in pediatric glioblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285547", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "Somatic mutations of the H3F3A and HIST1H3B genes encoding the histone H3 variants, H3.3 and H3.1, were recently identified in high-grade gliomas arising in the thalamus, pons and spinal cord of children and young adults.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26517431", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661320", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Recurrent mutations affecting the histone H3.3 residues Lys27 or indirectly Lys36 are frequent drivers of pediatric high-grade gliomas (over 30% of HGGs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23417712", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25525250", "endSection": "title"}, {"offsetInBeginSection": 72, "offsetInEndSection": 241, "text": "Recent studies on high-grade pediatric GBM have identified two recurrent mutations (K27M and G34R/V) in genes encoding histone H3 (H3F3A for H3.3 and HIST1H3B for H3.1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907119", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22286061", "endSection": "title"}]}, {"body": "Which cellular function is associated with transcription factors forkhead 1 and 2 (Fkh1 and Fkh2)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22438832", "http://www.ncbi.nlm.nih.gov/pubmed/12702877", "http://www.ncbi.nlm.nih.gov/pubmed/15777722", "http://www.ncbi.nlm.nih.gov/pubmed/22265405"], "ideal_answer": ["Forkhead transcription factors establish origin timing and long-range clustering in S. cerevisiae. Here we show that the yeast Forkhead transcription factors, Fkh1 and Fkh2, are global determinants of replication origin timing. Forkhead box O (FOXO) transcription factors have a conserved function in regulating metazoan lifespan. Fkh1 and Fkh2 bind Fkh-activated origins, and interact physically with ORC, providing a plausible mechanism to cluster origins. Instead, we show that Fkh1 and Fkh2 are required for the clustering of early origins and their association with the key initiation factor Cdc45 in G1 phase, suggesting that Fkh1 and Fkh2 selectively recruit origins to emergent replication factories. ", "Forkhead transcription factors establish origin timing and long-range clustering in S. cerevisiae. Fkh1 and Fkh2 are required for the clustering of early origins and their association with the key initiation factor Cdc45 in G1 phase. Fkh1 and Fkh2 selectively recruit origins to emergent replication factories. They both bind Fkh-activated origins, and interact physically with ORC, providing a plausible mechanism to cluster origins.", "Forkhead transcription factors establish origin timing and long-range clustering in S. cerevisiae. Forkhead box O (FOXO) transcription factors have a conserved function in regulating metazoan lifespan. Fkh1 and Fkh2 bind Fkh-activated origins, and interact physically with ORC, providing a plausible mechanism to cluster origins. Here we describe the remaining two genes, fhl1 and fkh2, that code for proteins containing fork-head-associated domains (FHA) besides their FKHs. This may reflect a general feature of gene regulation in eukaryotes. ", "Forkhead transcription factors establish origin timing and long-range clustering in S. cerevisiae.", "Forkhead transcription factors establish origin timing and long-range clustering in S. cerevisiae. Here we show that the yeast Forkhead transcription factors, Fkh1 and Fkh2, are global determinants of replication origin timing. Fkh1 and Fkh2 bind Fkh-activated origins, and interact physically with ORC, providing a plausible mechanism to cluster origins. Instead, we show that Fkh1 and Fkh2 are required for the clustering of early origins and their association with the key initiation factor Cdc45 in G1 phase, suggesting that Fkh1 and Fkh2 selectively recruit origins to emergent replication factories. Forkhead box O (FOXO) transcription factors have a conserved function in regulating metazoan lifespan. ", "Instead, we show that Fkh1 and Fkh2 are required for the clustering of early origins and their association with the key initiation factor Cdc45 in G1 phase, suggesting that Fkh1 and Fkh2 selectively recruit origins to emergent replication factories. Fkh1 and Fkh2 bind Fkh-activated origins, and interact physically with ORC, providing a plausible mechanism to cluster origins. Here we show that the yeast Forkhead transcription factors, Fkh1 and Fkh2, are global determinants of replication origin timing.", "Here we show that the yeast Forkhead transcription factors, Fkh1 and Fkh2, are global determinants of replication origin timing. Forkhead box O (FOXO) transcription factors have a conserved function in regulating metazoan lifespan.", "Forkhead transcription factors establish origin timing and long-range clustering in S. cerevisiae. Here we show that the yeast Forkhead transcription factors, Fkh1 and Fkh2, are global determinants of replication origin timing."], "type": "factoid", "id": "58eb4ce7eda5a57672000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Forkhead transcription factors establish origin timing and long-range clustering in S. cerevisiae.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22265405", "endSection": "title"}, {"offsetInBeginSection": 335, "offsetInEndSection": 463, "text": "Here we show that the yeast Forkhead transcription factors, Fkh1 and Fkh2, are global determinants of replication origin timing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22265405", "endSection": "abstract"}, {"offsetInBeginSection": 561, "offsetInEndSection": 938, "text": "Instead, we show that Fkh1 and Fkh2 are required for the clustering of early origins and their association with the key initiation factor Cdc45 in G1 phase, suggesting that Fkh1 and Fkh2 selectively recruit origins to emergent replication factories. Fkh1 and Fkh2 bind Fkh-activated origins, and interact physically with ORC, providing a plausible mechanism to cluster origins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22265405", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 231, "text": "Forkhead box O (FOXO) transcription factors have a conserved function in regulating metazoan lifespan. A key function in this process involves the regulation of the cell cycle and stress responses including free radical scavenging.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22438832", "endSection": "abstract"}, {"offsetInBeginSection": 478, "offsetInEndSection": 761, "text": "We report that the deletion of both FKH genes impedes normal lifespan and stress resistance, particularly in stationary phase cells, which are non-responsive to caloric restriction. Conversely, increased expression of the FKHs leads to extended lifespan and improved stress response.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22438832", "endSection": "abstract"}, {"offsetInBeginSection": 1186, "offsetInEndSection": 1471, "text": "This study establishes the FKHs role as evolutionarily conserved regulators of lifespan in yeast and identifies the APC as a novel component of this mechanism under certain conditions, likely through combined regulation of stress response, genomic stability, and cell cycle regulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22438832", "endSection": "abstract"}, {"offsetInBeginSection": 336, "offsetInEndSection": 633, "text": "The genome of Schizosaccharomyces pombe has four genes that code for proteins containing fork-head domains (FKH), two of which have been characterised. Here we describe the remaining two genes, fhl1 and fkh2, that code for proteins containing fork-head-associated domains (FHA) besides their FKHs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15777722", "endSection": "abstract"}, {"offsetInBeginSection": 263, "offsetInEndSection": 466, "text": "Here we show that the yeast forkhead transcription factors, Fkh1p and Fkh2p, associate with the coding regions of active genes and influence, in opposing ways, transcriptional elongation and termination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12702877", "endSection": "abstract"}, {"offsetInBeginSection": 602, "offsetInEndSection": 830, "text": "Our results suggest that, in addition to their documented promoter function, Fkh1p and Fkh2p coordinate early transcription elongation and pre-mRNA processing. This may reflect a general feature of gene regulation in eukaryotes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12702877", "endSection": "abstract"}, {"offsetInBeginSection": 333, "offsetInEndSection": 461, "text": "Here we show that the yeast Forkhead transcription factors, Fkh1 and Fkh2, are global determinants of replication origin timing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22265405", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "The Saccharomyces cerevisiae Forkhead Box (FOX) proteins, Fkh1 and Fkh2, regulate diverse cellular processes including transcription, long-range DNA interactions during homologous recombination, and replication origin timing and long-range origin clustering.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26728715", "endSection": "abstract"}]}, {"body": "What is the role of the Ctf4-interacting-peptide or CIP-box?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27397685"], "ideal_answer": ["Crystallographic analysis classifies CIP-boxes into two related groups that target different sites on Ctf4. Mutations in the CIP-box motifs of the Dna2 nuclease or the rDNA-associated protein Tof2 do not perturb DNA synthesis genome-wide, but instead lead to a dramatic shortening of chromosome 12 that contains the large array of rDNA repeats. Data reveal unexpected complexity of Ctf4 function, as a hub that connects multiple accessory factors to the replisome. Most strikingly, Ctf4-dependent recruitment of CIP-box proteins couples other processes to DNA synthesis, including rDNA copy-number regulation."], "concepts": ["http://www.biosemantics.org/jochem#4264134", "http://www.biosemantics.org/jochem#4265011"], "type": "summary", "id": "58815f26713cbdfd3d000002", "snippets": [{"offsetInBeginSection": 264, "offsetInEndSection": 1010, "text": " Here, we identify new Ctf4 partners in\u00a0addition to Pol \u03b1 and helicase, all of which contain a \"Ctf4-interacting-peptide\" or CIP-box. Crystallographic analysis classifies CIP-boxes into two related groups that target different sites on Ctf4. Mutations in the CIP-box motifs of the Dna2 nuclease or the rDNA-associated protein Tof2 do not perturb DNA synthesis genome-wide, but instead lead to a dramatic shortening of chromosome 12 that contains the large array of rDNA repeats. Our data reveal unexpected complexity of Ctf4 function, as a hub that connects multiple accessory factors to the replisome. Most strikingly, Ctf4-dependent recruitment of CIP-box proteins couples other processes to DNA synthesis, including rDNA copy-number regulation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27397685", "endSection": "abstract"}, {"offsetInBeginSection": 502, "offsetInEndSection": 738, "text": "Mutations in the CIP-box motifs of the Dna2 nuclease or the rDNA-associated protein Tof2 do not perturb DNA synthesis genome-wide, but instead lead to a dramatic shortening of chromosome 12 that contains the large array of rDNA repeats.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27397685", "endSection": "abstract"}, {"offsetInBeginSection": 506, "offsetInEndSection": 742, "text": "Mutations in the CIP-box motifs of the Dna2 nuclease or the rDNA-associated protein Tof2 do not perturb DNA synthesis genome-wide, but instead lead to a dramatic shortening of chromosome 12 that contains the large array of rDNA repeats.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27397685", "endSection": "abstract"}]}, {"body": "What type of genome, (RNA or DNA, double stranded single stranded) is found in the the virus that causes blue tongue disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22549161"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0042776", "o": "http://linkedlifedata.com/resource/umls/label/A0491591"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0491591", "o": "virus"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0319157", "o": "virus"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0042776", "o": "Viruses"}], "ideal_answer": ["The Bluetongue virus (BTV) genome contains ten double-stranded RNA segments.", "Bluetongue virus (BTV) genome contains ten double-stranded RNA segments. ", "Bluetongue virus (BTV) genome contains ten double-stranded RNA segments.", "Bluetongue virus (BTV) genome contains ten double-stranded RNA segments", "bluetongue virus (btv) genome contains ten double-stranded rna segments."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:1301", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012330", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001820", "http://www.disease-ontology.org/api/metadata/DOID:0050498"], "type": "factoid", "id": "58f3c4b970f9fc6f0f00000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Bluetongue virus (BTV) genome contains ten double-stranded RNA segments", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22549161", "endSection": "abstract"}]}, {"body": "What is a \"chemobrain\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25176562", "http://www.ncbi.nlm.nih.gov/pubmed/26653737", "http://www.ncbi.nlm.nih.gov/pubmed/25687405", "http://www.ncbi.nlm.nih.gov/pubmed/27041861", "http://www.ncbi.nlm.nih.gov/pubmed/27709283"], "ideal_answer": ["The term \"chemobrain\" is sometimes used to denote deficits in neuropsychological functioning that may occur as a result of cancer treatment."], "type": "factoid", "id": "58efa1b870f9fc6f0f000003", "snippets": [{"offsetInBeginSection": 322, "offsetInEndSection": 563, "text": "Frequency of chemotherapy-related cognitive impairment or \"chemobrain\" is mentioned to be significant in literature, although very little is known about the chemotherapy-caused chemobrain and its connection with metal homeostasis alteration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26653737", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 185, "text": "Cognitive decline or dementia is a debilitating problem of neurological disorders such as Alzheimer's and Parkinson's disease, including special conditions like chemobrain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27041861", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 219, "text": "Most cancer patients treated with systemic adjuvant chemotherapy endure long-lasting side effects including decrease in concentration, forgetfulness and slower thinking, which are globally termed \"chemobrain.\" ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27709283", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "The frequent use of chemotherapy to combat a range of malignancies can elicit severe cognitive dysfunction often referred to as \"chemobrain,\" a condition that can persist long after the cessation of treatment in as many as 75% of survivors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25687405", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 150, "text": "The term \"chemobrain\" is sometimes used to denote deficits in neuropsychological functioning that may occur as a result of cancer treatment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25176562", "endSection": "abstract"}]}, {"body": "Borden classification is used for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22107858", "http://www.ncbi.nlm.nih.gov/pubmed/20678361", "http://www.ncbi.nlm.nih.gov/pubmed/20678360", "http://www.ncbi.nlm.nih.gov/pubmed/22374275", "http://www.ncbi.nlm.nih.gov/pubmed/20849795", "http://www.ncbi.nlm.nih.gov/pubmed/23570149", "http://www.ncbi.nlm.nih.gov/pubmed/25479123", "http://www.ncbi.nlm.nih.gov/pubmed/23811958", "http://www.ncbi.nlm.nih.gov/pubmed/20966056", "http://www.ncbi.nlm.nih.gov/pubmed/26120845", "http://www.ncbi.nlm.nih.gov/pubmed/23582488", "http://www.ncbi.nlm.nih.gov/pubmed/25516093", "http://www.ncbi.nlm.nih.gov/pubmed/25746311", "http://www.ncbi.nlm.nih.gov/pubmed/25354667", "http://www.ncbi.nlm.nih.gov/pubmed/15842944", "http://www.ncbi.nlm.nih.gov/pubmed/26246101", "http://www.ncbi.nlm.nih.gov/pubmed/8893721", "http://www.ncbi.nlm.nih.gov/pubmed/20176602", "http://www.ncbi.nlm.nih.gov/pubmed/16286391", "http://www.ncbi.nlm.nih.gov/pubmed/19408992"], "ideal_answer": ["Borden classification systems is used for the prediction of clinical behavior of cranial dural arteriovenous fistulas."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002965", "http://www.disease-ontology.org/api/metadata/DOID:4", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"], "type": "factoid", "id": "5890fde5621ea6ff7e000009", "snippets": [{"offsetInBeginSection": 277, "offsetInEndSection": 545, "text": "The locations of DAVFs were the transverse-sigmoid sinus in 11, tentorium in 10, cranial vault in 9, and superior sagittal sinus, jugular bulb, foramen magnum, and middle cranial fossa in 1 each. Borden classification was type I in 7, type II in 3, and type III in 24.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25746311", "endSection": "abstract"}, {"offsetInBeginSection": 1001, "offsetInEndSection": 1236, "text": "Transarterial glue embolization is highly effective for Borden type III DAVF with direct cortical venous drainage, but has limitations for Borden type I and II DAVFs in which the affected sinus is part of the normal venous circulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25746311", "endSection": "abstract"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1082, "text": "The results of subtype (Borden and Cognard classification), venous reflux and fistula sites were also accurately exhibited in 4D-CTA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25354667", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 305, "text": "The commonly used Borden and Cognard classification systems for the prediction of clinical behavior of cranial dural arteriovenous shunts focus on the venous drainage, particularly the presence of leptomeningeal venous drainage, and on the direction of flow, particularly the presence of retrograde flow. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516093", "endSection": "abstract"}, {"offsetInBeginSection": 413, "offsetInEndSection": 527, "text": "The CS DAVFs and the NCS DAVFs were categorized using the Barrow and Borden classification systems, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25479123", "endSection": "abstract"}, {"offsetInBeginSection": 194, "offsetInEndSection": 388, "text": "The two most commonly used and clinically accepted DAVF classifications are the Merland-Cognard classification and the Borden classification, both based on the morphology of the venous drainage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22107858", "endSection": "abstract"}, {"offsetInBeginSection": 1153, "offsetInEndSection": 1371, "text": "When analyzed according to the Borden classification, none (0%) of 55 Type I intracranial dural AVFs, two (11%) of 18 Type II, and 14 (48%) of 29 Type III intracranial dural AVFs presented with hemorrhage (p < 0.0001).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8893721", "endSection": "abstract"}, {"offsetInBeginSection": 2651, "offsetInEndSection": 2855, "text": "The configuration of venous anatomy as reflected by both the Cognard and Borden classifications strongly predicts intracranial dural AVFs that will present with ICH or nonhemorrhagic neurological deficit.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8893721", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 388, "text": "The two most commonly used and clinically accepted DAVF classifications are the Merland-Cognard classification and the Borden classification, both based on the morphology of the venous drainage", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22107858", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 303, "text": "The commonly used Borden and Cognard classification systems for the prediction of clinical behavior of cranial dural arteriovenous shunts focus on the venous drainage, particularly the presence of leptomeningeal venous drainage, and on the direction of flow, particularly the presence of retrograde flow", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516093", "endSection": "abstract"}, {"offsetInBeginSection": 1163, "offsetInEndSection": 1383, "text": "When analyzed according to the Borden classification, none (0%) of 55 Type I intracranial dural AVFs, two (11%) of 18 Type II, and 14 (48%) of 29 Type III intracranial dural AVFs presented with hemorrhage (p &lt; 0.0001)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8893721", "endSection": "abstract"}, {"offsetInBeginSection": 476, "offsetInEndSection": 587, "text": "Borden classification showed Type III in 1 and Type II in 10 ncsDAVFs, and Type II in 4 and Type I in 6 csDAVFs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22374275", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "The recently proposed classification scheme of Borden, Wu, and Shucart (Borden(*)) should have the ability to identify those intracranial dural arteriovenous fistulae (ICDAVF) which will continue to behave in a benign fashion", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20678360", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 389, "text": "The two most commonly used and clinically accepted DAVF classifications are the Merland-Cognard classification and the Borden classification, both based on the morphology of the venous drainage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22107858", "endSection": "abstract"}, {"offsetInBeginSection": 397, "offsetInEndSection": 510, "text": "The CS DAVFs and the NCS DAVFs were categorized using the Barrow and Borden classification systems, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25479123", "endSection": "abstract"}, {"offsetInBeginSection": 1432, "offsetInEndSection": 1623, "text": "A multivariate logistic regression model showed that intracranial hemorrhage in patients with DAVFs was correlated with higher Borden classification (OR 5.880; 95% CI, 3.370-10.257; p<0.001).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26120845", "endSection": "abstract"}, {"offsetInBeginSection": 2668, "offsetInEndSection": 2873, "text": "The configuration of venous anatomy as reflected by both the Cognard and Borden classifications strongly predicts intracranial dural AVFs that will present with ICH or nonhemorrhagic neurological deficit..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8893721", "endSection": "abstract"}, {"offsetInBeginSection": 477, "offsetInEndSection": 589, "text": "Borden classification showed Type III in 1 and Type II in 10 ncsDAVFs, and Type II in 4 and Type I in 6 csDAVFs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22374275", "endSection": "abstract"}]}, {"body": "Which effects create neighborhoods of transcriptional regulation in eukaryotes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22084256", "http://www.ncbi.nlm.nih.gov/pubmed/27799341", "http://www.ncbi.nlm.nih.gov/pubmed/17025153"], "ideal_answer": ["Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes. Here, we present cross-organismic evidence suggesting that most EP pairs are compatible, largely determined by physical proximity rather than specific interactions. we find that the transcription of gene neighbors is correlated over distances that scale with genome size. We propose that enhancer sharing is commonplace among eukaryotes, and that EP distance is an important layer of information in gene regulation. ", "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes Here, we present cross-organismic evidence suggesting that most EP pairs are compatible, largely determined by physical proximity rather than specific interactions.", " we propose that enhancer sharing is commonplace among eukaryotes, and that ep distance is an important layer of information in gene regulation.", "Enhancers physically interact with transcriptional promoters, looping over distances that can span multiple regulatory elements. We propose that enhancer sharing is commonplace among eukaryotes, and that EP distance is an important layer of information in gene regulation.", "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes", "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes  We propose that enhancer sharing is commonplace among eukaryotes, and that EP distance is an important layer of information in gene regulation."], "type": "factoid", "id": "58c27b7102b8c60953000021", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799341", "endSection": "title"}, {"offsetInBeginSection": 307, "offsetInEndSection": 471, "text": "Here, we present cross-organismic evidence suggesting that most EP pairs are compatible, largely determined by physical proximity rather than specific interactions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799341", "endSection": "abstract"}, {"offsetInBeginSection": 511, "offsetInEndSection": 618, "text": "we find that the transcription of gene neighbors is correlated over distances that scale with genome size. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799341", "endSection": "abstract"}, {"offsetInBeginSection": 799, "offsetInEndSection": 943, "text": " We propose that enhancer sharing is commonplace among eukaryotes, and that EP distance is an important layer of information in gene regulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799341", "endSection": "abstract"}, {"offsetInBeginSection": 343, "offsetInEndSection": 897, "text": "This is especially true in mammalian systems, where regulation often occurs through long-range enhancers in gene-rich neighborhoods, rather than proximal promoters, preventing straightforward assignment of a binding site to a target gene.We present EMBER (Expectation Maximization of Binding and Expression pRofiles), a method that integrates high-throughput binding data (e.g. ChIP-chip or ChIP-seq) with gene expression data (e.g. DNA microarray) via an unsupervised machine learning algorithm for inferring the gene targets of sets of TF binding sites", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22084256", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Enhancer Sharing Promotes Neighborhoods of Transcriptional Regulation Across Eukaryotes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799341", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "One of the dogmas of transcriptional regulation in higher eukaryotes suggests the existence of transcriptional domains with no promoter-enhancer interactions between them.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17025153", "endSection": "abstract"}]}, {"body": "Is Pfh1 a component of the replisome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22426534", "http://www.ncbi.nlm.nih.gov/pubmed/27611590"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1325592", "o": "replisome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1325592", "o": "http://linkedlifedata.com/resource/umls/label/A11591254"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11591254", "o": "replisome"}], "ideal_answer": ["No. Pfh1 Is an Accessory Replicative Helicase that Interacts with the Replisome to Facilitate Fork Progression and Preserve Genome Integrity. DNA replication through hard-to-replicate sites, including both highly transcribed RNA Pol II and Pol III genes, requires the S. pombe Pfh1 helicase."], "type": "yesno", "id": "5881e8e8713cbdfd3d000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Pfh1 Is an Accessory Replicative Helicase that Interacts with the Replisome to Facilitate Fork Progression and Preserve Genome Integrity", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611590", "endSection": "title"}, {"offsetInBeginSection": 288, "offsetInEndSection": 754, "text": "Although the Schizosaccharomyces pombe 5'-to-3' DNA helicase Pfh1 is known to promote fork progression, its genomic targets, dynamics, and mechanisms of action are largely unknown. Here we address these questions by integrating genome-wide identification of Pfh1 binding sites, comprehensive analysis of the effects of Pfh1 depletion on replication and DNA damage, and proteomic analysis of Pfh1 interaction partners by immunoaffinity purification mass spectrometry.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611590", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "DNA replication through hard-to-replicate sites, including both highly transcribed RNA Pol II and Pol III genes, requires the S. pombe Pfh1 helicase.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426534", "endSection": "title"}, {"offsetInBeginSection": 347, "offsetInEndSection": 546, "text": "Here, we show that Pfh1 is required for efficient fork movement in the ribosomal DNA, the mating type locus, tRNA, 5S ribosomal RNA genes, and genes that are highly transcribed by RNA polymerase II. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426534", "endSection": "abstract"}, {"offsetInBeginSection": 1109, "offsetInEndSection": 1245, "text": " Thus, Pfh1 promotes DNA replication and separation of converged replication forks and suppresses DNA damage at hard-to-replicate sites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426534", "endSection": "abstract"}, {"offsetInBeginSection": 960, "offsetInEndSection": 1102, "text": "Cells depleted of Pfh1 were inviable if they also lacked the human TIMELESS homolog Swi1, a replisome component that stabilizes stalled forks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426534", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Pfh1 Is an Accessory Replicative Helicase that Interacts with the Replisome to Facilitate Fork Progression and Preserve Genome Integrity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611590", "endSection": "title"}, {"offsetInBeginSection": 1810, "offsetInEndSection": 1979, "text": "Thus, we conclude that Pfh1 is an accessory DNA helicase that interacts with the replisome and promotes replication and suppresses DNA damage at hard-to-replicate sites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611590", "endSection": "abstract"}, {"offsetInBeginSection": 1585, "offsetInEndSection": 1810, "text": "Consistent with this interpretation, Pfh1 co-purified with many key replisome components, including the hexameric MCM helicase, replicative DNA polymerases, RPA, and the processivity clamp PCNA in an S phase dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611590", "endSection": "abstract"}, {"offsetInBeginSection": 1295, "offsetInEndSection": 1585, "text": "Although Pfh1 affected replication and suppressed DNA damage at discrete sites throughout the genome, Pfh1 and the replicative DNA polymerase bound to similar extents to both Pfh1-dependent and independent sites, suggesting that Pfh1 is proximal to the replication machinery during S phase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611590", "endSection": "abstract"}, {"offsetInBeginSection": 967, "offsetInEndSection": 1108, "text": "Cells depleted of Pfh1 were inviable if they also lacked the human TIMELESS homolog Swi1, a replisome component that stabilizes stalled forks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426534", "endSection": "abstract"}, {"offsetInBeginSection": 347, "offsetInEndSection": 544, "text": "Here, we show that Pfh1 is required for efficient fork movement in the ribosomal DNA, the mating type locus, tRNA, 5S ribosomal RNA genes, and genes that are highly transcribed by RNA polymerase II", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426534", "endSection": "abstract"}, {"offsetInBeginSection": 1110, "offsetInEndSection": 1244, "text": "Thus, Pfh1 promotes DNA replication and separation of converged replication forks and suppresses DNA damage at hard-to-replicate sites", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426534", "endSection": "abstract"}, {"offsetInBeginSection": 967, "offsetInEndSection": 1109, "text": "Cells depleted of Pfh1 were inviable if they also lacked the human TIMELESS homolog Swi1, a replisome component that stabilizes stalled forks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426534", "endSection": "abstract"}, {"offsetInBeginSection": 1818, "offsetInEndSection": 1987, "text": "Thus, we conclude that Pfh1 is an accessory DNA helicase that interacts with the replisome and promotes replication and suppresses DNA damage at hard-to-replicate sites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611590", "endSection": "abstract"}, {"offsetInBeginSection": 1592, "offsetInEndSection": 1817, "text": "Consistent with this interpretation, Pfh1 co-purified with many key replisome components, including the hexameric MCM helicase, replicative DNA polymerases, RPA, and the processivity clamp PCNA in an S phase dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611590", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Pfh1 Is an Accessory Replicative Helicase that Interacts with the Replisome to Facilitate Fork Progression and Preserve Genome Integrity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611590", "endSection": "title"}]}, {"body": "What is the function of mTOR?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21871173", "http://www.ncbi.nlm.nih.gov/pubmed/12864941", "http://www.ncbi.nlm.nih.gov/pubmed/27889578", "http://www.ncbi.nlm.nih.gov/pubmed/25898924", "http://www.ncbi.nlm.nih.gov/pubmed/25893295"], "ideal_answer": ["The mTOR protein regulates assembly of the translation initiation machinery and are master regulators of cellular survival, growth and metabolism."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0065009"], "type": "summary", "id": "58f3c8f470f9fc6f0f00000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Protein synthesis regulation via mammalian target of rapamycin complex 1 (mTORC1) signaling pathway has key roles in neural development and function,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25898924", "endSection": "abstract"}, {"offsetInBeginSection": 268, "offsetInEndSection": 464, "text": "mTOR regulates assembly of the translation initiation machinery by interacting with the eukaryotic initiation factor eIF3 complex and by controlling phosphorylation of key translational regulators", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25898924", "endSection": "abstract"}, {"offsetInBeginSection": 232, "offsetInEndSection": 364, "text": "Mammalian target of rapamycin (mTOR) complexes, mTORC1 and mTORC2, are master regulators of cellular survival, growth and metabolism", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25893295", "endSection": "abstract"}, {"offsetInBeginSection": 41, "offsetInEndSection": 468, "text": " (mTOR) is a serine-threonine kinase that controls several important aspects of mammalian cell function. mTOR activity is modulated by various intra- and extracellular factors; in turn, mTOR changes rates of translation, transcription, protein degradation, cell signaling, metabolism, and cytoskeleton dynamics. mTOR has been repeatedly shown to participate in neuronal development and the proper functioning of mature neurons.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27889578", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 167, "text": "mammalian target of rapamycin (mTOR), a member of the phosphoinositide 3-kinase related kinase (PIKK) family, plays a central role in the regulation of cell growth", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19182527", "endSection": "abstract"}, {"offsetInBeginSection": 30, "offsetInEndSection": 228, "text": "(mTOR) is a serine/threonine kinase and that forms two multiprotein complexes known as the mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTOR regulates cell growth, proliferation and survival", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21871173", "endSection": "abstract"}, {"offsetInBeginSection": 34, "offsetInEndSection": 195, "text": "(mTOR), a downstream effector of the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) signaling pathway that mediates cell survival and proliferation,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12864941", "endSection": "abstract"}]}, {"body": "What is the indication for valbenazine?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25809133", "http://www.ncbi.nlm.nih.gov/pubmed/27819145"], "ideal_answer": ["Valbenazine granted breakthrough drug status for treating tardive dyskinesia."], "type": "factoid", "id": "58f0b0c070f9fc6f0f000006", "snippets": [{"offsetInBeginSection": 571, "offsetInEndSection": 747, "text": "VMAT2 inhibitors (e.g. deutetrabenazine and valbenazine) have been studied in the treatment of HD-related chorea, tardive dyskinesia and tics associated with Tourette syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27819145", "endSection": "abstract"}, {"offsetInBeginSection": -1, "offsetInEndSection": 76, "text": "Valbenazine granted breakthrough drug status for treating tardive dyskinesia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25809133", "endSection": "title"}, {"offsetInBeginSection": 810, "offsetInEndSection": 1000, "text": "The FDA lowered approval hurdles for valbenazine due to a successful Phase II trial, which showed a distinctive improvement in tardive dyskinesia symptoms during valbenazine administration. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25809133", "endSection": "abstract"}]}, {"body": "List features of the Kaufman Oculocerebrofacial Syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8275567", "http://www.ncbi.nlm.nih.gov/pubmed/23687348", "http://www.ncbi.nlm.nih.gov/pubmed/7573151", "http://www.ncbi.nlm.nih.gov/pubmed/24615390", "http://www.ncbi.nlm.nih.gov/pubmed/25691420", "http://www.ncbi.nlm.nih.gov/pubmed/25792360"], "ideal_answer": ["Clinical features of the Kaufman Oculocerebrofacial Syndrome include hypotonia, developmental delay, intellectual disability, low cholesterol levels, microcephaly, long narrow face, ocular anomalies, and long thin hands and feet."], "type": "list", "id": "5895b7157d9090f353000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "A pair of sisters was ascertained for multiple congenital defects, including marked craniofacial dysmorphisms with blepharophimosis, and severe psychomotor delay. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25691420", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "Genetic syndromes involving both brain and eye abnormalities are numerous and include syndromes such as Warburg micro syndrome, Kaufman oculocerebrofacial syndrome, Cerebro-oculo-facio-skeletal syndrome, Kahrizi syndrome and others. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25792360", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 375, "text": "Biallelic mutations of UBE3B have recently been shown to cause Kaufman oculocerebrofacial syndrome (also reported as blepharophimosis-ptosis-intellectual disability syndrome), an autosomal recessive condition characterized by hypotonia, developmental delay, intellectual disability, congenital anomalies, characteristic facial dysmorphic features, and low cholesterol levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24615390", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 393, "text": "BACKGROUND: Kaufman oculocerebrofacial syndrome (KOS) is a developmental disorder characterised by reduced growth, microcephaly, ocular anomalies (microcornea, strabismus, myopia, and pale optic disk), distinctive facial features (narrow palpebral fissures, telecanthus, sparse and laterally broad eyebrows, preauricular tags, and micrognathia), mental retardation, and generalised hypotonia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23687348", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "Kaufman oculocerebrofacial syndrome (KOS) is a rare autosomal recessive disorder characterized by severe mental retardation, microcephaly, long narrow face, ocular anomalies, and long thin hands and feet. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7573151", "endSection": "abstract"}, {"offsetInBeginSection": 126, "offsetInEndSection": 299, "text": "Both showed psychomotor retardation, microcephaly, blepharophimosis and delayed growth as the main features; the infant also presented preauricular tags and large clitoris. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8275567", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 380, "text": "Kaufman oculocerebrofacial syndrome (KOS) is a developmental disorder characterised by reduced growth, microcephaly, ocular anomalies (microcornea, strabismus, myopia, and pale optic disk), distinctive facial features (narrow palpebral fissures, telecanthus, sparse and laterally broad eyebrows, preauricular tags, and micrognathia), mental retardation, and generalised hypotonia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23687348", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 374, "text": "Biallelic mutations of UBE3B have recently been shown to cause Kaufman oculocerebrofacial syndrome (also reported as blepharophimosis-ptosis-intellectual disability syndrome), an autosomal recessive condition characterized by hypotonia, developmental delay, intellectual disability, congenital anomalies, characteristic facial dysmorphic features, and low cholesterol levels", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24615390", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 379, "text": "Kaufman oculocerebrofacial syndrome (KOS) is a developmental disorder characterised by reduced growth, microcephaly, ocular anomalies (microcornea, strabismus, myopia, and pale optic disk), distinctive facial features (narrow palpebral fissures, telecanthus, sparse and laterally broad eyebrows, preauricular tags, and micrognathia), mental retardation, and generalised hypotonia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23687348", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Kaufman oculocerebrofacial syndrome (KOS) is a rare autosomal recessive disorder characterized by severe mental retardation, microcephaly, long narrow face, ocular anomalies, and long thin hands and feet", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7573151", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Kaufman oculocerebrofacial syndrome (KOS) is a rare autosomal recessive disorder characterized by severe mental retardation, microcephaly, long narrow face, ocular anomalies, and long thin hands and feet.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7573151", "endSection": "abstract"}]}, {"body": "What is the role of DNA Repair Cofactors ATMIN and NBS1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26544571"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0012899", "o": "DNA repair"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0012899", "o": "http://linkedlifedata.com/resource/umls/label/A18609617"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18609617", "o": "dna repair"}, {"p": "http://www.w3.org/2004/02/skos/core#exactMatch", "s": "http://purl.uniprot.org/uniprot/O43070", "o": "http://purl.uniprot.org/uniprot/O43070"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://purl.uniprot.org/intact/EBI-2125045", "o": "nbs1"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_4F34333037300013", "o": "nbs1"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://purl.uniprot.org/uniprot/O43070", "o": "NBS1_SCHPO"}, {"p": "http://purl.uniprot.org/core/encodedBy", "s": "http://purl.uniprot.org/uniprot/O43070", "o": "http://linkedlifedata.com/resource/#_4F34333037300013"}], "ideal_answer": ["The DNA double-strand break signaling kinase ATM and its cofactor NBS1 are required during T cell development and for the maintenance of genomic stability. The role of a second ATM cofactor, ATMIN (also known as ASCIZ) in T cells is much less clear, and whether ATMIN and NBS1 function in synergy in T cells is unknown.", "The DNA Repair Cofactors ATMIN and NBS1 are required to suppress T Cell activation. Loss of NBS1 led to a developmental block at the double-positive stage of T cell development, as well as reduced TCR\u03b1 recombination, that was unexpectedly neither exacerbated nor alleviated by concomitant loss of ATMIN. In contrast, loss of both ATMIN and NBS1 enhanced DNA damage that drove spontaneous peripheral T cell hyperactivation, proliferation as well as excessive production of proinflammatory cytokines and chemokines, leading to a highly inflammatory environment. Intriguingly, the disease causing T cells were largely proficient for both ATMIN and NBS1. In vivo this resulted in severe intestinal inflammation, colitis and premature death."], "concepts": ["http://www.uniprot.org/uniprot/NBS1_SCHPO", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004260", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045643", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053843", "http://www.uniprot.org/uniprot/NBS1_ARATH"], "type": "factoid", "id": "58853c56e56acf5176000018", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "DNA Repair Cofactors ATMIN and NBS1 Are Required to Suppress T Cell Activation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26544571", "endSection": "title"}, {"offsetInBeginSection": 452, "offsetInEndSection": 1366, "text": "Here, we investigate the roles of ATMIN and NBS1, either alone or in combination, using murine models. We show loss of NBS1 led to a developmental block at the double-positive stage of T cell development, as well as reduced TCR\u03b1 recombination, that was unexpectedly neither exacerbated nor alleviated by concomitant loss of ATMIN. In contrast, loss of both ATMIN and NBS1 enhanced DNA damage that drove spontaneous peripheral T cell hyperactivation, proliferation as well as excessive production of proinflammatory cytokines and chemokines, leading to a highly inflammatory environment. Intriguingly, the disease causing T cells were largely proficient for both ATMIN and NBS1. In vivo this resulted in severe intestinal inflammation, colitis and premature death. Our findings reveal a novel model for an intestinal bowel disease phenotype that occurs upon combined loss of the DNA repair cofactors ATMIN and NBS1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26544571", "endSection": "abstract"}, {"offsetInBeginSection": 1208, "offsetInEndSection": 1358, "text": "Our findings reveal a novel model for an intestinal bowel disease phenotype that occurs upon combined loss of the DNA repair cofactors ATMIN and NBS1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26544571", "endSection": "abstract"}, {"offsetInBeginSection": 778, "offsetInEndSection": 1033, "text": "In contrast, loss of both ATMIN and NBS1 enhanced DNA damage that drove spontaneous peripheral T cell hyperactivation, proliferation as well as excessive production of proinflammatory cytokines and chemokines, leading to a highly inflammatory environment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26544571", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "DNA Repair Cofactors ATMIN and NBS1 Are Required to Suppress T Cell Activation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26544571", "endSection": "title"}, {"offsetInBeginSection": 1216, "offsetInEndSection": 1365, "text": "Our findings reveal a novel model for an intestinal bowel disease phenotype that occurs upon combined loss of the DNA repair cofactors ATMIN and NBS1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26544571", "endSection": "abstract"}, {"offsetInBeginSection": 1216, "offsetInEndSection": 1366, "text": "Our findings reveal a novel model for an intestinal bowel disease phenotype that occurs upon combined loss of the DNA repair cofactors ATMIN and NBS1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26544571", "endSection": "abstract"}, {"offsetInBeginSection": 783, "offsetInEndSection": 1038, "text": "In contrast, loss of both ATMIN and NBS1 enhanced DNA damage that drove spontaneous peripheral T cell hyperactivation, proliferation as well as excessive production of proinflammatory cytokines and chemokines, leading to a highly inflammatory environment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26544571", "endSection": "abstract"}, {"offsetInBeginSection": 555, "offsetInEndSection": 782, "text": "We show loss of NBS1 led to a developmental block at the double-positive stage of T cell development, as well as reduced TCR\u03b1 recombination, that was unexpectedly neither exacerbated nor alleviated by concomitant loss of ATMIN.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26544571", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "DNA Repair Cofactors ATMIN and NBS1 Are Required to Suppress T Cell Activation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26544571", "endSection": "title"}]}, {"body": "The MMR vaccine protects against what 3 viruses?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7686463", "http://www.ncbi.nlm.nih.gov/pubmed/26265115"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0065828", "o": "http://linkedlifedata.com/resource/umls/label/A18558018"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18558018", "o": "mmr vaccine"}], "ideal_answer": ["The MMR vaccine provides immunity to measles, mumps and rubella.", " measles, mumps and rubella (mmr) vaccine ."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012411", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012412", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008458", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D022542", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009109", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009108", "http://www.disease-ontology.org/api/metadata/DOID:934"], "type": "list", "id": "58f4b73b70f9fc6f0f000014", "snippets": [{"offsetInBeginSection": 29, "offsetInEndSection": 71, "text": " measles, mumps and rubella (MMR) vaccine ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26265115", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Measles, mumps, rubella (MMR) vaccine is a live vaccine preparation containing attenuated strains of all 3 viruses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7686463", "endSection": "abstract"}]}, {"body": "List cardinal features of the Triple A syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26354489", "http://www.ncbi.nlm.nih.gov/pubmed/27411173", "http://www.ncbi.nlm.nih.gov/pubmed/27385299", "http://www.ncbi.nlm.nih.gov/pubmed/16938764", "http://www.ncbi.nlm.nih.gov/pubmed/20200814", "http://www.ncbi.nlm.nih.gov/pubmed/12752575", "http://www.ncbi.nlm.nih.gov/pubmed/11196451", "http://www.ncbi.nlm.nih.gov/pubmed/12429595", "http://www.ncbi.nlm.nih.gov/pubmed/17880786", "http://www.ncbi.nlm.nih.gov/pubmed/15217518", "http://www.ncbi.nlm.nih.gov/pubmed/27555148", "http://www.ncbi.nlm.nih.gov/pubmed/27698338", "http://www.ncbi.nlm.nih.gov/pubmed/22538409", "http://www.ncbi.nlm.nih.gov/pubmed/20687490", "http://www.ncbi.nlm.nih.gov/pubmed/21656342", "http://www.ncbi.nlm.nih.gov/pubmed/26243364"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0326926", "o": "cardinal"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0326926", "o": "http://linkedlifedata.com/resource/umls/label/A18618465"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18618465", "o": "cardinal"}], "ideal_answer": ["Triple A syndrome, also known as Allgrove syndrome, is a rare disease, and presents mainly in children. Its cardinal symptoms are achalasia, alacrima, and adrenal insufficiency."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:0050602"], "type": "list", "id": "5895bfdc7d9090f35300000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 244, "text": "UNLABELLED: Triple A syndrome (alacrima, achalasia, adrenal failure, progressive neurodegenerative disease) is caused by mutations in the AAAS gene which encodes the protein alacrima achalasia adrenal insufficiency neurologic disorder (ALADIN).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26243364", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Triple A syndrome, also known as Allgrove syndrome, is a rare disease, and presents mainly in children. Its cardinal symptoms are achalasia, alacrima, and adrenocorticotropic hormone (ACTH) insensitivity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27385299", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "BACKGROUND: Oesophageal achalasia is well-recognized but relatively rare in children, occasionally appearing as the \"triple A\" syndrome (with adrenal insufficiency and alacrima).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27411173", "endSection": "abstract"}, {"offsetInBeginSection": 192, "offsetInEndSection": 358, "text": "Patients usually display the triad of achalasia, alacrima, and adrenocorticotropin (ACTH) insensitive adrenal insufficiency, though the presentation is inconsistent. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27698338", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Allgrove (Triple A) syndrome is a rare autosomal recessive disorder characterized by cardinal features of adrenal insufficiency due to adrenocorticotropic hormone (ACTH) resistance, achalasia, and alacrimia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26354489", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "Triple A syndrome, also known as Allgrove syndrome, is a rare autosomal recessive disorder characterized by three cardinal symptoms: adrenal insufficiency due to ACTH insensitivity, achalasia and alacrima.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20200814", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "Allgrove (Triple A) syndrome is a rare autosomal recessive disorder characterized by cardinal features of adrenal insufficiency due to adrenocorticotropic hormone (ACTH) resistance, achalasia, and alacrimia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26354489", "endSection": "abstract"}]}, {"body": "Describe the applicability of Basset in the context of deep learning", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27197224"], "ideal_answer": ["Basset is an open source package which applies CNNs to learn the functional activity of DNA sequences from genomics data. Basset was trained on a compendium of accessible genomic sites mapped in 164 cell types by DNase-seq, and demonstrated greater predictive accuracy than previous methods. Basset predictions for the change in accessibility between variant alleles were far greater for Genome-wide association study (GWAS) SNPs that are likely to be causal relative to nearby SNPs in linkage disequilibrium with them. With Basset, a researcher can perform a single sequencing assay in their cell type of interest and simultaneously learn that cell's chromatin accessibility code and annotate every mutation in the genome with its influence on present accessibility and latent potential for accessibility. Thus, Basset offers a powerful computational approach to annotate and interpret the noncoding genome."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000069553", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000069550"], "type": "summary", "id": "5891c2e7621ea6ff7e00000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Basset: learning the regulatory code of the accessible genome with deep convolutional neural networks.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27197224", "endSection": "title"}, {"offsetInBeginSection": 375, "offsetInEndSection": 1287, "text": "We introduce the open source package Basset to apply CNNs to learn the functional activity of DNA sequences from genomics data. We trained Basset on a compendium of accessible genomic sites mapped in 164 cell types by DNase-seq, and demonstrate greater predictive accuracy than previous methods. Basset predictions for the change in accessibility between variant alleles were far greater for Genome-wide association study (GWAS) SNPs that are likely to be causal relative to nearby SNPs in linkage disequilibrium with them. With Basset, a researcher can perform a single sequencing assay in their cell type of interest and simultaneously learn that cell's chromatin accessibility code and annotate every mutation in the genome with its influence on present accessibility and latent potential for accessibility. Thus, Basset offers a powerful computational approach to annotate and interpret the noncoding genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27197224", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Basset: learning the regulatory code of the accessible genome with deep convolutional neural networks.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27197224", "endSection": "title"}]}, {"body": "Does the Abelson-related gene (ARG) gene encode for a serine kinase?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18411439", "http://www.ncbi.nlm.nih.gov/pubmed/25849507", "http://www.ncbi.nlm.nih.gov/pubmed/15987940", "http://www.ncbi.nlm.nih.gov/pubmed/12220663", "http://www.ncbi.nlm.nih.gov/pubmed/1923513", "http://www.ncbi.nlm.nih.gov/pubmed/23707396", "http://www.ncbi.nlm.nih.gov/pubmed/2649173", "http://www.ncbi.nlm.nih.gov/pubmed/15765532", "http://www.ncbi.nlm.nih.gov/pubmed/18810762", "http://www.ncbi.nlm.nih.gov/pubmed/12821941", "http://www.ncbi.nlm.nih.gov/pubmed/19563810", "http://www.ncbi.nlm.nih.gov/pubmed/9828110", "http://www.ncbi.nlm.nih.gov/pubmed/10590083"], "ideal_answer": ["No, the ARG gene encodes for a nonreceptor tyrosine kinase."], "concepts": ["http://www.uniprot.org/uniprot/ABL2_HUMAN", "http://www.uniprot.org/uniprot/ABL2_MOUSE"], "type": "yesno", "id": "58db94948acda34529000017", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "One isoform of Arg/Abl2 tyrosine kinase is nuclear and the other seven cytosolic isoforms differently modulate cell morphology, motility and the cytoskeleton.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23707396", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "The non-receptor tyrosine kinase Abelson related gene (Arg/Abl2) regulates cell migration and morphogenesis by modulating the cytoskeleton. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23707396", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "The human Arg (Abl2) nonreceptor tyrosine kinase has a role in cytoskeletal rearrangements by its C-terminal F-actin- and microtubule-binding sequences. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18810762", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10590083", "endSection": "title"}, {"offsetInBeginSection": 844, "offsetInEndSection": 1041, "text": " The ARG gene encodes for a nonreceptor tyrosine kinase characterized by high homology with c-Abl in the TK, SH2, and SH3 domains. This is the first report on ARG involvement in a human malignancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10590083", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Ultraviolet-A and -B differentially modify the tyrosine-kinase profile of human keratinocytes and induce the expression of Arg+.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18411439", "endSection": "title"}, {"offsetInBeginSection": 434, "offsetInEndSection": 648, "text": "Arg (Abelson-related gene, Abl2) was the PTK with the highest prevalence (30% of all PTKs) and UVA led to a further induction of Arg expression reaching nine-fold mRNA baseline expression at 17 h after irradiation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18411439", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 303, "text": "To investigate the expression profile of protein tyrosine kinases (PTKs) in normal human epidermal keratinocytes (NHEK) in response to UVA and UVB we employed a reversed transcriptase polymerase chain reaction (PCR) approach using degenerate primers derived from the conserved catalytic domain of PTKs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18411439", "endSection": "abstract"}, {"offsetInBeginSection": 339, "offsetInEndSection": 671, "text": "By 3'rapid amplification of cDNA ends-polymerase chain reaction (3'RACE-PCR), a novel fusion transcript was identified between the ETV6 and the Abelson-related gene (ARG) at 1q25, resulting in a chimeric protein consisting of the HLH oligomerization domain of ETV6 and the SH2, SH3, and protein tyrosine kinase (PTK) domains of ARG.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10590083", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "The non-receptor tyrosine kinase Abelson related gene (Arg/Abl2) regulates cell migration and morphogenesis by modulating the cytoskeleton.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23707396", "endSection": "abstract"}, {"offsetInBeginSection": 432, "offsetInEndSection": 646, "text": "Arg (Abelson-related gene, Abl2) was the PTK with the highest prevalence (30% of all PTKs) and UVA led to a further induction of Arg expression reaching nine-fold mRNA baseline expression at 17 h after irradiation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18411439", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 282, "text": "We studied the relationship of direct karyotypes, determined at diagnosis and remission, to Abelson-related tyrosine kinase activity and the cytogenetic features of erythroid and myeloid colonies derived from remission marrow of six children with acute lymphoblastic leukemia (ALL).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2649173", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "ABL2/ARG (ABL-related gene) belongs to the ABL (Abelson tyrosine-protein kinase) family of tyrosine kinases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25849507", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "The non-receptor tyrosine kinase Abelson related gene (Arg/Abl2) regulates cell migration and morphogenesis by modulating the cytoskeleton", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23707396", "endSection": "abstract"}, {"offsetInBeginSection": 845, "offsetInEndSection": 974, "text": "The ARG gene encodes for a nonreceptor tyrosine kinase characterized by high homology with c-Abl in the TK, SH2, and SH3 domains.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10590083", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "ABL2/ARG (ABL-related gene) belongs to the ABL (Abelson tyrosine-protein kinase) family of tyrosine kinases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25849507", "endSection": "abstract"}, {"offsetInBeginSection": 215, "offsetInEndSection": 374, "text": "We report that the Abelson (Abl) and Abl-related gene (Arg) nonreceptor tyrosine kinases are required for maintenance of cortical dendrites in the mouse brain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15987940", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "The products of the human ARG gene and the human ABL gene characterize the Abelson family of non-receptor tyrosine protein kinases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12220663", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "The products of the human Arg gene and human, mouse, Drosophila, and nematode Abl genes characterize the Abelson family of nonreceptor tyrosine protein kinase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9828110", "endSection": "abstract"}, {"offsetInBeginSection": 341, "offsetInEndSection": 673, "text": "By 3'rapid amplification of cDNA ends-polymerase chain reaction (3'RACE-PCR), a novel fusion transcript was identified between the ETV6 and the Abelson-related gene (ARG) at 1q25, resulting in a chimeric protein consisting of the HLH oligomerization domain of ETV6 and the SH2, SH3, and protein tyrosine kinase (PTK) domains of ARG.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10590083", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10590083", "endSection": "title"}]}, {"body": "What organism causes tularemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23473220", "http://www.ncbi.nlm.nih.gov/pubmed/21607086", "http://www.ncbi.nlm.nih.gov/pubmed/26189939", "http://www.ncbi.nlm.nih.gov/pubmed/18304778", "http://www.ncbi.nlm.nih.gov/pubmed/21687806", "http://www.ncbi.nlm.nih.gov/pubmed/25494920", "http://www.ncbi.nlm.nih.gov/pubmed/22662210", "http://www.ncbi.nlm.nih.gov/pubmed/25847026", "http://www.ncbi.nlm.nih.gov/pubmed/25266682", "http://www.ncbi.nlm.nih.gov/pubmed/20885922", "http://www.ncbi.nlm.nih.gov/pubmed/26336102", "http://www.ncbi.nlm.nih.gov/pubmed/19863554", "http://www.ncbi.nlm.nih.gov/pubmed/24351753"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0041351", "o": "Tularemia"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0041351", "o": "http://linkedlifedata.com/resource/umls/label/A18613230"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18613230", "o": "tularemia"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0041351", "o": "http://linkedlifedata.com/resource/umls/label/A18594521"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18594521", "o": "tularaemia"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0041351", "o": "http://linkedlifedata.com/resource/umls/label/A18668851"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18668851", "o": "tularemias"}], "ideal_answer": ["Francisella tularensis, the agent of tularemia, is a Gram-negative coccobacillus primarily pathogen for animals and occasionally for humans. F. tularensis is the causative agent of zoonotic tularemia. ", "francisella tularensis, the agent of tularemia, is a gram-negative coccobacillus primarily pathogen for animals and occasionally for humans.", "Francisella tularensis, the agent of tularemia, is a Gram-negative coccobacillus primarily pathogen for animals and occasionally for humans. ", "Francisella tularensis, the agent of tularemia, is a Gram-negative coccobacillus primarily pathogen for animals and occasionally for humans."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", "http://www.disease-ontology.org/api/metadata/DOID:14239", "http://www.disease-ontology.org/api/metadata/DOID:13226", "http://www.biosemantics.org/jochem#4244019", "http://www.disease-ontology.org/api/metadata/DOID:2122", "http://www.disease-ontology.org/api/metadata/DOID:2123", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014406", "http://www.disease-ontology.org/api/metadata/DOID:11990", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=organisms_category"], "type": "factoid", "id": "58f4b9d470f9fc6f0f000016", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Francisella tularensis, the agent of tularemia, is a Gram-negative coccobacillus primarily pathogen for animals and occasionally for humans. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26189939", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 208, "text": "F. tularensis is the causative agent of zoonotic tularemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26336102", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Tularemia is a zoonosis caused by Francisella tularensis that can be transmitted by several ways to human being and cause different clinical manifestations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25847026", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Tularemia is a bacterial zoonotic disease that is caused by Francisella tularensis and among the infectious reasons that cause fever of unknown origin (FUO) in children", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23473220", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "The bacterium Francisella tularensis causes the vector-borne zoonotic disease tularemia, and may infect a wide range of hosts including invertebrates, mammals and birds", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25266682", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Francisella tularensis, the Gram-negative bacterium that causes tularemia, is considered a potential bioterrorism threat due to its low infectivity dose and the high morbidity and mortality from respiratory disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24351753", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Francisella tularensis causes disease (tularemia) in a large number of mammals, including man", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25494920", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "The tularemia-causing bacterium Francisella tularensis is a facultative intracellular organism with a complex intracellular lifecycle that ensures its survival and proliferation in a variety of mammalian cell types, including professional phagocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21687806", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Francisella tularensis is a highly virulent bacterium that causes tularemia, a disease that is often fatal if untreated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18304778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Tularemia, caused by the gram-negative bacterium Francisella tularensis, is a severe, sometimes fatal disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22662210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Tularemia, caused by the bacterium Francisella tularensis, where F.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20885922", "endSection": "abstract"}]}, {"body": "Is Prochlorococcus the most abundant photosynthetic organism?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25977791", "http://www.ncbi.nlm.nih.gov/pubmed/19549842", "http://www.ncbi.nlm.nih.gov/pubmed/11595938", "http://www.ncbi.nlm.nih.gov/pubmed/25435307"], "ideal_answer": ["Yes, the marine cyanobacterium Prochlorococcus is the smallest and most abundant photosynthetic organism on Earth."], "type": "yesno", "id": "58ea659c3e8b6dc87c000013", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "The marine cyanobacterium Prochlorococcus is the smallest and most abundant photosynthetic organism on Earth.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25435307", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "The marine cyanobacterium Prochlorococcus is the numerically dominant photosynthetic organism in the oligotrophic oceans, and a model system in marine microbial ecology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25977791", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "The marine cyanobacterium Prochlorococcus is the most abundant photosynthetic organism in oligotrophic regions of the oceans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19549842", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "The oceanic picoplankton Prochlorococcus - probably the most abundant photosynthetic organism on our planet - can grow at great depths where light intensity is very low.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11595938", "endSection": "abstract"}]}, {"body": "List 3 features of IRVAN syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24221466", "http://www.ncbi.nlm.nih.gov/pubmed/22454754", "http://www.ncbi.nlm.nih.gov/pubmed/15348989", "http://www.ncbi.nlm.nih.gov/pubmed/26922651", "http://www.ncbi.nlm.nih.gov/pubmed/9121757", "http://www.ncbi.nlm.nih.gov/pubmed/24766157", "http://www.ncbi.nlm.nih.gov/pubmed/25383801", "http://www.ncbi.nlm.nih.gov/pubmed/25390402", "http://www.ncbi.nlm.nih.gov/pubmed/27491854", "http://www.ncbi.nlm.nih.gov/pubmed/21563921", "http://www.ncbi.nlm.nih.gov/pubmed/12504719", "http://www.ncbi.nlm.nih.gov/pubmed/25802506", "http://www.ncbi.nlm.nih.gov/pubmed/24269400", "http://www.ncbi.nlm.nih.gov/pubmed/27239579"], "ideal_answer": ["Idiopathic retinal vasculitis, aneurysms, and neuroretinitis is coined as IRVAN syndrome."], "type": "list", "id": "5895dd6a7d9090f35300000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Fluorescein photodiagnosis of idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome: A case report and long-term outcome of photocoagulation therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27491854", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome is a disease characterized by multiple retinal macroaneurysms, neuroretinitis and peripheral capillary non-perfusion, leading to irreversible visual loss.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27491854", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "[Early treatment of idiopathic vasculitis, aneurysms and neuroretinitis (IRVAN). A case report].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24269400", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "CASE REPORT: A 55 year old woman presented with retinal vasculitis, multiple aneurysms, macular exudation and widespread retinal nonperfusion and was diagnosed with IRVAN.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24269400", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "A 7-year-old girl with IRVAN (idiopathic retinal vasculitis, aneurysms, and neuroretinitis) syndrome was monitored for 9 years.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24766157", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "Vision loss associated with the idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome most commonly occurs from macular edema or complications related to neovascularization. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24221466", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "PURPOSE: To report a case of idiopathic retinal vasculitis, aneurysms and neuroretinitis (IRVAN) syndrome associated with positive perinuclear antineutrophil cytoplasmic antibody (P-ANCA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22454754", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "PURPOSE: We report our experience in treating 2 patients of idiopathic retinal vasculitis, aneurysm, and neuroretinitis (IRVAN) syndrome with antitumor necrosis factor agent, infliximab, who showed a very favorable response to treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21563921", "endSection": "abstract"}, {"offsetInBeginSection": 576, "offsetInEndSection": 702, "text": "Fluorescein angiography delineated saccular aneurysms of the retinal arteriolar vasculature, and IRVAN syndrome was diagnosed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15348989", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 381, "text": "The authors describe the clinical feature of ten patients with a new syndrome characterized by the presence of retinal vasculitis, multiple macroaneurysms, neuro-retinitis, and peripheral capillary nonperfusion.The authors evaluated ten patients identified to have clinical features compatible with the syndrome of idiopathic retinal vasculitis, aneurysms and neuroretinits (IRVAN)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9121757", "endSection": "abstract"}, {"offsetInBeginSection": 212, "offsetInEndSection": 383, "text": "The authors evaluated ten patients identified to have clinical features compatible with the syndrome of idiopathic retinal vasculitis, aneurysms and neuroretinits (IRVAN).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9121757", "endSection": "abstract"}]}, {"body": "Which are the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) inhibitors that are FDA approved?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26548330", "http://www.ncbi.nlm.nih.gov/pubmed/27086681", "http://www.ncbi.nlm.nih.gov/pubmed/26785741", "http://www.ncbi.nlm.nih.gov/pubmed/27533159", "http://www.ncbi.nlm.nih.gov/pubmed/27661220", "http://www.ncbi.nlm.nih.gov/pubmed/26345307", "http://www.ncbi.nlm.nih.gov/pubmed/26445204", "http://www.ncbi.nlm.nih.gov/pubmed/26822080", "http://www.ncbi.nlm.nih.gov/pubmed/26798848", "http://www.ncbi.nlm.nih.gov/pubmed/27567901", "http://www.ncbi.nlm.nih.gov/pubmed/26652782", "http://www.ncbi.nlm.nih.gov/pubmed/26886466", "http://www.ncbi.nlm.nih.gov/pubmed/27207595", "http://www.ncbi.nlm.nih.gov/pubmed/26596726", "http://www.ncbi.nlm.nih.gov/pubmed/23889692", "http://www.ncbi.nlm.nih.gov/pubmed/27186592", "http://www.ncbi.nlm.nih.gov/pubmed/26968977"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0243077", "o": "inhibitors"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0243077", "o": "http://linkedlifedata.com/resource/umls/label/A8396238"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8396238", "o": "inhibitors"}], "ideal_answer": ["The PCSK9 inhibitors that are FDA approved are:\n1) Alirocumab and \n2) Evolocumab."], "concepts": ["http://www.uniprot.org/uniprot/PCSK9_MACMU", "http://www.uniprot.org/uniprot/PCSK9_PANTR", "http://www.uniprot.org/uniprot/PCSK9_COLGU", "http://www.uniprot.org/uniprot/PCSK9_CALJA", "http://www.uniprot.org/uniprot/PCSK9_SAGLB", "http://www.uniprot.org/uniprot/PCSK9_PONPY", "http://www.uniprot.org/uniprot/PCSK9_LAGLA", "http://www.uniprot.org/uniprot/PCSK9_MACNE", "http://www.uniprot.org/uniprot/PCSK9_HUMAN", "http://www.uniprot.org/uniprot/PCSK9_ATEGE", "http://www.uniprot.org/uniprot/PCSK9_PANPA", "http://www.uniprot.org/uniprot/PCSK9_PLEMO"], "type": "list", "id": "58dbb3f18acda34529000019", "snippets": [{"offsetInBeginSection": 626, "offsetInEndSection": 776, "text": "Inhibition of the PCSK9 protein by monoclonal antibodies results in a dramatic 40%-60% lowering of serum low-density lipoprotein cholesterol (LDL-C). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26822080", "endSection": "abstract"}, {"offsetInBeginSection": 983, "offsetInEndSection": 1384, "text": "Alirocumab and evolocumab have been approved by the FDA for the treatment of patients with heterozygous familial hypercholesterolemia and patients with clinical atherosclerotic cardiovascular disease) who do not achieve their LDL-C target on maximal tolerated statin treatment and dietary modification. In addition, evolocumab has been approved by the FDA for homozygous familial hypercholesterolemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26822080", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 382, "text": "LDL cholesterol (LDLC) lowering has been revolutionized by PCSK9 inhibitors, Alirocumab (Praluent) and Evolocumab (Repatha), approved as adjuncts to maximally tolerated cholesterol lowering therapy in heterozygous (HeFH) or homozygous (HoFH) familial hypercholesterolemia, and/or clinical atherosclerotic cardiovascular disease (CVD) where LDLC lowering is insufficient.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26968977", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "A new class of lipid-lowering drugs, inhibitors of PCSK9 has been generating impressive clinical trial data over the last several years, and alirocumab (Praluent) has become the first to be approved by the US FDA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26785741", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "The second FDA-approved PCSK9 inhibitor evolocumab (Repatha) appears to be similar in efficacy and safety to alirocumab (Praluent), but no comparative studies are available. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26445204", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hypercholesterolemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27086681", "endSection": "abstract"}, {"offsetInBeginSection": 437, "offsetInEndSection": 944, "text": "Newer agents for LDL cholesterol reduction include the cholesterol ester transfer protein inhibitors, the microsomal triglyceride transfer protein inhibitor lomitapide, the apolipoprotein B antisense oligonucleotide mipomersen and several molecules that inhibit or interfere with proprotein convertase subtilisin/kexin 9 (PCSK9).Among the various PCSK9 inhibitors, human data are available for monoclonal antibodies against PCSK9 of which the two most advanced are alirocumab (SAR236553/REGN727) and AMG 145", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23889692", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "The 2 or 4\u2011week subcutaneous therapy with the recently approved antibodies alirocumab and evolocumab for inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) reduces low-density lipoprotein cholesterol (LDL-C) in addition to statins and ezetimibe by 50-60\u2009%.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27207595", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 487, "text": "In 2015 the U.S. Food and Drug Administration approved the first two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab (Praluent\u00ae; Sanofi/ Regeneron) and evolocumab (Repatha\u00ae; Amgen), for use in patients with heterozygous and homozygous familial hypercholesterolemia and for patients intolerant of statins or those with a major risk of cardiovascular disease (CVD) but unable to lower their LDL cholesterol (LDL-C) to optimal levels with statins and ezetimibe.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186592", "endSection": "abstract"}, {"offsetInBeginSection": 892, "offsetInEndSection": 1135, "text": "Very recent clinical trials have proven overwhelmingly the effectiveness and safety of PCSK9 inhibitors for lowering LDL-C. Both alirocumab and evolocumab have now been approved by the US FDA and there are some initial favorable outcomes data.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26596726", "endSection": "abstract"}, {"offsetInBeginSection": 17, "offsetInEndSection": 487, "text": "Food and Drug Administration approved the first two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab (Praluent\u00ae; Sanofi/ Regeneron) and evolocumab (Repatha\u00ae; Amgen), for use in patients with heterozygous and homozygous familial hypercholesterolemia and for patients intolerant of statins or those with a major risk of cardiovascular disease (CVD) but unable to lower their LDL cholesterol (LDL-C) to optimal levels with statins and ezetimibe.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186592", "endSection": "abstract"}]}, {"body": "Is dupilumab an antibody targeting the IL-1 receptor?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26440137", "http://www.ncbi.nlm.nih.gov/pubmed/27130691", "http://www.ncbi.nlm.nih.gov/pubmed/27690741", "http://www.ncbi.nlm.nih.gov/pubmed/26598956", "http://www.ncbi.nlm.nih.gov/pubmed/23688323", "http://www.ncbi.nlm.nih.gov/pubmed/27497276", "http://www.ncbi.nlm.nih.gov/pubmed/26308331"], "ideal_answer": ["No, Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways."], "type": "yesno", "id": "58df5efbc784871774000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "Atopic dermatitis (AD) is characterized by type 2 helper T (Th2) cell-driven inflammation. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", "endSection": "abstract"}, {"offsetInBeginSection": 625, "offsetInEndSection": 818, "text": "Dupilumab, a humanized monoclonal antibody to the interteukin-4R is the first antibody (i.e. 'biological') with published efficacy shown in controlled prospective studies in atopic dermatitis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26308331", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 248, "text": "Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", "endSection": "abstract"}, {"offsetInBeginSection": 1051, "offsetInEndSection": 1337, "text": "Best evidence of the clinical efficacy of novel immunologic approaches using biological agents in patients with AD is available for the anti-IL-4 receptor \u03b1-chain antibody dupilumab, but a number of studies are currently ongoing with other specific antagonists to immune system players.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27497276", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 187, "text": " Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130691", "endSection": "abstract"}, {"offsetInBeginSection": 1015, "offsetInEndSection": 1169, "text": "Dupilumab was also introduced as a possible treatment for patients with severe pemphigus. It can directly inhibit IL-4 by targeting IL-4 \u03b1-chain receptor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440137", "endSection": "abstract"}, {"offsetInBeginSection": 62, "offsetInEndSection": 217, "text": "We evaluated the efficacy and safety of dupilumab (SAR231893/REGN668), a fully human monoclonal antibody to the alpha subunit of the interleukin-4 receptor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23688323", "endSection": "abstract"}]}, {"body": "List active ingredients of the Stribild polypill.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24338165", "http://www.ncbi.nlm.nih.gov/pubmed/25553805", "http://www.ncbi.nlm.nih.gov/pubmed/27225853", "http://www.ncbi.nlm.nih.gov/pubmed/26286337", "http://www.ncbi.nlm.nih.gov/pubmed/23136357", "http://www.ncbi.nlm.nih.gov/pubmed/26045359", "http://www.ncbi.nlm.nih.gov/pubmed/26679246"], "ideal_answer": ["Active ingredients of Stribild are elvitegravir, cobicistat, emtricitabine and tenofovir. It is used for treatment of HIV infection."], "type": "list", "id": "5895dfc97d9090f353000010", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "PURPOSE: The purpose of this study is to assess postmarketing safety and tolerability of Stribild (elvitegravir [EVG]/cobicistat [COBI]/tenofovir disoproxil fumarate [TDF]/emtricitabine [FTC]).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27225853", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "INTRODUCTION: Co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir (EVG/COBI/FTC/TDF or Stribild\u2122) is the latest antiretroviral tablet approved in the EU. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25553805", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "BACKGROUND: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; Stribild(\u00ae)) is a guideline-recommended regimen for HIV treatment-na\u00efve patients and a switch option for virologically suppressed patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26045359", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 292, "text": "BACKGROUND: Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; Stribild(\u00ae)) is a recommended integrase inhibitor-based regimen in treatment guidelines from the US Department of Health and Human Services and the British HIV Association. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26286337", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild\u00ae): a review of its use in the management of HIV-1 infection in adults.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24338165", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 533, "text": "A new single-tablet, fixed-dose formulation consisting of elvitegravir, an HIV-1 integrase strand transfer inhibitor (INSTI); cobicistat, a pharmacokinetic enhancer; emtricitabine, a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil fumarate (tenofovir DF), a nucleotide reverse transcriptase inhibitor (elvitegravir/cobicistat/emtricitabine/tenofovir DF 150 mg/150 mg/200 mg/300 mg; Stribild\u00ae) is available in some countries for the once-daily treatment of HIV-1 infection in antiretroviral therapy-na\u00efve adults. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24338165", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 389, "text": "To review the clinical trials, pharmacologic characteristics, safety, and efficacy of the elvitegravir/cobicistat/emtricitabine/tenofovir single tablet formulation (Stribild).Literature searches were performed in MEDLINE (1948-September 2012) and PubMed (1966-September 2012) using the search terms GS-9137, elvitegravir, GS 9350, cobicistat, quad pill, Stribild, and integrase inhibitors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23136357", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 419, "text": "To evaluate dolutegravir and elvitegravir/cobicistat pharmacokinetics in HIV-negative volunteers up to 10 days after drug cessation.Healthy volunteers received 50 mg of dolutegravir once-daily for 10 days, then underwent a 9 day wash-out period, and then received elvitegravir/cobicistat as part of Stribild(\u00ae) (245 mg of tenofovir, 200 mg of emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat) for 10 days.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679246", "endSection": "abstract"}]}, {"body": "List clinical features of the IMAGe syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25517553", "http://www.ncbi.nlm.nih.gov/pubmed/25861374", "http://www.ncbi.nlm.nih.gov/pubmed/16835919", "http://www.ncbi.nlm.nih.gov/pubmed/25258553", "http://www.ncbi.nlm.nih.gov/pubmed/22634751", "http://www.ncbi.nlm.nih.gov/pubmed/25541901", "http://www.ncbi.nlm.nih.gov/pubmed/24313804", "http://www.ncbi.nlm.nih.gov/pubmed/24617583", "http://www.ncbi.nlm.nih.gov/pubmed/14760276", "http://www.ncbi.nlm.nih.gov/pubmed/21108398"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0683325", "o": "http://linkedlifedata.com/resource/umls/label/A18567231"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0683325", "o": "clinical aspects"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0683325", "o": "http://linkedlifedata.com/resource/umls/label/A18697112"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18697112", "o": "clinical aspects"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0683325", "o": "http://linkedlifedata.com/resource/umls/label/A1810832"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A1810832", "o": "clinical aspects"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0683325", "o": "http://linkedlifedata.com/resource/umls/label/A18585749"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18585749", "o": "aspects clinical"}], "ideal_answer": ["Clinical features of IMAGe syndrome include intra-uterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita and genital abnormalities. It is s caused by gain-of-function mutations of maternally expressed gene CDKN1C on chromosome 11p15.5."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:0050885"], "type": "list", "id": "5895e4637d9090f353000012", "snippets": [{"offsetInBeginSection": 171, "offsetInEndSection": 461, "text": "Recently, our group described gain-of-function mutations in the PCNA-binding site of CDKN1C that result in an undergrowth syndrome called IMAGe Syndrome (Intrauterine Growth Restriction, Metaphyseal dysplasia, Adrenal hypoplasia, and Genital anomalies), with life-threatening consequences. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25861374", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 220, "text": "IMAGe syndrome is an exceedingly rare condition first described in 1999. Components of the syndrome are intrauterine growth retardation (IUGR), metaphyseal dysplasia, congenital adrenal hypoplasia and genital anomalies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25541901", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 280, "text": "OBJECTIVE: Arboleda et al. have recently shown that IMAGe (intra-uterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita and genital abnormalities) syndrome is caused by gain-of-function mutations of maternally expressed gene CDKN1C on chromosome 11p15.5. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313804", "endSection": "abstract"}, {"offsetInBeginSection": 275, "offsetInEndSection": 493, "text": "Intriguing is that CDKN1C gain-of-function variations were recently found in patients with IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, congenital adrenal hypoplasia, and genital anomalies). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25258553", "endSection": "abstract"}]}, {"body": "Which gene mutations are predictive of response to anti-TNF therapy in Rheumatoid Arthritis patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26440629", "http://www.ncbi.nlm.nih.gov/pubmed/22044414", "http://www.ncbi.nlm.nih.gov/pubmed/25848939"], "ideal_answer": ["\u039cutations in TLR5 and TLR1 genes contribute to differential response to anti-TNF treatment in RA. Variation at FCGR2A and functionally related genes such as DHX32 and RGS12 is also associated with the response to anti-TNF therapy in rheumatoid arthritis."], "type": "list", "id": "58e7a1393e8b6dc87c00000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Genetic Variations in Pattern Recognition Receptor Loci Are Associated with Anti-TNF Response in Patients with Rheumatoid Arthritis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440629", "endSection": "title"}, {"offsetInBeginSection": 877, "offsetInEndSection": 1682, "text": "Six of twenty successfully genotyped polymorphisms were nominally associated with EULAR treatment response. Three of these were in weak to moderate linkage disequilibrium with polymorphisms previously reported associated with anti-TNF treatment response. TLR5(rs5744174) variant allele carriers (odds ratio(OR) = 1.7(1.1-2.5),p = 0.010,q = 0.46) and TLR1(rs4833095) homozygous variant carriers (OR = 2.8(1.1-7.4),p = 0.037,q = 0.46) had higher odds for a positive treatment response. NLRP3(rs10754558) variant allele carriers (odds ratio(OR) = 0.6(0.4-1.0),p = 0.045,q = 0.46) were more likely to have a negative treatment response. The association in TLR5(rs5744174) remained significant after correction for multiple comparisons among patients negative for RF (OR = 6.2(2.4-16.3),p = 0.0002,q = 0.024). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440629", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939", "endSection": "title"}, {"offsetInBeginSection": 306, "offsetInEndSection": 511, "text": "We aimed to validate this genetic association in a patient cohort from the Spanish population, and also to identify new genes functionally related to FCGR2A that are also associated with anti-TNF response.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939", "endSection": "abstract"}, {"offsetInBeginSection": 520, "offsetInEndSection": 642, "text": "A total of 348 RA patients treated with an anti-TNF therapy were included and genotyped for FCGR2A polymorphism rs1081274.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939", "endSection": "abstract"}, {"offsetInBeginSection": 812, "offsetInEndSection": 969, "text": " Using gene expression profiles from macrophages obtained from synovial fluid of RA patients, we searched for genes highly correlated with FCGR2A expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939", "endSection": "abstract"}, {"offsetInBeginSection": 1083, "offsetInEndSection": 1459, "text": "We found a significant association between FCGR2A and the response to adalimumab (P=0.022). Analyzing the subset of anti-CCP positive RA patients (78%), we also found a significant association between FCGR2A and the response to infliximab (P=0.035). DHX32 and RGS12 were the most consistently correlated genes with FCGR2A expression in RA synovial fluid macrophages (P<0.001).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939", "endSection": "abstract"}, {"offsetInBeginSection": 1460, "offsetInEndSection": 1684, "text": "We found a significant association between the genetic variation at DHX32 (rs12356233, corrected P=0.019) and a nominally significant association between RGS12 and the response to adalimumab (rs4690093, uncorrected P=0.040).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939", "endSection": "abstract"}, {"offsetInBeginSection": 1685, "offsetInEndSection": 1857, "text": "In the anti-CCP positive group of patients, we also found a nominally significant association between RGS12 and the response to infliximab (rs2857859, uncorrected P=0.042).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848939", "endSection": "abstract"}]}, {"body": "Which method is used for prediction of novel microRNA genes in cancer-associated genomic regions?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19324892"], "ideal_answer": ["SSCprofiler is a computational tool utilizing a probabilistic method based on Profile Hidden Markov Models to predict novel miRNA precursors. Via the simultaneous integration of biological features such as sequence, structure and conservation, SSCprofiler achieves a performance accuracy of 88.95% sensitivity and 84.16% specificity on a large set of human miRNA genes. The trained classifier is used to identify novel miRNA gene candidates located within cancer-associated genomic regions and rank the resulting predictions using expression information from a full genome tiling array. SSCprofiler is freely available as a web service at http://www.imbb.forth.gr/SSCprofiler.html."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683"], "type": "factoid", "id": "5895f18ce370baff39000001", "snippets": [{"offsetInBeginSection": 425, "offsetInEndSection": 1429, "text": " In this work we present a new computational tool (SSCprofiler) utilizing a probabilistic method based on Profile Hidden Markov Models to predict novel miRNA precursors. Via the simultaneous integration of biological features such as sequence, structure and conservation, SSCprofiler achieves a performance accuracy of 88.95% sensitivity and 84.16% specificity on a large set of human miRNA genes. The trained classifier is used to identify novel miRNA gene candidates located within cancer-associated genomic regions and rank the resulting predictions using expression information from a full genome tiling array. Finally, four of the top scoring predictions are verified experimentally using northern blot analysis. Our work combines both analytical and experimental techniques to show that SSCprofiler is a highly accurate tool which can be used to identify novel miRNA gene candidates in the human genome. SSCprofiler is freely available as a web service at http://www.imbb.forth.gr/SSCprofiler.html.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19324892", "endSection": "abstract"}, {"offsetInBeginSection": 426, "offsetInEndSection": 594, "text": "In this work we present a new computational tool (SSCprofiler) utilizing a probabilistic method based on Profile Hidden Markov Models to predict novel miRNA precursors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19324892", "endSection": "abstract"}, {"offsetInBeginSection": 1143, "offsetInEndSection": 1334, "text": "Our work combines both analytical and experimental techniques to show that SSCprofiler is a highly accurate tool which can be used to identify novel miRNA gene candidates in the human genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19324892", "endSection": "abstract"}]}, {"body": "Does the histone chaperone ASF1 interact with histones H1/H2?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22291963", "http://www.ncbi.nlm.nih.gov/pubmed/21329878", "http://www.ncbi.nlm.nih.gov/pubmed/18096807", "http://www.ncbi.nlm.nih.gov/pubmed/17690098", "http://www.ncbi.nlm.nih.gov/pubmed/19172748", "http://www.ncbi.nlm.nih.gov/pubmed/16229457", "http://www.ncbi.nlm.nih.gov/pubmed/21895891", "http://www.ncbi.nlm.nih.gov/pubmed/25618846", "http://www.ncbi.nlm.nih.gov/pubmed/23184661", "http://www.ncbi.nlm.nih.gov/pubmed/20048053", "http://www.ncbi.nlm.nih.gov/pubmed/26522166", "http://www.ncbi.nlm.nih.gov/pubmed/22106264", "http://www.ncbi.nlm.nih.gov/pubmed/20227376", "http://www.ncbi.nlm.nih.gov/pubmed/18334479", "http://www.ncbi.nlm.nih.gov/pubmed/17107956", "http://www.ncbi.nlm.nih.gov/pubmed/27036862", "http://www.ncbi.nlm.nih.gov/pubmed/16627621", "http://www.ncbi.nlm.nih.gov/pubmed/23569117", "http://www.ncbi.nlm.nih.gov/pubmed/17293877", "http://www.ncbi.nlm.nih.gov/pubmed/25781956", "http://www.ncbi.nlm.nih.gov/pubmed/22323608", "http://www.ncbi.nlm.nih.gov/pubmed/22463819", "http://www.ncbi.nlm.nih.gov/pubmed/17081967", "http://www.ncbi.nlm.nih.gov/pubmed/24824343", "http://www.ncbi.nlm.nih.gov/pubmed/20347990", "http://www.ncbi.nlm.nih.gov/pubmed/17166288", "http://www.ncbi.nlm.nih.gov/pubmed/19403047", "http://www.ncbi.nlm.nih.gov/pubmed/17576589", "http://www.ncbi.nlm.nih.gov/pubmed/19782028", "http://www.ncbi.nlm.nih.gov/pubmed/24209620"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C2752385", "o": "histone chaperone"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2752385", "o": "http://linkedlifedata.com/resource/umls/label/A17474145"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17474145", "o": "histone chaperone"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2752385", "o": "http://linkedlifedata.com/resource/umls/label/A17470574"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17470574", "o": "histone chaperone"}], "ideal_answer": ["No, the histone chaperone ASF1 interacts with histones H3/H4."], "concepts": ["http://www.uniprot.org/uniprot/ASF1_CANGA", "http://www.uniprot.org/uniprot/ASF1_CRYNJ", "http://www.uniprot.org/uniprot/ASF1_ASPFU", "http://www.uniprot.org/uniprot/ASF1_ENCCU", "http://www.uniprot.org/uniprot/ASF1_DEBHA", "http://www.uniprot.org/uniprot/ASF1_ASHGO", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056488", "http://www.uniprot.org/uniprot/ASF1_YARLI", "http://www.uniprot.org/uniprot/ASF1_DROME", "http://www.uniprot.org/uniprot/ASF1_KLULA", "http://www.uniprot.org/uniprot/ASF1_CHICK", "http://www.uniprot.org/uniprot/ASF1_USTMA", "http://www.uniprot.org/uniprot/ASF1_CANAL", "http://www.uniprot.org/uniprot/ASF1_CRYNB", "http://www.uniprot.org/uniprot/ASF1_COCIM"], "type": "yesno", "id": "58dcbb8c8acda34529000021", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "The C terminus of the histone chaperone Asf1 cross-links to histone H3 in yeast and promotes interaction with histones H3 and H4.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184661", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "The central histone H3/H4 chaperone Asf1 comprises a highly conserved globular core and a divergent C-terminal tail. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184661", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "The histone H3-H4 chaperone Asf1 is involved in chromatin assembly (or disassembly), histone exchange, regulation of transcription, and chromatin silencing in several organisms. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22291963", "endSection": "abstract"}, {"offsetInBeginSection": 846, "offsetInEndSection": 1051, "text": "An ASF1-EGFP fusion protein localizes to the nucleus. By tandem-affinity purification/mass spectrometry as well as yeast two-hybrid analysis, we identified histones H3 and H4 as ASF1 interaction partners. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22463819", "endSection": "abstract"}, {"offsetInBeginSection": 538, "offsetInEndSection": 671, "text": " This inhibition requires Asf1 binding to H3-H4 and Rtt109 KAT activity, but not tail acetylation of H3-H4 or K56 acetylation of H3. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22106264", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Asf1 is a conserved histone H3/H4 chaperone that can assemble and disassemble nucleosomes and promote histone acetylation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20048053", "endSection": "abstract"}, {"offsetInBeginSection": 387, "offsetInEndSection": 674, "text": "Here we characterize further interactions between budding yeast (Saccharomyces cerevisiae) Asf1 and Set2 using assays of intragenic transcription, H3/H4 posttranslational modification, coding region cross-linking of Asf1 and Set2, and cooccurrence of Asf1 and Set2 in protein complexes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20048053", "endSection": "abstract"}, {"offsetInBeginSection": 938, "offsetInEndSection": 1120, "text": "Consistent with this possibility, we show that Asf1 stimulates Set2 occupancy of the coding region of a highly transcribed gene by a mechanism that depends on Asf1 binding to H3/H4. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20048053", "endSection": "abstract"}, {"offsetInBeginSection": 275, "offsetInEndSection": 431, "text": "Drosophila histones H3 and H4 can also be produced as a soluble (H3H4)(2) heterotetrameric complex if they are co-expressed with the histone chaperone Asf1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20347990", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Structure and function of the histone chaperone CIA/ASF1 complexed with histones H3 and H4.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17293877", "endSection": "title"}, {"offsetInBeginSection": 139, "offsetInEndSection": 274, "text": "Newly synthesized histones H3-H4 first bind histone chaperone Asf1 and are then transferred to other chaperones for nucleosome assembly", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24209620", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "The C terminus of the histone chaperone Asf1 cross-links to histone H3 in yeast and promotes interaction with histones H3 and H4", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184661", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Histone chaperone Asf1 is required for histone H3 lysine 56 acetylation, a modification associated with S phase in mitosis and meiosis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16627621", "endSection": "title"}, {"offsetInBeginSection": 135, "offsetInEndSection": 243, "text": "Antisilencing function 1 (ASF1) is a major histone H3-H4 chaperone that deposits histones H3 and H4 onto DNA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16229457", "endSection": "abstract"}, {"offsetInBeginSection": 105, "offsetInEndSection": 344, "text": "Rtt109, a recently discovered histone acetyltransferase (HAT) from Saccharomyces cerevisiae, functions with the histone chaperone Asf1 to acetylate lysine K56 on histone H3 (H3K56), a modification associated with newly synthesized histones", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19172748", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "In this issue of Cell, English et al. present the first crystal structure of a histone chaperone (Asf1) bound to histones (the H3/H4 heterodimer)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17081967", "endSection": "abstract"}, {"offsetInBeginSection": 900, "offsetInEndSection": 1050, "text": "By tandem-affinity purification/mass spectrometry as well as yeast two-hybrid analysis, we identified histones H3 and H4 as ASF1 interaction partners.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22463819", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Anti-silencing function 1 (Asf1) is a highly conserved chaperone of histones H3/H4 that assembles or disassembles chromatin during transcription, replication, and repair.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17107956", "endSection": "abstract"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1258, "text": "Analysis of a panel of Asf1 mutations that modulate the ability of Asf1 to bind to histones H3/H4 demonstrates that the histone binding activity of Asf1 is required for the acetylation of Lys-9 and Lys-56 on newly synthesized H3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17107956", "endSection": "abstract"}, {"offsetInBeginSection": 887, "offsetInEndSection": 975, "text": "Thus Rad53 competes with histones H3-H4 and cochaperones HirA/CAF-I for binding to Asf1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22323608", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Structure and function of the histone chaperone CIA/ASF1 complexed with histones H3 and H4.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17293877", "endSection": "title"}, {"offsetInBeginSection": 261, "offsetInEndSection": 396, "text": "Currently, the best-characterized chaperone-histone interaction is that between the ubiquitous chaperone Asf1 and a dimer of H3 and H4.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21329878", "endSection": "abstract"}]}, {"body": "Is Hepatic mesenchymal hamartoma usually a malignant tumor?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23164031", "http://www.ncbi.nlm.nih.gov/pubmed/16833000", "http://www.ncbi.nlm.nih.gov/pubmed/19365132", "http://www.ncbi.nlm.nih.gov/pubmed/18022426", "http://www.ncbi.nlm.nih.gov/pubmed/23351454", "http://www.ncbi.nlm.nih.gov/pubmed/17493912", "http://www.ncbi.nlm.nih.gov/pubmed/16544232", "http://www.ncbi.nlm.nih.gov/pubmed/2267227", "http://www.ncbi.nlm.nih.gov/pubmed/15785401", "http://www.ncbi.nlm.nih.gov/pubmed/27833980", "http://www.ncbi.nlm.nih.gov/pubmed/8942272", "http://www.ncbi.nlm.nih.gov/pubmed/17713740", "http://www.ncbi.nlm.nih.gov/pubmed/18071280", "http://www.ncbi.nlm.nih.gov/pubmed/22935827", "http://www.ncbi.nlm.nih.gov/pubmed/20954316"], "ideal_answer": ["Mesenchymal hamartoma of the liver (MHL) is an uncommon benign hepatic tumor typically affecting children under 2 years of age.", "Mesenchymal hamartoma of the liver (MHL) is a benign and rare hepatic lesion, ", "mesenchymal hamartoma of the liver (mhl) is an uncommon benign hepatic tumor typically affecting children under 2 years of age."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006223", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006222", "http://www.disease-ontology.org/api/metadata/DOID:3467", "http://www.disease-ontology.org/api/metadata/DOID:6108", "http://www.disease-ontology.org/api/metadata/DOID:3462"], "type": "yesno", "id": "58f3cd1470f9fc6f0f00000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Mesenchymal hamartoma of the liver (MHL) is a benign and rare hepatic lesion, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27833980", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Mesenchymal hamartoma of the liver (MHL) is an uncommon benign hepatic tumor typically affecting children under 2 years of age", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22935827", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 359, "text": "This review on the pathology of hepatic tumors in childhood, from a personal series of 245 tumors, focuses on incidence, management, description of frequent tumors such as hepatoblastoma, fibrolamellar carcinoma, and undifferentiated sarcoma for malignant tumors, focal nodular hyperplasia, hepatocellular adenoma, and mesenchymal hamartoma for benign tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15785401", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Mesenchymal hamartoma of the liver is a rare benign liver tumor in children, usually arising from the right liver lobe and represents about 5 to 6% of all primary hepatic tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23351454", "endSection": "abstract"}, {"offsetInBeginSection": 122, "offsetInEndSection": 216, "text": "Hepatic mesenchymal hamartoma (HMH) is the second most common benign hepatic tumor in children", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23164031", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Hepatic mesenchymal hamartoma is a rare benign tumor in children, and infantile hepatic hemangioendothelioma is also a rare liver neoplasm", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17493912", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 358, "text": "This review on the pathology of hepatic tumors in childhood, from a personal series of 245 tumors, focuses on incidence, management, description of frequent tumors such as hepatoblastoma, fibrolamellar carcinoma, and undifferentiated sarcoma for malignant tumors, focal nodular hyperplasia, hepatocellular adenoma, and mesenchymal hamartoma for benign tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15785401", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Mesenchymal hamartoma is a rare and benign tumor.. Representing 5 to 8 % of childrens hepatic tumors, it is rarely described in adults", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16833000", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 319, "text": "We report a case of hepatic mesenchymal hamartoma, a rare benign tumour, in a 10-month-old infant.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8942272", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Hepatic mesenchymal hamartoma is a rare benign tumour in children.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16544232", "endSection": "abstract"}, {"offsetInBeginSection": 4673, "offsetInEndSection": 4780, "text": "Mesenchymal hamartoma is a benign lesion best treated by surgical resection, which usually results in cure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18022426", "endSection": "abstract"}, {"offsetInBeginSection": 758, "offsetInEndSection": 811, "text": "Hepatic mesenchymal hamartoma are rare benign tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19365132", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Hepatic mesenchymal hamartoma is a rare benign tumor in children, and infantile hepatic hemangioendothelioma is also a rare liver neoplasm.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17493912", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Mesenchymal hamartoma is an uncommon benign hepatic tumor arising from the mesenchyme of the portal triad.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20954316", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 124, "text": "esenchymal hamartoma of the liver (MHL) is an uncommon benign tumor found primarily in children younger than 2 years of age", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17713740", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 234, "text": " case of a prenatally recognized hepatic mesenchymal hamartoma is presented and the literature reviewed. These tumors are benign and usually present in early infancy with symptoms that are related to the mass effect on adjacent organ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2267227", "endSection": "abstract"}]}, {"body": "List clinical features of EEM syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25707507", "http://www.ncbi.nlm.nih.gov/pubmed/10420194", "http://www.ncbi.nlm.nih.gov/pubmed/11424132", "http://www.ncbi.nlm.nih.gov/pubmed/22140374", "http://www.ncbi.nlm.nih.gov/pubmed/15805154", "http://www.ncbi.nlm.nih.gov/pubmed/2628819", "http://www.ncbi.nlm.nih.gov/pubmed/16970031", "http://www.ncbi.nlm.nih.gov/pubmed/18199584", "http://www.ncbi.nlm.nih.gov/pubmed/6302256"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0683325", "o": "http://linkedlifedata.com/resource/umls/label/A18567231"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0683325", "o": "http://linkedlifedata.com/resource/umls/label/A18585749"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18585749", "o": "aspects clinical"}], "ideal_answer": ["EEM syndrome is characterized by ectodermal dysplasia, ectrodactyly and macular dystrophy."], "type": "list", "id": "5895e9977d9090f353000013", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM) are both caused by mutations in the CDH3 gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22140374", "endSection": "abstract"}, {"offsetInBeginSection": 320, "offsetInEndSection": 567, "text": "Loss-of-function mutations in CDH3, which encodes P-cadherin, result in two allelic autosomal recessive disorders: hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM) syndromes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25707507", "endSection": "abstract"}, {"offsetInBeginSection": 113, "offsetInEndSection": 348, "text": "Recently, mutations in the P-cadherin gene (CDH3) have been shown to cause two inherited diseases in humans: hypotrichosis with juvenile macular dystrophy (HJMD) and ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18199584", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "EEM syndrome is a rare condition characterised by ectodermal dysplasia, ectrodactyly and macular dystrophy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16970031", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "BACKGROUND: EEM syndrome is the rare association of ectodermal dysplasia, ectrodactyly, and macular dystrophy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15805154", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Distinct CDH3 mutations cause ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15805154", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome) in siblings.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11424132", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Association of ectodermal dysplasia, ectrodactyly, and macular dystrophy: the EEM syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6302256", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Association of ectodermal dysplasia, ectrodactyly and macular dystrophy: EEM syndrome (case report).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2628819", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "EEM syndrome is the rare association of ectodermal dysplasia, ectrodactyly, and macular dystrophy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15805154", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "We report a brother and sister with ectodermal dysplasia, ectrodactyly, and macular dystrophy (the EEM syndrome).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11424132", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Ectodermal dysplasia, ectrodactyly and macular dystrophy (EEM syndrome) in siblings.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11424132", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Distinct CDH3 mutations cause ectodermal dysplasia, ectrodactyly, macular dystrophy (EEM syndrome).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15805154", "endSection": "title"}]}, {"body": "How many times is CLAST faster than BLAST?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25495907"], "ideal_answer": ["was capable of identifying sequence similarities ~80.8 times faster than blast and 9.6 times faster than blat . ", "CLAST was capable of identifying sequence similarities ~80.8 times faster than BLAST and 9.6 times faster than BLAT", "clast was capable of identifying sequence similarities ~80.8 times faster than blast and 9.6 times faster than blat.", "CLAST was capable of identifying sequence similarities ~80.8 times faster than BLAST and 9.6 times faster than BLAT. ", "CLAST is capable of identifying sequence similarities ~80.8 times faster than BLAST"], "type": "factoid", "id": "58f6295a70f9fc6f0f000019", "snippets": [{"offsetInBeginSection": 920, "offsetInEndSection": 1035, "text": "CLAST was capable of identifying sequence similarities ~80.8 times faster than BLAST and 9.6 times faster than BLAT", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25495907", "endSection": "abstract"}, {"offsetInBeginSection": 888, "offsetInEndSection": 1011, "text": "First, CLAST was capable of identifying sequence similarities ~80.8 times faster than BLAST and 9.6 times faster than BLAT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25495907", "endSection": "abstract"}, {"offsetInBeginSection": 892, "offsetInEndSection": 1014, "text": "First, CLAST was capable of identifying sequence similarities ~80.8 times faster than BLAST and 9.6 times faster than BLAT", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25495907", "endSection": "abstract"}, {"offsetInBeginSection": 892, "offsetInEndSection": 1015, "text": "First, CLAST was capable of identifying sequence similarities ~80.8 times faster than BLAST and 9.6 times faster than BLAT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25495907", "endSection": "abstract"}, {"offsetInBeginSection": 893, "offsetInEndSection": 1016, "text": "First, CLAST was capable of identifying sequence similarities ~80.8 times faster than BLAST and 9.6 times faster than BLAT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25495907", "endSection": "abstract"}]}, {"body": "Which are the most common methods for circular RNA detection from RNASeq?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26657634", "http://www.ncbi.nlm.nih.gov/pubmed/27167008"], "ideal_answer": ["The main algorithms are circRNA_finder, find_circ, CIRCexplorer, CIRI, and MapSplice.", "Here, we use common RNAseq datasets to scrutinize and compare the output from five different algorithms; circRNA_finder, find_circ, CIRCexplorer, CIRI, and MapSplice and evaluate the levels of bona fide and false positive circRNAs based on RNase R resistance. ", "Here, we use common RNAseq datasets to scrutinize and compare the output from five different algorithms; circRNA_finder, find_circ, CIRCexplorer, CIRI, and MapSplice and evaluate the levels of bona fide and false positive circRNAs based on RNase R resistance.", "CircRNAs are novel members of the non-coding RNA family. Several pipelines have been developed to specifically identify these non-linear reads and consequently predict the landscape of circRNAs based on deep sequencing datasets. Here, we use common RNAseq datasets to scrutinize and compare the output from five different algorithms; circRNA_finder, find_circ, CIRCexplorer, CIRI, and MapSplice and evaluate the levels of bona fide and false positive circRNAs based on RNase R resistance.", ", use common rnaseq datasets to scrutinize and compare the output from five different algorithms; circrna_finder , find_circ , circexplorer , ciri , and mapsplice and evaluate the levels of bona fide and false positive circrnas based on rnase r resistance. . ", "here, we use common rnaseq datasets to scrutinize and compare the output from five different algorithms; circrna.finder, find.circ, circexplorer, ciri, and mapsplice and evaluate the levels of bona fide and false positive circrnas based on rnase r resistance."], "type": "list", "id": "58e640573e8b6dc87c000003", "snippets": [{"offsetInBeginSection": 492, "offsetInEndSection": 751, "text": "Here, we use common RNAseq datasets to scrutinize and compare the output from five different algorithms; circRNA_finder, find_circ, CIRCexplorer, CIRI, and MapSplice and evaluate the levels of bona fide and false positive circRNAs based on RNase R resistance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657634", "endSection": "abstract"}]}, {"body": "From which cell type is leptin secreted?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12242022", "http://www.ncbi.nlm.nih.gov/pubmed/11606782", "http://www.ncbi.nlm.nih.gov/pubmed/23376443", "http://www.ncbi.nlm.nih.gov/pubmed/22692856", "http://www.ncbi.nlm.nih.gov/pubmed/10443698", "http://www.ncbi.nlm.nih.gov/pubmed/12448771", "http://www.ncbi.nlm.nih.gov/pubmed/17639037", "http://www.ncbi.nlm.nih.gov/pubmed/17132702", "http://www.ncbi.nlm.nih.gov/pubmed/11979056", "http://www.ncbi.nlm.nih.gov/pubmed/11824506", "http://www.ncbi.nlm.nih.gov/pubmed/17149693", "http://www.ncbi.nlm.nih.gov/pubmed/26732322", "http://www.ncbi.nlm.nih.gov/pubmed/23016759", "http://www.ncbi.nlm.nih.gov/pubmed/24975960", "http://www.ncbi.nlm.nih.gov/pubmed/21371463", "http://www.ncbi.nlm.nih.gov/pubmed/23503941"], "ideal_answer": ["leptin is mainly produced and secreted by adipocytes, but other tissues and gastric glands have also recently been shown to produce it in a dual (endocrine and exocrine) mode.", " Although leptin is produced mainly by white adipose tissue, several laboratories have shown low levels of leptin production by a growing number of tissues including the anterior pituitary gland.", " Although leptin is produced mainly by white adipose tissue, several laboratories have shown low levels of leptin production by a growing number of tissues including the anterior pituitary gland. Lipolysis (stimulated by beta-adrenergic agents) and leptin secretion by adipocytes are down-regulated by neurons in coculture, effects apparently mediated by neuropeptide Y (NPY)", "Although leptin is produced mainly by white adipose tissue, several laboratories have shown low levels of leptin production by a growing number of tissues including the anterior pituitary gland. Lipolysis (stimulated by beta-adrenergic agents) and leptin secretion by adipocytes are down-regulated by neurons in coculture, effects apparently mediated by neuropeptide Y (NPY). Leptin is mainly produced and secreted by adipocytes, but other tissues and gastric glands have also recently been shown to produce it in a dual (endocrine and exocrine) mode. Leptin was also detected in some microglobules in whole saliva obtained from four healthy volunteers. Co-localization for leptin, leptin receptor and glucocorticoid receptor in the same cell type suggested a functional relationship between glucocorticoid hormone and leptin secretion also at the level of the salivary glands. ", "Leptin is mainly produced and secreted by adipocytes, but other tissues and gastric glands have also recently been shown to produce it in a dual (endocrine and exocrine) mode. Co-localization for leptin, leptin receptor and glucocorticoid receptor in the same cell type suggested a functional relationship between glucocorticoid hormone and leptin secretion also at the level of the salivary glands.", "Leptin is mainly produced and secreted by adipocytes, but other tissues and gastric glands have also recently been shown to produce it in a dual (endocrine and exocrine) mode.", "Co-localization for leptin, leptin receptor and glucocorticoid receptor in the same cell type suggested a functional relationship between glucocorticoid hormone and leptin secretion also at the level of the salivary glands. Leptin is mainly produced and secreted by adipocytes, but other tissues and gastric glands have also recently been shown to produce it in a dual (endocrine and exocrine) mode.", "Leptin is a 16 kDa protein that exerts important effects on the regulation of food intake and energy expenditure by interacting with the leptin receptor in the brain and in many other tissues. Although leptin is produced mainly by white adipose tissue, several laboratories have shown low levels of leptin production by a growing number of tissues including the anterior pituitary gland.", "Leptin was also detected in some microglobules in whole saliva obtained from four healthy volunteers. Co-localization for leptin, leptin receptor and glucocorticoid receptor in the same cell type suggested a functional relationship between glucocorticoid hormone and leptin secretion also at the level of the salivary glands.  Although leptin is produced mainly by white adipose tissue, several laboratories have shown low levels of leptin production by a growing number of tissues including the anterior pituitary gland."], "type": "factoid", "id": "58ee0dd5eda5a57672000013", "snippets": [{"offsetInBeginSection": 192, "offsetInEndSection": 387, "text": " Although leptin is produced mainly by white adipose tissue, several laboratories have shown low levels of leptin production by a growing number of tissues including the anterior pituitary gland.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11824506", "endSection": "abstract"}, {"offsetInBeginSection": 596, "offsetInEndSection": 775, "text": "Lipolysis (stimulated by beta-adrenergic agents) and leptin secretion by adipocytes are down-regulated by neurons in coculture, effects apparently mediated by neuropeptide Y (NPY)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11606782", "endSection": "abstract"}, {"offsetInBeginSection": 134, "offsetInEndSection": 309, "text": "Leptin is mainly produced and secreted by adipocytes, but other tissues and gastric glands have also recently been shown to produce it in a dual (endocrine and exocrine) mode.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12448771", "endSection": "abstract"}, {"offsetInBeginSection": 1288, "offsetInEndSection": 1613, "text": "Leptin was also detected in some microglobules in whole saliva obtained from four healthy volunteers. Co-localization for leptin, leptin receptor and glucocorticoid receptor in the same cell type suggested a functional relationship between glucocorticoid hormone and leptin secretion also at the level of the salivary glands.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12448771", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Leptin, a circulating hormone secreted mainly from adipose tissues, possesses protective effects on many cell types.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21371463", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Leptin, the adipocyte-secreted hormone that regulates weight, is known to link lipid metabolism with inflammation in various cell types", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24975960", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Leptin, a 16-kDa protein that is mainly secreted by adipocytes, plays a protective role in many cell types", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376443", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 339, "text": "Do the adipocytokines, leptin and adiponectin affect the granulosa cell expression of anti-Mullerian hormone (AMH) and its receptor (AMHR-II)?Leptin suppresses AMH mRNA levels in human luteinized granulosa cells through the JAK2/STAT3 pathway, while adiponectin has no such effect.AMH is one of the most reliable markers of ovarian reserve", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23503941", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Leptin, the adipocyte-secreted hormone, exerts its main function as regulator of food intake and energy expenditure through central effects at the hypothalamic level.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12242022", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Adipokines are a group of fat-secreted hormones and cytokines, including leptin and adiponectin, with important functions in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17132702", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Leptin, an adipose-secreted hormone, links metabolism and immunity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23016759", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Since the discovery of leptin secreted from adipocytes, specialized tissues and cells have been found that secrete the several peptides (or cytokines) that are characterized to negatively and positively regulate the metabolic process.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26732322", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 244, "text": "Adipokines (leptin, adiponectin, and hepatocyte growth factor (HGF)) secreted from adipose tissue have come to be recognized for their contribution to the mechanisms by which obesity and related metabolic disorders influence breast cancer risk.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17639037", "endSection": "abstract"}, {"offsetInBeginSection": 621, "offsetInEndSection": 916, "text": "These results show that there is a distinct female-type and male-type leptin pulsatility pattern and each is amenable to augmentation by gonadal steroids either involving mechanisms that impart leptin pulsatility patterns directly at the level of adipocytes and/or at hypothalamic target sites..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11979056", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Leptin is a circulating hormone secreted by adipose and a few other tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10443698", "endSection": "abstract"}, {"offsetInBeginSection": 788, "offsetInEndSection": 927, "text": "Cyclin D1 is expressed exclusively in luminal keratin 8 immunoreactive tumor cells and is dependent on the adipose secreted hormone leptin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22692856", "endSection": "abstract"}, {"offsetInBeginSection": 884, "offsetInEndSection": 1017, "text": "In gastric cells leptin follows a rapid regulated secretion pathway whereas adipocytes secrete leptin in a constitutive slow fashion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17149693", "endSection": "abstract"}]}, {"body": "Which tool is used for the identification of recurrent variants in noncoding regions?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26304545"], "ideal_answer": ["LARVA is an integrative framework for large-scale analysis of recurrent variants in noncoding annotations. It integrates variants with a comprehensive set of noncoding functional elements, modeling the mutation counts of the elements with a \u03b2-binomial distribution to handle overdispersion. LARVA, moreover, uses regional genomic features such as replication timing to better estimate local mutation rates and mutational hotspots. Furthermore, LARVA highlights several novel highly mutated regulatory sites that could potentially be noncoding drivers."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000071184", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012045"], "type": "factoid", "id": "589635dd78275d0c4a000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26304545", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1428, "text": "In cancer research, background models for mutation rates have been extensively calibrated in coding regions, leading to the identification of many driver genes, recurrently mutated more than expected. Noncoding regions are also associated with disease; however, background models for them have not been investigated in as much detail. This is partially due to limited noncoding functional annotation. Also, great mutation heterogeneity and potential correlations between neighboring sites give rise to substantial overdispersion in mutation count, resulting in problematic background rate estimation. Here, we address these issues with a new computational framework called LARVA. It integrates variants with a comprehensive set of noncoding functional elements, modeling the mutation counts of the elements with a \u03b2-binomial distribution to handle overdispersion. LARVA, moreover, uses regional genomic features such as replication timing to better estimate local mutation rates and mutational hotspots. We demonstrate LARVA's effectiveness on 760 whole-genome tumor sequences, showing that it identifies well-known noncoding drivers, such as mutations in the TERT promoter. Furthermore, LARVA highlights several novel highly mutated regulatory sites that could potentially be noncoding drivers. We make LARVA available as a software tool and release our highly mutated annotations as an online resource (larva.gersteinlab.org).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26304545", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26304545", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26304545", "endSection": "title"}]}, {"body": "What body parts are also known as phalanges?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19700363", "http://www.ncbi.nlm.nih.gov/pubmed/22250842", "http://www.ncbi.nlm.nih.gov/pubmed/2187446", "http://www.ncbi.nlm.nih.gov/pubmed/24486016", "http://www.ncbi.nlm.nih.gov/pubmed/16965880"], "ideal_answer": ["The anatomical structure of each finger is comprised of four phalanges (distal, middle, proximal, and metacarpal phalange). Toes are also known as phalages"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050278", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050277"], "type": "factoid", "id": "58f3c62970f9fc6f0f00000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Metacarpal and phalangeal fractures of the long fingers a", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24486016", "endSection": "abstract"}, {"offsetInBeginSection": 733, "offsetInEndSection": 857, "text": " The anatomical structure of each finger is comprised of four phalanges (distal, middle, proximal, and metacarpal phalange).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700363", "endSection": "abstract"}, {"offsetInBeginSection": 360, "offsetInEndSection": 488, "text": "arious features of the toes, humps in the toe line, phalange marks, flatfoot condition, pits, cracks, corns, etc., were studied.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16965880", "endSection": "abstract"}, {"offsetInBeginSection": 504, "offsetInEndSection": 722, "text": "802), in which physical injuries are listed, ranging from loss of single phalanges, differentiated between thumb, forefinger, small finger, and the other fingers, to death, is compared with modern grades of disability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2187446", "endSection": "abstract"}, {"offsetInBeginSection": 616, "offsetInEndSection": 742, "text": "They featured a prominent unpaired femur besides paired tibiotarsi, tarsometatarsi and species-specific phalanges of the toes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22250842", "endSection": "abstract"}, {"offsetInBeginSection": 362, "offsetInEndSection": 495, "text": "The bone structure is rarefied at the distal metaphyses of the metacarpals and the proximal metaphyses of the finger basal phalanges.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7366585", "endSection": "abstract"}]}, {"body": "Are selenium supplements recommended for prostate cancer prevention?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26957512", "http://www.ncbi.nlm.nih.gov/pubmed/25990689", "http://www.ncbi.nlm.nih.gov/pubmed/25854337", "http://www.ncbi.nlm.nih.gov/pubmed/25505227"], "ideal_answer": ["No. The SELECT study failed to show any significant risk reduction for prostate cancers ascribable to selenium and vitamin E supplementations."], "type": "yesno", "id": "58f0b40d70f9fc6f0f000008", "snippets": [{"offsetInBeginSection": 1431, "offsetInEndSection": 1794, "text": "Our meta-analysis in prospective studies demonstrated a significant inverse association between selenium status and CVD risk within a narrow selenium range and a null effect of selenium supplementation on CVD was observed in RCTs. These findings indicate the importance of considering selenium status, dose and safety in health assessment and future study design.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25990689", "endSection": "abstract"}, {"offsetInBeginSection": 1763, "offsetInEndSection": 1995, "text": "Selenium supplementation of 140 or more \u03bcg/day after diagnosis of nonmetastatic prostate cancer may increase risk of prostate cancer mortality. Caution is warranted regarding usage of such supplements among men with prostate cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25505227", "endSection": "abstract"}, {"offsetInBeginSection": 591, "offsetInEndSection": 729, "text": "The SELECT study failed to show any significant risk reduction for prostate cancers ascribable to selenium and vitamin E supplementations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25854337", "endSection": "abstract"}, {"offsetInBeginSection": 679, "offsetInEndSection": 1016, "text": "Vitamins and supplements, including selenium or vitamin E, have not been proven in clinical trials to prevent prostate cancer and in the case of Vitamin E has been found to increase the risk of incident prostate cancer. Ongoing and future trials may further elucidate the role of diet and immunotherapy for prevention of prostate cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26957512", "endSection": "abstract"}]}, {"body": "Which disease is treated with lucinactant?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15813666", "http://www.ncbi.nlm.nih.gov/pubmed/18822258", "http://www.ncbi.nlm.nih.gov/pubmed/22791092", "http://www.ncbi.nlm.nih.gov/pubmed/16896079", "http://www.ncbi.nlm.nih.gov/pubmed/23473590", "http://www.ncbi.nlm.nih.gov/pubmed/16452346", "http://www.ncbi.nlm.nih.gov/pubmed/23032799", "http://www.ncbi.nlm.nih.gov/pubmed/23118645", "http://www.ncbi.nlm.nih.gov/pubmed/22821059", "http://www.ncbi.nlm.nih.gov/pubmed/22859930", "http://www.ncbi.nlm.nih.gov/pubmed/17533176", "http://www.ncbi.nlm.nih.gov/pubmed/15805381", "http://www.ncbi.nlm.nih.gov/pubmed/15805380"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1609686", "o": "lucinactant"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1609686", "o": "http://linkedlifedata.com/resource/umls/label/A20633234"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A20633234", "o": "lucinactant"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1609686", "o": "http://linkedlifedata.com/resource/umls/label/A8604556"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8604556", "o": "lucinactant"}], "ideal_answer": ["Lucinactant us used for the prevention of respiratory distress syndrome in premature infants."], "concepts": ["http://www.biosemantics.org/jochem#4002240", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", "http://www.disease-ontology.org/api/metadata/DOID:4"], "type": "factoid", "id": "5896271178275d0c4a000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Lucinactant for the prevention of respiratory distress syndrome in premature infants.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23473590", "endSection": "title"}, {"offsetInBeginSection": 174, "offsetInEndSection": 795, "text": "Lucinactant is a synthetic surfactant containing sinapultide, a bioengineered peptide mimic of surfactant-associated protein B. A meta-analysis of clinical trials demonstrates that lucinactant is as effective as animal-derived surfactants in preventing RDS in premature neonates, and in vitro studies suggest it is more resistant to oxidative and protein-induced inactivation. Its synthetic origin confers lower infection and inflammation risks as well other potential benefits, which may make lucinactant an advantageous alternative to its animal-derived counterparts, which are presently the standard treatment for RDS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23473590", "endSection": "abstract"}, {"offsetInBeginSection": 164, "offsetInEndSection": 383, "text": "We evaluated whether intratracheal lucinactant, a synthetic, peptide-containing surfactant, was safe and well-tolerated in infants with acute hypoxemic respiratory failure, and assessed its effects on clinical outcomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22791092", "endSection": "abstract"}, {"offsetInBeginSection": 2555, "offsetInEndSection": 2747, "text": "An improvement in oxygenation and a significantly reduced requirement for retreatment suggests that lucinactant might improve lung function in infants with acute hypoxemic respiratory failure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22791092", "endSection": "abstract"}, {"offsetInBeginSection": 1316, "offsetInEndSection": 1527, "text": "CONCLUSION: These data suggest that early intervention with lucinactant may more effectively mitigate pulmonary pathophysiological sequelae of RDS than the animal-derived surfactants poractant alfa or beractant.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22821059", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Lucinactant for the treatment of respiratory distress syndrome in neonates.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23032799", "endSection": "title"}, {"offsetInBeginSection": 714, "offsetInEndSection": 977, "text": "The clinical trials that have been performed, although underpowered, may indicate that lucinactant is superior to phospholipid synthetic surfactant preparations and at least as effective as animal-derived surfactants in reducing morbidity and mortality from RDS. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23032799", "endSection": "abstract"}]}, {"body": "Which proteins control the degradation of cryptic unstable transcripts (CUTs) in yeast?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25210768", "http://www.ncbi.nlm.nih.gov/pubmed/19169244", "http://www.ncbi.nlm.nih.gov/pubmed/25680078", "http://www.ncbi.nlm.nih.gov/pubmed/16973436", "http://www.ncbi.nlm.nih.gov/pubmed/21878619"], "ideal_answer": ["Termination of cryptic unstable transcripts is directed by yeast RNA-binding proteins Nrd1 and Nab3. These cryptic unstable transcripts (CUTs) are rapidly degraded by the nuclear exosome. Key substrates for exosomal degradation include aberrant functional RNAs and cryptic unstable transcripts (CUTs). Yeast RNA binding proteins Nrd1 and Nab3 direct termination of sn/snoRNAs and recently have also been implicated in premature transcription termination of the NRD1 gene. These results suggest that transcription termination of CUTs directed by Nrd1 and Nab3 is a prerequisite for rapid degradation by the nuclear exosome. ", "Termination of cryptic unstable transcripts is directed by yeast RNA-binding proteins Nrd1 and Nab3. Key substrates for exosomal degradation include aberrant functional RNAs and cryptic unstable transcripts (CUTs). These cryptic unstable transcripts (CUTs) are rapidly degraded by the nuclear exosome. These transcripts are targeted for degradation immediately after synthesis by the action of the Nrd1-exosome-TRAMP complexes. Cryptic unstable transcripts (CUTs) were recently described as a principal class of RNA polymerase II transcripts in Saccharomyces cerevisiae. ", "The exosome and its nuclear specific subunit Rrp6 form a 3'-5' exonuclease complex that regulates diverse aspects of RNA biology including 3' end processing and degradation of a variety of noncoding RNAs (ncRNAs) and unstable transcripts. Known targets of the nuclear exosome include short (<1000 bp) RNAPII transcripts such as small noncoding RNAs (snRNAs), cryptic unstable transcripts (CUTs), and some stable unannotated transcripts (SUTs) that are terminated by an Nrd1, Nab3, and Sen1 (NNS) dependent mechanism. The MTREC complex physically interacts with the nuclear exosome and with various RNA-binding and RNA-processing complexes, coupling RNA processing to the RNA degradation machinery.", "Termination of cryptic unstable transcripts is directed by yeast RNA-binding proteins Nrd1 and Nab3 These cryptic unstable transcripts (CUTs) are rapidly degraded by the nuclear exosome. Yeast RNA binding proteins Nrd1 and Nab3 direct termination of sn/snoRNAs and recently have also been implicated in premature transcription termination of the NRD1 gene.", "Termination of cryptic unstable transcripts is directed by yeast RNA-binding proteins Nrd1 and Nab3. Yeast RNA binding proteins Nrd1 and Nab3 direct termination of sn/snoRNAs and recently have also been implicated in premature transcription termination of the NRD1 gene. These cryptic unstable transcripts (CUTs) are rapidly degraded by the nuclear exosome. These results suggest that transcription termination of CUTs directed by Nrd1 and Nab3 is a prerequisite for rapid degradation by the nuclear exosome. Key substrates for exosomal degradation include aberrant functional RNAs and cryptic unstable transcripts (CUTs). ", "Termination of cryptic unstable transcripts is directed by yeast RNA-binding proteins Nrd1 and Nab3", "Cryptic unstable transcripts (CUTs) were recently described as a principal class of RNA polymerase II transcripts in Saccharomyces cerevisiae. These transcripts are targeted for degradation immediately after synthesis by the action of the Nrd1-exosome and Trf4/5-Air1/2-Mtr4 polyadenylation (TRAMP) complexes. The termination of cryptic unstable transcripts is directed by yeast RNA-binding proteins Nrd1 and Nab3. Known targets of the nuclear exosome include short (<1000 bp) RNAPII transcripts such as small noncoding RNAs (snRNAs), cryptic unstable transcripts (CUTs), and some stable unannotated transcripts (SUTs) that are terminated by an Nrd1, Nab3, and Sen1 (NNS) dependent mechanism. Recent work suggests Nrd1 is necessary for transcriptome surveillance, regulating promoter directionality and suppressing antisense transcription independently of, or prior to, Rrp6 activity."], "type": "list", "id": "58adca6d9ef3c34033000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Termination of cryptic unstable transcripts is directed by yeast RNA-binding proteins Nrd1 and Nab3", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16973436", "endSection": "title"}, {"offsetInBeginSection": 118, "offsetInEndSection": 374, "text": "These cryptic unstable transcripts (CUTs) are rapidly degraded by the nuclear exosome. Yeast RNA binding proteins Nrd1 and Nab3 direct termination of sn/snoRNAs and recently have also been implicated in premature transcription termination of the NRD1 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16973436", "endSection": "abstract"}, {"offsetInBeginSection": 906, "offsetInEndSection": 1057, "text": " These results suggest that transcription termination of CUTs directed by Nrd1 and Nab3 is a prerequisite for rapid degradation by the nuclear exosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16973436", "endSection": "abstract"}, {"offsetInBeginSection": 121, "offsetInEndSection": 234, "text": "Key substrates for exosomal degradation include aberrant functional RNAs and cryptic unstable transcripts (CUTs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25210768", "endSection": "abstract"}, {"offsetInBeginSection": 1068, "offsetInEndSection": 1450, "text": "Lack of TRAMP activity stabilises \u223c 1600 CUTs in meiotic cells, which occupy 40% of the binding capacity of the nuclear cap binding complex (CBC). CBC mutants display defects in the formation of meiotic double strand breaks (DSBs), and we see similar defects in TRAMP mutants, suggesting that a key function of the nuclear exosome is to prevent saturation of the CBC complex by CUTs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25210768", "endSection": "abstract"}, {"offsetInBeginSection": 641, "offsetInEndSection": 895, "text": "We find that TRAMP mutants produce high levels of CUTs during meiosis that are undetectable in wild-type cells, showing that the nuclear exosome remains functional for CUT degradation, and we further report that the meiotic exosome complex contains Rrp6.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25210768", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "The exosome component Rrp6 is required for RNA polymerase II termination at specific targets of the Nrd1-Nab3 pathway.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25680078", "endSection": "title"}, {"offsetInBeginSection": 239, "offsetInEndSection": 515, "text": "Known targets of the nuclear exosome include short (<1000 bp) RNAPII transcripts such as small noncoding RNAs (snRNAs), cryptic unstable transcripts (CUTs), and some stable unannotated transcripts (SUTs) that are terminated by an Nrd1, Nab3, and Sen1 (NNS) dependent mechanism", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25680078", "endSection": "abstract"}, {"offsetInBeginSection": 628, "offsetInEndSection": 819, "text": "Recent work suggests Nrd1 is necessary for transcriptome surveillance, regulating promoter directionality and suppressing antisense transcription independently of, or prior to, Rrp6 activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25680078", "endSection": "abstract"}, {"offsetInBeginSection": 171, "offsetInEndSection": 439, "text": "Cryptic unstable transcripts (CUTs) were recently described as a principal class of RNA polymerase II transcripts in Saccharomyces cerevisiae. These transcripts are targeted for degradation immediately after synthesis by the action of the Nrd1-exosome-TRAMP complexes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169244", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 279, "text": "In Saccharomyces cerevisiae, non-coding RNAs, including cryptic unstable transcripts (CUTs), are subject to degradation by the exosome. The Trf4/5-Air1/2-Mtr4 polyadenylation (TRAMP) complex in S. cerevisiae is a nuclear exosome cofactor that recruits the exosome to degrade RNAs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21878619", "endSection": "abstract"}, {"offsetInBeginSection": 432, "offsetInEndSection": 652, "text": " The MTREC complex specifically binds to CUTs, meiotic mRNAs and unspliced pre-mRNA transcripts and targets these RNAs for degradation by the nuclear exosome, while the TRAMP complex has only a minor role in this process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25989903", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "The eukaryotic exosome exoribonuclease Rrp6 forms a complex with Rrp47 that functions in nuclear RNA quality control mechanisms, the degradation of cryptic unstable transcripts (CUTs), and in the 3 end maturation of stable RNAs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24106327", "endSection": "abstract"}, {"offsetInBeginSection": 630, "offsetInEndSection": 795, "text": "Nrd1 and Nab3 colocalize to regions of the genome expressing antisense CUTs, and these transcripts require yeast nuclear exosome and TRAMP components for degradation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16973436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 299, "text": "Genome-wide studies have identified abundant small, noncoding RNAs, including small nuclear RNAs, small nucleolar RNAs (snoRNAs), cryptic unstable transcripts (CUTs), and upstream regulatory RNAs (uRNAs), that are transcribed by RNA polymerase II (pol II) and terminated by an Nrd1-dependent pathway", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19854134", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 797, "text": "Nrd1 and Nab3 colocalize to regions of the genome expressing antisense CUTs, and these transcripts require yeast nuclear exosome and TRAMP components for degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16973436", "endSection": "abstract"}, {"offsetInBeginSection": 511, "offsetInEndSection": 775, "text": "Here, by examining the overlap of stable (SUTs, stable unannotated transcripts) and unstable (CUTs, cryptic unstable transcripts) transcripts with protein-coding genes, we show that the predicted Nrd1 and Nab3-binding site sequences occur at differing frequencies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27492286", "endSection": "abstract"}, {"offsetInBeginSection": 367, "offsetInEndSection": 510, "text": "Examples are the consensus binding site sequences of the RNA-binding proteins Nrd1 and Nab3 that target non-coding transcripts for degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27492286", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Termination of cryptic unstable transcripts is directed by yeast RNA-binding proteins Nrd1 and Nab3.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16973436", "endSection": "title"}, {"offsetInBeginSection": 187, "offsetInEndSection": 350, "text": "Some are designated Cryptic Unstable Transcripts (CUTs) because they are terminated by the Nrd1-Nab3-Sen1 pathway and then rapidly degraded by the nuclear exosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21826286", "endSection": "abstract"}]}, {"body": "Is there any involvement of L1 retrotransposition in the Rett syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23057747", "http://www.ncbi.nlm.nih.gov/pubmed/24389010", "http://www.ncbi.nlm.nih.gov/pubmed/22159035", "http://www.ncbi.nlm.nih.gov/pubmed/21085180"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1514925", "o": "http://linkedlifedata.com/resource/umls/label/A11585268"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11585268", "o": "retrotransposon transposition"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0035372", "o": "http://linkedlifedata.com/resource/umls/label/A18593781"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18593781", "o": "rett syndrome"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1514925", "o": "transposition, RNA-mediated"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1514925", "o": "http://linkedlifedata.com/resource/umls/label/A11610160"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11610160", "o": "retrotransposition"}], "ideal_answer": ["Yes. Recent studies indicate that long interspersed nuclear element-1 (L1) are mobilized in the genome of human neural progenitor cells and enhanced in Rett syndrome and ataxia telangiectasia."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015518", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020084", "http://www.disease-ontology.org/api/metadata/DOID:1206"], "type": "yesno", "id": "58965a4178275d0c4a00000e", "snippets": [{"offsetInBeginSection": 1585, "offsetInEndSection": 2128, "text": "Using neuronal progenitor cells derived from human induced pluripotent stem cells and human tissues, we revealed that patients with Rett syndrome (RTT), carrying MeCP2 mutations, have increased susceptibility for L1 retrotransposition. Our data demonstrate that L1 retrotransposition can be controlled in a tissue-specific manner and that disease-related genetic mutations can influence the frequency of neuronal L1 retrotransposition. Our findings add a new level of complexity to the molecular events that can lead to neurological disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21085180", "endSection": "abstract"}, {"offsetInBeginSection": 725, "offsetInEndSection": 903, "text": "Furthermore, some neurological diseases, such as Rett syndrome and ataxia telangiectasia, misregulate L1 retrotransposition, which could contribute to some pathological aspects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23057747", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "Recent studies indicate that long interspersed nuclear element-1 (L1) are mobilized in the genome of human neural progenitor cells and enhanced in Rett syndrome and ataxia telangiectasia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24389010", "endSection": "abstract"}, {"offsetInBeginSection": 321, "offsetInEndSection": 594, "text": "In addition, recent data indicate that engineered human L1s can undergo somatic retrotransposition in human neural progenitor cells and that an increase in human-specific L1 DNA content can be detected in the brains of normal controls, as well as in Rett syndrome patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22159035", "endSection": "abstract"}, {"offsetInBeginSection": 719, "offsetInEndSection": 896, "text": "Furthermore, some neurological diseases, such as Rett syndrome and ataxia telangiectasia, misregulate L1 retrotransposition, which could contribute to some pathological aspects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23057747", "endSection": "abstract"}, {"offsetInBeginSection": 1576, "offsetInEndSection": 1811, "text": "Using neuronal progenitor cells derived from human induced pluripotent stem cells and human tissues, we revealed that patients with Rett syndrome (RTT), carrying MeCP2 mutations, have increased susceptibility for L1 retrotransposition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21085180", "endSection": "abstract"}, {"offsetInBeginSection": 319, "offsetInEndSection": 592, "text": "In addition, recent data indicate that engineered human L1s can undergo somatic retrotransposition in human neural progenitor cells and that an increase in human-specific L1 DNA content can be detected in the brains of normal controls, as well as in Rett syndrome patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22159035", "endSection": "abstract"}, {"offsetInBeginSection": 1585, "offsetInEndSection": 1819, "text": "Using neuronal progenitor cells derived from human induced pluripotent stem cells and human tissues, we revealed that patients with Rett syndrome (RTT), carrying MeCP2 mutations, have increased susceptibility for L1 retrotransposition", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21085180", "endSection": "abstract"}, {"offsetInBeginSection": 725, "offsetInEndSection": 901, "text": "Furthermore, some neurological diseases, such as Rett syndrome and ataxia telangiectasia, misregulate L1 retrotransposition, which could contribute to some pathological aspects", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23057747", "endSection": "abstract"}, {"offsetInBeginSection": 1585, "offsetInEndSection": 1820, "text": "Using neuronal progenitor cells derived from human induced pluripotent stem cells and human tissues, we revealed that patients with Rett syndrome (RTT), carrying MeCP2 mutations, have increased susceptibility for L1 retrotransposition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21085180", "endSection": "abstract"}, {"offsetInBeginSection": 725, "offsetInEndSection": 902, "text": "Furthermore, some neurological diseases, such as Rett syndrome and ataxia telangiectasia, misregulate L1 retrotransposition, which could contribute to some pathological aspects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23057747", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Recent studies indicate that long interspersed nuclear element-1 (L1) are mobilized in the genome of human neural progenitor cells and enhanced in Rett syndrome and ataxia telangiectasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24389010", "endSection": "abstract"}]}, {"body": "Is Downs syndrome associated with decreased risk of leukemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19332933", "http://www.ncbi.nlm.nih.gov/pubmed/25332567", "http://www.ncbi.nlm.nih.gov/pubmed/16321814", "http://www.ncbi.nlm.nih.gov/pubmed/2955886"], "ideal_answer": ["No, multiple studies have established the incidence of leukemia in Down's syndrome patients to be 10- to 20-fold higher than that in the general population."], "type": "yesno", "id": "58f3d85170f9fc6f0f00000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 239, "text": "The association of Down's syndrome and leukemia has been documented for over 50 years. Multiple studies have established the incidence of leukemia in Down's syndrome patients to be 10- to 20-fold higher than that in the general population.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2955886", "endSection": "abstract"}, {"offsetInBeginSection": 274, "offsetInEndSection": 564, "text": "We present a case of congenital acute myeloid leukemia manifesting from the very first day of birth. Diagnosis of acute myeloid leukemia was suspected by the presence of blasts in the peripheral blood smear and was confirmed on bone marrow by flowcytometry. Karyotyping revealed Trisomy 21.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25332567", "endSection": "abstract"}, {"offsetInBeginSection": 928, "offsetInEndSection": 1040, "text": "Juvenile myelomonocytic leukemia (JMML) and a solitary cases of acute myeloid leukemia (AML) in Downs syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16321814", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 712, "text": "This was thus confirmed to be a case with transient leukemia with Downs syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19332933", "endSection": "abstract"}]}, {"body": "Which enzyme is inhibited by ixazomib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27119237", "http://www.ncbi.nlm.nih.gov/pubmed/26667773", "http://www.ncbi.nlm.nih.gov/pubmed/27121262", "http://www.ncbi.nlm.nih.gov/pubmed/26846321", "http://www.ncbi.nlm.nih.gov/pubmed/25377318", "http://www.ncbi.nlm.nih.gov/pubmed/26988986", "http://www.ncbi.nlm.nih.gov/pubmed/25919767", "http://www.ncbi.nlm.nih.gov/pubmed/26558304", "http://www.ncbi.nlm.nih.gov/pubmed/26658418", "http://www.ncbi.nlm.nih.gov/pubmed/26138345", "http://www.ncbi.nlm.nih.gov/pubmed/26588946", "http://www.ncbi.nlm.nih.gov/pubmed/26709701", "http://www.ncbi.nlm.nih.gov/pubmed/27783987", "http://www.ncbi.nlm.nih.gov/pubmed/27325500", "http://www.ncbi.nlm.nih.gov/pubmed/26141494", "http://www.ncbi.nlm.nih.gov/pubmed/23514361", "http://www.ncbi.nlm.nih.gov/pubmed/26872892", "http://www.ncbi.nlm.nih.gov/pubmed/27261328", "http://www.ncbi.nlm.nih.gov/pubmed/26337806", "http://www.ncbi.nlm.nih.gov/pubmed/25234165", "http://www.ncbi.nlm.nih.gov/pubmed/27702799", "http://www.ncbi.nlm.nih.gov/pubmed/25456369", "http://www.ncbi.nlm.nih.gov/pubmed/26811670", "http://www.ncbi.nlm.nih.gov/pubmed/26634271", "http://www.ncbi.nlm.nih.gov/pubmed/27259216", "http://www.ncbi.nlm.nih.gov/pubmed/25302026", "http://www.ncbi.nlm.nih.gov/pubmed/26947893"], "ideal_answer": ["Ixazomib is proteasome inhibitor. It is used for treatment of multiple myeloma."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004791"], "type": "factoid", "id": "589630f378275d0c4a000007", "snippets": [{"offsetInBeginSection": 144, "offsetInEndSection": 492, "text": "Over the past decade, MM therapy is significantly improved by the introduction of novel therapeutics such as immunomodulatory agents (thalidomide, lenalidomide, and pomalidomide), proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), monoclonal antibodies (daratumumab and elotuzumab), histone deacetylase (HDAC) inhibitors (Panobinostat).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27261328", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 516, "text": "Due to the largely incurable nature of multiple myeloma, the development of newer agents is ongoing and includes new oral PIs (ixazomib), immunotherapies (e.g., CD38- or SLAMF7-targeted antibodies), and small molecules. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26558304", "endSection": "abstract"}, {"offsetInBeginSection": 211, "offsetInEndSection": 394, "text": "Ixazomib (MLN9708-MLN2238), the second-generation proteasome inhibitor, selectivity and potency were similar to that of bortezomib, is currently being investigated in phase I studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26667773", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "In the last few weeks, the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26658418", "endSection": "abstract"}, {"offsetInBeginSection": 289, "offsetInEndSection": 551, "text": "Ixazomib, the first oral proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may be an attractive option for maintenance therapy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26588946", "endSection": "abstract"}, {"offsetInBeginSection": 710, "offsetInEndSection": 893, "text": "Since the introduction of bortezomib in 2003, several next-generation proteasome inhibitors have also been used clinically, including carfilzomib, oprozomib, ixazomib, and delanzomib.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26947893", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "AIM: The aim of the present study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121262", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121262", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Ixazomib is the first oral, proteasome inhibitor to reach phase III trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26141494", "endSection": "abstract"}, {"offsetInBeginSection": 233, "offsetInEndSection": 350, "text": "MLN2238 (ixazomib), an oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27783987", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 256, "text": "This population pharmacokinetic analysis of the investigational oral proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates on ixazomib pharmacokinetics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25377318", "endSection": "abstract"}]}, {"body": "Does PCSK9 (Proprotein convertase subtilisin/kexin type 9) binds with HDL-receptor (HDL-R)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27284008", "http://www.ncbi.nlm.nih.gov/pubmed/26040332", "http://www.ncbi.nlm.nih.gov/pubmed/20529551", "http://www.ncbi.nlm.nih.gov/pubmed/23675525", "http://www.ncbi.nlm.nih.gov/pubmed/26318398", "http://www.ncbi.nlm.nih.gov/pubmed/23400816", "http://www.ncbi.nlm.nih.gov/pubmed/25649668", "http://www.ncbi.nlm.nih.gov/pubmed/26256967", "http://www.ncbi.nlm.nih.gov/pubmed/22683370", "http://www.ncbi.nlm.nih.gov/pubmed/23690465", "http://www.ncbi.nlm.nih.gov/pubmed/24164109", "http://www.ncbi.nlm.nih.gov/pubmed/21692990", "http://www.ncbi.nlm.nih.gov/pubmed/23974119", "http://www.ncbi.nlm.nih.gov/pubmed/21122852", "http://www.ncbi.nlm.nih.gov/pubmed/23261172", "http://www.ncbi.nlm.nih.gov/pubmed/25679794", "http://www.ncbi.nlm.nih.gov/pubmed/26495026", "http://www.ncbi.nlm.nih.gov/pubmed/24094767", "http://www.ncbi.nlm.nih.gov/pubmed/18436719", "http://www.ncbi.nlm.nih.gov/pubmed/21497351", "http://www.ncbi.nlm.nih.gov/pubmed/22580899", "http://www.ncbi.nlm.nih.gov/pubmed/17702855", "http://www.ncbi.nlm.nih.gov/pubmed/20716520", "http://www.ncbi.nlm.nih.gov/pubmed/26056005", "http://www.ncbi.nlm.nih.gov/pubmed/23141813", "http://www.ncbi.nlm.nih.gov/pubmed/22300679", "http://www.ncbi.nlm.nih.gov/pubmed/25463543", "http://www.ncbi.nlm.nih.gov/pubmed/24685817", "http://www.ncbi.nlm.nih.gov/pubmed/25905719", "http://www.ncbi.nlm.nih.gov/pubmed/26548330", "http://www.ncbi.nlm.nih.gov/pubmed/24603306", "http://www.ncbi.nlm.nih.gov/pubmed/22907332", "http://www.ncbi.nlm.nih.gov/pubmed/26088304", "http://www.ncbi.nlm.nih.gov/pubmed/19828345", "http://www.ncbi.nlm.nih.gov/pubmed/26364362", "http://www.ncbi.nlm.nih.gov/pubmed/23106476", "http://www.ncbi.nlm.nih.gov/pubmed/26023080", "http://www.ncbi.nlm.nih.gov/pubmed/17493938", "http://www.ncbi.nlm.nih.gov/pubmed/22176652", "http://www.ncbi.nlm.nih.gov/pubmed/25744035", "http://www.ncbi.nlm.nih.gov/pubmed/25070550", "http://www.ncbi.nlm.nih.gov/pubmed/26195630", "http://www.ncbi.nlm.nih.gov/pubmed/25971287", "http://www.ncbi.nlm.nih.gov/pubmed/24144304"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1426592", "o": "PCSK9"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1426592", "o": "http://linkedlifedata.com/resource/umls/label/A20814698"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A20814698", "o": "proprotein convertase subtilisin/kexin type 9"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2611277", "o": "http://linkedlifedata.com/resource/umls/label/A19343187"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0062151", "o": "http://linkedlifedata.com/resource/umls/label/A8395721"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8395721", "o": "high density lipoprotein receptors"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0062151", "o": "http://linkedlifedata.com/resource/umls/label/A16773852"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A16773852", "o": "high density lipoprotein receptors"}], "ideal_answer": ["No, Proprotein Convertase Subtilisin Kexin 9 (PCSK9) binds with LDL-receptor (LDL-R) causing its degradation in the lysosome with the result of LDL-C accumulating in the blood."], "concepts": ["http://www.uniprot.org/uniprot/PCSK9_SAIBB", "http://www.uniprot.org/uniprot/PCSK9_MACMU", "http://www.uniprot.org/uniprot/PCSK9_PANTR", "http://www.uniprot.org/uniprot/PCSK9_COLGU", "http://www.uniprot.org/uniprot/PCSK9_CALJA", "http://www.uniprot.org/uniprot/PCSK9_LAGLA", "http://www.uniprot.org/uniprot/PCSK9_SAGLB", "http://www.uniprot.org/uniprot/PCSK9_HUMAN", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D043484", "http://www.uniprot.org/uniprot/PCSK9_PONPY", "http://amigo.geneontology.org/amigo/term/GO:1990666", "http://www.uniprot.org/uniprot/PCSK9_MACNE", "http://www.uniprot.org/uniprot/PCSK9_RAT", "http://www.uniprot.org/uniprot/PCSK9_ATEGE", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000071449", "http://www.uniprot.org/uniprot/PCSK9_PANPA", "http://www.uniprot.org/uniprot/PCSK9_PLEMO"], "type": "yesno", "id": "58db9aa28acda34529000018", "snippets": [{"offsetInBeginSection": 532, "offsetInEndSection": 747, "text": "Recently it was revealed that the secreted Proprotein Convertase Subtilisin Kexin 9 (PCSK9) binds with LDL-receptor (LDL-R) causing its degradation in the lysosome with the result of LDL-C accumulating in the blood.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25679794", "endSection": "abstract"}, {"offsetInBeginSection": 1066, "offsetInEndSection": 1296, "text": "The major goal of this study is to identify peptide/s from the catalytic domain of hPCSK9 that can block the binding of hPCSK9 and LDL-R and therefore can reduce LDL-R degradation leading to the clearance of LDL-C from the plasma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25679794", "endSection": "abstract"}, {"offsetInBeginSection": 1112, "offsetInEndSection": 1324, "text": "In vitro administration of SRT3025 to cultured AML12 hepatocytes attenuated Pcsk9 secretion and its binding to Ldlr, thereby reducing Pcsk9-mediated Ldlr degradation and increasing Ldlr expression and LDL uptake.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24603306", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 246, "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9), which involves in low-density lipoprotein cholesterol (LDL-C) metabolism by interacting with the LDL receptor, is considered as a potent therapeutic target for treating hypercholesterolemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056005", "endSection": "abstract"}, {"offsetInBeginSection": 828, "offsetInEndSection": 1030, "text": "Taken together, these results suggested that the IgG1-PA4 can be served as a potential candidate for the treatment of hypercholesterolemia by inhibiting PCSK9-mediated degradation of cell surface LDLRs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056005", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 262, "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein receptor, escorting it to\u00a0its destruction in the lysosome and thereby preventing the recirculation of the low-density lipoprotein receptor to the hepatocyte cell surface. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088304", "endSection": "abstract"}, {"offsetInBeginSection": 342, "offsetInEndSection": 447, "text": "However, statins have low efficiency because they also increase PCSK9 which targets LDLR for degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26318398", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 316, "text": "Inhibition of the enzyme PCSK9 (proprotein convertase subtilisin/kexin type 9), which is involved in depletion of the LDL-receptor, is a new pharmacologic approach. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26364362", "endSection": "abstract"}, {"offsetInBeginSection": 389, "offsetInEndSection": 510, "text": "Proprotein convertase subtilisin kexin type 9 (PCSK9) modulates LDL-c through post-translational degradation of the LDLR.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495026", "endSection": "abstract"}, {"offsetInBeginSection": 1656, "offsetInEndSection": 1837, "text": "Mechanistically, hepatic S1P KD was shown to decrease the liver and plasma levels of the protein proprotein convertase subtilisin/kexin type 9 (PCSK9), which degrades LDLR protein. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495026", "endSection": "abstract"}, {"offsetInBeginSection": 229, "offsetInEndSection": 376, "text": "We report here the development of sdAbs targeting human PCSK9 (proprotein convertase subtilisin/kexin type 9) as an alternative to anti-PCSK9 mAbs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27284008", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) protein plays an important role in LDL cholesterol (LDL-C) metabolism, due to its role in the degradation of the LDL receptor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24164109", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24094767", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400816", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted protein that binds to the epidermal growth factor-like-A domain of the low density lipoprotein receptor (LDLR) and mediates LDLR degradation in liver", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400816", "endSection": "abstract"}, {"offsetInBeginSection": 86, "offsetInEndSection": 191, "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds LDL receptors, targeting them for degradation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23141813", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9), which binds the low-density lipoprotein receptor and targets it for degradation, has emerged as an important regulator of serum cholesterol levels and cardiovascular disease risk", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26023080", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Secreted proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein receptor (LDLR) at the cell surface and disrupts the normal recycling of the LDLR", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22683370", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "Proprotein convertase, subtilisin/kexin type 9 (PCSK9), a key regulator of plasma LDL-cholesterol (LDL-c) and cardiovascular risk, is produced in liver and secreted into plasma where it binds hepatic LDL receptors (LDLR), leading to their degradation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20716520", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the hepatic low-density lipoprotein receptor (LDL-R) and is therefore a prominent therapeutic target for reducing LDL-cholesterol", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25744035", "endSection": "abstract"}, {"offsetInBeginSection": 289, "offsetInEndSection": 862, "text": "In the present study we scanned the related gene of a clinically diagnosed autosomal genetic hypercholesterolemia family for the possible mutations and established eukaryotic expression vector of mutation of proprotein convertase subtilisin/kexin type 9 (PCSK9) gene with gene recombination technique to investigate the contributions of the variation on low density lipoprotein receptor (LDL-R) metabolism and function alternation.Mutation detection was conducted for LDL-R, apolipoprotein B(100) (apoB(100)) and PCSK9 gene with nucleotide sequencing in a Chinese FH family", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529551", "endSection": "abstract"}, {"offsetInBeginSection": 172, "offsetInEndSection": 304, "text": "Proprotein convertase subtilisin-kexin type 9 (PCSK9) provides a key step in LDL metabolism by stimulating LDL receptor degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300679", "endSection": "abstract"}, {"offsetInBeginSection": 176, "offsetInEndSection": 323, "text": "The proprotein convertase subtilisin-kexin type 9 (PCSK9) pathway plays a key role in lipoprotein metabolism by promoting LDL-receptor degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23261172", "endSection": "abstract"}, {"offsetInBeginSection": 139, "offsetInEndSection": 237, "text": "Proprotein convertase subtilisin-kexin type 9 (PCSK9) plays a key role in LDL receptor processing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21122852", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 353, "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the LDL receptor (LDLr) in hepatocytes, and its expression in mouse liver has been shown to decrease with fenofibrate treatment.We developed a sandwich ELISA using recombinant human PCSK9 protein and 2 affinity-purified polyclonal antibodies directed against human PCSK9.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18436719", "endSection": "abstract"}, {"offsetInBeginSection": 290, "offsetInEndSection": 413, "text": "Proprotein convertase subtilisin kexin type 9 (PCSK9) enhances the degradation of the LDLR and modulates liver CD81 levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25463543", "endSection": "abstract"}, {"offsetInBeginSection": 98, "offsetInEndSection": 299, "text": "Low-density lipoprotein (LDL) metabolism is governed by proprotein convertase subtilisin-kexin type 9 (PCSK9), which down-regulates LDL receptor expression, resulting in higher LDL cholesterol (LDL-C).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23106476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Proprotein convertase subtilisin kexin type 9 (PCSK9) is gaining attention as a key regulator of serum LDL-cholesterol (LDLC).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17702855", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": "The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene regulates cholesterol homoeostasis by accelerating low-density lipoprotein receptor (LDLR) degradation resulting in the decreased catabolism of low-density lipoprotein (LDL) leading to hypercholesterolaemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25649668", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400816", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 218, "text": "Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted protein that binds to the epidermal growth factor-like-A domain of the low density lipoprotein receptor (LDLR) and mediates LDLR degradation in liver.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400816", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a regulator of LDL-cholesterol receptor homeostasis and emerges as a therapeutic target in the prevention of cardiovascular (CV) disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24685817", "endSection": "abstract"}, {"offsetInBeginSection": 181, "offsetInEndSection": 392, "text": "The present study was conducted to investigate the role of plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels, a regulator of LDL-receptor expression, in the occurrence of diabetic dyslipidemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21497351", "endSection": "abstract"}]}, {"body": "Hy's law measures failure for what organ?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24203912", "http://www.ncbi.nlm.nih.gov/pubmed/26116527", "http://www.ncbi.nlm.nih.gov/pubmed/23874514", "http://www.ncbi.nlm.nih.gov/pubmed/22928730", "http://www.ncbi.nlm.nih.gov/pubmed/24704526", "http://www.ncbi.nlm.nih.gov/pubmed/26159259", "http://www.ncbi.nlm.nih.gov/pubmed/23300062", "http://www.ncbi.nlm.nih.gov/pubmed/26122767", "http://www.ncbi.nlm.nih.gov/pubmed/25683797"], "ideal_answer": ["Hy's law correlates enzyme elevations with liver injury ad subsequent failure."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D065290", "http://www.disease-ontology.org/api/metadata/DOID:2044", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056486", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056487", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008111", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017114", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058625"], "type": "factoid", "id": "58f4b25e70f9fc6f0f000011", "snippets": [{"offsetInBeginSection": 169, "offsetInEndSection": 420, "text": " Hy's Law of drug-induced hepatocellular jaundice causing a case-fatality rate or need for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver Injury Network. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26116527", "endSection": "abstract"}, {"offsetInBeginSection": 399, "offsetInEndSection": 556, "text": "Enzyme elevations alone may not be harmful, but if caused by a drug and followed by jaundice (called 'Hy's law') there is a high possibility of serious DILI.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26159259", "endSection": "abstract"}, {"offsetInBeginSection": 1064, "offsetInEndSection": 1211, "text": "No additional alleles outside those associated with liver injury patterns were found to affect potential severity as measured by Hy's Law criteria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23874514", "endSection": "abstract"}, {"offsetInBeginSection": 255, "offsetInEndSection": 717, "text": "We compared its performance with that of Hy's Law, which predicts severity of DILI based on levels of alanine aminotransferase or aspartate aminotransferase and total bilirubin, and validated the model in a separate sample.We conducted a retrospective cohort study of 15,353 Kaiser Permanente Northern California members diagnosed with DILI from 2004 through 2010, liver aminotransferase levels above the upper limit of normal, and no pre-existing liver disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26122767", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26122767", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Hy's Law, which states that hepatocellular drug-induced liver injury (DILI) with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure (ALF).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24704526", "endSection": "abstract"}, {"offsetInBeginSection": 46, "offsetInEndSection": 116, "text": "Hy's law is a method used to identify drug-induced liver injury (DILI)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25683797", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 180, "text": "Potential severe liver injury is identified in clinical trials by ALT>3\u2009\u00d7\u2009upper limits of normal (ULN) and total bilirubin>2\u2009\u00d7\u2009ULN, and termed 'Hy's Law' by the US FDA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22928730", "endSection": "abstract"}, {"offsetInBeginSection": 120, "offsetInEndSection": 327, "text": "Severe liver injury is identified by the liver chemistry threshold of alanine aminotransferase (ALT)>3\u00d7 upper limit of normal (ULN) and bilirubin>2\u00d7 ULN, termed Hy's law by the Food and Drug Administration. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23300062", "endSection": "abstract"}]}, {"body": "Is apremilast effective for psoriatic arthritis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26220911", "http://www.ncbi.nlm.nih.gov/pubmed/25633241", "http://www.ncbi.nlm.nih.gov/pubmed/27272887", "http://www.ncbi.nlm.nih.gov/pubmed/26644232", "http://www.ncbi.nlm.nih.gov/pubmed/27022911", "http://www.ncbi.nlm.nih.gov/pubmed/26806620", "http://www.ncbi.nlm.nih.gov/pubmed/26923915", "http://www.ncbi.nlm.nih.gov/pubmed/27486641", "http://www.ncbi.nlm.nih.gov/pubmed/24595547", "http://www.ncbi.nlm.nih.gov/pubmed/27747762", "http://www.ncbi.nlm.nih.gov/pubmed/27836567", "http://www.ncbi.nlm.nih.gov/pubmed/25973439", "http://www.ncbi.nlm.nih.gov/pubmed/23134988", "http://www.ncbi.nlm.nih.gov/pubmed/22257911", "http://www.ncbi.nlm.nih.gov/pubmed/27307707", "http://www.ncbi.nlm.nih.gov/pubmed/27168275", "http://www.ncbi.nlm.nih.gov/pubmed/25827658", "http://www.ncbi.nlm.nih.gov/pubmed/23569359", "http://www.ncbi.nlm.nih.gov/pubmed/23580094", "http://www.ncbi.nlm.nih.gov/pubmed/26783350", "http://www.ncbi.nlm.nih.gov/pubmed/27538241", "http://www.ncbi.nlm.nih.gov/pubmed/26660203", "http://www.ncbi.nlm.nih.gov/pubmed/24797159", "http://www.ncbi.nlm.nih.gov/pubmed/26807876", "http://www.ncbi.nlm.nih.gov/pubmed/26503917", "http://www.ncbi.nlm.nih.gov/pubmed/26792812"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C1678805", "o": "APREMILAST"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1678805", "o": "http://linkedlifedata.com/resource/umls/label/A15589751"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A15589751", "o": "apremilast"}], "ideal_answer": ["Yes, apremilast, an oral phosphodiesterase 4 inhibitor, is effective for psoriatic arthritis."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015535", "http://www.disease-ontology.org/api/metadata/DOID:9008"], "type": "yesno", "id": "5896e22078275d0c4a000014", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26792812", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "OBJECTIVE: To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement, despite prior therapy with conventional disease-modifying antirheumatic drugs and/or biologic agents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26792812", "endSection": "abstract"}, {"offsetInBeginSection": 1638, "offsetInEndSection": 1835, "text": "CONCLUSIONS: Apremilast demonstrated clinically meaningful improvements in psoriatic arthritis and psoriasis at week 16; sustained improvements were seen with continued treatment through 52\u2005weeks. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26792812", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "OBJECTIVE: To review the pharmacology, efficacy, and safety of apremilast and determine its role relative to other agents in the treatment of psoriasis and psoriatic arthritis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350", "endSection": "abstract"}, {"offsetInBeginSection": 1356, "offsetInEndSection": 1495, "text": "CONCLUSIONS: Apremilast has a novel mechanism of action and is safe and effective for the management of psoriasis and psoriatic arthritis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350", "endSection": "abstract"}, {"offsetInBeginSection": 160, "offsetInEndSection": 269, "text": " In particular, apremilast has been recently approved for the treatment of psoriasis and psoriatic arthritis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26806620", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Apremilast, an oral phosphodiesterase 4 inhibitor, has an acceptable safety profile and is effective for treatment of plaque psoriasis and psoriatic arthritis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27538241", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 399, "text": "As part of the National Institute for Health and Clinical Excellence (NICE) single technology appraisal (STA) process, the manufacturer of apremilast was invited to submit evidence for its clinical and cost effectiveness for the treatment of active psoriatic arthritis (PsA) for whom disease-modifying anti-rheumatic drugs (DMARDs) have been inadequately effective, not tolerated or contraindicated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27272887", "endSection": "abstract"}, {"offsetInBeginSection": 84, "offsetInEndSection": 331, "text": "Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547", "endSection": "abstract"}, {"offsetInBeginSection": 897, "offsetInEndSection": 1095, "text": "In patients with psoriatic arthritis, there are no clinical trials comparing apremilast with TNF alpha antagonists, and no interpretable trials of apremilast after failure of a TNF alpha antagonist.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27486641", "endSection": "abstract"}, {"offsetInBeginSection": 85, "offsetInEndSection": 497, "text": "Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy.In the 24-week, placebo-controlled phase of PALACE 1, patients (N=504) were randomised (1:1:1) to placebo, apremilast 20 mg twice a day (BID) or apremilast 30 mg BID", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547", "endSection": "abstract"}, {"offsetInBeginSection": 1563, "offsetInEndSection": 1816, "text": "No imbalance in major adverse cardiac events, serious or opportunistic infections, malignancies or laboratory abnormalities was observed.Apremilast was effective in the treatment of psoriatic arthritis, improving signs and symptoms and physical function", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547", "endSection": "abstract"}, {"offsetInBeginSection": 92, "offsetInEndSection": 583, "text": "Apremilast is a novel oral PDE4 enzyme inhibitor capable of blocking leukocyte production of IL-12, IL-23, TNF-a, INF- with subsequent suppression of Th1 and Th17-mediated immune responses, and proven clinical efficacy for psoriasis as well as rheumatoid and psoriatic arthritis.Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) showed a significant (P&lt;0.05) decrease after 85 days of treatment with apremilast 20 mg twice daily in 8 patients with active discoid lupus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23134988", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 397, "text": "The purpose of this study is to give an overview of the new treatments approved by the U.S. Food and Drug Administration (FDA) for use in psoriatic arthritis (PsA).FDA has approved three new drugs for PsA: Certolizumab-pegol: a PEGylated Fc-free tumour necrosis factor inhibitor (TNFi); ustekinumab: an anti interleukin (IL)-12 and IL-23 mAb; and apremilast and oral phosphodiesterase 4 inhibitor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25633241", "endSection": "abstract"}, {"offsetInBeginSection": 1149, "offsetInEndSection": 1403, "text": "In all trials, the drug had an acceptable safety profile, with the most common adverse effects of diarrhea, nausea, and headache.Apremilast has a novel mechanism of action and is safe and effective for the management of psoriasis and psoriatic arthritis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350", "endSection": "abstract"}, {"offsetInBeginSection": 418, "offsetInEndSection": 597, "text": "Apremilast is a well-tolerated and effective phosphodiesterase type 4 inhibitor that is indicated for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27307707", "endSection": "abstract"}, {"offsetInBeginSection": 85, "offsetInEndSection": 498, "text": "Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy.In the 24-week, placebo-controlled phase of PALACE 1, patients (N=504) were randomised (1:1:1) to placebo, apremilast 20 mg twice a day (BID) or apremilast 30 mg BID.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547", "endSection": "abstract"}, {"offsetInBeginSection": 756, "offsetInEndSection": 961, "text": "Newer drugs in the treatment armamentarium that have shown efficacy for both psoriasis and psoriatic arthritis consist of the anti-IL-17 agent, secukinumab, and a phosphodiesterase-4 inhibitor, apremilast.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23580094", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 397, "text": "To review the pharmacology, efficacy, and safety of apremilast and determine its role relative to other agents in the treatment of psoriasis and psoriatic arthritis.A PubMed search (1946 to December 2015) using the terms apremilast and CC-10004 was conducted to identify relevant articles.In vitro or in vivo evaluations of apremilast published in the English language were eligible for inclusion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350", "endSection": "abstract"}, {"offsetInBeginSection": 903, "offsetInEndSection": 1101, "text": "In patients with psoriatic arthritis, there are no clinical trials comparing apremilast with TNF alpha antagonists, and no interpretable trials of apremilast after failure of a TNF alpha antagonist.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27486641", "endSection": "abstract"}, {"offsetInBeginSection": 1563, "offsetInEndSection": 1817, "text": "No imbalance in major adverse cardiac events, serious or opportunistic infections, malignancies or laboratory abnormalities was observed.Apremilast was effective in the treatment of psoriatic arthritis, improving signs and symptoms and physical function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547", "endSection": "abstract"}, {"offsetInBeginSection": 92, "offsetInEndSection": 581, "text": "Apremilast is a novel oral PDE4 enzyme inhibitor capable of blocking leukocyte production of IL-12, IL-23, TNF-a, INF- with subsequent suppression of Th1 and Th17-mediated immune responses, and proven clinical efficacy for psoriasis as well as rheumatoid and psoriatic arthritis.Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) showed a significant (P<0.05) decrease after 85 days of treatment with apremilast 20 mg twice daily in 8 patients with active discoid lupus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23134988", "endSection": "abstract"}, {"offsetInBeginSection": 1700, "offsetInEndSection": 1817, "text": "Apremilast was effective in the treatment of psoriatic arthritis, improving signs and symptoms and physical function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547", "endSection": "abstract"}, {"offsetInBeginSection": 1282, "offsetInEndSection": 1407, "text": "Apremilast has a novel mechanism of action and is safe and effective for the management of psoriasis and psoriatic arthritis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for treatment of active psoriatic arthritis in the psoriatic arthritis long-term assessment of clinical efficacy (PALACE) phase III clinical trial program.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25973439", "endSection": "abstract"}, {"offsetInBeginSection": 85, "offsetInEndSection": 332, "text": "Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24595547", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Apremilast: A Review in Psoriasis and Psoriatic Arthritis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26220911", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Drug safety evaluation of apremilast for treating psoriatic arthritis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827658", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Apremilast for the treatment of psoriatic arthritis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503917", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22257911", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27747762", "endSection": "title"}]}, {"body": "Is there any role of TBR1 in autism?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24441682", "http://www.ncbi.nlm.nih.gov/pubmed/26578866", "http://www.ncbi.nlm.nih.gov/pubmed/27325115", "http://www.ncbi.nlm.nih.gov/pubmed/25600067", "http://www.ncbi.nlm.nih.gov/pubmed/25309323", "http://www.ncbi.nlm.nih.gov/pubmed/23431145", "http://www.ncbi.nlm.nih.gov/pubmed/25232744"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0004352", "o": "http://linkedlifedata.com/resource/umls/label/A18645844"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18645844", "o": "autistic disorders"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0004352", "o": "Autism"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0004352", "o": "http://linkedlifedata.com/resource/umls/label/A0474209"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0474209", "o": "autism"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0004352", "o": "http://linkedlifedata.com/resource/umls/label/A18571407"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18571407", "o": "autistic disorder"}], "ideal_answer": ["Yes. Exome sequencing studies have identified multiple genes harboring de novo loss-of-function (LoF) variants in individuals with autism spectrum disorders (ASD), including T-Brain-1 (TBR1), a master regulator of cortical development. T-brain-1 (TBR1) is a brain-specific T-box transcription factor. In 1995, Tbr1 was first identified from a subtractive hybridization that compared mouse embryonic and adult telencephalons. Previous studies of Tbr1 (-\u2215-) mice have indicated critical roles for TBR1 in the development of the cerebral cortex, amygdala, and olfactory bulb. Neuronal migration and axonal projection are two important developmental features controlled by TBR1."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000067877", "http://www.uniprot.org/uniprot/TBR1_MOUSE", "http://www.disease-ontology.org/api/metadata/DOID:12849", "http://www.disease-ontology.org/api/metadata/DOID:0060042", "http://www.disease-ontology.org/api/metadata/DOID:0060041", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001321", "http://www.uniprot.org/uniprot/TBR1_HUMAN"], "type": "yesno", "id": "58965ed478275d0c4a000010", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "TBR1 regulates autism risk genes in the developing neocortex", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27325115", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1160, "text": "Exome sequencing studies have identified multiple genes harboring de novo loss-of-function (LoF) variants in individuals with autism spectrum disorders (ASD), including TBR1, a master regulator of cortical development. We performed ChIP-seq for TBR1 during mouse cortical neurogenesis and show that TBR1-bound regions are enriched adjacent to ASD genes. ASD genes were also enriched among genes that are differentially expressed in Tbr1 knockouts, which together with the ChIP-seq data, suggests direct transcriptional regulation. Of the nine ASD genes examined, seven were misexpressed in the cortices of Tbr1 knockout mice, including six with increased expression in the deep cortical layers. ASD genes with adjacent cortical TBR1 ChIP-seq peaks also showed unusually low levels of LoF mutations in a reference human population and among Icelanders. We then leveraged TBR1 binding to identify an appealing subset of candidate ASD genes. Our findings highlight a TBR1-regulated network of ASD genes in the developing neocortex that are relatively intolerant to LoF mutations, indicating that these genes may play critical roles in normal cortical development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27325115", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "T-Brain-1--A Potential Master Regulator in Autism Spectrum Disorders.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600067", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 521, "text": "T-Brain-1 (TBR1), a causative gene in autism spectrum disorders (ASDs), encodes a brain-specific T-box transcription factor. It is therefore possible that TBR1 controls the expression of other autism risk factors. The downstream genes of TBR1 have been identified using microarray and promoter analyses. In this study, we annotated individual genes downstream of TBR1 and investigated any associations with ASDs through extensive literature searches. Of 124 TBR1 target genes, 23 were reported to be associated with ASDs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600067", "endSection": "abstract"}, {"offsetInBeginSection": 840, "offsetInEndSection": 1513, "text": "Among these 24 genes, four transcription factors Auts2, Nfia, Nr4a2, and Sox5 were found, suggesting that TBR1 controls a transcriptional cascade relevant to autism pathogenesis. A further five of the 24 genes (Cd44, Cdh8, Cntn6, Gpc6, and Ntng1) encode membrane proteins that regulate cell adhesion and axonal outgrowth. These genes likely contribute to the role of TBR1 in regulation of neuronal migration and axonal extension. Besides, decreases in Grin2b expression and increases in Gad1 expression imply that neuronal activity may be aberrant in Tbr1 deficient mice. These analyses provide direction for future experiments to reveal the pathogenic mechanism of autism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600067", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 323, "text": "The activity-regulated gene expression of transcription factors is required for neural plasticity and function in response to neuronal stimulation. T-brain-1 (TBR1), a critical neuron-specific transcription factor for forebrain development, has been recognized as a high-confidence risk gene for autism spectrum disorders. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25309323", "endSection": "abstract"}, {"offsetInBeginSection": 91, "offsetInEndSection": 212, "text": "Disruptive mutations in the TBR1 gene have been repeatedly identified in patients with autism spectrum disorders (ASDs). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24441682", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 393, "text": "Next-generation sequencing recently revealed that recurrent disruptive mutations in a few genes may account for 1% of sporadic autism cases. Coupling these novel genetic data to empirical assays of protein function can illuminate crucial molecular networks. Here we demonstrate the power of the approach, performing the first functional analyses of TBR1 variants identified in sporadic autism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25232744", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 657, "text": "T-brain-1 (TBR1) is a brain-specific T-box transcription factor. In 1995, Tbr1 was first identified from a subtractive hybridization that compared mouse embryonic and adult telencephalons. Previous studies of Tbr1 (-\u2215-) mice have indicated critical roles for TBR1 in the development of the cerebral cortex, amygdala, and olfactory bulb. Neuronal migration and axonal projection are two important developmental features controlled by TBR1. Recently, recurrent de novo disruptive mutations in the TBR1 gene have been found in patients with autism spectrum disorders (ASDs). Human genetic studies have identified TBR1 as a high-confidence risk factor for ASDs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26578866", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "TBR1 regulates autism risk genes in the developing neocortex.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27325115", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "De novo TBR1 mutations in sporadic autism disrupt protein functions.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25232744", "endSection": "title"}, {"offsetInBeginSection": 945, "offsetInEndSection": 1033, "text": "In humans, PAX6, EOMES, and TBR1 have been linked to intellectual disability and autism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23431145", "endSection": "abstract"}, {"offsetInBeginSection": 124, "offsetInEndSection": 212, "text": "It is therefore possible that TBR1 controls the expression of other autism risk factors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600067", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Neuronal excitation upregulates Tbr1, a high-confidence risk gene of autism, mediating Grin2b expression in the adult brain.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25309323", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "T-Brain-1 (TBR1), a causative gene in autism spectrum disorders (ASDs), encodes a brain-specific T-box transcription factor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600067", "endSection": "abstract"}, {"offsetInBeginSection": 435, "offsetInEndSection": 567, "text": "Recently, recurrent de novo disruptive mutations in the TBR1 gene have been found in patients with autism spectrum disorders (ASDs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26578866", "endSection": "abstract"}, {"offsetInBeginSection": 256, "offsetInEndSection": 391, "text": "Here we demonstrate the power of the approach, performing the first functional analyses of TBR1 variants identified in sporadic autism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25232744", "endSection": "abstract"}, {"offsetInBeginSection": 832, "offsetInEndSection": 1010, "text": "Among these 24 genes, four transcription factors Auts2, Nfia, Nr4a2, and Sox5 were found, suggesting that TBR1 controls a transcriptional cascade relevant to autism pathogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600067", "endSection": "abstract"}, {"offsetInBeginSection": 90, "offsetInEndSection": 210, "text": "Disruptive mutations in the TBR1 gene have been repeatedly identified in patients with autism spectrum disorders (ASDs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24441682", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "T-Brain-1 (TBR1), a causative gene in autism spectrum disorders (ASDs), encodes a brain-specific T-box transcription factor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600067", "endSection": "abstract"}, {"offsetInBeginSection": 840, "offsetInEndSection": 1017, "text": "Among these 24 genes, four transcription factors Auts2, Nfia, Nr4a2, and Sox5 were found, suggesting that TBR1 controls a transcriptional cascade relevant to autism pathogenesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600067", "endSection": "abstract"}, {"offsetInBeginSection": 91, "offsetInEndSection": 210, "text": "Disruptive mutations in the TBR1 gene have been repeatedly identified in patients with autism spectrum disorders (ASDs)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24441682", "endSection": "abstract"}, {"offsetInBeginSection": 840, "offsetInEndSection": 1018, "text": "Among these 24 genes, four transcription factors Auts2, Nfia, Nr4a2, and Sox5 were found, suggesting that TBR1 controls a transcriptional cascade relevant to autism pathogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600067", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 213, "text": "It is therefore possible that TBR1 controls the expression of other autism risk factors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25600067", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "TBR1 regulates autism risk genes in the developing neocortex.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27325115", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "De novo TBR1 mutations in sporadic autism disrupt protein functions.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25232744", "endSection": "title"}, {"offsetInBeginSection": 939, "offsetInEndSection": 1160, "text": "Our findings highlight a TBR1-regulated network of ASD genes in the developing neocortex that are relatively intolerant to LoF mutations, indicating that these genes may play critical roles in normal cortical development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27325115", "endSection": "abstract"}]}, {"body": "What is the role of the MCM2-7 complex?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19805216", "http://www.ncbi.nlm.nih.gov/pubmed/23817338", "http://www.ncbi.nlm.nih.gov/pubmed/22045335", "http://www.ncbi.nlm.nih.gov/pubmed/24234446", "http://www.ncbi.nlm.nih.gov/pubmed/23376927", "http://www.ncbi.nlm.nih.gov/pubmed/17314092", "http://www.ncbi.nlm.nih.gov/pubmed/21070963", "http://www.ncbi.nlm.nih.gov/pubmed/12059957", "http://www.ncbi.nlm.nih.gov/pubmed/12694531", "http://www.ncbi.nlm.nih.gov/pubmed/12087101", "http://www.ncbi.nlm.nih.gov/pubmed/25319829", "http://www.ncbi.nlm.nih.gov/pubmed/18824790", "http://www.ncbi.nlm.nih.gov/pubmed/19481678", "http://www.ncbi.nlm.nih.gov/pubmed/19357199", "http://www.ncbi.nlm.nih.gov/pubmed/23518502", "http://www.ncbi.nlm.nih.gov/pubmed/24947836", "http://www.ncbi.nlm.nih.gov/pubmed/19540846", "http://www.ncbi.nlm.nih.gov/pubmed/22918581", "http://www.ncbi.nlm.nih.gov/pubmed/23720738", "http://www.ncbi.nlm.nih.gov/pubmed/26582917", "http://www.ncbi.nlm.nih.gov/pubmed/26940553", "http://www.ncbi.nlm.nih.gov/pubmed/15522891", "http://www.ncbi.nlm.nih.gov/pubmed/18606811", "http://www.ncbi.nlm.nih.gov/pubmed/12527764", "http://www.ncbi.nlm.nih.gov/pubmed/15108800", "http://www.ncbi.nlm.nih.gov/pubmed/15653632", "http://www.ncbi.nlm.nih.gov/pubmed/15286659", "http://www.ncbi.nlm.nih.gov/pubmed/23864661", "http://www.ncbi.nlm.nih.gov/pubmed/19270162", "http://www.ncbi.nlm.nih.gov/pubmed/23977294", "http://www.ncbi.nlm.nih.gov/pubmed/22351771", "http://www.ncbi.nlm.nih.gov/pubmed/21799014", "http://www.ncbi.nlm.nih.gov/pubmed/21460226", "http://www.ncbi.nlm.nih.gov/pubmed/19910535", "http://www.ncbi.nlm.nih.gov/pubmed/21196493"], "ideal_answer": ["The MCM2-7 complex is a ring-shaped heterohexamer helicase, that unwinds the DNA double helix ahead of the other replication machinery. During pre-replication complex (pre-RC) formation, origin recognition complex (ORC), Cdc6, and Cdt1 cooperatively load a double-hexameric MCM2-7 complex onto DNA. Loading of MCM2-7 is a prerequisite for licensing of eukaryotic DNA replication. During S phase MCM2-7 functions as part of the replicative helicase but within the pre-RC MCM2-7 is inactive."], "concepts": ["http://www.uniprot.org/uniprot/MCM2_YEAST", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064111", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064110", "http://www.uniprot.org/uniprot/MCM2_HUMAN", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064168", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064150", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064148", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064151", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012380", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064126", "http://www.uniprot.org/uniprot/MCM2_ARATH"], "type": "summary", "id": "58dcd0338acda34529000022", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "The role of the MCM2-7 helicase complex during Arabidopsis seed development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24947836", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "The MINICHROMOSOME MAINTENANCE 2-7 (MCM2-7) complex, a ring-shaped heterohexamer, unwinds the DNA double helix ahead of the other replication machinery. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24947836", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 317, "text": "MCM7 is one of the subunits of the MCM2-7 complex that plays a critical role in DNA replication initiation and cell proliferation of eukaryotic cells. After forming the pre-replication complex (pre-RC) with other components, the MCM2-7 complex is activated by DDK/cyclin-dependent kinase to initiate DNA replication. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23720738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Hexameric complexes of the six related Mcm2-7 proteins form the core of the replicative helicase. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23518502", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "MCM-BP regulates unloading of the MCM2-7 helicase in late S phase.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196493", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Origins of DNA replication are licensed by recruiting MCM2-7 to assemble the prereplicative complex (pre-RC). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196493", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Mec1 is one of multiple kinases that prime the Mcm2-7 helicase for phosphorylation by Cdc7.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21070963", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 237, "text": "Activation of the eukaryotic replicative DNA helicase, the Mcm2-7 complex, requires phosphorylation by Cdc7/Dbf4 (Dbf4-dependent kinase or DDK), which, in turn, depends on prior phosphorylation of Mcm2-7 by an unknown kinase (or kinases)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21070963", "endSection": "abstract"}, {"offsetInBeginSection": 210, "offsetInEndSection": 339, "text": "The heterohexameric complex of minichromosome maintenance proteins (MCM2-7 complex) plays an essential role in origin licensing. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19481678", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "A double-hexameric MCM2-7 complex is loaded onto origin DNA during licensing of eukaryotic DNA replication.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19910535", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 407, "text": "During pre-replication complex (pre-RC) formation, origin recognition complex (ORC), Cdc6, and Cdt1 cooperatively load the 6-subunit mini chromosome maintenance (MCM2-7) complex onto DNA. Loading of MCM2-7 is a prerequisite for DNA licensing that restricts DNA replication to once per cell cycle. During S phase MCM2-7 functions as part of the replicative helicase but within the pre-RC MCM2-7 is inactive. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19910535", "endSection": "abstract"}, {"offsetInBeginSection": 1056, "offsetInEndSection": 1592, "text": "The quaternary structure of MCM2-7 changes during pre-RC formation: MCM2-7 before loading is a single hexamer in solution but is transformed into a double-hexamer during pre-RC formation. Using electron microscopy (EM), we observed that loaded MCM2-7 encircles DNA. The loaded MCM2-7 complex can slide on DNA, and sliding is not directional. Our results provide key insights into mechanisms of pre-RC formation and have important implications for understanding the role of the MCM2-7 in establishment of bidirectional replication forks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19910535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Cdt1 is required for loading the replicative DNA helicase MCM2/7, a process known as DNA replication licensing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23817338", "endSection": "abstract"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1013, "text": "Both the Mcm4/6/7 and Mcm2~7 complexes stimulate RNA primer synthesis by DNA primase in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23977294", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "MCM7 is one of the subunits of the MCM2-7 complex that plays a critical role in DNA replication initiation and cell proliferation of eukaryotic cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23720738", "endSection": "abstract"}, {"offsetInBeginSection": 996, "offsetInEndSection": 1190, "text": "These biochemical data suggest that phosphorylation of MCM4 at these sites by CDK plays a direct role in dislodging MCM2-7 from chromatin and/or preventing re-loading of the complex to chromatin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23864661", "endSection": "abstract"}, {"offsetInBeginSection": 210, "offsetInEndSection": 337, "text": "The heterohexameric complex of minichromosome maintenance proteins (MCM2-7 complex) plays an essential role in origin licensing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19481678", "endSection": "abstract"}, {"offsetInBeginSection": 197, "offsetInEndSection": 482, "text": "In this report, we have used bimolecular fluorescence complementation assays in HeLa cells to examine the interactions between Cdc45, Mcm2-7, and the GINS complex (collectively called the CMG complex), which seem to play a key role in the formation and progression of replication forks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805216", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "The origin recognition complex (ORC) of Saccharomyces cerevisiae binds origin DNA and cooperates with Cdc6 and Cdt1 to load the replicative helicase MCM2-7 onto DNA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23376927", "endSection": "abstract"}, {"offsetInBeginSection": 106, "offsetInEndSection": 398, "text": "The CMG (Cdc45\u00b7Mcm2-7\u00b7GINS) complex, which is composed of Cdc45, Mcm2-7, and the GINS (Go-Ichi-Ni-San) complex consisting of Sld5 and Psf1 to Psf3, is recruited by Cdc6 and Cdt1 onto origins bound by the heterohexameric origin recognition complex (ORC) and functions as a replicative helicase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21799014", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "MCM7 is one of the subunits of the MCM2-7 complex that plays a critical role in DNA replication initiation and cell proliferation of eukaryotic cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23720738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "The MCM2-7 complex, which may act as a replicative helicase during DNA synthesis, plays a central role in S-phase genome stability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15108800", "endSection": "abstract"}, {"offsetInBeginSection": 210, "offsetInEndSection": 338, "text": "The heterohexameric complex of minichromosome maintenance proteins (MCM2-7 complex) plays an essential role in origin licensing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19481678", "endSection": "abstract"}, {"offsetInBeginSection": 349, "offsetInEndSection": 594, "text": "In this work, we demonstrate that subunits of the MCM2-7 complex are coordinately expressed during Arabidopsis (Arabidopsis thaliana) development and are abundant in proliferating and endocycling tissues, indicative of a role in DNA replication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19357199", "endSection": "abstract"}, {"offsetInBeginSection": 553, "offsetInEndSection": 723, "text": "Cdc6 and Cdt1 play an essential role in DNA replication initiation by loading the Mcm2-7 complex, which is required for unwinding the DNA helix, onto chromosomal origins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15522891", "endSection": "abstract"}, {"offsetInBeginSection": 913, "offsetInEndSection": 1134, "text": "Inspired by the role of the rigid region in promoters, we speculate that the rigid replication origins may facilitate binding of proteins, including the origin recognition complex (ORC), Cdc6, Cdt1 and the MCM2-7 complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18824790", "endSection": "abstract"}, {"offsetInBeginSection": 1024, "offsetInEndSection": 1220, "text": "Overall, our data identify a new Mcm protein, which does not form part of the Mcm2-7 complex and which is only structure-bound during S phase, thus suggesting its specific role in DNA replication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12527764", "endSection": "abstract"}, {"offsetInBeginSection": 232, "offsetInEndSection": 374, "text": "Using Mcm4/6/7 as a tool, we reveal a role for nucleotide binding by Saccharomyces cerevisiae Mcm2 in modulating DNA binding by Mcm complexes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19540846", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "The ORC/Cdc6/MCM2-7 complex facilitates MCM2-7 dimerization during prereplicative complex formation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24234446", "endSection": "title"}, {"offsetInBeginSection": 633, "offsetInEndSection": 825, "text": "Here, structural evidence for intermediates consisting of an ORC-Cdc6-Mcm2-7 complex and an ORC-Cdc6-Mcm2-7-Mcm2-7 complex are reported, which together provide new insights into DNA licensing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25319829", "endSection": "abstract"}, {"offsetInBeginSection": 1398, "offsetInEndSection": 1593, "text": "Our results provide key insights into mechanisms of pre-RC formation and have important implications for understanding the role of the MCM2-7 in establishment of bidirectional replication forks..", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19910535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "The Mcm proteins are a family of six homologous proteins (Mcm2-7) that play an important role in DNA replication.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12694531", "endSection": "abstract"}]}, {"body": "In which fields of DNA sequencing are Bloom filters applied?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26539459", "http://www.ncbi.nlm.nih.gov/pubmed/27412092", "http://www.ncbi.nlm.nih.gov/pubmed/25252952", "http://www.ncbi.nlm.nih.gov/pubmed/24565280", "http://www.ncbi.nlm.nih.gov/pubmed/27828710", "http://www.ncbi.nlm.nih.gov/pubmed/20472541", "http://www.ncbi.nlm.nih.gov/pubmed/25398208", "http://www.ncbi.nlm.nih.gov/pubmed/25183486"], "ideal_answer": ["A novel algorithm, fast and accurate classification of sequences (FACSs), is introduced that can accurately and rapidly classify sequences as belonging or not belonging to a reference sequence.  Classification of DNA sequences using Bloom filters Lighter is a fast, memory-efficient tool for correcting sequencing errors.", "A novel algorithm, fast and accurate classification of sequences (FACSs), is introduced that can accurately and rapidly classify sequences as belonging or not belonging to a reference sequence. Classification of DNA sequences using Bloom filters. Further, we note that Bloom filters would be suitable to implicitly store spaced seeds and be tolerant to sequencing errors. Lighter avoids counting k-mers. Fast lossless compression via cascading Bloom filters. ", "A novel algorithm, fast and accurate classification of sequences (FACSs), is introduced that can accurately and rapidly classify sequences as belonging or not belonging to a reference sequence. Classification of DNA sequences using Bloom filters. Instead, it uses a pair of Bloom filters, one holding a sample of the input k-mers and the other holding k-mers likely to be correct. Fast lossless compression via cascading Bloom filters. Lighter is a fast, memory-efficient tool for correcting sequencing errors. ", "A novel algorithm, fast and accurate classification of sequences (FACSs), is introduced that can accurately and rapidly classify sequences as belonging or not belonging to a reference sequence. Classification of DNA sequences using Bloom filters. Instead, it uses a pair of Bloom filters, one holding a sample of the input k-mers and the other holding k-mers likely to be correct. Lighter is a fast, memory-efficient tool for correcting sequencing errors. Lighter avoids counting k-mers. ", "Bloom Filters (BFs) reduce the memory footprint required to store millions of k-mers while allowing for fast set containment queries, at the cost of a low false positive rate (FPR). Cascading Bloom filters have been used to improve the memory usage and speed of DNA sequence compression.", "Further, we note that Bloom filters would be suitable to implicitly store spaced seeds and be tolerant to sequencing errors.  It uses a pair of cache oblivious Bloom filters, one holding a uniform sample of [Formula: see text]-spaced sequenced [Formula: see text]-mers and the other holding [Formula: see text]-mers classified as likely correct, using a simple statistical test."], "type": "list", "id": "58eb6061eda5a57672000005", "snippets": [{"offsetInBeginSection": 298, "offsetInEndSection": 492, "text": "A novel algorithm, fast and accurate classification of sequences (FACSs), is introduced that can accurately and rapidly classify sequences as belonging or not belonging to a reference sequence. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20472541", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "Classification of DNA sequences using Bloom filters", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20472541", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "Lighter is a fast, memory-efficient tool for correcting sequencing errors. Lighter avoids counting k-mers. Instead, it uses a pair of Bloom filters, one holding a sample of the input k-mers and the other holding k-mers likely to be correct.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25398208", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Fast lossless compression via cascading Bloom filters", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25252952", "endSection": "title"}, {"offsetInBeginSection": 1368, "offsetInEndSection": 1661, "text": "In contrast to reference-based methods that first align reads to the genome, we hash all reads into Bloom filters to encode, and decode by querying the same Bloom filters using read-length subsequences of the reference genome. Further compression is achieved by using a cascade of such filters", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25252952", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Using cascading Bloom filters to improve the memory usage for de Brujin graphs", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24565280", "endSection": "title"}, {"offsetInBeginSection": 286, "offsetInEndSection": 446, "text": "In this work, we show how to reduce the memory required by the data structure of Chikhi and Rizk (WABI'12) that represents de Brujin graphs using Bloom filters.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24565280", "endSection": "abstract"}, {"offsetInBeginSection": 824, "offsetInEndSection": 1006, "text": "We introduce a novel hash-based method for constructing the string graph. We use incremental hashing, and specifically a modification of the Karp-Rabin fingerprint, and Bloom filters", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25183486", "endSection": "abstract"}, {"offsetInBeginSection": 956, "offsetInEndSection": 1080, "text": "Further, we note that Bloom filters would be suitable to implicitly store spaced seeds and be tolerant to sequencing errors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26539459", "endSection": "abstract"}, {"offsetInBeginSection": 915, "offsetInEndSection": 1168, "text": " It uses a pair of cache oblivious Bloom filters, one holding a uniform sample of [Formula: see text]-spaced sequenced [Formula: see text]-mers and the other holding [Formula: see text]-mers classified as likely correct, using a simple statistical test.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27412092", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Improving Bloom Filter Performance on Sequence Data Using k-mer Bloom Filters", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27828710", "endSection": "title"}, {"offsetInBeginSection": 482, "offsetInEndSection": 647, "text": "BFs reduce the memory footprint required to store millions of k-mers while allowing for fast set containment queries, at the cost of a low false positive rate (FPR).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27828710", "endSection": "abstract"}, {"offsetInBeginSection": 1058, "offsetInEndSection": 1226, "text": "We consider several variants of such k-mer Bloom filters (kBFs), derive theoretical upper bounds for their FPR, and discuss their range of applications and limitations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27828710", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "Fast lossless compression via cascading Bloom filters.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25252952", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Fast lossless compression via cascading Bloom filters.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25252952", "endSection": "title"}]}, {"body": "Which 2 medications are included in the Qsymia pill?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23590816", "http://www.ncbi.nlm.nih.gov/pubmed/23531960", "http://www.ncbi.nlm.nih.gov/pubmed/24222976", "http://www.ncbi.nlm.nih.gov/pubmed/23565717", "http://www.ncbi.nlm.nih.gov/pubmed/25826792", "http://www.ncbi.nlm.nih.gov/pubmed/25661549", "http://www.ncbi.nlm.nih.gov/pubmed/23039320", "http://www.ncbi.nlm.nih.gov/pubmed/26313898", "http://www.ncbi.nlm.nih.gov/pubmed/24991373", "http://www.ncbi.nlm.nih.gov/pubmed/23625271", "http://www.ncbi.nlm.nih.gov/pubmed/24986038"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0013227", "o": "http://linkedlifedata.com/resource/umls/label/A18591068"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18591068", "o": "pharmaceutical preparations"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0025118", "o": "medicine"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0013227", "o": "http://linkedlifedata.com/resource/umls/label/A18628198"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18628198", "o": "pharmaceutical preparation"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0013227", "o": "http://linkedlifedata.com/resource/umls/label/A18683808"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18683808", "o": "medications"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0013227", "o": "drug"}], "ideal_answer": ["Qsymia pill includes phentermine and topiramate. It is used for treatment of obesity."], "type": "list", "id": "589a246c78275d0c4a000032", "snippets": [{"offsetInBeginSection": 235, "offsetInEndSection": 397, "text": "OBJECTIVE: To quantify the incremental cost-effectiveness of Qsymia (phentermine and topiramate extended-release) for health-related quality of life improvements.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24986038", "endSection": "abstract"}, {"offsetInBeginSection": 807, "offsetInEndSection": 1002, "text": "The intervention was diet and lifestyle advice plus the recommended dose of Qsymia (phentermine 7.5\u00a0mg plus topiramate 46.0\u00a0mg) vs. control, which included diet and lifestyle advice plus placebo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24986038", "endSection": "abstract"}, {"offsetInBeginSection": 449, "offsetInEndSection": 698, "text": "These include combinations (at low dose) of existing drugs, e.g., bupropion + naltrexone (Contrave), phentermine + topiramate (Qsymia), higher doses of existing drugs licensed for other indications (liraglutide, 3 mg), and new entities (lorcaserin).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25661549", "endSection": "abstract"}, {"offsetInBeginSection": 593, "offsetInEndSection": 960, "text": "RECENT FINDINGS: Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications available for the treatment of obesity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898", "endSection": "abstract"}, {"offsetInBeginSection": 769, "offsetInEndSection": 982, "text": "Adding to the current available pharmacotherapies for obesity, the Food and Drug Administration has recently approved 2 new combination medications known as lorcaserin (Belviq) and phentermine-topiramate (Qsymia).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23531960", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 326, "text": "After a long period of failure in development, two new medications (phentermine/topiramate ER - Qsymia\u2122 and lorcaserin - Belviq\u00ae) have been approved by the US Food and Drug Administration for long-term weight management in persons with obesity (BMI \u2265 30 kg/m(2)) or in overweight persons (BMI \u2265 27 kg/m(2)) with comorbidities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23625271", "endSection": "abstract"}, {"offsetInBeginSection": 758, "offsetInEndSection": 952, "text": "The intervention was diet and lifestyle advice plus the recommended dose of Qsymia (phentermine 7.5\u00a0mg plus topiramate 46.0\u00a0mg) vs. control, which included diet and lifestyle advice plus placebo", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24986038", "endSection": "abstract"}, {"offsetInBeginSection": 494, "offsetInEndSection": 924, "text": "Current antiobesity medications and pharmacological strategies will be reviewed.Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications available for the treatment of obesity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 917, "text": "Almost a decade after the Food and Drug Administration approved the first weight loss medication, it recently approved two novel anti-obesity drugs Belviq (lorcaserin) and Qsymia (topiramate and phentermine), thus signalling the beginning of a new era in the pharmacotherapy of obesity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25826792", "endSection": "abstract"}, {"offsetInBeginSection": 392, "offsetInEndSection": 865, "text": "Obesity is a public health crisis affecting approximately more than 33% of Americans and costing the healthcare system more than $190 billion annually.To review the 2 new drugs that were recently approved by the US Food and Drug Administration (FDA) for the treatment of obesity, lorcaserin HCl (Belviq) and phentermine/topiramate (Qsymia) and their potential impact on the treatment of obese patients.Lifestyle modification is the first and mainstay treatment for obesity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991373", "endSection": "abstract"}, {"offsetInBeginSection": 774, "offsetInEndSection": 987, "text": "Adding to the current available pharmacotherapies for obesity, the Food and Drug Administration has recently approved 2 new combination medications known as lorcaserin (Belviq) and phentermine-topiramate (Qsymia).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23531960", "endSection": "abstract"}, {"offsetInBeginSection": 575, "offsetInEndSection": 925, "text": "Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications available for the treatment of obesity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898", "endSection": "abstract"}, {"offsetInBeginSection": 544, "offsetInEndSection": 795, "text": "To review the 2 new drugs that were recently approved by the US Food and Drug Administration (FDA) for the treatment of obesity, lorcaserin HCl (Belviq) and phentermine/topiramate (Qsymia) and their potential impact on the treatment of obese patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991373", "endSection": "abstract"}]}, {"body": "Is sonidegib effective for basal cell carcinoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26867946", "http://www.ncbi.nlm.nih.gov/pubmed/27189494", "http://www.ncbi.nlm.nih.gov/pubmed/27636236", "http://www.ncbi.nlm.nih.gov/pubmed/26566923", "http://www.ncbi.nlm.nih.gov/pubmed/26780190", "http://www.ncbi.nlm.nih.gov/pubmed/26546616", "http://www.ncbi.nlm.nih.gov/pubmed/27695345", "http://www.ncbi.nlm.nih.gov/pubmed/25981810", "http://www.ncbi.nlm.nih.gov/pubmed/27538055", "http://www.ncbi.nlm.nih.gov/pubmed/26833519", "http://www.ncbi.nlm.nih.gov/pubmed/26323341", "http://www.ncbi.nlm.nih.gov/pubmed/24523439", "http://www.ncbi.nlm.nih.gov/pubmed/27511905", "http://www.ncbi.nlm.nih.gov/pubmed/24773312", "http://www.ncbi.nlm.nih.gov/pubmed/25646180", "http://www.ncbi.nlm.nih.gov/pubmed/27067394", "http://www.ncbi.nlm.nih.gov/pubmed/27096888", "http://www.ncbi.nlm.nih.gov/pubmed/26614022", "http://www.ncbi.nlm.nih.gov/pubmed/27376162"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0007117", "o": "http://linkedlifedata.com/resource/umls/label/A18627521"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18627521", "o": "basal cell carcinomas"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0007117", "o": "http://linkedlifedata.com/resource/umls/label/A0474410"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0474410", "o": "basal cell carcinoma"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0007117", "o": "BCC"}], "ideal_answer": ["Yes. Sonidegib, an oral smoothened antagonist, is indicated for the treatment of adults with locally advanced basal cell carcinoma (laBCC) who are not candidates for surgery or radiation therapy, or adults with recurrent laBCC following surgery or radiation therapy."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002280", "http://www.disease-ontology.org/api/metadata/DOID:2513"], "type": "yesno", "id": "589a246f78275d0c4a000034", "snippets": [{"offsetInBeginSection": 253, "offsetInEndSection": 556, "text": "This review of the literature aims to describe previous and current treatment options for oral therapy in locally advanced and metastatic NMSC otherwise unamenable to standard treatment. Oral Smoothened (Smo) inhibitors Vismodegib, Sonidegib, and Taladegib have shown to be effective in several trials. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566923", "endSection": "abstract"}, {"offsetInBeginSection": 589, "offsetInEndSection": 745, "text": "Sonidegib is a new smoothened inhibitor currently under investigation for treatment of laBCC, which demonstrates a comparable safety profile to vismodegib. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26780190", "endSection": "abstract"}, {"offsetInBeginSection": 881, "offsetInEndSection": 1067, "text": "The recent development of novel hedgehog pathway inhibitors for high-risk BCC (including oral vismodegib and sonidegib) may represent a paradigm shift towards medical management of NMSC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26833519", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 278, "text": "Sonidegib (Odomzo\u00ae), an oral smoothened (SMO) antagonist, is indicated for the treatment of adults with locally advanced basal cell carcinoma (laBCC) who are not candidates for surgery or radiation therapy, or adults with recurrent laBCC following surgery or radiation therapy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26867946", "endSection": "abstract"}, {"offsetInBeginSection": 1290, "offsetInEndSection": 1620, "text": "The acceptable benefit-risk profile of sonidegib, along with a paucity of treatment options and the seriousness of the condition, makes sonidegib an emerging option for the treatment of adults with laBCC that has recurred following surgery or radiation therapy, or in those who are not candidates for surgery or radiation therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26867946", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Sonidegib phosphate: new approval for basal cell carcinoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27376162", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695345", "endSection": "title"}, {"offsetInBeginSection": 2322, "offsetInEndSection": 2734, "text": "Serious adverse events occurred in 11 (14%) of 79 patients in the 200 mg group and 45 (30%) of 150 patients in the 800 mg group.The benefit-to-risk profile of 200 mg sonidegib might offer a new treatment option for patients with advanced basal cell carcinoma, a population that is difficult to treat.Novartis Pharmaceuticals Corporation.<CopyrightInformation>Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.</", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25981810", "endSection": "abstract"}, {"offsetInBeginSection": 591, "offsetInEndSection": 956, "text": "However, to date, Hh inhibitors, specifically those targeting Smoothened [such as vismodegib, BMS-833923, saridegib (IPI-926), sonidegib/erismodegib (LDE225), PF-04449913, LY2940680, LEQ 506, and TAK-441], have demonstrated good efficacy as monotherapy in patients with basal cell carcinoma and medulloblastoma, but have shown limited activity in other tumor types.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25646180", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 626, "text": "The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC in the BCC Outcomes with LDE225 Treatment study.This report provides long-term follow-up data collected up to 12\u00a0months after the last patient was randomized.In this multicenter, randomized, double-blind phase II study, patients were randomized 1:2 to sonidegib 200 or 800\u00a0mg. The primary end point was objective response rate assessed by central review.Objective response rates in the 200- and 800-mg arms were 57.6% and 43.8% in locally advanced B", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067394", "endSection": "abstract"}, {"offsetInBeginSection": 2322, "offsetInEndSection": 2735, "text": "Serious adverse events occurred in 11 (14%) of 79 patients in the 200 mg group and 45 (30%) of 150 patients in the 800 mg group.The benefit-to-risk profile of 200 mg sonidegib might offer a new treatment option for patients with advanced basal cell carcinoma, a population that is difficult to treat.Novartis Pharmaceuticals Corporation.<CopyrightInformation>Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.</C", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25981810", "endSection": "abstract"}, {"offsetInBeginSection": 384, "offsetInEndSection": 709, "text": "Oral sonidegib is approved in Switzerland for the treatment of adult patients with advanced basal cell carcinoma (BCC) and in the US and EU for the treatment of adult patients with locally advanced BCC that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26323341", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "Sonidegib phosphate: new approval for basal cell carcinoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27376162", "endSection": "title"}]}, {"body": "Which R package could be used for the identification of pediatric brain tumors?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27370569"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0220603", "o": "childhood brain tumor"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0220603", "o": "http://linkedlifedata.com/resource/umls/label/A4343117"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A4343117", "o": "childhood brain tumor"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0684010", "o": "R."}], "ideal_answer": ["MethPed", "The MethPed R package efficiently classifies pediatric brain tumors using the developed MethPed classifier. MethPed is available via Bioconductor: http://bioconductor.org/packages/MethPed/", "The MethPed classifier, which is a multiclass random forest algorithm, based on DNA methylation profiles from many subgroups of pediatric brain tumors"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010372"], "type": "factoid", "id": "587e2300fc7e8dd84f000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "MethPed: an R package for the identification of pediatric brain tumor subtypes", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370569", "endSection": "title"}, {"offsetInBeginSection": 193, "offsetInEndSection": 371, "text": "We have therefore developed the MethPed classifier, which is a multiclass random forest algorithm, based on DNA methylation profiles from many subgroups of pediatric brain tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370569", "endSection": "abstract"}, {"offsetInBeginSection": 647, "offsetInEndSection": 835, "text": "The MethPed R package efficiently classifies pediatric brain tumors using the developed MethPed classifier. MethPed is available via Bioconductor: http://bioconductor.org/packages/MethPed/", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370569", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 371, "text": "DNA methylation profiling of pediatric brain tumors offers a new way of diagnosing and subgrouping these tumors which improves current clinical diagnostics based on histopathology. We have therefore developed the MethPed classifier, which is a multiclass random forest algorithm, based on DNA methylation profiles from many subgroups of pediatric brain tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370569", "endSection": "abstract"}, {"offsetInBeginSection": 382, "offsetInEndSection": 633, "text": "e developed an R package that implements the MethPed classifier, making it easily available and accessible. The package can be used for estimating the probability that an unknown sample belongs to each of nine pediatric brain tumor diagnoses/subgroups", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370569", "endSection": "abstract"}, {"offsetInBeginSection": 647, "offsetInEndSection": 753, "text": "The MethPed R package efficiently classifies pediatric brain tumors using the developed MethPed classifier", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370569", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "MethPed: an R package for the identification of pediatric brain tumor subtypes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370569", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "MethPed: an R package for the identification of pediatric brain tumor subtypes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370569", "endSection": "title"}, {"offsetInBeginSection": 615, "offsetInEndSection": 722, "text": "The MethPed R package efficiently classifies pediatric brain tumors using the developed MethPed classifier.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370569", "endSection": "abstract"}, {"offsetInBeginSection": 361, "offsetInEndSection": 469, "text": "We developed an R package that implements the MethPed classifier, making it easily available and accessible.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370569", "endSection": "abstract"}]}, {"body": "Describe the usefulness of CAMUR in The Cancer Genome Atlas (TCGA)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26519501"], "ideal_answer": ["CAMUR is a new method that extracts multiple and equivalent classification models. CAMUR iteratively computes a rule-based classification model, calculates the power set of the genes present in the rules, iteratively eliminates those combinations from the data set, and performs again the classification procedure until a stopping criterion is verified. CAMUR includes an ad-hoc knowledge repository (database) and a querying tool. Three different types of RNA-seq data sets (Breast, Head and Neck, and Stomach Cancer) were analyzed from The Cancer Genome Atlas (TCGA) and CAMUR and its models were validated also on non-TCGA data. Experimental results show the efficacy of CAMUR by obtaining several reliable equivalent classification models, from which the most frequent genes, their relationships, and the relation with a particular cancer are deduced."], "type": "summary", "id": "5880b036c872c95565000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "CAMUR: Knowledge extraction from RNA-seq cancer data through equivalent classification rules", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26519501", "endSection": "title"}, {"offsetInBeginSection": 630, "offsetInEndSection": 1477, "text": "CAMUR, a new method that extracts multiple and equivalent classification models. CAMUR iteratively computes a rule-based classification model, calculates the power set of the genes present in the rules, iteratively eliminates those combinations from the data set, and performs again the classification procedure until a stopping criterion is verified. CAMUR includes an ad-hoc knowledge repository (database) and a querying tool.We analyze three different types of RNA-seq data sets (Breast, Head and Neck, and Stomach Cancer) from The Cancer Genome Atlas (TCGA) and we validate CAMUR and its models also on non-TCGA data. Our experimental results show the efficacy of CAMUR: we obtain several reliable equivalent classification models, from which the most frequent genes, their relationships, and the relation with a particular cancer are deduced", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26519501", "endSection": "abstract"}, {"offsetInBeginSection": 962, "offsetInEndSection": 1232, "text": "CAMUR includes an ad-hoc knowledge repository (database) and a querying tool.We analyze three different types of RNA-seq data sets (Breast, Head and Neck, and Stomach Cancer) from The Cancer Genome Atlas (TCGA) and we validate CAMUR and its models also on non-TCGA data.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26519501", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "CAMUR: Knowledge extraction from RNA-seq cancer data through equivalent classification rules.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26519501", "endSection": "title"}, {"offsetInBeginSection": 599, "offsetInEndSection": 690, "text": "We propose CAMUR, a new method that extracts multiple and equivalent classification models.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26519501", "endSection": "abstract"}]}, {"body": "Which markers are screened with the triple test for the detection of syndromes in fetus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21699408", "http://www.ncbi.nlm.nih.gov/pubmed/10585342", "http://www.ncbi.nlm.nih.gov/pubmed/8624312", "http://www.ncbi.nlm.nih.gov/pubmed/7544745", "http://www.ncbi.nlm.nih.gov/pubmed/18839465", "http://www.ncbi.nlm.nih.gov/pubmed/15512289", "http://www.ncbi.nlm.nih.gov/pubmed/14669430", "http://www.ncbi.nlm.nih.gov/pubmed/10521756", "http://www.ncbi.nlm.nih.gov/pubmed/16378329", "http://www.ncbi.nlm.nih.gov/pubmed/7485343", "http://www.ncbi.nlm.nih.gov/pubmed/9166168", "http://www.ncbi.nlm.nih.gov/pubmed/25330176", "http://www.ncbi.nlm.nih.gov/pubmed/8650125", "http://www.ncbi.nlm.nih.gov/pubmed/18306921", "http://www.ncbi.nlm.nih.gov/pubmed/11084551", "http://www.ncbi.nlm.nih.gov/pubmed/8630836"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0015965", "o": "Fetus"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0015965", "o": "http://linkedlifedata.com/resource/umls/label/A1392741"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A1392741", "o": "fetus"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0554819", "o": "triple test"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0554819", "o": "http://linkedlifedata.com/resource/umls/label/A18640308"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18640308", "o": "triple test"}], "ideal_answer": ["The markers that are screened with the triple test for the detection of syndromes in fetus are:\n1) alpha-fetoprotein (AFP), \n2) beta-chorionic gonadotrophin (beta-CG) and \n3) unconjugated oestriol (uE3)."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005333", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062145", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011258", "http://amigo.geneontology.org/amigo/term/GO:0007565"], "type": "list", "id": "58da2a348acda34529000014", "snippets": [{"offsetInBeginSection": 324, "offsetInEndSection": 515, "text": "Our study aimed at calculation and validation of the triple marker medians used in screening Egyptian females as well as to recommend programme conventions to unify screening in this country.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25330176", "endSection": "abstract"}, {"offsetInBeginSection": 619, "offsetInEndSection": 743, "text": "Chorionic gonadotropin (CG), \u03b1-fetoprotein (AFP) and unconjugated oestriol (uE3) were measured on Siemens Immulite analyzer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25330176", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Triple test screening for Down syndrome: an Egyptian-tailored study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25330176", "endSection": "title"}, {"offsetInBeginSection": 5, "offsetInEndSection": 272, "text": "The purpose of this article was to evaluate the reliability of maternal serum triple marker screening of alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol for the prenatal diagnosis of fetal chromosomal abnormalities in Turkish pregnant women.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21699408", "endSection": "abstract"}, {"offsetInBeginSection": 1174, "offsetInEndSection": 1285, "text": "Second trimester triple test is an effective screening tool for detecting fetal Down syndrome in Turkish women.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21699408", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "The aim of this prospective study was to compare triple test screening (alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome in women of 35 years of age or more. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15512289", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 251, "text": "The aim of this prospective study was to compare triple test screening (alpha-fetoprotein, beta-chorionic gonadotrophin and unconjugated oestriol) with amniocentesis in the detection of fetuses with Down's syndrome in women of 35 years of age or more.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15512289", "endSection": "abstract"}, {"offsetInBeginSection": 1559, "offsetInEndSection": 1953, "text": "None of the other five markers added more than 2% detection for the same false-positive rate.The performance of screening using maternal age and serum-free beta-hCG and PAPP-A at 10 weeks of pregnancy was better than the double test (alpha-fetoprotein and hCG with maternal age) and similar to the triple test (alpha-fetoprotein, unconjugated oestriol and hCG with maternal age) at 15-22 weeks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8624312", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 612, "text": "To make recommendations to physicians providing prenatal care on (1) whether prenatal screening for and diagnosis of Down syndrome (DS) is advisable and (2) alternative screening and diagnosis manoeuvres.\"Triple-marker\" screening of maternal serum levels of alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol; fetal ultrasonographic examination; amniocentesis; and chorionic villus sampling (CVS).Accuracy of detection of DS in fetuses, and risks to the mother, including psychologic distress, and to the fetus from the screening and diagnostic interventions.A MEDLINE search for relevant a", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8630836", "endSection": "abstract"}, {"offsetInBeginSection": 258, "offsetInEndSection": 507, "text": "A decision analytic model was designed for women at increased risk for a DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein (MSAFP) screening test, also known as a triple screen (+triple) test.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16378329", "endSection": "abstract"}, {"offsetInBeginSection": 302, "offsetInEndSection": 569, "text": "These tests have a limited detection rate for Down syndrome: approximately 40% for hCG or free beta-subunit alone, approximately 60% for the triple screen test, and approximately 70% for the quadruple marker test, all at 5%, or a relatively high, false-positive rate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10585342", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 301, "text": "Serum human chorionic gonadotropin (hCG) and hCG free beta-subunit tests are used in combination with unconjugated estriol and alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome in the second trimester of pregnancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10585342", "endSection": "abstract"}, {"offsetInBeginSection": 242, "offsetInEndSection": 452, "text": "Initial and revised screen-positive rates and detection rates were reviewed for women undergoing triple-marker testing (maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9166168", "endSection": "abstract"}]}, {"body": "What is the role of TAD protein domain?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26537679", "http://www.ncbi.nlm.nih.gov/pubmed/17404593", "http://www.ncbi.nlm.nih.gov/pubmed/17332356", "http://www.ncbi.nlm.nih.gov/pubmed/27196604", "http://www.ncbi.nlm.nih.gov/pubmed/9826771", "http://www.ncbi.nlm.nih.gov/pubmed/27713878", "http://www.ncbi.nlm.nih.gov/pubmed/15003254", "http://www.ncbi.nlm.nih.gov/pubmed/16101299", "http://www.ncbi.nlm.nih.gov/pubmed/10490619", "http://www.ncbi.nlm.nih.gov/pubmed/18243147", "http://www.ncbi.nlm.nih.gov/pubmed/14645574", "http://www.ncbi.nlm.nih.gov/pubmed/11223263", "http://www.ncbi.nlm.nih.gov/pubmed/17804822", "http://www.ncbi.nlm.nih.gov/pubmed/22949507", "http://www.ncbi.nlm.nih.gov/pubmed/26147604", "http://www.ncbi.nlm.nih.gov/pubmed/24019758", "http://www.ncbi.nlm.nih.gov/pubmed/17233836", "http://www.ncbi.nlm.nih.gov/pubmed/27502417", "http://www.ncbi.nlm.nih.gov/pubmed/26029824", "http://www.ncbi.nlm.nih.gov/pubmed/8086335", "http://www.ncbi.nlm.nih.gov/pubmed/24675874", "http://www.ncbi.nlm.nih.gov/pubmed/15663936", "http://www.ncbi.nlm.nih.gov/pubmed/16226227", "http://www.ncbi.nlm.nih.gov/pubmed/25961797", "http://www.ncbi.nlm.nih.gov/pubmed/26476216", "http://www.ncbi.nlm.nih.gov/pubmed/19220000", "http://www.ncbi.nlm.nih.gov/pubmed/19319663", "http://www.ncbi.nlm.nih.gov/pubmed/15641800", "http://www.ncbi.nlm.nih.gov/pubmed/8561893", "http://www.ncbi.nlm.nih.gov/pubmed/16596634", "http://www.ncbi.nlm.nih.gov/pubmed/20969867", "http://www.ncbi.nlm.nih.gov/pubmed/8806843", "http://www.ncbi.nlm.nih.gov/pubmed/23110116"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/umls/id/C0280090", "o": "TAD"}], "ideal_answer": ["TAD domain is a transcription activation domain found in transcription factors."], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012380"], "type": "factoid", "id": "58dcb47c8acda34529000020", "snippets": [{"offsetInBeginSection": 367, "offsetInEndSection": 567, "text": " Thus, nuclear ERK5 activates transcription factors by either direct phosphorylation or acting as co-activator thanks to a unique transcriptional activation TAD domain located at its C-terminal tail. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27713878", "endSection": "abstract"}, {"offsetInBeginSection": 1425, "offsetInEndSection": 1560, "text": "Although lacking kinase activity, these forms activate transcription by interacting with transcription factors through the TAD domain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27713878", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 579, "text": "Myc has an N-terminal transcription activation domain (TAD) that interacts with various coactivators and a C-terminal basic-helix-loop-helix-leucine zipper (bHLHZip) domain required for E box-specific DNA-binding and heterodimerization with its obligatory bHLHZip protein partner Max. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15003254", "endSection": "abstract"}, {"offsetInBeginSection": 542, "offsetInEndSection": 718, "text": "p300 worked synergistically with MRTF-A to activate the transcription of MYH9, MYL9 and CYR61. As identified by co-IP, p300 interacted with the C-terminal TAD domain of MRTF-A.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26476216", "endSection": "abstract"}, {"offsetInBeginSection": 343, "offsetInEndSection": 709, "text": "To investigate further the role of cytoplasmic sequestration of p53 in its inhibition by the E1B 55-kDa protein we systematically examined domains in both the Ad12 55-kDa protein and p53 that underpin their colocalization in the cytoplasmic body and show that the N-terminal transactivation domain (TAD) of p53 is essential for retaining p53 in the cytoplasmic body.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14645574", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 262, "text": "Physical interaction between the transactivation domain (TAD) of the mixed-lineage leukemia protein (MLL) and the KIX domain of the cyclic-AMP response element binding protein (CREB) binding protein (CBP) is necessary for MLL-mediated transcriptional activation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20969867", "endSection": "abstract"}, {"offsetInBeginSection": 173, "offsetInEndSection": 388, "text": "The IE62 possesses several domains essential for trans-activation, including an acidic trans-activation domain (TAD), a serine-rich tract (SRT), and binding domains for USF, TFIIB, and TATA box binding protein (TBP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26537679", "endSection": "abstract"}, {"offsetInBeginSection": 346, "offsetInEndSection": 712, "text": "To investigate further the role of cytoplasmic sequestration of p53 in its inhibition by the E1B 55-kDa protein we systematically examined domains in both the Ad12 55-kDa protein and p53 that underpin their colocalization in the cytoplasmic body and show that the N-terminal transactivation domain (TAD) of p53 is essential for retaining p53 in the cytoplasmic body.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14645574", "endSection": "abstract"}, {"offsetInBeginSection": 278, "offsetInEndSection": 473, "text": "We have characterized two transcription activation domains (TADs) in Da, called activation domain 1 (AD1) and loop-helix (LH), and have evaluated their roles in promoting peripheral neurogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949507", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 452, "text": "Particularly, the intrinsic histone acetyltransferase (HAT) activity and transactivation domains (TAD) play essential roles for their coactivating function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17332356", "endSection": "abstract"}]}, {"body": "What is the function of lncRNA?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27582466", "http://www.ncbi.nlm.nih.gov/pubmed/26117798", "http://www.ncbi.nlm.nih.gov/pubmed/24757148", "http://www.ncbi.nlm.nih.gov/pubmed/25994219", "http://www.ncbi.nlm.nih.gov/pubmed/26362525", "http://www.ncbi.nlm.nih.gov/pubmed/25855606", "http://www.ncbi.nlm.nih.gov/pubmed/26004688", "http://www.ncbi.nlm.nih.gov/pubmed/26308238", "http://www.ncbi.nlm.nih.gov/pubmed/24063787", "http://www.ncbi.nlm.nih.gov/pubmed/27802187", "http://www.ncbi.nlm.nih.gov/pubmed/24149621", "http://www.ncbi.nlm.nih.gov/pubmed/26302456", "http://www.ncbi.nlm.nih.gov/pubmed/25588719", "http://www.ncbi.nlm.nih.gov/pubmed/24473392", "http://www.ncbi.nlm.nih.gov/pubmed/24196393", "http://www.ncbi.nlm.nih.gov/pubmed/26297315"], "ideal_answer": ["Long noncoding RNAs (lncRNAs) are involved in a variety of biological processes, including the epigenetic control of gene expression, post-transcriptional regulation of mRNA, and cellular proliferation and differentiation"], "concepts": ["https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062085", "http://amigo.geneontology.org/amigo/term/GO:0065009"], "type": "summary", "id": "58f4c09f70f9fc6f0f000017", "snippets": [{"offsetInBeginSection": 17, "offsetInEndSection": 335, "text": "long noncoding RNAs (lncRNAs) have mainly been studied using cultured cell lines, and this approach has revealed the involvement of lncRNAs in a variety of biological processes, including the epigenetic control of gene expression, post-transcriptional regulation of mRNA, and cellular proliferation and differentiation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26117798", "endSection": "abstract"}, {"offsetInBeginSection": 118, "offsetInEndSection": 260, "text": " Many thousands of noncoding RNAs are transcribed and recognized as functional RNAs with diverse sizes, structures, and biological functions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26308238", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 317, "text": "Protection against infection and maintenance of homeostasis are the hallmarks of the innate immune system. The complex signaling cascades that occur following microbial infection have been studied intensely for a number of years and long noncoding RNA (lncRNA) represent novel regulatory components of these pathways.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26362525", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "Over the last decade, long noncoding RNAs (lncRNAs) have emerged as a fundamental molecular class whose members play pivotal roles in the regulation of the genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26297315", "endSection": "abstract"}, {"offsetInBeginSection": 675, "offsetInEndSection": 845, "text": "Through their numerous functions, lncRNAs play critical roles in the growth, development, senescence, death, and other important physiological and pathological processes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24473392", "endSection": "abstract"}, {"offsetInBeginSection": 105, "offsetInEndSection": 320, "text": "lncRNAs usually function through interactions with proteins, which implies the importance of identifying the binding proteins of lncRNAs in understanding the molecular mechanisms underlying the functions of lncRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24063787", "endSection": "abstract"}, {"offsetInBeginSection": 173, "offsetInEndSection": 362, "text": "Long non-coding RNAs (LncRNAs) are involved in multiple processes critical to normal cellular function and dysfunction of lncRNA MIAT may contribute to the pathophysiology of schizophrenia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26004688", "endSection": "abstract"}, {"offsetInBeginSection": 505, "offsetInEndSection": 630, "text": "lncRNAs function as adaptors that link specific chromatin loci with chromatin-remodeling complexes and transcription factors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24149621", "endSection": "abstract"}, {"offsetInBeginSection": 1669, "offsetInEndSection": 1862, "text": "The results indicate that lncRNA-CIR contributes to ECM degradation and plays a key role in the pathogenesis of OA. We propose that lncRNA-CIR could be used as a potential target in OA therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24757148", "endSection": "abstract"}, {"offsetInBeginSection": 196, "offsetInEndSection": 267, "text": "Here, we report that lncRNA#32 is associated with type I IFN signaling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582466", "endSection": "abstract"}, {"offsetInBeginSection": 815, "offsetInEndSection": 882, "text": "ur results reveal a role for lncRNA#32 in host antiviral responses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582466", "endSection": "abstract"}, {"offsetInBeginSection": 73, "offsetInEndSection": 170, "text": "Long noncoding RNAs (lncRNAs) have emerged as critical epigenetic regulators of gene expression. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25855606", "endSection": "abstract"}, {"offsetInBeginSection": 73, "offsetInEndSection": 169, "text": "RNAs and potent gene regulators, which play an important and varied role in cellular functions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25588719", "endSection": "abstract"}, {"offsetInBeginSection": 509, "offsetInEndSection": 669, "text": "lncRNAs have been reported to participate in a broad scope of biological processes, and lncRNA dysregulation leads to diverse human diseases, including cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27802187", "endSection": "abstract"}, {"offsetInBeginSection": 277, "offsetInEndSection": 646, "text": "however, as the discovery of lncRNA XIST and HOTAIR uncovers the emerging roles of lncRNAs in development and tumorigenesis. In the past decades, accumulating evidence have indicated that lncRNAs involve in a wide range of biological functions, such as X-chromosome inactivation, reprogramming stem cell pluripotency, regulation of the immune response and carcinogenesi", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26302456", "endSection": "abstract"}]}, {"body": "What is the function of the exosome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27583248", "http://www.ncbi.nlm.nih.gov/pubmed/26794715", "http://www.ncbi.nlm.nih.gov/pubmed/23719940", "http://www.ncbi.nlm.nih.gov/pubmed/16939780", "http://www.ncbi.nlm.nih.gov/pubmed/14727085", "http://www.ncbi.nlm.nih.gov/pubmed/23143101", "http://www.ncbi.nlm.nih.gov/pubmed/21059916", "http://www.ncbi.nlm.nih.gov/pubmed/18490724", "http://www.ncbi.nlm.nih.gov/pubmed/26704468", "http://www.ncbi.nlm.nih.gov/pubmed/27061439", "http://www.ncbi.nlm.nih.gov/pubmed/25619138", "http://www.ncbi.nlm.nih.gov/pubmed/27443883", "http://www.ncbi.nlm.nih.gov/pubmed/25968605", "http://www.ncbi.nlm.nih.gov/pubmed/18423480", "http://www.ncbi.nlm.nih.gov/pubmed/26814471", "http://www.ncbi.nlm.nih.gov/pubmed/16877764", "http://www.ncbi.nlm.nih.gov/pubmed/26850698", "http://www.ncbi.nlm.nih.gov/pubmed/24338844", "http://www.ncbi.nlm.nih.gov/pubmed/27693459"], "ideal_answer": ["Exosomes are 40-100-nm vesicles released by most cell types after fusion of multivesicular endosomes with the plasma membrane. Exosomes contain proteins and RNA species and can mediate communication and immune responses."], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0070062", "http://amigo.geneontology.org/amigo/term/GO:0000178", "http://amigo.geneontology.org/amigo/term/GO:0071971", "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063326", "http://amigo.geneontology.org/amigo/term/GO:1990563"], "type": "summary", "id": "58f4b3ee70f9fc6f0f000013", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Exosomes-secreted microRNAs play an important role in metastatic spread", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27693459", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 30, "text": "Exosome-mediated communication", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26814471", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 359, "text": "Cells are able to produce and release different types of vesicles, such as microvesicles and exosomes, in the extracellular microenvironment. According to the scientific community, both microvesicles and exosomes are able to take on and transfer different macromolecules from and to other cells, and in this way, they can influence the recipient cell function", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26814471", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 259, "text": " Exosomes are 40-100-nm vesicles released by most cell types after fusion of multivesicular endosomes with the plasma membrane. Exosomes, ubiquitary in body fluids including urines, contain proteins and RNA species specific of the tissue of origin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26850698", "endSection": "abstract"}, {"offsetInBeginSection": 299, "offsetInEndSection": 458, "text": " Exosomes, small membrane vesicles secreted into the extracellular environment, are emerging as another important intercellular messenger in immune responses. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27061439", "endSection": "abstract"}, {"offsetInBeginSection": 78, "offsetInEndSection": 223, "text": "the exosome is a complex of 3' -->5' exoribonucleases that plays a key role in the processing and degradation of a wide variety of RNA substrates", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16939780", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 93, "text": "RNA exosome is responsible for a wide variety of RNA processing and degradation reactions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23143101", "endSection": "abstract"}, {"offsetInBeginSection": 291, "offsetInEndSection": 543, "text": "ability of exosomes to carry and selectively deliver bioactive molecules (e.g., lipids, proteins, and nucleic acids) confers on them the capacity to modulate the activity of receptor cells, even if these cells are located in distant tissues or organs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27583248", "endSection": "abstract"}, {"offsetInBeginSection": 1655, "offsetInEndSection": 1759, "text": "Our data show that NKG2D is a likely physiological target for exosome-mediated immune evasion in cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18490724", "endSection": "abstract"}, {"offsetInBeginSection": 17, "offsetInEndSection": 126, "text": "Exosomes, a key component of cell paracrine secretion, can exert protective effects in various disease models", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26794715", "endSection": "abstract"}, {"offsetInBeginSection": 360, "offsetInEndSection": 568, "text": "Exosome secretion participates in the eradication of obsolete proteins but several findings, essentially in the immune system, indicate that exosomes constitute a potential mode of intercellular communication", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16877764", "endSection": "abstract"}, {"offsetInBeginSection": 140, "offsetInEndSection": 413, "text": "Exosomes, nano-sized extracellular vesicles, are believed to play important roles in intercellular communications. This study demonstrates that exosomes released from human macrophages negatively regulate endothelial cell migration through control of integrin trafficking. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24338844", "endSection": "abstract"}, {"offsetInBeginSection": 1342, "offsetInEndSection": 1551, "text": "We found that the majority of extracellular vesicles in the AH were in the exosome size range, suggesting that miRNAs housed within exosomes may function in communication between AH inflow and outflow tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25619138", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 70, "text": "umor cell-derived exosomes (TEX) suppress functions of immune cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26842680", "endSection": "abstract"}]}]}